{"meta":{"query_hash":"b1cf7d12156a","filters":{"topic":"HER2/EGFR in Cancer Research"},"cohort_total":1303,"direct_labels_cover":3,"predictions_cover":1303,"exported":1303,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/b1cf7d12156a","api":"https://metacan.xera.ac/api/v1/cohort?topic=HER2%2FEGFR+in+Cancer+Research"},"results":[{"id":"W121131437","doi":"10.1007/978-3-642-02112-1_7","title":"Epidermal Growth Factor (EGF) Receptor Signaling and Cancer","year":2009,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"ErbB; Epidermal growth factor; Receptor; Signal transduction; Epidermal growth factor receptor; Growth factor receptor; Receptor tyrosine kinase; Cancer research; Growth factor receptor inhibitor; Phosphorylation; Biology; Cell biology; Tyrosine phosphorylation; Tyrosine kinase; Cell surface receptor; Biochemistry","score_opus":0.0813281919803595,"score_gpt":0.36011725495210806,"score_spread":0.27878906297174855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W121131437","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001060561,0.010450949,0.000055054843,0.007115708,0.0003876931,0.0011536239,0.00018754248,0.00020320537,0.9793857],"genre_scores_gemma":[0.004976193,0.009198806,0.0010877188,0.0025337911,0.0018034629,0.000033545795,0.000059771155,0.00015001887,0.9801567],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975792,0.000023441753,0.00044025373,0.00065651606,0.00078842614,0.000512157],"domain_scores_gemma":[0.9985765,0.00015361128,0.000115270865,0.00036678163,0.00029476025,0.0004930717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020601678,0.00043990917,0.0007785073,0.0002512407,0.000079890204,0.000045165332,0.0001494049,0.00053254917,0.03433367],"category_scores_gemma":[0.000088195564,0.00036243972,0.0001646774,0.000041186795,0.0001687909,0.00006638381,0.00008987023,0.0010332603,0.000333392],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060522533,0.000087096654,0.0024788082,0.0021793079,0.00086665805,0.00052267197,0.0005014117,0.0000014267197,0.011212313,0.027265394,0.21762078,0.73665893],"study_design_scores_gemma":[0.0010275425,0.0004844411,0.00042358646,0.0016631309,0.0001391022,0.00005266817,0.000014084469,0.00001756911,0.005867189,0.0018218921,0.9878851,0.0006036619],"about_ca_topic_score_codex":0.00042594026,"about_ca_topic_score_gemma":0.000053536,"teacher_disagreement_score":0.7702643,"about_ca_system_score_codex":0.00040138935,"about_ca_system_score_gemma":0.0005835616,"threshold_uncertainty_score":0.99988276},"labels":[],"label_agreement":null},{"id":"W1259037943","doi":"","title":"Multiplexed in situ analysis of protein expression to predict response to trastuzumab","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Institute","funders":"","keywords":"Trastuzumab; Oncology; Breast cancer; Internal medicine; Multivariate analysis; Cohort; Estrogen receptor; Survival analysis; Cancer; Hierarchical clustering; Medicine; Tissue microarray; Biology; Cancer research; Cluster analysis; Artificial intelligence; Computer science","score_opus":0.12425819423436822,"score_gpt":0.5046287916801975,"score_spread":0.38037059744582924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1259037943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914266,0.00033502156,0.0003154752,0.0028525803,0.000049425285,0.0033717453,0.000059513597,0.000038366616,0.0015512555],"genre_scores_gemma":[0.9939872,0.000029636965,0.001363848,0.00012974901,0.0001415256,0.0010332959,0.000011228007,0.000051534396,0.003251962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99385333,0.0007051755,0.00067448337,0.00076608366,0.002712828,0.0012881105],"domain_scores_gemma":[0.9962597,0.0008006612,0.000050360908,0.0010065789,0.0009121967,0.0009705159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010842149,0.00019053386,0.0006707835,0.004879929,0.000092187,0.000028033328,0.000517999,0.00018184319,0.0008395516],"category_scores_gemma":[0.0037811345,0.00017003619,0.00015043617,0.009786966,0.00018465084,0.00007093064,0.00034680206,0.0009141322,0.00006962639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026126262,0.00026593608,0.016724518,0.00016868948,0.00013943412,0.0001792788,0.002875613,0.00032911962,0.9371452,0.000007331463,0.002546156,0.0134925],"study_design_scores_gemma":[0.0015145679,0.0011894939,0.25039464,0.0008365612,0.000036939666,0.0000013322945,0.000802856,0.00007944987,0.7351279,0.000007509375,0.009869105,0.00013960002],"about_ca_topic_score_codex":0.0025195268,"about_ca_topic_score_gemma":0.0049925516,"teacher_disagreement_score":0.23367012,"about_ca_system_score_codex":0.0021490648,"about_ca_system_score_gemma":0.0013813549,"threshold_uncertainty_score":0.91925013},"labels":[],"label_agreement":null},{"id":"W136595265","doi":"10.3390/curroncol13010001","title":"Does HER2/neu Overexpression in Breast Cancer Influence Adjuvant Chemotherapy and Hormonal Therapy Choices by Ontario Physicians? A Physician Survey","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hormonal therapy; Tyrosine kinase; Breast cancer; Adjuvant; Hormone; Oncology; HER2/neu; Chemotherapy; Internal medicine; Cancer research; Transmembrane protein; Glycoprotein; Cancer; Receptor; Biology; Genetics","score_opus":0.04944875264955394,"score_gpt":0.40636161428073864,"score_spread":0.3569128616311847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W136595265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918648,0.004489606,0.0000041374537,0.0019529294,0.0003037354,0.00067543704,0.00020588624,0.00003676114,0.00046671196],"genre_scores_gemma":[0.9932638,0.004210797,0.000025542853,0.0011191488,0.0005423651,0.0002399543,0.0001226177,0.000044040775,0.00043176138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769837,0.0002528836,0.00037967242,0.0006071246,0.0004570502,0.0006049258],"domain_scores_gemma":[0.9990435,0.00018104774,0.00017169339,0.00029317677,0.00017660676,0.00013394306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036025426,0.00029948252,0.00062476855,0.00012142952,0.00008136558,0.000034929122,0.00020461123,0.00017360275,0.00019745957],"category_scores_gemma":[0.0000127340545,0.00020012948,0.00006785837,0.00029992446,0.00030655146,0.00017621748,0.00006763742,0.0007130974,0.000008660222],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074379356,0.0011517593,0.7203907,0.00007105469,0.000026856913,0.000008788394,0.0004264399,0.0000071225613,0.039954193,0.0000057261495,0.0090928655,0.22812074],"study_design_scores_gemma":[0.0035897777,0.00029465026,0.86016786,0.00058270706,0.000007891203,0.0000060700827,0.00003173192,0.000070924485,0.0028327112,0.00009852707,0.13210122,0.00021590642],"about_ca_topic_score_codex":0.11698837,"about_ca_topic_score_gemma":0.08466273,"teacher_disagreement_score":0.22790483,"about_ca_system_score_codex":0.001070933,"about_ca_system_score_gemma":0.0007047321,"threshold_uncertainty_score":0.9320398},"labels":[],"label_agreement":null},{"id":"W1481580402","doi":"10.1111/j.1476-5381.2010.00742.x","title":"Kinetic analysis of novel mono‐ and multivalent VHH‐fragments and their application for molecular imaging of brain tumours","year":2010,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Institute for Biodiagnostics; McGill University; University of Calgary; Biotechnology Research Institute; University of Ottawa; Institute for Biological Sciences","funders":"Canadian Institutes of Health Research","keywords":"Biodistribution; In vivo; Surface plasmon resonance; Molecular imaging; Chemistry; Epidermal growth factor receptor; Biophysics; Single-domain antibody; Preclinical imaging; Pharmacokinetics; Affinities; Molecular biology; In vitro; Antibody; Receptor; Materials science; Biology; Stereochemistry; Biochemistry; Nanotechnology; Pharmacology","score_opus":0.0174384845330435,"score_gpt":0.3774108267549451,"score_spread":0.3599723422219016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1481580402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870022,0.001965414,0.008913791,0.0015437444,0.000100407786,0.00039015038,0.0000573867,0.000002488223,0.000024415831],"genre_scores_gemma":[0.9969655,0.00039593023,0.002250336,0.00025459533,0.000084013016,0.000018916371,0.0000052821724,0.000013972513,0.000011408432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990451,0.000049847742,0.0004242956,0.00014369469,0.00017140113,0.0001657016],"domain_scores_gemma":[0.9989047,0.00018633314,0.00031556786,0.00005954772,0.0004053995,0.00012841748],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006783414,0.00007749961,0.00042638715,0.00030299832,0.00002508222,0.000007596347,0.000100600824,0.00004621461,0.000044684595],"category_scores_gemma":[0.00014745051,0.000079304606,0.00010818552,0.00021446329,0.00019031977,0.000043181688,0.000043384425,0.00027629265,6.113993e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017067048,0.00023794969,0.015209705,0.00013635548,0.00050545204,0.000026444308,0.000107660424,0.000053660948,0.9332968,0.000009963707,0.0004815663,0.049763747],"study_design_scores_gemma":[0.011780013,0.0005696071,0.22205843,0.00020328222,0.0021674016,0.0018753834,0.00021592724,0.040827643,0.718339,0.00011798124,0.0016867681,0.00015854479],"about_ca_topic_score_codex":0.00012752115,"about_ca_topic_score_gemma":0.000019676085,"teacher_disagreement_score":0.2149578,"about_ca_system_score_codex":0.000027832337,"about_ca_system_score_gemma":0.000091195645,"threshold_uncertainty_score":0.32339478},"labels":[],"label_agreement":null},{"id":"W1482906151","doi":"10.5539/cco.v1n2p49","title":"Influence of Alternative Tubulin Inhibitors on the Potency of Epirubicin-Immunochemotherapeutic Synthesized with an Ultra Violet Light-Activated Intermediate","year":2012,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health","keywords":"Epirubicin; Chemistry; Potency; Biochemistry; In vitro; Internal medicine; Medicine; Chemotherapy","score_opus":0.07410527420465987,"score_gpt":0.4440767310897255,"score_spread":0.3699714568850656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1482906151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382555,0.0006231821,0.000004530197,0.0034425736,0.0001870148,0.0004996815,0.0000134924785,0.000014112643,0.0013898822],"genre_scores_gemma":[0.9955443,0.0022378773,0.000041442392,0.0017100289,0.00031690768,0.00006528503,0.0000021250087,0.000025480442,0.000056513953],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792874,0.00046099088,0.0007077201,0.00027174628,0.0002939806,0.0003368092],"domain_scores_gemma":[0.99679124,0.0019799778,0.00036369739,0.0003764479,0.00025258097,0.0002360445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012318305,0.00016823667,0.0007601165,0.00006973082,0.000037727532,0.000003298428,0.00020683437,0.00021170391,0.00017159752],"category_scores_gemma":[0.00064846355,0.00009380527,0.00008955674,0.00019937888,0.0009489514,0.00007808143,0.0000309772,0.0006529295,0.0000062572108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022677245,0.003578139,0.29407188,0.00035081062,0.0013469998,0.000034267632,0.004062092,0.000042016305,0.34609705,0.00046172386,0.00024149459,0.32703626],"study_design_scores_gemma":[0.0056334687,0.01689705,0.31899732,0.0012934896,0.00029319708,0.000022854503,0.00076522096,0.00004223813,0.6499545,0.00016830901,0.0057021137,0.00023023058],"about_ca_topic_score_codex":0.00045598153,"about_ca_topic_score_gemma":0.00004505271,"teacher_disagreement_score":0.32680604,"about_ca_system_score_codex":0.00014967645,"about_ca_system_score_gemma":0.0005330624,"threshold_uncertainty_score":0.3825268},"labels":[],"label_agreement":null},{"id":"W1487295350","doi":"10.18433/j3v59v","title":"Targeting the Calmodulin-Regulated ErbB/Grb7 Signaling Axis in Cancer Therapy","year":2013,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Signal transduction; ErbB; Epidermal growth factor receptor; Signal transducing adaptor protein; Receptor; Calmodulin; Cell biology; Biology; Cancer research; Epidermal growth factor; Biochemistry","score_opus":0.3828448787525353,"score_gpt":0.5710487369877085,"score_spread":0.18820385823517322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1487295350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037869478,0.9888428,0.00001542269,0.004071644,0.0012268979,0.0017060008,0.000013243059,0.000023725763,0.00031334462],"genre_scores_gemma":[0.0042268606,0.99185413,0.00036845697,0.0009810749,0.0022250456,0.00008549839,0.000002681526,0.00006734479,0.00018888847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921495,0.0012096483,0.002227176,0.0006166165,0.0025478469,0.001249231],"domain_scores_gemma":[0.9960665,0.0013202869,0.0010197171,0.00025834376,0.0005475137,0.00078765576],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007021405,0.000622592,0.002140179,0.0006653835,0.00034864745,0.00025697736,0.0017172002,0.00019162921,0.0055852234],"category_scores_gemma":[0.00047136954,0.00031619784,0.00083407294,0.0025967425,0.0011569826,0.00040533132,0.00021392955,0.0036643161,0.00008224258],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000109034234,0.00023372288,0.00041097027,0.002445531,0.00030499217,0.00022909022,0.00019830653,0.00015186908,0.001868412,0.000009294356,0.0036583391,0.99038047],"study_design_scores_gemma":[0.0016806582,0.00021718137,0.000010627431,0.007438128,0.00056695973,0.00038679558,0.000078412406,0.003060937,0.00127054,0.000026406666,0.98492134,0.00034202368],"about_ca_topic_score_codex":0.00034070053,"about_ca_topic_score_gemma":0.000003860488,"teacher_disagreement_score":0.9900384,"about_ca_system_score_codex":0.0008033394,"about_ca_system_score_gemma":0.0037658478,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W1505224726","doi":"10.1111/cbdd.12043","title":"Biological Effects of AL622, a Molecule Rationally Designed to Release an EGFR and a c‐Src Kinase Inhibitor","year":2012,"lang":"en","type":"article","venue":"Chemical Biology & Drug Design","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; Cytokinetics","keywords":"Proto-oncogene tyrosine-protein kinase Src; Chemistry; Linker; Transfection; Cancer research; Kinase; Cancer cell; Cell biology; Cancer; Biochemistry; Biology; Gene","score_opus":0.03622846146117841,"score_gpt":0.33662829650147064,"score_spread":0.3003998350402922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1505224726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921257,0.0015590019,0.0038255341,0.0011002837,0.00008885543,0.0011101057,0.000010576099,0.00006353551,0.000116421674],"genre_scores_gemma":[0.9826692,0.000057202386,0.015342448,0.0012326267,0.00033545334,0.00022186099,0.000054617314,0.000025499676,0.00006113544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795276,0.00046806174,0.00033477807,0.00046314386,0.00019129999,0.0005899866],"domain_scores_gemma":[0.9976817,0.00096728106,0.000062771695,0.00034099256,0.00014958685,0.00079770363],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007531241,0.00022634046,0.0004783193,0.00012046548,0.000046565925,0.0000083422265,0.00017197753,0.00030910087,0.00009179966],"category_scores_gemma":[0.0020705166,0.00017280263,0.000073354204,0.000260306,0.00042061374,0.000060293994,0.00012648979,0.00029474078,0.00005334953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095021323,0.00047209748,0.006046227,0.00011294682,0.000040105202,0.000028696004,0.00023849103,4.301452e-7,0.984965,0.0002925045,0.0031174181,0.0037358438],"study_design_scores_gemma":[0.0013567439,0.0010939882,0.0019906315,0.00009498417,0.00004157379,0.000038633305,0.000025967225,0.00004621591,0.99409044,0.00024584812,0.0007879044,0.00018709988],"about_ca_topic_score_codex":0.00002230858,"about_ca_topic_score_gemma":4.9188606e-7,"teacher_disagreement_score":0.011516914,"about_ca_system_score_codex":0.00011082303,"about_ca_system_score_gemma":0.00018627108,"threshold_uncertainty_score":0.7046687},"labels":[],"label_agreement":null},{"id":"W1507298324","doi":"10.1186/1471-2202-7-19","title":"Deficits in spatial learning and motor coordination in ADAM11-deficient mice","year":2006,"lang":"en","type":"article","venue":"BMC Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai; University of Toronto","keywords":"Neuroscience; Motor coordination; Cerebellum; Water maze; Hippocampus; Cell adhesion molecule; Synapse; Morris water navigation task; Motor learning; Biology; Spinal cord; Psychology; Cell biology","score_opus":0.03698199649797151,"score_gpt":0.33560298458090276,"score_spread":0.29862098808293125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1507298324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969767,0.00014009564,0.00075235433,0.00039801386,0.00013542327,0.0003744434,0.0000016582943,0.000025044163,0.0011962644],"genre_scores_gemma":[0.99865973,0.000015355214,0.00022357941,0.00010506841,0.0000408405,0.000026859203,0.0000012757358,0.000010701431,0.00091660663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984998,0.00009875237,0.00020643507,0.00039829387,0.0004620588,0.00033466518],"domain_scores_gemma":[0.9996394,0.00010810951,0.000040323834,0.00010461924,0.000040878916,0.00006666546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004976805,0.00008622483,0.0001307206,0.0002881107,0.00006070803,0.00004002612,0.000095808304,0.000040387677,0.000010315161],"category_scores_gemma":[0.00073464605,0.000084428495,0.000015785477,0.00068698416,0.00013769252,0.000084495376,0.000072302944,0.0002829659,0.0000078613675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006223015,0.00011485817,0.7608799,0.00006374786,5.7655807e-8,0.000055986144,0.000065436674,0.00078673795,0.23472343,0.00013514921,0.00004754921,0.003064941],"study_design_scores_gemma":[0.00085151545,0.00027656517,0.9487249,0.00008979075,0.0000017292422,0.00003664865,0.00005205104,0.044006035,0.0037765475,0.000029034334,0.002063276,0.000091860384],"about_ca_topic_score_codex":0.0018479751,"about_ca_topic_score_gemma":0.0014470003,"teacher_disagreement_score":0.2309469,"about_ca_system_score_codex":0.00013336471,"about_ca_system_score_gemma":0.00017587688,"threshold_uncertainty_score":0.34428942},"labels":[],"label_agreement":null},{"id":"W1525771749","doi":"10.18632/oncotarget.3036","title":"Predicting response to HER2 kinase inhibition","year":2014,"lang":"en","type":"letter","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Kinase; Cancer research; Medicine; Lapatinib; Cancer; Oncology; Internal medicine; Biology; Trastuzumab; Breast cancer; Cell biology","score_opus":0.041065228260144644,"score_gpt":0.35670946421454974,"score_spread":0.3156442359544051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1525771749","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08900363,0.00016860683,0.00013902721,0.8976897,0.00076156994,0.0012403198,0.00011817598,0.00025972593,0.010619266],"genre_scores_gemma":[0.010380938,0.000025357525,0.0018409457,0.9357033,0.016027864,0.0003187795,0.0007166237,0.0002554854,0.034730755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956138,0.0006088792,0.00052624,0.00083484256,0.0014864254,0.0009298119],"domain_scores_gemma":[0.99754125,0.00051559985,0.00014161323,0.0010923259,0.0003044824,0.00040475573],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018285061,0.00041904923,0.0007180497,0.00053344667,0.0001230271,0.000072895185,0.00023571412,0.001003803,0.0015878176],"category_scores_gemma":[0.0017352671,0.0003997174,0.00021574243,0.00043587192,0.00009492189,0.000057728397,0.00017378948,0.0032491263,0.0025975402],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001039296,0.000040928586,0.0042278212,0.00059215736,0.00004545306,0.0031419182,0.0002030627,0.0000032355676,0.0042793234,0.0000016144432,0.98592246,0.0005027087],"study_design_scores_gemma":[0.0009531017,0.001163311,0.0018462781,0.0014696799,0.000063563275,0.00016022385,0.000017476968,0.00005715628,0.0016883896,0.00004626268,0.9921837,0.00035085803],"about_ca_topic_score_codex":0.000300113,"about_ca_topic_score_gemma":0.000019974621,"teacher_disagreement_score":0.07862269,"about_ca_system_score_codex":0.0010290265,"about_ca_system_score_gemma":0.0007949293,"threshold_uncertainty_score":0.99984545},"labels":[],"label_agreement":null},{"id":"W1535415765","doi":"10.1038/modpathol.2011.206","title":"‘Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Fluorescence in situ hybridization; Biology; Breast carcinoma; Genetic heterogeneity; In situ; Fish <Actinopterygii>; Pathology; Molecular biology; Chromosome; Breast cancer; Phenotype; Genetics; Gene; Cancer; Medicine; Chemistry","score_opus":0.09402426994475052,"score_gpt":0.3758515445733378,"score_spread":0.28182727462858725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1535415765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99736506,0.001329035,0.00019403387,0.000089771194,0.00007722858,0.00069929654,0.000007659274,0.000024071725,0.00021383591],"genre_scores_gemma":[0.99869436,0.000030765936,0.0009450556,0.00008360619,0.000066795576,0.00011050348,0.000006116169,0.000030945477,0.00003185183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800676,0.00035498102,0.0004464899,0.00035508178,0.0003077042,0.00052899204],"domain_scores_gemma":[0.99912,0.00016723489,0.00007912922,0.00042020789,0.00009025967,0.00012315824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005475055,0.00014624969,0.00039489186,0.00023256608,0.000027116064,0.000005375585,0.00014582583,0.00009497633,0.000022923554],"category_scores_gemma":[0.0006810895,0.00014591467,0.000024397272,0.0004500386,0.00010065877,0.000059902788,0.00013092313,0.00028585154,0.000012985901],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006281767,0.0011599814,0.84469134,0.00007960397,0.000005880552,0.0010347255,0.0021210788,0.0001513967,0.14271171,0.0000010644161,0.00004889968,0.007931477],"study_design_scores_gemma":[0.0023231436,0.0013802573,0.969946,0.0001252611,0.000022260927,0.001017059,0.0004384493,0.0017486633,0.022752775,0.000027777623,0.000041407937,0.00017693857],"about_ca_topic_score_codex":0.0006188834,"about_ca_topic_score_gemma":0.00095639593,"teacher_disagreement_score":0.12525465,"about_ca_system_score_codex":0.00014169354,"about_ca_system_score_gemma":0.00010854358,"threshold_uncertainty_score":0.59502274},"labels":[],"label_agreement":null},{"id":"W1538972651","doi":"10.1158/0008-5472.can-03-3013","title":"Suppression of Ovarian Cancer Cell Tumorigenicity and Evasion of Cisplatin Resistance Using a Truncated Epidermal Growth Factor Receptor in a Rat Model","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"National Cancer Institute","keywords":"Epidermal growth factor receptor; Cisplatin; Epidermal growth factor; Ovarian cancer; Cancer research; Biology; MAPK/ERK pathway; Signal transduction; Tyrosine kinase; Cancer; Cell growth; Internal medicine; Endocrinology; Medicine; Receptor; Cell biology; Chemotherapy","score_opus":0.1587982255810195,"score_gpt":0.44702963869025175,"score_spread":0.2882314131092323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1538972651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99026406,0.006316344,0.00010170105,0.0012157237,0.00008501262,0.0011858993,0.00020978654,0.00001737438,0.0006041029],"genre_scores_gemma":[0.9916649,0.003926316,0.002789798,0.000038874125,0.00017746624,0.00017652432,0.000011201863,0.00006207503,0.0011528676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995645,0.00049132,0.0007598136,0.0006539365,0.0015838883,0.00086608354],"domain_scores_gemma":[0.99759054,0.0003179894,0.0001810212,0.0005278662,0.0010302222,0.00035236974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016582905,0.0002343082,0.0006887956,0.0004646354,0.00012235827,0.000019899639,0.00031003074,0.00022682073,0.0010586365],"category_scores_gemma":[0.00045365188,0.00020679382,0.00008625683,0.001077737,0.00043911854,0.00025570692,0.00025208964,0.0009270177,0.0000031203408],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031867959,0.0002224975,0.021012792,0.0017203159,0.00002284599,0.00001301405,0.0016862972,0.00086115894,0.9668662,0.000051494855,0.0020579845,0.0022986208],"study_design_scores_gemma":[0.0034745114,0.00017924816,0.0072418405,0.0021943443,0.000021337839,0.000003050127,0.00020676726,0.024209332,0.961562,0.00009390689,0.00060875545,0.00020494475],"about_ca_topic_score_codex":0.009921338,"about_ca_topic_score_gemma":0.004303938,"teacher_disagreement_score":0.023348171,"about_ca_system_score_codex":0.0016717901,"about_ca_system_score_gemma":0.0024748535,"threshold_uncertainty_score":0.9998545},"labels":[],"label_agreement":null},{"id":"W1539015594","doi":"10.1186/bcr1028","title":"Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells","year":2005,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Susan G. Komen; AstraZeneca","keywords":"Gefitinib; Surgical oncology; Cancer research; Breast cancer; Insulin-like growth factor; Epidermal growth factor receptor; Growth factor receptor inhibitor; Medicine; Oncology; Inhibitory postsynaptic potential; Internal medicine; Growth factor; Receptor; Cancer","score_opus":0.037751638025765595,"score_gpt":0.367743655658585,"score_spread":0.32999201763281943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1539015594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99085134,0.004004293,0.000007700351,0.0020080728,0.00021510043,0.0020319251,0.00047623733,0.000048014208,0.00035729015],"genre_scores_gemma":[0.99445313,0.0030645246,0.00015305768,0.00008305038,0.0010824547,0.0007749615,0.00002391278,0.000108843975,0.00025603356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936764,0.0007343736,0.0009844234,0.0009356421,0.0024327703,0.0012363907],"domain_scores_gemma":[0.9963944,0.00061928923,0.00027816606,0.00047167786,0.0017322437,0.00050422223],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017241667,0.0004066956,0.0009411853,0.0011532808,0.00022295032,0.00006769335,0.0003417322,0.00032415622,0.001009766],"category_scores_gemma":[0.00017213465,0.00037877052,0.00014341886,0.0015603055,0.001240541,0.00037858923,0.00030304806,0.001395615,0.000018380118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012972184,0.00069224293,0.03785966,0.0068818047,0.00010454039,0.0000333097,0.0017285827,0.000017348495,0.92743224,0.000088619774,0.0010966512,0.022767814],"study_design_scores_gemma":[0.0038224433,0.00045014292,0.100661285,0.006368666,0.00003647629,0.00003890786,0.00024849086,0.000057584144,0.887754,0.000078755154,0.0001619923,0.00032123015],"about_ca_topic_score_codex":0.013761691,"about_ca_topic_score_gemma":0.0010610933,"teacher_disagreement_score":0.06280163,"about_ca_system_score_codex":0.0012475655,"about_ca_system_score_gemma":0.0016249822,"threshold_uncertainty_score":0.99990344},"labels":[],"label_agreement":null},{"id":"W1549851394","doi":"10.1093/annonc/mdu364","title":"Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Roche","keywords":"Medicine; Trastuzumab; Adjuvant; Breast cancer; Cohort; Oncology; Cohort study; Cancer; Internal medicine; Surgery","score_opus":0.08889308378065346,"score_gpt":0.4284548250882904,"score_spread":0.33956174130763694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1549851394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284184,0.00013720056,0.00010814331,0.0007838055,0.000250302,0.0048056524,0.00077343767,0.0000031617308,0.0002964577],"genre_scores_gemma":[0.99766445,0.00047307808,0.000060233964,0.00007184857,0.00007270865,0.0014190145,0.00019439575,0.000011496873,0.00003279187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765766,0.00045813815,0.00075882446,0.00027273913,0.000615191,0.00023747972],"domain_scores_gemma":[0.9944857,0.0033624775,0.0005055424,0.00024304689,0.0013587401,0.00004451854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012291775,0.0001577179,0.0010149309,0.00026430513,0.00005397333,0.000007529909,0.00029809962,0.00007900529,0.00010925176],"category_scores_gemma":[0.0003189492,0.00008916546,0.00037777412,0.00028094073,0.0002863037,0.000036682468,0.000038804985,0.0000926748,4.708755e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26062867,0.010711808,0.48225695,0.00005970883,0.006847928,0.0000029328041,0.00555265,0.00036190578,0.000029120809,0.00013147395,0.00022192982,0.23319493],"study_design_scores_gemma":[0.1264936,0.045134537,0.82243377,0.00006678082,0.0024924972,0.000002110908,0.000675975,0.0016783958,0.00027647082,0.00010229487,0.00055272464,0.00009081732],"about_ca_topic_score_codex":0.0061716195,"about_ca_topic_score_gemma":0.003988155,"teacher_disagreement_score":0.34017682,"about_ca_system_score_codex":0.00020871626,"about_ca_system_score_gemma":0.00032571983,"threshold_uncertainty_score":0.9329683},"labels":[],"label_agreement":null},{"id":"W1558260067","doi":"10.1096/fasebj.28.1_supplement.802.13","title":"The EGF receptor is activated during mitosis and its cell signaling is mediated differently than in interphase (802.13)","year":2014,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Interphase; Phosphorylation; Cell biology; Mitosis; Nocodazole; Epidermal growth factor; Signal transduction; Chemistry; Cell cycle; Protein kinase B; Epidermal growth factor receptor; MAPK/ERK pathway; Receptor; Biology; Cell; Biochemistry; Cytoskeleton","score_opus":0.025972254779987897,"score_gpt":0.3005262758537149,"score_spread":0.274554021073727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558260067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906154,0.00089900004,0.000020560405,0.0075110565,0.000240952,0.00029665278,0.000014940173,0.000022771801,0.00037862343],"genre_scores_gemma":[0.9967255,0.0012664282,0.000021679216,0.00050657894,0.00048137637,0.0000144383985,0.0000031023553,0.0000434969,0.00093739096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976697,0.00044249708,0.00042906802,0.00023550438,0.000650673,0.00057255605],"domain_scores_gemma":[0.99839693,0.0006400805,0.00017513645,0.000305435,0.00014331119,0.0003390886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012782236,0.00021080543,0.00030355417,0.00017913073,0.00044049608,0.00016053973,0.0003728932,0.000104265244,0.0007529012],"category_scores_gemma":[0.00041545535,0.00011435419,0.00010124387,0.000314489,0.00011647054,0.00010154907,0.00013179846,0.0013166094,0.00007050327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007024942,0.00008396933,0.012042077,0.00006346221,0.00008082484,0.000024340194,0.003221977,0.000002362619,0.9801913,0.000001859351,0.0010710391,0.0025143286],"study_design_scores_gemma":[0.0028578325,0.00027762057,0.008180064,0.00055367127,0.00004444227,0.00011212046,0.0010071944,0.0011623078,0.98465616,0.000047128124,0.00095810887,0.00014337817],"about_ca_topic_score_codex":0.000076523735,"about_ca_topic_score_gemma":0.000027576696,"teacher_disagreement_score":0.0070044775,"about_ca_system_score_codex":0.00021208287,"about_ca_system_score_gemma":0.00012263554,"threshold_uncertainty_score":0.824374},"labels":[],"label_agreement":null},{"id":"W1565037297","doi":"10.1002/path.4202","title":"Dasatinib inhibits mammary tumour development in a genetically engineered mouse model","year":2013,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Research UK","keywords":"Dasatinib; Proto-oncogene tyrosine-protein kinase Src; Cancer research; Breast cancer; Cancer; ErbB; PTEN; Biology; Kinase; Medicine; Cre recombinase; Internal medicine; Genetically modified mouse; Tyrosine kinase; Transgene; Receptor; Signal transduction; PI3K/AKT/mTOR pathway; Gene; Cell biology; Genetics","score_opus":0.04213517269409412,"score_gpt":0.3176747396598824,"score_spread":0.2755395669657883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1565037297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98674864,0.00041456314,0.007382493,0.0045118835,0.000056995446,0.0002816236,9.241995e-7,0.000008784998,0.000594099],"genre_scores_gemma":[0.97011495,0.0002366707,0.028152687,0.00070424244,0.00009058769,0.00001588202,8.2712916e-7,0.000021476175,0.00066265906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998448,0.00019089004,0.0005646943,0.0000966089,0.00036707046,0.0003327199],"domain_scores_gemma":[0.99912024,0.00011315962,0.00011713371,0.00022098508,0.00026420457,0.0001642836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013328566,0.00011135425,0.00030805505,0.00022301346,0.000026420981,0.000010137796,0.00028203015,0.00009652456,0.000112383794],"category_scores_gemma":[0.00030027784,0.000070631155,0.00004439438,0.00014300915,0.00007779645,0.00006059934,0.000112622,0.0006620283,0.00007032354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022840362,0.00022576563,0.0018533544,0.000074951735,0.000043599637,0.0007509709,0.0037257904,0.002129036,0.97289336,0.00017657089,0.0025944354,0.015303785],"study_design_scores_gemma":[0.014239696,0.0035469818,0.19421479,0.0008246153,0.00015480525,0.023246618,0.0010214108,0.05310883,0.7003031,0.0061255274,0.002379825,0.00083381],"about_ca_topic_score_codex":0.000007825064,"about_ca_topic_score_gemma":0.000009411427,"teacher_disagreement_score":0.27259025,"about_ca_system_score_codex":0.00014252977,"about_ca_system_score_gemma":0.0006627366,"threshold_uncertainty_score":0.2880255},"labels":[],"label_agreement":null},{"id":"W1593299612","doi":"10.1158/1538-7445.am2014-753","title":"Abstract 753: Enhanced anti-tumor activity of erlotinib in combination with FAK tyrosine kinase inhibitors in non-small cell lung cancer","year":2014,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Erlotinib; T790M; Cancer research; Tyrosine kinase; Epidermal growth factor receptor; Medicine; Erlotinib Hydrochloride; EGFR inhibitors; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-kinase inhibitor; Gefitinib; Cancer; Internal medicine; Receptor","score_opus":0.04532424740537488,"score_gpt":0.3983098243007043,"score_spread":0.3529855768953294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1593299612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241436,0.0008024056,0.000075175245,0.0011023902,0.00016132223,0.0024271219,0.000032684376,0.000028368999,0.002956152],"genre_scores_gemma":[0.99740773,0.0005081669,0.00010451317,0.000056320034,0.00023100643,0.0011298385,0.000012215592,0.0000903637,0.0004598596],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955183,0.00035546866,0.000549015,0.0007838134,0.0016234115,0.0011699448],"domain_scores_gemma":[0.9975359,0.000445915,0.00017649445,0.00067269197,0.00083441276,0.00033459644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028573638,0.00028950113,0.0007245173,0.001096036,0.00009154364,0.000046262998,0.0003935961,0.00018882118,0.00048090133],"category_scores_gemma":[0.00034686932,0.00025736084,0.00007221389,0.0022314156,0.00041714616,0.00020751513,0.00017053928,0.001800369,0.000016667109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014446412,0.0010075131,0.2128247,0.0028808285,0.00002567378,0.00009373419,0.0008966609,0.00064733543,0.7617131,0.000021744174,0.0011794146,0.017264664],"study_design_scores_gemma":[0.0053903884,0.00057136157,0.3310405,0.0024898988,0.000010828354,0.0000017537723,0.00016452845,0.0013543906,0.65836775,0.000015195876,0.0003827951,0.00021057972],"about_ca_topic_score_codex":0.020162795,"about_ca_topic_score_gemma":0.017837051,"teacher_disagreement_score":0.1182158,"about_ca_system_score_codex":0.001700926,"about_ca_system_score_gemma":0.0020640537,"threshold_uncertainty_score":0.99998784},"labels":[],"label_agreement":null},{"id":"W1606941281","doi":"10.3390/curroncol13050019","title":"Receptor tyrosine kinases: role in cancer progression.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Medicine; Cancer; Gerontology; Tyrosine kinase; Library science; Oncology; Cancer research; Internal medicine; Receptor","score_opus":0.03675221050722706,"score_gpt":0.34455889534348677,"score_spread":0.3078066848362597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1606941281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9402465,0.011429041,0.0000046486084,0.010017201,0.00045099747,0.0030100762,0.00003394749,0.00015678615,0.0346508],"genre_scores_gemma":[0.9810318,0.00022078668,0.00023265193,0.0002913598,0.0007646315,0.008664075,0.000028320195,0.000039148203,0.008727262],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99829435,0.000049455266,0.0002458356,0.00029748448,0.00048347545,0.00062936725],"domain_scores_gemma":[0.9993796,0.000037626043,0.000043694316,0.0002744523,0.000085174266,0.00017948472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038962904,0.00011933505,0.00022559526,0.00016711743,0.000034427136,0.000025537422,0.00011929275,0.000092220296,0.00056016044],"category_scores_gemma":[0.00013968095,0.000097424825,0.0000463613,0.0005090775,0.000081306316,0.00006497809,0.000055088265,0.0002684126,0.000061800434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026608547,0.0004095567,0.38080192,0.00013707246,0.000012836632,0.000058254904,0.000051899297,0.000010103312,0.001891092,0.0000938271,0.059502408,0.55676496],"study_design_scores_gemma":[0.0013186489,0.00004317764,0.74215394,0.00012756263,0.000010022856,0.0000056545273,0.00002865069,0.00003463595,0.015293213,0.00009652091,0.24077305,0.00011490646],"about_ca_topic_score_codex":0.002229805,"about_ca_topic_score_gemma":0.0005776624,"teacher_disagreement_score":0.55665004,"about_ca_system_score_codex":0.0004909016,"about_ca_system_score_gemma":0.00016667738,"threshold_uncertainty_score":0.61333644},"labels":[],"label_agreement":null},{"id":"W1607152800","doi":"10.3747/co.v13i1.91","title":"Adjuvant Trastuzumab: Progress, Controversies, and the Steps Ahead","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"","keywords":"Trastuzumab; Medicine; Adjuvant; Breast cancer; Oncology; Clinical trial; Internal medicine; Cancer","score_opus":0.09057353432679374,"score_gpt":0.44662414739111606,"score_spread":0.3560506130643223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1607152800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6130257,0.22347765,0.00030085677,0.09322706,0.004254952,0.005927166,0.00008904585,0.0002815678,0.05941596],"genre_scores_gemma":[0.99629384,0.0010408093,0.00012635157,0.000367936,0.0009486664,0.00022856749,0.000033609344,0.000022791046,0.00093739986],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849635,0.00021146708,0.00026911224,0.0002753719,0.00032562212,0.0004220499],"domain_scores_gemma":[0.9989095,0.00050986616,0.0000769199,0.0002571119,0.00012556299,0.00012108464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005691781,0.00013667406,0.00044734517,0.00006528197,0.00010487818,0.000020963218,0.00012742393,0.00009853283,0.00016934636],"category_scores_gemma":[0.00017872226,0.00008459814,0.000071981245,0.00013717967,0.0011711813,0.00003355997,0.000089957175,0.00046889205,0.00004950265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021951094,0.00088511687,0.10026615,0.00030670542,0.00008493822,0.00012359447,0.00050943566,0.0000010442803,0.000101420475,0.011825148,0.28501663,0.5986847],"study_design_scores_gemma":[0.010637106,0.00076541095,0.033923242,0.00008102449,0.000098033765,0.0001194584,0.00017567193,0.00033053645,0.00006783251,0.0006261553,0.95308346,0.00009208148],"about_ca_topic_score_codex":0.00010383711,"about_ca_topic_score_gemma":0.00017189038,"teacher_disagreement_score":0.6680668,"about_ca_system_score_codex":0.0003712319,"about_ca_system_score_gemma":0.0004707371,"threshold_uncertainty_score":0.43152663},"labels":[],"label_agreement":null},{"id":"W1633933096","doi":"10.1016/j.anndiagpath.2015.08.001","title":"Detecting intratumoral heterogeneity in routine breast-HER2 testing: low yield of testing multiple blocks","year":2015,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"American Society of Clinical Oncology","keywords":"Medicine; Breast cancer; Immunohistochemistry; Pathology; Breast carcinoma; Biomarker; Genetic heterogeneity; Cancer; Oncology; Phenotype; Internal medicine; Biology; Gene","score_opus":0.26251326692040067,"score_gpt":0.4016394002811805,"score_spread":0.13912613336077984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1633933096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967275,0.0007203109,0.00008547514,0.00080719125,0.00015327378,0.00047035574,0.0000457691,0.000045156597,0.0009449575],"genre_scores_gemma":[0.9962569,0.00002975006,0.003116281,0.00031125927,0.00017648451,0.00005209563,0.000007955086,0.00003559178,0.000013701218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973453,0.0002503908,0.00083374727,0.00043926283,0.00042846968,0.00070278003],"domain_scores_gemma":[0.98901623,0.008747954,0.0003360574,0.0005147754,0.0010539483,0.00033103017],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0019871995,0.00022669786,0.00074932346,0.00028949094,0.00003244221,0.000007670905,0.00024499814,0.00021147437,0.00002883014],"category_scores_gemma":[0.1404759,0.000219801,0.000083304156,0.0008078262,0.0003122953,0.00006445925,0.00021320336,0.0005618745,0.000011659973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016600087,0.00047379828,0.9345929,0.0002416861,0.000020834244,0.0010169434,0.00032997728,0.00030533975,0.034215078,0.0000043155273,0.00023369619,0.028399436],"study_design_scores_gemma":[0.0023130649,0.0033456523,0.7656386,0.0022417188,0.000042086733,0.0017606008,0.0003046099,0.0026844407,0.22106189,0.00031622293,0.000018255212,0.0002728574],"about_ca_topic_score_codex":0.001559129,"about_ca_topic_score_gemma":0.00038081102,"teacher_disagreement_score":0.18684681,"about_ca_system_score_codex":0.00005198154,"about_ca_system_score_gemma":0.00049443945,"threshold_uncertainty_score":0.8963225},"labels":[],"label_agreement":null},{"id":"W1664877704","doi":"10.1016/j.ejca.2015.06.004","title":"Duration of Trastuzumab. In matters of the heart, one size may not fit all?","year":2015,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Intensive care medicine; Cancer","score_opus":0.11603175485353937,"score_gpt":0.3744749291052125,"score_spread":0.2584431742516732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1664877704","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036215786,0.0016645166,0.000008156344,0.9574599,0.0008803785,0.00041129248,0.00007054384,0.0000047467993,0.0032846797],"genre_scores_gemma":[0.38905448,0.0010888668,0.00063434464,0.5887656,0.0077681663,0.000009746588,0.000009375131,0.00025447225,0.012414902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538743,0.00094470946,0.0013065045,0.00019228534,0.0018470228,0.0003220452],"domain_scores_gemma":[0.9974143,0.00019428736,0.001095986,0.0004565102,0.0007216663,0.00011724046],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002246763,0.00022332616,0.00081737497,0.0002428796,0.000016681885,0.00001733442,0.0005045048,0.000117033655,0.0009085109],"category_scores_gemma":[0.00040953548,0.00014743257,0.00028889885,0.0002672008,0.00021543588,0.00007775448,0.000083956664,0.0023861513,0.000014579993],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042297563,0.00005808806,0.0013865308,0.0005717453,0.00020583368,0.00043442068,0.00068727735,0.00006661216,0.008526036,5.9778426e-7,0.9848778,0.002762048],"study_design_scores_gemma":[0.0019598692,0.00059027475,0.03366721,0.0030820156,0.00017242284,0.00014520633,0.000048155158,0.000005615471,0.0046370067,0.000005284716,0.9555556,0.00013133376],"about_ca_topic_score_codex":0.0001402405,"about_ca_topic_score_gemma":0.000034441415,"teacher_disagreement_score":0.36869425,"about_ca_system_score_codex":0.0005930795,"about_ca_system_score_gemma":0.0011314949,"threshold_uncertainty_score":0.99991536},"labels":[],"label_agreement":null},{"id":"W1679330090","doi":"10.1158/1538-7445.sabcs14-p6-09-07","title":"Abstract P6-09-07: The development of a prediction tool for moderate to severe diarrhea in HER-2/hormone positive metastatic breast cancer (MBC) patients receiving lapatinib in combination with letrozole (L-L)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Lapatinib; Letrozole; Diarrhea; Discontinuation; Internal medicine; Gee; Metastatic breast cancer; Receiver operating characteristic; Cancer; Oncology; Breast cancer; Generalized estimating equation; Statistics; Mathematics","score_opus":0.09324568005919245,"score_gpt":0.40662034562188604,"score_spread":0.31337466556269356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1679330090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99138874,0.0003042108,0.0002767717,0.0029481864,0.00008628836,0.0042098295,0.00038262235,0.000016524307,0.00038683295],"genre_scores_gemma":[0.9938859,0.00008740326,0.00093512423,0.00007942787,0.00007066018,0.004554294,0.00008165292,0.000055881985,0.00024965557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610776,0.0003053126,0.00061059184,0.00048443236,0.0017274617,0.00076441694],"domain_scores_gemma":[0.99697846,0.000385594,0.000110647015,0.0003206832,0.001945564,0.0002590624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033377216,0.00019979794,0.00041276478,0.0005164532,0.00013892206,0.000053329768,0.00025250032,0.000083183426,0.00006501181],"category_scores_gemma":[0.00045798125,0.00014751765,0.00003606559,0.0012435948,0.00013796735,0.00023430653,0.00012077822,0.0006870794,0.000012933979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03602075,0.00349725,0.5509249,0.0021556646,0.0005172001,0.000050944942,0.060791656,0.009217195,0.014830334,0.00008501991,0.010279905,0.3116292],"study_design_scores_gemma":[0.010243357,0.0012300842,0.97127616,0.0021474976,0.000021552441,0.0000051873017,0.0016369586,0.0019303429,0.010683111,0.00011245702,0.00048020724,0.00023306491],"about_ca_topic_score_codex":0.0048370576,"about_ca_topic_score_gemma":0.009719116,"teacher_disagreement_score":0.4203513,"about_ca_system_score_codex":0.0035275177,"about_ca_system_score_gemma":0.003365191,"threshold_uncertainty_score":0.92243356},"labels":[],"label_agreement":null},{"id":"W1724585481","doi":"","title":"Closing the personalized medicine information gap: HER2 test documentation practice.","year":2013,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Toronto; Alberta Bone and Joint Health Institute; Western University; McMaster University; Ontario Institute for Cancer Research; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Stage (stratigraphy); Breast cancer; Cancer; Immunohistochemistry; Fluorescence in situ hybridization; Adjuvant therapy; Disease; Companion diagnostic; Gene","score_opus":0.056645168947227396,"score_gpt":0.3604705696905919,"score_spread":0.3038254007433645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1724585481","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08479587,0.0013948265,0.00075579766,0.53326607,0.0009584417,0.011243212,0.000010350496,0.00030645623,0.36726898],"genre_scores_gemma":[0.98267406,0.00035110372,0.0004025179,0.00850683,0.0006189252,0.004342243,0.00006236697,0.0000211271,0.003020804],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981615,0.000111388385,0.0003378565,0.00013558549,0.00085968216,0.00039396365],"domain_scores_gemma":[0.9980968,0.0007245921,0.0001548617,0.00029772863,0.000532837,0.00019313364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013024405,0.000114358554,0.00016559016,0.000116051604,0.00013528348,0.00013000936,0.00012892198,0.0000614094,0.0013733251],"category_scores_gemma":[0.005882739,0.00007004374,0.000035689834,0.0004388674,0.00016371452,0.0012791773,0.000039660095,0.00030229776,0.00049110304],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019977389,0.00011191879,0.010602857,0.0002260909,0.00010967733,0.000007342473,0.00482341,0.0000032093408,0.00048749222,0.00087388756,0.18490689,0.7976475],"study_design_scores_gemma":[0.0034501478,0.00018028087,0.3837565,0.00009432858,0.00014158162,0.00014656258,0.0054237163,0.00045365695,0.00059968623,0.00042772124,0.6051697,0.00015612334],"about_ca_topic_score_codex":0.0013727971,"about_ca_topic_score_gemma":0.000015450934,"teacher_disagreement_score":0.8978782,"about_ca_system_score_codex":0.00030540544,"about_ca_system_score_gemma":0.00010075973,"threshold_uncertainty_score":0.99953955},"labels":[],"label_agreement":null},{"id":"W1748137726","doi":"10.1200/jco.2014.32.18_suppl.lba4","title":"First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Hazard ratio; Regimen; Clinical endpoint; Oncology; Anthracycline; Gastroenterology; Breast cancer; Cancer; Confidence interval; Clinical trial","score_opus":0.27672095696187204,"score_gpt":0.4792496435740614,"score_spread":0.20252868661218937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1748137726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810945,0.00069066376,0.00010523335,0.015359561,0.00042784668,0.0017083749,0.00031891323,0.000009027753,0.00028590474],"genre_scores_gemma":[0.9906993,0.0067951456,0.000369745,0.0005518329,0.0014042106,0.00006368158,0.000033562854,0.000040040413,0.000042495616],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9926824,0.002188846,0.0031955033,0.00043216444,0.0010473597,0.000453732],"domain_scores_gemma":[0.9853062,0.010041793,0.0028800038,0.0006511282,0.0008785874,0.00024227916],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057642963,0.00034156034,0.002863874,0.000112601934,0.00011044671,0.00002532268,0.00066528906,0.0003357883,0.000093934774],"category_scores_gemma":[0.0009352971,0.00015300924,0.000416298,0.00047971675,0.0009274644,0.00012824476,0.000051060673,0.0011744893,0.0000040005684],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61690706,0.02544352,0.048386835,0.000051064602,0.0018980918,0.00020563403,0.014038696,0.00023316176,0.0016683851,0.0000519421,0.00061798556,0.29049766],"study_design_scores_gemma":[0.35768485,0.09250093,0.5382621,0.0014134846,0.0003366209,0.00010186728,0.0017225777,0.0008287623,0.0023653095,0.00016076553,0.0044063884,0.00021628197],"about_ca_topic_score_codex":0.0062468983,"about_ca_topic_score_gemma":0.006474436,"teacher_disagreement_score":0.48987532,"about_ca_system_score_codex":0.00052548526,"about_ca_system_score_gemma":0.0023841355,"threshold_uncertainty_score":0.94434834},"labels":[],"label_agreement":null},{"id":"W1766320810","doi":"10.1111/j.1365-2559.2010.03602.x","title":"A novel method of cell embedding for tissue microarrays","year":2010,"lang":"en","type":"letter","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Embedding; Computer science; Content (measure theory); Information retrieval; DNA microarray; Tissue microarray; Computational biology; Artificial intelligence; Biology; Pathology; Medicine; Mathematics; Genetics; Gene expression; Gene; Immunohistochemistry","score_opus":0.05416591762640351,"score_gpt":0.40508664235903413,"score_spread":0.35092072473263064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1766320810","genre_codex":"commentary","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005429243,0.0022681798,0.44550845,0.51357746,0.0059042173,0.003838833,0.0010139085,0.00016799517,0.027178025],"genre_scores_gemma":[0.00009332576,0.00004646059,0.69160026,0.24790594,0.0052530942,0.0004596894,0.0004716443,0.00025515343,0.05391442],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974101,0.00013912164,0.00058620365,0.00076561514,0.00037318148,0.0007257765],"domain_scores_gemma":[0.99764794,0.00052393455,0.0003378164,0.0010000744,0.00038249706,0.00010776331],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00094702904,0.00035178743,0.0012039411,0.00050885003,0.00006630931,0.0000073034244,0.0004178973,0.002902249,0.0006436513],"category_scores_gemma":[0.0004181962,0.00034615904,0.00027064007,0.00015167335,0.00033795563,0.000019038844,0.000119753604,0.0045518363,0.00007628206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004867045,0.00004357459,0.0000121407,0.0014905855,0.0000045108413,0.00037531942,0.0002046472,2.7084354e-7,0.5294265,0.000012626978,0.4669429,0.0014382565],"study_design_scores_gemma":[0.0011436937,0.0005687948,0.00004669613,0.00011976912,0.0001863966,0.0019496604,0.000012172552,0.0000323899,0.07040333,0.000055878052,0.92523783,0.00024340521],"about_ca_topic_score_codex":0.000121389414,"about_ca_topic_score_gemma":0.00001801643,"teacher_disagreement_score":0.45902318,"about_ca_system_score_codex":0.00021407784,"about_ca_system_score_gemma":0.00068994664,"threshold_uncertainty_score":0.999899},"labels":[],"label_agreement":null},{"id":"W1782943140","doi":"10.1309/ajcpt41tcbuevdqc","title":"Advantages and Disadvantages of Technologies for HER2 Testing in Breast Cancer Specimens: Table 1","year":2015,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Lapatinib; Trastuzumab; Breast cancer; Medicine; Human Epidermal Growth Factor Receptor 2; Standardization; Medical physics; Oncology; Cancer; Internal medicine; Computer science","score_opus":0.24146479820065314,"score_gpt":0.5770063516071183,"score_spread":0.3355415534064652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1782943140","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003444796,0.99371296,0.000040580457,0.0013096301,0.00035265612,0.0007175393,0.00025454053,0.000020915315,0.00014636363],"genre_scores_gemma":[0.0010177519,0.9884162,0.009841939,0.000078862366,0.00045632044,0.00005933365,0.000005345079,0.000066784894,0.000057483616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99512297,0.0005585441,0.0029734625,0.0004514408,0.000391564,0.00050203584],"domain_scores_gemma":[0.99117225,0.0044465307,0.0030146004,0.00040935198,0.00073057547,0.00022671369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00418694,0.00034314353,0.0059982655,0.000519452,0.000023002998,0.000009365554,0.00041639814,0.000359344,0.00001987644],"category_scores_gemma":[0.0068914574,0.00023513554,0.0004185914,0.000753912,0.0022132343,0.00007450253,0.0002164692,0.001730582,0.0000019075355],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030012018,0.00019478664,0.031876154,0.0037786895,0.00014303651,0.0005283521,0.000021945714,9.94152e-7,0.00000814216,0.000010487742,0.00054930337,0.962588],"study_design_scores_gemma":[0.0027123925,0.008370108,0.0062918905,0.029659836,0.0012750458,0.00856985,0.0013747455,0.0000069504667,0.000004783096,0.00039253544,0.9409279,0.0004139131],"about_ca_topic_score_codex":0.00005518458,"about_ca_topic_score_gemma":0.000014285675,"teacher_disagreement_score":0.96217406,"about_ca_system_score_codex":0.00017864289,"about_ca_system_score_gemma":0.0021421534,"threshold_uncertainty_score":0.9588549},"labels":[],"label_agreement":null},{"id":"W1797772724","doi":"10.1200/jco.2006.24.18_suppl.514","title":"ER+ PR- breast cancer defines a unique subtype of breast cancer that is driven by growth factor signaling and may be more likely to respond to EGFR targeted therapies","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Breast cancer; Gefitinib; Tissue microarray; Cancer; Internal medicine; Oncology; Estrogen receptor; Microarray; Cancer research; Immunohistochemistry; Epidermal growth factor receptor; Fulvestrant; Pathology; Gene expression; Biology; Gene","score_opus":0.11404282470768969,"score_gpt":0.4747955722268884,"score_spread":0.3607527475191987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1797772724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8223865,0.0021255512,0.000090607384,0.17390734,0.00036561614,0.00042511252,0.0005841689,0.000012338033,0.00010276089],"genre_scores_gemma":[0.9823811,0.0020617482,0.0024370593,0.011098275,0.0012009782,0.000034884983,0.000004511903,0.000058565005,0.00072289637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596244,0.0005457503,0.0017355051,0.0003914075,0.0008503074,0.0005145618],"domain_scores_gemma":[0.99491763,0.0016268367,0.0009960032,0.00024410877,0.0014653297,0.00075009075],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001707064,0.0002721317,0.0017191551,0.00033005583,0.00006300765,0.000025267147,0.00033902502,0.00047315983,0.0011796664],"category_scores_gemma":[0.0006543325,0.00019460566,0.00029692618,0.00047242935,0.0003539124,0.00013681207,0.00012711815,0.0010663086,0.000004652347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014086675,0.0007598442,0.8330783,0.0001664917,0.00062051264,0.00021393102,0.0010181832,0.000034094734,0.042756468,0.000050208153,0.069442935,0.037772324],"study_design_scores_gemma":[0.0038857255,0.0041118856,0.9381608,0.0006329656,0.00022263848,0.00034348672,0.00025482877,0.000021639562,0.008047585,0.0001772957,0.043903835,0.00023734345],"about_ca_topic_score_codex":0.0038648322,"about_ca_topic_score_gemma":0.0013284246,"teacher_disagreement_score":0.16280906,"about_ca_system_score_codex":0.00047766982,"about_ca_system_score_gemma":0.0030965968,"threshold_uncertainty_score":0.9997334},"labels":[],"label_agreement":null},{"id":"W1813373450","doi":"","title":"ST6GAL1, COX-2 AND HB-EGF MRNA EXPRESSION IN BREAST CANCER SAMPLES FROM KASHAN, IRAN","year":2015,"lang":"en","type":"article","venue":"Middle East journal of cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Breast cancer; Proportional hazards model; Correlation; Histology; Immunohistochemistry; Metastasis; Cancer; Pathology; Reverse transcriptase; Internal medicine; Oncology; Gene; Biology; Polymerase chain reaction; Genetics","score_opus":0.16282187968548853,"score_gpt":0.3785528154159658,"score_spread":0.21573093573047727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1813373450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93794477,0.05353337,0.00009405636,0.0061764647,0.0008937074,0.0002845718,0.00030319596,0.000015983902,0.0007538774],"genre_scores_gemma":[0.99112475,0.004439399,0.0008732456,0.0006134302,0.002242959,0.000041150633,0.0000069613297,0.000061391605,0.00059672294],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99715245,0.00015624038,0.00068625616,0.00030474173,0.001204913,0.00049540977],"domain_scores_gemma":[0.99792105,0.00008275156,0.00033688432,0.00028011322,0.0005970772,0.00078212906],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007135832,0.00024349515,0.00065830495,0.00031225217,0.000054687043,0.00005555,0.00026507466,0.00015542787,0.001375126],"category_scores_gemma":[0.00013830472,0.00018847553,0.00010208521,0.0003364321,0.00017294523,0.00029165993,0.00011248745,0.00085257296,0.000013462812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025780497,0.00018654045,0.8855082,0.00016687361,0.00014251226,0.0003161579,0.0033222479,0.00021717306,0.023478711,0.00001141447,0.013262403,0.07080974],"study_design_scores_gemma":[0.017606594,0.00067037233,0.8424481,0.012465271,0.0002499741,0.0006871214,0.0047433604,0.000567505,0.016259558,0.0008374812,0.10280089,0.00066377484],"about_ca_topic_score_codex":0.00444259,"about_ca_topic_score_gemma":0.0024225195,"teacher_disagreement_score":0.089538485,"about_ca_system_score_codex":0.00075873226,"about_ca_system_score_gemma":0.001295712,"threshold_uncertainty_score":0.99953777},"labels":[],"label_agreement":null},{"id":"W1857349325","doi":"10.14740/wjon919w","title":"Trastuzumab Exposure in Early Pregnancy for a Young Lady With Locally Invasive Breast Cancer","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Pregnancy; Breast cancer; Adjuvant; Oncology; Obstetrics; Cancer; Internal medicine; Gynecology","score_opus":0.061963999291913215,"score_gpt":0.3812725102733918,"score_spread":0.3193085109814786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1857349325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619731,0.0066521023,0.00059492217,0.019507574,0.00094775896,0.0016486209,0.00004443734,0.000018404091,0.008613119],"genre_scores_gemma":[0.99475473,0.00030177922,0.0021014034,0.00037813777,0.0005878153,0.000120369754,0.0000015725947,0.000039037302,0.0017151629],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981322,0.00014393356,0.0005562609,0.00018968151,0.00052692165,0.0004509603],"domain_scores_gemma":[0.99784184,0.00022092467,0.0003244368,0.00016702231,0.0010417553,0.0004039977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007270681,0.00015344335,0.000644864,0.00045511356,0.000028826955,0.000017138993,0.00021571552,0.00011099898,0.00012508956],"category_scores_gemma":[0.00017805435,0.0001108118,0.00008841352,0.0004775105,0.00014839844,0.00014297143,0.00003342783,0.00070779416,0.0000063228167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01265117,0.0009308032,0.8471868,0.00025807868,0.000335066,0.003918796,0.005178264,0.0001935329,0.00075664703,0.00012546875,0.017126994,0.11133836],"study_design_scores_gemma":[0.059341747,0.04577764,0.791363,0.008890532,0.00044281952,0.0148813035,0.0027499702,0.00008005762,0.0010775874,0.00063486776,0.07422307,0.00053741847],"about_ca_topic_score_codex":0.00037629693,"about_ca_topic_score_gemma":0.019384865,"teacher_disagreement_score":0.110800944,"about_ca_system_score_codex":0.0017476844,"about_ca_system_score_gemma":0.0067079156,"threshold_uncertainty_score":0.9989231},"labels":[],"label_agreement":null},{"id":"W1859048196","doi":"","title":"À la recherche des patientes présentant un cancer HER2/neu positif : analyse rétrospective","year":2006,"lang":"fr","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Gynecology; Trastuzumab; Cancer; Breast cancer; Internal medicine","score_opus":0.20681717962571394,"score_gpt":0.46654891486572586,"score_spread":0.2597317352400119,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1859048196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6506343,0.10991029,0.0018199462,0.015094595,0.0018105867,0.0016815907,0.0003243829,0.00025855948,0.21846578],"genre_scores_gemma":[0.89308894,0.008261018,0.0107585145,0.0006880112,0.0023091834,0.0002649428,0.00005215534,0.00015184701,0.08442541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99429715,0.0018490265,0.00067802606,0.00082049245,0.000963316,0.0013919738],"domain_scores_gemma":[0.99633545,0.0017008943,0.00013875983,0.0006421336,0.00069586834,0.00048690164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002113909,0.00047061214,0.00065843633,0.00025777178,0.0002176325,0.00012648373,0.00031606917,0.000649844,0.01498835],"category_scores_gemma":[0.0008030189,0.00041018715,0.0002848704,0.001515182,0.0010392544,0.00021853752,0.00018244369,0.0017662372,0.00052368216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006472463,0.0020054304,0.590314,0.00085941097,0.00088588684,0.0011280284,0.0038718812,0.00013730444,0.014478299,0.0049970374,0.044327956,0.33634755],"study_design_scores_gemma":[0.005972031,0.0024014013,0.57983124,0.0042708106,0.0015603333,0.00037318288,0.010869978,0.004338176,0.2829794,0.024076572,0.08177293,0.0015539654],"about_ca_topic_score_codex":0.1036831,"about_ca_topic_score_gemma":0.019994212,"teacher_disagreement_score":0.3347936,"about_ca_system_score_codex":0.0062074857,"about_ca_system_score_gemma":0.0012706339,"threshold_uncertainty_score":0.999835},"labels":[],"label_agreement":null},{"id":"W1861748936","doi":"10.1158/1078-0432.ccr-15-0468","title":"Preclinical Efficacy and Safety Assessment of an Antibody–Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Takeda Pharmaceuticals International","keywords":"Breast cancer; Medicine; Antibody-drug conjugate; Cancer; Cancer research; Tissue microarray; Antibody; Immunohistochemistry; Cytotoxic T cell; Pharmacology; Pathology; Internal medicine; Monoclonal antibody; Immunology; In vitro; Biology","score_opus":0.3735274212817079,"score_gpt":0.6302471702096378,"score_spread":0.2567197489279299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1861748936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97296834,0.0018310108,0.00013022813,0.015148431,0.000386974,0.007891404,0.00035993662,0.00004570695,0.0012379676],"genre_scores_gemma":[0.99286634,0.00081253564,0.002131797,0.0003159737,0.0020222615,0.0011128958,0.000080751975,0.000085668726,0.0005717897],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915965,0.0024366386,0.0016485275,0.0010509581,0.0021761907,0.0010911683],"domain_scores_gemma":[0.98886627,0.0057860245,0.0002523708,0.001134667,0.0026503915,0.001310293],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.03278156,0.00026127236,0.0009780125,0.00015480703,0.0003222555,0.000090184185,0.00074301625,0.00027306555,0.0002444171],"category_scores_gemma":[0.006322674,0.00017344914,0.00023175217,0.000577134,0.0022000808,0.00013740337,0.000636213,0.002164004,0.00001136303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022906154,0.002251264,0.79078877,0.0015859389,0.00041778796,0.000091080154,0.0008002835,0.00004924801,0.006313026,0.00059024215,0.019826217,0.15437998],"study_design_scores_gemma":[0.03143685,0.011788653,0.84001094,0.0012014337,0.0002516979,0.00011104532,0.0014299812,0.016932268,0.0043891002,0.0009104755,0.090924054,0.0006135251],"about_ca_topic_score_codex":0.0009771547,"about_ca_topic_score_gemma":0.00015606078,"teacher_disagreement_score":0.15376645,"about_ca_system_score_codex":0.0003840755,"about_ca_system_score_gemma":0.0056003206,"threshold_uncertainty_score":0.99595493},"labels":[],"label_agreement":null},{"id":"W1867789233","doi":"10.1200/jco.2012.30.15_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lapatinib; Capecitabine; Medicine; Trastuzumab emtansine; Trastuzumab; Oncology; Internal medicine; Metastatic breast cancer; Breast cancer; Cancer; Gynecology; Colorectal cancer","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1867789233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W1889879569","doi":"10.14740/wjon934w","title":"FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?","year":2015,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Genotype; Oncology; Internal medicine; Single-nucleotide polymorphism; Allele; Cancer; Gene; Genetics; Biology","score_opus":0.02091081476966107,"score_gpt":0.33976451593695634,"score_spread":0.3188537011672953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1889879569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9826279,0.000605842,0.00006952891,0.014944172,0.0002889255,0.00047475245,0.00015217911,0.0000073304386,0.00082933175],"genre_scores_gemma":[0.9970461,0.000056089462,0.0011295131,0.0011661053,0.00027971863,0.000020146172,0.0000039475226,0.00003092124,0.00026745824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976994,0.0005529556,0.000453621,0.00024495434,0.00068446546,0.00036465065],"domain_scores_gemma":[0.9979463,0.0003707289,0.00022892065,0.0001578078,0.000605361,0.00069087656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009825618,0.0001659557,0.000616623,0.0006044373,0.000034667803,0.000014158081,0.00015282969,0.00009393936,0.0001268254],"category_scores_gemma":[0.00019858252,0.0001253932,0.00004340014,0.0005115787,0.00019565871,0.00011563181,0.00007147047,0.00067069154,0.000007835981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14588,0.0009260027,0.7761589,0.000009043228,0.00029924113,0.0010994531,0.006090302,0.00019895798,0.0006207078,0.000010432769,0.006245376,0.062461536],"study_design_scores_gemma":[0.011632377,0.013714817,0.96327573,0.00046483075,0.000102494174,0.00025027175,0.0005566463,0.00002911245,0.00019928091,0.000051967552,0.009603785,0.0001186722],"about_ca_topic_score_codex":0.0014234764,"about_ca_topic_score_gemma":0.0014364904,"teacher_disagreement_score":0.1871168,"about_ca_system_score_codex":0.0029383402,"about_ca_system_score_gemma":0.0026187124,"threshold_uncertainty_score":0.76836574},"labels":[],"label_agreement":null},{"id":"W1900170853","doi":"10.1038/sj.bjc.6603295","title":"Expression of oestrogen receptor-β in oestrogen receptor-α negative human breast tumours","year":2006,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Medical Research and Materiel Command; Canadian Institutes of Health Research; Strong; CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Oestrogen receptor; Phenotype; Estrogen receptor; Basal (medicine); Receptor; Progesterone receptor; Internal medicine; Breast cancer; Tissue microarray; Biology; Mammary gland; Gene isoform; Estrogen receptor alpha; Endocrinology; Estrogen; Cancer research; Immunohistochemistry; Medicine; Gene; Cancer; Genetics","score_opus":0.018497775031478175,"score_gpt":0.3388497727771877,"score_spread":0.32035199774570955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1900170853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801327,0.008871546,0.000013234773,0.0007082072,0.00027074353,0.00032576337,0.00015483501,0.000012944247,0.0016294561],"genre_scores_gemma":[0.99514765,0.0015407609,0.0012256005,0.000067351466,0.0012521609,0.000028258146,0.000016510625,0.000057748424,0.00066398917],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969961,0.00019931502,0.0009936183,0.0002554235,0.0010823137,0.00047320043],"domain_scores_gemma":[0.998149,0.00007120737,0.00057778176,0.00019426136,0.0007502776,0.00025747364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006934535,0.00018449675,0.00066343514,0.0002770986,0.000074859985,0.000043899116,0.00029875652,0.0001496611,0.002189304],"category_scores_gemma":[0.00012315271,0.00019407744,0.0002287428,0.000431593,0.00023504507,0.00023274569,0.00006379096,0.0008056241,0.00001019014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096407946,0.0006064177,0.46671823,0.00024373535,0.00009671466,0.00070717186,0.00026336545,0.0001521754,0.40578574,0.00004163915,0.07018015,0.054240603],"study_design_scores_gemma":[0.007963993,0.0008285242,0.47213688,0.0111242775,0.00010165192,0.0032578872,0.0005632738,0.000007728682,0.48441577,0.0005140746,0.018691456,0.00039447565],"about_ca_topic_score_codex":0.00707795,"about_ca_topic_score_gemma":0.001335904,"teacher_disagreement_score":0.07863004,"about_ca_system_score_codex":0.00066514855,"about_ca_system_score_gemma":0.0007977664,"threshold_uncertainty_score":0.999534},"labels":[],"label_agreement":null},{"id":"W1915169570","doi":"10.1186/1472-6890-6-2","title":"Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer","year":2006,"lang":"en","type":"article","venue":"BMC Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Manitoba","funders":"Manitoba Medical Service Foundation","keywords":"Medicine; Breast cancer; Immunohistochemistry; Oncology; Cancer; Internal medicine; Pathology","score_opus":0.09186309284021754,"score_gpt":0.4781727390351837,"score_spread":0.38630964619496616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1915169570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429697,0.00014688606,0.000022372315,0.0010069287,0.000103016515,0.0004583986,0.00008708217,0.000012337566,0.0038660162],"genre_scores_gemma":[0.99781024,0.0002392995,0.0010353727,0.00021253832,0.00017721542,0.0001163405,0.000070203845,0.000018104149,0.00032070884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99731946,0.0005760018,0.0010368025,0.00033481765,0.00032362685,0.00040930766],"domain_scores_gemma":[0.9983153,0.0008749568,0.00018616571,0.00045895964,0.000107804015,0.000056842004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019707857,0.00011698874,0.00045779021,0.000095247124,0.00002107596,0.000004884835,0.00021852214,0.00020219151,0.00046818884],"category_scores_gemma":[0.0003728582,0.000092458184,0.00009484331,0.00025886192,0.00035928393,0.0000248095,0.000080682024,0.0004852985,0.000026074082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045816842,0.00064235495,0.9497791,0.00012438651,0.0000036128351,0.00018366415,0.000099418525,0.000005062789,0.03980077,0.000026976762,0.0010769939,0.007799516],"study_design_scores_gemma":[0.0028320188,0.00019421612,0.99542487,0.00011906733,0.000015602578,0.000076317185,0.000076319346,0.00027109153,0.00028996795,0.0002441143,0.00037653357,0.00007987054],"about_ca_topic_score_codex":0.0033072457,"about_ca_topic_score_gemma":0.0008799047,"teacher_disagreement_score":0.045645807,"about_ca_system_score_codex":0.00024151136,"about_ca_system_score_gemma":0.0004126507,"threshold_uncertainty_score":0.5126339},"labels":[],"label_agreement":null},{"id":"W1930155869","doi":"","title":"Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Toxicity; Breast cancer; Cancer; Medicine; Internal medicine; Endocrinology; Cancer research; Pathology; Receptor","score_opus":0.033976140266475524,"score_gpt":0.31475742855074706,"score_spread":0.2807812882842715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1930155869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99208784,0.00064224546,0.000068014044,0.0014188449,0.0004998576,0.003675522,0.0005993538,0.00010828153,0.00090003136],"genre_scores_gemma":[0.99630755,0.0001245825,0.00051236403,0.000617815,0.00041997107,0.0013027418,0.000036144273,0.00011627159,0.00056257925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952071,0.0005053072,0.000805142,0.0009616983,0.0009070913,0.0016136841],"domain_scores_gemma":[0.9970519,0.00043474644,0.00027061877,0.00046844178,0.00049990864,0.001274395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000669131,0.0005671934,0.0011567394,0.00043727172,0.00026273268,0.000084752995,0.00033644834,0.00020660466,0.00030233833],"category_scores_gemma":[0.0009412728,0.00054188096,0.00016123595,0.00068971654,0.00032432866,0.0003540099,0.00024253743,0.000681797,0.000028152946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014393803,0.00081592676,0.52344733,0.0033741659,0.00066297204,0.00040661768,0.001833617,0.0000015126237,0.43323985,0.0003329868,0.0013497686,0.033095848],"study_design_scores_gemma":[0.0020111548,0.00032169188,0.552988,0.00021868742,0.00007353779,0.00015311086,0.000037783262,0.0000028919953,0.44358763,0.000007980666,0.00026856613,0.00032899994],"about_ca_topic_score_codex":0.0017388598,"about_ca_topic_score_gemma":0.00029909238,"teacher_disagreement_score":0.03276685,"about_ca_system_score_codex":0.00057567435,"about_ca_system_score_gemma":0.00028913273,"threshold_uncertainty_score":0.9997033},"labels":[],"label_agreement":null},{"id":"W1932286144","doi":"10.1111/his.12723","title":"Impact of the 2013 <scp>A</scp>merican <scp>S</scp>ociety of <scp>C</scp>linical <scp>O</scp>ncology/<scp>C</scp>ollege of <scp>A</scp>merican <scp>P</scp>athologists guideline recommendations for human epidermal growth factor receptor 2 (<scp>HER</scp>2) testing of invasive breast carcinoma: a focus on tumours assessed as ‘equivocal’ for <scp>HER</scp>2 gene amplification by fluorescence <i>in‐situ</i> hybridization","year":2015,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Pathological; Oncology; Cancer","score_opus":0.07644435501988396,"score_gpt":0.36364471400517234,"score_spread":0.2872003589852884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1932286144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9500321,0.004640211,0.009595064,0.0011992205,0.002998704,0.01287006,0.010523218,0.00089022174,0.007251187],"genre_scores_gemma":[0.9487028,0.0021996358,0.025471361,0.0018574276,0.002453225,0.0042888396,0.0064982637,0.0016116909,0.006916752],"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.96252155,0.006325245,0.011348621,0.0069429185,0.0050045797,0.007857099],"domain_scores_gemma":[0.8940721,0.07110724,0.01337224,0.0062438194,0.011621761,0.0035828198],"candidate_categories":["metaresearch","metaepi_narrow","sts","open_science","research_integrity"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.012194912,0.004749561,0.0092887655,0.0036792653,0.0018586599,0.00036539105,0.0064216126,0.004010085,0.000042167543],"category_scores_gemma":[0.21424286,0.004600408,0.0035641496,0.00816656,0.0073284027,0.0017585229,0.0024451339,0.005764114,0.00020484647],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00008199372,0.0058262055,0.12324458,0.0018068011,0.00070842897,0.0002721378,0.011640368,0.0008707126,0.36511353,0.0006158065,0.48862553,0.0011938905],"study_design_scores_gemma":[0.033468403,0.027555287,0.34034172,0.0030154483,0.0042564524,0.0038713492,0.05471759,0.0041365824,0.37267905,0.0033483151,0.15178393,0.00082586374],"about_ca_topic_score_codex":0.005487276,"about_ca_topic_score_gemma":0.0010132277,"teacher_disagreement_score":0.3368416,"about_ca_system_score_codex":0.0055791894,"about_ca_system_score_gemma":0.009376525,"threshold_uncertainty_score":0.9994408},"labels":[],"label_agreement":null},{"id":"W1941265576","doi":"10.1007/s00280-015-2761-4","title":"A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck","year":2015,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"Symphogen; Merck KGaA","keywords":"Medicine; Tolerability; Cetuximab; Internal medicine; Epidermal growth factor receptor; Adverse effect; Oncology; Head and neck cancer; Antibody; Head and neck squamous-cell carcinoma; Monoclonal antibody; Gastroenterology; Cancer; Immunology","score_opus":0.0269664643091963,"score_gpt":0.35541487793565163,"score_spread":0.3284484136264553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941265576","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99371374,0.0026298582,0.0000020322107,0.0013952091,0.0003013877,0.001680512,0.00004788715,0.0000026418263,0.00022675001],"genre_scores_gemma":[0.99899703,0.000120801444,0.000016899892,0.0005931526,0.00010508345,0.000037806025,0.0000025303943,0.00001832025,0.00010838378],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99887896,0.00016460152,0.00027490853,0.00020066039,0.000277701,0.0002031803],"domain_scores_gemma":[0.99925566,0.00006484044,0.00019871899,0.0002008663,0.00019797779,0.00008196826],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019733739,0.0001304272,0.00043384178,0.000047059875,0.000023633096,0.0000021633089,0.00015838165,0.00010728709,0.000085856074],"category_scores_gemma":[0.000015107636,0.000071354254,0.000045041183,0.00027449682,0.0006045526,0.000028873677,0.00005065517,0.00026430745,4.219146e-8],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031375274,0.0008332707,0.9132078,0.0006345057,0.000067276946,0.0000024635003,0.003968159,0.000031817613,0.044370253,0.0000056634576,0.0019464882,0.0035570222],"study_design_scores_gemma":[0.13394783,0.0031297011,0.20912224,0.00013603824,0.000083647676,0.0000030284714,0.00010563892,0.00006483083,0.6512954,0.00001921222,0.0019971216,0.00009530587],"about_ca_topic_score_codex":0.00036550494,"about_ca_topic_score_gemma":0.000035614365,"teacher_disagreement_score":0.7040856,"about_ca_system_score_codex":0.00006779959,"about_ca_system_score_gemma":0.0005816299,"threshold_uncertainty_score":0.2909742},"labels":[],"label_agreement":null},{"id":"W1941925635","doi":"10.1158/1538-7445.sabcs14-ot3-1-10","title":"Abstract OT3-1-10: HERmione: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with physician's choice of chemotherapy plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer, previously treated with pe","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Vinorelbine; Capecitabine; Internal medicine; Anthracycline; Oncology; Metastatic breast cancer; Taxane; Trastuzumab emtansine; Chemotherapy; Breast cancer; Lapatinib; Cancer; Colorectal cancer","score_opus":0.14428242805559724,"score_gpt":0.4836444026667105,"score_spread":0.3393619746111133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1941925635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97238463,0.005107907,0.00021607064,0.0018560811,0.00011101258,0.016742548,0.0003881923,0.000087712004,0.0031058486],"genre_scores_gemma":[0.9867595,0.0032675602,0.00067267026,0.0002021313,0.00051999,0.006225764,0.0001571364,0.0002904925,0.001904744],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9902269,0.0012923154,0.00149602,0.0015844058,0.003383456,0.0020168899],"domain_scores_gemma":[0.9930672,0.0013617577,0.0006193042,0.0011343342,0.0027186144,0.0010987571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042215404,0.00085038424,0.0036512539,0.0007835397,0.00025592724,0.00023368423,0.0010474344,0.00021184445,0.00075257756],"category_scores_gemma":[0.00041276487,0.0006287985,0.00019172211,0.0030387242,0.0020471811,0.0007536518,0.00027803646,0.002074497,0.000027748825],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9183907,0.0050821295,0.0007647016,0.001098661,0.0011529482,0.0008211931,0.0027915116,0.002673449,0.0033057118,0.000014431058,0.0015852028,0.062319398],"study_design_scores_gemma":[0.96442604,0.009596747,0.0018018545,0.008061421,0.00029768344,0.00012324272,0.0018081772,0.0046906034,0.007616558,0.000038020735,0.00077152305,0.0007681173],"about_ca_topic_score_codex":0.036009096,"about_ca_topic_score_gemma":0.008459313,"teacher_disagreement_score":0.06155128,"about_ca_system_score_codex":0.0059206346,"about_ca_system_score_gemma":0.01272497,"threshold_uncertainty_score":0.9996163},"labels":[],"label_agreement":null},{"id":"W1963526316","doi":"10.1371/journal.pone.0064817","title":"Odin (ANKS1A) Modulates EGF Receptor Recycling and Stability","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Hospital for Sick Children","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"HEK 293 cells; Endosome; Cell biology; Internalization; Epidermal growth factor receptor; Receptor; Endocytic cycle; Epidermal growth factor; Gene knockdown; Phosphorylation; Receptor tyrosine kinase; Biology; MAPK/ERK pathway; Tyrosine kinase; Signal transduction; Chemistry; Cell culture; Endocytosis; Biochemistry; Intracellular","score_opus":0.1547145327569723,"score_gpt":0.32065561314635765,"score_spread":0.16594108038938535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963526316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892666,0.0005938575,0.00000790707,0.005655034,0.00003528331,0.00085785275,0.000009218831,0.00009483554,0.00347943],"genre_scores_gemma":[0.99105984,0.0004291692,0.0065565063,0.00021069049,0.00023529932,0.00012764068,0.0000119952365,0.00003195955,0.0013368761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985006,0.000071547496,0.00023264902,0.000336962,0.00051309954,0.00034517658],"domain_scores_gemma":[0.9988626,0.00017818486,0.000035683686,0.00042152507,0.00022912063,0.00027283226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042472497,0.0001156958,0.00030962314,0.00006654663,0.00006432276,0.000041938587,0.00008592413,0.00009921732,0.0045235786],"category_scores_gemma":[0.0008089721,0.00010159183,0.00003172749,0.00015552122,0.0001281744,0.00011668986,0.00008814983,0.00034241602,0.0005763919],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009515007,0.0011879529,0.247178,0.0009044893,0.00017698815,0.0000044695157,0.0005733855,2.6763064e-7,0.73341715,0.000030164723,0.0023188477,0.0141131235],"study_design_scores_gemma":[0.002062498,0.00094146543,0.115375414,0.0013064848,0.0001467669,0.0000060896728,0.00042706158,0.0037514756,0.87204987,0.0014267336,0.002101304,0.0004048324],"about_ca_topic_score_codex":0.0003590127,"about_ca_topic_score_gemma":0.0000148477775,"teacher_disagreement_score":0.13863271,"about_ca_system_score_codex":0.00013873221,"about_ca_system_score_gemma":0.00007679517,"threshold_uncertainty_score":0.9963864},"labels":[],"label_agreement":null},{"id":"W1963612017","doi":"10.1097/00129039-200409000-00011","title":"Her2 Amplification","year":2004,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cegep de Sept Iles","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; Concordance; Fish <Actinopterygii>; Fluorescence in situ hybridization; Gene duplication; Biology; Molecular biology; In situ hybridization; Pathology; Medicine; Gene; Bioinformatics; Genetics; Gene expression; Chromosome; Fishery","score_opus":0.013604345253688015,"score_gpt":0.3185765279131056,"score_spread":0.30497218265941756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963612017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94425184,0.0012117912,0.0072411452,0.0020430894,0.00013719303,0.0006432222,0.0000078683015,0.00018438537,0.044279452],"genre_scores_gemma":[0.9921938,0.00004947504,0.004806708,0.0015137681,0.000091748065,0.00036268332,0.00020545101,0.00007511113,0.0007012334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799055,0.000019259252,0.00038587232,0.00063727674,0.00040906918,0.00055796193],"domain_scores_gemma":[0.9983272,0.00002034647,0.00010804632,0.0012023156,0.00013846201,0.00020363294],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020583662,0.00026464235,0.0003776124,0.00008716234,0.00010436487,0.000019004678,0.0003257461,0.00031312715,0.00055780826],"category_scores_gemma":[0.00008404365,0.00029231573,0.00013823705,0.0003229109,0.00038820304,0.00001971767,0.000112905276,0.00060388783,0.00061906787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017646328,0.0001794193,0.000032893095,0.000088986046,0.00006614433,0.00031516672,0.00007511092,0.000032964712,0.9938668,0.0025905094,0.0007840149,0.001791513],"study_design_scores_gemma":[0.0021622407,0.0001246854,0.0007660525,0.00003888063,0.00006378794,0.0008734312,0.00007690679,0.0000019805475,0.9907741,0.0016274842,0.0032271554,0.0002633123],"about_ca_topic_score_codex":0.00012179096,"about_ca_topic_score_gemma":6.856323e-8,"teacher_disagreement_score":0.047941968,"about_ca_system_score_codex":0.0007994086,"about_ca_system_score_gemma":0.000467527,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W1964407943","doi":"10.1007/s10549-012-2369-x","title":"A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Research Resources; GlaxoSmithKline","keywords":"Lapatinib; Pazopanib; Medicine; Clinical endpoint; Internal medicine; Cohort; Adverse effect; Breast cancer; Oncology; Cancer; Pharmacology; Randomized controlled trial; Trastuzumab; Sunitinib","score_opus":0.07212824753998884,"score_gpt":0.4215965446262711,"score_spread":0.34946829708628224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964407943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910557,0.0012479842,3.9042726e-7,0.0006971372,0.00013318862,0.0057515483,0.0006614042,0.000033202883,0.00041942566],"genre_scores_gemma":[0.99345374,0.0008223451,0.000024191457,0.000018369581,0.0002839321,0.0049802074,0.000049418784,0.000073419935,0.0002943899],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9950516,0.000680329,0.0006250026,0.00060465635,0.001788938,0.0012494635],"domain_scores_gemma":[0.9972669,0.00040477386,0.0001632711,0.0006030006,0.00078540196,0.0007766821],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013116446,0.00040588478,0.0011510033,0.0005222717,0.00023868245,0.000035476318,0.00017307514,0.000113578244,0.0009247999],"category_scores_gemma":[0.00006626198,0.00026691146,0.00009671812,0.00078963436,0.0005466706,0.00023242421,0.00018707874,0.00047569355,0.0000109695875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36702946,0.0141592175,0.54697275,0.00013435358,0.00075718446,0.000037677997,0.0031995568,0.0000038522217,0.000028208393,0.000021064614,0.00010616671,0.06755051],"study_design_scores_gemma":[0.5046924,0.009641299,0.48342982,0.00042944448,0.00017118976,0.000013526861,0.0009822639,0.000023618835,0.00015784896,0.0000039719507,0.00025728898,0.00019733871],"about_ca_topic_score_codex":0.023163283,"about_ca_topic_score_gemma":0.006663854,"teacher_disagreement_score":0.13766292,"about_ca_system_score_codex":0.0014437253,"about_ca_system_score_gemma":0.0010979082,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W1964525628","doi":"10.1016/s1470-2045(14)70181-0","title":"When is downstream pathway inhibition important?","year":2014,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Oncology; Internal medicine; Trastuzumab emtansine; Breast cancer; Vinorelbine; Taxane; Cancer; Everolimus; Metastatic breast cancer; Context (archaeology); Neratinib; Clinical trial; Chemotherapy","score_opus":0.0997091515519647,"score_gpt":0.3847506483452985,"score_spread":0.2850414967933338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964525628","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018929195,0.00048821565,0.000025237663,0.92127806,0.000737509,0.00094196765,0.00014971498,0.000145235,0.074341156],"genre_scores_gemma":[0.0022815599,0.0006792725,0.0003730253,0.9505557,0.033962,0.0003123933,0.00060854305,0.00010740546,0.011120147],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99639595,0.00063098996,0.0005857501,0.0006063208,0.0007611807,0.001019814],"domain_scores_gemma":[0.99729115,0.0005257832,0.0003480866,0.0015187919,0.00019506588,0.00012114879],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.001660512,0.00037106714,0.0013771976,0.00016410399,0.00011298387,0.000035101544,0.00048651017,0.0015216306,0.0038702034],"category_scores_gemma":[0.00021016225,0.00023951365,0.00021912997,0.00016620079,0.0004634633,0.000031216063,0.00018565152,0.0045847693,0.0013681452],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000170217,0.000042382722,0.0005603359,0.0004733989,0.00012181529,0.0017670899,0.00048154837,6.837535e-8,0.00034545816,0.00006840312,0.9849236,0.011045663],"study_design_scores_gemma":[0.0017865006,0.0010288332,0.0001365258,0.00025391628,0.0001240448,0.00088000327,0.0000199297,0.000017197295,0.00080278947,0.004480712,0.9902334,0.00023610846],"about_ca_topic_score_codex":0.00029622883,"about_ca_topic_score_gemma":0.00007788986,"teacher_disagreement_score":0.06322101,"about_ca_system_score_codex":0.00074148696,"about_ca_system_score_gemma":0.0011076418,"threshold_uncertainty_score":0.9997746},"labels":[],"label_agreement":null},{"id":"W1964775486","doi":"10.1371/journal.pone.0031723","title":"Specific and Sensitive Hydrolysis Probe-Based Real-Time PCR Detection of Epidermal Growth Factor Receptor Variant III in Oral Squamous Cell Carcinoma","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"Health Research Board; University of Calgary; Cancer Research Institute","keywords":"Epidermal growth factor receptor; Basal cell; Epidermal growth factor; Cancer research; Receptor; Chemistry; Biology; Molecular biology; Medicine; Pathology; Biochemistry","score_opus":0.050617691737500504,"score_gpt":0.2618416511089167,"score_spread":0.21122395937141622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964775486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733835,0.00019816078,0.00010445015,0.0003300787,0.000037028687,0.00094396045,0.00004525186,0.000043132153,0.00095957797],"genre_scores_gemma":[0.9970516,0.000052290612,0.0021563245,0.00003665451,0.00023556953,0.00005521144,0.000027111342,0.00004851473,0.00033672407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790853,0.00022769034,0.00039307735,0.000336223,0.0006058136,0.00052865135],"domain_scores_gemma":[0.9987996,0.00026837617,0.00012181363,0.00030557998,0.0002118753,0.00029274577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052539806,0.00019371645,0.0005825893,0.0003235408,0.000047450976,0.000011195556,0.00006314893,0.00015509718,0.0003764321],"category_scores_gemma":[0.00016449101,0.00018280059,0.00006460498,0.00041107237,0.00012207737,0.00012282188,0.000048433703,0.00035020112,0.00007532582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009267064,0.0016997252,0.05134515,0.00051793345,0.0000434235,0.000048915867,0.0009251474,9.72173e-7,0.9439012,0.0000051340235,0.000038044043,0.0005476374],"study_design_scores_gemma":[0.0026180148,0.0006829063,0.1023142,0.0001272364,0.00010546611,0.000009594123,0.00006651437,0.0013739596,0.89251786,0.000007998356,0.000014629442,0.0001616159],"about_ca_topic_score_codex":0.0014551844,"about_ca_topic_score_gemma":0.000037634643,"teacher_disagreement_score":0.05138334,"about_ca_system_score_codex":0.0003443982,"about_ca_system_score_gemma":0.00012246043,"threshold_uncertainty_score":0.7454392},"labels":[],"label_agreement":null},{"id":"W1964896818","doi":"10.1159/000055406","title":"Role of Herceptin&lt;sup&gt;®&lt;/sup&gt; in Primary Breast Cancer: Views from North America and Europe","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Oncology; Tamoxifen; Internal medicine; Population; Adjuvant; Regimen; Clinical trial; Adjuvant therapy; Asymptomatic; Trastuzumab; Antiestrogen; Cancer; Metastatic breast cancer","score_opus":0.06729062533461543,"score_gpt":0.40555167360208066,"score_spread":0.3382610482674652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1964896818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017485798,0.955742,0.0000028640518,0.0005715458,0.000173033,0.00191676,0.0008694468,0.000047851026,0.038927905],"genre_scores_gemma":[0.000045457466,0.9941385,0.0006134679,0.00067403796,0.0010003073,0.0005297158,0.0006667943,0.0001773577,0.0021543917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99462444,0.0012067511,0.0014954987,0.0011168121,0.00063633476,0.0009201872],"domain_scores_gemma":[0.9969947,0.0006178775,0.0006816191,0.0009827078,0.00026008993,0.00046305128],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050652714,0.0006779283,0.0049043903,0.0005128675,0.000055484135,0.000017602173,0.0006031963,0.0007166634,0.00414213],"category_scores_gemma":[0.00016209122,0.000563924,0.00033378744,0.0014831214,0.00062225177,0.00006743824,0.00049527973,0.0016087064,0.00045300717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001709041,0.00047752392,0.0025790688,0.0059784786,0.00021841114,0.00043832598,0.0003247069,0.0000028854772,0.00005138534,0.0000027323392,0.011464883,0.9782907],"study_design_scores_gemma":[0.0012203513,0.00094325474,0.0077262935,0.006492409,0.0006114985,0.00043998507,0.000042624706,0.000021135284,4.0457195e-7,0.000005457169,0.9820979,0.00039864078],"about_ca_topic_score_codex":0.0024252427,"about_ca_topic_score_gemma":0.004227767,"teacher_disagreement_score":0.97789204,"about_ca_system_score_codex":0.0018918058,"about_ca_system_score_gemma":0.0045439396,"threshold_uncertainty_score":0.99968123},"labels":[],"label_agreement":null},{"id":"W1965229389","doi":"10.1038/sj.onc.1209574","title":"Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4","year":2006,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal University Hospital","funders":"Medical Research and Materiel Command; U.S. Army Materiel Command; National Cancer Institute; U.S. Army Medical Command; U.S. Army","keywords":"ERBB4; Biology; ERBB3; ErbB; Carcinogenesis; Receptor tyrosine kinase; Mammary gland; Cancer research; Epidermal growth factor receptor; Internal medicine; Breast cancer; Receptor; Cancer; Medicine; Genetics","score_opus":0.023243280609411266,"score_gpt":0.32484009203234593,"score_spread":0.30159681142293465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965229389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98770195,0.00050350337,0.00034064235,0.0012841237,0.00006847162,0.00045461062,0.00006648963,0.000038184386,0.009542041],"genre_scores_gemma":[0.9976611,0.000049820927,0.00052312395,0.00014723583,0.00013423114,0.00002276464,0.000117678755,0.000026769281,0.001317237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843585,0.00006563307,0.00044182956,0.00018888059,0.0005958168,0.00027197873],"domain_scores_gemma":[0.9990015,0.000059095026,0.00016825895,0.00042482893,0.00024866997,0.00009767305],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027987457,0.0001272747,0.00035741643,0.0001497544,0.00002650403,0.000006172315,0.00015553385,0.00011203313,0.00020057826],"category_scores_gemma":[0.000060778617,0.00011737657,0.00009507607,0.000477123,0.00006554585,0.00010430505,0.000055536104,0.00015498191,0.000031531534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012112696,0.00019922611,0.002901791,0.00045946796,0.000024287652,0.000030247731,0.00011697051,0.000002891601,0.9405822,0.00004866677,0.046653528,0.008859582],"study_design_scores_gemma":[0.0014331131,0.00050442555,0.004418426,0.00019333533,0.00003192293,0.000042987584,0.000027739023,0.00037908566,0.9855253,0.00010476873,0.0072397506,0.00009911952],"about_ca_topic_score_codex":0.0008028869,"about_ca_topic_score_gemma":0.000025260675,"teacher_disagreement_score":0.044943113,"about_ca_system_score_codex":0.00016182446,"about_ca_system_score_gemma":0.00024529308,"threshold_uncertainty_score":0.47864777},"labels":[],"label_agreement":null},{"id":"W1966524957","doi":"10.1016/j.febslet.2014.09.017","title":"Amphiregulin induces human ovarian cancer cell invasion by down‐regulating E‐cadherin expression","year":2014,"lang":"en","type":"article","venue":"FEBS Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Amphiregulin; Cadherin; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Ovarian cancer; Biology; Cell biology; Slug; Cell growth; Cell; Cancer; Receptor","score_opus":0.03545871640016448,"score_gpt":0.32488384708821466,"score_spread":0.2894251306880502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966524957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98116904,0.00029212466,0.00032212972,0.013601888,0.00027177346,0.00045289512,0.000010979118,0.00012970324,0.0037494774],"genre_scores_gemma":[0.99087167,0.00005608778,0.0009947409,0.005600961,0.0009172517,0.00011326515,0.0000618732,0.00007579163,0.0013083753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975728,0.00018733199,0.00036539126,0.000547108,0.0007383036,0.0005890877],"domain_scores_gemma":[0.99884605,0.00009047558,0.00014025542,0.000570878,0.00005812305,0.00029423955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005240577,0.00025362548,0.00034612458,0.000098597266,0.0002450146,0.0000687398,0.00027450483,0.00017478011,0.0014721856],"category_scores_gemma":[0.00006249194,0.00022038977,0.000093292336,0.0002089162,0.00012426409,0.00016668346,0.00014724961,0.0004701817,0.000087866545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049326212,0.00005187629,0.005149611,0.00013552242,0.00001385134,0.000008550546,0.00040179552,0.00002664238,0.84243876,0.000010812067,0.14358246,0.008130803],"study_design_scores_gemma":[0.0023882957,0.0002241101,0.013098795,0.00084026525,0.000039329734,0.000007820703,0.00013529972,0.00021357185,0.8930688,0.000028730172,0.08957477,0.0003801998],"about_ca_topic_score_codex":0.0040417314,"about_ca_topic_score_gemma":0.00019772333,"teacher_disagreement_score":0.05400769,"about_ca_system_score_codex":0.00036085234,"about_ca_system_score_gemma":0.000069930524,"threshold_uncertainty_score":0.9994406},"labels":[],"label_agreement":null},{"id":"W1966679991","doi":"10.1016/j.clon.2013.08.011","title":"Trastuzumab Retreatment after Relapse on Adjuvant Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Final Results of the Retreatment after Herceptin Adjuvant Trial","year":2013,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Taxane; Breast cancer; Metastatic breast cancer; Adjuvant; Docetaxel; Adjuvant therapy; Cancer","score_opus":0.12712808958940675,"score_gpt":0.45457163262624756,"score_spread":0.3274435430368408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966679991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96651584,0.00053388363,0.0000095249425,0.019588191,0.0017443612,0.008627168,0.0020759283,0.000057248602,0.0008478791],"genre_scores_gemma":[0.9854932,0.0011175821,0.0004875528,0.001908724,0.002082101,0.005958631,0.00010548351,0.00011358646,0.0027331724],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9925515,0.0016266871,0.002533133,0.0013307752,0.00089868123,0.0010592297],"domain_scores_gemma":[0.9938203,0.0029073856,0.0007912803,0.001117005,0.000743371,0.00062062824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014290068,0.00063753844,0.0021029655,0.00015068759,0.00019346124,0.000029468521,0.000458346,0.00088714936,0.0041258796],"category_scores_gemma":[0.00095895573,0.00038168562,0.0012117248,0.00029799578,0.0010301188,0.000110016896,0.00015901189,0.0013082857,0.00016732005],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5364832,0.011631595,0.049954504,0.00013047256,0.001285428,0.00018455439,0.0016811353,0.0000022323845,0.00073871267,0.000037336078,0.021480141,0.37639067],"study_design_scores_gemma":[0.12619042,0.06435663,0.7996702,0.00051426707,0.00030385912,0.000040311814,0.00016460467,0.000020880958,0.0018036829,0.00014500027,0.006431275,0.00035883274],"about_ca_topic_score_codex":0.0012784506,"about_ca_topic_score_gemma":0.00045990938,"teacher_disagreement_score":0.74971575,"about_ca_system_score_codex":0.0030043477,"about_ca_system_score_gemma":0.0018940992,"threshold_uncertainty_score":0.9998635},"labels":[],"label_agreement":null},{"id":"W1966937303","doi":"10.1073/pnas.1014835108","title":"Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Manitoba","funders":"National Cancer Institute; Instituto de Salud Carlos III; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cancer research; Cyclin D; Cyclin E; Breast cancer; Cyclin E1; Cyclin D1; Cyclin A; Cyclin; Cyclin B; Cyclin A2; Cell cycle; Cancer; Biology; Medicine; Internal medicine","score_opus":0.0794277388188846,"score_gpt":0.3594816967174915,"score_spread":0.2800539578986069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1966937303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889346,0.00011194534,0.0000013161488,0.0027344243,0.000011398514,0.00046340923,0.00012539655,0.0000076107626,0.007609921],"genre_scores_gemma":[0.99782103,0.000100371406,0.0015014806,0.0002343604,0.00003956181,0.000048191527,2.96562e-7,0.000007918415,0.0002467693],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968834,0.000012481301,0.00053585327,0.00032805855,0.0020268722,0.00021334787],"domain_scores_gemma":[0.99851066,0.00006158713,0.00047012052,0.000021738939,0.00087229256,0.00006360697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011361499,0.00010883505,0.00024521266,0.0002736259,0.00008818231,0.000007455916,0.0006891227,0.00011244408,0.000187695],"category_scores_gemma":[0.00043494202,0.00007490637,0.000059276448,0.0012330009,0.0006234719,0.00030424687,0.00011791108,0.0002504484,0.0000016375802],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011389365,0.0016531198,0.4217072,0.0017715298,0.00008136314,4.8472312e-8,0.012674428,0.000035047386,0.46556342,0.085117124,0.007868097,0.002389675],"study_design_scores_gemma":[0.0007822682,0.00011674439,0.61447513,0.0016721333,0.000015329182,0.0000024285475,0.000445752,0.00056344346,0.3436615,0.03805018,0.000113479204,0.00010164817],"about_ca_topic_score_codex":0.00013368335,"about_ca_topic_score_gemma":8.5949597e-7,"teacher_disagreement_score":0.1927679,"about_ca_system_score_codex":0.00017176535,"about_ca_system_score_gemma":0.00018993994,"threshold_uncertainty_score":0.30545932},"labels":[],"label_agreement":null},{"id":"W1967993118","doi":"10.5114/wo.2010.974","title":"New targeted therapies in the treatment of patients with metastatic melanoma","year":2010,"lang":"pl","type":"article","venue":"Współczesna Onkologia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Metastatic melanoma; Melanoma; Oncology; Internal medicine; Targeted therapy; Cancer research; Cancer","score_opus":0.03216117638503764,"score_gpt":0.32580088293654336,"score_spread":0.29363970655150573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967993118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898607,0.00353615,0.000037187754,0.0021271433,0.00058318203,0.0023248298,0.000121308614,0.000032234973,0.0013772764],"genre_scores_gemma":[0.9942491,0.00057112076,0.0030608436,0.00024649737,0.00022710268,0.00013692782,0.00010834495,0.00005970547,0.0013403291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963941,0.0004731354,0.0006641745,0.0005664839,0.0010594676,0.0008426319],"domain_scores_gemma":[0.9973421,0.0007153872,0.00026984353,0.0012083926,0.0002354958,0.00022874524],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065780745,0.0004785416,0.00088565727,0.0003023016,0.00009473744,0.000048059937,0.00060649466,0.00022285811,0.0032420943],"category_scores_gemma":[0.00022514482,0.0002507424,0.0001548393,0.00084132317,0.0004940178,0.00009058912,0.00004290817,0.0007371388,0.00015812114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020183674,0.003983007,0.88119406,0.00021257761,0.00081106805,0.00024189026,0.01694389,0.000008118373,0.0016395246,0.00079360756,0.003136014,0.08901789],"study_design_scores_gemma":[0.010175495,0.014757289,0.9387301,0.00014987511,0.00037212472,0.000011596683,0.0017190934,0.0000524048,0.0024450817,0.00033134894,0.030905485,0.0003500573],"about_ca_topic_score_codex":0.002905794,"about_ca_topic_score_gemma":0.0024721036,"teacher_disagreement_score":0.08866783,"about_ca_system_score_codex":0.0002157843,"about_ca_system_score_gemma":0.00092867145,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W1968993470","doi":"10.1089/cbr.2008.0553","title":"<sup>111</sup> In-Labeled Immunoconjugates (ICs) Bispecific for the Epidermal Growth Factor Receptor (EGFR) and Cyclin-Dependent Kinase Inhibitor, p27 <sup>Kip1</sup>","year":2009,"lang":"en","type":"article","venue":"Cancer Biotherapy and Radiopharmaceuticals","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Internalization; Epidermal growth factor receptor; Molecular biology; Chemistry; Kinase; Epidermal growth factor; Trastuzumab; Cancer research; Receptor; Biology; Biochemistry; Cancer","score_opus":0.057479573944970046,"score_gpt":0.38831058519363243,"score_spread":0.3308310112486624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968993470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8351803,0.13032773,0.00016349145,0.029444791,0.00040226543,0.0038318501,0.000397855,0.00012588581,0.00012583863],"genre_scores_gemma":[0.83142334,0.1583752,0.00043759303,0.006680226,0.0017834937,0.00050798844,0.000026454501,0.000114738665,0.000650974],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957268,0.00031583838,0.0009401975,0.001068522,0.00067372253,0.0012748684],"domain_scores_gemma":[0.99728024,0.001074383,0.00015030536,0.00053539843,0.00024860448,0.00071109063],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001182917,0.0006486421,0.0010273616,0.00032728183,0.0004423446,0.00021387539,0.00037576474,0.00042963264,0.0011896633],"category_scores_gemma":[0.00016956776,0.0004608538,0.00022367736,0.00054755,0.00078024965,0.00027397307,0.00007522557,0.0010976617,0.000022203494],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014842321,0.0014060932,0.031139495,0.0014597713,0.0012795686,0.00018808457,0.006064998,0.0002495026,0.46992385,0.0013574404,0.012846412,0.45924246],"study_design_scores_gemma":[0.05114567,0.0041305483,0.018317023,0.0016947006,0.0005166474,0.00025701625,0.0016076356,0.029040473,0.37070307,0.0008414866,0.519409,0.002336748],"about_ca_topic_score_codex":0.0001521198,"about_ca_topic_score_gemma":0.00000929367,"teacher_disagreement_score":0.5065626,"about_ca_system_score_codex":0.0005207508,"about_ca_system_score_gemma":0.0004067306,"threshold_uncertainty_score":0.9997843},"labels":[],"label_agreement":null},{"id":"W1969115197","doi":"10.1309/ajcpdyz1xmf4hjwk","title":"Canadian Association of Pathologists–Association canadienne des pathologistes National Standards Committee/Immunohistochemistry","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; University Health Network; Canadian Cancer Society; Jewish General Hospital; London Health Sciences Centre; Vancouver Hospital and Health Sciences Centre; McMaster University; Mount Sinai Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan","funders":"","keywords":"Immunohistochemistry; Medicine; Pathology; Anatomical pathology","score_opus":0.03934688866447082,"score_gpt":0.4371159760607226,"score_spread":0.3977690873962518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969115197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98719406,0.00010423673,0.000067382476,0.005831167,0.0010107773,0.00013429546,0.00027850672,0.000013109264,0.0053664367],"genre_scores_gemma":[0.99275076,0.00024354906,0.0047892216,0.0009312014,0.0005721696,0.000007323155,0.000019565097,0.000025885773,0.0006603068],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952791,0.0007662499,0.0018363913,0.00027515454,0.001111871,0.00073125144],"domain_scores_gemma":[0.9889782,0.0021540895,0.0027060919,0.0003264907,0.005086606,0.00074852956],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018279789,0.00018234109,0.0011928247,0.00029974646,0.00011618122,0.000017021364,0.00037109756,0.00045951095,0.00038773575],"category_scores_gemma":[0.057994306,0.0001642418,0.0003900279,0.0004239541,0.00114159,0.00008020085,0.00005063352,0.0022193033,0.000009781572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003036459,0.00019431651,0.94552374,0.00003386845,0.00014408564,0.0005269081,0.0003030281,0.000004527109,0.015701247,0.00008999169,0.0059891557,0.031185478],"study_design_scores_gemma":[0.0022582847,0.0034658408,0.96370983,0.00009838523,0.00016680727,0.0010964624,0.0005310253,0.000015488107,0.00096522743,0.0014862115,0.025981614,0.00022484409],"about_ca_topic_score_codex":0.01809587,"about_ca_topic_score_gemma":0.07869876,"teacher_disagreement_score":0.06060289,"about_ca_system_score_codex":0.0038944916,"about_ca_system_score_gemma":0.006627406,"threshold_uncertainty_score":0.99992937},"labels":[],"label_agreement":null},{"id":"W1969175190","doi":"10.1073/pnas.1220763110","title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Alberta; Università degli Studi di Milano; European Commission; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Israel Cancer Research Fund","keywords":"Cetuximab; Epidermal growth factor receptor; Panitumumab; Monoclonal antibody; Triple-negative breast cancer; Cancer research; Antibody; EGFR inhibitors; Growth inhibition; Epidermal growth factor; Receptor; Chemistry; Breast cancer; Cell growth; Biology; Medicine; Cancer; Immunology; Internal medicine; Biochemistry","score_opus":0.073597400590453,"score_gpt":0.38499940610813116,"score_spread":0.31140200551767816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969175190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97082144,0.00014772912,0.0000045886704,0.020440593,0.000017059618,0.00067645335,0.00021738267,0.000006566089,0.0076682093],"genre_scores_gemma":[0.99827176,0.000118370306,0.000908939,0.00021773661,0.000028010736,0.000058424026,3.912529e-7,0.000004798423,0.00039158476],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975167,0.000008404584,0.00041917365,0.00019067674,0.0017115709,0.00015350843],"domain_scores_gemma":[0.99758863,0.00011816571,0.0003892257,0.0000116810015,0.0018303863,0.000061927625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084557914,0.000082105005,0.00024598662,0.0002953925,0.00008897075,0.000009698048,0.00034307534,0.000066803215,0.000086888875],"category_scores_gemma":[0.00051899074,0.00005598384,0.00006705118,0.0011789401,0.0011119349,0.00050772034,0.000116333606,0.00014995087,0.0000013632656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005169859,0.00029411423,0.011582979,0.00037133097,0.00004205257,2.7952034e-9,0.0011672231,0.0001264326,0.9419759,0.024361296,0.01881053,0.0012164547],"study_design_scores_gemma":[0.00067747774,0.0001484579,0.09986496,0.0007041994,0.000019556586,0.0000040531568,0.0007348736,0.0027658762,0.836128,0.058852855,0.000030048408,0.00006962421],"about_ca_topic_score_codex":0.00037941156,"about_ca_topic_score_gemma":4.970535e-7,"teacher_disagreement_score":0.10584787,"about_ca_system_score_codex":0.00009340222,"about_ca_system_score_gemma":0.00013559693,"threshold_uncertainty_score":0.40969703},"labels":[],"label_agreement":null},{"id":"W1969915666","doi":"10.1182/blood-2010-10-313940","title":"Constitutive activation of metalloproteinase ADAM10 in mantle cell lymphoma promotes cell growth and activates the TNFα/NFκB pathway","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Terry Fox Foundation; Cancer Research Institute","keywords":"ADAM10; Cyclin D1; Cell growth; Cancer research; Cell cycle; Cell biology; Biology; Cell culture; Mantle cell lymphoma; Disintegrin; Chemistry; Cell; Metalloproteinase; Immunology; Matrix metalloproteinase; Lymphoma; Biochemistry","score_opus":0.032896522401532104,"score_gpt":0.25513160406285285,"score_spread":0.22223508166132075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969915666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96920645,0.00038117895,0.00001997166,0.00015396447,0.000026368221,0.0009941518,0.000013771176,0.000020827676,0.029183332],"genre_scores_gemma":[0.99874884,0.00009178746,0.00076789985,0.00004519818,0.000037074286,0.000102621714,0.000005329663,0.000020620077,0.00018063399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988406,0.000103437866,0.00023097376,0.00026341053,0.00030318898,0.00025844734],"domain_scores_gemma":[0.99927604,0.00014438579,0.00010673945,0.00027935032,0.000105025414,0.00008843517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003235845,0.0001469042,0.00025792798,0.00012654126,0.000053987053,0.000010960142,0.00013217318,0.00009438154,0.00009691633],"category_scores_gemma":[0.00018747943,0.00010050226,0.00004487118,0.00027242198,0.00029237347,0.00011441244,0.00008742617,0.00017968903,0.000008881904],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037769205,0.0029557473,0.028464004,0.0007839875,0.00008454258,0.000107081236,0.0038020113,1.2347539e-7,0.9595621,0.00085588923,0.000036641155,0.0029701358],"study_design_scores_gemma":[0.0036973413,0.000458996,0.019891404,0.0001641391,0.000054191092,0.000018431165,0.00066579133,0.000010034524,0.974362,0.00042124043,0.00015547968,0.000100923295],"about_ca_topic_score_codex":0.0010141777,"about_ca_topic_score_gemma":0.000025732117,"teacher_disagreement_score":0.0295424,"about_ca_system_score_codex":0.000033874483,"about_ca_system_score_gemma":0.00033169662,"threshold_uncertainty_score":0.4098363},"labels":[],"label_agreement":null},{"id":"W1969929253","doi":"10.1016/j.cancergencyto.2007.05.030","title":"Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis","year":2008,"lang":"en","type":"article","venue":"Cancer Genetics and Cytogenetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University; London Health Sciences Centre","funders":"Canadian Breast Cancer Research Alliance; London Health Sciences Centre; Canada Research Chairs; Breast Cancer Alliance","keywords":"Biology; Karyotype; Fluorescence in situ hybridization; Breakpoint; Cell culture; Metastasis; Molecular biology; Chromosome; Aneuploidy; Cytogenetics; Cancer; Cancer research; Genetics; Gene","score_opus":0.04032510654948662,"score_gpt":0.32920249004575153,"score_spread":0.2888773834962649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969929253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451567,0.051777195,0.00032515766,0.00055394426,0.00018280689,0.0008684017,0.0009774381,0.000023234215,0.00013512131],"genre_scores_gemma":[0.8471121,0.15142217,0.00032033667,0.00025821148,0.00025891597,0.00017866193,0.00009214081,0.00010796705,0.00024948365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970497,0.00012279497,0.0007022042,0.00074597093,0.0007474488,0.00063190336],"domain_scores_gemma":[0.9975306,0.00003298745,0.0004353871,0.0005669848,0.00089650013,0.00053756754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017564379,0.0004616807,0.0007638075,0.00016876991,0.00023881883,0.000041440457,0.00023576603,0.00024148604,0.000319753],"category_scores_gemma":[0.000028154529,0.00044327456,0.00009731676,0.00052053505,0.00028682454,0.000049613693,0.00024160056,0.00020103937,0.0000034008099],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014833969,0.00023016406,0.053711057,0.0010748385,0.00029972848,0.00018089227,0.0007420187,0.0004024691,0.9331905,0.000045140994,0.00006739044,0.009907413],"study_design_scores_gemma":[0.0028834823,0.00084016385,0.16437724,0.0005940166,0.0008899534,0.00054547685,0.00007898795,0.00518729,0.82298476,0.000035603058,0.000971531,0.0006115165],"about_ca_topic_score_codex":0.0002634371,"about_ca_topic_score_gemma":0.00018974839,"teacher_disagreement_score":0.11066618,"about_ca_system_score_codex":0.0001958954,"about_ca_system_score_gemma":0.00075786567,"threshold_uncertainty_score":0.9998019},"labels":[],"label_agreement":null},{"id":"W1971160611","doi":"10.1021/jm0600390","title":"The Combi-Targeting Concept:  Synthesis of Stable Nitrosoureas Designed to Inhibit the Epidermal Growth Factor Receptor (EGFR)","year":2006,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; Royal Victoria Regional Health Centre","funders":"","keywords":"Chemistry; Potency; Epidermal growth factor receptor; Tyrosine kinase; Epidermal growth factor; EGFR inhibitors; IC50; Moiety; Stereochemistry; Receptor; Biochemistry; In vitro","score_opus":0.018175125596438173,"score_gpt":0.29717429876118195,"score_spread":0.27899917316474376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971160611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96344626,0.004787387,0.00041377917,0.026676118,0.0002899908,0.00039370835,0.000035053967,0.000018931389,0.0039387764],"genre_scores_gemma":[0.9959976,0.00018880876,0.0005645911,0.00033037705,0.0019010057,0.000014575783,0.0000035907574,0.000039187435,0.0009602302],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961149,0.00020165677,0.0011335524,0.00019948173,0.0017839936,0.0005664279],"domain_scores_gemma":[0.9954337,0.0021342435,0.00068462384,0.0003446717,0.0010064786,0.00039628992],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025422338,0.00023555817,0.0006571846,0.00005929643,0.00024025774,0.000039339087,0.00057181617,0.00014714578,0.00071088166],"category_scores_gemma":[0.005320743,0.00012679564,0.00024257485,0.00036028516,0.00047322307,0.00007345908,0.00008717581,0.0010187487,0.000009412057],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012192901,0.00017633771,0.010723252,0.00041937912,0.00018510033,0.00011372402,0.00042441452,0.000020532894,0.8608626,0.000025783913,0.122599594,0.003230005],"study_design_scores_gemma":[0.0012357071,0.00034024805,0.0030013917,0.001052549,0.00014805689,0.00036371243,0.0015540625,0.000016111806,0.9773875,0.00010041933,0.014664082,0.00013618283],"about_ca_topic_score_codex":0.00018411838,"about_ca_topic_score_gemma":0.0000035978937,"teacher_disagreement_score":0.11652489,"about_ca_system_score_codex":0.00037228107,"about_ca_system_score_gemma":0.0008134587,"threshold_uncertainty_score":0.77836555},"labels":[],"label_agreement":null},{"id":"W1971209307","doi":"10.1016/j.ctrv.2013.09.001","title":"HER2 testing: Current status and future directions","year":2013,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Genentech","keywords":"Medicine; Clinical Oncology; Human Epidermal Growth Factor Receptor 2; Medical physics; Breast cancer; Oncology; Intensive care medicine; Gynecology; Cancer; Internal medicine","score_opus":0.33526958615058944,"score_gpt":0.5178544713757319,"score_spread":0.1825848852251425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971209307","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000020958855,0.98678756,7.317486e-7,0.000226004,0.0012476037,0.008060629,0.00015984353,0.00010230295,0.0034132276],"genre_scores_gemma":[3.0020473e-8,0.9774729,0.0005003219,0.000047874008,0.0033891941,0.014586846,0.00021445875,0.00012932188,0.0036590623],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655,0.00036281403,0.0009963785,0.0009705487,0.00034913063,0.00077108864],"domain_scores_gemma":[0.997474,0.00017533588,0.00045985304,0.000996841,0.00015682349,0.0007371301],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023052077,0.0009095986,0.0038680607,0.00024502625,0.00016164828,0.00008780938,0.00014940709,0.0002669213,0.0014958365],"category_scores_gemma":[0.00009705018,0.0005292612,0.00068961876,0.0008778781,0.00012461164,0.00007023862,0.00008368607,0.00067060697,0.0006735604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000030258554,0.00016553556,0.00020031404,0.041749854,0.00024163236,0.000012402659,0.000052837753,6.0771503e-9,8.558041e-8,0.000008040383,0.012704704,0.9448616],"study_design_scores_gemma":[0.0004277085,0.00036847207,0.000051130137,0.043917254,0.0031065994,0.000072692004,0.000006395453,7.2416566e-7,3.6927406e-7,0.000003840234,0.9516737,0.0003711474],"about_ca_topic_score_codex":0.0007592016,"about_ca_topic_score_gemma":0.00008299767,"teacher_disagreement_score":0.94449043,"about_ca_system_score_codex":0.0030563727,"about_ca_system_score_gemma":0.0019993074,"threshold_uncertainty_score":0.9997159},"labels":[],"label_agreement":null},{"id":"W1973729526","doi":"10.1007/s10549-008-0267-z","title":"Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; National Cancer Institute; University of Manitoba; Manitoba Health Research Council","keywords":"Immunohistochemistry; Estrogen receptor; Breast cancer; Tissue microarray; Cancer research; Estrogen receptor alpha; Estrogen receptor beta; Antibody; Phosphorylation; Estrogen; Biology; Epitope; Cancer; Internal medicine; Pathology; Medicine; Immunology; Cell biology","score_opus":0.0845461179765854,"score_gpt":0.39014807308163685,"score_spread":0.30560195510505145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973729526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98899406,0.0060032033,0.000011639512,0.0008579389,0.00003897026,0.0022120404,0.0016391327,0.000013057309,0.0002299676],"genre_scores_gemma":[0.99520504,0.0021773537,0.0006043093,0.0000049766495,0.0001574245,0.0009743561,0.00029592722,0.000045120538,0.00053550577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99757063,0.0001285289,0.00047317197,0.00054148794,0.00065758446,0.0006286091],"domain_scores_gemma":[0.9982545,0.00023048918,0.00009982926,0.00041744567,0.000723239,0.00027450873],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036832324,0.00023065672,0.000578622,0.00032651186,0.00017710989,0.000013011039,0.00015566943,0.00012889632,0.00030252026],"category_scores_gemma":[0.000030024763,0.00019735484,0.00010964239,0.00041044748,0.0006902449,0.000075752214,0.00007843433,0.00023507331,0.000008383932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059662974,0.0014992909,0.17559558,0.00023742422,0.00019808579,0.00005355488,0.0014471759,0.0000030673768,0.78220063,0.00011034696,0.0009790151,0.031709522],"study_design_scores_gemma":[0.0065548564,0.0019863127,0.14688326,0.0003937734,0.000025999809,0.00024753818,0.00026358332,0.0000104006185,0.8415578,0.000030904674,0.0018998177,0.00014574693],"about_ca_topic_score_codex":0.018188758,"about_ca_topic_score_gemma":0.00017808679,"teacher_disagreement_score":0.05935716,"about_ca_system_score_codex":0.0012492856,"about_ca_system_score_gemma":0.00069194107,"threshold_uncertainty_score":0.9883492},"labels":[],"label_agreement":null},{"id":"W1974449499","doi":"10.2144/000113354","title":"A Proximity Ligation Assay Using Transiently Transfected, Epitope-Tagged Proteins: Application for in Situ Detection of Dimerized Receptor Tyrosine Kinases","year":2010,"lang":"en","type":"article","venue":"BioTechniques","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Toronto Western Hospital; Hospital for Sick Children","funders":"National Cancer Institute; Sick Kids Foundation","keywords":"Proximity ligation assay; Epitope; Epidermal growth factor receptor; Immunoprecipitation; Receptor tyrosine kinase; Tyrosine kinase; Receptor; Transfection; Molecular biology; Biology; Cell biology; Target protein; Ligand (biochemistry); Chemistry; Computational biology; Antibody; Biochemistry; Immunology; Gene","score_opus":0.03177015599344328,"score_gpt":0.3461302312628107,"score_spread":0.3143600752693674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974449499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74921507,0.00008308542,0.2434125,0.00056875707,0.000064973916,0.0063872775,0.000027146933,0.00020208333,0.000039130875],"genre_scores_gemma":[0.9509553,0.000079248886,0.047048982,0.000026138929,0.00013341583,0.0016557138,0.00004928389,0.000040020645,0.000011901692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850947,0.00011502401,0.00044871008,0.0003604562,0.00031513098,0.0002512131],"domain_scores_gemma":[0.9991002,0.00007550632,0.0001264727,0.00033504755,0.00028343344,0.00007931692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010812789,0.00016172204,0.00034002078,0.00029874925,0.000061364175,0.000014287476,0.00010620286,0.0003826645,0.000012943558],"category_scores_gemma":[0.00037223691,0.00015253354,0.0001064,0.0005552638,0.00012932163,0.00015159995,0.000010706614,0.0004343935,0.0000011170501],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000750248,0.00024932678,0.00025858424,0.00047138185,0.000010797104,5.089956e-7,0.00014742845,3.9765342e-7,0.91091335,0.000056965215,0.000009025083,0.08713196],"study_design_scores_gemma":[0.0011454077,0.00065913197,0.0014474691,0.0003240223,0.00003387492,0.000006210313,0.000016778135,0.0008792529,0.99298614,0.00017338643,0.0021876788,0.0001406208],"about_ca_topic_score_codex":0.0008289839,"about_ca_topic_score_gemma":0.0006237468,"teacher_disagreement_score":0.20174025,"about_ca_system_score_codex":0.00017276345,"about_ca_system_score_gemma":0.00020619207,"threshold_uncertainty_score":0.6220137},"labels":[],"label_agreement":null},{"id":"W1974685860","doi":"10.5858/arpa.2013-0953-sa","title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1793,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Clinical Oncology; Guideline; Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Clinical Practice; Oncology; Internal medicine; Cancer; Gynecology; Pathology; Family medicine","score_opus":0.1532947712403345,"score_gpt":0.5152501178346831,"score_spread":0.3619553465943486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974685860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8521412,0.00042883115,0.0008750385,0.13997295,0.00050548057,0.0019178595,0.003456158,0.00005952069,0.00064296654],"genre_scores_gemma":[0.6896255,0.0037383414,0.29611498,0.008851372,0.0009784298,0.0003409917,0.00023072524,0.00007944138,0.000040242467],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910239,0.0024328043,0.004577677,0.0008277802,0.00047266358,0.00066520105],"domain_scores_gemma":[0.9821828,0.011010535,0.003388465,0.00075893896,0.002223975,0.00043531373],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0056857904,0.00034913,0.0028000644,0.0003626922,0.00008800121,0.0000019897407,0.0004924967,0.00023630139,0.00034587368],"category_scores_gemma":[0.015697544,0.00028699823,0.00032451365,0.001244267,0.008920459,0.00015459176,0.00024072069,0.0012728483,0.000004837413],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011834559,0.0018776075,0.6272201,0.00042062445,0.0003099643,0.00008883084,0.0010780469,0.0000026273847,0.05261379,0.0002626434,0.063304216,0.25163808],"study_design_scores_gemma":[0.008372521,0.010881273,0.9298538,0.000751562,0.00033574048,0.000113934235,0.006649384,0.00041168102,0.0011769781,0.00037080268,0.04074084,0.00034151558],"about_ca_topic_score_codex":0.002598291,"about_ca_topic_score_gemma":0.0001756352,"teacher_disagreement_score":0.30263364,"about_ca_system_score_codex":0.00012100795,"about_ca_system_score_gemma":0.002165741,"threshold_uncertainty_score":0.9999582},"labels":[],"label_agreement":null},{"id":"W1974840376","doi":"10.1186/1471-2407-14-166","title":"Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study","year":2014,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Pfizer","keywords":"Medicine; Trastuzumab; Tolerability; Sunitinib; Internal medicine; Adverse effect; Lapatinib; Breast cancer; Oncology; Clinical endpoint; Metastatic breast cancer; Cancer; Surgery; Clinical trial","score_opus":0.055248083394234544,"score_gpt":0.40422131192543503,"score_spread":0.3489732285312005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974840376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99276984,0.00051044696,0.00027147817,0.0015926756,0.00008203199,0.0030966657,0.0015533571,0.00001587086,0.00010761381],"genre_scores_gemma":[0.996959,0.00090305187,0.00014579116,0.00002925829,0.00013817604,0.00152125,0.000032815133,0.000024553685,0.00024610866],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875337,0.000108326116,0.0002464028,0.0003448648,0.00031667433,0.00023034106],"domain_scores_gemma":[0.9986557,0.00063542504,0.00012603364,0.00033937336,0.00016164801,0.00008181957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031831537,0.0001543354,0.00038244142,0.00007005495,0.0001147192,0.000009753926,0.00007382997,0.00004216011,0.000059984603],"category_scores_gemma":[0.000057387057,0.000095894895,0.000038572456,0.00021505375,0.00010951031,0.00006418712,0.000018958091,0.00010006457,2.390287e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060199894,0.0052746935,0.041165948,0.00009578439,0.00018452879,0.0000029966743,0.006479692,0.00031229248,0.002072665,0.000016162041,0.000106085456,0.88408923],"study_design_scores_gemma":[0.13162503,0.020386389,0.82347673,0.00045826886,0.00028396258,0.0000044194912,0.0020806356,0.0054835076,0.0051218164,0.000026432712,0.010847192,0.00020561316],"about_ca_topic_score_codex":0.024579782,"about_ca_topic_score_gemma":0.07143072,"teacher_disagreement_score":0.88388366,"about_ca_system_score_codex":0.0006729497,"about_ca_system_score_gemma":0.00047325375,"threshold_uncertainty_score":0.98191565},"labels":[],"label_agreement":null},{"id":"W1975577601","doi":"10.1097/pas.0b013e3181b72865","title":"HER2 Intermediate Breast Cancers","year":2009,"lang":"en","type":"letter","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.0248011963571624,"score_gpt":0.3455573383850037,"score_spread":0.3207561420278413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975577601","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08431527,0.0013293598,0.000023155817,0.9104742,0.00081361434,0.0002445379,0.000051964653,0.000025674404,0.0027222482],"genre_scores_gemma":[0.11492806,0.00773818,0.00028683344,0.85075796,0.023657192,0.00001750186,0.000034172375,0.00015965734,0.0024204368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99560946,0.001099408,0.00096103013,0.00035262795,0.0010969829,0.00088050263],"domain_scores_gemma":[0.9965928,0.00068424945,0.0012845953,0.0006711704,0.0004577918,0.00030935588],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014091927,0.00039126741,0.0018620802,0.0003993726,0.000070851,0.000028758826,0.00088621455,0.00033044597,0.00064166344],"category_scores_gemma":[0.00010372443,0.00022751445,0.0006288619,0.0005117803,0.0025063339,0.00004356348,0.00011928571,0.007135653,0.000113716414],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014021506,0.000044505177,0.00051101146,0.000049288778,0.0002031531,0.09960108,0.00016103122,0.0000062089416,0.00007166256,0.0000035342612,0.7708115,0.12713484],"study_design_scores_gemma":[0.0011858133,0.0038258145,0.0048329746,0.00039369025,0.00022596143,0.14057887,0.000111946334,0.0000047555945,0.000016704005,0.00017532185,0.8484219,0.00022628726],"about_ca_topic_score_codex":0.000119513585,"about_ca_topic_score_gemma":0.0000040184245,"teacher_disagreement_score":0.12690856,"about_ca_system_score_codex":0.00071902253,"about_ca_system_score_gemma":0.0012195669,"threshold_uncertainty_score":0.9951549},"labels":[],"label_agreement":null},{"id":"W1976545696","doi":"10.1097/01.pai.0000213138.01536.2e","title":"PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; Fluorescence in situ hybridization; Breast cancer; Gene duplication; Concordance; Tissue microarray; In situ hybridization; Pathology; HER2/neu; SKBR3; Cancer; Biology; Cancer research; Molecular biology; Gene; Medicine; Oncology; Internal medicine; Gene expression; Genetics","score_opus":0.012150194241980812,"score_gpt":0.3499342812423337,"score_spread":0.3377840870003529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976545696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971271,0.0034534496,0.0205,0.0004928375,0.0000818914,0.0021989725,0.00007930972,0.00003745187,0.0018851147],"genre_scores_gemma":[0.99265516,0.00034847262,0.0046186596,0.0002552229,0.000039123097,0.0017766396,0.00016199217,0.0000826984,0.000062007115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971766,0.000030668347,0.0008760204,0.0006837557,0.00040657198,0.0008264104],"domain_scores_gemma":[0.9982801,0.00023866349,0.00031200793,0.0008331327,0.00020639348,0.00012970611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011782122,0.0003577208,0.00065936556,0.0001916473,0.000089928704,0.000014785298,0.00034912262,0.00036938218,0.00007953357],"category_scores_gemma":[0.00009142176,0.00035644727,0.00011882265,0.00056650414,0.00056943664,0.000030607727,0.00020571554,0.0008727264,7.048227e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005824451,0.00034009002,0.0028036379,0.00048970827,0.00010405674,0.00008469709,0.00013853161,0.000060630067,0.99351424,0.00017155558,0.00009117064,0.0016192398],"study_design_scores_gemma":[0.004502673,0.00010912553,0.032636724,0.00026791383,0.00009409066,0.0006124651,0.00031073493,0.00013224992,0.96081376,0.0000617219,0.00013465992,0.00032386955],"about_ca_topic_score_codex":0.00083901954,"about_ca_topic_score_gemma":0.0000047845083,"teacher_disagreement_score":0.032700468,"about_ca_system_score_codex":0.0015073044,"about_ca_system_score_gemma":0.0009096343,"threshold_uncertainty_score":0.9998888},"labels":[],"label_agreement":null},{"id":"W1976913414","doi":"10.1067/mob.2003.347","title":"Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer","year":2003,"lang":"en","type":"article","venue":"American Journal of Obstetrics and Gynecology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Monoclonal antibody; Antibody; Immune system; Antigen; Immunology; Ovarian cancer; Internal medicine; Cancer; Adverse effect; Gastroenterology","score_opus":0.021191614882539463,"score_gpt":0.32938766422337024,"score_spread":0.3081960493408308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976913414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953281,0.0020587759,0.0002197867,0.001245386,0.0005292605,0.00035656817,0.000015549023,0.0000060198504,0.00024055],"genre_scores_gemma":[0.9950297,0.0015453228,0.0029373937,0.0001716031,0.00004152619,0.000026583906,0.0000014779889,0.000034475477,0.00021193578],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99761534,0.00036140016,0.00059538224,0.00025743514,0.0005705631,0.00059985544],"domain_scores_gemma":[0.9955351,0.002255089,0.0006160786,0.0002505302,0.000809456,0.0005337602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012073399,0.00020588268,0.0009844714,0.0006153589,0.00006653295,0.00001591106,0.00016336453,0.000062532796,0.00018383023],"category_scores_gemma":[0.0038188894,0.00013995783,0.000052570485,0.0014440194,0.0005005299,0.00005571466,0.00004615339,0.0005893085,0.0000018724647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014022237,0.0006802478,0.82922095,0.00015063788,0.0009690829,0.0015779855,0.0026280808,0.0001763055,0.0042770826,0.00018603678,0.00011228132,0.14599907],"study_design_scores_gemma":[0.0060928874,0.042720035,0.92796993,0.0002648906,0.00016128515,0.00088693266,0.0021294346,0.00003197297,0.0005959801,0.00002376507,0.018861774,0.00026112303],"about_ca_topic_score_codex":0.00015166726,"about_ca_topic_score_gemma":0.000039305825,"teacher_disagreement_score":0.14573795,"about_ca_system_score_codex":0.00051248015,"about_ca_system_score_gemma":0.0015727069,"threshold_uncertainty_score":0.57073146},"labels":[],"label_agreement":null},{"id":"W1977290575","doi":"10.1016/j.nucmedbio.2013.03.005","title":"Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments","year":2013,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Nuclear medicine; Pharmacokinetics; Breast carcinoma; Spleen; Ductal carcinoma; Carcinoma; Radiology; Pathology; Breast cancer; Internal medicine; Cancer","score_opus":0.02024150232607888,"score_gpt":0.3179105145745654,"score_spread":0.2976690122484865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977290575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99819887,0.000036562506,0.0000074334916,0.00034973468,0.00009477634,0.0010464245,0.000032975364,0.0000023504354,0.00023089202],"genre_scores_gemma":[0.99980354,0.000009698038,0.000036580772,0.000059255937,0.000045813857,0.000012203383,0.000015451637,0.000010613747,0.0000068507507],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99888283,0.00016100009,0.00043273057,0.00016605154,0.0002191045,0.000138304],"domain_scores_gemma":[0.9992522,0.00008029246,0.00022036138,0.00015495114,0.00023978607,0.00005239341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021604176,0.0001032776,0.00046547316,0.00012956322,0.000021670834,0.0000011217005,0.00007239359,0.00006423433,0.000096018484],"category_scores_gemma":[0.00011298146,0.000058666865,0.000043973738,0.0002275041,0.0004412782,0.000041522595,0.00003166134,0.0001678208,4.656408e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07226758,0.0037456423,0.36521488,0.00049936183,0.00035894153,0.000012078966,0.006335939,6.2092306e-7,0.5137054,0.000084242274,0.000098524506,0.03767681],"study_design_scores_gemma":[0.08707295,0.056914456,0.80703646,0.00080820394,0.00013332033,0.000024634388,0.003200828,0.00011382281,0.04453828,0.00002594275,0.000037330006,0.000093747534],"about_ca_topic_score_codex":0.0017847081,"about_ca_topic_score_gemma":0.0000904615,"teacher_disagreement_score":0.4691671,"about_ca_system_score_codex":0.000052714386,"about_ca_system_score_gemma":0.00012272649,"threshold_uncertainty_score":0.26979566},"labels":[],"label_agreement":null},{"id":"W1977874955","doi":"10.1097/pai.0b013e318169fc1c","title":"Systematic Review of HER2 Breast Cancer Testing","year":2008,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Concordance; Breast cancer; Medicine; Trastuzumab; Cochrane Library; Critical appraisal; Fish <Actinopterygii>; Oncology; MEDLINE; Internal medicine; Cancer; Meta-analysis; Pathology; Alternative medicine; Biology","score_opus":0.03304839716079931,"score_gpt":0.3771348958789459,"score_spread":0.34408649871814656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977874955","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002636728,0.98850185,0.000028257899,0.00007653824,0.0001382313,0.004522615,0.00018899988,0.00009736585,0.006419789],"genre_scores_gemma":[0.00004715359,0.9929707,0.0006237812,0.00062304863,0.00012117013,0.0043771015,0.0003945467,0.0002711132,0.0005713736],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99429446,0.00023570724,0.0025648768,0.0011200642,0.0009376285,0.0008472562],"domain_scores_gemma":[0.9945109,0.00030711567,0.0016826381,0.0026371046,0.000586757,0.00027550795],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005271313,0.0009930435,0.007309839,0.0002068078,0.00009539077,0.000010322317,0.0010133006,0.0008624083,0.0006709794],"category_scores_gemma":[0.00068891764,0.0008781779,0.0011550796,0.0011534065,0.0006363495,0.000016489614,0.00037202027,0.0016415925,0.00016356425],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016010708,0.00011655567,3.7558377e-7,0.900226,0.0009206034,0.0008068845,0.000009057986,1.3855541e-7,0.0732145,0.000012274838,0.0020814028,0.022596173],"study_design_scores_gemma":[0.0004484181,0.000064534775,7.515733e-7,0.9520191,0.0052657,0.022703858,0.000007673556,5.797381e-7,0.0014837581,0.000004248497,0.017330373,0.0006710032],"about_ca_topic_score_codex":0.00014148187,"about_ca_topic_score_gemma":2.5433408e-8,"teacher_disagreement_score":0.07173074,"about_ca_system_score_codex":0.0013836814,"about_ca_system_score_gemma":0.0029785666,"threshold_uncertainty_score":0.9993669},"labels":[],"label_agreement":null},{"id":"W1978986213","doi":"10.5539/cco.v2n1p17","title":"Improved Survival of HER2-Positive Metastatic Breast Cancer in Routine Care","year":2012,"lang":"en","type":"article","venue":"Cancer and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Radiation therapy; Metastasis; Chemotherapy; Cancer; Hormonal therapy","score_opus":0.11095570523052116,"score_gpt":0.5247413960935513,"score_spread":0.41378569086303013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978986213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756229,0.012370827,0.000022538066,0.005548931,0.0013228059,0.00070181163,0.00037848952,0.000017360906,0.0040143305],"genre_scores_gemma":[0.99319017,0.004675855,0.0001513793,0.0007703883,0.00073294557,0.00013973562,0.00001222652,0.000024975592,0.00030233676],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99789906,0.00034005527,0.00071863754,0.000314181,0.00021602276,0.00051206147],"domain_scores_gemma":[0.99818766,0.0007524412,0.00016292355,0.00021122489,0.00028171824,0.00040404696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010681826,0.00015269575,0.0009569018,0.0000745068,0.000027122522,0.0000038819253,0.00010163887,0.000211454,0.000826945],"category_scores_gemma":[0.00023006595,0.00012148163,0.00012561871,0.00023804471,0.000448114,0.00006200029,0.00010230275,0.000620729,0.000005420168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012655915,0.00051419775,0.7370019,0.0002266457,0.00017845024,0.000020822801,0.0007906456,0.0000015134597,0.00032994905,0.00007399053,0.00023368491,0.2593626],"study_design_scores_gemma":[0.0059153824,0.0015164946,0.9846398,0.00022618286,0.00028409535,0.000026486687,0.0014638957,0.00010989275,0.00036349695,0.000016677419,0.005291069,0.0001465283],"about_ca_topic_score_codex":0.0047784955,"about_ca_topic_score_gemma":0.0048940084,"teacher_disagreement_score":0.25921607,"about_ca_system_score_codex":0.00058684015,"about_ca_system_score_gemma":0.0013255933,"threshold_uncertainty_score":0.90544677},"labels":[],"label_agreement":null},{"id":"W1979488703","doi":"10.1002/ijc.11599","title":"HER‐2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors","year":2003,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Response Biomedical (Canada)","funders":"National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Colorectal Cancer Alliance","keywords":"Biology; Cytoplasm; Oncogene; Immunohistochemistry; Molecular biology; Cell culture; Immunoelectron microscopy; Cell; Colorectal cancer; Pathology; Cancer; Cell cycle; Cancer research; Cell biology; Immunology; Medicine; Biochemistry","score_opus":0.023545232991041953,"score_gpt":0.3872312312991643,"score_spread":0.36368599830812237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979488703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940162,0.0029394205,0.0002790017,0.0014174478,0.00040938615,0.0001457306,0.000007690194,0.0000052350383,0.00077989505],"genre_scores_gemma":[0.9962762,0.0023506938,0.00024490347,0.0003243166,0.0004450943,0.000024750718,0.0000033334552,0.000018154593,0.00031255162],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987347,0.00006365953,0.00038434094,0.00013995523,0.0005485489,0.00012880281],"domain_scores_gemma":[0.9988195,0.00005677205,0.00022012873,0.00004475372,0.00074068387,0.0001182095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002808583,0.000097790966,0.00019225817,0.00017653446,0.00003825486,0.000037949372,0.00008972765,0.00006342787,0.001123612],"category_scores_gemma":[0.00015331137,0.000081545266,0.00002980377,0.00011457466,0.00007639444,0.00022516075,0.000024975288,0.00022154136,7.864753e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058858993,0.00017184157,0.6257929,0.00009338304,0.000096990356,0.000034208057,0.0009544456,0.00034345416,0.35746637,0.00027145512,0.007331835,0.006854522],"study_design_scores_gemma":[0.005913753,0.0003962628,0.17845406,0.002567101,0.000038208847,0.00009919653,0.0006586271,0.00022916491,0.76088595,0.00050056295,0.050014704,0.00024238341],"about_ca_topic_score_codex":0.0006667187,"about_ca_topic_score_gemma":0.0004055458,"teacher_disagreement_score":0.44733885,"about_ca_system_score_codex":0.000471541,"about_ca_system_score_gemma":0.00038489015,"threshold_uncertainty_score":0.9997895},"labels":[],"label_agreement":null},{"id":"W1979791033","doi":"10.1038/bjc.2011.355","title":"Molecular characterisation of formalin-fixed paraffin-embedded (FFPE) breast tumour specimens using a custom 512-gene breast cancer bead array-based platform","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute; McGill University; Université du Québec","funders":"National Institute of General Medical Sciences; Winship Cancer Institute; National Cancer Institute; National Institutes of Health; Georgia Research Alliance; Emory University","keywords":"Breast cancer; Bead; Pathology; Medicine; Cancer; Biology; Materials science; Internal medicine","score_opus":0.05657751986548907,"score_gpt":0.3345027286124366,"score_spread":0.2779252087469475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979791033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199826,0.0035701913,0.0016605101,0.0006001033,0.0006773338,0.00052286393,0.000643467,0.000026079088,0.00030117156],"genre_scores_gemma":[0.99423593,0.0011397352,0.0029678752,0.00044458103,0.0010000425,0.0000379849,0.000020561985,0.000101624966,0.00005166984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962928,0.0000945981,0.0012173887,0.00032857896,0.0013636824,0.0007029203],"domain_scores_gemma":[0.99653363,0.000033445707,0.0010738051,0.00030021742,0.0015516866,0.0005072313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000745228,0.0003138689,0.00090762204,0.00036136102,0.00011491271,0.00006643326,0.0003456905,0.00020036912,0.0024820461],"category_scores_gemma":[0.000046581637,0.00033592948,0.00039103226,0.00048598283,0.00021597235,0.00047221017,0.00004698867,0.0007560957,0.000008752613],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943636,0.0006556733,0.020829039,0.00059517415,0.0006888456,0.0020154854,0.0008907034,0.0007610391,0.8879905,0.000022610247,0.0005622905,0.08104504],"study_design_scores_gemma":[0.0075464435,0.00050071866,0.2670901,0.0058633727,0.0006346591,0.012453574,0.00026574556,0.0012328158,0.70282865,0.000062868785,0.00095624186,0.00056478736],"about_ca_topic_score_codex":0.004819203,"about_ca_topic_score_gemma":0.00053663226,"teacher_disagreement_score":0.24626106,"about_ca_system_score_codex":0.000940222,"about_ca_system_score_gemma":0.002461046,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W1979836319","doi":"10.1158/0008-5472.sabcs-09-5111","title":"A Phase 1 Study To Assess the Safety, Tolerability and Pharmacokinetics of ARRY-380 – An Oral Inhibitor of HER2.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tolerability; Medicine; Pharmacokinetics; Dosing; Nausea; Rash; Adverse effect; Pharmacology; Internal medicine; Cancer; Toxicity; Pharmacodynamics; Breast cancer; Oncology; Gastroenterology","score_opus":0.2830463335743338,"score_gpt":0.5830860017591729,"score_spread":0.3000396681848391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979836319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013567,0.00064897106,0.000031696538,0.0054391907,0.000102301274,0.0028568306,0.000082366685,0.000019222403,0.00068375573],"genre_scores_gemma":[0.99854684,0.00027774496,0.00015720644,0.00020854775,0.00031203145,0.00014538187,0.000004661842,0.00002764085,0.00031995383],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99548656,0.00090225774,0.00057013956,0.0005227299,0.0018901413,0.0006281445],"domain_scores_gemma":[0.9968158,0.00035436882,0.00006816433,0.00092599535,0.0013341759,0.0005014706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051289783,0.00017037507,0.0005543246,0.00027597402,0.00013985868,0.000039359726,0.000477148,0.00006503572,0.00047740914],"category_scores_gemma":[0.00058954145,0.00012059997,0.00005892571,0.0012436629,0.0005182666,0.000094540716,0.00024066263,0.00085008185,0.0000047553826],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01231369,0.014240807,0.06580758,0.00082244567,0.00021487786,0.000108910055,0.011625861,0.00008075566,0.54097825,0.00014258055,0.010320551,0.34334368],"study_design_scores_gemma":[0.028335424,0.06630943,0.21099976,0.0009897781,0.00022487191,0.000034426605,0.011994822,0.0011254146,0.64078605,0.0006222609,0.037950505,0.0006272446],"about_ca_topic_score_codex":0.0012960857,"about_ca_topic_score_gemma":0.00031668862,"teacher_disagreement_score":0.34271643,"about_ca_system_score_codex":0.0003155133,"about_ca_system_score_gemma":0.0010421129,"threshold_uncertainty_score":0.5227295},"labels":[],"label_agreement":null},{"id":"W1980168308","doi":"10.1007/s10549-007-9656-y","title":"HER2/neu in systemic therapy for women with breast cancer: a systematic review","year":2007,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Cancer Care Ontario; McMaster University; Mount Sinai Hospital; Sunnybrook Health Science Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Taxane; Oncology; Internal medicine; Anthracycline; Breast cancer; Hazard ratio; Meta-analysis; Adjuvant therapy; Confidence interval; Regimen; Relative risk; Cochrane Library; Clinical trial; Randomized controlled trial; Cancer; Gynecology","score_opus":0.17333335732310998,"score_gpt":0.5007484195405519,"score_spread":0.327415062217442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980168308","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001540021,0.9648531,0.0000018438694,0.0010838109,0.00007773079,0.031109218,0.0024494894,0.00006129554,0.00020951836],"genre_scores_gemma":[0.000338089,0.89988697,0.000018859173,0.00011809979,0.00045254148,0.09579606,0.000098704644,0.00024337345,0.0030472775],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99204427,0.00082439504,0.0014323806,0.0015069977,0.0018766907,0.0023152456],"domain_scores_gemma":[0.99543124,0.0007663171,0.00039270954,0.0013326148,0.0009751321,0.0011020089],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031471315,0.0010589412,0.006181797,0.0010702542,0.00023004107,0.00014038236,0.0004811685,0.00039154897,0.00037209675],"category_scores_gemma":[0.00004805762,0.00059656904,0.00038228446,0.0019651805,0.00037690531,0.00010453413,0.000112933085,0.0009723306,0.00004244979],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001182572,0.0004283852,0.00015797604,0.5376742,0.0012198853,0.0002986959,0.00010792277,1.03208194e-7,3.863731e-7,0.000011088657,0.0003017987,0.458617],"study_design_scores_gemma":[0.0042464496,0.0024036951,0.00016769061,0.836479,0.00086253206,0.005277406,0.00016221337,0.0000023587422,0.0000011766011,0.000007797032,0.14989357,0.00049611984],"about_ca_topic_score_codex":0.006638586,"about_ca_topic_score_gemma":0.0016457177,"teacher_disagreement_score":0.45812088,"about_ca_system_score_codex":0.013001779,"about_ca_system_score_gemma":0.007352615,"threshold_uncertainty_score":0.9999763},"labels":[],"label_agreement":null},{"id":"W1980356205","doi":"10.1016/j.radonc.2009.06.017","title":"The deletion mutant EGFRvIII significantly contributes to stress resistance typical for the tumour microenvironment","year":2009,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"KWF Kankerbestrijding","keywords":"In vivo; Cancer research; Clonogenic assay; Cell culture; In vitro; Epidermal growth factor receptor; Cell growth; Biology; Mutant; Tumor microenvironment; Chemistry; Receptor; Gene; Genetics; Tumor cells","score_opus":0.021359013602000293,"score_gpt":0.3457004025610288,"score_spread":0.32434138895902853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980356205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4820144,0.050341867,0.016418315,0.4456214,0.00043446585,0.004476192,0.000086385306,0.000050546925,0.0005564364],"genre_scores_gemma":[0.969016,0.01390805,0.0013873263,0.011677702,0.000555336,0.0003336818,0.000008740011,0.000026507212,0.0030866538],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99888045,0.00011719908,0.00021800502,0.0002495075,0.00015964686,0.00037521916],"domain_scores_gemma":[0.9986609,0.0008781099,0.000049648468,0.0002490203,0.00004415635,0.000118150725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006256888,0.000112826856,0.00024752555,0.000030317664,0.00042201023,0.000025796468,0.00015226848,0.0001008324,0.000052106985],"category_scores_gemma":[0.00009830606,0.00006219798,0.00005675148,0.000088145636,0.00023041993,0.00001194597,0.000016687929,0.00017800268,0.000005459429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025779905,0.00045455885,0.0026348904,0.00006477442,0.0002896596,0.00007351768,0.0012458178,0.000049757047,0.5781329,0.0072774044,0.07323542,0.3107614],"study_design_scores_gemma":[0.0022431798,0.0019637733,0.04334985,0.000036204394,0.000035070687,0.000029394721,0.0001690677,0.00022434999,0.01547812,0.00033606688,0.93605596,0.00007894007],"about_ca_topic_score_codex":0.000008484425,"about_ca_topic_score_gemma":0.00033602654,"teacher_disagreement_score":0.86282057,"about_ca_system_score_codex":0.0009305402,"about_ca_system_score_gemma":0.00011847767,"threshold_uncertainty_score":0.3245804},"labels":[],"label_agreement":null},{"id":"W1980543089","doi":"10.1016/j.nucmedbio.2014.09.011","title":"Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab","year":2014,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; McMaster University; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research","keywords":"Biodistribution; Clinical trial; Pharmacokinetics; Dosimetry; Medicine; Pharmacology; Regulatory authority; Medical physics; Toxicity; Oncology; Nuclear medicine; Internal medicine; In vivo; Biotechnology; Biology","score_opus":0.3390109953650138,"score_gpt":0.5810161384611477,"score_spread":0.24200514309613397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1980543089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863771,0.0009773214,0.001883564,0.0051843743,0.0010427277,0.004322307,0.00015091899,0.000031009742,0.00003067976],"genre_scores_gemma":[0.99099934,0.0026195678,0.0013908846,0.00071918673,0.0038308112,0.00016552683,0.00021936829,0.000024550935,0.000030767962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961797,0.0004995251,0.0021796122,0.0006389214,0.00021542714,0.0002867858],"domain_scores_gemma":[0.9949187,0.003236878,0.0007560025,0.00038629622,0.00045998016,0.00024212924],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007207821,0.00019353119,0.0015506836,0.00012967254,0.000106331,0.0000029650396,0.00013867389,0.00041104126,0.000016700196],"category_scores_gemma":[0.01253006,0.00013906843,0.00024546334,0.0001522605,0.0019869357,0.00003466249,0.000105924,0.00030878006,6.3467854e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.514295,0.0017728942,0.00083671015,0.00046491038,0.000719185,5.730553e-7,0.00018762112,5.44181e-8,0.014158059,0.0012013968,0.012908984,0.4534546],"study_design_scores_gemma":[0.7362436,0.14462575,0.0010311488,0.00015430369,0.0014217271,0.000013481846,0.00020325802,0.004062719,0.0020690889,0.0010304423,0.1089474,0.00019706985],"about_ca_topic_score_codex":0.000016875636,"about_ca_topic_score_gemma":0.0000021972555,"teacher_disagreement_score":0.45325753,"about_ca_system_score_codex":0.000039634986,"about_ca_system_score_gemma":0.0002102684,"threshold_uncertainty_score":0.9957878},"labels":[],"label_agreement":null},{"id":"W1981249718","doi":"10.1074/jbc.275.9.6600","title":"Characterization of a Repressor Element and a Juxtaposed Tissue-restricted Activator Element Located on the Distal neu Gene Promoter","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Occupational Cancer Research Centre; Cancer Care Ontario; Ontario Institute for Cancer Research","funders":"","keywords":"Repressor; Molecular biology; Biology; Promoter; Gene; Transcription (linguistics); DNA; Reporter gene; Base pair; Response element; Activator (genetics); Transcription factor; Genetics; Gene expression","score_opus":0.043327417591045324,"score_gpt":0.32051227406763716,"score_spread":0.27718485647659186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981249718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965715,0.00006975854,0.000022568023,0.0026348836,0.000016853957,0.0003111101,0.000029212091,0.000008418161,0.00033574246],"genre_scores_gemma":[0.998728,0.00034768225,0.00008085787,0.00017017109,0.00020888273,0.000013846464,0.00003518489,0.000008880087,0.00040650374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986691,0.00007236331,0.0005034024,0.00017597228,0.00038014908,0.00019904997],"domain_scores_gemma":[0.9991515,0.00007479728,0.00026759773,0.00020160661,0.00015669041,0.00014775876],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003090272,0.00012624892,0.00029585982,0.00002282939,0.0000396605,0.000016754539,0.00013970288,0.00012226086,0.0020885712],"category_scores_gemma":[0.00021705743,0.00006618174,0.00006538422,0.0001510172,0.000121509474,0.000026248068,0.000036931167,0.0003649835,0.0000026710347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013047326,0.0003277766,0.0011959011,0.00006753087,0.00007154391,0.000056738336,0.000048155707,9.2127647e-7,0.98757994,0.0000013713043,0.00014248087,0.009202928],"study_design_scores_gemma":[0.0009982558,0.0010788506,0.024891084,0.0001499402,0.000026649956,0.00010970833,0.000023867664,0.00003905033,0.96702504,0.000014490576,0.0055761924,0.00006685065],"about_ca_topic_score_codex":0.000003529327,"about_ca_topic_score_gemma":6.262948e-8,"teacher_disagreement_score":0.023695182,"about_ca_system_score_codex":0.00009656762,"about_ca_system_score_gemma":0.00009625916,"threshold_uncertainty_score":0.99882364},"labels":[],"label_agreement":null},{"id":"W1982624212","doi":"10.1016/j.semcancer.2005.01.003","title":"ETV6–NTRK3: a chimeric protein tyrosine kinase with transformation activity in multiple cell lineages","year":2005,"lang":"en","type":"review","venue":"Seminars in Cancer Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada); University of British Columbia","funders":"","keywords":"Transformation (genetics); Tyrosine kinase; Cell biology; Receptor tyrosine kinase; Chimeric gene; Biology; Gene; Signal transduction; Genetics; Gene expression","score_opus":0.08058589550381658,"score_gpt":0.4234648176214793,"score_spread":0.34287892211766274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982624212","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060636983,0.9872578,0.000045551584,0.0005052708,0.0001582691,0.004849743,0.00023675383,0.00005332366,0.0008295858],"genre_scores_gemma":[0.0067807576,0.9873491,0.00077531417,0.00007898355,0.0004081231,0.0036467686,0.0002772142,0.00010914457,0.0005745843],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996607,0.0005016273,0.0008141361,0.0008668696,0.00030702737,0.0009033175],"domain_scores_gemma":[0.99855614,0.00024899628,0.00033523768,0.00059603463,0.00008238589,0.0001812314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007343025,0.00063671893,0.0022829801,0.00083770225,0.000050621613,0.000016007685,0.00034305165,0.0008555642,0.00025724396],"category_scores_gemma":[0.000105418425,0.00047468365,0.00020883829,0.001400948,0.00032686652,0.00010043682,0.00007535169,0.0019064295,0.00003865847],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042892862,0.00038749594,0.00074075616,0.01536894,0.00004531841,0.00009059411,0.00025870983,0.0000109692755,0.00056184706,0.000003990196,0.00015634,0.9819461],"study_design_scores_gemma":[0.0023674986,0.0010999709,0.00016465527,0.03501982,0.00015715201,0.000059865142,0.000036079655,0.00013646427,0.001670519,0.0000044026597,0.9587495,0.00053410983],"about_ca_topic_score_codex":0.0021763153,"about_ca_topic_score_gemma":0.0040519885,"teacher_disagreement_score":0.981412,"about_ca_system_score_codex":0.001792777,"about_ca_system_score_gemma":0.0019539036,"threshold_uncertainty_score":0.99977046},"labels":[],"label_agreement":null},{"id":"W1983589811","doi":"10.1016/j.neuroscience.2007.04.066","title":"Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and hippocampus","year":2007,"lang":"en","type":"article","venue":"Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University; Douglas Mental Health University Institute","funders":"Canadian Institutes of Health Research","keywords":"Biology; Hippocampal formation; Neuroscience; Dendritic spine; ERBB4; Glial fibrillary acidic protein; Hippocampus; Cerebral cortex; Astrocyte; Immunocytochemistry; Cell biology; Receptor tyrosine kinase; Central nervous system; Endocrinology; Immunohistochemistry; Kinase; Immunology","score_opus":0.029569792642449317,"score_gpt":0.32988400967044784,"score_spread":0.30031421702799854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983589811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970165,0.000071757946,0.000025941343,0.00048475468,0.00033335717,0.00042821912,0.000009666836,0.000022713095,0.0016070755],"genre_scores_gemma":[0.9969884,0.000025119249,0.0016971654,0.00061537215,0.000051303843,0.000008580282,0.0000029881007,0.000014187726,0.0005968432],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99824774,0.000037364778,0.00028400883,0.0004169634,0.0005840564,0.00042988564],"domain_scores_gemma":[0.99946135,0.00007505064,0.000053965425,0.0001412229,0.000059661877,0.00020876629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005954376,0.0001110168,0.00018634497,0.00019749519,0.00005375738,0.000017226588,0.00018163922,0.000059362534,0.00012311831],"category_scores_gemma":[0.00043910963,0.000100241006,0.000022130936,0.00067150523,0.000459229,0.0001212959,0.00013623352,0.0002879396,0.000018536986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020476607,0.00010700037,0.26817772,0.00007606523,6.999138e-7,0.00020246851,0.00028276246,4.9013784e-7,0.7125159,0.00003647724,0.0011469229,0.017248731],"study_design_scores_gemma":[0.0009939559,0.0004953433,0.8532714,0.00009930017,0.0000024190838,0.00036526108,0.00015145939,0.00021645101,0.14152731,0.000017159517,0.0027444952,0.00011541281],"about_ca_topic_score_codex":0.000055893874,"about_ca_topic_score_gemma":0.000037392892,"teacher_disagreement_score":0.58509374,"about_ca_system_score_codex":0.00010035167,"about_ca_system_score_gemma":0.00038728572,"threshold_uncertainty_score":0.40877095},"labels":[],"label_agreement":null},{"id":"W1984634863","doi":"10.1002/pros.22475","title":"“Combi‐targeting” mitozolomide: Conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer","year":2012,"lang":"en","type":"article","venue":"The Prostate","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research; China Scholarship Council; Prostate Cancer Canada","keywords":"DU145; In vivo; LNCaP; Cancer research; Epidermal growth factor receptor; DNA damage; Comet assay; Cytotoxicity; Prostate cancer; Pharmacology; Apoptosis; Biology; Cancer; Molecular biology; In vitro; Medicine; Biochemistry; Internal medicine; DNA","score_opus":0.08884745670678014,"score_gpt":0.36372449310603977,"score_spread":0.27487703639925964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984634863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958385,0.0038394846,0.000011190868,0.0024889077,0.00022730854,0.003593515,0.00002918008,0.00006051811,0.00016607101],"genre_scores_gemma":[0.9966905,0.0004483365,0.0004909653,0.00035844947,0.0003020469,0.0012387268,0.000013905334,0.000059672817,0.0003974012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749106,0.0002310747,0.000560579,0.0003132557,0.00059083017,0.0008132214],"domain_scores_gemma":[0.99885905,0.00014210002,0.00016663267,0.00046840636,0.0001714958,0.0001923022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014401614,0.0002665019,0.0004170525,0.000117908414,0.00019583177,0.00004301721,0.00022274633,0.000050313698,0.000028689012],"category_scores_gemma":[0.00013034603,0.00014186717,0.00008258557,0.0003341309,0.0001594696,0.00019410386,0.00007034262,0.00026751295,0.00001102491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015424185,0.0007819651,0.031683706,0.0002763746,0.00007751422,0.000010430086,0.15972559,0.0017913771,0.7784167,0.000018861574,0.00008982926,0.025585245],"study_design_scores_gemma":[0.006022351,0.0022902563,0.021005666,0.0012635805,0.00011613032,0.00001812013,0.01545896,0.00097119535,0.9409705,0.000041353047,0.011429025,0.00041289526],"about_ca_topic_score_codex":0.001260139,"about_ca_topic_score_gemma":0.00016976953,"teacher_disagreement_score":0.16255379,"about_ca_system_score_codex":0.00041902423,"about_ca_system_score_gemma":0.00023756597,"threshold_uncertainty_score":0.57851756},"labels":[],"label_agreement":null},{"id":"W1984729575","doi":"10.1016/s1470-2045(09)70295-5","title":"Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?","year":2009,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Progesterone receptor; Oncology; Concordance; Biopsy; Internal medicine; Hormone receptor; Cancer; Estrogen receptor; Gynecology","score_opus":0.16106710979578487,"score_gpt":0.44171524985814115,"score_spread":0.2806481400623563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984729575","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013145709,0.00034963407,0.000009982097,0.9794904,0.00028377416,0.002009734,0.0008110713,0.00009007185,0.0038096325],"genre_scores_gemma":[0.010475367,0.00049557426,0.0005097581,0.977997,0.0048284363,0.0023856726,0.00014407176,0.00011402278,0.0030501042],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955978,0.0008200251,0.00047888418,0.0007373504,0.0007593382,0.0016066078],"domain_scores_gemma":[0.99743503,0.0005196975,0.00018723149,0.0012412597,0.0001712266,0.00044556506],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001272954,0.0004746002,0.0018079319,0.00036684243,0.000073236326,0.000038422073,0.00079156714,0.00033616362,0.0020564133],"category_scores_gemma":[0.00012316198,0.00029364388,0.00007847405,0.0007103347,0.0002557715,0.000037005495,0.00015035762,0.0037231469,0.00009701874],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0080392845,0.000176355,0.0013780001,0.0005549127,0.0002790722,0.008837014,0.0008806263,0.000016501639,0.0000431552,0.000018515904,0.9561264,0.023650184],"study_design_scores_gemma":[0.0040829075,0.0014164011,0.016177466,0.0006158013,0.00020114459,0.0006305479,0.00012853209,0.000024038656,0.0000061565397,0.0002313964,0.976135,0.00035061451],"about_ca_topic_score_codex":0.0015895981,"about_ca_topic_score_gemma":0.00087102957,"teacher_disagreement_score":0.02329957,"about_ca_system_score_codex":0.0031252452,"about_ca_system_score_gemma":0.0027546475,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W1985285674","doi":"10.1016/j.annpat.2011.10.013","title":"Détermination de l’amplification de l’oncogène HER-2 dans le cancer du sein invasif par hybridation chromogénique in situ double couleur (dc-CISH) : étude comparative avec l’hybridation fluorescente in situ (FISH)","year":2011,"lang":"fr","type":"review","venue":"Annales de Pathologie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Biology; Molecular biology; Medicine","score_opus":0.19465328660041734,"score_gpt":0.4239853753041589,"score_spread":0.22933208870374158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985285674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69369906,0.27743816,0.013231373,0.0025598754,0.00075681775,0.006819021,0.0003151535,0.00025077505,0.0049297307],"genre_scores_gemma":[0.51066166,0.4834012,0.00097550807,0.00033295163,0.0005195118,0.00191092,0.0017801486,0.00011398769,0.00030411704],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9903324,0.0032162394,0.0020520822,0.0016183023,0.00078950834,0.0019914436],"domain_scores_gemma":[0.9958527,0.0006375421,0.0011344544,0.0011382672,0.00072434224,0.0005126643],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0062265582,0.0010377994,0.0021550185,0.001017188,0.00026267112,0.00017778283,0.001068697,0.0010802632,0.0002493403],"category_scores_gemma":[0.0010679063,0.0011266895,0.00038344035,0.0014563642,0.0006670041,0.00074357766,0.00033346406,0.0024092179,0.00036632188],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016207619,0.0045797173,0.17105936,0.025122829,0.00042505423,0.006310635,0.034433406,0.0011657024,0.10731017,0.0011835102,0.008912656,0.6378762],"study_design_scores_gemma":[0.008686314,0.0014026493,0.6268247,0.044495802,0.0010054824,0.0020097855,0.0027082604,0.0057675666,0.19451258,0.0011405017,0.10849817,0.002948216],"about_ca_topic_score_codex":0.0051260353,"about_ca_topic_score_gemma":0.0293351,"teacher_disagreement_score":0.634928,"about_ca_system_score_codex":0.008698045,"about_ca_system_score_gemma":0.0062046098,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W1985328983","doi":"10.1200/jco.2007.12.8033","title":"Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; American Society of Clinical Oncology","keywords":"Medicine; Tissue microarray; Oncology; Internal medicine; Human Epidermal Growth Factor Receptor 2; Biomarker; Clinical Oncology; Trastuzumab; Epidermal growth factor receptor; Estrogen receptor; Immunohistochemistry; Pathology; Cancer; Breast cancer; Biology","score_opus":0.6171535550304519,"score_gpt":0.662183900523995,"score_spread":0.04503034549354312,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985328983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9562887,0.00012058134,0.0016672508,0.038513336,0.00023532192,0.0017590241,0.0014034497,0.0000023590546,0.0000099925865],"genre_scores_gemma":[0.9534707,0.00023839547,0.043558564,0.002148185,0.00039658675,0.00015511768,0.000008642542,0.000019280033,0.0000045297065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922943,0.001091524,0.0055632433,0.00034606794,0.00038721817,0.0003176273],"domain_scores_gemma":[0.9796314,0.011696144,0.006004799,0.00033739136,0.002138332,0.00019190476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0134263765,0.0001690615,0.002454156,0.00017569361,0.000045360404,0.0000022433533,0.0004889064,0.00020178882,0.000020989737],"category_scores_gemma":[0.007849749,0.000107237574,0.0005607657,0.00053415087,0.0011416489,0.000055987828,0.00009331077,0.00070849323,1.8957378e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032393436,0.0019124974,0.9130435,0.00024614035,0.00015136284,0.0000037946568,0.0003330205,0.00001681072,0.037523836,0.00012499097,0.0007110463,0.04269364],"study_design_scores_gemma":[0.00397934,0.00966637,0.98045963,0.00021876098,0.00015389286,0.000007825081,0.0011549186,0.00024059451,0.002933277,0.000054265845,0.0010472118,0.00008393278],"about_ca_topic_score_codex":0.0015588894,"about_ca_topic_score_gemma":0.0023143755,"teacher_disagreement_score":0.067416094,"about_ca_system_score_codex":0.00039209743,"about_ca_system_score_gemma":0.0019386114,"threshold_uncertainty_score":0.93974495},"labels":[],"label_agreement":null},{"id":"W1986004507","doi":"10.1158/0008-5472.sabcs-4115","title":"Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Tolerability; Medicine; Metastatic breast cancer; Trastuzumab; Taxane; Internal medicine; Sunitinib; Dosing; Breast cancer; Clinical endpoint; Lapatinib; Placebo; Oncology; Pharmacology; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.1784208525827542,"score_gpt":0.5111586758417982,"score_spread":0.332737823259044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986004507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864847,0.0009497005,0.00004309775,0.0053049647,0.00003120829,0.0043615834,0.0026934652,0.000008457414,0.0001227993],"genre_scores_gemma":[0.9964685,0.0022619436,0.00006170927,0.000016232045,0.0000931956,0.0009208565,0.00004237977,0.000020930644,0.00011425315],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99743265,0.00037324315,0.00039945144,0.00039670357,0.00097291515,0.000425061],"domain_scores_gemma":[0.99733424,0.0013211836,0.0001171408,0.00042396394,0.0006688668,0.00013457866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013398152,0.00015871688,0.00053318683,0.0002899771,0.00017629916,0.000016627979,0.00015962296,0.000046843837,0.000101696365],"category_scores_gemma":[0.00015073687,0.00010061841,0.000050602874,0.0007500339,0.00038847464,0.00008800435,0.00003310695,0.00030459434,2.5076818e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10631632,0.013145925,0.003241605,0.00018119944,0.00047600738,0.000054576623,0.013802581,0.000057622856,0.015687523,0.00005147593,0.0001958999,0.84678924],"study_design_scores_gemma":[0.2288283,0.14225863,0.49478382,0.0017396867,0.000588543,0.00002580448,0.011194964,0.0028676926,0.11406375,0.00041561568,0.002818165,0.00041502793],"about_ca_topic_score_codex":0.029989218,"about_ca_topic_score_gemma":0.009240391,"teacher_disagreement_score":0.8463742,"about_ca_system_score_codex":0.00087681436,"about_ca_system_score_gemma":0.0014231614,"threshold_uncertainty_score":0.9764702},"labels":[],"label_agreement":null},{"id":"W1986396848","doi":"10.1016/j.drup.2008.04.001","title":"Progress and challenges in the identification of biomarkers for EGFR and VEGFR targeting anticancer agents","year":2008,"lang":"en","type":"review","venue":"Drug Resistance Updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Fondation de France; American Association for Cancer Research","keywords":"Medicine; Biomarker; Biomarker discovery; Trastuzumab; Imatinib; Drug; Clinical trial; Breast cancer; Druggability; Personalized medicine; Sunitinib; Oncology; Cancer; Pharmacology; Bioinformatics; Cancer research; Internal medicine; Biology; Proteomics","score_opus":0.1392766723441191,"score_gpt":0.4201719401740726,"score_spread":0.2808952678299535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986396848","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004401326,0.99478686,0.0000018974462,0.0019667044,0.000092531074,0.0024160896,0.000093073024,0.000015361325,0.00018735806],"genre_scores_gemma":[0.0010605725,0.997253,0.00042579585,0.000020899513,0.00010221217,0.00073844666,0.00012863084,0.00005194875,0.0002185001],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756205,0.00024000794,0.000811452,0.0005712656,0.00046029183,0.00035492942],"domain_scores_gemma":[0.9983803,0.00052920805,0.0004248497,0.00045174037,0.0001415042,0.00007239567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014179582,0.00028122324,0.0010340309,0.00024383607,0.00009964693,0.00004018622,0.00027048003,0.0001505932,0.000006599477],"category_scores_gemma":[0.00037891144,0.00019344257,0.00012625153,0.0003547504,0.000496749,0.00007105821,0.00006441647,0.0002534679,0.0000018586742],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000111361,0.00011231022,0.00045522736,0.1043303,0.00021338041,0.000030860945,0.0011142761,2.8692646e-8,0.0000069974853,0.00026514646,0.0099557815,0.8834043],"study_design_scores_gemma":[0.0004174492,0.000027384782,0.0006188655,0.012918235,0.00018080887,0.00001800541,0.000434662,0.000011019926,0.00004260354,0.00006999879,0.98508763,0.00017334528],"about_ca_topic_score_codex":0.0000104759965,"about_ca_topic_score_gemma":0.000055792298,"teacher_disagreement_score":0.97513187,"about_ca_system_score_codex":0.00011301419,"about_ca_system_score_gemma":0.0002182159,"threshold_uncertainty_score":0.7888359},"labels":[],"label_agreement":null},{"id":"W1986405458","doi":"10.1179/joc.2011.23.1.32","title":"Trastuzumab and Vinorelbine in Early Stages of HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"Journal of Chemotherapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Vinorelbine; Trastuzumab; Oncology; Medicine; Breast cancer; Internal medicine; Chemotherapy; Cancer; Cisplatin","score_opus":0.027853901849152547,"score_gpt":0.3377025580965879,"score_spread":0.30984865624743535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986405458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951889,0.0018068443,0.000026282662,0.0018781708,0.000058328937,0.00015701343,0.000017021308,0.0000033498009,0.00086412264],"genre_scores_gemma":[0.9952223,0.0034773014,0.0006419756,0.00027013023,0.00016242336,0.0000030751928,2.5651659e-7,0.00002541576,0.00019717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99886465,0.00004624306,0.00039970715,0.00010555464,0.00039046354,0.00019339229],"domain_scores_gemma":[0.9992021,0.000043417385,0.00021599284,0.00011482336,0.00028282873,0.00014087935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037500402,0.00010838768,0.0004132236,0.00021109205,0.000011960879,0.000007122585,0.00010324153,0.0000719589,0.0006534326],"category_scores_gemma":[0.000015366386,0.000081537655,0.0000757304,0.00019200316,0.00013477405,0.00010118124,0.000011656447,0.00033887982,9.90863e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039508343,0.00060243753,0.83830667,0.00016225681,0.00023689159,0.00018519198,0.0087854685,0.0000010825139,0.056725428,0.000028255607,0.00084442436,0.09017107],"study_design_scores_gemma":[0.0037590726,0.0013809833,0.91239476,0.0005811049,0.000023548184,0.00032879613,0.00018285334,0.0000053327617,0.080794126,0.0001405773,0.000335335,0.00007353107],"about_ca_topic_score_codex":0.00058622984,"about_ca_topic_score_gemma":0.000048973485,"teacher_disagreement_score":0.09009754,"about_ca_system_score_codex":0.00015968634,"about_ca_system_score_gemma":0.00027797028,"threshold_uncertainty_score":0.7154629},"labels":[],"label_agreement":null},{"id":"W1987039060","doi":"10.1016/j.molimm.2011.05.016","title":"Novel method for differentiation between Trastuzumab and host adaptive response","year":2011,"lang":"en","type":"article","venue":"Molecular Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; Epitope; Monoclonal antibody; Epidermal growth factor receptor; Antibody; SKBR3; Atezolizumab; Cancer research; Mutant; Biology; Pertuzumab; Cancer; Immune system; Cancer cell; Breast cancer; Immunology; Immunotherapy; Biochemistry; Human breast; Genetics; Gene","score_opus":0.08670512800503326,"score_gpt":0.3691413584816509,"score_spread":0.28243623047661764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987039060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5007801,0.000621785,0.49696478,0.00059186824,0.00006547126,0.0006250636,0.00003181337,0.000033023665,0.00028610183],"genre_scores_gemma":[0.92758626,0.000023295515,0.07174661,0.00016360862,0.000032577274,0.00015871508,0.000021893087,0.000040102295,0.00022694745],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987372,0.00025277585,0.00020882607,0.000324559,0.00014220808,0.00033441474],"domain_scores_gemma":[0.9991406,0.0002664663,0.000060144786,0.000314518,0.00014107711,0.00007715648],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005538957,0.00013915266,0.00031702608,0.00018798397,0.000063443156,0.000007920672,0.00010950627,0.00018858707,0.0000682246],"category_scores_gemma":[0.00039611035,0.00013085561,0.00007639954,0.00012521714,0.00013801621,0.000030048019,0.000083324914,0.00024189515,0.000011540792],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004562592,0.0001109642,0.0013971728,0.000030774823,0.0003812982,0.000025403395,0.00095318304,8.98216e-8,0.9746361,0.001062011,0.000050745824,0.01678967],"study_design_scores_gemma":[0.004282156,0.0039361743,0.4964185,0.00005479706,0.00021337399,0.00013612077,0.0002657852,0.00022237765,0.49140286,0.0005983206,0.0022663306,0.00020320763],"about_ca_topic_score_codex":0.0001543875,"about_ca_topic_score_gemma":0.0000058855635,"teacher_disagreement_score":0.4950213,"about_ca_system_score_codex":0.00012130706,"about_ca_system_score_gemma":0.00014233991,"threshold_uncertainty_score":0.5336137},"labels":[],"label_agreement":null},{"id":"W1987122879","doi":"10.1016/s1368-7646(03)00024-4","title":"The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery","year":2003,"lang":"en","type":"review","venue":"Drug Resistance Updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Breast Cancer Society of Canada; Cancer Research Society","keywords":"ErbB; Biology; Receptor tyrosine kinase; Receptor; Drug discovery; Signal transduction; Cancer research; Context (archaeology); Cell signaling; Bioinformatics; Cell biology; Genetics","score_opus":0.1794879031040422,"score_gpt":0.4597632419439453,"score_spread":0.2802753388399031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987122879","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00039482792,0.9888625,0.00007838844,0.0064772596,0.000225968,0.0025668677,0.00047060294,0.000026427273,0.0008971205],"genre_scores_gemma":[0.00035099295,0.9856692,0.0009060206,0.00016269836,0.0002864587,0.00047394668,0.00030718272,0.00009494929,0.011748583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99661285,0.0004264247,0.001300643,0.0007928692,0.00030496292,0.0005622268],"domain_scores_gemma":[0.99526715,0.0030693903,0.0003919193,0.0008299757,0.00014659429,0.00029493927],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023936399,0.0004449474,0.0017797295,0.00019009235,0.0002772326,0.00021433397,0.00040958772,0.00022923452,0.000020234935],"category_scores_gemma":[0.0007608687,0.00029916965,0.00024266311,0.0003029466,0.00087957503,0.00017613794,0.00018155416,0.00087827066,0.000007391382],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018295342,0.00013213375,0.0042394744,0.021370754,0.00033142348,0.000027796616,0.00024087986,6.048754e-8,6.201404e-7,0.0019428997,0.2467198,0.7248112],"study_design_scores_gemma":[0.00045658226,0.00006297731,0.00030354166,0.013355231,0.00025174447,0.000011352752,0.00043739955,8.454636e-7,0.000007858036,0.0009899351,0.9838315,0.00029101892],"about_ca_topic_score_codex":0.000010410623,"about_ca_topic_score_gemma":0.00015362096,"teacher_disagreement_score":0.7371117,"about_ca_system_score_codex":0.0002620954,"about_ca_system_score_gemma":0.0011784846,"threshold_uncertainty_score":0.99994606},"labels":[],"label_agreement":null},{"id":"W1987951388","doi":"10.1089/dna.2005.24.351","title":"HER2-Mediated Internalization of a Targeted Prodrug Cytotoxic Conjugate Is Dependent on the Valency of the Targeting Ligand","year":2005,"lang":"en","type":"article","venue":"DNA and Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"National Institute of Neurological Disorders and Stroke; National Institutes of Health; National Cancer Institute; National Institute for Health and Care Research; Susan G. Komen; Susan G. Komen for the Cure","keywords":"Internalization; Prodrug; Biology; Cytotoxicity; Cytotoxic T cell; Downregulation and upregulation; Ligand (biochemistry); Cancer research; Conjugate; Receptor; Biochemistry; Cell biology; Pharmacology; In vitro","score_opus":0.01696157687622419,"score_gpt":0.2839249945242098,"score_spread":0.2669634176479856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987951388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99483156,0.0009999457,0.000030337835,0.0018396406,0.00008722094,0.00044221923,0.000026123458,0.000008356443,0.0017345829],"genre_scores_gemma":[0.9981421,0.0006049383,0.000020918029,0.0006633575,0.00008042769,0.000017119306,0.000013300473,0.000009806536,0.00044800565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990897,0.0001562504,0.0002673976,0.00017143157,0.00014354975,0.00017164032],"domain_scores_gemma":[0.99941117,0.00011552449,0.00013530736,0.00020156728,0.000094904964,0.00004154239],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004087521,0.00008757214,0.0001850023,0.000044077817,0.00004253649,0.0000034586035,0.00013344083,0.00008759315,0.00026140374],"category_scores_gemma":[0.00016873558,0.0000449264,0.0000464017,0.00012383159,0.0001914395,0.0000119948245,0.00006510275,0.00017866721,0.00001135085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013541676,0.00009355359,0.031870037,0.00012105212,0.000032332533,0.0000011935081,0.0012579305,0.000003170316,0.9642434,0.00013511162,0.0008133646,0.0012934306],"study_design_scores_gemma":[0.0006160234,0.00034257164,0.0027431354,0.0000931135,0.000018650018,0.0000027756423,0.0001485106,0.00042733375,0.9892667,0.000096363925,0.006196989,0.00004781483],"about_ca_topic_score_codex":0.000091715956,"about_ca_topic_score_gemma":0.0000178015,"teacher_disagreement_score":0.029126903,"about_ca_system_score_codex":0.000026199545,"about_ca_system_score_gemma":0.00007229769,"threshold_uncertainty_score":0.28621876},"labels":[],"label_agreement":null},{"id":"W1988187875","doi":"10.1042/bj20110921","title":"The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist","year":2012,"lang":"en","type":"article","venue":"Biochemical Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"ErbB; ERBB4; Neuregulin; Tyrosine phosphorylation; Receptor tyrosine kinase; ERBB3; Cell biology; Phosphorylation; Cancer research; Biology; Neuregulin 1; Tyrosine kinase; Platelet-derived growth factor receptor; Chemistry; Receptor; Signal transduction; Biochemistry; Growth factor","score_opus":0.03743538225188499,"score_gpt":0.36104776715802245,"score_spread":0.3236123849061375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988187875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97503716,0.00768065,0.000041919313,0.014712537,0.00059279194,0.00022783504,0.000025666877,0.00001904498,0.001662427],"genre_scores_gemma":[0.9941704,0.0016626673,0.0006741206,0.0006382461,0.0021978137,0.000005099518,0.0000038314956,0.000028966395,0.00061881205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979494,0.00008388048,0.00044174888,0.00014126343,0.00079269963,0.00059101277],"domain_scores_gemma":[0.9986365,0.00015640863,0.000144481,0.00033346078,0.00021536916,0.0005138124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088944973,0.00013602004,0.00025372,0.000050811486,0.0001601605,0.000045119108,0.00028728248,0.00013766931,0.0007965364],"category_scores_gemma":[0.0004839394,0.00008138709,0.00018500385,0.00021359377,0.00033649185,0.000051453502,0.00009235556,0.0008040056,0.00011972048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000362558,0.00016379736,0.0050544254,0.000045304423,0.000065004155,0.000013040351,0.00024137425,1.6686217e-8,0.8203706,0.000054628697,0.16203938,0.011589885],"study_design_scores_gemma":[0.00077131455,0.00019018962,0.0020669284,0.00013924479,0.000037484962,0.0007840251,0.00020774617,0.0000137377165,0.797808,0.00007652741,0.19781017,0.00009462625],"about_ca_topic_score_codex":0.00001109616,"about_ca_topic_score_gemma":2.6448294e-7,"teacher_disagreement_score":0.035770793,"about_ca_system_score_codex":0.00016671045,"about_ca_system_score_gemma":0.00030421588,"threshold_uncertainty_score":0.8721515},"labels":[],"label_agreement":null},{"id":"W1988557714","doi":"10.1016/j.ctrv.2003.10.002","title":"Epidermal growth factor receptor: a promising target in solid tumours","year":2003,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Monoclonal antibody; Tyrosine kinase; Cancer research; Cancer; Receptor tyrosine kinase; Signal transduction; Targeted therapy; EGFR inhibitors; Cetuximab; Blockade; Pharmacology; Receptor; Immunology; Antibody; Internal medicine; Biology; Cell biology","score_opus":0.2218575342477881,"score_gpt":0.48518779668646167,"score_spread":0.2633302624386736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988557714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010353569,0.9832271,0.000005201561,0.0002506722,0.00068928854,0.010952605,0.00025530116,0.00006665038,0.004542847],"genre_scores_gemma":[0.000001971731,0.982815,0.0011000521,0.00022113489,0.0007580787,0.009762565,0.00035632245,0.0002449556,0.0047398764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99328786,0.0012672376,0.002140364,0.0014232382,0.0005969771,0.001284344],"domain_scores_gemma":[0.99710065,0.00018091834,0.0007959245,0.0011678564,0.00012660588,0.0006280295],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.000790698,0.0013495771,0.0074592438,0.0005395356,0.00009866651,0.00006892691,0.00036947074,0.00051350804,0.0039162305],"category_scores_gemma":[0.00027531755,0.00088363036,0.0016107925,0.0011373882,0.00013426322,0.00011925014,0.00007191265,0.0009851505,0.0010625252],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020143476,0.00033247203,0.0008249507,0.045196943,0.00027562713,0.00016903851,0.00012600033,1.3487012e-7,0.000002645503,0.000009127849,0.0105285635,0.94251436],"study_design_scores_gemma":[0.0010756458,0.0003924149,0.000017473149,0.08023968,0.0010157553,0.00009540491,0.000006099575,8.4092346e-7,0.000039376886,0.0000070222245,0.91651666,0.000593631],"about_ca_topic_score_codex":0.00041399742,"about_ca_topic_score_gemma":0.00008933489,"teacher_disagreement_score":0.9419207,"about_ca_system_score_codex":0.009079195,"about_ca_system_score_gemma":0.0040913112,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W1988717588","doi":"10.3390/cancers4030725","title":"Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics","year":2012,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Pathological; Pathology; Biomarker; Kappa; Immunohistochemistry; Lymph node; Oncology; Cancer; Internal medicine; Biology","score_opus":0.059697679766819174,"score_gpt":0.37771644454020675,"score_spread":0.3180187647733876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988717588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975131,0.0013827397,0.000068188485,0.00018127705,0.00016978584,0.00026899338,0.0003218215,0.000057518835,0.000036541667],"genre_scores_gemma":[0.9972002,0.001014182,0.00139528,0.00012539158,0.000080063284,0.000058438945,0.000077531964,0.000023468543,0.00002545327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827635,0.00018052777,0.0004248077,0.00043442516,0.0002987187,0.00038517843],"domain_scores_gemma":[0.99875194,0.00045032904,0.00017702098,0.00028634732,0.00009439341,0.00023998633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003940644,0.00021096594,0.000778324,0.00024918895,0.00005864399,0.000020236876,0.00008510596,0.00017727405,0.000097512966],"category_scores_gemma":[0.0002346849,0.00013105624,0.00005823205,0.00038056084,0.00059539155,0.000099445984,0.00009921139,0.00034571928,0.0000016967705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011164015,0.000057295852,0.93442994,0.000059109683,0.00011008342,0.00009689711,0.0036678638,0.000011340016,0.059046056,0.0000067264596,0.000034846293,0.0013634592],"study_design_scores_gemma":[0.0012023156,0.0002627018,0.9828211,0.00039341193,0.00025882391,0.000018774577,0.0023806777,0.008377741,0.004092129,0.0000030503404,0.000019522064,0.00016973149],"about_ca_topic_score_codex":0.0011194615,"about_ca_topic_score_gemma":0.00010242565,"teacher_disagreement_score":0.05495393,"about_ca_system_score_codex":0.0003510108,"about_ca_system_score_gemma":0.00014019953,"threshold_uncertainty_score":0.5344318},"labels":[],"label_agreement":null},{"id":"W1988936433","doi":"10.1002/cncr.20970","title":"Coexpression of the type 1 growth factor receptor family members HER‐1, HER‐2, and HER‐3 has a synergistic negative prognostic effect on breast carcinoma survival","year":2005,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; St. Paul's Hospital; University of British Columbia; BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Medicine; Oncology; Internal medicine; Breast carcinoma; Univariate analysis; Breast cancer; Tissue microarray; Proportional hazards model; Survival analysis; Multivariate analysis; Lymph node; Log-rank test; Immunohistochemistry; Carcinoma; Pathology; Cancer","score_opus":0.045872047031467245,"score_gpt":0.3330101099408247,"score_spread":0.28713806290935745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988936433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99252766,0.001590553,0.0000060820566,0.0018186222,0.0006622457,0.0012118614,0.00016501745,0.000042070744,0.0019759086],"genre_scores_gemma":[0.9976445,0.00014275074,0.00006385833,0.00026897283,0.00044788406,0.0001545473,0.000008129467,0.00006395122,0.001205415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977634,0.00032577477,0.00028211888,0.00045581674,0.0007399365,0.00043294317],"domain_scores_gemma":[0.99820113,0.00066951074,0.00012800991,0.0004320964,0.00031306097,0.0002561743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026681644,0.00028034815,0.00048271017,0.000081449776,0.00013616557,0.000031777385,0.00021203226,0.00014958439,0.00077288033],"category_scores_gemma":[0.00068036164,0.00017726286,0.00009880341,0.00041111553,0.00045598645,0.000069355556,0.00010783474,0.00048590708,0.000034580684],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056938794,0.00043747426,0.7000325,0.0021978312,0.00041357824,0.000044865952,0.0034099044,0.00011138123,0.21323249,0.00014254326,0.031086953,0.043196633],"study_design_scores_gemma":[0.0054475726,0.0026656764,0.8680302,0.0038930993,0.00024972841,0.000027188244,0.00039203567,0.0007336597,0.10689846,0.00003325892,0.011095737,0.0005333764],"about_ca_topic_score_codex":0.0017045558,"about_ca_topic_score_gemma":0.00022462873,"teacher_disagreement_score":0.16799773,"about_ca_system_score_codex":0.0005232702,"about_ca_system_score_gemma":0.0006011693,"threshold_uncertainty_score":0.84624976},"labels":[],"label_agreement":null},{"id":"W1989502045","doi":"10.4137/cmt.s3783","title":"Lapatinib, a Dual-Targeted Small Molecule Inhibitor of EGFR and HER2, in HER2-Amplified Breast Cancer: From Bench to Bedside","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lapatinib; Trastuzumab; Breast cancer; Cancer research; Medicine; Tyrosine kinase; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Metastatic breast cancer; Cancer; Targeted therapy; Pertuzumab; Letrozole; Oncology; Internal medicine; Receptor; Tamoxifen","score_opus":0.18813864389023785,"score_gpt":0.4205964844946525,"score_spread":0.23245784060441463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989502045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402804,0.0034767236,0.00008578692,0.008040126,0.0007047638,0.0011682558,0.000068313006,0.00006630378,0.0023617009],"genre_scores_gemma":[0.98587966,0.002799896,0.0015934297,0.008247524,0.0010684179,0.00010392742,0.000032636042,0.0000894745,0.00018501024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99561256,0.00041550788,0.0018029172,0.00083338044,0.00074102666,0.00059463555],"domain_scores_gemma":[0.99661493,0.00096634874,0.00029944882,0.0008687962,0.0004891451,0.0007613144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009217748,0.0004055147,0.0014054594,0.00033188422,0.000055950826,0.000010464709,0.00030865296,0.00045686885,0.00081539433],"category_scores_gemma":[0.00053699245,0.00029656064,0.0001325081,0.0007770206,0.0008615247,0.000056653487,0.00019653808,0.0010579894,0.000026903796],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079604685,0.0039112996,0.70064384,0.000657806,0.0011976447,0.0008598748,0.027942803,0.0000035518558,0.0699002,0.0006806348,0.00316946,0.18307242],"study_design_scores_gemma":[0.013587725,0.0067991274,0.93150735,0.0035850534,0.0005789172,0.000060021808,0.0018348596,0.00035260964,0.023557331,0.0025945308,0.014802751,0.00073969987],"about_ca_topic_score_codex":0.007467125,"about_ca_topic_score_gemma":0.002485818,"teacher_disagreement_score":0.23086353,"about_ca_system_score_codex":0.00013806287,"about_ca_system_score_gemma":0.000499358,"threshold_uncertainty_score":0.9999487},"labels":[],"label_agreement":null},{"id":"W1989558595","doi":"10.1097/01.pgp.0000152026.39268.57","title":"Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma","year":2005,"lang":"en","type":"article","venue":"International Journal of Gynecological Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Pathology; Ovarian carcinoma; Fluorescence in situ hybridization; Serous fluid; Biology; Carcinoma; Ovarian cancer; Stage (stratigraphy); Cancer; Medicine; Chromosome; Gene","score_opus":0.04215770612288521,"score_gpt":0.40388880445555314,"score_spread":0.3617310983326679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989558595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111044,0.00062614185,0.0010735727,0.0050594914,0.00026663023,0.0002577299,0.000015262893,0.000008150946,0.0015825477],"genre_scores_gemma":[0.97923136,0.0005103215,0.019459296,0.00044572,0.00014221216,0.000017530923,0.0000075442836,0.000012998665,0.00017299985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99786484,0.0002739795,0.00078124844,0.00028105342,0.0005607459,0.00023811539],"domain_scores_gemma":[0.9982929,0.0004895059,0.00042134777,0.00015502263,0.00047016775,0.00017104496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010698444,0.00014495313,0.00046088916,0.00030397536,0.00003147918,0.00002101667,0.00023490842,0.00020356374,0.0005335558],"category_scores_gemma":[0.00075895793,0.000112303846,0.0000700083,0.00010369008,0.00022769232,0.00016526658,0.00014974299,0.00059025624,0.000002914453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007973888,0.0009322817,0.68844765,0.000057995912,0.00005338152,0.0014892379,0.000327681,0.00025995448,0.24678804,0.0011568097,0.00018735522,0.0595022],"study_design_scores_gemma":[0.0036639695,0.0014955937,0.98562443,0.00013224961,0.000014325702,0.0007310354,0.00027200163,0.00052899803,0.0029657362,0.00050373696,0.003969683,0.00009822617],"about_ca_topic_score_codex":0.00002099735,"about_ca_topic_score_gemma":0.000051912193,"teacher_disagreement_score":0.29717675,"about_ca_system_score_codex":0.00037896444,"about_ca_system_score_gemma":0.00020658056,"threshold_uncertainty_score":0.5842062},"labels":[],"label_agreement":null},{"id":"W1990275745","doi":"10.1158/1078-0432.ccr-09-0931","title":"Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; National Institutes of Health","keywords":"Trastuzumab; Medicine; Cyclophosphamide; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.31175981025520483,"score_gpt":0.6359241077453549,"score_spread":0.3241642974901501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990275745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823413,0.0028646113,0.000003948356,0.0058280067,0.00014267195,0.0014478762,0.00041141236,0.000043254553,0.0069169216],"genre_scores_gemma":[0.9941761,0.003237955,0.000043256456,0.0003930943,0.0009556734,0.00016891652,0.0000203941,0.00004353187,0.0009611028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99432635,0.0008423201,0.0009536457,0.00093322893,0.001819646,0.0011248132],"domain_scores_gemma":[0.99555063,0.0012397878,0.00016771478,0.0006943851,0.0013684006,0.0009790648],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002813603,0.00033419157,0.0012525573,0.0003774434,0.00029457128,0.00006039546,0.00039382937,0.00029931925,0.0015795244],"category_scores_gemma":[0.00028915753,0.00025548326,0.00037803335,0.0011020447,0.0016682255,0.000112507405,0.00014809352,0.0024422726,0.00004554257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024975238,0.005587191,0.6289237,0.00046534507,0.0015742388,0.0004466595,0.003061949,0.00018424087,0.016748106,0.0007585673,0.080173895,0.23710085],"study_design_scores_gemma":[0.0037582647,0.010017383,0.97946674,0.0011853576,0.00005483135,0.000025798998,0.0001932323,0.00011163477,0.0035885584,0.00036864678,0.0009883964,0.00024118485],"about_ca_topic_score_codex":0.007891753,"about_ca_topic_score_gemma":0.0005591569,"teacher_disagreement_score":0.350543,"about_ca_system_score_codex":0.0012926867,"about_ca_system_score_gemma":0.0020552077,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W1990719422","doi":"10.1007/s10549-012-2157-7","title":"Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis","year":2012,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Pertuzumab; Medicine; Rash; Internal medicine; Oncology; Trastuzumab; Incidence (geometry); Breast cancer; Docetaxel; Clinical trial; Cancer","score_opus":0.271116512031164,"score_gpt":0.5036414260120149,"score_spread":0.2325249139808509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990719422","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004046652,0.9932876,0.000029234092,0.00085071754,0.000022928109,0.003087877,0.001923586,0.0000229103,0.00037045014],"genre_scores_gemma":[0.015699783,0.9792815,0.00004861939,0.000011013481,0.00024670974,0.002208925,0.00040525733,0.000098438264,0.0019997426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945008,0.0013460491,0.00055528485,0.0008158607,0.0018274388,0.00095455965],"domain_scores_gemma":[0.99651384,0.0006349859,0.00035940242,0.001277997,0.0006945991,0.00051916717],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015030971,0.0005994469,0.0039724135,0.00083887106,0.00033921414,0.00009045327,0.0003077816,0.00018700291,0.0015597007],"category_scores_gemma":[0.000028955565,0.00025475663,0.0012368012,0.002829462,0.00077429845,0.000082790284,0.0001605486,0.00075030525,0.00003430229],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003186727,0.0010116197,0.0058444343,0.0047391327,0.33286646,0.00006593847,0.00021488414,0.0000037467385,0.000003827044,0.00003797571,0.00017946473,0.6547138],"study_design_scores_gemma":[0.00094159174,0.0016302326,0.0060059032,0.00089083234,0.45516133,0.00020918097,0.00008934411,0.000012491355,0.000013358241,0.0000042194483,0.5347413,0.00030021268],"about_ca_topic_score_codex":0.017310511,"about_ca_topic_score_gemma":0.001423074,"teacher_disagreement_score":0.65441364,"about_ca_system_score_codex":0.00088790304,"about_ca_system_score_gemma":0.00209834,"threshold_uncertainty_score":0.99999046},"labels":[],"label_agreement":null},{"id":"W1990829939","doi":"10.1038/modpathol.3800118","title":"Analysis of epidermal growth factor receptor and activated epidermal growth factor receptor expression in pituitary adenomas and carcinomas","year":2004,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"National Cancer Institute; National Institutes of Health","keywords":"Epidermal growth factor receptor; Epidermal growth factor; Biology; Growth factor receptor; Growth factor receptor inhibitor; Internal medicine; Endocrinology; TGF alpha; Cancer research; Receptor expression; Receptor; Medicine","score_opus":0.03998788086667816,"score_gpt":0.31347896644590045,"score_spread":0.2734910855792223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990829939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99419355,0.0017270697,0.00097457645,0.0018457824,0.00012099054,0.000665105,0.00028275946,0.000064179614,0.0001260044],"genre_scores_gemma":[0.996594,0.0006177675,0.0020764105,0.00024797814,0.000102495556,0.00007237092,0.00013526215,0.00006606054,0.00008766722],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99644756,0.00048218822,0.00077799475,0.0010056229,0.0004924986,0.00079415477],"domain_scores_gemma":[0.9982652,0.00033750577,0.00022130148,0.00052292005,0.00022864205,0.0004244066],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041182182,0.0004094453,0.0013238054,0.0011527512,0.00009827305,0.000017879358,0.0002084733,0.0004958515,0.00039696027],"category_scores_gemma":[0.00065395987,0.00036503255,0.0001695322,0.00078605866,0.0004786668,0.00024816988,0.0002789708,0.0007417381,0.000011040004],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004993503,0.00019768672,0.45947117,0.00021978948,0.00017523071,0.00024921683,0.0033223608,0.000022459457,0.53338975,0.00002670802,0.00005511552,0.0023711612],"study_design_scores_gemma":[0.003096132,0.00060660334,0.78088397,0.00015476378,0.00018994095,0.000093703755,0.00021426911,0.00033188856,0.21374956,0.0002988494,0.00005480378,0.0003255094],"about_ca_topic_score_codex":0.00073232665,"about_ca_topic_score_gemma":0.0001428128,"teacher_disagreement_score":0.3214128,"about_ca_system_score_codex":0.00032358422,"about_ca_system_score_gemma":0.00025664901,"threshold_uncertainty_score":0.99988014},"labels":[],"label_agreement":null},{"id":"W1991720804","doi":"10.13034/cysj-2013-008","title":"SLAK-1, a proposed antibody-conjugated illudin analogue that selectively targets breast cancer<sup>1</sup>","year":2013,"lang":"en","type":"article","venue":"Journal of Student Science and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Conjugated system; Breast cancer; Antibody; Cancer; Chemistry; Molecular biology; Biology; Genetics; Organic chemistry","score_opus":0.024877469565184114,"score_gpt":0.3624262542020876,"score_spread":0.3375487846369035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991720804","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711812,0.00097310886,0.000059092275,0.026716603,0.000114961855,0.0005905804,0.000007116685,0.00004770893,0.00030963722],"genre_scores_gemma":[0.9977336,0.0012227398,0.00046517397,0.0003227474,0.00010891416,0.000019967918,6.6246184e-7,0.000015074556,0.00011112373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99704075,0.00003780804,0.00043158,0.00038329235,0.0014278262,0.00067877374],"domain_scores_gemma":[0.99687123,0.000035989055,0.00028075543,0.00024685593,0.0022572123,0.0003079552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011799653,0.00018880598,0.00051459036,0.001392047,0.00028852772,0.00010696855,0.0006808478,0.0001664775,0.00019697618],"category_scores_gemma":[0.00023063931,0.00013001083,0.00005474521,0.002571745,0.001800738,0.00047173,0.00026073185,0.0007739939,0.000023277666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008038963,0.00030472397,0.7446848,0.0000518288,0.00013846491,0.00023900803,0.0005808747,0.000009718153,0.22722104,0.00022440167,0.0020542073,0.024410516],"study_design_scores_gemma":[0.0030913616,0.0022707356,0.9437304,0.0004951,0.000099904886,0.0042148987,0.004258521,0.0010526433,0.037212096,0.00087270467,0.0023984567,0.00030315702],"about_ca_topic_score_codex":0.00020586852,"about_ca_topic_score_gemma":0.000020062542,"teacher_disagreement_score":0.1990456,"about_ca_system_score_codex":0.00046858078,"about_ca_system_score_gemma":0.0014337488,"threshold_uncertainty_score":0.66348946},"labels":[],"label_agreement":null},{"id":"W1991836995","doi":"10.1038/sj.bjc.6602098","title":"Sustained antiproliferative mechanisms by RB24, a targeted precursor of multiple inhibitors of epidermal growth factor receptor and a DNA alkylating agent in the A431 epidermal carcinoma of the vulva cell line","year":2004,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada; Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Epidermal growth factor receptor; A431 cells; Biology; Epidermal growth factor; Tyrosine kinase; Epidermoid carcinoma; Cancer research; Autophosphorylation; DNA synthesis; Molecular biology; Biochemistry; DNA; Kinase; Receptor; Cell cycle; Cancer; Cell; Protein kinase A; Oncogene","score_opus":0.018930168018259818,"score_gpt":0.2920890244876561,"score_spread":0.2731588564693963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991836995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98712885,0.009281238,0.0001878282,0.0019030242,0.00020016609,0.0009209275,0.00031740917,0.0000036562305,0.000056906734],"genre_scores_gemma":[0.99759054,0.001000272,0.0008994892,0.00018973065,0.00021207085,0.00002661389,0.0000056394783,0.00003481333,0.000040841063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967258,0.00042523403,0.0012351602,0.00022044059,0.0009919697,0.00040137558],"domain_scores_gemma":[0.9974657,0.0003299354,0.0009787123,0.00018188858,0.0008877584,0.0001559501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010925219,0.00019689275,0.0007522508,0.00015317579,0.00007635802,0.00002146037,0.0002954762,0.00013023453,0.000096811724],"category_scores_gemma":[0.001177305,0.0001440418,0.00021355576,0.00046554988,0.0002896017,0.00016696933,0.00011348764,0.0007044138,2.0053461e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018224801,0.0010590384,0.13368413,0.0019050987,0.00029905228,0.0003394507,0.012684994,0.00029126278,0.82656103,0.000045339348,0.0025269762,0.018781135],"study_design_scores_gemma":[0.0072477795,0.001169034,0.08518853,0.0022942638,0.000084604915,0.00029179797,0.0024110456,0.00015241519,0.90065926,0.00019225368,0.00015485709,0.00015415838],"about_ca_topic_score_codex":0.0030585206,"about_ca_topic_score_gemma":0.0005473188,"teacher_disagreement_score":0.074098215,"about_ca_system_score_codex":0.00025657384,"about_ca_system_score_gemma":0.00097625516,"threshold_uncertainty_score":0.5873854},"labels":[],"label_agreement":null},{"id":"W1992301100","doi":"10.1158/0008-5472.can-06-1595","title":"Multiple Acquired Renal Carcinoma Tumor Capabilities Abolished upon Silencing of ADAM17","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Ottawa","funders":"","keywords":"Autocrine signalling; Cancer research; Carcinogenesis; Cancer; Gene silencing; Cancer cell; Biology; Epidermal growth factor receptor; Paracrine signalling; Receptor","score_opus":0.08061258326414547,"score_gpt":0.4013514787068154,"score_spread":0.32073889544267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992301100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860393,0.004650674,0.00001535077,0.0010551063,0.00021806298,0.0012529901,0.00012572363,0.00007557962,0.006567259],"genre_scores_gemma":[0.9930111,0.00013701737,0.0002918148,0.00005986794,0.0012179551,0.0006024618,0.000033064673,0.00008897269,0.0045577427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942781,0.00041890753,0.0006786631,0.00072601537,0.0025036496,0.001394668],"domain_scores_gemma":[0.99617594,0.00072261225,0.000103478,0.0010206976,0.0016036796,0.00037361393],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021973604,0.0002551618,0.000648387,0.000654086,0.00024674158,0.000060906954,0.00052185677,0.000155369,0.0019641828],"category_scores_gemma":[0.0011326015,0.00023085903,0.00018127791,0.0011919838,0.00084728503,0.00016743182,0.00027663907,0.00075479824,0.000062408224],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021214401,0.00028281705,0.14316586,0.0017126242,0.000059932336,0.00025133582,0.0013627836,0.00017532267,0.8164502,0.00037216212,0.030592898,0.003452636],"study_design_scores_gemma":[0.0037551336,0.0009102671,0.124621764,0.0009286853,0.000034961013,0.000045557215,0.002022583,0.0011098932,0.84780496,0.00052816095,0.017899202,0.00033882132],"about_ca_topic_score_codex":0.047988586,"about_ca_topic_score_gemma":0.003160994,"teacher_disagreement_score":0.04482759,"about_ca_system_score_codex":0.0013546582,"about_ca_system_score_gemma":0.0027879777,"threshold_uncertainty_score":0.99894816},"labels":[],"label_agreement":null},{"id":"W1992381279","doi":"10.1016/j.bbamcr.2011.03.006","title":"Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling","year":2011,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University; University of British Columbia","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Epidermal growth factor; Epidermal growth factor receptor; Somatostatin receptor; Somatostatin receptor 1; Signal transduction; Cell biology; Cyclin-dependent kinase 8; ERBB3; Cancer research; ErbB; Phosphorylation; EGFR inhibitors; HEK 293 cells; Somatostatin receptor 2; Somatostatin; Biology; Receptor; Endocrinology; Receptor tyrosine kinase; Biochemistry; Notch signaling pathway","score_opus":0.06273415189932313,"score_gpt":0.3378670819149432,"score_spread":0.27513293001562006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992381279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98910433,0.00037393585,0.000015329517,0.0014611437,0.00006934167,0.001365106,0.00022571124,0.00009277523,0.0072923233],"genre_scores_gemma":[0.9955137,0.0007008723,0.0026745978,0.00025988396,0.00012990291,0.0001282518,0.0001694569,0.00017281214,0.00025053544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99336326,0.0012110855,0.0007173498,0.0010866467,0.0023296303,0.0012920505],"domain_scores_gemma":[0.9962577,0.0008517945,0.00021750116,0.0009640634,0.00087278726,0.000836159],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014079708,0.00047499762,0.00076191913,0.00079754274,0.00018963452,0.000072260984,0.00064556865,0.00036012576,0.0009011931],"category_scores_gemma":[0.0010252323,0.00042691894,0.00025062312,0.0011976497,0.00085546076,0.00013192503,0.000465032,0.0015130013,0.00037520108],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012265772,0.00084014074,0.00011977695,0.00050589937,0.0001534836,0.00004621764,0.0021291343,1.6997984e-7,0.9920707,0.0003474178,0.0015439986,0.001016515],"study_design_scores_gemma":[0.0014285845,0.002169735,0.0016769724,0.00035580032,0.000031038777,0.000004768962,0.00061664777,0.00009832803,0.9922854,0.00027864307,0.00068405457,0.00037007025],"about_ca_topic_score_codex":0.00041982057,"about_ca_topic_score_gemma":0.0000029988767,"teacher_disagreement_score":0.0070417877,"about_ca_system_score_codex":0.00019956139,"about_ca_system_score_gemma":0.0008142557,"threshold_uncertainty_score":0.99981827},"labels":[],"label_agreement":null},{"id":"W1992785655","doi":"10.1006/bbrc.2000.3731","title":"Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3","year":2000,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre; University of Alberta","funders":"","keywords":"ERBB3; Receptor; Drug resistance; Chemistry; Pharmacology; Biology; Biochemistry; Epidermal growth factor receptor; Microbiology","score_opus":0.08551839111255723,"score_gpt":0.41578677843615414,"score_spread":0.3302683873235969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992785655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9627584,0.0017337471,0.000014280017,0.017725287,0.000011353728,0.0008906117,0.00003734979,0.00006621741,0.016762722],"genre_scores_gemma":[0.97361016,0.0043384386,0.008260965,0.00014901956,0.00011019692,0.00028090648,0.000051758743,0.000032976564,0.013165565],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971594,0.0003883769,0.00032224602,0.00050783536,0.0009324264,0.00068966567],"domain_scores_gemma":[0.9965692,0.0010597557,0.000031314565,0.0015634334,0.0003248067,0.00045147672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006785671,0.00018055915,0.00034406284,0.00014631492,0.00031367873,0.000090428985,0.00075671147,0.00012588993,0.0005876102],"category_scores_gemma":[0.00032971628,0.00012561401,0.000053249067,0.0013405206,0.0018790117,0.00009311188,0.0003079641,0.001356983,0.00017919467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017515902,0.00081454567,0.000051570267,0.0001753779,0.000018957828,0.000010767015,0.0004071943,1.373912e-7,0.9738204,0.00037687778,0.0129436,0.009628967],"study_design_scores_gemma":[0.0018900938,0.00036219845,0.0011060064,0.0016537675,0.000016276446,0.000004883831,0.0002969665,0.00022990104,0.85820407,0.00037306699,0.13554788,0.0003148691],"about_ca_topic_score_codex":0.00020334296,"about_ca_topic_score_gemma":0.00017848927,"teacher_disagreement_score":0.12260428,"about_ca_system_score_codex":0.00022713126,"about_ca_system_score_gemma":0.0004427627,"threshold_uncertainty_score":0.6923297},"labels":[],"label_agreement":null},{"id":"W1992809873","doi":"10.1245/s10434-007-9771-3","title":"EGFR, HER2, and HER3 Expression in Laryngeal Primary Tumors and Corresponding Metastases","year":2008,"lang":"en","type":"article","venue":"Annals of Surgical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancerfonden; National Natural Science Foundation of China; Cancer Research Society","keywords":"Medicine; Epidermal growth factor receptor; Surgical oncology; Lymph node; Primary tumor; Immunohistochemistry; Carcinoma; Targeted therapy; Laryngeal Neoplasm; Pathology; Oncology; Cancer research; Metastasis; Receptor; Cancer; Internal medicine","score_opus":0.1372243667815465,"score_gpt":0.42939965239453903,"score_spread":0.29217528561299255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992809873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785988,0.0049397517,0.0000028350191,0.006757468,0.000048180857,0.0002576419,0.000013587001,0.000016290349,0.00936548],"genre_scores_gemma":[0.9762681,0.021738762,0.0006014522,0.0007295656,0.000086629516,0.00001669772,0.0000158678,0.000014833071,0.00052807445],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983375,0.00031855152,0.00038269843,0.0002977803,0.00030338127,0.00036005338],"domain_scores_gemma":[0.9985744,0.00083689566,0.00008435382,0.00015297509,0.00008667723,0.00026473752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085333886,0.00012844004,0.0006771699,0.0002395354,0.000050857903,0.0000042322795,0.00007093731,0.0001538618,0.00029835847],"category_scores_gemma":[0.000109837354,0.000093426315,0.00005460204,0.00023352807,0.00047726993,0.00008633152,0.00012542767,0.00035075692,0.000005179336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011827629,0.0017569046,0.56313854,0.0009400549,0.00011766019,0.034235373,0.0014481703,0.000013260625,0.016099053,0.0002889702,0.033250354,0.336884],"study_design_scores_gemma":[0.005496603,0.003962855,0.38050494,0.0005351088,0.000022906066,0.0034622091,0.00028747463,0.000076646946,0.015471862,0.00021101243,0.5897277,0.00024070751],"about_ca_topic_score_codex":0.00017445798,"about_ca_topic_score_gemma":0.000027589731,"teacher_disagreement_score":0.5564773,"about_ca_system_score_codex":0.00004333056,"about_ca_system_score_gemma":0.00028589353,"threshold_uncertainty_score":0.38098145},"labels":[],"label_agreement":null},{"id":"W1992844744","doi":"10.1074/jbc.m106239200","title":"Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins","year":2001,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Effector; Phosphorylation; ErbB; Transformation (genetics); Cell biology; Biology; Cancer research; Computational biology; Signal transduction; Genetics; Gene","score_opus":0.06143622664116654,"score_gpt":0.341590139487884,"score_spread":0.2801539128467175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992844744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944752,0.00073337037,0.0011762334,0.0011384878,0.000068027875,0.00030834126,0.000015154619,0.000031233525,0.0020539933],"genre_scores_gemma":[0.9975255,0.0005887398,0.00094713614,0.00009188987,0.00065536064,0.000012237276,0.000056136712,0.000011586431,0.00011137197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985162,0.00005738951,0.0005334065,0.00015485863,0.00046282532,0.00027532596],"domain_scores_gemma":[0.99895483,0.00022958154,0.00024058779,0.0001414114,0.00023520677,0.00019840652],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005363333,0.00015353362,0.00036082024,0.000024125195,0.00006379206,0.000021911883,0.00014852275,0.00023613004,0.00086603954],"category_scores_gemma":[0.0011131449,0.0000967018,0.00019293171,0.00019719389,0.00012169665,0.00012116704,0.000021932203,0.00058598095,0.000028957964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012663188,0.00025683825,0.07292485,0.0002623165,0.000054222895,0.00015909162,0.00025786858,0.000007455607,0.9162217,0.0000020585758,0.0004883883,0.008098935],"study_design_scores_gemma":[0.0030482393,0.001068639,0.06394987,0.00030640702,0.000052774732,0.00073537056,0.0001697161,0.0002892213,0.9076173,0.00020270755,0.0223589,0.00020089609],"about_ca_topic_score_codex":0.0000087492,"about_ca_topic_score_gemma":0.0000015570705,"teacher_disagreement_score":0.02187051,"about_ca_system_score_codex":0.0001977225,"about_ca_system_score_gemma":0.00010706332,"threshold_uncertainty_score":0.94825256},"labels":[],"label_agreement":null},{"id":"W1993832282","doi":"10.1007/s10911-008-9082-8","title":"The Role of NRG3 in Mammary Development","year":2008,"lang":"en","type":"review","venue":"Journal of Mammary Gland Biology and Neoplasia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Breakthrough Cancer Research","keywords":"Biology; ERBB4; Morphogenesis; ErbB; Mammary gland; Neuregulin; Receptor tyrosine kinase; Cell biology; Cancer research; Kinase; Gene; Signal transduction; Cancer; Breast cancer; Genetics","score_opus":0.033215898353138006,"score_gpt":0.35856208930900224,"score_spread":0.32534619095586426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993832282","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009422545,0.99713963,0.0000071152085,0.00023807095,0.00020471842,0.00027282644,0.0000047944277,0.0000031632685,0.0011874483],"genre_scores_gemma":[0.00021256662,0.99875844,0.00047345733,0.00003553108,0.00022160998,0.000010839891,0.000012721166,0.00001378766,0.0002610604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979063,0.00032776836,0.0010700607,0.00017830616,0.00021878617,0.0002987548],"domain_scores_gemma":[0.99836797,0.0005883823,0.0005627335,0.00022139367,0.000116595984,0.0001429012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009284421,0.00023230929,0.0014484923,0.00033353397,0.00007678498,0.000010041821,0.0003509634,0.0004312528,0.000012217978],"category_scores_gemma":[0.0001402071,0.00011780625,0.00022111082,0.0002262747,0.00018242642,0.000043963497,0.00014589223,0.001018839,0.000004117197],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016857134,0.00005496794,0.005377173,0.0014982672,0.0002667239,0.00042555103,0.00007184832,1.8233228e-8,0.000005232936,0.00009988996,0.00094829896,0.99108344],"study_design_scores_gemma":[0.00064410624,0.00045036938,0.0020895728,0.0040441593,0.000070147675,0.009606051,0.000018087423,8.883039e-7,0.000016098405,0.00017138441,0.9827858,0.000103334125],"about_ca_topic_score_codex":0.000006715579,"about_ca_topic_score_gemma":0.000022538785,"teacher_disagreement_score":0.99098015,"about_ca_system_score_codex":0.000105074505,"about_ca_system_score_gemma":0.0022154944,"threshold_uncertainty_score":0.48039994},"labels":[],"label_agreement":null},{"id":"W1994749565","doi":"10.1038/sj.cgt.7700117","title":"Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562","year":2000,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Lymphoma Research Foundation","keywords":"K562 cells; MYB; Leukemia; Molecular biology; Biology; Cell culture; Chronic myelogenous leukemia; Gene silencing; Cancer research; Chemistry; Gene expression; Gene; Biochemistry; Immunology; Genetics","score_opus":0.048304029365198474,"score_gpt":0.37605356969522835,"score_spread":0.3277495403300299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1994749565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955734,0.0023565528,0.0000024483877,0.00017201978,0.00014033043,0.0013349287,0.000023001436,0.000028249759,0.00036905936],"genre_scores_gemma":[0.9972787,0.001292808,0.000032567572,0.000221998,0.00062065397,0.000066396045,0.000019318815,0.00005715217,0.00041043898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980445,0.0003076679,0.0004142436,0.00039070286,0.0005670607,0.00027582247],"domain_scores_gemma":[0.99896926,0.000092228096,0.00016800033,0.00048692556,0.00015371112,0.00012988047],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045897198,0.00022968698,0.00044754622,0.00011795897,0.00012280549,0.000013386828,0.00018477124,0.00017257704,0.00029398457],"category_scores_gemma":[0.000030483054,0.00015263617,0.00008916177,0.00026245264,0.000104933155,0.000086005915,0.000025019459,0.00034902178,0.0000032801688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010220595,0.000285249,0.0042078914,0.00021769467,0.000020532405,0.00000481735,0.00054909993,0.0002066872,0.9576969,0.0000016166017,0.00006600167,0.035721414],"study_design_scores_gemma":[0.003721461,0.0038011097,0.017916616,0.0005777594,0.000019949424,0.000004954475,0.000017853414,0.00036066584,0.97310436,0.00000964779,0.00032942308,0.00013619088],"about_ca_topic_score_codex":0.00008166179,"about_ca_topic_score_gemma":0.000012632477,"teacher_disagreement_score":0.03558522,"about_ca_system_score_codex":0.00021197597,"about_ca_system_score_gemma":0.00031537304,"threshold_uncertainty_score":0.6224323},"labels":[],"label_agreement":null},{"id":"W1995492023","doi":"10.1186/s12916-014-0129-y","title":"Advances in treating HER2-positive breast cancer: an interview with Sunil Verma","year":2014,"lang":"en","type":"article","venue":"BMC Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre","funders":"","keywords":"Medicine; Breast cancer; Cancer; Oncology; Internal medicine","score_opus":0.04296304446602,"score_gpt":0.39898249484147136,"score_spread":0.35601945037545135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995492023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84657824,0.021665942,0.0053772638,0.028266802,0.00068143604,0.0026249234,0.0000635017,0.0003355348,0.094406374],"genre_scores_gemma":[0.9927946,0.0025964912,0.0009435967,0.0016122044,0.001129762,0.00015863206,0.000049732018,0.000060556686,0.0006544674],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976391,0.00034274923,0.00039093924,0.0004865764,0.00066103216,0.0004795923],"domain_scores_gemma":[0.9985493,0.00027846007,0.00010588735,0.0004921196,0.00021050294,0.00036373784],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001107347,0.00024240396,0.00064372923,0.00021750083,0.000058296053,0.000010373976,0.00020199605,0.00007447434,0.0009228969],"category_scores_gemma":[0.00020893599,0.00015783984,0.00003604096,0.0005556097,0.0003264291,0.00020115773,0.000045705598,0.0003959357,0.000020969619],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009333139,0.000199978,0.3848943,0.0012123954,0.000027819822,0.000112336114,0.0017667423,0.0000462601,0.00060114,0.0002359895,0.0006541788,0.6093155],"study_design_scores_gemma":[0.016410138,0.008198687,0.87644374,0.02903721,0.00025178207,0.0009644487,0.0039994563,0.005086895,0.0012544636,0.00013802543,0.057555992,0.0006591344],"about_ca_topic_score_codex":0.0025691593,"about_ca_topic_score_gemma":0.008668563,"teacher_disagreement_score":0.6086564,"about_ca_system_score_codex":0.00031799774,"about_ca_system_score_gemma":0.00030612512,"threshold_uncertainty_score":0.9999904},"labels":[],"label_agreement":null},{"id":"W1995517580","doi":"10.1007/s10549-011-1896-1","title":"TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Sunnybrook Health Science Centre; St. Michael's Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Adjuvant; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.056476571669289696,"score_gpt":0.3589421221986461,"score_spread":0.30246555052935636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995517580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990145,0.0012016258,0.0000062494014,0.0008291324,0.00005210655,0.0018295044,0.005858105,0.000012176535,0.00006608882],"genre_scores_gemma":[0.9909719,0.006911681,0.00020247935,0.000009949349,0.000087254084,0.0015100493,0.00016745066,0.000031304786,0.00010788491],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998112,0.00008198858,0.00031847498,0.00048390136,0.0005369628,0.0004666305],"domain_scores_gemma":[0.9988751,0.00012617258,0.0000844849,0.0002206832,0.00047044817,0.0002231158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027768774,0.0001866095,0.0004076652,0.00034574317,0.00008175214,0.000018182413,0.00006781179,0.00009526148,0.00015372508],"category_scores_gemma":[0.000018152574,0.00013304329,0.000027434322,0.00035161892,0.0002401073,0.00014271986,0.000050557344,0.00020048644,0.000001052982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006326378,0.0017912871,0.7757727,0.000107910535,0.0001057902,0.000013817111,0.0007156539,0.0000028564302,0.00007266298,0.000041392643,0.000037487625,0.21501204],"study_design_scores_gemma":[0.014827419,0.00374133,0.9781704,0.0007728058,0.000053036805,0.000010308643,0.00020412111,0.00029799587,0.0012815368,0.00047708658,0.00006837908,0.00009557799],"about_ca_topic_score_codex":0.21937238,"about_ca_topic_score_gemma":0.04468502,"teacher_disagreement_score":0.21491647,"about_ca_system_score_codex":0.00078244455,"about_ca_system_score_gemma":0.0003376086,"threshold_uncertainty_score":0.97274697},"labels":[],"label_agreement":null},{"id":"W1995674745","doi":"10.1177/1078155213506478","title":"Trastuzumab therapy in breast cancer: To reload or not to reload?","year":2013,"lang":"en","type":"editorial","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.10153406861746643,"score_gpt":0.5481237729204406,"score_spread":0.4465897043029741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995674745","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012761651,0.0020469339,0.000021539674,0.26864555,0.7095859,0.0027299887,0.0002115993,0.00004095817,0.003955851],"genre_scores_gemma":[0.002572056,0.07719156,0.00405274,0.021464905,0.88836527,0.0004088417,0.000015788499,0.00026449218,0.0056643705],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99174136,0.0015556925,0.0021103837,0.0007389314,0.0027278187,0.0011257988],"domain_scores_gemma":[0.9831182,0.008323625,0.0018996566,0.0006220666,0.0045299646,0.0015065352],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060876952,0.0006325352,0.0021415453,0.0014053499,0.00011560112,0.00011847941,0.0011696399,0.00091247674,0.0047453237],"category_scores_gemma":[0.012078854,0.0004799809,0.0002979549,0.0012565599,0.000124095,0.0008704839,0.0002433429,0.008916247,0.00065161515],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07886564,0.0012815904,0.00011419005,0.00015023972,0.0006440671,0.005042016,0.0011596499,0.000030964704,0.0031437038,9.191501e-7,0.73078895,0.17877807],"study_design_scores_gemma":[0.016441366,0.007966634,0.00043960378,0.00103001,0.0004866754,0.004050193,0.00039862172,0.000010998686,0.0007130074,0.0000034778332,0.968032,0.00042738166],"about_ca_topic_score_codex":0.0042053666,"about_ca_topic_score_gemma":0.00029449732,"teacher_disagreement_score":0.24718066,"about_ca_system_score_codex":0.008530559,"about_ca_system_score_gemma":0.027428856,"threshold_uncertainty_score":0.99976516},"labels":[],"label_agreement":null},{"id":"W1996149704","doi":"10.1097/pas.0b013e31820e6237","title":"The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Progesterone receptor; Breast cancer; Medicine; Immunohistochemistry; Estrogen receptor; Internal medicine; Fixation (population genetics); Estrogen; Receptor; Oncology; Gynecology; Endocrinology; Urology; Cancer; Population","score_opus":0.04011181376275936,"score_gpt":0.3518738265315343,"score_spread":0.31176201276877497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996149704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421567,0.0013358617,0.0000021592953,0.003525132,0.00009420927,0.000701714,0.000007401757,0.0000027173528,0.00011512452],"genre_scores_gemma":[0.99856776,0.0011148145,0.000068086556,0.00003751674,0.00008999976,0.00009872085,0.0000015904358,0.000014156359,0.0000073357533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995812,0.0026002533,0.000549146,0.00014554057,0.0006807288,0.00021235649],"domain_scores_gemma":[0.9969588,0.0014519173,0.0008323554,0.00029474977,0.00039334333,0.00006886077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005469511,0.0001237677,0.0004947785,0.00008261355,0.00006200362,0.0000044048084,0.00025586024,0.00006218484,0.000130731],"category_scores_gemma":[0.00064270815,0.000053180265,0.00009236509,0.00026849445,0.0013745168,0.000038542123,0.000066937326,0.0005846155,0.0000020613948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03294745,0.00030747766,0.1461276,0.00008815968,0.00016626297,0.000052014027,0.0042755827,0.00002071439,0.6289941,0.0000515925,0.00047928645,0.18648978],"study_design_scores_gemma":[0.008012338,0.018748807,0.31040934,0.0018278741,0.0003591377,0.0020912273,0.0018333133,0.000091023496,0.65567946,0.00035814728,0.00037236963,0.0002169523],"about_ca_topic_score_codex":0.00008997445,"about_ca_topic_score_gemma":0.0000054059974,"teacher_disagreement_score":0.18627281,"about_ca_system_score_codex":0.00017097128,"about_ca_system_score_gemma":0.00025140707,"threshold_uncertainty_score":0.5064464},"labels":[],"label_agreement":null},{"id":"W1996494247","doi":"10.1038/onc.2010.365","title":"The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells","year":2010,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Michael Smith Health Research BC; Child and Family Research Institute; Breast Cancer Alliance","keywords":"Trastuzumab; CD44; Biology; Cancer research; Cell culture; Cancer cell; Cancer; Population; Cell; Molecular biology; Breast cancer; Medicine; Biochemistry","score_opus":0.013583241705343727,"score_gpt":0.30749476806958176,"score_spread":0.293911526364238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996494247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953563,0.0006900341,0.0000038185776,0.0015292782,0.0002694659,0.0009403777,0.00022068081,0.000041382656,0.0009486436],"genre_scores_gemma":[0.9957002,0.00065113505,0.0011660517,0.000032753436,0.00024417046,0.00020641922,0.000020885813,0.0000720883,0.0019063257],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974519,0.00020327579,0.0005087953,0.00043302283,0.0007862184,0.0006167696],"domain_scores_gemma":[0.99844086,0.00030158766,0.00022825443,0.0005727178,0.00020960762,0.0002469824],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010617297,0.00024769653,0.00043071806,0.00015171505,0.00016115069,0.00003629479,0.00035248962,0.0002009522,0.00046749855],"category_scores_gemma":[0.00014488533,0.00017691684,0.00007331059,0.0006334569,0.00023612728,0.00011202242,0.00012334669,0.0007796229,0.000018862715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012132638,0.00016962073,0.0020556292,0.00022638564,0.00002420486,0.000027863354,0.00024124958,0.0000021670676,0.9900664,0.000003924738,0.0022236747,0.0037455987],"study_design_scores_gemma":[0.0014174836,0.0000727524,0.0008284662,0.0008958992,0.000017010667,0.000011790701,0.0001557203,0.000010271869,0.98799413,0.00001371079,0.008409734,0.00017305034],"about_ca_topic_score_codex":0.0013113758,"about_ca_topic_score_gemma":0.0010735344,"teacher_disagreement_score":0.006186059,"about_ca_system_score_codex":0.00036768115,"about_ca_system_score_gemma":0.0005848463,"threshold_uncertainty_score":0.721446},"labels":[],"label_agreement":null},{"id":"W1996750641","doi":"10.1309/ajcpzsv2w1cpgrjw","title":"HER2 Testing of Multifocal Invasive Breast Carcinoma","year":2013,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Medicine; Breast carcinoma; Carcinoma; Pathology; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.1217815960190142,"score_gpt":0.4510944160237823,"score_spread":0.32931282000476814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996750641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944027,0.00011443665,0.00018004606,0.0034820177,0.00031433834,0.0002019318,0.000007072605,0.000009279552,0.0012881428],"genre_scores_gemma":[0.9816167,0.00006718186,0.01631897,0.0011584873,0.00073911174,0.0000058711266,0.0000010099819,0.000028717164,0.000063986234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996195,0.0007419443,0.0019308889,0.00024609079,0.00048618607,0.0003998423],"domain_scores_gemma":[0.99232185,0.0038590056,0.0014107953,0.0003704723,0.0014784175,0.0005594404],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0020002848,0.00014956071,0.0013718808,0.00018366643,0.000028631055,0.000007755504,0.00030532878,0.00012597058,0.000359987],"category_scores_gemma":[0.009835161,0.000111715985,0.00033806253,0.00040821324,0.0018877983,0.00008013948,0.000110609326,0.0011866385,0.00008994935],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030311177,0.0002720658,0.68899125,0.00003355352,0.000054055658,0.0008187286,0.00011105452,0.0000038501025,0.0046344097,0.000006675644,0.0008418828,0.3039294],"study_design_scores_gemma":[0.0019530859,0.008896928,0.9792234,0.00019326036,0.000074184194,0.0076679806,0.00071893533,0.00009250568,0.0006252639,0.00015397964,0.00029983275,0.000100688536],"about_ca_topic_score_codex":0.00044591463,"about_ca_topic_score_gemma":0.000011763875,"teacher_disagreement_score":0.3038287,"about_ca_system_score_codex":0.00005513821,"about_ca_system_score_gemma":0.0010806753,"threshold_uncertainty_score":0.9985054},"labels":[],"label_agreement":null},{"id":"W1997043452","doi":"10.1200/jco.2014.59.7559","title":"Reply to E.A. Rakha et al","year":2015,"lang":"fr","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine","score_opus":0.4547363669323985,"score_gpt":0.6349800255671316,"score_spread":0.18024365863473313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997043452","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003414262,0.0048089195,0.00027278098,0.90793395,0.039072685,0.0007144833,0.000043201235,0.000016381447,0.043723345],"genre_scores_gemma":[0.00069157087,0.0049186773,0.008552977,0.8932666,0.062014814,0.000017812647,0.000017358328,0.00014525057,0.030374944],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771824,0.007375939,0.009348145,0.00087969523,0.0036084692,0.001605349],"domain_scores_gemma":[0.96626556,0.019282414,0.0048464937,0.0012227645,0.004589847,0.0037929353],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity","insufficient_payload"],"category_scores_codex":[0.0557453,0.0006029106,0.006506801,0.0006726534,0.0000642287,0.00005939585,0.0015688228,0.0032553608,0.0049719913],"category_scores_gemma":[0.09269742,0.0004671006,0.00187229,0.00056406675,0.0010282518,0.00018867395,0.0006247858,0.024011377,0.004673751],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004832674,0.0011440545,0.004736393,0.00015989278,0.0008920166,0.02780129,0.00019929565,0.000026017035,0.000026381127,0.00005677613,0.78913623,0.17098896],"study_design_scores_gemma":[0.008494383,0.051511586,0.0055598556,0.0017943423,0.0006564015,0.0033396257,0.00010436287,0.000031082374,0.000011097386,0.0004488102,0.92768246,0.00036597738],"about_ca_topic_score_codex":0.00029896587,"about_ca_topic_score_gemma":0.000086046675,"teacher_disagreement_score":0.17062297,"about_ca_system_score_codex":0.003024483,"about_ca_system_score_gemma":0.0422316,"threshold_uncertainty_score":0.9997781},"labels":[],"label_agreement":null},{"id":"W1997091177","doi":"10.1073/pnas.1505649112","title":"iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling","year":2015,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute; Biotechnology and Biological Sciences Research Council; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Upstream (networking); Biology; Computational biology; Cell biology; Computer science; Telecommunications","score_opus":0.09462102397983845,"score_gpt":0.3813311216611781,"score_spread":0.28671009768133965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997091177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013036,0.0003523789,5.176462e-7,0.0049625505,0.000022636286,0.00020491394,0.000011231692,0.000007529184,0.004307882],"genre_scores_gemma":[0.9986323,0.000028362745,0.0008783991,0.000081618906,0.00012073753,0.0000059077997,9.4888286e-8,0.0000051295633,0.00024745773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969559,0.000007677904,0.00032534674,0.00022197074,0.0023330306,0.00015613054],"domain_scores_gemma":[0.9987648,0.0000844868,0.00038202983,0.000014523244,0.00065303396,0.00010109513],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021003322,0.00008038343,0.00021593685,0.00019317352,0.000073856776,0.000014402335,0.0005149843,0.000081617334,0.00002182462],"category_scores_gemma":[0.0014000833,0.000052710147,0.000052176623,0.0005625608,0.0011631184,0.00020383226,0.00022824139,0.00018242863,7.0594086e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002355435,0.00020413255,0.27790463,0.00074935297,0.000080178936,1.02712285e-7,0.0015708787,0.00018474807,0.6964064,0.016074467,0.0051953155,0.001394204],"study_design_scores_gemma":[0.0005838598,0.0001657207,0.042081237,0.00048599453,0.000029532923,0.000027389535,0.0018729921,0.00047403912,0.9357023,0.018349625,0.00015478484,0.00007251024],"about_ca_topic_score_codex":0.000028584987,"about_ca_topic_score_gemma":1.4951796e-7,"teacher_disagreement_score":0.23929587,"about_ca_system_score_codex":0.00006558382,"about_ca_system_score_gemma":0.00014564139,"threshold_uncertainty_score":0.4285558},"labels":[],"label_agreement":null},{"id":"W1997519635","doi":"10.1038/sj.clpt.6100096","title":"Molecular Imaging as a Tool for Personalized and Targeted Anticancer Therapy","year":2007,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Library science; Citation; Psychology; Sociology; Computer science","score_opus":0.32858627950061575,"score_gpt":0.6135134024562962,"score_spread":0.2849271229556804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997519635","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044709994,0.98830146,0.0004695393,0.0039666547,0.0015308482,0.00488975,0.00006972408,0.000115036324,0.00020989995],"genre_scores_gemma":[0.000029467485,0.91737396,0.001040402,0.078649156,0.0014951167,0.0005525332,0.00008292021,0.00022842549,0.000547998],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950816,0.0008058282,0.0015206812,0.0010935792,0.00049316284,0.0010051407],"domain_scores_gemma":[0.99503505,0.00320054,0.00041433232,0.00051313406,0.00040420046,0.00043271208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025347394,0.0006842519,0.003014565,0.00026624056,0.00014040933,0.0000429246,0.0004318215,0.0008432132,0.00077604846],"category_scores_gemma":[0.00012968743,0.00054016593,0.0012202159,0.0004015225,0.0014335418,0.00004036486,0.00014056482,0.0020455208,0.00007264081],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011376232,0.00042836272,0.00020319363,0.0039572082,0.003330116,0.00028583256,0.00004975732,6.94434e-8,0.00022707769,0.000047355643,0.007950394,0.982383],"study_design_scores_gemma":[0.006152824,0.00086506864,0.000022411861,0.0013061312,0.00530887,0.00016301457,0.000011842701,0.00009929731,0.00010257207,0.00009128029,0.9853918,0.00048489106],"about_ca_topic_score_codex":0.000004406111,"about_ca_topic_score_gemma":2.794585e-7,"teacher_disagreement_score":0.9818981,"about_ca_system_score_codex":0.00025183437,"about_ca_system_score_gemma":0.0019805888,"threshold_uncertainty_score":0.999705},"labels":[],"label_agreement":null},{"id":"W1997955685","doi":"10.3816/cbc.2006.n.038","title":"Molecular Predictive Factors in Patients Receiving Trastuzumab-Based Chemotherapy for Metastatic Disease","year":2006,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Michael Smith Health Research BC","keywords":"Medicine; Trastuzumab; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Chemotherapy; Disease; Cancer","score_opus":0.04488971125718346,"score_gpt":0.41535157853292376,"score_spread":0.3704618672757403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997955685","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243116,0.000217745,0.0013997986,0.0029009867,0.00031065897,0.0018587625,0.00065659656,0.00005884444,0.00016544694],"genre_scores_gemma":[0.99719465,0.000031881944,0.00036562825,0.0013002037,0.00026327418,0.00050071743,0.00015838082,0.00007626454,0.00010897968],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997394,0.00016455294,0.00073465524,0.00060207734,0.0005708877,0.00053380546],"domain_scores_gemma":[0.99818826,0.0005800346,0.00013846946,0.000382864,0.00029795835,0.00041243705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005182984,0.00023939776,0.0005693367,0.0001312919,0.00004602567,0.000022178865,0.00016515343,0.00008928574,0.0003387987],"category_scores_gemma":[0.00046797947,0.00020063971,0.0003176345,0.00032875605,0.00021439558,0.00006739608,0.000024008486,0.00038166047,0.000007159077],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003539648,0.0014105485,0.97030884,0.00020142873,0.00008021693,0.000020553021,0.000022586813,0.000418064,0.000050474555,0.000011807355,0.0018160942,0.022119738],"study_design_scores_gemma":[0.009864765,0.00050706696,0.9842064,0.00039042468,0.00011597445,4.8570877e-7,0.000016085683,0.0029712708,0.00029913356,0.00019137579,0.0012479464,0.00018909849],"about_ca_topic_score_codex":0.00039741676,"about_ca_topic_score_gemma":0.000087711196,"teacher_disagreement_score":0.021930639,"about_ca_system_score_codex":0.0005963996,"about_ca_system_score_gemma":0.00097118143,"threshold_uncertainty_score":0.81818503},"labels":[],"label_agreement":null},{"id":"W1998071315","doi":"10.1007/s12154-009-0023-9","title":"Measuring and interpreting the selectivity of protein kinase inhibitors","year":2009,"lang":"en","type":"article","venue":"Journal of Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Selectivity; Kinase; Protein kinase inhibitor; Protein kinase A; Small molecule; Chemistry; Computational biology; Chemical biology; Biochemistry; Biology","score_opus":0.03466070349873216,"score_gpt":0.33809482695497317,"score_spread":0.303434123456241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998071315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932761,0.0009658088,0.00004092172,0.0051171365,0.000032910408,0.00011133707,5.497556e-7,0.000003366723,0.000451857],"genre_scores_gemma":[0.99920386,0.000026005258,0.00038515328,0.00015263337,0.00022071566,0.000001164276,1.6850348e-7,0.000003841338,0.0000064766627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923813,0.00008874637,0.0002969085,0.000079326965,0.00014772097,0.00014914684],"domain_scores_gemma":[0.99935526,0.00014107414,0.00016153819,0.000081542246,0.00017521666,0.00008534299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008059302,0.0000601598,0.0002478906,0.00005664657,0.00001440884,0.00000415089,0.000089968635,0.000085087646,0.000014398755],"category_scores_gemma":[0.0014246145,0.00003425778,0.00006401928,0.00010663069,0.0001552086,0.000023269638,0.00003477665,0.0005175244,4.4403464e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028935735,0.000047684814,0.0059827333,0.000028152774,0.00002018228,0.000009786104,0.000099123245,1.0907071e-7,0.9490378,0.000034514796,0.00011520637,0.044335384],"study_design_scores_gemma":[0.00045532538,0.00073625305,0.0013372008,0.00027920335,0.000014161067,0.00023653629,0.000024292443,0.000020412652,0.9951268,0.00089676236,0.0008398293,0.00003326633],"about_ca_topic_score_codex":0.000007051718,"about_ca_topic_score_gemma":3.497266e-7,"teacher_disagreement_score":0.04608899,"about_ca_system_score_codex":0.00006704001,"about_ca_system_score_gemma":0.00010576671,"threshold_uncertainty_score":0.22484148},"labels":[],"label_agreement":null},{"id":"W1998331864","doi":"10.4161/cc.3.9.1127","title":"Developmental Timing of Activated erbB2 Expression Plays a Critical Role in the Induction of Mammary Tumors","year":2004,"lang":"en","type":"article","venue":"Cell Cycle","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; Germline; Carcinogenesis; Mammary gland; Allele; Genetically modified mouse; Penetrance; Cancer research; Endogeny; Oncogene; Transgene; Mammary tumor; Regulation of gene expression; Gene; Genetics; Cancer; Phenotype; Cell cycle; Endocrinology; Breast cancer","score_opus":0.03732561836379729,"score_gpt":0.3324290827669174,"score_spread":0.29510346440312013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998331864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907737,0.00009604944,0.00007573156,0.0003808565,0.000026782902,0.00021701137,0.0000020501107,0.00001095522,0.008416904],"genre_scores_gemma":[0.9975286,0.000011732211,0.0023125722,0.000049674476,0.000031992127,0.00001984299,0.000005282303,0.000011355549,0.000028963641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990424,0.000055955727,0.00022373965,0.00014132523,0.00035259913,0.00018396259],"domain_scores_gemma":[0.9996401,0.00008490257,0.000036649704,0.00013834421,0.000047476457,0.000052542622],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002741099,0.00006950959,0.00015076074,0.000105469015,0.000031701544,0.000004924367,0.00012655956,0.00006796099,0.00009368219],"category_scores_gemma":[0.00013607777,0.000052340718,0.000030248424,0.00025405298,0.00008962866,0.0000823247,0.000059302933,0.00025982002,0.0000086168375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010798553,0.00027481766,0.001380703,0.00017309582,0.0000030422204,0.000032346194,0.002494024,0.000041641106,0.9938601,0.00004478697,0.00011143193,0.001476018],"study_design_scores_gemma":[0.00084212836,0.00011986944,0.018934755,0.0004065275,0.0000045917373,0.00003215234,0.0025429467,0.000047483416,0.97658074,0.00035889575,0.00008004392,0.000049877115],"about_ca_topic_score_codex":0.0001893984,"about_ca_topic_score_gemma":0.000006081343,"teacher_disagreement_score":0.01755405,"about_ca_system_score_codex":0.000149522,"about_ca_system_score_gemma":0.00026137882,"threshold_uncertainty_score":0.21343926},"labels":[],"label_agreement":null},{"id":"W1998655933","doi":"10.1074/jbc.275.14.9946","title":"Genuine Monovalent Ligands of TrkA Nerve Growth Factor Receptors Reveal a Novel Pharmacological Mechanism of Action","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Tropomyosin receptor kinase A; Receptor; Internalization; Tyrosine kinase; Cell biology; Receptor tyrosine kinase; Chemistry; Allosteric regulation; Low-affinity nerve growth factor receptor; Biochemistry; Biology; Nerve growth factor","score_opus":0.11230203858458988,"score_gpt":0.37958071790451814,"score_spread":0.26727867931992827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998655933","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979511,0.00039163826,0.00007070494,0.0005808355,0.00012346751,0.00014370648,0.00003583822,0.000012994117,0.00068972004],"genre_scores_gemma":[0.99646497,0.0015910091,0.0008498497,0.0000734174,0.00057264476,0.0000048003576,0.0000075709872,0.0000115170915,0.00042421964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980229,0.00004277592,0.00089386984,0.00021137489,0.00054687314,0.00028220538],"domain_scores_gemma":[0.99855566,0.00013539917,0.0004723647,0.00013608468,0.00040980414,0.00029069814],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055163424,0.00018087284,0.000685275,0.000053542364,0.000026003125,0.0000054032434,0.00025440386,0.00036794553,0.005570425],"category_scores_gemma":[0.00035429234,0.000114338785,0.0003447079,0.0002465138,0.00018402694,0.000044916735,0.00004840682,0.00075410656,0.000004259838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018199328,0.0007210425,0.00218801,0.00022541377,0.00015040356,0.000045658624,0.00004708184,0.0000047658214,0.9883683,0.000004325082,0.0007974955,0.005627599],"study_design_scores_gemma":[0.0020125934,0.0017789932,0.0035580392,0.00017520817,0.00007328391,0.0003800881,0.0000734503,0.000038150672,0.99083877,0.00009639005,0.0008700495,0.000104977575],"about_ca_topic_score_codex":0.000008108505,"about_ca_topic_score_gemma":7.1161175e-8,"teacher_disagreement_score":0.0055661653,"about_ca_system_score_codex":0.00018919082,"about_ca_system_score_gemma":0.00016957454,"threshold_uncertainty_score":0.9953386},"labels":[],"label_agreement":null},{"id":"W1998827682","doi":"10.1186/1471-2407-11-420","title":"The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Drug Research and Development; BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Gefitinib; Trastuzumab; In vivo; Cytostasis; Medicine; Cancer research; Everolimus; Breast cancer; SKBR3; PI3K/AKT/mTOR pathway; Pharmacology; Cell growth; Growth inhibition; Surgical oncology; Vinorelbine; Cancer; Oncology; Signal transduction; Internal medicine; Cytotoxicity; Epidermal growth factor receptor; In vitro; Biology; Chemotherapy; Cisplatin","score_opus":0.044814712231167134,"score_gpt":0.32160145844209626,"score_spread":0.27678674621092914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998827682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99624103,0.0014816392,0.0000456359,0.00014204209,0.00008030976,0.00047244332,0.00025482322,0.000009095497,0.0012729524],"genre_scores_gemma":[0.99882454,0.00079769536,0.00014389046,0.000021641352,0.000060619062,0.000036858677,0.0000013668999,0.000022617842,0.0000907999],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99862975,0.00015440815,0.00032681978,0.00024440014,0.00041901,0.00022558495],"domain_scores_gemma":[0.9986964,0.00029474386,0.00026410457,0.00019223035,0.0004587336,0.000093806455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051042676,0.00013418029,0.0003857016,0.000087180495,0.00006635727,0.00000802786,0.000054588912,0.00006684159,0.000085258056],"category_scores_gemma":[0.000084014006,0.00010117999,0.000050449205,0.0002149368,0.00060343114,0.00009107548,0.00007713902,0.00017996943,2.5796564e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034298867,0.00049458427,0.45002934,0.0026629828,0.00022911596,0.0000140912925,0.009053877,0.000010049196,0.500852,0.001166357,0.0007448959,0.031312797],"study_design_scores_gemma":[0.0014560529,0.00015961136,0.58236235,0.000915043,0.000050769533,0.000024530022,0.00052293355,0.00022832418,0.41399288,0.00019150974,0.00001752753,0.00007846149],"about_ca_topic_score_codex":0.012858565,"about_ca_topic_score_gemma":0.0019073361,"teacher_disagreement_score":0.132333,"about_ca_system_score_codex":0.00016615046,"about_ca_system_score_gemma":0.00048421888,"threshold_uncertainty_score":0.99371487},"labels":[],"label_agreement":null},{"id":"W1999442391","doi":"10.1016/s1470-2045(08)70177-3","title":"Part II: Milestones in personalised medicine—trastuzumab","year":2008,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Trastuzumab; Oncology; Medicine; Imatinib; Breast cancer; Internal medicine; Oncogene; Cancer; Ovarian cancer; Cancer research; Bioinformatics; Myeloid leukemia; Biology; Cell cycle","score_opus":0.269792299096941,"score_gpt":0.452685699643005,"score_spread":0.18289340054606396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999442391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8238352,0.0015243185,0.000004999004,0.107687265,0.00042775518,0.00046080354,0.000006820878,0.00006542072,0.06598742],"genre_scores_gemma":[0.98200756,0.002252728,0.00022893936,0.0073509463,0.0028694414,0.0001486875,0.000016591473,0.000027680875,0.0050974255],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980972,0.00032269786,0.00029909992,0.00027223662,0.0004222255,0.0005865631],"domain_scores_gemma":[0.99882334,0.0004123964,0.0000630777,0.00048509773,0.000083016974,0.00013305976],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011750585,0.0001431879,0.00069952477,0.000115408606,0.000168829,0.0000021044532,0.00031391234,0.00014696113,0.0019002953],"category_scores_gemma":[0.00040591398,0.00008843211,0.000053313,0.00036483165,0.0008881162,0.000027880411,0.00009745077,0.0006778377,0.00015541403],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024005196,0.00061630324,0.11662166,0.00020639338,0.00011797685,0.0026460106,0.02232324,0.000017224163,0.0039770617,0.0025638249,0.8317631,0.016746681],"study_design_scores_gemma":[0.0058348915,0.0019484237,0.11412207,0.0001440876,0.000029859022,0.001216903,0.0008304686,0.000108138236,0.00022115256,0.00031645177,0.87510806,0.00011948488],"about_ca_topic_score_codex":0.00058646325,"about_ca_topic_score_gemma":0.00043821064,"teacher_disagreement_score":0.15817237,"about_ca_system_score_codex":0.0004789611,"about_ca_system_score_gemma":0.00066905795,"threshold_uncertainty_score":0.9990121},"labels":[],"label_agreement":null},{"id":"W1999461982","doi":"10.1007/s10549-008-0033-2","title":"Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of Calgary; Western University; Cancer Care Ontario","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Metastatic breast cancer; Multivariate analysis; Oncology; Univariate analysis; Cancer; Proportional hazards model; Prognostic variable","score_opus":0.11164049616071636,"score_gpt":0.4002757301324612,"score_spread":0.28863523397174484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999461982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97902215,0.01022196,0.0000056109184,0.0048664687,0.00004398999,0.002291633,0.0032059138,0.000022663347,0.00031959105],"genre_scores_gemma":[0.98899007,0.0061445837,0.00023683885,0.000031886564,0.00017235923,0.0011358879,0.000024377157,0.000076864075,0.0031871109],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99552757,0.0004341138,0.0005539657,0.00070867175,0.0016448605,0.0011308069],"domain_scores_gemma":[0.99784374,0.00033830456,0.0001437945,0.0005773458,0.00055524777,0.00054158457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089733285,0.00037654352,0.00095408375,0.00061801367,0.00013772937,0.000020858073,0.00021001925,0.00012810282,0.0028303869],"category_scores_gemma":[0.000043211283,0.0002887025,0.00012542821,0.00081381085,0.000892776,0.00010988593,0.00014525527,0.0004108649,0.000022109205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004611985,0.004147132,0.85718924,0.0016630515,0.0013708671,0.002014697,0.004111076,0.000082072285,0.021111663,0.00015753711,0.0007302447,0.10281041],"study_design_scores_gemma":[0.0077893506,0.002190933,0.9709188,0.0017486588,0.00012685875,0.00084442564,0.00045022572,0.0004214478,0.014208588,0.00020171588,0.0008167173,0.00028233006],"about_ca_topic_score_codex":0.03679738,"about_ca_topic_score_gemma":0.0053202673,"teacher_disagreement_score":0.11372949,"about_ca_system_score_codex":0.0013321498,"about_ca_system_score_gemma":0.002073121,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W1999612798","doi":"10.1074/jbc.m113.475301","title":"Mutation of the Salt Bridge-forming Residues in the ETV6-SAM Domain Interface Blocks ETV6-NTRK3-induced Cellular Transformation","year":2013,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; British Columbia Knowledge Development Fund; Michael Smith Health Research BC; Conquer Cancer Foundation","keywords":"Salt bridge; Chemistry; Tyrosine; Receptor tyrosine kinase; Protein kinase B; Tyrosine kinase; Cell biology; Phosphorylation; Signal transduction; Biology; Molecular biology; Biochemistry; Gene; Mutant","score_opus":0.05373030542084133,"score_gpt":0.33754060868248587,"score_spread":0.2838103032616445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999612798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921826,0.0003243571,0.00020769848,0.005187055,0.000056414345,0.0003131436,0.0000031321792,0.0000060269904,0.0017195886],"genre_scores_gemma":[0.9993228,0.00008787578,0.00016348706,0.00016382757,0.00019898359,0.000011188314,0.000003605475,0.0000067484566,0.00004149729],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982991,0.0001586252,0.000696083,0.00011255148,0.00050381734,0.00022980351],"domain_scores_gemma":[0.99893147,0.00023533303,0.00032579945,0.00020791411,0.00022104742,0.00007846174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013222991,0.00012090943,0.000288996,0.00003828909,0.000052432126,0.000024841329,0.0003753602,0.0002125802,0.00023608516],"category_scores_gemma":[0.00050626224,0.00005673141,0.00016052874,0.00024092424,0.00013597996,0.00009364647,0.00003626108,0.0008858759,0.000004298235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014606051,0.00010202522,0.002803142,0.00013006458,0.000023025335,0.000021699312,0.001224917,0.000016506352,0.9910606,0.0000068997083,0.00034954437,0.004115529],"study_design_scores_gemma":[0.00092366396,0.00031579658,0.029774863,0.00036563497,0.000018272167,0.00029481246,0.0018081339,0.000093446295,0.9651211,0.00077287457,0.0004390125,0.000072422576],"about_ca_topic_score_codex":0.000064259344,"about_ca_topic_score_gemma":0.0000030797473,"teacher_disagreement_score":0.02697172,"about_ca_system_score_codex":0.00014366258,"about_ca_system_score_gemma":0.00014032508,"threshold_uncertainty_score":0.38487393},"labels":[],"label_agreement":null},{"id":"W2000042618","doi":"10.1136/jcp.2008.056291","title":"Expression of epidermal growth factor receptor in relation to <i>BRCA1</i> status, basal-like markers and prognosis in breast cancer","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University; McGill University Health Centre; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Breast cancer; Epidermal growth factor receptor; Cytokeratin; Immunohistochemistry; Oncology; Progesterone receptor; Internal medicine; Tissue microarray; Basal (medicine); Pathology; Univariate analysis; Biology; Cancer; Medicine; Multivariate analysis; Cancer research; Estrogen receptor","score_opus":0.09197521465323369,"score_gpt":0.4300134908668419,"score_spread":0.33803827621360816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000042618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990448,0.0004178828,0.000037694055,0.008220139,0.00041377937,0.00031906815,0.00003047432,0.000004014555,0.00010892935],"genre_scores_gemma":[0.99110645,0.004749491,0.0030108693,0.00079539994,0.0002551241,0.000014659591,0.0000019625718,0.000019932077,0.0000460953],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964301,0.00076952967,0.0017602036,0.00025301205,0.00044501285,0.00034212047],"domain_scores_gemma":[0.99770105,0.0009510279,0.0005117398,0.00013501711,0.000325198,0.00037593927],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021579496,0.00012190616,0.0008497277,0.00036751074,0.000020367856,0.0000032253429,0.00010636351,0.00028861375,0.00024114005],"category_scores_gemma":[0.0023428807,0.00009482682,0.00012215792,0.00031701234,0.00023160591,0.0001362273,0.00007512897,0.0010493775,0.0000043367936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039134747,0.00035188533,0.97102255,0.00008573256,0.000013602298,0.000536587,0.00041129213,0.000009644012,0.010340577,0.0000019486972,0.00465668,0.008656004],"study_design_scores_gemma":[0.003492727,0.0011368521,0.9922563,0.0006709257,0.000012721821,0.00035359678,0.00007120268,0.000019483936,0.0010933479,0.0000354495,0.0007792594,0.00007814093],"about_ca_topic_score_codex":0.00011183996,"about_ca_topic_score_gemma":0.000047517315,"teacher_disagreement_score":0.02123372,"about_ca_system_score_codex":0.00014622256,"about_ca_system_score_gemma":0.00059940957,"threshold_uncertainty_score":0.45590812},"labels":[],"label_agreement":null},{"id":"W2000193382","doi":"10.1158/0008-5472.sabcs11-p1-06-07","title":"P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Mount Sinai Hospital; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Anthracycline; Oncology; Internal medicine; Adjuvant; Immunohistochemistry; Biomarker; Cancer; Clinical trial; Biology","score_opus":0.07569601257387051,"score_gpt":0.39045621716267986,"score_spread":0.3147602045888094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000193382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382603,0.0011665343,0.00002143378,0.00067388284,0.0001239297,0.0018964544,0.0020999338,0.000018080136,0.00017369486],"genre_scores_gemma":[0.9939526,0.0038938324,0.00023137429,0.000025899628,0.00016009675,0.0012928797,0.00016311601,0.000050257735,0.00022997423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997368,0.00015444933,0.0004566483,0.0005397428,0.0009060594,0.00057510403],"domain_scores_gemma":[0.99820244,0.00025605795,0.00011721169,0.0003399949,0.0008962547,0.00018805469],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093344046,0.0001689968,0.00044229947,0.0005074538,0.00008073073,0.00001800835,0.00017946806,0.00015924082,0.00045756137],"category_scores_gemma":[0.0001683303,0.00013934029,0.00003478075,0.0006783789,0.0003489978,0.00019328862,0.000098989236,0.0006198917,0.0000044020107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030917984,0.0007154449,0.9457384,0.00032932445,0.00005169754,0.000008497843,0.0013944423,0.000020101808,0.0008132832,0.0000887102,0.0005546044,0.04719374],"study_design_scores_gemma":[0.007998114,0.0013971559,0.98130924,0.0011688286,0.00003013554,0.0000015190733,0.00029375745,0.0006855784,0.0057630655,0.00081880164,0.00041474178,0.00011906811],"about_ca_topic_score_codex":0.098677956,"about_ca_topic_score_gemma":0.02056908,"teacher_disagreement_score":0.07810888,"about_ca_system_score_codex":0.0007267076,"about_ca_system_score_gemma":0.0005265225,"threshold_uncertainty_score":0.997303},"labels":[],"label_agreement":null},{"id":"W2000474546","doi":"10.1371/journal.pone.0069325","title":"Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Universitat de Barcelona; Generalitat de Catalunya; Universitat de Girona","keywords":"Epidermal growth factor receptor; EGFR inhibitors; Internalization; Epidermal growth factor; Cancer research; Cancer cell; Cell growth; Cell biology; Phosphorylation; Growth factor; Biology; Chemistry; Receptor; Cancer; Pharmacology; Biochemistry","score_opus":0.13600609727588403,"score_gpt":0.32604322474359304,"score_spread":0.190037127467709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000474546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99705434,0.000019778738,0.00019845706,0.0006998492,0.0000078776175,0.00071860966,0.0000048246043,0.000047594727,0.0012486656],"genre_scores_gemma":[0.95365494,0.0000065673944,0.04584176,0.00008671664,0.00006789101,0.00011939464,0.000005938169,0.000030369247,0.00018642958],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998387,0.000060531624,0.0001988345,0.00025086556,0.0007682092,0.00033460147],"domain_scores_gemma":[0.99894154,0.000091337184,0.000086059714,0.00026205432,0.0003926416,0.00022639129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014780638,0.00013475279,0.00035428646,0.00010028041,0.00006528099,0.000014984665,0.000116524185,0.000061151106,0.0007307316],"category_scores_gemma":[0.0001726937,0.00010462644,0.000020919286,0.00020253872,0.00009758354,0.00019345024,0.00006725045,0.00026787474,0.00006145867],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002582784,0.0028257594,0.10800094,0.0008989414,0.0006148361,0.000023729453,0.0039947378,4.7036536e-7,0.862227,0.000021008214,0.000045128236,0.021089159],"study_design_scores_gemma":[0.0006163122,0.00033184706,0.2743499,0.00043309698,0.000027512748,0.0000030931783,0.00014022326,0.00016905305,0.72378325,0.000014330646,0.000029301711,0.0001020846],"about_ca_topic_score_codex":0.0002591934,"about_ca_topic_score_gemma":0.000063419146,"teacher_disagreement_score":0.16634896,"about_ca_system_score_codex":0.00020070033,"about_ca_system_score_gemma":0.0004342009,"threshold_uncertainty_score":0.80009985},"labels":[],"label_agreement":null},{"id":"W2000570160","doi":"10.1155/2012/135819","title":"The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study","year":2012,"lang":"en","type":"article","venue":"Cardiology Research and Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Trastuzumab; Ejection fraction; Breast cancer; Stage (stratigraphy); Cardiotoxicity; Internal medicine; Algorithm; Observational study; Cancer; Chemotherapy; Heart failure","score_opus":0.4389692035418175,"score_gpt":0.5643795326448076,"score_spread":0.12541032910299005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000570160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99345696,0.0018401053,0.000003183191,0.0011572959,0.00009050482,0.0014999821,0.00002135961,0.000003831729,0.0019267637],"genre_scores_gemma":[0.9940112,0.004987592,0.000082606304,0.00003777596,0.00011860883,0.00054238614,0.0000054537422,0.0000117466925,0.00020262037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505687,0.0030504498,0.00035059222,0.00025229185,0.0008013793,0.00048841024],"domain_scores_gemma":[0.9947028,0.0039996747,0.000111002606,0.0005031145,0.00057223375,0.0001111333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011271596,0.000095216485,0.0002651915,0.000086613814,0.00024397235,0.000019209412,0.00033489286,0.000065010696,0.000045380668],"category_scores_gemma":[0.00055154937,0.000054183667,0.000038879334,0.0004483832,0.000634469,0.00032704603,0.00020973304,0.0006394276,0.0000038102562],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003838276,0.0009746713,0.9608442,0.000060186878,0.00020646855,0.000024141904,0.021976095,0.0000018548183,0.000108910746,0.00006510844,0.000100375146,0.011799698],"study_design_scores_gemma":[0.0012803626,0.0018873627,0.9306314,0.00004901665,0.000018845063,0.000023518229,0.06470209,0.000008671418,0.00001440273,0.00002016437,0.0013192276,0.000044905908],"about_ca_topic_score_codex":0.0007099268,"about_ca_topic_score_gemma":0.000054481083,"teacher_disagreement_score":0.042726003,"about_ca_system_score_codex":0.00008545804,"about_ca_system_score_gemma":0.00018365763,"threshold_uncertainty_score":0.39065328},"labels":[],"label_agreement":null},{"id":"W2000786845","doi":"10.1158/0008-5472.can-06-1898","title":"ErbB-2 Induces the <i>Cyclin D1</i> Gene in Prostate Epithelial Cells <i>In vitro</i> and <i>In vivo</i>","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute","keywords":"Cancer research; Cyclin D1; ErbB; LNCaP; Biology; Prostate cancer; DU145; Cyclin D; Cyclin B; Carcinogenesis; Prostate; Cell cycle; Cancer; Signal transduction; Cell biology","score_opus":0.06950052905009499,"score_gpt":0.41905375034486486,"score_spread":0.34955322129476984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000786845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828965,0.0042791544,0.000003664753,0.0059773736,0.00029816537,0.002327587,0.00009747514,0.000025131878,0.0040949476],"genre_scores_gemma":[0.9891264,0.006482796,0.0001318254,0.00096827897,0.00049050414,0.00040990525,0.0000060412585,0.000080595964,0.002303653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99417245,0.00056702463,0.0007349814,0.0008593491,0.0017008454,0.0019653721],"domain_scores_gemma":[0.9976348,0.0009649898,0.000063394255,0.0006925928,0.0002462314,0.00039793778],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010115395,0.00027615565,0.0005377839,0.0009426124,0.0001416298,0.0000942669,0.0005209991,0.0002159348,0.00018709038],"category_scores_gemma":[0.00032069828,0.00020991213,0.00006543712,0.002541137,0.00078496296,0.00014941282,0.00035896112,0.0026986466,0.000054524327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030988324,0.00021393939,0.013225412,0.0002374227,0.000013868341,0.000927303,0.0017323282,0.000025085938,0.96171916,0.000022426357,0.0026889194,0.01609528],"study_design_scores_gemma":[0.0036544476,0.0002032346,0.009790448,0.00037267793,0.0000054774823,0.000027788139,0.0010548391,0.00005177966,0.9505097,0.0002549474,0.03384908,0.00022552638],"about_ca_topic_score_codex":0.0088832835,"about_ca_topic_score_gemma":0.009483942,"teacher_disagreement_score":0.03116016,"about_ca_system_score_codex":0.0011167258,"about_ca_system_score_gemma":0.001256193,"threshold_uncertainty_score":0.99960214},"labels":[],"label_agreement":null},{"id":"W2000828606","doi":"10.1016/j.jval.2012.08.2198","title":"PCN158 Adherence to Human Epidermal Growth Factor Receptor-2 (HER2) Testing &amp; Adjuvant Trastuzumab Treatment Guidelines in a Canadian Province","year":2012,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Bone and Joint Health Institute; Princess Margaret Cancer Centre; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cohort; Breast cancer; Oncology; Odds ratio; Cancer registry; Cancer","score_opus":0.33491114660301574,"score_gpt":0.46467707360967625,"score_spread":0.1297659270066605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000828606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98437166,0.0019736313,0.000022907105,0.008725889,0.00032683313,0.0029491403,0.00009714053,0.00007369189,0.0014591328],"genre_scores_gemma":[0.98684865,0.00014848894,0.009641665,0.001444962,0.0005946708,0.00033148768,0.000031898362,0.00006910003,0.0008890587],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529016,0.00045147366,0.0011080301,0.0005586854,0.0005592677,0.0020323945],"domain_scores_gemma":[0.99680144,0.00031836863,0.00013873917,0.00050162454,0.00021608672,0.002023719],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018902406,0.00031958093,0.0006851423,0.0006423672,0.00015561626,0.000025973308,0.00023064819,0.00013828925,0.00035238266],"category_scores_gemma":[0.0025280623,0.00028561905,0.0000609845,0.0008985461,0.00005463583,0.0001365882,0.00005179127,0.0004795904,0.00024128672],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0000733977,0.00032823664,0.8823046,0.0005939527,0.000014019185,0.00005514684,0.004472435,0.0002127229,0.0007844491,0.00013057113,0.0030806728,0.10794977],"study_design_scores_gemma":[0.0037450371,0.0054498385,0.8725051,0.0037815948,0.000014575096,0.00011527172,0.0006097067,0.0012556342,0.0009930265,0.00009207205,0.11066162,0.0007765197],"about_ca_topic_score_codex":0.9656567,"about_ca_topic_score_gemma":0.81146055,"teacher_disagreement_score":0.15419619,"about_ca_system_score_codex":0.009171613,"about_ca_system_score_gemma":0.008022923,"threshold_uncertainty_score":0.9999596},"labels":[],"label_agreement":null},{"id":"W2001633715","doi":"10.1002/cncr.24114","title":"Adjuvant targeted therapy in early breast cancer","year":2009,"lang":"en","type":"review","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency; McGill University; Alberta Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Breast cancer; Internal medicine; Adjuvant; Cancer; Adjuvant therapy; Clinical trial; Chemotherapy","score_opus":0.12475098361661355,"score_gpt":0.472917085885185,"score_spread":0.3481661022685715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001633715","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016048181,0.9938677,9.992978e-7,0.0008558147,0.00066948077,0.0023334331,0.0005300547,0.00008675874,0.0014953049],"genre_scores_gemma":[0.00009516955,0.99114144,0.000027666489,0.00073157775,0.0017693468,0.0020663885,0.000075886666,0.00018179724,0.003910753],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963788,0.00020758765,0.0007878304,0.00087201933,0.00079567963,0.00095811504],"domain_scores_gemma":[0.9982318,0.00007582959,0.00023896417,0.0008330146,0.00023163916,0.00038871256],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036360024,0.00064650294,0.00272392,0.0005023361,0.00005008564,0.000045581553,0.00046749145,0.0005913272,0.005016779],"category_scores_gemma":[0.000030476467,0.00047882213,0.0005126268,0.001266247,0.00013321359,0.00007920295,0.00006201931,0.0016205256,0.00021587523],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000092963484,0.00008841152,0.0009399981,0.0055653406,0.00018295467,0.00018781268,0.00011431973,0.0000010384096,0.000004008938,0.000006792126,0.012800061,0.9800163],"study_design_scores_gemma":[0.0011187597,0.00017263895,0.0065612937,0.03792125,0.00020029122,0.00006582624,0.000005424355,0.0000033941517,0.000006098593,0.000011189749,0.9534828,0.0004509975],"about_ca_topic_score_codex":0.004214137,"about_ca_topic_score_gemma":0.0005077429,"teacher_disagreement_score":0.9795653,"about_ca_system_score_codex":0.002527478,"about_ca_system_score_gemma":0.0048720813,"threshold_uncertainty_score":0.99976635},"labels":[],"label_agreement":null},{"id":"W2001948214","doi":"10.1016/j.ctrv.2012.05.004","title":"The evolving landscape of protein kinases in breast cancer: Clinical implications","year":2012,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Druggability; Medicine; Kinase; Breast cancer; Carcinogenesis; Cancer; Drug discovery; Bioinformatics; Cancer research; Internal medicine; Biology; Gene","score_opus":0.3287504679105725,"score_gpt":0.5473864501181303,"score_spread":0.21863598220755776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001948214","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012635693,0.9872307,8.885619e-7,0.0016799241,0.00027852415,0.009067719,0.0005243339,0.000025108055,0.0011801663],"genre_scores_gemma":[0.000040796633,0.9717134,0.00007885334,0.000045032015,0.0010592927,0.025408281,0.00011237896,0.00009053401,0.0014513935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99505323,0.00090592675,0.002316475,0.00066979724,0.00034532262,0.0007092312],"domain_scores_gemma":[0.99633336,0.00050666224,0.0010766211,0.0015675924,0.0001807308,0.00033503622],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015440413,0.0006144379,0.0039129574,0.00018003116,0.0001229293,0.00003417489,0.000471487,0.0003120262,0.0007977727],"category_scores_gemma":[0.00013690119,0.00031059654,0.001220885,0.0009125472,0.00023313913,0.0000686915,0.000109986715,0.000615919,0.00012022209],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021803897,0.00033204322,0.012979975,0.017466538,0.00028604528,0.000004955747,0.000020881174,5.1092886e-8,6.0793815e-7,0.000039159473,0.004086837,0.9647611],"study_design_scores_gemma":[0.0005650681,0.00014705025,0.0021784634,0.055488724,0.0019830891,0.00003727404,0.0000051191505,9.623194e-7,0.0000013260388,0.000006518656,0.93936396,0.00022245663],"about_ca_topic_score_codex":0.0015241756,"about_ca_topic_score_gemma":0.0010199123,"teacher_disagreement_score":0.96453863,"about_ca_system_score_codex":0.0020061708,"about_ca_system_score_gemma":0.0031145485,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W2002083419","doi":"10.1039/c4ib00062e","title":"The EGFR demonstrates linear signal transmission","year":2014,"lang":"en","type":"article","venue":"Integrative Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Cancer Research UK","keywords":"Transmission (telecommunications); SIGNAL (programming language); Computational biology; Biology; Chemistry; Biophysics; Computer science; Telecommunications","score_opus":0.03196739022355707,"score_gpt":0.3882039810596925,"score_spread":0.35623659083613546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002083419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49369472,0.008979001,0.2341937,0.08027484,0.0014149467,0.0026851455,0.00006366823,0.00046170468,0.17823228],"genre_scores_gemma":[0.99531376,0.0003159646,0.0016227101,0.00048986496,0.0003679438,0.000049333306,0.000019423918,0.000015759935,0.0018052086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99873674,0.00035782502,0.00021094563,0.00024155661,0.00012497915,0.00032792473],"domain_scores_gemma":[0.99863595,0.00078215497,0.00003976441,0.0002039627,0.00020277509,0.0001353728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057031197,0.00013825043,0.00022893283,0.00005084504,0.00016173618,0.000012577041,0.0001811244,0.00015296822,0.00042056327],"category_scores_gemma":[0.00033713994,0.00006403051,0.000089339315,0.00013964182,0.00059366587,0.000018871222,0.00002369456,0.00048492424,0.00017224762],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065169815,0.00009023523,0.013877021,0.000025949275,0.00010552793,0.0000111325835,0.00056844164,0.0000014965922,0.22547783,0.024350103,0.007929653,0.7269109],"study_design_scores_gemma":[0.0008240138,0.002537745,0.0028671469,0.00013255478,0.000023265742,0.0000468572,0.00050365715,0.0040679565,0.15864386,0.0061583193,0.8240468,0.00014785586],"about_ca_topic_score_codex":0.0001065899,"about_ca_topic_score_gemma":0.00005920434,"teacher_disagreement_score":0.8161171,"about_ca_system_score_codex":0.000070937625,"about_ca_system_score_gemma":0.00020085232,"threshold_uncertainty_score":0.46048728},"labels":[],"label_agreement":null},{"id":"W2002914543","doi":"10.1371/journal.pone.0063458","title":"Serum HER 2 Extracellular Domain Level Is Correlated with Tissue HER 2 Status in Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency","keywords":"Immunohistochemistry; Cancer; Metastasis; Medicine; Pathology; Gastroenterology; Adenocarcinoma; Internal medicine","score_opus":0.09346606272102356,"score_gpt":0.29512173842365824,"score_spread":0.20165567570263468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002914543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992118,0.0022809678,0.000922334,0.0014886201,0.00006283303,0.0024219856,0.00004925555,0.00010150219,0.0005545044],"genre_scores_gemma":[0.95147306,0.000121524834,0.02051746,0.00031256885,0.00014416306,0.00040261206,0.00006351308,0.00013041233,0.026834674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623483,0.00022567433,0.00053415966,0.00061181234,0.0013048092,0.0010887218],"domain_scores_gemma":[0.99833226,0.0001139897,0.00012987826,0.00060891215,0.00030135704,0.00051357277],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003903156,0.00034789726,0.00066687854,0.0004366016,0.000078180456,0.00006573932,0.00016553553,0.00014262157,0.014130205],"category_scores_gemma":[0.00012063651,0.0002648908,0.000048995364,0.0011076119,0.00014913926,0.0002559594,0.00006906072,0.00085787,0.0016100478],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003408717,0.006569391,0.876728,0.001917117,0.0014741322,0.0040640486,0.003020333,0.000046296,0.07792953,0.00002135656,0.009032047,0.015789015],"study_design_scores_gemma":[0.016937725,0.007678912,0.92219263,0.0020344527,0.0008865221,0.0004761964,0.0021931697,0.0042808815,0.040939007,0.00016121096,0.0014286523,0.00079063926],"about_ca_topic_score_codex":0.0015169885,"about_ca_topic_score_gemma":0.0002551554,"teacher_disagreement_score":0.04546461,"about_ca_system_score_codex":0.00056773546,"about_ca_system_score_gemma":0.0005187686,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W2003433778","doi":"10.1200/jco.2002.99.002","title":"HER-2/<i>neu</i> Serum Levels Vis-à-Vis Hormonal Response in Metastatic Breast Cancer","year":2002,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Internal medicine; Citation; Clinical Oncology; Multivariate analysis; Oncology; Hormone; Cancer; Gastroenterology; Library science","score_opus":0.33728410643388906,"score_gpt":0.5535752643029328,"score_spread":0.21629115786904374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003433778","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.058124676,0.0027487024,0.000023231518,0.93306273,0.0032932695,0.0006352478,0.00049031747,0.000019171119,0.0016026411],"genre_scores_gemma":[0.09140145,0.005755288,0.0020403569,0.86667466,0.025019689,0.0000693218,0.0000128705815,0.00025294977,0.008773433],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9835009,0.0057835598,0.00622607,0.000728877,0.002494955,0.0012656366],"domain_scores_gemma":[0.9815683,0.012274405,0.0033049108,0.00069998484,0.0012950784,0.00085732946],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.015398525,0.000592001,0.005229778,0.0009954463,0.00005936103,0.000042283402,0.000938627,0.0026328433,0.008779211],"category_scores_gemma":[0.007214082,0.00044909044,0.0014765554,0.0006838656,0.000753474,0.00018656331,0.00022484761,0.018800836,0.00026037922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014417851,0.0010470202,0.011211985,0.00029748946,0.0009187169,0.049294315,0.00007449542,0.000015021943,0.000047890524,0.0000014412187,0.8071956,0.11547819],"study_design_scores_gemma":[0.00780815,0.010015825,0.25220323,0.0009894887,0.0005689669,0.0055843038,0.000026956262,0.000073484145,0.000006672838,0.00008006455,0.722339,0.00030386765],"about_ca_topic_score_codex":0.00020437523,"about_ca_topic_score_gemma":0.00013713916,"teacher_disagreement_score":0.24099123,"about_ca_system_score_codex":0.00231389,"about_ca_system_score_gemma":0.01413652,"threshold_uncertainty_score":0.9997961},"labels":[],"label_agreement":null},{"id":"W2003852222","doi":"10.1158/1078-0432.ccr-05-2242","title":"Expression and Nuclear Localization of ErbB3 in Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; University of British Columbia; Centre Hospitalier de l’Université de Montréal","funders":"Institut Du Cancer de Montréal","keywords":"DU145; LNCaP; Prostate cancer; Prostate; Cancer; Tissue microarray; Pathology; Biology; Cancer research; PCA3; Immunohistochemistry; Medicine; Internal medicine","score_opus":0.22629727301224037,"score_gpt":0.5769018912532754,"score_spread":0.35060461824103506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003852222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98617303,0.005502269,0.000016599686,0.0034330846,0.00014991926,0.0011168314,0.000032800417,0.000029878482,0.0035455588],"genre_scores_gemma":[0.9884919,0.009010677,0.000149757,0.00016734585,0.00041352253,0.00021207695,0.000009926914,0.00005047041,0.001494317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963874,0.00051531283,0.0007884847,0.0005502142,0.0011645711,0.000593993],"domain_scores_gemma":[0.99816895,0.00049053296,0.00008974137,0.00040373873,0.0006007697,0.0002462966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031783646,0.00012475155,0.00045897928,0.0003096953,0.000089490786,0.000029207671,0.00018160086,0.00018921813,0.00091807655],"category_scores_gemma":[0.00068327424,0.000104113315,0.00006745477,0.0008893008,0.00087208033,0.00009070755,0.0002440933,0.0010607616,0.000020588515],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002379992,0.0005237274,0.90577245,0.0009529085,0.000019522968,0.000084423664,0.0003273757,0.0001560695,0.011464205,0.00031936818,0.03216454,0.04583543],"study_design_scores_gemma":[0.012177426,0.002261298,0.67830485,0.0057214815,0.000042897555,0.000013028069,0.0007108574,0.008308733,0.019322775,0.0027758186,0.26986203,0.00049881334],"about_ca_topic_score_codex":0.0094314385,"about_ca_topic_score_gemma":0.0013697366,"teacher_disagreement_score":0.23769748,"about_ca_system_score_codex":0.00031078546,"about_ca_system_score_gemma":0.0007985032,"threshold_uncertainty_score":0.99999523},"labels":[],"label_agreement":null},{"id":"W2003885794","doi":"10.1158/0008-5472.can-12-1339-t","title":"Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; University of Pennsylvania","keywords":"Trastuzumab; Cancer research; Tumor microenvironment; Cytotoxic T cell; CD8; PTEN; Medicine; PI3K/AKT/mTOR pathway; Breast cancer; T cell; Protein kinase B; Mammary tumor; Antibody; Cancer; Immunology; Antigen; Immune system; Biology; Internal medicine; Signal transduction; In vitro; Cell biology; Tumor cells","score_opus":0.05514960438187381,"score_gpt":0.39744508346180224,"score_spread":0.3422954790799284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2003885794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120927,0.005034117,0.000012207,0.0011283878,0.00024435893,0.0014910224,0.0004605966,0.000023407269,0.0003966365],"genre_scores_gemma":[0.99756277,0.0005889439,0.00026050324,0.00005862496,0.00040946028,0.00050278165,0.0000034656216,0.00007382295,0.0005396201],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99526554,0.0010194634,0.0005781989,0.0005008656,0.0015578826,0.0010780371],"domain_scores_gemma":[0.99652284,0.00099657,0.0001527696,0.00042174826,0.0012003758,0.0007056731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058002206,0.0002359519,0.0006596607,0.0006910034,0.00015241031,0.000024106805,0.0002286309,0.0001353365,0.00060986076],"category_scores_gemma":[0.00065723626,0.0002028111,0.00009422802,0.001288855,0.00063629,0.00016509151,0.0002604097,0.0008380672,0.000017756436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013366496,0.00026826712,0.014375802,0.0014842524,0.00007627568,0.000020129148,0.0021362586,0.000017953913,0.95929325,0.000028174467,0.0053350893,0.003598041],"study_design_scores_gemma":[0.0017357352,0.0010154976,0.08164292,0.0011566917,0.00004001738,0.000018083294,0.0015199353,0.000016569784,0.90964043,0.000009962232,0.0030280934,0.00017609113],"about_ca_topic_score_codex":0.0047127292,"about_ca_topic_score_gemma":0.00011368214,"teacher_disagreement_score":0.06726712,"about_ca_system_score_codex":0.0013300965,"about_ca_system_score_gemma":0.0016080717,"threshold_uncertainty_score":0.82703966},"labels":[],"label_agreement":null},{"id":"W2004714285","doi":"10.1038/sj.onc.1208230","title":"Targeted disruption of ErbB2/Neu in the mammary epithelium results in impaired ductal outgrowth","year":2004,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital; McMaster University","funders":"Canadian Institutes of Health Research; U.S. Department of Defense","keywords":"Biology; Mammary gland; Morphogenesis; Genetically modified mouse; Receptor tyrosine kinase; Endocrinology; Internal medicine; Tyrosine kinase; Cancer research; Epithelium; Mammary tumor; Cancer; Receptor; Transgene; Breast cancer; Cell biology; Kinase; Signal transduction; Gene; Genetics; Medicine","score_opus":0.03604846698600035,"score_gpt":0.3439230656669381,"score_spread":0.30787459868093775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004714285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860972,0.0007333454,0.000043253178,0.008519061,0.000115253795,0.00064210995,0.00006134623,0.000024114386,0.0037642724],"genre_scores_gemma":[0.9982192,0.00027395124,0.00076972,0.00024538854,0.00016511095,0.000051657767,0.000070129594,0.000021908625,0.0001829442],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981236,0.00016825211,0.00048037086,0.0002917838,0.0005690779,0.0003669412],"domain_scores_gemma":[0.999156,0.00008432708,0.000081135055,0.00051702344,0.00007437221,0.000087162865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012101338,0.00013372234,0.0002867558,0.00024616582,0.000024428547,0.000010394335,0.0002524535,0.000114648064,0.000027172078],"category_scores_gemma":[0.00035388023,0.00009675249,0.000079228696,0.00077338424,0.00009560579,0.0000794004,0.00006521838,0.00034579518,0.000032081487],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040490106,0.0021532427,0.05459466,0.0004997118,0.00008182635,0.0030705712,0.012493652,0.00032430183,0.8931434,0.0007998772,0.0017381891,0.027051536],"study_design_scores_gemma":[0.020943116,0.0023845201,0.75879765,0.00092782185,0.0000492481,0.00044402308,0.0015649945,0.00036770783,0.20775977,0.0024254455,0.0038884329,0.00044729616],"about_ca_topic_score_codex":0.0012614161,"about_ca_topic_score_gemma":0.0009293289,"teacher_disagreement_score":0.70420295,"about_ca_system_score_codex":0.00037577134,"about_ca_system_score_gemma":0.00045406818,"threshold_uncertainty_score":0.3945452},"labels":[],"label_agreement":null},{"id":"W2006035341","doi":"10.1080/01635581.2013.756921","title":"Dietary Flaxseed–Trastuzumab Interactive Effects on the Growth of HER2-Overexpressing Human Breast Tumors (BT-474)","year":2013,"lang":"en","type":"article","venue":"Nutrition and Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nutrition Society","funders":"","keywords":"Medicine; Protein kinase A; Trastuzumab; Apoptosis; Internal medicine; Endocrinology; MAPK/ERK pathway; Mammary tumor; Cancer research; Estrogen receptor; AKT2; Basal (medicine); Kinase; AKT1; Protein kinase B; Breast cancer; Biology; Cancer; Cell biology; Biochemistry","score_opus":0.02676153708598555,"score_gpt":0.33925665738997374,"score_spread":0.3124951203039882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006035341","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867494,0.00088049436,0.000005009624,0.0074435775,0.00011282455,0.0010549234,0.000052703515,0.00003388835,0.003667139],"genre_scores_gemma":[0.9973261,0.00039054942,0.00003052535,0.0009852091,0.0003625598,0.00047810187,0.000017048427,0.000024146728,0.00038578475],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99887425,0.00010770498,0.00018385296,0.0002365259,0.00036649406,0.00023114697],"domain_scores_gemma":[0.9992387,0.00017977347,0.0000738087,0.00018895697,0.00019681716,0.00012188872],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000116517986,0.00014100505,0.00024747656,0.00008836035,0.00012441116,0.000038553342,0.00008755824,0.00006404784,0.0011030708],"category_scores_gemma":[0.000037380465,0.00008819377,0.00006836611,0.00013757328,0.00013513268,0.0001231649,0.000038704944,0.00036006843,0.00002384389],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013960585,0.0016528323,0.033144414,0.0057638264,0.0003889528,0.00006285929,0.0027517122,0.0000015474457,0.593879,0.0010857297,0.13541242,0.22446068],"study_design_scores_gemma":[0.0066576423,0.0018538007,0.5891606,0.01478011,0.000119541,0.00012865842,0.0018133193,0.00018530319,0.37571177,0.002465417,0.006692101,0.00043171577],"about_ca_topic_score_codex":0.0019360352,"about_ca_topic_score_gemma":0.00003233371,"teacher_disagreement_score":0.5560162,"about_ca_system_score_codex":0.00019343261,"about_ca_system_score_gemma":0.00006107768,"threshold_uncertainty_score":0.99981004},"labels":[],"label_agreement":null},{"id":"W2006069672","doi":"10.1016/j.aanat.2010.12.002","title":"Complex patterns of ADAM12 mRNA and protein splice variants in the human placenta","year":2011,"lang":"en","type":"article","venue":"Annals of Anatomy - Anatomischer Anzeiger","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"RWTH Aachen University; Deutsche Forschungsgemeinschaft","keywords":"Cytotrophoblast; Syncytium; Placenta; Syncytiotrophoblast; Blot; Immunohistochemistry; Trophoblast; Biology; In situ hybridization; Molecular biology; Virology; Messenger RNA; Immunology; Gene; Pregnancy; Genetics; Virus; Fetus","score_opus":0.19892840454113753,"score_gpt":0.4124213046702093,"score_spread":0.2134929001290718,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006069672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974874,0.00054835284,0.000010511305,0.0017639165,0.000016726055,0.0011566782,0.000039889823,0.000016478998,0.021573406],"genre_scores_gemma":[0.99807596,0.00022429993,0.00022860081,0.00093874393,0.000048096892,0.00006995539,0.000014132735,0.00003649321,0.00036372538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763155,0.0002386845,0.0005980819,0.00037734542,0.00066320295,0.00049111847],"domain_scores_gemma":[0.99862534,0.000071469876,0.00019032655,0.0006646295,0.00026710023,0.00018115315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012474918,0.00023040472,0.00053819653,0.0002894916,0.000060812414,0.000012610599,0.0004178496,0.00014618713,0.0015038159],"category_scores_gemma":[0.00007399672,0.0001696509,0.000121371035,0.00039789587,0.00025853128,0.00013570981,0.00013283662,0.0004449895,0.000011160357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011524754,0.0024669582,0.90697044,0.0019224964,0.000534952,0.0004876853,0.01187529,4.7506836e-7,0.033447932,0.01216107,0.020202035,0.008778207],"study_design_scores_gemma":[0.0025408086,0.0006678504,0.9262763,0.000621538,0.00004555914,0.00004025203,0.0021460315,0.000088442896,0.055882655,0.0009419065,0.010474647,0.0002739956],"about_ca_topic_score_codex":0.0048236055,"about_ca_topic_score_gemma":0.00029561482,"teacher_disagreement_score":0.02320191,"about_ca_system_score_codex":0.000019258174,"about_ca_system_score_gemma":0.0001538301,"threshold_uncertainty_score":0.99940896},"labels":[],"label_agreement":null},{"id":"W2006371959","doi":"10.1158/0008-5472.sabcs12-p5-15-02","title":"Abstract P5-15-02: The benefit of targeted therapeutics in medical oncology since the development of trastuzumab","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.23133876086043306,"score_gpt":0.5183204141789531,"score_spread":0.2869816533185201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006371959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674124,0.009665901,0.000019130908,0.016093716,0.00020552463,0.0010665932,0.000016054197,0.000011345469,0.005509313],"genre_scores_gemma":[0.9971124,0.0014558607,0.00018282505,0.0002805946,0.0002915251,0.00035356963,0.000006144093,0.000035175464,0.00028190875],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946992,0.00039896285,0.00073401455,0.00025939618,0.0028711823,0.0010372711],"domain_scores_gemma":[0.9967447,0.0016221649,0.000116954,0.0006346793,0.00059576414,0.00028575683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008545118,0.0001540418,0.00043427458,0.00024696658,0.00016340466,0.000010380608,0.0008732578,0.00024798288,0.0024193695],"category_scores_gemma":[0.00055386877,0.00008503131,0.00007784311,0.001077299,0.001202382,0.000060534367,0.0002805807,0.0017756146,0.00004197365],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021789062,0.00216439,0.0723716,0.0011847101,0.00056515815,0.00005503616,0.03807058,0.000037542988,0.12415501,0.0019347225,0.005452642,0.7518297],"study_design_scores_gemma":[0.0026795086,0.00061989523,0.5695731,0.00089516456,0.00003509126,0.00002984153,0.005374625,0.00013650858,0.21040125,0.0002347814,0.20980385,0.0002163503],"about_ca_topic_score_codex":0.00094620854,"about_ca_topic_score_gemma":0.0022589236,"teacher_disagreement_score":0.7516133,"about_ca_system_score_codex":0.0012159789,"about_ca_system_score_gemma":0.006212186,"threshold_uncertainty_score":0.99942166},"labels":[],"label_agreement":null},{"id":"W2006937919","doi":"10.3389/fgene.2015.00017","title":"ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics","year":2015,"lang":"en","type":"review","venue":"Frontiers in Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fondation du cancer du sein du Québec","keywords":"ErbB; ERBB4; ERBB3; Biology; Receptor tyrosine kinase; Single-nucleotide polymorphism; Cancer research; Neuregulin; Computational biology; Genetics; Gene; Receptor; Genotype","score_opus":0.13994944969110415,"score_gpt":0.450494039254615,"score_spread":0.31054458956351083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006937919","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000109286375,0.99073887,0.0020660874,0.0015622117,0.00084763987,0.0040831715,0.00047790707,0.00003238464,0.00008245405],"genre_scores_gemma":[0.000012995708,0.9703833,0.02575345,0.00046565873,0.00033860523,0.0012989597,0.00010405757,0.00014808308,0.0014949059],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99766964,0.0002522926,0.00061166304,0.000611977,0.00032469616,0.0005297612],"domain_scores_gemma":[0.9981188,0.00016588632,0.0001405702,0.00082243374,0.0003109873,0.00044133145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005792094,0.00039188794,0.0014392398,0.00070443685,0.000069590154,0.00003674842,0.0003496398,0.00047896194,0.000010686951],"category_scores_gemma":[0.00016945707,0.00033892508,0.00015909459,0.0007894563,0.00014697564,0.000018596842,0.00013235549,0.00044774142,0.00000627717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002875809,0.00004913921,0.00046757143,0.0026675975,0.00020281835,0.0000052907353,0.00045854383,0.0000030999768,0.00002316205,0.000008262922,0.051400088,0.94442683],"study_design_scores_gemma":[0.0006579691,0.00036730675,0.00040271756,0.002736211,0.0005929657,0.000014145514,0.0000526929,0.000049711634,0.00001592344,0.00028354017,0.99449646,0.0003303237],"about_ca_topic_score_codex":0.00002361205,"about_ca_topic_score_gemma":0.00003302452,"teacher_disagreement_score":0.9440965,"about_ca_system_score_codex":0.0010918807,"about_ca_system_score_gemma":0.0031031554,"threshold_uncertainty_score":0.9999063},"labels":[],"label_agreement":null},{"id":"W2006951838","doi":"10.4161/cbt.7.4.5533","title":"Differential sensitivity of A549 non small lung carcinoma cell responses to epidermal growth factor receptor pathway inhibitors","year":2008,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Epidermal growth factor receptor; A549 cell; Motility; Epidermal growth factor; Cancer research; Cell growth; Biology; EGFR inhibitors; Cell biology; Growth factor receptor; Apoptosis; Cell; Receptor; Signal transduction; Biochemistry","score_opus":0.0625310769672316,"score_gpt":0.3354780181004788,"score_spread":0.2729469411332472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006951838","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384624,0.0016592749,0.0002870669,0.0016702636,0.000942137,0.0010269257,0.00036557385,0.000058157417,0.00014434461],"genre_scores_gemma":[0.9948725,0.002010307,0.00023317152,0.00087685033,0.0009959275,0.00015587563,0.000040742474,0.00006301012,0.00075159525],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727213,0.00067728927,0.00045768233,0.00063674175,0.00025952284,0.00069663144],"domain_scores_gemma":[0.99821126,0.00042955056,0.00014781888,0.00049703027,0.00035626366,0.00035804507],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003353611,0.00033709678,0.0007589652,0.00027596887,0.00013695144,0.0000064785645,0.00018696023,0.00033099667,0.00091067096],"category_scores_gemma":[0.0001326315,0.00027181316,0.00022070238,0.00033332003,0.00044144457,0.000039202332,0.00009738747,0.00046371107,0.00003300455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023760262,0.0001240708,0.39117157,0.000074982745,0.00006284965,0.0000561274,0.0010261062,4.954689e-7,0.5975764,0.000003467916,0.0015760525,0.0059518875],"study_design_scores_gemma":[0.00180078,0.0010081193,0.30331796,0.00007018371,0.000011543349,0.000025546135,0.0000446207,0.0000211558,0.6896315,0.0000042362462,0.0038583046,0.00020602043],"about_ca_topic_score_codex":0.0021309748,"about_ca_topic_score_gemma":0.00010768675,"teacher_disagreement_score":0.09205515,"about_ca_system_score_codex":0.0003539353,"about_ca_system_score_gemma":0.0009585162,"threshold_uncertainty_score":0.9999734},"labels":[],"label_agreement":null},{"id":"W2007855317","doi":"10.1016/s0009-9236(03)90662-x","title":"Pharmacokinetics of Trastuzumab in Combination With Paclitaxel Given Every 3 Weeks in Women With HER2 Positive Metastatic Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Paclitaxel; Medicine; Metastatic breast cancer; Pharmacokinetics; Oncology; Breast cancer; Internal medicine; Cancer","score_opus":0.07312905217516238,"score_gpt":0.44980259319497,"score_spread":0.37667354101980766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007855317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886063,0.0007389501,0.0001366171,0.0083536375,0.0002594615,0.0013991203,0.00008177604,0.000024376222,0.00039979094],"genre_scores_gemma":[0.98533446,0.002061727,0.00056544563,0.011475883,0.000075695025,0.0002784469,0.000008635251,0.0000657557,0.00013395639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99623793,0.0011642099,0.0008997045,0.00050288637,0.00049938477,0.00069587864],"domain_scores_gemma":[0.9978549,0.0010078244,0.00026209897,0.00023959563,0.00038213228,0.00025345804],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014591853,0.00029514442,0.0008973419,0.00027716803,0.000036875652,0.000009032274,0.00020632081,0.00016910111,0.00065550854],"category_scores_gemma":[0.000024511677,0.00022989992,0.000069246125,0.00086043886,0.00082526397,0.00009242154,0.00003549054,0.0012462023,0.000008379075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052828286,0.023355825,0.8239048,0.0009074769,0.005611564,0.0014410623,0.0064195585,0.0013367047,0.025007904,0.00008507616,0.0026188325,0.056482926],"study_design_scores_gemma":[0.06571095,0.0149338385,0.8920719,0.00078355003,0.001802181,0.00025839044,0.0020665561,0.0019482023,0.0128370635,0.0003767826,0.0064697843,0.00074078713],"about_ca_topic_score_codex":0.00009308847,"about_ca_topic_score_gemma":0.00008471256,"teacher_disagreement_score":0.068167135,"about_ca_system_score_codex":0.0007369183,"about_ca_system_score_gemma":0.0012029995,"threshold_uncertainty_score":0.93750465},"labels":[],"label_agreement":null},{"id":"W2008691121","doi":"10.5858/arpa.2013-0604-oa","title":"HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation","year":2014,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; University Health Network; BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Medicine; Trastuzumab; HER2/neu; Tissue microarray; Cancer; External quality assessment; Pathology; Internal medicine; Oncology; Companion diagnostic; Breast cancer","score_opus":0.019046056051971363,"score_gpt":0.3665332145124135,"score_spread":0.34748715846044215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008691121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873225,0.0028318507,0.0018300002,0.0011683487,0.00026548252,0.00044261466,0.000111299065,0.000039678354,0.005988206],"genre_scores_gemma":[0.9938534,0.00030019158,0.005008524,0.0003629806,0.00019116668,0.000102680104,0.000052413387,0.000039314094,0.000089341156],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973358,0.00048169817,0.0008653212,0.00044838293,0.00047393361,0.00039488618],"domain_scores_gemma":[0.99753803,0.0008581488,0.00045482462,0.00059880276,0.00038183096,0.00016838485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012955347,0.00023286851,0.00082279096,0.00042004892,0.00003686255,0.0000022653232,0.00027565865,0.00013461336,0.0001624118],"category_scores_gemma":[0.001973537,0.00020817053,0.000042913176,0.0010232946,0.0010200669,0.00005380511,0.00009499265,0.00063361955,0.0000015096182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010406331,0.00018666591,0.16785362,0.0005062086,0.000037205176,0.00005034711,0.00091091933,0.000014471138,0.82217723,0.00011887745,0.0006767837,0.0073636333],"study_design_scores_gemma":[0.007327939,0.0036904037,0.9151429,0.0034255353,0.00021063768,0.00006331677,0.0008041976,0.0025182106,0.063213184,0.00033843736,0.0028987469,0.0003665111],"about_ca_topic_score_codex":0.00036320754,"about_ca_topic_score_gemma":0.000022581424,"teacher_disagreement_score":0.758964,"about_ca_system_score_codex":0.00018719837,"about_ca_system_score_gemma":0.0010976095,"threshold_uncertainty_score":0.84889483},"labels":[],"label_agreement":null},{"id":"W2008692957","doi":"10.1016/j.mpdhp.2014.10.002","title":"ER, PR and HER2 testing in breast cancer","year":2014,"lang":"en","type":"article","venue":"Diagnostic histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Breast cancer; Estrogen receptor; Oncology; Biomarker; Medicine; Cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Targeted therapy; Bioinformatics; Biology","score_opus":0.029263649304944607,"score_gpt":0.3369614672014343,"score_spread":0.30769781789648964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008692957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98137826,0.0018936797,0.000100485544,0.006728034,0.0003687337,0.00040043818,0.0000206257,0.00006953157,0.009040211],"genre_scores_gemma":[0.9965132,0.000289801,0.000775259,0.001494984,0.00027866376,0.000200652,0.000005633825,0.000033021977,0.00040877436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998595,0.00015938027,0.00024656276,0.0003871839,0.0001791655,0.0004327161],"domain_scores_gemma":[0.9977135,0.001677613,0.000048875256,0.0002793568,0.000102357604,0.00017827487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005555947,0.00013604973,0.00034346056,0.00017926321,0.000053814827,0.00000837403,0.00009153623,0.00012450381,0.00027498553],"category_scores_gemma":[0.005077451,0.00012882707,0.00002249119,0.00025994424,0.0002667946,0.000031813666,0.00007582229,0.0003677144,0.00007083768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003274064,0.00008938048,0.9188241,0.00014034644,0.000002081073,0.00061914354,0.00035606034,0.000007686097,0.0018684856,0.00020113662,0.0025766382,0.07528224],"study_design_scores_gemma":[0.0010853268,0.00021931416,0.98171866,0.00032042863,0.000023882723,0.0012479371,0.00003388331,0.00042018003,0.000065973014,0.00022770396,0.0145033505,0.00013338274],"about_ca_topic_score_codex":0.0013005403,"about_ca_topic_score_gemma":0.00036962918,"teacher_disagreement_score":0.07514885,"about_ca_system_score_codex":0.0002016347,"about_ca_system_score_gemma":0.00019253112,"threshold_uncertainty_score":0.607855},"labels":[],"label_agreement":null},{"id":"W2010059199","doi":"10.1016/j.ctrv.2013.01.002","title":"HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials","year":2013,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Lapatinib; Pertuzumab; Trastuzumab; Oncology; Breast cancer; Internal medicine; Neoadjuvant therapy; Clinical trial; Targeted therapy; Chemotherapy; Cancer","score_opus":0.30647694075076715,"score_gpt":0.523487102194639,"score_spread":0.21701016144387186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010059199","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000011974976,0.9419979,7.973655e-7,0.00076476886,0.00045185944,0.055518366,0.0008389103,0.000049193666,0.0003770357],"genre_scores_gemma":[2.663882e-7,0.90732044,0.000091757414,0.0005736791,0.00047570167,0.089308135,0.0002797023,0.00020374083,0.0017465944],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98434377,0.0051125917,0.0073756026,0.0012476845,0.0009837135,0.00093663955],"domain_scores_gemma":[0.99161756,0.0007375827,0.004275792,0.0024697243,0.00040636928,0.0004929754],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0048592133,0.0016194619,0.03128399,0.0005753308,0.000050868726,0.000041973788,0.0006983014,0.0005008341,0.0072481786],"category_scores_gemma":[0.00060249376,0.00083511206,0.00402048,0.0018401105,0.00014675714,0.000102286285,0.00008129886,0.00067542586,0.0004744997],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000017677437,0.00022148446,0.000021317876,0.50589734,0.00083548157,0.000026818341,0.000030981966,3.8320625e-8,9.2402746e-7,0.0000018814698,0.005243374,0.48770267],"study_design_scores_gemma":[0.00092919637,0.00025512697,0.0000032930939,0.50699776,0.005260452,0.000068852845,0.00000371872,5.7566524e-7,0.0000032957007,0.0000010985075,0.48617998,0.0002966801],"about_ca_topic_score_codex":0.004154501,"about_ca_topic_score_gemma":0.00013105941,"teacher_disagreement_score":0.487406,"about_ca_system_score_codex":0.0053990805,"about_ca_system_score_gemma":0.004483171,"threshold_uncertainty_score":0.9996553},"labels":[],"label_agreement":null},{"id":"W2010208199","doi":"10.1158/0008-5472.sabcs13-p4-12-16","title":"Abstract P4-12-16: Safety profile and costs of related adverse events of trastuzumab emtansine compared to other regimens in the Canadian health care system","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Trastuzumab emtansine; Medicine; Trastuzumab; Taxane; Lapatinib; Internal medicine; Capecitabine; Docetaxel; Adverse effect; Oncology; Breast cancer; Cancer","score_opus":0.08097982633674465,"score_gpt":0.42649058274963975,"score_spread":0.3455107564128951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010208199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738208,0.002016606,0.0000013979122,0.0072725355,0.00007907848,0.00556481,0.00041211327,0.000015523041,0.010817107],"genre_scores_gemma":[0.99863774,0.00013521474,0.000055919118,0.00017332083,0.0000501265,0.000458729,0.000040291037,0.000044102824,0.00040457465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961586,0.00053171854,0.0006471673,0.0004079577,0.0013636095,0.00089095935],"domain_scores_gemma":[0.9974927,0.00025042225,0.00010888066,0.00068241585,0.00083119975,0.00063438964],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022402364,0.00016443705,0.00053515437,0.0006021531,0.00017985623,0.000012606874,0.00036638294,0.00013497772,0.0007427401],"category_scores_gemma":[0.00020165491,0.00012416606,0.00005407257,0.0010432921,0.0002774848,0.00006769335,0.0000702099,0.00079961773,0.00004858089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006951863,0.0012088197,0.47965178,0.027910594,0.0010273447,0.00054930925,0.15285477,0.0006371426,0.031279422,0.0025346624,0.21412152,0.08127276],"study_design_scores_gemma":[0.005527937,0.0013298431,0.93726355,0.008609486,0.000021691878,0.00003857976,0.03603424,0.0001328159,0.0032830297,0.00001570473,0.00745051,0.00029262295],"about_ca_topic_score_codex":0.79717296,"about_ca_topic_score_gemma":0.6717651,"teacher_disagreement_score":0.45761174,"about_ca_system_score_codex":0.0064844075,"about_ca_system_score_gemma":0.005590883,"threshold_uncertainty_score":0.99732953},"labels":[],"label_agreement":null},{"id":"W2012258371","doi":"10.1159/000326671","title":"Assessment of Thin-Layer Breast Aspirates for Immunocytochemical Evaluation of HER2 Status","year":2003,"lang":"en","type":"article","venue":"Acta Cytologica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Immunostaining; Medicine; Pathology; Immunohistochemistry; Immunocytochemistry; Staining; Fluorescence in situ hybridization; Biology; Gene","score_opus":0.14559067214893495,"score_gpt":0.4630585170960219,"score_spread":0.31746784494708696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012258371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792683,0.000515264,0.00018542285,0.0005014661,0.00008097247,0.0017135732,0.000057632747,0.000023383747,0.017653976],"genre_scores_gemma":[0.9934889,0.00007035916,0.00589988,0.00008711631,0.000029604496,0.00029280726,0.000043584318,0.000016895625,0.000070871116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99788886,0.00021816701,0.00042538092,0.0002705322,0.0008373456,0.0003596982],"domain_scores_gemma":[0.9980506,0.00032853265,0.00017985205,0.00042627825,0.0009136111,0.000101144855],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001731684,0.00013236325,0.0004258727,0.00008064707,0.000037645677,0.000007720163,0.00013563145,0.00015657404,0.0011747403],"category_scores_gemma":[0.0011546562,0.000099933386,0.00011699524,0.00020718173,0.00015357143,0.000049417926,0.000041113093,0.00020961533,0.000003643089],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040014653,0.00085239863,0.08024921,0.00038640134,0.0002389751,0.0000044106087,0.00015310482,0.00003196757,0.9016265,0.0023942161,0.0023756584,0.011286973],"study_design_scores_gemma":[0.007791614,0.0030144462,0.3969603,0.00028317803,0.0005000182,0.00013497891,0.00064117694,0.0033985937,0.5711559,0.0031750947,0.012622019,0.00032268045],"about_ca_topic_score_codex":0.000050689472,"about_ca_topic_score_gemma":0.000003855472,"teacher_disagreement_score":0.33047062,"about_ca_system_score_codex":0.00027097896,"about_ca_system_score_gemma":0.00093860546,"threshold_uncertainty_score":0.99973834},"labels":[],"label_agreement":null},{"id":"W2012505736","doi":"10.1038/modpathol.2013.103","title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","year":2013,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Polysomy; Trastuzumab; Breast cancer; Genetic heterogeneity; Fluorescence in situ hybridization; Chromosome 17 (human); Cancer; Biology; Oncology; Pathology; Internal medicine; Chromosome; Medicine; Genetics; Phenotype; Gene","score_opus":0.14856773862352984,"score_gpt":0.48226546491079003,"score_spread":0.3336977262872602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012505736","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.057034064,0.9399823,0.0002511252,0.00077674363,0.00008040815,0.0015622517,0.00017253471,0.000015758065,0.00012482476],"genre_scores_gemma":[0.02367755,0.97475195,0.00040491065,0.00012471863,0.0001270089,0.0007173411,0.00008361251,0.00005521908,0.00005767362],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99691963,0.0006200631,0.0011963486,0.0007001208,0.00017273767,0.00039109102],"domain_scores_gemma":[0.9985589,0.00017591326,0.0002961187,0.0006931928,0.000118381235,0.00015750913],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048615123,0.00026367969,0.0018164723,0.00039645706,0.000019882862,0.000008622415,0.00021403121,0.0005202153,0.000054704098],"category_scores_gemma":[0.0000868833,0.00023382112,0.0001666448,0.00034179652,0.00027426574,0.000031172938,0.00018214402,0.00069584633,0.000016762815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013099278,0.00016879557,0.08918157,0.003767342,0.000030647698,0.000096552256,0.000039852937,0.0000045134975,0.00011028671,0.000007740407,0.00014376994,0.90643585],"study_design_scores_gemma":[0.0029689844,0.00044184626,0.85036206,0.011743135,0.00072496803,0.005167658,0.000010248046,0.00042109803,0.0000326423,0.0005916957,0.12674066,0.00079498155],"about_ca_topic_score_codex":0.00044052157,"about_ca_topic_score_gemma":0.0011507901,"teacher_disagreement_score":0.90564084,"about_ca_system_score_codex":0.00026712805,"about_ca_system_score_gemma":0.00081673294,"threshold_uncertainty_score":0.95349485},"labels":[],"label_agreement":null},{"id":"W2013058114","doi":"10.1038/ncb1134","title":"Memo mediates ErbB2-driven cell motility","year":2004,"lang":"en","type":"article","venue":"Nature Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Roche Diagnostics; Krebsliga Schweiz","keywords":"Motility; Cell biology; Lamellipodium; Cell migration; Biology; Actin; Actin cytoskeleton; Signal transducing adaptor protein; Kinase; Cytoskeleton; Phosphorylation; Cell; Biochemistry","score_opus":0.01527616212539192,"score_gpt":0.3427650390801068,"score_spread":0.3274888769547149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013058114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91855127,0.009514116,0.000058428912,0.006961127,0.0012752747,0.0007104369,0.0000676809,0.00017434434,0.06268731],"genre_scores_gemma":[0.9940903,0.0006505326,0.0016211203,0.0017159038,0.00060419785,0.000025758993,0.0001402316,0.000031906387,0.001120012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981913,0.000113153175,0.00026227767,0.0005571573,0.00026397235,0.00061211485],"domain_scores_gemma":[0.99871886,0.00016661678,0.00006727651,0.0005671443,0.00019116871,0.0002889614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034967627,0.0002164183,0.00040856274,0.00014301977,0.00007349305,0.000009191345,0.00031170185,0.0011176147,0.00081643363],"category_scores_gemma":[0.0002516194,0.00016701041,0.00012988794,0.00030265618,0.00027840608,0.000029093788,0.00013024444,0.0018484263,0.00053199055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004011124,0.0008765104,0.07365453,0.0007354465,0.00008297156,0.00030986906,0.0006538447,0.000057965026,0.90073955,0.0007182648,0.015771123,0.0059988196],"study_design_scores_gemma":[0.0042635715,0.001115073,0.018237842,0.0000612245,0.00006690006,0.000035453155,0.00010882065,0.000050673407,0.72706795,0.0025648098,0.24612412,0.00030357434],"about_ca_topic_score_codex":0.00011040388,"about_ca_topic_score_gemma":0.000068132074,"teacher_disagreement_score":0.230353,"about_ca_system_score_codex":0.00027592946,"about_ca_system_score_gemma":0.0004414722,"threshold_uncertainty_score":0.8939376},"labels":[],"label_agreement":null},{"id":"W2013797830","doi":"10.1186/bcr2904","title":"Luminal-B breast cancer and novel therapeutic targets","year":2011,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Breast cancer; Surgical oncology; Estrogen receptor; Medicine; Cancer research; Gene expression profiling; Bioinformatics; Pathological; Endocrine system; Oncology; Cancer; Internal medicine; Gene; Gene expression; Biology; Hormone; Genetics","score_opus":0.289696687158721,"score_gpt":0.5148012716975511,"score_spread":0.2251045845388301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013797830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001763823,0.9860907,0.00001059733,0.0024687243,0.00061048084,0.0037279446,0.0034744234,0.00011781513,0.0034816652],"genre_scores_gemma":[0.00022037597,0.98067605,0.00005876616,0.00020418111,0.0034903693,0.0047081984,0.00010183004,0.00046245765,0.010077774],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990891,0.0006373692,0.0010415389,0.0019991486,0.0027383326,0.0026926335],"domain_scores_gemma":[0.99446875,0.00042154716,0.00027638418,0.0017036882,0.0016512453,0.0014783721],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028171584,0.001052014,0.0030568477,0.0014492613,0.0004691933,0.0002151341,0.0011845732,0.0009408694,0.009073609],"category_scores_gemma":[0.00007648634,0.0008072461,0.0005897849,0.002276122,0.001475065,0.0001951918,0.0009284308,0.0045127645,0.00048948004],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040410165,0.00032841548,0.0004892402,0.035986114,0.0008816942,0.00015061442,0.0001806792,8.3167755e-8,0.000024381416,0.00032718794,0.011909137,0.94931835],"study_design_scores_gemma":[0.0011780952,0.000166385,0.0032428445,0.03280868,0.0007677325,0.004235284,0.00006832238,0.000008451707,0.000006369632,0.00005492904,0.9567365,0.0007264026],"about_ca_topic_score_codex":0.017111428,"about_ca_topic_score_gemma":0.0008975865,"teacher_disagreement_score":0.94859195,"about_ca_system_score_codex":0.0027922601,"about_ca_system_score_gemma":0.01039704,"threshold_uncertainty_score":0.99943787},"labels":[],"label_agreement":null},{"id":"W2014836885","doi":"10.1111/tbj.12284","title":"Trastuzumab Beyond Progression for HER2 Positive Metastatic Breast Cancer: Progression-Free Survival on First-Line Therapy Predicts Overall Survival Impact","year":2014,"lang":"en","type":"article","venue":"The Breast Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre","funders":"Roche Canada","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Docetaxel; Breast cancer; Chemotherapy; Retrospective cohort study; Paclitaxel; Cohort; Cancer","score_opus":0.03977329334124006,"score_gpt":0.3970839875597167,"score_spread":0.3573106942184766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014836885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89664793,0.0029094815,0.0025381253,0.08285029,0.0025635294,0.006253747,0.0033089118,0.00024594614,0.002682031],"genre_scores_gemma":[0.99316156,0.0009651403,0.0005751277,0.00044104015,0.0039577875,0.00031137958,0.00008381918,0.00018436028,0.0003198117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99396485,0.0008619567,0.0007667761,0.00057821145,0.0025290295,0.0012991844],"domain_scores_gemma":[0.9957485,0.0010235705,0.0005087922,0.00092209585,0.00089919305,0.0008978421],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0038679896,0.00061897817,0.00094979553,0.00024958866,0.0009945368,0.00026123534,0.0009166886,0.00016486814,0.00082439446],"category_scores_gemma":[0.0003032042,0.00032948705,0.0005568225,0.00038799457,0.0003548504,0.00025768284,0.00015614647,0.0014321719,0.000023865798],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053091634,0.0040757563,0.056698773,0.0004458981,0.0026558982,0.0002510373,0.001927721,0.00068650197,0.0019191039,0.0004684453,0.02099864,0.8567806],"study_design_scores_gemma":[0.044696543,0.020333357,0.882493,0.0064206426,0.0007811496,0.019624574,0.00035050165,0.008620626,0.002522788,0.005953515,0.006962195,0.001241061],"about_ca_topic_score_codex":0.00022807573,"about_ca_topic_score_gemma":0.00013540378,"teacher_disagreement_score":0.8555395,"about_ca_system_score_codex":0.0008982863,"about_ca_system_score_gemma":0.0010500016,"threshold_uncertainty_score":0.9999157},"labels":[],"label_agreement":null},{"id":"W2015918488","doi":"10.1038/modpathol.2011.198","title":"HER2 testing in gastric cancer: a practical approach","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Immunohistochemistry; Cancer; Breast cancer; Medicine; Fluorescence in situ hybridization; Pathology; Capecitabine; Oncology; CISH; In situ hybridization; Stomach cancer; Adenocarcinoma; Metastatic breast cancer; Companion diagnostic; Internal medicine; Biology; Colorectal cancer","score_opus":0.2028628030829037,"score_gpt":0.4404619443020513,"score_spread":0.23759914121914763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015918488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95841205,0.0021653802,0.010713154,0.0023062485,0.00021709593,0.0005898629,0.0000074296927,0.000095562325,0.025493234],"genre_scores_gemma":[0.9708495,0.000055510984,0.027438993,0.00054970174,0.0004147441,0.00025345365,0.000006515475,0.000037144175,0.0003943942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811083,0.00020709126,0.00024231421,0.00032349632,0.00028708577,0.00082916446],"domain_scores_gemma":[0.9991043,0.00019957163,0.000050524704,0.00033025217,0.000075601245,0.0002397301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008816857,0.00013205007,0.00031362002,0.0001913346,0.00003781253,0.000008221945,0.00008706413,0.00017620962,0.00011486655],"category_scores_gemma":[0.000997125,0.00011833917,0.000035856556,0.0004227777,0.00011607612,0.00009102512,0.00010457512,0.00070906477,0.000078850964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013104783,0.0006877966,0.91370106,0.00015980685,0.000014395684,0.0005946415,0.0013130016,0.00007240425,0.012135771,0.00016597766,0.0010854867,0.069938585],"study_design_scores_gemma":[0.00465626,0.0009599193,0.905867,0.00022775448,0.00012411112,0.016720122,0.00048016605,0.058927193,0.0015336057,0.0009204183,0.008987335,0.00059614726],"about_ca_topic_score_codex":0.00029808344,"about_ca_topic_score_gemma":0.00003196081,"teacher_disagreement_score":0.06934244,"about_ca_system_score_codex":0.00029392846,"about_ca_system_score_gemma":0.0003577828,"threshold_uncertainty_score":0.48257315},"labels":[],"label_agreement":null},{"id":"W2016074317","doi":"10.3747/co.19.960","title":"Outcomes of Women with Early-Stage Breast Cancer Receiving Adjuvant Trastuzumab","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Stage (stratigraphy); Cancer; Hazard ratio; Population; Adjuvant; Cohort; Retrospective cohort study; Confidence interval; Gynecology","score_opus":0.12985228809018168,"score_gpt":0.46645928155331545,"score_spread":0.3366069934631338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016074317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936206,0.001769073,0.00005171771,0.0012892104,0.0009554161,0.0004766517,0.000077738296,0.000042869786,0.0017167344],"genre_scores_gemma":[0.997995,0.0004679268,0.0001422444,0.00008765297,0.0003928355,0.000276941,0.0000061153874,0.000037555208,0.0005936941],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978657,0.00013162689,0.0003340586,0.0002491112,0.00046173143,0.00095778686],"domain_scores_gemma":[0.99866813,0.0001613719,0.00014932425,0.00033861923,0.00019557963,0.00048699626],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066123577,0.00018402586,0.0007052154,0.00015613218,0.000045301556,0.000005745651,0.0001621448,0.00010872937,0.0022407717],"category_scores_gemma":[0.00008841111,0.00013005092,0.000059004145,0.0002623311,0.00024058472,0.000106600004,0.00008850857,0.0004866299,0.000049559032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051400124,0.0006758382,0.84520286,0.00027120326,0.0001188989,0.000010282664,0.0036331047,0.000001752945,0.00037116362,0.00005116892,0.0008658964,0.14828381],"study_design_scores_gemma":[0.001977166,0.0008538797,0.90205914,0.00017361363,0.00005606027,0.000054054934,0.0006548652,0.000011860901,0.00026185342,0.000004421979,0.0937657,0.00012740816],"about_ca_topic_score_codex":0.00033231667,"about_ca_topic_score_gemma":0.000104785766,"teacher_disagreement_score":0.1481564,"about_ca_system_score_codex":0.0021818166,"about_ca_system_score_gemma":0.00085226266,"threshold_uncertainty_score":0.9986713},"labels":[],"label_agreement":null},{"id":"W2016827479","doi":"10.3747/co.v17i4.700","title":"Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of Toronto; Université de Sherbrooke; University of Ottawa; Centre hospitalier universitaire de Québec; Hôpital du Saint-Sacrement; Health Sciences Centre; Ottawa Hospital; Santé Montérégie; University of Alberta; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Anthracycline; Population; Stage (stratigraphy); Disease; Clinical trial; Cancer; Adjuvant; Gynecology","score_opus":0.2447587637129754,"score_gpt":0.5587603142850097,"score_spread":0.3140015505720343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016827479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89318377,0.0018218518,0.00024157653,0.072262235,0.0061073108,0.0022302044,0.00014345818,0.00005618874,0.023953428],"genre_scores_gemma":[0.9947962,0.0028820154,0.0004083152,0.00033045796,0.001075374,0.00022211757,0.000009023093,0.000021099484,0.0002554091],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980343,0.0004129585,0.00047831345,0.00030973335,0.0004013013,0.0003633968],"domain_scores_gemma":[0.99826455,0.00048230976,0.0001741008,0.00066247163,0.00027253287,0.00014402352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021967315,0.0001253824,0.00035830782,0.00003534686,0.00012510696,0.000013038506,0.0004332726,0.0001334124,0.0004055958],"category_scores_gemma":[0.000055191947,0.00006754606,0.00015497605,0.00022054593,0.00089279306,0.000027973585,0.00028605058,0.0014177994,0.000035450314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006018999,0.0008808442,0.08859527,0.00022867467,0.00035197657,0.000042519438,0.0010661947,0.0000053158633,0.00016711417,0.0028509307,0.015188852,0.89002043],"study_design_scores_gemma":[0.0015438086,0.00053864974,0.72990733,0.00024783073,0.00026655453,0.000068576686,0.0004610777,0.00020177821,0.00016180055,0.00018111702,0.2663225,0.00009899169],"about_ca_topic_score_codex":0.0005027926,"about_ca_topic_score_gemma":0.00030592945,"teacher_disagreement_score":0.8899214,"about_ca_system_score_codex":0.00017761953,"about_ca_system_score_gemma":0.0004224083,"threshold_uncertainty_score":0.61597115},"labels":[],"label_agreement":null},{"id":"W2016909614","doi":"10.3747/co.22.2363","title":"Targeted Therapy in her2-Positive Metastatic Breast Cancer: A Review of the Literature","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Metastatic breast cancer; Breast cancer; Targeted therapy; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Internal medicine; Cancer; Disease; Trastuzumab; Natural history","score_opus":0.265833073951816,"score_gpt":0.5634664620124306,"score_spread":0.29763338806061457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016909614","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000584058,0.9902138,5.634534e-7,0.0019753862,0.0013924025,0.0047626705,0.0010915953,0.000015340078,0.00054238667],"genre_scores_gemma":[0.000003715299,0.99724555,0.000031142936,0.00040119296,0.00038106643,0.0013655848,0.00032577149,0.0000655395,0.00018045823],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99490005,0.002264229,0.0010974491,0.0005421843,0.00069679524,0.0004992903],"domain_scores_gemma":[0.9972298,0.00025552808,0.0006678596,0.00078171375,0.0008498017,0.00021526124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001576109,0.00047966477,0.0038554731,0.000285186,0.000028349054,0.000010407672,0.0005973376,0.00031599685,0.00056123926],"category_scores_gemma":[0.00030591286,0.00026194798,0.00067000184,0.0019374744,0.00027723867,0.000038007995,0.00018994113,0.0021549773,0.000030965846],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004264052,0.00044264406,0.00006877572,0.17196654,0.00019041689,0.00004936471,0.00022661543,3.3126014e-8,2.6081847e-7,0.000013732277,0.024043942,0.80295503],"study_design_scores_gemma":[0.0006130794,0.0002843106,0.00006168586,0.34022158,0.0004883152,0.0002982535,0.000008506825,7.8221854e-7,5.6969986e-7,0.0000141271175,0.6578788,0.00012994962],"about_ca_topic_score_codex":0.00007865695,"about_ca_topic_score_gemma":0.000037478083,"teacher_disagreement_score":0.8028251,"about_ca_system_score_codex":0.0020546864,"about_ca_system_score_gemma":0.008117767,"threshold_uncertainty_score":0.99998325},"labels":[],"label_agreement":null},{"id":"W2017265537","doi":"10.3389/fonc.2013.00023","title":"Can pharmacological receptor tyrosine kinase inhibitors sensitize poor outcome breast tumors to immune-based therapies?","year":2013,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Canadian Institutes of Health Research; Susan G. Komen for the Cure","keywords":"Medicine; Tyrosine kinase; Immune system; Cancer research; Receptor tyrosine kinase; Oncology; Receptor; Breast cancer; Internal medicine; Immunology; Cancer","score_opus":0.02863190148130483,"score_gpt":0.3510033395204924,"score_spread":0.32237143803918755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017265537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8623066,0.0005973499,0.0002878497,0.12961616,0.0032420019,0.0025070903,0.00006722576,0.00015785702,0.0012179011],"genre_scores_gemma":[0.9683106,0.00004788287,0.017014261,0.011485757,0.0006674357,0.0006387549,0.000055298093,0.00007887643,0.00170116],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964395,0.00053180533,0.00080130534,0.0006493287,0.000507156,0.0010709174],"domain_scores_gemma":[0.9982892,0.00021392215,0.00013717702,0.00041270495,0.00027787747,0.0006690672],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086375227,0.00035491056,0.0010521213,0.0005919017,0.000100220364,0.000033416243,0.0003307232,0.00038194074,0.0026980692],"category_scores_gemma":[0.00036687098,0.000300152,0.00017498658,0.0007818722,0.00041821104,0.000067791494,0.00015203842,0.0009905922,0.0003937572],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022163878,0.001111401,0.27020845,0.000121425204,0.00015613867,0.0009280347,0.0006874185,0.00006736066,0.15100114,0.000021061862,0.45770574,0.11577543],"study_design_scores_gemma":[0.031326436,0.010793404,0.42061892,0.00066385313,0.0002620091,0.0006256815,0.005377129,0.0038058837,0.07519956,0.0003727782,0.4488649,0.0020894546],"about_ca_topic_score_codex":0.001627762,"about_ca_topic_score_gemma":0.00008979653,"teacher_disagreement_score":0.15041046,"about_ca_system_score_codex":0.0025389225,"about_ca_system_score_gemma":0.0008651876,"threshold_uncertainty_score":0.99994504},"labels":[],"label_agreement":null},{"id":"W2017526027","doi":"10.1016/j.bbrc.2015.03.180","title":"Transforming growth factor-α induces human ovarian cancer cell invasion by down-regulating E-cadherin in a Snail-independent manner","year":2015,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"Canadian Institutes of Health Research; China Scholarship Council","keywords":"Amphiregulin; Snail; Cadherin; Transforming growth factor; Epidermal growth factor; Biology; Transcription factor; Cancer research; Cell biology; Growth factor; Epidermal growth factor receptor; Receptor; Cell; Gene; Genetics","score_opus":0.20629836130672247,"score_gpt":0.4363558832850915,"score_spread":0.23005752197836904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017526027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98292416,0.002264206,0.0000082762635,0.01076804,0.000017423383,0.00072430976,0.000054460877,0.000039929124,0.003199209],"genre_scores_gemma":[0.9967758,0.00177659,0.00040379475,0.00007740922,0.00012025252,0.00030075567,0.00010917286,0.00003152162,0.00040470966],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969399,0.00034685747,0.00039488077,0.00047089442,0.0011756804,0.0006717866],"domain_scores_gemma":[0.99762315,0.0003342916,0.000045192395,0.0008699355,0.00042990837,0.0006975297],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093090447,0.00019800526,0.00033141693,0.00015704498,0.00029237865,0.00009207011,0.00074095966,0.00024121221,0.00008603093],"category_scores_gemma":[0.0002882016,0.00016243472,0.00007516835,0.0007460931,0.0007103814,0.00016740678,0.00062945497,0.0014262426,0.000022917488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000099113604,0.0006995449,0.0019170027,0.00014173413,0.000017144814,0.0000040937107,0.0007058153,9.7905954e-8,0.9887027,0.00072724733,0.003202812,0.003782681],"study_design_scores_gemma":[0.0029392983,0.00056559563,0.0066199177,0.0005885736,0.000021686617,0.0000067878973,0.0014081812,0.0004962787,0.9773148,0.0014641231,0.008188458,0.00038631182],"about_ca_topic_score_codex":0.01192621,"about_ca_topic_score_gemma":0.00058498204,"teacher_disagreement_score":0.013851648,"about_ca_system_score_codex":0.0005853133,"about_ca_system_score_gemma":0.00038585244,"threshold_uncertainty_score":0.99465346},"labels":[],"label_agreement":null},{"id":"W2018630641","doi":"10.1074/jbc.m500313200","title":"Human Tumorous Imaginal Disc 1 (TID1) Associates with Trk Receptor Tyrosine Kinases and Regulates Neurite Outgrowth in nnr5-TrkA Cells","year":2005,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Robarts Clinical Trials","funders":"","keywords":"Tropomyosin receptor kinase A; Trk receptor; Receptor tyrosine kinase; Neurite; Low-affinity nerve growth factor receptor; Imaginal disc; Kinase; Cell biology; Receptor Protein-Tyrosine Kinases; Tyrosine kinase; Mitogen-activated protein kinase; Receptor; Signal transduction; Biology; Chemistry; Neurotrophin; Gene; In vitro; Drosophila melanogaster; Biochemistry","score_opus":0.02441895128307746,"score_gpt":0.31010602066520454,"score_spread":0.28568706938212707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018630641","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99325126,0.001967226,0.0000020699626,0.0036639627,0.00002777459,0.000111739006,0.000016568125,0.000018301696,0.0009411142],"genre_scores_gemma":[0.99674594,0.00041894312,0.001221226,0.00018096648,0.0007018923,0.0000049962337,0.000011514307,0.000019363495,0.00069518253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830556,0.00006733585,0.00054255786,0.0002748444,0.00040177666,0.00040792674],"domain_scores_gemma":[0.99893886,0.00013335724,0.00028429902,0.00015976572,0.00018422311,0.00029950487],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005286943,0.00021905797,0.0005767146,0.00006138783,0.00006084899,0.000049845094,0.00018983781,0.00017176942,0.0004424853],"category_scores_gemma":[0.00024966587,0.00013367756,0.00010111629,0.0001866565,0.0003690675,0.000088150606,0.0000737772,0.00083817955,0.000005364896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005288079,0.00036882475,0.17753302,0.00011652568,0.000040195195,0.00035673744,0.00004830688,0.0000034833297,0.8174946,0.0000033083663,0.0020701478,0.001436064],"study_design_scores_gemma":[0.0029379055,0.0014278741,0.14167744,0.000676267,0.000046628807,0.0007912057,0.00022174953,0.000024500978,0.8475815,0.00011648661,0.0042349244,0.00026352264],"about_ca_topic_score_codex":0.000021275771,"about_ca_topic_score_gemma":0.0000058127707,"teacher_disagreement_score":0.035855576,"about_ca_system_score_codex":0.0003355175,"about_ca_system_score_gemma":0.00011455025,"threshold_uncertainty_score":0.54512125},"labels":[],"label_agreement":null},{"id":"W2018650005","doi":"10.1158/1078-0432.ccr-09-1192","title":"Tipifarnib Plus Tamoxifen in Tamoxifen-Resistant Metastatic Breast Cancer: A Negative Phase II and Screening of Potential Therapeutic Markers by Proteomic Analysis","year":2010,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Tamoxifen; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Cancer; Metastasis","score_opus":0.1474246640642809,"score_gpt":0.5366681232496262,"score_spread":0.3892434591853453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018650005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855586,0.002023397,0.00023956825,0.008292738,0.00016252976,0.0026443903,0.0008551182,0.000034529905,0.0001891269],"genre_scores_gemma":[0.9940011,0.0023925363,0.00085242157,0.00022805513,0.0003093489,0.0010659964,0.00004030255,0.000082808045,0.0010274346],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9921339,0.0015416155,0.0015162545,0.0012305577,0.0022646862,0.0013129528],"domain_scores_gemma":[0.9954248,0.0013838287,0.00032710852,0.0009338626,0.0010438059,0.0008866093],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008562845,0.00037014973,0.001557197,0.0010621056,0.00030858422,0.00008678342,0.00063625,0.00032149564,0.0029425917],"category_scores_gemma":[0.0012834545,0.0002855204,0.00040447494,0.0033420117,0.0023590568,0.00018094858,0.0005117346,0.0037597944,0.00000812281],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06217347,0.004054722,0.19669971,0.0015025905,0.0068371873,0.00047587708,0.0017636917,0.0002255492,0.28077838,0.00008419331,0.0071122223,0.4382924],"study_design_scores_gemma":[0.08402399,0.014099888,0.7711992,0.0023370958,0.004612201,0.00009970438,0.0023864328,0.0824796,0.02615709,0.0014601654,0.009181516,0.0019631162],"about_ca_topic_score_codex":0.021494878,"about_ca_topic_score_gemma":0.0060317926,"teacher_disagreement_score":0.5744995,"about_ca_system_score_codex":0.00049833144,"about_ca_system_score_gemma":0.0028736207,"threshold_uncertainty_score":0.9999597},"labels":[],"label_agreement":null},{"id":"W2018698872","doi":"10.1200/jco.2006.10.0651","title":"Trastuzumab-Associated Peripheral Vascular Toxicity","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Toxicity; Peripheral; Cardiotoxicity; Oncology; Internal medicine; Breast cancer; Pharmacology; Cancer","score_opus":0.22312135106304717,"score_gpt":0.5646926958525449,"score_spread":0.3415713447894977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018698872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750635,0.00053306774,0.0010782408,0.0056378325,0.0017009302,0.00019278604,0.0000017518067,0.00001763415,0.015774254],"genre_scores_gemma":[0.9897507,0.000528723,0.0027287793,0.0036772825,0.0024878087,0.0000012738201,0.0000014388349,0.000024860909,0.0007991658],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9949766,0.0005994737,0.0027193085,0.00019746232,0.0009958466,0.0005113532],"domain_scores_gemma":[0.9944218,0.0024819414,0.001079606,0.00023351333,0.00091507105,0.00086810306],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018966641,0.00013392724,0.0015723961,0.00015026653,0.000051977288,0.0000102974445,0.00025945017,0.00066031946,0.0010346047],"category_scores_gemma":[0.013948715,0.00009840496,0.00087457465,0.0002817922,0.0003107345,0.00008150453,0.00005635103,0.0023148758,0.00004136602],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068618506,0.0072709885,0.3587375,0.000064335385,0.0016272214,0.0062007704,0.00038767685,0.000021235466,0.002497554,0.00017476449,0.042222034,0.5739341],"study_design_scores_gemma":[0.008740809,0.01910623,0.68943805,0.00010721402,0.00022253659,0.0003694844,0.0001825484,0.00007751687,0.00035940332,0.00024998724,0.28103474,0.00011151927],"about_ca_topic_score_codex":0.000036101945,"about_ca_topic_score_gemma":0.00017023031,"teacher_disagreement_score":0.57382256,"about_ca_system_score_codex":0.0010047193,"about_ca_system_score_gemma":0.0032401737,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W2019089983","doi":"10.1158/0008-5472.sabcs-09-5114","title":"Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; BC Cancer Agency; Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Oncology; Internal medicine; Cohort; Metastatic breast cancer; Breast cancer; Cancer; Pharmacology","score_opus":0.22807095443971398,"score_gpt":0.4791410790961227,"score_spread":0.2510701246564087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019089983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815622,0.0022000049,0.000006705908,0.011689715,0.0000359475,0.004298599,0.000096902746,0.000047721896,0.00006218358],"genre_scores_gemma":[0.9920927,0.0055243983,0.0003492877,0.0005959896,0.00024363404,0.0006711911,0.000035766967,0.00004817978,0.00043882008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946032,0.0010344179,0.00056933216,0.0013131611,0.0012389236,0.0012409311],"domain_scores_gemma":[0.9970831,0.0003831332,0.00009913877,0.00045774062,0.0009902705,0.0009865864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014241032,0.0004019727,0.00078237086,0.0003481057,0.00027143836,0.00014987994,0.00031945322,0.00029800241,0.0003405096],"category_scores_gemma":[0.00033628655,0.00024749446,0.000054069304,0.0014411976,0.0005787105,0.00016653189,0.00016892802,0.001215268,0.000009743968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037483394,0.0009385481,0.9031129,0.00005886729,0.00014008646,0.00014443757,0.0013743482,0.0000117577865,0.0005460023,0.0000031130842,0.00076895393,0.055417623],"study_design_scores_gemma":[0.008146276,0.012865623,0.975897,0.0010190287,0.000017834978,0.000027064925,0.0002157185,0.00003601583,0.0003692203,0.000012756214,0.0010746296,0.0003187911],"about_ca_topic_score_codex":0.0015842724,"about_ca_topic_score_gemma":0.00092876167,"teacher_disagreement_score":0.07278417,"about_ca_system_score_codex":0.0011149644,"about_ca_system_score_gemma":0.0017477564,"threshold_uncertainty_score":0.99999774},"labels":[],"label_agreement":null},{"id":"W2019184486","doi":"10.1016/s0896-6273(00)81176-9","title":"Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses","year":2000,"lang":"en","type":"article","venue":"Neuron","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":382,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Neuregulin; ERBB4; Neuregulin 1; Postsynaptic density; Long-term potentiation; Synaptic plasticity; Neuroscience; Postsynaptic potential; ErbB; Cell biology; Neurotransmission; Receptor tyrosine kinase; Biology; Signal transduction; Kinase; Chemistry; Receptor; Biochemistry","score_opus":0.025219585103816167,"score_gpt":0.31733038654952317,"score_spread":0.292110801445707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019184486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994648,0.00016132253,0.000007860538,0.0014308101,0.00004918464,0.00025911035,0.000003820798,0.00003052241,0.0034093854],"genre_scores_gemma":[0.9964578,0.00006349657,0.00014331735,0.00018333568,0.00009301909,0.000011618079,0.0000151623635,0.000031684845,0.0030005432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988152,0.0000826235,0.00024153509,0.00025595888,0.00037273002,0.00023194663],"domain_scores_gemma":[0.99938136,0.00019379002,0.00006360725,0.0002401743,0.000048828977,0.000072217204],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015822794,0.00010164932,0.00019877794,0.00006902051,0.000034062115,0.000009829877,0.00007590822,0.000051483068,0.0017207785],"category_scores_gemma":[0.00010596229,0.00008712572,0.0000313608,0.00023607492,0.000055792283,0.00007948107,0.000022535714,0.00026203782,0.000038406048],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001696903,0.00017466643,0.0409617,0.00027161097,0.000018689367,0.00009752059,0.0005343408,0.0017721937,0.9000326,0.0000055897917,0.009329621,0.04510456],"study_design_scores_gemma":[0.005767382,0.0040580854,0.21281281,0.0028294034,0.000106105836,0.00039608742,0.00023517422,0.020899624,0.6415866,0.000051882966,0.1107307,0.00052613113],"about_ca_topic_score_codex":0.00016934761,"about_ca_topic_score_gemma":0.00004718372,"teacher_disagreement_score":0.25844598,"about_ca_system_score_codex":0.00010852925,"about_ca_system_score_gemma":0.000054242337,"threshold_uncertainty_score":0.99919176},"labels":[],"label_agreement":null},{"id":"W2019669516","doi":"10.4137/cmo.s6460","title":"Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations","year":2012,"lang":"en","type":"article","venue":"Clinical Medicine Insights Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.2429678331864455,"score_gpt":0.5547950459468237,"score_spread":0.3118272127603782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019669516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7605424,0.007107382,0.00126294,0.20107277,0.009720377,0.005016505,0.0003204794,0.00017295154,0.0147842085],"genre_scores_gemma":[0.9724276,0.0041415077,0.003043061,0.011489479,0.007945736,0.0004558364,0.000052353484,0.000061707,0.00038273603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953961,0.0009269317,0.002027852,0.0006819435,0.00026004933,0.0007071455],"domain_scores_gemma":[0.9841303,0.013423,0.00034278366,0.00044647287,0.00035310915,0.0013042927],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0032351683,0.0003003116,0.0018206295,0.0001777836,0.0001966301,0.000013197838,0.00012964869,0.00042913322,0.0019954448],"category_scores_gemma":[0.0032016134,0.00021412077,0.00024291273,0.00011510147,0.0029977877,0.00015082111,0.00009869793,0.001014953,0.00009799232],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042929864,0.005145566,0.36165863,0.00052905746,0.002587123,0.00035035252,0.0030577704,0.0000046422115,0.00029151532,0.03040992,0.29192063,0.2997518],"study_design_scores_gemma":[0.026429325,0.019219197,0.5070374,0.0005586756,0.0023628725,0.0022557266,0.0012819569,0.0010320981,0.00013867,0.0064464896,0.4326529,0.0005846916],"about_ca_topic_score_codex":0.0003861795,"about_ca_topic_score_gemma":0.0005894329,"teacher_disagreement_score":0.2991671,"about_ca_system_score_codex":0.00044312997,"about_ca_system_score_gemma":0.0020659436,"threshold_uncertainty_score":0.9997155},"labels":[],"label_agreement":null},{"id":"W2019887943","doi":"10.1186/1471-2407-9-165","title":"Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis","year":2009,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Centre for Advancing Health Outcomes; University of British Columbia","funders":"Canadian Institutes of Health Research; Sanofi","keywords":"Kappa; Concordance; Medicine; Immunohistochemistry; Fish <Actinopterygii>; Pathology; Breast cancer; Cohen's kappa; Internal medicine; Tissue microarray; Reproducibility; Surgical oncology; Cancer; Biology","score_opus":0.06874392968058383,"score_gpt":0.4566391556024249,"score_spread":0.38789522592184106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019887943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98231715,0.000399666,0.013853701,0.0017687269,0.000048101738,0.0011481153,0.00006893412,0.000027614004,0.00036801334],"genre_scores_gemma":[0.9593565,0.00012160957,0.039901968,0.00029320605,0.000029464636,0.00016300581,0.0000615409,0.000015335727,0.000057412286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972435,0.00022175882,0.0005890869,0.0010908692,0.00054652966,0.00030820692],"domain_scores_gemma":[0.9979316,0.00009937402,0.00018863563,0.0011388048,0.0004895585,0.0001520069],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013736413,0.00020032642,0.00074235274,0.00022406026,0.00003745766,0.00002872642,0.00014868008,0.00005441933,0.0001343897],"category_scores_gemma":[0.00026699496,0.00016881921,0.00008829415,0.0011207315,0.0002532912,0.0000991697,0.00008654666,0.00030992544,0.0000011473463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013620954,0.0005470321,0.9227686,0.0002335049,0.00014701423,0.00003485045,0.00049333926,0.0005716107,0.0708197,0.00008014438,0.0007716012,0.002170519],"study_design_scores_gemma":[0.0015705595,0.0008013285,0.97907346,0.0003664156,0.00018565332,0.000004205072,0.00034757645,0.0037869983,0.013534896,0.000024031462,0.00012912184,0.00017573021],"about_ca_topic_score_codex":0.0023818996,"about_ca_topic_score_gemma":0.003646411,"teacher_disagreement_score":0.057284802,"about_ca_system_score_codex":0.0015697127,"about_ca_system_score_gemma":0.00074019097,"threshold_uncertainty_score":0.68842477},"labels":[],"label_agreement":null},{"id":"W2020124426","doi":"10.1159/000055398","title":"Testing for HER2 Status","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"American Society of Clinical Oncology","keywords":"Concordance; Medicine; Oncology; Breast cancer; Internal medicine; Immunohistochemistry; Gold standard (test); Pathology; Cancer","score_opus":0.4448169212812722,"score_gpt":0.5934718822558205,"score_spread":0.14865496097454828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020124426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.884142e-7,0.9113249,0.000036931786,0.00022195197,0.00050568057,0.0022319336,0.000053370735,0.00007038737,0.085553944],"genre_scores_gemma":[2.2325906e-7,0.9806677,0.007051043,0.00024168304,0.0015654746,0.0011478851,0.00017240767,0.00011181896,0.009041747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99771154,0.00018210501,0.00054812897,0.00047305643,0.00023205293,0.0008530999],"domain_scores_gemma":[0.99680436,0.0019915882,0.00021716458,0.00044732107,0.0002263471,0.00031324578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064632285,0.00027624407,0.0021324458,0.00021890776,0.00006477908,0.000012184263,0.00019371985,0.00065708446,0.00067175244],"category_scores_gemma":[0.0021322125,0.00021947728,0.00031365865,0.0005253948,0.00011526846,0.000014991089,0.00009727938,0.00078348065,0.00039501573],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016998061,0.00012333241,0.00004307185,0.020123286,0.00009387276,0.00024092915,0.000012323698,4.003323e-8,7.132953e-7,0.00004600226,0.03261568,0.94668376],"study_design_scores_gemma":[0.0005915673,0.0028594139,0.000007811031,0.006606484,0.00057803735,0.0006849352,0.000012047223,0.000004351485,2.493982e-7,0.000045163837,0.9884418,0.00016813813],"about_ca_topic_score_codex":0.00013419092,"about_ca_topic_score_gemma":0.00004845689,"teacher_disagreement_score":0.9558261,"about_ca_system_score_codex":0.0018443852,"about_ca_system_score_gemma":0.006053702,"threshold_uncertainty_score":0.99958104},"labels":[],"label_agreement":null},{"id":"W2020371671","doi":"10.1007/s00280-013-2229-3","title":"Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor","year":2013,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Paclitaxel; Epidermal growth factor receptor; Cancer research; Chemotherapy; Medicine; Pharmacology; Cell cycle; Cancer; Oncology; Biology; Internal medicine","score_opus":0.0884284157506157,"score_gpt":0.4195852517613815,"score_spread":0.3311568360107658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020371671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989235,0.004632916,0.000052182793,0.0038667405,0.00017719311,0.001833012,0.0001657636,0.000010749641,0.000026471955],"genre_scores_gemma":[0.9891379,0.007698632,0.00085423177,0.0008853473,0.00038462578,0.00082554005,0.0000085088195,0.000029583938,0.00017565393],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893075,0.00006343981,0.00028794634,0.0003102724,0.00013109724,0.0002765019],"domain_scores_gemma":[0.99920774,0.00019769714,0.00015520777,0.000114489405,0.00016106112,0.00016383246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012883541,0.00017289919,0.0004165431,0.00007248528,0.00010001848,0.0000138646865,0.000054143544,0.00010283623,0.00080162205],"category_scores_gemma":[0.000009144609,0.000121998884,0.000053143278,0.00008260964,0.00023762022,0.00007351711,0.000027085542,0.00009589298,3.3093846e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075340056,0.00009641114,0.038402975,0.00047558232,0.0002166799,5.716975e-7,0.00368598,0.000019248013,0.9278444,0.000015948293,0.0015919807,0.0268968],"study_design_scores_gemma":[0.004474232,0.0011614854,0.018257622,0.00012106008,0.000083741295,0.0000035863732,0.00025642203,0.00032345107,0.970789,0.00004121214,0.0043633236,0.0001248485],"about_ca_topic_score_codex":0.0014040421,"about_ca_topic_score_gemma":0.000024350773,"teacher_disagreement_score":0.04294459,"about_ca_system_score_codex":0.000100067715,"about_ca_system_score_gemma":0.00008511997,"threshold_uncertainty_score":0.87771994},"labels":[],"label_agreement":null},{"id":"W2022055121","doi":"10.1186/1471-2407-7-110","title":"External influences and priority-setting for anti-cancer agents: a case study of media coverage in adjuvant trastuzumab for breast cancer","year":2007,"lang":"en","type":"review","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"Cancer Care Ontario","keywords":"Trastuzumab; Medicine; Breast cancer; Vinorelbine; Oncology; Docetaxel; Internal medicine; Adjuvant; Cancer; Pharmacy; Surgical oncology; Clinical trial; Family medicine; Cisplatin; Chemotherapy","score_opus":0.20780236134818136,"score_gpt":0.5198323342998467,"score_spread":0.3120299729516653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022055121","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13495435,0.8501748,0.00014555507,0.000032130924,0.00065768784,0.009558761,0.0044357665,0.000027079655,0.000013855101],"genre_scores_gemma":[0.016633134,0.97163534,0.00041521748,0.00010077803,0.001527201,0.009298668,0.00002817968,0.00017862876,0.00018285168],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949844,0.00020650448,0.0016740193,0.0011624637,0.0009561214,0.0010165211],"domain_scores_gemma":[0.9966825,0.0010891067,0.0008099826,0.0005395214,0.00051513215,0.00036373007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015666948,0.0007228433,0.0032386428,0.00068166154,0.00013840181,0.00006114411,0.00035678048,0.00041942784,0.00032291995],"category_scores_gemma":[0.00027651762,0.0005904612,0.00043162145,0.0007264571,0.00019824978,0.00015899347,0.00016383918,0.0007829269,9.957577e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004441278,0.00039658212,0.05453993,0.05544536,0.0003759054,0.00039062268,0.0019113905,0.00002358992,0.0000070866445,0.0000019951062,0.00031474486,0.8861487],"study_design_scores_gemma":[0.034468286,0.0023339423,0.06741419,0.19332784,0.007944264,0.003470881,0.006332545,0.00046883963,0.00005983482,0.000028268538,0.68127936,0.0028717099],"about_ca_topic_score_codex":0.015718183,"about_ca_topic_score_gemma":0.041619606,"teacher_disagreement_score":0.88327694,"about_ca_system_score_codex":0.0017688167,"about_ca_system_score_gemma":0.004560041,"threshold_uncertainty_score":0.99965465},"labels":[],"label_agreement":null},{"id":"W2022184484","doi":"10.2174/1381612053382205","title":"Development of Molecular Targeted Anticancer Agents: Successes, Failures and Future Directions","year":2005,"lang":"en","type":"review","venue":"Current Pharmaceutical Design","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Medicine; Trastuzumab; Myeloid leukemia; Targeted therapy; Bevacizumab; Chronic myelogenous leukemia; Clinical trial; Cancer; Bioinformatics; Breast cancer; Cancer research; Leukemia; Immunology; Biology; Internal medicine; Chemotherapy","score_opus":0.2605662726175213,"score_gpt":0.5193172596919667,"score_spread":0.25875098707444544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022184484","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000044841827,0.9940104,0.0021225521,0.00050719007,0.00075329526,0.0022341216,0.000055298824,0.00008028104,0.00023239384],"genre_scores_gemma":[0.000032807704,0.9900207,0.008338286,0.000055535187,0.0008533375,0.00042006414,0.00012214346,0.00009705437,0.000060059683],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99625534,0.00042411356,0.0010089328,0.0007312395,0.0009213295,0.00065904047],"domain_scores_gemma":[0.998255,0.00022151775,0.00021164869,0.00041311892,0.00023631957,0.00066236436],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006581978,0.00057698647,0.0016986073,0.00039499658,0.00011672083,0.00004497826,0.00030522657,0.00030804056,0.0012932649],"category_scores_gemma":[0.00013766237,0.0004575854,0.00030252073,0.00082047645,0.00027443486,0.00007369498,0.0001763246,0.0012859922,0.0000723091],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040987597,0.00032790468,0.000003285577,0.02537801,0.0004209768,0.000035397523,0.00007344623,2.954664e-7,0.00004906277,0.00018900183,0.002157825,0.9713238],"study_design_scores_gemma":[0.0006209911,0.000058485937,0.000008945213,0.008382226,0.0014484872,0.000049380953,0.000009847943,0.000057852587,0.0005643296,0.0000052020664,0.98840517,0.00038910907],"about_ca_topic_score_codex":0.0000037219133,"about_ca_topic_score_gemma":0.0000011826631,"teacher_disagreement_score":0.9862473,"about_ca_system_score_codex":0.0004511687,"about_ca_system_score_gemma":0.0020152924,"threshold_uncertainty_score":0.99978757},"labels":[],"label_agreement":null},{"id":"W2022706281","doi":"10.1158/1535-7163.targ-11-a143","title":"Abstract A143: ARRY-380, a selective HER2 inhibitor: From drug design to clinical evaluation.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Kingston General Hospital","funders":"","keywords":"Pharmacokinetics; Pharmacology; Kinase; Drug; Potency; Metastatic breast cancer; Tyrosine-kinase inhibitor; Medicine; Cancer; Chemistry; Breast cancer; Cancer research; Internal medicine; In vitro; Biochemistry","score_opus":0.23610018967859558,"score_gpt":0.45589901344279576,"score_spread":0.21979882376420018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022706281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9269699,0.01376309,0.03446997,0.0054656877,0.0023208691,0.006510867,0.0001268966,0.00036220296,0.0100105135],"genre_scores_gemma":[0.9804429,0.00050311117,0.009402084,0.007985017,0.0006816472,0.0005936514,0.000018665942,0.00014308089,0.00022985344],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99593353,0.0005552204,0.0006625554,0.0007945616,0.0014102539,0.0006438591],"domain_scores_gemma":[0.997477,0.00020709737,0.00014659809,0.00086664583,0.0008270036,0.0004756417],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017454254,0.0003425168,0.0005359605,0.00016252628,0.00009963118,0.00004593922,0.00036412387,0.00025724797,0.0016459061],"category_scores_gemma":[0.000161191,0.00031931725,0.00024151144,0.0005406017,0.00016089038,0.00007285552,0.00009124363,0.0008342298,0.00033887604],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005455342,0.0020256182,0.04434065,0.00012494139,0.003891628,0.0005576905,0.014998071,0.00042051726,0.16024844,0.00008306697,0.022282746,0.7455713],"study_design_scores_gemma":[0.0077626584,0.0018191879,0.11648499,0.00072300516,0.0015749884,0.00001754244,0.0006224409,0.0032338465,0.80272645,0.004270824,0.059536006,0.00122804],"about_ca_topic_score_codex":0.0016724201,"about_ca_topic_score_gemma":0.00023684792,"teacher_disagreement_score":0.7443433,"about_ca_system_score_codex":0.0007652486,"about_ca_system_score_gemma":0.0020656704,"threshold_uncertainty_score":0.9999259},"labels":[],"label_agreement":null},{"id":"W2023063845","doi":"10.1191/1078155202jp089oa","title":"Clinical effectiveness of trastuzumab: early experience","year":2002,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Baker Hughes (Canada); University of Alberta; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cardiotoxicity; Clinical trial; Oncology; Breast cancer; Metastatic breast cancer; Adverse effect; Cancer; Incidence (geometry); Surgery; Chemotherapy","score_opus":0.25688355352266745,"score_gpt":0.5927217133347364,"score_spread":0.335838159812069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023063845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722401,0.0018190244,0.00027871664,0.0038614857,0.0012426215,0.00035183542,0.0000019360593,0.000010622792,0.020193676],"genre_scores_gemma":[0.991538,0.0036524935,0.003114051,0.00079039665,0.0006880272,0.000011620003,2.233051e-7,0.000023146,0.00018205612],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952825,0.0023836081,0.001155393,0.00020311668,0.00066846464,0.00030694433],"domain_scores_gemma":[0.98949265,0.007629161,0.0010816583,0.00023572026,0.0011793362,0.00038144793],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066110757,0.00013527912,0.0007904868,0.00019630515,0.00005261562,0.000012759967,0.00030695598,0.00012316518,0.001019053],"category_scores_gemma":[0.0065414305,0.000110077504,0.00026003274,0.00034620365,0.00038450025,0.0006405265,0.00006441271,0.001673494,0.00007718688],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039972913,0.014288905,0.3394736,0.0007732089,0.0019126071,0.011794838,0.006156471,0.00003099268,0.09892056,0.0001655566,0.020428607,0.46608174],"study_design_scores_gemma":[0.020802945,0.015159347,0.07828908,0.00044310934,0.0008533422,0.011914155,0.00087421347,0.0002961064,0.025314014,0.000035203604,0.84582376,0.0001947306],"about_ca_topic_score_codex":0.000047583922,"about_ca_topic_score_gemma":7.1131143e-7,"teacher_disagreement_score":0.82539517,"about_ca_system_score_codex":0.00041423104,"about_ca_system_score_gemma":0.0007303439,"threshold_uncertainty_score":0.99989414},"labels":[],"label_agreement":null},{"id":"W2023431277","doi":"10.1158/1535-7163.mct-15-0067","title":"AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody–Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML","year":2015,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Antibody-drug conjugate; Pharmacology; Medicine; Drug; Conjugate; Antibody; Immunology; Monoclonal antibody","score_opus":0.05551429481243274,"score_gpt":0.3826702077750343,"score_spread":0.32715591296260155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023431277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92036736,0.043054942,0.024462776,0.0069615915,0.00038785356,0.0040639723,0.00020711217,0.00011569559,0.00037867387],"genre_scores_gemma":[0.98246336,0.0019013813,0.0059444597,0.006702167,0.0003176448,0.00062888255,0.0001320088,0.00022911819,0.001680999],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968098,0.00018801475,0.0005676459,0.00081256015,0.00064097764,0.0009810089],"domain_scores_gemma":[0.99806863,0.00010121067,0.00018482209,0.0006410477,0.00042882166,0.00057546375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008142739,0.00046412257,0.0007404587,0.00030589022,0.00011607911,0.0001603316,0.00035516487,0.00021897128,0.000043989905],"category_scores_gemma":[0.00004410677,0.00044538683,0.00020366111,0.0004214701,0.00022269641,0.00015710032,0.00008551475,0.00036528055,0.000008812786],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004629747,0.00074699544,0.006248447,0.0007706166,0.0005782331,0.00017477103,0.006226867,0.00065701525,0.9119869,0.00072637247,0.0010621701,0.0661919],"study_design_scores_gemma":[0.03794439,0.00737045,0.004762929,0.00063242466,0.0014183837,0.00014566378,0.0045124227,0.03868015,0.61364263,0.022992816,0.2658356,0.0020620858],"about_ca_topic_score_codex":0.0015387563,"about_ca_topic_score_gemma":0.00030422088,"teacher_disagreement_score":0.29834422,"about_ca_system_score_codex":0.00031707707,"about_ca_system_score_gemma":0.0017823704,"threshold_uncertainty_score":0.9997998},"labels":[],"label_agreement":null},{"id":"W2023764867","doi":"10.1016/j.clbc.2012.01.001","title":"Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute; U.S. Public Health Service; Genentech; National Institutes of Health; Mayo Clinic","keywords":"Vinorelbine; Capecitabine; Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Phases of clinical research; Chemotherapy; Colorectal cancer","score_opus":0.10161322086899631,"score_gpt":0.4580827344753126,"score_spread":0.3564695136063163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023764867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98142207,0.0018237936,0.00006984749,0.0017256708,0.00048636412,0.00623501,0.008208971,0.000018594792,0.000009709939],"genre_scores_gemma":[0.99276006,0.0014194757,0.00017597165,0.000049968603,0.0007800653,0.0041146073,0.00025928646,0.00006544553,0.00037513077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961931,0.00027088445,0.0015671486,0.0006632444,0.0005856442,0.00071994384],"domain_scores_gemma":[0.99747473,0.0006261388,0.00056582515,0.00035020278,0.00047932487,0.000503765],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005156058,0.0004610636,0.0016593429,0.00022125346,0.00010123108,0.000013300971,0.00013060009,0.00011291187,0.0020311847],"category_scores_gemma":[0.000053925865,0.00030221403,0.00034460018,0.0004811492,0.00039229693,0.00019435376,0.000055599812,0.00021370356,7.619102e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21851927,0.10922541,0.4784179,0.0004808726,0.0022668922,0.000030062145,0.0019997738,0.000037032685,0.0000445165,0.000018587352,0.00012285137,0.18883681],"study_design_scores_gemma":[0.28470117,0.102959454,0.60824776,0.00070371083,0.001400618,0.00006328277,0.0004579861,0.0005470576,0.00018114423,0.0000061498877,0.0004783273,0.0002533657],"about_ca_topic_score_codex":0.010188073,"about_ca_topic_score_gemma":0.07804325,"teacher_disagreement_score":0.18858345,"about_ca_system_score_codex":0.0020376407,"about_ca_system_score_gemma":0.0011193004,"threshold_uncertainty_score":0.999943},"labels":[],"label_agreement":null},{"id":"W2023982632","doi":"10.1016/s0399-8320(04)94872-5","title":"Nouvelles approches pharmacologiques de traitement des cancers","year":2004,"lang":"fr","type":"review","venue":"Gastroentérologie Clinique et Biologique","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Medicine; Gynecology","score_opus":0.14535946250255677,"score_gpt":0.4674084473057148,"score_spread":0.322048984803158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023982632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077259457,0.9557063,0.016350988,0.004143573,0.0026255269,0.008810774,0.0012637443,0.0010212528,0.0023518691],"genre_scores_gemma":[0.0068503045,0.9397767,0.040753663,0.0040826164,0.0018212893,0.0046483884,0.00079424743,0.00029253264,0.0009802593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9765184,0.010115558,0.003486473,0.0027729825,0.0008004818,0.006306094],"domain_scores_gemma":[0.9902005,0.0042109056,0.0015326886,0.0014274236,0.00069403136,0.0019344044],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.01911139,0.002330753,0.0050121597,0.0006846267,0.00045413477,0.00016773654,0.0022871555,0.0038682641,0.0026586484],"category_scores_gemma":[0.008334204,0.0018819367,0.0019927672,0.0009266089,0.004870872,0.00021278867,0.0010519818,0.0074067004,0.00056145084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020611759,0.0019274899,0.019416606,0.07314094,0.0028633692,0.0021776801,0.0013676111,0.0013666401,0.0010481023,0.0016103559,0.005305555,0.88771445],"study_design_scores_gemma":[0.0036418734,0.015713567,0.0047309464,0.057641294,0.002094453,0.0009210919,0.0011499405,0.00010306263,0.0020702407,0.0027280643,0.90735286,0.0018525725],"about_ca_topic_score_codex":0.0012347539,"about_ca_topic_score_gemma":0.0010223833,"teacher_disagreement_score":0.90204734,"about_ca_system_score_codex":0.022009462,"about_ca_system_score_gemma":0.037652325,"threshold_uncertainty_score":0.9989431},"labels":[],"label_agreement":null},{"id":"W2024076573","doi":"10.1016/j.jconrel.2015.02.001","title":"Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models","year":2015,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Nebraska Department of Health and Human Services; Foundation for the National Institutes of Health; U.S. Department of Defense","keywords":"Doxorubicin; Nanocarriers; In vivo; Breast cancer; Trastuzumab; Chemistry; Pharmacology; Cytotoxicity; Cancer research; Drug delivery; Chemotherapy; Drug; Cancer; In vitro; Medicine; Biology; Internal medicine; Biochemistry","score_opus":0.03961456749424253,"score_gpt":0.33281772068589316,"score_spread":0.29320315319165063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024076573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902947,0.0006157332,0.0037561934,0.0033162949,0.00013476641,0.0011265995,0.00005680336,0.00001612281,0.00068278523],"genre_scores_gemma":[0.99879164,0.00005347255,0.00045383887,0.00023250935,0.00019104316,0.00004624402,0.0000040469995,0.000049896982,0.00017731938],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9960235,0.00046191417,0.0010536301,0.00026589146,0.0017118274,0.00048327065],"domain_scores_gemma":[0.995872,0.0003669453,0.0012011899,0.00033253556,0.001634236,0.00059309404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016904782,0.00028911378,0.001550277,0.0006851091,0.000058069665,0.000038569902,0.00022525212,0.000121143115,0.00007528161],"category_scores_gemma":[0.0006069473,0.00020233313,0.00026743728,0.0005278506,0.00017320628,0.00030992462,0.000027962413,0.0008202529,0.0000026345976],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09468913,0.0041528796,0.07647461,0.0007726284,0.0009646188,0.0034805436,0.0006830734,0.4373809,0.36906227,0.00017860415,0.0019498104,0.010210931],"study_design_scores_gemma":[0.16907853,0.0044270307,0.036606435,0.005732717,0.0008101598,0.00071558845,0.0005413472,0.7558055,0.025411163,0.0002787305,0.000070872484,0.00052196835],"about_ca_topic_score_codex":0.0008882549,"about_ca_topic_score_gemma":0.0001247397,"teacher_disagreement_score":0.3436511,"about_ca_system_score_codex":0.0009556929,"about_ca_system_score_gemma":0.0036301569,"threshold_uncertainty_score":0.8250906},"labels":[],"label_agreement":null},{"id":"W2024170532","doi":"10.1038/modpathol.3800555","title":"Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm","year":2006,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Concordance; Immunohistochemistry; Fluorescence in situ hybridization; Gene duplication; Biology; In situ hybridization; Human Epidermal Growth Factor Receptor 2; Pathology; Molecular biology; Medicine; Cancer; Bioinformatics; Gene; Breast cancer; Genetics; Gene expression","score_opus":0.03722846614933295,"score_gpt":0.32165529426484235,"score_spread":0.2844268281155094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024170532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95123094,0.00039380798,0.03792398,0.0015719043,0.00015210705,0.0012855453,0.000010304729,0.000051325173,0.0073800636],"genre_scores_gemma":[0.98830396,0.000036538273,0.01003244,0.00076898036,0.00028479786,0.00026435594,0.000051808915,0.000042400654,0.0002147325],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99721,0.00040381833,0.00053924625,0.00065843633,0.0005073886,0.0006810613],"domain_scores_gemma":[0.99891984,0.00023308289,0.0000904704,0.00048858806,0.00018959271,0.00007840389],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011663157,0.00021722776,0.00039209248,0.000511323,0.0000649634,0.000035716443,0.00034096919,0.000119272554,0.000022085878],"category_scores_gemma":[0.0004544693,0.00019305854,0.00003917289,0.0014053251,0.000114201284,0.00012628522,0.00013758792,0.0005379793,0.00007008533],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020909359,0.0011711686,0.26967412,0.00019748187,0.000017314413,0.0125891175,0.006908541,0.020593455,0.5256953,0.00034989978,0.0008828094,0.16171166],"study_design_scores_gemma":[0.007130662,0.0013624735,0.6925157,0.0010231559,0.00004247799,0.0027673258,0.0005390908,0.17523946,0.109535754,0.007439262,0.001479257,0.0009254279],"about_ca_topic_score_codex":0.0013729036,"about_ca_topic_score_gemma":0.003284063,"teacher_disagreement_score":0.42284152,"about_ca_system_score_codex":0.00055890065,"about_ca_system_score_gemma":0.00030223274,"threshold_uncertainty_score":0.7872699},"labels":[],"label_agreement":null},{"id":"W2024823531","doi":"10.1158/0008-5472.sabcs13-p4-12-11","title":"Abstract P4-12-11: Patient preference for subcutaneous trastuzumab via handheld syringe versus intravenous infusion in HER2-positive early breast cancer: Cohort 2 of the PrefHer study","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Cohort; Crossover study; Breast cancer; Clinical endpoint; Randomization; Randomized controlled trial; Internal medicine; Oncology; Cancer; Pathology","score_opus":0.08074014626197955,"score_gpt":0.3842851056611099,"score_spread":0.30354495939913034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024823531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985234,0.0005394574,0.0000059456506,0.0009345677,0.00041156274,0.011699196,0.00027265368,0.00003135611,0.0008712179],"genre_scores_gemma":[0.99220437,0.00041381657,0.00002146865,0.000037599726,0.00023260328,0.006575524,0.000010721563,0.00008964643,0.00041426346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945559,0.00038204674,0.00070646644,0.0008395241,0.0022487505,0.0012673221],"domain_scores_gemma":[0.99643946,0.00056668377,0.00016622097,0.0009296061,0.0015370401,0.0003610024],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010971546,0.0003305011,0.00064021436,0.00035402627,0.00026916832,0.00009382271,0.0007163343,0.00022574402,0.0013670854],"category_scores_gemma":[0.00022737047,0.00024337132,0.00014124395,0.0008848202,0.00049605005,0.0001677428,0.0003903951,0.0013433929,0.000031232463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013785906,0.0034362914,0.6810864,0.0012524428,0.0005593176,0.00016377207,0.014571995,0.00020713345,0.06459246,0.000018757622,0.0019883632,0.21833715],"study_design_scores_gemma":[0.0045199106,0.005354808,0.96936023,0.0012287813,0.000064482825,0.000026428457,0.001313642,0.00014363561,0.017359985,0.00004677051,0.00030796288,0.0002733628],"about_ca_topic_score_codex":0.1398055,"about_ca_topic_score_gemma":0.027125712,"teacher_disagreement_score":0.2882738,"about_ca_system_score_codex":0.0025600025,"about_ca_system_score_gemma":0.0018063756,"threshold_uncertainty_score":0.9995458},"labels":[],"label_agreement":null},{"id":"W2024903800","doi":"10.1016/s1470-2045(13)70383-8","title":"Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Clinical endpoint; Breast cancer; Internal medicine; Population; Surgery; Oncology; Clinical trial; Cancer","score_opus":0.11089225089377973,"score_gpt":0.41324273047037563,"score_spread":0.3023504795765959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024903800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98665726,0.00001862491,0.000030587013,0.0014520307,0.00007204372,0.01095211,0.00016727282,0.000018821831,0.00063125207],"genre_scores_gemma":[0.9960765,0.000024928944,0.00046606845,0.00024833894,0.00014669934,0.0027515744,0.000034638233,0.000033971453,0.00021728234],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9979556,0.00050604716,0.0004073259,0.00035882657,0.0003229823,0.00044921302],"domain_scores_gemma":[0.9983242,0.0004306408,0.00019823508,0.00044459937,0.00048184887,0.00012044411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006726031,0.0001777201,0.0008233569,0.0000637702,0.00007258895,0.000039767758,0.0005096229,0.00011292661,0.00032563097],"category_scores_gemma":[0.00008046901,0.000101732665,0.000016394779,0.00022421729,0.00017956874,0.0001391882,0.00007495715,0.00032806123,0.0000072044563],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.64803696,0.01971039,0.16542637,0.00028251263,0.0005025218,0.00014465778,0.013310817,0.000020517418,0.0016874294,0.00006186318,0.0006780553,0.15013793],"study_design_scores_gemma":[0.10890289,0.086550355,0.8025949,0.00016079914,0.00012170668,0.00007566154,0.00086707727,0.0001375835,0.00028555395,0.000071695904,0.00007334756,0.00015843622],"about_ca_topic_score_codex":0.004386217,"about_ca_topic_score_gemma":0.00898566,"teacher_disagreement_score":0.6371685,"about_ca_system_score_codex":0.0004572294,"about_ca_system_score_gemma":0.0012625956,"threshold_uncertainty_score":0.66306776},"labels":[],"label_agreement":null},{"id":"W2025510375","doi":"10.1073/pnas.0306802101","title":"Germ-line expression of an oncogenic <i>erbB2</i> allele confers resistance to <i>erbB2</i> -induced mammary tumorigenesis","year":2004,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McGill University; Royal University Hospital; Lunenfeld-Tanenbaum Research Institute","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; U.S. Department of Defense","keywords":"Carcinogenesis; Biology; Allele; Mammary tumor; Mammary gland; Genetically modified mouse; Oncogene; Cancer research; Population; Germline; Transgene; Gene; Cancer; Genetics; Medicine; Cell cycle","score_opus":0.08221381654363341,"score_gpt":0.3839007725629311,"score_spread":0.3016869560192977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025510375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98116666,0.00026138054,0.000007247438,0.011845275,0.000028992206,0.0005744826,0.000024171577,0.000023606564,0.0060681985],"genre_scores_gemma":[0.98991305,0.00009453513,0.008472606,0.00095903623,0.00013963543,0.000035436402,5.870667e-7,0.0000132210025,0.00037187306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99569994,0.000015641115,0.0006174192,0.00047013751,0.002871803,0.00032507046],"domain_scores_gemma":[0.9983145,0.00009741815,0.00045858906,0.00004260421,0.0008905114,0.00019634998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002091016,0.00016172758,0.0003754707,0.000320016,0.00017397678,0.00002073358,0.001236735,0.0001290893,0.000021635627],"category_scores_gemma":[0.00086331007,0.00011467126,0.00012632826,0.0015515977,0.00057933736,0.0004697171,0.00024553787,0.00027522,0.0000029104447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018737455,0.00015932035,0.00079220714,0.00025017792,0.000013919754,1.348687e-7,0.00030864932,0.00008822817,0.99152195,0.0051542167,0.0010714346,0.00045238037],"study_design_scores_gemma":[0.0006611555,0.00034437177,0.010944872,0.0005135399,0.000017343067,0.00001447296,0.00021230354,0.000035039026,0.97750324,0.008670217,0.0009684422,0.00011501219],"about_ca_topic_score_codex":0.000032827662,"about_ca_topic_score_gemma":9.977305e-7,"teacher_disagreement_score":0.014018726,"about_ca_system_score_codex":0.00018962029,"about_ca_system_score_gemma":0.0004987497,"threshold_uncertainty_score":0.4676158},"labels":[],"label_agreement":null},{"id":"W2027515445","doi":"10.1097/sla.0b013e3181dbb77e","title":"HER-3 Overexpression Is Prognostic of Reduced Breast Cancer Survival","year":2010,"lang":"en","type":"article","venue":"Annals of Surgery","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; St. Paul's Hospital; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"","keywords":"Medicine; Breast cancer; Tissue microarray; Cancer; Oncology; Immunohistochemistry; Internal medicine; Lymphovascular invasion; Estrogen receptor; Univariate analysis; Pathology; Multivariate analysis; Metastasis","score_opus":0.3353829394354498,"score_gpt":0.4594446625524266,"score_spread":0.12406172311697683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027515445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899018,0.0003958417,9.0166463e-7,0.0070213364,0.0004753728,0.00023035776,0.00018421035,0.000023071121,0.0017671378],"genre_scores_gemma":[0.99798566,0.0006742826,0.000037770587,0.0003426312,0.0003413925,0.00003169062,0.000011280859,0.000032896725,0.000542381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981163,0.00006408759,0.00044998556,0.0002502795,0.0007480487,0.00037130606],"domain_scores_gemma":[0.99787015,0.00054486486,0.00019031063,0.00047364968,0.000703287,0.00021771652],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089503784,0.00013397798,0.00052608055,0.0001902937,0.000028874481,0.0000071565587,0.00012046673,0.00014183173,0.002770905],"category_scores_gemma":[0.00058330555,0.00011099641,0.00020879017,0.0003355099,0.00019484022,0.0000873717,0.00006730355,0.0003487404,0.000017874538],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041503969,0.00027020072,0.46840414,0.0006271653,0.00007953358,0.000017013648,0.00012804808,4.8191777e-7,0.4299396,0.00002068292,0.07332447,0.026773635],"study_design_scores_gemma":[0.00021012034,0.00004596085,0.5922111,0.0013427414,0.00001757103,0.000019939791,0.00003760101,0.000016099544,0.40174773,0.0000649038,0.004178988,0.00010722753],"about_ca_topic_score_codex":0.0011037246,"about_ca_topic_score_gemma":0.000017350543,"teacher_disagreement_score":0.12380698,"about_ca_system_score_codex":0.0000109908115,"about_ca_system_score_gemma":0.000698389,"threshold_uncertainty_score":0.9981407},"labels":[],"label_agreement":null},{"id":"W2028678591","doi":"10.1097/00128360-200301000-00011","title":"Demonstration of Her-2 Protein in Cervical Carcinomas","year":2003,"lang":"en","type":"article","venue":"Journal of Lower Genital Tract Disease","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"","keywords":"Medicine; Staining; Immunohistochemistry; Pathology; Cervix; Lymph node; Breast cancer; Cervical cancer; Cancer; Oncology; Internal medicine","score_opus":0.034484311770550016,"score_gpt":0.32984190846087963,"score_spread":0.2953575966903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028678591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939462,0.0011128401,0.000057353784,0.00072396087,0.00012355024,0.00038424082,0.000010950487,0.0000044223466,0.0036364663],"genre_scores_gemma":[0.9989173,0.000021313623,0.0005780961,0.000061630875,0.00013394287,0.000008068559,0.0000017105514,0.000020054858,0.00025787784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805963,0.00014397921,0.0006466744,0.00012774477,0.00077558175,0.00024640668],"domain_scores_gemma":[0.99870944,0.000059553025,0.00018932877,0.00019477496,0.0002980676,0.0005488467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005796297,0.0001193013,0.0003104572,0.00024251537,0.000015371887,0.00001589811,0.00010707686,0.00007145688,0.00041782513],"category_scores_gemma":[0.0005333722,0.000098688724,0.00022137963,0.00028491113,0.000080223224,0.00018444721,0.000010742361,0.0004673041,0.000012719354],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067069535,0.006982643,0.8917416,0.0010299674,0.00012286895,0.013403202,0.00036288967,0.000058490376,0.07124191,0.0005740062,0.0006482992,0.007127217],"study_design_scores_gemma":[0.00502283,0.0024406335,0.9698461,0.0006740981,0.00017591893,0.0006920761,0.0003712866,0.00010865023,0.017362444,0.0007438948,0.0023275027,0.00023451986],"about_ca_topic_score_codex":0.000012783542,"about_ca_topic_score_gemma":0.000007953129,"teacher_disagreement_score":0.078104585,"about_ca_system_score_codex":0.00017961116,"about_ca_system_score_gemma":0.0013091555,"threshold_uncertainty_score":0.45748922},"labels":[],"label_agreement":null},{"id":"W2029678186","doi":"10.1007/s10120-011-0118-1","title":"Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study","year":2011,"lang":"en","type":"article","venue":"Gastric Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Research Foundation","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Medicine; Hazard ratio; Trastuzumab; Internal medicine; Capecitabine; Oncology; Confidence interval; Chemotherapy; Regimen; Cancer; Population; Breast cancer; Colorectal cancer","score_opus":0.03215206981824119,"score_gpt":0.3282366159019147,"score_spread":0.2960845460836735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029678186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99119407,0.0007297638,0.00045230146,0.000074961994,0.00038939802,0.0060542636,0.0009675722,0.000041089967,0.00009659139],"genre_scores_gemma":[0.9952356,0.00037246445,0.00055769173,0.00006631785,0.00016624476,0.0031028844,0.00006766578,0.00011091943,0.00032019275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99446255,0.0003063821,0.0012678684,0.0011018321,0.0016781118,0.0011832392],"domain_scores_gemma":[0.9964843,0.00030175538,0.0008822235,0.00092238537,0.0010744152,0.00033496085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005199897,0.0006316124,0.001706044,0.0015706829,0.00015836145,0.000019292407,0.0005883093,0.00016449008,0.0010090303],"category_scores_gemma":[0.00017816386,0.00042584547,0.00048675362,0.008906179,0.00034907783,0.00021550614,0.0001353181,0.00065113517,0.0000014903795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022107268,0.0046150335,0.90595466,0.00027874892,0.002615648,0.000024479257,0.0056481184,0.003936906,0.00043757903,0.0000014134457,0.00021619225,0.054163944],"study_design_scores_gemma":[0.018605113,0.007163869,0.965781,0.000547046,0.004084921,0.00000863003,0.0021545514,0.00064265484,0.00067800086,0.0000014285649,0.000037809026,0.00029497495],"about_ca_topic_score_codex":0.025394687,"about_ca_topic_score_gemma":0.023048295,"teacher_disagreement_score":0.05982633,"about_ca_system_score_codex":0.002892395,"about_ca_system_score_gemma":0.0019963933,"threshold_uncertainty_score":0.99990416},"labels":[],"label_agreement":null},{"id":"W2030031549","doi":"10.3747/co.v18i1.623","title":"Immune Therapy for Breast Cancer in 2010—Hype or Hope?","year":2011,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Toronto; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Breast cancer; Immune system; Cancer; Bioinformatics; Immunology; Internal medicine; Biology","score_opus":0.38223391733961404,"score_gpt":0.5307872293519582,"score_spread":0.14855331201234417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030031549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90841454,0.043079473,0.00030821457,0.016889794,0.013150683,0.0065481025,0.000496393,0.00018244541,0.010930329],"genre_scores_gemma":[0.96550983,0.024444042,0.0008329559,0.0006927399,0.0016588734,0.0027526598,0.000037177142,0.00010511895,0.00396659],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857527,0.00009226673,0.00032394493,0.0003156717,0.00017628176,0.00051657885],"domain_scores_gemma":[0.9991256,0.00012649427,0.00007446547,0.00031521768,0.00020491736,0.00015329354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046216114,0.00014791089,0.00043827592,0.0001764248,0.00003864278,0.00000525122,0.00020873173,0.00015356095,0.0068860753],"category_scores_gemma":[0.00007931361,0.00010605353,0.000084112224,0.00026157434,0.00015426254,0.000047571564,0.000060056966,0.00041000472,0.00008574876],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048729726,0.0011781744,0.07220334,0.00016033823,0.00004837279,0.000042335465,0.0010616182,3.4569447e-7,0.001494185,0.00009322544,0.019622086,0.899223],"study_design_scores_gemma":[0.0080450345,0.0020843525,0.44260636,0.00023247107,0.000027757502,0.00010710283,0.00016236541,0.000118640965,0.0015108532,0.00016361175,0.54475814,0.00018331586],"about_ca_topic_score_codex":0.00057371083,"about_ca_topic_score_gemma":0.00073604076,"teacher_disagreement_score":0.8990397,"about_ca_system_score_codex":0.00053816964,"about_ca_system_score_gemma":0.0012779431,"threshold_uncertainty_score":0.9940218},"labels":[],"label_agreement":null},{"id":"W2030287014","doi":"10.1038/87310","title":"Ewing tumor cells activate distinct signaling pathways in monolayer versus anchorage-independent cultures","year":2001,"lang":"en","type":"article","venue":"Nature Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Institute of Indigenous Peoples' Health; Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Biology; Signal transduction; Cell biology; Monolayer; Cancer research; Tumor cells; Cell culture; Genetics; Biochemistry","score_opus":0.04396581008631634,"score_gpt":0.35316148163552935,"score_spread":0.309195671549213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030287014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896518,0.0043427437,0.00007559148,0.00027064362,0.0008804283,0.00054685137,0.000018480225,0.00007019714,0.0041432637],"genre_scores_gemma":[0.99641025,0.0004474831,0.001610167,0.00031405588,0.0008570984,0.000030856896,0.000019891038,0.00006478638,0.0002454073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974187,0.00008878356,0.0003395481,0.00053760724,0.00092060026,0.0006947447],"domain_scores_gemma":[0.9988545,0.00012560276,0.0000831786,0.00049328705,0.00017407065,0.00026934073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003883145,0.0002763207,0.00035224,0.00019323708,0.00009338895,0.00006404223,0.00029081956,0.00042705607,0.00022208471],"category_scores_gemma":[0.00021009013,0.0002409129,0.00010935854,0.0005459804,0.000039967665,0.000052746665,0.00013646181,0.0020716237,0.000056409783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023537972,0.00042526875,0.087169565,0.00029895164,0.00014832067,0.0037175275,0.001614628,0.0017528135,0.87218565,0.000026783657,0.0042403894,0.026066327],"study_design_scores_gemma":[0.006559974,0.0007272937,0.07161798,0.0005051647,0.000103916405,0.000113146634,0.00082331273,0.0020528992,0.8351447,0.00019433137,0.08147287,0.0006844375],"about_ca_topic_score_codex":0.000043008855,"about_ca_topic_score_gemma":0.00010647595,"teacher_disagreement_score":0.07723248,"about_ca_system_score_codex":0.00044580593,"about_ca_system_score_gemma":0.0002767575,"threshold_uncertainty_score":0.9824143},"labels":[],"label_agreement":null},{"id":"W2030789072","doi":"10.1093/emboj/20.13.3342","title":"N‐arginine dibasic convertase is a specific receptor for heparin‐binding EGF‐like growth factor that mediates cell migration","year":2001,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Medical Research Council; Bayer Yakuhin; National Institutes of Health; National Institute of General Medical Sciences; Medical Research Council Canada","keywords":"Biology; Epidermal growth factor; Receptor; Biochemistry; Cell biology; Growth factor; Cell migration; Cell; Molecular biology","score_opus":0.0788249204008761,"score_gpt":0.3347640994761005,"score_spread":0.25593917907522434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030789072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806966,0.0014907891,0.00061700965,0.013745762,0.0012672853,0.00078958744,0.000080312886,0.000046900706,0.0012657145],"genre_scores_gemma":[0.9806093,0.0075425697,0.00085162156,0.00097192253,0.0025896516,0.000057743433,0.00005969812,0.00008195343,0.0072355145],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976527,0.00014009803,0.00042051217,0.0002828391,0.00085176673,0.0006520524],"domain_scores_gemma":[0.9982981,0.0004287309,0.00022791972,0.00034707537,0.00028799858,0.00041018866],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000954527,0.00024603956,0.00037534052,0.00021450683,0.00040277376,0.00016079628,0.00035561147,0.00010220346,0.005745787],"category_scores_gemma":[0.00015128961,0.00016025806,0.0002313423,0.0002497691,0.00012840607,0.0002054265,0.000055415854,0.00079744036,0.0004091683],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026818542,0.00046617648,0.1477478,0.00029789866,0.0003187779,0.0002361453,0.011277405,0.0000045263905,0.09807326,0.00008631071,0.7236621,0.015147779],"study_design_scores_gemma":[0.009338715,0.0016904433,0.011960422,0.0005312802,0.00022268348,0.0013930826,0.0035549186,0.0010206838,0.2678585,0.0008638557,0.7009125,0.0006529536],"about_ca_topic_score_codex":0.000061544415,"about_ca_topic_score_gemma":0.00003813077,"teacher_disagreement_score":0.16978525,"about_ca_system_score_codex":0.00036329706,"about_ca_system_score_gemma":0.0002743254,"threshold_uncertainty_score":0.9951631},"labels":[],"label_agreement":null},{"id":"W2032037224","doi":"10.1038/sj.onc.1203685","title":"Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis","year":2000,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Montréal; Université de Montréal; McGill University; Jewish General Hospital","funders":"Medical Research Council","keywords":"Autocrine signalling; Neuregulin; Paracrine signalling; Biology; Angiogenesis; Cancer research; Receptor tyrosine kinase; ErbB; Neuregulin 1; Vascular endothelial growth factor; ERBB3; Cancer cell; Growth factor; Endocrinology; Internal medicine; Receptor; Cell biology; Cancer; Signal transduction; Medicine","score_opus":0.02377665788304897,"score_gpt":0.3135931693418926,"score_spread":0.28981651145884363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032037224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930798,0.005002748,0.000016889797,0.0003676006,0.00006951838,0.00062261,0.00012406232,0.000060713977,0.00065604574],"genre_scores_gemma":[0.9923871,0.0048618224,0.00050746376,0.00014706078,0.0003123922,0.0000954344,0.000020113752,0.00006245675,0.0016061527],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981823,0.00012264901,0.00027398858,0.00049598736,0.00044453808,0.00048051952],"domain_scores_gemma":[0.99925977,0.00010770026,0.00003897876,0.00023433645,0.00012931225,0.00022992633],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021438228,0.00023217291,0.00039815277,0.00017763358,0.00006782236,0.000030658,0.00010519276,0.00017594484,0.0040647467],"category_scores_gemma":[0.000042314678,0.00021224197,0.00011028502,0.00045657685,0.000105978026,0.00008620059,0.00003265316,0.00018274711,0.000071842325],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046255422,0.00018507194,0.073559515,0.00018816597,0.00016739377,0.000066648936,0.0006147873,0.00025926263,0.8311035,0.0000067370775,0.00028450473,0.09310185],"study_design_scores_gemma":[0.003623352,0.00048282318,0.15500472,0.0002818748,0.00010564306,0.000028623626,0.000047546582,0.0024986335,0.8279105,0.0001349231,0.009500406,0.0003809826],"about_ca_topic_score_codex":0.002822018,"about_ca_topic_score_gemma":0.0003492321,"teacher_disagreement_score":0.09272087,"about_ca_system_score_codex":0.00036479655,"about_ca_system_score_gemma":0.00027397377,"threshold_uncertainty_score":0.99684566},"labels":[],"label_agreement":null},{"id":"W2032199025","doi":"10.2174/1568009023333926","title":"Mutant Epidermal Growth Factor Receptors as Targets for Cancer Therapy","year":2002,"lang":"en","type":"review","venue":"Current Cancer Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Receptor; Epidermal growth factor receptor; Epidermal growth factor; Cancer research; Extracellular; Biology; Tyrosine kinase; Epitope; Cancer; Receptor tyrosine kinase; Cancer cell; Mutant; Growth factor receptor; Mutation; Growth factor receptor inhibitor; Antibody; Cell biology; Immunology; Biochemistry; Genetics; Gene","score_opus":0.1673419595737975,"score_gpt":0.45933838070023336,"score_spread":0.29199642112643587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032199025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004072738,0.97253066,0.00003859626,0.0013877968,0.013688733,0.008563158,0.0029452178,0.00028058555,0.00052452256],"genre_scores_gemma":[0.00003446104,0.9745407,0.00014735955,0.00035086562,0.00643283,0.012565389,0.0007473466,0.0005821708,0.0045988397],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914201,0.00045578048,0.0018537529,0.0021799747,0.0017381926,0.0023522386],"domain_scores_gemma":[0.9950316,0.0005784906,0.00097423396,0.0012332166,0.0009497646,0.0012327126],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006487587,0.001786817,0.0048086112,0.0007336297,0.0003696609,0.00012200729,0.0011111015,0.0006787755,0.015174318],"category_scores_gemma":[0.00046521972,0.0013875364,0.002107522,0.0010207915,0.00034278003,0.00022570549,0.00023828626,0.0023775122,0.0005379965],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011578918,0.00031793144,0.00013955518,0.03265094,0.0007627598,0.00004061937,0.0004412232,7.320617e-7,0.0000049696296,0.000032314187,0.16758469,0.7979085],"study_design_scores_gemma":[0.001950321,0.00023175181,0.000014921014,0.026643394,0.00078290555,0.00003705114,0.00001823144,0.000029288247,0.0003478258,0.000062571424,0.9685433,0.001338427],"about_ca_topic_score_codex":0.000868723,"about_ca_topic_score_gemma":0.00011962255,"teacher_disagreement_score":0.80095863,"about_ca_system_score_codex":0.003578826,"about_ca_system_score_gemma":0.0046423967,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W2032699899","doi":"10.1158/0008-5472.sabcs-4058","title":"Combination effects of herceptin, pertuzumab and bevacizumab in a HER2-overexpressing breast cancer xenograft model.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Bevacizumab; Breast cancer; Metastatic breast cancer; Combination therapy; Metastasis; Internal medicine; Chemotherapy; Oncology; Cancer; Pharmacology; Cancer research","score_opus":0.06386456340538994,"score_gpt":0.4504525453210939,"score_spread":0.386587981915704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032699899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484284,0.0060866443,0.000054506952,0.005930121,0.00006805172,0.0013635112,0.0000389885,0.000039614853,0.0015757267],"genre_scores_gemma":[0.99388313,0.0041866507,0.00020184032,0.0002199887,0.00014730023,0.00036679037,0.000007686404,0.000048741225,0.0009378624],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961955,0.00032906362,0.0003999172,0.00060644775,0.0015571356,0.0009119355],"domain_scores_gemma":[0.99814165,0.00022357087,0.00007107191,0.0004940932,0.0007304512,0.0003391472],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010802712,0.00022320078,0.0005282762,0.00068003585,0.0001474067,0.000065484586,0.00026672517,0.0002087416,0.00027341273],"category_scores_gemma":[0.00025299098,0.00020591395,0.000073152056,0.0011089679,0.00040761306,0.0002081816,0.00014456069,0.0011038375,0.0000070074348],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003113389,0.0011259138,0.033378135,0.004032788,0.000096766,0.00019704638,0.005540428,0.0006166189,0.50047183,0.00057266664,0.006838366,0.44401607],"study_design_scores_gemma":[0.026533682,0.003844015,0.7229454,0.019472381,0.00012824526,0.00019922368,0.0012901273,0.07847883,0.1387752,0.005084866,0.0020555982,0.0011924206],"about_ca_topic_score_codex":0.0038429038,"about_ca_topic_score_gemma":0.00033982767,"teacher_disagreement_score":0.68956727,"about_ca_system_score_codex":0.0015412441,"about_ca_system_score_gemma":0.0013484816,"threshold_uncertainty_score":0.8396927},"labels":[],"label_agreement":null},{"id":"W2033053403","doi":"10.1038/sj.onc.1208898","title":"The c-Src tyrosine kinase associates with the catalytic domain of ErbB-2: implications for ErbB-2 mediated signaling and transformation","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Biology; ErbB; Proto-oncogene tyrosine-protein kinase Src; Tyrosine kinase; Transformation (genetics); Receptor tyrosine kinase; Cancer research; Protein kinase domain; Signal transduction; Cell biology; Tyrosine; Genetics; Biochemistry; Gene; Mutant","score_opus":0.02874161291172162,"score_gpt":0.33401668820393904,"score_spread":0.3052750752922174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033053403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91850024,0.002573395,0.001698977,0.0746973,0.000022600461,0.0015046037,0.00017002657,0.000033756198,0.0007990882],"genre_scores_gemma":[0.9979093,0.0003363905,0.0009115027,0.00027620728,0.00014337694,0.00011838142,0.00009324514,0.000023621667,0.0001879842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990451,0.00004534965,0.0002500524,0.00014086922,0.0002625914,0.00025606868],"domain_scores_gemma":[0.99866515,0.00064122875,0.000101465834,0.00026105833,0.00024243175,0.00008868898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087021245,0.000103089726,0.00017881325,0.00004433177,0.00027025398,0.000026687325,0.00012742534,0.000051786537,0.000012232685],"category_scores_gemma":[0.00012519567,0.000054805143,0.000048419242,0.00023345022,0.00018716887,0.00006300326,0.000015297917,0.00012706735,0.000005635597],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010731699,0.00032977795,0.0067969547,0.00041911655,0.00049745553,0.000002690914,0.006289375,0.00015202483,0.8095329,0.0028741015,0.0065398556,0.1654926],"study_design_scores_gemma":[0.013729104,0.0025489053,0.059629817,0.00056421495,0.0009445717,0.00013358086,0.003459199,0.004135249,0.7090529,0.001713786,0.20343107,0.0006575718],"about_ca_topic_score_codex":0.0000558113,"about_ca_topic_score_gemma":0.0004818937,"teacher_disagreement_score":0.19689122,"about_ca_system_score_codex":0.00015113947,"about_ca_system_score_gemma":0.0002215586,"threshold_uncertainty_score":0.22348888},"labels":[],"label_agreement":null},{"id":"W2033475362","doi":"10.1158/0008-5472.sabcs12-s5-6","title":"Abstract S5-6: Activating HER2 mutations in HER2 gene amplification negative breast cancers.","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Biology; Breast cancer; Mutation; Germline mutation; Somatic cell; Cancer research; Genetics; Trastuzumab; Cancer; COLD-PCR; Exon; Gefitinib; Gene; Point mutation; Molecular biology; Epidermal growth factor receptor","score_opus":0.20732919088547383,"score_gpt":0.5058111658886728,"score_spread":0.29848197500319895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033475362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98353225,0.0016608336,0.00005676656,0.00459475,0.0002597065,0.0015744744,0.00012096385,0.00007581655,0.008124439],"genre_scores_gemma":[0.99478406,0.0007015857,0.00046811343,0.00015339644,0.0012243696,0.0014986717,0.000060869006,0.00008949497,0.0010194193],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954707,0.0002473263,0.00048802292,0.00057600054,0.0016430033,0.0015749651],"domain_scores_gemma":[0.997188,0.00054568605,0.00010678776,0.0006567748,0.0008713417,0.0006314395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025777915,0.00023139156,0.00038224782,0.00067386765,0.000321039,0.0000866679,0.00034207906,0.00019936498,0.002573287],"category_scores_gemma":[0.00076748495,0.00022400553,0.000083820705,0.0021109886,0.0004443965,0.00047141252,0.00013849049,0.0017634813,0.00031849113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013300988,0.00093651994,0.30311435,0.0011128252,0.00026493604,0.000105216015,0.013162555,0.0005172682,0.43656638,0.0007092142,0.012505338,0.22967531],"study_design_scores_gemma":[0.0019361696,0.00013601554,0.8656869,0.00079445366,0.000015750533,0.00006166639,0.003715836,0.00020592645,0.11803489,0.00029002505,0.008770095,0.0003522478],"about_ca_topic_score_codex":0.03044012,"about_ca_topic_score_gemma":0.0021361245,"teacher_disagreement_score":0.5625726,"about_ca_system_score_codex":0.005188732,"about_ca_system_score_gemma":0.0026004442,"threshold_uncertainty_score":0.99863017},"labels":[],"label_agreement":null},{"id":"W2034014431","doi":"10.2165/11588350-000000000-00000","title":"Adjuvant Trastuzumab for Breast Cancer","year":2011,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Cancer Centre; Atlantic School of Theology; Cancer Care Nova Scotia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Adjuvant; Quality of Life Research; Medicine; Oncology; Health economics; Internal medicine; Public health; Cancer; Pathology","score_opus":0.1428086307434459,"score_gpt":0.43489554137371356,"score_spread":0.29208691063026765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034014431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.951658,0.0017343957,0.0008799535,0.006279948,0.0022135747,0.0026282738,0.0019186416,0.00022609967,0.03246112],"genre_scores_gemma":[0.9922938,0.0010182732,0.0013873744,0.00243714,0.00088316284,0.0004650306,0.000015524483,0.000071887975,0.00142786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99892545,0.000014585044,0.00025725728,0.00030069047,0.000084034946,0.00041800295],"domain_scores_gemma":[0.9992984,0.00004085813,0.0000594669,0.00021783728,0.0000995288,0.0002839088],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023639014,0.00014392928,0.00028049893,0.0000845444,0.000058182024,0.0000131965435,0.00016497803,0.000054200184,0.0068373973],"category_scores_gemma":[0.000009946561,0.00013873636,0.00012488758,0.000055587952,0.00006933795,0.00009509296,0.00004020196,0.00018832462,0.0001893531],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00455405,0.0007020192,0.047004297,0.00081320724,0.0007242264,0.000049673406,0.0022260298,0.00003212882,0.022400416,0.0011436775,0.13672706,0.7836232],"study_design_scores_gemma":[0.01998586,0.0008736315,0.10507319,0.00023165795,0.0007824557,0.00054921815,0.0004912229,0.018281337,0.22615868,0.0012301117,0.6251389,0.0012037414],"about_ca_topic_score_codex":0.0003014517,"about_ca_topic_score_gemma":0.0000358531,"teacher_disagreement_score":0.78241944,"about_ca_system_score_codex":0.00041308277,"about_ca_system_score_gemma":0.00042350913,"threshold_uncertainty_score":0.9940705},"labels":[],"label_agreement":null},{"id":"W2034281669","doi":"10.1038/sj.onc.1206983","title":"Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression","year":2003,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McMaster University","funders":"Natural Sciences and Engineering Research Council of Canada; U.S. Army","keywords":"Biology; Cancer research; Amphiregulin; Epidermal growth factor receptor; Mammary tumor; Carcinogenesis; ErbB; Oncogene; Tumor progression; Genetically modified mouse; Epidermal growth factor; Metastasis; Transgene; Cancer; Signal transduction; Breast cancer; Receptor; Cell biology; Gene; Cell cycle","score_opus":0.05198894877530207,"score_gpt":0.3542389475828333,"score_spread":0.30224999880753123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034281669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422854,0.0005258387,0.000105870786,0.0017819229,0.00017164175,0.00090605736,0.00003766974,0.000052771185,0.0021897005],"genre_scores_gemma":[0.9963238,0.00028774707,0.0021997038,0.0004265671,0.000104526094,0.00007262051,0.00007222108,0.000045874127,0.000466914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753416,0.0002468071,0.0005198857,0.0004011366,0.0008583873,0.00043961065],"domain_scores_gemma":[0.9987761,0.00014780433,0.00017736274,0.00039695096,0.00026720576,0.00023457067],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005707768,0.00019707596,0.00041547857,0.0002995986,0.000037042402,0.000012926625,0.0001591701,0.00016214026,0.0010717071],"category_scores_gemma":[0.0008868454,0.00017249625,0.00008291966,0.0006088203,0.00007700079,0.00015472285,0.00006576032,0.00037665054,0.000079867925],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038537616,0.0004986155,0.17220005,0.00039545746,0.000047270674,0.00008880554,0.0005112504,0.0000010842799,0.81396514,0.000067824316,0.003134219,0.008704914],"study_design_scores_gemma":[0.002578163,0.00044499637,0.02195371,0.0004809076,0.000010782447,0.000014884644,0.00013022848,0.00008615013,0.96839666,0.000075547556,0.0056505697,0.00017740637],"about_ca_topic_score_codex":0.00017261268,"about_ca_topic_score_gemma":0.000026270855,"teacher_disagreement_score":0.15443152,"about_ca_system_score_codex":0.0004861556,"about_ca_system_score_gemma":0.00072507915,"threshold_uncertainty_score":0.99984145},"labels":[],"label_agreement":null},{"id":"W2034398380","doi":"10.1038/modpathol.3800774","title":"Standardization of HER2 testing: results of an international proficiency-testing ring study","year":2007,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunohistochemistry; Medicine; Breast cancer; Pathology; Fish <Actinopterygii>; Anatomical pathology; Cancer; Internal medicine; Oncology; Biology","score_opus":0.13295152696789742,"score_gpt":0.4354257715679868,"score_spread":0.30247424460008937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034398380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513432,0.000024253028,0.035583444,0.000056766858,0.0001301378,0.00047872696,0.000024712243,0.000042436583,0.012316343],"genre_scores_gemma":[0.9857934,0.0000012364893,0.013963839,0.000017969001,0.00009664476,0.00000890292,0.000013993954,0.00001965165,0.000084367784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99818254,0.00010264874,0.00056560274,0.0003278479,0.00056758424,0.00025379914],"domain_scores_gemma":[0.9983017,0.00023755534,0.0002089958,0.00036004864,0.00081750826,0.000074192016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026747966,0.00009113526,0.00025381334,0.00023927465,0.00003836461,0.000005416376,0.00017808728,0.00007409606,0.0000082108345],"category_scores_gemma":[0.003623521,0.00008575116,0.000023212631,0.00035121007,0.0001229052,0.00006984394,0.00009579582,0.00019236267,0.0000015078058],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010354003,0.0012362314,0.5643208,0.00011436974,0.000026938276,0.0005510318,0.0055716275,0.0035213279,0.28122118,0.000059249283,0.000006673473,0.14233513],"study_design_scores_gemma":[0.0049900063,0.0057265842,0.8718441,0.00023245903,0.00004599367,0.0002825855,0.0011570188,0.044670716,0.07035835,0.00044403368,0.00008167997,0.00016643711],"about_ca_topic_score_codex":0.000120521174,"about_ca_topic_score_gemma":0.000062036794,"teacher_disagreement_score":0.3075233,"about_ca_system_score_codex":0.00011059284,"about_ca_system_score_gemma":0.00020607914,"threshold_uncertainty_score":0.43379548},"labels":[],"label_agreement":null},{"id":"W2034827497","doi":"10.3747/co.19.1049","title":"Future of Personalized Medicine in Non-Small-Cell Lung Cancer","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Lung cancer; Personalized medicine; Clinical trial; Targeted therapy; Bioinformatics; ErbB; Precision medicine; Cancer research; Computational biology; Cancer; Oncology; Pathology; Internal medicine; Biology","score_opus":0.14506551953330715,"score_gpt":0.49732441473731803,"score_spread":0.3522588952040109,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034827497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8485503,0.12546179,0.0000715259,0.006822348,0.0043356195,0.000937607,0.000014200957,0.000022619677,0.013783962],"genre_scores_gemma":[0.9827697,0.010920552,0.00024111927,0.00035173484,0.0043971036,0.00028004945,0.000029913983,0.000036945472,0.0009728638],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829894,0.00015019283,0.00038925302,0.00023120464,0.0003544132,0.00057601853],"domain_scores_gemma":[0.99900466,0.00014869707,0.00012244002,0.00026118424,0.0001710394,0.00029195426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007608153,0.00015780845,0.0006239816,0.00024667798,0.000023144956,0.0000013721527,0.00016306763,0.00018762884,0.0029747684],"category_scores_gemma":[0.000086891276,0.00012273189,0.000072965435,0.0003931999,0.0002482973,0.00003945441,0.00007818056,0.0006477814,0.000024764286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038076678,0.0010707517,0.81937677,0.0018730031,0.000044092474,0.000023848383,0.00787045,0.0000012171542,0.0060819127,0.00024386198,0.065843485,0.09718984],"study_design_scores_gemma":[0.009157543,0.0007154651,0.14854409,0.00083029794,0.00017254437,0.000031204367,0.0018379345,0.0003414843,0.0014255752,0.000016540896,0.8367459,0.00018143519],"about_ca_topic_score_codex":0.00028220192,"about_ca_topic_score_gemma":0.00014833285,"teacher_disagreement_score":0.7709024,"about_ca_system_score_codex":0.00073435664,"about_ca_system_score_gemma":0.0006386758,"threshold_uncertainty_score":0.99793667},"labels":[],"label_agreement":null},{"id":"W2034917939","doi":"10.1111/his.12336","title":"Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma <i>in situ</i>","year":2013,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Government of Ontario","keywords":"Tissue microarray; Ductal carcinoma; Biomarker; In situ; Breast cancer; Biomarker discovery; DNA microarray; Immunohistochemistry; Computational biology; Cancer; Oncology; Pathology; Biology; Computer science; Medicine; Internal medicine; Chemistry; Proteomics","score_opus":0.08097265473608932,"score_gpt":0.35776919644008653,"score_spread":0.2767965417039972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2034917939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9021976,0.0013013316,0.028917724,0.005145341,0.0004520324,0.0091711,0.0000684298,0.00011057951,0.052635867],"genre_scores_gemma":[0.8657023,0.000017633296,0.12253255,0.0014093013,0.00031723228,0.0033534844,0.00005966712,0.00013954594,0.0064682965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958073,0.0001722254,0.0005924586,0.0013700235,0.0005032035,0.0015547918],"domain_scores_gemma":[0.99774694,0.0002576534,0.000059065293,0.0008246128,0.00039498537,0.0007167379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019777084,0.00036262415,0.0008267216,0.001151111,0.00024911494,0.000071684,0.0004297811,0.0003741886,0.00016515533],"category_scores_gemma":[0.00038576793,0.0003697535,0.000057670204,0.0009164192,0.0004464904,0.0000908839,0.00044804497,0.00067159394,0.0004117758],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005919955,0.0003577011,0.00060273224,0.00027800945,0.0000063841753,0.000095812036,0.0035335352,0.000030671657,0.9508488,0.0006045775,0.037862517,0.005187218],"study_design_scores_gemma":[0.010521607,0.005344544,0.03353078,0.00028656938,0.00008011555,0.0030715324,0.006156531,0.0007125091,0.37281096,0.00013327292,0.56581414,0.0015374128],"about_ca_topic_score_codex":0.0009218127,"about_ca_topic_score_gemma":0.00012300722,"teacher_disagreement_score":0.57803786,"about_ca_system_score_codex":0.00042455117,"about_ca_system_score_gemma":0.00037003105,"threshold_uncertainty_score":0.9998754},"labels":[],"label_agreement":null},{"id":"W2035064666","doi":"10.1038/onc.2012.283","title":"Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs","year":2012,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Institutes of Health; Canadian Institutes of Health Research; Fondation du cancer du sein du Québec","keywords":"In vivo; Trastuzumab; Cytotoxicity; Doxorubicin; Pharmacology; Cancer research; Monoclonal antibody; Metastasis; Antibody-drug conjugate; Metastatic breast cancer; Biology; Cancer; Breast cancer; In vitro; Chemotherapy; Antibody; Immunology","score_opus":0.030106146075399257,"score_gpt":0.35764700341101024,"score_spread":0.327540857335611,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035064666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917623,0.0029483247,0.000011142587,0.0016582577,0.00006172304,0.0010203077,0.00019679753,0.000026570426,0.0023145864],"genre_scores_gemma":[0.99461293,0.00043987972,0.0012729343,0.00056443387,0.00021505241,0.00048221252,0.000011404482,0.00007499812,0.002326136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982502,0.00008833389,0.00032334882,0.00031460435,0.0004356661,0.0005878384],"domain_scores_gemma":[0.99894404,0.000031564006,0.00007153812,0.0004363786,0.00014530057,0.00037115664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027264055,0.00024617102,0.0005334458,0.00014135863,0.000018882009,0.000008447001,0.00008742975,0.000087572385,0.008822821],"category_scores_gemma":[0.000003647334,0.00017918172,0.00008109747,0.00050777226,0.00006289299,0.000064764274,0.000036260466,0.00012034234,0.00003899911],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045863613,0.0014751878,0.031677946,0.00025410368,0.00033383985,0.000029475259,0.005333276,0.00001696574,0.9063786,0.0000011843708,0.0004886174,0.049424425],"study_design_scores_gemma":[0.005889897,0.0012251514,0.009958629,0.00036597284,0.0003411939,0.000057982943,0.00067903893,0.00010481813,0.9745948,7.8885563e-7,0.0065152324,0.00026653046],"about_ca_topic_score_codex":0.004470352,"about_ca_topic_score_gemma":0.0010084473,"teacher_disagreement_score":0.068216145,"about_ca_system_score_codex":0.0013350527,"about_ca_system_score_gemma":0.0004351665,"threshold_uncertainty_score":0.99208325},"labels":[],"label_agreement":null},{"id":"W2035214881","doi":"10.3111/13696998.2014.979938","title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","year":2014,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; Ottawa Hospital; Roche (Canada)","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Neoadjuvant therapy; Inflammatory breast cancer; Cancer","score_opus":0.024272920471406934,"score_gpt":0.34425611307015447,"score_spread":0.3199831925987475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035214881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938768,0.0006126849,0.001214225,0.003320165,0.00021187722,0.00059934653,0.00013300429,0.0000022849456,0.000029595662],"genre_scores_gemma":[0.9947027,0.0044027837,0.00015020491,0.00045053795,0.00019933796,0.000052071842,0.0000037575207,0.00002735978,0.000011252718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978677,0.00016711326,0.00086526433,0.00022861957,0.00054045237,0.00033082048],"domain_scores_gemma":[0.9973892,0.0011500838,0.00039959676,0.000171605,0.000356778,0.00053271325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018830914,0.00017305868,0.0011229481,0.00032590426,0.000032116,0.000016670068,0.00024332729,0.0001428619,0.0002742638],"category_scores_gemma":[0.00038647937,0.0001268817,0.00016908863,0.00024822922,0.00016046688,0.00011056827,0.0000364499,0.00048301189,2.3460112e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010872399,0.00019272762,0.19124466,0.00023860276,0.0017463185,0.0001173548,0.00045283025,0.004465755,0.00013843967,0.00008002468,0.00010830066,0.79034257],"study_design_scores_gemma":[0.014095132,0.0021825947,0.92369646,0.0012404437,0.00038630178,0.0003141745,0.00059858704,0.053156465,0.00076902745,0.00005262251,0.003274414,0.0002337756],"about_ca_topic_score_codex":0.138711,"about_ca_topic_score_gemma":0.5153628,"teacher_disagreement_score":0.7901088,"about_ca_system_score_codex":0.0021892237,"about_ca_system_score_gemma":0.009132836,"threshold_uncertainty_score":0.99648446},"labels":[],"label_agreement":null},{"id":"W2035360235","doi":"10.1016/j.ctrv.2006.01.005","title":"Trastuzumab after primary treatment for early stage HER2-positive breast cancer reduces recurrence","year":2006,"lang":"en","type":"article","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Adjuvant; Internal medicine; Chemotherapy; Stage (stratigraphy); Metastatic breast cancer; Monoclonal antibody; Cancer; Antibody; Immunology","score_opus":0.06632819832425466,"score_gpt":0.4043932864000384,"score_spread":0.3380650880757837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035360235","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47394997,0.49153888,0.00008243247,0.005135572,0.0008629719,0.014920123,0.0061933547,0.00016556769,0.0071511306],"genre_scores_gemma":[0.29041955,0.5820333,0.0016838106,0.0008622535,0.003164763,0.06766719,0.00071411446,0.00023852328,0.0532165],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666524,0.0001806667,0.00077097554,0.0010454166,0.00044579897,0.000891921],"domain_scores_gemma":[0.9983466,0.00010601426,0.00027013355,0.0006997672,0.00023233512,0.00034514873],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022912235,0.0006912529,0.0013737868,0.00014396431,0.00016658974,0.00007896041,0.00017318486,0.00015017927,0.0014964868],"category_scores_gemma":[0.000009932557,0.00046285533,0.0006019143,0.0003934772,0.00019220512,0.0001757064,0.000031652267,0.0001602013,0.0001073484],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019449609,0.0015250278,0.049471717,0.00081126945,0.0004384781,0.0001146462,0.00066282594,0.0000060209913,0.0007766204,0.00002088073,0.011121812,0.93310577],"study_design_scores_gemma":[0.0052924203,0.0030613097,0.17517713,0.0026952273,0.00091937475,0.00004043868,0.00003555267,0.0000119540455,0.008060314,0.000021178623,0.8041495,0.00053558557],"about_ca_topic_score_codex":0.013849682,"about_ca_topic_score_gemma":0.0021059655,"teacher_disagreement_score":0.93257016,"about_ca_system_score_codex":0.008277643,"about_ca_system_score_gemma":0.0013762275,"threshold_uncertainty_score":0.9997823},"labels":[],"label_agreement":null},{"id":"W2035903801","doi":"10.1007/s10549-007-9887-y","title":"New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up","year":2008,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Breast Cancer Research Alliance; Sanofi; Breast Cancer Alliance","keywords":"Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Fluorescence in situ hybridization; Population; Cancer; Medicine; Cohort; Trastuzumab; Fish <Actinopterygii>; Pathology; Biology; Gene; Genetics","score_opus":0.05632076209097779,"score_gpt":0.43925768052665604,"score_spread":0.38293691843567823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2035903801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536276,0.00036570325,0.00017901548,0.0012902144,0.00003582804,0.0017634113,0.00057235576,0.00004128481,0.00038943553],"genre_scores_gemma":[0.9951441,0.0005390083,0.00039282948,0.0000968208,0.00012666178,0.0006201213,0.00039722107,0.000051638366,0.0026315914],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99592924,0.00019620471,0.0003914387,0.0007373308,0.0018745053,0.0008712536],"domain_scores_gemma":[0.9970303,0.00018866395,0.00008117336,0.00073857716,0.0007313478,0.0012299345],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048812092,0.00029255054,0.0008348611,0.0008493446,0.0002773301,0.000049590853,0.0001708639,0.000101429825,0.0028975164],"category_scores_gemma":[0.000048102298,0.00021712316,0.00018952509,0.002642064,0.00015868443,0.00008817285,0.00007506814,0.0002352664,0.00005573132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006066364,0.00074681366,0.97977835,0.00010138272,0.0032535095,0.0004868909,0.00020603486,0.000023311479,0.00016357252,0.000016092532,0.00118118,0.0079765245],"study_design_scores_gemma":[0.007433429,0.0011437131,0.9879902,0.00031665928,0.00081980973,0.0001069598,0.000033592696,0.00008769151,0.0016649592,0.0000068643285,0.00021729432,0.00017884815],"about_ca_topic_score_codex":0.13935672,"about_ca_topic_score_gemma":0.030685391,"teacher_disagreement_score":0.10867132,"about_ca_system_score_codex":0.0014743191,"about_ca_system_score_gemma":0.0022494777,"threshold_uncertainty_score":0.998014},"labels":[],"label_agreement":null},{"id":"W2037737356","doi":"10.1158/0008-5472.can-11-3513","title":"Uncoupling of PI3K from ErbB3 Impairs Mammary Gland Development but Does Not Impact on ErbB2-Induced Mammary Tumorigenesis","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Mammary gland; Carcinogenesis; ERBB3; Cancer; PI3K/AKT/mTOR pathway; Internal medicine; Cancer research; Biology; Endocrinology; Medicine; Breast cancer; Cell biology; Signal transduction; Epidermal growth factor receptor","score_opus":0.13422335716945008,"score_gpt":0.4469408649623257,"score_spread":0.31271750779287566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037737356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919712,0.0027468663,0.00011595851,0.0015894794,0.0006189011,0.0012049085,0.00016047228,0.00009408781,0.0014981461],"genre_scores_gemma":[0.9932195,0.001295076,0.0011190149,0.00017327862,0.0013556993,0.0005369624,0.000060148253,0.00011782944,0.0021224997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99301785,0.00035881082,0.0007302506,0.0007893873,0.003101897,0.002001776],"domain_scores_gemma":[0.9955747,0.0008882962,0.0001380319,0.0013770066,0.0008204212,0.001201537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034722812,0.00043208967,0.0008255499,0.000790168,0.0002961731,0.00009123784,0.0008687382,0.0002936111,0.0011862569],"category_scores_gemma":[0.00046734037,0.00029728079,0.00022944922,0.001031453,0.0002226735,0.00033384797,0.000585952,0.0014121496,0.00019595852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032564595,0.00071160746,0.2262598,0.00094723934,0.0007436349,0.00026441802,0.0024176997,0.000021689544,0.6675004,0.00011038583,0.0048337528,0.09293291],"study_design_scores_gemma":[0.001832088,0.0006235827,0.21565937,0.0008275213,0.000031995583,0.000015056983,0.00037567844,0.00009768569,0.7749468,0.00009212064,0.0051232167,0.00037487363],"about_ca_topic_score_codex":0.008829351,"about_ca_topic_score_gemma":0.00025605605,"teacher_disagreement_score":0.10744641,"about_ca_system_score_codex":0.002926534,"about_ca_system_score_gemma":0.004849358,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W2038780142","doi":"10.1016/j.ejca.2015.02.005","title":"Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer","year":2015,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline","keywords":"Medicine; Minimal clinically important difference; Quality of life (healthcare); Lapatinib; Placebo; Breast cancer; Discontinuation; SF-36; Randomized controlled trial; Internal medicine; Physical therapy; Adverse effect; Cancer; Health related quality of life; Disease; Alternative medicine","score_opus":0.09232333326504484,"score_gpt":0.4008121555903717,"score_spread":0.3084888223253269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2038780142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936742,0.002172035,0.000010051433,0.001166592,0.0003245349,0.0015589356,0.00018181559,0.000010904081,0.0009009281],"genre_scores_gemma":[0.9986515,0.00044012483,0.00009931056,0.000091634414,0.00033582526,0.00003744605,0.0000027479373,0.00008276202,0.00025863657],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877687,0.005707784,0.0041269073,0.00027157026,0.0014628047,0.0006622377],"domain_scores_gemma":[0.9938034,0.0005223629,0.003686737,0.00030881437,0.0009247441,0.00075398467],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01585239,0.00026073493,0.0029233657,0.000520531,0.00002568544,0.000014757889,0.00033295396,0.00007749933,0.0006465787],"category_scores_gemma":[0.003489321,0.00020442414,0.00029934067,0.00043472016,0.00023784717,0.00019850656,0.00007254731,0.0009934782,0.0000011859387],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80764824,0.00085054245,0.14349452,0.0008131264,0.00050185906,0.0000667301,0.021513646,0.00028315917,0.016391605,0.000013329624,0.0009370564,0.0074861986],"study_design_scores_gemma":[0.67160183,0.002602907,0.3206353,0.0024761152,0.000033930763,0.0000060302737,0.0010906919,0.00003956471,0.0010632331,0.000009932566,0.00026535644,0.00017514329],"about_ca_topic_score_codex":0.00998591,"about_ca_topic_score_gemma":0.00047116823,"teacher_disagreement_score":0.17714079,"about_ca_system_score_codex":0.001644889,"about_ca_system_score_gemma":0.0041221203,"threshold_uncertainty_score":0.9966067},"labels":[],"label_agreement":null},{"id":"W2040371382","doi":"10.2967/jnumed.109.069716","title":"Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize <i>HER2</i>-Amplified Human Breast Cancer Cells to the Auger Electron–Emitting Radiotherapeutic Agent <sup>111</sup>In-NLS-Trastuzumab","year":2010,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; McMaster University; University of Toronto","funders":"Cancer Research UK; Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; Doxorubicin; Chemistry; Methotrexate; Cancer research; Molecular biology; Cancer; Breast cancer; Chemotherapy; Medicine; Internal medicine; Biology","score_opus":0.025095790872974363,"score_gpt":0.3553990813217046,"score_spread":0.33030329044873025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040371382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93495893,0.0019693007,0.00003633691,0.06041395,0.00056399417,0.0007668407,0.0000118450625,0.00003364481,0.0012451324],"genre_scores_gemma":[0.9839045,0.001163696,0.0011326259,0.009672887,0.0034624548,0.000011035806,0.0000018557579,0.00014715714,0.0005038138],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956883,0.00040585996,0.0011744692,0.00046982028,0.0013401409,0.00092138746],"domain_scores_gemma":[0.99725676,0.00044569594,0.00042470603,0.0006362708,0.00044014663,0.00079643686],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004052325,0.0004107635,0.0011569929,0.0005598843,0.00023986034,0.00006278486,0.00045119194,0.00021749397,0.0015377355],"category_scores_gemma":[0.000313039,0.0002578248,0.00018083912,0.0007252518,0.00042916494,0.00013055086,0.00009012776,0.0026562796,0.00002782099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011968964,0.00022902558,0.0023259108,0.00020889941,0.0003909823,0.00061084644,0.007340393,0.00010208142,0.9192945,0.00015646951,0.046201363,0.02194264],"study_design_scores_gemma":[0.02771456,0.010596599,0.19251299,0.006248696,0.0017267894,0.018837303,0.010392508,0.0027359403,0.026561007,0.0004596409,0.7006868,0.0015271584],"about_ca_topic_score_codex":0.0006880333,"about_ca_topic_score_gemma":0.00018618764,"teacher_disagreement_score":0.8927335,"about_ca_system_score_codex":0.00054913515,"about_ca_system_score_gemma":0.00037093824,"threshold_uncertainty_score":0.9999874},"labels":[],"label_agreement":null},{"id":"W2041576667","doi":"10.1073/pnas.97.7.3444","title":"Amplification of the <i>neu/erbB-2</i> oncogene in a mouse model of mammary tumorigenesis","year":2000,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Cancer Institute","keywords":"Mammary gland; Carcinogenesis; Biology; Genetically modified mouse; Mouse mammary tumor virus; Endogeny; Mammary tumor; Cancer research; ErbB; Oncogene; HER2/neu; Transgene; Gene; Breast cancer; Endocrinology; Cancer; Cell cycle; Genetics","score_opus":0.09758280350511378,"score_gpt":0.36622042648022635,"score_spread":0.26863762297511257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041576667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866522,0.00018976092,0.0000020609134,0.0058264737,0.00000690154,0.00035004667,0.00002765585,0.0000048744414,0.006940041],"genre_scores_gemma":[0.99674857,0.00028941678,0.0017555427,0.00022219786,0.000029248074,0.000015721313,1.03021065e-7,0.0000051757693,0.00093405653],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972823,0.000011336008,0.00048838754,0.00021323007,0.001851269,0.00015347847],"domain_scores_gemma":[0.99911594,0.00008588628,0.00033861343,0.000028074473,0.00039540845,0.00003605124],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017288674,0.000078185454,0.00021379514,0.00018750774,0.00006394842,0.0000059866325,0.00095652876,0.00007586873,0.00002646073],"category_scores_gemma":[0.00040720013,0.00004718921,0.000090584945,0.0012399235,0.0008582688,0.00020795614,0.00010676108,0.00018180169,7.399129e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006136797,0.00012689819,0.013506962,0.00022158712,0.00000960216,3.5163943e-9,0.00034442847,0.001101265,0.97680855,0.0055444944,0.0002654222,0.0020093936],"study_design_scores_gemma":[0.0002712555,0.000053012667,0.038543917,0.0002307118,0.000010340853,0.0000036852812,0.00009377769,0.00865054,0.9412815,0.010751274,0.000063571635,0.000046407615],"about_ca_topic_score_codex":0.00004794126,"about_ca_topic_score_gemma":4.129134e-7,"teacher_disagreement_score":0.03552707,"about_ca_system_score_codex":0.000083384235,"about_ca_system_score_gemma":0.00025997285,"threshold_uncertainty_score":0.3162327},"labels":[],"label_agreement":null},{"id":"W2041762805","doi":"10.1371/journal.pone.0071987","title":"Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Alberta Innovates; Terry Fox Research Institute","keywords":"Epithelial–mesenchymal transition; Trastuzumab; CD44; Mesenchymal stem cell; Cancer research; Lapatinib; Breast cancer; Phenotype; Biology; Cancer cell; Cancer; Immunology; Cell; Metastasis; Cell biology; Genetics; Gene","score_opus":0.025350801212130927,"score_gpt":0.2765852262329153,"score_spread":0.2512344250207844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041762805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9689348,0.0016123339,0.000011068221,0.026718238,0.00003719467,0.0014180905,0.00017855922,0.000054479948,0.0010352453],"genre_scores_gemma":[0.9938961,0.0005586895,0.0016011329,0.0010325114,0.00036319622,0.0004560948,0.00001651451,0.00004884153,0.0020268837],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99797094,0.00013356074,0.00028162214,0.00043923198,0.00066361664,0.0005110248],"domain_scores_gemma":[0.9989983,0.00010065554,0.000040506777,0.0002653661,0.0002989322,0.0002962633],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022550212,0.00020662666,0.00043274267,0.00019165323,0.00007589475,0.000046234647,0.00010516903,0.00011540405,0.0012719324],"category_scores_gemma":[0.00005125599,0.00019052361,0.00004059089,0.00037269594,0.00014237886,0.00013809961,0.000028898246,0.0003693017,0.00012140837],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003912153,0.0021187593,0.015985647,0.0009362947,0.000468527,0.0020058374,0.013402107,0.0000058551364,0.94726884,0.000052893953,0.0012001562,0.012642917],"study_design_scores_gemma":[0.0044684107,0.0014073962,0.8783162,0.006543888,0.00023496702,0.00069569837,0.0023068718,0.0004005192,0.10380134,0.00050743675,0.00050379167,0.00081343163],"about_ca_topic_score_codex":0.0032273042,"about_ca_topic_score_gemma":0.0033695656,"teacher_disagreement_score":0.8623306,"about_ca_system_score_codex":0.000385107,"about_ca_system_score_gemma":0.00018929558,"threshold_uncertainty_score":0.99964106},"labels":[],"label_agreement":null},{"id":"W2042012206","doi":"10.1007/s12282-015-0587-x","title":"HER2-directed therapy: current treatment options for HER2-positive breast cancer","year":2015,"lang":"en","type":"review","venue":"Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Surgical oncology; Oncology; Targeted therapy; Cancer; Internal medicine; Metastatic breast cancer","score_opus":0.17407789079844727,"score_gpt":0.4954471902524908,"score_spread":0.3213692994540435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042012206","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010192227,0.9555372,0.000016577618,0.0024230268,0.0017834476,0.0077930433,0.031435832,0.00030753104,0.0006931676],"genre_scores_gemma":[0.0000132629875,0.96487844,0.00013166666,0.00014703863,0.004855835,0.023237927,0.0014086381,0.00039846622,0.0049287137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947756,0.0003879397,0.0009676658,0.0014500606,0.001089734,0.00132902],"domain_scores_gemma":[0.9956083,0.0002074508,0.00047975066,0.0010987864,0.0016179378,0.000987723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004474757,0.0012542446,0.0033731693,0.00043979095,0.00023502849,0.00011166331,0.0004723756,0.00057190476,0.003273701],"category_scores_gemma":[0.000022514167,0.0008962456,0.0012836665,0.0010230636,0.00027612702,0.000116151175,0.00011581335,0.00084371644,0.000200162],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00053039344,0.0008180889,0.00010818719,0.0067653,0.0015996649,0.000027134703,0.00015182466,0.0000032426365,0.0000013020522,0.000027770375,0.03667679,0.9532903],"study_design_scores_gemma":[0.0030801964,0.00038691674,0.0008518751,0.029136118,0.0022322948,0.00072237157,0.000024185172,0.00003098027,0.000004459067,0.000014415316,0.9627163,0.000799878],"about_ca_topic_score_codex":0.00727214,"about_ca_topic_score_gemma":0.00095024344,"teacher_disagreement_score":0.95249045,"about_ca_system_score_codex":0.009578917,"about_ca_system_score_gemma":0.01212217,"threshold_uncertainty_score":0.9993488},"labels":[],"label_agreement":null},{"id":"W2042147906","doi":"10.1097/01.pap.0000184177.65919.5e","title":"Prognostic and Predictive Molecular Markers in DCIS","year":2005,"lang":"en","type":"review","venue":"Advances in Anatomic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Ductal carcinoma; Medicine; Breast cancer; Oncology; Mammography; Angiogenesis; Extracellular matrix; Cancer; Internal medicine; Pathology; Bioinformatics; Biology","score_opus":0.027658947053845168,"score_gpt":0.4261770229758327,"score_spread":0.3985180759219875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042147906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005707655,0.99349314,0.00006598813,0.000082576335,0.00019211712,0.0019722322,0.000057622565,0.00002989199,0.0035356602],"genre_scores_gemma":[0.0010964207,0.99690115,0.00085819705,0.00013628467,0.000086802,0.00069826265,0.00007167628,0.00007257749,0.00007863317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969511,0.0005202963,0.0007338299,0.0008679283,0.00027017956,0.0006566726],"domain_scores_gemma":[0.99872005,0.00044094335,0.00017911123,0.00046168463,0.000042465286,0.00015573144],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007106168,0.00040507884,0.0019098418,0.0009011009,0.000018780005,0.000008352966,0.00025167115,0.0005073399,0.000062888015],"category_scores_gemma":[0.0007529868,0.0003616801,0.00013966656,0.00068445504,0.00046648885,0.00010500539,0.00017614753,0.0013178618,0.00003677811],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006151321,0.000070249516,0.002270792,0.0061218766,0.00002742424,0.0049709766,0.000060138194,0.000004506164,0.0000012151471,0.000099481564,0.00004016129,0.9862717],"study_design_scores_gemma":[0.0010406156,0.00033797804,0.00070194347,0.013610207,0.00020250573,0.0015895336,0.000053601947,0.00010036403,0.0000015444532,0.00039007433,0.9816475,0.0003241697],"about_ca_topic_score_codex":0.00001154715,"about_ca_topic_score_gemma":0.00009156503,"teacher_disagreement_score":0.9859475,"about_ca_system_score_codex":0.00069822086,"about_ca_system_score_gemma":0.0005897856,"threshold_uncertainty_score":0.99988353},"labels":[],"label_agreement":null},{"id":"W2042702856","doi":"10.1002/cncr.20418","title":"The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma","year":2004,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":159,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Regional Laboratory Medicine Program","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Odds ratio; Retrospective cohort study; Breast carcinoma; Confidence interval; Lymph node; Metastatic breast cancer; Cancer","score_opus":0.011740488913623292,"score_gpt":0.27161435400797174,"score_spread":0.25987386509434846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2042702856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949276,0.003426146,0.000014500071,0.00025060584,0.00013641606,0.0007908274,0.0002751766,0.000017048405,0.0001617135],"genre_scores_gemma":[0.9991537,0.00030237282,0.00004039638,0.000057704732,0.00010799532,0.00025226822,0.000007620051,0.000032400698,0.000045566896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998482,0.00009267086,0.00024136764,0.00022484179,0.00052073266,0.00043841085],"domain_scores_gemma":[0.9991931,0.000041382915,0.00008497286,0.00036730745,0.00018315492,0.00013012889],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017455078,0.00014626746,0.00027992012,0.0000645382,0.0000533045,0.00001547471,0.00013181426,0.000044968667,0.000083529274],"category_scores_gemma":[0.000013558551,0.000078909914,0.00006785045,0.00027936572,0.00016296051,0.000050058065,0.000020169744,0.00023418109,0.000004717609],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029703192,0.00015216171,0.9579172,0.00012747903,0.00012236934,0.000037334048,0.0005817783,0.00020279469,0.000025024283,0.00002503258,0.0001038378,0.037734672],"study_design_scores_gemma":[0.0050245263,0.0005988415,0.9919969,0.00034585115,0.000050861145,0.0000102713375,0.00026988453,0.000012651774,0.0009190171,0.000005442371,0.0006772872,0.00008850334],"about_ca_topic_score_codex":0.0044916556,"about_ca_topic_score_gemma":0.0010960407,"teacher_disagreement_score":0.03764617,"about_ca_system_score_codex":0.0009009615,"about_ca_system_score_gemma":0.00061906787,"threshold_uncertainty_score":0.679007},"labels":[],"label_agreement":null},{"id":"W2043070875","doi":"10.3747/co.v15i3.249","title":"The Cost Burden of Trastuzumab and Bevacizumab Therapy for Solid Tumours in Canada","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Bevacizumab; Breast cancer; Oncology; Metastatic breast cancer; Context (archaeology); Colorectal cancer; Internal medicine; Targeted therapy; Lung cancer; Cancer; Intensive care medicine; Chemotherapy","score_opus":0.17774581717795576,"score_gpt":0.46265116577872767,"score_spread":0.2849053486007719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043070875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98447144,0.008812209,0.000023037352,0.0042764065,0.00056493963,0.0012682048,0.000030703886,0.0000058524483,0.00054718036],"genre_scores_gemma":[0.9918676,0.0074892626,0.000034822042,0.000064705724,0.0001817856,0.00024821033,0.000010003628,0.000014082588,0.0000895162],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988564,0.000086030595,0.00028025347,0.00018175224,0.00023568975,0.00035983353],"domain_scores_gemma":[0.99896514,0.0005335024,0.00006999021,0.00018113333,0.00013433551,0.00011592334],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003024653,0.00009475966,0.000331087,0.00005912669,0.00009037496,0.0000027234591,0.00013481533,0.00004912066,0.000032316922],"category_scores_gemma":[0.00017887235,0.00006601267,0.000034601064,0.000122029734,0.0002369164,0.000015208901,0.000031874337,0.0002659721,0.0000010940103],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016676658,0.00028369925,0.10108701,0.00015339191,0.000054391512,0.000077827455,0.0021338419,0.000021217322,0.00064552814,0.00012221589,0.039688416,0.85406476],"study_design_scores_gemma":[0.008824349,0.0021748168,0.10936068,0.000107409614,0.00001958992,0.00021638247,0.0015521859,0.0013254664,0.0019238213,0.00012662845,0.87422496,0.00014372122],"about_ca_topic_score_codex":0.13360201,"about_ca_topic_score_gemma":0.41808587,"teacher_disagreement_score":0.85392106,"about_ca_system_score_codex":0.0012225952,"about_ca_system_score_gemma":0.0058141653,"threshold_uncertainty_score":0.99982196},"labels":[],"label_agreement":null},{"id":"W2043605505","doi":"10.1038/bjc.2013.609","title":"Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial","year":2013,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK; Government of Ontario; Ontario Institute for Cancer Research; Pfizer","keywords":"Tamoxifen; Exemestane; Hazard ratio; Internal medicine; Oncology; Medicine; Breast cancer; Subgroup analysis; Tissue microarray; Confidence interval; Estrogen receptor; Prospective cohort study; Cancer","score_opus":0.0407244504869702,"score_gpt":0.3703711812747373,"score_spread":0.3296467307877671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2043605505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878712,0.007767573,0.0000019802205,0.001027548,0.0005603536,0.0009609413,0.00008998434,0.000007825535,0.0017125411],"genre_scores_gemma":[0.9912781,0.0045842887,0.00012524202,0.00015279683,0.00097372074,0.000093482195,0.0000057571156,0.000023091305,0.002763485],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980873,0.00006404945,0.0006136188,0.00014550854,0.00082732615,0.00026220607],"domain_scores_gemma":[0.9979252,0.00010489764,0.00047254728,0.0002186472,0.0010994197,0.00017925618],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002836488,0.00012777971,0.00064852764,0.00022709362,0.000072463015,0.00007822374,0.00021057062,0.000081438535,0.003361654],"category_scores_gemma":[0.0005488621,0.00008835023,0.00037997396,0.001071668,0.00013057108,0.00015842295,0.000036106878,0.00029163682,0.000009645842],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029630817,0.0017055676,0.34909308,0.000177258,0.009503363,0.00008868959,0.000977098,0.00021958932,0.0066268677,0.00002161534,0.10809858,0.49385747],"study_design_scores_gemma":[0.039534323,0.006502652,0.8213824,0.0014706352,0.0024208804,0.00022025118,0.00026703332,0.000077741424,0.010379299,0.000038825732,0.117491744,0.00021420777],"about_ca_topic_score_codex":0.0071356096,"about_ca_topic_score_gemma":0.0025160955,"teacher_disagreement_score":0.49364325,"about_ca_system_score_codex":0.0007900934,"about_ca_system_score_gemma":0.0010063271,"threshold_uncertainty_score":0.99947596},"labels":[],"label_agreement":null},{"id":"W2044083199","doi":"10.1016/s1470-2045(12)70013-x","title":"Don't pick the loser: lessons from the GeparQuinto trial","year":2012,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Taxane; Trastuzumab; Medicine; Lapatinib; Anthracycline; Oncology; Internal medicine; Epirubicin; Breast cancer; Docetaxel; Regimen; Chemotherapy; Cancer","score_opus":0.253008395605485,"score_gpt":0.4743445344544751,"score_spread":0.22133613884899012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044083199","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0045629116,0.003960639,0.000014306686,0.9515893,0.0046727345,0.0025556823,0.000250821,0.00010025749,0.032293346],"genre_scores_gemma":[0.00533635,0.001621507,0.00009878996,0.8205509,0.15748172,0.00084475835,0.00029140848,0.00012164878,0.013652927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.993484,0.0028457276,0.00055920606,0.0005713605,0.0010527525,0.0014869455],"domain_scores_gemma":[0.9897723,0.006509757,0.000351248,0.003093469,0.00015101247,0.00012220173],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0037632403,0.0004553913,0.0014704196,0.000055905333,0.00039784328,0.00007721762,0.002565215,0.001364105,0.004237229],"category_scores_gemma":[0.0007282671,0.00018579653,0.0003617266,0.00026351798,0.0012205084,0.00003946741,0.000630907,0.008403945,0.0017509811],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066204723,0.00007669606,0.00029167635,0.000058890342,0.00043306692,0.00023696206,0.0011759327,4.826823e-7,0.0000430977,0.0002483823,0.9823861,0.008428233],"study_design_scores_gemma":[0.015018788,0.00074125594,0.0010245255,0.0000994577,0.0005477885,0.00012273349,0.00015593969,0.0000066149323,0.0000267582,0.0014583906,0.98058677,0.0002109542],"about_ca_topic_score_codex":0.0032015971,"about_ca_topic_score_gemma":0.0014417649,"teacher_disagreement_score":0.15280898,"about_ca_system_score_codex":0.00080290955,"about_ca_system_score_gemma":0.0014223959,"threshold_uncertainty_score":0.99993235},"labels":[],"label_agreement":null},{"id":"W2045058534","doi":"10.1158/0008-5472.sabcs10-p3-14-07","title":"Abstract P3-14-07: A Phase 1 Study To Assess the Safety, Tolerability and PK of ARRY-380 — An Oral HER2 Inhibitor","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Cmax; Nausea; Tolerability; Rash; Dosing; Adverse effect; Lapatinib; Trastuzumab; Internal medicine; Pharmacokinetics; Gastroenterology; Pharmacology; Cancer; Breast cancer","score_opus":0.2525772356432266,"score_gpt":0.5622187609640096,"score_spread":0.309641525320783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045058534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98820895,0.00022089611,0.000009687643,0.005832156,0.0003595156,0.0035494196,0.000114167524,0.00004127178,0.0016639066],"genre_scores_gemma":[0.9975332,0.00008362281,0.00015596078,0.00015999486,0.00079816947,0.00057490234,0.00000862125,0.00006267249,0.00062287546],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9945706,0.00064460427,0.00061086967,0.0008385971,0.0023616892,0.0009736325],"domain_scores_gemma":[0.99528027,0.00070515065,0.000072039235,0.001612425,0.0014516677,0.00087843166],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009088592,0.00024288041,0.0005979352,0.00029444776,0.00035224872,0.00014217629,0.0006994085,0.00014900317,0.0029276756],"category_scores_gemma":[0.0015130867,0.00016907125,0.00007950444,0.0009795959,0.00089320855,0.0001936331,0.0004916233,0.002555559,0.00007007775],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010556092,0.009013863,0.21423991,0.0010834765,0.00027968,0.00027005214,0.010442156,0.000019603956,0.5082555,0.00017144594,0.014733595,0.23093466],"study_design_scores_gemma":[0.01678376,0.017833492,0.728973,0.00066644285,0.000117546515,0.00006344219,0.014119705,0.00033969726,0.12741621,0.00055671873,0.092291966,0.00083803973],"about_ca_topic_score_codex":0.0068151206,"about_ca_topic_score_gemma":0.008558055,"teacher_disagreement_score":0.5147331,"about_ca_system_score_codex":0.00038077898,"about_ca_system_score_gemma":0.0020085596,"threshold_uncertainty_score":0.9997986},"labels":[],"label_agreement":null},{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","score_opus":0.02317066928127298,"score_gpt":0.34360082901363015,"score_spread":0.32043015973235717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045324973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97999555,0.00092691893,0.000052363554,0.008859907,0.00034688425,0.004907409,0.00010155092,0.000031815616,0.0047775866],"genre_scores_gemma":[0.9950919,0.0005534944,0.00007404354,0.0012902034,0.0015434965,0.00060358265,0.0000059766307,0.000039558126,0.0007977135],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978175,0.00022533696,0.0005415392,0.0002585997,0.0005830252,0.00057400344],"domain_scores_gemma":[0.99868214,0.00041473107,0.00013679113,0.0005004937,0.00014917427,0.0001166824],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023777392,0.00019150748,0.0014044679,0.00011708843,0.000032587883,0.000014282305,0.0002584889,0.00011113797,0.000961168],"category_scores_gemma":[0.0001459721,0.00011692213,0.00024526473,0.00033070875,0.00018133293,0.000037047783,0.000022995831,0.00042467657,0.000016935299],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97585046,0.00024495268,0.00637919,0.00006373886,0.00023880364,0.000055274355,0.0017250973,0.0000021581404,0.0027929747,0.000027796692,0.0027368097,0.009882736],"study_design_scores_gemma":[0.93086547,0.00057677634,0.063792154,0.00033593443,0.00008515679,0.000014356914,0.00022089809,0.000053343105,0.003066059,0.000084206105,0.00078139885,0.00012423903],"about_ca_topic_score_codex":0.0007980884,"about_ca_topic_score_gemma":0.0006316266,"teacher_disagreement_score":0.05741296,"about_ca_system_score_codex":0.00028569618,"about_ca_system_score_gemma":0.00034562187,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W2045375334","doi":"10.12968/bjon.2012.21.sup4.s18","title":"An overview of drug development for metastatic breast cancer","year":2012,"lang":"en","type":"review","venue":"British Journal of Nursing","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Breast cancer; Multidisciplinary approach; Disease; Intensive care medicine; Metastatic breast cancer; Drug development; Radiation therapy; Cancer; Clinical trial; Drug; Oncology; Internal medicine; Pharmacology","score_opus":0.36923911357679706,"score_gpt":0.5368313989316446,"score_spread":0.1675922853548475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045375334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000059193164,0.99783784,0.00015741828,0.00011616536,0.00070382684,0.00083794905,0.00019194183,0.000006525193,0.000089166904],"genre_scores_gemma":[0.00009420163,0.9893238,0.009290591,0.000035483907,0.0009374231,0.000045288016,0.000030318344,0.00010363978,0.00013923252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666834,0.00026551558,0.0014942572,0.00020590103,0.00086691976,0.0004990782],"domain_scores_gemma":[0.9973012,0.00015634325,0.0011158233,0.00020536261,0.00075734715,0.00046392225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018856066,0.00026259484,0.0024047925,0.00031130746,0.00008291374,0.00005758748,0.0003286523,0.000111624,0.00035551403],"category_scores_gemma":[0.00007439857,0.00024989003,0.0005887691,0.0003071594,0.0001105866,0.00020047186,0.000019190937,0.0006864721,0.0000033246654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037881622,0.00044896177,0.000009575281,0.042181455,0.00042333393,0.00012038258,0.00022780657,3.7906406e-7,0.0000021562055,0.000005834186,0.0030494707,0.95349276],"study_design_scores_gemma":[0.00063617085,0.000095421754,0.00023140441,0.33415878,0.0026309243,0.02422801,0.00007924998,0.0000015919563,0.000009191218,0.000020264713,0.6377346,0.0001743861],"about_ca_topic_score_codex":0.0000729288,"about_ca_topic_score_gemma":0.00002411157,"teacher_disagreement_score":0.95331836,"about_ca_system_score_codex":0.0012701926,"about_ca_system_score_gemma":0.003521885,"threshold_uncertainty_score":0.99999535},"labels":[],"label_agreement":null},{"id":"W2045950562","doi":"10.1016/s1470-2045(09)70087-7","title":"Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study","year":2009,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Internal medicine; Breast cancer; Response Evaluation Criteria in Solid Tumors; Oncology; Inflammatory breast cancer; Trastuzumab; Anthracycline; Cohort; Progressive disease; Metastatic breast cancer; Cancer; Refractory (planetary science); Taxane; Gastroenterology; Chemotherapy","score_opus":0.0591464160017507,"score_gpt":0.4011642093019165,"score_spread":0.3420177933001658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045950562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99317026,0.00012342699,7.803016e-7,0.003733417,0.0001135068,0.0020040441,0.00007584815,0.000022822143,0.00075590936],"genre_scores_gemma":[0.99862367,0.00022000115,0.000055885223,0.000551856,0.00018806821,0.00013752433,0.000007468698,0.00002569771,0.0001898218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701905,0.00095985853,0.0005948839,0.00039381627,0.0005643815,0.00046802495],"domain_scores_gemma":[0.998422,0.00036070493,0.000305572,0.0006916629,0.00013754547,0.00008249694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017935339,0.00021321846,0.00083483756,0.00011859633,0.00010826487,0.000011807612,0.00033154048,0.00014704965,0.000062691615],"category_scores_gemma":[0.00018047396,0.00011351811,0.00003301568,0.00041946402,0.00028820962,0.0000822313,0.000097782264,0.0008037238,7.806316e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06819284,0.0030503024,0.8744791,0.000045514586,0.00006917744,0.00006635314,0.005372385,0.000029042643,0.00064689777,0.0000068234153,0.000575564,0.047465965],"study_design_scores_gemma":[0.058242355,0.009106859,0.92976576,0.0004260856,0.000031581138,0.00001229342,0.0005324653,0.00005765484,0.00011336888,0.000026823784,0.0015585796,0.00012615869],"about_ca_topic_score_codex":0.0011506161,"about_ca_topic_score_gemma":0.005954369,"teacher_disagreement_score":0.055286646,"about_ca_system_score_codex":0.0004892116,"about_ca_system_score_gemma":0.0008560717,"threshold_uncertainty_score":0.46291342},"labels":[],"label_agreement":null},{"id":"W2046583400","doi":"10.1016/s1470-2045(02)00676-9","title":"Trastuzumab: hopes and realities","year":2002,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":169,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Mary's Hospital; McGill University; Montreal General Hospital; Royal Victoria Hospital","funders":"","keywords":"Trastuzumab; Political science; Medicine; Internal medicine; Breast cancer; Cancer","score_opus":0.39974076953613047,"score_gpt":0.5236081176257247,"score_spread":0.12386734808959421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046583400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000062507606,0.92502415,0.0000018898052,0.005375589,0.00021476464,0.0009129678,0.000058693684,0.00006593886,0.06833977],"genre_scores_gemma":[0.0000054448496,0.98595333,0.00014778516,0.0010502848,0.0025772837,0.00029718998,0.000032216627,0.000057165078,0.00987927],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977141,0.0007145994,0.0004019195,0.00034670543,0.0002690998,0.00055359275],"domain_scores_gemma":[0.99807894,0.00088926265,0.00015343793,0.00069465704,0.000051759274,0.00013196278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011126227,0.00027891112,0.002736175,0.000114577495,0.00009123498,0.000024326562,0.00036015385,0.0004075839,0.0007625805],"category_scores_gemma":[0.00022217976,0.00015382581,0.00017445559,0.0002053471,0.000509972,0.0000184379,0.00016815223,0.0011706697,0.00027590606],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024755589,0.000030971627,0.0000048786264,0.011444029,0.00013844142,0.00012223539,0.00021884812,1.4862845e-8,1.0916722e-7,0.0006143583,0.11734895,0.8700524],"study_design_scores_gemma":[0.0005156162,0.00056972395,0.000018550672,0.003755905,0.0005347277,0.0011590562,0.000045518824,0.000001972819,1.9732117e-7,0.00013275082,0.9931282,0.00013777894],"about_ca_topic_score_codex":0.00016665188,"about_ca_topic_score_gemma":0.00006793722,"teacher_disagreement_score":0.8757793,"about_ca_system_score_codex":0.00049615593,"about_ca_system_score_gemma":0.00067408563,"threshold_uncertainty_score":0.83497214},"labels":[],"label_agreement":null},{"id":"W2047034979","doi":"10.1097/01.mp.0000038462.62634.b1","title":"The Role of HER2/neu Overexpression/Amplification in the Progression of Ductal Carcinoma In Situ to Invasive Carcinoma of the Breast","year":2002,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Ductal carcinoma; Pathology; Invasive ductal carcinoma; In situ; HER2/neu; Carcinoma in situ; Medicine; Breast carcinoma; Immunohistochemistry; Carcinoma; Biology; Breast cancer; Internal medicine; Cancer; Chemistry","score_opus":0.03184448073635069,"score_gpt":0.3110719908158152,"score_spread":0.2792275100794645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047034979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316895,0.0011229119,0.0000118337,0.002645335,0.00004436499,0.0010486351,0.000025743304,0.0000042775405,0.0019279617],"genre_scores_gemma":[0.99954385,0.00003982831,0.000065719425,0.00009640923,0.000039213195,0.00014530981,0.0000040712193,0.000017556464,0.000048035567],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978663,0.0005543813,0.00048135078,0.00028362754,0.0005072351,0.00030714058],"domain_scores_gemma":[0.99840665,0.0002913703,0.00019700037,0.00089442596,0.00016182628,0.000048705406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00068664044,0.00012561427,0.00030630102,0.00013187593,0.00005603824,0.0000049218897,0.0005076809,0.00013302299,0.000031087355],"category_scores_gemma":[0.00031717515,0.00006478144,0.00007636565,0.0004089139,0.00033374922,0.000035201578,0.00020500088,0.00035630108,0.000004226025],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022013109,0.00028951993,0.4754181,0.00008086562,0.0000043924188,0.000040079103,0.010218695,0.00003671817,0.50142735,0.00021279568,0.00012871473,0.011922608],"study_design_scores_gemma":[0.0007553922,0.00033265498,0.8500682,0.0002642004,0.0000105497265,0.00031981344,0.0016797866,0.0008357869,0.14485562,0.00074268103,0.000073042036,0.00006224527],"about_ca_topic_score_codex":0.00033509918,"about_ca_topic_score_gemma":0.00042425614,"teacher_disagreement_score":0.37465012,"about_ca_system_score_codex":0.00007115727,"about_ca_system_score_gemma":0.00013757635,"threshold_uncertainty_score":0.26417103},"labels":[],"label_agreement":null},{"id":"W2047065833","doi":"10.1073/pnas.1302553110","title":"iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Institutes of Health; Alexander von Humboldt-Stiftung","keywords":"Ectodomain; Cell biology; Disintegrin; Biology; Receptor; Metalloproteinase; Chemistry; Matrix metalloproteinase; Biochemistry","score_opus":0.06677136800725088,"score_gpt":0.37229593489883434,"score_spread":0.30552456689158347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047065833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474276,0.00018110857,0.0000020341595,0.008135138,0.000017297618,0.0007298926,0.000010228183,0.000012326771,0.006169243],"genre_scores_gemma":[0.99908566,0.000030476185,0.00032755916,0.00021368731,0.00007438229,0.000034498848,8.9472074e-8,0.0000063922744,0.0002272766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996724,0.000023684543,0.00042910464,0.00025046163,0.0023097524,0.00026297226],"domain_scores_gemma":[0.99808824,0.000502146,0.0004262968,0.00001798725,0.00090061396,0.0000647205],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034031936,0.00010797743,0.00027396547,0.0001652975,0.00018884953,0.000031730877,0.0007681214,0.00009385173,0.00012528148],"category_scores_gemma":[0.0016690042,0.00005760585,0.000096310905,0.0010441188,0.0012033901,0.00032910745,0.00013319086,0.00038225923,0.00000408735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007070937,0.000091255635,0.047167663,0.00015877633,0.00005767911,1.7459563e-8,0.00029253736,0.00025536594,0.9435679,0.0065182443,0.0010097129,0.0008101645],"study_design_scores_gemma":[0.00065507303,0.00017813446,0.35152698,0.00023273956,0.000028243003,0.000016557915,0.00035247204,0.007849939,0.6192407,0.019795679,0.00004916958,0.00007429662],"about_ca_topic_score_codex":0.000121438075,"about_ca_topic_score_gemma":4.988678e-7,"teacher_disagreement_score":0.32432714,"about_ca_system_score_codex":0.00009828474,"about_ca_system_score_gemma":0.00017099686,"threshold_uncertainty_score":0.44339406},"labels":[],"label_agreement":null},{"id":"W2047560376","doi":"10.1074/jbc.m800073200","title":"ErbB4-Neuregulin Signaling Modulates Synapse Development and Dendritic Arborization through Distinct Mechanisms","year":2008,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Mental Health","keywords":"ERBB4; Neuregulin 1; Receptor tyrosine kinase; Cell biology; Synapse; Excitatory synapse; Glutamatergic; Biology; Neuroscience; Postsynaptic potential; Neuregulin; Excitatory postsynaptic potential; Inhibitory postsynaptic potential; Signal transduction; Chemistry; Receptor; Glutamate receptor; Biochemistry","score_opus":0.06885269894920246,"score_gpt":0.3139734565449161,"score_spread":0.24512075759571364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047560376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945987,0.00082732557,0.003627636,0.00047487195,0.00004685364,0.000079575446,0.000002191363,0.000017868224,0.00032499686],"genre_scores_gemma":[0.9881651,0.00024998584,0.0109990565,0.000116469404,0.00031700035,0.000004181748,0.000009392186,0.000011047832,0.00012779026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987101,0.000036350382,0.00046860258,0.00018847107,0.00035856836,0.00023793864],"domain_scores_gemma":[0.9992082,0.00012608425,0.00016919666,0.000099334495,0.00020007807,0.00019711551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031731272,0.00013959724,0.00033800615,0.000023032399,0.00010459988,0.0000136715125,0.00011195792,0.00018796013,0.00021571033],"category_scores_gemma":[0.00055695843,0.000094292685,0.00007185602,0.0001192932,0.00015781388,0.000047330283,0.00005623277,0.00041714788,0.0000038049639],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019273297,0.0001526557,0.008076702,0.00017573628,0.00006575179,0.00088565703,0.00016067826,0.000014832563,0.98922163,0.000027523356,0.00014398417,0.00088209845],"study_design_scores_gemma":[0.0007862772,0.00028578556,0.008259474,0.00024332016,0.000024687555,0.0029010247,0.00010743332,0.00007133888,0.9852402,0.000842921,0.001102718,0.0001347877],"about_ca_topic_score_codex":0.0000014267665,"about_ca_topic_score_gemma":8.026085e-8,"teacher_disagreement_score":0.007371421,"about_ca_system_score_codex":0.00012437232,"about_ca_system_score_gemma":0.00020686458,"threshold_uncertainty_score":0.38451442},"labels":[],"label_agreement":null},{"id":"W2048180653","doi":"10.1007/s00702-013-1091-0","title":"NRG3 gene is associated with the risk and age at onset of Alzheimer disease","year":2013,"lang":"en","type":"article","venue":"Journal of Neural Transmission","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health","keywords":"Single-nucleotide polymorphism; Haplotype; Biology; SNP; Genetics; Alzheimer's disease; Gene; Disease; Allele; Genotype; Medicine; Internal medicine","score_opus":0.049461132406249324,"score_gpt":0.3302373574795915,"score_spread":0.28077622507334216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048180653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851292,0.0034014124,0.000029121356,0.011046234,0.000027799366,0.00027566776,0.000016236761,0.000004618887,0.00006976028],"genre_scores_gemma":[0.99783045,0.0011322043,0.00014547686,0.00041586815,0.000057960828,0.0000029217022,0.000002386227,0.000018575438,0.00039414625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858505,0.00016794127,0.00029471322,0.00010479689,0.0006652189,0.00018228171],"domain_scores_gemma":[0.99885696,0.00014569014,0.00022280194,0.00014758998,0.0002172973,0.0004096572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034018554,0.000108022425,0.00028302934,0.000071078684,0.00008813228,0.000016537879,0.00009980098,0.00004898633,0.0005525425],"category_scores_gemma":[0.000069837726,0.000050364055,0.00011556014,0.00014037936,0.00013722733,0.000090079186,0.000017121527,0.0004063677,0.0000030970061],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0092779165,0.0010892269,0.32362506,0.0004026239,0.0017391685,0.0045357137,0.00500662,0.00015005084,0.3081386,0.0000015066203,0.13194732,0.21408617],"study_design_scores_gemma":[0.0034066152,0.0015822646,0.96141595,0.00066016894,0.0008212099,0.0004682053,0.000076545424,0.0017840423,0.024274595,0.00006919164,0.0053191525,0.00012209201],"about_ca_topic_score_codex":0.000048318878,"about_ca_topic_score_gemma":0.0000026952293,"teacher_disagreement_score":0.63779086,"about_ca_system_score_codex":0.000040116964,"about_ca_system_score_gemma":0.00010612342,"threshold_uncertainty_score":0.6049953},"labels":[],"label_agreement":null},{"id":"W2048250189","doi":"10.1007/s10549-011-1840-4","title":"Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial","year":2011,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; University of British Columbia; McMaster University; Queen's University; St. Michael's Hospital; Hamilton Health Sciences; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Gene duplication; Oncology; Internal medicine; Anthracycline; Medicine; Breast cancer; Biology; Chromosome; Genetics; Cancer; Gene","score_opus":0.4511763596314084,"score_gpt":0.5504747129697497,"score_spread":0.0992983533383413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048250189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692452,0.011862638,0.00001748004,0.011941474,0.00028996955,0.00540149,0.0010120774,0.000051577146,0.00017810521],"genre_scores_gemma":[0.9695594,0.024760652,0.00020163275,0.000096806594,0.0018127551,0.002151734,0.00007945633,0.00005795957,0.0012796074],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9905265,0.004250976,0.001438279,0.0010265562,0.0018555536,0.00090215984],"domain_scores_gemma":[0.9896905,0.007057765,0.0003791566,0.0013945668,0.0006494135,0.0008285957],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011311777,0.00034722523,0.0012108074,0.00022193509,0.00029351545,0.00007122278,0.00047961337,0.00026228846,0.0041124034],"category_scores_gemma":[0.0040184674,0.00020497787,0.00035221517,0.0006627478,0.0011937043,0.00018590606,0.00024047578,0.00070539303,0.0001042572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6918171,0.003842662,0.09308809,0.00011438648,0.0012486494,0.00020711204,0.0013794658,2.7524905e-7,0.00833957,0.00008431332,0.005952237,0.19392611],"study_design_scores_gemma":[0.06329102,0.017705966,0.90340817,0.0016357326,0.00043852802,0.00010645801,0.00041140753,0.000087810935,0.004704538,0.00045659384,0.007515563,0.00023820008],"about_ca_topic_score_codex":0.024980664,"about_ca_topic_score_gemma":0.0007941213,"teacher_disagreement_score":0.8103201,"about_ca_system_score_codex":0.0009922807,"about_ca_system_score_gemma":0.0026092685,"threshold_uncertainty_score":0.996798},"labels":[],"label_agreement":null},{"id":"W2048272960","doi":"10.1016/j.bbrc.2004.11.053","title":"ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter","year":2004,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Susan G. Komen; Susan G. Komen for the Cure; U.S. Department of Defense","keywords":"VEGF receptors; Core (optical fiber); Cell biology; Chemistry; Promoter; Molecular biology; Cancer research; Biology; Gene; Biochemistry; Gene expression; Computer science; Telecommunications","score_opus":0.15905167231891118,"score_gpt":0.443353538389809,"score_spread":0.2843018660708978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048272960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9257944,0.0020186075,0.000031578416,0.06739069,0.000015289137,0.0010804639,0.000021066006,0.0000492669,0.0035985964],"genre_scores_gemma":[0.994035,0.002254843,0.0027253907,0.00024420128,0.000105481784,0.00019729801,0.000042528176,0.000018599112,0.00037662344],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793917,0.00019775057,0.00024716783,0.00035035238,0.0007550384,0.0005105432],"domain_scores_gemma":[0.99719876,0.00056200783,0.00002722103,0.0017695588,0.00022823259,0.00021422551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004858767,0.00013820454,0.00021052906,0.00007467331,0.0002964386,0.00007193672,0.000982098,0.00015825078,0.000026796888],"category_scores_gemma":[0.0002888699,0.00008602236,0.00007526835,0.00076344615,0.0015606942,0.00010024866,0.0012968233,0.0013483033,0.00006361169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009248749,0.0007166848,0.00012963473,0.00011145098,0.000013664734,0.0000071864556,0.00043830115,3.998613e-7,0.9858849,0.0074387477,0.0034945733,0.0016719422],"study_design_scores_gemma":[0.0016632834,0.00044954737,0.006953797,0.0016124732,0.0000122427,0.000021273796,0.0002885955,0.0005842084,0.92773336,0.03988201,0.020569172,0.00023002284],"about_ca_topic_score_codex":0.00038914033,"about_ca_topic_score_gemma":0.0000074030067,"teacher_disagreement_score":0.06824059,"about_ca_system_score_codex":0.00019403124,"about_ca_system_score_gemma":0.00028614473,"threshold_uncertainty_score":0.5857782},"labels":[],"label_agreement":null},{"id":"W2048623699","doi":"10.1186/1471-2407-9-433","title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","year":2009,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":210,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Eli Lilly Canada; Michael Smith Health Research BC; Sanofi; BC Cancer Agency; Eli Lilly and Company","keywords":"Trastuzumab; Medicine; Mucinous carcinoma; Oncology; Carboplatin; Mucinous Tumor; Surgical oncology; Ovarian cancer; Chemotherapy; Internal medicine; Targeted therapy; Paclitaxel; Immunohistochemistry; Cancer; Pathology; Adenocarcinoma; Breast cancer; Cisplatin","score_opus":0.06060265793451496,"score_gpt":0.3509393049700187,"score_spread":0.2903366470355037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048623699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917222,0.004237492,0.000040788804,0.0027053715,0.00001770325,0.0008696469,0.00006868532,0.000016165772,0.0003219155],"genre_scores_gemma":[0.99750763,0.0012071995,0.0004459954,0.00038054344,0.00008352822,0.000094838855,0.000017929691,0.000019793148,0.00024254124],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99872696,0.000063630476,0.00021699411,0.00035150116,0.00038161885,0.00025930238],"domain_scores_gemma":[0.9993366,0.000042027525,0.00007602908,0.00030206074,0.00009809554,0.00014518121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016016315,0.00014241479,0.00028545046,0.00012845613,0.000037601632,0.000016532516,0.00006409732,0.000083673505,0.0001567622],"category_scores_gemma":[0.000016841963,0.00010768728,0.000021678181,0.00025130462,0.00009861789,0.0000528193,0.00001614625,0.00017423283,2.3793193e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004586752,0.00038839952,0.80468583,0.0003978701,0.00005548092,0.000023968276,0.009896623,0.000039424835,0.1303326,0.00007955317,0.0036090577,0.04590444],"study_design_scores_gemma":[0.0039226203,0.00094717275,0.95513123,0.00037994332,0.000015499983,0.000019463376,0.0002908294,0.00044089556,0.03553255,0.00005694307,0.0031308322,0.0001320158],"about_ca_topic_score_codex":0.010905353,"about_ca_topic_score_gemma":0.0022925849,"teacher_disagreement_score":0.15044542,"about_ca_system_score_codex":0.00020276115,"about_ca_system_score_gemma":0.0004768853,"threshold_uncertainty_score":0.9956811},"labels":[],"label_agreement":null},{"id":"W2048686497","doi":"10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Metastatic breast cancer; Pharmacology; Breast cancer; Cancer","score_opus":0.17231465087547926,"score_gpt":0.5133159105305432,"score_spread":0.3410012596550639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048686497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850538,0.00072789256,0.00037996055,0.0064355186,0.00043525972,0.00037411603,0.000003208208,0.0000037985121,0.0065864963],"genre_scores_gemma":[0.9953814,0.0012870209,0.002532978,0.00045343465,0.00017994997,0.000002092042,0.0000011107978,0.000017015662,0.00014496688],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631506,0.00064575515,0.002104535,0.00017523032,0.0005280122,0.00023137603],"domain_scores_gemma":[0.9947877,0.0033063758,0.00096408016,0.00016325123,0.00045010756,0.0003284669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049344073,0.00011459052,0.0012457985,0.00019851445,0.000018281817,0.000005268186,0.00012260964,0.0002488541,0.00017701766],"category_scores_gemma":[0.004898801,0.00008153623,0.00014298373,0.00021123627,0.0003986943,0.00006745432,0.00003018094,0.001140609,0.0000030115743],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036104307,0.00805772,0.53279865,0.00024052283,0.00046357146,0.0012439834,0.00030255443,0.00002954982,0.00055622065,0.00082424685,0.0018427864,0.4175359],"study_design_scores_gemma":[0.04647345,0.04615868,0.8598821,0.00036753848,0.00021879208,0.00058708957,0.00014420085,0.00011375595,0.0003577825,0.00063765777,0.044954672,0.00010428928],"about_ca_topic_score_codex":0.000015397889,"about_ca_topic_score_gemma":0.00009280396,"teacher_disagreement_score":0.41743162,"about_ca_system_score_codex":0.00020143893,"about_ca_system_score_gemma":0.0022709386,"threshold_uncertainty_score":0.5864676},"labels":[],"label_agreement":null},{"id":"W2048798052","doi":"10.1097/00006231-200505000-00006","title":"Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments","year":2005,"lang":"en","type":"article","venue":"Nuclear Medicine Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Biodistribution; HER2/neu; Antibody; Breast cancer; Medicine; Chemistry; Molecular biology; Cancer; Internal medicine; Immunology; Biology; Biochemistry; In vitro","score_opus":0.08266441590882018,"score_gpt":0.43228369902485714,"score_spread":0.34961928311603696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048798052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.968082,0.0042246287,0.000020158393,0.021486992,0.00014349756,0.00088527193,0.000031218213,0.00008066042,0.005045551],"genre_scores_gemma":[0.9922713,0.0023917775,0.0037555771,0.0009285012,0.00026356964,0.00006012829,0.000044273325,0.00010041897,0.00018447737],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99692637,0.0003943645,0.0009824149,0.00042017063,0.0007063011,0.0005703752],"domain_scores_gemma":[0.997132,0.00017411707,0.00025756753,0.0019678855,0.00023157494,0.00023686927],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00090148364,0.00027366367,0.0006357626,0.0006828047,0.00022319957,0.000015939122,0.0010758555,0.00014495643,0.0014366085],"category_scores_gemma":[0.0001374478,0.00025880407,0.00008664791,0.0009090913,0.0005693379,0.00023256382,0.0005674581,0.0012133606,0.00003407407],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026450615,0.002003154,0.26854876,0.0004366811,0.00007134945,0.000031450858,0.0193318,0.00027012822,0.6585231,0.00027949168,0.0076657897,0.042573806],"study_design_scores_gemma":[0.013526758,0.0003687296,0.8506387,0.017099008,0.00020087251,0.0002202091,0.013668046,0.020088587,0.001973636,0.00010905579,0.08134728,0.0007591075],"about_ca_topic_score_codex":0.010289999,"about_ca_topic_score_gemma":0.0034046099,"teacher_disagreement_score":0.65654945,"about_ca_system_score_codex":0.0012201397,"about_ca_system_score_gemma":0.00026432954,"threshold_uncertainty_score":0.9999864},"labels":[],"label_agreement":null},{"id":"W2048901403","doi":"10.1016/j.nucmedbio.2009.05.003","title":"In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy","year":2009,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Cancer Research UK","keywords":"Trastuzumab; SKBR3; In vivo; Chemistry; Molecular biology; Cancer research; Antibody; Monoclonal antibody; Cancer cell; Breast cancer; Cancer; Biology; Medicine; Immunology; Internal medicine; Human breast","score_opus":0.046645326687403066,"score_gpt":0.3696165900322034,"score_spread":0.3229712633448003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048901403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898326,0.0008606468,5.7692887e-7,0.008252777,0.00009952479,0.00048115707,0.0000074446734,0.000021512536,0.00044378362],"genre_scores_gemma":[0.99501693,0.0038081352,0.00018428446,0.00041990608,0.00045141327,0.000014989604,9.3930544e-7,0.000023771197,0.00007963518],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9986171,0.000113906055,0.00038521562,0.00033128881,0.00017009128,0.00038238917],"domain_scores_gemma":[0.999527,0.00003281069,0.00007076832,0.00019345489,0.000051175877,0.00012482879],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032139945,0.00016413086,0.0004948226,0.00030151932,0.000031751526,0.0000034836162,0.00011752832,0.00020009487,0.0014037854],"category_scores_gemma":[0.000027100366,0.000116900505,0.000032307184,0.0002916531,0.00019114479,0.000057995196,0.000030816664,0.00045742752,0.0000036864838],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010867734,0.00013712278,0.021282693,0.00010148793,0.000007962867,0.000039917435,0.002261368,0.0000010666828,0.9537862,0.000010424306,0.0003363063,0.020948675],"study_design_scores_gemma":[0.011479753,0.003460581,0.63763475,0.00398076,0.000015381382,0.00010433492,0.0028732473,0.000064928914,0.3330959,0.00018193675,0.006798782,0.0003096395],"about_ca_topic_score_codex":0.0012258552,"about_ca_topic_score_gemma":0.000019063973,"teacher_disagreement_score":0.6206903,"about_ca_system_score_codex":0.00015397965,"about_ca_system_score_gemma":0.00005382515,"threshold_uncertainty_score":0.9995091},"labels":[],"label_agreement":null},{"id":"W2049479627","doi":"10.1200/jco.2003.11.038","title":"<i>neu</i>/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II","year":2003,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Citation; Breast cancer; Oncology; Hormonal therapy; Clinical Oncology; Internal medicine; Cancer; Adjuvant; Clinical trial; Adjuvant therapy; Gynecology; Library science","score_opus":0.12406823849787108,"score_gpt":0.49276206234913544,"score_spread":0.36869382385126437,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049479627","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5040693,0.000718512,3.8005004e-7,0.4935661,0.0006327364,0.00062824413,0.000038940965,0.0000026944558,0.000343096],"genre_scores_gemma":[0.15726672,0.007763148,0.00024136766,0.8242906,0.0088084275,0.00022027531,0.000010145421,0.00009914855,0.001300225],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9860812,0.006723175,0.0037744085,0.00063246844,0.0016138513,0.0011748896],"domain_scores_gemma":[0.9889757,0.008399026,0.0013339885,0.00047972868,0.0003201019,0.0004914674],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.02790052,0.0004159489,0.0026598733,0.0006846309,0.000059380054,0.000033068958,0.000648839,0.0017573192,0.0006937293],"category_scores_gemma":[0.005221363,0.00025808063,0.0002114447,0.00053361215,0.00030689765,0.00015756128,0.00020160392,0.010794389,0.0000062025388],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05061081,0.0011823245,0.043977916,0.000084845706,0.00012378917,0.007813501,0.0033198574,0.000020200076,0.00073665753,0.0000013363754,0.85764587,0.03448291],"study_design_scores_gemma":[0.010518135,0.014138358,0.20844242,0.001531718,0.000026259224,0.00079031184,0.0003421874,0.0000067271544,0.000010005807,0.00012268953,0.7638647,0.0002065065],"about_ca_topic_score_codex":0.0002087055,"about_ca_topic_score_gemma":0.000376642,"teacher_disagreement_score":0.3468026,"about_ca_system_score_codex":0.0021096962,"about_ca_system_score_gemma":0.007927944,"threshold_uncertainty_score":0.9999871},"labels":[],"label_agreement":null},{"id":"W2049589423","doi":"10.1007/s12609-013-0121-0","title":"Novel Therapies for Metastatic HER2 Positive Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Current Breast Cancer Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Lapatinib; Metastatic breast cancer; Docetaxel; Oncology; Trastuzumab emtansine; Internal medicine; Breast cancer; Cancer","score_opus":0.06508384817084498,"score_gpt":0.4015346760583286,"score_spread":0.3364508278874836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049589423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7356547,0.07972042,0.008016005,0.11727514,0.0174382,0.025343265,0.012478287,0.0011003208,0.0029736399],"genre_scores_gemma":[0.98520833,0.0015015671,0.0007286846,0.00084633526,0.0018813346,0.0079194885,0.00017735537,0.00018620554,0.0015506671],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962584,0.000054144974,0.0007934237,0.0009303331,0.0009773355,0.000986411],"domain_scores_gemma":[0.9967706,0.00010153381,0.0004113272,0.0007487787,0.0013988389,0.0005689186],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041748607,0.00047006144,0.0007594104,0.00021097451,0.00019343662,0.0001281116,0.00018831877,0.00009649626,0.0048803343],"category_scores_gemma":[0.00005010704,0.00037634614,0.00032693526,0.00045539104,0.00026056543,0.00033593242,0.00010231844,0.00047405454,0.000048658378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005298155,0.0012058138,0.11063633,0.001600613,0.0011100882,0.00014880228,0.0010395193,0.00004330008,0.011515085,0.00011931776,0.061641943,0.81040937],"study_design_scores_gemma":[0.0036998105,0.0002394475,0.9073501,0.0033441111,0.0007632257,0.010955919,0.0004115316,0.00067817554,0.0026555224,0.0006758546,0.06816934,0.0010569136],"about_ca_topic_score_codex":0.010067598,"about_ca_topic_score_gemma":0.0003084582,"teacher_disagreement_score":0.80935246,"about_ca_system_score_codex":0.0009631177,"about_ca_system_score_gemma":0.001605139,"threshold_uncertainty_score":0.99986887},"labels":[],"label_agreement":null},{"id":"W2049693836","doi":"10.1007/s12020-011-9524-8","title":"Cross-talk and modulation of signaling between somatostatin and growth factor receptors","year":2011,"lang":"en","type":"review","venue":"Endocrine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"G protein-coupled receptor; Signal transduction; Biology; Receptor; Receptor tyrosine kinase; Cell biology; Rhodopsin-like receptors; Somatostatin receptor; Growth factor receptor; Epidermal growth factor; Epidermal growth factor receptor; Metabotropic receptor; Genetics","score_opus":0.13315848609970424,"score_gpt":0.4335789883210327,"score_spread":0.30042050222132843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049693836","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024163898,0.97413415,0.0000441246,0.000021464486,0.000101473735,0.00093454606,0.00016778042,0.000039999155,0.00039254525],"genre_scores_gemma":[0.011937718,0.98603207,0.0007846128,0.00000542801,0.000283673,0.00004428217,0.00017196842,0.00007920394,0.0006610311],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818605,0.00011573479,0.00064643467,0.00040985312,0.0003245455,0.00031740434],"domain_scores_gemma":[0.9987856,0.00031943858,0.00026700986,0.00026971346,0.00014182556,0.00021640406],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021214643,0.00030106324,0.0014048208,0.0002726836,0.000046974943,0.000026626829,0.00010432733,0.00012804051,0.0006485347],"category_scores_gemma":[0.00033524772,0.00024151523,0.00012676817,0.00022190619,0.0001854433,0.00007827819,0.00013378031,0.00043582666,0.000012398839],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015089418,0.000022192187,0.017826501,0.03534699,0.00017299603,0.00003190474,0.00013412538,2.8151183e-8,0.00004393576,0.000049815033,0.0000619246,0.9462945],"study_design_scores_gemma":[0.0012593879,0.0005075504,0.010502466,0.017452884,0.00057814195,0.00023807841,0.000019821613,0.0000059966,0.0012479567,0.00018169382,0.96753186,0.00047419008],"about_ca_topic_score_codex":0.00025882866,"about_ca_topic_score_gemma":0.0000026408632,"teacher_disagreement_score":0.96746993,"about_ca_system_score_codex":0.000080832324,"about_ca_system_score_gemma":0.00018268096,"threshold_uncertainty_score":0.9848705},"labels":[],"label_agreement":null},{"id":"W2049978627","doi":"10.1097/jto.0b013e31817c6094","title":"Association of Phosphorylated Epidermal Growth Factor Receptor with Survival in Patients with Locally Advanced Non-small Cell Lung Cancer Treated with Radiotherapy","year":2008,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph's Hospital; McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"University of Toronto","keywords":"Medicine; Epidermal growth factor receptor; Lung cancer; Univariate analysis; Immunohistochemistry; Radiation therapy; Internal medicine; Oncology; Cancer; MAPK/ERK pathway; Prospective cohort study; Epidermal growth factor; Pathology; Cancer research; Receptor; Kinase; Biology; Multivariate analysis","score_opus":0.016138289761563358,"score_gpt":0.3563431171994241,"score_spread":0.34020482743786074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049978627","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688673,0.00046277125,0.00040627457,0.0009061822,0.00016169384,0.0008355346,0.00002517759,0.000012690244,0.00030291616],"genre_scores_gemma":[0.9917831,0.0008868435,0.006295343,0.00013943376,0.00012809348,0.000026351161,0.0000115431285,0.000068768466,0.0006605339],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713296,0.0003828307,0.0007604532,0.00026896317,0.0009460052,0.00050880696],"domain_scores_gemma":[0.99622047,0.00030126478,0.0012799276,0.00019143439,0.0017448855,0.00026202743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060602045,0.00026727465,0.0011583387,0.00036004887,0.00005464418,0.0000072180546,0.00019426011,0.00026490248,0.00026374924],"category_scores_gemma":[0.00009639851,0.0001711601,0.00008254107,0.0007379702,0.00014190961,0.0001807691,0.000016939746,0.00088210043,0.0000015615469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037832912,0.0010623392,0.9474027,0.00019608818,0.0005293721,0.00031192877,0.0009231668,0.00048317152,0.0028587438,1.9897841e-7,0.0005492754,0.007850072],"study_design_scores_gemma":[0.016515104,0.018284759,0.93965596,0.00086028787,0.00022111642,0.000075061296,0.00014645564,0.00017628804,0.023061585,5.8965975e-7,0.0007559658,0.00024684993],"about_ca_topic_score_codex":0.00036609793,"about_ca_topic_score_gemma":0.00044551748,"teacher_disagreement_score":0.021317806,"about_ca_system_score_codex":0.0029965346,"about_ca_system_score_gemma":0.0026005183,"threshold_uncertainty_score":0.78358334},"labels":[],"label_agreement":null},{"id":"W2051210210","doi":"10.1007/s10585-006-9034-x","title":"Naturally occurring resistance of bone marrow mononuclear and metastatic cancer cells to anticancer agents","year":2006,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; NOSM University; University of Calgary; Lakehead University; Thunder Bay Regional Health Sciences Centre","funders":"","keywords":"Bone marrow; Medicine; Chemotherapy; Cisplatin; Paclitaxel; Chemosensitivity assay; Cancer; Cancer cell; Ascites; Doxorubicin; Pleural effusion; Peripheral blood mononuclear cell; Hematology; Cancer research; Internal medicine; Oncology; Pathology; Biology; In vitro","score_opus":0.0984071611901411,"score_gpt":0.46769499226900446,"score_spread":0.36928783107886337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051210210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845513,0.011653737,0.00004673531,0.0009468741,0.00046573544,0.0009540774,0.00016498729,0.000048416096,0.0011681225],"genre_scores_gemma":[0.97869474,0.00045312344,0.018109813,0.0013958671,0.00021920027,0.00012501112,0.000008109133,0.00007180101,0.00092235266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632764,0.00024438452,0.0012279693,0.0007706661,0.0008451949,0.0005841266],"domain_scores_gemma":[0.9982165,0.0003075237,0.00024027015,0.00057159597,0.00016991633,0.0004941763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009465843,0.00031037975,0.0010800228,0.0001786577,0.000093986186,0.00004197501,0.00021531938,0.00009973774,0.0010216205],"category_scores_gemma":[0.00022559881,0.00027501906,0.00028699412,0.00046897455,0.00044381982,0.000120900135,0.00026998835,0.00041778074,0.00005897093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045833443,0.00309423,0.039162524,0.0011846208,0.0010091515,0.00054549775,0.00075114646,0.00006481122,0.8535269,0.000658612,0.071605995,0.023813184],"study_design_scores_gemma":[0.005171386,0.0013577736,0.04041213,0.0010077024,0.00049891736,0.000019996245,0.0008682621,0.0001509194,0.89176357,0.00014569187,0.057947513,0.000656133],"about_ca_topic_score_codex":0.0006488842,"about_ca_topic_score_gemma":0.00010398517,"teacher_disagreement_score":0.038236696,"about_ca_system_score_codex":0.00021895034,"about_ca_system_score_gemma":0.0001718114,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W2051827896","doi":"10.1158/0008-5472.sabcs11-ot1-02-02","title":"OT1-02-02: HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2−Positive Metastatic Breast Cancer (LPT112515).","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Discontinuation; Paclitaxel; Cancer; Chemotherapy","score_opus":0.13753868251921628,"score_gpt":0.4509132527718353,"score_spread":0.31337457025261906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2051827896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769894,0.0012350237,0.00011641694,0.010129708,0.00017451475,0.003778074,0.0013035638,0.00004648498,0.0062268353],"genre_scores_gemma":[0.9931733,0.0005685073,0.00034160682,0.00038138824,0.0002702155,0.0031932935,0.000045202083,0.00010424469,0.0019222549],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940432,0.0009729486,0.0005277834,0.00079613144,0.0023728504,0.0012871389],"domain_scores_gemma":[0.99660933,0.00046235885,0.00012956861,0.00087654433,0.001397261,0.0005249131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021750075,0.000325608,0.0006607802,0.00064624293,0.00020518577,0.000047602534,0.00063388865,0.00013207171,0.009573545],"category_scores_gemma":[0.0002102251,0.00021161557,0.000106896965,0.0021211118,0.00073698343,0.00021691356,0.00024870504,0.0015007133,0.000121727455],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04644396,0.005135656,0.07967512,0.005053833,0.0017859994,0.0017913616,0.09152138,0.00061142835,0.20251098,0.0010610392,0.22747475,0.33693448],"study_design_scores_gemma":[0.010076784,0.0073114564,0.48222342,0.010996338,0.00027303968,0.00025910485,0.012135124,0.00046741514,0.45873782,0.00040455646,0.016075086,0.0010398584],"about_ca_topic_score_codex":0.035183113,"about_ca_topic_score_gemma":0.015109069,"teacher_disagreement_score":0.40254828,"about_ca_system_score_codex":0.0015420081,"about_ca_system_score_gemma":0.0021381804,"threshold_uncertainty_score":0.9913318},"labels":[],"label_agreement":null},{"id":"W2052080762","doi":"10.1158/0008-5472.sabcs12-p5-18-08","title":"Abstract P5-18-08: Identification of ErbB2 function in the heart: implication for anti-ErbB2 therapy in breast cancer","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Cancer; Breast cancer; Cardiac function curve; Heart development; Pressure overload; Receptor tyrosine kinase; Lapatinib; Internal medicine; Endocrinology; Heart failure; Receptor; Biology; Chemotherapy; Embryonic stem cell","score_opus":0.2143064985937281,"score_gpt":0.5200085182150096,"score_spread":0.3057020196212815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052080762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786083,0.005051341,0.000040353305,0.012504237,0.00025558,0.0029741344,0.00013282665,0.000018719962,0.00041449303],"genre_scores_gemma":[0.9912548,0.003532122,0.000019033345,0.00020836586,0.0007268186,0.0039491877,0.00004264001,0.00004652048,0.00022048439],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99662066,0.00028978227,0.0005850625,0.00041413563,0.0011960253,0.0008943186],"domain_scores_gemma":[0.99787104,0.00041543145,0.00011598313,0.0007114546,0.00073663273,0.00014943036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006154838,0.00015447778,0.00031739112,0.00057141075,0.00012888951,0.00005067613,0.00035969188,0.00016786641,0.0008836513],"category_scores_gemma":[0.00016411766,0.000117545256,0.000093590344,0.0015170225,0.00023530002,0.0002959301,0.00004543417,0.000777601,0.000047452173],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013441372,0.00056291505,0.3230415,0.00054991525,0.000038634134,0.0000012987713,0.0014444988,0.000047396526,0.59797585,0.00029698058,0.017826704,0.05687019],"study_design_scores_gemma":[0.0015837407,0.00013739141,0.9393252,0.00024343806,0.000008637806,0.000008349071,0.0005545557,0.000071581315,0.043062255,0.00020243664,0.014696827,0.000105556945],"about_ca_topic_score_codex":0.005791512,"about_ca_topic_score_gemma":0.00058083906,"teacher_disagreement_score":0.6162837,"about_ca_system_score_codex":0.00089255493,"about_ca_system_score_gemma":0.0008284857,"threshold_uncertainty_score":0.9675362},"labels":[],"label_agreement":null},{"id":"W2052249651","doi":"10.1016/j.ctrv.2014.08.003","title":"Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis","year":2014,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Receptor tyrosine kinase; Odds ratio; Oncology; Breast cancer; Internal medicine; Meta-analysis; Confidence interval; Cancer; Fibroblast growth factor receptor; Epidermal growth factor receptor; Receptor; Tyrosine kinase; Cancer research; Fibroblast growth factor","score_opus":0.23622312007243446,"score_gpt":0.4790153302447197,"score_spread":0.24279221017228525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052249651","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007072238,0.98940957,0.000019995054,0.0005343053,0.00019712288,0.008154965,0.0013946521,0.000040816023,0.00024153125],"genre_scores_gemma":[0.000010311599,0.968399,0.00095522683,0.00010047415,0.0003926102,0.026702086,0.00049126113,0.00015284552,0.0027962148],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99264365,0.0013285434,0.002806205,0.0015704352,0.00084143766,0.0008097227],"domain_scores_gemma":[0.9948295,0.00050731644,0.0017641084,0.0021670344,0.00027935967,0.00045271145],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001113711,0.0012831396,0.016664924,0.0009322058,0.00006157307,0.000031773256,0.00050551246,0.0004408822,0.0061239647],"category_scores_gemma":[0.0002281432,0.0007288818,0.006258165,0.0034379773,0.00018426264,0.00008390816,0.000121688776,0.0006175871,0.00017393804],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006349124,0.0004953945,0.0007892434,0.061024416,0.02993627,0.000033663553,0.000047910744,0.0000060615725,0.000012171319,0.0000031110112,0.0042081624,0.9033801],"study_design_scores_gemma":[0.0005394372,0.00020146112,0.000034991313,0.029091313,0.26965058,0.000011970764,0.0000018106317,0.0000051834018,0.000035573627,0.0000012662905,0.7000739,0.0003525172],"about_ca_topic_score_codex":0.0017967739,"about_ca_topic_score_gemma":0.00068013836,"teacher_disagreement_score":0.9030276,"about_ca_system_score_codex":0.003242685,"about_ca_system_score_gemma":0.0017505732,"threshold_uncertainty_score":0.9999921},"labels":[],"label_agreement":null},{"id":"W2052627379","doi":"10.4236/jct.2012.36149","title":"Breast Cancer Therapies Present and Future","year":2012,"lang":"en","type":"article","venue":"Journal of Cancer Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Langara College; BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Disease; Metastatic breast cancer; Anticipation (artificial intelligence); Acknowledgement; Oncology; Cancer; Metastasis; Internal medicine","score_opus":0.043276471542809336,"score_gpt":0.40893733565084156,"score_spread":0.3656608641080322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052627379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6188975,0.32172722,0.000010044314,0.057321563,0.0012329675,0.00023169038,0.000021539106,0.0000113481865,0.0005461516],"genre_scores_gemma":[0.7121352,0.26432484,0.00019331677,0.0014986347,0.021005115,0.000036525693,4.3973506e-7,0.00004526886,0.00076065905],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99843395,0.00007783538,0.00031100443,0.00010743616,0.00068033877,0.00038945384],"domain_scores_gemma":[0.9988469,0.000042220738,0.00020564943,0.00017916979,0.00035871178,0.0003673604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048615853,0.00015689826,0.00037263255,0.00013294081,0.00006355662,0.00003303518,0.00013336011,0.000091329624,0.0025197137],"category_scores_gemma":[0.0000027432861,0.000099166595,0.00012069935,0.00017932664,0.000105506864,0.0002417453,0.00001996107,0.00045371082,0.000003120081],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001640845,0.00016304788,0.24091138,0.00006676038,0.00053849356,0.000016104286,0.0024203137,0.0000025160423,0.007563831,0.00004435272,0.023631826,0.7230005],"study_design_scores_gemma":[0.0021391057,0.00022442492,0.35100257,0.00015429313,0.00004159832,0.0005232129,0.0003554,0.000004695136,0.003079486,0.00004507272,0.642333,0.000097158925],"about_ca_topic_score_codex":0.00023918843,"about_ca_topic_score_gemma":0.000015001385,"teacher_disagreement_score":0.7229034,"about_ca_system_score_codex":0.0002324646,"about_ca_system_score_gemma":0.0004107715,"threshold_uncertainty_score":0.9983921},"labels":[],"label_agreement":null},{"id":"W2052707876","doi":"10.1158/0008-5472.sabcs13-p1-08-09","title":"Abstract P1-08-09: EGFR expression is associated with decreased response from HER2 targeted therapeutics in the neo-adjuvant setting in the NeoALTTO trial","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Smiths Detection (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Adjuvant; Cancer; Pathological; Randomized controlled trial","score_opus":0.13457686107845843,"score_gpt":0.4477739577996906,"score_spread":0.3131970967212322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052707876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634606,0.0021671006,0.0000043943555,0.028356034,0.000111211244,0.0048215436,0.00008894767,0.00004258781,0.0009475697],"genre_scores_gemma":[0.9931938,0.00038527252,0.000078412995,0.0027136959,0.0004756905,0.0025934335,0.000067464825,0.00008945996,0.00040276413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98883796,0.0046825903,0.0006892495,0.00076725637,0.0035037466,0.0015191745],"domain_scores_gemma":[0.99067247,0.006950444,0.00015944018,0.001343766,0.00059282215,0.00028106826],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011774105,0.00034012125,0.0005585279,0.00047119224,0.00036563634,0.000327269,0.0012494841,0.00034056083,0.002240503],"category_scores_gemma":[0.0024195781,0.00018387394,0.00011816148,0.0020837344,0.0004744812,0.00021698189,0.00015785145,0.0033195287,0.00015531215],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26859277,0.0031796223,0.0652519,0.00028429853,0.00047467757,0.0024848063,0.074920155,0.00012066681,0.40025964,0.000018316701,0.10253819,0.08187494],"study_design_scores_gemma":[0.08573823,0.0033833066,0.79943854,0.0042980607,0.000082887775,0.0000224306,0.02560048,0.0013949389,0.045080148,0.0008789676,0.03326426,0.00081772957],"about_ca_topic_score_codex":0.021690791,"about_ca_topic_score_gemma":0.00274953,"teacher_disagreement_score":0.73418665,"about_ca_system_score_codex":0.0013587417,"about_ca_system_score_gemma":0.0026820637,"threshold_uncertainty_score":0.99897987},"labels":[],"label_agreement":null},{"id":"W2052815331","doi":"10.1016/s0140-6736(09)62069-9","title":"Challenging the dogma on trastuzumab: a matter of the heart","year":2010,"lang":"en","type":"letter","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Regimen; Chemotherapy; Clinical endpoint; Neoadjuvant therapy; Hazard ratio; Chemotherapy regimen; Cancer; Clinical trial","score_opus":0.07993825610166451,"score_gpt":0.3581730562135883,"score_spread":0.2782348001119238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052815331","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008443589,0.00035549977,0.000002396592,0.9629551,0.00074791396,0.00088464457,0.00006497808,0.00003223683,0.026513625],"genre_scores_gemma":[0.06507233,0.00012266426,0.000026240106,0.9075543,0.017618803,0.00012987733,0.000013547227,0.00009571215,0.009366521],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974872,0.00031009887,0.0002667053,0.00029707764,0.001023492,0.00061544986],"domain_scores_gemma":[0.9966158,0.0005309786,0.00012295334,0.0026217317,0.00007254599,0.0000359929],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009588806,0.000255112,0.00067939196,0.000057938872,0.00017004987,0.000037527832,0.0012737381,0.0005411364,0.0013890613],"category_scores_gemma":[0.000109167,0.00009872554,0.00024721373,0.000178763,0.00042923118,0.000014417136,0.00019240478,0.008392239,0.0005524071],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006660328,0.00001567426,0.0006777505,0.00032535233,0.000076107106,0.000020366891,0.00049827615,0.0000017561212,0.00038186126,0.000034686167,0.9973902,0.00051137194],"study_design_scores_gemma":[0.00052535045,0.00008923505,0.009100303,0.00063814345,0.00006421939,0.00006928079,0.00003798408,0.000016202244,0.00064399285,0.00028622572,0.98841906,0.00011001007],"about_ca_topic_score_codex":0.00016454016,"about_ca_topic_score_gemma":0.000027485965,"teacher_disagreement_score":0.056628734,"about_ca_system_score_codex":0.000096781085,"about_ca_system_score_gemma":0.00017099368,"threshold_uncertainty_score":0.9995238},"labels":[],"label_agreement":null},{"id":"W2052953726","doi":"10.1158/1538-7445.am2013-lb-63","title":"Abstract LB-63: Relationship between tumor biomarkers (BM) and efficacy in EMILIA, a phase III study of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab emtansine; Lapatinib; Medicine; Trastuzumab; Hazard ratio; Metastatic breast cancer; Internal medicine; Oncology; Breast cancer; Cancer; Antibody-drug conjugate; Progression-free survival; Capecitabine; Proportional hazards model; Chemotherapy; Antibody; Confidence interval; Monoclonal antibody; Immunology","score_opus":0.15458355897690865,"score_gpt":0.48886552015526247,"score_spread":0.33428196117835385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052953726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98914117,0.0019858205,0.0000037690804,0.0025141418,0.000058222766,0.005540346,0.0003036806,0.0000270216,0.0004258483],"genre_scores_gemma":[0.9971889,0.00030473954,0.00005230396,0.00004288452,0.00014933047,0.0018791547,0.000034221874,0.00008833765,0.00026008527],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99409676,0.0008318365,0.0010950849,0.0009381321,0.0018216451,0.0012165637],"domain_scores_gemma":[0.9957941,0.002031468,0.0001618767,0.00066319725,0.00077440933,0.00057493494],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029096426,0.0003562946,0.001010272,0.0015862323,0.00016266882,0.00007916025,0.00038636706,0.0001314331,0.0013979189],"category_scores_gemma":[0.0008033966,0.00032310493,0.0000839686,0.002844251,0.0006942938,0.00031588113,0.00019887881,0.0017551475,0.000036747548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033898351,0.0051883115,0.9196471,0.0011955393,0.000467965,0.00065134006,0.0093453415,0.000051452935,0.015315865,0.0000129596365,0.001809661,0.042924657],"study_design_scores_gemma":[0.02046168,0.0014278726,0.96767235,0.0017203827,0.00007711963,0.000022017988,0.0062961318,0.00011261402,0.0018252454,0.00007687646,0.00004375218,0.00026392925],"about_ca_topic_score_codex":0.11057312,"about_ca_topic_score_gemma":0.01398658,"teacher_disagreement_score":0.09658654,"about_ca_system_score_codex":0.0021065937,"about_ca_system_score_gemma":0.0021575943,"threshold_uncertainty_score":0.9999221},"labels":[],"label_agreement":null},{"id":"W2053128405","doi":"10.1007/s00044-014-1237-0","title":"A review of new approaches in Her-2 targeting and 1H MRI application","year":2014,"lang":"en","type":"review","venue":"Medicinal Chemistry Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer; Trastuzumab; Magnetic resonance imaging; Biomarker; Cancer research; Cancer; Chemistry; Medical physics; Medicine; Radiology; Internal medicine; Biochemistry","score_opus":0.3666462089674463,"score_gpt":0.5315942859567334,"score_spread":0.1649480769892871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053128405","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007843091,0.9836223,0.000040063172,0.001502071,0.000019329435,0.00234239,0.000009122632,0.000021213036,0.01243566],"genre_scores_gemma":[0.000029354447,0.995858,0.00031154114,0.000063206586,0.0010003025,0.00061800994,0.0002643977,0.00008576446,0.001769426],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942833,0.00050227676,0.0013291575,0.00096389244,0.002080616,0.00084072637],"domain_scores_gemma":[0.9969142,0.0008055103,0.00030708374,0.0010332908,0.00027984875,0.0006600317],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009912924,0.0004105934,0.00285548,0.0002931764,0.00005961887,0.000017626297,0.000603565,0.00052011764,0.00041831163],"category_scores_gemma":[0.002445423,0.00031994373,0.0002359425,0.001591174,0.0005854591,0.000030196892,0.0003722498,0.0031496182,0.000044120072],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018655843,0.00004591136,0.000040746654,0.47808608,0.00003332441,0.000020480415,0.00003121969,1.8350873e-8,0.000036157908,0.000005255348,0.013107092,0.5085751],"study_design_scores_gemma":[0.00034892384,0.00009812899,0.0000026959856,0.28258166,0.00013634606,0.00013922589,0.000050122886,0.000026762977,0.000113152564,0.000028796225,0.7163247,0.00014949722],"about_ca_topic_score_codex":0.00032495544,"about_ca_topic_score_gemma":0.0000050260333,"teacher_disagreement_score":0.7032176,"about_ca_system_score_codex":0.00058435946,"about_ca_system_score_gemma":0.002969094,"threshold_uncertainty_score":0.99992526},"labels":[],"label_agreement":null},{"id":"W2053311062","doi":"10.1158/0008-5472.sabcs-09-5044","title":"Prospective Evaluation of Joint Symptoms in Postmenopausal Women Initiating Aromatase Inhibitors for Early Stage Breast Cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Brief Pain Inventory; Grip strength; Internal medicine; Discontinuation; Joint pain; Physical therapy; Cancer; Stage (stratigraphy); Chronic pain","score_opus":0.13473932912777978,"score_gpt":0.48232960110874196,"score_spread":0.34759027198096215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053311062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900279,0.0010999521,0.000005549351,0.0018624888,0.00013140199,0.0049621454,0.0008450311,0.000037871578,0.001027642],"genre_scores_gemma":[0.9939562,0.00019254765,0.00007506028,0.00011063682,0.0005304492,0.0047488543,0.000040054387,0.00005758805,0.00028861716],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9939086,0.000485448,0.000658885,0.0006930472,0.0029770934,0.0012769243],"domain_scores_gemma":[0.9961258,0.0002326669,0.0001534979,0.0005331782,0.0025708776,0.00038399035],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0070912633,0.00022976944,0.00055300555,0.00083329756,0.00015825695,0.000061862636,0.00025785246,0.00016473579,0.00094810774],"category_scores_gemma":[0.0009037971,0.00021485747,0.000071044415,0.0015266102,0.00028290876,0.00025113096,0.00010808631,0.00091395766,0.000012483951],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008707812,0.0016594061,0.26165673,0.00214262,0.00038549866,0.00011823348,0.01766389,0.00060141995,0.48958558,0.00079028297,0.004365115,0.21232341],"study_design_scores_gemma":[0.01173905,0.005397621,0.8538862,0.002512992,0.000063430096,0.000018769888,0.0028565382,0.0014756118,0.1191187,0.0021375015,0.0003762788,0.00041730085],"about_ca_topic_score_codex":0.004367654,"about_ca_topic_score_gemma":0.0004641612,"teacher_disagreement_score":0.5922295,"about_ca_system_score_codex":0.006853378,"about_ca_system_score_gemma":0.004542062,"threshold_uncertainty_score":0.99996513},"labels":[],"label_agreement":null},{"id":"W2053744053","doi":"10.1016/j.yexcr.2008.10.034","title":"ErbB receptors and cell polarity: New pathways and paradigms for understanding cell migration and invasion","year":2008,"lang":"en","type":"review","venue":"Experimental Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Biology; ErbB; Receptor tyrosine kinase; Signal transduction; Cell polarity; Cell migration; Carcinogenesis; Cell biology; Cancer research; Cell; Cancer; Genetics","score_opus":0.46247054392137305,"score_gpt":0.4763953289026991,"score_spread":0.013924784981326044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053744053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0024138074,0.986358,0.000056106946,0.00013970601,0.0001487035,0.004292825,0.000052965366,0.000038046972,0.0064998236],"genre_scores_gemma":[0.0063695763,0.9871794,0.000985093,0.000025930412,0.00038839725,0.00021546513,0.00025963597,0.0001625968,0.0044139093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99542946,0.00049302843,0.0006001666,0.0011941552,0.00127936,0.0010038288],"domain_scores_gemma":[0.9973162,0.0009201303,0.00014160629,0.00050584384,0.00009344255,0.0010227937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011338282,0.00054385775,0.0012632249,0.00073447055,0.0006323381,0.00024223624,0.00022455363,0.00060667546,0.00016138883],"category_scores_gemma":[0.00009073085,0.00047439462,0.00018982908,0.00051652227,0.0006463848,0.00016935308,0.0003963802,0.0013995225,0.000029633526],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014879836,0.002495881,0.0004944043,0.11006656,0.0002478892,0.00047498062,0.019873269,1.7613591e-7,0.06817897,0.0013828279,0.15459089,0.6407062],"study_design_scores_gemma":[0.002455556,0.0024604914,0.000004074588,0.0056874645,0.00008396793,0.00016539001,0.003923282,0.000036676756,0.027762387,0.00022729071,0.95665556,0.00053785637],"about_ca_topic_score_codex":0.0006633153,"about_ca_topic_score_gemma":0.00003500146,"teacher_disagreement_score":0.80206466,"about_ca_system_score_codex":0.001635241,"about_ca_system_score_gemma":0.0014816006,"threshold_uncertainty_score":0.99977076},"labels":[],"label_agreement":null},{"id":"W2054350484","doi":"10.1007/s10549-013-2490-5","title":"MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Medicine; Cancer research; Chimera (genetics); Pathology; Biology; Gene","score_opus":0.0593012011594051,"score_gpt":0.39596892794450966,"score_spread":0.3366677267851046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054350484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874088,0.008668786,3.7409183e-7,0.0011433301,0.000039230315,0.002126633,0.0001715313,0.00003272168,0.00040860364],"genre_scores_gemma":[0.9956384,0.0031071603,0.00014986566,0.000045970177,0.00013599181,0.00045976308,0.000024994022,0.00007334497,0.00036454413],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967439,0.000209736,0.00046621318,0.0007704538,0.00074733404,0.0010623632],"domain_scores_gemma":[0.99850094,0.00021823269,0.00009291286,0.00045017933,0.00031859227,0.00041912287],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004373642,0.00035585105,0.00066437427,0.00063664006,0.00028971405,0.00016153244,0.00017651843,0.00003398431,0.0005098577],"category_scores_gemma":[0.00002251563,0.00028702794,0.00007283968,0.0005163312,0.0007560341,0.00013090727,0.000105607134,0.00045802002,0.000029529314],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021220478,0.0013513414,0.22860308,0.00037696693,0.000244747,0.0028244336,0.00055837637,0.000006122607,0.73477966,0.00006662345,0.00045739443,0.028609185],"study_design_scores_gemma":[0.029630145,0.0074059935,0.4882652,0.0049201143,0.00015422994,0.0108602885,0.0025224814,0.0011361763,0.4499131,0.0006185346,0.0034589162,0.0011148298],"about_ca_topic_score_codex":0.05594511,"about_ca_topic_score_gemma":0.00089974276,"teacher_disagreement_score":0.28486657,"about_ca_system_score_codex":0.0016540914,"about_ca_system_score_gemma":0.00046629645,"threshold_uncertainty_score":0.99995816},"labels":[],"label_agreement":null},{"id":"W2054706573","doi":"10.2967/jnumed.109.062224","title":"Micro-SPECT/CT with <sup>111</sup>In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated <i>HER2</i> Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Pertuzumab; Trastuzumab; Biodistribution; Chemistry; Molecular biology; In vivo; Downregulation and upregulation; Pathology; Nuclear medicine; Medicine; In vitro; Breast cancer; Cancer; Internal medicine; Biochemistry; Biology","score_opus":0.015957895086321016,"score_gpt":0.29818524253828493,"score_spread":0.28222734745196393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054706573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97968537,0.0014934099,0.000004632072,0.017874155,0.000071601426,0.000579234,0.0000147856,0.00003845837,0.000238339],"genre_scores_gemma":[0.99611384,0.00054945546,0.00039422375,0.0020908534,0.0006823165,0.000004208017,0.0000057804114,0.00009415028,0.000065157255],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996001,0.00042607952,0.0010986003,0.00049890974,0.0012221683,0.00075322407],"domain_scores_gemma":[0.997906,0.00035976767,0.00046678627,0.00031454663,0.00039585106,0.0005570489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021658223,0.0004213118,0.0011239364,0.0012522261,0.00013907666,0.000043549815,0.00022586544,0.000085237574,0.00021990479],"category_scores_gemma":[0.0003893526,0.00031808607,0.00009736761,0.0010829292,0.0004068909,0.00029793355,0.00004643556,0.0014697338,0.000009817599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041188817,0.0006960121,0.019171879,0.00032296524,0.00022404797,0.022577267,0.009118501,0.0005271895,0.8866924,0.000015784171,0.0026348084,0.016830334],"study_design_scores_gemma":[0.01745777,0.0080629885,0.93213195,0.0072720703,0.00018255811,0.02449706,0.003396636,0.0016395705,0.002177358,0.000029929006,0.0027361137,0.000416013],"about_ca_topic_score_codex":0.0010705553,"about_ca_topic_score_gemma":0.0003584704,"teacher_disagreement_score":0.91296005,"about_ca_system_score_codex":0.0015166517,"about_ca_system_score_gemma":0.00057237654,"threshold_uncertainty_score":0.9999271},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","score_opus":0.18881223491172663,"score_gpt":0.5311267806640083,"score_spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055235037","genre_codex":"empirical","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5985378,0.000105501465,0.000059802278,0.029696796,0.00035280126,0.36383355,0.0003623278,0.000061582236,0.0069898204],"genre_scores_gemma":[0.21918662,0.00020062082,0.0017318189,0.0064199204,0.0023177478,0.76850456,0.000079095444,0.00009989448,0.0014597122],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9966963,0.001062556,0.0006635443,0.00046211842,0.0004041742,0.0007112891],"domain_scores_gemma":[0.997268,0.00075883436,0.000323923,0.00076644553,0.0006293235,0.0002534773],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002291285,0.0002651981,0.0014645834,0.000070961556,0.00018718764,0.00006841885,0.0009037923,0.00019302501,0.0034208298],"category_scores_gemma":[0.00015159142,0.00015942618,0.00008639585,0.00020568584,0.00037404735,0.0001681933,0.00017125536,0.00046581536,0.000056674766],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7537297,0.006436328,0.000091984475,0.0001540822,0.00032896493,0.000018733776,0.0012104472,0.000008798616,0.066954084,0.0002454347,0.027943831,0.1428776],"study_design_scores_gemma":[0.8416265,0.033629015,0.0005422068,0.00021146153,0.0000697222,0.000078150544,0.00020758959,0.0011826596,0.01226596,0.00039222592,0.10958391,0.00021057457],"about_ca_topic_score_codex":0.006577065,"about_ca_topic_score_gemma":0.00023309169,"teacher_disagreement_score":0.40467104,"about_ca_system_score_codex":0.00037830314,"about_ca_system_score_gemma":0.0017562559,"threshold_uncertainty_score":0.99749017},"labels":[],"label_agreement":null},{"id":"W2055644704","doi":"10.1016/j.jss.2008.11.232","title":"192. HER-3 Expression Shows Prognostic Utility for Breast Cancer Survival: A Study of 4046 Patients","year":2009,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Breast cancer; Medicine; Oncology; Cancer; Internal medicine; Protein expression; Breast carcinoma; Bioinformatics; Biology; Gene; Genetics","score_opus":0.25494562783494623,"score_gpt":0.5222534090486812,"score_spread":0.267307781213735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055644704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357826,0.0005410268,0.000018029872,0.0026937183,0.00018641278,0.0019809948,0.00007245335,0.00001002183,0.00091908127],"genre_scores_gemma":[0.9984989,0.0003674894,0.00010681583,0.000020491912,0.0005075345,0.00005718542,0.0000028770637,0.000028294844,0.00041042347],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926466,0.0008376713,0.0010295977,0.00034699493,0.0043440093,0.000795173],"domain_scores_gemma":[0.99194556,0.0017284232,0.00025910177,0.00041914458,0.0049422323,0.0007055066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0066228593,0.00017960754,0.00080042373,0.00047404144,0.00014633327,0.000045874323,0.00046357425,0.00015413393,0.0009185492],"category_scores_gemma":[0.0018833351,0.000120534954,0.00024913397,0.00080798875,0.00019539137,0.00016093378,0.00013934342,0.0013685419,0.000005054454],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019591874,0.0127177695,0.7703024,0.00048659387,0.00015302803,0.00047416383,0.00074820645,0.000010884704,0.002837025,0.00001925145,0.010095362,0.18256342],"study_design_scores_gemma":[0.014757708,0.014401475,0.95523715,0.0014537269,0.000068028494,0.00009324101,0.0010564004,0.0002146929,0.0019753717,0.0002895819,0.010285735,0.00016687006],"about_ca_topic_score_codex":0.00014290704,"about_ca_topic_score_gemma":0.000035013814,"teacher_disagreement_score":0.18493475,"about_ca_system_score_codex":0.00035981965,"about_ca_system_score_gemma":0.001017547,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W2056264529","doi":"10.1016/j.semradonc.2007.10.006","title":"Tissue Microarrays in Clinical Oncology","year":2008,"lang":"en","type":"review","venue":"Seminars in Radiation Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Centre for Advancing Health Outcomes; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Tissue microarray; Medicine; Precision oncology; Clinical Oncology; Biomarker; Oncology; Molecular biomarkers; Biomarker discovery; Internal medicine; Computational biology; Pathology; Bioinformatics; Immunohistochemistry; Cancer; Proteomics; Biology; Gene","score_opus":0.1738491061078373,"score_gpt":0.5683243816508772,"score_spread":0.39447527554303985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056264529","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009543523,0.9633902,0.0000056507465,0.0010878142,0.0018437589,0.002552771,0.000027753664,0.00004564872,0.030951023],"genre_scores_gemma":[0.000017998707,0.9930737,0.0014144421,0.00061899866,0.0012562734,0.0006903927,0.00034160767,0.00010914033,0.002477439],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920601,0.002628462,0.0029384948,0.0010422212,0.00043994767,0.00089077733],"domain_scores_gemma":[0.99468935,0.0032893987,0.0007861422,0.0007556365,0.00010846137,0.00037104342],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0030711696,0.0004895771,0.0047328817,0.0014881046,0.000047283418,0.000008557414,0.00049308664,0.0032396165,0.0007099782],"category_scores_gemma":[0.0026160653,0.00046987276,0.00043728447,0.0013608576,0.0005120888,0.00005730976,0.0001725981,0.0036737488,0.0011672913],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000095915144,0.0007768997,0.0014396795,0.0025407702,0.000059171205,0.0034170344,0.0002926146,0.0000016693955,0.0000011812062,0.000037475773,0.05425066,0.93708694],"study_design_scores_gemma":[0.002263858,0.0026534528,0.00047297718,0.0059062545,0.00012876687,0.0019474,0.000044339813,0.0000139636495,0.0000029728938,0.000018922661,0.9862224,0.0003247042],"about_ca_topic_score_codex":0.00019887215,"about_ca_topic_score_gemma":0.00050230743,"teacher_disagreement_score":0.9367622,"about_ca_system_score_codex":0.006287244,"about_ca_system_score_gemma":0.012335242,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W2056274073","doi":"10.1093/annonc/mdt081.2","title":"Trastuzumab Beyond Progression for Metastatic HER2+ Breast Cancer (MBC): Survival Outcomes in a Canadian Population","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Nova Scotia; Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Internal medicine; Cohort; Oncology; Population; Cancer; Hazard ratio; Breast cancer; Surgery; Confidence interval","score_opus":0.13781537271264574,"score_gpt":0.5099880635076068,"score_spread":0.37217269079496107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056274073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392728,0.00031644816,0.000010317582,0.056108885,0.00028682462,0.0019419363,0.00018543543,0.00001509924,0.0018622023],"genre_scores_gemma":[0.99667746,0.00009818201,0.00085501873,0.0010229979,0.00008676503,0.00076498865,0.00006435664,0.000028330818,0.0004018974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822956,0.00014571415,0.00043532668,0.00025008526,0.00029135268,0.0006479299],"domain_scores_gemma":[0.99869186,0.00022674733,0.00012230998,0.00020125299,0.00039117204,0.0003666859],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070807216,0.00013710238,0.0006260101,0.00035900698,0.000044641794,0.000010169118,0.0001223644,0.00013330962,0.0008062524],"category_scores_gemma":[0.00022929032,0.000110830246,0.000096580625,0.00025091344,0.00008540083,0.00010830013,0.000023297947,0.00019065564,0.00001840646],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022912378,0.000412165,0.60862046,0.0002526905,0.00011230183,0.000029522402,0.0003251796,0.000016036638,0.00046590628,0.00020667756,0.007292745,0.3820372],"study_design_scores_gemma":[0.0019369867,0.0016748897,0.9811994,0.00012510158,0.0000335499,0.000023602124,0.000200883,0.0004365274,0.00034954917,0.00081837206,0.013080142,0.000120990415],"about_ca_topic_score_codex":0.660821,"about_ca_topic_score_gemma":0.6807251,"teacher_disagreement_score":0.3819162,"about_ca_system_score_codex":0.00055061525,"about_ca_system_score_gemma":0.0017080464,"threshold_uncertainty_score":0.88278985},"labels":[],"label_agreement":null},{"id":"W2056793446","doi":"10.1038/labinvest.3780396","title":"EGFR and ErbB2 Differentially Regulate Raf-1 Translocation and Activation","year":2002,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northeast Cancer Centre","funders":"","keywords":"Endocytosis; SKBR3; Epidermal growth factor; ERBB3; Transfection; Cell biology; Epidermal growth factor receptor; Signal transduction; Biology; Cell surface receptor; Receptor; Cancer research; Cell culture; Chemistry; Cancer cell; Receptor tyrosine kinase; Cancer; Biochemistry","score_opus":0.039409676281349414,"score_gpt":0.2768893961973752,"score_spread":0.23747971991602576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056793446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903819,0.0005131915,0.00024328199,0.008002452,0.00006476418,0.00041206012,0.0000079237125,0.0000817343,0.00029268983],"genre_scores_gemma":[0.9974564,0.00041275038,0.0007272418,0.0007470829,0.00014703762,0.000039652914,0.000038233113,0.000023898883,0.00040771122],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99894845,0.00010248735,0.00020871109,0.0002688584,0.00030986077,0.00016160012],"domain_scores_gemma":[0.9992975,0.00004339969,0.000066195666,0.00019399228,0.00019342014,0.0002054823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022587266,0.000119441494,0.00015369555,0.00012335482,0.00010716128,0.00005369075,0.000034586614,0.00012181258,0.00014407556],"category_scores_gemma":[0.00014444868,0.00010409395,0.000012956138,0.0003488394,0.00020972903,0.00026492466,0.0000124994085,0.00018476766,0.000013678629],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000089741705,0.00007193773,0.043171983,0.00054567266,0.00005460789,0.000006961696,0.0039729737,0.0000101315045,0.8834128,0.0024286024,0.0039213956,0.06231324],"study_design_scores_gemma":[0.0040348526,0.00049092923,0.54646105,0.00078008685,0.00011327764,0.000023560395,0.00028079536,0.015460382,0.41345197,0.0027817513,0.01565817,0.00046316415],"about_ca_topic_score_codex":0.000031822474,"about_ca_topic_score_gemma":0.000020288808,"teacher_disagreement_score":0.5032891,"about_ca_system_score_codex":0.00008829841,"about_ca_system_score_gemma":0.00007470743,"threshold_uncertainty_score":0.42448282},"labels":[],"label_agreement":null},{"id":"W2057194480","doi":"10.3747/co.v16i4.469","title":"The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Santé Montérégie; Cancer Care Nova Scotia; Hôpital du Saint-Sacrement; Ottawa Hospital; Health Sciences Centre; University of Alberta; University of Toronto; Université de Sherbrooke; Centre hospitalier universitaire de Québec; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; University of Ottawa","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Targeted therapy; Pertuzumab; Clinical trial; Adjuvant; Cancer; Disease","score_opus":0.07348489514262137,"score_gpt":0.4417653748954514,"score_spread":0.36828047975283007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057194480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684013,0.023412967,0.000016552858,0.005527881,0.00019934117,0.00059385586,0.000028840781,0.00002798657,0.001791288],"genre_scores_gemma":[0.99721116,0.0020398146,0.00017354243,0.00017845599,0.00012305476,0.00017855753,0.0000035403145,0.000019107252,0.0000727429],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982633,0.00025420357,0.00031924926,0.0002443093,0.00037702636,0.0005419312],"domain_scores_gemma":[0.9990599,0.00021014256,0.00013362273,0.00029726521,0.00016929096,0.00012975093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052104855,0.00015334845,0.00043638947,0.000112150665,0.00007012972,0.000016018614,0.00019693836,0.00005703726,0.00034036246],"category_scores_gemma":[0.0000514073,0.000092079,0.000036603702,0.0003568768,0.00027807034,0.00005540644,0.000035330337,0.00044696525,0.000006607472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021170573,0.00075887854,0.042877965,0.00009333024,0.00009658786,0.000022292272,0.0040902263,0.000023194947,0.006841204,0.00014265944,0.0007569649,0.9421796],"study_design_scores_gemma":[0.0065258374,0.0037420343,0.6056721,0.001261639,0.00008573334,0.0001397814,0.0081702275,0.00062752125,0.004162762,0.002816969,0.36646268,0.00033267404],"about_ca_topic_score_codex":0.00020283807,"about_ca_topic_score_gemma":0.00023955615,"teacher_disagreement_score":0.94184697,"about_ca_system_score_codex":0.0007163963,"about_ca_system_score_gemma":0.0008192503,"threshold_uncertainty_score":0.37548724},"labels":[],"label_agreement":null},{"id":"W2057655573","doi":"10.1093/ajh/hpu094","title":"Vascular Induction of a Disintegrin and Metalloprotease 17 by Angiotensin II Through Hypoxia Inducible Factor 1α","year":2014,"lang":"en","type":"article","venue":"American Journal of Hypertension","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health; American Heart Association","keywords":"Angiotensin II; Metalloproteinase; Renin–angiotensin system; Endocrinology; Disintegrin; Internal medicine; Hypoxia (environmental); Downregulation and upregulation; Medicine; Hypoxia-inducible factors; Vascular smooth muscle; Biology; Matrix metalloproteinase; Receptor; Chemistry; Biochemistry; Gene","score_opus":0.04220785733757095,"score_gpt":0.29871163519001437,"score_spread":0.25650377785244344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057655573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933107,0.0013960644,0.0010454722,0.0037837343,0.00013638558,0.00021123527,0.0000050122594,0.000011800771,0.00009961858],"genre_scores_gemma":[0.99282396,0.0005197806,0.005679371,0.0006405742,0.00019755223,0.000002094166,0.0000035772223,0.000035485034,0.00009758876],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997931,0.00021046145,0.00053067884,0.00025841748,0.0007893964,0.00028006206],"domain_scores_gemma":[0.99818414,0.00009659789,0.00045561945,0.00034259926,0.00064114993,0.00027987757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006382754,0.00019007412,0.0008501628,0.0002116527,0.00008846774,0.000014819834,0.00012051312,0.00008163238,0.000064126005],"category_scores_gemma":[0.00066715153,0.00013320417,0.00020667072,0.0004217126,0.00043493637,0.00024153822,0.00008000468,0.0005735111,0.0000031652123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050707127,0.00034021374,0.0019047387,0.000046604528,0.0003075259,0.00007168412,0.0005713171,0.0000060973484,0.8705682,0.000018116745,0.007870241,0.11778818],"study_design_scores_gemma":[0.01368648,0.04035977,0.1639957,0.0031533523,0.0019238492,0.009643392,0.0055820416,0.001014749,0.5711457,0.00096869224,0.18721113,0.0013151313],"about_ca_topic_score_codex":0.00070416357,"about_ca_topic_score_gemma":0.0000036274446,"teacher_disagreement_score":0.29942247,"about_ca_system_score_codex":0.00008387084,"about_ca_system_score_gemma":0.00017116604,"threshold_uncertainty_score":0.54319084},"labels":[],"label_agreement":null},{"id":"W2058595915","doi":"10.1097/00001813-200112004-00003","title":"Maximizing the response to Herceptin® therapy through optimal use and patient selection","year":2001,"lang":"en","type":"review","venue":"Anti-Cancer Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunohistochemistry; Medicine; Concordance; Oncology; Breast cancer; Trastuzumab; Metastatic breast cancer; Internal medicine; Targeted therapy; Cancer; Disease; Fluorescence in situ hybridization; Gene; Biology","score_opus":0.17277203939993846,"score_gpt":0.44606148375622434,"score_spread":0.2732894443562859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058595915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018827736,0.97485393,0.00004529744,0.002119873,0.00034444523,0.0032484864,0.000054685675,0.00010353307,0.00040200018],"genre_scores_gemma":[0.000341002,0.9930012,0.00086080644,0.001901197,0.00055168546,0.00088090764,0.000018673585,0.00018130666,0.0022631781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99604666,0.00078148127,0.0006679043,0.00088380487,0.00083940517,0.0007807594],"domain_scores_gemma":[0.99788344,0.0005897749,0.00024281903,0.00077235437,0.0002689068,0.00024271877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084203365,0.0005864025,0.0014822666,0.00023779151,0.0003068845,0.00021395306,0.00030673674,0.0003411278,0.00061198225],"category_scores_gemma":[0.00018755729,0.00037411178,0.00035696282,0.0012951435,0.00018261511,0.00019780039,0.00019348807,0.0011203927,0.00012817416],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066453754,0.00008119849,0.00014462585,0.0014293543,0.0002608382,0.000029935916,0.002177771,0.000008980207,0.000055488515,0.000005423769,0.011977856,0.983164],"study_design_scores_gemma":[0.0006280463,0.0005447843,0.00017830648,0.007664186,0.00023151725,0.00014388742,0.0002749382,0.000010918971,0.000091588015,0.0000023589926,0.9898449,0.00038452266],"about_ca_topic_score_codex":0.0013295313,"about_ca_topic_score_gemma":0.000026023494,"teacher_disagreement_score":0.98277944,"about_ca_system_score_codex":0.0007511907,"about_ca_system_score_gemma":0.0010542162,"threshold_uncertainty_score":0.9998711},"labels":[],"label_agreement":null},{"id":"W2058901727","doi":"10.1111/j.1524-4733.2009.00511.x","title":"The Cost-Utility of Sequential Adjuvant Trastuzumab in Women with Her2/Neu-Positive Breast Cancer: An Analysis Based On Updated Results from the HERA Trial","year":2009,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Economic evaluation; Relative risk; Demography; Cancer; Confidence interval","score_opus":0.057001828599170044,"score_gpt":0.3867357524686461,"score_spread":0.3297339238694761,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058901727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97081655,0.00023271695,0.000038512157,0.024275936,0.000102921775,0.0026535038,0.0017103407,0.000025408113,0.00014409375],"genre_scores_gemma":[0.997567,0.00023075737,0.00006259243,0.0015707324,0.00020277513,0.00014227601,0.00019011695,0.00002032853,0.000013438529],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9942905,0.0023099794,0.0009745497,0.0006144299,0.0010605798,0.0007499978],"domain_scores_gemma":[0.9973445,0.00090360123,0.00030470328,0.00095882796,0.00018293,0.0003054236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004464751,0.0002271013,0.00076824374,0.00023359375,0.00016416857,0.0000359856,0.000346443,0.000110494606,0.00012522703],"category_scores_gemma":[0.00017990694,0.00013010867,0.00008750954,0.0018565671,0.00021646525,0.00006405965,0.000020699103,0.0008253837,0.0000018557919],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69803506,0.0025653716,0.031404525,0.000065633365,0.00040892104,0.00012019818,0.009774342,0.045670155,0.00010163308,0.000030162393,0.0006345199,0.2111895],"study_design_scores_gemma":[0.04376943,0.0052848854,0.8342984,0.00053536403,0.00008125597,0.0000031540035,0.0011746527,0.114184044,0.00017784876,0.00007195375,0.00026839337,0.00015064409],"about_ca_topic_score_codex":0.16736041,"about_ca_topic_score_gemma":0.020606149,"teacher_disagreement_score":0.8028939,"about_ca_system_score_codex":0.0021686337,"about_ca_system_score_gemma":0.0034591423,"threshold_uncertainty_score":0.9972652},"labels":[],"label_agreement":null},{"id":"W2059162955","doi":"10.1016/j.ygyno.2005.11.043","title":"Remission of a negative Her2/Neu overexpressive metastatic ovarian cancer patient by the single agent of trastuzumab as salvage therapy","year":2006,"lang":"en","type":"letter","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Cetuximab; Bevacizumab; Oncology; HER2/neu; Internal medicine; Ovarian cancer; Fluorescence in situ hybridization; Targeted therapy; Cancer; Chemotherapy; Colorectal cancer; Breast cancer","score_opus":0.06132552669997006,"score_gpt":0.3740022859081994,"score_spread":0.31267675920822935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059162955","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32415769,0.011343348,0.00009219736,0.5976336,0.0024795665,0.011184641,0.0025573543,0.00014432735,0.050407298],"genre_scores_gemma":[0.43864188,0.0034218496,0.0025391723,0.5324685,0.0018976439,0.0039946353,0.0014630405,0.0003995606,0.01517375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99384356,0.0018196866,0.0013098979,0.0008732157,0.0012162891,0.00093733903],"domain_scores_gemma":[0.9929181,0.003796897,0.0016065491,0.0009399632,0.00059019844,0.00014832927],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006648202,0.0006118477,0.001973168,0.00025269328,0.00013587983,0.000016243108,0.0006530108,0.0012324437,0.0056617847],"category_scores_gemma":[0.0009854462,0.00038083087,0.00042868947,0.00047957082,0.0010051051,0.000048159134,0.00023111653,0.0025828443,0.000027146956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057155604,0.0013174337,0.0002499102,0.00041805994,0.00067134877,0.0009394716,0.001312961,0.000029327686,0.019352384,0.000008875909,0.9173337,0.05779492],"study_design_scores_gemma":[0.0038779594,0.016405936,0.001608643,0.00045001222,0.00039588564,0.00008817304,0.00053858344,0.000021362837,0.037423424,0.000934858,0.9378696,0.0003855822],"about_ca_topic_score_codex":0.003499416,"about_ca_topic_score_gemma":0.00018179721,"teacher_disagreement_score":0.1144842,"about_ca_system_score_codex":0.0025417511,"about_ca_system_score_gemma":0.0027499322,"threshold_uncertainty_score":0.99986434},"labels":[],"label_agreement":null},{"id":"W2059170159","doi":"10.1002/cncr.22806","title":"Cost‐effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2‐positive breast cancer","year":2007,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Cost-effectiveness analysis; Internal medicine; Life expectancy; Cost effectiveness; Clinical trial; Quality-adjusted life year; Cancer; Population","score_opus":0.07170571895907751,"score_gpt":0.4652865692052998,"score_spread":0.3935808502462223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059170159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99071175,0.003544612,0.0010493763,0.0008388738,0.00010513579,0.0021966833,0.0011175013,0.000008662883,0.00042739927],"genre_scores_gemma":[0.9981444,0.00048271287,0.00008259526,0.000099533005,0.0001410336,0.0009241514,0.000036206013,0.000021582631,0.00006779614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984907,0.00012007468,0.00035749492,0.0002782428,0.00037992932,0.0003735413],"domain_scores_gemma":[0.9984318,0.00074748584,0.0001379717,0.00028273225,0.0003232438,0.00007679072],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009162023,0.000151467,0.00066668075,0.0003089409,0.00003989118,0.000005154189,0.00011345418,0.00007404165,0.00017581435],"category_scores_gemma":[0.000038414022,0.00009950556,0.00024900472,0.0011998947,0.00013343329,0.000033905464,0.0000127774265,0.00008385432,4.8712076e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003242469,0.00072120235,0.49497765,0.0005186426,0.0024646341,0.000036364745,0.007395334,0.0015446886,0.011996652,0.00006177967,0.00013905509,0.47690153],"study_design_scores_gemma":[0.0027184668,0.00057083817,0.9446737,0.00045780983,0.0013195904,0.000006205397,0.0013394865,0.0009010666,0.047095172,0.000010388269,0.0008078996,0.00009938781],"about_ca_topic_score_codex":0.008943667,"about_ca_topic_score_gemma":0.0059956806,"teacher_disagreement_score":0.47680214,"about_ca_system_score_codex":0.0016083175,"about_ca_system_score_gemma":0.0004958674,"threshold_uncertainty_score":0.99765587},"labels":[],"label_agreement":null},{"id":"W2059715478","doi":"10.1016/j.cell.2012.12.030","title":"Architecture and Membrane Interactions of the EGF Receptor","year":2013,"lang":"en","type":"article","venue":"Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Howard Hughes Medical Institute","keywords":"Extracellular; Transmembrane protein; Biology; Transmembrane domain; Biophysics; Cell biology; Intracellular; Cell membrane; Kinase; Membrane; Biochemistry; Receptor","score_opus":0.019523464147139107,"score_gpt":0.3043025665013322,"score_spread":0.28477910235419307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2059715478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94633484,0.00024537605,0.000019910856,0.0069920016,0.00020021826,0.0003802268,0.0000046981245,0.000012320927,0.0458104],"genre_scores_gemma":[0.9802866,0.000058260746,0.00041785836,0.00025130203,0.00010002409,0.000021821443,0.0000016482832,0.000009980336,0.018852526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99956316,0.000030176683,0.000083073435,0.00008827452,0.0001331646,0.00010215135],"domain_scores_gemma":[0.99956113,0.00006958648,0.000022950602,0.00022637944,0.000054443684,0.000065487926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000587387,0.000044361717,0.00008552661,0.000031377338,0.00002726973,0.0000072257844,0.00006855663,0.000026497297,0.002785189],"category_scores_gemma":[0.000057588022,0.000026246134,0.000031662214,0.00009406967,0.00008951218,0.000017915834,0.00004996629,0.00023050081,0.00012467091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024630495,0.00007341958,0.0029698606,0.00029829322,0.000015967358,9.052983e-7,0.0008762715,0.0000036740257,0.93402165,0.000016179056,0.04495725,0.016741903],"study_design_scores_gemma":[0.00055164675,0.00011240731,0.011228675,0.00014567774,0.000019230636,0.000020888334,0.00026353815,0.000089132,0.68574667,0.00013644954,0.3016267,0.000058932874],"about_ca_topic_score_codex":0.00016658918,"about_ca_topic_score_gemma":0.000016523252,"teacher_disagreement_score":0.25666946,"about_ca_system_score_codex":0.000021174394,"about_ca_system_score_gemma":0.000049353588,"threshold_uncertainty_score":0.9981264},"labels":[],"label_agreement":null},{"id":"W2060062311","doi":"10.3892/or.17.2.465","title":"Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor","year":2007,"lang":"en","type":"article","venue":"Oncology Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lapatinib; Cancer research; Tyrosine-kinase inhibitor; ErbB; MCF-7; Epidermal growth factor receptor; Cancer; Apoptosis; Biology; Breast cancer; Receptor tyrosine kinase; Cell culture; Kinase; Trastuzumab; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.01930924732753868,"score_gpt":0.3442483565456914,"score_spread":0.3249391092181527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060062311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904645,0.0010376803,0.000055085602,0.00085442927,0.00036387905,0.00066272257,0.000031442927,0.000037583748,0.007910717],"genre_scores_gemma":[0.99732786,0.00027953714,0.0006753557,0.00012045635,0.0006850933,0.00006621315,0.000019072673,0.000046434598,0.00077998167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746203,0.00007190068,0.00095351465,0.00047981573,0.00059723854,0.00043546918],"domain_scores_gemma":[0.9978001,0.00020349449,0.0006476451,0.0003949165,0.000668977,0.0002848527],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001068594,0.00022040741,0.00073314324,0.0002026856,0.000050687166,0.0000064062147,0.00003668844,0.0003092589,0.00023485854],"category_scores_gemma":[0.00014769526,0.00017482063,0.00007230022,0.0003675914,0.00061465637,0.00008938529,0.00008948628,0.00033214936,0.0000018329856],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002087291,0.0013714257,0.19085474,0.0017381014,0.00014834909,0.009787059,0.00091934856,0.000011869011,0.7694129,0.000035893478,0.0050454442,0.018587587],"study_design_scores_gemma":[0.006175804,0.0067800223,0.17450872,0.002603358,0.00059397164,0.014150106,0.0013867381,0.00004099537,0.7785633,0.00010706138,0.014597125,0.0004927547],"about_ca_topic_score_codex":0.0017630657,"about_ca_topic_score_gemma":0.0020979766,"teacher_disagreement_score":0.018094834,"about_ca_system_score_codex":0.00044234408,"about_ca_system_score_gemma":0.0013935828,"threshold_uncertainty_score":0.71289784},"labels":[],"label_agreement":null},{"id":"W2060234566","doi":"10.1158/1538-7445.am2012-770","title":"Abstract 770: Overcoming Trastuzumab resistance with the novel pan-erbb inhibitor AZD8931","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Medicine; Cancer research; Breast cancer; Monoclonal antibody; Tyrosine-kinase inhibitor; ErbB; Tyrosine kinase; Cancer; Internal medicine; Oncology; Pharmacology; Antibody; Immunology; Receptor","score_opus":0.14736024053927196,"score_gpt":0.4481766815643935,"score_spread":0.3008164410251215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060234566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93713427,0.009895686,0.000118527176,0.020486841,0.00038387126,0.0019962618,0.00008191034,0.000111713016,0.029790899],"genre_scores_gemma":[0.9837658,0.000552543,0.00032956115,0.0004175701,0.0025469789,0.00059021084,0.000009631555,0.00012704637,0.011660668],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99375343,0.00019472532,0.00036750973,0.00060541206,0.0030267576,0.0020521702],"domain_scores_gemma":[0.9965913,0.00078416895,0.00008502777,0.0011509788,0.00073094916,0.000657524],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038117957,0.0002988299,0.00042901895,0.00028867603,0.00060652447,0.0001486172,0.000619972,0.00018561381,0.0015326535],"category_scores_gemma":[0.00041126614,0.00018870833,0.0001150341,0.0013397716,0.0009080326,0.00032807002,0.0002275373,0.002359722,0.00027490518],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005335618,0.0011267754,0.021104587,0.0018184341,0.00047198543,0.00018514637,0.0070368117,0.00001372724,0.5900534,0.0017324456,0.34391412,0.027206957],"study_design_scores_gemma":[0.003951608,0.0004781168,0.19017263,0.0017467235,0.000065339285,0.000068125155,0.003114772,0.000021373617,0.09402149,0.000050993884,0.70578235,0.00052649056],"about_ca_topic_score_codex":0.0011311775,"about_ca_topic_score_gemma":0.00095994765,"teacher_disagreement_score":0.4960319,"about_ca_system_score_codex":0.0018163191,"about_ca_system_score_gemma":0.0018845762,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W2061961124","doi":"10.3747/co.v17i2.422","title":"One Year of Complete Clinical Response in a Metastatic Breast Cancer Patient Treated with a Combination of Lapatinib and Gemcitabine","year":2010,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lapatinib; Medicine; Capecitabine; Gemcitabine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Tyrosine-kinase inhibitor; Chemotherapy; Cancer; Combination therapy; Epidermal growth factor receptor; Trastuzumab; Colorectal cancer","score_opus":0.21236500145766643,"score_gpt":0.4999086760678354,"score_spread":0.28754367461016894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2061961124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974082,0.00017472477,0.000009988389,0.0013833601,0.00013885423,0.00064087496,0.00013736285,0.0000078686335,0.00009873117],"genre_scores_gemma":[0.9991102,0.00015142983,0.00055768935,0.000026263277,0.000025051915,0.00008510239,0.000021801556,0.000013094448,0.000009341747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983866,0.00043305865,0.0005257769,0.00020987746,0.00026484014,0.00017982064],"domain_scores_gemma":[0.99855137,0.00057089777,0.00021249661,0.00020170597,0.00034823196,0.00011528918],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00090041704,0.000088694076,0.0005576336,0.00020216114,0.000011797789,0.0000020364168,0.00006092083,0.00007050621,0.00023741875],"category_scores_gemma":[0.00034088717,0.00007212846,0.000033490865,0.00025016099,0.00043484409,0.00002474351,0.00004831399,0.00044752093,0.0000032324153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017930498,0.0037976424,0.8256998,0.00039176087,0.00008901687,0.00001763453,0.0007319926,0.0000016040374,0.010861698,0.00016671108,0.0001981679,0.14011347],"study_design_scores_gemma":[0.009497037,0.0068039815,0.97938067,0.00031396156,0.00009338976,0.000025997278,0.00012588825,0.00050633895,0.0005422962,0.000035280624,0.0026023404,0.00007279116],"about_ca_topic_score_codex":0.00027495748,"about_ca_topic_score_gemma":0.00059047394,"teacher_disagreement_score":0.1536809,"about_ca_system_score_codex":0.00010158587,"about_ca_system_score_gemma":0.0005476759,"threshold_uncertainty_score":0.2941313},"labels":[],"label_agreement":null},{"id":"W2062151299","doi":"10.1038/onc.2009.312","title":"Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity","year":2009,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McGill University","funders":"National Cancer Institute; U.S. Department of Defense","keywords":"Biology; Cell biology; Apoptosis; Cell growth; MAPK/ERK pathway; Signal transduction; Protein kinase B; Cancer research; Paclitaxel; Gene knockdown; Cancer; Biochemistry; Genetics","score_opus":0.06726552474081585,"score_gpt":0.36744907643768554,"score_spread":0.3001835516968697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062151299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99263656,0.00015993422,0.0022957765,0.0019022373,0.000052619813,0.0020055936,0.00028751267,0.00001570845,0.0006440818],"genre_scores_gemma":[0.99293315,0.00010535249,0.005418607,0.0003062866,0.00016657278,0.00010088538,0.00014050059,0.000022772048,0.0008058963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986843,0.00003159753,0.00039760067,0.00030209144,0.0003301956,0.000254218],"domain_scores_gemma":[0.998982,0.000062388666,0.00017569082,0.00026635476,0.0003987463,0.000114815666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004359782,0.00013080577,0.00034229833,0.00011728487,0.00007193055,0.000014838908,0.000049585982,0.00016391916,0.00005082786],"category_scores_gemma":[0.00008384474,0.00012502978,0.00010969677,0.00017532513,0.000041645966,0.00012595636,0.0000190898,0.00008657413,0.0000025892894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077935803,0.0003961316,0.000932049,0.0009398525,0.000013677217,3.12051e-7,0.0004603484,4.855148e-7,0.9882678,0.000044616158,0.0012590358,0.0069063706],"study_design_scores_gemma":[0.003064763,0.0025170867,0.0007525102,0.00013359314,0.00010107866,0.0000019719305,0.00009467539,0.0009659121,0.9910803,0.00051843293,0.00066217367,0.000107517575],"about_ca_topic_score_codex":0.00014191451,"about_ca_topic_score_gemma":0.00001543054,"teacher_disagreement_score":0.006798853,"about_ca_system_score_codex":0.00012916427,"about_ca_system_score_gemma":0.00018081031,"threshold_uncertainty_score":0.50985664},"labels":[],"label_agreement":null},{"id":"W2063273481","doi":"10.1007/s00702-008-0182-9","title":"Neuregulin 1 and age of onset in the major psychoses","year":2009,"lang":"en","type":"article","venue":"Journal of Neural Transmission","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Centre for Addiction and Mental Health","funders":"Canadian Institutes of Health Research; National Alliance for Research on Schizophrenia and Depression","keywords":"Proband; Haplotype; Schizophrenia (object-oriented programming); Bipolar disorder; Psychosis; Age of onset; Neuregulin 1; Psychiatry; Psychology; Mania; Medicine; Genetics; Allele; Disease; Biology; Internal medicine; Mood; Gene; Mutation","score_opus":0.05868095437224368,"score_gpt":0.39548942485298677,"score_spread":0.3368084704807431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063273481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651993,0.001976048,0.000054763634,0.03211789,0.00004672407,0.0001562401,0.0000012430615,0.0000025967356,0.0004451995],"genre_scores_gemma":[0.99761355,0.0007723879,0.0005058551,0.0009269419,0.00009314212,4.8384845e-7,6.521239e-7,0.0000058989444,0.00008110198],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9988005,0.00013198599,0.00037329935,0.00007900891,0.00047673326,0.00013845853],"domain_scores_gemma":[0.9995148,0.00010817669,0.00008962932,0.000114585906,0.00005746824,0.000115323666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051178486,0.000076406,0.0002444222,0.00014665835,0.00002343197,0.0000118967,0.00013682271,0.000050695824,0.000062953855],"category_scores_gemma":[0.000052734824,0.000040511983,0.00008596076,0.000204681,0.00005414586,0.00006557546,0.0000032636049,0.0004722021,4.8876916e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004141862,0.0007750579,0.016031303,0.00033821963,0.00002731269,0.002757418,0.003242744,0.000019244517,0.48643455,0.000023315852,0.009253704,0.4769553],"study_design_scores_gemma":[0.0042108307,0.004868228,0.954037,0.0011695733,0.00006724099,0.0029017555,0.00027050232,0.00023429014,0.012186003,0.0009535691,0.019006668,0.00009433975],"about_ca_topic_score_codex":0.000007391046,"about_ca_topic_score_gemma":0.0000019831068,"teacher_disagreement_score":0.9380057,"about_ca_system_score_codex":0.000014273385,"about_ca_system_score_gemma":0.000056014407,"threshold_uncertainty_score":0.20515095},"labels":[],"label_agreement":null},{"id":"W2064047759","doi":"10.1016/s1470-2045(10)70297-7","title":"Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"Genentech","keywords":"Medicine; Breast cancer; Internal medicine; Discontinuation; Trastuzumab; Oncology; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer","score_opus":0.1137773007743218,"score_gpt":0.37204568943079974,"score_spread":0.25826838865647794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064047759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324552,0.0001503602,0.0000091443535,0.0101790745,0.00018095902,0.0011005031,0.00008801618,0.00005179819,0.055784978],"genre_scores_gemma":[0.9950726,0.000068906906,0.0004910829,0.0032106803,0.00050953246,0.00017981202,0.0000057900565,0.00003715214,0.00042444625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980269,0.0004205777,0.0002363085,0.00029849424,0.00033014605,0.0006875733],"domain_scores_gemma":[0.99855727,0.00043961155,0.000117814554,0.0005395789,0.00024091669,0.000104836865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008817233,0.00017529537,0.0004900378,0.000054594184,0.0001244183,0.000012200766,0.00042004182,0.00011382848,0.00045352775],"category_scores_gemma":[0.00010596235,0.00008749304,0.000033161792,0.00039162126,0.00029083103,0.000050643353,0.00014863211,0.0007459852,0.00007347353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016429834,0.0002923263,0.9640808,0.00004089275,0.000070148766,0.00008248053,0.0020300609,0.00000956863,0.00002590978,0.00018067729,0.0013277048,0.030216452],"study_design_scores_gemma":[0.0032700854,0.0014508598,0.99051666,0.00022974244,0.000051379855,0.00008404573,0.00025287442,0.00006767064,0.00019401331,0.00019672822,0.0035721085,0.00011385618],"about_ca_topic_score_codex":0.0074049635,"about_ca_topic_score_gemma":0.0024572401,"teacher_disagreement_score":0.06261743,"about_ca_system_score_codex":0.00059231784,"about_ca_system_score_gemma":0.00059994916,"threshold_uncertainty_score":0.9992048},"labels":[],"label_agreement":null},{"id":"W2064282349","doi":"10.4137/bcbcr.s6374","title":"Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Basic and Clinical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Lapatinib; Breast cancer; Medicine; Oncology; Cancer; Internal medicine; Trastuzumab; Adverse effect","score_opus":0.21577710336506944,"score_gpt":0.5485440153192331,"score_spread":0.3327669119541637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064282349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322594,0.0032230054,0.0000028332695,0.009829116,0.00008859987,0.0010191347,0.00016351862,0.000006495442,0.0024413324],"genre_scores_gemma":[0.98998946,0.00903662,0.00006644288,0.00017631304,0.00032041795,0.0002047342,0.0000028163718,0.000017989678,0.00018522571],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962534,0.00069324166,0.00074044534,0.00040466627,0.001242093,0.00066616153],"domain_scores_gemma":[0.9972709,0.0013530093,0.00009509772,0.00055936986,0.00037417514,0.00034748233],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007977853,0.00013819654,0.00053787313,0.00011960296,0.00007026016,0.00001544071,0.00027024455,0.00013428736,0.00077025854],"category_scores_gemma":[0.00016708861,0.000089612186,0.000082528364,0.00065846636,0.0012939041,0.00007814254,0.00029755582,0.0008938547,0.0000051256584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016757566,0.00079424016,0.65651435,0.00083574606,0.00009583332,0.0000061488868,0.00032012598,4.07235e-7,0.00003125735,0.0004679216,0.0006115533,0.33864665],"study_design_scores_gemma":[0.0029448383,0.00022728514,0.99301755,0.0009064317,0.000061025225,0.000031803334,0.00077446835,0.00004095633,0.000038548373,0.000111076486,0.0017673967,0.00007861254],"about_ca_topic_score_codex":0.004277994,"about_ca_topic_score_gemma":0.000268256,"teacher_disagreement_score":0.33856806,"about_ca_system_score_codex":0.00012671188,"about_ca_system_score_gemma":0.00038557526,"threshold_uncertainty_score":0.8433791},"labels":[],"label_agreement":null},{"id":"W2064695567","doi":"10.1016/j.jbi.2015.03.009","title":"Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles","year":2015,"lang":"en","type":"article","venue":"Journal of Biomedical Informatics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Intertek (Canada)","funders":"National Center for Advancing Translational Sciences; National Center for Chronic Disease Prevention and Health Promotion; National Center for Research Resources; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute","keywords":"Drug; Side effect (computer science); Medicine; Erlotinib; Anticancer drug; Imatinib; Pharmacology; Cancer; Bioinformatics; Oncology; Internal medicine; Computer science; Epidermal growth factor receptor; Biology","score_opus":0.029976354621585793,"score_gpt":0.3485802429429896,"score_spread":0.31860388832140385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064695567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779154,0.00024955164,0.009254898,0.0013264393,0.00035291287,0.00030980684,0.000024912468,0.000037159378,0.00065280654],"genre_scores_gemma":[0.9818962,0.0000709832,0.017222542,0.0004708535,0.0002551866,0.00000625441,0.000025782341,0.000018557907,0.00003363457],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954955,0.00017196836,0.0014289493,0.00008409208,0.00238644,0.00043303572],"domain_scores_gemma":[0.9961945,0.00095840485,0.0010117238,0.00021566752,0.00078694697,0.00083275104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002172292,0.00017751355,0.0008045305,0.00029689664,0.00004637621,0.000032627227,0.00021133937,0.00027811684,0.00022403912],"category_scores_gemma":[0.0028912937,0.00010947794,0.00014064806,0.00068960094,0.00039172455,0.00032144669,0.00006813599,0.00079141697,0.000037084654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012632592,0.02127641,0.053006094,0.006113639,0.0072166817,0.0032497887,0.13827433,0.00039044733,0.11943867,0.00013689579,0.18235189,0.45591256],"study_design_scores_gemma":[0.07356312,0.05472838,0.22305933,0.017001694,0.003226703,0.002312611,0.06977022,0.45009273,0.06819965,0.0029950656,0.033496056,0.0015544387],"about_ca_topic_score_codex":0.000021526723,"about_ca_topic_score_gemma":0.000012514027,"teacher_disagreement_score":0.45435813,"about_ca_system_score_codex":0.00053529174,"about_ca_system_score_gemma":0.0011756646,"threshold_uncertainty_score":0.4464381},"labels":[],"label_agreement":null},{"id":"W2064731204","doi":"10.1074/jbc.m002172200","title":"ADAM 12, a Disintegrin Metalloprotease, Interacts with Insulin-like Growth Factor-binding Protein-3","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Winnipeg; University of Manitoba","funders":"","keywords":"Disintegrin; Metalloproteinase; Immunoprecipitation; Proteases; Proteolysis; Biology; Growth factor; Molecular biology; Biochemistry; Chemistry; Matrix metalloproteinase; Receptor; Gene","score_opus":0.05014929115601866,"score_gpt":0.3165801696925174,"score_spread":0.2664308785364987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064731204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914944,0.0003512064,0.00002722972,0.0009733219,0.000037247104,0.0003116028,0.000014960991,0.00003017501,0.0067598587],"genre_scores_gemma":[0.9941127,0.00021268097,0.0014710891,0.00015148628,0.00042405038,0.000019697096,0.000010417975,0.000023316723,0.003574578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979408,0.00007523252,0.0005933744,0.00029184914,0.000662125,0.0004366417],"domain_scores_gemma":[0.998586,0.000106466665,0.00026314292,0.00023423486,0.00029580813,0.0005143309],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042017037,0.0002584766,0.00059600244,0.000055229862,0.000059904472,0.000049984897,0.0003363022,0.00025127482,0.0059322054],"category_scores_gemma":[0.0005959131,0.00014135138,0.00022557071,0.00022445346,0.0002144352,0.00010794133,0.00005701231,0.001474456,0.000044486416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004077793,0.0006242343,0.0080671385,0.00030959008,0.00028870054,0.0017142876,0.00008152703,0.0000017302365,0.9693831,0.000003539411,0.0006114496,0.014836914],"study_design_scores_gemma":[0.0030967747,0.0024870166,0.0082581695,0.0015604425,0.00006773789,0.0029980885,0.00019996204,0.000011658878,0.9635132,0.00009848068,0.017361302,0.00034715785],"about_ca_topic_score_codex":0.000015619822,"about_ca_topic_score_gemma":0.0000010417934,"teacher_disagreement_score":0.016749851,"about_ca_system_score_codex":0.00030282003,"about_ca_system_score_gemma":0.00032957658,"threshold_uncertainty_score":0.9949765},"labels":[],"label_agreement":null},{"id":"W2065683374","doi":"10.1158/1535-7163.mct-06-0389","title":"C35 (<i>C17orf37</i>) is a novel tumor biomarker abundantly expressed in breast cancer","year":2006,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"Cancer Institute, University of Pittsburgh; Tufts University School of Medicine; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Biology; Biomarker; Breast cancer; Gene; Immunohistochemistry; Cancer; Oncogene; Cancer research; Complementary DNA; Open reading frame; Pathology; Gene expression; Medicine; Immunology; Genetics; Cell cycle; Peptide sequence","score_opus":0.04298584457033967,"score_gpt":0.3514532504766201,"score_spread":0.30846740590628047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065683374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9397132,0.01919918,0.0026927087,0.030690001,0.0006258231,0.0017528719,0.0009716275,0.00020774246,0.0041468926],"genre_scores_gemma":[0.9786737,0.0012843519,0.0007330253,0.016795535,0.00032962282,0.0006254093,0.000027423464,0.00020469965,0.0013262195],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649096,0.0000897865,0.0005775153,0.0007753567,0.001052904,0.0010134904],"domain_scores_gemma":[0.99846494,0.00004325218,0.00013979367,0.0008273729,0.00030870238,0.0002159584],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029867908,0.00044764503,0.00058479526,0.00032390075,0.000090189,0.000083897445,0.00038055098,0.0002016373,0.0010331725],"category_scores_gemma":[0.000006621681,0.0004208793,0.00022341518,0.0010255931,0.000250634,0.000090301124,0.000108494154,0.00057673786,0.00003598792],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006940464,0.00059729785,0.060779694,0.00026351705,0.00027055026,0.00036449276,0.00030456716,0.00014960303,0.9179223,0.00015667504,0.003202247,0.015295012],"study_design_scores_gemma":[0.011589588,0.00019907324,0.25927845,0.0014396427,0.0004374269,0.00025503457,0.00015433626,0.006167866,0.34783038,0.0006361777,0.37065586,0.0013561717],"about_ca_topic_score_codex":0.008307308,"about_ca_topic_score_gemma":0.00065720495,"teacher_disagreement_score":0.5700919,"about_ca_system_score_codex":0.000903073,"about_ca_system_score_gemma":0.0010892663,"threshold_uncertainty_score":0.99988},"labels":[],"label_agreement":null},{"id":"W2066998622","doi":"10.1038/onc.2014.340","title":"Amplified Ras-MAPK signal states correlate with accelerated EGFR internalization, cytostasis and delayed HER2 tumor onset in Fer-deficient model systems","year":2014,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University of Waterloo; Ontario Institute for Cancer Research","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Health Canada; Cancer Research Institute","keywords":"Cytostasis; Biology; Internalization; Cancer research; Carcinogenesis; MAPK/ERK pathway; ATRX; Signal transduction; Immunology; Genetics; Cancer; Mutation; Receptor","score_opus":0.038493480504389735,"score_gpt":0.3192166501895523,"score_spread":0.2807231696851626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066998622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9596099,0.0007033576,0.03747379,0.00027916633,0.00009391444,0.0008274553,0.00009209238,0.000076194134,0.0008440977],"genre_scores_gemma":[0.99774915,0.00017348994,0.0005467442,0.000359169,0.000058491525,0.00012174037,0.00016866975,0.00007129095,0.00075123913],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99766153,0.00019065388,0.000508405,0.0005100983,0.00061971764,0.0005095982],"domain_scores_gemma":[0.99865544,0.00015902567,0.0001392566,0.00036959464,0.00036919166,0.00030749515],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007104866,0.00026311603,0.000498024,0.0002758326,0.000090901325,0.00011608299,0.00016508906,0.000101622594,0.00011099618],"category_scores_gemma":[0.000101161306,0.00021036301,0.000035539248,0.00052894244,0.00012493269,0.000087408385,0.000085599306,0.00032853067,0.000040608134],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017394742,0.0023791417,0.24406454,0.002664035,0.0011887162,0.0016459019,0.008595997,0.5048754,0.17300023,0.0014058987,0.022974815,0.019810593],"study_design_scores_gemma":[0.006338507,0.0016429012,0.0029779878,0.0011763332,0.00012097747,0.00038836166,0.0006747378,0.9688604,0.013617835,0.00011781567,0.003596136,0.00048802077],"about_ca_topic_score_codex":0.0019068546,"about_ca_topic_score_gemma":0.00044684965,"teacher_disagreement_score":0.463985,"about_ca_system_score_codex":0.00041962878,"about_ca_system_score_gemma":0.00041162272,"threshold_uncertainty_score":0.8578355},"labels":[],"label_agreement":null},{"id":"W2067395077","doi":"10.2147/ijwh.s47357","title":"Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations","year":2014,"lang":"en","type":"review","venue":"International Journal of Women s Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Disease; Clinical trial; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Cancer; Targeted therapy","score_opus":0.11594759933645989,"score_gpt":0.5152411216543599,"score_spread":0.3992935223179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067395077","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076657883,0.966688,0.000016289408,0.02089486,0.0025033408,0.00092866085,0.00101607,0.000013385663,0.00027363916],"genre_scores_gemma":[0.010393839,0.9845036,0.00019207812,0.001339622,0.0033064585,0.000054216798,0.000040112045,0.000055989054,0.00011404459],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99494374,0.00088535476,0.0026701808,0.00037621844,0.0006209619,0.00050355203],"domain_scores_gemma":[0.99589825,0.001025457,0.0015042581,0.0001778865,0.0005986702,0.00079549267],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028097944,0.00030555914,0.0025149393,0.00077284075,0.000084039675,0.00009094441,0.0003078583,0.00024271228,0.0018180372],"category_scores_gemma":[0.00042280625,0.00025329686,0.00037273453,0.000081512146,0.0002419663,0.00015892377,0.00010313225,0.0015803631,0.000033598662],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002512405,0.0003179246,0.007989077,0.0040694987,0.0012360642,0.00024092782,0.0008368138,0.0000014865741,6.5510517e-7,0.0013364546,0.010805012,0.9729149],"study_design_scores_gemma":[0.0039267153,0.0015244285,0.012602447,0.028426556,0.00012546784,0.0068162763,0.00013330078,0.000020181047,0.0000010809778,0.00036348682,0.9456599,0.0004001885],"about_ca_topic_score_codex":0.0009221996,"about_ca_topic_score_gemma":0.0002035095,"teacher_disagreement_score":0.9725146,"about_ca_system_score_codex":0.008497882,"about_ca_system_score_gemma":0.009866156,"threshold_uncertainty_score":0.99999195},"labels":[],"label_agreement":null},{"id":"W2069824527","doi":"10.1038/onc.2011.617","title":"MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition","year":2012,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Trastuzumab; Biology; Chromatin immunoprecipitation; Kinase; Molecular biology; Cancer research; Small interfering RNA; Phosphorylation; Cell culture; Gene; Gene expression; Cell biology; Transfection; Genetics; Cancer; Promoter; Breast cancer","score_opus":0.05093400353462508,"score_gpt":0.3643168706496098,"score_spread":0.31338286711498475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069824527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794054,0.00665558,0.00036226818,0.01054358,0.00012077203,0.00097206887,0.0005381641,0.00006588738,0.0013363061],"genre_scores_gemma":[0.975546,0.00023640074,0.013161414,0.0016301185,0.0006170446,0.00029075996,0.00016291953,0.000075226606,0.00828014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795616,0.000088466746,0.00035307085,0.00037272932,0.0004611176,0.0007684839],"domain_scores_gemma":[0.99876606,0.00015714476,0.000101572165,0.00035000165,0.00016885826,0.00045634643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010470621,0.00019436725,0.00035061184,0.00011956878,0.00019600078,0.000029789066,0.00006961673,0.00013976403,0.00022872064],"category_scores_gemma":[0.0003319095,0.00018732063,0.00007911095,0.00028589,0.00010650594,0.00009893005,0.000054221597,0.00019999183,0.000011060422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009205967,0.00014275803,0.0029036116,0.00020756184,0.000055134908,0.000012334062,0.0012619263,3.566165e-7,0.87928367,0.000041591327,0.112183355,0.0029870793],"study_design_scores_gemma":[0.002114417,0.00033439152,0.0005697638,0.000114683215,0.000058929647,0.000038490773,0.00018898267,0.00007438184,0.79187167,0.00013430283,0.20431694,0.00018307356],"about_ca_topic_score_codex":0.00010564094,"about_ca_topic_score_gemma":0.00012262088,"teacher_disagreement_score":0.09213358,"about_ca_system_score_codex":0.0004045099,"about_ca_system_score_gemma":0.00044603372,"threshold_uncertainty_score":0.7638714},"labels":[],"label_agreement":null},{"id":"W2071102398","doi":"10.1023/a:1017938608460","title":"Loss of androgen receptor associated protein 70 (ARA70) expression in a subset of HER2-positive breast cancers","year":2001,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada; Health Sciences Centre; Mount Sinai Hospital; Lunenfeld-Tanenbaum Research Institute; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Medical Research Council","keywords":"Androgen receptor; Cancer research; Biology; Transactivation; Breast cancer; Endocrinology; Internal medicine; Cancer; Gene expression; Medicine; Prostate cancer; Gene","score_opus":0.052325602305618654,"score_gpt":0.3874648457897417,"score_spread":0.33513924348412305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071102398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906717,0.0023838212,0.0000019126026,0.002191689,0.000028061666,0.0021202774,0.0017887339,0.00001851431,0.00079527363],"genre_scores_gemma":[0.992991,0.0045410614,0.00006379188,0.000012287413,0.00009163093,0.0010042492,0.0001025578,0.00004348908,0.0011499544],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657995,0.00037735052,0.000455003,0.0005559814,0.0011746587,0.00085705915],"domain_scores_gemma":[0.99817383,0.0001323164,0.00013241499,0.00039719648,0.00072050147,0.00044375166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007084361,0.00025777667,0.0006658206,0.00043719987,0.00009852584,0.000020138657,0.00015800243,0.00016663654,0.00069545023],"category_scores_gemma":[0.000053011576,0.00019963815,0.0000973492,0.0010784632,0.000566729,0.000103567174,0.00010984948,0.00035863245,0.000009065486],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0187628,0.0034650615,0.8024711,0.00045665924,0.00063926267,0.0006238405,0.001801819,0.000016804359,0.07443839,0.00004589046,0.0010895431,0.096188806],"study_design_scores_gemma":[0.017948905,0.0061660316,0.6837769,0.0075531686,0.0000776449,0.0004847808,0.0011935077,0.00010711816,0.2802229,0.00016167494,0.001877481,0.0004298937],"about_ca_topic_score_codex":0.046160974,"about_ca_topic_score_gemma":0.004938389,"teacher_disagreement_score":0.2057845,"about_ca_system_score_codex":0.002947015,"about_ca_system_score_gemma":0.00202163,"threshold_uncertainty_score":0.9601907},"labels":[],"label_agreement":null},{"id":"W2071130163","doi":"10.1097/01.mp.0000052102.90815.82","title":"Current Perspectives on HER2 Testing: A Review of National Testing Guidelines","year":2003,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Medical physics; Quality assurance; Trastuzumab; Pathology; Test (biology); Fish <Actinopterygii>; External quality assessment; Intensive care medicine; Internal medicine; Breast cancer; Cancer; Biology","score_opus":0.5663146011887417,"score_gpt":0.5638883755037888,"score_spread":0.0024262256849528763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071130163","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000028975169,0.98667043,0.0001731025,0.0002826513,0.00024511167,0.0015141123,0.00009527697,0.000061612955,0.010954823],"genre_scores_gemma":[0.0000028987042,0.9913377,0.0067914226,0.00047667243,0.00050385634,0.00038154257,0.000072165945,0.00010275657,0.00033098928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955535,0.0006369342,0.0013988882,0.0009248111,0.0010071904,0.00047867396],"domain_scores_gemma":[0.9944148,0.0010473102,0.00066787883,0.0006995932,0.003010923,0.0001594934],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002179524,0.00049232825,0.00260078,0.00041371785,0.000061516694,0.000008539159,0.00032302452,0.00029986963,0.00015711269],"category_scores_gemma":[0.024393275,0.000382747,0.0004260402,0.00084224826,0.00022924592,0.000023458162,0.0001265485,0.0011368876,0.00011487812],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000043087925,0.00019151076,0.00003416441,0.14531535,0.000048138936,0.00011731416,0.000056469624,0.0000015939944,0.0000035271637,0.0001419519,0.0054072007,0.84867847],"study_design_scores_gemma":[0.00020566523,0.00036048322,0.000008503651,0.25871152,0.00029278963,0.0012301471,0.000008955059,0.00006495525,7.18178e-7,0.00024871592,0.7386353,0.00023221548],"about_ca_topic_score_codex":0.000007846818,"about_ca_topic_score_gemma":8.497561e-7,"teacher_disagreement_score":0.84844625,"about_ca_system_score_codex":0.000589016,"about_ca_system_score_gemma":0.00320684,"threshold_uncertainty_score":0.99986243},"labels":[],"label_agreement":null},{"id":"W2071275412","doi":"10.1158/0008-5472.can-05-4045","title":"Mechanisms of Tumor Regression and Resistance to Estrogen Deprivation and Fulvestrant in a Model of Estrogen Receptor–Positive, HER-2/<i>neu</i>-Positive Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":151,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Fulvestrant; Endocrinology; Internal medicine; Estrogen receptor; Estrogen; Gefitinib; Protein kinase B; Breast cancer; Medicine; Cancer research; Tamoxifen; Epidermal growth factor receptor; Cancer; Biology; Phosphorylation","score_opus":0.04513150536202543,"score_gpt":0.38115746349442364,"score_spread":0.3360259581323982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071275412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894938,0.0040737973,0.0004789929,0.003144091,0.000038961352,0.0015449915,0.0007264718,0.00001691377,0.00048199587],"genre_scores_gemma":[0.99388015,0.0009864251,0.004024853,0.0000765339,0.000091606984,0.00049320806,0.000022401167,0.000058821337,0.00036600465],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964509,0.00026918764,0.0005529249,0.0007080631,0.0013093948,0.00070952665],"domain_scores_gemma":[0.9980156,0.00018897127,0.00013278729,0.00041257864,0.00092696055,0.00032309335],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011614765,0.00023862591,0.00057257724,0.00055106013,0.000110918765,0.000029460054,0.00022027522,0.00014076187,0.000083783714],"category_scores_gemma":[0.00010956206,0.00021485153,0.000056418754,0.0010614484,0.00045853326,0.0001491847,0.00021944832,0.00057692605,0.000001987093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038871036,0.00020254872,0.030176777,0.0007537007,0.00005688337,0.00004308003,0.0007151936,0.00036338565,0.9536425,0.004136315,0.0009989634,0.0050235586],"study_design_scores_gemma":[0.0029717837,0.0005956574,0.0859918,0.005861696,0.000052658914,0.000035360237,0.00039722183,0.0016621494,0.89636135,0.005613191,0.00012532446,0.00033180663],"about_ca_topic_score_codex":0.0078114215,"about_ca_topic_score_gemma":0.0018732309,"teacher_disagreement_score":0.05728114,"about_ca_system_score_codex":0.0006495716,"about_ca_system_score_gemma":0.0011640362,"threshold_uncertainty_score":0.9987956},"labels":[],"label_agreement":null},{"id":"W2072485456","doi":"10.1021/pr500987r","title":"Glycoproteomic Comparison of Clinical Triple-Negative and Luminal Breast Tumors","year":2015,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; National Research Council Canada","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec","keywords":"Breast cancer; Estrogen receptor; Cancer research; Immunohistochemistry; Biology; Tissue microarray; Western blot; Internal medicine; Oncology; Cancer; Medicine; Gene","score_opus":0.4559443937309339,"score_gpt":0.5997107197676118,"score_spread":0.14376632603667794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072485456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911339,0.0010280758,0.000109159286,0.0041253995,0.00021237429,0.0015533825,0.000014800788,0.000008062738,0.0018148294],"genre_scores_gemma":[0.9909489,0.0001352864,0.0065991404,0.00001687734,0.0013294267,0.000033797056,0.0000011503876,0.000035843117,0.0008995372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922095,0.0014303653,0.0018460278,0.00030592462,0.0035562094,0.0006519762],"domain_scores_gemma":[0.99278766,0.0007815338,0.00064659154,0.00039142175,0.004118606,0.0012742169],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020087864,0.00017086655,0.0012580109,0.0008462634,0.000091345886,0.000052230855,0.00043452796,0.00021145026,0.00017101198],"category_scores_gemma":[0.008649543,0.00012642691,0.0002148393,0.0008880357,0.0012438289,0.00020589297,0.0002731216,0.0032219815,0.00004378751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038102295,0.0030231832,0.78682095,0.0019442842,0.0006387391,0.0015259555,0.0044554267,0.000011824949,0.043253142,0.00017679571,0.04671843,0.07332899],"study_design_scores_gemma":[0.05037482,0.06601335,0.69252956,0.007827954,0.00024903394,0.013155395,0.018448984,0.0034711491,0.12851779,0.0059666075,0.0126444595,0.0008008984],"about_ca_topic_score_codex":0.00026413237,"about_ca_topic_score_gemma":0.000013816543,"teacher_disagreement_score":0.09429139,"about_ca_system_score_codex":0.0003773828,"about_ca_system_score_gemma":0.0043743392,"threshold_uncertainty_score":0.999701},"labels":[],"label_agreement":null},{"id":"W2072648072","doi":"10.1038/modpathol.3880440","title":"HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization","year":2001,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":220,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Breast cancer; Stain; Concordance; Fluorescence in situ hybridization; Pathology; Medicine; Polyclonal antibodies; Trastuzumab; Monoclonal antibody; Staining; Cancer; Antibody; Biology; Internal medicine; Immunology; Gene","score_opus":0.019161283652451934,"score_gpt":0.2999954879935629,"score_spread":0.28083420434111095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072648072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99829566,0.00034024994,0.00025952377,0.00040692688,0.000020149866,0.0003381085,0.00001487905,0.000015754773,0.00030874347],"genre_scores_gemma":[0.9989743,0.00043459935,0.00038656493,0.000052767,0.000016430671,0.000055100696,0.000020846346,0.00001897631,0.00004041945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878556,0.000090710106,0.0002829583,0.00036384907,0.00019382463,0.0002831135],"domain_scores_gemma":[0.9993612,0.000029794322,0.000076815624,0.00033336383,0.00014242323,0.00005639904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033450517,0.00014415078,0.00040843192,0.00010261465,0.00002249258,0.000005464957,0.000091816386,0.00007887442,0.00003293362],"category_scores_gemma":[0.000017934373,0.00011482477,0.000014213787,0.0002152825,0.00034079448,0.000069528825,0.00006241419,0.00028924883,6.618288e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027810747,0.00022129723,0.8934633,0.0004370022,0.00001285635,0.00019397712,0.0008012751,0.00054945285,0.098755285,0.0000022791376,0.000009028592,0.0027731657],"study_design_scores_gemma":[0.0024197807,0.00032366335,0.9799068,0.00061505,0.00001507822,0.0006973332,0.00007452,0.0072935564,0.008521289,0.000011429952,0.0000063929497,0.000115099276],"about_ca_topic_score_codex":0.0004306936,"about_ca_topic_score_gemma":0.00048554633,"teacher_disagreement_score":0.090234,"about_ca_system_score_codex":0.00027968426,"about_ca_system_score_gemma":0.00019145486,"threshold_uncertainty_score":0.4682418},"labels":[],"label_agreement":null},{"id":"W2072990829","doi":"10.1158/1078-0432.ccr-08-0121","title":"Expression of t-DARPP Mediates Trastuzumab Resistance in Breast Cancer Cells","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; Genentech","keywords":"Trastuzumab; Gene knockdown; Cancer research; Apoptosis; Molecular biology; Cell culture; Small interfering RNA; Biology; Cancer cell; Cancer; Medicine; Internal medicine; Breast cancer; Transfection; Biochemistry","score_opus":0.2929450628927039,"score_gpt":0.5554410195244822,"score_spread":0.2624959566317783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072990829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749329,0.0097265355,0.0000072406365,0.00869845,0.0005058381,0.0011896646,0.00025757172,0.000048622052,0.0046331547],"genre_scores_gemma":[0.95641595,0.037571914,0.0003901434,0.00023515538,0.00102038,0.0005920862,0.000009764009,0.00008108894,0.0036835356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99237645,0.0010629476,0.0014391537,0.0009938744,0.002852866,0.0012746885],"domain_scores_gemma":[0.9948262,0.0020234943,0.00017586396,0.0010063375,0.0012317214,0.0007363722],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048229643,0.00026092614,0.0010413639,0.00053215626,0.00018116483,0.000017890141,0.0007103624,0.00041464638,0.0035502391],"category_scores_gemma":[0.0009952554,0.00021647195,0.00025260705,0.0017830061,0.0020382972,0.00013811022,0.00034040379,0.002635074,0.00010304794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008890569,0.0017413006,0.69475484,0.0014711322,0.00008602676,0.00080307963,0.0013640735,0.000028532191,0.098206826,0.00006564604,0.17968722,0.012900735],"study_design_scores_gemma":[0.007318908,0.0007173664,0.82385445,0.00389945,0.000029416742,0.000029028683,0.00037152873,0.000087496024,0.12787353,0.00037510452,0.035011366,0.00043234252],"about_ca_topic_score_codex":0.00298042,"about_ca_topic_score_gemma":0.0019225237,"teacher_disagreement_score":0.14467585,"about_ca_system_score_codex":0.00093968504,"about_ca_system_score_gemma":0.0043413746,"threshold_uncertainty_score":0.9996659},"labels":[],"label_agreement":null},{"id":"W2073149046","doi":"10.1158/1538-7445.am2011-1352","title":"Abstract 1352: Mechanism of action of AL622, a molecule rationally designed to release an EGFR and a Src kinase inhibitor","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gefitinib; Transfection; EGFR inhibitors; Proto-oncogene tyrosine-protein kinase Src; Chemistry; Cancer research; Epidermal growth factor receptor; Cell growth; Western blot; Kinase; Pharmacology; Receptor; Biology; Biochemistry; Gene","score_opus":0.23121162410328822,"score_gpt":0.4647197616200853,"score_spread":0.2335081375167971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073149046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953625,0.00034036543,0.00030501204,0.00077242765,0.00007966573,0.0012476258,0.00005063421,0.000022679858,0.0018190738],"genre_scores_gemma":[0.9968143,0.00028202566,0.0016936769,0.00009566087,0.00017088334,0.00034788589,0.000010835253,0.000045677447,0.0005390376],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709505,0.00022223973,0.0003848802,0.0004509614,0.0013583576,0.0004885233],"domain_scores_gemma":[0.9974006,0.00013634773,0.00008014633,0.0005208502,0.0012851353,0.0005769362],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015849009,0.00014155784,0.00031913794,0.00054608413,0.00009153884,0.000018332741,0.00021813018,0.00013714927,0.0014341499],"category_scores_gemma":[0.0005929342,0.00013302219,0.0000563739,0.0006738027,0.00024430733,0.00016301453,0.00012636339,0.0004667191,0.000023890074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025237068,0.00035268872,0.00060569705,0.00065218966,0.00004726877,0.00007611534,0.0014002958,0.0000035349515,0.98082036,0.0012805731,0.0016739314,0.010563668],"study_design_scores_gemma":[0.0012811034,0.0018675238,0.010350282,0.00045670732,0.000018343362,0.000010033787,0.000585383,0.00007819629,0.98409426,0.000694775,0.0004442044,0.00011920234],"about_ca_topic_score_codex":0.0037754744,"about_ca_topic_score_gemma":0.00046103817,"teacher_disagreement_score":0.010444465,"about_ca_system_score_codex":0.0003524681,"about_ca_system_score_gemma":0.0015592999,"threshold_uncertainty_score":0.9994787},"labels":[],"label_agreement":null},{"id":"W2073871328","doi":"10.1159/000055399","title":"Dose Scheduling – Herceptin&lt;sup&gt;®&lt;/sup&gt;","year":2001,"lang":"en","type":"review","venue":"Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pharmacokinetics; Taxane; Paclitaxel; Pharmacology; Regimen; Capecitabine; Trastuzumab; Metastatic breast cancer; Docetaxel; Oncology; Oral administration; Internal medicine; Breast cancer; Chemotherapy; Cancer; Colorectal cancer","score_opus":0.1837246228174495,"score_gpt":0.4974194244479117,"score_spread":0.3136948016304622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073871328","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008396973,0.86865294,0.00004754871,0.0012463724,0.0009331136,0.0024673492,0.00004976249,0.00023435942,0.12628458],"genre_scores_gemma":[0.00001899433,0.9616999,0.0043121297,0.00085254456,0.004453475,0.00078785577,0.00035232937,0.00033492548,0.027187834],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926857,0.0011858257,0.0016510619,0.0015163252,0.0011113433,0.0018497495],"domain_scores_gemma":[0.99522597,0.0011697569,0.0005491405,0.0017238358,0.0003968246,0.00093448634],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.002227885,0.0009939289,0.0050676037,0.00082168216,0.00021004879,0.0000617439,0.0010167689,0.0025101209,0.0120201],"category_scores_gemma":[0.0012739162,0.0008410581,0.0010740622,0.0014686916,0.00055256154,0.000088133296,0.00057684263,0.0033430145,0.008727089],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000085005886,0.00049430085,0.000023481976,0.013156387,0.00038808538,0.0022505748,0.00015489945,0.000006741469,0.000014845266,0.00016989498,0.038698733,0.9445571],"study_design_scores_gemma":[0.0016489663,0.0019312279,0.000011765984,0.010957012,0.0011919799,0.0023964518,0.000062691935,0.0000769384,0.0000011493039,0.000044133354,0.9810284,0.0006493261],"about_ca_topic_score_codex":0.00010261835,"about_ca_topic_score_gemma":0.00017299432,"teacher_disagreement_score":0.94390774,"about_ca_system_score_codex":0.0038925936,"about_ca_system_score_gemma":0.0070505333,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W2074695616","doi":"10.1007/s10549-012-2236-9","title":"Management of small HER2 overexpressing tumours","year":2012,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Odds ratio; Chemotherapy; Cancer; Gynecology; Confidence interval","score_opus":0.29971512262007144,"score_gpt":0.4988222990774509,"score_spread":0.19910717645737946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074695616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022939402,0.9902469,0.0000022556856,0.00022258091,0.00010432796,0.0028842322,0.00054633507,0.000032719952,0.0057312767],"genre_scores_gemma":[0.0008183095,0.9902547,0.00032960408,0.0000054746265,0.00049925596,0.0021172075,0.00010199281,0.00012629168,0.0057471544],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958081,0.00032485026,0.0005828262,0.0007658761,0.0012232742,0.0012950323],"domain_scores_gemma":[0.99767506,0.00017896228,0.0001701546,0.0008737866,0.00028496177,0.0008170634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074014394,0.0005389326,0.0018135777,0.0005503127,0.0001736798,0.000069491,0.000267325,0.00024625243,0.0007213858],"category_scores_gemma":[0.0000059768604,0.00036664883,0.00036194394,0.0006771763,0.00044677654,0.000059709004,0.00036178651,0.000636182,0.00007856559],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023408768,0.0007555787,0.00051860657,0.037319418,0.0012565067,0.0003979323,0.00006246133,8.7504255e-8,0.0000012001321,0.00019037981,0.0002500585,0.9590137],"study_design_scores_gemma":[0.0015242208,0.00071039447,0.0015605259,0.054465935,0.0014972739,0.00054104166,0.000085264815,0.0000014003313,0.000028955079,0.000031575684,0.93926245,0.00029098842],"about_ca_topic_score_codex":0.0028598255,"about_ca_topic_score_gemma":0.000091326016,"teacher_disagreement_score":0.9587227,"about_ca_system_score_codex":0.0022818004,"about_ca_system_score_gemma":0.0013137115,"threshold_uncertainty_score":0.9998785},"labels":[],"label_agreement":null},{"id":"W2075638718","doi":"10.1016/j.jval.2014.08.2164","title":"Overall Survival in Patients with HER2+ Early Stage Breast Cancer Patients Treated with Trastuzumab in the US Department of Defense Practice Setting","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Trastuzumab; Medicine; Adjuvant; Internal medicine; Breast cancer; Oncology; Stage (stratigraphy); Adjuvant therapy; Cancer; Clinical trial; Clinical Practice; Surgery; Physical therapy","score_opus":0.026365130467483195,"score_gpt":0.33172896818348613,"score_spread":0.30536383771600295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075638718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590534,0.00006044731,0.0000047852336,0.0012786327,0.000045113717,0.0021781845,0.00015235772,0.000013558588,0.0003615511],"genre_scores_gemma":[0.99880016,0.00006326079,0.00024164663,0.0005997927,0.000033979733,0.00014615514,0.000052187912,0.000044473632,0.000018342407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956364,0.0014362816,0.0006301238,0.00040497255,0.0012182851,0.0006739529],"domain_scores_gemma":[0.9983365,0.0005361681,0.0003168011,0.0004004512,0.00024447098,0.0001656092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002053138,0.0002165864,0.0004838654,0.00022986442,0.000049494123,0.000019246841,0.00015883349,0.00007230056,0.000022480242],"category_scores_gemma":[0.00022200287,0.00013885362,0.000026189304,0.0006836049,0.00007546844,0.0001521513,0.000031673408,0.0005727801,0.0000028563315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003531314,0.0015776441,0.9868777,0.0004098811,0.000026655733,0.000024518013,0.0029967998,0.0018492157,9.849385e-7,0.000030179186,0.000036630514,0.0026385188],"study_design_scores_gemma":[0.009126879,0.0038949086,0.98452485,0.0011232103,0.000014538154,0.000004110654,0.00026722593,0.00051837065,0.000009715808,0.0000036934834,0.0003842884,0.00012821356],"about_ca_topic_score_codex":0.15105693,"about_ca_topic_score_gemma":0.00952634,"teacher_disagreement_score":0.14153059,"about_ca_system_score_codex":0.0014059958,"about_ca_system_score_gemma":0.0009133293,"threshold_uncertainty_score":0.85459626},"labels":[],"label_agreement":null},{"id":"W2075966869","doi":"10.1007/s12012-012-9183-x","title":"The Dual-Targeted HER1/HER2 Tyrosine Kinase Inhibitor Lapatinib Strongly Potentiates the Cardiac Myocyte-Damaging Effects of Doxorubicin","year":2012,"lang":"en","type":"article","venue":"Cardiovascular Toxicology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Apotex (Canada)","funders":"Canadian Institutes of Health Research; Canada Research Chairs","keywords":"Lapatinib; Cardiotoxicity; Doxorubicin; Tyrosine-kinase inhibitor; Pharmacology; Tyrosine kinase; Myocyte; Medicine; Trastuzumab; Chemistry; Internal medicine; Receptor; Cancer; Chemotherapy; Breast cancer","score_opus":0.014463149592621903,"score_gpt":0.2814317603408668,"score_spread":0.2669686107482449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075966869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8424278,0.14976692,0.0001718605,0.0013620458,0.003114174,0.00207069,0.000020822528,0.00010093336,0.0009647442],"genre_scores_gemma":[0.9956333,0.001359935,0.00019176221,0.00022760646,0.0017275907,0.00035236077,0.000027816437,0.00009809461,0.00038151778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99495953,0.0016532626,0.0005537109,0.0004680248,0.0010900045,0.0012754658],"domain_scores_gemma":[0.99608594,0.0012199361,0.00014952161,0.0018077682,0.00038595448,0.0003508775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035252918,0.00037078807,0.0011065865,0.000144177,0.00040402703,0.000044431818,0.0003773456,0.00029205286,0.000057877205],"category_scores_gemma":[0.0016463782,0.00022822393,0.0013385314,0.0005990397,0.00077497313,0.00011427129,0.00033436326,0.0008498847,0.00007931169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013036347,0.0015187557,0.08375538,0.002741009,0.022459166,0.0008644228,0.0038594846,0.00081084383,0.66354275,0.0023377375,0.0382069,0.17859991],"study_design_scores_gemma":[0.003946241,0.00083565916,0.14215358,0.0002717047,0.0020385145,0.0001874191,0.00084772153,0.00012722737,0.65007704,0.00003083869,0.19905269,0.00043135445],"about_ca_topic_score_codex":0.00019749287,"about_ca_topic_score_gemma":0.000012694054,"teacher_disagreement_score":0.17816855,"about_ca_system_score_codex":0.00029514328,"about_ca_system_score_gemma":0.00031117786,"threshold_uncertainty_score":0.9306702},"labels":[],"label_agreement":null},{"id":"W2076363741","doi":"10.1016/j.radonc.2009.06.021","title":"Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells","year":2009,"lang":"en","type":"article","venue":"Radiotherapy and Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"KWF Kankerbestrijding","keywords":"Cetuximab; Internalization; Glioma; Flow cytometry; Cancer research; Epidermal growth factor receptor; Chemistry; Radiosensitivity; Clonogenic assay; Cell culture; Downregulation and upregulation; Cell; Biology; Molecular biology; Receptor; Antibody; Monoclonal antibody; Immunology; Medicine; Radiation therapy; Internal medicine; Biochemistry; Genetics","score_opus":0.05783316915741105,"score_gpt":0.38166028477161335,"score_spread":0.3238271156142023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076363741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97905326,0.0048736236,0.000059352587,0.015162032,0.00007496083,0.0005120493,0.0000062124386,0.0000100137095,0.00024847113],"genre_scores_gemma":[0.99196523,0.0059205405,0.0005379342,0.0014329267,0.000087169545,0.000017611019,0.0000012837245,0.0000053108606,0.000031983942],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989789,0.00019839857,0.00023032255,0.00022343123,0.00011885251,0.0002500647],"domain_scores_gemma":[0.9995058,0.00020946967,0.000049700146,0.0001025854,0.00003577334,0.00009665518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006935653,0.00009256386,0.00033919982,0.00015264012,0.00004975536,0.00000777612,0.00008086649,0.00014368343,0.00008865328],"category_scores_gemma":[0.000054051907,0.00005507378,0.00002423763,0.00026303003,0.00019588888,0.000020703159,0.000014553656,0.0001627359,0.0000027077726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006291758,0.000116589144,0.0027245288,0.000020012783,0.000015910638,0.00019694863,0.0009894752,0.000004536699,0.934299,0.00078651484,0.00015569627,0.060061645],"study_design_scores_gemma":[0.01083877,0.03496573,0.06162721,0.0005091001,0.000044072447,0.0028310306,0.0016460217,0.0015738765,0.7679948,0.0009442217,0.11654979,0.0004753393],"about_ca_topic_score_codex":0.000050692022,"about_ca_topic_score_gemma":0.00006540632,"teacher_disagreement_score":0.16630413,"about_ca_system_score_codex":0.00019030784,"about_ca_system_score_gemma":0.00014179152,"threshold_uncertainty_score":0.22458436},"labels":[],"label_agreement":null},{"id":"W2076365212","doi":"10.1016/j.bmc.2009.09.038","title":"Synthesis and radiopharmacological investigation of 3-[4′-[18F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor","year":2009,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Tyrosine-kinase inhibitor; Enzyme inhibitor; Tyrosine kinase; Chemical synthesis; Stereochemistry; Kinase; Biochemistry; Enzyme; In vitro; Signal transduction","score_opus":0.034886476533503435,"score_gpt":0.31876738183386943,"score_spread":0.283880905300366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076365212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859153,0.0051488136,0.000012774746,0.006768601,0.00008719556,0.00036438013,0.000015795413,0.00009337316,0.0015937823],"genre_scores_gemma":[0.9960675,0.00082884176,0.0005767117,0.0009242184,0.0010143424,0.000022534718,0.0000241843,0.00003277401,0.0005088589],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973953,0.00006712674,0.00060367223,0.00053291506,0.0009313806,0.00046962488],"domain_scores_gemma":[0.99823076,0.0002170976,0.00018593099,0.000400994,0.00024842628,0.0007168039],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006595811,0.00028844472,0.00064858166,0.000097077085,0.00008875654,0.000020844464,0.0002147411,0.0002790113,0.0017991976],"category_scores_gemma":[0.001448935,0.00025202503,0.00008681321,0.0005149975,0.00050701573,0.00007381607,0.00007786026,0.0005682522,0.000028903058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045943205,0.00018755675,0.00417593,0.0006410478,0.000051425213,0.00020334685,0.00012937681,1.6239909e-7,0.985186,0.000017270253,0.0024238005,0.006524651],"study_design_scores_gemma":[0.0018067425,0.0006040926,0.024205469,0.00085518544,0.00023107104,0.00046728502,0.00016333359,0.000033631797,0.9708481,0.00017994604,0.0003995536,0.00020563383],"about_ca_topic_score_codex":0.000059989055,"about_ca_topic_score_gemma":7.248145e-7,"teacher_disagreement_score":0.020029537,"about_ca_system_score_codex":0.00027310426,"about_ca_system_score_gemma":0.00068714074,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W2078864821","doi":"10.1503/cmaj.090574","title":"Ranibizumab and the eye","year":2011,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Epidermal growth factor receptor; Medicine; Immunohistochemistry; Cancer research; Sanger sequencing; Oncology; Internal medicine; Druggability; Copy-number variation; Cancer; Biology; Gene; Mutation","score_opus":0.051965385983189935,"score_gpt":0.3803389735490467,"score_spread":0.3283735875658568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078864821","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022009754,0.970556,0.0000048437773,0.0107034715,0.00076525204,0.0005487757,0.000026497497,0.000011116354,0.017381795],"genre_scores_gemma":[0.0000065787963,0.98765165,0.000025867534,0.0036080254,0.00313819,0.0000390229,0.000012930221,0.000047794554,0.0054699564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99572873,0.00084880815,0.000767164,0.0002282951,0.0017525557,0.00067446963],"domain_scores_gemma":[0.995584,0.00054302,0.00038868954,0.0002367345,0.00037613578,0.0028713893],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060701887,0.00024306755,0.0013649428,0.00030434714,0.00031126244,0.00012065328,0.00038248763,0.0010047604,0.009325132],"category_scores_gemma":[0.005807365,0.000139751,0.00042125364,0.00033396346,0.00022235705,0.000041178097,0.000041042902,0.0041449033,0.00050152984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009017802,0.0000063420166,0.000103221035,0.00082576583,0.00030899316,0.00043343529,0.00009676088,1.1914769e-9,1.0287871e-9,0.00043295923,0.094646186,0.9031373],"study_design_scores_gemma":[0.001560568,0.000038522456,0.0000671529,0.005418953,0.00048740456,0.0021728266,0.00003308677,0.0000035832086,1.0639321e-8,0.00008865554,0.9900017,0.00012753293],"about_ca_topic_score_codex":0.0034859348,"about_ca_topic_score_gemma":0.007566111,"teacher_disagreement_score":0.9030098,"about_ca_system_score_codex":0.0025354,"about_ca_system_score_gemma":0.020440878,"threshold_uncertainty_score":0.99815255},"labels":[],"label_agreement":null},{"id":"W2078881615","doi":"10.1056/nejmoa054504","title":"<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; McMaster University; Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Cancer; Cancer research; Human Epidermal Growth Factor Receptor 2","score_opus":0.01893375892135406,"score_gpt":0.3470915491465274,"score_spread":0.32815779022517333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078881615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9099076,0.0068215793,0.0002780094,0.08137783,0.00034845388,0.00023530041,0.000013020863,0.000007189432,0.0010110643],"genre_scores_gemma":[0.9890909,0.0020507183,0.0005391211,0.001786011,0.0051757246,0.0000026448427,0.0000015852225,0.000029137465,0.0013241242],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99820846,0.00008810723,0.00055408466,0.000140195,0.0007759087,0.0002332617],"domain_scores_gemma":[0.99845207,0.00020246812,0.00021367973,0.00018054823,0.0005369614,0.00041430182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011432731,0.00013792099,0.0006502356,0.00029216585,0.000025296731,0.0000051931665,0.00012054731,0.00006161714,0.00057063764],"category_scores_gemma":[0.00017379949,0.0000876851,0.000051114635,0.0003241511,0.00014972282,0.00004627052,0.000021388127,0.0003105117,0.0000015998577],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013592777,0.00015700345,0.1112704,0.00030603792,0.00015788391,0.0005137905,0.0013673127,0.00006061738,0.187937,0.000097225085,0.09938434,0.5851556],"study_design_scores_gemma":[0.07098971,0.0038331447,0.61748886,0.0036710375,0.00019494726,0.004959335,0.00024301608,0.000022680588,0.014865469,0.0004650442,0.28309673,0.00017003364],"about_ca_topic_score_codex":0.002059819,"about_ca_topic_score_gemma":0.00016846028,"teacher_disagreement_score":0.58498555,"about_ca_system_score_codex":0.00009771296,"about_ca_system_score_gemma":0.0005582748,"threshold_uncertainty_score":0.6248082},"labels":[],"label_agreement":null},{"id":"W2079324061","doi":"10.1002/1097-4652(200002)186:2<233::aid-jcp1017>3.0.co;2-l","title":"Regulation of heparin-binding EGF-like growth factor expression in Ha-ras transformed human Mammary epithelial cells","year":2001,"lang":"en","type":"article","venue":"Journal of Cellular Physiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Epidermal growth factor; Heparin-binding EGF-like growth factor; Biology; MAPK/ERK pathway; Tyrosine kinase; Molecular biology; Growth factor; Cell culture; Transfection; Monoclonal antibody; Cell biology; Signal transduction; Epidermal growth factor receptor; Receptor; Antibody; Immunology; Biochemistry","score_opus":0.032947315627009956,"score_gpt":0.3177514584656081,"score_spread":0.2848041428385981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079324061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99717665,0.00020379233,0.0011906697,0.0002491346,0.00035097607,0.00027595335,0.0000060794555,0.000009196781,0.000537525],"genre_scores_gemma":[0.99804115,0.00046882467,0.0005368753,0.00004699403,0.0004236812,0.000004358452,0.000015604672,0.000030116567,0.00043237675],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976859,0.0002678266,0.00089854246,0.00021611819,0.00053890236,0.00039268876],"domain_scores_gemma":[0.99875593,0.000122015255,0.00043557238,0.00026106203,0.00025009425,0.00017532165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005233786,0.00018129415,0.00069804257,0.0005128825,0.0000545886,0.000008730538,0.00026673477,0.00019812422,0.00037901962],"category_scores_gemma":[0.00005447866,0.00014675238,0.00023619016,0.0002874792,0.00012454989,0.00019583604,0.000046617464,0.0006363487,0.000010784333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086317054,0.00026636253,0.0030655554,0.00021461306,0.000043046697,0.00016687231,0.00043021748,0.00003796322,0.9934523,0.00006673697,0.00027327728,0.0011198503],"study_design_scores_gemma":[0.0027258329,0.0009835813,0.064858295,0.00033188442,0.000026883134,0.00009959755,0.00006690804,0.000116947114,0.927938,0.0011244359,0.0016057604,0.000121917605],"about_ca_topic_score_codex":0.00004745332,"about_ca_topic_score_gemma":0.000010118378,"teacher_disagreement_score":0.06551438,"about_ca_system_score_codex":0.00021818717,"about_ca_system_score_gemma":0.00025011937,"threshold_uncertainty_score":0.59843886},"labels":[],"label_agreement":null},{"id":"W2079349186","doi":"10.1016/j.bbrc.2013.03.062","title":"HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells","year":2013,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Child and Family Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Cadherin; Cancer research; Ovarian cancer; Biology; Epidermal growth factor; Gene knockdown; Slug; Cancer; Cancer cell; Tyrosine kinase; Receptor tyrosine kinase; Epidermal growth factor receptor; Receptor; Signal transduction; Cell biology; Cell; Cell culture; Genetics","score_opus":0.13816716400308032,"score_gpt":0.4295027855072308,"score_spread":0.2913356215041505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079349186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864831,0.0003886252,0.0000031995335,0.011174128,0.000016351436,0.0008078847,0.000033839802,0.000025200181,0.001067662],"genre_scores_gemma":[0.99787474,0.0007899076,0.0005410202,0.00005495227,0.0001223614,0.00037481985,0.000058369573,0.000021844993,0.00016201634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975791,0.00036301176,0.00043008706,0.0003391432,0.0007722081,0.00051647046],"domain_scores_gemma":[0.9971856,0.0007458572,0.00006039552,0.0009706554,0.00066221855,0.00037525813],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004862024,0.00015228648,0.00035287306,0.0002315272,0.00016302703,0.000043617318,0.0006072027,0.00019613223,0.00045138257],"category_scores_gemma":[0.00046506265,0.00012443501,0.000079590296,0.00086297997,0.000984329,0.00011413093,0.0005558077,0.0009536666,0.000052538813],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000328095,0.000497961,0.0040239324,0.00016128735,0.000024043662,8.1851226e-7,0.00017473444,8.1880636e-8,0.98856205,0.0014998476,0.0011193216,0.0039031063],"study_design_scores_gemma":[0.0006406375,0.00019317471,0.20943199,0.00020212914,0.000008324387,9.514141e-7,0.00009280788,0.00063557056,0.7866273,0.0017519861,0.0002931737,0.00012194983],"about_ca_topic_score_codex":0.010393049,"about_ca_topic_score_gemma":0.00010591826,"teacher_disagreement_score":0.20540807,"about_ca_system_score_codex":0.00019132072,"about_ca_system_score_gemma":0.0002341323,"threshold_uncertainty_score":0.9961968},"labels":[],"label_agreement":null},{"id":"W2079374922","doi":"10.1186/1475-2867-8-18","title":"Ebp1 expression in benign and malignant prostate","year":2008,"lang":"en","type":"article","venue":"Cancer Cell International","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Saint-Luc; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal; Canadian Urological Oncology Group; AstraZeneca","keywords":"Prostate; Medicine; Expression (computer science); Pathology; Computer science; Internal medicine; Cancer","score_opus":0.04630524633137489,"score_gpt":0.3573188501169256,"score_spread":0.3110136037855507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079374922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96830165,0.0025966694,0.00005716127,0.0015916646,0.00040928824,0.0003213519,0.000029917146,0.000023770366,0.026668495],"genre_scores_gemma":[0.98212254,0.0048104064,0.000556574,0.00036003703,0.0002444066,0.00013369106,0.000019896057,0.00001873994,0.011733733],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989552,0.000019962665,0.00017942468,0.00026071022,0.00039254533,0.00019216632],"domain_scores_gemma":[0.9995942,0.000027939212,0.000037176345,0.00012754269,0.00010442811,0.000108677516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011248983,0.000090665904,0.00012912552,0.00008718936,0.00003503756,0.000011572218,0.00009852851,0.000049588525,0.0015919285],"category_scores_gemma":[0.00002561775,0.00007546902,0.00002713417,0.00007309507,0.00008370138,0.000091718306,0.00007181213,0.00016971571,0.00002212203],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081170036,0.00033414774,0.660619,0.00023754977,0.000042290314,0.0009240655,0.004021493,0.0001033242,0.27561277,0.00016234799,0.041122172,0.016009135],"study_design_scores_gemma":[0.00654825,0.00032424243,0.28998026,0.0011411976,0.000015673535,0.00027621028,0.00045062238,0.0029258532,0.44000363,0.00028437714,0.2576378,0.00041189574],"about_ca_topic_score_codex":0.00048665202,"about_ca_topic_score_gemma":0.00010751895,"teacher_disagreement_score":0.37063876,"about_ca_system_score_codex":0.00038362303,"about_ca_system_score_gemma":0.0002308345,"threshold_uncertainty_score":0.99932075},"labels":[],"label_agreement":null},{"id":"W2079556349","doi":"10.1007/s00403-003-0391-x","title":"Proliferation?differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes","year":2003,"lang":"en","type":"article","venue":"Archives of Dermatological Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health","keywords":"Neuregulin; Epidermal growth factor; Biology; Colocalization; Epidermis (zoology); ERBB3; Cell biology; ErbB; Epidermal growth factor receptor; Epiregulin; ERBB4; Endocrinology; Internal medicine; Receptor; Cancer research; Amphiregulin; Signal transduction; Anatomy; Receptor tyrosine kinase; Medicine; Biochemistry","score_opus":0.10116434887944394,"score_gpt":0.3737964244524777,"score_spread":0.27263207557303376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079556349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959965,0.00049231615,0.00007914573,0.00066724385,0.000019233448,0.00089613296,0.000014382573,0.00001423643,0.0018208477],"genre_scores_gemma":[0.9988799,0.00038478756,0.0005132187,0.000009225215,0.000009046142,0.00004638923,0.00006967647,0.000013906185,0.000073822695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508405,0.0025958754,0.0006670746,0.0003457643,0.00085416186,0.00045307598],"domain_scores_gemma":[0.9954195,0.0039265375,0.00013555124,0.00024011073,0.000110508074,0.00016778846],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011760711,0.00017161005,0.00041509562,0.00041757498,0.00036842978,0.000044141012,0.00018431275,0.00016757027,0.000084744155],"category_scores_gemma":[0.0040169978,0.00010766265,0.000056885703,0.000427404,0.00080157653,0.00015161604,0.000099802885,0.0010824326,0.0000017152794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008832901,0.00024066033,0.9357619,0.00026069558,0.000019431234,0.000006024191,0.004542548,0.0000012249677,0.04956653,0.008920074,0.00017058793,0.00042197402],"study_design_scores_gemma":[0.0012770172,0.00034989908,0.839264,0.00034731827,0.000013398172,0.000037974252,0.0015303683,0.00033951894,0.15051234,0.006171911,0.00003734543,0.00011893728],"about_ca_topic_score_codex":0.000045700643,"about_ca_topic_score_gemma":0.0000150483565,"teacher_disagreement_score":0.10094581,"about_ca_system_score_codex":0.000036226476,"about_ca_system_score_gemma":0.00010725017,"threshold_uncertainty_score":0.48090115},"labels":[],"label_agreement":null},{"id":"W2079698093","doi":"10.1016/j.jprot.2013.06.034","title":"Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification","year":2013,"lang":"en","type":"article","venue":"Journal of Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Canadian Cancer Society; Alberta Cancer Foundation","keywords":"Biology; Breast cancer; Cancer; Cancer research; Epidermal growth factor receptor; Transfection; Gene; Proteomics; Effector; Cancer cell; Biomarker; Molecular biology; Cell biology; Genetics","score_opus":0.037396852642592654,"score_gpt":0.33723612929447366,"score_spread":0.29983927665188104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079698093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99068797,0.00027225516,0.003762827,0.002122225,0.000056601795,0.002950169,0.00009086931,0.00001410201,0.000042978398],"genre_scores_gemma":[0.92221403,0.00043802452,0.07652874,0.0001000698,0.00023712122,0.0003004062,0.0000084737085,0.000057450405,0.00011570558],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973385,0.00020976347,0.00086067826,0.00034471045,0.0008120441,0.00043432062],"domain_scores_gemma":[0.9963451,0.000078070465,0.0014383482,0.0003939669,0.0014261565,0.00031836092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092196284,0.00028987258,0.0010547108,0.00076651445,0.00010719263,0.00010435165,0.0002660682,0.00016375854,0.0002616037],"category_scores_gemma":[0.00008253557,0.0002140661,0.00016678119,0.0009245805,0.0002589128,0.00039635395,0.0000767999,0.0006653335,0.0000053991303],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020189085,0.00019246539,0.0440918,0.00047142452,0.0012958219,0.000014698588,0.00089115236,0.00063327304,0.9485084,0.000012594749,0.00016531967,0.0017041462],"study_design_scores_gemma":[0.0026430401,0.0013196019,0.36439654,0.0011660892,0.0012035761,0.00023943321,0.00045994928,0.0054312237,0.6227843,0.000055021523,0.000016330558,0.00028486692],"about_ca_topic_score_codex":0.0012259562,"about_ca_topic_score_gemma":0.00011415907,"teacher_disagreement_score":0.32572407,"about_ca_system_score_codex":0.00042226887,"about_ca_system_score_gemma":0.0007198502,"threshold_uncertainty_score":0.87293625},"labels":[],"label_agreement":null},{"id":"W2080119134","doi":"10.3747/co.v17i1.517","title":"Pathology Re-Review as an Essential Component of Breast Cancer Management","year":2010,"lang":"en","type":"letter","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Cancer; Pathology; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.14138602076453471,"score_gpt":0.5111257768656063,"score_spread":0.3697397561010716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080119134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037087046,0.04628393,0.00003104737,0.9264396,0.011085036,0.0034031102,0.0005766206,0.000095257805,0.008376735],"genre_scores_gemma":[0.0019336403,0.29758704,0.0005982373,0.66789097,0.021287737,0.0027279817,0.004149155,0.000331728,0.0034935563],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543446,0.0006807068,0.0009813278,0.0010013168,0.001004924,0.00089726935],"domain_scores_gemma":[0.99715805,0.00012716808,0.00054737495,0.0013580791,0.00053072965,0.00027861775],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007958428,0.0004991135,0.001838377,0.00040874537,0.00006252249,0.000010776155,0.0007396816,0.001613777,0.0101430835],"category_scores_gemma":[0.000047327005,0.00043633487,0.00033545957,0.00028100229,0.00068490644,0.00004311884,0.00044259767,0.006885836,0.00031702017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013391608,0.00066576875,0.000433395,0.016988514,0.00019522927,0.0025750126,0.00005869204,1.4040405e-7,0.0002313288,0.000053467535,0.80800825,0.17065628],"study_design_scores_gemma":[0.0014773905,0.00071902364,0.0017195347,0.0049828505,0.0009421178,0.0010300627,0.0000151801905,0.000008739561,0.00006447798,0.00007848183,0.98863614,0.0003260209],"about_ca_topic_score_codex":0.00022198782,"about_ca_topic_score_gemma":0.00012773587,"teacher_disagreement_score":0.25854862,"about_ca_system_score_codex":0.0007446941,"about_ca_system_score_gemma":0.0011719839,"threshold_uncertainty_score":0.99980885},"labels":[],"label_agreement":null},{"id":"W2080518844","doi":"10.1158/1078-0432.ccr-07-0701","title":"Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":506,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Trastuzumab; Gefitinib; Lapatinib; Erlotinib; Cancer research; Epidermal growth factor receptor; ErbB; In vivo; Epidermal growth factor; Growth factor receptor; Biology; Cancer; Receptor; Medicine; Breast cancer; Internal medicine","score_opus":0.12656251714838357,"score_gpt":0.4760326595411657,"score_spread":0.3494701423927821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080518844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9713251,0.0019974788,0.00005551491,0.019900883,0.0005317498,0.0044667497,0.00086637953,0.00006621258,0.00078994414],"genre_scores_gemma":[0.9820852,0.003660092,0.00054696447,0.0023889693,0.003466727,0.00085544324,0.000014426884,0.00016835667,0.0068137897],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99208087,0.00086882565,0.0013438124,0.0015782112,0.0018990709,0.0022292114],"domain_scores_gemma":[0.99040633,0.0061042528,0.0001742863,0.0008250521,0.0012340111,0.0012560908],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011247864,0.000445604,0.0010040691,0.0003155386,0.0006452368,0.00016639997,0.00062037155,0.0004904439,0.0012262616],"category_scores_gemma":[0.002103018,0.00033623033,0.00015968514,0.0015642138,0.00083417393,0.000116960975,0.0003695892,0.0026200241,0.000022782106],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030185862,0.0009955278,0.1269149,0.0015117486,0.00037201354,0.000102886326,0.0014134422,0.000030396624,0.18427606,0.0011632575,0.6370759,0.015958032],"study_design_scores_gemma":[0.018007083,0.006794556,0.4895768,0.008240636,0.00013171237,0.000028601087,0.0011611824,0.00015818593,0.28390256,0.0010134834,0.18908677,0.0018984588],"about_ca_topic_score_codex":0.0014511957,"about_ca_topic_score_gemma":0.009862454,"teacher_disagreement_score":0.4479891,"about_ca_system_score_codex":0.0012895941,"about_ca_system_score_gemma":0.0011548597,"threshold_uncertainty_score":0.999909},"labels":[],"label_agreement":null},{"id":"W2081516478","doi":"10.1158/0008-5472.can-12-3925","title":"β-Catenin Signaling Is a Critical Event in ErbB2-Mediated Mammary Tumor Progression","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Institute of Cancer Research; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung","keywords":"Cancer research; Tumor progression; Mammary tumor; Cancer; Catenin; Breast cancer; Wnt signaling pathway; Metastasis; Biology; Tumor initiation; Genetically modified mouse; Signal transduction; Transgene; Cell biology; Gene; Genetics","score_opus":0.13100631178326783,"score_gpt":0.5175240876879034,"score_spread":0.38651777590463554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081516478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9332862,0.0066161724,0.00007972641,0.052590966,0.00020811302,0.0032056617,0.000034825032,0.00013357181,0.0038447988],"genre_scores_gemma":[0.99195856,0.0005820102,0.0007084497,0.00091852614,0.00043628967,0.0035527474,0.000022169612,0.00008205971,0.0017391634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9939724,0.000543032,0.0005440508,0.0007970693,0.0024553551,0.0016880742],"domain_scores_gemma":[0.9965458,0.0007560246,0.0000379456,0.0006485157,0.001182115,0.000829578],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024256639,0.00023259017,0.00045267757,0.0007668521,0.00017373453,0.00015790928,0.00053005037,0.00019576731,0.0074150097],"category_scores_gemma":[0.0018524226,0.00019384071,0.00010316885,0.0017292448,0.0005163866,0.00027224835,0.00043391055,0.0020385997,0.0014445318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093770475,0.0010538214,0.06486081,0.0024636928,0.00009146413,0.0021498632,0.0017542178,0.000009899434,0.71276504,0.00061867194,0.13790743,0.0753874],"study_design_scores_gemma":[0.013464323,0.004811689,0.11133107,0.017196393,0.00006562759,0.00035715775,0.003570688,0.016236478,0.713592,0.006835266,0.110548675,0.0019906443],"about_ca_topic_score_codex":0.0027619225,"about_ca_topic_score_gemma":0.00006912011,"teacher_disagreement_score":0.07339676,"about_ca_system_score_codex":0.0012886993,"about_ca_system_score_gemma":0.0021990389,"threshold_uncertainty_score":0.99933296},"labels":[],"label_agreement":null},{"id":"W2081555496","doi":"10.1158/0008-5472.sabcs12-ot1-1-07","title":"Abstract OT1-1-07: Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515)","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Metastatic breast cancer; Tolerability; Internal medicine; Discontinuation; Oncology; Breast cancer; Chemotherapy; Adverse effect; Cancer","score_opus":0.10302319983605311,"score_gpt":0.44882617489008764,"score_spread":0.3458029750540345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081555496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395365,0.00088621053,0.000018577086,0.00871872,0.00017372456,0.0026415319,0.0018906549,0.000034705616,0.001682228],"genre_scores_gemma":[0.99536806,0.0003050514,0.00013595463,0.00025343636,0.00072141,0.0022280933,0.00010997327,0.00010936282,0.00076863205],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9939891,0.00075948023,0.0005883718,0.00063603255,0.0024161073,0.0016108789],"domain_scores_gemma":[0.9966054,0.0007264593,0.00016181085,0.00064299995,0.0011521267,0.0007111961],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021840283,0.00035435485,0.0006775186,0.00056021643,0.00027683793,0.00006121122,0.0005177455,0.00015122285,0.020445049],"category_scores_gemma":[0.0002775742,0.00023249642,0.00011937812,0.0014510792,0.0005892706,0.00037872465,0.00019462609,0.0016679832,0.00020572341],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099527035,0.0032352782,0.18306673,0.0034376378,0.00089323975,0.00016526674,0.027025284,0.00014469816,0.52366734,0.00038197378,0.1731347,0.07489516],"study_design_scores_gemma":[0.0025744003,0.0010422776,0.8491528,0.002243545,0.000055855904,0.000033966055,0.002126045,0.000013901218,0.13716404,0.000026330714,0.005207715,0.00035914328],"about_ca_topic_score_codex":0.015860368,"about_ca_topic_score_gemma":0.002765113,"teacher_disagreement_score":0.6660861,"about_ca_system_score_codex":0.0018729884,"about_ca_system_score_gemma":0.0011556017,"threshold_uncertainty_score":0.9906931},"labels":[],"label_agreement":null},{"id":"W2081649373","doi":"10.1007/s10637-005-5860-y","title":"A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group","year":2005,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Jewish General Hospital; Hamilton Regional Laboratory Medicine Program; Ottawa Regional Cancer Foundation","funders":"","keywords":"Cancer; Medicine; Investigational Drugs; Drug; Cancer drugs; Family medicine; Gerontology; Internal medicine; Clinical trial; Pharmacology","score_opus":0.14092656980953736,"score_gpt":0.45770799104479143,"score_spread":0.3167814212352541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081649373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933965,0.000044115826,0.0000016500543,0.004982414,0.0002327543,0.0050602383,0.00020314369,0.00000991382,0.00012611043],"genre_scores_gemma":[0.9973891,0.0000019208674,0.0011374841,0.0005896441,0.00032683427,0.00020177294,0.000053396412,0.000029327834,0.00027054493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99147934,0.0010450002,0.0025727085,0.0004592684,0.004133163,0.0003105111],"domain_scores_gemma":[0.9956384,0.00068586867,0.0015928297,0.00045841007,0.0012416808,0.00038282629],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030242517,0.00027710665,0.0010727535,0.00022706528,0.000088447625,0.000013773342,0.000660679,0.000090340174,0.00009407355],"category_scores_gemma":[0.0037621772,0.00017543639,0.00014383033,0.0014185566,0.000923373,0.00023019407,0.00021146037,0.00060486887,6.402267e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012732828,0.016917836,0.947262,0.00013574553,0.00054041663,0.0000020008297,0.0070896107,0.0033222968,0.00012176849,0.00031123834,0.016891528,0.006132259],"study_design_scores_gemma":[0.04801336,0.002802613,0.9426417,0.00090892805,0.00019601431,0.0000017440441,0.0011682882,0.0006381269,0.0010380632,0.00086630485,0.001525231,0.00019966948],"about_ca_topic_score_codex":0.21032289,"about_ca_topic_score_gemma":0.30482167,"teacher_disagreement_score":0.0944988,"about_ca_system_score_codex":0.00052462105,"about_ca_system_score_gemma":0.024907338,"threshold_uncertainty_score":0.98062056},"labels":[],"label_agreement":null},{"id":"W2082207901","doi":"10.1002/ijc.24884","title":"The effects of gefitinib in tamoxifen‐resistant and hormone‐insensitive breast cancer: A phase II study","year":2009,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"National Cancer Institute; World Health Organization","keywords":"Gefitinib; Tamoxifen; Breast cancer; Medicine; Epidermal growth factor receptor; Internal medicine; Estrogen receptor; Oncology; EGFR inhibitors; Cancer; Cancer research; Endocrinology","score_opus":0.014515962207241582,"score_gpt":0.4154056267011625,"score_spread":0.4008896644939209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082207901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784229,0.010540017,0.000008297662,0.009977785,0.00044479457,0.00037099083,0.000041459814,0.0000036505874,0.00019013464],"genre_scores_gemma":[0.9927334,0.0061698696,0.000021671434,0.0003840955,0.0005374139,0.000019219884,6.4206176e-7,0.000011167746,0.00012250834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979926,0.00009361952,0.00051794725,0.0001361346,0.001063805,0.0001959248],"domain_scores_gemma":[0.9981968,0.0002702749,0.00032001466,0.00010949796,0.0009776278,0.00012579688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005315553,0.00011832787,0.00031874815,0.00022249954,0.000054584223,0.000030168841,0.00021786596,0.000039085095,0.000037306858],"category_scores_gemma":[0.00021028476,0.00007832281,0.00008046858,0.00016852806,0.00011262339,0.00009883764,0.00005040988,0.00037273765,4.1330344e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029349344,0.0035244478,0.06204504,0.00007674968,0.0016509679,0.0031916946,0.006085335,0.000050993276,0.14958943,0.0002791186,0.0052569224,0.73889995],"study_design_scores_gemma":[0.02527903,0.009459881,0.94725597,0.0019419221,0.00019974333,0.0005213595,0.00087165897,0.00019955437,0.009190813,0.00043355362,0.0044763056,0.00017020159],"about_ca_topic_score_codex":0.00080459786,"about_ca_topic_score_gemma":0.00068784895,"teacher_disagreement_score":0.88521093,"about_ca_system_score_codex":0.0004621699,"about_ca_system_score_gemma":0.00056316267,"threshold_uncertainty_score":0.31939113},"labels":[],"label_agreement":null},{"id":"W2082211942","doi":"10.1186/1471-2407-10-255","title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","year":2010,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":161,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cetuximab; Trastuzumab; Monoclonal antibody; Medicine; Immunohistochemistry; Distribution (mathematics); Cancer research; Surgical oncology; Carcinoma; Antibody; Pathology; Internal medicine; Cancer; Immunology; Breast cancer","score_opus":0.03490997489727181,"score_gpt":0.366115816217177,"score_spread":0.33120584131990516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082211942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335486,0.003140327,0.00006002015,0.002066683,0.0004746233,0.00044237115,0.0000747911,0.000017697637,0.0003686365],"genre_scores_gemma":[0.99840486,0.00032407398,0.000057235542,0.0001125724,0.00022993509,0.000076580145,0.000004315043,0.000017125636,0.00077327254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883604,0.000060591352,0.00023141314,0.00018490106,0.00042622173,0.00026084],"domain_scores_gemma":[0.9991805,0.00014312519,0.000097649456,0.00037006376,0.00013830359,0.00007034454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040810206,0.00011348655,0.00019858197,0.00001834811,0.00020934509,0.0000263582,0.00017935726,0.0000629526,0.0000701454],"category_scores_gemma":[0.00014108409,0.00005788962,0.00007244198,0.0001617167,0.00062426477,0.00003615865,0.00007228773,0.0004416176,0.0000030340598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011982559,0.00022804544,0.8165585,0.0005458822,0.0002547835,0.0000066484704,0.0028284583,0.00006261614,0.108814746,0.0069607585,0.0069979243,0.055543378],"study_design_scores_gemma":[0.001177832,0.00014798867,0.9363226,0.00017870769,0.00007571343,0.000051424853,0.00036307672,0.0016433476,0.048487134,0.0007726478,0.010658267,0.00012124069],"about_ca_topic_score_codex":0.00045768806,"about_ca_topic_score_gemma":0.0016048807,"teacher_disagreement_score":0.11976412,"about_ca_system_score_codex":0.000099334415,"about_ca_system_score_gemma":0.00069634506,"threshold_uncertainty_score":0.23606703},"labels":[],"label_agreement":null},{"id":"W2082991733","doi":"10.1006/gyno.2002.6682","title":"General Keynote: Expression of Epidermal Growth Factor Receptor Family in Transgenic Mouse Models of Human Breast Cancer","year":2003,"lang":"en","type":"review","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Breast cancer; Genetically modified mouse; Human Epidermal Growth Factor Receptor 2; Cancer research; Transgene; Epidermal growth factor receptor; Expression (computer science); Cancer; Oncology; Internal medicine; Genetics; Gene; Biology","score_opus":0.16879511054871607,"score_gpt":0.4461844866397767,"score_spread":0.2773893760910606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082991733","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.033674274,0.9580452,0.000048259193,0.00017910516,0.00066358637,0.0034685615,0.0011971213,0.000054688593,0.0026692294],"genre_scores_gemma":[0.0056830603,0.990448,0.0010668309,0.00017582692,0.0002210541,0.0010272497,0.00016364691,0.00012251904,0.0010918351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933016,0.0018185674,0.0022335255,0.0009785801,0.0006349647,0.001032818],"domain_scores_gemma":[0.99670845,0.00084264384,0.000991267,0.00074176874,0.00038845217,0.00032741812],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010130003,0.00070158415,0.005376391,0.0007798657,0.00006313673,0.0000059685763,0.0006831283,0.0020094046,0.0035245582],"category_scores_gemma":[0.00022739224,0.0005399789,0.0008056764,0.00073516625,0.0005186943,0.000096859425,0.00017363626,0.0016690153,0.000024897472],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005149423,0.003309236,0.0013816884,0.056305394,0.00056102604,0.00019802658,0.00058986386,0.00008420986,0.01930648,0.0005862684,0.010177192,0.9069857],"study_design_scores_gemma":[0.012406585,0.009892713,0.0030309716,0.020529624,0.0020754356,0.00025840604,0.00024416723,0.00007694055,0.005745939,0.00082238036,0.9425201,0.0023967489],"about_ca_topic_score_codex":0.000831008,"about_ca_topic_score_gemma":0.00026069404,"teacher_disagreement_score":0.9323429,"about_ca_system_score_codex":0.0024621645,"about_ca_system_score_gemma":0.0043922327,"threshold_uncertainty_score":0.9997052},"labels":[],"label_agreement":null},{"id":"W2083053655","doi":"10.1038/sj.bjc.6601881","title":"HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review","year":2004,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Research Society","keywords":"Medicine; Lymph node; Trastuzumab; Breast cancer; Immunohistochemistry; Oncology; Cancer; CISH; Pathology; Cancer research; Internal medicine; Gene expression; Biology; Gene; In situ hybridization","score_opus":0.05765193668666164,"score_gpt":0.4376919582824539,"score_spread":0.38004002159579225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083053655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006865993,0.9947594,0.000004871195,0.00070248405,0.00045227827,0.00092643104,0.0030140253,0.000008261552,0.00006363219],"genre_scores_gemma":[0.0000072730422,0.9973495,0.0006309283,0.00045974445,0.0009946034,0.000056514175,0.00020455384,0.00008403481,0.00021285629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961281,0.00042676355,0.0012820726,0.00063731254,0.00102528,0.0005004913],"domain_scores_gemma":[0.9976243,0.00014908024,0.00088465295,0.0004667217,0.00036890135,0.0005063927],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018383417,0.0004468663,0.0029639464,0.0004608569,0.000077036304,0.00023418252,0.0005530704,0.00026680736,0.00066754746],"category_scores_gemma":[0.00019046756,0.00038293633,0.00022303175,0.0008286336,0.0001761624,0.00053251645,0.00029112233,0.0025045297,0.0000015165776],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010486217,0.000044472476,0.00059361325,0.14678521,0.0001299104,0.008942643,0.00001807596,3.5125174e-7,0.0000017876476,6.0661097e-7,0.015883947,0.8274945],"study_design_scores_gemma":[0.0007067158,0.000037394017,0.0009627454,0.4696558,0.00081198354,0.045996863,0.000004509101,5.2202057e-7,5.6214685e-7,0.0000031729992,0.4816472,0.00017252934],"about_ca_topic_score_codex":0.0006916266,"about_ca_topic_score_gemma":0.0003425904,"teacher_disagreement_score":0.827322,"about_ca_system_score_codex":0.0009787322,"about_ca_system_score_gemma":0.004913216,"threshold_uncertainty_score":0.99986225},"labels":[],"label_agreement":null},{"id":"W2084312945","doi":"10.1007/s10549-010-0733-2","title":"Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes","year":2010,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Advancing Health Outcomes; University of British Columbia","funders":"School of Medicine, Indiana University; Eli Lilly and Company","keywords":"Breast cancer; Protein kinase C; Tissue microarray; Estrogen receptor; Cancer research; Cancer; Immunohistochemistry; Medicine; Internal medicine; Pathology; Biology; Oncology; Endocrinology; Kinase; Cell biology","score_opus":0.031178596612747553,"score_gpt":0.35196370857803233,"score_spread":0.32078511196528475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2084312945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863301,0.001578705,0.000010461665,0.0073141926,0.00013204566,0.002436783,0.001974405,0.000041367904,0.0001819731],"genre_scores_gemma":[0.9921915,0.0028441395,0.00006759018,0.00001482601,0.0005075246,0.002875283,0.00007826292,0.000084092,0.0013367779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958528,0.00021417228,0.00045075855,0.00088417006,0.0015213585,0.0010766875],"domain_scores_gemma":[0.997641,0.00008754314,0.00014342717,0.0006509365,0.00079852453,0.0006785213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003630901,0.0004249027,0.00067889545,0.00054031925,0.0002416795,0.0000762453,0.00022068112,0.00024088145,0.0033897029],"category_scores_gemma":[0.000010533742,0.00028925427,0.00009463074,0.0007999075,0.0006814051,0.00021270252,0.00014475486,0.0009383435,0.000012011709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010997131,0.0014694278,0.7310394,0.00050747837,0.00017019075,0.00020863011,0.0003558027,0.000020338623,0.17242505,0.000076784345,0.00017524936,0.08255453],"study_design_scores_gemma":[0.008395454,0.0008848382,0.9165532,0.0020977512,0.00010238768,0.0003474309,0.0001592966,0.0003705991,0.07009527,0.000047733465,0.00062474236,0.00032131604],"about_ca_topic_score_codex":0.069047935,"about_ca_topic_score_gemma":0.0165603,"teacher_disagreement_score":0.1855138,"about_ca_system_score_codex":0.0011405316,"about_ca_system_score_gemma":0.0019849339,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2085093059","doi":"10.3747/co.v16i5.510","title":"The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers","year":2009,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Santé Montérégie; BC Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Centre hospitalier universitaire de Québec; Sunnybrook Health Science Centre; Hôpital du Saint-Sacrement","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Targeted therapy; Neoadjuvant therapy; Human Epidermal Growth Factor Receptor 2; Adjuvant; Pertuzumab; Internal medicine; Stage (stratigraphy); Clinical trial; Cancer","score_opus":0.06684936890207013,"score_gpt":0.4379933897950619,"score_spread":0.3711440208929918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085093059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89501065,0.07957117,0.000025832282,0.009312061,0.0011306746,0.0010187906,0.000036870755,0.00006834894,0.013825623],"genre_scores_gemma":[0.99634904,0.002951354,0.00011893882,0.00014377106,0.00027493,0.000045791276,0.00000994729,0.000017865379,0.0000883764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99815047,0.00024580778,0.00041215855,0.0002770344,0.0003809395,0.0005335926],"domain_scores_gemma":[0.99901086,0.00018678501,0.000137885,0.0003714262,0.00016006963,0.00013297184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053726777,0.00015952338,0.00042526814,0.00012390106,0.00008830212,0.000015772714,0.00025755394,0.0001251277,0.0001899504],"category_scores_gemma":[0.00011447547,0.00011099104,0.000087798035,0.00031932158,0.00029792436,0.000049870832,0.000053606174,0.00058503676,0.000014992044],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005728813,0.00034062457,0.03881644,0.00004323614,0.00003001432,0.000018779974,0.0015372031,0.000020663392,0.014789406,0.00034049727,0.002403229,0.941087],"study_design_scores_gemma":[0.003340598,0.0015972905,0.26100615,0.0007659108,0.00003577159,0.00011138267,0.00272807,0.0012472891,0.0054619242,0.0023919237,0.7210771,0.0002365726],"about_ca_topic_score_codex":0.00045539695,"about_ca_topic_score_gemma":0.00042076845,"teacher_disagreement_score":0.94085044,"about_ca_system_score_codex":0.0009066505,"about_ca_system_score_gemma":0.0010177421,"threshold_uncertainty_score":0.45260832},"labels":[],"label_agreement":null},{"id":"W2085770486","doi":"10.1016/j.jsbmb.2005.02.001","title":"Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway","year":2005,"lang":"en","type":"article","venue":"The Journal of Steroid Biochemistry and Molecular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Estrogen receptor; ERBB3; Estrogen receptor alpha; Signal transduction; Estrogen receptor beta; ErbB; Phosphorylation; Biology; Neuregulin; Fulvestrant; Tyrosine phosphorylation; Cell biology; MAPK/ERK pathway; Cancer research; Chemistry; Receptor tyrosine kinase; Cancer; Breast cancer","score_opus":0.010584261150853662,"score_gpt":0.30548024091043136,"score_spread":0.2948959797595777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085770486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98596025,0.011363749,0.00032230243,0.0018334729,0.00004015258,0.00016841516,0.000033568856,0.0000065847835,0.0002715362],"genre_scores_gemma":[0.9976107,0.0014266775,0.00041170043,0.00018559564,0.00016104941,0.0000039803967,0.000016302207,0.000016967744,0.00016702001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868816,0.00019438069,0.00043720295,0.000186547,0.00024574608,0.00024797217],"domain_scores_gemma":[0.99886936,0.000064338965,0.00036115132,0.00028082533,0.00025843736,0.00016591088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006363856,0.0001568716,0.00035889173,0.00004850777,0.00005419164,0.0000068690315,0.00021731028,0.00020742223,0.000036900812],"category_scores_gemma":[0.00012828012,0.00009930077,0.00009423477,0.00011545357,0.00026133438,0.00002850341,0.00010900459,0.000498447,0.0000018338092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015141879,0.00012226227,0.00033207118,0.00004783737,0.00021690574,0.000012323722,0.00015222764,0.0000024674052,0.9908079,0.0000031440782,0.0016369639,0.005151732],"study_design_scores_gemma":[0.0013260598,0.0011625165,0.000087518194,0.00011813858,0.00006697865,0.0004971801,0.00016206047,0.0000068548807,0.99350125,0.000026587606,0.002956793,0.00008807454],"about_ca_topic_score_codex":0.000015603708,"about_ca_topic_score_gemma":2.644614e-7,"teacher_disagreement_score":0.011650489,"about_ca_system_score_codex":0.00009115781,"about_ca_system_score_gemma":0.00019245292,"threshold_uncertainty_score":0.4049368},"labels":[],"label_agreement":null},{"id":"W2086553369","doi":"10.1016/j.cellsig.2008.11.012","title":"Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: Agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells","year":2008,"lang":"en","type":"article","venue":"Cellular Signalling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of British Columbia; McGill University","funders":"","keywords":"Somatostatin receptor; Epidermal growth factor; GRB2; Somatostatin receptor 1; Biology; Somatostatin receptor 2; Cell biology; MAPK/ERK pathway; Epidermal growth factor receptor; Cancer research; Signal transduction; Receptor; Somatostatin; Agonist; Signal transducing adaptor protein; Endocrinology; Biochemistry","score_opus":0.026069455954734814,"score_gpt":0.2526054131560498,"score_spread":0.22653595720131497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086553369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99601597,0.00088047987,0.0013649156,0.000453209,0.00020781432,0.00083147036,0.00009453534,0.000041432188,0.00011017921],"genre_scores_gemma":[0.9975644,0.00070235814,0.0011599783,0.00007519748,0.0001548562,0.000060337858,0.00002816138,0.00007716693,0.00017754019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706227,0.00025843753,0.00064302766,0.0005681309,0.0009102411,0.0005579015],"domain_scores_gemma":[0.9987535,0.00017284299,0.00028382769,0.0003208387,0.00024175926,0.0002272551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040590332,0.0003296449,0.00053849095,0.00018880768,0.00020044409,0.00003075533,0.00021799376,0.00017175925,0.00045106537],"category_scores_gemma":[0.000032870917,0.00023904453,0.000115110095,0.00043110066,0.00031089972,0.00014709268,0.00008760181,0.0005924715,0.000010108347],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029126144,0.00012325415,0.09119068,0.00032487,0.00006575503,0.000057088535,0.0016750671,0.0022846716,0.90136224,0.000007847991,0.000036907393,0.00258033],"study_design_scores_gemma":[0.0015728712,0.00016902962,0.010224518,0.0008986161,0.000028127599,0.000071980896,0.00022681941,0.0036887047,0.98268086,0.000022084234,0.00011905905,0.00029730969],"about_ca_topic_score_codex":0.0010719685,"about_ca_topic_score_gemma":0.00006198154,"teacher_disagreement_score":0.08131861,"about_ca_system_score_codex":0.0002582074,"about_ca_system_score_gemma":0.00042894698,"threshold_uncertainty_score":0.9747953},"labels":[],"label_agreement":null},{"id":"W2086661954","doi":"10.1186/bcr1776","title":"Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study","year":2007,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Concordance; Breast cancer; Medicine; Immunohistochemistry; Oncology; Fish <Actinopterygii>; Internal medicine; Pathology; Cancer; Biology; In situ hybridization; Fishery; Gene; Genetics","score_opus":0.1242535920657148,"score_gpt":0.526977088041126,"score_spread":0.4027234959754112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086661954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104387,0.00021551581,0.00021018492,0.004101887,0.00025738863,0.0031693117,0.0002817751,0.000018904342,0.00070118933],"genre_scores_gemma":[0.9970016,0.00069433823,0.0001223894,0.00003697497,0.000561425,0.0013619586,0.00005461803,0.000047944242,0.000118758115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99541575,0.00035376986,0.0006378518,0.00055699085,0.002126806,0.00090885034],"domain_scores_gemma":[0.997637,0.0004930706,0.00011349253,0.0005291777,0.001015967,0.00021134198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0074343807,0.00016686885,0.00031698577,0.00084733515,0.00012323454,0.00006945189,0.0004654852,0.000080406455,0.00048806856],"category_scores_gemma":[0.00011058278,0.00013736833,0.000066942564,0.0012243834,0.00017361523,0.0003128942,0.00017079922,0.00074952445,0.000003088748],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015516971,0.0010688521,0.8608748,0.00015634898,0.00009936246,0.000027907188,0.0011530239,0.00073283794,0.01851997,0.000100485784,0.000104458515,0.11561027],"study_design_scores_gemma":[0.0040448676,0.0002950333,0.9846186,0.00031265884,0.00001947488,0.000034767287,0.0027962083,0.0036455945,0.003650068,0.000037789767,0.00042573697,0.00011921373],"about_ca_topic_score_codex":0.053880025,"about_ca_topic_score_gemma":0.0439713,"teacher_disagreement_score":0.1237438,"about_ca_system_score_codex":0.004250287,"about_ca_system_score_gemma":0.0022199196,"threshold_uncertainty_score":0.9995722},"labels":[],"label_agreement":null},{"id":"W2088169167","doi":"10.1097/cad.0b013e328331178f","title":"Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status","year":2009,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institut National Du Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Chemotherapy; Metastatic breast cancer; Trastuzumab; Univariate analysis; Cancer; Proportional hazards model; Confidence interval; Multivariate analysis","score_opus":0.014285805433521878,"score_gpt":0.33397448165097277,"score_spread":0.3196886762174509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088169167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976827,0.00046959164,0.0000052458067,0.0016337617,0.00013137689,0.0071231104,0.00019097385,0.00008985265,0.0005878341],"genre_scores_gemma":[0.9938578,0.0031339559,0.00017778084,0.00063874276,0.00015004494,0.0015258795,0.000022318527,0.0000926162,0.00040084662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954588,0.00016919899,0.00069821643,0.0011524174,0.0013136513,0.0012077164],"domain_scores_gemma":[0.9980832,0.00008606771,0.0002572225,0.0006672236,0.00059571303,0.00031062015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044594952,0.0005500986,0.0011270441,0.00042982041,0.00011927492,0.00005351597,0.00031013016,0.00013078592,0.0003490452],"category_scores_gemma":[0.00005592607,0.00043703153,0.00008808972,0.0016907728,0.00018976093,0.00045263133,0.00006368823,0.0007991,0.0000141029295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005803773,0.0035476214,0.910733,0.0000629964,0.00016019758,0.000076249904,0.0041216537,0.00019884972,0.000093857045,0.0000026093448,0.00007466297,0.075124525],"study_design_scores_gemma":[0.027643915,0.0035753998,0.96553385,0.00075626135,0.00004013214,0.0000027684234,0.0005831208,0.00013327325,0.000937725,0.000042318643,0.00026814576,0.00048310796],"about_ca_topic_score_codex":0.018437259,"about_ca_topic_score_gemma":0.015302919,"teacher_disagreement_score":0.074641414,"about_ca_system_score_codex":0.0019473297,"about_ca_system_score_gemma":0.0009561047,"threshold_uncertainty_score":0.99980813},"labels":[],"label_agreement":null},{"id":"W2088605318","doi":"10.1007/s00280-007-0579-4","title":"Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety","year":2007,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Pfizer","keywords":"Pharmacokinetics; Dosing; Medicine; Adverse effect; Toxicity; Internal medicine; Tyrosine-kinase inhibitor; Incidence (geometry); Pharmacology; Clinical trial; Gastroenterology; Oncology; Cancer","score_opus":0.018120891819779165,"score_gpt":0.380221315198652,"score_spread":0.3621004233788728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088605318","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595,0.000862981,0.00028257226,0.0010473753,0.00025647547,0.0012765747,0.00017565483,0.000021133541,0.00012726527],"genre_scores_gemma":[0.9927102,0.0036593063,0.00063719845,0.0023781827,0.00034889448,0.000060901693,0.000053915715,0.000056387802,0.00009502686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99802685,0.00010759538,0.00066476135,0.0004569559,0.00027499217,0.00046884103],"domain_scores_gemma":[0.99865633,0.00026648547,0.0002638366,0.00015165741,0.00035102406,0.00031068234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045440605,0.0002673466,0.00068386446,0.00015240176,0.0000681952,0.000008645914,0.00008147581,0.00014636393,0.00030760447],"category_scores_gemma":[0.000019416957,0.0002096827,0.00003761998,0.00035711945,0.0006251605,0.0000800028,0.000038497084,0.0005541956,0.0000010003587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036223136,0.001162974,0.85456276,0.0003434265,0.00028908078,0.00013388321,0.0009988424,0.000027053513,0.029902762,0.000013726139,0.00039250916,0.075949825],"study_design_scores_gemma":[0.02972538,0.004384826,0.86893165,0.0007791701,0.00019394346,0.000026310958,0.0001098873,0.00034206873,0.0906793,0.0000067781425,0.0044937776,0.00032689434],"about_ca_topic_score_codex":0.00006234399,"about_ca_topic_score_gemma":0.00003264805,"teacher_disagreement_score":0.07562293,"about_ca_system_score_codex":0.00017145414,"about_ca_system_score_gemma":0.00031806043,"threshold_uncertainty_score":0.85506123},"labels":[],"label_agreement":null},{"id":"W2089842133","doi":"10.1158/1535-7163.targ-09-c49","title":"Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer","year":2009,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Medicine; Metastatic breast cancer; Panitumumab; Cetuximab; Triple-negative breast cancer; Cyclophosphamide; Breast cancer; Cancer; Bevacizumab; Docetaxel; Trastuzumab; Oncology; Combination therapy; Cancer research; Targeted therapy; Pharmacology; Monoclonal antibody; Chemotherapy; Epidermal growth factor receptor; Internal medicine; Immunology; Antibody; Colorectal cancer","score_opus":0.03126555443784302,"score_gpt":0.3740643119938047,"score_spread":0.3427987575559617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089842133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836489,0.008072258,0.0005971683,0.005842614,0.000036197187,0.0015383213,0.00010885808,0.000015535374,0.00014015903],"genre_scores_gemma":[0.9868608,0.011076447,0.00064711383,0.0010894393,0.0000246058,0.000190171,0.000008583743,0.000039176743,0.00006363666],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99827766,0.000080803744,0.00042788964,0.0004600347,0.00039555482,0.0003580541],"domain_scores_gemma":[0.99905515,0.00013275036,0.0001854758,0.0003530849,0.00014826017,0.00012529678],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002331247,0.00028910162,0.0006336567,0.00012276255,0.000064876134,0.000025863294,0.00012320967,0.00012360259,0.000023089991],"category_scores_gemma":[0.000009602504,0.00019403102,0.00009206787,0.00027995513,0.00038930812,0.00006884074,0.000027755415,0.00032276622,6.0166815e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037246495,0.002333823,0.07436846,0.0003453919,0.00214738,0.00010093594,0.0088383565,0.016588291,0.13970788,0.00038319206,0.000021991538,0.7179178],"study_design_scores_gemma":[0.06135195,0.0031687936,0.7062993,0.00078626315,0.00076046266,0.000041083054,0.0003784693,0.13081264,0.09421481,0.0014696334,0.00014646791,0.0005701154],"about_ca_topic_score_codex":0.0009033838,"about_ca_topic_score_gemma":0.00022409909,"teacher_disagreement_score":0.7173477,"about_ca_system_score_codex":0.0006466905,"about_ca_system_score_gemma":0.00065123354,"threshold_uncertainty_score":0.7912355},"labels":[],"label_agreement":null},{"id":"W2091242368","doi":"10.1172/jci57100","title":"Breast cancer — one term, many entities?","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Breast cancer; Cancer; Breast tumor; Disease; Computational biology; Bioinformatics; Medicine; Tumor heterogeneity; Biology; Cancer research; Pathology; Internal medicine","score_opus":0.4923396356444193,"score_gpt":0.5576649504711761,"score_spread":0.06532531482675685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091242368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032363928,0.9944799,0.000027733568,0.0011736498,0.001960803,0.0005799041,0.000059187616,0.000018379176,0.0013768089],"genre_scores_gemma":[0.00004250942,0.98967093,0.0009831282,0.00046381925,0.0063121286,0.000030998246,0.000025528967,0.000080048914,0.0023909071],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936466,0.00072093756,0.003961255,0.00032607443,0.0010058901,0.00033923588],"domain_scores_gemma":[0.9938841,0.0006151853,0.0032004179,0.0004680142,0.00093709206,0.00089520577],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038523958,0.00032546086,0.0032387935,0.00039241242,0.000049049195,0.000054024265,0.00043715708,0.00074818986,0.0019671582],"category_scores_gemma":[0.0012391527,0.00023593886,0.0013622643,0.00037889657,0.0005203221,0.00021243886,0.00009528938,0.0028942206,0.00019079365],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008333334,0.00018025769,0.0024850876,0.013481006,0.0006351708,0.00008628201,0.000037543705,7.27137e-8,0.0000011139333,0.0001898431,0.016338397,0.96648186],"study_design_scores_gemma":[0.00083060167,0.0004880415,0.0054179765,0.073517255,0.002561336,0.0009940295,0.0000062694503,0.000003160471,0.0000039711963,0.00056485506,0.9153983,0.0002141975],"about_ca_topic_score_codex":0.00005452657,"about_ca_topic_score_gemma":0.0000090969115,"teacher_disagreement_score":0.9662677,"about_ca_system_score_codex":0.00038003974,"about_ca_system_score_gemma":0.0052570663,"threshold_uncertainty_score":0.99940616},"labels":[],"label_agreement":null},{"id":"W2091805528","doi":"10.1002/cncr.23350","title":"Prognostic significance of HER‐2 status in women with inflammatory breast cancer","year":2008,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada","funders":"National Cancer Institute; Susan G. Komen for the Cure","keywords":"Medicine; Internal medicine; Trastuzumab; Breast cancer; Proportional hazards model; Univariate analysis; Anthracycline; Disease; Multivariate analysis; Oncology; Survival analysis; Inflammatory breast cancer; Regimen; Cancer; Chemotherapy; Surgery; Gastroenterology","score_opus":0.02885500294830198,"score_gpt":0.3240925398947564,"score_spread":0.29523753694645444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2091805528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940088,0.0030417053,0.000009542166,0.0007406189,0.00010889622,0.00093117147,0.000116722425,0.000042559834,0.0010000052],"genre_scores_gemma":[0.993531,0.0029779896,0.0000918436,0.0003179396,0.0002182237,0.0017853517,0.0000027896276,0.000056582227,0.0010182812],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785125,0.000057416455,0.00033165363,0.00037157614,0.00062706636,0.00076103996],"domain_scores_gemma":[0.998822,0.00007253081,0.00011027807,0.00036987773,0.00029899384,0.00032634102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018253656,0.00019056452,0.000434272,0.00017191813,0.000042393305,0.0000060326106,0.00014204331,0.000088611814,0.0016289307],"category_scores_gemma":[0.000047981684,0.00015425961,0.00003101426,0.0006436461,0.00043102485,0.000096296084,0.000038583545,0.00037662382,0.000016599824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017410861,0.00012708917,0.97211486,0.0006729789,0.00007745388,0.00026115478,0.0023654082,0.00028514277,0.006080076,0.000009232406,0.0018174467,0.014448083],"study_design_scores_gemma":[0.0022776423,0.00028300533,0.98278725,0.0010134017,0.000019012563,0.000055949407,0.00031929792,0.000054330158,0.0026485946,0.000011100334,0.010332607,0.00019777859],"about_ca_topic_score_codex":0.0020100824,"about_ca_topic_score_gemma":0.00091628917,"teacher_disagreement_score":0.014250305,"about_ca_system_score_codex":0.001449625,"about_ca_system_score_gemma":0.0035736128,"threshold_uncertainty_score":0.99928373},"labels":[],"label_agreement":null},{"id":"W2092014058","doi":"10.1016/j.apradiso.2014.10.011","title":"Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin)","year":2014,"lang":"en","type":"article","venue":"Applied Radiation and Isotopes","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University Health Network; McMaster University; University of Toronto","funders":"Genentech","keywords":"Pertuzumab; Trastuzumab; Medicine; Breast cancer; Nuclear medicine; Cancer; Internal medicine","score_opus":0.014629073940783582,"score_gpt":0.3476201015675357,"score_spread":0.33299102762675215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092014058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95812297,0.00026690273,0.029955123,0.0060495893,0.00012570493,0.0048080967,0.0001734802,0.000031303152,0.00046685155],"genre_scores_gemma":[0.99703515,0.00006748,0.0008437339,0.00047086552,0.00017108973,0.0011050717,0.0000234502,0.000022182718,0.0002609607],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9990753,0.00006484412,0.0002724985,0.00022339134,0.00019770258,0.00016627561],"domain_scores_gemma":[0.9987471,0.00064474647,0.00012235342,0.00016519205,0.0002534577,0.000067164045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00078317005,0.00010319507,0.00022777457,0.00011371779,0.00011665767,0.000018484827,0.0000625607,0.000039813367,0.000044154403],"category_scores_gemma":[0.00018510826,0.00007856052,0.000051553485,0.00017311928,0.0000696638,0.000055152734,0.000014929134,0.00006551824,0.0000015894847],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029435487,0.00020782396,0.0032946474,0.0004484893,0.00017142334,1.4622738e-7,0.008443776,0.0008508785,0.3195953,0.0020372781,0.006738733,0.628776],"study_design_scores_gemma":[0.015746541,0.0058637983,0.513512,0.00046346386,0.00055150845,0.000056897767,0.0049336315,0.0953864,0.30432296,0.00047013036,0.058094576,0.0005980822],"about_ca_topic_score_codex":0.00028137548,"about_ca_topic_score_gemma":0.000056571633,"teacher_disagreement_score":0.62817794,"about_ca_system_score_codex":0.00016398689,"about_ca_system_score_gemma":0.0001687226,"threshold_uncertainty_score":0.3203605},"labels":[],"label_agreement":null},{"id":"W2092796790","doi":"10.1007/s11095-005-4586-z","title":"Trastuzumab and Liposomal Doxorubicin in the Treatment of MCF-7 Xenograft Tumor-Bearing Mice: Combination Does Not Affect Drug Serum Levels","year":2005,"lang":"en","type":"article","venue":"Pharmaceutical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Doxorubicin; Trastuzumab; Pharmacology; Medicine; Liposome; Chemotherapy; Drug; Cancer; Breast cancer; Internal medicine; Chemistry","score_opus":0.22241735679233038,"score_gpt":0.5189544992396271,"score_spread":0.29653714244729673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092796790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9708275,0.001365416,0.000004957645,0.023888655,0.000054715412,0.0014476083,0.000037214315,0.00002790298,0.002346009],"genre_scores_gemma":[0.9970762,0.001083629,0.00013532485,0.00025910142,0.00027011166,0.00019898152,0.000004878591,0.00003542119,0.00093632354],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99507964,0.0010514106,0.00043194575,0.00049237016,0.0019357536,0.001008901],"domain_scores_gemma":[0.9968161,0.0021598705,0.00003711359,0.00038424946,0.00024378579,0.00035886714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039946088,0.00021475383,0.00041664456,0.0004835049,0.00018418077,0.000079341684,0.00031020245,0.000082756684,0.00038705269],"category_scores_gemma":[0.00043233714,0.0001293596,0.0000969929,0.0007932449,0.0006023724,0.00013121268,0.00012257326,0.0010379036,0.00005573594],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031412644,0.0064316634,0.08044208,0.0013277754,0.00021819607,0.00051309477,0.013209149,0.000017872177,0.3124153,0.001733224,0.00068064546,0.57986975],"study_design_scores_gemma":[0.009241689,0.0024167686,0.1592481,0.00032230228,0.0000761071,0.000096771095,0.0016108339,0.008936325,0.79319984,0.00021209798,0.024403816,0.00023532868],"about_ca_topic_score_codex":0.00035495142,"about_ca_topic_score_gemma":0.0002467031,"teacher_disagreement_score":0.57963437,"about_ca_system_score_codex":0.00073107186,"about_ca_system_score_gemma":0.00031868793,"threshold_uncertainty_score":0.5275131},"labels":[],"label_agreement":null},{"id":"W2095720296","doi":"10.1200/jco.2008.16.3972","title":"Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Cancer Centre; McMaster University","funders":"","keywords":"Medicine; Receptor; Cancer research; Pharmacology; Internal medicine","score_opus":0.20157290432113878,"score_gpt":0.49655173568329786,"score_spread":0.2949788313621591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095720296","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1546556,0.003229857,0.0002920454,0.8353546,0.003865026,0.0007139567,0.000011602664,0.000023974955,0.0018532837],"genre_scores_gemma":[0.10628515,0.017089617,0.040565,0.7810305,0.051232222,0.000037232516,0.000024601752,0.0005457564,0.0031899556],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904274,0.002013036,0.004139289,0.000422358,0.0023614778,0.0006364724],"domain_scores_gemma":[0.9889444,0.0037695302,0.0046829986,0.0006496224,0.0015947579,0.0003586563],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.005859896,0.0003499911,0.0032745297,0.00027393393,0.00008715048,0.00001128709,0.0006542569,0.0015133771,0.00042190723],"category_scores_gemma":[0.005425009,0.00020192182,0.0011797567,0.00037786693,0.0010593538,0.000056767516,0.00022204687,0.01143881,0.000043818083],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023428546,0.00096721627,0.01681352,0.00047938552,0.0018452414,0.010395827,0.00018620223,0.0001383214,0.0018681651,0.000008280151,0.9477478,0.017207177],"study_design_scores_gemma":[0.0050295065,0.008883334,0.0024558296,0.0018706141,0.00068211835,0.0015308679,0.000056028875,0.000024249406,0.0008899606,0.000056864556,0.9783002,0.00022039747],"about_ca_topic_score_codex":0.000107942345,"about_ca_topic_score_gemma":0.00001703618,"teacher_disagreement_score":0.054324184,"about_ca_system_score_codex":0.00054083753,"about_ca_system_score_gemma":0.0068535237,"threshold_uncertainty_score":0.99978286},"labels":[],"label_agreement":null},{"id":"W2095851238","doi":"10.1002/cncr.24574","title":"Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients","year":2009,"lang":"en","type":"letter","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton","funders":"National Cancer Institute","keywords":"Medicine; Trastuzumab; Breast cancer; Concordance; Human Epidermal Growth Factor Receptor 2; Test (biology); Cancer; Documentation; Oncology; Test strategy; Gynecology; Intensive care medicine; Internal medicine","score_opus":0.10021456395726112,"score_gpt":0.465394555760633,"score_spread":0.36517999180337185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095851238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7850328,0.0032149216,0.000019584786,0.196532,0.001961027,0.005453997,0.0023629786,0.00011503289,0.005307629],"genre_scores_gemma":[0.7804354,0.005193178,0.00042881694,0.19862707,0.011841382,0.0019168339,0.00081491267,0.00036492973,0.00037751053],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554205,0.0010706899,0.00095492863,0.0008644129,0.0008653363,0.000702581],"domain_scores_gemma":[0.995409,0.0022658973,0.00053682487,0.00040410738,0.0012027789,0.00018137059],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0013656504,0.00043519455,0.0012230235,0.00025324605,0.00007023285,0.000057946596,0.00025170474,0.0007959742,0.0003982956],"category_scores_gemma":[0.0009590555,0.0003957262,0.00012197199,0.00038886635,0.00032382866,0.0002836852,0.000120857985,0.003249514,0.0000060643247],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044649988,0.00024221485,0.83959424,0.0048873457,0.0001588504,0.00025731244,0.00009353534,0.0000040310083,0.00014455173,0.000004959063,0.11523843,0.03892801],"study_design_scores_gemma":[0.0032431083,0.00062145846,0.9544442,0.00812604,0.00019942697,0.000028655712,0.00005570299,0.000010030743,0.00014706934,0.00003439349,0.032695048,0.0003948086],"about_ca_topic_score_codex":0.012808401,"about_ca_topic_score_gemma":0.00026600636,"teacher_disagreement_score":0.11484999,"about_ca_system_score_codex":0.00095365115,"about_ca_system_score_gemma":0.001468911,"threshold_uncertainty_score":0.99984944},"labels":[],"label_agreement":null},{"id":"W2096365365","doi":"10.1007/s40261-015-0302-x","title":"Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System","year":2015,"lang":"en","type":"article","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); Santé Montérégie; Thornhill Medical (Canada)","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab emtansine; Capecitabine; Trastuzumab; Adverse effect; Oncology; Internal medicine; Breast cancer; Clinical trial; Metastatic breast cancer; Taxane; Cancer; Colorectal cancer","score_opus":0.08230834484887428,"score_gpt":0.41124979316270993,"score_spread":0.32894144831383565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096365365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96636826,0.0014734796,0.00007485132,0.01846394,0.00024542274,0.007149821,0.0061378265,0.000009356395,0.000077069366],"genre_scores_gemma":[0.99821967,0.00012028889,0.0009426129,0.0002302806,0.00004949294,0.00022636495,0.00013304812,0.00002228934,0.000055978475],"study_design_codex":"qualitative","study_design_gemma":"observational","domain_scores_codex":[0.99721557,0.0006730088,0.0011052256,0.00029217787,0.00050174183,0.00021227483],"domain_scores_gemma":[0.99508095,0.0018503055,0.00061537477,0.00043224168,0.0016534836,0.00036764937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009043886,0.00016070408,0.0007370588,0.000050707742,0.0001139132,0.0000025137592,0.00018158571,0.000067235014,0.000016873157],"category_scores_gemma":[0.0011540302,0.0000808318,0.00013010464,0.00043137206,0.0006793708,0.000039723713,0.00003106932,0.00016963258,7.4911907e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06871605,0.0028356425,0.25477776,0.0044070063,0.007376547,0.00002510167,0.5005025,0.02076925,0.0014808845,0.0046037654,0.006764259,0.12774117],"study_design_scores_gemma":[0.022979928,0.0057442854,0.82884216,0.0077523193,0.0010128183,0.000012305422,0.11575898,0.013616842,0.003639916,0.00017344346,0.00023362582,0.00023336486],"about_ca_topic_score_codex":0.259359,"about_ca_topic_score_gemma":0.35511288,"teacher_disagreement_score":0.57406443,"about_ca_system_score_codex":0.0027365948,"about_ca_system_score_gemma":0.0064600785,"threshold_uncertainty_score":0.9991724},"labels":[],"label_agreement":null},{"id":"W2096433824","doi":"10.1186/bcr3690","title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","year":2014,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; PTEN; Pertuzumab; Tensin; Oncology; Medicine; Internal medicine; Biomarker; Breast cancer; Immunohistochemistry; Anthracycline; Epidermal growth factor receptor; Surgical oncology; Cancer; Biology; PI3K/AKT/mTOR pathway; Signal transduction; Genetics","score_opus":0.184716968103055,"score_gpt":0.5171683837353311,"score_spread":0.33245141563227615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2096433824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888669,0.00023862196,0.00008038418,0.0053664404,0.00006153342,0.0051196106,0.00022558068,0.000014507658,0.000026389049],"genre_scores_gemma":[0.9976775,0.000019012929,0.000103602375,0.00015702735,0.000057352256,0.0018702911,0.000004241929,0.0000486307,0.000062314575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99069005,0.0051550586,0.0005910147,0.00063811237,0.0023124197,0.00061333354],"domain_scores_gemma":[0.99256164,0.0047353823,0.00013186506,0.0012442097,0.0010835532,0.00024333263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.017389558,0.00021556944,0.00074384484,0.0011575008,0.00024537975,0.000036318444,0.0006714841,0.00008667542,0.000071052986],"category_scores_gemma":[0.002873233,0.00012131555,0.00021384549,0.0034830899,0.00063845713,0.00007616513,0.00018722322,0.0004705924,6.3659945e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07020688,0.00213747,0.7564736,0.00017877444,0.002151413,0.0000032058276,0.01842058,0.0047930866,0.039995857,0.000018437117,0.00012250688,0.10549819],"study_design_scores_gemma":[0.006311532,0.005621982,0.94351685,0.00019930121,0.00026622368,0.0000014368418,0.0060001817,0.0360146,0.0018811612,0.000017220822,0.000061845436,0.00010763724],"about_ca_topic_score_codex":0.0033734695,"about_ca_topic_score_gemma":0.0015581072,"teacher_disagreement_score":0.18704328,"about_ca_system_score_codex":0.0006638987,"about_ca_system_score_gemma":0.0020792414,"threshold_uncertainty_score":0.6026909},"labels":[],"label_agreement":null},{"id":"W2097111905","doi":"10.1093/annonc/mdu438.2","title":"Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc)","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Hazard ratio; Adjuvant; Oncology; Clinical endpoint; Breast cancer; Surgery; Cancer; Clinical trial; Confidence interval","score_opus":0.1481050724017683,"score_gpt":0.4505014088418088,"score_spread":0.3023963364400405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097111905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95865476,0.0011680132,0.0000018355573,0.035066653,0.00022397359,0.0021095853,0.00075570797,0.0000048314214,0.0020146207],"genre_scores_gemma":[0.99623,0.002152321,0.000013268309,0.0007122364,0.00043499738,0.00028613684,0.000026519163,0.000018528128,0.00012599856],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959451,0.0016750251,0.00084855413,0.00036561504,0.00073041196,0.00043526932],"domain_scores_gemma":[0.9965192,0.0017378085,0.00042532073,0.00089928624,0.00029447075,0.00012390915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00249781,0.00021857012,0.00092231744,0.00010377901,0.00005548109,0.000008632347,0.00053188857,0.00014177639,0.000033846347],"category_scores_gemma":[0.00062758365,0.00011140251,0.00016999777,0.00042367596,0.00068652123,0.000046475685,0.00010019518,0.00029573843,0.0000013783604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44041944,0.021968009,0.05110054,0.00036744447,0.00061256124,0.00028857746,0.046404835,0.00004895809,0.0036511174,0.0007248222,0.009448688,0.42496502],"study_design_scores_gemma":[0.2511022,0.029993506,0.6975762,0.00073030696,0.0002560871,0.00003644375,0.0033803978,0.00013033072,0.0054779523,0.0008494824,0.010226102,0.00024093121],"about_ca_topic_score_codex":0.0125769405,"about_ca_topic_score_gemma":0.011839604,"teacher_disagreement_score":0.64647573,"about_ca_system_score_codex":0.00012106251,"about_ca_system_score_gemma":0.0007855762,"threshold_uncertainty_score":0.9939984},"labels":[],"label_agreement":null},{"id":"W2097261126","doi":"10.1158/0008-5472.can-04-3468","title":"An Identity Crisis for <i>fps/fes</i>: Oncogene or Tumor Suppressor?","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Queen's University","funders":"","keywords":"Cancer research; Mutation; Mdm2; Suppressor; Biology; Oncogene; Cancer; Somatic cell; Genetically modified mouse; Tyrosine kinase; Transgene; Gene; Genetics; Signal transduction; Cell cycle","score_opus":0.24452441533077324,"score_gpt":0.5695611574949402,"score_spread":0.32503674216416695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097261126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9509462,0.004877318,0.0006771045,0.033021428,0.0006357366,0.0048830537,0.0006452434,0.00028049745,0.0040333774],"genre_scores_gemma":[0.97578317,0.0011940993,0.0028987017,0.0023189543,0.0045118337,0.0035651776,0.00006588445,0.00019023036,0.009471932],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99388367,0.00036159292,0.0005061286,0.0009958578,0.0024839276,0.0017688471],"domain_scores_gemma":[0.9954144,0.00041833636,0.00006423601,0.0013744166,0.0016901039,0.0010385247],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034263928,0.00027292452,0.00055759866,0.00055498106,0.00047817404,0.00023809726,0.0009689839,0.00018488945,0.006390319],"category_scores_gemma":[0.0008142827,0.00022514915,0.00018643751,0.0012644712,0.00037701055,0.00062228384,0.0002657037,0.0011096073,0.0004037841],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059320237,0.0009915713,0.0025621837,0.001347564,0.00021448506,0.00031974673,0.0010905142,0.000064866545,0.32290968,0.0007137676,0.60894555,0.054908056],"study_design_scores_gemma":[0.003689142,0.0018282697,0.0014534068,0.0002455896,0.000060447812,0.00007293429,0.00082623615,0.0005682847,0.3421716,0.0003950868,0.6483496,0.00033941324],"about_ca_topic_score_codex":0.0024452421,"about_ca_topic_score_gemma":0.0038569227,"teacher_disagreement_score":0.054568645,"about_ca_system_score_codex":0.0015857312,"about_ca_system_score_gemma":0.002862808,"threshold_uncertainty_score":0.994518},"labels":[],"label_agreement":null},{"id":"W2097591523","doi":"10.1158/1055-9965.epi-09-1023","title":"Assessment of Automated Image Analysis of Breast Cancer Tissue Microarrays for Epidemiologic Studies","year":2010,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Cancer Research UK","keywords":"Tissue microarray; Breast cancer; Medicine; DNA microarray; Pathology; Cancer; Oncology; Computational biology; Internal medicine; Biology; Genetics; Gene expression; Gene","score_opus":0.12960050648887747,"score_gpt":0.5566568023448623,"score_spread":0.4270562958559848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097591523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9424465,0.021211633,0.011816785,0.016776403,0.0021088459,0.0035181665,0.0015089256,0.00028436308,0.00032839103],"genre_scores_gemma":[0.93842125,0.006332562,0.052141443,0.00041596804,0.00025218044,0.0016201846,0.00036418386,0.00004952372,0.00040269998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953892,0.0010783087,0.0017858178,0.0008101429,0.00023307119,0.00070343283],"domain_scores_gemma":[0.9939308,0.0026792053,0.0013114477,0.0007336014,0.0011379811,0.00020696307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00798572,0.00033737146,0.0024461276,0.0007248297,0.00009970207,0.0000032142495,0.0003035212,0.0004547952,0.0008635874],"category_scores_gemma":[0.002609215,0.0002735168,0.0007455953,0.0011548953,0.0011638292,0.00009749388,0.00011910776,0.00040966284,0.000002298075],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044914888,0.00020391631,0.58828336,0.0010646756,0.011434224,0.0000025651907,0.00006479429,0.00014204433,0.36461335,0.00041328053,0.016411899,0.01691675],"study_design_scores_gemma":[0.0014695721,0.0004944147,0.9664069,0.00049632567,0.0046699774,0.000011162969,0.00014450363,0.015049383,0.008432455,0.0010654427,0.001515915,0.00024396961],"about_ca_topic_score_codex":0.0015106444,"about_ca_topic_score_gemma":0.0014489136,"teacher_disagreement_score":0.37812355,"about_ca_system_score_codex":0.00035887517,"about_ca_system_score_gemma":0.0007170114,"threshold_uncertainty_score":0.9999717},"labels":[],"label_agreement":null},{"id":"W2097680149","doi":"10.1093/annonc/mdf295","title":"Trastuzumab therapy for the metastatic patient: does the primary match?","year":2002,"lang":"en","type":"letter","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Primary tumor; Internal medicine; Cancer; Metastasis","score_opus":0.21853642125591463,"score_gpt":0.4468525590948695,"score_spread":0.22831613783895485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097680149","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015902711,0.010191252,0.00004962144,0.9770558,0.0007232878,0.0033311152,0.0002536491,0.000026205402,0.006778787],"genre_scores_gemma":[0.0035929598,0.014760607,0.00036769552,0.97106105,0.0026456043,0.0014199412,0.00015065282,0.00011544468,0.0058860458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970088,0.0004739745,0.00064579106,0.0003994431,0.0007656544,0.00070631196],"domain_scores_gemma":[0.99390095,0.004198653,0.00040132765,0.00093988015,0.0004950178,0.000064195236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009818736,0.00031606146,0.000990473,0.00014850766,0.00014853025,0.00002087446,0.0006637393,0.00047425006,0.0012036521],"category_scores_gemma":[0.00025567712,0.00013234712,0.00046953757,0.00020048341,0.0006466639,0.00003337278,0.000087914304,0.0017120882,0.000047034555],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028367917,0.00017420923,0.000022161841,0.00033987765,0.0006216678,0.00011582158,0.0007083317,0.0000010708476,0.00003440968,0.00001328407,0.7179891,0.2796964],"study_design_scores_gemma":[0.0011606794,0.006172489,0.00027664157,0.000098250704,0.00017361266,0.000091047856,0.00015861512,0.000021619997,0.00045584174,0.0007291753,0.9905227,0.00013932312],"about_ca_topic_score_codex":0.0001413313,"about_ca_topic_score_gemma":0.000020035173,"teacher_disagreement_score":0.27955708,"about_ca_system_score_codex":0.0001467913,"about_ca_system_score_gemma":0.0007756318,"threshold_uncertainty_score":0.99970937},"labels":[],"label_agreement":null},{"id":"W2097934619","doi":"10.1093/annonc/mdp447","title":"Activity of fulvestrant in HER2-overexpressing advanced breast cancer","year":2009,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Fulvestrant; Medicine; Internal medicine; Oncology; Trastuzumab; Cancer; Breast cancer; Metastatic breast cancer; Population; Hormone receptor; Endocrine system; Tamoxifen; Gynecology; Hormone","score_opus":0.13496576755862585,"score_gpt":0.5092962090046241,"score_spread":0.37433044144599825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097934619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97140265,0.0006282416,0.000013763814,0.016710378,0.00006891441,0.00025011264,0.00003714003,0.0000107184405,0.010878099],"genre_scores_gemma":[0.9976879,0.001013467,0.0003555953,0.0007316576,0.00007463384,0.000013600564,0.0000016977074,0.000009995622,0.000111500056],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99875444,0.000110662935,0.0003094552,0.00021001103,0.00027174273,0.0003436897],"domain_scores_gemma":[0.9991727,0.00009711091,0.00015540881,0.00024768413,0.00021707849,0.00011001077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039213314,0.00010172448,0.0005393804,0.0001525458,0.000014219569,0.0000020618502,0.00011899547,0.0001440501,0.00028483963],"category_scores_gemma":[0.000093132796,0.00009256497,0.000077321034,0.00026551585,0.00015943017,0.000087807566,0.00002707079,0.00029413844,0.000002756274],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017075952,0.00076229195,0.011045927,0.00013690224,0.000024469518,0.00006429188,0.00024400263,0.00007140642,0.28674364,0.000063907675,0.0010105625,0.698125],"study_design_scores_gemma":[0.0025158243,0.0031603007,0.783827,0.00070146477,0.000015456035,0.00006374935,0.000090609414,0.00010288599,0.20054366,0.0004183899,0.008443929,0.00011669708],"about_ca_topic_score_codex":0.0008697531,"about_ca_topic_score_gemma":0.00023285532,"teacher_disagreement_score":0.77278113,"about_ca_system_score_codex":0.0001084065,"about_ca_system_score_gemma":0.0007617713,"threshold_uncertainty_score":0.377469},"labels":[],"label_agreement":null},{"id":"W2098010907","doi":"10.1200/jco.2009.22.8361","title":"Are <i>HER2</i> and <i>TOP2A</i> Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Adjuvant; Adjuvant chemotherapy; Chemotherapy; Cancer; Trastuzumab; Predictive value","score_opus":0.16127825424187406,"score_gpt":0.5170535328735052,"score_spread":0.35577527863163116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098010907","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0102144275,0.0024404423,0.0011268064,0.97763675,0.0026257667,0.004390529,0.0013389057,0.000040490086,0.00018586442],"genre_scores_gemma":[0.0073329736,0.0060757254,0.007963047,0.9445143,0.032102484,0.0004698231,0.00009003169,0.00024660668,0.0012050172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99273324,0.0006349563,0.0037465333,0.00084089185,0.0010656908,0.0009786682],"domain_scores_gemma":[0.97630095,0.014808189,0.005332921,0.00047016368,0.0023421382,0.00074561115],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.004579144,0.0006084795,0.004594249,0.00039131037,0.00012191786,0.000048639795,0.00054830016,0.00288305,0.00026239152],"category_scores_gemma":[0.009049217,0.00041016805,0.0013440518,0.0002718797,0.00087359495,0.00012015251,0.00005011955,0.004386732,0.0000044673443],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050847918,0.0010816036,0.018467924,0.0011579917,0.0014496843,0.0021830138,0.000022838032,0.0000046210653,0.000028896755,4.6039284e-7,0.75593036,0.1688247],"study_design_scores_gemma":[0.02900098,0.040780127,0.04924831,0.0029110215,0.0018056743,0.0013825451,0.0000511149,0.00035922084,0.00009375252,0.00023483958,0.8737466,0.00038582415],"about_ca_topic_score_codex":0.000043091975,"about_ca_topic_score_gemma":0.0000950752,"teacher_disagreement_score":0.16843888,"about_ca_system_score_codex":0.00075617206,"about_ca_system_score_gemma":0.011752545,"threshold_uncertainty_score":0.999835},"labels":[],"label_agreement":null},{"id":"W2098544382","doi":"10.1093/jnci/93.24.1852","title":"Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)","year":2001,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":889,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Cell growth; Cancer research; Growth inhibition; Insulin-like growth factor; Receptor; Growth factor; Growth factor receptor; Biology; Endocrinology; Internal medicine; Chemistry; Cancer cell; Breast cancer; Medicine; Cancer; Biochemistry","score_opus":0.09529036687241335,"score_gpt":0.38763124921505876,"score_spread":0.29234088234264544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098544382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9686438,0.0019439203,0.00035518085,0.02216863,0.0024000455,0.00043631624,0.00007957635,0.000017738746,0.0039547794],"genre_scores_gemma":[0.9870555,0.0012669631,0.0031961668,0.0035197309,0.0023379805,0.000020428799,0.0000020470418,0.000027112837,0.0025741057],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997117,0.00008299334,0.0005409529,0.00021282515,0.0017625216,0.00028370015],"domain_scores_gemma":[0.99765164,0.00011596333,0.00026677418,0.00012670697,0.0015337303,0.00030518934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071850466,0.00016658926,0.00031636842,0.00024059828,0.00020168212,0.000056294448,0.00034709374,0.000091673726,0.00041705798],"category_scores_gemma":[0.000959401,0.0001166918,0.00014017375,0.000651221,0.00015477133,0.0002971017,0.000075229866,0.0006300123,0.000018298264],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014444337,0.0009471534,0.15367578,0.0010566923,0.0016662332,0.0003594916,0.008331344,0.0034531944,0.29903018,0.0053843963,0.45678303,0.054868177],"study_design_scores_gemma":[0.0036699423,0.0004135195,0.11669784,0.0015994544,0.00009634787,0.0004814916,0.00014016654,0.00003788308,0.010089169,0.0014538955,0.86497617,0.0003441462],"about_ca_topic_score_codex":0.00007958608,"about_ca_topic_score_gemma":0.00024330226,"teacher_disagreement_score":0.4081931,"about_ca_system_score_codex":0.001583122,"about_ca_system_score_gemma":0.0016268871,"threshold_uncertainty_score":0.47585535},"labels":[],"label_agreement":null},{"id":"W2098749503","doi":"10.1158/1078-0432.ccr-15-0156","title":"An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"In vivo; Cancer research; Antigen; Monoclonal antibody; Antibody; Biology; Immunohistochemistry; Cytotoxic T cell; In vitro; Immunology","score_opus":0.32669273389124903,"score_gpt":0.5304941585481654,"score_spread":0.20380142465691636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098749503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881286,0.0045930627,0.000052784155,0.0028004453,0.00037774036,0.0025215324,0.00022224871,0.0001815951,0.0011219626],"genre_scores_gemma":[0.99166197,0.0043639247,0.0011095835,0.0009071955,0.00081349746,0.0003692859,0.000084451385,0.00015863022,0.000531495],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888879,0.002468127,0.0021828006,0.0013946109,0.003091441,0.001975093],"domain_scores_gemma":[0.9910163,0.0021961762,0.00036370195,0.0014455132,0.0033644028,0.0016138649],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.014377146,0.00045310953,0.0018424728,0.0008388289,0.00020025081,0.000121149315,0.0011542286,0.00022037697,0.0003189991],"category_scores_gemma":[0.0074481512,0.00039397008,0.00029788792,0.0022197203,0.0024389357,0.000356562,0.00052687596,0.0019608918,0.00011425136],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010033057,0.0019932976,0.9125383,0.0018501143,0.00023669358,0.002769221,0.0019365102,0.0010112356,0.039456375,0.000048451908,0.016798807,0.0113279335],"study_design_scores_gemma":[0.051673573,0.008813522,0.6685107,0.015741147,0.0002048174,0.00017370384,0.007162976,0.106992565,0.074826606,0.0010957287,0.06207912,0.0027255695],"about_ca_topic_score_codex":0.012733836,"about_ca_topic_score_gemma":0.003652931,"teacher_disagreement_score":0.24402763,"about_ca_system_score_codex":0.0013782553,"about_ca_system_score_gemma":0.008338029,"threshold_uncertainty_score":0.9998512},"labels":[],"label_agreement":null},{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","score_opus":0.0562133101311759,"score_gpt":0.35611518970783484,"score_spread":0.2999018795766589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098775844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9361155,0.008374429,0.00032092055,0.034603443,0.0014011761,0.00045887704,0.000021480888,0.00002007256,0.018684076],"genre_scores_gemma":[0.99158895,0.002112307,0.0003403463,0.00082651176,0.004402332,0.000003954023,0.0000022694298,0.000029002447,0.0006943451],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978446,0.00013390307,0.0006494033,0.00016872992,0.0008380458,0.0003653333],"domain_scores_gemma":[0.9985645,0.00010503861,0.0002131328,0.0001806952,0.00035533868,0.0005812882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001221812,0.000172218,0.00068210094,0.00039362826,0.000025533554,0.000004465833,0.00018463908,0.00008623733,0.0037533112],"category_scores_gemma":[0.00020833666,0.000108719265,0.000076100274,0.00036226248,0.00017416244,0.000095231204,0.000024722236,0.0008607353,0.000012043195],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067420714,0.00037414016,0.17643543,0.0001321616,0.00022541832,0.004684907,0.01348217,0.000007409836,0.004231422,0.00009507214,0.022408398,0.7711814],"study_design_scores_gemma":[0.0794105,0.005039817,0.874982,0.004858377,0.00025075686,0.011159658,0.0011768397,0.000047745038,0.0018216067,0.00053832296,0.020514922,0.00019945954],"about_ca_topic_score_codex":0.0038643584,"about_ca_topic_score_gemma":0.0006298395,"teacher_disagreement_score":0.77098197,"about_ca_system_score_codex":0.0003495156,"about_ca_system_score_gemma":0.00088603765,"threshold_uncertainty_score":0.9971574},"labels":[],"label_agreement":null},{"id":"W2098898117","doi":"10.1016/s1470-2045(11)70231-5","title":"HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data","year":2011,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Amis de l'Institut Bordet; Cancer Research UK; Strategiske Forskningsråd","keywords":"Anthracycline; Internal medicine; Oncology; Medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Adjuvant; Chemotherapy; Methotrexate; Cancer; Confidence interval","score_opus":0.43518734685932126,"score_gpt":0.5262071644404532,"score_spread":0.09101981758113198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098898117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053428137,0.9810751,0.00001646411,0.001971715,0.00011357496,0.003919573,0.011092628,0.000020546575,0.0012560858],"genre_scores_gemma":[0.00096024014,0.9950384,0.0006355856,0.00036861247,0.00030922994,0.0014931833,0.0008823695,0.00006850537,0.00024390616],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962712,0.0008118865,0.001106093,0.0008052682,0.00046702666,0.0005385103],"domain_scores_gemma":[0.9947843,0.0015606148,0.0013285469,0.0018970377,0.00026290969,0.00016657765],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018300174,0.00048879115,0.008480076,0.0003619417,0.000066293134,0.000010018741,0.00080240803,0.0003735364,0.00095230626],"category_scores_gemma":[0.00015774384,0.0002686893,0.001091053,0.00055436284,0.00053411117,0.0000475321,0.00030884834,0.0003498516,0.00000269925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038821243,0.0004549126,0.00011739662,0.0023179774,0.22241807,0.000022669232,0.0017073323,0.0000015490269,0.0000010313018,0.00006042619,0.0015357832,0.76748073],"study_design_scores_gemma":[0.0021648556,0.008791714,0.00021542287,0.00055172696,0.31585014,0.0001218113,0.0003623083,0.00005872585,0.000009017431,0.000039366347,0.67166495,0.00016995374],"about_ca_topic_score_codex":0.0030347356,"about_ca_topic_score_gemma":0.00058209966,"teacher_disagreement_score":0.7673108,"about_ca_system_score_codex":0.00054670003,"about_ca_system_score_gemma":0.0021766876,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W2099461930","doi":"10.1016/j.ygyno.2009.10.004","title":"HER2 Overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","year":2010,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Carboplatin; Ovarian cancer; Targeted therapy; Oncology; Ovarian carcinomas; Cancer research; Internal medicine; Ovarian carcinoma; Cancer; Chemotherapy; Breast cancer; Cisplatin","score_opus":0.04329109243936597,"score_gpt":0.34701284403533467,"score_spread":0.3037217515959687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099461930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901992,0.0003420733,0.000008861395,0.0067033973,0.00008000748,0.0011825701,0.00003374722,0.000024558738,0.0014255706],"genre_scores_gemma":[0.9972256,0.00036882248,0.0013722548,0.000604187,0.00005927737,0.00017817317,0.000029038902,0.00001936632,0.00014331362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984118,0.00019638389,0.0003150329,0.00045652664,0.0002411133,0.00037916514],"domain_scores_gemma":[0.99874026,0.00044339936,0.00014055075,0.00035891793,0.0001320812,0.00018481955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051756925,0.00016896229,0.00049126474,0.00018329344,0.0000624141,0.000010471962,0.00011458565,0.00034757494,0.00052047387],"category_scores_gemma":[0.00020456927,0.00012093196,0.000024421617,0.00022729069,0.00041144248,0.00004149163,0.000067950445,0.0005625505,0.0000012375315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016224158,0.00097212795,0.69064265,0.0001501361,0.00006347373,0.00016194489,0.0048418925,0.0000030902563,0.24816535,0.0002251814,0.0015581725,0.051593542],"study_design_scores_gemma":[0.0049876147,0.00561573,0.95703995,0.000032307125,0.00002016657,0.00014922976,0.0005957195,0.0001990911,0.015651757,0.0002400566,0.01533169,0.00013666507],"about_ca_topic_score_codex":0.00230918,"about_ca_topic_score_gemma":0.0037129857,"teacher_disagreement_score":0.2663973,"about_ca_system_score_codex":0.0002062459,"about_ca_system_score_gemma":0.00066079403,"threshold_uncertainty_score":0.5698824},"labels":[],"label_agreement":null},{"id":"W2099688742","doi":"10.5858/2008-132-61-htiaps","title":"HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.","year":2008,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Mount Sinai Hospital","funders":"","keywords":"Trastuzumab; Concordance; Immunohistochemistry; Medicine; Breast cancer; Oncology; Internal medicine; Context (archaeology); Metastatic breast cancer; Cancer; Fish <Actinopterygii>; Population; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.06859739418384475,"score_gpt":0.3079721304124999,"score_spread":0.23937473622865513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099688742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965257,0.00002278196,0.0000045827796,0.00008676559,0.00001157842,0.0031203148,0.000046361438,0.000035961995,0.00014592646],"genre_scores_gemma":[0.9967928,8.975988e-7,0.00019214708,0.000041469997,0.000018666013,0.0028125923,0.000028048225,0.000040943458,0.000072465264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99811465,0.00010176403,0.0003143226,0.0002952687,0.00076576474,0.00040823614],"domain_scores_gemma":[0.9990183,0.00013169597,0.00012065465,0.00025629706,0.00030994898,0.00016311016],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018988634,0.00016092781,0.00039944472,0.00025780065,0.000050296425,0.0000068971303,0.000080778,0.00002492507,0.000041693107],"category_scores_gemma":[0.00011009189,0.0001084954,0.000018892293,0.0011530512,0.000054566815,0.00006777347,0.000011597086,0.00017876709,7.9417185e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012897061,0.0019374934,0.97789913,0.00010051725,0.00009295052,0.00008887056,0.00031243826,0.0006286054,0.0000018258704,1.5207407e-7,0.000012003612,0.017636286],"study_design_scores_gemma":[0.009344777,0.0007503665,0.9891538,0.00011638147,0.000091529066,0.000010235395,0.00013466143,0.00025264674,0.000027886448,4.871927e-7,0.0000035549622,0.00011366958],"about_ca_topic_score_codex":0.016885845,"about_ca_topic_score_gemma":0.004067765,"teacher_disagreement_score":0.017522616,"about_ca_system_score_codex":0.00047009633,"about_ca_system_score_gemma":0.00027656334,"threshold_uncertainty_score":0.9896608},"labels":[],"label_agreement":null},{"id":"W2099718130","doi":"10.1371/journal.pone.0012766","title":"Deficiency of the Metalloproteinase-Disintegrin ADAM8 Is Associated with Thymic Hyper-Cellularity","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Disintegrin; Metalloproteinase; Biology; Medicine; Matrix metalloproteinase; Internal medicine","score_opus":0.0682251485582779,"score_gpt":0.2739221455789857,"score_spread":0.20569699702070782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099718130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885931,0.00020393766,0.000009595789,0.002417962,0.000042468404,0.0008548147,0.000032747303,0.000049234655,0.0077961623],"genre_scores_gemma":[0.9951855,0.000016798009,0.0009097666,0.00021853688,0.0000569303,0.000051904102,0.0000071301965,0.000035698784,0.0035177656],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772817,0.000085889806,0.00024631392,0.00028612575,0.0012962874,0.00035718695],"domain_scores_gemma":[0.9984454,0.00010039686,0.00011774483,0.0007977353,0.0004081563,0.0001305817],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006153061,0.0001493786,0.0003937763,0.000070460716,0.00010166879,0.000016135808,0.00034523563,0.00014763854,0.0010752375],"category_scores_gemma":[0.0010592681,0.00008946056,0.00009639983,0.0005214428,0.0003450021,0.000046905265,0.00010754055,0.0010604397,0.000056659854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010326352,0.0028476042,0.07182918,0.00020516866,0.0002573463,0.000016165824,0.0002570348,2.2548082e-7,0.9235539,0.00024057312,0.00022041996,0.00046912313],"study_design_scores_gemma":[0.001272225,0.00055032223,0.05509952,0.00065143965,0.00038868294,0.000012566753,0.000077384095,0.00026006138,0.9410167,0.00023119278,0.0002838565,0.00015609933],"about_ca_topic_score_codex":0.00053789694,"about_ca_topic_score_gemma":0.00044853098,"teacher_disagreement_score":0.01746275,"about_ca_system_score_codex":0.0000968006,"about_ca_system_score_gemma":0.00045416132,"threshold_uncertainty_score":0.99983793},"labels":[],"label_agreement":null},{"id":"W2099988058","doi":"10.1186/1471-2407-11-313","title":"Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study","year":2011,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer; Amgen; American Heart Association","keywords":"Erlotinib; Gemcitabine; Medicine; Pharmacokinetics; Pharmacology; Nausea; Adverse effect; Internal medicine; Phases of clinical research; Oncology; Tolerability; Epidermal growth factor receptor; Gastroenterology; Toxicity; Chemotherapy; Cancer","score_opus":0.11214556829817944,"score_gpt":0.42831665357852666,"score_spread":0.3161710852803472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099988058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944413,0.0019787252,0.00034087742,0.00013979214,0.000030637635,0.0028742636,0.000091474576,0.00000603226,0.0000969559],"genre_scores_gemma":[0.99770224,0.0012668116,0.00045361897,0.000017941678,0.00003885892,0.00034666673,0.0000034604377,0.000017719234,0.00015267295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99920833,0.000037159993,0.0002509259,0.00016771755,0.00019101273,0.00014482322],"domain_scores_gemma":[0.99940115,0.00015211868,0.000090557274,0.00016299309,0.00013839513,0.00005478568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022827028,0.00009967397,0.0002958427,0.000074477444,0.000024515664,0.000002713181,0.000044538894,0.000020810738,0.00006742563],"category_scores_gemma":[0.000028517969,0.000060374317,0.000020430003,0.00014834112,0.00013676718,0.000025905747,0.000015192827,0.00005045352,1.12786026e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031557724,0.018981261,0.71929705,0.0013326566,0.00056033436,0.000023828201,0.03415921,0.00005534953,0.0075868177,0.0001451092,0.00021417483,0.1860865],"study_design_scores_gemma":[0.1571675,0.042539526,0.7191453,0.0005957762,0.00078468985,0.000019566774,0.004708065,0.010904518,0.060840264,0.00007768065,0.0029615758,0.00025553047],"about_ca_topic_score_codex":0.0013842918,"about_ca_topic_score_gemma":0.0014591442,"teacher_disagreement_score":0.18583098,"about_ca_system_score_codex":0.00009421669,"about_ca_system_score_gemma":0.0001628617,"threshold_uncertainty_score":0.24619932},"labels":[],"label_agreement":null},{"id":"W2100723992","doi":"10.1038/modpathol.3880372","title":"Defining a Test for HER-2/neu Evaluation in Breast Cancer in the Diagnostic Setting","year":2001,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Concordance; Immunohistochemistry; Breast cancer; Medicine; HER2/neu; Cancer; Gene duplication; Pathology; Oncology; Internal medicine; Gene; Biology","score_opus":0.06017018288462389,"score_gpt":0.4127420588739982,"score_spread":0.3525718759893743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100723992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97750145,0.001977146,0.0008041575,0.017198697,0.000101816695,0.0013444617,0.00004619221,0.000020959726,0.0010051226],"genre_scores_gemma":[0.99606884,0.0002689018,0.00021941321,0.0014398529,0.00013996607,0.0017619439,0.000023034403,0.000026078862,0.00005194381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836576,0.00026581032,0.00026299703,0.00032614428,0.00032240467,0.00045687077],"domain_scores_gemma":[0.9976832,0.0018333988,0.000048953138,0.00027240335,0.000119697404,0.00004232505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023905262,0.000108306085,0.0002130717,0.0001642176,0.000051640356,0.0000135119435,0.00013423871,0.00011465039,0.00011817117],"category_scores_gemma":[0.0020717415,0.00008457901,0.000036355694,0.00028351028,0.000063331296,0.000040438656,0.000028715618,0.00034118554,0.000016851709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009916046,0.00016534295,0.7896224,0.00006350137,0.000004230299,0.0004018325,0.0038174377,0.0012355725,0.0019081127,0.00004607866,0.00029731618,0.20233898],"study_design_scores_gemma":[0.0031498123,0.00022194629,0.88228136,0.00032179715,0.000042556512,0.0010377713,0.0004560877,0.10885483,0.000076652344,0.0029000975,0.0005249945,0.0001320638],"about_ca_topic_score_codex":0.0003444958,"about_ca_topic_score_gemma":0.0021909133,"teacher_disagreement_score":0.20220691,"about_ca_system_score_codex":0.00029090038,"about_ca_system_score_gemma":0.00030763668,"threshold_uncertainty_score":0.3449032},"labels":[],"label_agreement":null},{"id":"W2100784179","doi":"10.1007/s00428-002-0752-4","title":"Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray","year":2003,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Vimentin; Adenocarcinoma; Pathology; Carcinoembryonic antigen; Tissue microarray; Immunostaining; Carcinoma; Biopsy; Medicine; Immunohistochemistry; Biology; Cancer; Internal medicine","score_opus":0.07062212850741136,"score_gpt":0.4187798839344638,"score_spread":0.34815775542705246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100784179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674811,0.019282456,0.001537898,0.0005594553,0.0005681973,0.0015424779,0.00010645886,0.00014300029,0.008778963],"genre_scores_gemma":[0.9726963,0.0019125632,0.023838907,0.0005701729,0.00043692638,0.00006157401,0.000096310025,0.00009797658,0.00028927106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940305,0.0012488716,0.0012841338,0.00125091,0.000890285,0.0012953379],"domain_scores_gemma":[0.995432,0.0019227848,0.00043307606,0.0013511812,0.00026072157,0.0006002165],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00248342,0.0006640772,0.0017329797,0.0007168482,0.00025877287,0.000036364854,0.00060302136,0.0005419666,0.00048647754],"category_scores_gemma":[0.004873301,0.00051282643,0.00030727556,0.0011135304,0.0024726156,0.00012867995,0.0004585684,0.0016802052,0.00005863141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002322198,0.00078354386,0.028585173,0.0008257949,0.0006960786,0.0007626634,0.0014259176,0.000044810375,0.9436732,0.0039641196,0.001023208,0.01589329],"study_design_scores_gemma":[0.02316592,0.010613476,0.07027645,0.0012677485,0.0019567949,0.0009607703,0.003928959,0.0016230276,0.83742756,0.012485869,0.034318548,0.001974895],"about_ca_topic_score_codex":0.00040401824,"about_ca_topic_score_gemma":0.000009025721,"teacher_disagreement_score":0.10624566,"about_ca_system_score_codex":0.00012987677,"about_ca_system_score_gemma":0.0010351647,"threshold_uncertainty_score":0.9997323},"labels":[],"label_agreement":null},{"id":"W2100891604","doi":"10.1016/j.ctrv.2008.03.013","title":"Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review","year":2008,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; McMaster University; Cancer Care Ontario; Sunnybrook Health Science Centre; Kingston General Hospital","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Internal medicine; Adjuvant; Cochrane Library; Adjuvant therapy; Randomized controlled trial; Clinical trial; Neoadjuvant therapy; Cancer","score_opus":0.11580775246216311,"score_gpt":0.432500353013039,"score_spread":0.3166926005508759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100891604","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015886399,0.966803,0.0000021316293,0.00036936832,0.00022525185,0.03129635,0.0005733471,0.00011701,0.0005976166],"genre_scores_gemma":[0.000004144998,0.91234195,0.00008487021,0.00096724357,0.00048148766,0.084212616,0.00013381476,0.00037907858,0.001394772],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.989544,0.0017649268,0.0036117681,0.0019796952,0.0013182233,0.0017814288],"domain_scores_gemma":[0.9939998,0.00026470263,0.0020198934,0.0026520763,0.0002462655,0.0008172964],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00092044054,0.0022954026,0.018972032,0.0005496428,0.0001871878,0.00009243819,0.0007872889,0.00046674977,0.0017541472],"category_scores_gemma":[0.00007326105,0.0012342962,0.0014430733,0.002116147,0.00026512612,0.0002051381,0.00009505624,0.0011444535,0.0002719463],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009318912,0.00033900538,0.000027166101,0.47101685,0.0007439572,0.00037634315,0.0002333798,3.1775375e-7,4.215894e-7,4.0301515e-7,0.0017265115,0.5254425],"study_design_scores_gemma":[0.001486905,0.0006976659,0.00001289613,0.5082056,0.0019844216,0.0011653834,0.000017044795,8.5860466e-7,6.492065e-7,4.4578618e-7,0.48586574,0.00056237995],"about_ca_topic_score_codex":0.0013283481,"about_ca_topic_score_gemma":0.0002483493,"teacher_disagreement_score":0.52488005,"about_ca_system_score_codex":0.017802404,"about_ca_system_score_gemma":0.0064958413,"threshold_uncertainty_score":0.9991584},"labels":[],"label_agreement":null},{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","score_opus":0.11767038809995356,"score_gpt":0.4940915774878471,"score_spread":0.37642118938789354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101299592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943802,0.0001513959,0.0000057437333,0.0030078746,0.00065406127,0.0016188542,0.000103742765,0.000009105857,0.000069074464],"genre_scores_gemma":[0.99752045,0.00038485762,0.001035235,0.00017488778,0.0007341576,0.000052552878,0.0000072528546,0.00005035172,0.000040228268],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99484026,0.00079705316,0.0024155667,0.0003954509,0.0010440657,0.0005075799],"domain_scores_gemma":[0.9949994,0.0013586063,0.0018869031,0.00023811475,0.00093776104,0.0005792216],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002145088,0.00029863825,0.002299356,0.00033962989,0.00011960561,0.000018832507,0.0002688412,0.00034302523,0.0006943983],"category_scores_gemma":[0.001115085,0.00019125934,0.00032560882,0.0002493767,0.00065487437,0.00027816737,0.00007010836,0.0023388048,0.000001079243],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38938922,0.03580938,0.25648358,0.00017304243,0.0010685539,0.0002874907,0.001490457,6.2773694e-7,0.003964001,0.000012826969,0.00012807448,0.31119275],"study_design_scores_gemma":[0.2802149,0.096727155,0.62020695,0.0002387832,0.00016344155,0.00011410259,0.000111460125,0.0000086574955,0.0018008122,0.00001776745,0.00024566206,0.00015027935],"about_ca_topic_score_codex":0.00012408086,"about_ca_topic_score_gemma":0.00019682074,"teacher_disagreement_score":0.3637234,"about_ca_system_score_codex":0.00043818323,"about_ca_system_score_gemma":0.0029863843,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W2101687615","doi":"10.1016/j.jss.2005.02.006","title":"Expression of ZER6 in ERα-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Petroleum Technology Research Centre","keywords":"Estrogen receptor; Breast cancer; Estrogen receptor alpha; Biology; Cancer research; Western blot; Estrogen; Gene isoform; Transfection; Estrogen receptor beta; Breast carcinoma; Cancer; Cell culture; Endocrinology; Gene; Genetics","score_opus":0.11655404637524946,"score_gpt":0.5118174318911838,"score_spread":0.3952633855159343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101687615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632808,0.0030190267,0.000008630212,0.024984807,0.00007063009,0.00028643993,0.000022988932,0.0000040668306,0.008322634],"genre_scores_gemma":[0.99234486,0.005392388,0.00028854315,0.000041411047,0.00087148993,0.0000109022885,9.3917504e-7,0.00002190532,0.0010275871],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9951173,0.0005025948,0.0007290782,0.00019032402,0.0028558315,0.0006048741],"domain_scores_gemma":[0.99654514,0.00090727437,0.00014287849,0.00022563992,0.0016784664,0.00050061184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004631342,0.00010737945,0.0005167729,0.00079409155,0.000048891136,0.000021034459,0.00030447548,0.00015193124,0.0026788616],"category_scores_gemma":[0.00038033823,0.00007431516,0.00016621457,0.0009313778,0.00032240435,0.0001814132,0.00015526926,0.0019344414,0.000032726657],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025867045,0.0037513513,0.23041794,0.0007544146,0.00018382102,0.00890851,0.0020661056,0.00036603835,0.24946783,0.0005192641,0.06118655,0.41651112],"study_design_scores_gemma":[0.018402377,0.0032804648,0.4689301,0.011970682,0.000044520035,0.0048387875,0.0012849575,0.000720338,0.32990006,0.0005386873,0.15969981,0.00038923218],"about_ca_topic_score_codex":0.00025495066,"about_ca_topic_score_gemma":0.000035548626,"teacher_disagreement_score":0.4161219,"about_ca_system_score_codex":0.0007468041,"about_ca_system_score_gemma":0.0012319218,"threshold_uncertainty_score":0.99823284},"labels":[],"label_agreement":null},{"id":"W2102299301","doi":"10.1023/b:brea.0000036783.88387.47","title":"HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel","year":2004,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Amis de l'Institut Bordet","keywords":"Docetaxel; Medicine; Internal medicine; Breast cancer; Oncology; Doxorubicin; Population; Odds ratio; Cancer; Cohort; Chemotherapy","score_opus":0.049143343182379784,"score_gpt":0.3644664732989722,"score_spread":0.3153231301165924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2102299301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897237,0.0014478129,0.0000057860398,0.002652736,0.00007106007,0.0043671955,0.0010052497,0.000054906814,0.00067154586],"genre_scores_gemma":[0.99360114,0.0018002155,0.0000888497,0.000069247486,0.0001368745,0.0024975212,0.00012128659,0.00011210965,0.0015727264],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99506253,0.0002562019,0.0006504389,0.0010197763,0.0017967166,0.001214312],"domain_scores_gemma":[0.99750733,0.00014965086,0.00019368439,0.00054270943,0.0009276834,0.00067895843],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040390927,0.00053258403,0.00092583295,0.00066245615,0.0001866476,0.000069600384,0.00016885894,0.00017495094,0.00076821446],"category_scores_gemma":[0.000051039933,0.00033909787,0.0001213649,0.0013340748,0.0004335856,0.00024860172,0.00010535852,0.0004105605,0.000014792544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13717486,0.009372644,0.6993963,0.0003833756,0.0009291383,0.00052094174,0.0013518359,0.0004658784,0.0045482954,0.000016830669,0.00008850069,0.14575137],"study_design_scores_gemma":[0.054889232,0.013476274,0.919961,0.003153642,0.0001881227,0.00026194705,0.00040658255,0.00005810584,0.0067802803,0.00006389258,0.00040149203,0.0003594475],"about_ca_topic_score_codex":0.0667501,"about_ca_topic_score_gemma":0.019265411,"teacher_disagreement_score":0.22056465,"about_ca_system_score_codex":0.006329662,"about_ca_system_score_gemma":0.0013168551,"threshold_uncertainty_score":0.9999061},"labels":[],"label_agreement":null},{"id":"W2103114638","doi":"10.1158/1078-0432.ccr-14-2993","title":"PTEN Loss Is Associated with Worse Outcome in <i>HER2</i> -Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"National Cancer Institute","keywords":"PTEN; Trastuzumab; Breast cancer; Medicine; Immunohistochemistry; Population; Cancer; Oncology; Internal medicine; Cancer research; Pathology; Biology; PI3K/AKT/mTOR pathway; Apoptosis","score_opus":0.332316024989978,"score_gpt":0.5229535913488315,"score_spread":0.19063756635885348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103114638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711282,0.0005581154,0.0000070670467,0.020282602,0.00032653194,0.0024920085,0.001904467,0.00013833336,0.003162632],"genre_scores_gemma":[0.97307533,0.00054695393,0.00004629922,0.0041491613,0.00045457477,0.0011108838,0.00011557372,0.00022963223,0.02027159],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9858378,0.0016943198,0.0018426913,0.0018730888,0.0061774924,0.0025746133],"domain_scores_gemma":[0.9891338,0.0018683564,0.00047652324,0.0013532414,0.005344125,0.0018240048],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008716968,0.0006241375,0.0018433501,0.00053148554,0.00028157947,0.0001770633,0.0010541948,0.000781829,0.0014485957],"category_scores_gemma":[0.0049120137,0.0004693261,0.00024449357,0.0037557506,0.0018208711,0.00029795972,0.00038628728,0.0046481704,0.00016963715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.014517877,0.002092455,0.91926944,0.00015140123,0.0005340161,0.00048653706,0.0009074916,0.000013205912,0.000018808496,0.000009536848,0.058483835,0.0035153679],"study_design_scores_gemma":[0.023989143,0.0020813418,0.96030915,0.0030683721,0.00013843014,0.000007138829,0.0004122418,0.0001577294,0.00022263477,0.00008929592,0.00882819,0.000696322],"about_ca_topic_score_codex":0.009231568,"about_ca_topic_score_gemma":0.029131778,"teacher_disagreement_score":0.049655642,"about_ca_system_score_codex":0.006327055,"about_ca_system_score_gemma":0.0069742636,"threshold_uncertainty_score":0.9997758},"labels":[],"label_agreement":null},{"id":"W2103495720","doi":"10.1111/j.1365-2559.2011.03974.x","title":"Effect of prolonged formalin fixation on immunohistochemical staining for the proliferation marker Ki67","year":2011,"lang":"en","type":"letter","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre","funders":"","keywords":"Medicine; Clinical pharmacology; Gerontology; Pharmacology","score_opus":0.03643296119477207,"score_gpt":0.3493574119247354,"score_spread":0.31292445072996333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103495720","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12593865,0.00690232,0.005759783,0.8077375,0.0059330375,0.032470956,0.00034956462,0.0003986793,0.014509467],"genre_scores_gemma":[0.43507177,0.00031871567,0.0030702406,0.48563623,0.014378044,0.023946183,0.004856288,0.000788899,0.03193363],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975924,0.0005136651,0.0005225616,0.00045481345,0.00044160418,0.00047494346],"domain_scores_gemma":[0.99754626,0.0010281145,0.0003552602,0.00074967404,0.0002800388,0.00004064383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020004793,0.00029777354,0.00068089116,0.00023617382,0.00012676846,0.000007820825,0.00026578567,0.00095555367,0.00015446525],"category_scores_gemma":[0.001225708,0.00020114165,0.00023749293,0.000104451625,0.00032540166,0.000032329524,0.00005710246,0.0017972973,0.000031603933],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008329821,0.00007214739,0.0013196681,0.0035586378,0.00004742687,0.0002241218,0.001045099,0.0000014242229,0.015613131,0.00009602356,0.9583733,0.011319166],"study_design_scores_gemma":[0.0033236986,0.011452521,0.0026882095,0.000499043,0.0005486938,0.00034985438,0.000010113056,0.0003620127,0.018304747,0.0001121875,0.96200424,0.00034470425],"about_ca_topic_score_codex":0.000024248222,"about_ca_topic_score_gemma":0.0000025412066,"teacher_disagreement_score":0.3221013,"about_ca_system_score_codex":0.0005339056,"about_ca_system_score_gemma":0.00032487974,"threshold_uncertainty_score":0.82023185},"labels":[],"label_agreement":null},{"id":"W2103707992","doi":"10.3816/cbc.2009.n.019","title":"Phase I Study of Nonpegylated Liposomal Doxorubicin plus Trastuzumab in Patients with HER2-Positive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Doxorubicin; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.037202716011297425,"score_gpt":0.43187942971137866,"score_spread":0.3946767137000812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103707992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928052,0.00020846986,0.0000072819407,0.002919678,0.00029417482,0.0024636283,0.0008549072,0.00005999202,0.00038666427],"genre_scores_gemma":[0.99791974,0.000121496465,0.00003657749,0.00091803016,0.00052594277,0.00018221608,0.000046759564,0.00006972524,0.00017950548],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951991,0.00035900006,0.001388889,0.0009796391,0.0012509725,0.00082244375],"domain_scores_gemma":[0.9972054,0.00023720734,0.00034963898,0.0006992043,0.0009173665,0.0005912191],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059552904,0.00043702996,0.0013712692,0.00025151076,0.00007443216,0.000025841124,0.00029781304,0.00028193562,0.0011951054],"category_scores_gemma":[0.00007298303,0.00033376866,0.00017758546,0.0011205553,0.00035897826,0.00017224287,0.000083219216,0.0011746987,0.000022338218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028701684,0.022818033,0.7501715,0.00007306363,0.0003559002,0.00019434057,0.0008127352,0.00010939706,0.00011105143,0.0000033681072,0.00064303743,0.19600588],"study_design_scores_gemma":[0.055110585,0.013010752,0.9292996,0.0011860235,0.00026125927,0.00004017546,0.00030696343,0.00025594427,0.000109170345,0.0000056368767,0.00007997273,0.00033393243],"about_ca_topic_score_codex":0.0055611217,"about_ca_topic_score_gemma":0.0015936114,"teacher_disagreement_score":0.19567195,"about_ca_system_score_codex":0.0011154391,"about_ca_system_score_gemma":0.00159405,"threshold_uncertainty_score":0.9999114},"labels":[],"label_agreement":null},{"id":"W2103722534","doi":"","title":"SERUM LEVEL OF HER-2 EXTRACELLULAR DOMAIN IN IRANIAN PATIENTS WITH BREAST CANCER: A FOLLOW-UP STUDY","year":2005,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Metastasis; Internal medicine; Cancer; Oncology; Distant metastasis; Gastroenterology; CA 15-3; Metastatic breast cancer; CA15-3; Pathology","score_opus":0.06205799042741082,"score_gpt":0.34321852772474626,"score_spread":0.2811605372973354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103722534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943716,0.00020213562,0.000064311585,0.00174536,0.00006156477,0.0016269415,0.000112080226,0.000029478559,0.0017865525],"genre_scores_gemma":[0.99328625,0.000018409126,0.00096447364,0.00012953764,0.000090512054,0.000101057216,0.0000062680583,0.000046222867,0.005357244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767715,0.0000980905,0.00041069055,0.00037736935,0.0009620533,0.0004746285],"domain_scores_gemma":[0.9989879,0.000032841213,0.00007129993,0.00047347543,0.00022895461,0.00020554323],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045618427,0.00019220567,0.00043376998,0.00020657845,0.000035796693,0.000011930578,0.00018445888,0.00007551212,0.0021080256],"category_scores_gemma":[0.000018096931,0.00014026035,0.000052703883,0.00053217873,0.0000789845,0.000107090906,0.00006410584,0.00030050316,0.000037238857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011260353,0.0018852353,0.9468087,0.00009913992,0.00009029924,0.00005018761,0.0018445828,0.00001619774,0.00039313562,0.000017114719,0.0006261501,0.047043238],"study_design_scores_gemma":[0.015616243,0.0010347558,0.9782947,0.0002550115,0.00003708735,0.000008971414,0.0016026099,0.000068199224,0.00062761747,0.0000070706938,0.0022762795,0.00017149272],"about_ca_topic_score_codex":0.0051241866,"about_ca_topic_score_gemma":0.029479424,"teacher_disagreement_score":0.046871744,"about_ca_system_score_codex":0.00040866612,"about_ca_system_score_gemma":0.00038038494,"threshold_uncertainty_score":0.9988042},"labels":[],"label_agreement":null},{"id":"W2103725500","doi":"10.1159/000119747","title":"Adjuvant and Neoadjuvant Therapy with Lapatinib in ErbB2-Overexpressing Breast Cancer","year":2008,"lang":"en","type":"article","venue":"Breast Care","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Lapatinib; Adjuvant; Oncology; Breast cancer; Neoadjuvant therapy; Internal medicine; Trastuzumab; Adjuvant therapy; Cancer","score_opus":0.030207635558624314,"score_gpt":0.31920669491883774,"score_spread":0.2889990593602134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103725500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688155,0.007620763,0.00000688745,0.0017178352,0.000067354595,0.0005720399,0.00034921788,0.00006458275,0.002719784],"genre_scores_gemma":[0.9971745,0.0013456293,0.00027459805,0.00045776844,0.00027409205,0.00012383614,0.00003395125,0.00006295347,0.00025264765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981821,0.000065373504,0.00022375265,0.00045058975,0.0005832964,0.0004948481],"domain_scores_gemma":[0.9990072,0.000039006663,0.00005824461,0.00036989737,0.00026343626,0.00026221137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009340767,0.00023539625,0.0004121733,0.00014345978,0.00012080569,0.00002750463,0.00011403624,0.00010506914,0.00040659605],"category_scores_gemma":[0.000009862482,0.00017213596,0.000045180157,0.0003113711,0.00023326564,0.00011815754,0.000060382234,0.00039671324,0.000011403856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014124103,0.000102513426,0.71052486,0.00019335303,0.00003803903,0.00069338264,0.004559614,0.000018716873,0.0034662758,0.00000828459,0.00082056376,0.27816203],"study_design_scores_gemma":[0.0052686855,0.00024170968,0.98155665,0.0014226123,0.0000147511455,0.005118982,0.0014961238,0.0000855889,0.0007908407,0.0000042309784,0.0037499187,0.00024989972],"about_ca_topic_score_codex":0.0040461505,"about_ca_topic_score_gemma":0.000751084,"teacher_disagreement_score":0.2779121,"about_ca_system_score_codex":0.00027930908,"about_ca_system_score_gemma":0.0006676194,"threshold_uncertainty_score":0.7019501},"labels":[],"label_agreement":null},{"id":"W2103735100","doi":"10.4161/cc.6.23.4949","title":"ErbB-2 Receptor Cooperates with E6/E7 Oncoproteins of HPV Type 16 in Breast Tumorigenesis","year":2007,"lang":"en","type":"article","venue":"Cell Cycle","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"ErbB; Cancer research; Carcinogenesis; Biology; Genetically modified mouse; Transgene; Breast cancer; Mammary gland; Cancer; Gene; Genetics","score_opus":0.015359304325813313,"score_gpt":0.3021665776746916,"score_spread":0.2868072733488783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103735100","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626196,0.0006066297,0.000046490884,0.0003951454,0.000106878775,0.00047972653,0.0000128062275,0.000034327866,0.0356984],"genre_scores_gemma":[0.9952411,0.0001330875,0.0009228335,0.00011682425,0.00017218424,0.000011289178,0.000017382794,0.000045745302,0.0033395186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998581,0.00003972251,0.00028060516,0.00027015572,0.0004100841,0.00041843794],"domain_scores_gemma":[0.9990625,0.00007032532,0.000056971807,0.0003684435,0.00024497995,0.00019678703],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000551522,0.00013662076,0.00030099036,0.0001592663,0.000034691537,0.000009957778,0.00014277142,0.00008927166,0.0031809355],"category_scores_gemma":[0.000043267642,0.00010852229,0.000033266086,0.0007045139,0.00013304595,0.00004764458,0.000042673182,0.00024751152,0.00026898488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050393394,0.0017521725,0.3227452,0.0013284059,0.00008173175,0.00043291957,0.0015321206,0.000114365146,0.56437576,0.000094966614,0.011828706,0.09067435],"study_design_scores_gemma":[0.002443099,0.0011230072,0.11375066,0.00027401952,0.000023267688,0.00005555163,0.00072761945,0.000051379728,0.8675738,0.000018950113,0.013724171,0.00023445488],"about_ca_topic_score_codex":0.001641402,"about_ca_topic_score_gemma":0.0006002758,"teacher_disagreement_score":0.3031981,"about_ca_system_score_codex":0.0002983525,"about_ca_system_score_gemma":0.00043626202,"threshold_uncertainty_score":0.9977303},"labels":[],"label_agreement":null},{"id":"W2105398998","doi":"10.1158/1078-0432.ccr-08-2635","title":"Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Biomedical Imaging and Bioengineering; National Cancer Institute","keywords":"Trastuzumab; Medicine; Apoptosis; Breast cancer; Positron emission tomography; Cancer; Cancer research; Immunohistochemistry; Annexin; Annexin A5; Pathology; Oncology; Internal medicine; Nuclear medicine; Biology","score_opus":0.3413549984427097,"score_gpt":0.6007117179825404,"score_spread":0.2593567195398307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105398998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236141,0.0044072703,0.000046812605,0.06720478,0.00038546987,0.002483754,0.00022602628,0.00008125432,0.0015505478],"genre_scores_gemma":[0.9833018,0.012147627,0.00032806338,0.002146623,0.00082456286,0.00046718374,0.0000075022263,0.00008990608,0.0006867383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9890011,0.0029042386,0.0020464407,0.0014706122,0.0028546632,0.0017229758],"domain_scores_gemma":[0.9919628,0.0034655936,0.00017357546,0.001521692,0.0015841142,0.001292248],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.021277482,0.00036042376,0.0013210634,0.0010532904,0.00013246156,0.00006923268,0.0010517575,0.00041275544,0.0013651827],"category_scores_gemma":[0.0032923182,0.00030618327,0.0004059543,0.002927356,0.001160728,0.00024083056,0.00034084712,0.0026763834,0.000050913688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061837893,0.0017647763,0.5312965,0.00015242212,0.00018331585,0.0002679947,0.0004245188,0.00033754288,0.010291386,0.000040048944,0.02706086,0.36634275],"study_design_scores_gemma":[0.007468374,0.0028927228,0.97278166,0.0018228587,0.000024122492,0.000025099805,0.0001720023,0.0043489574,0.0016693225,0.00068508525,0.007772821,0.00033695216],"about_ca_topic_score_codex":0.00415523,"about_ca_topic_score_gemma":0.0003495113,"teacher_disagreement_score":0.4414852,"about_ca_system_score_codex":0.0009938179,"about_ca_system_score_gemma":0.005083622,"threshold_uncertainty_score":0.999939},"labels":[],"label_agreement":null},{"id":"W2105662969","doi":"10.2174/138945009788488378","title":"Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer","year":2009,"lang":"en","type":"article","venue":"Current Drug Targets","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tyrosine kinase; Cancer; Cancer research; Medicine; Protein-Tyrosine Kinases; Internal medicine; Receptor","score_opus":0.05965188982531681,"score_gpt":0.403468311836028,"score_spread":0.34381642201071116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105662969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90237343,0.08476924,0.000017771657,0.009605877,0.00082995836,0.0011984286,0.00006621555,0.000029977347,0.0011091109],"genre_scores_gemma":[0.99397933,0.0049438863,0.0000941093,0.00016462349,0.00047580127,0.00010578109,0.000028943363,0.00001304883,0.00019446135],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99861604,0.00004457001,0.0002904436,0.0002403827,0.00046967648,0.00033887336],"domain_scores_gemma":[0.99934393,0.000053367963,0.00006204213,0.00035073175,0.000085417574,0.00010453349],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021260376,0.00015804726,0.00028349517,0.00013807366,0.000035732017,0.000009833459,0.00013712535,0.000036768717,0.0001249856],"category_scores_gemma":[0.000042391188,0.00009781943,0.00010245058,0.0003763438,0.00007417849,0.000036691315,0.000011732657,0.000181334,0.000016066977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033641575,0.008112975,0.08088566,0.0002615954,0.00004523616,0.00006765187,0.009113413,0.000054312124,0.02394915,0.00029840443,0.032979798,0.8438954],"study_design_scores_gemma":[0.007344035,0.0015234215,0.23030302,0.0010528904,0.0001111713,0.000011194765,0.00042068856,0.00040418888,0.1092424,0.00019471683,0.6490674,0.0003248713],"about_ca_topic_score_codex":0.0004615679,"about_ca_topic_score_gemma":0.00018585364,"teacher_disagreement_score":0.84357053,"about_ca_system_score_codex":0.00035391402,"about_ca_system_score_gemma":0.00021292895,"threshold_uncertainty_score":0.39889607},"labels":[],"label_agreement":null},{"id":"W2105730286","doi":"10.1136/jcp.2011.089847","title":"HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"In situ hybridisation; Medicine; Pathology; In situ hybridization; Immunohistochemistry; Medical physics; Biology","score_opus":0.5332641908238643,"score_gpt":0.5904470552369654,"score_spread":0.05718286441310105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105730286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97377306,0.00021262768,0.009086556,0.013447686,0.0004152077,0.00039288937,0.000005342604,0.000003987381,0.0026626312],"genre_scores_gemma":[0.8381481,0.000150088,0.16051516,0.00083727174,0.0003127976,0.000011200119,0.0000011522637,0.000007800487,0.000016411073],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973482,0.0011028942,0.0011035794,0.00013053385,0.00012716539,0.00018766426],"domain_scores_gemma":[0.9945631,0.004638016,0.00035775648,0.00013819576,0.00021338034,0.00008954831],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013260025,0.00006323948,0.00039060068,0.00019708757,0.00002719517,0.000007029231,0.0001231868,0.00010191607,0.000047588328],"category_scores_gemma":[0.009790318,0.000041383806,0.000082795545,0.00025319055,0.00012186057,0.000054004457,0.00003122296,0.0007710634,0.0000015893709],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037862707,0.00026027398,0.5024229,0.000023638444,0.000010631057,0.00018882775,0.00050016906,6.8159113e-7,0.0006103844,0.00007715221,0.0006786669,0.49484804],"study_design_scores_gemma":[0.0021025923,0.0014384313,0.98668945,0.00011628506,0.000034801073,0.0040562623,0.0003953221,0.00007926282,0.00005283148,0.0039542364,0.0010412209,0.000039291557],"about_ca_topic_score_codex":0.000019553141,"about_ca_topic_score_gemma":0.000057285917,"teacher_disagreement_score":0.49480876,"about_ca_system_score_codex":0.000038964605,"about_ca_system_score_gemma":0.00022095219,"threshold_uncertainty_score":0.99855065},"labels":[],"label_agreement":null},{"id":"W2105980005","doi":"10.1158/1055-9965.epi-08-0713","title":"Sampling Strategies for Tissue Microarrays to Evaluate Biomarkers in Ovarian Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"National Cancer Institute","keywords":"Tissue microarray; Immunohistochemistry; Ovarian cancer; Cancer; Sampling (signal processing); Pathology; DNA microarray; Medicine; Biology; Oncology; Cancer research; Internal medicine; Gene expression; Gene; Computer science; Genetics","score_opus":0.18471134206552095,"score_gpt":0.5129714561115281,"score_spread":0.3282601140460071,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105980005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49087238,0.075989656,0.18414499,0.21985747,0.0055361046,0.018815411,0.00035826376,0.00050151325,0.0039242217],"genre_scores_gemma":[0.893752,0.0043582865,0.08362607,0.00915886,0.0014155717,0.00538007,0.0003871944,0.00015934599,0.0017626128],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953862,0.00076568703,0.0011637688,0.0011356617,0.0002700813,0.0012786221],"domain_scores_gemma":[0.99777704,0.0006221771,0.0002987145,0.0005887637,0.00028692017,0.0004263793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0055711684,0.000412,0.0010102886,0.0006204989,0.00015633558,0.000029161634,0.0003247891,0.00045580132,0.00058418285],"category_scores_gemma":[0.0010827394,0.00039812937,0.0002706156,0.0007940899,0.00019894962,0.0001988756,0.000059164693,0.00036300137,0.000033201304],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006352814,0.0003113674,0.083988406,0.0006894276,0.0013217417,0.000025850175,0.0006579036,0.0010991713,0.29397416,0.001575926,0.058847196,0.55115604],"study_design_scores_gemma":[0.013004325,0.004014009,0.7472987,0.0057872757,0.0008798278,0.00006220382,0.0012418703,0.003253568,0.01925872,0.06036375,0.14313072,0.0017049874],"about_ca_topic_score_codex":0.0025141998,"about_ca_topic_score_gemma":0.002315417,"teacher_disagreement_score":0.66331035,"about_ca_system_score_codex":0.0011348553,"about_ca_system_score_gemma":0.0014170735,"threshold_uncertainty_score":0.99984705},"labels":[],"label_agreement":null},{"id":"W2106198994","doi":"10.1200/jco.2004.09.128","title":"The Combination of <i>p53</i> Mutation and <i>neu/erb</i>B-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Credit Valley Hospital; Lunenfeld-Tanenbaum Research Institute; University of Toronto; North York General Hospital; Mount Sinai Hospital","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Breast cancer; Internal medicine; Oncology; Mutation; Disease; Cancer; Cancer research; Gene; Biology; Genetics","score_opus":0.13034729828871386,"score_gpt":0.4943392522767907,"score_spread":0.3639919539880768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106198994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9705966,0.00025806093,0.000148325,0.025991173,0.000358814,0.00034696452,0.000013392824,0.0000039208144,0.002282762],"genre_scores_gemma":[0.9974398,0.0011394299,0.00024829703,0.0009199802,0.000098757235,0.000011362351,0.000002005459,0.000013408842,0.00012693],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964928,0.0011451306,0.0014271047,0.00015294511,0.0005889852,0.00019301004],"domain_scores_gemma":[0.9919287,0.004908873,0.0015205834,0.00011922273,0.0013680008,0.00015459814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066203275,0.00009339448,0.0007415534,0.000099155775,0.00005276736,0.000011714702,0.00010066516,0.00022547551,0.00004781905],"category_scores_gemma":[0.006147475,0.00005751034,0.00009086115,0.00035694943,0.00039437713,0.00010307668,0.000014913639,0.00082489225,0.0000014965768],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0079999985,0.0027560405,0.85300565,0.00007956824,0.00061190047,0.00019235187,0.0010336429,0.00007666786,0.0006747078,0.0014836971,0.0038852075,0.12820056],"study_design_scores_gemma":[0.010983234,0.0042348546,0.9783172,0.0002766186,0.00014444783,0.00018121733,0.00059315015,0.00034575598,0.0007425043,0.0012707043,0.002833412,0.00007690729],"about_ca_topic_score_codex":0.00021766376,"about_ca_topic_score_gemma":0.0008757693,"teacher_disagreement_score":0.12812366,"about_ca_system_score_codex":0.00034566838,"about_ca_system_score_gemma":0.002013841,"threshold_uncertainty_score":0.7359546},"labels":[],"label_agreement":null},{"id":"W2106635812","doi":"10.1369/jhc.6a7017.2006","title":"Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections","year":2006,"lang":"en","type":"article","venue":"Journal of Histochemistry & Cytochemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"Barbara Ann Karmanos Cancer Institute","keywords":"Trastuzumab; Immunohistochemistry; Polyclonal antibodies; Humanized antibody; Antibody; Tissue microarray; Staining; Breast cancer; Monoclonal antibody; HER2/neu; Primary and secondary antibodies; Monoclonal; Medicine; Molecular biology; Pathology; Cancer; Cancer research; Biology; Immunology; Internal medicine","score_opus":0.013305496391511278,"score_gpt":0.30601956472144026,"score_spread":0.29271406832992897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106635812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9578424,0.00052229635,0.00031370434,0.000225303,0.00019377173,0.0001862613,0.000058227542,0.000044534918,0.040613476],"genre_scores_gemma":[0.9919708,0.000033906777,0.00039298547,0.000019204714,0.0015048123,0.000015933432,0.000021534981,0.00005565363,0.0059852037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971863,0.00003401122,0.000979717,0.00033606568,0.0010560355,0.00040789554],"domain_scores_gemma":[0.9977027,0.000112320275,0.0007314665,0.00048403963,0.0006825589,0.0002868725],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004418942,0.00029821278,0.00064082455,0.00018387253,0.00013519147,0.000025097594,0.00027063483,0.00031498287,0.00049417285],"category_scores_gemma":[0.00020360616,0.0002894955,0.00034955397,0.0004515587,0.00023159976,0.00007773315,0.000043037395,0.0010111858,0.00001794341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005212012,0.0004348982,0.00072609074,0.00059326744,0.00008871455,0.00016313755,0.000039842078,0.00008339356,0.9898155,0.0000010817084,0.00488294,0.0026499876],"study_design_scores_gemma":[0.0012876706,0.00043411186,0.0014712536,0.00076400914,0.00014387043,0.0045527355,0.00018513452,0.000015276772,0.98545754,0.00001521683,0.0054629077,0.00021026087],"about_ca_topic_score_codex":0.000066504814,"about_ca_topic_score_gemma":0.0000033581418,"teacher_disagreement_score":0.034628272,"about_ca_system_score_codex":0.0016786442,"about_ca_system_score_gemma":0.0006239311,"threshold_uncertainty_score":0.9999557},"labels":[],"label_agreement":null},{"id":"W2106837862","doi":"10.3747/co.19.1173","title":"Testing for HER2 in Breast Cancer: Current Pathology Challenges Faced in Canada","year":2012,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Queen's University; McGill University; University of Manitoba; University of British Columbia; Saskatoon City Hospital; Vancouver General Hospital; Mount Sinai Hospital; Toronto General Hospital; University Health Network; University of Toronto; Dalhousie University; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital; Women's College Hospital; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Breast cancer; Human Epidermal Growth Factor Receptor 2; Clinical Oncology; MEDLINE; Core biopsy; Pathology; Medical physics; Family medicine; Cancer; Internal medicine","score_opus":0.3436562265670484,"score_gpt":0.5002725317108598,"score_spread":0.15661630514381142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106837862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90884036,0.072654404,0.000013785062,0.011283333,0.004811809,0.0014420637,0.00013364574,0.00003090783,0.00078967196],"genre_scores_gemma":[0.9934563,0.0041822507,0.00014850157,0.00012701002,0.0008547718,0.0011606482,0.000023591927,0.000034444463,0.000012478078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99751323,0.00023032787,0.0004696623,0.00039118904,0.00026195182,0.001133643],"domain_scores_gemma":[0.99858934,0.00056493795,0.00011099695,0.00025155547,0.00017080935,0.00031235116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079857133,0.00020292404,0.00060553366,0.0002291118,0.00003568486,0.00000343641,0.00017901398,0.0001268202,0.00012557229],"category_scores_gemma":[0.00040752775,0.00019119828,0.00004360265,0.00031863197,0.000083240186,0.000059326474,0.000110995934,0.0007564354,0.000010834779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007865701,0.00033966344,0.5126716,0.0004094226,0.000005378935,0.000025745812,0.0003835923,0.000005950064,0.00013971304,0.000054766526,0.001867368,0.48401818],"study_design_scores_gemma":[0.0026163543,0.00021207158,0.7740466,0.00044544425,0.000018890387,0.00013857966,0.00054102397,0.0003885135,0.00005796897,0.00004436139,0.22130714,0.00018303121],"about_ca_topic_score_codex":0.19956864,"about_ca_topic_score_gemma":0.7943717,"teacher_disagreement_score":0.5948031,"about_ca_system_score_codex":0.0053994,"about_ca_system_score_gemma":0.0054390305,"threshold_uncertainty_score":0.9984187},"labels":[],"label_agreement":null},{"id":"W2107337979","doi":"10.1128/mcb.24.11.4636-4650.2004","title":"Mutations in the SAM Domain of the ETV6-NTRK3 Chimeric Tyrosine Kinase Block Polymerization and Transformation Activity","year":2004,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Children’s Health Research Institute","funders":"","keywords":"Fusion protein; Biology; ETV6; Chimeric gene; Fusion gene; Mutant; Tyrosine kinase; Molecular biology; Tyrosine; Protein kinase domain; Transformation (genetics); Cell biology; Gene; Signal transduction; Biochemistry; Chromosomal translocation; Recombinant DNA; Gene expression","score_opus":0.010897383421098703,"score_gpt":0.2835636639335447,"score_spread":0.272666280512446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107337979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608184,0.0011840101,0.0076507246,0.0042864755,0.0000270977,0.00042213808,0.000009470222,0.00000521355,0.00033303947],"genre_scores_gemma":[0.99948436,0.00008753002,0.000099929406,0.0002501711,0.0000135044165,0.000022145523,0.000030022926,0.000006612844,0.0000057378056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99932325,0.0001822858,0.00012967891,0.00012645783,0.000104537765,0.00013378507],"domain_scores_gemma":[0.99972713,0.000023543376,0.00003730422,0.0001599749,0.00002140268,0.00003066554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021243797,0.000074207506,0.0001244471,0.00006371558,0.00006481859,0.000006983171,0.000059996084,0.00007466606,0.000006390685],"category_scores_gemma":[0.000030239125,0.000045576006,0.000033890723,0.0002773522,0.00022601658,0.000020772684,0.000018044166,0.0001430102,6.368718e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042846827,0.00007403482,0.0015903388,0.000046161753,0.0000126469295,0.000008068592,0.0011110054,0.000027301523,0.99024665,0.0023355263,0.0000011344283,0.004504306],"study_design_scores_gemma":[0.0018095592,0.0003733658,0.025854345,0.000047907,0.000047203917,0.00007415352,0.00033346668,0.00014944102,0.96870273,0.002054655,0.00046782952,0.000085333326],"about_ca_topic_score_codex":0.0002681089,"about_ca_topic_score_gemma":0.00003442565,"teacher_disagreement_score":0.024264006,"about_ca_system_score_codex":0.000021347587,"about_ca_system_score_gemma":0.000069645015,"threshold_uncertainty_score":0.18585356},"labels":[],"label_agreement":null},{"id":"W2107723446","doi":"10.1007/s10549-012-2076-7","title":"Expression of activated type I receptor tyrosine kinases in early breast cancer","year":2012,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"AstraZeneca","keywords":"Breast cancer; Medicine; Tissue microarray; Immunohistochemistry; Internal medicine; Oncology; Cancer; Cohort; Receptor","score_opus":0.09947066223487866,"score_gpt":0.42730410465319474,"score_spread":0.3278334424183161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107723446","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879607,0.007193711,4.05439e-7,0.00273391,0.00013346337,0.0009371338,0.00056283653,0.000027822034,0.0004500509],"genre_scores_gemma":[0.9891377,0.00832388,0.000065651744,0.000023849449,0.00045065585,0.0006189058,0.000033378597,0.000049737617,0.0012962293],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718374,0.00019636513,0.0002924763,0.0004152286,0.0009001286,0.0010120373],"domain_scores_gemma":[0.99825245,0.00013385626,0.00006270313,0.0004001138,0.00052258524,0.00062827975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000427613,0.0002386408,0.000456737,0.0004099414,0.00011163259,0.00002887074,0.00012060174,0.00013273531,0.0019799678],"category_scores_gemma":[0.000034700624,0.00016965263,0.00005641518,0.0009485614,0.00031438016,0.00020924886,0.00012325657,0.00035725202,0.000037901376],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066429623,0.0016514256,0.68817383,0.00020599744,0.00010918534,0.00002830651,0.0006574725,0.0000018616715,0.2238373,0.000033509827,0.0017840397,0.0768741],"study_design_scores_gemma":[0.00331183,0.0009367399,0.7763776,0.0012124226,0.000024590554,0.000072881405,0.00018520842,0.00000465021,0.21465686,0.0000118153275,0.003059983,0.00014537203],"about_ca_topic_score_codex":0.035118803,"about_ca_topic_score_gemma":0.0006759597,"teacher_disagreement_score":0.0882038,"about_ca_system_score_codex":0.0014317585,"about_ca_system_score_gemma":0.0008121266,"threshold_uncertainty_score":0.99893236},"labels":[],"label_agreement":null},{"id":"W2108422856","doi":"10.1016/j.schres.2008.03.025","title":"Neuregulin-1 and the P300 waveform—A preliminary association study using a psychosis endophenotype","year":2008,"lang":"en","type":"article","venue":"Schizophrenia Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Western Hospital","funders":"Psychiatry Research Trust; Wellcome Trust; National Institute for Health and Care Research; Schizophrenia Research Fund","keywords":"Endophenotype; Psychosis; Neuregulin 1; Psychology; Schizoaffective disorder; Schizophrenia (object-oriented programming); Latency (audio); Single-nucleotide polymorphism; Audiology; Mismatch negativity; Cognition; Neuroscience; Electroencephalography; Medicine; Psychiatry; Biology; Genetics; Genotype; Gene; Computer science","score_opus":0.13449240926788908,"score_gpt":0.41660735057205006,"score_spread":0.282114941304161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108422856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848921,0.0013902739,0.000009717324,0.007944038,0.00019145613,0.0029282987,0.00000902998,0.00006664602,0.0025684575],"genre_scores_gemma":[0.9940524,0.0005773664,0.0006851379,0.0001408034,0.0007016324,0.00028804835,0.0000051664297,0.000063809704,0.0034855974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99354607,0.0014354849,0.00043807476,0.000630456,0.0029816271,0.0009682725],"domain_scores_gemma":[0.99666387,0.0012204587,0.000093224226,0.0008857267,0.0008014871,0.000335255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058703073,0.00022112568,0.00047623675,0.00047775943,0.0011091122,0.000106854284,0.0003960714,0.00017794377,0.00021481757],"category_scores_gemma":[0.002042576,0.00014789832,0.00011548756,0.0014184125,0.00065692957,0.00014470362,0.00041938078,0.0018741428,0.00015795213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.116856575,0.003851266,0.73783195,0.0006886073,0.0014516484,0.001637534,0.022506846,0.000036621575,0.007805035,0.001655298,0.046312325,0.059366282],"study_design_scores_gemma":[0.046846665,0.0070281397,0.9223949,0.00036795842,0.0002779956,0.0007916791,0.0034962683,0.00763694,0.0017312731,0.0026195147,0.0061718244,0.0006368572],"about_ca_topic_score_codex":0.0013341552,"about_ca_topic_score_gemma":0.00011192458,"teacher_disagreement_score":0.18456292,"about_ca_system_score_codex":0.00068290625,"about_ca_system_score_gemma":0.00075094635,"threshold_uncertainty_score":0.85305065},"labels":[],"label_agreement":null},{"id":"W2108572537","doi":"10.1002/ijc.10647","title":"Antiproliferative, antiangiogenic and proapoptotic activity of h‐R3: A humanized anti‐EGFR antibody","year":2002,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; In vivo; Oncogene; A431 cells; Apoptosis; Epidermal growth factor receptor; Monoclonal antibody; Epidermal growth factor; Cell culture; In vitro; Cytotoxic T cell; Cell growth; Antibody; Biology; Cell cycle; Cancer; Immunology; Medicine; Receptor; Internal medicine; Biochemistry","score_opus":0.05122474526373232,"score_gpt":0.42221908015241655,"score_spread":0.3709943348886842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108572537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98933446,0.0049907765,0.0003270782,0.003484544,0.00055322563,0.00022104113,0.000026377902,0.000008443729,0.0010540226],"genre_scores_gemma":[0.9938309,0.004567231,0.00038749835,0.00017269552,0.0006305036,0.000005113383,0.0000017356138,0.000022457745,0.00038181798],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980242,0.00006894255,0.0004638843,0.00017028497,0.0010704075,0.00020227504],"domain_scores_gemma":[0.9980478,0.000074743635,0.0004073338,0.00013372648,0.0011919341,0.0001444387],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032365622,0.00013796109,0.00044312354,0.000373473,0.00003518427,0.00003966151,0.00024422698,0.00007034986,0.0013582231],"category_scores_gemma":[0.0001653434,0.00011128126,0.00017353676,0.00019039157,0.00018125025,0.00024001274,0.00006649844,0.00032978033,0.0000074486397],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013640912,0.00074097473,0.34801683,0.0002292432,0.002182246,0.00046470395,0.0009007434,0.000034233333,0.58120376,0.00026520656,0.003290172,0.061307814],"study_design_scores_gemma":[0.013728294,0.0016763306,0.6541964,0.0024628087,0.00050051964,0.0019144171,0.00013157228,0.004132475,0.30346006,0.00027014082,0.017091673,0.0004353332],"about_ca_topic_score_codex":0.000089119974,"about_ca_topic_score_gemma":0.000015562577,"teacher_disagreement_score":0.30617955,"about_ca_system_score_codex":0.00019411313,"about_ca_system_score_gemma":0.00023210458,"threshold_uncertainty_score":0.9995547},"labels":[],"label_agreement":null},{"id":"W2109765959","doi":"10.1158/0008-5472.can-05-0755","title":"Copy Number Aberrations in Mouse Breast Tumors Reveal Loci and Genes Important in Tumorigenic Receptor Tyrosine Kinase Signaling","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Biology; Amplicon; Receptor tyrosine kinase; Carcinogenesis; Cancer research; Locus (genetics); Genetics; Copy-number variation; Gene; Signal transduction; Genome","score_opus":0.06851699653895069,"score_gpt":0.4221883660174637,"score_spread":0.35367136947851296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2109765959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860508,0.0050737187,0.0000044049825,0.0067879683,0.000062390274,0.0011611903,0.00012075578,0.00004012596,0.0006986859],"genre_scores_gemma":[0.9888075,0.0031779765,0.0005810712,0.00017698364,0.0007460962,0.00069706456,0.000045562643,0.00008303371,0.0056847236],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957688,0.000352595,0.0007238495,0.0007169524,0.0012386155,0.0011992299],"domain_scores_gemma":[0.9982585,0.00019368556,0.00006716775,0.0005119673,0.00045458853,0.0005141174],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026871387,0.0002368651,0.0004820774,0.00060606824,0.0001710752,0.00008851008,0.00026418763,0.0001572234,0.0029574486],"category_scores_gemma":[0.00027069464,0.00022598305,0.00006033377,0.001587664,0.0004235144,0.00020812836,0.00017774128,0.0014217679,0.00016114255],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00090849254,0.00037410067,0.59974724,0.00040399123,0.00003291485,0.00035069595,0.0012929253,0.00012922072,0.36851427,0.00017575982,0.0148820095,0.013188374],"study_design_scores_gemma":[0.014214874,0.0009564112,0.13399187,0.0037718704,0.000044178913,0.0006792487,0.0035094873,0.0020511125,0.7775723,0.0004216888,0.061233625,0.0015533308],"about_ca_topic_score_codex":0.0064294967,"about_ca_topic_score_gemma":0.0068265866,"teacher_disagreement_score":0.46575537,"about_ca_system_score_codex":0.0019652585,"about_ca_system_score_gemma":0.0018666513,"threshold_uncertainty_score":0.997954},"labels":[],"label_agreement":null},{"id":"W2110827195","doi":"10.1309/pef8-gl6f-ywmc-ag56","title":"Assessment of Interlaboratory Variation in the Immunohistochemical Determination of Estrogen Receptor Status Using a Breast Cancer Tissue Microarray","year":2002,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital; Royal Columbian Hospital; Kelowna General Hospital; University of British Columbia; University of British Columbia Hospital","funders":"","keywords":"Kappa; Concordance; Tissue microarray; Breast cancer; Grading (engineering); Medicine; Reproducibility; Pathology; Immunohistochemistry; Estrogen receptor; Cohen's kappa; Cancer; Internal medicine; Biology; Mathematics; Statistics","score_opus":0.06939456895177747,"score_gpt":0.4871054210943099,"score_spread":0.4177108521425324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110827195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99580604,0.00050894584,0.001781091,0.0013064789,0.00030485794,0.00015058795,0.00003936987,0.0000020159314,0.000100629324],"genre_scores_gemma":[0.97880703,0.00065695815,0.019990005,0.00027968246,0.00023744225,0.000005488824,0.0000017918836,0.000014136454,0.0000074477193],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99651057,0.0011160155,0.0015683968,0.00016548387,0.00042073458,0.00021882947],"domain_scores_gemma":[0.9967599,0.00069903256,0.0014351774,0.0002576571,0.0007456731,0.00010257891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021250944,0.00009816121,0.0007717083,0.0001627115,0.000014877013,0.00000413248,0.0001977103,0.00010085594,0.0002725818],"category_scores_gemma":[0.00086050475,0.0000726524,0.00014069323,0.00043488885,0.00071303797,0.00005759423,0.000034419572,0.00073707156,0.0000015159925],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058491755,0.00086200767,0.18468344,0.00006465027,0.00006757441,0.00017468007,0.0012432925,0.000012241804,0.6017012,0.00002160848,0.00016166136,0.2104227],"study_design_scores_gemma":[0.0044321506,0.007391778,0.97179604,0.0006620325,0.00030496306,0.0020180158,0.0015208503,0.0012498824,0.008615121,0.0000796649,0.0017287827,0.00020074341],"about_ca_topic_score_codex":0.000120699595,"about_ca_topic_score_gemma":0.0000067360093,"teacher_disagreement_score":0.7871126,"about_ca_system_score_codex":0.00024948578,"about_ca_system_score_gemma":0.000790047,"threshold_uncertainty_score":0.320225},"labels":[],"label_agreement":null},{"id":"W2111347432","doi":"10.1200/jco.2009.23.1910","title":"Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"GlaxoSmithKline","keywords":"Trastuzumab; Medicine; Regimen; Loading dose; Cardiotoxicity; Metastatic breast cancer; Internal medicine; Pharmacokinetics; Chemotherapy; Adverse effect; Breast cancer; Phases of clinical research; Oncology; Cancer; Pharmacology; Gastroenterology","score_opus":0.17936158971020888,"score_gpt":0.5111639668432632,"score_spread":0.33180237713305427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111347432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9482951,0.0008163252,0.00007545816,0.045470547,0.0007212446,0.00024453228,0.000012272621,0.000009352378,0.00435513],"genre_scores_gemma":[0.9890291,0.0016185397,0.0011626056,0.0064658816,0.0005445302,0.0000011517138,0.0000016533257,0.000013326157,0.0011631784],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9963504,0.00045340994,0.0022172416,0.0002110415,0.00044344514,0.00032444444],"domain_scores_gemma":[0.99513984,0.0015367972,0.001126449,0.00017986586,0.0015016132,0.00051542383],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019923965,0.00014557103,0.0014249603,0.0001429984,0.000048467293,0.00001538873,0.00015929903,0.000308735,0.0004415334],"category_scores_gemma":[0.0020519942,0.000108346925,0.0002637381,0.00022812015,0.00041871262,0.00013035299,0.000036879657,0.0013582021,0.000021720669],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027352976,0.006154386,0.20529673,0.00032926895,0.0021804122,0.004765701,0.0061841058,0.00009753335,0.046527527,0.000996375,0.1131494,0.5869656],"study_design_scores_gemma":[0.018141938,0.052147254,0.80486137,0.00073416246,0.00050092064,0.0009524326,0.001409414,0.0005642239,0.007979327,0.0014930895,0.11096104,0.00025481157],"about_ca_topic_score_codex":0.000019961872,"about_ca_topic_score_gemma":0.000019182746,"teacher_disagreement_score":0.5995647,"about_ca_system_score_codex":0.00018559473,"about_ca_system_score_gemma":0.0019225455,"threshold_uncertainty_score":0.5900788},"labels":[],"label_agreement":null},{"id":"W2111973486","doi":"10.1158/0008-5472.can-05-1829","title":"Epidermal Growth Factor–Independent Transformation of Ba/F3 Cells with Cancer-Derived Epidermal Growth Factor Receptor Mutants Induces Gefitinib-Sensitive Cell Cycle Progression","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":187,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Gefitinib; Epidermal growth factor receptor; Cancer research; Growth factor receptor inhibitor; Epidermal growth factor; Transformation (genetics); Mutant; Cancer; Biology; Cell biology; Chemistry; Internal medicine; Receptor; Medicine; Genetics; Gene","score_opus":0.08131793499971414,"score_gpt":0.40494700614049417,"score_spread":0.32362907114078004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111973486","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854651,0.0012942548,0.00013573625,0.00587246,0.00029253087,0.003320544,0.0009958021,0.00012217698,0.0025013941],"genre_scores_gemma":[0.99288005,0.0037782693,0.0006258467,0.00019848761,0.0009198447,0.0008235533,0.00008299973,0.00016830237,0.0005226321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9907029,0.0009503986,0.0010783034,0.0011377992,0.004080233,0.00205035],"domain_scores_gemma":[0.99467516,0.0005999819,0.00035912337,0.00064871804,0.0026986632,0.0010183332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014316187,0.00060017884,0.0010619126,0.00082430773,0.00045178464,0.00011560024,0.00061872596,0.0004772996,0.0033573783],"category_scores_gemma":[0.00024231429,0.0004776565,0.00022281567,0.0013642027,0.0008723433,0.0008165968,0.00020880325,0.0022848146,0.00016408524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033271154,0.00063439325,0.007653458,0.0019779645,0.00022498872,0.00011789511,0.008411945,0.00010574484,0.9247961,0.000037716738,0.0013624517,0.051350225],"study_design_scores_gemma":[0.0042392444,0.0012540881,0.024027577,0.0015585711,0.00005049989,0.00002754793,0.001535038,0.000323054,0.96526444,0.000019604726,0.0012023333,0.0004980133],"about_ca_topic_score_codex":0.004248712,"about_ca_topic_score_gemma":0.0008972368,"teacher_disagreement_score":0.05085221,"about_ca_system_score_codex":0.0020152426,"about_ca_system_score_gemma":0.003102413,"threshold_uncertainty_score":0.9997675},"labels":[],"label_agreement":null},{"id":"W2112168902","doi":"10.1158/0008-5472.can-10-2840","title":"Transcriptional Control of the <i>ERBB2</i> Amplicon by ERRα and PGC-1β Promotes Mammary Gland Tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Carcinogenesis; Amplicon; Coactivator; Cancer research; Promoter; Estrogen receptor; Gene; Transcriptional regulation; Genetics; Cancer; Breast cancer; Transcription factor; Gene expression; Polymerase chain reaction","score_opus":0.049304997911372044,"score_gpt":0.3891240746085691,"score_spread":0.3398190766971971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112168902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707272,0.0061283344,0.00010594493,0.019063579,0.00027015182,0.0015718588,0.00030298618,0.000030044499,0.0017998777],"genre_scores_gemma":[0.9948064,0.0009621924,0.000082143684,0.00032665627,0.00037309589,0.00048340295,0.000010900765,0.00004190077,0.002913278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968394,0.00025273697,0.0003001557,0.00046091067,0.0014803199,0.00066650234],"domain_scores_gemma":[0.99801266,0.000316299,0.000049969163,0.00067045423,0.0006107879,0.0003398329],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001647768,0.00016313168,0.00034329886,0.00015084173,0.00023292421,0.00006105001,0.00047676626,0.00015994959,0.0006645551],"category_scores_gemma":[0.0003128522,0.0001118203,0.000097957665,0.0005390782,0.0009481192,0.00009771962,0.00011847031,0.0012813563,0.000011524719],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039116293,0.00012499036,0.048772007,0.00040446897,0.0000713956,0.00001141412,0.00021752369,4.9369453e-7,0.92441195,0.0011113079,0.014010205,0.01047308],"study_design_scores_gemma":[0.007315629,0.0008098608,0.15910505,0.0005053193,0.00007852173,0.00013803711,0.00014703913,0.00028978012,0.49868822,0.0015419637,0.33101958,0.00036098337],"about_ca_topic_score_codex":0.0014208729,"about_ca_topic_score_gemma":0.00044033845,"teacher_disagreement_score":0.42572373,"about_ca_system_score_codex":0.0001374136,"about_ca_system_score_gemma":0.0012530651,"threshold_uncertainty_score":0.7276413},"labels":[],"label_agreement":null},{"id":"W2112324274","doi":"10.1053/j.seminoncol.2004.07.019","title":"Optimizing treatment of HER2-positive metastatic breast cancer","year":2004,"lang":"en","type":"article","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Trastuzumab; Tolerability; Metastatic breast cancer; Breast cancer; Dosing; Oncology; Internal medicine; Regimen; Adverse effect; Clinical trial; Cancer","score_opus":0.044490724554963196,"score_gpt":0.42812279568189776,"score_spread":0.38363207112693454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112324274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9667418,0.007066236,0.00011406351,0.0117623145,0.00034280942,0.0011694131,0.00012439664,0.00003275198,0.012646202],"genre_scores_gemma":[0.978567,0.006639906,0.013244241,0.00032898595,0.00012604703,0.00030094248,0.000017152968,0.000036522124,0.000739199],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998665,0.000106590494,0.00032174855,0.00027970775,0.00023357457,0.0003934251],"domain_scores_gemma":[0.9992372,0.0002011214,0.00008686507,0.00023267668,0.000109702276,0.00013248032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002309243,0.00014771972,0.000572238,0.00021116222,0.000026929361,0.0000032762316,0.000089781606,0.00010581377,0.00042635624],"category_scores_gemma":[0.000041650444,0.00012492124,0.000082253435,0.00034360922,0.00023744773,0.00003402375,0.00003661637,0.0001763932,0.000020682292],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035014134,0.008378497,0.047240306,0.00047884427,0.00075141963,0.0064316723,0.02733485,0.005299314,0.031733587,0.0007976582,0.0012951083,0.86675733],"study_design_scores_gemma":[0.09214059,0.090549864,0.19855225,0.013828365,0.00216959,0.011623172,0.024626963,0.0014471271,0.45800123,0.004383103,0.10051976,0.0021579922],"about_ca_topic_score_codex":0.00321058,"about_ca_topic_score_gemma":0.0010028703,"teacher_disagreement_score":0.86459935,"about_ca_system_score_codex":0.00370582,"about_ca_system_score_gemma":0.0013198801,"threshold_uncertainty_score":0.96905905},"labels":[],"label_agreement":null},{"id":"W2113167936","doi":"10.1634/theoncologist.2011-0379","title":"Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer","year":2012,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ministry of Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genentech; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Regimen; Cost effectiveness; Oncology; Adjuvant; Quality of life (healthcare); Internal medicine; Quality-adjusted life year; Cancer","score_opus":0.1251169310672112,"score_gpt":0.4951463378981687,"score_spread":0.37002940683095753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113167936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9572618,0.0010928325,0.000054289183,0.0053463234,0.00041842292,0.0022040068,0.000076523094,0.000037054648,0.03350873],"genre_scores_gemma":[0.99810666,0.00026527766,0.000037641417,0.00028059632,0.00036238017,0.00048013416,0.000008917397,0.00003159313,0.0004268203],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718416,0.0012055548,0.0003151288,0.00022291839,0.0004759725,0.0005962775],"domain_scores_gemma":[0.99727565,0.0018130735,0.00014700106,0.00046975497,0.0001724568,0.00012209029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003683753,0.0001764974,0.00048347632,0.00010054421,0.00013847002,0.000030872816,0.0003235161,0.00009049332,0.00023428095],"category_scores_gemma":[0.00016723307,0.0000922778,0.00009234797,0.0006641687,0.0007698597,0.00015480562,0.00013916941,0.0006671869,0.000019737601],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017414079,0.0011937898,0.8300159,0.00040327522,0.00019073486,0.000077436205,0.0024689669,0.00018785715,0.016205188,0.0011195183,0.0011465992,0.1452493],"study_design_scores_gemma":[0.0012378071,0.00020252242,0.98984915,0.0006642818,0.000083640545,0.00006047906,0.0010732482,0.00010703899,0.005458059,0.00007198261,0.001086306,0.000105490544],"about_ca_topic_score_codex":0.019114083,"about_ca_topic_score_gemma":0.0036065802,"teacher_disagreement_score":0.15983322,"about_ca_system_score_codex":0.0020519714,"about_ca_system_score_gemma":0.0007719591,"threshold_uncertainty_score":0.9874177},"labels":[],"label_agreement":null},{"id":"W2113538442","doi":"10.1309/ajcp1iu7btsaqgyz","title":"Tissue Microarray for Routine Clinical Breast Biomarker Analysis","year":2010,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; Biomarker; Estrogen receptor; Immunohistochemistry; Breast cancer; Breast tissue; Pathology; Medicine; Oestrogen receptor; Oncology; Internal medicine; Bioinformatics; Biology; Cancer; Genetics","score_opus":0.09791513455714052,"score_gpt":0.539994501317924,"score_spread":0.4420793667607835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113538442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727067,0.0001009213,0.009505721,0.014897715,0.0018721862,0.00030381477,0.000058239526,0.00002014817,0.0005345776],"genre_scores_gemma":[0.95921725,0.000216209,0.03483843,0.002643606,0.0026322503,0.000009296604,0.000014266103,0.00004502867,0.00038364987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939797,0.0010262165,0.0034017242,0.00052291504,0.00048277157,0.00058669946],"domain_scores_gemma":[0.9914607,0.003902688,0.0017534412,0.0007591037,0.0011683707,0.0009557244],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012424577,0.00022563699,0.0025668873,0.00046778587,0.000063313724,0.000020627602,0.000498323,0.00034900176,0.00071283267],"category_scores_gemma":[0.007919811,0.00016754595,0.0015859196,0.00097440253,0.0025521838,0.000060218288,0.00009564789,0.002212533,0.00006203598],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002501601,0.0006166331,0.5299829,0.000013043445,0.0010082808,0.00049587287,0.00003161115,8.5135963e-7,0.004835027,0.000025935702,0.003873003,0.4566152],"study_design_scores_gemma":[0.0043498008,0.007704359,0.9127003,0.0000316539,0.00184531,0.00386715,0.000119345714,0.000096458556,0.00025633167,0.00012767743,0.06870186,0.00019973592],"about_ca_topic_score_codex":0.00003747288,"about_ca_topic_score_gemma":0.0000653107,"teacher_disagreement_score":0.45641547,"about_ca_system_score_codex":0.00003172063,"about_ca_system_score_gemma":0.000816475,"threshold_uncertainty_score":0.9612478},"labels":[],"label_agreement":null},{"id":"W2114163915","doi":"10.1158/0008-5472.can-09-1591","title":"β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Cancer research; Breast cancer; Metastatic breast cancer; Medicine; Protein kinase B; Integrin; Epidermal growth factor receptor; Cancer; Growth factor receptor; Internal medicine; Oncology; Signal transduction; Biology; Receptor; Cell biology","score_opus":0.06515304618792937,"score_gpt":0.4467056461121283,"score_spread":0.38155259992419893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114163915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799196,0.0022743286,0.000021005857,0.012454842,0.0002258271,0.0028742433,0.00027156866,0.000037857782,0.0019207387],"genre_scores_gemma":[0.9958853,0.0013699753,0.000017661892,0.0005205152,0.00064236653,0.0007477104,0.000020371168,0.000060820985,0.0007352943],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99396884,0.0011691703,0.0005994743,0.0007729082,0.0021100962,0.0013794902],"domain_scores_gemma":[0.9967159,0.00074460934,0.00011997687,0.0006306684,0.0013007148,0.00048809778],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014560077,0.00034160764,0.0007675652,0.0006090713,0.0003206023,0.000064117914,0.000681849,0.0002295823,0.0016532291],"category_scores_gemma":[0.0006821146,0.00024369275,0.00018477492,0.0017152018,0.0007697659,0.00020211628,0.00015665371,0.0023624538,0.000038008457],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028246124,0.0014271555,0.1699949,0.0015410752,0.00041785275,0.00037712228,0.010890977,0.000022561531,0.69992816,0.0013417631,0.018402228,0.09283159],"study_design_scores_gemma":[0.0029797906,0.0012028746,0.5923154,0.0020553574,0.000025627063,0.000028734807,0.00050379336,0.00004213062,0.39990517,0.00035476562,0.00033849428,0.00024788413],"about_ca_topic_score_codex":0.007885813,"about_ca_topic_score_gemma":0.00064422836,"teacher_disagreement_score":0.4223205,"about_ca_system_score_codex":0.0023936718,"about_ca_system_score_gemma":0.0021534567,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W2114536437","doi":"10.1128/mcb.22.4.1073-1078.2002","title":"The Catalytic Activity of the ErbB-2 Receptor Tyrosine Kinase Is Essential for Embryonic Development","year":2002,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; ErbB; Receptor tyrosine kinase; ROR1; Tropomyosin receptor kinase C; Tyrosine kinase; Receptor Protein-Tyrosine Kinases; Epidermal growth factor receptor; Epidermal growth factor; Cell biology; Cancer research; Signal transduction; Receptor; Molecular biology; Genetics; Platelet-derived growth factor receptor; Growth factor","score_opus":0.023360079035843306,"score_gpt":0.2937013517597644,"score_spread":0.2703412727239211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114536437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857116,0.005876243,0.0022005134,0.0049976604,0.00020494773,0.0006643783,0.000017157261,0.000009511866,0.00031800076],"genre_scores_gemma":[0.99761385,0.0001784486,0.00018399929,0.00022517459,0.00005125994,0.000045528956,0.000014190538,0.000016774675,0.0016707685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99906605,0.00009278726,0.00015760063,0.0002432192,0.0001429435,0.0002973696],"domain_scores_gemma":[0.9993409,0.00006583111,0.00006054242,0.0003788874,0.00008186508,0.00007195428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027956694,0.00011413693,0.00019281296,0.000030484423,0.00017495803,0.000010626631,0.00016363754,0.00010839507,0.00008802947],"category_scores_gemma":[0.00010354623,0.00006581657,0.00010002605,0.00012639063,0.00031078656,0.000008720139,0.00011880068,0.00015780007,0.000012355824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000094401956,0.000079306235,0.0005314804,0.00010378093,0.000089663044,0.0000047819976,0.00018264282,3.4213227e-7,0.9714837,0.00029713867,0.0013745446,0.0257582],"study_design_scores_gemma":[0.0006595511,0.00017477002,0.00030924685,0.00002599025,0.00003774656,0.000008355641,0.000020904412,0.0002062321,0.91194534,0.00006202602,0.086477205,0.00007260958],"about_ca_topic_score_codex":0.000032299733,"about_ca_topic_score_gemma":0.0000134653865,"teacher_disagreement_score":0.08510266,"about_ca_system_score_codex":0.000050747483,"about_ca_system_score_gemma":0.0001123806,"threshold_uncertainty_score":0.26839218},"labels":[],"label_agreement":null},{"id":"W2114882691","doi":"10.1158/0008-5472.can-06-4724","title":"Distinct ErbB-2–Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"ErbB; Cancer research; Biology; HER2/neu; Receptor tyrosine kinase; Signal transduction; Metastasis; Mammary tumor; Proto-oncogene tyrosine-protein kinase Src; Carcinogenesis; Cancer; Breast cancer; Cell biology; Genetics","score_opus":0.11648727915294524,"score_gpt":0.40277159034118404,"score_spread":0.2862843111882388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114882691","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879097,0.0030687624,0.0021440473,0.0022207554,0.00005635153,0.0019743566,0.000059676462,0.00013883041,0.002427525],"genre_scores_gemma":[0.9946804,0.00043407295,0.0026241585,0.00014050401,0.00039260028,0.00037990537,0.000051336447,0.0000758384,0.0012211875],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9954936,0.0002635255,0.00039102187,0.0007883407,0.0017926187,0.0012708942],"domain_scores_gemma":[0.9976979,0.00031738015,0.00005667791,0.00049421575,0.00081704435,0.00061676744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004717494,0.0002653367,0.00041702366,0.0004607615,0.00036058042,0.000102163904,0.00032404714,0.00018290081,0.00045426923],"category_scores_gemma":[0.0002962756,0.00019779567,0.00006654061,0.0009979915,0.0008253763,0.00015988041,0.0001413501,0.0015210225,0.000019317189],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032109828,0.0003420305,0.038602535,0.0016437225,0.00011677259,0.0071086157,0.0024104097,0.000009224384,0.910989,0.0048056236,0.0005901898,0.030170925],"study_design_scores_gemma":[0.011742406,0.009524065,0.476261,0.0063571194,0.00013116164,0.0035192508,0.0033118676,0.001553665,0.46255082,0.006180117,0.017077662,0.001790881],"about_ca_topic_score_codex":0.0005351626,"about_ca_topic_score_gemma":0.0002775162,"teacher_disagreement_score":0.44843814,"about_ca_system_score_codex":0.0006892193,"about_ca_system_score_gemma":0.0019509715,"threshold_uncertainty_score":0.80658734},"labels":[],"label_agreement":null},{"id":"W2115369621","doi":"10.1158/1055-9965.epi-08-1101","title":"HER-2/neu Overexpression as a Predictor for the Transition from <i>In situ</i> to Invasive Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health","keywords":"Ductal carcinoma; Progesterone receptor; Breast cancer; Estrogen receptor; Oncology; Pathology; Immunohistochemistry; Medicine; Internal medicine; Univariate analysis; Cancer; Biology; Multivariate analysis","score_opus":0.06706633794037227,"score_gpt":0.42468656363259105,"score_spread":0.3576202256922188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115369621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.762265,0.017548185,0.009128156,0.20146422,0.0014054043,0.0068541775,0.0007566132,0.00015165999,0.00042653087],"genre_scores_gemma":[0.97388554,0.004183535,0.001677133,0.015116153,0.0013231348,0.002945218,0.00027553187,0.000051785373,0.0005419867],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99663085,0.0006956102,0.00077033276,0.0008574136,0.00029115475,0.00075462356],"domain_scores_gemma":[0.99721164,0.0014963812,0.00023508884,0.0005422038,0.00019101467,0.00032365674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018212853,0.0003107274,0.0006802579,0.00019109757,0.00016266556,0.000014243464,0.0002897556,0.00037978307,0.00066426856],"category_scores_gemma":[0.0007137045,0.00023338791,0.00031650515,0.00040229698,0.00016034684,0.00016177865,0.00004438401,0.00039244205,0.000027994654],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018971834,0.0006389376,0.10705288,0.000403681,0.0010334456,0.000033319295,0.001671594,0.0008128058,0.3237166,0.00026000777,0.21854766,0.3268572],"study_design_scores_gemma":[0.006142048,0.001262156,0.9430333,0.00565189,0.000432038,0.000036153266,0.0003534039,0.0013147778,0.011402327,0.016857928,0.013038165,0.00047583497],"about_ca_topic_score_codex":0.0037071607,"about_ca_topic_score_gemma":0.0024943938,"teacher_disagreement_score":0.8359804,"about_ca_system_score_codex":0.0009167632,"about_ca_system_score_gemma":0.0007115186,"threshold_uncertainty_score":0.9517283},"labels":[],"label_agreement":null},{"id":"W2115509290","doi":"10.1128/mcb.21.5.1540-1551.2001","title":"Grb2 and Shc Adapter Proteins Play Distinct Roles in Neu (ErbB-2)-Induced Mammary Tumorigenesis: Implications for Human Breast Cancer","year":2001,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Toronto; McMaster University","funders":"National Cancer Institute; Medical Research Council; Natural Sciences and Engineering Research Council of Canada; Cancer Research Society","keywords":"ErbB; Biology; Cancer research; Carcinogenesis; Receptor tyrosine kinase; HER2/neu; Signal transduction; Cell biology; Breast cancer; Cancer; Genetics","score_opus":0.0338421572962207,"score_gpt":0.34101334699826424,"score_spread":0.30717118970204355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115509290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98618,0.00361827,0.004022225,0.004729624,0.000034901695,0.0010755667,0.00009456407,0.000028393126,0.00021642115],"genre_scores_gemma":[0.9981849,0.00026985604,0.0002416902,0.00031887685,0.00010932681,0.00059643266,0.00012285095,0.000031082454,0.00012498267],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987244,0.000084097126,0.00023583123,0.00047487268,0.000074016985,0.00040680618],"domain_scores_gemma":[0.99937445,0.000025339137,0.00004490941,0.0003141954,0.000073156596,0.00016795668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018966547,0.00017676617,0.00029905708,0.0001303399,0.000118779666,0.000021123175,0.00011795081,0.00016043814,0.00003551896],"category_scores_gemma":[0.000019356565,0.0001536093,0.00005760027,0.00014813888,0.00011892193,0.000026979953,0.000074212185,0.00017508966,0.0000016123184],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000114078066,0.00008766622,0.10241874,0.00008104407,0.000045364246,0.000080850565,0.00007839063,6.3285626e-7,0.8716209,0.0021100296,0.000040571464,0.023321753],"study_design_scores_gemma":[0.005277967,0.0014139643,0.7773872,0.0002972877,0.00016777322,0.00056432496,0.00011716848,0.00021484222,0.19063705,0.0060873986,0.017088413,0.00074659317],"about_ca_topic_score_codex":0.0009281686,"about_ca_topic_score_gemma":0.0008228005,"teacher_disagreement_score":0.68098384,"about_ca_system_score_codex":0.00006071902,"about_ca_system_score_gemma":0.0001142664,"threshold_uncertainty_score":0.62640053},"labels":[],"label_agreement":null},{"id":"W2117274017","doi":"10.3747/co.2007.131","title":"Updated Recommendations from the Canadian National Consensus Meeting on HER2/neu Testing in Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; HER2/neu; Breast cancer; Clinical Oncology; Family medicine; Test (biology); Medical physics; Gynecology; Cancer; Internal medicine","score_opus":0.3046895607523,"score_gpt":0.5141459403054996,"score_spread":0.20945637955319962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117274017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.73392385,0.0007022383,0.000006225939,0.20398383,0.002588825,0.0009055131,0.00072736875,0.00006623759,0.057095893],"genre_scores_gemma":[0.99553174,0.000054463384,0.0003836035,0.0027332327,0.00091082824,0.00006654258,0.00022620893,0.000021631271,0.00007174758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983016,0.0001953343,0.00035529822,0.00028421756,0.00035005127,0.00051350123],"domain_scores_gemma":[0.9973438,0.001681925,0.00009114022,0.00016336095,0.0004562992,0.00026349194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014644277,0.00011812467,0.00019922893,0.00023020472,0.00022402298,0.000018222521,0.0001504654,0.00012335752,0.00095595187],"category_scores_gemma":[0.0010743602,0.00009565297,0.000030202913,0.00058117544,0.00014686695,0.00001750902,0.00003997296,0.0008433386,0.000078557714],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013496162,0.00022902366,0.6203492,0.000013688465,0.000035729812,0.00007967507,0.0004595978,0.00006826053,0.0002567269,0.00029557582,0.12679058,0.25128692],"study_design_scores_gemma":[0.0013346748,0.00009328382,0.5168871,0.0003745735,0.000018719193,0.00005976945,0.0003561788,0.0012531037,0.00006790846,0.00017281652,0.47926313,0.00011871223],"about_ca_topic_score_codex":0.25408086,"about_ca_topic_score_gemma":0.79319555,"teacher_disagreement_score":0.5391147,"about_ca_system_score_codex":0.0038486319,"about_ca_system_score_gemma":0.0041305926,"threshold_uncertainty_score":0.99997544},"labels":[],"label_agreement":null},{"id":"W2117342082","doi":"10.1158/1055-9965.epi-08-1202","title":"Heritable Variation of<i>ERBB2</i>and Breast Cancer Risk","year":2009,"lang":"en","type":"article","venue":"Cancer Epidemiology Biomarkers & Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institute on Drug Abuse","keywords":"Breast cancer; Linkage disequilibrium; Haplotype; Biology; Single-nucleotide polymorphism; Odds ratio; Genetics; Oncology; Internal medicine; Locus (genetics); Cancer; Allele; Genotype; Gene; Medicine","score_opus":0.05187997438453702,"score_gpt":0.41210538428016175,"score_spread":0.36022540989562474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2117342082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84927875,0.08282567,0.009798415,0.05150698,0.001616072,0.0025168841,0.0003320987,0.00022069711,0.001904435],"genre_scores_gemma":[0.96833754,0.024140343,0.004540037,0.001081803,0.0004659449,0.00023540568,0.000056070927,0.000032790507,0.0011100961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971774,0.0007832252,0.0007312938,0.00056779425,0.00020726396,0.00053302967],"domain_scores_gemma":[0.99834377,0.00033260207,0.0004711867,0.00039017262,0.00023272661,0.0002295689],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028597726,0.00021929397,0.0006953698,0.00018299134,0.00011400932,0.000006480824,0.00012400559,0.0003023761,0.0006859181],"category_scores_gemma":[0.00049708877,0.0001983004,0.00017835443,0.0003635998,0.00024692572,0.00014956319,0.000043440064,0.00032654332,0.00001071467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011859165,0.00016010691,0.6796813,0.0002464822,0.00054150197,0.000004698289,0.00015668343,0.00005006552,0.010313029,0.00045651494,0.01071832,0.2964854],"study_design_scores_gemma":[0.0015191805,0.00036401738,0.9831015,0.0006288237,0.0003297759,0.000041059793,0.000030718013,0.0011104664,0.00049146445,0.008130441,0.004075657,0.00017689285],"about_ca_topic_score_codex":0.0033228495,"about_ca_topic_score_gemma":0.00024568656,"teacher_disagreement_score":0.30342022,"about_ca_system_score_codex":0.0003910773,"about_ca_system_score_gemma":0.00040060325,"threshold_uncertainty_score":0.80864555},"labels":[],"label_agreement":null},{"id":"W2118056343","doi":"10.1038/sj.embor.7400491","title":"Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation","year":2005,"lang":"en","type":"article","venue":"EMBO Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale; Ariad Pharmaceuticals","keywords":"Endocytosis; Cell biology; Epidermal growth factor receptor; Receptor; Enzyme-linked receptor; Receptor-mediated endocytosis; Growth factor receptor; Insulin-like growth factor 1 receptor; Tropomyosin receptor kinase C; ERBB3; Biology; Epidermal growth factor; Co-receptor; Chemistry; Platelet-derived growth factor receptor; Signal transduction; Biochemistry; Growth factor","score_opus":0.020544255728969736,"score_gpt":0.30299625935480295,"score_spread":0.2824520036258332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118056343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98077226,0.0005349124,0.0031066074,0.009371748,0.0008196699,0.0020075003,0.00019147915,0.00022913872,0.002966717],"genre_scores_gemma":[0.9916297,0.00018499559,0.001648262,0.0006435865,0.0009209961,0.00021637387,0.00039220412,0.00011496078,0.004248909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961521,0.00025744212,0.001166579,0.0006986289,0.0011294156,0.00059586007],"domain_scores_gemma":[0.99719596,0.00023769494,0.00071009254,0.00075599,0.00068979623,0.00041044538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006834007,0.00034797727,0.0007217261,0.00022884925,0.00012310201,0.000036485944,0.00014858946,0.0002562589,0.009285388],"category_scores_gemma":[0.0019719033,0.00031424224,0.00021872016,0.0005290755,0.00017019692,0.00036388464,0.000051219144,0.00041575806,0.00016180317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004020417,0.00044097516,0.07181487,0.00015341744,0.00018777078,0.000020739326,0.0004800571,0.000007095796,0.7845952,0.000044606615,0.12924218,0.012611086],"study_design_scores_gemma":[0.0013966677,0.00032547698,0.005629041,0.00020907268,0.000046994202,0.00004223143,0.000064333064,0.00004532986,0.74658865,0.00001545376,0.24535692,0.00027981392],"about_ca_topic_score_codex":0.00032835946,"about_ca_topic_score_gemma":0.0000069032667,"teacher_disagreement_score":0.11611474,"about_ca_system_score_codex":0.0004793905,"about_ca_system_score_gemma":0.00048340415,"threshold_uncertainty_score":0.999931},"labels":[],"label_agreement":null},{"id":"W2118143278","doi":"10.1073/pnas.1201105109","title":"Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2 <sup>+</sup> :ERα <sup>−</sup> breast cancer","year":2012,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; University Health Network","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Trastuzumab; Oncology; Breast cancer; Internal medicine; Medicine; Gene signature; Lymph node; Chemotherapy; Cancer; Estrogen receptor; Cancer research; Hazard ratio; Lapatinib; Biology; Gene expression; Gene; Confidence interval","score_opus":0.11283602596926387,"score_gpt":0.417958517329261,"score_spread":0.30512249135999714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118143278","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98563325,0.0008832039,0.000010161562,0.009520285,0.000109487526,0.0012802855,0.00062383054,0.00006407302,0.0018754401],"genre_scores_gemma":[0.99019897,0.0001022774,0.0045143478,0.0023636466,0.0021184713,0.00015629087,0.0000067706937,0.000037910595,0.0005013225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99390614,0.00006050996,0.0013323118,0.00072489475,0.0031662898,0.00080986146],"domain_scores_gemma":[0.99679375,0.00091648416,0.00086712406,0.000059635015,0.0009929235,0.00037009481],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005604058,0.00033428095,0.00072063965,0.00030336477,0.00045271483,0.000064167085,0.0015738303,0.00038601732,0.00019660567],"category_scores_gemma":[0.0014618955,0.00023914888,0.00037434508,0.0010437683,0.0010910932,0.0009247939,0.0004740648,0.0011425753,0.0000068473673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004107019,0.0010144613,0.8083726,0.0013618754,0.00043331785,4.6407476e-7,0.002512433,0.0008762592,0.1589291,0.004350135,0.01804181,0.0036968351],"study_design_scores_gemma":[0.005311758,0.00074387086,0.78604424,0.0018995747,0.0004267251,0.000114032504,0.0025397039,0.026788862,0.15549155,0.016049841,0.0036610551,0.0009287705],"about_ca_topic_score_codex":0.00014355314,"about_ca_topic_score_gemma":5.846995e-7,"teacher_disagreement_score":0.025912603,"about_ca_system_score_codex":0.0002707301,"about_ca_system_score_gemma":0.00035183338,"threshold_uncertainty_score":0.9752208},"labels":[],"label_agreement":null},{"id":"W2118430013","doi":"10.1128/mcb.25.9.3831-3841.2005","title":"Dok-R Mediates Attenuation of Epidermal Growth Factor-Dependent Mitogen-Activated Protein Kinase and Akt Activation through Processive Recruitment of c-Src and Csk","year":2005,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; Tyrosine-protein kinase CSK; Protein kinase B; Biology; Cell biology; Epidermal growth factor; SH3 domain; Tyrosine kinase; MAPK/ERK pathway; Src family kinase; Phosphorylation; Cancer research; Molecular biology; Signal transduction; Biochemistry; Receptor","score_opus":0.05038912150552269,"score_gpt":0.3366343023050747,"score_spread":0.28624518079955197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118430013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927124,0.0029627432,0.001913194,0.0010903166,0.000022175756,0.0011652115,0.000019941337,0.00001159504,0.00010242278],"genre_scores_gemma":[0.9986687,0.00029026807,0.0006486625,0.000112313064,0.00004292242,0.00010648712,0.00008024665,0.00001691964,0.000033499986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988157,0.00016122562,0.00029892958,0.00032646017,0.00018974749,0.00020789569],"domain_scores_gemma":[0.99935734,0.000049109894,0.00016529247,0.0001449128,0.00019501334,0.00008830271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018405261,0.00015174386,0.00032572608,0.000094333256,0.00003940862,0.000006398535,0.000047472713,0.00017239012,0.00002333229],"category_scores_gemma":[0.00016611544,0.00012492572,0.00003220821,0.00011449932,0.00022621611,0.00006494284,0.00006785696,0.00014658802,7.452604e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024646387,0.00008139303,0.005271105,0.00034471042,0.00008558786,0.000010741617,0.0006593853,9.558951e-7,0.9811198,0.00033619555,0.0000055018622,0.011838137],"study_design_scores_gemma":[0.0014282418,0.0006728386,0.0021102012,0.00011161223,0.00003806311,0.000011205187,0.00014613857,0.000050246705,0.9945162,0.0004639315,0.0003452256,0.00010612932],"about_ca_topic_score_codex":0.00015673133,"about_ca_topic_score_gemma":0.000005134774,"teacher_disagreement_score":0.013396343,"about_ca_system_score_codex":0.000043665033,"about_ca_system_score_gemma":0.000088319684,"threshold_uncertainty_score":0.5094323},"labels":[],"label_agreement":null},{"id":"W2119416636","doi":"10.1200/jco.2007.15.4716","title":"HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy","year":2008,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"","keywords":"Medicine; Chemotherapy; Topoisomerase; Oncology; Internal medicine; Pharmacology; Genetics; DNA; Biology","score_opus":0.2872185641950503,"score_gpt":0.6115991896106241,"score_spread":0.3243806254155738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119416636","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027361475,0.96217746,0.000004667658,0.007012128,0.0012957184,0.0008548792,0.000014906865,0.0000084422345,0.0012703057],"genre_scores_gemma":[0.00019633908,0.9922131,0.0011735465,0.001858022,0.002349861,0.000014457862,0.0000019023324,0.000063614076,0.0021291869],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99138445,0.0021027536,0.00487929,0.00035301162,0.0009145346,0.0003659672],"domain_scores_gemma":[0.98681134,0.008165242,0.0026856842,0.0004735358,0.000657748,0.0012064653],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007600624,0.00031869783,0.007037538,0.0005473605,0.000049394115,0.000005769776,0.00041426474,0.0012432329,0.00045315753],"category_scores_gemma":[0.01857802,0.00021104785,0.0013628915,0.00043000217,0.00053084065,0.000049047354,0.00018191746,0.0027047915,0.00003673993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009253846,0.00099226,0.000519273,0.0017204592,0.00079340825,0.0015175737,0.00014084943,1.4891562e-7,0.000004398506,0.000004679884,0.032935675,0.95211744],"study_design_scores_gemma":[0.003622006,0.040877845,0.0015290811,0.0066852486,0.0005264243,0.0037596554,0.000020471569,3.5982663e-7,0.0000037482193,0.000018242792,0.94282144,0.00013547628],"about_ca_topic_score_codex":0.000020277817,"about_ca_topic_score_gemma":0.000005334232,"teacher_disagreement_score":0.95198196,"about_ca_system_score_codex":0.00044111998,"about_ca_system_score_gemma":0.013925866,"threshold_uncertainty_score":0.999596},"labels":[],"label_agreement":null},{"id":"W2119525612","doi":"10.1158/0008-5472.sabcs11-ot1-02-13","title":"OT1-02-13: Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Internal medicine; Breast cancer; Ejection fraction; Cardiology; Biomarker; Heart failure; Troponin; Brain natriuretic peptide; Oncology; Cancer; Natriuretic peptide; Chemotherapy; Myocardial infarction","score_opus":0.1620393432808645,"score_gpt":0.4198216100360337,"score_spread":0.2577822667551692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119525612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773955,0.003831633,0.0000013101705,0.0014242947,0.0020227986,0.00752076,0.00068140455,0.00011003402,0.007012286],"genre_scores_gemma":[0.98347235,0.006655001,0.000037841965,0.0002220442,0.0010776077,0.0073391763,0.00006493331,0.00026233392,0.000868702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9890812,0.00231159,0.0010389478,0.0015881294,0.0034368092,0.002543295],"domain_scores_gemma":[0.995335,0.00095164776,0.00021579501,0.0015389026,0.0012586395,0.00070005574],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053870277,0.0006819359,0.0012590078,0.0011287449,0.0005410009,0.00016933803,0.0011101005,0.00041779762,0.0021589892],"category_scores_gemma":[0.00055660144,0.00048479153,0.0005037688,0.0027596336,0.0009413666,0.00028685533,0.00034645677,0.0022433088,0.0001538792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04794694,0.0013309487,0.4173092,0.00027894965,0.00083700503,0.00006201005,0.005677173,0.000003116225,0.0055433433,0.000008161712,0.02309931,0.49790385],"study_design_scores_gemma":[0.027372679,0.0025147828,0.9475425,0.0014192146,0.00007789549,0.0000037476714,0.0010168098,0.000081080296,0.0094789015,0.00002186389,0.009825159,0.00064535055],"about_ca_topic_score_codex":0.01376071,"about_ca_topic_score_gemma":0.00079748925,"teacher_disagreement_score":0.5302333,"about_ca_system_score_codex":0.0042226976,"about_ca_system_score_gemma":0.0032729863,"threshold_uncertainty_score":0.9997604},"labels":[],"label_agreement":null},{"id":"W2120171585","doi":"10.1016/j.ejca.2013.02.012","title":"Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Rash; T790M; Pharmacodynamics; Pharmacokinetics; Adverse effect; Pharmacology; Internal medicine; Epidermal growth factor receptor; Cohort; Discontinuation; Oncology; Cancer; Gefitinib","score_opus":0.03850557109698171,"score_gpt":0.38690989731739417,"score_spread":0.34840432622041245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120171585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973969,0.0008707579,0.0000209001,0.00046056026,0.00011346727,0.0010204092,0.000013525587,0.0000068076333,0.00009667974],"genre_scores_gemma":[0.99802935,0.00013452202,0.0012635131,0.00023320873,0.00011458341,0.000016037437,0.0000017287188,0.000066276734,0.0001407623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99760026,0.00041567584,0.0006662238,0.00026305421,0.0007288755,0.00032588627],"domain_scores_gemma":[0.9982056,0.000045020744,0.00030126737,0.00024023738,0.0006634512,0.0005444475],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076916977,0.00021154432,0.00059133285,0.00032863667,0.00004270214,0.000047602683,0.00014602447,0.000013790875,0.0001888175],"category_scores_gemma":[0.00015288936,0.00013903408,0.000026548178,0.0003802154,0.00011260198,0.00035379265,0.00008144047,0.00035747484,0.000004464539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019291397,0.0080552315,0.4320484,0.00039305538,0.00032125603,0.0019135351,0.009575479,0.000248469,0.0118706245,0.0000018990614,0.0020993259,0.5141813],"study_design_scores_gemma":[0.061608437,0.078581765,0.84971166,0.0017242631,0.00024448332,0.000082090904,0.0031181087,0.00009589472,0.0025225088,0.0000046810487,0.001967581,0.00033850872],"about_ca_topic_score_codex":0.00019247024,"about_ca_topic_score_gemma":0.00029493426,"teacher_disagreement_score":0.5138428,"about_ca_system_score_codex":0.00013119492,"about_ca_system_score_gemma":0.0002445763,"threshold_uncertainty_score":0.5669645},"labels":[],"label_agreement":null},{"id":"W2120746859","doi":"10.1093/jnci/djt360","title":"Validated or Not Validated? That Is the Question","year":2014,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Epirubicin; Cyclophosphamide; Medicine; Oncology; Chemotherapy; Internal medicine; Doxorubicin; Fluorouracil","score_opus":0.251135481940737,"score_gpt":0.4613854406328746,"score_spread":0.21024995869213764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120746859","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013483525,0.00060901797,0.00018084793,0.98652995,0.0077700675,0.00071330793,0.00030797886,0.00002639613,0.0025140876],"genre_scores_gemma":[0.016358452,0.0011489037,0.0003033688,0.9295703,0.031655714,0.00007492594,0.00008210514,0.000097088676,0.020709122],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925212,0.00046980352,0.0009082504,0.0003525667,0.0052735084,0.0004746634],"domain_scores_gemma":[0.99482137,0.00041095234,0.0012721817,0.00053045456,0.0028210504,0.00014396705],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024032902,0.00040492017,0.0006960114,0.0003777134,0.00035041798,0.00017742874,0.0014201059,0.0006676534,0.0013076471],"category_scores_gemma":[0.0012962526,0.000194521,0.00056593015,0.0006369785,0.00046428677,0.00030674608,0.00017395568,0.004834008,0.00008163149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005330113,0.000030390042,0.00023740572,0.00025597744,0.0006003335,0.00016363239,0.00011170587,0.0002329136,0.00050587533,0.00006880619,0.9960646,0.0011953356],"study_design_scores_gemma":[0.0012523751,0.00015458986,0.0008570641,0.0017274308,0.0005152487,0.0015758753,0.000006483188,0.00009919181,0.008112795,0.00036913145,0.9851018,0.0002279958],"about_ca_topic_score_codex":0.00038571007,"about_ca_topic_score_gemma":0.00008158225,"teacher_disagreement_score":0.056959625,"about_ca_system_score_codex":0.0023518372,"about_ca_system_score_gemma":0.005725102,"threshold_uncertainty_score":0.9999115},"labels":[],"label_agreement":null},{"id":"W2121378565","doi":"10.2478/s11535-006-0014-6","title":"Targeting of solid tumors and blood malignancies by antibody-based therapies — EGFR-pathway as an example","year":2006,"lang":"en","type":"article","venue":"Open Life Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"Canadian Institutes of Health Research; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation","keywords":"ERBB3; ErbB; Epidermal growth factor receptor; Cancer research; Receptor tyrosine kinase; MAPK/ERK pathway; Epidermal growth factor; PI3K/AKT/mTOR pathway; Tyrosine kinase; Protein kinase B; Signal transduction; Biology; ERBB4; Receptor; Cell biology; Biochemistry","score_opus":0.06080071927829519,"score_gpt":0.3812281827530076,"score_spread":0.32042746347471246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121378565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98946,0.0023119778,0.000041157207,0.0012510809,0.000055714612,0.0005119156,0.000037434318,0.000026276635,0.006304436],"genre_scores_gemma":[0.99487185,0.00008292493,0.0036905657,0.00047157033,0.00010176972,0.000025671397,0.00002375542,0.000015688898,0.0007161791],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783325,0.00012611771,0.00034408658,0.0004927696,0.0007647776,0.00043900637],"domain_scores_gemma":[0.9991252,0.0001449339,0.00014002358,0.0002638456,0.00013684151,0.0001891741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021013014,0.000147473,0.00036375274,0.000120079734,0.00033745504,0.00016562907,0.00060467777,0.000048784765,0.00036635273],"category_scores_gemma":[0.00019870349,0.00010970895,0.000031939315,0.0005211992,0.0011171456,0.00039208514,0.00015706342,0.00011329027,0.00000945431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008301243,0.00039152804,0.15273875,0.00015606891,0.000022726717,0.000030462363,0.00097300555,0.000060932303,0.8381775,0.001318513,0.004796764,0.0012507607],"study_design_scores_gemma":[0.0031978535,0.0046879663,0.034607254,0.00079265237,0.00005163706,0.00004630708,0.00834467,0.0017529259,0.91547114,0.0018714305,0.028543115,0.0006330571],"about_ca_topic_score_codex":0.015102848,"about_ca_topic_score_gemma":0.00012895855,"teacher_disagreement_score":0.11813149,"about_ca_system_score_codex":0.000016762431,"about_ca_system_score_gemma":0.0010242873,"threshold_uncertainty_score":0.9914557},"labels":[],"label_agreement":null},{"id":"W2121576318","doi":"10.1016/j.ctrv.2009.12.012","title":"Lapatinib and HER2 status: Results of a meta-analysis of randomized phase III trials in metastatic breast cancer","year":2010,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Hazard ratio; Randomized controlled trial; Adverse effect; Cancer; Clinical trial; Discontinuation; Trastuzumab; Confidence interval","score_opus":0.46909519296310337,"score_gpt":0.5766936765117843,"score_spread":0.1075984835486809,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121576318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040166757,0.9683095,0.000008464715,0.00023979596,0.00013182487,0.017673345,0.013252798,0.000013102081,0.00033098852],"genre_scores_gemma":[0.000025661058,0.974455,0.0006489185,0.000048958165,0.00011476966,0.022735998,0.0008453511,0.00008844045,0.0010369046],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9807263,0.0075210864,0.009021831,0.0012042772,0.00086088054,0.00066560355],"domain_scores_gemma":[0.9863501,0.0047238017,0.0064563537,0.0016417715,0.00038302885,0.00044493738],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.0146318115,0.0011608305,0.060307283,0.0016028843,0.000035178746,0.0000292783,0.00028473928,0.0003269775,0.0037340706],"category_scores_gemma":[0.0023464677,0.00058803445,0.012293901,0.0028150412,0.00046138486,0.00007808586,0.00007596121,0.000604945,0.000006864657],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011952405,0.0007444082,0.000008524059,0.022958089,0.2045764,0.000023385008,0.0003143863,0.0000019364472,0.0000027178423,0.000006666448,0.00034526456,0.7590658],"study_design_scores_gemma":[0.08201721,0.00016831998,0.0000012017348,0.0057706255,0.44184506,0.000005985759,0.000008770611,0.0000110922465,0.000008912219,0.0000025962615,0.4699716,0.00018863742],"about_ca_topic_score_codex":0.017997846,"about_ca_topic_score_gemma":0.0055438713,"teacher_disagreement_score":0.75887716,"about_ca_system_score_codex":0.00098428,"about_ca_system_score_gemma":0.0030388157,"threshold_uncertainty_score":0.9996571},"labels":[],"label_agreement":null},{"id":"W2121601348","doi":"10.1200/jco.2011.36.6385","title":"Testing for Discordance at Metastatic Relapse: Does It Matter?","year":2012,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.379901934180019,"score_gpt":0.5724041181961178,"score_spread":0.1925021840160988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121601348","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008415815,0.0012704182,0.00030343822,0.9768909,0.007657237,0.00086145865,0.00006221053,0.000013831491,0.0045246957],"genre_scores_gemma":[0.0021515896,0.00038133728,0.058751814,0.8606025,0.0493299,0.000085799904,0.000038252743,0.00017755665,0.028481245],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99180156,0.0010774365,0.004633018,0.0004325543,0.0011269522,0.0009285079],"domain_scores_gemma":[0.9672566,0.026199412,0.0043154364,0.0005575166,0.0010957714,0.00057524804],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0089098,0.00036523514,0.003702276,0.0002527072,0.000090676236,0.000024062683,0.00060021126,0.0013172631,0.00168611],"category_scores_gemma":[0.021812467,0.0002147712,0.0011812751,0.00018732222,0.00052313396,0.0001383677,0.00023244823,0.007853501,0.00034768367],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013133168,0.00035443,0.030101957,0.0010806207,0.0006408284,0.0029074112,0.000042997686,0.0000012542239,0.000067305155,0.0000027560864,0.93264014,0.030846983],"study_design_scores_gemma":[0.0040983954,0.008406089,0.011781555,0.0010491044,0.0013259045,0.0021705078,0.000027541477,0.000016677484,0.000019815707,0.00043951249,0.9704445,0.00022038727],"about_ca_topic_score_codex":0.000022009615,"about_ca_topic_score_gemma":0.000032544867,"teacher_disagreement_score":0.11628839,"about_ca_system_score_codex":0.0009672064,"about_ca_system_score_gemma":0.0036383031,"threshold_uncertainty_score":0.99997926},"labels":[],"label_agreement":null},{"id":"W2121850323","doi":"10.1038/sj.onc.1208892","title":"NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis","year":2005,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of British Columbia; BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Amplicon; Biology; Carcinogenesis; Fluorescence in situ hybridization; Locus (genetics); Gene duplication; Estrogen receptor; Comparative genomic hybridization; Breast cancer; Genetics; Gene; Cancer research; Molecular biology; Cancer; Chromosome; Polymerase chain reaction","score_opus":0.09046705075895692,"score_gpt":0.4284531646079335,"score_spread":0.3379861138489766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121850323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99529094,0.00026260922,0.000070693604,0.0028063096,0.000087550434,0.0009399408,0.00025436084,0.000037800033,0.0002498148],"genre_scores_gemma":[0.99721843,0.0004020804,0.0010135665,0.00027785837,0.0003087329,0.00021706989,0.00014439144,0.000044866905,0.00037299638],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975172,0.00012444441,0.0007871945,0.00046453296,0.0007364474,0.00037017238],"domain_scores_gemma":[0.9986539,0.00005026222,0.0002843281,0.00038271552,0.00039715788,0.00023165265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001394784,0.00015115147,0.0004176978,0.00015781363,0.00003568097,0.00001809227,0.00018657441,0.00014799765,0.00023426909],"category_scores_gemma":[0.00013550799,0.00013135183,0.000070016205,0.0005308844,0.00011648495,0.00011129197,0.000046359153,0.00025860927,0.000021919896],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008731497,0.003451821,0.43327922,0.00007678311,0.00021116126,0.000016832024,0.00016728278,0.00007722708,0.37060404,0.0000060736193,0.0005670381,0.19066939],"study_design_scores_gemma":[0.0053380914,0.0005954949,0.8835709,0.0003960524,0.00012001561,0.000022490227,0.000058943326,0.0018495847,0.106231116,0.0000023206508,0.0016468883,0.000168094],"about_ca_topic_score_codex":0.0008953561,"about_ca_topic_score_gemma":0.0025073446,"teacher_disagreement_score":0.4502917,"about_ca_system_score_codex":0.00066607253,"about_ca_system_score_gemma":0.0004988461,"threshold_uncertainty_score":0.5356372},"labels":[],"label_agreement":null},{"id":"W2121944733","doi":"10.1093/annonc/mds594","title":"An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital; London Health Sciences Centre","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Lapatinib; Medicine; Breast cancer; Internal medicine; Oncology; Clinical endpoint; Estrogen receptor; Cancer; Biomarker; Adverse effect; Clinical trial; Trastuzumab","score_opus":0.19327971489460452,"score_gpt":0.5173170746045165,"score_spread":0.324037359709912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121944733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886172,0.00012231486,2.7879702e-7,0.0014684642,0.00010129396,0.0072535104,0.000060798895,0.000019709716,0.0023564256],"genre_scores_gemma":[0.99673843,0.000051374845,0.00004227591,0.000268829,0.00019319353,0.0024702952,0.0000019272402,0.000051203268,0.00018243784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99450433,0.0022288882,0.00088171667,0.0005213749,0.0009968817,0.00086678145],"domain_scores_gemma":[0.9967657,0.0007462821,0.0004336691,0.00093532,0.0007539918,0.00036507196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042914734,0.00028650882,0.0012878762,0.00021572475,0.0001023804,0.000024369887,0.0009261772,0.00013075484,0.0004202394],"category_scores_gemma":[0.0001699125,0.00018153494,0.000024927409,0.00094640325,0.00035487398,0.00030716186,0.00044710768,0.0007188587,0.000008399242],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014275823,0.08978207,0.7302342,0.000039151204,0.00056753843,0.00014039325,0.12373707,0.000013121066,0.000075796845,0.0000099273575,0.00028882432,0.04083611],"study_design_scores_gemma":[0.022346336,0.12409738,0.7737611,0.000076321856,0.000074920325,0.000025006897,0.078757465,0.000011236626,0.000099848956,0.000011937438,0.00059281435,0.00014561952],"about_ca_topic_score_codex":0.02223237,"about_ca_topic_score_gemma":0.012272324,"teacher_disagreement_score":0.0449796,"about_ca_system_score_codex":0.00023561048,"about_ca_system_score_gemma":0.0009095804,"threshold_uncertainty_score":0.9842787},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","score_opus":0.06039123479763487,"score_gpt":0.3881995916148677,"score_spread":0.32780835681723286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123591186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991364,0.00062415435,0.000035673347,0.0016070766,0.00009459064,0.0057829297,0.00009619097,0.000025801271,0.0018199647],"genre_scores_gemma":[0.9948663,0.0020799239,0.0010205805,0.0005565817,0.00021305663,0.0009848844,0.0000042989313,0.00005015329,0.00022418257],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973057,0.0006045143,0.00058696745,0.00047970162,0.00030872686,0.000714398],"domain_scores_gemma":[0.99807256,0.0007802699,0.0002570654,0.00042898356,0.00018015005,0.0002809792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012268149,0.00028160147,0.0013826881,0.00007187853,0.00009425821,0.00002452541,0.00037797246,0.00016648805,0.00053421175],"category_scores_gemma":[0.00018251331,0.0001635873,0.000020910848,0.00026439741,0.00074774714,0.00014242057,0.00022013525,0.00057035714,0.0000041162943],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7835139,0.0014757863,0.0012245548,0.00012937323,0.00023867193,0.00033712073,0.011193513,0.000004279875,0.00085414754,0.000033903343,0.000086587475,0.20090817],"study_design_scores_gemma":[0.9200645,0.021745184,0.052397255,0.000736895,0.00013850472,0.00032958286,0.0016262453,0.00023671793,0.00031059448,0.000027563321,0.002144502,0.00024246814],"about_ca_topic_score_codex":0.00152276,"about_ca_topic_score_gemma":0.0019324941,"teacher_disagreement_score":0.2006657,"about_ca_system_score_codex":0.00069442374,"about_ca_system_score_gemma":0.0015359735,"threshold_uncertainty_score":0.6670897},"labels":[],"label_agreement":null},{"id":"W2123895170","doi":"10.3747/co.22.2322","title":"Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline","year":2015,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; Regional Municipality of Durham; Ottawa Hospital; Kingston General Hospital","funders":"","keywords":"Trastuzumab; Medicine; Pertuzumab; Lapatinib; Neratinib; Oncology; Internal medicine; Breast cancer; Targeted therapy; Cancer; Clinical trial; Adjuvant therapy; Guideline; Neoadjuvant therapy; Pathology","score_opus":0.36218816961786476,"score_gpt":0.5593257468535162,"score_spread":0.19713757723565145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123895170","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003170162,0.93008375,0.00011413833,0.001221686,0.004379211,0.061349303,0.002751828,0.000048362966,0.000020035703],"genre_scores_gemma":[0.00010439526,0.93617404,0.000038747126,0.00041728318,0.0013877666,0.06095622,0.00022910458,0.00019640509,0.00049602636],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9906949,0.0024790892,0.00342611,0.0011333984,0.0012943355,0.00097218406],"domain_scores_gemma":[0.98556143,0.002813264,0.003210094,0.0021724817,0.0059429235,0.0002998182],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0053636986,0.0010348218,0.0077006337,0.00020286578,0.00026780428,0.000045452914,0.0020219171,0.00064369757,0.00019974964],"category_scores_gemma":[0.00078135985,0.0004977133,0.002107586,0.000697852,0.00036729075,0.00008590072,0.0002180777,0.0013021746,0.000020755686],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032415352,0.00011831388,0.00020879207,0.7272661,0.0012394444,0.0000026799921,0.0011428389,0.0000018728335,0.0000030832855,0.00001078656,0.026980877,0.24270107],"study_design_scores_gemma":[0.0011952206,0.0007045782,0.000016249855,0.5490738,0.004033904,0.00030987177,0.0002029053,0.000010959815,0.0000021087264,0.0000017049188,0.44417748,0.00027118207],"about_ca_topic_score_codex":0.01052483,"about_ca_topic_score_gemma":0.0037796882,"teacher_disagreement_score":0.4171966,"about_ca_system_score_codex":0.011236613,"about_ca_system_score_gemma":0.025109958,"threshold_uncertainty_score":0.99974746},"labels":[],"label_agreement":null},{"id":"W2124076816","doi":"10.1124/jpet.109.160085","title":"The Combi-Targeting Concept: Selective Targeting of the Epidermal Growth Factor Receptor- and Her2-Expressing Cancer Cells by the Complex Combi-Molecule RB24","year":2010,"lang":"en","type":"article","venue":"Journal of Pharmacology and Experimental Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Epidermal growth factor; Cancer; Receptor; Cancer cell; Growth factor receptor inhibitor; Chemistry; Cell biology; Biology; Medicine; Internal medicine; Breast cancer; Biochemistry","score_opus":0.036086851710191145,"score_gpt":0.39376324219632186,"score_spread":0.3576763904861307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124076816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9748932,0.016040007,0.000015401847,0.007254636,0.0012191563,0.00039909934,0.00002432607,0.000006839816,0.00014729743],"genre_scores_gemma":[0.995167,0.0013994284,0.00017269263,0.002781475,0.00036845537,0.000013410245,0.0000014950241,0.000028495386,0.00006750621],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980671,0.00051512657,0.00050368963,0.00016424716,0.00037693704,0.00037293028],"domain_scores_gemma":[0.99839604,0.000646274,0.00047680596,0.00010014314,0.00026166876,0.00011905673],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007012424,0.00019466321,0.000350552,0.000031156913,0.00068327575,0.00004676778,0.00031176535,0.00011798038,0.00027715904],"category_scores_gemma":[0.00003338768,0.000101375634,0.00010670731,0.00012741786,0.001317957,0.00008459894,0.00015080778,0.0013009881,6.469105e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045349795,0.00015655765,0.0037021486,0.000022352704,0.00032622312,0.0000031614718,0.0035607857,0.0000034262068,0.97066516,0.000026199497,0.01995794,0.001122535],"study_design_scores_gemma":[0.0021172764,0.00037975638,0.0011647163,0.000036730627,0.000103011895,0.00006231054,0.0022576253,0.000364842,0.9740164,0.000029511433,0.019363282,0.000104524646],"about_ca_topic_score_codex":0.000057287627,"about_ca_topic_score_gemma":0.000002813615,"teacher_disagreement_score":0.020273805,"about_ca_system_score_codex":0.000096602176,"about_ca_system_score_gemma":0.00020955372,"threshold_uncertainty_score":0.56522185},"labels":[],"label_agreement":null},{"id":"W2124824379","doi":"10.1111/j.1524-4741.2007.00396.x","title":"Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare Event","year":2007,"lang":"en","type":"article","venue":"The Breast Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; HER2/neu; Fluorescence in situ hybridization; Immunohistochemistry; Concordance; Breast carcinoma; Chromogenic in situ hybridization; Cancer research; Ductal carcinoma; clone (Java method); Oncology; In situ hybridization; Gene duplication; Cancer; Trastuzumab; Pathology; Gene; Internal medicine; Gene expression; Biology; Chromosome; Genetics","score_opus":0.031158404634053304,"score_gpt":0.3798291547736526,"score_spread":0.3486707501395993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124824379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871015,0.0010582089,0.0001076934,0.010326846,0.0003207057,0.00026449346,0.00006153,0.000013837426,0.000745196],"genre_scores_gemma":[0.99815685,0.00029287013,0.00008372821,0.0003337654,0.00095119874,0.0000072375237,0.0000022618897,0.000030157162,0.00014195916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758583,0.00017414735,0.00059309514,0.00017968491,0.0008369401,0.0006302873],"domain_scores_gemma":[0.9987639,0.000068632515,0.000189883,0.00034695648,0.00027930376,0.00035132316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024143208,0.00016823772,0.00036478267,0.00020022158,0.0001034206,0.000029371588,0.00035882418,0.000083774285,0.000845768],"category_scores_gemma":[0.000032238288,0.00010924818,0.00015864852,0.00046323222,0.0002037708,0.000088549634,0.00009064887,0.0011002818,0.00001851221],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032720533,0.000537241,0.8367076,0.00018175105,0.00016227114,0.0010689904,0.00082174,0.00013346999,0.0138611095,0.00006679295,0.0035341075,0.13965286],"study_design_scores_gemma":[0.0017360928,0.00014449187,0.95560163,0.00065474765,0.000037616064,0.0356591,0.00036889236,0.00008827174,0.0048249,0.00014747288,0.0006202662,0.00011650002],"about_ca_topic_score_codex":0.0009461874,"about_ca_topic_score_gemma":0.00073114777,"teacher_disagreement_score":0.13953635,"about_ca_system_score_codex":0.0005364941,"about_ca_system_score_gemma":0.00067061273,"threshold_uncertainty_score":0.9260567},"labels":[],"label_agreement":null},{"id":"W2125219284","doi":"10.1136/jclinpath-2013-201819","title":"HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Breast cancer; Turnaround time; Clinical trial; Human Epidermal Growth Factor Receptor 2; Oncology; Adjuvant; Disease; Internal medicine; Adjuvant therapy; Intensive care medicine; Medical physics; Cancer; Computer science","score_opus":0.3399490467106761,"score_gpt":0.5409334627099476,"score_spread":0.20098441599927147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125219284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.859337,0.0009430081,0.0058453796,0.124139555,0.0042871777,0.0032763707,0.00012566113,0.00003202417,0.002013844],"genre_scores_gemma":[0.85039306,0.00041720323,0.13970543,0.0053006858,0.003810883,0.00021476667,0.000013246212,0.000053500866,0.00009125138],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9937104,0.0011337766,0.003932751,0.00037433914,0.00031630666,0.0005324161],"domain_scores_gemma":[0.89865434,0.09603076,0.0016292421,0.00041472403,0.0027043326,0.00056657527],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.015113524,0.00016900354,0.0012045027,0.00020716914,0.00007733871,0.000029733174,0.00028082373,0.00043487738,0.00020305731],"category_scores_gemma":[0.2565468,0.00013559764,0.00053922995,0.0002500752,0.00026750588,0.0002574272,0.00008394402,0.0016553457,0.000045801942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011533753,0.0017680537,0.3197316,0.00013307114,0.00007168263,0.00046590963,0.00008796303,0.0000035119206,0.0001365094,0.00011930951,0.038054142,0.6382749],"study_design_scores_gemma":[0.011381652,0.012684481,0.90051407,0.00039392928,0.00025708205,0.0046530003,0.00045484625,0.00063503726,0.000019930458,0.0030301004,0.06578775,0.0001881571],"about_ca_topic_score_codex":0.000030841256,"about_ca_topic_score_gemma":0.000014818665,"teacher_disagreement_score":0.63808674,"about_ca_system_score_codex":0.00010811418,"about_ca_system_score_gemma":0.001278328,"threshold_uncertainty_score":0.7497156},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","score_opus":0.0317431920055709,"score_gpt":0.327746268557953,"score_spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125620887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861064,0.00008037547,0.000029323826,0.0012603024,0.00012222835,0.01065909,0.00018105566,0.000018316392,0.0015429087],"genre_scores_gemma":[0.9924694,0.000118228796,0.00048422947,0.0002472261,0.0002929461,0.00598994,0.000012433144,0.000047391208,0.00033825505],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9983104,0.00028604502,0.00034372698,0.00029445052,0.0002965003,0.0004688609],"domain_scores_gemma":[0.9988332,0.00029477046,0.00019032467,0.00034932155,0.00023596094,0.00009641372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004283765,0.00021672936,0.0014567061,0.00008817028,0.000031444535,0.000005919117,0.00015160191,0.000117492105,0.0003424112],"category_scores_gemma":[0.000024280613,0.00010693829,0.00013956633,0.00016125411,0.00023586857,0.000034811754,0.000014578484,0.00018500206,0.000005137856],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9043131,0.001344048,0.08148384,0.000030326328,0.00080757705,0.000019322293,0.0048755277,5.714757e-7,0.000038994556,0.000019111632,0.00011944926,0.0069481684],"study_design_scores_gemma":[0.7753505,0.032881625,0.19053718,0.00011370447,0.00028636077,0.0000052371292,0.00015475294,0.000011443968,0.00020606918,0.000017644581,0.00033458762,0.00010086752],"about_ca_topic_score_codex":0.0012226381,"about_ca_topic_score_gemma":0.0011301577,"teacher_disagreement_score":0.12896255,"about_ca_system_score_codex":0.00063356105,"about_ca_system_score_gemma":0.00079115096,"threshold_uncertainty_score":0.4360817},"labels":[],"label_agreement":null},{"id":"W2125819588","doi":"10.1074/mcp.m112.019919","title":"Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways","year":2012,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lapatinib; Phosphorylation; Profiling (computer programming); Chemistry; Computational biology; Cancer research; Pharmacology; Biology; Medicine; Computer science; Internal medicine; Biochemistry; Trastuzumab; Breast cancer; Cancer","score_opus":0.03578254199293283,"score_gpt":0.30133680016272824,"score_spread":0.2655542581697954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2125819588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98287904,0.001632062,0.010672715,0.00015894245,0.00012228206,0.0025976775,0.00001974379,0.000051880645,0.0018656662],"genre_scores_gemma":[0.9723915,0.000026814596,0.0267936,0.00010735128,0.000118239564,0.00026305814,0.00013030664,0.00008923195,0.00007993434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972482,0.00024626878,0.00067910313,0.00037027904,0.00076915056,0.00068703905],"domain_scores_gemma":[0.99866325,0.000045790446,0.00021818174,0.00061374524,0.00020417634,0.00025483905],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014404032,0.00025802822,0.00050446193,0.00023883324,0.000043853765,0.000021376749,0.00021537958,0.00026491983,0.0001725154],"category_scores_gemma":[0.000309928,0.0002603581,0.00016262676,0.000496834,0.00010855046,0.00013104669,0.00011774369,0.000544706,0.000044424505],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000206761,0.00034523438,0.06074368,0.00045469668,0.000036728678,0.00008295065,0.0005672396,0.00019043878,0.93575066,0.00031250648,0.00003549694,0.0012735887],"study_design_scores_gemma":[0.0014459603,0.00025558783,0.0015425467,0.00024110747,0.000035646055,0.000008380172,0.00013522804,0.0029157458,0.99242824,0.00025849,0.000503083,0.00023000875],"about_ca_topic_score_codex":0.00022331269,"about_ca_topic_score_gemma":0.0000046612763,"teacher_disagreement_score":0.059201133,"about_ca_system_score_codex":0.00024787697,"about_ca_system_score_gemma":0.00036928177,"threshold_uncertainty_score":0.99998486},"labels":[],"label_agreement":null},{"id":"W2127154017","doi":"10.1016/j.ctrv.2009.08.001","title":"Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions","year":2009,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Pfizer","keywords":"Lapatinib; Medicine; Trastuzumab; Tyrosine kinase; Receptor tyrosine kinase; Breast cancer; Tyrosine-kinase inhibitor; ErbB; Monoclonal antibody; Cancer research; Cancer; Pharmacology; Internal medicine; Receptor; Immunology; Antibody","score_opus":0.08835437902740187,"score_gpt":0.4363174976594466,"score_spread":0.34796311863204477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127154017","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023762193,0.99,3.9800844e-7,0.0011387636,0.0013633895,0.0056112153,0.0014258875,0.00008709894,0.000349462],"genre_scores_gemma":[0.0000015179044,0.99123573,0.00008468509,0.00010831982,0.003741029,0.0028499952,0.0004047716,0.00011582621,0.0014581309],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959797,0.0003494605,0.0010576113,0.0012725798,0.0004366808,0.0009039633],"domain_scores_gemma":[0.9975273,0.00007831456,0.0005105413,0.0008544147,0.0001488652,0.0008805487],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027850928,0.0011360057,0.0040463917,0.0003923787,0.00026171328,0.000105872576,0.00014091577,0.00034270424,0.0006545746],"category_scores_gemma":[0.00001876416,0.0007380182,0.00061719184,0.0009881448,0.00020462577,0.00013256955,0.00009885655,0.0007524151,0.00006257434],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002711262,0.00026629167,0.0005707325,0.028223643,0.00028616568,0.000033485874,0.00010403792,2.2402528e-8,5.60484e-7,0.000008983382,0.01670652,0.9537724],"study_design_scores_gemma":[0.0010685286,0.00031510904,0.00055567146,0.05066307,0.0044891387,0.00016203972,0.000016071433,5.846521e-7,0.0000021211497,0.0000032180615,0.9421912,0.0005332504],"about_ca_topic_score_codex":0.0018827834,"about_ca_topic_score_gemma":0.00058365555,"teacher_disagreement_score":0.9532392,"about_ca_system_score_codex":0.004031075,"about_ca_system_score_gemma":0.0020380593,"threshold_uncertainty_score":0.9997923},"labels":[],"label_agreement":null},{"id":"W2127376103","doi":"10.1158/1078-0432.ccr-05-0754","title":"Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Research Manitoba","keywords":"Apoptosis; Trastuzumab; Etoposide; Cancer research; Cell culture; Medicine; Chemistry; Breast cancer; Biology; Cancer; Chemotherapy; Internal medicine","score_opus":0.19438652816364593,"score_gpt":0.5409689330364883,"score_spread":0.34658240487284236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127376103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786486,0.0011742507,0.0003400614,0.0066288877,0.00076594,0.0016437158,0.00010110813,0.00019053453,0.0105068805],"genre_scores_gemma":[0.97898287,0.00086373393,0.0029887839,0.00087502296,0.0029332908,0.00027490116,0.000046188507,0.0001747172,0.012860504],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.990336,0.0015037721,0.0013993409,0.0016610717,0.0030524998,0.0020473301],"domain_scores_gemma":[0.9939799,0.002117963,0.00014584571,0.001420345,0.0010747313,0.0012612498],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0061304113,0.00040024004,0.0009956335,0.00044920674,0.0005568197,0.00027070876,0.00063882093,0.00052580616,0.0023894848],"category_scores_gemma":[0.001727669,0.00035581674,0.0003412188,0.0013004543,0.00082768826,0.00018000454,0.0007374668,0.0028161777,0.0008857065],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074071385,0.000365575,0.0038625523,0.00021256547,0.000026636946,0.000032647305,0.00010462371,0.000077533645,0.56200045,0.000014204287,0.41470793,0.01785458],"study_design_scores_gemma":[0.0023813655,0.0009993502,0.004562179,0.002725702,0.000043693224,0.000010354993,0.00029839607,0.00047891864,0.8936335,0.00015339725,0.09421549,0.0004976992],"about_ca_topic_score_codex":0.006447995,"about_ca_topic_score_gemma":0.00006851084,"teacher_disagreement_score":0.33163303,"about_ca_system_score_codex":0.0009222298,"about_ca_system_score_gemma":0.0012110764,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W2127462608","doi":"10.1053/j.seminoncol.2004.07.020","title":"Maximizing clinical benefit with trastuzumab","year":2004,"lang":"en","type":"review","venue":"Seminars in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Vinorelbine; Oncology; Metastatic breast cancer; Internal medicine; Taxane; Capecitabine; Breast cancer; Chemotherapy; Gemcitabine; Clinical trial; Cancer; Colorectal cancer","score_opus":0.17623130803002254,"score_gpt":0.5363274342574647,"score_spread":0.36009612622744214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127462608","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006723323,0.97785324,0.000013190027,0.00039766578,0.00060446246,0.0019174712,0.000020773528,0.00006288511,0.019063072],"genre_scores_gemma":[0.000012567621,0.99066335,0.005594985,0.00022158556,0.00063745154,0.00045225272,0.0000948467,0.00015882138,0.0021641504],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99555314,0.0004099705,0.0015236709,0.0010124539,0.00056688633,0.00093388103],"domain_scores_gemma":[0.99688333,0.0013378393,0.00039765367,0.0008770732,0.000118510725,0.00038556132],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001990373,0.00053795124,0.004351234,0.00057188503,0.000051287774,0.00001571997,0.0005125382,0.0015879557,0.0004958661],"category_scores_gemma":[0.000520955,0.00040216726,0.0004942119,0.00085524993,0.000541638,0.000034983128,0.00021431856,0.0034580666,0.0003100894],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017875587,0.0005113414,0.00031243084,0.014653869,0.00017081923,0.004632958,0.00010155565,0.0000018271948,6.7137314e-8,0.0001140451,0.0015587282,0.9777636],"study_design_scores_gemma":[0.0018340746,0.004645756,0.000046632875,0.08123073,0.00059344707,0.0029267133,0.00007080985,0.0000016295339,4.071354e-7,0.000099020974,0.9082304,0.0003203428],"about_ca_topic_score_codex":0.00009520855,"about_ca_topic_score_gemma":0.00025476076,"teacher_disagreement_score":0.9774433,"about_ca_system_score_codex":0.005213581,"about_ca_system_score_gemma":0.008918379,"threshold_uncertainty_score":0.999843},"labels":[],"label_agreement":null},{"id":"W2128338277","doi":"10.1186/1471-2407-12-500","title":"Identification of PADI2 as a potential breast cancer biomarker and therapeutic target","year":2012,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; U.S. Army Medical Research Acquisition Activity; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of Science; National Cancer Institute; National Institutes of Health; U.S. Department of Energy; U.S. Department of Defense","keywords":"Breast cancer; Cancer research; Cancer; Cell cycle; Surgical oncology; Biology; Medicine; Oncology; Internal medicine","score_opus":0.05164357233437762,"score_gpt":0.396314670605598,"score_spread":0.3446710982712204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128338277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647472,0.029916566,0.00053886604,0.0023052576,0.00078423537,0.0007079585,0.00021617278,0.000041383515,0.000742356],"genre_scores_gemma":[0.9957204,0.0010929662,0.00010498455,0.00028653236,0.00050163403,0.00023934928,0.000007480208,0.000034482193,0.0020121601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99858075,0.00007066898,0.00028447117,0.0002330395,0.00045903967,0.00037202155],"domain_scores_gemma":[0.99916637,0.000031087882,0.000111904235,0.00029590353,0.00018683997,0.00020788636],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042239722,0.00012770994,0.00023060717,0.00011040144,0.000052119736,0.000017859571,0.00008748114,0.00009308854,0.003086627],"category_scores_gemma":[0.000024978972,0.000107183005,0.0000687995,0.0002492824,0.00016957172,0.000096828706,0.000044915123,0.00013099382,0.000037569953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078513846,0.00019868375,0.64761823,0.00062583096,0.00021475655,0.0000030548754,0.0005875372,0.000014479069,0.27548087,0.00016517843,0.0037843978,0.07052184],"study_design_scores_gemma":[0.0011246217,0.00003986296,0.96476436,0.00015319524,0.00015072376,0.000079730504,0.00013209223,0.0008294759,0.021759767,0.00010036274,0.010715438,0.00015037705],"about_ca_topic_score_codex":0.0022349705,"about_ca_topic_score_gemma":0.0001285477,"teacher_disagreement_score":0.31714612,"about_ca_system_score_codex":0.0002111622,"about_ca_system_score_gemma":0.00046656895,"threshold_uncertainty_score":0.99782467},"labels":[],"label_agreement":null},{"id":"W2128639169","doi":"10.1093/annonc/12.suppl_1.s43","title":"Pharmacologic insights into the future of trastuzumab","year":2001,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation; Hamilton Regional Laboratory Medicine Program; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Clinical trial; Regimen; Breast cancer; Pharmacokinetics; Metastatic breast cancer; Pharmacodynamics; Pharmacology; Internal medicine; Cancer","score_opus":0.31034816364364753,"score_gpt":0.5674658620510857,"score_spread":0.2571176984074382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128639169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017512133,0.97431266,0.0000022980978,0.0035346088,0.0006475697,0.0013893275,0.00001254691,0.000018534505,0.019907337],"genre_scores_gemma":[0.00030025776,0.9960494,0.000076708624,0.0010020855,0.0014226998,0.00019934803,0.000040264178,0.000045796263,0.0008634476],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968385,0.0008073493,0.0010318744,0.00038441995,0.0005042538,0.00043358872],"domain_scores_gemma":[0.9972771,0.0007749642,0.00067808677,0.000612554,0.0004856832,0.00017160947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009392479,0.00033748202,0.0029151824,0.00034374566,0.00005740291,0.000003871006,0.00068546477,0.00077895867,0.0010805547],"category_scores_gemma":[0.00015712056,0.00018525572,0.00069989456,0.00088723574,0.00056053087,0.000028907618,0.00018152282,0.0012160711,0.00007778567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008728527,0.00041264002,0.000005079907,0.01080034,0.00047579996,0.00018753708,0.0004582237,2.2166795e-7,0.0000095895675,0.00017851229,0.05541376,0.931971],"study_design_scores_gemma":[0.00050070387,0.0038453592,0.00001314503,0.0025536683,0.0006305848,0.00015587285,0.00014358308,0.0000011875538,0.000062091596,0.00021211054,0.99175006,0.00013166125],"about_ca_topic_score_codex":0.000084443695,"about_ca_topic_score_gemma":0.000056014665,"teacher_disagreement_score":0.9363363,"about_ca_system_score_codex":0.00021830802,"about_ca_system_score_gemma":0.002744631,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W2128958667","doi":"10.1503/cmaj.061011","title":"Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis","year":2007,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Fonds de Recherche du Québec - Santé; McGill University; McGill University Health Centre","funders":"","keywords":"Concordance; Breast cancer; Medicine; Immunohistochemistry; Trastuzumab; Fluorescence in situ hybridization; Gold standard (test); Internal medicine; In situ hybridization; Oncology; Cancer; Pathology; Biology","score_opus":0.07575837233168622,"score_gpt":0.4433496187504585,"score_spread":0.3675912464187723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128958667","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014366564,0.9896783,0.00013368769,0.0029754697,0.00023479425,0.005702488,0.000941306,0.000016846538,0.00031566384],"genre_scores_gemma":[0.000008862745,0.99400043,0.00007874779,0.0032401897,0.0011185559,0.0010966795,0.00011171661,0.00006869684,0.00027612],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9938649,0.0012929859,0.0014870162,0.00044603457,0.00196529,0.0009437792],"domain_scores_gemma":[0.9892589,0.004011817,0.0010840677,0.00024323245,0.002175448,0.0032265598],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.012669587,0.00041255075,0.0047889864,0.0009647607,0.0003290694,0.00013205032,0.000292905,0.00088106404,0.0007531193],"category_scores_gemma":[0.013185715,0.00031697858,0.0008435008,0.0023457385,0.00007292717,0.000066551955,0.000030840834,0.0021225102,0.000026016798],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000003872346,0.000017857765,0.00093095005,0.57116354,0.0045623207,0.0003236667,0.000015626407,9.8927e-8,1.1638892e-8,0.0000071916015,0.004004181,0.41897067],"study_design_scores_gemma":[0.0004401591,0.00008177846,0.0008117471,0.6027372,0.035119407,0.0029822749,0.000019898967,0.000029763449,2.6912726e-8,0.0000033223846,0.35750628,0.000268166],"about_ca_topic_score_codex":0.0057930904,"about_ca_topic_score_gemma":0.01153245,"teacher_disagreement_score":0.4187025,"about_ca_system_score_codex":0.010111232,"about_ca_system_score_gemma":0.016166737,"threshold_uncertainty_score":0.99992824},"labels":[],"label_agreement":null},{"id":"W2128964123","doi":"10.1093/annonc/mdq027","title":"Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Refractory (planetary science); Follicular lymphoma; Gastroenterology; Neutropenia; Adverse effect; Lymphoma; Cohort; Pharmacokinetics; CD20; Toxicity; Phases of clinical research; Oncology; Surgery","score_opus":0.06645319039979994,"score_gpt":0.4201120801170726,"score_spread":0.35365888971727266,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128964123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948375,0.000099259196,0.0000011123402,0.00048747333,0.00014265355,0.0014988818,0.00006728959,0.000015764253,0.0028500669],"genre_scores_gemma":[0.99926645,0.000057277182,0.00023671037,0.00014328898,0.00005152953,0.000052037718,0.000034469707,0.000038333706,0.00011992842],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968682,0.0002926726,0.0011237152,0.00043802662,0.00083028263,0.0004470981],"domain_scores_gemma":[0.99688375,0.0002669411,0.00065475266,0.0008461792,0.0011735953,0.00017476398],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011972993,0.00021332545,0.0011818812,0.0005344402,0.000043908127,0.0000029660453,0.0003258777,0.00027747612,0.00018742615],"category_scores_gemma":[0.00089141726,0.00017343652,0.00010957882,0.0005735131,0.00036793487,0.000084911495,0.0001652676,0.00043620716,0.000005374223],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15482445,0.21334113,0.3203138,0.00096205267,0.0015359839,0.0012087816,0.015083832,0.000018282662,0.077676274,0.00020702882,0.014735062,0.20009331],"study_design_scores_gemma":[0.2016475,0.25674537,0.49723643,0.00036447504,0.00014877475,0.00001962706,0.000978971,0.00003756288,0.016774733,0.000060464976,0.025697298,0.000288785],"about_ca_topic_score_codex":0.0012064992,"about_ca_topic_score_gemma":0.0009290901,"teacher_disagreement_score":0.19980453,"about_ca_system_score_codex":0.00007131648,"about_ca_system_score_gemma":0.0009868981,"threshold_uncertainty_score":0.70725363},"labels":[],"label_agreement":null},{"id":"W2129172826","doi":"10.1161/circulationaha.105.571414","title":"Altered Expression of Disintegrin Metalloproteinases and Their Inhibitor in Human Dilated Cardiomyopathy","year":2006,"lang":"en","type":"article","venue":"Circulation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; St. Michael's Hospital","funders":"","keywords":"Disintegrin; ADAM10; Integrin; Matrix metalloproteinase; Medicine; Dilated cardiomyopathy; Cell biology; Metalloproteinase; Internal medicine; Receptor; Pathology; Biology; Heart failure","score_opus":0.029393268866539014,"score_gpt":0.3083434272021627,"score_spread":0.27895015833562364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129172826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99765486,0.00058219983,0.00031116046,0.000064331434,0.00003848763,0.000489834,0.0000060761226,0.000024406156,0.0008286215],"genre_scores_gemma":[0.99962324,0.00000676761,0.000083288214,0.000006090683,0.0001402751,0.00002981829,0.00006330796,0.000015757561,0.000031455726],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991222,0.00007302876,0.00026564932,0.00019733765,0.00020550175,0.00013629004],"domain_scores_gemma":[0.9995887,0.000029425095,0.00006215199,0.00020072126,0.00007721226,0.00004176439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024320683,0.00009183785,0.0002352891,0.00017516901,0.000032145002,0.000010882431,0.000034451146,0.00007393439,0.00003480095],"category_scores_gemma":[0.000054297067,0.00007277114,0.00004720169,0.00020774617,0.00006327886,0.000074002965,0.000029112089,0.00012640377,0.000001384252],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036424542,0.000054008244,0.2090423,0.00010716522,0.0000047268672,0.000004839569,0.00014119555,0.000076064025,0.7884183,0.0000666247,0.00003836736,0.0020099797],"study_design_scores_gemma":[0.0006989581,0.000044377328,0.631249,0.0002964679,0.000007772409,0.0000065232693,0.000056211516,0.0003965596,0.3665624,0.00049990794,0.00012622571,0.000055585213],"about_ca_topic_score_codex":0.00072530005,"about_ca_topic_score_gemma":0.000050854684,"teacher_disagreement_score":0.4222067,"about_ca_system_score_codex":0.000093053015,"about_ca_system_score_gemma":0.000041785068,"threshold_uncertainty_score":0.2967521},"labels":[],"label_agreement":null},{"id":"W2129233814","doi":"10.1371/journal.pone.0010789","title":"Epistatic and Functional Interactions of Catechol-O-Methyltransferase (COMT) and AKT1 on Neuregulin1-ErbB Signaling in Cell Models","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Mental Health; Medical Research Council; National Institutes of Health; School of Medicine, New York University; University College, Oxford; York University","keywords":"Catechol-O-methyl transferase; Phosphorylation; Neuregulin; Signal transduction; AKT1; ErbB; Cell biology; Chemistry; MAPK/ERK pathway; HEK 293 cells; Cancer research; Biology; Endocrinology; Protein kinase B; Receptor; Biochemistry; Genotype; Gene","score_opus":0.11362211924003425,"score_gpt":0.3115481540192685,"score_spread":0.19792603477923426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129233814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967107,0.00013253895,0.00014194199,0.0012383239,0.000033066954,0.00036136206,0.000024376759,0.000019945837,0.0013377267],"genre_scores_gemma":[0.997413,0.00015468373,0.0016535645,0.00017595578,0.00006666848,0.000034172568,0.000013850956,0.000023212784,0.000464931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989312,0.00003792923,0.00026005262,0.00024303456,0.00034914602,0.00017863578],"domain_scores_gemma":[0.9992142,0.00031422352,0.00002991942,0.00019814116,0.00010030073,0.00014323121],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025709652,0.000105320025,0.00025101824,0.00022509198,0.000039866096,0.000014465047,0.000041856758,0.0000662453,0.00030703278],"category_scores_gemma":[0.00010716644,0.00010044171,0.000021466467,0.0001862391,0.000116833224,0.00008571836,0.000016759577,0.00072265475,0.000009281852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041631013,0.0013001114,0.004538462,0.00054497074,0.00004529967,0.000019577303,0.00039505714,0.00010265749,0.99120533,0.00014460865,0.000066201894,0.0012214384],"study_design_scores_gemma":[0.0035982637,0.0009227578,0.013290219,0.00094177306,0.00018050517,0.000025471976,0.00018848659,0.022627527,0.95572877,0.0021443213,0.0001104216,0.00024145987],"about_ca_topic_score_codex":0.00016993158,"about_ca_topic_score_gemma":0.00011711634,"teacher_disagreement_score":0.035476513,"about_ca_system_score_codex":0.000031647312,"about_ca_system_score_gemma":0.0000942396,"threshold_uncertainty_score":0.4095894},"labels":[],"label_agreement":null},{"id":"W2129508275","doi":"10.14694/edbook_am.2015.35.e41","title":"Neoadjuvant and Adjuvant Therapy for HER2 Positive Disease","year":2015,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Clinical trial; Disease; Chemotherapy; Adjuvant; Metastatic breast cancer; Pertuzumab; Adjuvant therapy; Cancer; Targeted therapy","score_opus":0.30777071585932586,"score_gpt":0.6224921145437846,"score_spread":0.31472139868445875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129508275","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047499467,0.962302,0.00002898282,0.03262757,0.00039677732,0.0027811076,0.00030341325,0.000018168012,0.0014944227],"genre_scores_gemma":[0.000013542823,0.9686348,0.0075295307,0.0104577895,0.0019417626,0.0009578268,0.0005664943,0.000076209195,0.009822065],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596745,0.0005707418,0.0016982568,0.0007855772,0.0005605419,0.0004174464],"domain_scores_gemma":[0.98730594,0.008845156,0.0013176951,0.00049682014,0.0009708525,0.0010635346],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0022187275,0.00038291307,0.0041681537,0.00006306208,0.00008095549,0.000009742988,0.00028348563,0.0004026704,0.000315116],"category_scores_gemma":[0.0014794206,0.0002929014,0.0017797033,0.00023327992,0.003337992,0.00005030027,0.00011343156,0.00094596547,0.000033120148],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033173422,0.0010077199,0.00046727125,0.0016375533,0.00063224585,0.0000025669578,0.00013716544,6.617326e-8,9.676116e-8,0.00017117157,0.18898045,0.806632],"study_design_scores_gemma":[0.0014882465,0.0038959887,0.003350817,0.002091225,0.0009157907,0.000021746275,0.00019174097,0.000011632816,1.250891e-7,0.00034765896,0.98743755,0.0002474778],"about_ca_topic_score_codex":0.000086155436,"about_ca_topic_score_gemma":0.0000021127805,"teacher_disagreement_score":0.8063845,"about_ca_system_score_codex":0.0006473897,"about_ca_system_score_gemma":0.033754546,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W2129726505","doi":"10.1158/1078-0432.ccr-05-1109","title":"Strategies for Delaying or Treating<i>In vivo</i>Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Oncosuisse; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; National Science Foundation","keywords":"Trastuzumab; In vivo; Breast cancer; Medicine; Acquired resistance; Human breast; Oncology; Cancer; Internal medicine; Cancer research; Biology; Biotechnology","score_opus":0.276028954774144,"score_gpt":0.5780301207621373,"score_spread":0.3020011659879933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129726505","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9706702,0.0021063222,0.00009867468,0.013112736,0.00033454446,0.0043440294,0.0004569888,0.00009834551,0.008778142],"genre_scores_gemma":[0.97884136,0.0006017819,0.00077888614,0.00048332257,0.0021018318,0.0051357932,0.000020125479,0.0001396983,0.01189721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923752,0.00070558436,0.0017167472,0.0014034521,0.0017144032,0.0020846399],"domain_scores_gemma":[0.99554217,0.0020011417,0.00012946367,0.0008372295,0.00090653467,0.0005834792],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059699123,0.00036745946,0.0011030626,0.00087322557,0.00032231165,0.00019986345,0.0006886587,0.00038450176,0.0015840447],"category_scores_gemma":[0.000690495,0.0003116832,0.00024073392,0.0026794479,0.00067640364,0.00022483696,0.000214684,0.0012864138,0.000022266979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043593325,0.003503259,0.6226859,0.0035442866,0.00019956798,0.0012694254,0.0018008333,0.0011999657,0.03175789,0.0033765796,0.23968458,0.047384396],"study_design_scores_gemma":[0.034318686,0.00557103,0.7129303,0.0115643125,0.00011780632,0.000044294502,0.0060278773,0.0012039925,0.007958958,0.0050059007,0.21337196,0.0018848431],"about_ca_topic_score_codex":0.031468928,"about_ca_topic_score_gemma":0.25506195,"teacher_disagreement_score":0.22359303,"about_ca_system_score_codex":0.0024788608,"about_ca_system_score_gemma":0.004561378,"threshold_uncertainty_score":0.99993354},"labels":[],"label_agreement":null},{"id":"W2131178461","doi":"10.1634/theoncologist.2010-0137","title":"Treatment Beyond Progression: Is It Moving from Belief to Evidence?","year":2010,"lang":"en","type":"letter","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; MEDLINE; Internal medicine; Family medicine; Cancer","score_opus":0.17719670831203707,"score_gpt":0.4723174421791335,"score_spread":0.2951207338670965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131178461","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004025612,0.0022165591,0.000009061978,0.9682551,0.0012220059,0.0026189045,0.0001714337,0.00010986318,0.021371432],"genre_scores_gemma":[0.002609836,0.0009955929,0.0025687073,0.89580494,0.018522747,0.0014899123,0.00019518004,0.00013125238,0.07768183],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612296,0.00028609324,0.0004889391,0.00089840253,0.0013448809,0.00085874327],"domain_scores_gemma":[0.995799,0.0014975067,0.00021314812,0.0020023088,0.0002151642,0.00027283968],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.000620178,0.00050999166,0.000896127,0.0001442987,0.00029249038,0.00013479471,0.00096384634,0.0017649942,0.006573674],"category_scores_gemma":[0.00072297,0.00027960358,0.00026802026,0.000288596,0.0005526681,0.000051553074,0.00044495557,0.0048365216,0.0026165748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019282279,0.00010650049,0.0006398753,0.00009342603,0.00014954926,0.002094521,0.0010478038,2.9677207e-7,0.0007517574,0.0000016971585,0.92232144,0.07260029],"study_design_scores_gemma":[0.0006327607,0.0027446747,0.0005022687,0.0011244192,0.00029449674,0.00008465634,0.00010341214,0.000012153116,0.0018025782,0.00012670338,0.9922872,0.0002846578],"about_ca_topic_score_codex":0.0035100405,"about_ca_topic_score_gemma":0.00057332206,"teacher_disagreement_score":0.07245019,"about_ca_system_score_codex":0.0018833694,"about_ca_system_score_gemma":0.0015874007,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2131281105","doi":"10.18632/oncotarget.1170","title":"A Tumor initiating cell-enriched prognostic signature for HER2+:ERα− breast cancer; rationale, new features, controversies and future directions","year":2013,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University Health Network","funders":"Government of Ontario","keywords":"Medicine; Breast cancer; Cancer research; Oncology; Cancer; Internal medicine","score_opus":0.014213901404842072,"score_gpt":0.2996179213194829,"score_spread":0.2854040199146408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131281105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44596833,0.11732205,0.00063998194,0.38785776,0.0037786942,0.019917013,0.0023497718,0.00082248915,0.021343902],"genre_scores_gemma":[0.8969885,0.0037845469,0.016658936,0.014557544,0.016432991,0.0041892584,0.00086269615,0.00027720994,0.04624828],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984114,0.00005682309,0.00023843966,0.00041314343,0.0004054709,0.00047470583],"domain_scores_gemma":[0.9982919,0.0005690276,0.00010952845,0.00021146282,0.00044010542,0.00037799502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016321722,0.00023502005,0.00036600122,0.00011791132,0.0002528908,0.00011284778,0.00010142497,0.00016309065,0.0014881205],"category_scores_gemma":[0.0003588727,0.00019759094,0.00009800728,0.00030960204,0.00007863779,0.00022295723,0.000047573205,0.0005272243,0.00002722258],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003849228,0.0002324244,0.05865707,0.0007335386,0.00019518228,0.00003175119,0.0011353728,0.000012978442,0.011936201,0.0003574866,0.90688616,0.019436916],"study_design_scores_gemma":[0.0053223437,0.000490033,0.36043844,0.0002686369,0.00020852782,0.00020953831,0.0013942453,0.0005228585,0.00079893076,0.000619807,0.62929386,0.0004327664],"about_ca_topic_score_codex":0.0015820772,"about_ca_topic_score_gemma":0.0004487456,"teacher_disagreement_score":0.4510202,"about_ca_system_score_codex":0.00025086242,"about_ca_system_score_gemma":0.00097164785,"threshold_uncertainty_score":0.99942464},"labels":[],"label_agreement":null},{"id":"W2131551233","doi":"10.3747/co.20.1523","title":"Outcomes of her2-positive Early-Stage Breast Cancer in the Trastuzumab Era: A Population-Based Study of Canadian Patients","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Institute for Clinical Evaluative Sciences; McMaster University; University of Toronto","funders":"","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Oncology; Confidence interval; Progesterone receptor; Human Epidermal Growth Factor Receptor 2; Estrogen receptor; Hormone receptor; Proportional hazards model; Stage (stratigraphy); Cancer; Population; Gynecology","score_opus":0.08963955385321012,"score_gpt":0.43641089297444924,"score_spread":0.34677133912123914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131551233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949661,0.00007215768,0.0000010726473,0.0018176992,0.00030223533,0.0021380354,0.000386042,0.0000050328613,0.00031163325],"genre_scores_gemma":[0.99934137,0.000012517516,0.000010490659,0.00012323391,0.00003880825,0.00039084427,0.000037307695,0.0000143026045,0.000031150248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982561,0.00033635486,0.0004284671,0.00021381902,0.00043203225,0.00033325714],"domain_scores_gemma":[0.9988278,0.00023745997,0.00014067469,0.00027358593,0.00037043443,0.00015000565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026027908,0.00012833618,0.00045009612,0.0005294998,0.000039250095,0.000004926223,0.00019862273,0.00007915032,0.0006668591],"category_scores_gemma":[0.00009076442,0.00008887869,0.0000574494,0.000578232,0.000072076546,0.0000433949,0.000024069433,0.00036351025,0.000009970671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007349737,0.0022349686,0.96845055,0.000068438174,0.000043833723,0.00000643347,0.0035555912,0.000030636354,0.000007317621,0.000011194812,0.00044132984,0.025076216],"study_design_scores_gemma":[0.0030568023,0.0014146562,0.99348,0.00008331344,0.000038441507,7.047399e-7,0.00126058,0.00010512534,0.0000110620085,0.000005928553,0.00047428635,0.00006906267],"about_ca_topic_score_codex":0.6876275,"about_ca_topic_score_gemma":0.5526899,"teacher_disagreement_score":0.13493757,"about_ca_system_score_codex":0.0009568422,"about_ca_system_score_gemma":0.0010483988,"threshold_uncertainty_score":0.73016393},"labels":[],"label_agreement":null},{"id":"W2131849559","doi":"10.6000/1929-2279.2012.01.01.14","title":"Present and Emerging Targeted Therapy for Metastatic Breast Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lapatinib; Trastuzumab; Targeted therapy; Metastatic breast cancer; Bevacizumab; Medicine; Breast cancer; Cancer research; Cancer; Epidermal growth factor receptor; Vascular endothelial growth factor; Estrogen receptor; Clinical trial; Oncology; Internal medicine; Chemotherapy; VEGF receptors","score_opus":0.1362072820073554,"score_gpt":0.5161103061489057,"score_spread":0.3799030241415503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131849559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7718494,0.16959165,0.00012060852,0.05594251,0.0005787654,0.0014846374,0.00019758685,0.000018527342,0.00021632604],"genre_scores_gemma":[0.9474904,0.046185676,0.0012394397,0.0003372718,0.0035208035,0.0003522729,0.000005718943,0.00007648811,0.00079192757],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961384,0.00029470603,0.0005420137,0.00021570915,0.0017144851,0.001094683],"domain_scores_gemma":[0.99642503,0.0004738692,0.00020377923,0.00025213792,0.0018702192,0.00077498116],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004100147,0.00018546302,0.00053006894,0.00057293003,0.00020505193,0.000090421745,0.0002756859,0.00006555066,0.0017022792],"category_scores_gemma":[0.00023013918,0.00012832425,0.00015528934,0.000557686,0.00028243958,0.00045109092,0.000101720856,0.00085177575,0.0000059457107],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008069344,0.00090917863,0.25510332,0.0012638286,0.0021315531,0.00007644864,0.0026338722,0.00006592796,0.08661227,0.00024438775,0.2490981,0.39379176],"study_design_scores_gemma":[0.009529737,0.0017671371,0.15717557,0.0012561996,0.00022889907,0.00057140575,0.0017195853,0.0006648645,0.086011544,0.0008577185,0.73981667,0.0004006837],"about_ca_topic_score_codex":0.00080973434,"about_ca_topic_score_gemma":0.000044207813,"teacher_disagreement_score":0.49071854,"about_ca_system_score_codex":0.00049058284,"about_ca_system_score_gemma":0.0012138571,"threshold_uncertainty_score":0.9992103},"labels":[],"label_agreement":null},{"id":"W2132557004","doi":"10.1158/1078-0432.ccr-06-1539","title":"First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Rash; Pharmacokinetics; Adverse effect; Gastroenterology; Internal medicine; Nausea; Dosing; Pharmacodynamics; Cmax; Toxicity; Pharmacology","score_opus":0.14627582029163708,"score_gpt":0.5347873946819192,"score_spread":0.38851157439028206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132557004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99526775,0.00044235037,0.000008388403,0.0008391081,0.00013795504,0.0027838955,0.00002638375,0.000010177902,0.00048397822],"genre_scores_gemma":[0.99904436,0.00042678017,0.00011878908,0.00007225881,0.00011783486,0.00007864534,0.00000211555,0.000045397614,0.00009382299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939594,0.00072711846,0.0015242059,0.00066326646,0.002327927,0.0007980845],"domain_scores_gemma":[0.99558604,0.0018458064,0.00024546686,0.0009087343,0.0010694137,0.0003445519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007431003,0.0001951778,0.000836161,0.00023749155,0.00013720582,0.000017156655,0.00052195037,0.00012934706,0.00017319105],"category_scores_gemma":[0.001515948,0.0001255723,0.00008679118,0.0011982861,0.0014335493,0.000069814494,0.0007135029,0.0015358926,0.0000016444017],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007918871,0.0030928773,0.95741993,0.0005726839,0.000060453527,0.000026554433,0.0008301279,0.00023079415,0.00047787366,0.000005057582,0.00013242109,0.029232351],"study_design_scores_gemma":[0.010113853,0.0049965,0.9763444,0.0015917792,0.00003119589,0.0000012743567,0.000831921,0.00013730589,0.0050423,0.00003684484,0.00074564666,0.00012699621],"about_ca_topic_score_codex":0.001307867,"about_ca_topic_score_gemma":0.0020583058,"teacher_disagreement_score":0.029105354,"about_ca_system_score_codex":0.000327796,"about_ca_system_score_gemma":0.00069697667,"threshold_uncertainty_score":0.66727746},"labels":[],"label_agreement":null},{"id":"W2132628497","doi":"10.1093/jnci/djp334","title":"A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Biomarker; Drug development; Food and drug administration; Biomarker discovery; Medicine; Risk analysis (engineering); Drug; Computer science; Computational biology; Biology; Pharmacology; Proteomics","score_opus":0.13847322546901603,"score_gpt":0.4302700547783281,"score_spread":0.29179682930931206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132628497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8624738,0.034731682,0.0000026899313,0.09682009,0.00033555282,0.00030562576,0.000006180423,0.0000054353627,0.005318939],"genre_scores_gemma":[0.98472095,0.012095019,0.0012130529,0.0012277915,0.00016759333,0.000011434754,5.0228897e-7,0.000007750017,0.0005559364],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984997,0.00005247896,0.00029895586,0.00018000233,0.00081431435,0.00015458412],"domain_scores_gemma":[0.9992038,0.00006328503,0.00012360983,0.000054574302,0.00043812377,0.000116591626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088003784,0.00012534075,0.00022633822,0.0002798041,0.000091771544,0.000026132768,0.00009015319,0.000050282688,0.000015906948],"category_scores_gemma":[0.00022451456,0.00008194728,0.000026974958,0.00014742928,0.00015476315,0.00012305859,0.000050540653,0.0002617695,8.0820365e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004523696,0.00081825687,0.028333317,0.00044731377,0.0010055497,0.00030965862,0.04148472,0.00006977021,0.005829263,0.019249849,0.03011656,0.86781204],"study_design_scores_gemma":[0.0021022116,0.000111006564,0.88548285,0.00094935024,0.000018704832,0.000265647,0.0005186439,0.000043631928,0.0014814971,0.0019077844,0.106994666,0.00012403559],"about_ca_topic_score_codex":0.000061571736,"about_ca_topic_score_gemma":0.00033250902,"teacher_disagreement_score":0.867688,"about_ca_system_score_codex":0.0010885464,"about_ca_system_score_gemma":0.00090315443,"threshold_uncertainty_score":0.3341713},"labels":[],"label_agreement":null},{"id":"W2133154503","doi":"10.1007/s10549-009-0364-7","title":"Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; Breast cancer; Cancer research; Gene silencing; Medicine; Oncology; Cancer; Internal medicine; Biology; Gene; Genetics","score_opus":0.047857390762481605,"score_gpt":0.3666355244360162,"score_spread":0.3187781336735346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133154503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9456804,0.009880857,0.0000016829085,0.035664152,0.00007765836,0.0026803182,0.0050807823,0.000051722574,0.00088244595],"genre_scores_gemma":[0.97448635,0.021557204,0.00012009777,0.0006518372,0.0002848825,0.0014953214,0.000038796603,0.000084217754,0.0012812791],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994394,0.00030668685,0.00059061416,0.0015440648,0.0013310541,0.0018335523],"domain_scores_gemma":[0.9972363,0.00016632333,0.000103133985,0.0007011922,0.0003243557,0.0014686708],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066310714,0.0006102115,0.0010195317,0.00090256624,0.00027820363,0.00020353538,0.00024659073,0.00021443563,0.00019960225],"category_scores_gemma":[0.000017711758,0.0005224708,0.000065736866,0.0012352857,0.0005377112,0.00023471357,0.00016129686,0.00077382347,0.0000051493025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019063253,0.0019714925,0.65057707,0.0011648656,0.00044793307,0.0038178428,0.0048809047,0.00008467848,0.03225752,0.00010591883,0.0066941837,0.27893436],"study_design_scores_gemma":[0.009084326,0.00081415416,0.980904,0.002642503,0.00005705675,0.00045020715,0.000884222,0.000033367174,0.0019685857,0.00011924601,0.0025423209,0.0005000034],"about_ca_topic_score_codex":0.07185091,"about_ca_topic_score_gemma":0.122850925,"teacher_disagreement_score":0.33032694,"about_ca_system_score_codex":0.008712465,"about_ca_system_score_gemma":0.0029647343,"threshold_uncertainty_score":0.99972266},"labels":[],"label_agreement":null},{"id":"W2133208325","doi":"10.1093/annonc/mdh031","title":"Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Trastuzumab; Medicine; Internal medicine; Oncology; Chemotherapy; Cisplatin; Lung cancer; Breast cancer; Cancer","score_opus":0.09359131375202594,"score_gpt":0.46961814393279155,"score_spread":0.3760268301807656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133208325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710367,0.0007521531,0.00021502258,0.0016556876,0.0001720039,0.0040304977,0.000036349105,0.000011625381,0.022089975],"genre_scores_gemma":[0.99463844,0.00090440403,0.001353439,0.00046350935,0.00012273838,0.00064914423,0.000011493201,0.00004373403,0.0018130692],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691546,0.00077521184,0.0009249526,0.00038799303,0.0004531819,0.0005431993],"domain_scores_gemma":[0.9976724,0.00082898594,0.0004298276,0.00032839744,0.0005461326,0.00019426302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023456626,0.0002467242,0.0020453637,0.0003267022,0.000043104923,0.0000044319104,0.00016410109,0.0002471567,0.00083827524],"category_scores_gemma":[0.0006677067,0.00017043704,0.00018155151,0.000532261,0.00045498094,0.000058102487,0.000042473992,0.00045606509,0.000002925137],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9727659,0.0051843524,0.0015476611,0.00038010732,0.00039732864,0.00020531724,0.0031035587,0.0000452561,0.003930291,0.00006374787,0.0019388204,0.010437643],"study_design_scores_gemma":[0.9094246,0.035389293,0.00012818455,0.00050033454,0.00025997,0.000033627155,0.00040375543,0.0006179571,0.050610527,0.000026201373,0.0024244008,0.0001811193],"about_ca_topic_score_codex":0.0015932829,"about_ca_topic_score_gemma":0.0012297885,"teacher_disagreement_score":0.06334128,"about_ca_system_score_codex":0.00018878667,"about_ca_system_score_gemma":0.003389291,"threshold_uncertainty_score":0.9178526},"labels":[],"label_agreement":null},{"id":"W2133432676","doi":"10.3747/co.v15i3.300","title":"Trastuzumab: A Cardiologist’s Perspective","year":2008,"lang":"en","type":"editorial","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Human Epidermal Growth Factor Receptor 2; Oncology; Breast cancer; Internal medicine; Monoclonal antibody; Clinical trial; Adjuvant; Perspective (graphical); Cancer; Antibody; Chemotherapy; Immunology; Artificial intelligence","score_opus":0.22241149420100934,"score_gpt":0.5407209232273045,"score_spread":0.3183094290262951,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133432676","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017459085,0.02691624,0.000051007184,0.00093099586,0.92269087,0.0011234684,0.00034711542,0.0001760621,0.04758966],"genre_scores_gemma":[0.0006911548,0.026909899,0.00011289206,0.000041492047,0.96789557,0.00048069132,0.0006484077,0.00011484432,0.003105032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99544567,0.0004867694,0.00055993506,0.0011416428,0.0014141594,0.0009518115],"domain_scores_gemma":[0.99556893,0.0012761201,0.00023518591,0.00082159386,0.0016504667,0.00044768868],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00063332485,0.000518335,0.0018172166,0.00039705425,0.00014024101,0.000016917154,0.00048760514,0.0019675891,0.000437679],"category_scores_gemma":[0.0052318485,0.00045686142,0.00052885304,0.00033236257,0.0009099123,0.000033307115,0.00025544586,0.005105088,0.0006439825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00047637962,0.00050356094,0.00029354365,0.00033442932,0.00026727974,0.0008245386,0.0007963809,7.6094096e-7,0.000008696648,0.000052305924,0.9749725,0.021469628],"study_design_scores_gemma":[0.0023552836,0.003000244,0.00021075498,0.00028641164,0.00025365653,0.00018630904,0.00037427974,0.000007955145,0.000009777753,0.00009888581,0.9928603,0.0003561049],"about_ca_topic_score_codex":0.00031218972,"about_ca_topic_score_gemma":0.00008110254,"teacher_disagreement_score":0.045204725,"about_ca_system_score_codex":0.009784162,"about_ca_system_score_gemma":0.011680484,"threshold_uncertainty_score":0.9997883},"labels":[],"label_agreement":null},{"id":"W2133441588","doi":"10.1186/1746-1596-8-17","title":"Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens","year":2013,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Breast cancer; Classifier (UML); Fluorescence in situ hybridization; Gene duplication; Enumeration; Software; Biology; Computer science; Artificial intelligence; Pathology; Pattern recognition (psychology); Computational biology; Gene; Cancer; Medicine; Mathematics; Genetics","score_opus":0.0668948548099688,"score_gpt":0.3769452753394337,"score_spread":0.3100504205294649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133441588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890913,0.00016290083,0.0006197574,0.008200163,0.0001569673,0.0013607017,0.00032285068,0.000026460762,0.000058902653],"genre_scores_gemma":[0.99848944,0.00017568919,0.00025923704,0.00021325744,0.00011650501,0.0004951113,0.00010283126,0.000019025967,0.0001288753],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99848557,0.0002196884,0.00050100853,0.00026439116,0.0002583536,0.00027098504],"domain_scores_gemma":[0.9972018,0.001620937,0.0002598174,0.00048380025,0.00036251557,0.00007113401],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003539398,0.00012073291,0.0004167093,0.00024417244,0.000054946453,0.000008500476,0.00022913898,0.00013093444,0.001561853],"category_scores_gemma":[0.0015112042,0.000074808966,0.00014930757,0.00087810674,0.00020710882,0.000046323632,0.000051212643,0.0001664119,0.000013369904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003947551,0.00018715275,0.7651552,0.00007667928,0.00033237418,0.0000026182493,0.0010809553,0.00022359217,0.22187194,0.00025297873,0.0067369957,0.0040400634],"study_design_scores_gemma":[0.0006728557,0.00006268957,0.9560981,0.00004497913,0.00039323256,0.0000061354626,0.00008682642,0.0017331478,0.04061449,0.000118217366,0.0001053465,0.00006401572],"about_ca_topic_score_codex":0.0034039377,"about_ca_topic_score_gemma":0.00024126745,"teacher_disagreement_score":0.1909429,"about_ca_system_score_codex":0.00016885501,"about_ca_system_score_gemma":0.00023573883,"threshold_uncertainty_score":0.99935085},"labels":[],"label_agreement":null},{"id":"W2133999831","doi":"10.1158/1078-0432.ccr-03-0785","title":"Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development","year":2004,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Drug development; Mechanism (biology); Surrogate endpoint; Medicine; Drug; Oncology; Intensive care medicine; Pharmacology; Internal medicine","score_opus":0.5913131394625564,"score_gpt":0.6546057634251068,"score_spread":0.06329262396255042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133999831","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00044822128,0.98571104,0.000031548036,0.0035317878,0.0005608471,0.008783014,0.00015508493,0.000034775665,0.0007436642],"genre_scores_gemma":[0.00007289586,0.98617595,0.0037633698,0.00016471608,0.00059084396,0.0064370786,0.00023574146,0.000133398,0.002425985],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.991773,0.0018212096,0.002067676,0.00147096,0.0015422689,0.001324899],"domain_scores_gemma":[0.9907318,0.0067810495,0.00026919524,0.0006344535,0.0007681117,0.00081538846],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.015308747,0.00043874417,0.0026936815,0.0009710575,0.00021513063,0.00006528238,0.0005948842,0.00089641975,0.00085343537],"category_scores_gemma":[0.003421026,0.00036487254,0.0004281132,0.0010603642,0.0009090026,0.00006717769,0.0006144171,0.0028970544,0.00016776088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000549611,0.0003778575,0.00017085053,0.028450694,0.00040199643,0.00020177354,0.00022232407,3.2838264e-7,0.0000015358299,0.00050779537,0.004699688,0.96441555],"study_design_scores_gemma":[0.0036588877,0.00064172957,0.0001172525,0.022276606,0.00012405925,0.00003135523,0.00008572267,0.00001665273,0.000018175037,0.0008871986,0.97183317,0.00030918492],"about_ca_topic_score_codex":0.00046376593,"about_ca_topic_score_gemma":0.0022781072,"teacher_disagreement_score":0.96713346,"about_ca_system_score_codex":0.0048629325,"about_ca_system_score_gemma":0.031122355,"threshold_uncertainty_score":0.9998803},"labels":[],"label_agreement":null},{"id":"W2134169490","doi":"10.5539/gjhs.v7n1p98","title":"Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Global Journal of Health Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Regimen; Oncology; Adjuvant; Internal medicine; Cost effectiveness; Cost-effectiveness analysis; Randomized controlled trial; Clinical trial; Adjuvant therapy; Cohort; Cancer; Gynecology","score_opus":0.11303152186607289,"score_gpt":0.5009627399978569,"score_spread":0.387931218131784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134169490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147576,0.0009736589,0.0019075221,0.0044121183,0.00017465817,0.0008538245,0.00009127233,0.0000023168138,0.00010887353],"genre_scores_gemma":[0.9991017,0.0002458124,0.00026630788,0.0002726308,0.00006760604,0.000039221963,7.152437e-7,0.0000031932104,0.0000027882581],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99758124,0.00021201014,0.00053992093,0.00018734002,0.0010285531,0.0004509085],"domain_scores_gemma":[0.99846315,0.0001917892,0.00034975857,0.00022458173,0.0005443183,0.00022640341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005841658,0.00009456455,0.00060987554,0.00032249527,0.00011990259,0.000024007588,0.00037333163,0.000026363128,0.000014792701],"category_scores_gemma":[0.00012520439,0.000052617608,0.00016960433,0.0024996107,0.00030785787,0.00010753887,0.000018192459,0.00012265511,6.428897e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065215956,0.0003084031,0.6722375,0.0001130992,0.00011591442,0.0000079377105,0.00043634043,0.00092595693,0.0002094235,0.00017274186,0.00006658186,0.3247539],"study_design_scores_gemma":[0.0016830114,0.0021469586,0.9933353,0.0002526107,0.00015114491,0.00015204988,0.00021641482,0.0014406287,0.00014379722,0.00006693344,0.00037111316,0.00004000772],"about_ca_topic_score_codex":0.003922403,"about_ca_topic_score_gemma":0.0005380533,"teacher_disagreement_score":0.32471392,"about_ca_system_score_codex":0.0022789824,"about_ca_system_score_gemma":0.0031618767,"threshold_uncertainty_score":0.59594595},"labels":[],"label_agreement":null},{"id":"W2134496677","doi":"10.1053/s0046-8177(03)00411-8","title":"Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer","year":2003,"lang":"en","type":"article","venue":"Human Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Tissue microarray; Synaptophysin; Neuroendocrine differentiation; Breast cancer; Pathology; Enolase; Progesterone receptor; Immunohistochemistry; Biology; Immunostaining; Chromogranin A; Breast carcinoma; Estrogen receptor; Univariate analysis; Carcinoma; Cancer; Oncology; Internal medicine; Medicine; Multivariate analysis","score_opus":0.036436739262175305,"score_gpt":0.36019780607332796,"score_spread":0.3237610668111527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134496677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99768406,0.00092648994,0.000040304447,0.00052764337,0.000050469258,0.00039595415,0.00004316142,0.000013717537,0.0003181957],"genre_scores_gemma":[0.9990357,0.00026302514,0.000047483936,0.000113377624,0.000025523936,0.000098912125,0.000023398285,0.00001634929,0.00037621535],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987218,0.00021626476,0.00028905857,0.0003350834,0.00016042557,0.0002774138],"domain_scores_gemma":[0.9994604,0.000062957166,0.00008388439,0.00020792974,0.00010644839,0.00007836718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015493107,0.000111379944,0.00042447748,0.000477818,0.0000316684,0.0000058359587,0.00006209855,0.000041908635,0.0007740264],"category_scores_gemma":[0.000104402825,0.00010434934,0.000038758248,0.000625554,0.00010286664,0.000027338383,0.0000241795,0.00019267909,0.0000045222214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000341068,0.00012836591,0.60586625,0.00014109185,0.00006814779,0.0002517961,0.00019911304,0.000016509048,0.39189968,0.00034159023,0.00006053507,0.0009928142],"study_design_scores_gemma":[0.000763432,0.00015365612,0.96195084,0.000043573204,0.00030187925,0.00013885577,0.000028102153,0.00008092042,0.036156915,0.000042979445,0.0002591851,0.00007965304],"about_ca_topic_score_codex":0.00012546265,"about_ca_topic_score_gemma":0.00041604167,"teacher_disagreement_score":0.35608461,"about_ca_system_score_codex":0.00006421777,"about_ca_system_score_gemma":0.000067882946,"threshold_uncertainty_score":0.8475046},"labels":[],"label_agreement":null},{"id":"W2135530224","doi":"10.1200/jco.2014.57.1513","title":"Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":135,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly and Company","keywords":"Ramucirumab; Docetaxel; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Hazard ratio; Clinical endpoint; Taxane; Breast cancer; Placebo; Chemotherapy; Progression-free survival; Cancer; Randomized controlled trial; Pathology; Confidence interval","score_opus":0.1991386133547665,"score_gpt":0.5626661216359241,"score_spread":0.3635275082811576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135530224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9504351,0.0004403009,0.00078652863,0.040949814,0.0010457942,0.005105356,0.000084203224,0.0000072184016,0.0011456574],"genre_scores_gemma":[0.9909129,0.0010933442,0.002710428,0.0027740446,0.0019776134,0.0002523033,0.000009661021,0.00003282902,0.00023686833],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9849678,0.005427701,0.00752074,0.00030600335,0.0013916522,0.00038605218],"domain_scores_gemma":[0.95537364,0.03720142,0.005337568,0.0004337223,0.0012980845,0.0003555851],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.060486425,0.00022026755,0.005796141,0.00035196054,0.00004490346,0.000010307088,0.00038229357,0.00028009995,0.0006346181],"category_scores_gemma":[0.0560234,0.00012369204,0.0011073354,0.00038790662,0.0004563042,0.00008785962,0.00006305752,0.0013517357,0.0000035634948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7939595,0.0032441316,0.000051365638,0.00008870941,0.0007396224,0.00002647677,0.00033288685,0.00041333292,0.00060543395,0.000011204743,0.003051179,0.19747615],"study_design_scores_gemma":[0.9504265,0.03569443,0.00092225964,0.0006341785,0.0008725091,0.00007492074,0.00005789293,0.007953767,0.00016397693,0.0003044512,0.002799246,0.000095847994],"about_ca_topic_score_codex":0.00025345176,"about_ca_topic_score_gemma":0.00036307596,"teacher_disagreement_score":0.1973803,"about_ca_system_score_codex":0.00043742725,"about_ca_system_score_gemma":0.004580464,"threshold_uncertainty_score":0.96742696},"labels":[],"label_agreement":null},{"id":"W2135655765","doi":"10.1158/0008-5472.can-10-2229","title":"Receptor Tyrosine Kinase Signaling Favors a Protumorigenic State in Breast Cancer Cells by Inhibiting the Adaptive Immune Response","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immune system; Cancer research; Biology; Tumor progression; Signal transduction; Syk; Breast cancer; Carcinogenesis; Acquired immune system; Receptor tyrosine kinase; Mammary tumor; Tyrosine kinase; Cancer; Immunology; Cell biology","score_opus":0.05529221576837432,"score_gpt":0.4000468603426212,"score_spread":0.34475464457424687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135655765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773043,0.00323562,0.000014724249,0.0147805335,0.00042865652,0.0033802143,0.00058655656,0.00007092853,0.00019846136],"genre_scores_gemma":[0.98913157,0.0012098148,0.00013868802,0.0002501149,0.0006570749,0.0037139202,0.000016511516,0.00015836043,0.004723931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99266744,0.0014586817,0.0007318266,0.0009579157,0.0022214826,0.0019626643],"domain_scores_gemma":[0.99607944,0.0010816875,0.00014913299,0.00088795606,0.0012400023,0.0005617541],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009559749,0.00037019415,0.00056284503,0.00060664164,0.00050888065,0.00017485408,0.0007686718,0.00021321354,0.0031942057],"category_scores_gemma":[0.00065402203,0.00027640696,0.00014408618,0.002576892,0.0010798124,0.00020347782,0.0004334941,0.0049461834,0.00018603734],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009419537,0.00018747798,0.0025702568,0.00019482033,0.00005785451,0.000132832,0.0021040014,0.000053769003,0.9628593,0.000018751052,0.010482581,0.011918846],"study_design_scores_gemma":[0.0025999183,0.00044040434,0.0048590824,0.0013804112,0.000016484644,0.000032755288,0.0013142831,0.0003055213,0.9750402,0.00008740732,0.013557595,0.00036591664],"about_ca_topic_score_codex":0.024011534,"about_ca_topic_score_gemma":0.0017974421,"teacher_disagreement_score":0.02221409,"about_ca_system_score_codex":0.0019466603,"about_ca_system_score_gemma":0.004595891,"threshold_uncertainty_score":0.9999688},"labels":[],"label_agreement":null},{"id":"W2135995176","doi":"10.1200/jop.2011.000315","title":"Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?","year":2011,"lang":"en","type":"article","venue":"Journal of Oncology Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Princess Margaret Cancer Centre; University Health Network; University of Toronto; St. Joseph’s Healthcare Hamilton; University of Calgary","funders":"National Cancer Institute","keywords":"Medicine; Targeted therapy; MEDLINE; Cancer; Internal medicine","score_opus":0.2166946998944679,"score_gpt":0.5339195624607045,"score_spread":0.3172248625662366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135995176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87241536,0.0034054394,0.009753442,0.02902861,0.0035834492,0.0039004197,0.00004962784,0.000027690896,0.07783593],"genre_scores_gemma":[0.77757514,0.003089962,0.21590957,0.0018242034,0.0007550737,0.000065990804,0.0000046395385,0.000051563427,0.0007238528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822927,0.00028373027,0.0008031126,0.00014254624,0.00032534244,0.00021602905],"domain_scores_gemma":[0.9940609,0.0030500852,0.001156322,0.00025090468,0.0013110675,0.00017076904],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053962283,0.00009437886,0.0004395249,0.0002633856,0.000051379342,0.000009498628,0.00019530262,0.0001626479,0.002182086],"category_scores_gemma":[0.0069641396,0.00007369667,0.0001685644,0.00010295971,0.00010529722,0.00040991878,0.000028624729,0.00045083856,0.000045032935],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053556103,0.0031897398,0.012802789,0.00011584679,0.0014270428,0.00041489053,0.0049951235,0.000055950484,0.018055338,0.0008456774,0.14359325,0.76094824],"study_design_scores_gemma":[0.009477675,0.02338372,0.016277649,0.00010547992,0.00046962837,0.0026231701,0.0016837857,0.00015229672,0.010616146,0.0016078036,0.9334916,0.00011106752],"about_ca_topic_score_codex":0.000036188776,"about_ca_topic_score_gemma":0.000015389673,"teacher_disagreement_score":0.78989834,"about_ca_system_score_codex":0.0005944471,"about_ca_system_score_gemma":0.004592203,"threshold_uncertainty_score":0.99873006},"labels":[],"label_agreement":null},{"id":"W2136094622","doi":"10.1111/j.1464-410x.2007.06992.x","title":"Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer","year":2007,"lang":"en","type":"article","venue":"British Journal of Urology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Université de Montréal; Sanofi","keywords":"Biochemical recurrence; Prostate cancer; Proportional hazards model; Medicine; breakpoint cluster region; Oncology; Prostatectomy; Urology; Internal medicine; Univariate analysis; Cancer; Multivariate analysis; Receptor","score_opus":0.011159341666500316,"score_gpt":0.2947671631631771,"score_spread":0.28360782149667674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136094622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633354,0.0019785692,0.000018686751,0.0008309656,0.0002168512,0.0002638753,0.00001722178,0.000008317933,0.00033199493],"genre_scores_gemma":[0.99785227,0.0009536307,0.00029505845,0.0006156832,0.00020978412,0.000003465479,0.0000041367534,0.00002657505,0.000039394006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983128,0.000063368,0.00045436696,0.00018465787,0.0005220613,0.0004627984],"domain_scores_gemma":[0.9989456,0.000060434526,0.00017494091,0.00010778504,0.00044120158,0.00027007147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006753258,0.00009364132,0.00031100685,0.00017553837,0.00002873252,0.000016579173,0.00016200768,0.00012827235,0.00023156634],"category_scores_gemma":[0.00032096897,0.00009060865,0.00004277145,0.00027356372,0.00022501571,0.00008410848,0.000042730888,0.00092428044,0.000007558262],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008176242,0.00082150527,0.78351647,0.00013793196,0.000075990276,0.0047310954,0.00028927892,0.00002032958,0.00062218047,0.0000046763644,0.014550844,0.18705347],"study_design_scores_gemma":[0.00614919,0.002978181,0.9775804,0.00082628924,0.000031110558,0.0021104452,0.000025530397,0.000020101508,0.00046083544,0.00003013276,0.009679309,0.00010842659],"about_ca_topic_score_codex":0.00012293573,"about_ca_topic_score_gemma":0.000119516764,"teacher_disagreement_score":0.19406399,"about_ca_system_score_codex":0.00017550221,"about_ca_system_score_gemma":0.00032248814,"threshold_uncertainty_score":0.401559},"labels":[],"label_agreement":null},{"id":"W2136765170","doi":"10.1186/2193-1801-3-236","title":"Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis","year":2014,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lapatinib; Medicine; Trastuzumab; Discontinuation; Hazard ratio; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Proportional hazards model; Cancer; Confidence interval","score_opus":0.07301305932988728,"score_gpt":0.417565083098142,"score_spread":0.3445520237682547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136765170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983809,0.000025985662,0.00001284204,0.00016726746,0.00012922878,0.00042965033,0.00029912157,0.000019289795,0.00053569494],"genre_scores_gemma":[0.99965125,0.000056927554,0.00006062313,0.00002726075,0.00002679823,0.00009347007,0.00003075714,0.000023877585,0.000029024835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99857134,0.00010766505,0.00041846142,0.00036659965,0.00025439213,0.00028155118],"domain_scores_gemma":[0.9991634,0.0001921512,0.00015713046,0.00028831133,0.000069812704,0.00012920138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016665991,0.00019583311,0.0009199767,0.00044419794,0.000030323063,0.000014276662,0.000073967436,0.000047653048,0.00026033778],"category_scores_gemma":[0.00006528889,0.00016059956,0.00012310586,0.00025982852,0.000062727624,0.00003928974,0.000036215184,0.00015882583,0.000013993904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006869082,0.00051197864,0.98911375,0.0000497959,0.0010088976,0.0000033087015,0.0008719952,0.00033976292,0.000022548997,0.000026866455,0.0000070958795,0.007357095],"study_design_scores_gemma":[0.00656276,0.0021173973,0.98522276,0.00007884648,0.00052687107,3.902604e-7,0.0001428301,0.0046298583,0.0005665344,0.0000052684386,0.000025632966,0.00012087247],"about_ca_topic_score_codex":0.012504731,"about_ca_topic_score_gemma":0.013840675,"teacher_disagreement_score":0.0072362223,"about_ca_system_score_codex":0.001980162,"about_ca_system_score_gemma":0.00014337989,"threshold_uncertainty_score":0.99407107},"labels":[],"label_agreement":null},{"id":"W2137204308","doi":"10.1128/mcb.00034-09","title":"Tyrosine Phosphorylation of Grb2: Role in Prolactin/Epidermal Growth Factor Cross Talk in Mammary Epithelial Cell Growth and Differentiation","year":2009,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; McGill University Health Centre; McGill University","keywords":"Biology; GRB2; Epidermal growth factor; Cell biology; MAPK/ERK pathway; Tyrosine phosphorylation; Phosphorylation; Cell growth; Growth factor; Signal transduction; Cellular differentiation; Anti-apoptotic Ras signalling cascade; Tyrosine kinase; Cancer research; Receptor; Biochemistry","score_opus":0.009672646828723545,"score_gpt":0.2723362416139576,"score_spread":0.26266359478523404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137204308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939249,0.0031147278,0.0018173562,0.00040340872,0.000038051687,0.00041361456,0.000013417364,0.000011925391,0.00026261059],"genre_scores_gemma":[0.99917644,0.00031802617,0.00021458755,0.00012316596,0.000028518894,0.000013812524,0.00008694169,0.000013180636,0.00002533739],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875426,0.00015928029,0.0003246812,0.00033878715,0.0001329756,0.00029003774],"domain_scores_gemma":[0.9995924,0.000032543703,0.00007864824,0.00014958117,0.000060230188,0.00008656314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020055282,0.00015041605,0.00032042433,0.00020776117,0.00002517608,0.000015042332,0.000070081594,0.00021230764,0.000020005475],"category_scores_gemma":[0.000081548016,0.00013736816,0.000043767304,0.00018963433,0.000096925134,0.00005856438,0.000051419647,0.00024768052,0.0000010286055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002959368,0.00013174754,0.20636357,0.00010819035,0.000006053046,0.000058262915,0.00016531788,0.0000010657004,0.7892097,0.0003027914,0.000001055879,0.0033562984],"study_design_scores_gemma":[0.0015634532,0.00042572757,0.34689277,0.000031519427,0.000008063512,0.00001060248,0.0000132409705,0.00036881477,0.6494477,0.0011297421,0.0000185758,0.00008983205],"about_ca_topic_score_codex":0.000260851,"about_ca_topic_score_gemma":0.00001523377,"teacher_disagreement_score":0.1405292,"about_ca_system_score_codex":0.000039352424,"about_ca_system_score_gemma":0.000056515506,"threshold_uncertainty_score":0.5601711},"labels":[],"label_agreement":null},{"id":"W2138282377","doi":"10.1242/dev.01425","title":"Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development","year":2004,"lang":"en","type":"article","venue":"Development","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Biology; Mutant; Allele; Receptor; Cell biology; Signal transduction; Gene knockin; Knockout mouse; Null allele; Genetics; Gene","score_opus":0.2179819336539109,"score_gpt":0.3744139215533196,"score_spread":0.1564319878994087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138282377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763686,0.00030339137,0.020572973,0.0003098251,0.00017055325,0.0017572574,0.000018808456,0.0000785821,0.00041998812],"genre_scores_gemma":[0.7715094,0.000015311807,0.22695087,0.00010361935,0.000075107004,0.00032020494,0.000097110875,0.00008111209,0.0008472432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948495,0.00003126348,0.001902797,0.0007416549,0.0015896531,0.00088513707],"domain_scores_gemma":[0.9978492,0.00009941824,0.00048212716,0.00043914904,0.0008252357,0.0003048529],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001383537,0.00045316803,0.00084612536,0.00061542,0.0003290546,0.000030054298,0.00035659104,0.00024128993,0.00016755227],"category_scores_gemma":[0.00017132935,0.00045403815,0.00015189039,0.0006569212,0.00011092102,0.00017138134,0.00022323936,0.00027450235,0.000033912023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018631062,0.0011686097,0.032171436,0.008124861,0.0015463609,0.00007377565,0.061622154,0.0056403717,0.8334167,0.0005734054,0.00030222794,0.05349702],"study_design_scores_gemma":[0.0042841546,0.000114671624,0.046902634,0.0024702016,0.000038202164,0.000017592289,0.00042208712,0.00012415154,0.9385154,0.00018064477,0.0064556007,0.00047463924],"about_ca_topic_score_codex":0.000035317702,"about_ca_topic_score_gemma":0.00003952478,"teacher_disagreement_score":0.2063779,"about_ca_system_score_codex":0.0016489903,"about_ca_system_score_gemma":0.0045267087,"threshold_uncertainty_score":0.99979115},"labels":[],"label_agreement":null},{"id":"W2138501761","doi":"10.1158/1078-0432.ccr-03-0463","title":"Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Celecoxib; Breast cancer; Internal medicine; Oncology; Regimen; Rash; Cancer","score_opus":0.1846703249882754,"score_gpt":0.5588671635938909,"score_spread":0.3741968386056155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138501761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989969,0.00141669,0.00000407746,0.0014707239,0.00011758747,0.006370603,0.0005236071,0.00002861287,0.00009910311],"genre_scores_gemma":[0.9938066,0.0006120263,0.00013624357,0.00015283444,0.00017101155,0.004655345,0.000026889387,0.00010399455,0.00033504303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922078,0.0010230208,0.0015937513,0.0012800952,0.0025790518,0.0013162759],"domain_scores_gemma":[0.9963981,0.00065482483,0.00021432886,0.000782755,0.0011235746,0.00082644547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026982678,0.00042029368,0.0013697597,0.0007057408,0.00021577382,0.00005868447,0.0004021233,0.00021158003,0.0008149935],"category_scores_gemma":[0.0005454462,0.0003375211,0.00019606903,0.0012519521,0.0010153807,0.00016608386,0.00027200536,0.0016163745,0.000009928872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018413788,0.06630662,0.73253495,0.000696503,0.0004787645,0.00040579826,0.002416289,0.000039058294,0.00011752381,0.0000023656346,0.0003404721,0.17824785],"study_design_scores_gemma":[0.108510435,0.04603155,0.8404961,0.0015098889,0.0002602902,0.0000057335174,0.00090790907,0.00040801495,0.0011526187,0.000060989223,0.0003147758,0.00034168706],"about_ca_topic_score_codex":0.0068572797,"about_ca_topic_score_gemma":0.0074469917,"teacher_disagreement_score":0.17790617,"about_ca_system_score_codex":0.0019925695,"about_ca_system_score_gemma":0.0037636552,"threshold_uncertainty_score":0.9999077},"labels":[],"label_agreement":null},{"id":"W2138694026","doi":"10.1309/vp4w-5c55-7m09-6tx3","title":"Comparison of HER2/<i>neu</i>Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry","year":2001,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto","funders":"","keywords":"Immunohistochemistry; Concordance; Polymerase chain reaction; Medicine; Pathology; Real-time polymerase chain reaction; Biology; Molecular biology; Internal medicine; Gene; Genetics","score_opus":0.10119660765092921,"score_gpt":0.5448628036480689,"score_spread":0.44366619599713975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138694026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99275875,0.0025823961,0.0006524036,0.0022252535,0.00023992163,0.000115823204,0.000012820383,0.0000074448812,0.0014052032],"genre_scores_gemma":[0.99363446,0.002568635,0.0029361972,0.00049426046,0.000161715,0.0000028924271,0.000008348638,0.000023740353,0.00016973652],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9966661,0.00063868053,0.0016925083,0.0002533794,0.00040836565,0.00034098318],"domain_scores_gemma":[0.9957369,0.0015316532,0.0016469737,0.0002753149,0.00041159807,0.000397586],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017052455,0.00015272654,0.0014158394,0.00012447103,0.000036985097,0.0000069271296,0.00013989565,0.00013901493,0.000103667975],"category_scores_gemma":[0.0024066323,0.0001306085,0.0002069669,0.0003092074,0.0016296664,0.000066491215,0.000043321274,0.0011221522,0.000007749867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004912057,0.001231618,0.4073263,0.000058873087,0.00017352476,0.00048526347,0.00044129152,0.0000015387536,0.4694044,0.000020935988,0.0032413711,0.112702824],"study_design_scores_gemma":[0.019176504,0.07577175,0.7607774,0.0010415089,0.00079432316,0.008442007,0.017136509,0.00045175233,0.06565093,0.00028757637,0.049566902,0.0009028372],"about_ca_topic_score_codex":0.00019977076,"about_ca_topic_score_gemma":0.0000040574623,"teacher_disagreement_score":0.40375346,"about_ca_system_score_codex":0.00007822645,"about_ca_system_score_gemma":0.00046147112,"threshold_uncertainty_score":0.6004574},"labels":[],"label_agreement":null},{"id":"W2139479159","doi":"10.1186/1746-1596-2-8","title":"Quantitative image analysis of immunohistochemical stains using a CMYK color model","year":2007,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":185,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Magenta; H&E stain; Hue; RGB color model; Immunohistochemistry; Cyan; Artificial intelligence; Pathology; Computer science; Medicine; Physics","score_opus":0.07958119339257745,"score_gpt":0.45928764611825873,"score_spread":0.37970645272568126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139479159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066701,0.0005921668,0.09063699,0.0001697914,0.000058196365,0.00035777185,0.00010008694,0.000027749511,0.001387156],"genre_scores_gemma":[0.9592365,0.00007769377,0.040251903,0.00022679481,0.00002761314,0.000027075575,0.00006309946,0.00002567011,0.0000636634],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99817795,0.00009923076,0.0004994675,0.00035812857,0.00035436265,0.0005108691],"domain_scores_gemma":[0.9963684,0.002506554,0.00014028205,0.000441299,0.00037690537,0.00016653458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010052097,0.00015273552,0.0006980644,0.0006722508,0.000048620543,0.000004917808,0.0001514387,0.00017778199,0.00013550576],"category_scores_gemma":[0.0070699826,0.00014667683,0.00020365282,0.0010901676,0.0005930087,0.000033837296,0.0000975265,0.00032544488,0.000018868746],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007141187,0.0005365595,0.038665824,0.0001224277,0.00068718585,0.0023789606,0.002107045,0.0019809315,0.94939345,0.0024315135,0.00032247903,0.0006594922],"study_design_scores_gemma":[0.005504761,0.0033442597,0.22400966,0.0003830651,0.008288181,0.00044742288,0.003256347,0.5989922,0.15305524,0.0015366336,0.00028162476,0.0009005588],"about_ca_topic_score_codex":0.0001659064,"about_ca_topic_score_gemma":0.000049605103,"teacher_disagreement_score":0.7963382,"about_ca_system_score_codex":0.00034625607,"about_ca_system_score_gemma":0.00036711895,"threshold_uncertainty_score":0.846394},"labels":[],"label_agreement":null},{"id":"W2140055441","doi":"10.1200/jco.2008.20.6847","title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"F. Hoffmann-La Roche; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Anastrozole; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Hazard ratio; Oncology; Breast cancer; Aromatase inhibitor; Gynecology; Cancer; Tamoxifen; Confidence interval","score_opus":0.11580627615224622,"score_gpt":0.47668609962928,"score_spread":0.3608798234770338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140055441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97077835,0.0010881997,0.00049559196,0.020548416,0.0006116487,0.0045135417,0.0018284846,0.0000152234115,0.000120574296],"genre_scores_gemma":[0.9937772,0.0020087,0.0014094501,0.00061375956,0.0017335201,0.00024216641,0.000076864024,0.000045072127,0.00009327806],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99110466,0.0027716924,0.0036937261,0.00053027924,0.001140434,0.0007592262],"domain_scores_gemma":[0.9754562,0.019104429,0.0029651925,0.00047365561,0.0013577172,0.00064285484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053987373,0.00046579607,0.004309883,0.00014632133,0.00030576973,0.000037925,0.0005020463,0.00021140395,0.00026733108],"category_scores_gemma":[0.0016871078,0.00022356385,0.00062498654,0.0003559278,0.0009306339,0.00017837674,0.00004351179,0.0010581925,0.0000035300995],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86924887,0.012952169,0.0004964037,0.0000064242704,0.008329374,0.0002063151,0.0053148167,0.000050077284,0.0015050139,0.0000149211355,0.0024772997,0.09939834],"study_design_scores_gemma":[0.6699985,0.24951392,0.07060336,0.0001101166,0.002884705,0.00006199613,0.0047472655,0.00012977561,0.0006227593,0.000032678938,0.0011049231,0.0001899796],"about_ca_topic_score_codex":0.0014147405,"about_ca_topic_score_gemma":0.00041513468,"teacher_disagreement_score":0.23656176,"about_ca_system_score_codex":0.0021523093,"about_ca_system_score_gemma":0.0031180016,"threshold_uncertainty_score":0.9116669},"labels":[],"label_agreement":null},{"id":"W2140243420","doi":"10.1128/mcb.22.13.4714-4722.2002","title":"ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival","year":2002,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Lunenfeld-Tanenbaum Research Institute","funders":"Medical Research Council","keywords":"Biology; Myocyte; Regeneration (biology); Cell biology; Skeletal muscle; Anatomy","score_opus":0.04059659643877128,"score_gpt":0.30595585026725386,"score_spread":0.2653592538284826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140243420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97016174,0.012983305,0.0052397614,0.0017767771,0.00018203474,0.00064431963,0.000039981416,0.000033518925,0.0089385705],"genre_scores_gemma":[0.9954976,0.00033718592,0.0006138165,0.0006992908,0.0001065501,0.00005123146,0.000034719484,0.00003192735,0.0026276854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99881464,0.00007761356,0.00017328515,0.00042264484,0.00010911429,0.00040271145],"domain_scores_gemma":[0.99939054,0.00004008946,0.000033029544,0.00028382184,0.00005722154,0.00019530577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022965908,0.0001483182,0.0002762766,0.00007659636,0.00007894706,0.00001711613,0.000074458294,0.0001860368,0.00038098593],"category_scores_gemma":[0.000038209615,0.00013325101,0.00007594278,0.00009687088,0.0002026962,0.0000141100345,0.0000798673,0.00014223291,0.000033457673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007225052,0.0001248465,0.0018996733,0.00022181957,0.000054656422,0.00010290373,0.0003570269,1.9534912e-7,0.97439474,0.0006416259,0.0020635675,0.020066675],"study_design_scores_gemma":[0.0051666494,0.0029470543,0.0012468495,0.0000589438,0.00013470967,0.00006054787,0.00030337842,0.0012183122,0.6163199,0.0008478195,0.37124276,0.00045309289],"about_ca_topic_score_codex":0.000058214027,"about_ca_topic_score_gemma":0.0000037509528,"teacher_disagreement_score":0.3691792,"about_ca_system_score_codex":0.000021219841,"about_ca_system_score_gemma":0.000024862506,"threshold_uncertainty_score":0.54338187},"labels":[],"label_agreement":null},{"id":"W2140405230","doi":"10.1002/mc.20766","title":"Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells","year":2011,"lang":"en","type":"article","venue":"Molecular Carcinogenesis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Canadian Urological Oncology Group","keywords":"Biology; ERBB3; Prostate cancer; Cancer; Cancer research; Cell biology; Prostate; Cancer cell; Pinocytosis; Endocytosis; Cell; Signal transduction; Genetics","score_opus":0.028259815987639977,"score_gpt":0.27550411101191624,"score_spread":0.24724429502427625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140405230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945242,0.0029347932,0.00011247697,0.00041453968,0.00013339931,0.0007678076,0.000017752374,0.000058938862,0.0010361333],"genre_scores_gemma":[0.9972556,0.001023481,0.00058262656,0.0007012922,0.00004852343,0.0000993396,0.000009488566,0.00010007529,0.00017953006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809617,0.0001227156,0.00033228853,0.00052647357,0.0004419527,0.0004803724],"domain_scores_gemma":[0.9991103,0.000010065796,0.000066338784,0.0004239853,0.00013987941,0.00024944093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021560924,0.00022427033,0.00033193175,0.00029668323,0.000068022135,0.000026788803,0.000112223825,0.00012709836,0.00023023132],"category_scores_gemma":[0.00002703649,0.00022058457,0.00008429532,0.0005745516,0.00015755117,0.00006336987,0.00010002009,0.00017286392,0.000026875792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045434796,0.00013479724,0.28879896,0.0005879091,0.00008825119,0.0009872835,0.0031937202,0.00011779328,0.69154316,0.000097230615,0.00096868654,0.013027861],"study_design_scores_gemma":[0.0013755064,0.00019598771,0.06776135,0.00032077302,0.000105101724,0.000034213113,0.00022227001,0.001186462,0.9249453,0.00006247688,0.0034766444,0.00031393973],"about_ca_topic_score_codex":0.0034484616,"about_ca_topic_score_gemma":0.00016349605,"teacher_disagreement_score":0.23340213,"about_ca_system_score_codex":0.00025784923,"about_ca_system_score_gemma":0.0001600387,"threshold_uncertainty_score":0.8995178},"labels":[],"label_agreement":null},{"id":"W2140841327","doi":"10.1158/0008-5472.can-08-4766","title":"Src Stimulates Fibroblast Growth Factor Receptor-2 Shedding by an ADAM15 Splice Variant Linked to Breast Cancer","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; University of California, San Francisco; Wellcome Trust","keywords":"Proto-oncogene tyrosine-protein kinase Src; Cancer research; Biology; Breast cancer; Cancer; Src family kinase; splice; Cell biology; Kinase; Biochemistry; Gene; Genetics","score_opus":0.08792739972269824,"score_gpt":0.4507606643172731,"score_spread":0.3628332645945748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140841327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95577323,0.0024359182,0.0002173973,0.034341037,0.00037726268,0.0028805528,0.0015286836,0.00031976722,0.0021261412],"genre_scores_gemma":[0.9883355,0.0017451158,0.00066154025,0.0015552142,0.0020557789,0.00059812283,0.00009069163,0.00016866821,0.0047893925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923473,0.00046563253,0.0006007027,0.0014570607,0.0028366616,0.0022926705],"domain_scores_gemma":[0.99449944,0.00029100655,0.000079279416,0.0011415028,0.001901242,0.0020875253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015199705,0.00048257058,0.00073197315,0.00070598756,0.00051258015,0.00023906968,0.0010184789,0.0003637274,0.010887058],"category_scores_gemma":[0.0004465073,0.00043327708,0.00014268754,0.0023327419,0.0002799784,0.00043088984,0.00030057796,0.0020237386,0.0004985155],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002012728,0.00044694805,0.005149509,0.00039487626,0.0001328702,0.00012732475,0.0016789355,0.00018667078,0.73122686,0.000110767534,0.19565706,0.06287546],"study_design_scores_gemma":[0.015746633,0.013804531,0.31826082,0.013098741,0.00019375682,0.00038400062,0.0026595378,0.0063500446,0.35583714,0.0008601232,0.26834053,0.0044641793],"about_ca_topic_score_codex":0.009836718,"about_ca_topic_score_gemma":0.00052365754,"teacher_disagreement_score":0.37538972,"about_ca_system_score_codex":0.0028477858,"about_ca_system_score_gemma":0.0021467984,"threshold_uncertainty_score":0.9998119},"labels":[],"label_agreement":null},{"id":"W2140914212","doi":"10.5966/sctm.2011-0016","title":"Functional Impairment of Human Resident Cardiac Stem Cells by the Cardiotoxic Antineoplastic Agent Trastuzumab","year":2012,"lang":"en","type":"article","venue":"Stem Cells Translational Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Heart Rhythm Society; Canadian Institutes of Health Research; National Institutes of Health; Deutsche Forschungsgemeinschaft; National Heart, Lung, and Blood Institute; Heart and Stroke Foundation of Canada","keywords":"Cardiotoxicity; In vivo; Stem cell; In vitro; Apoptosis; Trastuzumab; Medicine; Pharmacology; Ejection fraction; Cancer research; Internal medicine; Cancer; Chemotherapy; Cell biology; Heart failure; Biology; Breast cancer; Biotechnology; Biochemistry","score_opus":0.04812689393510634,"score_gpt":0.3156046184696444,"score_spread":0.26747772453453805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140914212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96268004,0.018475223,0.0017806008,0.0052297525,0.003377003,0.003167077,0.00048623572,0.00009947359,0.0047046114],"genre_scores_gemma":[0.9940037,0.0002690749,0.00004189805,0.00016646627,0.0015394972,0.000118911514,0.00012528771,0.00006173643,0.003673432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99496794,0.0003192777,0.0009673505,0.00042536645,0.002622024,0.00069801905],"domain_scores_gemma":[0.9978607,0.0006379915,0.0002068101,0.0005364682,0.00027586476,0.00048215358],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016045149,0.0003583166,0.00080205244,0.00021008098,0.0002144588,0.000010882096,0.00021192574,0.0001504683,0.0014465329],"category_scores_gemma":[0.00000779581,0.00023974954,0.00030938195,0.00044209475,0.0004617524,0.00009713615,0.000033450528,0.00050048233,0.000076326556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007531159,0.00067094166,0.04620528,0.00155654,0.0010877141,0.000028196784,0.0047896,0.00040309018,0.76786125,0.00055743154,0.16924645,0.006840416],"study_design_scores_gemma":[0.012763686,0.0044661458,0.18773022,0.0021228776,0.0021169535,0.00017687124,0.0065994617,0.00031585226,0.68481284,0.00009288561,0.09779218,0.0010100332],"about_ca_topic_score_codex":0.00019075916,"about_ca_topic_score_gemma":0.000009040502,"teacher_disagreement_score":0.14152494,"about_ca_system_score_codex":0.00028168573,"about_ca_system_score_gemma":0.0003596206,"threshold_uncertainty_score":0.9994663},"labels":[],"label_agreement":null},{"id":"W2141506913","doi":"10.1586/14737167.8.5.433","title":"Is trastuzumab a cost-effective treatment for breast cancer?","year":2008,"lang":"en","type":"article","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Cost effectiveness; Internal medicine; Cancer; Intensive care medicine; Risk analysis (engineering)","score_opus":0.14571005024597344,"score_gpt":0.6090204262930101,"score_spread":0.4633103760470367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141506913","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.15490876,0.59786093,0.00022792608,0.15983729,0.0016029293,0.07354113,0.0048460015,0.00019756649,0.0069774715],"genre_scores_gemma":[0.077002116,0.88524354,0.00082581426,0.008603211,0.000849628,0.022868162,0.000057519344,0.000145912,0.0044041094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99620795,0.00034844442,0.0008907957,0.00077166856,0.0007361599,0.0010450067],"domain_scores_gemma":[0.9964702,0.0010706506,0.0001696931,0.0007799833,0.00092110084,0.00058836077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016454573,0.00039339936,0.001585462,0.00038785255,0.00026462454,0.000020118754,0.00048350412,0.000110032866,0.0037074294],"category_scores_gemma":[0.0001994897,0.00030414262,0.0007713733,0.0004181943,0.00043398564,0.00014387222,0.00015009295,0.0004903433,0.00019775791],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011732365,0.0010978421,0.02106976,0.008578575,0.0012929233,0.00007000573,0.0021008635,0.0000032433995,0.0043357983,0.00006110522,0.20294856,0.7572681],"study_design_scores_gemma":[0.007745227,0.0011887966,0.010225705,0.0034255204,0.000118529846,0.00024928083,0.00016115747,0.00059904397,0.030954173,0.000018007138,0.944926,0.00038853634],"about_ca_topic_score_codex":0.0010345146,"about_ca_topic_score_gemma":0.000025417205,"teacher_disagreement_score":0.75687957,"about_ca_system_score_codex":0.0036709341,"about_ca_system_score_gemma":0.0021276155,"threshold_uncertainty_score":0.99994105},"labels":[],"label_agreement":null},{"id":"W2141917836","doi":"10.2967/jnumed.106.037937","title":"111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer","year":2007,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":188,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Connaught Fund; Cancer Research UK; Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance","keywords":"Trastuzumab; HER2/neu; NLS; Breast cancer; Cancer research; Medicine; Chemistry; Nuclear localization sequence; Oncology; Cancer; Internal medicine; Gene","score_opus":0.05070695068423739,"score_gpt":0.38856828936995635,"score_spread":0.337861338685719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141917836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97486573,0.0012997409,0.007417049,0.01364164,0.00053714257,0.0012780669,0.000013387192,0.00011443846,0.0008327892],"genre_scores_gemma":[0.9883033,0.00082513515,0.0025786362,0.0053983387,0.0024306618,0.000009611242,0.000010361191,0.00021606738,0.0002278635],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958273,0.00015844354,0.0011543259,0.00044113316,0.0015135888,0.0009051792],"domain_scores_gemma":[0.997059,0.00018952816,0.00071500015,0.00039529524,0.0009887137,0.0006524604],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027151306,0.00038216956,0.0009806842,0.00048253834,0.00026922434,0.00005351231,0.00038582506,0.0001853617,0.0012784598],"category_scores_gemma":[0.00016168146,0.00026371572,0.0001595375,0.00067619426,0.00041287678,0.00029933295,0.000023166804,0.0009067035,0.000009532312],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055576194,0.002971656,0.011759547,0.0027005316,0.0035999396,0.001994812,0.027706953,0.0031176517,0.604936,0.0017922262,0.0472081,0.23663636],"study_design_scores_gemma":[0.11681188,0.10350663,0.12621543,0.021601897,0.006389837,0.034695785,0.0447314,0.09970665,0.009782342,0.0008087302,0.43172032,0.004029097],"about_ca_topic_score_codex":0.00033901026,"about_ca_topic_score_gemma":0.00008797783,"teacher_disagreement_score":0.5951537,"about_ca_system_score_codex":0.0012989044,"about_ca_system_score_gemma":0.0006046605,"threshold_uncertainty_score":0.9999815},"labels":[],"label_agreement":null},{"id":"W2142716729","doi":"10.1007/s12253-015-9927-6","title":"Computer Aided Semi-Automated Evaluation of HER2 Immunodetection—A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy","year":2015,"lang":"en","type":"article","venue":"Pathology & Oncology Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Kappa; Tissue microarray; Medicine; Immunohistochemistry; Immunostaining; Quality assurance; Pathology; Medical physics; Mathematics; External quality assessment","score_opus":0.41795412429575285,"score_gpt":0.5636507555172239,"score_spread":0.14569663122147103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142716729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98561263,0.0012841915,0.002649597,0.0051506455,0.0004926959,0.0036194555,0.00002235341,0.000106253276,0.0010621956],"genre_scores_gemma":[0.9960023,0.00026592828,0.002341623,0.0001491507,0.00031687305,0.0007020719,0.00006425111,0.0000461528,0.00011161999],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9919844,0.0041393777,0.0009328274,0.00051871716,0.0015358297,0.000888837],"domain_scores_gemma":[0.9896905,0.002746156,0.0004422928,0.0007968192,0.0061663156,0.00015793032],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033050846,0.0001853485,0.00071821077,0.00050923903,0.0002682824,0.000015654543,0.0004622837,0.000502873,0.00017088656],"category_scores_gemma":[0.006074444,0.00013722492,0.00016175695,0.0008888568,0.0013056281,0.000111578105,0.00025235774,0.0009997331,0.00003106753],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046477835,0.0017553042,0.031709913,0.0004189018,0.00051073683,0.00010255968,0.006977607,0.0033974163,0.5014107,0.00011538153,0.025241759,0.4237119],"study_design_scores_gemma":[0.021050174,0.018566316,0.10510497,0.00029893848,0.00025660088,0.0011719823,0.003752132,0.72275025,0.11420325,0.0016099926,0.010874331,0.00036107158],"about_ca_topic_score_codex":0.0004324202,"about_ca_topic_score_gemma":0.00008618011,"teacher_disagreement_score":0.71935284,"about_ca_system_score_codex":0.0008249193,"about_ca_system_score_gemma":0.0039035233,"threshold_uncertainty_score":0.99567765},"labels":[],"label_agreement":null},{"id":"W2143564454","doi":"10.18632/oncotarget.4405","title":"Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration","year":2015,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Cancer Agency; Fondazione Pezcoller; Associazione Italiana per la Ricerca sul Cancro; Cancer Research UK","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Cancer","score_opus":0.025957806823524852,"score_gpt":0.31786258972631415,"score_spread":0.2919047829027893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143564454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909442,0.00037657382,0.0038264915,0.0018181226,0.000077655415,0.00042775433,0.00012983548,0.00004198441,0.0023573742],"genre_scores_gemma":[0.9966184,0.000022623977,0.0021731171,0.00021753633,0.00010653605,0.000016058808,0.000066268505,0.00002609623,0.0007533821],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99782246,0.00021304778,0.00040775296,0.0003894335,0.0008053158,0.0003619951],"domain_scores_gemma":[0.99853295,0.00008840342,0.00009398131,0.000442685,0.00033298365,0.0005090073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014409333,0.00018595424,0.000604284,0.00034645697,0.00004639901,0.00003085412,0.00009984221,0.0001657241,0.00009256172],"category_scores_gemma":[0.00012877231,0.00017390022,0.00012903067,0.001028516,0.00011202894,0.0001454783,0.000049838698,0.00046690006,0.000040275827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006548265,0.00042240068,0.3146396,0.00026878316,0.0002865929,0.00019002183,0.0032916374,0.0006383693,0.67585707,0.00002602657,0.0015087153,0.0022159452],"study_design_scores_gemma":[0.0021478275,0.0011378325,0.93081546,0.00018860085,0.00052903075,0.00019595762,0.0011370819,0.004706516,0.05595725,0.00006290913,0.0027718693,0.00034965196],"about_ca_topic_score_codex":0.0028598402,"about_ca_topic_score_gemma":0.00070100336,"teacher_disagreement_score":0.6198998,"about_ca_system_score_codex":0.00023553018,"about_ca_system_score_gemma":0.00050370244,"threshold_uncertainty_score":0.70914453},"labels":[],"label_agreement":null},{"id":"W2143666642","doi":"10.1517/14740338.2011.533168","title":"Lapatinib for breast cancer: a review of the current literature","year":2010,"lang":"en","type":"review","venue":"Expert Opinion on Drug Safety","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Breast cancer; Trastuzumab; Cancer; Oncology; Metastatic breast cancer; Internal medicine; Tyrosine-kinase inhibitor; Disease","score_opus":0.0746250945156274,"score_gpt":0.4797467624904513,"score_spread":0.40512166797482385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143666642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.4219412e-8,0.9748762,0.0000046162418,0.0094596045,0.0051534693,0.0058628363,0.003683892,0.000038121638,0.0009212356],"genre_scores_gemma":[1.736053e-7,0.9921155,0.00010927589,0.001168618,0.0029840115,0.0023048255,0.00058599416,0.00012239246,0.00060918793],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99626386,0.0004112726,0.0011910924,0.0006904739,0.0009789692,0.00046432315],"domain_scores_gemma":[0.9964885,0.00045163487,0.00065176457,0.0016117644,0.00055707025,0.00023927013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010244773,0.00057578005,0.0024081948,0.00014617902,0.00013190022,0.000021904478,0.0007605343,0.00033490124,0.0005825293],"category_scores_gemma":[0.0004711648,0.00031434087,0.0014814246,0.00075862795,0.0001478959,0.00004169983,0.00019273121,0.0021688489,0.000028527038],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005354019,0.00009850595,0.0000010426877,0.16753475,0.00005142424,5.459701e-7,0.00009799214,1.6983154e-8,3.0862142e-7,0.00014556316,0.12029952,0.7117168],"study_design_scores_gemma":[0.00030469388,0.0000362366,0.000007724082,0.42594296,0.000042921398,0.00003432832,0.0000018261425,0.0000012249282,0.000002368562,0.0000035390108,0.57346183,0.00016034313],"about_ca_topic_score_codex":0.000023830158,"about_ca_topic_score_gemma":0.000004381742,"teacher_disagreement_score":0.71155643,"about_ca_system_score_codex":0.00045047828,"about_ca_system_score_gemma":0.0024142782,"threshold_uncertainty_score":0.99993086},"labels":[],"label_agreement":null},{"id":"W2143681410","doi":"10.1038/bjc.2011.516","title":"Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer","year":2012,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Terry Fox Foundation; Boehringer Ingelheim","keywords":"Trastuzumab; Lapatinib; Medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Bevacizumab; Adjuvant; Cancer; Cancer research; Chemotherapy","score_opus":0.0989027358661728,"score_gpt":0.4448493664120509,"score_spread":0.3459466305458781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143681410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008884898,0.995285,0.00012092205,0.0003441204,0.0008618696,0.0011187895,0.0010363943,0.000013893247,0.0011301687],"genre_scores_gemma":[0.0013617714,0.9951816,0.0003156793,0.0002681497,0.0018370266,0.0002949184,0.000024333176,0.0001957071,0.0005207693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950398,0.00038855692,0.0017212617,0.00043080715,0.0014412603,0.0009782962],"domain_scores_gemma":[0.997143,0.00021706075,0.0010863737,0.0002730313,0.00075755874,0.00052301853],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001209508,0.0005864907,0.0033611795,0.0005731843,0.00008242081,0.00024231404,0.00052503735,0.00032414676,0.002810367],"category_scores_gemma":[0.000028989863,0.00053200487,0.00085599214,0.00088136335,0.00028808237,0.00048786565,0.00007159828,0.0027001605,0.00001817615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010859484,0.00044767774,0.000107412605,0.011794674,0.0015161352,0.0012171974,0.00017704567,0.000011225087,0.000009171196,0.000041055497,0.000663385,0.98390645],"study_design_scores_gemma":[0.0020382027,0.00026290028,0.003966557,0.10711539,0.0042890417,0.027009265,0.00024976203,0.00000425999,0.0000044107314,0.000081230035,0.8544194,0.00055955583],"about_ca_topic_score_codex":0.005213878,"about_ca_topic_score_gemma":0.0036919706,"teacher_disagreement_score":0.9833469,"about_ca_system_score_codex":0.002660702,"about_ca_system_score_gemma":0.008942854,"threshold_uncertainty_score":0.9997131},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","score_opus":0.2509656558099983,"score_gpt":0.5050140510855577,"score_spread":0.25404839527555945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144648936","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00085443025,0.97499794,0.000015735128,0.00081785355,0.0016866432,0.004815883,0.00015956798,0.00025714678,0.016394807],"genre_scores_gemma":[0.001170985,0.9925544,0.0003061966,0.0006061313,0.0016977626,0.00031986064,0.0002365285,0.00015617172,0.002951924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99201244,0.002213276,0.0023969477,0.0009924154,0.0010849261,0.0012999641],"domain_scores_gemma":[0.9941779,0.0033101446,0.00072921434,0.0011742662,0.00015161111,0.00045686404],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005214107,0.00069312984,0.00323603,0.00032711047,0.0001877309,0.00010485001,0.001084568,0.0011733877,0.0009907439],"category_scores_gemma":[0.0025960836,0.00045674888,0.0007404728,0.0009537217,0.0008560323,0.000096061915,0.00044769832,0.0034408972,0.0005204474],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015343732,0.0008835969,0.0007536177,0.007352759,0.00042767808,0.0024838615,0.00019651666,5.363864e-7,2.443877e-7,0.0001816145,0.014480523,0.97308564],"study_design_scores_gemma":[0.00097463786,0.0015857074,0.00055799703,0.013269978,0.00049689546,0.00021279854,0.00023124268,0.00001830358,0.0000011456889,0.000082096245,0.98206234,0.00050688087],"about_ca_topic_score_codex":0.00044118165,"about_ca_topic_score_gemma":0.0005070983,"teacher_disagreement_score":0.97257876,"about_ca_system_score_codex":0.004655972,"about_ca_system_score_gemma":0.00116641,"threshold_uncertainty_score":0.9999225},"labels":[],"label_agreement":null},{"id":"W2144847294","doi":"10.1517/14712590903439702","title":"Trastuzumab for gastric cancer","year":2009,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Alberta Cancer Foundation","funders":"","keywords":"Medicine; Trastuzumab; Cancer; Oncology; Chemotherapy; Internal medicine; Targeted therapy; Breast cancer","score_opus":0.4923854008211455,"score_gpt":0.5606512124964915,"score_spread":0.06826581167534601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144847294","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000023368605,0.992976,0.00010119243,0.0011370778,0.0009546525,0.0037121256,0.00011373189,0.00014979717,0.00085304875],"genre_scores_gemma":[0.000003644708,0.989655,0.0005545637,0.0024611903,0.0034786216,0.0031167108,0.0004334987,0.00007711248,0.00021963767],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969794,0.0002997121,0.0006512192,0.0009284998,0.00042473536,0.0007163912],"domain_scores_gemma":[0.9982831,0.00052548683,0.00019536972,0.00057514745,0.000111904126,0.00030901065],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004123911,0.0006268144,0.0022246107,0.00024593776,0.00011607007,0.000033691358,0.00043469176,0.00085928483,0.0014195753],"category_scores_gemma":[0.00015159808,0.00034287755,0.0010317706,0.0004617801,0.0001325405,0.00001902191,0.000031158183,0.0007300481,0.00010807658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037760223,0.00033021547,0.0000022588865,0.00023452927,0.00013412692,0.0000057856587,0.000019859184,8.809516e-8,0.000011627649,0.00013452616,0.031585723,0.9671637],"study_design_scores_gemma":[0.0012231063,0.0057916623,0.000020069578,0.005934399,0.000002593671,0.00003693195,0.000006753194,0.000002222381,0.000014818866,0.00006243358,0.9865436,0.00036140982],"about_ca_topic_score_codex":0.00001635981,"about_ca_topic_score_gemma":2.557041e-7,"teacher_disagreement_score":0.96680224,"about_ca_system_score_codex":0.0006381519,"about_ca_system_score_gemma":0.0005859279,"threshold_uncertainty_score":0.9999023},"labels":[],"label_agreement":null},{"id":"W2145136050","doi":"10.1200/jco.2005.04.1558","title":"Trastuzumab Cardiac Side Effects: Only Time Will Tell","year":2005,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Cardiotoxicity; Internal medicine; Oncology; Cancer; Breast cancer; Chemotherapy","score_opus":0.10497524475678915,"score_gpt":0.5073804816476659,"score_spread":0.40240523689087676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145136050","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0076884283,0.0046102307,0.000033978493,0.9195149,0.007057326,0.0009390633,0.000038255323,0.000040681763,0.06007714],"genre_scores_gemma":[0.0015504728,0.005363125,0.0037538197,0.8183977,0.13721003,0.00001823912,0.00004781715,0.00022101137,0.03343777],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9884752,0.0029046955,0.0049186344,0.00060039666,0.0020980383,0.0010030144],"domain_scores_gemma":[0.9770658,0.017298874,0.0029508823,0.0007621483,0.001050146,0.00087215134],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.008202267,0.0005217475,0.0062826695,0.00048611965,0.00005549763,0.000031683805,0.0008043576,0.0046676993,0.0013418689],"category_scores_gemma":[0.012796869,0.00038202005,0.0027687976,0.0002701342,0.0006766565,0.00015420793,0.00017098324,0.019432193,0.0013761832],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010540544,0.0005344368,0.0010537755,0.0003098582,0.0011842184,0.014120271,0.000025492867,0.000001958964,0.000047066515,0.000001550411,0.7378998,0.24376756],"study_design_scores_gemma":[0.005121254,0.022050893,0.0071697,0.00085288595,0.001421723,0.0018634967,0.0000068319227,0.00001346146,0.00003336976,0.000082845276,0.9610841,0.00029942955],"about_ca_topic_score_codex":0.000030329713,"about_ca_topic_score_gemma":0.00000826873,"teacher_disagreement_score":0.24346814,"about_ca_system_score_codex":0.0017978736,"about_ca_system_score_gemma":0.01548875,"threshold_uncertainty_score":0.99986315},"labels":[],"label_agreement":null},{"id":"W2145330014","doi":"10.1093/annonc/mdu327.46","title":"Data-Driven Timing of Optimal Lvef Assessment in Breast Cancer Patients Exposed to Trastuzumab","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.2328503529427616,"score_gpt":0.5129398822640531,"score_spread":0.2800895293212915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145330014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852744,0.0000377527,0.00014345002,0.008952466,0.00014682839,0.0004979206,0.0003012854,0.000009301874,0.0046366155],"genre_scores_gemma":[0.99560076,0.000105610896,0.002978359,0.0010046706,0.00010938857,0.000055022374,0.00007283865,0.000020132902,0.00005324316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99816865,0.0001820404,0.00050983165,0.000328045,0.000434422,0.00037703497],"domain_scores_gemma":[0.9985751,0.00019151662,0.00015804003,0.0005074496,0.00038914484,0.00017873474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079057517,0.0001141737,0.0005775406,0.00023605478,0.000017425209,0.0000034686025,0.0003693226,0.00011410572,0.00047193677],"category_scores_gemma":[0.00016667429,0.00010468115,0.000046292844,0.00025448948,0.00010295064,0.00007582963,0.00026625497,0.00025371826,0.000010796158],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001853204,0.0038501804,0.36382186,0.00052727124,0.0002340271,0.000041637657,0.0017350384,0.00121593,0.018617308,0.000117541065,0.061045587,0.54694045],"study_design_scores_gemma":[0.005125073,0.009603108,0.91887283,0.0005388936,0.00005237661,0.000012834253,0.00031287348,0.007361751,0.0063718986,0.000021533655,0.051515743,0.00021109729],"about_ca_topic_score_codex":0.000701804,"about_ca_topic_score_gemma":0.0003710671,"teacher_disagreement_score":0.55505097,"about_ca_system_score_codex":0.00020635915,"about_ca_system_score_gemma":0.00087475276,"threshold_uncertainty_score":0.51673764},"labels":[],"label_agreement":null},{"id":"W2145344722","doi":"10.1007/s10585-013-9629-y","title":"Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread","year":2013,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Immunohistochemistry; Pathology; Gastroenterology; Oncology","score_opus":0.12165425616383725,"score_gpt":0.4458009730392224,"score_spread":0.32414671687538515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145344722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374163,0.0018628315,0.000024191795,0.00053084013,0.0005329526,0.0017867591,0.00005294239,0.0000523508,0.0014154804],"genre_scores_gemma":[0.99129176,0.00009242158,0.007002236,0.00050510827,0.0002683573,0.00018559216,0.000031165746,0.0000868409,0.00053649396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99401706,0.00088037335,0.0023675337,0.0010350876,0.0009806762,0.000719288],"domain_scores_gemma":[0.9964874,0.0012221853,0.00037918056,0.00077808014,0.00018002388,0.0009531567],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018789663,0.00043609965,0.0016242384,0.00019559701,0.00006467145,0.000041507054,0.0003444652,0.00039907187,0.0021033813],"category_scores_gemma":[0.00079249777,0.00032040518,0.00036283126,0.00037354534,0.001153423,0.0002502152,0.00035241805,0.0010827113,0.000107696025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026333448,0.0035158703,0.957679,0.00024235157,0.00007026941,0.00011078858,0.00030286197,0.0000011302334,0.01319759,0.000015550948,0.005944543,0.016286755],"study_design_scores_gemma":[0.027255477,0.016538015,0.75608456,0.00048101178,0.00030283642,0.00006972495,0.0027410672,0.00033146556,0.19074252,0.000042824668,0.004671438,0.00073906814],"about_ca_topic_score_codex":0.0010753646,"about_ca_topic_score_gemma":0.000024871273,"teacher_disagreement_score":0.2015944,"about_ca_system_score_codex":0.00015455029,"about_ca_system_score_gemma":0.00027650906,"threshold_uncertainty_score":0.9999248},"labels":[],"label_agreement":null},{"id":"W2145378676","doi":"10.1093/annonc/mdn292","title":"Anthracycline–trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies","year":2008,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Dalhousie University","funders":"","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Anthracycline; Doxorubicin; Breast cancer; Oncology; Internal medicine; Adjuvant; Pharmacology; Cancer; Chemotherapy","score_opus":0.2965734513227626,"score_gpt":0.5799490487503968,"score_spread":0.2833755974276342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145378676","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00026046176,0.9927558,0.000019624193,0.0024529824,0.0008531776,0.0016850575,0.0007344216,0.000038950104,0.0011995331],"genre_scores_gemma":[0.00020048016,0.9955008,0.0003457162,0.00016983706,0.0026924873,0.0007764129,0.00010496736,0.000087317756,0.000121959354],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99674165,0.00023311003,0.0010046419,0.00078631844,0.00046696025,0.0007673426],"domain_scores_gemma":[0.99736834,0.00043106233,0.00072443875,0.000579071,0.0005742107,0.00032285982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030965838,0.00053382065,0.0029554944,0.00028361782,0.00015938238,0.000032141066,0.00034949483,0.0006254889,0.00018217156],"category_scores_gemma":[0.00008410895,0.0004226257,0.00046572828,0.00032897716,0.0008528144,0.0001676116,0.00015699615,0.00088776933,0.0000047076733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015119949,0.00030578935,0.00002483258,0.018359981,0.00018414427,0.000067625435,0.0005721363,3.6410984e-7,0.00001012203,0.00014791555,0.029766995,0.9504089],"study_design_scores_gemma":[0.0007440863,0.0011406526,0.00013135748,0.012510355,0.00021294472,0.001200414,0.0004543597,0.000006295968,0.000019073328,0.000046477824,0.9832161,0.00031787972],"about_ca_topic_score_codex":0.00020215512,"about_ca_topic_score_gemma":0.000032405518,"teacher_disagreement_score":0.95344913,"about_ca_system_score_codex":0.00026559772,"about_ca_system_score_gemma":0.0052251867,"threshold_uncertainty_score":0.99982256},"labels":[],"label_agreement":null},{"id":"W2145824104","doi":"10.1186/1476-4598-9-75","title":"Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy","year":2010,"lang":"en","type":"article","venue":"Molecular Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":227,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Tyrosine kinase; Biology; Angiogenesis; Receptor tyrosine kinase; Cancer research; Tyrosine-kinase inhibitor; Monoclonal antibody; Cancer; Kinase; Acquired resistance; Cancer cell; Signal transduction; Immunology; Antibody; Cell biology; Genetics","score_opus":0.019740080904640748,"score_gpt":0.33466908602350537,"score_spread":0.3149290051188646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145824104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9645577,0.005081842,0.017331665,0.008022756,0.00058112893,0.0015159369,0.00008178096,0.00010882353,0.0027183297],"genre_scores_gemma":[0.9844683,0.00015535839,0.00995812,0.0037754679,0.00009717095,0.0003704611,0.000020186639,0.00011077796,0.0010441638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99748164,0.000076886754,0.00036391578,0.00055324996,0.0009611015,0.00056322326],"domain_scores_gemma":[0.9979402,0.000022046645,0.000095480726,0.001050222,0.0004828859,0.00040916936],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034106124,0.00026628992,0.000461778,0.0002184876,0.00005321446,0.000023487133,0.00034880918,0.00018629798,0.0013788069],"category_scores_gemma":[0.00019197572,0.0002478843,0.00018066351,0.00078250497,0.00013429242,0.000045304292,0.00009375779,0.00025187552,0.000039205705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005525135,0.00014554207,0.00020999055,0.00010563368,0.00009790012,0.00034135117,0.0001251194,0.000035158202,0.9879879,0.0027704148,0.0028066135,0.0048218803],"study_design_scores_gemma":[0.0015100938,0.00027888094,0.0013931692,0.00015914705,0.000033656255,0.0000061506776,0.000017488963,0.0000569072,0.96106344,0.00088852085,0.034358136,0.0002343975],"about_ca_topic_score_codex":0.00027274375,"about_ca_topic_score_gemma":0.00017853048,"teacher_disagreement_score":0.031551525,"about_ca_system_score_codex":0.00015445858,"about_ca_system_score_gemma":0.0005568477,"threshold_uncertainty_score":0.9999973},"labels":[],"label_agreement":null},{"id":"W2145944809","doi":"10.2967/jnumed.108.060772","title":"Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncogene; Cancer; Targeted therapy; Cancer research; Gene; Cancer therapy; Biology; Computational biology; Term (time); Addiction; Genetics; Neuroscience; Physics","score_opus":0.03568112765676891,"score_gpt":0.3784747913586057,"score_spread":0.3427936637018368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145944809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7302815,0.029445011,0.001069419,0.2262502,0.0007627136,0.0012756324,0.0000064521437,0.00010717618,0.010801949],"genre_scores_gemma":[0.98290265,0.0011903717,0.0031494366,0.011709871,0.0008635473,0.0000051740158,0.0000018361332,0.000069137044,0.00010798282],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802995,0.000056663564,0.0004840956,0.00018615968,0.0008504985,0.00039260724],"domain_scores_gemma":[0.99843985,0.00011083143,0.0003117531,0.00021712169,0.00060094526,0.00031952208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008932012,0.00018322241,0.00064387027,0.0003095291,0.00009262447,0.000018689952,0.00018450904,0.000050935087,0.00041657907],"category_scores_gemma":[0.00029548473,0.00011557925,0.000118868826,0.00032746192,0.0001339393,0.00010612469,0.000011710948,0.00050894864,0.000002194858],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007572288,0.00037443035,0.0053127795,0.00020018281,0.00058885245,0.0021206313,0.0046089184,0.00012377194,0.6242888,0.0002032324,0.101419255,0.25318685],"study_design_scores_gemma":[0.05823419,0.03315007,0.043926895,0.014194198,0.0009712099,0.0036727432,0.0044952515,0.0058945655,0.02369324,0.0007507108,0.81015027,0.00086665],"about_ca_topic_score_codex":0.00004516312,"about_ca_topic_score_gemma":0.0000014869432,"teacher_disagreement_score":0.708731,"about_ca_system_score_codex":0.0002206145,"about_ca_system_score_gemma":0.0002777675,"threshold_uncertainty_score":0.4713185},"labels":[],"label_agreement":null},{"id":"W2146284460","doi":"10.1158/0008-5472.can-11-3594","title":"HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute","keywords":"Epithelium; Cancer research; Breast cancer; Medicine; Internal medicine; Oncology; Pathology; Cancer","score_opus":0.19696368002746906,"score_gpt":0.46742808663521285,"score_spread":0.2704644066077438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146284460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8966153,0.0027556294,0.00023889233,0.09477616,0.00042873615,0.004119286,0.0002472588,0.000057174577,0.00076154113],"genre_scores_gemma":[0.99009186,0.0003568323,0.0001533236,0.001569102,0.0019228642,0.0033943073,0.000013048036,0.0000643675,0.0024343242],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996945,0.00020372603,0.00021692408,0.00034623037,0.0010750653,0.0012130127],"domain_scores_gemma":[0.9977029,0.00044973617,0.000042223663,0.0005430387,0.000665696,0.0005964377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025857186,0.00016547913,0.00025941085,0.00027647163,0.00036388217,0.000092257156,0.00027992102,0.00008857776,0.0003982941],"category_scores_gemma":[0.000485256,0.00011346033,0.000049927152,0.0006528566,0.00015068804,0.00019336857,0.0002232709,0.00045903164,0.00016759404],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048440234,0.0003467087,0.011068905,0.0038558773,0.00023056523,0.000017894336,0.020821873,0.0000066513808,0.3081239,0.0005884674,0.34046894,0.3096262],"study_design_scores_gemma":[0.0035095555,0.0027365503,0.02952114,0.0014982793,0.00009306205,0.00045404723,0.0033616666,0.0008977903,0.27323624,0.00022900527,0.6839375,0.0005251704],"about_ca_topic_score_codex":0.00079597626,"about_ca_topic_score_gemma":0.00072228507,"teacher_disagreement_score":0.34346852,"about_ca_system_score_codex":0.0005678446,"about_ca_system_score_gemma":0.00043785735,"threshold_uncertainty_score":0.46267778},"labels":[],"label_agreement":null},{"id":"W2146684793","doi":"10.1158/1078-0432.ccr-05-1855","title":"Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers <i>In vitro</i> and in an Animal Model","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Cetuximab; Epidermal growth factor receptor; Cancer research; Pancreatic cancer; EGFR inhibitors; Monoclonal antibody; Cytotoxic T cell; Medicine; In vivo; CD3; Antibody; Cancer; Epidermal growth factor; Immunology; Receptor; Biology; Antigen; In vitro; Internal medicine; CD8","score_opus":0.1702311512438923,"score_gpt":0.505965953970119,"score_spread":0.3357348027262267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146684793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875036,0.0011254243,0.00004491007,0.005876692,0.00032614692,0.0026954531,0.00048017563,0.00009549132,0.0018521277],"genre_scores_gemma":[0.9936588,0.0027713194,0.00054764264,0.00049757503,0.0012764363,0.00034854366,0.000075883865,0.00017131,0.00065253465],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9896778,0.0017252596,0.0013928149,0.0023326678,0.0023350508,0.0025364086],"domain_scores_gemma":[0.99471223,0.001728541,0.00017224533,0.0010208058,0.0009526046,0.0014135578],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004961343,0.0005840177,0.0017506429,0.0012483873,0.00027119266,0.0002065222,0.00072546955,0.0006443388,0.00019775191],"category_scores_gemma":[0.0011134084,0.00056561216,0.0002268709,0.0027330902,0.0011823685,0.0005387428,0.00055343757,0.00388215,0.00009008827],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008602826,0.001508145,0.28357765,0.00043593632,0.000035797966,0.00051260856,0.00030649328,0.00027139767,0.6947602,0.000025011685,0.0054155756,0.0045483583],"study_design_scores_gemma":[0.008169197,0.0026891134,0.69902253,0.0009826558,0.000035036574,0.000015349562,0.00024386226,0.018415162,0.26815066,0.00009757449,0.0012402872,0.0009385694],"about_ca_topic_score_codex":0.0197066,"about_ca_topic_score_gemma":0.0046471623,"teacher_disagreement_score":0.42660952,"about_ca_system_score_codex":0.003349229,"about_ca_system_score_gemma":0.0040076384,"threshold_uncertainty_score":0.9996795},"labels":[],"label_agreement":null},{"id":"W2146706444","doi":"10.1016/j.clon.2012.05.009","title":"Dual Blockade of HER2 — Twice as Good or Twice as Toxic?","year":2012,"lang":"en","type":"review","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital; University of Toronto","funders":"","keywords":"Medicine; Blockade; Dual (grammatical number); Oncology; Pharmacology; Internal medicine; Receptor","score_opus":0.557896555394812,"score_gpt":0.6558580151693912,"score_spread":0.09796145977457926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146706444","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032303648,0.9107559,0.0000025177071,0.0018688798,0.0030299518,0.0022582104,0.000057945665,0.0000885413,0.08161507],"genre_scores_gemma":[0.00012520005,0.9650356,0.00079721,0.0018137262,0.007882899,0.00031105764,0.00009797067,0.00018480513,0.02375152],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98995024,0.0026145368,0.0040018195,0.001150847,0.0010301676,0.0012524005],"domain_scores_gemma":[0.98101294,0.013937962,0.0014867513,0.0016873273,0.0004380794,0.0014369414],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0059460737,0.00068763655,0.007842654,0.0002878713,0.00006521064,0.000013864373,0.0008928786,0.0036347874,0.010049194],"category_scores_gemma":[0.01203861,0.00047679414,0.0016150693,0.0007990022,0.0012710206,0.000061641644,0.00076973817,0.004624742,0.008156886],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009657615,0.0023338685,0.00011476015,0.014663814,0.0009356483,0.0011430369,0.00005795588,2.1314518e-8,0.0000024709589,0.00028472499,0.015479485,0.96401846],"study_design_scores_gemma":[0.0021748834,0.017257027,0.00008516853,0.0061184173,0.0038872396,0.0016793404,0.000044847297,7.508413e-7,0.000007021146,0.000056051984,0.96828705,0.00040217338],"about_ca_topic_score_codex":0.00028120028,"about_ca_topic_score_gemma":0.00013564223,"teacher_disagreement_score":0.96361625,"about_ca_system_score_codex":0.00092689076,"about_ca_system_score_gemma":0.015738076,"threshold_uncertainty_score":0.9997684},"labels":[],"label_agreement":null},{"id":"W2147073360","doi":"10.1164/rccm.200909-1396oc","title":"The Metalloprotease-Disintegrin ADAM8 Is Essential for the Development of Experimental Asthma","year":2010,"lang":"en","type":"article","venue":"American Journal of Respiratory and Critical Care Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Immunology; Proinflammatory cytokine; Asthma; Inflammation; Context (archaeology); Ovalbumin; Metalloproteinase; Biology; Internal medicine; Matrix metalloproteinase; Immune system","score_opus":0.037281504803695624,"score_gpt":0.4054293672336085,"score_spread":0.3681478624299129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147073360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96772516,0.01698924,0.0018409622,0.011954336,0.0006099515,0.0004784579,0.000008334756,0.0000071047516,0.00038643018],"genre_scores_gemma":[0.99602085,0.000039089773,0.0018780903,0.0011792248,0.0008014465,0.000034332625,5.902836e-7,0.000019842011,0.000026514477],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979259,0.0001096181,0.00066035264,0.00016480667,0.0008475305,0.00029184093],"domain_scores_gemma":[0.9971359,0.0011912553,0.00018116222,0.00026614437,0.0008828635,0.00034270083],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0015368932,0.00015151413,0.00046057013,0.00008511643,0.00030850124,0.000018879657,0.00025724608,0.000045882596,0.00021182216],"category_scores_gemma":[0.0016608877,0.000071419076,0.00015663786,0.00017786173,0.0031549078,0.00004760885,0.000056849298,0.00068178866,0.0000010223472],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003149916,0.00020177884,0.002338574,0.00031344395,0.0004140184,0.00009598162,0.00975748,2.1232529e-7,0.24534963,0.0027474174,0.003257111,0.7323744],"study_design_scores_gemma":[0.0043158587,0.016810842,0.0075207604,0.0006528055,0.00046549237,0.00053639925,0.11938043,0.00003099424,0.34480515,0.00014997978,0.50505733,0.00027394854],"about_ca_topic_score_codex":0.000020272386,"about_ca_topic_score_gemma":0.000024536226,"teacher_disagreement_score":0.7321005,"about_ca_system_score_codex":0.00005004221,"about_ca_system_score_gemma":0.0006591636,"threshold_uncertainty_score":0.9995579},"labels":[],"label_agreement":null},{"id":"W2147874203","doi":"10.2217/cpr.12.25","title":"Recent treatment advances in HER2-positive metastatic breast cancer: a clinical approach","year":2012,"lang":"en","type":"article","venue":"Clinical Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.2620384103364028,"score_gpt":0.593386484545966,"score_spread":0.3313480742095632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147874203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.30606207,0.22755225,0.0014023234,0.17216639,0.009265775,0.0115454495,0.00051160157,0.00047631143,0.27101782],"genre_scores_gemma":[0.6137748,0.34560752,0.026104521,0.008395106,0.0038786063,0.00074856286,0.00007167204,0.00011969814,0.0012995406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99357665,0.0025517042,0.0016334691,0.0007306421,0.00065002317,0.0008575285],"domain_scores_gemma":[0.9904929,0.0070400843,0.0004378032,0.0006864016,0.0004040862,0.0009387665],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.007347206,0.0002951942,0.0010444555,0.00010171109,0.00007626577,0.000033237993,0.00020129878,0.00022948101,0.000588366],"category_scores_gemma":[0.00927748,0.00022261441,0.0002944037,0.00056924607,0.00043127564,0.000853519,0.00011637457,0.0014484575,0.00040404088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035311873,0.012252452,0.21048734,0.000084150335,0.00032998223,0.00014901819,0.00025700577,0.000007717863,0.0000030013114,0.00019493104,0.002497653,0.77020556],"study_design_scores_gemma":[0.005339435,0.0020108582,0.18212023,0.00019884406,0.0006627448,0.0004584109,0.0011281575,0.00030339888,0.000015621878,0.000048416543,0.8074433,0.0002705843],"about_ca_topic_score_codex":0.00040422578,"about_ca_topic_score_gemma":0.000084098894,"teacher_disagreement_score":0.80494565,"about_ca_system_score_codex":0.00076519966,"about_ca_system_score_gemma":0.0009981667,"threshold_uncertainty_score":0.9990678},"labels":[],"label_agreement":null},{"id":"W2148454974","doi":"10.1155/2014/289836","title":"Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series","year":2014,"lang":"en","type":"article","venue":"ISRN Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Vinorelbine; Medicine; Trastuzumab; Metastatic breast cancer; Concomitant; Breast cancer; Internal medicine; Oncology; Cancer; Chemotherapy; Surgery","score_opus":0.042178716202751834,"score_gpt":0.381553796655331,"score_spread":0.3393750804525792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148454974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9744018,0.00012151212,0.0008513541,0.010159836,0.000291908,0.0011302036,0.000047885085,0.00011089599,0.01288463],"genre_scores_gemma":[0.995581,0.00011296692,0.0020422153,0.00051256677,0.00025497403,0.0002925929,0.000011367446,0.000036869882,0.0011554542],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817955,0.00020984306,0.0003051673,0.00042159474,0.00037824886,0.0005055887],"domain_scores_gemma":[0.9991083,0.00009468214,0.00010519318,0.0002939183,0.00022835945,0.00016952242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046587194,0.0001972106,0.0007020151,0.00023453924,0.00007100695,0.000016602507,0.00012206826,0.000118204676,0.0005320675],"category_scores_gemma":[0.00019734306,0.0001360888,0.000036946145,0.0006002604,0.0004823884,0.00015132086,0.000046970512,0.00048383226,0.000041237872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01805105,0.0020451744,0.85013276,0.0004886286,0.0002987,0.00091507565,0.0032435546,0.00014605735,0.009759578,0.0024005328,0.0016245065,0.110894375],"study_design_scores_gemma":[0.021383999,0.03542908,0.8365487,0.0011331037,0.00037765485,0.007210509,0.0019806237,0.0017826213,0.0044501065,0.00067379646,0.0883322,0.0006975888],"about_ca_topic_score_codex":0.002611145,"about_ca_topic_score_gemma":0.06631125,"teacher_disagreement_score":0.110196784,"about_ca_system_score_codex":0.003017188,"about_ca_system_score_gemma":0.0018648106,"threshold_uncertainty_score":0.95072615},"labels":[],"label_agreement":null},{"id":"W2148572592","doi":"10.1200/jco.2011.37.5824","title":"Quantitative Reverse Transcriptase Polymerase Chain Reaction and the Onco<i>type</i> DX Test for Assessment of Human Epidermal Growth Factor Receptor 2 Status: Time to Reflect Again?","year":2011,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Reverse transcriptase; Epidermal growth factor receptor; Polymerase chain reaction; Real-time polymerase chain reaction; Receptor; Cancer research; Molecular biology; Virology; Internal medicine; Biology; Genetics; Gene","score_opus":0.3018020567412538,"score_gpt":0.5489705288848127,"score_spread":0.24716847214355886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148572592","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.035982516,0.00084295316,0.00026022462,0.95110184,0.0025154736,0.003248551,0.0006722931,0.000022576174,0.0053535705],"genre_scores_gemma":[0.033852752,0.006400503,0.032866534,0.89120525,0.019773277,0.00024380597,0.0003854465,0.0004002355,0.014872213],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913979,0.0027295032,0.003766128,0.00050755305,0.00094788347,0.0006510208],"domain_scores_gemma":[0.9781704,0.015994633,0.0031132242,0.00044270154,0.0016912522,0.00058782205],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009022688,0.0003904223,0.0034108264,0.00040049932,0.00011334188,0.000018133129,0.00038777036,0.0013229345,0.0009049745],"category_scores_gemma":[0.015886778,0.00024959358,0.0009005709,0.00026812733,0.00088880677,0.00013667495,0.00007211799,0.0054759113,0.000028891038],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014034374,0.0010178824,0.0009927623,0.00047901832,0.00096391764,0.00049545476,0.0005357327,1.6235963e-7,0.013274223,0.00007260301,0.9568207,0.011313128],"study_design_scores_gemma":[0.014666909,0.06772722,0.0037283264,0.0006273959,0.0009870917,0.0001409208,0.00016322163,0.00002606431,0.0005040103,0.0002886017,0.91085976,0.00028049754],"about_ca_topic_score_codex":0.00036816156,"about_ca_topic_score_gemma":0.00004128241,"teacher_disagreement_score":0.06670934,"about_ca_system_score_codex":0.00067398703,"about_ca_system_score_gemma":0.0046843225,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W2148689234","doi":"","title":"Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Breast cancer; Metastatic breast cancer; Cancer; Chemotherapy; Oncology; Univariate analysis; Anthracycline; Gastroenterology; Multivariate analysis","score_opus":0.033990501467147397,"score_gpt":0.2991339824245392,"score_spread":0.2651434809573918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148689234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896089,0.002024099,0.000019627922,0.0005051582,0.00013413488,0.007323476,0.00007547508,0.00007980438,0.00022936592],"genre_scores_gemma":[0.9926433,0.00014254371,0.00013540896,0.00013765266,0.00014466084,0.0062993006,0.000019743386,0.000110065186,0.00036732506],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99587584,0.00024487425,0.0005673838,0.00082977366,0.0012817626,0.0012003848],"domain_scores_gemma":[0.99839187,0.00018076565,0.00018309701,0.00046521545,0.00020298074,0.00057606585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006769054,0.00040602882,0.0006858135,0.00029313605,0.0001331674,0.00010417497,0.00020207171,0.000092058195,0.00027915294],"category_scores_gemma":[0.00017907347,0.0003266573,0.000057055837,0.0009185568,0.00015549822,0.00023847166,0.00010968817,0.0006210928,0.000006623487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000626647,0.00075577694,0.83122534,0.00023661871,0.00022859304,0.0006544427,0.0011891468,0.00003058558,0.00005015764,0.000004076995,0.000038644655,0.16495997],"study_design_scores_gemma":[0.0088911,0.00042229233,0.98827374,0.0002945155,0.00017253625,0.000088534456,0.0007829288,0.000100822566,0.000013627186,0.00003117288,0.0005775876,0.00035115602],"about_ca_topic_score_codex":0.01093417,"about_ca_topic_score_gemma":0.004837878,"teacher_disagreement_score":0.1646088,"about_ca_system_score_codex":0.0018212551,"about_ca_system_score_gemma":0.0004843772,"threshold_uncertainty_score":0.9999185},"labels":[],"label_agreement":null},{"id":"W2149775431","doi":"10.1158/0008-5472.can-05-3561","title":"Disruption of the Y-Box Binding Protein-1 Results in Suppression of the Epidermal Growth Factor Receptor and HER-2","year":2006,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":157,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; Child and Family Research Institute; University of British Columbia","funders":"","keywords":"Chromatin immunoprecipitation; Epidermal growth factor receptor; Biology; Receptor; Estrogen receptor; Molecular biology; Cancer research; Epidermal growth factor; Promoter; Breast cancer; Cancer; Gene expression; Gene; Genetics","score_opus":0.09333588458577985,"score_gpt":0.4254608625046686,"score_spread":0.33212497791888873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149775431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890113,0.0005497462,0.0000021090332,0.0074246074,0.0001289119,0.0017398875,0.00016700928,0.000008413708,0.00096800225],"genre_scores_gemma":[0.99614036,0.00019343842,0.00006874706,0.0000122636875,0.00014989733,0.00020498356,0.0000061231854,0.000027400338,0.0031968139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99650455,0.0006860081,0.0004757016,0.00035166164,0.0014596971,0.0005224137],"domain_scores_gemma":[0.99850124,0.0002936382,0.00012820598,0.00057029474,0.00041514676,0.00009149294],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017148359,0.00012136828,0.00027431388,0.00022923602,0.00014872482,0.00001957181,0.00037971223,0.00013511282,0.00016274702],"category_scores_gemma":[0.0011687115,0.00006756938,0.000078213736,0.0011260414,0.0006859703,0.0000870324,0.00038348834,0.00089971157,0.0000046160135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078821776,0.00009815172,0.14195554,0.00063640345,0.000010803812,0.0000028544482,0.0004623898,0.0000058863557,0.8503636,0.00015748653,0.0030444649,0.0024741928],"study_design_scores_gemma":[0.0015189761,0.00014501247,0.21756718,0.0019387734,0.0000047287144,0.0000027894614,0.00019058773,0.00002879203,0.7763329,0.00014998352,0.0020517106,0.000068572],"about_ca_topic_score_codex":0.0062232073,"about_ca_topic_score_gemma":0.0006305558,"teacher_disagreement_score":0.075611636,"about_ca_system_score_codex":0.00045400453,"about_ca_system_score_gemma":0.0006588938,"threshold_uncertainty_score":0.94076693},"labels":[],"label_agreement":null},{"id":"W2149908785","doi":"10.1056/nejmoa052306","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5098,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Chemotherapy; Adjuvant; Monoclonal antibody; Internal medicine; Adjuvant chemotherapy; Cancer; Stage (stratigraphy); Antibody; Immunology","score_opus":0.016119267416777456,"score_gpt":0.34601867080272986,"score_spread":0.3298994033859524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149908785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81341666,0.010760334,0.0001550208,0.1728565,0.00043621773,0.00030690196,0.000014135733,0.000011965943,0.0020422589],"genre_scores_gemma":[0.9793025,0.004123266,0.0003886745,0.0039481204,0.011104124,0.000007923018,0.0000023536734,0.00003704003,0.0010859882],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99774176,0.00010600425,0.00065417535,0.0001848242,0.0009270871,0.00038614465],"domain_scores_gemma":[0.9987222,0.00010888622,0.0001777487,0.00018192585,0.00029071688,0.0005184981],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010290872,0.00019681676,0.00069227605,0.00035707376,0.000021223566,0.000008737885,0.00015269204,0.000094805,0.004447939],"category_scores_gemma":[0.000095021045,0.00012599767,0.0000886556,0.0003301532,0.00014679799,0.00011602555,0.000015968199,0.00083957857,0.000014314768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007043089,0.0002360957,0.06269674,0.0000623342,0.0001330964,0.0011044997,0.004351454,0.00003782617,0.0029156685,0.000008362491,0.019396277,0.90201455],"study_design_scores_gemma":[0.11140306,0.0027100288,0.6978382,0.0041782353,0.00014977418,0.007013271,0.00039045175,0.00014915064,0.0015753678,0.00010206018,0.17427333,0.00021710563],"about_ca_topic_score_codex":0.00073595444,"about_ca_topic_score_gemma":0.00066007377,"teacher_disagreement_score":0.9017975,"about_ca_system_score_codex":0.0005802396,"about_ca_system_score_gemma":0.00073102367,"threshold_uncertainty_score":0.9964621},"labels":[],"label_agreement":null},{"id":"W2149953725","doi":"10.1093/annonc/mdt069","title":"Is adjuvant trastuzumab a cost-effective therapy for HER-2/neu-positive T1bN0 breast cancer?","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Capital District Health Authority","funders":"Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Chemotherapy; Cancer","score_opus":0.14112045725974376,"score_gpt":0.4968204685723518,"score_spread":0.35570001131260803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149953725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8421176,0.0041437284,0.00022968171,0.12961632,0.00046344605,0.01479422,0.0009889562,0.00006814959,0.007577895],"genre_scores_gemma":[0.9769383,0.0029311918,0.00019035,0.010912477,0.00045625103,0.0076276995,0.000026018093,0.000057455673,0.0008602453],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99795586,0.00020325198,0.00038252145,0.00044387675,0.00033586545,0.00067860144],"domain_scores_gemma":[0.9971198,0.0006928545,0.00017876863,0.00033418147,0.0013858421,0.00028858206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047992976,0.00022753388,0.00080750394,0.00016663277,0.00007753688,0.0000129971495,0.00021008629,0.00025894333,0.0015844805],"category_scores_gemma":[0.00010066899,0.00018398424,0.0003006939,0.00025475913,0.0003253087,0.000109223576,0.000052384283,0.00033726858,0.0001082989],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024083753,0.0008217493,0.0041023716,0.00011929772,0.00055213185,0.00002403781,0.0016612323,0.0000058132896,0.01095334,0.00005948241,0.09447311,0.8848191],"study_design_scores_gemma":[0.014589598,0.035513975,0.41852266,0.00053876813,0.0001493844,0.0003091059,0.0011284682,0.0008319172,0.13522723,0.0011762173,0.39148334,0.0005293224],"about_ca_topic_score_codex":0.002611666,"about_ca_topic_score_gemma":0.00014417965,"teacher_disagreement_score":0.88428974,"about_ca_system_score_codex":0.0003701688,"about_ca_system_score_gemma":0.001166813,"threshold_uncertainty_score":0.9993282},"labels":[],"label_agreement":null},{"id":"W2150308444","doi":"10.1007/s10637-010-9444-0","title":"A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Académie française","keywords":"Nimotuzumab; Medicine; Toxicity; Epidermal growth factor receptor; Pharmacodynamics; Rash; Pharmacology; Internal medicine; Cetuximab; Pharmacokinetics; Phases of clinical research; Oncology; Monoclonal antibody; Antibody; Cancer; Immunology","score_opus":0.027555083651461375,"score_gpt":0.35338870311606624,"score_spread":0.3258336194646049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150308444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497074,0.000013904952,0.000036020243,0.0028092014,0.0002965807,0.001419421,0.00008349289,0.000035530335,0.00033508535],"genre_scores_gemma":[0.99553436,0.000009862081,0.0027258748,0.0005340096,0.00040583411,0.0000570039,0.0005815571,0.000036386304,0.0001150879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747777,0.00014004404,0.0005594631,0.0003519516,0.0011379139,0.00033288542],"domain_scores_gemma":[0.998332,0.00024383816,0.00023845166,0.00037497163,0.0004798551,0.00033086425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042010657,0.00020443863,0.00033564714,0.00019676119,0.00009331027,0.000030149864,0.00022549248,0.00012467243,0.00017748427],"category_scores_gemma":[0.00090525975,0.00014247515,0.00006344522,0.0004892603,0.00046600137,0.00039121704,0.00004113388,0.00047099957,0.000014867266],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.050013054,0.0032990307,0.55219626,0.00028026223,0.00015397173,0.000012417131,0.0072256397,0.0002631521,0.33409595,0.0036980733,0.0024568178,0.046305362],"study_design_scores_gemma":[0.14531843,0.0035739096,0.8036984,0.00047247394,0.00003810875,0.0000034433756,0.00020899416,0.0010520916,0.04119474,0.0018613656,0.0021559543,0.00042207036],"about_ca_topic_score_codex":0.00019173836,"about_ca_topic_score_gemma":0.00007036992,"teacher_disagreement_score":0.29290122,"about_ca_system_score_codex":0.00011539959,"about_ca_system_score_gemma":0.0014968251,"threshold_uncertainty_score":0.5809968},"labels":[],"label_agreement":null},{"id":"W2150713593","doi":"10.1309/ajcpv2i0hgpmgbsq","title":"Emerging Technologies for Assessing HER2 Amplification","year":2009,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Immunohistochemistry; In situ hybridization; Trastuzumab; Human Epidermal Growth Factor Receptor 2; Fluorescence in situ hybridization; Chromogenic; Concordance; Breast cancer; Pathology; In situ; Fish <Actinopterygii>; Biology; Medicine; Cancer; Internal medicine; Chemistry; Bioinformatics; Genetics; Messenger RNA","score_opus":0.3066237885235228,"score_gpt":0.620314042129059,"score_spread":0.31369025360553626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150713593","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019813163,0.98816913,0.006797793,0.0028920926,0.00075085805,0.0007471238,0.00001149427,0.0000735199,0.00035987294],"genre_scores_gemma":[0.00037318928,0.9685273,0.029393785,0.00032706434,0.0011699512,0.00004081761,0.000016756532,0.00007307372,0.00007807081],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99385643,0.00091539935,0.0037073079,0.0005115567,0.00046849964,0.0005407838],"domain_scores_gemma":[0.9905873,0.003356591,0.0044489503,0.0006927081,0.0006838209,0.00023066241],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.005589417,0.00035798716,0.0054940726,0.0006331853,0.00007550463,0.00003859119,0.0006407442,0.0005780347,0.000020920344],"category_scores_gemma":[0.011025504,0.00025702067,0.0016937676,0.00070555805,0.0011764835,0.000084224834,0.00008391576,0.002656928,0.000022046572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000081352126,0.00017158304,0.00018645237,0.0015635212,0.00015838897,0.00033669686,0.000012704313,2.8286712e-7,0.0000020287912,0.000052039388,0.0013236566,0.9961113],"study_design_scores_gemma":[0.00058112707,0.0039014088,0.00028000088,0.008059585,0.0010652425,0.0026736865,0.0002628791,0.0000036794606,0.0000013162179,0.00042557728,0.98253393,0.0002115489],"about_ca_topic_score_codex":0.000002631016,"about_ca_topic_score_gemma":7.35489e-7,"teacher_disagreement_score":0.99589974,"about_ca_system_score_codex":0.00020133985,"about_ca_system_score_gemma":0.0020893351,"threshold_uncertainty_score":0.9999882},"labels":[],"label_agreement":null},{"id":"W2151247845","doi":"10.1128/mcb.00895-14","title":"ERBB2 Deficiency Alters an E2F-1-Dependent Adaptive Stress Response and Leads to Cardiac Dysfunction","year":2014,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biology; Cardiac function curve; Tyrosine kinase; Breast cancer; Gene silencing; E2F; Tamoxifen; Cancer research; Heart failure; Cancer; Internal medicine; Signal transduction; Medicine; Cell biology; Gene; Cell cycle; Genetics","score_opus":0.017575858495515035,"score_gpt":0.2986838417813371,"score_spread":0.2811079832858221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151247845","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772229,0.0017044554,0.019189816,0.0006575997,0.00017399117,0.00040226433,0.000020825848,0.000031437805,0.0005966687],"genre_scores_gemma":[0.9986563,0.000060293598,0.00037969492,0.0005153167,0.000079137135,0.000040664785,0.000039690512,0.00002495974,0.00020394225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806505,0.0006664104,0.0001676135,0.0005339381,0.00018820656,0.00037875562],"domain_scores_gemma":[0.99911666,0.000067744535,0.000029907711,0.00036921186,0.00008364889,0.0003328449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008742048,0.0001644435,0.00028838348,0.0001614277,0.00009191792,0.000022058324,0.00008434978,0.00016087023,0.000028131746],"category_scores_gemma":[0.0001509602,0.00014426131,0.00005103854,0.00012874605,0.00017722529,0.000025842046,0.00010536816,0.00021032523,0.00002162275],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013143579,0.000055052362,0.012165296,0.000038036727,0.000028743143,0.0000603738,0.00026930452,0.0000176948,0.9691984,0.0009107647,0.000057309255,0.015884653],"study_design_scores_gemma":[0.002552652,0.013508465,0.025572123,0.00010347394,0.00019062258,0.000095565316,0.00085909275,0.0008946571,0.9387921,0.00046542124,0.016348675,0.00061716815],"about_ca_topic_score_codex":0.00016273523,"about_ca_topic_score_gemma":0.000016194996,"teacher_disagreement_score":0.03040633,"about_ca_system_score_codex":0.00005997863,"about_ca_system_score_gemma":0.00007295496,"threshold_uncertainty_score":0.5882806},"labels":[],"label_agreement":null},{"id":"W2151287258","doi":"10.1634/theoncologist.2013-0217","title":"HER Story: The Next Chapter in HER-2-Directed Therapy for Advanced Breast Cancer","year":2013,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Jewish General Hospital; St. Michael's Hospital; University of Toronto; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Disease; Breast cancer; Clinical trial; Cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2","score_opus":0.25965523279335295,"score_gpt":0.48847452959125165,"score_spread":0.2288192967978987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151287258","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010008291,0.9739714,0.0000036625486,0.012468346,0.0006894482,0.008984207,0.00014546113,0.00012730055,0.0035100465],"genre_scores_gemma":[0.00012810105,0.97708374,0.00011218418,0.0012143479,0.0010713924,0.009923153,0.000036849702,0.00015979366,0.010270451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969179,0.0006224199,0.0005729641,0.00061146717,0.00049553724,0.00077971997],"domain_scores_gemma":[0.9967415,0.0012731127,0.00036781753,0.001214793,0.0002580153,0.00014479959],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015739738,0.0005500502,0.0018228964,0.00013865653,0.00022972954,0.00007001686,0.0009838364,0.0004369195,0.0022984114],"category_scores_gemma":[0.00020118443,0.00024329036,0.00048321567,0.00047873968,0.00069251156,0.000073396404,0.00014869735,0.0015849624,0.0002528569],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022755905,0.000115682094,0.000022315373,0.0018051172,0.00018926452,0.000013836315,0.00013757982,0.0000014884642,0.000007672252,0.000084436906,0.017000556,0.9803945],"study_design_scores_gemma":[0.0013770596,0.00037149945,0.00026694342,0.0046450947,0.00019300374,0.00007241337,0.000105104424,0.000021639498,0.0000020284854,0.000042457323,0.9926241,0.00027862657],"about_ca_topic_score_codex":0.0013745392,"about_ca_topic_score_gemma":0.0009957473,"teacher_disagreement_score":0.9801159,"about_ca_system_score_codex":0.0015087955,"about_ca_system_score_gemma":0.001492895,"threshold_uncertainty_score":0.9986136},"labels":[],"label_agreement":null},{"id":"W2151480309","doi":"10.1016/j.biopha.2006.08.003","title":"Protein tyrosine kinase signaling diversity and susceptibility to targeted kinase inhibitors","year":2006,"lang":"en","type":"review","venue":"Biomedicine & Pharmacotherapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University","funders":"National Cancer Institute","keywords":"Receptor tyrosine kinase; Tyrosine kinase; Cancer research; Biology; Kinase; Signal transduction; JAK-STAT signaling pathway; Cell biology","score_opus":0.08842263659665611,"score_gpt":0.4154246812867952,"score_spread":0.3270020446901391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151480309","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011535038,0.9784273,0.00007825299,0.0010167012,0.00057325844,0.007699656,0.0002729139,0.00026472955,0.00013217905],"genre_scores_gemma":[0.0024269884,0.9898794,0.0006793429,0.0010165973,0.003131543,0.00042756926,0.00039863764,0.00023874248,0.0018011611],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99420315,0.00045539247,0.0012339985,0.0015217592,0.0015041552,0.001081519],"domain_scores_gemma":[0.99696,0.00016366271,0.00037214058,0.00088337046,0.00034609908,0.0012747163],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016536098,0.001051685,0.002881937,0.0012248029,0.00053886726,0.000046704794,0.00049481995,0.00048193612,0.0011715823],"category_scores_gemma":[0.00013647646,0.00081870495,0.000503419,0.002100399,0.0005470143,0.000096573116,0.0006567466,0.001196823,0.00009056639],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039647185,0.00052164873,0.0005326401,0.022600688,0.00031336542,0.00053149206,0.00025968236,2.3150322e-7,0.037863642,0.0000036108415,0.022350198,0.9146263],"study_design_scores_gemma":[0.003479362,0.0013024816,0.00008805425,0.014815104,0.00079085404,0.000052403342,0.00002096206,0.0000087075205,0.0050416053,0.000008083445,0.9736866,0.00070581184],"about_ca_topic_score_codex":0.0013745965,"about_ca_topic_score_gemma":0.000020794414,"teacher_disagreement_score":0.9513364,"about_ca_system_score_codex":0.0010537523,"about_ca_system_score_gemma":0.00077478186,"threshold_uncertainty_score":0.9997415},"labels":[],"label_agreement":null},{"id":"W2151570682","doi":"10.1093/annonc/mdt393","title":"Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"Roche","keywords":"Medicine; CISH; Trastuzumab; Immunohistochemistry; Adenocarcinoma; Internal medicine; Biopsy; Pathology; Oncology; Cancer; Gastroenterology; In situ hybridization; Breast cancer; Gene expression","score_opus":0.07667223111877967,"score_gpt":0.4079110863048577,"score_spread":0.331238855186078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151570682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743307,0.00020883529,0.0000110780065,0.0006583828,0.000041732303,0.0011417116,0.000017519447,0.0000070148585,0.00048067555],"genre_scores_gemma":[0.99931306,0.00017479995,0.00025932133,0.0000638233,0.000018160497,0.00008525947,0.0000076221,0.000012346613,0.00006561323],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980163,0.000253763,0.0007335382,0.00029686047,0.0003905803,0.0003089456],"domain_scores_gemma":[0.99826705,0.0003473948,0.00020337373,0.00028081448,0.00073266967,0.00016869493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005969996,0.00013257292,0.0010714593,0.0013208935,0.000018268065,0.000004459967,0.00012031184,0.00012535363,0.00023631899],"category_scores_gemma":[0.00029435745,0.000115659124,0.000118231634,0.0018299397,0.00016074195,0.000054363427,0.00011067516,0.00017310918,0.000005774332],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016042247,0.004161895,0.9717328,0.00009584192,0.00074277766,0.000038470946,0.0015684743,0.0001880547,0.003991291,0.0000040671043,0.00043920375,0.01543292],"study_design_scores_gemma":[0.003902698,0.022038557,0.96655077,0.00002901623,0.00025561854,0.000004297603,0.0011522755,0.00045756894,0.005413012,0.0000135501605,0.000107531756,0.000075085925],"about_ca_topic_score_codex":0.00481116,"about_ca_topic_score_gemma":0.00068356626,"teacher_disagreement_score":0.01787666,"about_ca_system_score_codex":0.00009965928,"about_ca_system_score_gemma":0.000145729,"threshold_uncertainty_score":0.7273066},"labels":[],"label_agreement":null},{"id":"W2151726776","doi":"10.1200/jco.2012.30.15_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Breast cancer; Oncology; Protocol (science); Internal medicine; Clinical Oncology; Trastuzumab; Cancer; Family medicine; Gynecology; Medical physics; Alternative medicine; Pathology","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151726776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94013697,0.00091584394,0.00008974701,0.012276723,0.0012081746,0.04212932,0.00004195896,0.0000070123288,0.0031942797],"genre_scores_gemma":[0.9838424,0.00048173394,0.0027831194,0.0008897895,0.0021485768,0.009691785,0.0000022954962,0.00003328781,0.00012705813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936948,0.0013379408,0.0028573277,0.000158161,0.0015871547,0.0003646521],"domain_scores_gemma":[0.99112034,0.0018459149,0.0022361148,0.0002704108,0.0040997355,0.00042748955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024644936,0.00013708453,0.0016154298,0.00013298602,0.000032825636,0.0000043454224,0.0002488505,0.0003251904,0.0016335975],"category_scores_gemma":[0.0034152688,0.000091467584,0.00048161933,0.0001625422,0.0002609333,0.00013134308,0.000045521723,0.0007153476,0.0000077601535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020236887,0.006634393,0.09463601,0.0002627431,0.00066728826,0.000008745417,0.0003462345,0.00011119784,0.005010878,0.00008480216,0.008060211,0.8639406],"study_design_scores_gemma":[0.0700965,0.05195431,0.5099943,0.0012002937,0.0008726258,0.00049257034,0.00036410222,0.0022832728,0.010746404,0.0006732101,0.35109973,0.00022263138],"about_ca_topic_score_codex":0.00033248847,"about_ca_topic_score_gemma":0.00004430386,"teacher_disagreement_score":0.863718,"about_ca_system_score_codex":0.00045304434,"about_ca_system_score_gemma":0.007840122,"threshold_uncertainty_score":0.999279},"labels":[],"label_agreement":null},{"id":"W2152175171","doi":"10.1200/jco.2014.55.6092","title":"Human Epidermal Growth Factor Receptor 2 Testing in Primary Breast Cancer in the Era of Standardized Testing: A Canadian Prospective Study","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Saskatchewan; Saskatoon City Hospital; University of British Columbia; Health Sciences Centre; Ottawa Hospital; Kingston General Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Breast cancer; Cancer; Epidermal growth factor receptor; Internal medicine; Gynecology","score_opus":0.19290715174566359,"score_gpt":0.5111243683464978,"score_spread":0.3182172166008342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152175171","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98282707,0.000072643845,0.0000040056743,0.010448518,0.00031887877,0.0008913515,0.00003186771,0.0000049952205,0.0054007],"genre_scores_gemma":[0.9964626,0.000018884217,0.0012200809,0.0011713249,0.0010501142,0.00003189872,5.8440816e-7,0.000022981145,0.000021565944],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936507,0.0021918234,0.0026152227,0.00026396287,0.0007963075,0.0004820232],"domain_scores_gemma":[0.9898365,0.0069625685,0.0011757537,0.00023449225,0.0013484474,0.00044219533],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.013325313,0.00015981137,0.0016882103,0.0002966168,0.000063830215,0.000013695964,0.00039441398,0.00024702094,0.0002364558],"category_scores_gemma":[0.026222568,0.00010227962,0.00016281987,0.0007169801,0.00029684472,0.00009612106,0.00006250345,0.003117137,0.000002639405],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011096586,0.0013335547,0.91298574,0.00005576673,0.00008590631,0.00044726027,0.00087211805,0.000012392303,0.00031656743,0.000014594544,0.0004906073,0.08227581],"study_design_scores_gemma":[0.009220016,0.0108512165,0.9778371,0.00037719336,0.000059567985,0.00019263176,0.0005126063,0.00004440057,0.00001612877,0.00014341169,0.00065680005,0.00008893865],"about_ca_topic_score_codex":0.041980904,"about_ca_topic_score_gemma":0.09512591,"teacher_disagreement_score":0.08218687,"about_ca_system_score_codex":0.001726287,"about_ca_system_score_gemma":0.011022792,"threshold_uncertainty_score":0.9991827},"labels":[],"label_agreement":null},{"id":"W2152419134","doi":"10.1200/jco.2005.08.091","title":"Multicenter, Randomized Phase II Trial of Oral CI-1033 for Previously Treated Advanced Ovarian Cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôtel-Dieu de Québec; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Ovarian cancer; Gastroenterology; Adverse effect; Toxicity; Population; Nausea; Cancer; Phases of clinical research; Oncology","score_opus":0.23491025272936084,"score_gpt":0.6057291711774904,"score_spread":0.37081891844812953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152419134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9657034,0.0017330146,0.0007336203,0.023994429,0.0023731932,0.0041575613,0.000036603768,0.00001772184,0.0012504256],"genre_scores_gemma":[0.96532345,0.0052163326,0.021364292,0.0018798789,0.00423308,0.00022134178,0.000009130766,0.00005080979,0.0017016589],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99273556,0.0012130417,0.0047062174,0.0002732845,0.0006079123,0.00046398578],"domain_scores_gemma":[0.98810834,0.0069230874,0.0027811455,0.00029486744,0.001281871,0.0006106652],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011092048,0.00020160343,0.0040885448,0.00020382706,0.00005732,0.0000070876063,0.00029103292,0.00046648033,0.0008751375],"category_scores_gemma":[0.025545185,0.0001342186,0.0014445033,0.00018611678,0.00046595128,0.00013138639,0.000063913096,0.0010301482,0.000006413042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6134435,0.0063762655,0.00019437597,0.000054887372,0.0006353855,0.000050324838,0.00010755679,0.000025563299,0.00049445045,0.00001873059,0.0042274836,0.37437147],"study_design_scores_gemma":[0.71761715,0.045378864,0.00010202765,0.0002148242,0.00091009703,0.000029651053,0.000026454763,0.0012975384,0.0007498118,0.000049149963,0.23354167,0.00008274385],"about_ca_topic_score_codex":0.00008493864,"about_ca_topic_score_gemma":0.00017589497,"teacher_disagreement_score":0.37428874,"about_ca_system_score_codex":0.00040864042,"about_ca_system_score_gemma":0.0036335278,"threshold_uncertainty_score":0.98266304},"labels":[],"label_agreement":null},{"id":"W2152647863","doi":"10.1200/jco.2007.13.5467","title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":545,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Trastuzumab; Medicine; Ejection fraction; Heart failure; Internal medicine; Breast cancer; Cyclophosphamide; Cardiac function curve; Cardiology; Cardiotoxicity; Oncology; Paclitaxel; Cancer; Surgery; Chemotherapy","score_opus":0.11133423106210778,"score_gpt":0.47525447235477447,"score_spread":0.3639202412926667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152647863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886541,0.0031885693,0.000025445344,0.006069997,0.000548415,0.0009791497,0.00034298058,0.000005115723,0.0001862351],"genre_scores_gemma":[0.96280223,0.035162617,0.0002486367,0.0006255523,0.0008317106,0.00007386308,0.000014782782,0.000025795693,0.00021479669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99420196,0.0012147679,0.0026250535,0.00038188926,0.0010083987,0.0005679351],"domain_scores_gemma":[0.99504733,0.0023958362,0.0013536145,0.0003398576,0.00034016947,0.0005231797],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025908414,0.0002804208,0.003697306,0.0002533825,0.00008055151,0.000008652992,0.00025103416,0.00029152815,0.0002584341],"category_scores_gemma":[0.0004613649,0.00013362928,0.0007527096,0.001007721,0.00065279496,0.00009560601,0.000034615012,0.0010193486,5.8799765e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19290383,0.0021697988,0.7532604,0.00002272634,0.003701412,0.0006226674,0.0009912968,0.00009813567,0.000050260853,0.0000021666617,0.0017451862,0.044432145],"study_design_scores_gemma":[0.07699766,0.022044957,0.8792937,0.00012106622,0.004063047,0.0001806988,0.00048406865,0.00012097494,0.00001913991,0.0000017908902,0.016537732,0.00013520369],"about_ca_topic_score_codex":0.007729495,"about_ca_topic_score_gemma":0.027723093,"teacher_disagreement_score":0.12603328,"about_ca_system_score_codex":0.0012004686,"about_ca_system_score_gemma":0.0051494525,"threshold_uncertainty_score":0.9988781},"labels":[],"label_agreement":null},{"id":"W2152734037","doi":"10.1038/sj.bjc.6605560","title":"Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer","year":2010,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of New Brunswick","funders":"","keywords":"NONMEM; Dosing; Medicine; Pharmacokinetics; Population; Breast cancer; Covariate; Monoclonal antibody; Oncology; Cancer; Pharmacology; Antibody; Internal medicine; Immunology; Statistics; Mathematics","score_opus":0.03689079871606183,"score_gpt":0.4347484097484792,"score_spread":0.3978576110324174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152734037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99411476,0.0017823845,0.000016658252,0.0012896834,0.0014387162,0.00062990806,0.0005800612,0.000010554457,0.0001372679],"genre_scores_gemma":[0.9963678,0.0011254698,0.00011897218,0.00036844332,0.0018238953,0.000028686274,0.000011028088,0.00004835749,0.00010733229],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997305,0.00014726119,0.0007112132,0.0002355319,0.0013017032,0.00029929559],"domain_scores_gemma":[0.99811584,0.00007491243,0.000548203,0.00027673843,0.0007588991,0.00022539226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004237113,0.0001750014,0.00051437743,0.00011730006,0.00013068429,0.00006069082,0.00037609672,0.000095290634,0.0031211043],"category_scores_gemma":[0.000095218165,0.00014818697,0.0002121429,0.00027168184,0.00014878387,0.00012119215,0.00006685949,0.0011703466,0.000002287118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017030719,0.0017428928,0.41995683,0.00005975992,0.0004744443,0.00034938473,0.0004373779,0.00010108462,0.42013848,0.000003741949,0.0023457916,0.15268713],"study_design_scores_gemma":[0.0105492985,0.00048181321,0.96311945,0.0009962996,0.00034126028,0.00043350345,0.00012975099,0.00015582808,0.021453718,0.000042354324,0.00215221,0.0001445215],"about_ca_topic_score_codex":0.010888608,"about_ca_topic_score_gemma":0.0037133892,"teacher_disagreement_score":0.5431626,"about_ca_system_score_codex":0.00021216333,"about_ca_system_score_gemma":0.0006206854,"threshold_uncertainty_score":0.99779016},"labels":[],"label_agreement":null},{"id":"W2152743371","doi":"10.1186/s12964-014-0047-9","title":"TrkB interacts with ErbB4 and regulates NRG1-induced NR2B phosphorylation in cortical neurons before synaptogenesis","year":2014,"lang":"en","type":"article","venue":"Cell Communication and Signaling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Medicine, New York University; National Institutes of Health; York University; Multiple Sclerosis Society; Okinawa Institute of Science and Technology Graduate University; National Institute of Neurological Disorders and Stroke; University of South Carolina","keywords":"Tropomyosin receptor kinase B; ErbB; Neuregulin 1; Cell biology; Neuroscience; Chemistry; Synaptogenesis; Neurotrophic factors; Receptor; Signal transduction; Biology; Biochemistry","score_opus":0.027448658851044132,"score_gpt":0.297390197927738,"score_spread":0.2699415390766939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152743371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616945,0.00065615785,0.00016217801,0.0013054642,0.000012974241,0.00026656102,6.0278603e-7,0.00002916197,0.0013974338],"genre_scores_gemma":[0.9983098,0.00020659082,0.0010747773,0.00021911965,0.000021937918,0.000022233215,0.000021114109,0.000021698599,0.00010272806],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989831,0.0002375382,0.00023277888,0.00020038254,0.00017332015,0.0001728949],"domain_scores_gemma":[0.99894315,0.0003399243,0.00006183464,0.00043317658,0.00008970481,0.00013221354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005648396,0.00010646993,0.00019811452,0.00010615032,0.00013249432,0.000046243455,0.000106095256,0.00007494908,0.000046975467],"category_scores_gemma":[0.00014578504,0.00009030863,0.000017488888,0.00016543691,0.00011143221,0.00007470242,0.00008762111,0.00034536075,0.000004334153],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013673706,0.0005231179,0.2067674,0.00073525676,0.0000795151,0.000023391203,0.011449765,0.00024194528,0.66971266,0.0018479835,0.00019952172,0.107052095],"study_design_scores_gemma":[0.006762854,0.0020647673,0.46040574,0.0018204941,0.00018159844,0.000108544285,0.0026132353,0.108463176,0.4124553,0.0009309922,0.0035900972,0.00060322066],"about_ca_topic_score_codex":0.00013260356,"about_ca_topic_score_gemma":0.00011021571,"teacher_disagreement_score":0.25725734,"about_ca_system_score_codex":0.000049850667,"about_ca_system_score_gemma":0.000050260216,"threshold_uncertainty_score":0.36826792},"labels":[],"label_agreement":null},{"id":"W2152770850","doi":"10.1158/1078-0432.ccr-07-1216","title":"TACE/ADAM-17: A Component of the Epidermal Growth Factor Receptor Axis and a Promising Therapeutic Target in Colorectal Cancer","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Amphiregulin; Epidermal growth factor receptor; Ectodomain; Cancer research; Epidermal growth factor; TGF alpha; Tyrosine kinase; Receptor tyrosine kinase; Growth factor receptor; EGFR inhibitors; Transforming growth factor; Biology; Chemistry; Kinase; Signal transduction; Cell biology; Receptor; Biochemistry","score_opus":0.30923134052828233,"score_gpt":0.5201451766951082,"score_spread":0.21091383616682585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2152770850","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97482973,0.007463951,0.0000056136582,0.0146106575,0.00034842288,0.0021107267,0.0001011959,0.000025880388,0.0005038035],"genre_scores_gemma":[0.98881257,0.008562584,0.00018521758,0.00048448402,0.0005058483,0.00057844364,0.0000041637472,0.000061008977,0.00080565363],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936633,0.0015543557,0.0010814205,0.0007797108,0.0018670855,0.0010541037],"domain_scores_gemma":[0.9960777,0.002006484,0.00016470601,0.0005039876,0.00076770334,0.00047941957],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035372577,0.00024672967,0.0009051337,0.0002664878,0.00028056905,0.000026899615,0.00052916206,0.0003039021,0.0015919142],"category_scores_gemma":[0.0019359234,0.00016838961,0.0002321086,0.00119184,0.0024875482,0.00009800028,0.0004887086,0.0025638505,0.000016716584],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026590596,0.0005375446,0.9555396,0.00041575692,0.0001354406,0.00004990658,0.0012213629,0.000006953998,0.023610208,0.000032541655,0.0064642495,0.009327371],"study_design_scores_gemma":[0.00376742,0.0009469284,0.9608072,0.00096479134,0.000018571283,0.000026047566,0.00017811892,0.00056549074,0.022473935,0.00016252034,0.009875576,0.00021338287],"about_ca_topic_score_codex":0.0066302563,"about_ca_topic_score_gemma":0.0011143911,"teacher_disagreement_score":0.014126174,"about_ca_system_score_codex":0.00079627085,"about_ca_system_score_gemma":0.0032948873,"threshold_uncertainty_score":0.9999847},"labels":[],"label_agreement":null},{"id":"W2153242757","doi":"10.3816/cbc.2004.n.010","title":"Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case Histories","year":2004,"lang":"en","type":"review","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Roche (Canada); St. Boniface Hospital; Lions Gate Hospital; Ottawa Regional Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Regimen; Oncology; Internal medicine; Vinorelbine; Taxane; Metastatic breast cancer; Breast cancer; Chemotherapy; Cardiotoxicity; Cancer; Surgery; Cisplatin","score_opus":0.3380781820358026,"score_gpt":0.5386034532522701,"score_spread":0.20052527121646752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153242757","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056570556,0.9835534,0.0000065385943,0.0013873691,0.00081458775,0.0030637123,0.010993686,0.00004350005,0.00008060883],"genre_scores_gemma":[0.000098081844,0.99564844,0.00095697906,0.00028503872,0.0009736993,0.0009797247,0.0005378609,0.00011991697,0.0004002551],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938587,0.00053966435,0.0030335218,0.0010102417,0.0011418083,0.00041605294],"domain_scores_gemma":[0.99335086,0.0011855833,0.0016080425,0.0015981009,0.001443834,0.0008135845],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007958433,0.00055266457,0.0048779887,0.0001411332,0.0000741275,0.000015725589,0.0003576842,0.00047604437,0.0018732923],"category_scores_gemma":[0.003194371,0.00040818666,0.001729186,0.0010229258,0.0010538214,0.00014381408,0.00021274512,0.0014120529,0.000015470136],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000226962,0.0009099335,0.0040685292,0.23528627,0.00071581616,0.0011822617,0.000035841487,1.2909793e-7,1.09682674e-7,0.00007823575,0.008642148,0.74885374],"study_design_scores_gemma":[0.00052734563,0.00023700799,0.0040381704,0.40873224,0.0044605867,0.00025812944,0.000005645005,8.166246e-7,2.2037665e-7,0.000056822802,0.58144087,0.0002421893],"about_ca_topic_score_codex":0.001145304,"about_ca_topic_score_gemma":0.000094504234,"teacher_disagreement_score":0.74861157,"about_ca_system_score_codex":0.0021906947,"about_ca_system_score_gemma":0.01169082,"threshold_uncertainty_score":0.999837},"labels":[],"label_agreement":null},{"id":"W2153491150","doi":"10.1093/annonc/mdf651","title":"Novel endpoints and design of early clinical trials","year":2002,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Clinical trial; Clinical study design; Endpoint Determination; Surrogate endpoint; Medical physics; Intensive care medicine; Oncology; Internal medicine","score_opus":0.9128397694569303,"score_gpt":0.7023489934726278,"score_spread":0.21049077598430255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153491150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022544797,0.99281347,0.00023677446,0.0005779963,0.0003000193,0.0019881465,0.0000970834,0.000011241954,0.003952747],"genre_scores_gemma":[0.000025103518,0.9957432,0.0025305306,0.00023624444,0.0005053795,0.00008758937,0.000012015347,0.0000496344,0.00081030076],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922151,0.0032715313,0.0031901568,0.00047823126,0.0004381874,0.00040680624],"domain_scores_gemma":[0.9869481,0.010155328,0.0015869373,0.0005710831,0.00042713428,0.00031146966],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016567973,0.00028648405,0.007371359,0.0003647541,0.000017342138,0.0000052351647,0.0002897027,0.001131027,0.00062886067],"category_scores_gemma":[0.011170239,0.0002107793,0.00084891956,0.00028514987,0.0005980891,0.000028483444,0.00015012336,0.00090811733,0.00006410969],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026393755,0.00060107093,0.00002503027,0.009308824,0.0006385355,0.00006415826,0.00003769756,5.7454262e-8,0.00001006151,0.00005359144,0.020620648,0.9683764],"study_design_scores_gemma":[0.0014876295,0.009610493,0.000056624565,0.0072301156,0.0008201963,0.00016754282,0.000005183088,0.0000036786719,0.000019343952,0.000047369987,0.98042023,0.00013160084],"about_ca_topic_score_codex":0.00005491195,"about_ca_topic_score_gemma":0.000002478002,"teacher_disagreement_score":0.9682448,"about_ca_system_score_codex":0.000051259067,"about_ca_system_score_gemma":0.0020083238,"threshold_uncertainty_score":0.9971591},"labels":[],"label_agreement":null},{"id":"W2154671238","doi":"10.1016/j.breast.2012.12.004","title":"Experts' opinion: Recommendations for retesting breast cancer metastases for HER2 and hormone receptor status","year":2013,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Hormone receptor; Oncology; Breast cancer; Human Epidermal Growth Factor Receptor 2; Hormone; Metastatic breast cancer; Internal medicine; Cancer; Regimen; Hormone therapy; Receptor","score_opus":0.08686729125714283,"score_gpt":0.3959840605294179,"score_spread":0.3091167692722751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154671238","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14623092,0.020133793,0.00385035,0.7898715,0.0020328073,0.017712083,0.017392294,0.0005521785,0.0022240607],"genre_scores_gemma":[0.8749364,0.009734738,0.060711075,0.0069509083,0.008384081,0.027110634,0.0019534356,0.00051433285,0.0097043915],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986214,0.00006981299,0.0002490808,0.00030460127,0.00021349109,0.0005415856],"domain_scores_gemma":[0.9983326,0.0006027142,0.0000890156,0.00034931445,0.00036692055,0.0002594338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004507156,0.00016940752,0.00026484072,0.00006342847,0.00031504585,0.00008011482,0.00013149402,0.00005681105,0.0010365284],"category_scores_gemma":[0.00019055243,0.00011450289,0.00007789129,0.00017312607,0.00014548325,0.00015534046,0.000074678625,0.00013991886,0.000018694167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000504004,0.000097660166,0.001982533,0.00021495874,0.00018410389,3.7571814e-7,0.00070604426,0.0000017644339,0.006224049,0.00028615977,0.5953747,0.39442366],"study_design_scores_gemma":[0.0074939732,0.0010298407,0.042320147,0.0012086678,0.00025154473,0.0009957084,0.0056719473,0.0029778467,0.0017850907,0.00092438876,0.9346556,0.0006852336],"about_ca_topic_score_codex":0.0021067478,"about_ca_topic_score_gemma":0.00004737817,"teacher_disagreement_score":0.7829206,"about_ca_system_score_codex":0.00016295076,"about_ca_system_score_gemma":0.00023177422,"threshold_uncertainty_score":0.9998767},"labels":[],"label_agreement":null},{"id":"W2155724119","doi":"10.1158/1078-0432.ccr-05-1652","title":"Application of Oligonucleotide Microarrays to Assess the Biological Effects of Neoadjuvant Imatinib Mesylate Treatment for Localized Prostate Cancer","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Imatinib mesylate; Prostate cancer; Tissue microarray; Cancer research; Medicine; Cancer; Immunohistochemistry; Pathology; Laser capture microdissection; Gene expression; Oncology; Biology; Internal medicine; Imatinib; Gene","score_opus":0.27743457004309985,"score_gpt":0.5688233716791935,"score_spread":0.29138880163609365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155724119","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756176,0.0041079298,0.0014630826,0.007979418,0.00025576414,0.009861013,0.00025952933,0.000043373257,0.0004122845],"genre_scores_gemma":[0.9847086,0.0034969635,0.0018085793,0.00026732564,0.00064557226,0.008159419,0.000040044248,0.000063382504,0.0008101207],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953185,0.0008280014,0.0012522116,0.0007483767,0.0009742841,0.00087866996],"domain_scores_gemma":[0.9924579,0.004711038,0.00024975277,0.000893357,0.0013611992,0.00032674422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004120099,0.00024301626,0.0009990076,0.00018810958,0.00015517822,0.000026671265,0.0005110753,0.0002487052,0.000108970446],"category_scores_gemma":[0.0015620195,0.00014260244,0.00035636761,0.0008800137,0.0010555034,0.000034753724,0.00020422562,0.00061008096,0.000023937182],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012847879,0.0023686816,0.20272064,0.0025803798,0.00047327092,0.00002688823,0.00047402046,0.0004185744,0.32048672,0.0011971667,0.016088596,0.44031718],"study_design_scores_gemma":[0.013381171,0.011744256,0.17871642,0.0013530577,0.00022099589,0.00000568357,0.0002024445,0.0022627565,0.61397886,0.0018539192,0.17586946,0.00041097272],"about_ca_topic_score_codex":0.008566867,"about_ca_topic_score_gemma":0.0006759658,"teacher_disagreement_score":0.4399062,"about_ca_system_score_codex":0.0005748531,"about_ca_system_score_gemma":0.0012850906,"threshold_uncertainty_score":0.9980352},"labels":[],"label_agreement":null},{"id":"W2155980759","doi":"10.3747/co.2008.199","title":"Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group","year":2008,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Oncology; Anthracycline; Breast cancer; Internal medicine; Adjuvant therapy; Population; Clinical trial; Adjuvant; Targeted therapy; Intensive care medicine; Cancer; Chemotherapy","score_opus":0.22211101870424318,"score_gpt":0.42467998267004725,"score_spread":0.20256896396580407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155980759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94149214,0.0064051426,0.000036207002,0.008706801,0.0044994424,0.0022955458,0.000050742783,0.00006438961,0.036449607],"genre_scores_gemma":[0.9931391,0.0054155714,0.00021119021,0.0001178019,0.00032737138,0.00022910512,0.000029328205,0.00003285019,0.0004976938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99798876,0.00026166573,0.00040517972,0.00033690638,0.00042634664,0.00058111496],"domain_scores_gemma":[0.99890995,0.000083678424,0.00011406955,0.00051285286,0.000102477796,0.00027697062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003964051,0.00017456803,0.00043598455,0.00027445977,0.0004465197,0.000009042245,0.00031182612,0.0001130606,0.00024524523],"category_scores_gemma":[0.000038563543,0.00013454944,0.00020063299,0.0005111635,0.00027123772,0.000035333465,0.00010201769,0.0006051214,0.000028751825],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002258326,0.000933671,0.16880602,0.00026924978,0.0004286114,0.00012920497,0.0043936768,0.00001296185,0.0007396972,0.00092577544,0.025224771,0.7979105],"study_design_scores_gemma":[0.0017855184,0.00030124726,0.3249565,0.00023697273,0.000057125817,0.0000654759,0.0004626867,0.00002505309,0.0004234867,0.000037492548,0.6715206,0.0001278348],"about_ca_topic_score_codex":0.004947954,"about_ca_topic_score_gemma":0.021216655,"teacher_disagreement_score":0.7977827,"about_ca_system_score_codex":0.0026356215,"about_ca_system_score_gemma":0.0010590171,"threshold_uncertainty_score":0.9966436},"labels":[],"label_agreement":null},{"id":"W2156373035","doi":"10.1021/cb500129t","title":"Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?","year":2014,"lang":"en","type":"review","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Small molecule; Drug discovery; Kinase; Binding site; Chemistry; Stereochemistry; Active site; Plasma protein binding; Biophysics; Enzyme; Combinatorial chemistry; Biochemistry; Biology","score_opus":0.13086901584217306,"score_gpt":0.41855666171176176,"score_spread":0.2876876458695887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156373035","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035208694,0.9873563,0.002636426,0.00026243212,0.0004565541,0.004670174,0.00036893887,0.000087738656,0.00064058066],"genre_scores_gemma":[0.0061123106,0.97993517,0.0046568266,0.00005739399,0.0014093049,0.0013269546,0.00572604,0.00013455687,0.0006414516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975631,0.00018345348,0.0008266499,0.000707325,0.00022384127,0.0004956015],"domain_scores_gemma":[0.99814343,0.000517876,0.00035600923,0.0006263692,0.00019758115,0.00015874229],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005711362,0.00038242628,0.0021987548,0.00022179825,0.00005216236,0.000013090811,0.00035859365,0.0007671116,0.000019634035],"category_scores_gemma":[0.0013672692,0.00027631424,0.0003970696,0.00042875414,0.00025338773,0.00009233845,0.0002959732,0.0006396149,0.000016319846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000523376,0.0005701897,0.000018762015,0.062044974,0.00046599994,0.0000037525956,0.00019656589,5.713794e-7,0.056460723,0.0013185489,0.010352756,0.8680438],"study_design_scores_gemma":[0.0012582602,0.0006125578,4.7029605e-8,0.004128956,0.0005175031,0.000012096587,0.000012212173,0.000076773824,0.026015898,0.00020624696,0.9668044,0.00035504697],"about_ca_topic_score_codex":0.000012857053,"about_ca_topic_score_gemma":7.717849e-7,"teacher_disagreement_score":0.95645165,"about_ca_system_score_codex":0.0002789055,"about_ca_system_score_gemma":0.00057225616,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","score_opus":0.39172005433816587,"score_gpt":0.5739504872546254,"score_spread":0.18223043291645952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158179945","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013638576,0.96213764,0.000003794673,0.0047400687,0.00075698114,0.0059504695,0.00012974568,0.000025171697,0.02611972],"genre_scores_gemma":[0.000042362513,0.9928949,0.0005066438,0.0009603435,0.0024196634,0.0014925742,0.000028993501,0.00016147939,0.0014930641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98578453,0.0077217245,0.0028142326,0.0009705826,0.0014627426,0.0012461598],"domain_scores_gemma":[0.9877647,0.006816526,0.0016856885,0.0020206966,0.0013287391,0.0003836151],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.015143493,0.00060081214,0.00895162,0.00043330865,0.00008685899,0.000009156713,0.0012228203,0.0009977088,0.0012725111],"category_scores_gemma":[0.0028298688,0.0003285006,0.0008824637,0.0017587129,0.0012556056,0.000030494271,0.00031496075,0.004996294,0.00009774208],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054930756,0.000577866,0.0009038722,0.32551903,0.0005920468,0.000107480606,0.00011001945,1.2251978e-7,0.0000022088884,0.000091811286,0.16155949,0.50998676],"study_design_scores_gemma":[0.001717922,0.0031959591,0.000033387652,0.22319888,0.000964565,0.000066200904,0.000018922985,0.0000011000875,0.000059878334,0.000015395375,0.7705081,0.00021965725],"about_ca_topic_score_codex":0.0005597971,"about_ca_topic_score_gemma":0.0001393926,"teacher_disagreement_score":0.60894865,"about_ca_system_score_codex":0.0011440917,"about_ca_system_score_gemma":0.01195771,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W2158757667","doi":"10.1124/mol.107.036111","title":"The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor","year":2007,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia","funders":"National Cancer Institute; Canadian Breast Cancer Research Alliance; Breast Cancer Alliance","keywords":"Chromatin immunoprecipitation; Molecular biology; Protein kinase B; Biology; Cell culture; Epidermal growth factor receptor; Growth inhibition; Cancer research; Cell growth; Phosphorylation; Receptor; Promoter; Biochemistry; Gene expression; Gene","score_opus":0.025892257351910173,"score_gpt":0.3415121767235288,"score_spread":0.3156199193716186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158757667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9819034,0.0039433683,0.002118692,0.0033471123,0.00304046,0.0043779635,0.00023929012,0.0003258026,0.0007039344],"genre_scores_gemma":[0.99072355,0.0004490355,0.003069452,0.0014756734,0.0015657112,0.0006891137,0.00016141188,0.0003078588,0.0015582106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99076873,0.0010267154,0.001666408,0.0017152919,0.0020265311,0.0027963144],"domain_scores_gemma":[0.9955882,0.0010072559,0.00060402014,0.0010678129,0.0005179656,0.0012147384],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027738197,0.00095803983,0.0012154911,0.00059700914,0.00082698243,0.00016949709,0.0011396966,0.00071638054,0.0031518769],"category_scores_gemma":[0.00093933474,0.00080689637,0.000516311,0.0010987377,0.0006842491,0.0002898889,0.000809563,0.0025202483,0.0006678876],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013290906,0.0005116263,0.0044446457,0.00019968017,0.0007826856,0.0019884831,0.00047166992,0.000005555512,0.96556324,0.00005230329,0.0045193634,0.020131677],"study_design_scores_gemma":[0.0055756867,0.0007421879,0.0029838958,0.00032068757,0.000317593,0.000092859686,0.00029136994,0.00004293893,0.97705317,0.00011623032,0.011692219,0.00077117066],"about_ca_topic_score_codex":0.0009847065,"about_ca_topic_score_gemma":0.000055959477,"teacher_disagreement_score":0.019360507,"about_ca_system_score_codex":0.0017156776,"about_ca_system_score_gemma":0.0009640075,"threshold_uncertainty_score":0.99978095},"labels":[],"label_agreement":null},{"id":"W2158888632","doi":"10.1177/1078155206069163","title":"Acute reactions to chemotherapy agents","year":2006,"lang":"en","type":"review","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Chemotherapy; Drug reaction; Cancer chemotherapy; Intensive care medicine; Hypersensitivity reaction; Pharmacology; Drug; Internal medicine","score_opus":0.29334632879909167,"score_gpt":0.6308276500863238,"score_spread":0.3374813212872321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158888632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012446453,0.93577725,0.000092775575,0.02087704,0.0021110026,0.0013184721,0.000027155065,0.0000252512,0.0397586],"genre_scores_gemma":[0.00000236323,0.9737418,0.007540188,0.0057390877,0.003375042,0.000066359506,0.000015587435,0.0001243553,0.009395194],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99524415,0.0010972121,0.0018693778,0.00035713526,0.00088793406,0.00054420833],"domain_scores_gemma":[0.99293435,0.002074328,0.0026699072,0.00044873066,0.0011717225,0.0007009886],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003103474,0.00042411993,0.0025939932,0.0009065959,0.000087573055,0.000052581094,0.00056273845,0.0003441541,0.0013750007],"category_scores_gemma":[0.0017194264,0.00033118724,0.00084853644,0.00092470617,0.00008831318,0.00044602086,0.000104310544,0.0038997629,0.00065227377],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006999333,0.0007488403,0.0000026161588,0.001720105,0.0018064596,0.0039417804,0.00005294725,9.730745e-7,0.00002735794,0.0000039887072,0.3802084,0.6107866],"study_design_scores_gemma":[0.0031731387,0.0014147996,0.0000028411748,0.0035192242,0.008015379,0.04108031,0.000024150326,0.0000022854765,0.000019921625,0.000004812413,0.9425286,0.00021452285],"about_ca_topic_score_codex":0.00008556741,"about_ca_topic_score_gemma":0.0000023441182,"teacher_disagreement_score":0.6105721,"about_ca_system_score_codex":0.002952137,"about_ca_system_score_gemma":0.0070815883,"threshold_uncertainty_score":0.999914},"labels":[],"label_agreement":null},{"id":"W2159471993","doi":"10.2217/14796694.2.6.765","title":"Erbb Receptors and Epithelial-Cadherin–Catenin Complex In Human Carcinomas","year":2006,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cadherin; Medicine; Receptor; Catenin; ErbB; Cancer research; Signal transduction; Internal medicine; Biology; Cell biology; Cell; Wnt signaling pathway; Genetics","score_opus":0.1385490509996071,"score_gpt":0.46228533226736784,"score_spread":0.3237362812677608,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159471993","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025790793,0.9620643,0.0000010658687,0.0010851618,0.0009791148,0.0018744034,0.00008312137,0.00006793749,0.03358697],"genre_scores_gemma":[0.00009160034,0.9885082,0.0005681449,0.00017988503,0.004188462,0.00026573124,0.0006641167,0.00014742283,0.0053863935],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962773,0.00071255973,0.0009773178,0.0008594119,0.00038059047,0.000792827],"domain_scores_gemma":[0.99851924,0.00021440779,0.00029917678,0.0005711103,0.00009650674,0.00029954812],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006912357,0.00057809585,0.0033058191,0.00061024976,0.00009609414,0.000020723335,0.00034195042,0.001451502,0.0012208739],"category_scores_gemma":[0.000057299207,0.00046624822,0.0003054508,0.00061159366,0.00043425316,0.000029010329,0.00017802304,0.0020295195,0.00017842991],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037936636,0.00021618545,0.00024621628,0.010556607,0.00008069934,0.0006406705,0.000162156,7.3309145e-8,0.00003205761,0.00037884535,0.074056715,0.91359186],"study_design_scores_gemma":[0.0012049628,0.00096948957,0.00081421336,0.0040624365,0.00033084815,0.0005773322,0.00007001243,8.5855476e-7,0.0000032546889,0.000052544405,0.99155277,0.00036128977],"about_ca_topic_score_codex":0.0006533348,"about_ca_topic_score_gemma":0.0010528505,"teacher_disagreement_score":0.917496,"about_ca_system_score_codex":0.0019800502,"about_ca_system_score_gemma":0.0015802461,"threshold_uncertainty_score":0.99984485},"labels":[],"label_agreement":null},{"id":"W2159702901","doi":"","title":"A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Colorectal cancer; Epidermal growth factor receptor; Cancer; Medicine; Epidermal growth factor; Immunohistochemistry; Cancer research; Apoptosis; Pathology; Internal medicine; Biology; Receptor","score_opus":0.041943268200244736,"score_gpt":0.32484394502425135,"score_spread":0.2829006768240066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159702901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928875,0.00029424415,0.0000012987446,0.00045552928,0.0007314265,0.005164648,0.000119500015,0.000023960294,0.00032191654],"genre_scores_gemma":[0.9948718,0.000048390582,0.000031214582,0.00016249288,0.00007091865,0.0044770213,0.0000077331615,0.000046068224,0.00028438156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99705774,0.0005362443,0.0005489584,0.00037748448,0.0008298172,0.00064978766],"domain_scores_gemma":[0.9989316,0.00016423168,0.00015899357,0.0002611803,0.00024809627,0.00023590108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057963474,0.00021708908,0.00046835802,0.00021157307,0.000058110596,0.000014884254,0.00021214657,0.000052257335,0.00031309293],"category_scores_gemma":[0.0011768087,0.00015138472,0.00009876609,0.0009128087,0.00012661796,0.00009787039,0.00008911871,0.00045263884,0.000007770353],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052698416,0.0032368104,0.97575325,0.00022424464,0.00015122136,0.000017104441,0.0012251155,0.000012165469,0.0031764645,0.000014028999,0.0012776981,0.014384912],"study_design_scores_gemma":[0.0074324934,0.0003170136,0.9542797,0.00005423395,0.0000901009,0.0000022612637,0.0003003468,0.000048874692,0.036542453,0.000009340968,0.00076593895,0.00015721685],"about_ca_topic_score_codex":0.0010296537,"about_ca_topic_score_gemma":0.00067861605,"teacher_disagreement_score":0.033365987,"about_ca_system_score_codex":0.0006717089,"about_ca_system_score_gemma":0.00028587927,"threshold_uncertainty_score":0.617329},"labels":[],"label_agreement":null},{"id":"W2159967578","doi":"10.1056/nejmoa1209124","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3784,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Trastuzumab emtansine; Trastuzumab; Antibody-drug conjugate; Medicine; Cytotoxic T cell; Metastatic breast cancer; Conjugate; Breast cancer; Oncology; Antibody; Linker; Cancer research; Cancer; Monoclonal antibody; Pharmacology; Internal medicine; Immunology; In vitro; Biology","score_opus":0.0357706020618461,"score_gpt":0.39034594249539695,"score_spread":0.3545753404335508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159967578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72529364,0.039729353,0.00963101,0.21094857,0.006238988,0.0018684707,0.00016407638,0.000062337254,0.0060635796],"genre_scores_gemma":[0.97185105,0.002040032,0.0017684299,0.0013906917,0.021257857,0.000013685038,0.00001150036,0.00005183685,0.0016148938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99776185,0.00008162382,0.00060294906,0.00014983471,0.00084566174,0.0005580746],"domain_scores_gemma":[0.997428,0.00044970444,0.00027949392,0.00019004167,0.0007106965,0.00094203395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013519053,0.00020722221,0.0007178122,0.0002349825,0.00006507075,0.000007291228,0.00014921639,0.000088962144,0.0011171537],"category_scores_gemma":[0.0005590814,0.00013222877,0.00012675748,0.00027265892,0.00014940997,0.00018917685,0.000018543851,0.00053021096,0.000006138941],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008621866,0.00030989584,0.020367386,0.0003004878,0.0004013149,0.00019106107,0.0033253038,0.000024384231,0.020415148,0.00016120983,0.07395464,0.8719273],"study_design_scores_gemma":[0.19057487,0.010111936,0.21077129,0.0063281343,0.0011971542,0.015641635,0.0014390391,0.000090728434,0.00763286,0.00040777618,0.55534947,0.00045509127],"about_ca_topic_score_codex":0.00019016428,"about_ca_topic_score_gemma":0.000059232894,"teacher_disagreement_score":0.8714722,"about_ca_system_score_codex":0.00037442998,"about_ca_system_score_gemma":0.0007732613,"threshold_uncertainty_score":0.999796},"labels":[],"label_agreement":null},{"id":"W2160094174","doi":"10.1074/jbc.m107430200","title":"Phosphorylation-dependent Interactions between ADAM15 Cytoplasmic Domain and Src Family Protein-tyrosine Kinases","year":2002,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Proto-oncogene tyrosine-protein kinase Src; Cell biology; Phosphorylation; Tyrosine phosphorylation; SH2 domain; Biology; Src family kinase; Tyrosine-protein kinase CSK; Jurkat cells; SH3 domain; Biochemistry; Chemistry; T cell","score_opus":0.07511904364356263,"score_gpt":0.32698705736043826,"score_spread":0.2518680137168756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160094174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926046,0.0021878285,0.00008407469,0.001825404,0.00004952054,0.00016449488,0.00002025598,0.000017984734,0.0030458057],"genre_scores_gemma":[0.9967268,0.00049605564,0.0010103858,0.00010967972,0.00061655446,0.000008385672,0.0000069737557,0.000011328421,0.0010138011],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986378,0.0000447607,0.0004934019,0.00019574306,0.00038487295,0.00024342592],"domain_scores_gemma":[0.99894804,0.00017141535,0.00022742139,0.00015635608,0.00019993006,0.00029681457],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033348732,0.00014888127,0.00037762674,0.000045976634,0.0000773356,0.000032561802,0.00013743836,0.0001648577,0.0011769475],"category_scores_gemma":[0.0004053499,0.000101629026,0.00011618393,0.00013415894,0.0001711745,0.00006559729,0.00007085186,0.000757368,0.000019365774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002104875,0.00021074082,0.047205735,0.00010362575,0.00008228171,0.00023699904,0.00004744372,0.0000015467226,0.9435322,0.000004387236,0.0023393275,0.006025194],"study_design_scores_gemma":[0.0029322077,0.001260814,0.07372758,0.0007379575,0.00008478181,0.0015779841,0.00046815298,0.000045949335,0.8867796,0.00057382125,0.031506304,0.00030486044],"about_ca_topic_score_codex":0.0000069458342,"about_ca_topic_score_gemma":4.439576e-7,"teacher_disagreement_score":0.056752637,"about_ca_system_score_codex":0.00020279792,"about_ca_system_score_gemma":0.00006401388,"threshold_uncertainty_score":0.99973613},"labels":[],"label_agreement":null},{"id":"W2160227358","doi":"10.1016/j.bmcl.2007.01.002","title":"New C-5 substituted pyrrolotriazine dual inhibitors of EGFR and HER2 protein tyrosine kinases","year":2007,"lang":"en","type":"article","venue":"Bioorganic & Medicinal Chemistry Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Recherche Industrielle du Québec","funders":"","keywords":"Chemistry; Morpholine; Kinase; Tyrosine kinase; Biochemistry; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Signal transduction; Cancer","score_opus":0.017555498955955266,"score_gpt":0.2870311224545731,"score_spread":0.2694756234986178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160227358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798638,0.0016530784,0.00037353003,0.016788537,0.00017041762,0.00056433334,0.000011643483,0.000099894554,0.00047471767],"genre_scores_gemma":[0.9957825,0.000056649056,0.00094512047,0.0007349762,0.001838167,0.000009593126,0.00004742604,0.000060186998,0.00052540057],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707425,0.000026989432,0.0006718522,0.00053007546,0.0010412204,0.0006556095],"domain_scores_gemma":[0.99837184,0.00009845084,0.00019378249,0.00048330027,0.00014950261,0.00070309686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081036973,0.0003321824,0.0005838162,0.00012866809,0.00006592806,0.00001538875,0.00018408414,0.00022937851,0.0008435392],"category_scores_gemma":[0.00066043553,0.0002915451,0.00009036223,0.0006645574,0.00054465927,0.00006606528,0.00010650629,0.0005956396,0.000017738976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066591555,0.00009284568,0.0046168095,0.0007774435,0.00007879024,0.000575452,0.00016383205,1.4849661e-7,0.97773653,0.0000073306123,0.01138002,0.0039048546],"study_design_scores_gemma":[0.0034326992,0.00019377026,0.0094675245,0.00082109944,0.00011727199,0.00048301954,0.00020257152,0.0000034386242,0.97852874,0.0000074290506,0.0065038693,0.00023855307],"about_ca_topic_score_codex":0.00043782758,"about_ca_topic_score_gemma":0.00001893794,"teacher_disagreement_score":0.016053561,"about_ca_system_score_codex":0.00029840932,"about_ca_system_score_gemma":0.00051674637,"threshold_uncertainty_score":0.9999537},"labels":[],"label_agreement":null},{"id":"W2161167126","doi":"10.1186/2191-219x-1-15","title":"A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT","year":2011,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Ontario Institute for Cancer Research","keywords":"Medicine; DOTA; Biodistribution; Trastuzumab; Nuclear medicine; Radioligand; Cancer research; Molecular biology; Receptor; Cancer; Chemistry; Internal medicine; In vitro; Chelation; Breast cancer; Biology; Biochemistry","score_opus":0.27577670028732565,"score_gpt":0.5097644154305634,"score_spread":0.23398771514323774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161167126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99130344,0.0018465472,0.00016490291,0.00031700722,0.00026594603,0.004207527,0.00020353064,0.0000649797,0.0016261305],"genre_scores_gemma":[0.9879308,0.00014623052,0.009002185,0.0001212339,0.00023244122,0.00024805445,0.000045435474,0.00020408341,0.0020695834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99271965,0.0007026893,0.0011595627,0.0012242635,0.0018988961,0.0022949355],"domain_scores_gemma":[0.9959468,0.0011733009,0.0002500596,0.0009514535,0.0011407373,0.0005376344],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002941397,0.00051163445,0.0013064913,0.0013015381,0.00037772532,0.00011791433,0.0009543205,0.000046227513,0.0012412122],"category_scores_gemma":[0.0010645699,0.00041773505,0.0002581529,0.0020024762,0.0009249485,0.00021438059,0.00054972514,0.0017349785,0.00015384368],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033874705,0.005388199,0.2946937,0.003550273,0.00056172983,0.040170312,0.00923239,0.000021451831,0.58651525,0.000055904802,0.013683958,0.012252142],"study_design_scores_gemma":[0.012183343,0.008549787,0.02288354,0.0053365612,0.00019702976,0.012363222,0.013371821,0.0061046546,0.90579224,0.00014671228,0.01181764,0.0012534386],"about_ca_topic_score_codex":0.009387734,"about_ca_topic_score_gemma":0.0016276992,"teacher_disagreement_score":0.31927702,"about_ca_system_score_codex":0.002091631,"about_ca_system_score_gemma":0.0023138255,"threshold_uncertainty_score":0.99982744},"labels":[],"label_agreement":null},{"id":"W2161820433","doi":"10.1016/j.schres.2007.12.474","title":"Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients","year":2008,"lang":"en","type":"article","venue":"Schizophrenia Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":178,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health","keywords":"Neuregulin 1; ERBB4; Prefrontal cortex; Cytoplasm; Schizophrenia (object-oriented programming); Neuregulin; Internal medicine; Receptor; Endocrinology; Psychosis; Chemistry; Psychology; Biology; Medicine; Neuroscience; Cognition; Biochemistry; Psychiatry; Receptor tyrosine kinase","score_opus":0.07418656636318365,"score_gpt":0.36201245867689796,"score_spread":0.2878258923137143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161820433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305415,0.00060384197,0.0000018991954,0.0017473516,0.000050581002,0.0029251329,0.000031220225,0.000032747655,0.0015530471],"genre_scores_gemma":[0.99776345,0.00018669148,0.00058414845,0.000057832443,0.00018879019,0.00032231666,0.000038534767,0.000052071344,0.00080616475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99419224,0.00094253244,0.0005905235,0.0006310636,0.0026952229,0.0009483954],"domain_scores_gemma":[0.9976808,0.00034760294,0.00008425781,0.0009312788,0.0006692387,0.0002868373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023590375,0.0002399757,0.00047475,0.0006992251,0.0002876782,0.00003772104,0.0006113616,0.00020605241,0.00018704195],"category_scores_gemma":[0.0011676208,0.0001699015,0.00009323724,0.0017316387,0.0011964467,0.00013700943,0.00032650222,0.0019411528,0.000088580426],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.058245283,0.0058970926,0.54601383,0.0023963726,0.0003231306,0.0018837067,0.007140891,0.0000056199124,0.29479074,0.0041362797,0.017788276,0.06137874],"study_design_scores_gemma":[0.008374775,0.002027799,0.9796352,0.00034318116,0.000011662978,0.00011058698,0.00022006336,0.00026503234,0.0068391883,0.0007049661,0.0012781296,0.0001894322],"about_ca_topic_score_codex":0.0005919897,"about_ca_topic_score_gemma":0.00025050552,"teacher_disagreement_score":0.43362135,"about_ca_system_score_codex":0.00019052604,"about_ca_system_score_gemma":0.0011452868,"threshold_uncertainty_score":0.8433451},"labels":[],"label_agreement":null},{"id":"W2162419009","doi":"10.1080/02841860410028574","title":"ErbB4 is downregulated in renal cell carcinoma A quantitative RT-PCR and immunohistochemical analysis of the epidermal growth factor receptor family","year":2004,"lang":"en","type":"article","venue":"Acta Oncologica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Cancerfonden","keywords":"Immunohistochemistry; ERBB4; Renal cell carcinoma; Medicine; Pathology; Epidermal growth factor receptor; ERBB3; Messenger RNA; Renal cortex; Kidney; Real-time polymerase chain reaction; Cancer research; Kidney cancer; Receptor; Biology; Internal medicine; Gene","score_opus":0.051236160636602135,"score_gpt":0.34623992357320915,"score_spread":0.295003762936607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162419009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920401,0.0006637808,0.000014043315,0.0046141306,0.000049174614,0.0005679214,0.00008766399,0.000020426147,0.0019427673],"genre_scores_gemma":[0.9973807,0.00012412986,0.0016103183,0.00058223563,0.00003074002,0.000043753153,0.00002510731,0.00001603527,0.00018700442],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99792886,0.00021119662,0.00051065977,0.0004462899,0.00049353694,0.00040945932],"domain_scores_gemma":[0.9986098,0.0004032191,0.00019212748,0.00042786438,0.00021810507,0.00014891289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036385728,0.00020698764,0.0007204022,0.00029453036,0.00007610026,0.000013064158,0.00029846738,0.00025907828,0.00043004067],"category_scores_gemma":[0.00051885215,0.00013430108,0.00022850397,0.0015674429,0.00047442957,0.00006455373,0.0001933898,0.00055719743,0.000009874612],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079850364,0.00043560597,0.06049097,0.00007683461,0.0002868448,0.00003830592,0.002686923,0.000011803407,0.93249136,0.00010988718,0.0022284526,0.00034451426],"study_design_scores_gemma":[0.0024576539,0.0011125539,0.8843291,0.00007761956,0.00033496888,0.0000072350267,0.0004937346,0.00013296961,0.10968595,0.00016939046,0.0010213587,0.00017746337],"about_ca_topic_score_codex":0.001479246,"about_ca_topic_score_gemma":0.000058164856,"teacher_disagreement_score":0.8238381,"about_ca_system_score_codex":0.0007345516,"about_ca_system_score_gemma":0.000513673,"threshold_uncertainty_score":0.5476639},"labels":[],"label_agreement":null},{"id":"W2162804910","doi":"10.1158/1078-0432.ccr-04-1347","title":"Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Gefitinib; Paclitaxel; Pharmacology; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Medicine; Dosing; Chemotherapy; Internal medicine; Cancer","score_opus":0.17029377243080993,"score_gpt":0.516426543690462,"score_spread":0.34613277125965214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162804910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95747304,0.00034621792,0.00006475596,0.0346811,0.00043681244,0.0057137567,0.00089990045,0.000043875083,0.0003405207],"genre_scores_gemma":[0.9925739,0.0000973594,0.0008885485,0.0015059785,0.0024230857,0.0015082514,0.00002841178,0.00009475632,0.0008797048],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931902,0.0013709588,0.001269062,0.0009560334,0.002056352,0.0011573776],"domain_scores_gemma":[0.9911189,0.0054425243,0.00026650884,0.0007824406,0.001718726,0.0006708893],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0059227603,0.0002813584,0.0008659059,0.00019620793,0.00048133673,0.000076952005,0.00049089565,0.00025381387,0.00095492415],"category_scores_gemma":[0.009554314,0.00021600613,0.00047666288,0.0009589948,0.00079365144,0.00013647518,0.00037987027,0.0019455445,0.0000446572],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02729616,0.0022401316,0.24340545,0.0024882935,0.0006182552,0.000113867405,0.009580172,0.000033618464,0.2031779,0.00036420726,0.17071785,0.3399641],"study_design_scores_gemma":[0.0073030093,0.0096726185,0.28999886,0.0023268613,0.00011994269,0.000051396568,0.004705469,0.00079292664,0.6209002,0.00018212246,0.0632031,0.0007434808],"about_ca_topic_score_codex":0.000717657,"about_ca_topic_score_gemma":0.00019836285,"teacher_disagreement_score":0.4177223,"about_ca_system_score_codex":0.0009546887,"about_ca_system_score_gemma":0.0019429259,"threshold_uncertainty_score":0.99995834},"labels":[],"label_agreement":null},{"id":"W2162816109","doi":"10.1016/j.nucmedbio.2010.06.010","title":"A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer","year":2010,"lang":"en","type":"article","venue":"Nuclear Medicine and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Nuclear medicine; Cancer research; Cancer","score_opus":0.06651125855918073,"score_gpt":0.4213531490704426,"score_spread":0.35484189051126186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162816109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.974712,0.00024010413,0.00010716259,0.02222005,0.00073804025,0.0009828495,0.00031142912,0.000055053253,0.0006332976],"genre_scores_gemma":[0.99440205,0.00028558995,0.00030245678,0.003711572,0.0006043077,0.00010699737,0.00013276574,0.00004570592,0.00040852927],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99851614,0.00008533803,0.00041718973,0.00041246254,0.0001682952,0.00040057173],"domain_scores_gemma":[0.99861735,0.0003869098,0.000119187374,0.0002664765,0.0003847757,0.00022529763],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046944042,0.00018797355,0.0005632326,0.0002814087,0.00013642051,0.000008452995,0.00009909662,0.00013315467,0.0028395164],"category_scores_gemma":[0.00032212675,0.0001334559,0.000080713675,0.00028430668,0.0005079782,0.00005583884,0.000061081824,0.00030406768,0.000010841561],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00427871,0.000364066,0.054177903,0.0005386263,0.0004984486,0.000036291447,0.0038766474,0.000003081706,0.6807415,0.0005173319,0.17899004,0.07597737],"study_design_scores_gemma":[0.012003097,0.0077763684,0.7711155,0.0041842195,0.0008287735,0.0039867116,0.017373178,0.00074801076,0.0041352254,0.0009463399,0.1758971,0.0010054832],"about_ca_topic_score_codex":0.0028361313,"about_ca_topic_score_gemma":0.0005023508,"teacher_disagreement_score":0.7169376,"about_ca_system_score_codex":0.00014810187,"about_ca_system_score_gemma":0.0003013918,"threshold_uncertainty_score":0.998072},"labels":[],"label_agreement":null},{"id":"W2162854541","doi":"10.1016/s1470-2045(12)70508-9","title":"Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":131,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Adjuvant; Medicine; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer; Trastuzumab; Gynecology","score_opus":0.07012591633160038,"score_gpt":0.43312643149354113,"score_spread":0.36300051516194076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162854541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9583134,0.00089959224,0.00019712056,0.016438672,0.0007040156,0.010826145,0.00071770285,0.00008856259,0.011814777],"genre_scores_gemma":[0.97340095,0.00056931196,0.00025942796,0.0026061388,0.0062675728,0.012500803,0.000025021456,0.00006587848,0.0043048672],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99697,0.0006431795,0.0004200011,0.00030043916,0.000399548,0.0012668484],"domain_scores_gemma":[0.99700576,0.0016115445,0.00025164025,0.00049090566,0.00026300858,0.00037713218],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031772368,0.00025030988,0.0016684793,0.00007509331,0.00016571653,0.00002378903,0.00028195578,0.00016863836,0.0011341055],"category_scores_gemma":[0.00028716942,0.00013693534,0.00013803635,0.00018825127,0.00035563423,0.00008770498,0.00004865575,0.00052650156,0.00004688924],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.95526165,0.000985699,0.0014646892,0.00010709206,0.00060583977,0.00003696105,0.0036695998,0.0000032830844,0.00064589526,0.00022607045,0.008144134,0.02884906],"study_design_scores_gemma":[0.8459197,0.009523089,0.0023845248,0.00007631385,0.00023568254,0.00011448001,0.00060916104,0.00008333527,0.00034138912,0.00003601993,0.14050385,0.0001724331],"about_ca_topic_score_codex":0.0005403818,"about_ca_topic_score_gemma":0.00021453135,"teacher_disagreement_score":0.13235971,"about_ca_system_score_codex":0.00084532896,"about_ca_system_score_gemma":0.00096989167,"threshold_uncertainty_score":0.999779},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","score_opus":0.10727531899554954,"score_gpt":0.43749981331845356,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162901058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97645533,0.00021121831,0.00030190306,0.008558732,0.0003009627,0.012748362,0.00053736806,0.000046446094,0.0008397009],"genre_scores_gemma":[0.99407697,0.00023058416,0.0004911964,0.00030713328,0.00054700114,0.0036311368,0.00027537998,0.00005668483,0.0003839034],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976958,0.00026163115,0.00044901963,0.0004166292,0.0005957697,0.00058117224],"domain_scores_gemma":[0.9972435,0.0006641244,0.0003778719,0.00045165574,0.0009928999,0.0002699285],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057486893,0.00030498137,0.0012115391,0.00009925956,0.000113024566,0.000014335804,0.00020479965,0.00014960412,0.00007479532],"category_scores_gemma":[0.00011442007,0.00016838349,0.00010742452,0.0002730631,0.0002982128,0.00009537329,0.000036522724,0.0002469804,0.000008672566],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.956636,0.0056366078,0.0013402315,0.0001130174,0.00063471234,0.000027853079,0.0031878937,0.0005460073,0.00002694526,0.0000484198,0.00049187714,0.031310443],"study_design_scores_gemma":[0.92902184,0.062473096,0.0010240938,0.00024644166,0.0006221152,0.000034966604,0.00060532294,0.0007358648,0.00068745395,0.00004291158,0.0043245493,0.00018132658],"about_ca_topic_score_codex":0.0011013348,"about_ca_topic_score_gemma":0.0019008245,"teacher_disagreement_score":0.056836486,"about_ca_system_score_codex":0.0023579716,"about_ca_system_score_gemma":0.0019362107,"threshold_uncertainty_score":0.68664795},"labels":[],"label_agreement":null},{"id":"W2163167967","doi":"10.1136/jclinpath-2014-202571","title":"Updated UK Recommendations for HER2 assessment in breast cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Bioinformatics; Oncology; Medical physics; Cancer; Internal medicine; Biology","score_opus":0.18503428653284512,"score_gpt":0.5861699026089259,"score_spread":0.4011356160760807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163167967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6765222,0.00012608815,0.0047703125,0.31278133,0.0027281875,0.00049966294,0.00006483872,0.000012783538,0.0024946067],"genre_scores_gemma":[0.9793003,0.0006895268,0.012754465,0.0052892542,0.0015620398,0.000030756837,0.000013623053,0.000022453845,0.00033757338],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725866,0.000541294,0.0014984491,0.0001819568,0.00024396004,0.0002756517],"domain_scores_gemma":[0.9974541,0.0010888609,0.00048807904,0.00021149508,0.00052003085,0.00023740638],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0057580834,0.00009029715,0.0007127333,0.00017385847,0.000030419267,0.000009488323,0.00016535007,0.00020781647,0.0011710993],"category_scores_gemma":[0.0012223885,0.00006879479,0.00022185569,0.00016071204,0.0001217719,0.000047404974,0.000041281666,0.0010963405,0.000011096769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00116793,0.0007685304,0.69315,0.000055797085,0.00009113592,0.00017059491,0.00005379666,0.000029100616,0.00059794984,0.000528876,0.11927072,0.18411559],"study_design_scores_gemma":[0.006499833,0.0017585441,0.8068628,0.0002190244,0.000075274394,0.0006537225,0.000060948987,0.0006302654,0.00003362231,0.0016848379,0.18143179,0.00008935873],"about_ca_topic_score_codex":0.000028801678,"about_ca_topic_score_gemma":0.00008555206,"teacher_disagreement_score":0.30749208,"about_ca_system_score_codex":0.00014664713,"about_ca_system_score_gemma":0.00081374444,"threshold_uncertainty_score":0.999742},"labels":[],"label_agreement":null},{"id":"W2164130095","doi":"10.1200/jco.2009.22.6449","title":"Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out","year":2009,"lang":"en","type":"editorial","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Anthracycline; Topoisomerase; Chemotherapy; Cancer research; Jury; Oncology; Internal medicine; Pharmacology; Cancer; DNA; Genetics; Breast cancer; Biology; Law","score_opus":0.16040805004886502,"score_gpt":0.5645761933137886,"score_spread":0.40416814326492356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164130095","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012543816,0.0047174105,0.0003269053,0.18791893,0.7908926,0.0010350109,0.00009210869,0.00003153722,0.002441709],"genre_scores_gemma":[0.009570504,0.020559441,0.0016939811,0.015189566,0.9508021,0.000013856346,0.000037862865,0.00008028083,0.0020524159],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929044,0.0009535135,0.003510545,0.00046999782,0.0017319565,0.0004295777],"domain_scores_gemma":[0.9786445,0.014879885,0.003260383,0.0007098921,0.0018550684,0.0006502646],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009624848,0.00033624395,0.0026172735,0.00023256466,0.00008515495,0.000050549635,0.00057456375,0.0023349868,0.00036603282],"category_scores_gemma":[0.021457948,0.00020208767,0.0007292997,0.00017970074,0.0007294815,0.00007993211,0.000058781032,0.006384262,0.000043358945],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004005304,0.0008404614,0.00046247503,0.000083238214,0.00021375091,0.00015013681,0.000095198964,9.184947e-7,0.00003840543,0.0000034345946,0.730341,0.26376566],"study_design_scores_gemma":[0.008426649,0.011034365,0.005279296,0.0003599215,0.0004489876,0.00004390932,0.00003837487,0.000052299893,0.000075883596,0.00027384877,0.9737953,0.000171183],"about_ca_topic_score_codex":0.000034932917,"about_ca_topic_score_gemma":0.00004201038,"teacher_disagreement_score":0.26359448,"about_ca_system_score_codex":0.0004468727,"about_ca_system_score_gemma":0.010513439,"threshold_uncertainty_score":0.9989602},"labels":[],"label_agreement":null},{"id":"W2165824128","doi":"10.1200/jco.2005.04.1764","title":"Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Metastatic breast cancer; Carboplatin; Oncology; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin","score_opus":0.1106490242730566,"score_gpt":0.49162201900925406,"score_spread":0.38097299473619745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165824128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955129,0.001266957,0.00010166724,0.0012574489,0.000087597975,0.0013282793,0.000026186628,0.0000070898413,0.0004118642],"genre_scores_gemma":[0.99757576,0.00032152951,0.0015092655,0.00017626336,0.00024198148,0.0000804974,0.0000013444973,0.00003608923,0.000057253525],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99329275,0.0018297257,0.003149078,0.00037473452,0.0008749313,0.00047878112],"domain_scores_gemma":[0.992612,0.0043118168,0.0018930077,0.00022459314,0.00048584776,0.000472747],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006595757,0.00028274744,0.0043945657,0.00030356363,0.000054791646,0.000027099351,0.00013799377,0.00015864869,0.0001369904],"category_scores_gemma":[0.00062026334,0.0001683255,0.000117828575,0.00033680644,0.0010064676,0.0001759819,0.000050569786,0.0012211322,2.39146e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8510159,0.013153989,0.07557525,0.00026270453,0.0016169542,0.0015903512,0.004553001,0.00021981512,0.0005077478,0.000012159934,0.00026472355,0.051227354],"study_design_scores_gemma":[0.76101846,0.03697765,0.18938826,0.0008845881,0.00086673535,0.00097484875,0.008674904,0.0006541506,0.000025567308,0.00013481824,0.0002043644,0.0001956741],"about_ca_topic_score_codex":0.0020770035,"about_ca_topic_score_gemma":0.0019356859,"teacher_disagreement_score":0.11381302,"about_ca_system_score_codex":0.00047373818,"about_ca_system_score_gemma":0.0021978612,"threshold_uncertainty_score":0.68641144},"labels":[],"label_agreement":null},{"id":"W2165862193","doi":"10.1200/jco.2008.16.5282","title":"Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500?","year":2008,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lapatinib; Medicine; Realm; Internal medicine; Cancer; Trastuzumab; Breast cancer","score_opus":0.4819093635843679,"score_gpt":0.6027211488448957,"score_spread":0.12081178526052777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165862193","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034723967,0.00094963424,0.000034313543,0.9192411,0.0019759783,0.00075410644,0.00002563354,0.000009882067,0.04228541],"genre_scores_gemma":[0.015914062,0.016362634,0.013370673,0.91339713,0.03542701,0.000044189386,0.000035119476,0.0001918672,0.0052573103],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98833644,0.00218765,0.0064241397,0.00031910278,0.002128137,0.0006045319],"domain_scores_gemma":[0.9761247,0.017418632,0.0044318717,0.00084019854,0.00093937793,0.00024524445],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012402029,0.00031563843,0.0040238593,0.00043525358,0.00003796912,0.000011180024,0.0011564455,0.002699958,0.00066210335],"category_scores_gemma":[0.016035426,0.0001844187,0.0011164743,0.0003981977,0.00088287913,0.00005762569,0.000139465,0.01401528,0.00009117587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006315122,0.0013803701,0.0039275396,0.00057412544,0.00030950853,0.012510821,0.0005760377,0.000002505352,0.000009496916,0.00002430702,0.9574203,0.022633472],"study_design_scores_gemma":[0.0040383893,0.011441911,0.008573782,0.0010421391,0.00030525035,0.0032219558,0.00016828628,0.000027621638,0.000013068061,0.00078102585,0.970239,0.00014756976],"about_ca_topic_score_codex":0.000081987804,"about_ca_topic_score_gemma":0.00006349143,"teacher_disagreement_score":0.037028097,"about_ca_system_score_codex":0.00040061335,"about_ca_system_score_gemma":0.0067331595,"threshold_uncertainty_score":0.99889773},"labels":[],"label_agreement":null},{"id":"W2166317024","doi":"10.1200/jco.2010.29.5071","title":"Human Epidermal Growth Factor Receptor 2 Testing: Where Are We?","year":2010,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Cancer research; Epidermal growth factor; Receptor; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.41265828075769156,"score_gpt":0.5553228378694964,"score_spread":0.14266455711180487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166317024","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012987008,0.0009205565,0.000012694098,0.9684516,0.0075991247,0.00048490954,0.000054985583,0.00004113035,0.009447997],"genre_scores_gemma":[0.005675014,0.0024819404,0.01095034,0.81075996,0.15306675,0.000025771456,0.0000329542,0.0003019365,0.016705343],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98935306,0.0017829065,0.0054293196,0.00062918407,0.0018305818,0.0009749182],"domain_scores_gemma":[0.9790979,0.009934111,0.0062915077,0.0007160623,0.0029318684,0.00102857],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0054147844,0.0005219983,0.004789971,0.00045477768,0.00012483305,0.000046184505,0.0010645518,0.008931633,0.0075347973],"category_scores_gemma":[0.028077966,0.00037931875,0.0014724006,0.00029343105,0.0008911403,0.00013141689,0.00025224502,0.04866324,0.00035970882],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036280943,0.0005458743,0.037543528,0.0006212558,0.0004489729,0.010946811,0.00002994757,1.4653365e-7,0.00025418797,0.000003821592,0.9121981,0.037044525],"study_design_scores_gemma":[0.0039548283,0.011499518,0.03029109,0.0011011644,0.00035617192,0.0014796385,0.000024872737,0.0000031293523,0.0000422611,0.00028007873,0.95065653,0.00031073138],"about_ca_topic_score_codex":0.00007359951,"about_ca_topic_score_gemma":0.00009193201,"teacher_disagreement_score":0.15769164,"about_ca_system_score_codex":0.0006396926,"about_ca_system_score_gemma":0.0074138436,"threshold_uncertainty_score":0.9998659},"labels":[],"label_agreement":null},{"id":"W2166653378","doi":"10.1016/j.jval.2014.03.522","title":"Cost-Utility Analysis of Newer HER2- Testing Technologies to Target Trastuzumab in the Adjuvant Breast Cancer Setting","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Calgary; Ontario Institute for Cancer Research; McMaster University","funders":"","keywords":"CISH; Trastuzumab; Medicine; Chromogenic in situ hybridization; Oncology; Breast cancer; Internal medicine; Cost effectiveness; Cancer; Biology; In situ hybridization","score_opus":0.1293870136368234,"score_gpt":0.426012675525422,"score_spread":0.2966256618885986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166653378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9436251,0.0012750358,0.0005992508,0.051821157,0.0000906023,0.0017215245,0.00012844351,0.000102031365,0.0006368367],"genre_scores_gemma":[0.99518585,0.00008653395,0.0035341836,0.00092193164,0.00005555164,0.00017770485,0.0000074738505,0.00001786047,0.000012929035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969626,0.00059678603,0.00072429754,0.00041881306,0.00063419924,0.00066329236],"domain_scores_gemma":[0.9979646,0.0009581747,0.00016029632,0.0006392616,0.00016203013,0.00011564377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005355961,0.00015215499,0.0006687809,0.00069914275,0.00007028811,0.000013447276,0.00033729646,0.00010033861,0.00006117075],"category_scores_gemma":[0.0023891379,0.00011003249,0.00007398975,0.0040234183,0.0001108938,0.00003799368,0.000094232455,0.00064125186,0.0000040536597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007846089,0.00015109753,0.76278514,0.00047284577,0.00004612884,0.0000126166515,0.0023903542,0.014727342,0.00011942311,0.00004983142,0.00036959123,0.21879716],"study_design_scores_gemma":[0.0005311334,0.00026242604,0.8615636,0.00079663354,0.00004239155,0.00001689386,0.0023970853,0.1324659,0.00014319977,0.00019972124,0.0014750474,0.00010592502],"about_ca_topic_score_codex":0.0669909,"about_ca_topic_score_gemma":0.0034907833,"teacher_disagreement_score":0.21869124,"about_ca_system_score_codex":0.00074695406,"about_ca_system_score_gemma":0.0008427564,"threshold_uncertainty_score":0.9392221},"labels":[],"label_agreement":null},{"id":"W2166656480","doi":"10.1016/s1470-2045(09)70230-x","title":"Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009","year":2009,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Summit; Statement (logic); Breast cancer; Oncology; Internal medicine; Medicine; Political science; Cancer; Geography; Cartography; Law","score_opus":0.12434831521486477,"score_gpt":0.48312958374674864,"score_spread":0.35878126853188386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166656480","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000071899,0.88655156,0.0000044544618,0.059892792,0.0005377293,0.0041064,0.002049373,0.000035534973,0.046750236],"genre_scores_gemma":[0.00035318302,0.9945443,0.00036516532,0.0013739041,0.0012350183,0.000846244,0.00017826524,0.000070763526,0.001033147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933098,0.002852161,0.0014025343,0.00072434364,0.0006536251,0.0010575554],"domain_scores_gemma":[0.99606013,0.0014397745,0.0008267585,0.001315714,0.00018988657,0.0001677242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028273826,0.00055247266,0.004088838,0.00017714717,0.000095235555,0.00001734067,0.0011208392,0.0006281101,0.0011378052],"category_scores_gemma":[0.000051503543,0.00030647163,0.00035404472,0.00071420695,0.0007201951,0.000018205024,0.0003781211,0.0020924436,0.00014612207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064524874,0.0004380401,0.00016012677,0.0029948938,0.0012403397,0.0017336719,0.0003764571,0.0000041889093,8.406495e-7,0.0004942429,0.05789101,0.93402094],"study_design_scores_gemma":[0.0025137893,0.0009474272,0.0057789786,0.012819355,0.0015794218,0.000206213,0.000864374,0.0000048014713,0.000002117298,0.00022452995,0.97481394,0.00024503464],"about_ca_topic_score_codex":0.00340663,"about_ca_topic_score_gemma":0.006225097,"teacher_disagreement_score":0.9337759,"about_ca_system_score_codex":0.0039589508,"about_ca_system_score_gemma":0.0028812427,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2167505689","doi":"10.1158/0008-5472.can-05-0108","title":"Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Institute of Environmental Health Sciences; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute","keywords":"Breast cancer; Metastasis; Cancer research; Biology; Tissue microarray; Cancer; Microarray analysis techniques; Microarray; Pathology; Gene expression; Gene; Medicine; Genetics","score_opus":0.3637211878877031,"score_gpt":0.5562513565462694,"score_spread":0.19253016865856637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167505689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871787,0.0032156357,0.00015077197,0.00619621,0.000042815027,0.0015287739,0.0012858341,0.00005018244,0.00035112276],"genre_scores_gemma":[0.9931503,0.0012091325,0.0013024338,0.00044140324,0.00053919636,0.0007640959,0.000027932601,0.00013043993,0.0024350847],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99393827,0.00042742628,0.00069660984,0.00084806,0.0027595342,0.0013300999],"domain_scores_gemma":[0.9944718,0.00027938394,0.00025490415,0.0008979907,0.002730689,0.001365271],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020496757,0.000306028,0.0007557029,0.0006601549,0.00034604722,0.00006947558,0.0005713066,0.00015942095,0.0014375461],"category_scores_gemma":[0.0006278557,0.0002470455,0.00018678368,0.0017122293,0.0007284232,0.00016049886,0.00036244374,0.0010195798,0.000023437959],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016813505,0.0027680385,0.29038852,0.0015043356,0.0026535601,0.00057013624,0.0035905608,0.083224125,0.4046409,0.00017638742,0.016893715,0.17677619],"study_design_scores_gemma":[0.044790734,0.011454763,0.45997894,0.049761962,0.00434926,0.00013552724,0.0031225085,0.23359762,0.17465019,0.0010735005,0.011289239,0.005795754],"about_ca_topic_score_codex":0.0026666862,"about_ca_topic_score_gemma":0.0014512164,"teacher_disagreement_score":0.22999072,"about_ca_system_score_codex":0.0017885951,"about_ca_system_score_gemma":0.0052489145,"threshold_uncertainty_score":0.99999815},"labels":[],"label_agreement":null},{"id":"W2167525778","doi":"10.1128/mcb.01731-08","title":"c-Src Associates with ErbB2 through an Interaction between Catalytic Domains and Confers Enhanced Transforming Potential","year":2009,"lang":"en","type":"article","venue":"Molecular and Cellular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia; McGill University","funders":"National Institutes of Health; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Proto-oncogene tyrosine-protein kinase Src; Gefitinib; Biology; Erlotinib; Tyrosine kinase; Protein kinase domain; SH3 domain; SH2 domain; Epidermal growth factor receptor; Cancer research; Cell biology; Signal transduction; Mutant; Biochemistry; Receptor; Gene","score_opus":0.016692664800076164,"score_gpt":0.3224125090321391,"score_spread":0.30571984423206294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167525778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96398324,0.00058194273,0.032779764,0.0010396849,0.00003608481,0.00031223265,0.000008099439,0.000030570376,0.0012283999],"genre_scores_gemma":[0.99877924,0.00015389439,0.00043227855,0.00030832103,0.0000790353,0.000008641903,0.00018406483,0.000016473276,0.00003805871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99894655,0.0000934223,0.00016648136,0.00034538418,0.00012683265,0.0003213505],"domain_scores_gemma":[0.9995853,0.000021617489,0.000041992436,0.00015859299,0.0000554542,0.00013709972],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017062074,0.00015252856,0.00030163772,0.000063793115,0.0000878564,0.000025256515,0.000055170483,0.00016381248,0.000019163623],"category_scores_gemma":[0.000014345742,0.00012289059,0.00004254024,0.00008924926,0.00016242436,0.00008285493,0.000014527224,0.00025214805,0.0000027840465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019106799,0.000050068415,0.0020751848,0.000037582362,0.00011382432,0.00012379617,0.0005950222,0.0000020277741,0.9788501,0.00036665652,0.0000055630067,0.017589064],"study_design_scores_gemma":[0.002377008,0.0033926112,0.0042012027,0.00007669567,0.00022560928,0.000106441265,0.00060604507,0.00008677393,0.98632133,0.001161473,0.0011987807,0.0002460009],"about_ca_topic_score_codex":0.0001844611,"about_ca_topic_score_gemma":0.000019502198,"teacher_disagreement_score":0.03479601,"about_ca_system_score_codex":0.000052312196,"about_ca_system_score_gemma":0.0000659484,"threshold_uncertainty_score":0.50113326},"labels":[],"label_agreement":null},{"id":"W2167610854","doi":"10.1158/1541-7786.mcr-11-0531","title":"<i>In Situ</i> Analysis of Mutant EGFRs Prevalent in Glioblastoma Multiforme Reveals Aberrant Dimerization, Activation, and Differential Response to Anti-EGFR Targeted Therapy","year":2012,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; Toronto Western Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Proximity ligation assay; Cetuximab; Epidermal growth factor receptor; Mutant; Cancer research; Cell culture; EGFR inhibitors; Biology; Chemistry; Monoclonal antibody; Receptor; Molecular biology; Antibody; Biochemistry; Immunology; Gene","score_opus":0.04354928422118057,"score_gpt":0.40579152181399997,"score_spread":0.36224223759281937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167610854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921642,0.0016376834,0.0005799579,0.003481197,0.00006877174,0.0019478512,0.000048600712,0.000017237633,0.000054519453],"genre_scores_gemma":[0.9976716,0.0010378443,0.00014287692,0.00029456298,0.000062377025,0.00053013314,0.000020445052,0.000059427646,0.00018075612],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944994,0.0013286378,0.00068661454,0.00059321173,0.0018167994,0.0010753545],"domain_scores_gemma":[0.99787223,0.00033040284,0.00009842365,0.00066956173,0.00057171844,0.00045765532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033480015,0.0002467753,0.0007413769,0.002836953,0.00008310726,0.000037212594,0.00026339293,0.00017050722,0.0004937854],"category_scores_gemma":[0.0008993302,0.00022166545,0.00012940231,0.005849694,0.00021839766,0.00018137324,0.00018645906,0.000610208,0.000008508696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059414073,0.00046802644,0.1321133,0.00015357182,0.00033136233,0.000045344495,0.002676274,0.00027942643,0.8560764,0.000024467909,0.00017016122,0.0017202401],"study_design_scores_gemma":[0.0018457249,0.00037805986,0.43129978,0.00023595459,0.00004740153,0.000002472991,0.00014563427,0.00043945646,0.5647421,0.000011222288,0.00070420885,0.00014798345],"about_ca_topic_score_codex":0.0019520166,"about_ca_topic_score_gemma":0.00042944262,"teacher_disagreement_score":0.29918647,"about_ca_system_score_codex":0.00079576415,"about_ca_system_score_gemma":0.00047378652,"threshold_uncertainty_score":0.9039255},"labels":[],"label_agreement":null},{"id":"W2167655328","doi":"10.1038/cr.2014.37","title":"Biomarker-guided sequential targeted therapies to overcome therapy resistance in rapidly evolving highly aggressive mammary tumors","year":2014,"lang":"en","type":"article","venue":"Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; Susan G. Komen; University of Pennsylvania; National Cancer Institute; National Institutes of Health","keywords":"Lapatinib; Trastuzumab; PTEN; PI3K/AKT/mTOR pathway; Cancer research; Biomarker; Biology; Targeted therapy; Breast cancer; Cancer; Medicine; Bioinformatics; Pharmacology; Signal transduction; Cell biology; Genetics","score_opus":0.1014900660765387,"score_gpt":0.40599398359236116,"score_spread":0.30450391751582245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167655328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93018335,0.016614508,0.00030698316,0.010113934,0.00030814955,0.0026451757,0.000018286453,0.00016675443,0.039642856],"genre_scores_gemma":[0.9837377,0.0016961098,0.002471023,0.00056133,0.00035983848,0.00037658607,0.00002619805,0.00012354467,0.0106476415],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99211824,0.001735504,0.00067164586,0.001053669,0.0026465796,0.0017743711],"domain_scores_gemma":[0.99553704,0.0010927359,0.00012773098,0.0014861935,0.0010462474,0.0007100601],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060072565,0.00035781247,0.0006503417,0.0012742735,0.00029482384,0.000228914,0.0010395522,0.00025148474,0.00096995116],"category_scores_gemma":[0.0017521305,0.00031426238,0.00016164703,0.0026324245,0.0004200131,0.00023424016,0.00044228457,0.0013665827,0.00039644126],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034962005,0.000631403,0.029501269,0.0008258926,0.00013432534,0.0016161007,0.004694507,0.0000108353015,0.7958361,0.0009536286,0.13210274,0.030196978],"study_design_scores_gemma":[0.013756744,0.0026799997,0.374243,0.0032194688,0.000015329275,0.000057428566,0.00097627135,0.0015788889,0.31034032,0.0053501385,0.2863853,0.0013971382],"about_ca_topic_score_codex":0.00087095634,"about_ca_topic_score_gemma":0.0002962133,"teacher_disagreement_score":0.48549578,"about_ca_system_score_codex":0.0010690297,"about_ca_system_score_gemma":0.0012588422,"threshold_uncertainty_score":0.9999433},"labels":[],"label_agreement":null},{"id":"W2167955103","doi":"10.1093/annonc/mdq786","title":"Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?","year":2011,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Breast Cancer Research Foundation","keywords":"Medicine; Coping (psychology); Breast cancer; Oncology; Internal medicine; Gynecology; Clinical psychology; Cancer","score_opus":0.2047006578842925,"score_gpt":0.45608003687345433,"score_spread":0.25137937898916185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167955103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74044687,0.011512312,0.00008429647,0.09812764,0.0004392382,0.0028869007,0.00051108847,0.00013972963,0.14585194],"genre_scores_gemma":[0.9856619,0.009745528,0.00043283773,0.002179726,0.00028979944,0.00031891657,0.000015936705,0.000052776653,0.0013025478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805653,0.00012976084,0.00035230228,0.00044554094,0.00038013252,0.000635743],"domain_scores_gemma":[0.9983025,0.00014799947,0.00018283752,0.0004373578,0.0006202835,0.0003090244],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030656977,0.0002525157,0.00075420615,0.0001817879,0.00007390751,0.000008562013,0.0001785606,0.00020266355,0.0014119588],"category_scores_gemma":[0.000022283502,0.00018076511,0.0001280233,0.00023417483,0.00048029702,0.000066495864,0.00006982792,0.00027026486,0.000038895054],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016938752,0.00479081,0.14932717,0.0005059574,0.0027157564,0.002659722,0.019645374,0.00009773708,0.002113708,0.0020532156,0.04111424,0.75803757],"study_design_scores_gemma":[0.026302323,0.12858813,0.18333659,0.00505604,0.0011271735,0.0032436922,0.00804497,0.00043843608,0.09167555,0.0027098542,0.5478695,0.0016077581],"about_ca_topic_score_codex":0.009259902,"about_ca_topic_score_gemma":0.002788246,"teacher_disagreement_score":0.7564298,"about_ca_system_score_codex":0.0005116776,"about_ca_system_score_gemma":0.0016980978,"threshold_uncertainty_score":0.9995009},"labels":[],"label_agreement":null},{"id":"W2168110569","doi":"10.1186/1559-0275-9-5","title":"Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue","year":2012,"lang":"en","type":"article","venue":"Clinical Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre; Canada Research Chairs; Medical Council of Canada; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Epidermal growth factor receptor; Immunohistochemistry; Immunoassay; Epidermal growth factor; Receptor tyrosine kinase; EGFR inhibitors; Cancer research; Lung cancer; Molecular biology; Receptor; Pathology; Chemistry; Biology; Antibody; Medicine; Internal medicine; Immunology","score_opus":0.12304287529507994,"score_gpt":0.4495219361459454,"score_spread":0.3264790608508654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168110569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968165,0.00015238194,0.0004997369,0.0006044545,0.00053737767,0.0011377792,0.00003385878,0.000059605463,0.00015831851],"genre_scores_gemma":[0.98808616,0.00019687533,0.010276236,0.0000815832,0.0009941228,0.00010591324,0.0000547343,0.00004251752,0.00016187773],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966268,0.00038771852,0.0014372837,0.0003747248,0.0005132226,0.00066026667],"domain_scores_gemma":[0.99762774,0.0006857883,0.0003625385,0.00046743845,0.00042370494,0.00043282166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022022235,0.00020172064,0.00098103,0.0004718731,0.00004590715,0.000013166382,0.00019838125,0.0003109997,0.0002088735],"category_scores_gemma":[0.0056572855,0.00018552404,0.0002502267,0.0018766902,0.00014036884,0.0002490608,0.00010001385,0.0010832526,0.00007384927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006984721,0.00050949556,0.88359416,0.00017197132,0.00031846884,0.000006853267,0.00021117265,0.000004357743,0.10987989,0.000019936271,0.00022547951,0.0043597277],"study_design_scores_gemma":[0.0013491014,0.00044493683,0.7574906,0.00013620185,0.0002853253,0.0000045667452,0.00006398055,0.0005909291,0.2385381,0.000014882957,0.00090450724,0.0001768664],"about_ca_topic_score_codex":0.00046410586,"about_ca_topic_score_gemma":0.000031306903,"teacher_disagreement_score":0.12865822,"about_ca_system_score_codex":0.00040945833,"about_ca_system_score_gemma":0.0003046864,"threshold_uncertainty_score":0.75654507},"labels":[],"label_agreement":null},{"id":"W2168114460","doi":"10.1093/protein/13.3.143","title":"NMR study of the differential contributions of residues of transforming growth factor alpha to association with its receptor","year":2000,"lang":"en","type":"article","venue":"Protein Engineering Design and Selection","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute; University of Alberta","funders":"","keywords":"Heteronuclear molecule; Receptor; Epitope; TGF alpha; Transforming growth factor; Chemistry; Ligand (biochemistry); Epidermal growth factor receptor; Biophysics; Biochemistry; Stereochemistry; Nuclear magnetic resonance spectroscopy; Biology; Cell biology; Genetics; Antibody","score_opus":0.014903116135764451,"score_gpt":0.26236625666395147,"score_spread":0.24746314052818702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168114460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719611,0.00004456828,0.025971679,0.00011004686,0.000014989171,0.0018557884,0.000009570306,0.000020836731,0.000011451131],"genre_scores_gemma":[0.9991311,0.000017938624,0.00049078296,0.0000015837636,0.00003085011,0.00011145214,0.0000010580392,0.0000120482355,0.00020322941],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991763,0.000058210615,0.00019982427,0.00010714451,0.00032603572,0.00013245596],"domain_scores_gemma":[0.9995589,0.000049505128,0.000051661802,0.00005764474,0.00023809553,0.000044139902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022082876,0.00007667466,0.00019607917,0.000089375666,0.00003791536,0.000005074888,0.000040551495,0.000054567507,0.00005313329],"category_scores_gemma":[0.00016919128,0.000055062057,0.000024594605,0.00036629784,0.000008517004,0.000041464424,0.0000043957784,0.00013718053,3.9347424e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050189625,0.0002016365,0.0053913826,0.00022347503,0.00011194736,1.5517035e-7,0.0013874314,0.0009513764,0.98903877,0.000019793943,0.000014428737,0.0021577221],"study_design_scores_gemma":[0.0010651516,0.0018534616,0.02745695,0.00023541584,0.000045248504,0.0000013699718,0.000027228647,0.0014921998,0.9677084,0.0000030436026,0.000056124925,0.000055396573],"about_ca_topic_score_codex":0.00014943951,"about_ca_topic_score_gemma":0.000014303312,"teacher_disagreement_score":0.027169988,"about_ca_system_score_codex":0.00016173768,"about_ca_system_score_gemma":0.00008701483,"threshold_uncertainty_score":0.22453655},"labels":[],"label_agreement":null},{"id":"W2168198903","doi":"10.1007/s00259-008-0923-x","title":"Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts","year":2008,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"North York General Hospital; University Health Network; University of Toronto","funders":"","keywords":"Trastuzumab; Medicine; Biodistribution; Nuclear medicine; Immunohistochemistry; Breast cancer; Cancer research; Cancer; Internal medicine; Chemistry; In vitro","score_opus":0.03705302276047759,"score_gpt":0.3158584600833648,"score_spread":0.2788054373228872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168198903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881708,0.0008268575,0.000109299435,0.009660688,0.000056431734,0.000239968,0.000004095843,0.000014062507,0.0009177747],"genre_scores_gemma":[0.9967022,0.00022289682,0.0011334541,0.0015951094,0.0002464971,3.6864387e-7,0.0000023728155,0.00007082204,0.000026257043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99716204,0.00072801305,0.00083785626,0.00024933316,0.0006672952,0.0003554639],"domain_scores_gemma":[0.998691,0.00018991294,0.00029877698,0.00022801026,0.0002589516,0.00033335152],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003312944,0.0001944548,0.0005682434,0.00041744934,0.00021998613,0.000023939621,0.0002289303,0.000022757955,0.00002441939],"category_scores_gemma":[0.00090634625,0.0001501768,0.00009309517,0.00035785665,0.00033756296,0.000073747644,0.00013582739,0.00078656204,0.000005562412],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011794969,0.0001414886,0.058411777,0.00008791296,0.0002098447,0.02096859,0.028738929,0.000012718015,0.86771077,0.000015748115,0.005237972,0.017284779],"study_design_scores_gemma":[0.0030194118,0.002145089,0.97183156,0.001043352,0.00020973045,0.0065118684,0.0038294757,0.000032664106,0.001312767,0.000014439124,0.0098584145,0.00019120831],"about_ca_topic_score_codex":0.00012825216,"about_ca_topic_score_gemma":0.000008261791,"teacher_disagreement_score":0.9134198,"about_ca_system_score_codex":0.00018862967,"about_ca_system_score_gemma":0.00013564566,"threshold_uncertainty_score":0.6124032},"labels":[],"label_agreement":null},{"id":"W2168372454","doi":"10.1200/jco.2014.56.9590","title":"Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Hazard ratio; Breast cancer; Docetaxel; Clinical endpoint; Pertuzumab; Cancer; Clinical trial; Confidence interval","score_opus":0.3663924786049742,"score_gpt":0.5653644802031109,"score_spread":0.19897200159813672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168372454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701577,0.000698577,0.00021655275,0.023228085,0.0019270469,0.0012988972,0.00086208724,0.00001995906,0.0015910998],"genre_scores_gemma":[0.98441476,0.0018609967,0.006523249,0.0015882119,0.0037401663,0.000072370385,0.000031092266,0.00006282827,0.0017063344],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99316204,0.0008637575,0.0039016365,0.00042803574,0.0010235514,0.0006209902],"domain_scores_gemma":[0.98731804,0.0049543716,0.0031305163,0.00031962976,0.0032607939,0.0010166349],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0051754755,0.00029352197,0.002657166,0.00022613673,0.000078471894,0.000012650956,0.00047101485,0.0005803033,0.00051870506],"category_scores_gemma":[0.009260351,0.00019574934,0.0006668935,0.0002989958,0.0005606575,0.00019932124,0.00007393187,0.0015994053,0.00001191243],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3210934,0.003299223,0.011080873,0.00019652773,0.0009435716,0.00045986383,0.0011180202,0.00004823882,0.003423689,0.00007210546,0.06657383,0.59169066],"study_design_scores_gemma":[0.21080253,0.21438357,0.36308277,0.0014007081,0.00051106274,0.0015418527,0.0014301983,0.00021435325,0.010291003,0.0006419319,0.19500262,0.00069741486],"about_ca_topic_score_codex":0.00032206925,"about_ca_topic_score_gemma":0.0002705607,"teacher_disagreement_score":0.5909932,"about_ca_system_score_codex":0.0012830805,"about_ca_system_score_gemma":0.012791321,"threshold_uncertainty_score":0.99908507},"labels":[],"label_agreement":null},{"id":"W2168391786","doi":"10.2174/092986706779026174","title":"Targeting the EGFR Pathway for Cancer Therapy","year":2006,"lang":"en","type":"review","venue":"Current Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Strong; CancerCare Manitoba Foundation; Manitoba Medical Service Foundation; Manitoba Health Research Council","keywords":"Cetuximab; Medicine; Gefitinib; Panitumumab; Pertuzumab; Lapatinib; Erlotinib; Amphiregulin; Epidermal growth factor receptor; Lung cancer; Targeted therapy; Trastuzumab; Cancer; Cancer research; Breast cancer; Epidermal growth factor; Oncology; Internal medicine; Colorectal cancer; Receptor","score_opus":0.19499287347279368,"score_gpt":0.49035764617935623,"score_spread":0.2953647727065626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168391786","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011287508,0.99365234,0.00006497968,0.00053398166,0.0012104199,0.0023249139,0.000256893,0.00007958992,0.0018656194],"genre_scores_gemma":[0.000010312007,0.98313797,0.00003417711,0.00009238454,0.009994989,0.0027400923,0.0010383618,0.00014633391,0.0028053657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963025,0.00008464606,0.00091098726,0.00076668366,0.0010882,0.000846987],"domain_scores_gemma":[0.9976383,0.0005308299,0.0004345174,0.00077275466,0.00030831364,0.00031532752],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010037274,0.0006634517,0.0018521349,0.000061237384,0.00020131287,0.00003875947,0.00067169126,0.00041055892,0.00086544827],"category_scores_gemma":[0.0004167707,0.00037422526,0.00076521374,0.0003948779,0.0003347525,0.000023568015,0.000099917714,0.001961304,0.000027426095],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030191508,0.00008843413,0.000014938897,0.063966125,0.00012837455,0.000016137663,0.000032193588,2.438215e-7,0.0000688583,0.0000033356098,0.09916617,0.836485],"study_design_scores_gemma":[0.000806595,0.000065134365,0.0000010554593,0.03248009,0.00052808714,0.00006835352,0.000030567684,0.000016074659,0.0003160703,0.0000142969375,0.96534145,0.00033220922],"about_ca_topic_score_codex":0.00004716673,"about_ca_topic_score_gemma":0.0000014745304,"teacher_disagreement_score":0.8661753,"about_ca_system_score_codex":0.00081431825,"about_ca_system_score_gemma":0.0031503942,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W2168482167","doi":"10.1158/1078-0432.ccr-03-0244","title":"Treatment of HER-2/<b> <i>neu</i> </b> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/<b> <i>neu</i> </b> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Gefitinib; Trastuzumab; Medicine; Cancer research; Epidermal growth factor receptor; In vivo; Estrogen receptor; Breast cancer; Growth inhibition; Cell growth; Cancer; Internal medicine; Pharmacology; Biology","score_opus":0.08032479363375436,"score_gpt":0.4131441111757406,"score_spread":0.33281931754198624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168482167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987444,0.0041265497,0.000120255914,0.004446451,0.00020163617,0.0027050925,0.00029352368,0.00009655385,0.0005659827],"genre_scores_gemma":[0.98263127,0.013965473,0.00090127974,0.00040957797,0.00060929917,0.00093502714,0.000031165047,0.00017080414,0.00034610907],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930032,0.0010840138,0.0010795244,0.0016118299,0.0019484896,0.0012729318],"domain_scores_gemma":[0.994379,0.0024301629,0.0003764241,0.00063452235,0.001049795,0.0011301307],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013821151,0.00063596515,0.0013733499,0.0004230391,0.0005490114,0.00019035558,0.00024780838,0.00037292382,0.00019911052],"category_scores_gemma":[0.00028054282,0.00048644838,0.00016933479,0.0007151874,0.001310902,0.0006338054,0.00021279322,0.00152051,0.000011235316],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037837155,0.012295036,0.42391104,0.012093493,0.0006934237,0.00058146723,0.006056848,0.00046229604,0.3295547,0.00041661717,0.0070089498,0.16908899],"study_design_scores_gemma":[0.07755496,0.028561393,0.20857987,0.013490973,0.00053816166,0.00037653776,0.0021006004,0.0019818689,0.6583262,0.0034214405,0.0028491998,0.0022187782],"about_ca_topic_score_codex":0.0061456785,"about_ca_topic_score_gemma":0.00020638277,"teacher_disagreement_score":0.32877153,"about_ca_system_score_codex":0.001256876,"about_ca_system_score_gemma":0.0012743612,"threshold_uncertainty_score":0.9997587},"labels":[],"label_agreement":null},{"id":"W2168960014","doi":"10.1158/1078-0432.ccr-04-2208","title":"A Haplotype Analysis of <i>HER-2</i> Gene Polymorphisms: Association with Breast Cancer Risk, HER-2 Protein Expression in the Tumor, and Disease Recurrence in Korea","year":2005,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"inVentiv Health Clinical","funders":"College of Medicine, Seoul National University; Seoul National University","keywords":"Haplotype; Single-nucleotide polymorphism; Linkage disequilibrium; Breast cancer; Genetics; Biology; Tag SNP; Allele; SNP; Minor allele frequency; Case-control study; Cancer; Genotype; Oncology; Internal medicine; Medicine; Gene","score_opus":0.10833714557625322,"score_gpt":0.4753167939647972,"score_spread":0.36697964838854397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168960014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97538954,0.0050992337,0.000010320604,0.017271454,0.00003460726,0.0016179889,0.00037103638,0.000015558657,0.00019025795],"genre_scores_gemma":[0.99256027,0.004804438,0.00020707192,0.0004174981,0.00035325807,0.0012698863,0.000020136571,0.000035745823,0.00033171332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928603,0.002281813,0.00090059725,0.00080417277,0.002344476,0.00080864085],"domain_scores_gemma":[0.99629974,0.0014639288,0.0002935096,0.0007635967,0.00065854663,0.00052069145],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009493703,0.00020764346,0.0007483145,0.0006645523,0.000121511956,0.000053539025,0.00046202433,0.00017555944,0.00048726785],"category_scores_gemma":[0.0027841807,0.00013471246,0.00014550383,0.0038106497,0.0005645939,0.00016033054,0.00019340479,0.0022100506,0.000009356355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041700467,0.00072437635,0.9633761,0.00011302392,0.00016810413,0.000074551936,0.00043804958,0.00014065308,0.0010906525,0.000008567797,0.0013603239,0.02833555],"study_design_scores_gemma":[0.0024859663,0.00038327748,0.9907979,0.0011189538,0.0002102214,0.0000023471712,0.00013835491,0.0019559264,0.0010395709,0.000069030095,0.001638628,0.00015981658],"about_ca_topic_score_codex":0.015308791,"about_ca_topic_score_gemma":0.020104846,"teacher_disagreement_score":0.028175734,"about_ca_system_score_codex":0.0011189687,"about_ca_system_score_gemma":0.002348733,"threshold_uncertainty_score":0.9977757},"labels":[],"label_agreement":null},{"id":"W2169031646","doi":"10.1309/ajcpw37qgecdycdo","title":"Tissue Microarray for Routine Analysis of Breast Biomarkers in the Clinical Laboratory","year":2009,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; Concordance; Medicine; Pathology; Stain; Histopathology; Breast cancer; Immunohistochemistry; Staining; Internal medicine; Cancer","score_opus":0.07992140352272116,"score_gpt":0.5231641085861471,"score_spread":0.443242705063426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169031646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775398,0.0003791298,0.0011775525,0.02005565,0.0002675167,0.00028660428,0.000060978175,0.0000051633597,0.00022759926],"genre_scores_gemma":[0.9876362,0.00043738904,0.006274326,0.005049859,0.00056093873,0.0000039585893,0.000007390078,0.000013737499,0.000016210723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937284,0.0020911566,0.0030636706,0.00030599043,0.0004408152,0.00036997302],"domain_scores_gemma":[0.99280465,0.004139318,0.0015463056,0.00053191517,0.0007077358,0.00027008576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015197513,0.0001484942,0.0020694288,0.0005132269,0.000026041449,0.000007793317,0.00048775287,0.00017607697,0.000071976785],"category_scores_gemma":[0.005110232,0.00009515357,0.00081141863,0.0018722125,0.001469921,0.000041494968,0.000026779886,0.0009904971,0.0000043339305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050164694,0.0013300437,0.56383294,0.000015902378,0.0012264886,0.00063081086,0.00025552395,0.000010617363,0.0018816821,0.000043797798,0.0032852802,0.42247045],"study_design_scores_gemma":[0.002803451,0.011296953,0.9771091,0.00005741955,0.0011421212,0.00037323657,0.00063767424,0.00004396561,0.000099436365,0.000084539366,0.0062593934,0.000092744056],"about_ca_topic_score_codex":0.000025652578,"about_ca_topic_score_gemma":0.000029255876,"teacher_disagreement_score":0.4223777,"about_ca_system_score_codex":0.00004240307,"about_ca_system_score_gemma":0.0007117497,"threshold_uncertainty_score":0.6117794},"labels":[],"label_agreement":null},{"id":"W2169052759","doi":"","title":"Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.","year":2003,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"ErbB; Biology; Cancer research; Tumor microenvironment; Angiogenesis; Receptor; Tumor progression; Cancer; Genetics","score_opus":0.04022559267485461,"score_gpt":0.2614301391182426,"score_spread":0.221204546443388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169052759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994661,0.00029450195,0.00011185286,0.000302774,0.00009962348,0.001548945,0.00005836781,0.000014625664,0.0029083295],"genre_scores_gemma":[0.9963551,0.00004819366,0.0009770857,0.000019052526,0.000009330143,0.00019549199,0.00003732297,0.000020939053,0.0023374665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998531,0.00014568745,0.00042520475,0.00017868604,0.00049104926,0.0002283701],"domain_scores_gemma":[0.99907535,0.00017248235,0.00023559305,0.00031524315,0.000089169625,0.0001121664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047815294,0.00009164039,0.00026902862,0.00010654602,0.000023733284,0.000002552024,0.00007839247,0.000058912705,0.00038298566],"category_scores_gemma":[0.00089013187,0.00007800499,0.00006551722,0.0002178933,0.00019378918,0.000049721886,0.000024994199,0.00008080271,0.0000015983006],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009647726,0.0027798323,0.038482986,0.00047412238,0.00007037546,0.0000010742184,0.00026158715,0.00001641361,0.88942385,0.000056236524,0.03697113,0.030497646],"study_design_scores_gemma":[0.0028379655,0.00020182908,0.25118965,0.0002475209,0.000026049709,0.0000029507132,0.00015206281,0.000054440377,0.7356531,0.000046933063,0.009522072,0.00006544948],"about_ca_topic_score_codex":0.00005027557,"about_ca_topic_score_gemma":0.0000038822322,"teacher_disagreement_score":0.21270666,"about_ca_system_score_codex":0.00025676825,"about_ca_system_score_gemma":0.0000684169,"threshold_uncertainty_score":0.41934243},"labels":[],"label_agreement":null},{"id":"W2169149961","doi":"10.2967/jnumed.109.067231","title":"<sup>18</sup>F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice","year":2009,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biodistribution; Medicine; Breast cancer; Cancer; Nuclear medicine; Internal medicine; In vivo; Biology","score_opus":0.0455967457794242,"score_gpt":0.36205929155645106,"score_spread":0.31646254577702687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169149961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95719993,0.002849909,0.0000040482587,0.03845147,0.0002884251,0.0005110379,0.00006813688,0.000043323827,0.00058371236],"genre_scores_gemma":[0.9920971,0.0013054955,0.00031087705,0.0033557962,0.0025057315,0.000006451935,0.00001682462,0.000106594285,0.00029517376],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9950497,0.0005264322,0.0014621839,0.0005299271,0.0015647365,0.00086698995],"domain_scores_gemma":[0.9967204,0.0005704547,0.0006211777,0.0004844885,0.0007921619,0.0008113413],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001161701,0.00051221973,0.0015368751,0.0011648249,0.00016694806,0.000049911825,0.0006295103,0.00008696904,0.0065389844],"category_scores_gemma":[0.0007193444,0.0003855492,0.0003242943,0.0007854792,0.0004259575,0.00020818842,0.00009457354,0.0019809764,0.0000660751],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04641432,0.0030308876,0.04832451,0.00040361716,0.0017309365,0.058262795,0.01573334,0.00020257177,0.67484194,0.00026364,0.12007936,0.030712059],"study_design_scores_gemma":[0.014979146,0.008342456,0.9377165,0.005888111,0.00069641974,0.010187812,0.006502568,0.0006932946,0.0012070583,0.0003606679,0.012902343,0.00052364473],"about_ca_topic_score_codex":0.001652656,"about_ca_topic_score_gemma":0.00020756396,"teacher_disagreement_score":0.88939196,"about_ca_system_score_codex":0.0010635504,"about_ca_system_score_gemma":0.00061894517,"threshold_uncertainty_score":0.99985963},"labels":[],"label_agreement":null},{"id":"W2169519275","doi":"10.1158/0008-5472.can-13-1055","title":"Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 Activation","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Neuregulin; Breast cancer; Autocrine signalling; Neuregulin 1; Medicine; Cancer research; Trastuzumab; Lapatinib; Cancer; In vivo; Oncology; Internal medicine; Receptor; Biology","score_opus":0.06370755747525297,"score_gpt":0.39784602243945827,"score_spread":0.3341384649642053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169519275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919647,0.0005063039,0.00006119656,0.0032408403,0.00011429739,0.002137975,0.000048770125,0.0001538291,0.0017721007],"genre_scores_gemma":[0.99612164,0.0001374637,0.00076963985,0.00010190979,0.0006302878,0.0009109425,0.000026823443,0.00011556262,0.0011857426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950828,0.00042960915,0.0006369744,0.00066271087,0.0019982785,0.0011896187],"domain_scores_gemma":[0.99673593,0.0005516911,0.0001643198,0.00058237906,0.001502117,0.00046355117],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016844873,0.00026917408,0.00052855967,0.00045053213,0.00024470664,0.00012684197,0.00042667103,0.00013865418,0.0033550526],"category_scores_gemma":[0.00035998353,0.00024658686,0.000118313415,0.001304582,0.00025967084,0.0003077307,0.0002441862,0.001252898,0.00012481926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017289394,0.0002534669,0.0023625006,0.0011948999,0.000100895966,0.000023486105,0.00059723656,0.00005166893,0.970618,0.000015280402,0.007718505,0.016891183],"study_design_scores_gemma":[0.001477038,0.000498958,0.0020068884,0.0011112257,0.000021489901,0.000034037672,0.00044683818,0.0016119771,0.99031574,0.00013800035,0.0021025124,0.00023529712],"about_ca_topic_score_codex":0.007115683,"about_ca_topic_score_gemma":0.000030778145,"teacher_disagreement_score":0.019697756,"about_ca_system_score_codex":0.0008650608,"about_ca_system_score_gemma":0.0013686807,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W2169680251","doi":"10.5858/2000-124-0234-peatei","title":"p53, ErbB2, and TAG-72 Expression in the Spectrum of Ductal Carcinoma In Situ of the Breast Classified by the Van Nuys System","year":2000,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ductal carcinoma; Pathology; Breast cancer; Differential diagnosis; Immunohistochemistry; Context (archaeology); Carcinoma in situ; Carcinoma; P53 expression; Biology; Breast carcinoma; Cancer; Medicine; Internal medicine","score_opus":0.012849247681886283,"score_gpt":0.2772095502662124,"score_spread":0.26436030258432613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169680251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98323375,0.0032750012,0.000006039826,0.006171071,0.00009263845,0.00071477704,0.00010340155,0.0000087179815,0.0063945926],"genre_scores_gemma":[0.9991394,0.00027295042,0.00003862609,0.00027127305,0.00011986956,0.00003682557,0.000010859417,0.000020865502,0.00008928359],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9968032,0.00128444,0.000682203,0.0003289917,0.0005289816,0.00037213814],"domain_scores_gemma":[0.9980446,0.0007459972,0.00022548946,0.0008477103,0.000054119344,0.000082066785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013888286,0.0001954992,0.0006415511,0.00019041535,0.00006430638,0.0000022444153,0.0005099477,0.00010779245,0.00009396164],"category_scores_gemma":[0.00019349257,0.00009304666,0.000054740212,0.00060333067,0.0025695483,0.000038295435,0.00011504654,0.0006717697,0.0000015355971],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007758758,0.00023384781,0.2834925,0.0005642903,0.000024773193,0.0004089651,0.014543301,0.0000039552624,0.6959146,0.0004829799,0.0012592203,0.0022956538],"study_design_scores_gemma":[0.0036802741,0.0007753456,0.937056,0.0015509571,0.00006835706,0.0008191029,0.0115566775,0.00006280748,0.043634158,0.00023690867,0.0004589175,0.0001004666],"about_ca_topic_score_codex":0.00018559207,"about_ca_topic_score_gemma":0.00018869586,"teacher_disagreement_score":0.6535635,"about_ca_system_score_codex":0.000041326326,"about_ca_system_score_gemma":0.00028255655,"threshold_uncertainty_score":0.94676083},"labels":[],"label_agreement":null},{"id":"W2170181527","doi":"10.1186/s13058-015-0568-1","title":"Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy","year":2015,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"GlaxoSmithKline; Avon Foundation for Women","keywords":"Medicine; Hazard ratio; Breast cancer; Internal medicine; Oncology; Hormone receptor; Adjuvant therapy; Hormone therapy; Proportional hazards model; Trastuzumab; Estrogen receptor; Cancer; Adjuvant; Surgical oncology; Gynecology; Confidence interval","score_opus":0.10834116408560235,"score_gpt":0.43908163209744927,"score_spread":0.3307404680118469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170181527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98897797,0.0024651315,0.0000044714507,0.0042490684,0.00020003688,0.0020154845,0.00076005416,0.00005737186,0.0012704049],"genre_scores_gemma":[0.9941412,0.0035849873,0.000037654812,0.000115837494,0.00035144936,0.00077628164,0.00006484731,0.00012357112,0.0008041369],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927488,0.0006030437,0.00062393973,0.00097054517,0.0034998201,0.0015538699],"domain_scores_gemma":[0.9941783,0.0001259345,0.00015942266,0.0009611901,0.003696145,0.0008790313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016848531,0.00040792438,0.0008409757,0.0008331847,0.00011167171,0.000079921025,0.00071149314,0.00024047095,0.0017150225],"category_scores_gemma":[0.000099513105,0.0003081462,0.00009649559,0.0030649076,0.00090079696,0.00028134524,0.00024520594,0.0013562042,0.00007817229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067631225,0.0011209509,0.86613137,0.00036555022,0.00014160202,0.0001647828,0.00067297864,0.0000329834,0.0006537825,0.000008573012,0.003389279,0.12055503],"study_design_scores_gemma":[0.009186939,0.0009771897,0.9828489,0.002710542,0.000019806434,0.00013740272,0.00015173302,0.00007108987,0.0027881074,0.000016595077,0.00077396806,0.00031771668],"about_ca_topic_score_codex":0.03959893,"about_ca_topic_score_gemma":0.008140026,"teacher_disagreement_score":0.12023731,"about_ca_system_score_codex":0.0020420225,"about_ca_system_score_gemma":0.00536717,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W2171670688","doi":"10.1186/bcr2427","title":"Tailored targeted therapy for all: a realistic and worthwhile objective against","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Tamoxifen; Endocrine system; Breast cancer; Oncology; Metastatic breast cancer; Diethylstilbestrol; Cancer; Internal medicine; Adjuvant; Surgical oncology; Adjuvant therapy; Ovarian cancer; Targeted therapy; Hormone","score_opus":0.0992520777201737,"score_gpt":0.45478780698907706,"score_spread":0.35553572926890337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171670688","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8774156,0.014978055,0.0002319553,0.08163136,0.00031536346,0.010522538,0.0012861703,0.0003697424,0.013249215],"genre_scores_gemma":[0.99002916,0.004271416,0.00041108666,0.0015444855,0.0007825276,0.0012433989,0.000108684224,0.00007473194,0.0015345411],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99603206,0.0002554457,0.0003176463,0.0008099897,0.001326248,0.0012586126],"domain_scores_gemma":[0.9971352,0.00033568256,0.00005262819,0.000607115,0.0012645595,0.0006047651],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017120038,0.00024939876,0.0004593185,0.00046529237,0.00029232228,0.00011325622,0.00027933606,0.00018402415,0.00038675085],"category_scores_gemma":[0.00032060032,0.00020960312,0.00011122321,0.0009168461,0.00038288784,0.00011400012,0.00007608173,0.0009490388,0.000023774357],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017705826,0.00083294295,0.01736217,0.00042026458,0.00045093897,0.00023205868,0.0022252586,0.000023879604,0.06200137,0.0013166739,0.09066425,0.80676436],"study_design_scores_gemma":[0.017591074,0.0049483967,0.85636145,0.0011702371,0.00007284893,0.00033659456,0.001206063,0.002575938,0.011481523,0.0057986085,0.09752203,0.00093523966],"about_ca_topic_score_codex":0.0020662865,"about_ca_topic_score_gemma":0.00024433873,"teacher_disagreement_score":0.8389993,"about_ca_system_score_codex":0.00073193875,"about_ca_system_score_gemma":0.0015636692,"threshold_uncertainty_score":0.85473675},"labels":[],"label_agreement":null},{"id":"W2172081236","doi":"10.1124/mol.106.023911","title":"Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor","year":2006,"lang":"en","type":"article","venue":"Molecular Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of British Columbia","funders":"National Cancer Institute","keywords":"Trastuzumab; SKBR3; Protein kinase B; PI3K/AKT/mTOR pathway; Cancer research; Medicine; Apoptosis; Growth inhibition; Breast cancer; Pharmacology; Chemistry; Cancer; Internal medicine; Biochemistry","score_opus":0.01630541155249776,"score_gpt":0.32560526798965805,"score_spread":0.3092998564371603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2172081236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98867714,0.0047408664,0.0022598214,0.0012523691,0.00057936873,0.0010520378,0.00026003137,0.00008449635,0.0010938507],"genre_scores_gemma":[0.9947425,0.00011397696,0.0024301014,0.0015700758,0.00038736296,0.00018511128,0.000028872046,0.0001410681,0.0004009406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963359,0.00024647344,0.0006595986,0.0008849148,0.0007210701,0.0011520089],"domain_scores_gemma":[0.99895924,0.000078899946,0.00019257725,0.00033132298,0.00017351701,0.00026443574],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035761055,0.00042501296,0.0006544436,0.0002686602,0.00014761118,0.00006123131,0.00027405005,0.00026661987,0.0012309315],"category_scores_gemma":[0.000015108128,0.00047858304,0.0001528903,0.0005157824,0.00021688893,0.00013661083,0.00016634111,0.00085444044,0.000016979851],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008633957,0.0006896363,0.0012100207,0.00024533743,0.0000803111,0.0010371922,0.00011473781,0.0007473813,0.9838751,0.000011619735,0.010551908,0.0005733482],"study_design_scores_gemma":[0.0068159546,0.00007506755,0.0019840256,0.00042651038,0.00013279711,0.000113199145,0.000045685832,0.0019220364,0.983297,0.000024971281,0.004729284,0.00043350516],"about_ca_topic_score_codex":0.004797642,"about_ca_topic_score_gemma":0.00042767535,"teacher_disagreement_score":0.006065333,"about_ca_system_score_codex":0.002209206,"about_ca_system_score_gemma":0.00072648644,"threshold_uncertainty_score":0.9997666},"labels":[],"label_agreement":null},{"id":"W2178732328","doi":"10.1093/annonc/mdv395","title":"Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Associazione Italiana per la Ricerca sul Cancro","keywords":"Medicine; Immune system; Immunology; Trastuzumab; Cancer research; Breast cancer; Cancer; Internal medicine","score_opus":0.2799415670746014,"score_gpt":0.4692287805792134,"score_spread":0.18928721350461203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2178732328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882634,0.002196804,0.000016364473,0.016185438,0.0001647446,0.0008648077,0.000016812055,0.000020260444,0.001708419],"genre_scores_gemma":[0.99804896,0.00020241583,0.00048271444,0.0008612651,0.000101764796,0.00011762968,0.000011534957,0.000013800539,0.00015990718],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99674445,0.00182055,0.00056465855,0.00018585366,0.00040944823,0.00027505797],"domain_scores_gemma":[0.9981094,0.00074979116,0.00020105485,0.00043169924,0.00044368673,0.000064339365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040952372,0.00011424118,0.0005604958,0.00011922884,0.000017082175,0.0000047498906,0.00020818223,0.0001845074,0.000206494],"category_scores_gemma":[0.0012283192,0.000074854,0.00010575552,0.00035001035,0.0003048891,0.000041944455,0.000058840564,0.00028310157,0.00001520206],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7236115,0.0023980783,0.01178126,0.00012738793,0.00016039287,0.0010033435,0.019667517,0.00011052414,0.04179356,0.00017967664,0.010417912,0.18874885],"study_design_scores_gemma":[0.065142006,0.047164273,0.77591467,0.00024435375,0.000047975325,0.00016304675,0.004083752,0.00094694,0.0026670368,0.0035853717,0.09979353,0.00024705037],"about_ca_topic_score_codex":0.00046626988,"about_ca_topic_score_gemma":0.00013475904,"teacher_disagreement_score":0.7641334,"about_ca_system_score_codex":0.000064782784,"about_ca_system_score_gemma":0.0005177424,"threshold_uncertainty_score":0.30524573},"labels":[],"label_agreement":null},{"id":"W2185702273","doi":"","title":"Analysis of the HER2/neu gene amplification in microdissected breast cancer tumour samples.","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Laser capture microdissection; Microdissection; Breast cancer; Biology; Gene duplication; Ductal carcinoma; Immunohistochemistry; Pathology; Polymerase chain reaction; Concordance; Mammary gland; genomic DNA; Cancer; Carcinoma; DNA; Molecular biology; Gene; Medicine; Gene expression; Genetics","score_opus":0.03769942574498235,"score_gpt":0.30197102997128955,"score_spread":0.2642716042263072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185702273","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993941,0.00046459277,0.00003208065,0.0036735458,0.00007477602,0.000884953,0.00019603333,0.000023215827,0.0007097832],"genre_scores_gemma":[0.9977656,0.000062794876,0.000042710653,0.00012925801,0.0001319804,0.0010781666,0.000063825435,0.000019112822,0.0007065313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984508,0.00009351384,0.00035863832,0.00028158852,0.00042506555,0.0003903971],"domain_scores_gemma":[0.99908656,0.00005591058,0.000113777016,0.00047285348,0.00018733332,0.00008358742],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042844363,0.00010592433,0.000318389,0.00035833046,0.000034353976,0.000015406566,0.00020782708,0.000068159454,0.000177598],"category_scores_gemma":[0.00008551995,0.000077694305,0.00013709732,0.0026183578,0.00010089234,0.000032557728,0.000045202374,0.000190858,0.0000029053863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000930124,0.00016369495,0.94398504,0.000050599607,0.0001820372,0.0000037002467,0.00006207761,0.00022523694,0.03173415,0.000029957022,0.0010190523,0.022451451],"study_design_scores_gemma":[0.00046600515,0.0000035069786,0.9786503,0.000017696038,0.00027625376,0.0000068877957,0.000022969441,0.00014858977,0.01953022,0.000021483238,0.0007855701,0.00007051987],"about_ca_topic_score_codex":0.020897072,"about_ca_topic_score_gemma":0.009399155,"teacher_disagreement_score":0.034665264,"about_ca_system_score_codex":0.00042975607,"about_ca_system_score_gemma":0.00016051531,"threshold_uncertainty_score":0.9856229},"labels":[],"label_agreement":null},{"id":"W2188941506","doi":"10.1152/ajpheart.2000.278.6.h1815","title":"Somatostatin receptor subtype expression and function in human vascular tissue","year":2000,"lang":"en","type":"article","venue":"American Journal of Physiology-Heart and Circulatory Physiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Somatostatin receptor; Endocrinology; Somatostatin; Internal medicine; Umbilical vein; Receptor; Vascular smooth muscle; Chemistry; Biology; Pathology; Medicine; In vitro; Smooth muscle","score_opus":0.01630701663107245,"score_gpt":0.30391253841830324,"score_spread":0.2876055217872308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2188941506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9982373,0.0011262437,0.0000011406737,0.00024922585,0.000106030726,0.00017616339,0.000002523335,0.000014716498,0.00008665666],"genre_scores_gemma":[0.9980796,0.00056831975,0.00023856817,0.0006860003,0.00033490878,0.000010110867,0.00001013232,0.000028355558,0.000044015],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99817735,0.00039653326,0.0004608387,0.00038555014,0.00020575029,0.00037399447],"domain_scores_gemma":[0.99909335,0.00009608957,0.00019670941,0.00027226965,0.000107813146,0.00023378791],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036382105,0.00019702176,0.00078783376,0.00020801599,0.00010839141,0.000007873631,0.000091059985,0.00011855599,0.00092684786],"category_scores_gemma":[0.00003290199,0.00016433372,0.000093876275,0.00023615187,0.00078983954,0.0001111208,0.000037537597,0.0005610026,0.000026285828],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046554598,0.00011961291,0.0069042672,0.0000686496,0.000057166348,0.0000016723523,0.00024462648,0.000021074438,0.9843101,0.000021652657,0.00075554615,0.0070300736],"study_design_scores_gemma":[0.0015043673,0.0028351003,0.9690929,0.00015563269,0.000039913015,0.00012097391,0.0003434018,0.000024124023,0.010129589,0.00066523853,0.014923098,0.00016565435],"about_ca_topic_score_codex":0.0000720508,"about_ca_topic_score_gemma":0.0000029698474,"teacher_disagreement_score":0.9741805,"about_ca_system_score_codex":0.000059409696,"about_ca_system_score_gemma":0.00013083663,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2222365833","doi":"10.1080/15384047.2015.1071737","title":"The small GTPase ADP-Ribosylation Factor 1 mediates the sensitivity of triple negative breast cancer cells to EGFR tyrosine kinase inhibitors","year":2015,"lang":"en","type":"article","venue":"Cancer Biology & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Gefitinib; Cancer research; Epidermal growth factor receptor; Small GTPase; Tyrosine kinase; Protein kinase B; Receptor tyrosine kinase; Signal transduction; Proto-oncogene tyrosine-protein kinase Src; Biology; Cell biology; Chemistry; Receptor; Biochemistry","score_opus":0.07590822992918955,"score_gpt":0.3694510427871348,"score_spread":0.29354281285794526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2222365833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9597655,0.007802398,0.00009117742,0.027979536,0.0017349315,0.0015972016,0.00090401195,0.000047773614,0.000077456054],"genre_scores_gemma":[0.9904129,0.0055047604,0.000059674596,0.0019159232,0.001224828,0.00042638386,0.000025734207,0.00004566233,0.00038413823],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975946,0.00069211074,0.00039182993,0.00043474528,0.00032993962,0.0005567586],"domain_scores_gemma":[0.9973756,0.0007053159,0.00021162408,0.0005667763,0.00081049127,0.00033017088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011835273,0.00028042126,0.000467081,0.00010123034,0.00018930931,0.000024485069,0.0002527486,0.00019600274,0.00021660923],"category_scores_gemma":[0.0002473933,0.00014893386,0.0001271533,0.0005625035,0.0006887132,0.000052217045,0.00008865985,0.00042370943,0.000023583005],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004763899,0.00018473215,0.07949371,0.00003978356,0.00038252314,0.000013865913,0.005429121,0.0001040562,0.6170312,0.00007302632,0.01800971,0.27447438],"study_design_scores_gemma":[0.0047067814,0.0011198651,0.09518296,0.00019626468,0.00006600553,0.000014852594,0.0010504714,0.0003515505,0.8284988,0.00027242608,0.06817665,0.00036339223],"about_ca_topic_score_codex":0.009534937,"about_ca_topic_score_gemma":0.004643768,"teacher_disagreement_score":0.27411097,"about_ca_system_score_codex":0.0005611506,"about_ca_system_score_gemma":0.001114579,"threshold_uncertainty_score":0.99706066},"labels":[],"label_agreement":null},{"id":"W2227532783","doi":"10.1002/bimj.201500051","title":"Relaxed Poisson cure rate models","year":2015,"lang":"en","type":"article","venue":"Biometrical Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Poisson distribution; Cure rate; Negative binomial distribution; Mathematics; Applied mathematics; Computer science; Statistics; Mathematical optimization; Medicine; Surgery","score_opus":0.34782676182974553,"score_gpt":0.4396721505269094,"score_spread":0.09184538869716385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2227532783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.54413116,0.04277187,0.06369379,0.12327037,0.006581738,0.001929252,0.00006544065,0.00055762305,0.21699879],"genre_scores_gemma":[0.98242784,0.0010049996,0.0058637434,0.00092296104,0.0018114222,0.0000076080655,0.0000063860653,0.00005425882,0.007900801],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974071,0.00018154731,0.00038104947,0.00021803487,0.0012927548,0.0005195277],"domain_scores_gemma":[0.99736917,0.00013949964,0.00009472108,0.00026038967,0.0006187974,0.0015174394],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019861874,0.00013803667,0.00032154555,0.0016279751,0.00008394255,0.00010467381,0.00023779701,0.00017446843,0.00036623803],"category_scores_gemma":[0.0017623703,0.00009987139,0.00014195484,0.003988299,0.000083617284,0.00016885814,0.000086438165,0.0009440087,0.0003790274],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013688097,0.0007514435,0.013475475,0.000073790434,0.00022647162,0.002653314,0.00033456893,0.00009943208,0.007271812,0.0006969107,0.75335455,0.2196934],"study_design_scores_gemma":[0.01189674,0.004438387,0.015764354,0.00034363844,0.00016305032,0.0063033644,0.0003707776,0.01287091,0.0047344826,0.0092347,0.9332866,0.0005930183],"about_ca_topic_score_codex":0.000023470806,"about_ca_topic_score_gemma":5.2471853e-7,"teacher_disagreement_score":0.43829668,"about_ca_system_score_codex":0.0006670013,"about_ca_system_score_gemma":0.0007296997,"threshold_uncertainty_score":0.48717567},"labels":[],"label_agreement":null},{"id":"W2231730507","doi":"10.1242/dmm.023143","title":"Use of a genetically engineered mouse model as a preclinical tool for HER2 breast cancer","year":2015,"lang":"en","type":"article","venue":"Disease Models & Mechanisms","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Medical Research Council; Indian Council of Medical Research; World Cancer Research Fund; Cancer Research UK; AstraZeneca","keywords":"Genetically engineered; Breast cancer; Genetically modified organism; Cancer; Computational biology; Biology; Medicine; Cancer research; Genetics; Gene","score_opus":0.18130911999274252,"score_gpt":0.40367889509363825,"score_spread":0.22236977510089573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2231730507","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3913551,0.00039029904,0.6000897,0.002468655,0.00015115736,0.0026196567,0.002686054,0.00016102307,0.00007829882],"genre_scores_gemma":[0.9466248,0.00015619842,0.048033454,0.0011214196,0.0001813685,0.0013543639,0.000096692165,0.00014608722,0.0022855867],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969616,0.00007180199,0.000578502,0.0006289231,0.0011279576,0.0006312124],"domain_scores_gemma":[0.996515,0.00012692712,0.00008823513,0.0008535777,0.00096548157,0.0014507805],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004941274,0.00029870283,0.00056845736,0.00013522571,0.000040558567,0.000042791755,0.000268489,0.00018830769,0.00012143175],"category_scores_gemma":[0.0004925339,0.00027062368,0.0003046391,0.00017326626,0.00009028594,0.0002037181,0.00014576943,0.00024129714,0.000018714332],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029501002,0.0042817066,0.00044205316,0.0022570256,0.0009384722,0.00015484667,0.0013284696,0.73569554,0.0762851,0.11334416,0.011997096,0.023774512],"study_design_scores_gemma":[0.002779784,0.0004028761,0.000064315325,0.00018478328,0.00031643527,0.000008583825,0.000022640836,0.9432552,0.00768123,0.044826716,0.00017226815,0.000285192],"about_ca_topic_score_codex":0.00018892494,"about_ca_topic_score_gemma":0.000012755909,"teacher_disagreement_score":0.5552697,"about_ca_system_score_codex":0.0002494952,"about_ca_system_score_gemma":0.0026670697,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W2238367440","doi":"","title":"Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.","year":2014,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Immunohistochemistry; Real-time polymerase chain reaction; Biology; Human Epidermal Growth Factor Receptor 2; Fluorescence in situ hybridization; Cancer; Pathology; Fish <Actinopterygii>; Molecular biology; Oncology; Medicine; Internal medicine; Gene; Genetics","score_opus":0.04828264927471493,"score_gpt":0.34999250503658097,"score_spread":0.30170985576186604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2238367440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98470056,0.0021292726,0.0002689796,0.004284631,0.00027897806,0.0019289294,0.00006650354,0.00006459986,0.00627752],"genre_scores_gemma":[0.9962898,0.000348638,0.00095303886,0.00018486679,0.00012942166,0.0012820768,0.000010057341,0.000034890647,0.00076723803],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9979253,0.00023127875,0.0003927673,0.00033947022,0.0005418368,0.0005693683],"domain_scores_gemma":[0.99881786,0.000270924,0.00013028471,0.00032541595,0.00017007407,0.00028545182],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014369343,0.00017042764,0.0004744857,0.00021060002,0.0000376388,0.000019770181,0.0001432864,0.00013236103,0.00014329994],"category_scores_gemma":[0.00044129373,0.000139514,0.000049547863,0.00032166974,0.00017276245,0.00015016331,0.00010293941,0.000311576,0.000009923403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029912845,0.0005598291,0.276599,0.0014119216,0.0001384907,0.000058947546,0.0036995362,0.00006804585,0.01747918,0.0009362343,0.008915726,0.6871418],"study_design_scores_gemma":[0.004001629,0.00017295223,0.9232477,0.0004918367,0.00003829225,0.000029937115,0.00036188736,0.0015502992,0.0609637,0.00020547796,0.008685382,0.00025089478],"about_ca_topic_score_codex":0.0008854326,"about_ca_topic_score_gemma":0.00043409455,"teacher_disagreement_score":0.6868909,"about_ca_system_score_codex":0.00015557362,"about_ca_system_score_gemma":0.00010878363,"threshold_uncertainty_score":0.56892157},"labels":[],"label_agreement":null},{"id":"W2240030606","doi":"","title":"Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.","year":2002,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Trastuzumab; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Receptor; Growth inhibition; Insulin-like growth factor; Cancer cell; Breast cancer; Biology; Insulin-like growth factor 1 receptor; Growth factor; Cancer; Signal transduction; Cell growth; Cell biology; Biochemistry","score_opus":0.03867077100561481,"score_gpt":0.28176609990914636,"score_spread":0.24309532890353155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240030606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923158,0.002464606,0.00001944244,0.00092144957,0.00038038284,0.0010636122,0.00015847269,0.00006839222,0.0026078166],"genre_scores_gemma":[0.9948542,0.0036245338,0.00010393524,0.0001947672,0.00030535774,0.00056456,0.000021042542,0.00007160263,0.00025999476],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971881,0.00019786268,0.0005883059,0.0005301619,0.0007090768,0.00078652095],"domain_scores_gemma":[0.9987587,0.00020545725,0.00019857533,0.0002240473,0.0002474893,0.00036578567],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004855296,0.00028047204,0.00052667805,0.0003535427,0.00009076179,0.0000533191,0.00011851064,0.00019425637,0.0005180141],"category_scores_gemma":[0.00042229833,0.0002653493,0.000070861286,0.00058851787,0.00028531693,0.00023960754,0.00007245215,0.0005237356,0.0000106992975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073645246,0.0010957515,0.729198,0.0048343106,0.00022863456,0.00028303033,0.0037042145,0.00003423393,0.11032301,0.00009801968,0.022166656,0.12729773],"study_design_scores_gemma":[0.0034377477,0.00009724931,0.7875535,0.0011238048,0.000069307505,0.00003848442,0.00036253993,0.00024822328,0.20513926,0.00009824182,0.0012959248,0.000535738],"about_ca_topic_score_codex":0.0037593686,"about_ca_topic_score_gemma":0.0001582622,"teacher_disagreement_score":0.12676199,"about_ca_system_score_codex":0.0005694897,"about_ca_system_score_gemma":0.00008679228,"threshold_uncertainty_score":0.99997985},"labels":[],"label_agreement":null},{"id":"W2240108656","doi":"10.1074/jbc.m115.686782","title":"Activated ErbB3 Translocates to the Nucleus via Clathrin-independent Endocytosis, Which Is Associated with Proliferating Cells","year":2015,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Genentech; Bundesministerium für Bildung und Forschung","keywords":"Importin; Cell biology; Receptor tyrosine kinase; Nuclear transport; ERBB3; Nucleus; Endocytosis; Cell nucleus; Biology; Nuclear localization sequence; Clathrin; Phosphorylation; Receptor; Biochemistry","score_opus":0.06859584557137426,"score_gpt":0.3241824761786407,"score_spread":0.25558663060726644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240108656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99186176,0.0002497683,0.00012863147,0.0058428952,0.00006259602,0.00029241,0.000016446174,0.000028572655,0.0015169049],"genre_scores_gemma":[0.9982392,0.000055020893,0.00038495922,0.0006470325,0.00043850252,0.000014533078,0.000006521569,0.000021412054,0.00019282434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783736,0.00011040755,0.00050820684,0.000249713,0.00085412967,0.0004401652],"domain_scores_gemma":[0.997818,0.00018496103,0.0002666112,0.00023673702,0.0009150957,0.0005785774],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011339871,0.00020890858,0.0004876701,0.000031639884,0.000084444415,0.000054288514,0.00036380085,0.0002662533,0.0003029234],"category_scores_gemma":[0.0008662046,0.00010285377,0.00011600523,0.0004221889,0.000089156594,0.00004843901,0.00006414428,0.0011699077,0.000018010633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010140644,0.00027837447,0.005876273,0.000035345754,0.00021063427,0.00018477521,0.00049391686,0.00006609981,0.98705786,3.8754789e-7,0.0033789945,0.0014032561],"study_design_scores_gemma":[0.0018645969,0.001391021,0.0014001105,0.00026418074,0.00005538536,0.0005576542,0.00050013297,0.0001116607,0.98970515,0.000024713989,0.003977519,0.0001479071],"about_ca_topic_score_codex":0.000015358724,"about_ca_topic_score_gemma":0.000006131684,"teacher_disagreement_score":0.0063774185,"about_ca_system_score_codex":0.0004011731,"about_ca_system_score_gemma":0.00052524504,"threshold_uncertainty_score":0.5082732},"labels":[],"label_agreement":null},{"id":"W2240613603","doi":"10.1200/jco.2007.25.18_suppl.10587","title":"Gamma-Secretase, ErbB4 nuclear localization and neuregulin expression correlates with prostate cancer patient clinical outcome","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Notre-Dame","funders":"","keywords":"ERBB4; Neuregulin 1; Tissue microarray; Prostate cancer; Neuregulin; ErbB; Cancer research; ERBB3; Cancer; Medicine; Nuclear receptor; Prostate; Pathology; Biology; Receptor; Internal medicine; Epidermal growth factor receptor","score_opus":0.15648146223078616,"score_gpt":0.5332042680161554,"score_spread":0.3767228057853692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2240613603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987641,0.0009448253,0.0007426911,0.007873727,0.0014588643,0.0004939773,0.000005569832,0.000020127936,0.00081922335],"genre_scores_gemma":[0.9873858,0.002518083,0.0033764446,0.004975485,0.0014589997,0.0000046715923,0.000003859032,0.0000499717,0.00022666327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99402624,0.0006530443,0.0037471133,0.00034353885,0.0008109415,0.00041914007],"domain_scores_gemma":[0.9934637,0.002553736,0.0019215562,0.000255013,0.0008466678,0.0009593154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007297441,0.00018861519,0.0014622249,0.00015682874,0.00007905651,0.000019805062,0.00015551689,0.00058932917,0.0003131229],"category_scores_gemma":[0.004276243,0.000116942894,0.0002569821,0.00022411083,0.00064089027,0.00013738235,0.00010950476,0.0021557705,0.000018720277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017902961,0.000903584,0.74086124,0.00007547082,0.00012716003,0.0013767261,0.00021177255,0.000075253825,0.00011230767,0.000017858209,0.01043503,0.22790065],"study_design_scores_gemma":[0.012698096,0.03528589,0.5725037,0.00074269716,0.00035482954,0.0006986607,0.0004131659,0.0012261912,0.00018545093,0.0001087277,0.37556428,0.0002183027],"about_ca_topic_score_codex":0.000031657586,"about_ca_topic_score_gemma":0.00006611559,"teacher_disagreement_score":0.36512926,"about_ca_system_score_codex":0.00018960937,"about_ca_system_score_gemma":0.0012520178,"threshold_uncertainty_score":0.936587},"labels":[],"label_agreement":null},{"id":"W2242287470","doi":"10.1309/ajcp95qbhqwggnjp","title":"Is “Polysomy” in Breast Carcinoma the “New Equivocal” in<i>HER2</i>Testing?","year":2015,"lang":"en","type":"editorial","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services; University of Calgary","funders":"","keywords":"Concordance; Guideline; Medicine; Polysomy; Medical physics; Breast cancer; MEDLINE; Test (biology); Oncology; Pathology; Internal medicine; Cancer; Fluorescence in situ hybridization","score_opus":0.12071685347181535,"score_gpt":0.492529699416863,"score_spread":0.3718128459450476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2242287470","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2187042,0.0034186193,0.00005820425,0.042012505,0.73130405,0.00083306705,0.00015424118,0.00003121261,0.003483911],"genre_scores_gemma":[0.16806427,0.0011662437,0.0016234637,0.0034840526,0.8247072,0.000016754644,0.000018344901,0.00015928881,0.00076034444],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9895585,0.0025461514,0.004000656,0.0007187799,0.0021616155,0.0010142634],"domain_scores_gemma":[0.9829489,0.01024087,0.002848415,0.0011412115,0.0016759048,0.0011447031],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012536887,0.00048143076,0.0035569058,0.0006091574,0.000035957648,0.000034497756,0.0013187116,0.0010590861,0.00016893893],"category_scores_gemma":[0.028734438,0.00032450413,0.00061554665,0.00132573,0.0022991798,0.00007978076,0.0003670934,0.01030711,0.000090106245],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019485414,0.00031046543,0.14660743,0.00004572039,0.00006511922,0.0060213455,0.00034917443,0.0000031134005,0.000015189759,0.0000016852298,0.7609169,0.08371533],"study_design_scores_gemma":[0.00830609,0.011630867,0.116997525,0.0012379718,0.00026130624,0.0040329876,0.000563751,0.000031045063,0.000004705965,0.0006594779,0.85582554,0.0004487398],"about_ca_topic_score_codex":0.0020623468,"about_ca_topic_score_gemma":0.00025970678,"teacher_disagreement_score":0.09490865,"about_ca_system_score_codex":0.00054597436,"about_ca_system_score_gemma":0.014930721,"threshold_uncertainty_score":0.9999207},"labels":[],"label_agreement":null},{"id":"W2244529370","doi":"10.1200/jco.2009.27.15_suppl.1022","title":"Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Tolerability; Internal medicine; Oncology; Metastatic breast cancer; Adverse effect; Breast cancer; Cancer; Pharmacology","score_opus":0.06210822724411943,"score_gpt":0.48343892075951683,"score_spread":0.4213306935153974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2244529370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862758,0.00024142474,0.000051926596,0.012395793,0.00019637145,0.0005382972,0.0000167145,0.0000075712355,0.00027609704],"genre_scores_gemma":[0.9970405,0.0003024792,0.0009584936,0.0014392704,0.00020406119,0.000011632367,0.0000017194026,0.000017421822,0.000024437895],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99726295,0.000555268,0.0010616848,0.00031079992,0.00047828312,0.00033100712],"domain_scores_gemma":[0.99734575,0.0011763128,0.0005769065,0.00018997818,0.00031416898,0.00039687715],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012027026,0.00019303562,0.0015548593,0.00013190672,0.00004511292,0.000011280819,0.000097011456,0.00025399393,0.00007252801],"category_scores_gemma":[0.00035399487,0.00012366344,0.0002882431,0.00018198042,0.00016861976,0.00017210844,0.000009363599,0.000819459,8.918722e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025421828,0.003702798,0.4704886,0.0000074021896,0.00012341139,0.00016773105,0.000103422586,0.00004547987,0.00008322527,9.613908e-7,0.000014856114,0.49984026],"study_design_scores_gemma":[0.030116856,0.052213315,0.9162807,0.0002462883,0.00010689039,0.000026782709,0.00003092231,0.00016404752,0.00013379545,0.000031197855,0.0005453129,0.000103890205],"about_ca_topic_score_codex":0.00023865719,"about_ca_topic_score_gemma":0.00030860005,"teacher_disagreement_score":0.49973637,"about_ca_system_score_codex":0.0017431912,"about_ca_system_score_gemma":0.0028555593,"threshold_uncertainty_score":0.50656396},"labels":[],"label_agreement":null},{"id":"W2248932904","doi":"10.1200/jco.2009.27.15_suppl.e12006","title":"HER-2 gene amplification in circulating tumor cells (CTCs): Concordance with amplification status in primary breast cancers and metastatic lesions","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Circulating tumor cell; Medicine; Concordance; Metastatic breast cancer; Breast cancer; DAPI; Cancer; Primary tumor; Pathology; Oncology; Fish <Actinopterygii>; Immunohistochemistry; Gene duplication; Liquid biopsy; Internal medicine; Metastasis; Staining; Gene; Biology","score_opus":0.15562619119841944,"score_gpt":0.4837212781029476,"score_spread":0.32809508690452815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2248932904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99226695,0.0007640425,0.0007019495,0.004744386,0.00016332412,0.00048628676,0.000010744907,0.0000073239485,0.00085498864],"genre_scores_gemma":[0.982409,0.0012064792,0.014389703,0.0017094908,0.000223577,0.000012701255,0.0000069968974,0.000016957514,0.000025073681],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9961373,0.0005825312,0.0021015538,0.0003029281,0.00049068773,0.0003849537],"domain_scores_gemma":[0.99628717,0.0014816031,0.0012230985,0.00023205546,0.00036906038,0.0004070036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036926407,0.00014198145,0.0011249123,0.00027285644,0.000034997433,0.000016307147,0.00013222184,0.00012740357,0.000028632],"category_scores_gemma":[0.0009912447,0.00011044271,0.00008816998,0.00045549232,0.0002424595,0.0001569652,0.000021099591,0.0011991744,0.0000041039134],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006235893,0.0016709286,0.47599012,0.00016975061,0.000104005194,0.0014975282,0.0005151285,0.0013059872,0.024512544,0.00018848,0.00036793927,0.48744172],"study_design_scores_gemma":[0.0067013926,0.004093448,0.9847996,0.0003796247,0.000072220726,0.0008629379,0.0003158315,0.0005352851,0.00015273612,0.00032190053,0.0016540817,0.00011091932],"about_ca_topic_score_codex":0.00030968347,"about_ca_topic_score_gemma":0.0004146533,"teacher_disagreement_score":0.5088095,"about_ca_system_score_codex":0.0013654198,"about_ca_system_score_gemma":0.0049095647,"threshold_uncertainty_score":0.8709357},"labels":[],"label_agreement":null},{"id":"W2252494760","doi":"10.1200/jco.2006.24.18_suppl.10565","title":"Adjuvant trastuzumab (T) therapy in HER2+ breast cancer after ASCO 2005: Patients’ attitudes and immediate economic burden","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adjuvant; Trastuzumab; Breast cancer; Adjuvant therapy; Internal medicine; Cancer; Disease; Clinical trial; Oncology; Chemotherapy; Medical record; Adjuvant chemotherapy; Gynecology; Family medicine","score_opus":0.0655376748397551,"score_gpt":0.47146357321154275,"score_spread":0.40592589837178766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252494760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98220026,0.0031920848,0.0000028061088,0.012735291,0.00092741835,0.0002851772,0.000028914994,0.0000052359746,0.00062281615],"genre_scores_gemma":[0.9848848,0.010324781,0.00023119687,0.0011145471,0.0031386816,0.000024757328,0.0000025472002,0.000028188027,0.00025049222],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965559,0.00036681743,0.0020347724,0.0002620087,0.00035445174,0.0004260143],"domain_scores_gemma":[0.9978576,0.0007041372,0.0006819409,0.00016639191,0.00021984495,0.00037009924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024129318,0.00016599138,0.0013224134,0.00019047389,0.000021797341,0.000016663222,0.00016413427,0.0003444073,0.0012481933],"category_scores_gemma":[0.00019832225,0.00011833984,0.00024064578,0.000072865776,0.0003081044,0.00013453384,0.000054644588,0.0011317846,0.00003178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004794337,0.00089587196,0.77275777,0.00002617996,0.000107289314,0.0002945058,0.00005687646,0.000039697527,0.000027046772,0.000004356936,0.004513743,0.21648233],"study_design_scores_gemma":[0.012327402,0.0043777754,0.9416498,0.00016880357,0.00004148649,0.00012957284,0.00002710187,0.00005998203,0.0000133271105,0.00009846854,0.04100137,0.00010493986],"about_ca_topic_score_codex":0.0014744347,"about_ca_topic_score_gemma":0.0030674357,"teacher_disagreement_score":0.21637739,"about_ca_system_score_codex":0.00083784264,"about_ca_system_score_gemma":0.0025340104,"threshold_uncertainty_score":0.9996648},"labels":[],"label_agreement":null},{"id":"W2252768637","doi":"","title":"Recomendaciones para la determinación de HER2 en cáncer de mama. Consenso Nacional de la Sociedad Española de Anatomía Patológica ( SEAP ) y de la Sociedad Española de Oncología Médica ( SEOM )","year":2009,"lang":"es","type":"article","venue":"Repository of Digital Objects for Teaching Research and Culture (University of Valencia)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Breast tumours; Cancer; Pathology; Oncology; Internal medicine","score_opus":0.026112584638773452,"score_gpt":0.3695545830909914,"score_spread":0.3434419984522179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2252768637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977916,0.0020001784,0.0006674805,0.002454134,0.000042497973,0.0007716258,0.00026681693,0.00009463321,0.015786614],"genre_scores_gemma":[0.984936,0.0018552109,0.006299731,0.000106306295,0.0003155266,0.000010144885,0.000033057833,0.00005493491,0.0063890987],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921376,0.0034052413,0.00043817292,0.0008164632,0.0013646511,0.0018378879],"domain_scores_gemma":[0.9930158,0.0044078236,0.00033802987,0.00047481197,0.00054253824,0.0012209709],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.0073642917,0.0004743248,0.00088611274,0.00043227847,0.001518902,0.00036588917,0.0008616401,0.0012916247,0.00003239916],"category_scores_gemma":[0.002118688,0.00051839603,0.0005512289,0.0004083448,0.0028348558,0.0005176247,0.0003280707,0.0030835837,0.000005584907],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071482905,0.0063320184,0.3868246,0.0068075303,0.0019980508,0.007910084,0.15131275,0.00008509217,0.30915132,0.006554399,0.042937156,0.0729387],"study_design_scores_gemma":[0.018919993,0.02087069,0.47487372,0.011066933,0.0015751402,0.012269458,0.20698777,0.0074959267,0.04963907,0.01988371,0.1732351,0.0031825022],"about_ca_topic_score_codex":0.00041620503,"about_ca_topic_score_gemma":0.000042232885,"teacher_disagreement_score":0.25951225,"about_ca_system_score_codex":0.0031051207,"about_ca_system_score_gemma":0.0051649064,"threshold_uncertainty_score":0.9998789},"labels":[],"label_agreement":null},{"id":"W2257109151","doi":"10.1200/jco.2008.26.15_suppl.1026","title":"Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Rash; Internal medicine; Clinical endpoint; Mucositis; Gastroenterology; Metastatic breast cancer; Phases of clinical research; Nausea; Oncology; Cancer; Clinical trial; Breast cancer; Chemotherapy","score_opus":0.13427893998033577,"score_gpt":0.4944826051640951,"score_spread":0.36020366518375935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257109151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490935,0.00055048504,0.000009960394,0.002539209,0.00024368567,0.0013565696,0.00012934428,0.000005688503,0.00025568568],"genre_scores_gemma":[0.99542934,0.0031083187,0.0007814906,0.00014414126,0.00036223934,0.000037529524,0.0000055312094,0.000039098286,0.000092314294],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932857,0.0010085368,0.003685377,0.00038315827,0.0011940539,0.00044316743],"domain_scores_gemma":[0.99395156,0.0015692427,0.002517158,0.00027401082,0.0012468998,0.00044113284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026965842,0.00026854995,0.0028171774,0.00038050953,0.00007786016,0.000005912281,0.00024024902,0.00027327467,0.00007956419],"category_scores_gemma":[0.0014501027,0.00017694385,0.00034271943,0.000447778,0.0008861643,0.00018107441,0.00006367017,0.0013020441,5.3385173e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7115776,0.046046194,0.035539318,0.0001711593,0.0011122539,0.0010005321,0.0028524913,0.000019573807,0.0004336694,0.00000305375,0.00039278998,0.20085135],"study_design_scores_gemma":[0.40983406,0.24039856,0.34606293,0.00093148125,0.0002317678,0.00051206886,0.00023330894,0.000073574505,0.0009734442,0.000011562111,0.00059004413,0.00014720025],"about_ca_topic_score_codex":0.0003552867,"about_ca_topic_score_gemma":0.00017462112,"teacher_disagreement_score":0.31052363,"about_ca_system_score_codex":0.0006182542,"about_ca_system_score_gemma":0.0047405814,"threshold_uncertainty_score":0.8409588},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"nonrandomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"agree"},{"id":"W2259869327","doi":"10.1111/his.12795","title":"Biomarker assessment and molecular testing for prognostication in breast cancer","year":2015,"lang":"en","type":"review","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Breast cancer; Biomarker; Molecular pathology; Progesterone receptor; Biomarker discovery; Cancer; Medicine; Oncology; Molecular biomarkers; Pathological; Internal medicine; Oestrogen receptor; Targeted therapy; Bioinformatics; Pathology; Estrogen receptor; Biology; Gene; Proteomics; Genetics","score_opus":0.23248445004154325,"score_gpt":0.5190583341670709,"score_spread":0.28657388412552764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2259869327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006949655,0.9952566,0.00017968008,0.0005905782,0.000203763,0.002434085,0.00011827128,0.000030000714,0.0011175195],"genre_scores_gemma":[0.00010354988,0.9895871,0.0060130525,0.00012049304,0.00013648884,0.0036222595,0.00014340374,0.000081913575,0.0001917275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99825436,0.00021835696,0.00044224167,0.00052653305,0.00020738975,0.00035112587],"domain_scores_gemma":[0.99885625,0.00022238196,0.00017054184,0.0003210827,0.00028421276,0.00014552404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010073981,0.00023289066,0.0011239125,0.0003365807,0.00002981427,0.000010157022,0.000107210806,0.0003039018,0.000027549186],"category_scores_gemma":[0.00034484384,0.00020003621,0.00007968316,0.00033242704,0.00015765487,0.00001989677,0.00008186683,0.0003685343,0.000007554295],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015638574,0.00006303209,0.0035211325,0.014814515,0.000007920207,0.0002646373,0.000022979293,5.901564e-8,0.00007634155,0.0000864571,0.0011797932,0.9799475],"study_design_scores_gemma":[0.000575289,0.00018183186,0.01100432,0.007507072,0.00044006394,0.001670248,0.0000052408427,0.00007525001,3.047038e-7,0.00007011942,0.978272,0.00019822048],"about_ca_topic_score_codex":0.00008279774,"about_ca_topic_score_gemma":0.000012508798,"teacher_disagreement_score":0.97974926,"about_ca_system_score_codex":0.0013637333,"about_ca_system_score_gemma":0.0024351145,"threshold_uncertainty_score":0.815724},"labels":[],"label_agreement":null},{"id":"W2261765766","doi":"10.1093/annonc/mdw047","title":"Statistical controversies in clinical research: statistical significance—too much of a good thing …","year":2016,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Breast cancer; Hazard ratio; Oncology; Trastuzumab; Internal medicine; Clinical trial; Statistical significance; Medical physics; Cancer; Confidence interval","score_opus":0.7268183586394775,"score_gpt":0.6943052263126884,"score_spread":0.032513132326789096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2261765766","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005376966,0.9693535,0.0004395415,0.003431123,0.00039169725,0.0023988711,0.0016282981,0.000017366321,0.02228584],"genre_scores_gemma":[0.0009775354,0.99532074,0.0020108852,0.0002968697,0.000454257,0.0001959592,0.00007828578,0.000073716306,0.0005917532],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98784983,0.0053696726,0.00317354,0.00087810983,0.0014860131,0.0012428274],"domain_scores_gemma":[0.9455471,0.05118682,0.0007061842,0.00083682034,0.0011917613,0.0005313332],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014226026,0.00037499383,0.005568401,0.0008352818,0.000044220542,0.000011606646,0.0006371779,0.0011619532,0.0012740002],"category_scores_gemma":[0.032886516,0.00027065462,0.00047881636,0.0006222383,0.0030236193,0.000045622153,0.00039294024,0.002802022,0.00020488312],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076618424,0.0009357567,0.00024988074,0.014522037,0.0003753881,0.00082449894,0.00008745696,3.444987e-8,0.0000040483415,0.022913394,0.075835966,0.8834854],"study_design_scores_gemma":[0.0020050085,0.008360625,0.0003024598,0.012687507,0.00019155885,0.000051738847,0.00012089001,0.000004966433,0.000007355612,0.0025730003,0.97349304,0.00020185724],"about_ca_topic_score_codex":0.000385938,"about_ca_topic_score_gemma":0.00009847388,"teacher_disagreement_score":0.8976571,"about_ca_system_score_codex":0.00043843695,"about_ca_system_score_gemma":0.0099185975,"threshold_uncertainty_score":0.99997455},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","score_opus":0.04734896813518842,"score_gpt":0.3900358492526455,"score_spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264000214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999234,0.00041613763,0.00009621986,0.015315072,0.00041398627,0.012587519,0.0002594172,0.0000558643,0.0008634477],"genre_scores_gemma":[0.98718923,0.00031599985,0.00013311187,0.0028059112,0.0014675491,0.0075665126,0.000032997614,0.00007094114,0.00041777093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959418,0.001144232,0.00066567294,0.00059343065,0.00067377905,0.0009810483],"domain_scores_gemma":[0.99716645,0.0012969549,0.0002734593,0.00064282055,0.00036524297,0.00025508276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014908942,0.0003979465,0.0016640909,0.00018026745,0.0000987517,0.000033773107,0.00033577357,0.00023442211,0.0017216203],"category_scores_gemma":[0.000106633786,0.00018019552,0.00018369165,0.000253747,0.00041360746,0.00009667927,0.00004490789,0.0005783624,0.000056618053],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90583587,0.0028865994,0.013377731,0.000025568155,0.00034868772,0.00013164995,0.0006484192,0.000025587895,0.00028856227,0.0000062894715,0.00089527835,0.07552978],"study_design_scores_gemma":[0.96825814,0.008802828,0.018161023,0.00033243877,0.00016377025,0.000013295726,0.000047666425,0.00022325478,0.00048289483,0.0000072509065,0.0032524853,0.00025492458],"about_ca_topic_score_codex":0.00047519946,"about_ca_topic_score_gemma":0.0015867901,"teacher_disagreement_score":0.07527485,"about_ca_system_score_codex":0.0010288445,"about_ca_system_score_gemma":0.001560501,"threshold_uncertainty_score":0.9991909},"labels":[],"label_agreement":null},{"id":"W2268024701","doi":"10.1200/jco.2009.27.15_suppl.e11550","title":"Trastuzumab-mediated cardiotoxicity in the nontrial setting: Evaluation of patients receiving adjuvant trastuzumab at an academic centre","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Cardiotoxicity; Trastuzumab; Ejection fraction; Internal medicine; Discontinuation; Breast cancer; Incidence (geometry); Hazard ratio; Oncology; Cancer; Heart failure; Chemotherapy; Confidence interval","score_opus":0.25340602469883244,"score_gpt":0.5571225239931855,"score_spread":0.30371649929435307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268024701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98938185,0.00033886422,0.000012301156,0.007189529,0.00090497936,0.0009154036,0.000013324088,0.0000062329987,0.0012374992],"genre_scores_gemma":[0.99641067,0.00042549995,0.00022807704,0.0012430777,0.0016399825,0.00000451837,0.00001849646,0.000014446166,0.00001521739],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98798716,0.005272851,0.0035457336,0.00027852398,0.002473436,0.00044228754],"domain_scores_gemma":[0.9917496,0.00425409,0.0019662078,0.00030340324,0.0013497648,0.0003769425],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033445,0.00016797752,0.0015893546,0.00021981476,0.00005341184,0.000007152079,0.0004348447,0.00068172044,0.00016697888],"category_scores_gemma":[0.03104263,0.00010784672,0.00043407618,0.0003613269,0.00018854487,0.00018663354,0.00004280002,0.0027099554,0.000008514824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009941703,0.002958659,0.4169782,0.000028363107,0.00014403199,0.00012855131,0.0021451013,0.00019707407,0.00083697215,0.000005189694,0.004576226,0.56205994],"study_design_scores_gemma":[0.020296533,0.014220902,0.9586867,0.0002058722,0.00036942452,0.000055609835,0.000431315,0.0013434114,0.00015881234,0.00018768811,0.003950866,0.000092880604],"about_ca_topic_score_codex":0.00002575342,"about_ca_topic_score_gemma":0.0001677859,"teacher_disagreement_score":0.561967,"about_ca_system_score_codex":0.0016173795,"about_ca_system_score_gemma":0.0037188793,"threshold_uncertainty_score":0.9995908},"labels":[],"label_agreement":null},{"id":"W2268068174","doi":"","title":"Bivalent binding properties of epidermal growth factor receptor targeted monoclonal antibodies: Factors contributing to differences in observed clinical profiles.","year":2008,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nimotuzumab; Cetuximab; Monoclonal antibody; Epidermal growth factor receptor; Antibody; Chemistry; Panitumumab; Cancer research; Cell culture; Molecular biology; Antibody-dependent cell-mediated cytotoxicity; A431 cells; Cell growth; Monoclonal; Cell; Receptor; Immunology; Cell cycle; Medicine; Biology; Biochemistry; Molecular medicine","score_opus":0.6654379160890438,"score_gpt":0.5353623484376453,"score_spread":0.1300755676513985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2268068174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022776,0.0018801318,0.000011625006,0.0038725524,0.0007907136,0.0027335093,0.00029318422,0.00007821624,0.00011231414],"genre_scores_gemma":[0.99188745,0.00536453,0.00042389278,0.0001669517,0.0008866157,0.00035680266,0.000036963942,0.000080342405,0.00079642585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9877321,0.0027190477,0.0031389666,0.0013567242,0.0027803003,0.0022728406],"domain_scores_gemma":[0.99145186,0.004348836,0.0003296946,0.00074595213,0.0018824381,0.0012411914],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00965691,0.00042069497,0.0020711743,0.0007372042,0.0003966279,0.000048932925,0.0009120623,0.00057394296,0.0010736772],"category_scores_gemma":[0.028076975,0.00030844708,0.00051878224,0.0017893753,0.0021847037,0.00018669153,0.0009178454,0.003435248,0.00012930168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026390606,0.00085571164,0.9763698,0.0006334714,0.00017467211,0.00008857019,0.000813844,0.000001406441,0.013176118,0.000017746184,0.0029323846,0.0022972138],"study_design_scores_gemma":[0.003018601,0.0018462015,0.93575794,0.0018479018,0.000017273353,0.0000043321224,0.0007120272,0.00015108688,0.055408712,0.000012593316,0.00089169235,0.00033166612],"about_ca_topic_score_codex":0.0030467662,"about_ca_topic_score_gemma":0.0002204489,"teacher_disagreement_score":0.042232595,"about_ca_system_score_codex":0.0007429819,"about_ca_system_score_gemma":0.0036025373,"threshold_uncertainty_score":0.99993676},"labels":[],"label_agreement":null},{"id":"W2273027008","doi":"10.1200/jco.2004.22.14_suppl.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Lung cancer; Pharmacokinetics; Internal medicine; Cancer; Adenocarcinoma; Oncology; Colorectal cancer; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273027008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845714,0.0002686808,0.000001824143,0.009457051,0.00060182717,0.0005515142,0.0001607316,0.00000586946,0.00049536314],"genre_scores_gemma":[0.9973455,0.0005942558,0.00073419866,0.00061601383,0.0006505777,0.000015145489,0.000008545325,0.000015408998,0.00002036426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947932,0.0007607155,0.0031804207,0.0003040799,0.0006735688,0.00028806418],"domain_scores_gemma":[0.9948031,0.002469732,0.0012552612,0.00020956207,0.0006438021,0.0006185621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025856316,0.00014802604,0.0013263623,0.00014593585,0.00003058895,0.0000098715645,0.00019278345,0.00033093742,0.00009086655],"category_scores_gemma":[0.0049506417,0.00011342236,0.0001523055,0.00022755374,0.00069668447,0.00015329002,0.00010449066,0.0015891779,0.0000030956153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03159426,0.008777791,0.94087195,0.00003608258,0.00023206937,0.001080526,0.001348892,0.0001135346,0.00009480638,0.000050118015,0.002187704,0.013612237],"study_design_scores_gemma":[0.039546635,0.023106936,0.9341145,0.00048652652,0.00016099204,0.000096253956,0.00050826767,0.00010140201,0.00006025362,0.00024906074,0.0014794135,0.00008975811],"about_ca_topic_score_codex":0.0008887728,"about_ca_topic_score_gemma":0.00054123445,"teacher_disagreement_score":0.014329145,"about_ca_system_score_codex":0.00036873698,"about_ca_system_score_gemma":0.0051861536,"threshold_uncertainty_score":0.9200014},"labels":[],"label_agreement":null},{"id":"W2273061735","doi":"10.1186/s40064-016-1736-1","title":"Patterns in target-directed breast cancer research","year":2016,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Jewish General Hospital; BC Cancer Agency; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Canada","keywords":"Medicine; Breast cancer; Clinical trial; Oncology; Internal medicine; Adjuvant; Targeted therapy; Cancer","score_opus":0.07568231208982774,"score_gpt":0.4258451894115393,"score_spread":0.3501628773217116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273061735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763492,0.0006260901,0.000048508005,0.015610688,0.00032982483,0.0006152485,0.000086102686,0.00017976659,0.006154605],"genre_scores_gemma":[0.9914673,0.0007093791,0.00022986485,0.00014544975,0.0005658271,0.00023417598,0.000002318699,0.000058848767,0.0065868623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970714,0.00018952583,0.0002767815,0.00049906224,0.0010008336,0.0009623971],"domain_scores_gemma":[0.99852896,0.00019231816,0.000029775267,0.00059149135,0.00034223194,0.00031523066],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012051997,0.00014903252,0.00029215304,0.00050288584,0.0000666386,0.000024281399,0.00026243876,0.00013135419,0.0056781615],"category_scores_gemma":[0.00027823052,0.000102196595,0.000061950486,0.0007293639,0.00013228881,0.00008474696,0.00020680494,0.00057621585,0.0005898437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004183035,0.0001444231,0.8282032,0.00017470917,0.00003563964,0.00038687655,0.00025442164,0.0000012754555,0.07627424,0.000115904535,0.0045602997,0.08943071],"study_design_scores_gemma":[0.0019897115,0.00010499243,0.94404453,0.0013477011,0.0000055850464,0.00004933513,0.000055375047,0.00006342679,0.017332487,0.00015255851,0.03467722,0.00017707536],"about_ca_topic_score_codex":0.0047899047,"about_ca_topic_score_gemma":0.0015817073,"teacher_disagreement_score":0.11584134,"about_ca_system_score_codex":0.0011984817,"about_ca_system_score_gemma":0.0006787151,"threshold_uncertainty_score":0.9952308},"labels":[],"label_agreement":null},{"id":"W2273565724","doi":"10.1016/j.ejca.2015.12.024","title":"Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Hazard ratio; Adjuvant therapy; Cancer; Confidence interval","score_opus":0.03275624306295245,"score_gpt":0.33879298892192,"score_spread":0.30603674585896756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2273565724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862705,0.006074477,0.00011247454,0.0051745544,0.0006826311,0.00023892456,0.0003275128,0.000011298407,0.0011076466],"genre_scores_gemma":[0.98865813,0.008454086,0.00006047013,0.00028908672,0.0009910247,0.0000105465115,0.0000015361585,0.00006584312,0.0014693019],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973834,0.00023684274,0.0009106181,0.0002185123,0.0009946275,0.00025600332],"domain_scores_gemma":[0.9973442,0.00007681908,0.00082946575,0.00036471547,0.0011423406,0.00024245807],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073278445,0.00015842132,0.0004099532,0.00015277059,0.000041202315,0.000028629804,0.0002668141,0.000033035518,0.0027205017],"category_scores_gemma":[0.000056398203,0.00009806039,0.00015925642,0.00018794579,0.00012965502,0.0001705462,0.00004231344,0.00024418722,0.000040524093],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012488266,0.00009517019,0.21756743,0.000024329225,0.00026656728,0.000089396824,0.00096366415,0.000014938814,0.11377527,0.000011861413,0.006794526,0.65914804],"study_design_scores_gemma":[0.0025375772,0.00061383704,0.90352863,0.0016363615,0.00006917956,0.00003431808,0.000046694164,0.000005356615,0.05289247,0.000034006833,0.03847027,0.00013127833],"about_ca_topic_score_codex":0.00046685323,"about_ca_topic_score_gemma":0.000042438496,"teacher_disagreement_score":0.68596125,"about_ca_system_score_codex":0.00027176933,"about_ca_system_score_gemma":0.0003455623,"threshold_uncertainty_score":0.9981911},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","score_opus":0.13866766770733222,"score_gpt":0.47618576035695515,"score_spread":0.33751809264962296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2277879584","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040604067,0.99430054,4.1272867e-7,0.00093331875,0.00016428568,0.0015537804,0.00068017206,0.000012058148,0.0023148316],"genre_scores_gemma":[0.00008853808,0.99661684,0.000010189698,0.000038879236,0.0005385281,0.00076281175,0.000027691955,0.000040106992,0.0018764395],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982003,0.00019487613,0.00046854012,0.00031945825,0.00047471502,0.00034209585],"domain_scores_gemma":[0.9988558,0.00021624514,0.00014090059,0.00064441684,0.000056775953,0.000085861975],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027099877,0.00028660902,0.0013396499,0.0002082659,0.000020514839,0.000009270268,0.00027335493,0.00019370334,0.0009609775],"category_scores_gemma":[0.000013758527,0.00012112733,0.0004157675,0.0003961801,0.00013630779,0.000015162048,0.000018391263,0.0001755761,0.00018151503],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000024277608,0.00029285986,0.00006555648,0.00612644,0.00012389754,0.000042348984,0.00029722106,3.522457e-9,0.0000014432121,0.00001872783,0.0027338997,0.9902733],"study_design_scores_gemma":[0.00065193,0.00027825913,0.00025364215,0.019181877,0.00028854606,0.00010665746,0.000034340625,1.2056748e-7,0.0000054370653,0.000003411,0.97908443,0.00011131807],"about_ca_topic_score_codex":0.0008009699,"about_ca_topic_score_gemma":0.0000817705,"teacher_disagreement_score":0.990162,"about_ca_system_score_codex":0.0011763931,"about_ca_system_score_gemma":0.0014983151,"threshold_uncertainty_score":0.99995226},"labels":[],"label_agreement":null},{"id":"W2280120506","doi":"10.1136/jclinpath-2015-203066","title":"Evaluation of cell-line-derived xenograft tumours as controls for immunohistochemical testing for ER and PR","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. John’s Health Sciences Centre; Memorial University of Newfoundland","funders":"","keywords":"Immunohistochemistry; Biomarker; Estrogen receptor; Medicine; Pathology; Breast tumours; Progesterone receptor; Oncology; Anatomical pathology; Breast cancer; Cancer research; Biology; Internal medicine; Cancer","score_opus":0.4007843313420886,"score_gpt":0.5600717471712227,"score_spread":0.15928741582913408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2280120506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918002,0.0016751114,0.0021807384,0.0022278603,0.00047558857,0.0010508214,0.000010730732,0.000006125187,0.00057286257],"genre_scores_gemma":[0.9732694,0.000035789,0.025377508,0.00032980574,0.00085210643,0.00004932422,0.000004096808,0.000023777671,0.000058190235],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967716,0.00047700832,0.0015907147,0.00019481196,0.00071082555,0.0002550692],"domain_scores_gemma":[0.98963803,0.003971605,0.0009619633,0.00018733744,0.004918371,0.0003226721],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018655749,0.00010963568,0.00090329564,0.000105756946,0.000028451466,0.0000074921463,0.00013178273,0.00025043753,0.00001553174],"category_scores_gemma":[0.06919529,0.0000848829,0.00025069466,0.0000811211,0.00032477998,0.000050287206,0.000040071813,0.0005006789,0.0000020977297],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014336178,0.0013033699,0.045235045,0.00038913626,0.00025265207,0.00013894218,0.0004924009,0.0000800317,0.842853,0.000055829878,0.005653635,0.089209765],"study_design_scores_gemma":[0.31056526,0.18856785,0.14663674,0.0023321041,0.010566183,0.010005202,0.0024402298,0.04428312,0.20132932,0.069619015,0.012441173,0.001213802],"about_ca_topic_score_codex":0.000003743061,"about_ca_topic_score_gemma":0.0000010451112,"teacher_disagreement_score":0.64152366,"about_ca_system_score_codex":0.00009892154,"about_ca_system_score_gemma":0.0018432479,"threshold_uncertainty_score":0.93864524},"labels":[],"label_agreement":null},{"id":"W2281951751","doi":"10.1159/000419801","title":"Tumor Cell Subpopulation Interactions Mediated by Transforming Growth Factor � May Contribute to Clonal Dominance of Metastatically Competent Cells in Primary Tumors","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Dominance (genetics); Primary (astronomy); Biology; Cancer research; Transforming growth factor; Tumor cells; Cell biology; Genetics; Gene; Physics","score_opus":0.04378340730407314,"score_gpt":0.32215297821723077,"score_spread":0.2783695709131576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281951751","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11797358,0.0024985347,0.014430492,0.008640276,0.0018821313,0.01853546,0.022033963,0.00036421922,0.81364137],"genre_scores_gemma":[0.7500559,0.00035246907,0.00625926,0.0010884997,0.00022416329,0.00023183222,0.0035362027,0.00030044245,0.23795122],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959971,0.00007496379,0.0013696274,0.00059357623,0.0014140593,0.00055067835],"domain_scores_gemma":[0.9974773,0.00048327315,0.00031229452,0.00036398607,0.0007942322,0.0005689326],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006207796,0.00048119738,0.0013919641,0.0005809937,0.00003328408,0.000020664891,0.00025350394,0.0001846336,0.0018242926],"category_scores_gemma":[0.00014799405,0.00042513054,0.00022657015,0.000169954,0.00014418589,0.00013513655,0.000078492354,0.0009844964,0.00014254627],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016165456,0.0034205718,0.008608054,0.014298877,0.0015712201,0.002775658,0.0037155123,0.00016482937,0.72282284,0.026317107,0.18275507,0.017384805],"study_design_scores_gemma":[0.024064176,0.005481758,0.010617349,0.009372591,0.0010076659,0.00024050432,0.00035451734,0.0011469546,0.29829925,0.002389612,0.64356035,0.0034653053],"about_ca_topic_score_codex":0.0006327064,"about_ca_topic_score_gemma":0.00043386896,"teacher_disagreement_score":0.63208234,"about_ca_system_score_codex":0.0013326874,"about_ca_system_score_gemma":0.0010319507,"threshold_uncertainty_score":0.99982005},"labels":[],"label_agreement":null},{"id":"W2286693725","doi":"10.1158/1078-0432.ccr-15-2499","title":"Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lapatinib; Trastuzumab emtansine; Trastuzumab; Capecitabine; Medicine; Cancer; Breast cancer; Metastatic breast cancer; Biomarker; Cancer research; Oncology; PTEN; Antibody-drug conjugate; Internal medicine; Antibody; Immunology; Biology; Monoclonal antibody; Apoptosis; Colorectal cancer","score_opus":0.3463970865185873,"score_gpt":0.593692150892299,"score_spread":0.24729506437371168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286693725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98851156,0.0011751609,0.000010332964,0.0064906273,0.00008553887,0.003188279,0.00035347027,0.00002018746,0.00016487042],"genre_scores_gemma":[0.9980296,0.00059738406,0.000049283957,0.000059214864,0.00023376354,0.00067253155,0.000008703526,0.00006162274,0.0002879092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923195,0.0023755569,0.0016953027,0.0010210847,0.0016114158,0.0009771285],"domain_scores_gemma":[0.9884327,0.009506914,0.00017775562,0.00066019676,0.00062494626,0.00059745903],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008415799,0.0002652148,0.0011924093,0.00096804084,0.000103433005,0.000026519316,0.00035813564,0.0001546754,0.0005441614],"category_scores_gemma":[0.00437605,0.0001912407,0.000115909264,0.0023546994,0.0012648732,0.00015861259,0.00026092213,0.0015210843,0.000016205513],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077655492,0.004392078,0.91238755,0.00025649043,0.00019908267,0.0003963962,0.0011716684,0.0000019637375,0.00042405172,0.000012552454,0.0005464008,0.0724462],"study_design_scores_gemma":[0.041369718,0.0035658032,0.9510526,0.0019034639,0.00009412418,0.000012633605,0.0013737648,0.000040570038,0.00019878872,0.00010960202,0.00008933609,0.00018959332],"about_ca_topic_score_codex":0.01761047,"about_ca_topic_score_gemma":0.013888734,"teacher_disagreement_score":0.0722566,"about_ca_system_score_codex":0.0012494025,"about_ca_system_score_gemma":0.0024913414,"threshold_uncertainty_score":0.98893136},"labels":[],"label_agreement":null},{"id":"W2290707026","doi":"10.1158/0008-5472.can-15-2782","title":"Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"National Cancer Institute; National Institutes of Health; Chesapeake Research Consortium; Cancer Research UK; Susan G. Komen for the Cure","keywords":"Cancer; Cancer research; Breast cancer; Oncogene; Carcinogenesis; Mammary tumor; Biology; Tumor progression; CDH1; Mouse mammary tumor virus; Cre recombinase; Suppressor; Immunology; Cell cycle; Cell; Genetically modified mouse; Transgene; Gene; Genetics","score_opus":0.12419411833151517,"score_gpt":0.5201761263797922,"score_spread":0.395982008048277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2290707026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8129648,0.0056630247,0.000115307215,0.1656199,0.00042390247,0.0038370097,0.0002980244,0.00024780977,0.010830205],"genre_scores_gemma":[0.9883528,0.0012669928,0.0006267648,0.00090435793,0.0006717106,0.0019702397,0.000010143289,0.000107634725,0.0060893963],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933889,0.00071415934,0.0005170747,0.0009833528,0.0026604247,0.0017361131],"domain_scores_gemma":[0.99503094,0.0017842174,0.00004739979,0.000997302,0.0012352238,0.0009049429],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025834853,0.00026720876,0.0005346646,0.00081213564,0.00017907404,0.00007956004,0.00058439985,0.00024040327,0.004251716],"category_scores_gemma":[0.005729342,0.00017708434,0.00011070683,0.0018752582,0.0012441451,0.00030466128,0.00049753673,0.0013526792,0.0008300897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005155063,0.0009330945,0.074042216,0.0016786561,0.00013224706,0.003852444,0.0017998264,3.2970462e-7,0.4454882,0.0028090437,0.28696138,0.17714751],"study_design_scores_gemma":[0.018321328,0.003439227,0.116332375,0.01788149,0.00004433492,0.00025031678,0.0011112684,0.00051511225,0.5751643,0.008636852,0.25701118,0.0012922239],"about_ca_topic_score_codex":0.0006262638,"about_ca_topic_score_gemma":0.00016052193,"teacher_disagreement_score":0.17585528,"about_ca_system_score_codex":0.0020252888,"about_ca_system_score_gemma":0.003372114,"threshold_uncertainty_score":0.9999479},"labels":[],"label_agreement":null},{"id":"W2306887678","doi":"10.1038/srep23383","title":"Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; Cancer Research UK; Public Health Agency; Friends of the Cancer Centre","keywords":"Genetic heterogeneity; Breast cancer; Computational biology; Tumour heterogeneity; Identification (biology); Disease; Spatial heterogeneity; Phenotype; Tumor heterogeneity; Biology; Bioinformatics; Medicine; Cancer; Internal medicine; Genetics; Gene","score_opus":0.09417006070467217,"score_gpt":0.4169705485494891,"score_spread":0.32280048784481696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2306887678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849638,0.00029200214,0.005154083,0.0048233527,0.0012296785,0.0028992658,0.0006097203,0.000015638752,0.000012475547],"genre_scores_gemma":[0.99667794,0.00011439339,0.0003548714,0.000005519067,0.00007527852,0.0018576109,0.00014601338,0.000023050474,0.0007452994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975562,0.000044612574,0.0010336649,0.0007129268,0.00035759553,0.00029499855],"domain_scores_gemma":[0.99698985,0.00016853638,0.0006699772,0.0010004548,0.0010641083,0.00010710143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018472373,0.00013170087,0.00037233945,0.00031276405,0.000112721915,0.000026076897,0.00011289558,0.000077193945,0.00002252377],"category_scores_gemma":[0.0002885164,0.0000928698,0.00020646614,0.00047260296,0.0003470948,0.00010800022,0.00001801607,0.00002723122,0.0000016283689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024213156,0.00039221,0.12559122,0.00029635837,0.000035473728,0.0000016293457,0.00016308053,0.000010966694,0.8520823,0.00017039615,0.0012101413,0.01980405],"study_design_scores_gemma":[0.00093299535,0.0001082534,0.24521229,0.00021427205,0.00006272276,0.000046459736,0.000050645398,0.00014374811,0.74986935,0.0007636947,0.0025115935,0.00008397595],"about_ca_topic_score_codex":0.00030805636,"about_ca_topic_score_gemma":0.00043192197,"teacher_disagreement_score":0.11962106,"about_ca_system_score_codex":0.0004580957,"about_ca_system_score_gemma":0.000743399,"threshold_uncertainty_score":0.37871206},"labels":[],"label_agreement":null},{"id":"W2312520979","doi":"10.1158/1538-7445.am10-535a","title":"Abstract 535A: The tyrosine kinase Src co-operates with the ERM family member ezrin to promote Met activation and ECM degradation in a breast epithelial cell model","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Ezrin; Proto-oncogene tyrosine-protein kinase Src; Invadopodia; Filopodia; Phosphorylation; Src family kinase; Cortactin; Cell biology; Moesin; Cancer research; Chemistry; Tyrosine phosphorylation; Cell migration; Biology; Cell; Cancer cell; Cytoskeleton; Cancer; Actin; Biochemistry","score_opus":0.0869883775831335,"score_gpt":0.4163157521679209,"score_spread":0.3293273745847874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2312520979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710065,0.00016542891,0.00005328356,0.024627296,0.000042186402,0.002160759,0.00009626829,0.00002360101,0.0018246355],"genre_scores_gemma":[0.9961038,0.00020360664,0.00031294482,0.0004301709,0.000296761,0.00093507837,0.00002398923,0.00005954932,0.0016340894],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970116,0.00018067943,0.00024181115,0.0005226863,0.0013435349,0.000699683],"domain_scores_gemma":[0.9981015,0.00028311243,0.000047570335,0.000664086,0.00062807935,0.00027569177],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002672041,0.00020461078,0.00024300393,0.00027205163,0.00033228466,0.0001898865,0.00037230342,0.00012862429,0.00026262534],"category_scores_gemma":[0.00016693803,0.00010951828,0.00003177078,0.00088093936,0.00042347165,0.00020053521,0.00014416158,0.0018245203,0.000044920762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013434773,0.00014130505,0.0028627913,0.0001455991,0.000023538832,0.00001985007,0.0014020156,0.0004311911,0.9679034,0.00008539754,0.0041012014,0.021540262],"study_design_scores_gemma":[0.0035180892,0.0005850397,0.1367925,0.00050913496,0.000031030224,0.000043658754,0.0013704353,0.006958789,0.8359803,0.0001571495,0.013694314,0.00035955448],"about_ca_topic_score_codex":0.0049493224,"about_ca_topic_score_gemma":0.0030088217,"teacher_disagreement_score":0.1339297,"about_ca_system_score_codex":0.00036698676,"about_ca_system_score_gemma":0.0013354943,"threshold_uncertainty_score":0.79267347},"labels":[],"label_agreement":null},{"id":"W2313186082","doi":"10.1158/0008-5472.sabcs-09-606","title":"Benefits of Adding Paclitaxel to Adjuvant Doxorubicin/Cyclophosphamide Depending on HER2 &amp; ER Status: Analysis of Tumor Tissue Microarrays and Immunohistochemistry in CALGB 9344 (Intergroup 0148).","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Tissue microarray; Immunohistochemistry; Breast cancer; Paclitaxel; Medicine; Concordance; Internal medicine; Doxorubicin; Cyclophosphamide; Oncology; Adjuvant; Cancer; Proportional hazards model; Chemotherapy","score_opus":0.05532989185998875,"score_gpt":0.42910622241684604,"score_spread":0.3737763305568573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313186082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848782,0.010420532,0.000027001888,0.0008203055,0.00006677919,0.0009333794,0.00027412252,0.000021463557,0.002558262],"genre_scores_gemma":[0.9957756,0.0017311253,0.0007777651,0.00019167077,0.00009551586,0.00016182785,0.0000578476,0.00005281048,0.0011558632],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951181,0.00020537009,0.0008845812,0.0008721663,0.0016308457,0.0012889369],"domain_scores_gemma":[0.9972282,0.00041279534,0.00015554504,0.0009770241,0.00063312054,0.00059331127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019436729,0.00030868212,0.0011425258,0.0017687381,0.00010808162,0.000037648304,0.00043551036,0.00016832321,0.0008592721],"category_scores_gemma":[0.0009618477,0.00029523275,0.00015795339,0.003419624,0.0003090987,0.000084821324,0.00023282178,0.0011134255,0.000019000334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020052865,0.0002850219,0.038039558,0.0006371441,0.00033579807,0.00007049726,0.002371925,0.0006537963,0.92240095,0.00010437968,0.0018428905,0.031252746],"study_design_scores_gemma":[0.0023701862,0.0014303762,0.20956548,0.0039640097,0.00021405921,0.000014253255,0.0012807774,0.000090517526,0.77399373,0.000040303807,0.006618724,0.0004175529],"about_ca_topic_score_codex":0.009500942,"about_ca_topic_score_gemma":0.0016392904,"teacher_disagreement_score":0.17152593,"about_ca_system_score_codex":0.0014671821,"about_ca_system_score_gemma":0.0006206789,"threshold_uncertainty_score":0.99995},"labels":[],"label_agreement":null},{"id":"W2313487475","doi":"10.1158/0008-5472.sabcs-3045","title":"Deletion of STAT5 prevents HER2/Neu/ErbB2-induced mammary tumor development.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"STAT5; Cancer research; Biology; Oncogene; HER2/neu; Genetically modified mouse; Mammary tumor; Cytokine; Mouse mammary tumor virus; Cancer; Breast cancer; Transgene; Signal transduction; Immunology; Cell cycle; Cell biology; Gene; Virus","score_opus":0.16704424792469927,"score_gpt":0.488980963841901,"score_spread":0.32193671591720174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313487475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984861,0.0013931753,0.00012296572,0.0032956176,0.0001484804,0.0014551779,0.0000142471545,0.000076150165,0.008633155],"genre_scores_gemma":[0.9917886,0.00061540626,0.0014445889,0.00036087728,0.0002803543,0.0003111397,0.000027438447,0.000050275372,0.005121278],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948817,0.00035061466,0.000565384,0.0006148066,0.002467772,0.0011197451],"domain_scores_gemma":[0.997518,0.00013747178,0.000092551665,0.0007802386,0.0009692591,0.0005024623],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002258201,0.00021544805,0.00045956383,0.00059670774,0.0001860404,0.000047503974,0.0005658074,0.00014329399,0.0009267965],"category_scores_gemma":[0.0003805262,0.00020066997,0.000095101306,0.0013048075,0.00016006776,0.00018068288,0.00019664533,0.0010800628,0.00014256238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012990304,0.00081486825,0.009339807,0.0011906946,0.000168704,0.00042692805,0.001327507,0.000008121199,0.6055256,0.0006649023,0.031146565,0.34808728],"study_design_scores_gemma":[0.0032039876,0.0019003807,0.092529364,0.0016188741,0.000023348673,0.00006011581,0.00026556457,0.00009378754,0.8234989,0.0010788756,0.0753263,0.0004004728],"about_ca_topic_score_codex":0.0004954233,"about_ca_topic_score_gemma":0.000077419994,"teacher_disagreement_score":0.34768683,"about_ca_system_score_codex":0.0012703507,"about_ca_system_score_gemma":0.004053047,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2315066014","doi":"10.1002/cam4.573","title":"A time and motion study of subcutaneous versus intravenous trastuzumab in patients with <scp>HER</scp>2‐positive early breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Medicine; Cohort; Breast cancer; Adjuvant; Internal medicine; Cohort study; Cancer; Surgery","score_opus":0.01498154332615628,"score_gpt":0.29637300469971,"score_spread":0.28139146137355375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315066014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958309,0.0007724309,0.000011522497,0.00091790466,0.00022844713,0.0016155164,0.00016891843,0.000031693136,0.0004226435],"genre_scores_gemma":[0.99855816,0.00033047437,0.000009454923,0.000080537495,0.00030003785,0.0001661182,0.000011313743,0.00005793916,0.0004859717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974655,0.00011528884,0.0004230003,0.0005304118,0.00095636834,0.00050941284],"domain_scores_gemma":[0.9983812,0.00031399162,0.0001649408,0.00034547827,0.0004913989,0.00030298886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025478067,0.0002752822,0.00070214755,0.00028644543,0.000047684385,0.0000062438326,0.00013635706,0.00010608624,0.00039258046],"category_scores_gemma":[0.0001417237,0.00016613278,0.000024495492,0.00052835775,0.0004927621,0.00010148655,0.000048780774,0.00029132122,0.00000920758],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009916894,0.0016340532,0.75784934,0.00024620432,0.0005618463,0.00040741768,0.016641919,0.000018419016,0.0034096076,0.000004936848,0.0008366182,0.20847277],"study_design_scores_gemma":[0.030163454,0.017209604,0.94834733,0.0022284354,0.00026153497,0.00004131281,0.0011814851,0.000027168731,0.00033891975,0.0000046323503,0.000092119306,0.000103981634],"about_ca_topic_score_codex":0.0067675626,"about_ca_topic_score_gemma":0.0014832993,"teacher_disagreement_score":0.2083688,"about_ca_system_score_codex":0.0009774083,"about_ca_system_score_gemma":0.00035882552,"threshold_uncertainty_score":0.99984646},"labels":[],"label_agreement":null},{"id":"W2318415095","doi":"10.1186/s40064-016-2008-9","title":"Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice","year":2016,"lang":"en","type":"article","venue":"SpringerPlus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"U.S. Navy; Genentech; U.S. Department of Defense","keywords":"Trastuzumab; Medicine; Adjuvant; Breast cancer; Clinical Practice; Oncology; Metastatic breast cancer; Internal medicine; Cancer; Family medicine","score_opus":0.02936261070029393,"score_gpt":0.37791381142766783,"score_spread":0.3485512007273739,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318415095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951356,0.00007631219,0.00007495136,0.0018580282,0.00012018414,0.0010045974,0.000053192627,0.00003529012,0.0016418564],"genre_scores_gemma":[0.99820465,0.00013283915,0.0008611356,0.00013627882,0.000105560764,0.0001381214,0.000006039535,0.00006794023,0.0003474133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970367,0.00023948954,0.0005861188,0.00058635115,0.00090311555,0.00064824766],"domain_scores_gemma":[0.99828506,0.00046208486,0.00015669936,0.0004945917,0.00031709427,0.00028445604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00097368396,0.00024908545,0.0006403439,0.0002505278,0.000027879187,0.000019247927,0.00016403748,0.000086043845,0.00027320196],"category_scores_gemma":[0.00035946426,0.00013885986,0.000047542155,0.0006564023,0.00020047296,0.0002264016,0.00006031013,0.00051139505,0.000071291186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00768816,0.0009965827,0.9078894,0.000074292155,0.00010187648,0.0004826406,0.0001430321,0.000009231286,0.00005349767,0.000006295046,0.00006820268,0.08248677],"study_design_scores_gemma":[0.017753717,0.0015983277,0.9778506,0.001377468,0.00007761041,0.000029039154,0.00011180097,0.000046466546,0.00006771943,0.0000019277256,0.0008711235,0.00021417301],"about_ca_topic_score_codex":0.003513362,"about_ca_topic_score_gemma":0.0036019504,"teacher_disagreement_score":0.0822726,"about_ca_system_score_codex":0.00090674544,"about_ca_system_score_gemma":0.0009881193,"threshold_uncertainty_score":0.5662541},"labels":[],"label_agreement":null},{"id":"W2318605753","doi":"10.1056/nejm200103153441101","title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11512,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Epirubicin; Anthracycline; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Doxorubicin; Metastatic breast cancer; Paclitaxel; Cancer; Gastroenterology","score_opus":0.10357860673608633,"score_gpt":0.40995768050192266,"score_spread":0.30637907376583634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318605753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95428663,0.0060921623,0.0039035862,0.033733293,0.0006772438,0.0007884944,0.000098320044,0.000019783762,0.00040049086],"genre_scores_gemma":[0.9658299,0.020634057,0.0037223042,0.002662125,0.0053898995,0.000014894754,0.000026377174,0.00008570019,0.001634727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99721205,0.000110819,0.000793234,0.00022349146,0.001220991,0.00043942375],"domain_scores_gemma":[0.99718183,0.0007055916,0.00054501236,0.00030187587,0.0007113615,0.000554338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010538889,0.00026453036,0.0011014721,0.0003355203,0.000050644612,0.000019556623,0.00023346313,0.00008223623,0.0011276766],"category_scores_gemma":[0.00043856463,0.00017021844,0.00019784206,0.00033579595,0.00022384418,0.00021815719,0.000025228614,0.00047153927,0.0000014818056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029249864,0.00073944806,0.12504898,0.0014039663,0.0021987376,0.0013461481,0.0037248633,0.0008181735,0.114683114,0.00007175334,0.10942852,0.61128646],"study_design_scores_gemma":[0.21796587,0.006786396,0.078457445,0.010279746,0.0011612909,0.009575605,0.001049772,0.0023824964,0.014749533,0.00055694574,0.6564719,0.0005630027],"about_ca_topic_score_codex":0.0011280805,"about_ca_topic_score_gemma":0.00011067682,"teacher_disagreement_score":0.61072344,"about_ca_system_score_codex":0.00022971633,"about_ca_system_score_gemma":0.0011303298,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W2318822787","doi":"10.1158/0008-5472.sabcs11-p1-12-12","title":"P1-12-12: Evaluation of Ile655Val HER2 Polymorphism Associated with Cardiac Toxicity Following the Administration of Trastuzumab in Women with Non-Metastatic Breast Cancer.","year":2011,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Hôpital du Saint-Sacrement","funders":"","keywords":"Trastuzumab; Breast cancer; Medicine; Metastatic breast cancer; Ejection fraction; Population; Toxicity; Oncology; Internal medicine; Genotype; Cardiac toxicity; Genotyping; Cancer; Biology; Heart failure; Genetics","score_opus":0.15211811148307627,"score_gpt":0.4311966634983403,"score_spread":0.279078552015264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2318822787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99393594,0.00060851057,0.000018962786,0.00058740797,0.00009618976,0.0024147357,0.00020418972,0.000015945152,0.002118097],"genre_scores_gemma":[0.9973144,0.00016566645,0.000054108234,0.000032950145,0.00009636705,0.002034976,0.000017040593,0.00006283914,0.00022164205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99282676,0.0011388273,0.000555319,0.0005067911,0.004047769,0.0009245157],"domain_scores_gemma":[0.9972576,0.0003600299,0.00022375598,0.0006318966,0.0012722756,0.00025443154],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00782504,0.00023895303,0.0007009243,0.00040515565,0.00014749767,0.000025825362,0.00037829884,0.00011589918,0.0010065302],"category_scores_gemma":[0.00035727958,0.00016000871,0.00009392579,0.0015336478,0.00062888797,0.00018675893,0.00007641227,0.00084652635,0.0000029639536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05495494,0.0044224695,0.57668304,0.0020771276,0.005228163,0.00038672902,0.06571884,0.00088233425,0.13630223,0.00007689363,0.002161315,0.15110591],"study_design_scores_gemma":[0.00677982,0.0039368584,0.9163274,0.0027084085,0.00033895206,0.000018410872,0.006481116,0.00093866757,0.06205719,0.00009896237,0.000035486002,0.00027871024],"about_ca_topic_score_codex":0.013411167,"about_ca_topic_score_gemma":0.011007113,"teacher_disagreement_score":0.33964437,"about_ca_system_score_codex":0.0032883806,"about_ca_system_score_gemma":0.008514645,"threshold_uncertainty_score":0.99990666},"labels":[],"label_agreement":null},{"id":"W2319127466","doi":"10.1158/0008-5472.sabcs-09-5086","title":"Outcomes of Women with Early Stage HER2 Overexpressing Breast Cancer Receiving Adjuvant Trastuzumab: A Population Based Analysis.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Stage (stratigraphy); Population; Cancer; Adjuvant; Gynecology","score_opus":0.07056468673399381,"score_gpt":0.4438137434065366,"score_spread":0.3732490566725428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2319127466","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947467,0.0006569996,0.0001375605,0.0026856293,0.000045942128,0.0009054902,0.00022405213,0.000068502304,0.0005291373],"genre_scores_gemma":[0.99712336,0.00030794714,0.00028263486,0.00022987094,0.00016991433,0.00038165622,0.00002633098,0.0000637975,0.0014145134],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396795,0.00041562333,0.0005605155,0.00075020397,0.0028226282,0.0014831041],"domain_scores_gemma":[0.9970336,0.00027076062,0.00018133015,0.0008926855,0.001001526,0.0006201041],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021295464,0.00029401353,0.001031268,0.0012217191,0.00023542599,0.00011101717,0.0003794894,0.0001570393,0.002807306],"category_scores_gemma":[0.00018488451,0.00022682901,0.00016527316,0.0033823268,0.000234639,0.00026097536,0.000068594025,0.000977741,0.000007218421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023646706,0.0002477504,0.9496927,0.00032660583,0.0006248703,0.00005517209,0.0012757836,0.0013374693,0.011423022,0.000026239819,0.00025372347,0.032371994],"study_design_scores_gemma":[0.0019633349,0.00069437077,0.9920695,0.0007510816,0.00014439113,0.0000032153712,0.0003755698,0.0008164831,0.0025227924,0.000027604881,0.000400238,0.00023142737],"about_ca_topic_score_codex":0.037152678,"about_ca_topic_score_gemma":0.0024439334,"teacher_disagreement_score":0.04237679,"about_ca_system_score_codex":0.0044565676,"about_ca_system_score_gemma":0.0020288578,"threshold_uncertainty_score":0.99936515},"labels":[],"label_agreement":null},{"id":"W2320592393","doi":"10.1158/0008-5472.sabcs-2014","title":"Role of radiation induced ß1 – integrin expression in trastuzumab resistance in Her-2 positive breast cancer.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab; Breast cancer; Integrin; Protein kinase B; Cancer research; Transactivation; Cancer; Phosphorylation; Radiation therapy; Medicine; Cell; Chemistry; Biology; Internal medicine; Cell biology; Gene expression; Biochemistry","score_opus":0.057727053875883415,"score_gpt":0.4423883504464646,"score_spread":0.3846612965705812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2320592393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800238,0.007624816,0.0000049545274,0.005211013,0.000072087925,0.0013658961,0.00010465916,0.000024795874,0.0055679707],"genre_scores_gemma":[0.9961724,0.0022532383,0.000083776584,0.00010943508,0.0002507978,0.000484748,0.00001783988,0.000040204683,0.0005875447],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956082,0.0005837093,0.0005872952,0.0006595795,0.0015923168,0.00096889003],"domain_scores_gemma":[0.9982985,0.00023788157,0.00009859357,0.0005321508,0.0005531478,0.00027968094],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017855236,0.0002154677,0.0005465526,0.001057694,0.00007752873,0.00003206725,0.00040107113,0.00025420755,0.00059573015],"category_scores_gemma":[0.0002903756,0.00020117675,0.000074168034,0.0023859837,0.00018779805,0.00021960828,0.00009051869,0.0017523034,0.000014293466],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036646316,0.00044078808,0.033886015,0.00020421675,0.000016964768,0.000084014006,0.0036147314,0.00003700043,0.7716927,0.00017551993,0.0018707832,0.18431264],"study_design_scores_gemma":[0.002574437,0.00037121752,0.6305181,0.003296442,0.000005020793,0.0000063490443,0.001014807,0.00008508584,0.36054343,0.0006172627,0.00080018595,0.00016766619],"about_ca_topic_score_codex":0.00834134,"about_ca_topic_score_gemma":0.010287219,"teacher_disagreement_score":0.59663206,"about_ca_system_score_codex":0.003863541,"about_ca_system_score_gemma":0.0022490714,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2322736930","doi":"10.1021/acs.jproteome.5b00691","title":"Skin Barrier Defects Caused by Keratinocyte-Specific Deletion of ADAM17 or EGFR Are Based on Highly Similar Proteome and Degradome Alterations","year":2016,"lang":"en","type":"article","venue":"Journal of Proteome Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"European Research Council; Fritz Thyssen Stiftung; Deutsche Forschungsgemeinschaft; Michael Smith Health Research BC","keywords":"Filaggrin; Keratinocyte; Epidermal growth factor receptor; Biology; Cell biology; Proteases; Involucrin; Proteome; Receptor; Immunology; Biochemistry; Cell culture; Genetics","score_opus":0.1024478522872253,"score_gpt":0.39434117547165937,"score_spread":0.29189332318443406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2322736930","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9698437,0.001103542,0.0037192916,0.020550458,0.00012673863,0.0041398304,0.00014808301,0.000026882208,0.00034146808],"genre_scores_gemma":[0.9932153,0.0007370513,0.003085918,0.00014011007,0.00052771304,0.0003138261,0.000006439094,0.0000822232,0.0018913846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99336565,0.0010880101,0.0009908861,0.00045832875,0.003282317,0.00081482914],"domain_scores_gemma":[0.99468774,0.0010947527,0.00042534113,0.0006313629,0.0024085788,0.0007522534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049485383,0.00027701707,0.00072571414,0.0013053144,0.00028598262,0.00011989363,0.00036534472,0.00024812866,0.00079667504],"category_scores_gemma":[0.0029549904,0.00016348828,0.00018053708,0.00097221264,0.0005050875,0.00029661966,0.00009680133,0.0013320007,0.000039348848],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005790084,0.00058265356,0.004148979,0.0007649953,0.000106122556,0.0005310942,0.00020651045,0.000021619644,0.9553347,0.00006024075,0.026643738,0.0058092414],"study_design_scores_gemma":[0.012972358,0.01668715,0.015868519,0.0056896904,0.000052375945,0.00022615443,0.00022839723,0.0007088257,0.8987074,0.00040922777,0.048029672,0.0004202514],"about_ca_topic_score_codex":0.000028445138,"about_ca_topic_score_gemma":0.000025162932,"teacher_disagreement_score":0.05662734,"about_ca_system_score_codex":0.0008742354,"about_ca_system_score_gemma":0.001717521,"threshold_uncertainty_score":0.8723033},"labels":[],"label_agreement":null},{"id":"W2324246178","doi":"10.1038/sj.bmt.1703005","title":"HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support","year":2001,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Northeast Cancer Centre","funders":"","keywords":"Medicine; Mitoxantrone; Paclitaxel; Metastatic breast cancer; Cyclophosphamide; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer","score_opus":0.01132225414054212,"score_gpt":0.25430958259055975,"score_spread":0.24298732845001764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324246178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695194,0.00019374512,0.00012357425,0.00020037554,0.000023101324,0.0017942913,0.00060982443,0.00004378858,0.000059343383],"genre_scores_gemma":[0.99817824,0.0004671754,0.0005183266,0.000039370203,0.000008432534,0.00023198329,0.0003373723,0.000047914844,0.00017120177],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99796325,0.00012228229,0.00043903547,0.0004233598,0.0006900597,0.00036200366],"domain_scores_gemma":[0.99908876,0.000100976096,0.00020301147,0.00020103427,0.0002495667,0.00015666512],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012548886,0.0002616679,0.00049185305,0.00026414098,0.000050352704,0.000019500614,0.000059422106,0.0000903914,0.00015253825],"category_scores_gemma":[0.000004125741,0.000193103,0.000030882093,0.00042485647,0.00010355993,0.00019832392,0.0000076231136,0.00019781575,0.0000028943293],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076618725,0.0013487461,0.9758514,0.0014642868,0.000087902634,0.00036413068,0.0014031125,0.000020270616,0.0064517725,0.0000035722273,0.000023656325,0.005319267],"study_design_scores_gemma":[0.020113695,0.0023328688,0.95567405,0.0010312703,0.00044914693,0.00015100728,0.00011682318,0.000080059806,0.019832594,0.0000072739185,0.000005144513,0.00020606123],"about_ca_topic_score_codex":0.0015468491,"about_ca_topic_score_gemma":0.0004275176,"teacher_disagreement_score":0.020177355,"about_ca_system_score_codex":0.000112862464,"about_ca_system_score_gemma":0.00024625595,"threshold_uncertainty_score":0.7874512},"labels":[],"label_agreement":null},{"id":"W2324268404","doi":"10.1021/cn500193f","title":"Syntheses and Evaluation of Carbon-11- and Fluorine-18-Radiolabeled pan-Tropomyosin Receptor Kinase (Trk) Inhibitors: Exploration of the 4-Aza-2-oxindole Scaffold as Trk PET Imaging Agents","year":2014,"lang":"en","type":"article","venue":"ACS Chemical Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Montreal Neurological Institute and Hospital; Douglas Mental Health University Institute; McGill University; University of Alberta","funders":"Canada Foundation for Innovation","keywords":"Trk receptor; Tropomyosin; Oxindole; Chemistry; Kinase; Pharmacology; Tropomyosin receptor kinase A; Receptor; Cancer research; Biochemistry; Medicine; Neurotrophin","score_opus":0.07076252528135317,"score_gpt":0.3507855952758984,"score_spread":0.28002306999454524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324268404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973889,0.00012970761,0.000007875684,0.0014620895,0.00019781507,0.00055686396,0.000006145981,0.000018146497,0.00023247482],"genre_scores_gemma":[0.9994304,0.000082514365,0.0001179553,0.00017525301,0.00010397948,0.000042560412,0.0000022854963,0.000018564515,0.000026480824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973972,0.00025966,0.00034643087,0.0004668992,0.0012582368,0.00027159025],"domain_scores_gemma":[0.9987071,0.00028538302,0.00016253491,0.00042075792,0.0002733752,0.00015083044],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011552187,0.00015066432,0.0002674987,0.00008931457,0.00007619767,0.000035168086,0.00022539159,0.000043893,0.000016018987],"category_scores_gemma":[0.00599211,0.00011361776,0.00003951524,0.00046807938,0.00071384804,0.00023972828,0.00020209553,0.0001705357,8.848961e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000048392667,0.000082577506,0.015517141,0.000089487155,0.0000020400232,0.0000014733727,0.00016299337,0.0000036664896,0.9774941,0.00003550333,0.00019016587,0.0063724597],"study_design_scores_gemma":[0.00081966503,0.00012765465,0.0037258689,0.00036562778,0.00004740313,0.000028071976,0.00008228279,0.009906276,0.9844329,0.00013724578,0.00022728684,0.00009975331],"about_ca_topic_score_codex":0.00017295583,"about_ca_topic_score_gemma":0.0000038492403,"teacher_disagreement_score":0.011791272,"about_ca_system_score_codex":0.00008796637,"about_ca_system_score_gemma":0.00018606063,"threshold_uncertainty_score":0.71735483},"labels":[],"label_agreement":null},{"id":"W2324445651","doi":"10.1097/pai.0000000000000136","title":"HER2 Genetic Heterogeneity in Gastric Cancer","year":2015,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Cancer; Immunohistochemistry; Internal medicine; Medicine; Pathology; Breast cancer; Stomach; Epithelium; Gastroenterology; Biology; Oncology","score_opus":0.029831324548665352,"score_gpt":0.34917058982172816,"score_spread":0.31933926527306283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2324445651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823273,0.007109838,0.0004885569,0.00051730056,0.00017842266,0.0006038237,0.000011788318,0.00007375971,0.008689227],"genre_scores_gemma":[0.99500453,0.00013385717,0.0024761949,0.0010355593,0.00010354559,0.0007083263,0.0000586879,0.00008187837,0.00039739598],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973781,0.00006529688,0.0004975355,0.0007409096,0.0005205356,0.0007976412],"domain_scores_gemma":[0.99828494,0.000024691608,0.00011221824,0.0010359073,0.00015890722,0.00038332006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030629023,0.0003298037,0.0005581527,0.00016020997,0.00004103979,0.00001602776,0.00039560953,0.0003355243,0.00036412524],"category_scores_gemma":[0.00010282551,0.00036349034,0.00012028233,0.0005597387,0.0003310934,0.00001766094,0.0002184235,0.0007284878,0.00016778216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033760237,0.00017953817,0.004486427,0.000089338566,0.000066258195,0.0012020443,0.000078489466,0.00013683939,0.98830986,0.000019932108,0.0019900277,0.0031036192],"study_design_scores_gemma":[0.0051255827,0.0002812074,0.012742018,0.00008081992,0.00010385798,0.0016401304,0.00013109225,0.00007549543,0.97655666,0.00022432422,0.0025033108,0.00053548557],"about_ca_topic_score_codex":0.00073918444,"about_ca_topic_score_gemma":0.0000018826516,"teacher_disagreement_score":0.012677271,"about_ca_system_score_codex":0.0012737114,"about_ca_system_score_gemma":0.00089526986,"threshold_uncertainty_score":0.9998817},"labels":[],"label_agreement":null},{"id":"W2325353319","doi":"10.1093/annonc/mdt084.3","title":"Prognostic and Predictive Value of IHC4 and ERB1 in the Intergroup Exemestane Study (IES) - On Behalf of the Pathies Investigators","year":2013,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Exemestane; Internal medicine; Oncology; Breast cancer; Proportional hazards model; Gynecology; Biomarker; Immunohistochemistry; Cancer; Tamoxifen","score_opus":0.09515554137456515,"score_gpt":0.41380081089359,"score_spread":0.31864526951902483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2325353319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900594,0.0004664502,9.109699e-7,0.0066427058,0.000052647214,0.0016256163,0.000011717958,0.000003534869,0.0011370202],"genre_scores_gemma":[0.99892956,0.00023828293,0.00003220171,0.0005849095,0.000027242522,0.00014847293,0.0000011318854,0.000009325866,0.000028852732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837977,0.00054751884,0.00037475722,0.00017632364,0.0003381392,0.00018351924],"domain_scores_gemma":[0.99828917,0.0009678195,0.00016738498,0.00029091001,0.00021968875,0.00006502636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010797024,0.00010047401,0.00039452928,0.00012632509,0.000025299178,0.0000043518326,0.00018346524,0.00008930361,0.00002051119],"category_scores_gemma":[0.0015216005,0.00005493612,0.000034037927,0.00024203154,0.0010549582,0.00004548422,0.00014761352,0.00030151164,8.161558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035429292,0.0015609429,0.95893824,0.00030501568,0.00012886261,0.000024297036,0.021141915,0.0000049988907,0.0019331055,0.00071832404,0.0023831422,0.012506837],"study_design_scores_gemma":[0.0010403452,0.017814225,0.9659927,0.00033718217,0.000054098917,0.000020008883,0.009832884,0.000087178014,0.0029961953,0.0014570362,0.0003227759,0.000045368168],"about_ca_topic_score_codex":0.00088732684,"about_ca_topic_score_gemma":0.00018081737,"teacher_disagreement_score":0.016253281,"about_ca_system_score_codex":0.000022260247,"about_ca_system_score_gemma":0.00021700765,"threshold_uncertainty_score":0.38870373},"labels":[],"label_agreement":null},{"id":"W2326303359","doi":"10.1097/pai.0b013e3182910967","title":"Expression of Topoisomerase II-α in Triple Negative Breast Cancer","year":2013,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Triple-negative breast cancer; Anthracycline; Epidermal growth factor receptor; Medicine; Estrogen receptor; Progesterone receptor; Breast cancer; Immunophenotyping; Cancer research; Internal medicine; Oncology; Ki-67; Immunohistochemistry; Receptor; Cancer; Pathology; Immunology; Flow cytometry","score_opus":0.009304854452362104,"score_gpt":0.302455079980057,"score_spread":0.2931502255276949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326303359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99050105,0.0011339984,0.00005800471,0.001059105,0.00009336419,0.0009757999,0.000034689903,0.000034711225,0.006109284],"genre_scores_gemma":[0.99623346,0.00009360196,0.000983795,0.00048815252,0.00004725029,0.0011980226,0.000051167124,0.0000524104,0.00085211615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979551,0.00004865269,0.00054603175,0.00054050254,0.00037560967,0.00053412863],"domain_scores_gemma":[0.99860454,0.000048029273,0.00018022537,0.00079260353,0.00020777018,0.00016686166],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015734856,0.00027210228,0.0005932816,0.00014501452,0.00006410817,0.000007717996,0.0003106653,0.00029040317,0.0041512246],"category_scores_gemma":[0.00007179478,0.00026826686,0.00011996632,0.00041205308,0.0004099064,0.000041602427,0.0002438833,0.00061203266,0.00005663453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041120796,0.00028113573,0.0005227329,0.00015680652,0.000039686893,0.00008988275,0.00025565186,0.000012221554,0.99268585,0.000041166008,0.0028418193,0.0026618426],"study_design_scores_gemma":[0.0028895484,0.00009602581,0.007333807,0.00014909332,0.000028335593,0.00017663301,0.00022085966,0.000016151102,0.9885648,0.00023126765,0.00007948587,0.00021400752],"about_ca_topic_score_codex":0.002015006,"about_ca_topic_score_gemma":5.352203e-7,"teacher_disagreement_score":0.0068110744,"about_ca_system_score_codex":0.0004670328,"about_ca_system_score_gemma":0.00035308747,"threshold_uncertainty_score":0.99997693},"labels":[],"label_agreement":null},{"id":"W2326917709","doi":"10.1158/1538-7445.am2012-1249","title":"Abstract 1249: Modulation of epidermal growth factor induction of migration by integrin-linked kinase","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"RAC1; Cell biology; Cell migration; Motility; Integrin; Integrin-linked kinase; Epidermal growth factor; Cancer research; Tyrosine kinase; Signal transduction; Epidermal growth factor receptor; Biology; Kinase; Chemistry; Cell; Protein kinase A; Receptor; Cyclin-dependent kinase 2; Biochemistry","score_opus":0.19814498477933895,"score_gpt":0.46903170139245454,"score_spread":0.2708867166131156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2326917709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946708,0.0015997983,0.00012224371,0.0015992095,0.00025468765,0.00080001954,0.00009723985,0.000023974992,0.00083199376],"genre_scores_gemma":[0.9977999,0.0007891769,0.00013115251,0.000022070833,0.0005247649,0.00015326256,0.000076682765,0.000038939295,0.0004640647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968014,0.00023577968,0.0005197389,0.00028396118,0.0015232132,0.00063595054],"domain_scores_gemma":[0.9975911,0.00024203633,0.00014911633,0.00040126554,0.0012983753,0.00031810725],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016787595,0.00014422205,0.00034582053,0.00046953827,0.00007585432,0.000014094263,0.00018196592,0.00021518754,0.0012602989],"category_scores_gemma":[0.0008816779,0.00012722667,0.00009336416,0.0007761407,0.00032501871,0.00035520951,0.00007557504,0.0008809742,0.000034365028],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042791944,0.000289415,0.088897295,0.00075735326,0.000052827025,0.0000018720742,0.0009482758,0.000011537182,0.87433046,0.00013902353,0.007849234,0.02629479],"study_design_scores_gemma":[0.00079544616,0.00025980474,0.40759706,0.0003090503,0.000012548065,0.0000035614705,0.00028862944,0.00015514278,0.58767843,0.00008412906,0.0027145199,0.00010165174],"about_ca_topic_score_codex":0.0063284896,"about_ca_topic_score_gemma":0.00012107226,"teacher_disagreement_score":0.31869978,"about_ca_system_score_codex":0.0006804164,"about_ca_system_score_gemma":0.0005596756,"threshold_uncertainty_score":0.9996527},"labels":[],"label_agreement":null},{"id":"W2327283214","doi":"10.1158/0008-5472.sabcs-09-706","title":"Biomarker Profiles in Trastuzumab (T) Refractory HER2+ Inflammatory Breast Cancer (IBC) That Predict for Survival Benefit from Lapatinib (L) Monotherapy.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Oncology; Trastuzumab; Cohort; Biomarker; Breast cancer; Cancer; Immunohistochemistry; Progression-free survival; Overall survival; Proportional hazards model; Gastroenterology","score_opus":0.13191626037152934,"score_gpt":0.4425371703677506,"score_spread":0.3106209099962213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327283214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97491544,0.008550799,0.000032592154,0.008629634,0.00049683044,0.0039510657,0.0017599564,0.00014930483,0.001514347],"genre_scores_gemma":[0.98464197,0.0063662482,0.00017673527,0.00041693947,0.0015989206,0.003920872,0.00016147138,0.00017620133,0.0025406443],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934158,0.00042054034,0.0007125156,0.0012325977,0.002413421,0.0018051314],"domain_scores_gemma":[0.99650687,0.00076239393,0.00013939447,0.0010521661,0.00090133626,0.00063781627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024598807,0.00046233402,0.0008457208,0.00080267136,0.00026351423,0.00013365941,0.0007446172,0.000453437,0.0029794269],"category_scores_gemma":[0.00020764302,0.00041351415,0.00022523731,0.0010695976,0.00045173385,0.00032077622,0.00012412072,0.001531601,0.000046708545],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012978066,0.0009151389,0.3749737,0.0006877226,0.0003691074,0.00018158997,0.0020133099,0.000055699627,0.09365408,0.00014864022,0.02691693,0.487106],"study_design_scores_gemma":[0.00829262,0.00094263256,0.9067018,0.0018714675,0.00004019336,0.00001131814,0.0007150385,0.0006989052,0.018265035,0.00085759145,0.061034247,0.00056916935],"about_ca_topic_score_codex":0.009313239,"about_ca_topic_score_gemma":0.005217304,"teacher_disagreement_score":0.5317281,"about_ca_system_score_codex":0.0030253918,"about_ca_system_score_gemma":0.0030955926,"threshold_uncertainty_score":0.9998317},"labels":[],"label_agreement":null},{"id":"W2327569758","doi":"10.1136/jclinpath-2012-200974","title":"Validation of tissue microarrays in oral epithelial dysplasia using a novel virtual-array technique","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Cancer Research UK","keywords":"Tissue microarray; Immunohistochemistry; Virtual microscopy; Pathology; Reliability (semiconductor); Computer science; Intraclass correlation; Dysplasia; Oral mucosa; Medicine; Reproducibility; Computational biology; Pattern recognition (psychology); Artificial intelligence; Biology; Mathematics; Statistics; Physics","score_opus":0.16888939577211667,"score_gpt":0.49976395239135873,"score_spread":0.33087455661924203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327569758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97337496,0.00015314197,0.023965068,0.00070120615,0.0009656615,0.00033833593,0.000010439599,0.0000063065054,0.00048484877],"genre_scores_gemma":[0.9455586,0.0000875597,0.053055745,0.00021675338,0.0009979588,0.0000046843857,0.0000020214952,0.000025576133,0.000051111136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963702,0.0006070337,0.0020506994,0.00016299388,0.0004277398,0.00038134205],"domain_scores_gemma":[0.99758834,0.0006492341,0.0008630269,0.00025419446,0.00037298852,0.0002722342],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0083890185,0.00013095747,0.0009950043,0.00036812993,0.000020039139,0.0000051559937,0.00019234058,0.00044937554,0.00022398405],"category_scores_gemma":[0.0040285373,0.000105344836,0.00020357448,0.0002786813,0.00030900375,0.00015129428,0.00005490164,0.0012439042,0.00001893943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084816746,0.00083433744,0.121544644,0.000053373256,0.000029112696,0.00014093916,0.00020771088,0.000017888708,0.8708601,0.000071067996,0.000109649154,0.005283031],"study_design_scores_gemma":[0.007477746,0.0059088184,0.14205123,0.00069663406,0.00019041813,0.006936059,0.0001922887,0.0000357975,0.8241386,0.00030890078,0.011827996,0.00023552743],"about_ca_topic_score_codex":0.000022051738,"about_ca_topic_score_gemma":0.000004507847,"teacher_disagreement_score":0.046721496,"about_ca_system_score_codex":0.00009792018,"about_ca_system_score_gemma":0.0005631888,"threshold_uncertainty_score":0.5404214},"labels":[],"label_agreement":null},{"id":"W2328501245","doi":"10.1097/igc.0b013e31826d1438","title":"Expected Benefits of Topotecan Combined With Lapatinib in Recurrent Ovarian Cancer According to Biological Profile","year":2012,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Topotecan; Medicine; Lapatinib; Internal medicine; Oncology; Gefitinib; Epidermal growth factor receptor; Cancer; Chemotherapy; Pharmacology; Trastuzumab; Breast cancer","score_opus":0.09748817472018313,"score_gpt":0.41249245806051915,"score_spread":0.31500428334033603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328501245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123573,0.0010501365,0.00006202969,0.0051080333,0.0011139049,0.0004509138,0.00005672698,0.000012421386,0.00091010064],"genre_scores_gemma":[0.9962279,0.0004898885,0.0017096503,0.0005967229,0.0007301824,0.00015920427,0.0000067496703,0.000015617057,0.00006406879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997668,0.00012099915,0.0006951264,0.00019942674,0.0009028365,0.00041357736],"domain_scores_gemma":[0.9978028,0.00031900982,0.00036241018,0.000119086595,0.0010647732,0.00033192427],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006371661,0.00016584326,0.00053736963,0.0003315776,0.000025501078,0.00001805545,0.00039509247,0.00014082842,0.003429211],"category_scores_gemma":[0.00094683876,0.000106232554,0.000107352156,0.00041053724,0.000096796844,0.00013279676,0.00013191738,0.0005520354,0.000007146403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058042463,0.0008623593,0.9096294,0.00002890112,0.00020850784,0.00008030917,0.00048308333,0.00029024688,0.0040128506,0.00048275338,0.0007978747,0.07731944],"study_design_scores_gemma":[0.0034842272,0.003652209,0.97991264,0.00075988413,0.00003169602,0.00007195902,0.0003841128,0.000046841615,0.008323247,0.000054812055,0.0031080781,0.00017027122],"about_ca_topic_score_codex":0.00025810112,"about_ca_topic_score_gemma":0.00029315232,"teacher_disagreement_score":0.077149175,"about_ca_system_score_codex":0.0009866119,"about_ca_system_score_gemma":0.00044258506,"threshold_uncertainty_score":0.99748176},"labels":[],"label_agreement":null},{"id":"W2329129089","doi":"10.1158/0008-5472.sabcs10-p5-12-03","title":"Abstract P5-12-03: Concurrent vs. Sequential Administration of Adjuvant Trastuzumab in Early Stage Breast Cancer: A Systematic Review and Meta-Analysis","year":2010,"lang":"en","type":"review","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Breast cancer; Meta-analysis; Internal medicine; Randomized controlled trial; Stage (stratigraphy); Adjuvant; Clinical trial; Inclusion and exclusion criteria; Cancer; Pathology; Alternative medicine","score_opus":0.3509230911295733,"score_gpt":0.5485707472303206,"score_spread":0.1976476561007473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329129089","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022511037,0.98285025,0.0000031694772,0.0008358435,0.00012035019,0.011115829,0.0046241134,0.000027320544,0.00019800354],"genre_scores_gemma":[0.0075155078,0.98034614,0.000014771368,0.000055485205,0.00018089596,0.009974383,0.00023570251,0.00013605342,0.0015410526],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9890407,0.0018416868,0.0030154944,0.0014617087,0.0033961437,0.0012442934],"domain_scores_gemma":[0.994372,0.0007668011,0.0010797143,0.0017133822,0.0013288045,0.00073928],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007257372,0.000836053,0.012936709,0.0018520589,0.00012675703,0.00015913983,0.0009186392,0.00066049787,0.0057239705],"category_scores_gemma":[0.00053421344,0.0005888528,0.0022544384,0.003179655,0.0007231221,0.00017982285,0.0002856504,0.0042250673,0.000054282275],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008921843,0.00020645189,0.0000435481,0.9435706,0.034979776,0.00021053874,0.00013167935,6.540326e-7,0.000013146613,0.000030685165,0.00037083964,0.02035285],"study_design_scores_gemma":[0.0010595587,0.0006024236,0.00044638079,0.279312,0.62217706,0.00018895703,0.00006826094,0.000011524258,0.00004661404,0.000005123945,0.09518799,0.0008941054],"about_ca_topic_score_codex":0.007898045,"about_ca_topic_score_gemma":0.0077727144,"teacher_disagreement_score":0.6642586,"about_ca_system_score_codex":0.0019493222,"about_ca_system_score_gemma":0.00926013,"threshold_uncertainty_score":0.99965626},"labels":[],"label_agreement":null},{"id":"W2329465541","doi":"10.1158/0008-5472.sabcs-5118","title":"Phase II trial of neoadjuvant chemotherapy of sequential FEC100 followed by docetaxel, carboplatin and trastuzumab (TCH) for HER-2 over-expressing locally advanced breast cancer (LABC): a multi-centre study from British Columbia.","year":2009,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Kelowna General Hospital; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Docetaxel; Carboplatin; Breast cancer; Internal medicine; Epirubicin; Oncology; Chemotherapy; Cancer; Surgery; Cisplatin","score_opus":0.05717163578144839,"score_gpt":0.44103397805998534,"score_spread":0.38386234227853694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329465541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812282,0.0062288097,0.00011625272,0.001095372,0.00025009323,0.0075187306,0.003452749,0.000048776186,0.000061034396],"genre_scores_gemma":[0.99470556,0.0016851427,0.00047570426,0.00012411595,0.0005157079,0.000779135,0.00009013362,0.00011671535,0.0015077676],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99423283,0.0004103656,0.0010161437,0.0011242774,0.002047611,0.0011687949],"domain_scores_gemma":[0.99696654,0.000308517,0.00030416145,0.0006961217,0.0011896794,0.0005349533],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013152523,0.00033438485,0.0013311502,0.00018367748,0.0003710197,0.00019473684,0.00046251167,0.0002596883,0.0012628689],"category_scores_gemma":[0.00024730936,0.00041489195,0.00023439399,0.0007160511,0.00054045604,0.00022165645,0.00015736156,0.0008315374,7.5085904e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06630576,0.010244778,0.0038708483,0.0003556664,0.00046746686,0.000078466284,0.0019160592,0.000016503189,0.5128939,6.3253873e-7,0.01535869,0.3884912],"study_design_scores_gemma":[0.85972327,0.029239232,0.012155369,0.0043109586,0.00039235456,0.000027501086,0.0025910602,0.0019902594,0.082040265,0.000074357944,0.0064816396,0.00097372907],"about_ca_topic_score_codex":0.10799347,"about_ca_topic_score_gemma":0.030328602,"teacher_disagreement_score":0.7934175,"about_ca_system_score_codex":0.0010240098,"about_ca_system_score_gemma":0.0023097987,"threshold_uncertainty_score":0.9998303},"labels":[],"label_agreement":null},{"id":"W2329752051","doi":"10.1158/1538-7445.am10-5064","title":"Abstract 5064: The non-receptor tyrosine kinase Fer is required for activated ErbB2-mediated tumorigenesis","year":2010,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Carcinogenesis; Cell biology; Focal adhesion; Endocytosis; Biology; Internalization; Receptor tyrosine kinase; Tyrosine kinase; Cancer research; Signal transduction; Proto-oncogene tyrosine-protein kinase Src; Signal transducing adaptor protein; Cell; Cancer; Biochemistry","score_opus":0.12733841121686232,"score_gpt":0.4613987581692534,"score_spread":0.33406034695239106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2329752051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96152717,0.0007602231,0.000017940949,0.030029217,0.0010823308,0.0037192532,0.00050980045,0.000121930985,0.0022321285],"genre_scores_gemma":[0.98195976,0.0008113761,0.00025886565,0.0008785967,0.0024371068,0.003399317,0.00014948566,0.00019738171,0.009908099],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99438846,0.00015487846,0.00054350734,0.00093624217,0.0021754305,0.0018015011],"domain_scores_gemma":[0.9940986,0.0013110982,0.000109382505,0.0015324553,0.0021621743,0.00078626414],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0033952508,0.00036012733,0.000550909,0.00046040124,0.00071072526,0.00018955377,0.0009630845,0.0003820157,0.009527017],"category_scores_gemma":[0.002133878,0.0002504728,0.00023712254,0.0017584251,0.00094574393,0.00019147304,0.00025748333,0.0024250047,0.000923327],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014388778,0.00019003027,0.0016472663,0.00036271024,0.00011296973,0.000029401153,0.0004199712,0.0000012610457,0.78762853,0.000037893988,0.19619235,0.011938748],"study_design_scores_gemma":[0.002329226,0.00036227592,0.016563158,0.00023976475,0.000027859889,0.0000075423036,0.00023438172,0.0001113701,0.6724078,0.0000762296,0.30738932,0.00025104402],"about_ca_topic_score_codex":0.0028860932,"about_ca_topic_score_gemma":0.000493767,"teacher_disagreement_score":0.115220696,"about_ca_system_score_codex":0.00076821423,"about_ca_system_score_gemma":0.003025282,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W2330598133","doi":"10.1158/1538-7445.am2012-1243","title":"Abstract 1243: RET and integrin crosstalk provides functional plasticity","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cell biology; Integrin; Glial cell line-derived neurotrophic factor; Proto-oncogene tyrosine-protein kinase Src; Cancer research; Receptor tyrosine kinase; Biology; Cell adhesion; Chemistry; Neurotrophic factors; Signal transduction; Cell; Receptor; Genetics","score_opus":0.25617715126673013,"score_gpt":0.49153109932044164,"score_spread":0.23535394805371151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2330598133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859061,0.0037579567,0.000047800077,0.0026322226,0.00030489083,0.0007659857,0.000047951457,0.000096167634,0.0064408835],"genre_scores_gemma":[0.99299204,0.0006483327,0.00014937318,0.00015008432,0.0015618028,0.00042188397,0.000010272645,0.000064825115,0.004001393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99638987,0.00012912262,0.00026725998,0.00043172613,0.0015780737,0.0012039747],"domain_scores_gemma":[0.9978111,0.0004594274,0.000035878194,0.000322223,0.00059212407,0.0007792448],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020864736,0.00017381634,0.00027532346,0.00030126492,0.00030322853,0.000112924805,0.00016488977,0.00017089253,0.0029754434],"category_scores_gemma":[0.0012343157,0.0001412961,0.00005904439,0.0004995582,0.0008212359,0.00027245758,0.0002529693,0.0016139784,0.00026204987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038402642,0.0007359263,0.42944354,0.0025661716,0.00020436457,0.00014443332,0.0018755371,0.000022173861,0.30041036,0.0021967255,0.17727935,0.08128114],"study_design_scores_gemma":[0.0017098188,0.0004127914,0.74094903,0.0005634756,0.00002258317,0.00009301519,0.00062252604,0.00006749904,0.044911407,0.00029022733,0.21008879,0.00026883782],"about_ca_topic_score_codex":0.0015173595,"about_ca_topic_score_gemma":0.0001651272,"teacher_disagreement_score":0.31150547,"about_ca_system_score_codex":0.0008128432,"about_ca_system_score_gemma":0.0011914974,"threshold_uncertainty_score":0.99793595},"labels":[],"label_agreement":null},{"id":"W2331118477","doi":"10.1177/171516350613900109","title":"Use of Trastuzumab for Early-Stage Invasive Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Stage (stratigraphy); Internal medicine; Cancer; Biology","score_opus":0.09665679366048885,"score_gpt":0.3418393889493365,"score_spread":0.24518259528884767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2331118477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878039,0.0009018367,0.00010135202,0.00054202863,0.0013421191,0.0011271912,0.0076064686,0.000022842325,0.00055225677],"genre_scores_gemma":[0.9896594,0.0028656514,0.00036831538,0.0013484993,0.0015965656,0.000095258474,0.0000658107,0.0001146282,0.0038858263],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99638534,0.00011878609,0.0008282508,0.00046250052,0.0007807719,0.0014243809],"domain_scores_gemma":[0.99501485,0.0002557402,0.0003322578,0.00032690572,0.0016408658,0.0024294027],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048807496,0.00039959615,0.00063921395,0.00058647,0.00051480404,0.00015496623,0.0004568504,0.00009795456,0.0019520235],"category_scores_gemma":[0.0002047916,0.00040961447,0.00028135075,0.0007513658,0.00033738106,0.0003813184,0.000034877674,0.00075590925,0.00000492371],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0029212877,0.00044572874,0.17014393,0.004475885,0.001537625,0.123900704,0.0018219594,0.006400395,0.075251825,0.000252268,0.46679068,0.14605771],"study_design_scores_gemma":[0.01177801,0.0004390031,0.006930474,0.00045437223,0.0009238038,0.5509514,0.00003849794,0.00431513,0.0748408,0.000103435916,0.347584,0.001641078],"about_ca_topic_score_codex":0.43323287,"about_ca_topic_score_gemma":0.5094353,"teacher_disagreement_score":0.42705068,"about_ca_system_score_codex":0.005910585,"about_ca_system_score_gemma":0.018213406,"threshold_uncertainty_score":0.99983555},"labels":[],"label_agreement":null},{"id":"W2334856590","doi":"10.1097/pai.0000000000000039","title":"Predicting OncoDX Recurrence Scores With Immunohistochemical Markers","year":2014,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University; Ottawa Hospital","funders":"","keywords":"Immunohistochemistry; Medicine; Breast cancer; Internal medicine; Estrogen receptor; Oncology; Estrogen; Population; Cohort; Cancer; Gynecology","score_opus":0.008528528665359796,"score_gpt":0.2845737855243071,"score_spread":0.2760452568589473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2334856590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92322594,0.001197505,0.0025635401,0.0005284314,0.00017210846,0.00079632516,0.000011261581,0.00024000171,0.07126489],"genre_scores_gemma":[0.990765,0.000042623466,0.0066421,0.0008764346,0.00016160877,0.0005348529,0.00020078207,0.00013955128,0.0006370992],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99623233,0.000092122944,0.0006473158,0.0011564498,0.0008232073,0.0010485444],"domain_scores_gemma":[0.9971998,0.00016757878,0.00026145222,0.001738545,0.00025616496,0.00037650103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060434063,0.00054815045,0.000793249,0.00014052964,0.00020580454,0.00003837791,0.0006665553,0.0004522074,0.00051452394],"category_scores_gemma":[0.00038556932,0.0005323268,0.00018742312,0.0004785513,0.001168122,0.000040990024,0.00028231417,0.0014105091,0.00013642166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015587485,0.00015790475,0.0014746051,0.0002555231,0.0001656086,0.00025082624,0.00008264288,0.000011403957,0.98993313,0.00035501458,0.0018735194,0.0038810868],"study_design_scores_gemma":[0.0041975672,0.0009200316,0.0020310474,0.00041207057,0.00024890754,0.0023276573,0.00016894712,0.0001599427,0.9854247,0.00021780196,0.0030820363,0.0008092731],"about_ca_topic_score_codex":0.00013033928,"about_ca_topic_score_gemma":1.998896e-7,"teacher_disagreement_score":0.07062779,"about_ca_system_score_codex":0.00075156544,"about_ca_system_score_gemma":0.0005399035,"threshold_uncertainty_score":0.9997128},"labels":[],"label_agreement":null},{"id":"W2336389733","doi":"10.1200/jco.2006.24.18_suppl.13100","title":"Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Lapatinib; Erlotinib; Tyrosine-kinase inhibitor; Cancer research; Hsp90 inhibitor; Trastuzumab; SKBR3; EGFR inhibitors; Medicine; Apoptosis; Breast cancer; ErbB; Epidermal growth factor receptor; Transfection; Growth inhibition; MTT assay; Cell culture; Pharmacology; Cancer; Internal medicine; Biology; Hsp90; Heat shock protein; Human breast; Biochemistry","score_opus":0.06359530791566989,"score_gpt":0.43699860877867275,"score_spread":0.3734033008630029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2336389733","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98757505,0.00093114027,0.000065619184,0.009584352,0.00036100813,0.00031079154,0.00003452923,0.0000038870567,0.0011336158],"genre_scores_gemma":[0.99716896,0.00074060814,0.00040253,0.00017610921,0.0013194282,0.000008871258,0.0000031253687,0.000020614647,0.00015974807],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99613404,0.00046202823,0.0022591702,0.00017073964,0.0007751303,0.00019889865],"domain_scores_gemma":[0.9935233,0.001961035,0.002477636,0.00018182136,0.0016976206,0.00015856198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027216282,0.00013901557,0.0012534079,0.00014037368,0.00003001414,0.000005414017,0.000099944395,0.00029726615,0.00008884508],"category_scores_gemma":[0.0006961026,0.00008107002,0.00020738448,0.00027196883,0.00090049027,0.0001065113,0.00006247104,0.00069216476,7.516941e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04211944,0.02165462,0.31100702,0.0041144327,0.0010310578,0.0007801366,0.0011014042,0.00043980178,0.45003736,0.0016543377,0.04830498,0.117755406],"study_design_scores_gemma":[0.04297218,0.05614202,0.77184826,0.00393563,0.0016243221,0.00087160605,0.0013959911,0.00062522414,0.1096279,0.0009532783,0.009633117,0.00037047267],"about_ca_topic_score_codex":0.0007655989,"about_ca_topic_score_gemma":0.000716637,"teacher_disagreement_score":0.4608412,"about_ca_system_score_codex":0.00017162156,"about_ca_system_score_gemma":0.0019245815,"threshold_uncertainty_score":0.34141248},"labels":[],"label_agreement":null},{"id":"W2338010368","doi":"10.1093/jnci/djw037","title":"Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial","year":2016,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Lapatinib; Rash; Medicine; Hazard ratio; Internal medicine; Trastuzumab; Breast cancer; Confidence interval; Oncology; Proportional hazards model; Cancer; Surgery","score_opus":0.10597184761811394,"score_gpt":0.4644820131216851,"score_spread":0.3585101655035711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338010368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8978255,0.0013394081,0.000049176844,0.093155734,0.0035742174,0.0016906164,0.00019224246,0.000009181556,0.002163932],"genre_scores_gemma":[0.9930952,0.0012637184,0.000056242974,0.0024131385,0.0019762896,0.00016586375,0.000001495342,0.000016836533,0.0010112093],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99634755,0.0003833533,0.0010855664,0.00017508265,0.0017489174,0.0002595174],"domain_scores_gemma":[0.99770993,0.0006279175,0.0005946276,0.0001610674,0.0007746876,0.00013178203],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0040835743,0.00016944125,0.0006732036,0.00023186125,0.00013237249,0.000038745486,0.00041849437,0.0001052598,0.0005505872],"category_scores_gemma":[0.0015305686,0.0000695709,0.00028286225,0.00044178806,0.0004800871,0.00029602312,0.00006490082,0.00061610504,0.0000049238283],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90542644,0.0006390072,0.012705457,0.00009816603,0.0008602368,0.000092588445,0.0012731565,0.00024746853,0.0032513263,0.002989101,0.025268983,0.04714804],"study_design_scores_gemma":[0.9629721,0.00014046402,0.007305819,0.00073034497,0.00021193025,0.00052834826,0.00003453676,0.0001185387,0.0002802132,0.0011770466,0.026367804,0.00013287697],"about_ca_topic_score_codex":0.0004914258,"about_ca_topic_score_gemma":0.00033272238,"teacher_disagreement_score":0.09526972,"about_ca_system_score_codex":0.0008643269,"about_ca_system_score_gemma":0.002028413,"threshold_uncertainty_score":0.6028544},"labels":[],"label_agreement":null},{"id":"W2338311228","doi":"10.1136/annrheumdis-2015-eular.2291","title":"OP0251 Effects of 2 Years of Treatment with Romosozumab Followed by 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density","year":2015,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Bone mineral; Femoral neck; Denosumab; Sclerostin; Placebo; Postmenopausal women; Urology; Osteoporosis; Lumbar spine; Internal medicine; Surgery; Chemistry","score_opus":0.027252637847661573,"score_gpt":0.3156595177510587,"score_spread":0.28840687990339714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338311228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99766123,0.00086286356,0.0000028868362,0.00017514422,0.000024895064,0.001064053,0.000102407794,0.000008677352,0.00009783922],"genre_scores_gemma":[0.9991246,0.00015669533,0.0001701988,0.000028975986,0.000006751432,0.00007825007,0.000010959739,0.0000291763,0.00039437631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981446,0.0001749903,0.00042584835,0.00018985191,0.0007599926,0.00030469283],"domain_scores_gemma":[0.9982956,0.00034789482,0.00030960492,0.00057413196,0.00023764516,0.00023512998],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025786107,0.00017760716,0.00083386,0.00012292856,0.000011596203,0.0000047529297,0.0001931191,0.000046226163,0.00004253643],"category_scores_gemma":[0.00049004715,0.000100558325,0.000070229034,0.0003543076,0.00030609846,0.00005786986,0.00006961646,0.00006789127,0.000002291708],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24334499,0.027084047,0.5470708,0.028230026,0.00783205,0.00083330064,0.025085213,0.00081550126,0.029925676,0.00015331853,0.030617135,0.059007917],"study_design_scores_gemma":[0.079306245,0.104222566,0.5691597,0.025153046,0.0014789209,0.0001270909,0.0048446697,0.0004313224,0.21369767,0.00048651465,0.00018225583,0.0009100307],"about_ca_topic_score_codex":0.0009954973,"about_ca_topic_score_gemma":0.000097130694,"teacher_disagreement_score":0.183772,"about_ca_system_score_codex":0.00015771191,"about_ca_system_score_gemma":0.0011820538,"threshold_uncertainty_score":0.41006494},"labels":[],"label_agreement":null},{"id":"W2341528474","doi":"10.3747/co.23.2743","title":"Duration of Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer in Prolonged Remission","year":2016,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.13617154897183445,"score_gpt":0.5050269679512784,"score_spread":0.36885541897944396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2341528474","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0036934281,0.9904541,0.000013711909,0.00027872346,0.0004303101,0.004404363,0.00045421885,0.000012738208,0.0002584089],"genre_scores_gemma":[0.0035775013,0.99496484,0.000048960024,0.000007985503,0.00011329027,0.00094535656,0.00023265075,0.00005440123,0.000055013956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676836,0.00078889966,0.0009835028,0.0005212312,0.0005119866,0.00042599998],"domain_scores_gemma":[0.9984219,0.00026858595,0.0005518196,0.00029546305,0.0003182646,0.00014398669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005613704,0.00033059195,0.0020702826,0.00057815574,0.000018311244,0.0000044052877,0.00016937374,0.00024986232,0.00035006015],"category_scores_gemma":[0.00015326923,0.00019949717,0.00012292074,0.0006199985,0.00016659002,0.000063988526,0.0000660735,0.0008346293,0.000017358627],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062361185,0.0014117841,0.014674162,0.01423867,0.00008459968,0.000033152628,0.00020480083,2.4861518e-7,0.0000011511663,0.000004714046,0.00020950753,0.9685136],"study_design_scores_gemma":[0.009809402,0.0041188244,0.08573942,0.21605727,0.00082786375,0.000078968624,0.000040371502,0.000013046666,0.000008851759,0.00001712319,0.682783,0.0005058774],"about_ca_topic_score_codex":0.00008079582,"about_ca_topic_score_gemma":0.00030104237,"teacher_disagreement_score":0.96800774,"about_ca_system_score_codex":0.0035239796,"about_ca_system_score_gemma":0.0035079936,"threshold_uncertainty_score":0.92150843},"labels":[],"label_agreement":null},{"id":"W2343337356","doi":"10.1038/modpathol.2016.74","title":"A systematic comparison of three commercial estrogen receptor assays in a single clinical outcome breast cancer cohort","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; Alberta Health Services","funders":"Breast Cancer Society of Canada; Calgary Laboratory Services","keywords":"Medicine; Breast cancer; Oncology; Cohort; Pathology; Estrogen receptor; Internal medicine; Univariate analysis; Concordance; Tamoxifen; Predictive value; Estrogen; Multivariate analysis; Gynecology; Cancer","score_opus":0.18187959293200343,"score_gpt":0.46552209598601646,"score_spread":0.28364250305401306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343337356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892971,0.000651196,0.003734215,0.004113385,0.00041527406,0.0012714716,0.00013083396,0.000045174525,0.00034132827],"genre_scores_gemma":[0.99844956,0.00004238763,0.00062171614,0.00020820754,0.0001885405,0.00028562272,0.000006749146,0.000043956312,0.00015324788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964116,0.00063263247,0.0014812412,0.00047753393,0.0004868841,0.0005100936],"domain_scores_gemma":[0.99803925,0.0005748456,0.0003045272,0.00068701094,0.00020683932,0.00018755032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019970548,0.00019673881,0.001593468,0.0001778289,0.000029449122,0.000006396327,0.00027409906,0.00033395112,0.00032858385],"category_scores_gemma":[0.00067665643,0.00013234268,0.00018527248,0.00017395217,0.0003833929,0.00004342473,0.00015031625,0.0004178138,0.00011107923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004016738,0.00065998925,0.9747006,0.0018821275,0.00008979195,0.000087691325,0.00024501787,0.0000040645423,0.009614169,0.000058645328,0.00039847684,0.011857707],"study_design_scores_gemma":[0.0038702677,0.00079481705,0.9883517,0.003993322,0.00018759805,0.00022532958,0.000050178933,0.0012310669,0.0007661496,0.0002272335,0.000077864766,0.0002244411],"about_ca_topic_score_codex":0.00031911148,"about_ca_topic_score_gemma":0.0011428585,"teacher_disagreement_score":0.013651085,"about_ca_system_score_codex":0.00040118032,"about_ca_system_score_gemma":0.0002638712,"threshold_uncertainty_score":0.5396778},"labels":[],"label_agreement":null},{"id":"W2343845543","doi":"10.1007/s10549-016-3812-1","title":"Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Hôpital Charles-Le Moyne; Juravinski Cancer Centre; University Health Network; Hamilton Health Sciences; Princess Margaret Cancer Centre; Kingston General Hospital; Interior Health; Ottawa Hospital; BC Cancer Agency; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ipsen; AstraZeneca; Celgene; Genomic Health; Cancer Care Ontario; Pfizer; Cancer Research Institute","keywords":"Medicine; Internal medicine; PTEN; Cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Progressive disease; Metastatic breast cancer; Triple-negative breast cancer; Estrogen receptor; Clinical endpoint; Adverse effect; Clinical trial; Disease; Biology; PI3K/AKT/mTOR pathway","score_opus":0.12762285403095874,"score_gpt":0.4400756633405633,"score_spread":0.31245280930960456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343845543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699857,0.0012245558,9.642941e-7,0.0049915677,0.00013152452,0.008871657,0.0147420745,0.000028297172,0.000023622923],"genre_scores_gemma":[0.98702204,0.0032490292,0.00013661258,0.00003342523,0.0002385433,0.00857873,0.00013106246,0.00011597564,0.00049455307],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929707,0.0013433492,0.0010954667,0.0013039592,0.0016550021,0.001631541],"domain_scores_gemma":[0.99567777,0.00055721926,0.00037789563,0.0005508632,0.0011932792,0.0016429849],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013816219,0.000674206,0.0016748,0.0009543069,0.0004669993,0.000081982296,0.0002619687,0.00015489584,0.0039845253],"category_scores_gemma":[0.00020723902,0.00037297455,0.000099915844,0.0010144943,0.00067566545,0.00033413369,0.0001884327,0.0004918258,0.000007406356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026637692,0.006821732,0.5959875,0.00026309508,0.001418397,0.000046519235,0.002815307,2.1703819e-7,0.0007413381,0.00002745867,0.0007006662,0.36454007],"study_design_scores_gemma":[0.12310858,0.07292167,0.78897256,0.005066504,0.0004926612,0.00004534132,0.0022487591,0.000004951173,0.0043579345,0.000052178682,0.0018025406,0.0009263007],"about_ca_topic_score_codex":0.47958815,"about_ca_topic_score_gemma":0.48549688,"teacher_disagreement_score":0.36361375,"about_ca_system_score_codex":0.005713955,"about_ca_system_score_gemma":0.0036539382,"threshold_uncertainty_score":0.9998722},"labels":[],"label_agreement":null},{"id":"W2344122381","doi":"10.1038/onc.2016.109","title":"ErbB2-dependent downregulation of a pro-apoptotic protein Perp is required for oncogenic transformation of breast epithelial cells","year":2016,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Anoikis; Downregulation and upregulation; Biology; Cancer research; Lapatinib; Cell biology; Epidermal growth factor receptor; Carcinogenesis; Apoptosis; Cancer; Breast cancer; Programmed cell death","score_opus":0.039807096853957544,"score_gpt":0.3321288980800575,"score_spread":0.29232180122609996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344122381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836978,0.000114643786,0.008437353,0.002500799,0.00008707154,0.0036851317,0.00081785646,0.000033339715,0.00062603765],"genre_scores_gemma":[0.99557316,0.000046450685,0.0020057936,0.000030778723,0.00019947422,0.00030193213,0.00003722311,0.00004167929,0.001763489],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787045,0.00007460752,0.0006717067,0.00028782376,0.00075920275,0.00033622014],"domain_scores_gemma":[0.99862546,0.00006764549,0.00023848707,0.0004150954,0.0005104238,0.00014287101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007267432,0.00016699932,0.00042281993,0.00018457315,0.00004142284,0.000006617991,0.00015041785,0.00015684697,0.00040807758],"category_scores_gemma":[0.00006614289,0.00011813452,0.00021229073,0.0002132595,0.00012608634,0.0001469578,0.000024578156,0.000075115124,0.00004740217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014842334,0.00021310593,0.000066023844,0.00080521655,0.000076736294,0.0000014657893,0.00076032494,0.0000039814536,0.90884453,0.00010422026,0.00012450649,0.087515645],"study_design_scores_gemma":[0.0045818053,0.0011528933,0.0007936205,0.0005793046,0.00010458387,0.000032186035,0.000078062796,0.0002835404,0.99054885,0.00028603146,0.0014284179,0.00013071734],"about_ca_topic_score_codex":0.000079400554,"about_ca_topic_score_gemma":0.000019679357,"teacher_disagreement_score":0.087384924,"about_ca_system_score_codex":0.0003137613,"about_ca_system_score_gemma":0.0005732388,"threshold_uncertainty_score":0.4817386},"labels":[],"label_agreement":null},{"id":"W2346540202","doi":"10.1038/onc.2016.129","title":"The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment","year":2016,"lang":"en","type":"article","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Terry Fox Foundation; Susan G. Komen; U.S. Department of Defense; McGill University; Genentech; Susan G. Komen for the Cure","keywords":"Biology; Cancer research; Breast cancer; Oncogene; Metastasis; Cancer; Mammary gland; Carcinogenesis; Alternative splicing; Exon; Gene; Genetics; Cell cycle","score_opus":0.03296888147554756,"score_gpt":0.32506167720448775,"score_spread":0.2920927957289402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346540202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9377049,0.0045784535,0.00008810021,0.05349694,0.00023643042,0.002696633,0.0003799344,0.000054665175,0.00076389784],"genre_scores_gemma":[0.9810018,0.004163004,0.0011453587,0.002139038,0.0003576774,0.0013616645,0.000006740474,0.00012639827,0.009698304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969372,0.00018125227,0.00043315973,0.00066640973,0.00087254285,0.0009094081],"domain_scores_gemma":[0.9983923,0.00021560807,0.00014703012,0.000847387,0.00007622463,0.00032148015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076975324,0.0003145313,0.00043706645,0.00012751913,0.00015194893,0.00003601025,0.00039072192,0.00006897751,0.0022437351],"category_scores_gemma":[0.00005952793,0.00016869421,0.0001506183,0.00033803633,0.00030799184,0.00009763623,0.0002194741,0.00029144154,0.0006444087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010524885,0.0007442577,0.058908425,0.00029307924,0.0004248167,0.0013006573,0.0010317784,9.304054e-7,0.7912768,0.00004068178,0.012188467,0.13273759],"study_design_scores_gemma":[0.018210817,0.001317079,0.17294683,0.0039654807,0.00069023983,0.004434269,0.00073043315,0.00033926958,0.4566227,0.00062388304,0.3387729,0.0013461208],"about_ca_topic_score_codex":0.0010144354,"about_ca_topic_score_gemma":0.000577341,"teacher_disagreement_score":0.33465412,"about_ca_system_score_codex":0.0013292157,"about_ca_system_score_gemma":0.0008063018,"threshold_uncertainty_score":0.9986684},"labels":[],"label_agreement":null},{"id":"W2348629818","doi":"10.1016/j.gheart.2014.03.2169","title":"PW005 Safety and efficacy of dabigatran compared to warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation","year":2014,"lang":"en","type":"article","venue":"Global Heart","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Rheumatoid arthritis; Transforming growth factor; Angiogenesis; Apoptosis; Arthritis; Dabigatran; Cancer research; Atrial fibrillation; Immunology; Internal medicine; Warfarin; Biology","score_opus":0.03463131366891612,"score_gpt":0.3618158134097806,"score_spread":0.32718449974086444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2348629818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916223,0.00005661089,0.004741765,0.00082254776,0.00016233149,0.0023674208,0.000057260248,0.000021569154,0.000148145],"genre_scores_gemma":[0.99286216,0.000007867472,0.0066145626,0.00005705135,0.00026928016,0.00000901357,0.00015602204,0.000012300498,0.000011730193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987811,0.00004771353,0.00039940767,0.0002525096,0.00026760006,0.0002517007],"domain_scores_gemma":[0.9992953,0.00020347904,0.000062338026,0.00014129789,0.0001830508,0.00011455403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004056226,0.000101977916,0.00030960134,0.000076172706,0.000065995446,0.000015101337,0.000036992256,0.00008099508,0.0000058152355],"category_scores_gemma":[0.00077207474,0.00010341177,0.000079742815,0.00021724272,0.000034186003,0.00008754651,0.00001667537,0.000044467808,0.0000018958943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061605666,0.000042726504,0.93935764,0.00057956134,0.000021488728,9.132485e-8,0.00023656222,0.0039023778,0.000913816,0.0009904657,0.00025076908,0.047543965],"study_design_scores_gemma":[0.010011081,0.0011474602,0.95709693,0.00023307386,0.000028921046,0.0000027047306,0.000018838302,0.027743133,0.0003396295,0.00027570705,0.0029976491,0.00010485958],"about_ca_topic_score_codex":0.00014629097,"about_ca_topic_score_gemma":0.00010268117,"teacher_disagreement_score":0.047439106,"about_ca_system_score_codex":0.00031853342,"about_ca_system_score_gemma":0.0001429946,"threshold_uncertainty_score":0.42170095},"labels":[],"label_agreement":null},{"id":"W2356610050","doi":"10.1097/pai.0000000000000393","title":"The International Society for Immunohistochemistry and Molecular Morphology (ISIMM)","year":2016,"lang":"en","type":"editorial","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Excellence; Medicine; Pathology; Political science; Law","score_opus":0.008141490304131496,"score_gpt":0.3298680063074395,"score_spread":0.32172651600330804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2356610050","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.115365624,0.07659005,0.0075273267,0.016266493,0.7254486,0.009032943,0.0031041298,0.00080307206,0.045861773],"genre_scores_gemma":[0.09595328,0.019092752,0.018850697,0.008356171,0.72673225,0.026423844,0.022114385,0.0031754847,0.07930114],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933025,0.000058717207,0.0013035457,0.002172575,0.0015415949,0.0016210313],"domain_scores_gemma":[0.99371237,0.0012949597,0.0007631167,0.00274926,0.0010937956,0.0003865175],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012131203,0.0011926953,0.0014733011,0.00011409397,0.00056369964,0.00015415683,0.0020965536,0.003187552,0.00024453108],"category_scores_gemma":[0.0015255709,0.0010169588,0.0011532598,0.00021944028,0.0025023497,0.00003911568,0.0011775596,0.002882333,0.000073016425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076419674,0.000064829415,9.852331e-7,0.00029267446,0.0008891314,0.00018447652,0.000027154325,3.815712e-7,0.52375025,0.00013898332,0.47279644,0.0010904912],"study_design_scores_gemma":[0.0041790367,0.00020817749,0.0000022040267,0.00019136739,0.0004925346,0.00043314876,0.000073414405,0.0000074302675,0.38647592,0.0007695351,0.60636824,0.0007989847],"about_ca_topic_score_codex":0.000053892938,"about_ca_topic_score_gemma":7.778598e-8,"teacher_disagreement_score":0.13727435,"about_ca_system_score_codex":0.0022395456,"about_ca_system_score_gemma":0.002525864,"threshold_uncertainty_score":0.9994181},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","score_opus":0.0391025579184239,"score_gpt":0.3926124320995352,"score_spread":0.35350987418111135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2379981061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195963,0.00014583787,0.000084337895,0.002201405,0.00010013136,0.004381781,0.00053197204,0.000022694263,0.00057221384],"genre_scores_gemma":[0.99691164,0.00090649474,0.0004117213,0.00035562928,0.00015826874,0.0005735823,0.00002136768,0.000045279892,0.0006160266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99701023,0.0006587361,0.0006393618,0.00052728795,0.0005145281,0.0006498341],"domain_scores_gemma":[0.9975587,0.0009272776,0.00035278735,0.00058657036,0.00035239424,0.00022225226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009315777,0.0002798767,0.0016708447,0.00017698445,0.00007588004,0.000027188584,0.00045923115,0.0001639564,0.0010567012],"category_scores_gemma":[0.00025820133,0.00013603267,0.000069626774,0.0006935148,0.0005247497,0.00016406765,0.00020000011,0.00035733794,0.000008250068],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.80430627,0.0019323777,0.080806665,0.000069502596,0.0012644838,0.00012750982,0.0011836339,0.00002165848,0.00031059227,0.000025383479,0.00020121863,0.109750725],"study_design_scores_gemma":[0.800248,0.010094863,0.18535934,0.00044183873,0.0008347936,0.000008658558,0.000311298,0.0003504642,0.00017814893,0.0000052797927,0.0019486233,0.00021865466],"about_ca_topic_score_codex":0.0014808715,"about_ca_topic_score_gemma":0.0058472753,"teacher_disagreement_score":0.10953207,"about_ca_system_score_codex":0.0008623668,"about_ca_system_score_gemma":0.0012301556,"threshold_uncertainty_score":0.9998565},"labels":[],"label_agreement":null},{"id":"W2384003525","doi":"10.1097/pai.0000000000000372","title":"Paraffin-embedded Tissue Fragment Suspension (PETFS): A Novel Method for Quality Control Preparation in Immunohistochemistry","year":2016,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"University of Texas Medical Branch","keywords":"Immunohistochemistry; Staining; Pathology; Medicine","score_opus":0.02159386153486607,"score_gpt":0.4028005810116338,"score_spread":0.3812067194767677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2384003525","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6744595,0.0013328848,0.3147947,0.0019395812,0.00023750027,0.0032555638,0.00010559112,0.00015863604,0.0037160756],"genre_scores_gemma":[0.9574926,0.000036916266,0.036549244,0.0008889663,0.0001245994,0.0029548523,0.00026194841,0.00012352821,0.0015673647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99540436,0.00014152518,0.0013011551,0.0014136286,0.00067013816,0.001069179],"domain_scores_gemma":[0.9965507,0.0005623153,0.0004458547,0.0018089816,0.0003656609,0.00026648422],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015745544,0.0005927302,0.0011753212,0.00015661985,0.00013747733,0.000026237365,0.0005259328,0.0007384049,0.0005211871],"category_scores_gemma":[0.00074404955,0.00054094085,0.0002866858,0.0003198802,0.00040016943,0.000053901444,0.00017878285,0.00059267756,0.00007321781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045188833,0.00050967594,0.000029169436,0.0003190327,0.00016372686,0.00010605575,0.0001402696,0.0000358035,0.98650545,0.0006318405,0.0014002299,0.0056398455],"study_design_scores_gemma":[0.013148171,0.00036102344,0.00032952003,0.0001884997,0.00012708374,0.00038850907,0.00008734443,0.00011207986,0.98234,0.000399647,0.0019448788,0.00057328376],"about_ca_topic_score_codex":0.00017243015,"about_ca_topic_score_gemma":8.412295e-7,"teacher_disagreement_score":0.2830331,"about_ca_system_score_codex":0.0018119467,"about_ca_system_score_gemma":0.00071515905,"threshold_uncertainty_score":0.99970424},"labels":[],"label_agreement":null},{"id":"W2394193965","doi":"","title":"Expression of ERα and ERβ in normal human mammary gland and significance","year":2009,"lang":"en","type":"article","venue":"Journal of Jilin University","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Mammary gland; Stromal cell; Epithelium; Biology; Pathology; Myoepithelial cell; Staining; Endocrinology; Internal medicine; Medicine; Cancer research; Immunology; Breast cancer; Cancer","score_opus":0.02180350288837481,"score_gpt":0.30066919022028343,"score_spread":0.27886568733190864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2394193965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99724406,0.0003776176,0.00007017696,0.0006042587,0.00001944798,0.000067841014,0.0000021736553,0.0000021645117,0.001612255],"genre_scores_gemma":[0.99815506,0.00056783017,0.00083759415,0.000030950407,0.000040336796,1.4217269e-8,3.9504434e-7,0.0000021235244,0.00036571434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99940723,0.00005389548,0.00015003036,0.00007799657,0.00021117064,0.00009970377],"domain_scores_gemma":[0.99955344,0.000036659523,0.00010740155,0.00008225445,0.0000994579,0.00012078245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033297215,0.000050000504,0.0001972082,0.00018335982,0.00003437008,0.000004648609,0.00007965614,0.000052814234,0.000023366942],"category_scores_gemma":[0.00003223316,0.000044738794,0.000026610953,0.00011145799,0.00007267892,0.00014941789,0.000038575352,0.00026487323,1.6221558e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002481524,0.00034251643,0.5439934,0.00025955986,0.000027226855,0.002043303,0.0012354585,0.000013587896,0.432059,0.0002662738,0.0022435777,0.015034581],"study_design_scores_gemma":[0.0041348855,0.0013135348,0.9662512,0.000511666,0.000026138425,0.00017068585,0.00054977526,0.000044918303,0.023397278,0.00019654974,0.0033282817,0.000075071715],"about_ca_topic_score_codex":0.000038135317,"about_ca_topic_score_gemma":0.000018498858,"teacher_disagreement_score":0.4222578,"about_ca_system_score_codex":0.00007266986,"about_ca_system_score_gemma":0.00011327102,"threshold_uncertainty_score":0.1824395},"labels":[],"label_agreement":null},{"id":"W2397992828","doi":"10.1093/annonc/mdv336.12","title":"First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (NEO)adjuvant trastuzumab","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Lapatinib; Trastuzumab; Medicine; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Adjuvant therapy; Adjuvant; Cohort; Cancer","score_opus":0.1588409169490382,"score_gpt":0.45825894837672276,"score_spread":0.29941803142768453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397992828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810307,0.0009964238,0.000042823438,0.0145588685,0.00026542987,0.0016525197,0.0005640121,0.000031944244,0.0008572774],"genre_scores_gemma":[0.9931871,0.0008847791,0.0004991584,0.004175875,0.00016711227,0.0006998161,0.00006627837,0.00006771135,0.00025213716],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966857,0.00043384644,0.0008381557,0.0005166269,0.0007764344,0.0007492549],"domain_scores_gemma":[0.9973054,0.00042372715,0.0002705228,0.00038076905,0.0011727811,0.00044683472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089904055,0.00032942928,0.0011022903,0.0003651423,0.000042409043,0.000012944476,0.00024771155,0.00020658699,0.0013345366],"category_scores_gemma":[0.00033384137,0.00024408649,0.00015978616,0.0005932039,0.0003316787,0.00011260972,0.000061104,0.00048649465,0.00004801163],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053246588,0.014914503,0.20700468,0.0005929824,0.0006143455,0.0012298912,0.00849509,0.00052322814,0.00024236075,0.000009980585,0.013863996,0.6992624],"study_design_scores_gemma":[0.032955017,0.059018534,0.8561931,0.0012606157,0.00014533324,0.00007302514,0.000685953,0.0014144675,0.0062716273,0.000121611156,0.04125327,0.0006074103],"about_ca_topic_score_codex":0.0023920874,"about_ca_topic_score_gemma":0.005356982,"teacher_disagreement_score":0.69865495,"about_ca_system_score_codex":0.000674,"about_ca_system_score_gemma":0.0033637877,"threshold_uncertainty_score":0.99957836},"labels":[],"label_agreement":null},{"id":"W2398096674","doi":"10.1097/pas.0000000000000375","title":"Quantification of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Using the Ventana Image Analysis System","year":2015,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Pharmacists Association","funders":"","keywords":"Immunohistochemistry; Pathology; Medicine; Anatomy","score_opus":0.0825704966981115,"score_gpt":0.40592924277059794,"score_spread":0.32335874607248644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398096674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591184,0.0005947513,0.0010468866,0.0018701187,0.00011830974,0.00012069144,0.000016893207,0.00000901885,0.00031149204],"genre_scores_gemma":[0.99893814,0.00006613058,0.0006345689,0.00004073938,0.00025347157,0.0000031457262,0.000005818062,0.000017340362,0.00004062225],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972397,0.00091848907,0.0008043024,0.0001599701,0.00061344646,0.00026405658],"domain_scores_gemma":[0.99706703,0.00032060436,0.0011685535,0.00048839714,0.00076190033,0.00019348308],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002359355,0.00013080568,0.0008327091,0.00018498117,0.000100914134,0.0000136711715,0.0004313147,0.000051453335,0.00011405725],"category_scores_gemma":[0.00024848504,0.00007145986,0.00037070818,0.00086741324,0.0014140921,0.000047905745,0.000070034956,0.0005793016,0.000006924779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018807473,0.00022714924,0.024030827,0.00011893851,0.0010502501,0.0010264714,0.0015295108,0.000103330945,0.9663111,0.00022992029,0.0007273332,0.002764451],"study_design_scores_gemma":[0.017862322,0.018341243,0.25450397,0.001546252,0.014625676,0.06893815,0.09811218,0.005879098,0.5113567,0.0006021122,0.006161026,0.0020712363],"about_ca_topic_score_codex":0.00022045517,"about_ca_topic_score_gemma":8.700979e-7,"teacher_disagreement_score":0.45495433,"about_ca_system_score_codex":0.00035792374,"about_ca_system_score_gemma":0.00026205252,"threshold_uncertainty_score":0.52102816},"labels":[],"label_agreement":null},{"id":"W2400932267","doi":"10.1200/jco.2001.19.18.3795","title":"Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?","year":2001,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Citation; Medicine; Clinical Oncology; Breast cancer; Oncology; Cancer; Internal medicine; Library science","score_opus":0.3115095867459364,"score_gpt":0.5702496648245066,"score_spread":0.2587400780785702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2400932267","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09961685,0.0013694378,0.000049382103,0.8952749,0.0019254519,0.0012888869,0.00022620527,0.0000072088856,0.00024167616],"genre_scores_gemma":[0.018732114,0.058034714,0.006217168,0.8728094,0.03908669,0.00008431318,0.000028161492,0.00019282095,0.004814603],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933007,0.00081477186,0.003723821,0.00048846053,0.0009119313,0.00076031015],"domain_scores_gemma":[0.98638964,0.009558093,0.0018214816,0.0003853517,0.0013306923,0.00051473285],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0038312795,0.00035439548,0.0037854775,0.00062361866,0.000029544468,0.000021360682,0.0004168587,0.0014057396,0.00073503226],"category_scores_gemma":[0.004476731,0.00025874184,0.00062981306,0.00040043658,0.00031980738,0.00014438214,0.000099948295,0.0055910037,0.0000045177308],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011581924,0.0005581209,0.02732311,0.00023717785,0.00054691284,0.0025443116,0.00010490624,0.000012785571,0.00014757644,0.0000031642867,0.77845055,0.17848948],"study_design_scores_gemma":[0.010109122,0.016548408,0.037890386,0.0008464818,0.00020047053,0.0019414674,0.00001894054,0.000018616656,0.000054401957,0.00009568752,0.9320783,0.00019773857],"about_ca_topic_score_codex":0.0006089751,"about_ca_topic_score_gemma":0.00075057254,"teacher_disagreement_score":0.17829174,"about_ca_system_score_codex":0.0006819207,"about_ca_system_score_gemma":0.005841567,"threshold_uncertainty_score":0.99998647},"labels":[],"label_agreement":null},{"id":"W2402233591","doi":"10.1200/jco.2016.67.0182","title":"Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":129,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Cancer Care Ontario; American Society of Clinical Oncology","keywords":"Medicine; Trastuzumab; Oncology; Docetaxel; Internal medicine; Guideline; Breast cancer; Taxane; Regimen; Carboplatin; Context (archaeology); Population; Anthracycline; Cancer; Gynecology; Chemotherapy; Pathology; Cisplatin","score_opus":0.1880175702403382,"score_gpt":0.5514264082407141,"score_spread":0.36340883800037593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2402233591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9329226,0.0007421565,0.012171488,0.048815522,0.0015765716,0.0029542288,0.0007120868,0.000016271726,0.00008907947],"genre_scores_gemma":[0.75926214,0.00762028,0.22333966,0.0057803537,0.0036120568,0.00010765647,0.000045619043,0.000095746,0.00013648567],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9857831,0.0028379154,0.009220058,0.00073130353,0.0008825757,0.000545053],"domain_scores_gemma":[0.96223456,0.013131504,0.011896664,0.00041848846,0.011749666,0.0005691337],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.013102326,0.00038251103,0.004139156,0.00012355456,0.0001319188,0.000007853254,0.00048637573,0.00091737614,0.00030238484],"category_scores_gemma":[0.010687575,0.00022738789,0.0016564255,0.00031806013,0.00226991,0.0003214072,0.00009678935,0.0015335,3.6410424e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06594611,0.0035838727,0.121072486,0.000109341614,0.0028614192,0.0000065141126,0.0035146773,0.00007741615,0.00469206,0.00003460938,0.02716114,0.77094036],"study_design_scores_gemma":[0.061756637,0.1823955,0.5112915,0.00079109933,0.0014287973,0.000158994,0.009443157,0.002335298,0.008310781,0.00016828006,0.22142866,0.00049127836],"about_ca_topic_score_codex":0.022106655,"about_ca_topic_score_gemma":0.023698114,"teacher_disagreement_score":0.7704491,"about_ca_system_score_codex":0.0016789504,"about_ca_system_score_gemma":0.018711917,"threshold_uncertainty_score":0.9976458},"labels":[],"label_agreement":null},{"id":"W2406500056","doi":"10.1158/1538-7445.sabcs15-pd5-04","title":"Abstract PD5-04: NSABP FB-7: A phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (N+T) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neratinib; Trastuzumab; Medicine; Pertuzumab; Internal medicine; Breast cancer; Regimen; Docetaxel; Oncology; Neoadjuvant therapy; Lapatinib; Metastatic breast cancer; Chemotherapy; Cancer","score_opus":0.050687440653441856,"score_gpt":0.424429407720223,"score_spread":0.3737419670667811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406500056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692052,0.0040569007,0.00021996329,0.010445783,0.00010082717,0.014758277,0.00081829197,0.00009225184,0.00030249124],"genre_scores_gemma":[0.97172004,0.00634518,0.00090510206,0.0006969451,0.00036370553,0.015834976,0.00003438325,0.00028075682,0.0038189287],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98929596,0.0016975146,0.0013050303,0.002134354,0.0031131394,0.0024540294],"domain_scores_gemma":[0.9928724,0.0029391649,0.00039160726,0.0008108276,0.001741447,0.0012445118],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005031714,0.0010848541,0.002719004,0.00055048167,0.0008542574,0.00034113086,0.00044442515,0.00032568295,0.0020394498],"category_scores_gemma":[0.00069981924,0.00051723426,0.000101611884,0.0016536147,0.0026385407,0.00078096526,0.00017898672,0.0018447425,0.000005467684],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.72927874,0.0010141702,0.00025361028,0.00016916957,0.0006774916,0.00068880914,0.008854296,0.000063856016,0.06474862,0.000008347954,0.000824506,0.1934184],"study_design_scores_gemma":[0.89578104,0.07384039,0.0015622346,0.0058542755,0.000114822345,0.00032128528,0.005978601,0.00040422534,0.014503202,0.000015846463,0.0006523374,0.00097173575],"about_ca_topic_score_codex":0.0058281776,"about_ca_topic_score_gemma":0.008493086,"teacher_disagreement_score":0.19244666,"about_ca_system_score_codex":0.0039610057,"about_ca_system_score_gemma":0.013026555,"threshold_uncertainty_score":0.9998626},"labels":[],"label_agreement":null},{"id":"W2407897745","doi":"","title":"[Expression of human epidermal growth factor receptor 2 in mucinous carcinoma of breast].","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Mucinous carcinoma; Epidermal growth factor receptor; Breast carcinoma; Human Epidermal Growth Factor Receptor 2; Cancer research; Oncology; Epidermal growth factor; Carcinoma; Internal medicine; Receptor; Biology; Medicine; Breast cancer; Adenocarcinoma; Cancer","score_opus":0.09909011265428457,"score_gpt":0.3295671305210075,"score_spread":0.23047701786672292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2407897745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99296266,0.00025699128,0.0000036734532,0.0005892091,0.00012691002,0.00087200396,0.000046934598,0.000019860505,0.005121772],"genre_scores_gemma":[0.99885875,0.000009335569,0.00013071552,0.000038774127,0.00015401987,0.00030693435,0.000015996755,0.000026869671,0.00045862945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99807924,0.0001411532,0.0004460816,0.0002424674,0.0006387978,0.00045226078],"domain_scores_gemma":[0.9987794,0.000072884766,0.00012536562,0.00036034122,0.00028861032,0.00037336728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006460864,0.00012158367,0.00043250172,0.0002646561,0.00001444973,0.0000044022486,0.00018183552,0.00011343591,0.0001877736],"category_scores_gemma":[0.000490593,0.00010236787,0.00007056958,0.00029719732,0.00012727351,0.00007933719,0.00010525595,0.00024784208,0.000008739854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046295678,0.00037137192,0.9336064,0.00046071087,0.000016036644,0.00003445844,0.0010616053,8.8574825e-7,0.026698727,0.000054012984,0.0052296077,0.03200327],"study_design_scores_gemma":[0.0019123607,0.00013970703,0.843807,0.00006414634,0.000007487266,0.000018238701,0.00012214674,0.0000055565392,0.15351874,0.000050734245,0.0002794772,0.00007445982],"about_ca_topic_score_codex":0.0014266393,"about_ca_topic_score_gemma":0.00003983958,"teacher_disagreement_score":0.12682,"about_ca_system_score_codex":0.00024715543,"about_ca_system_score_gemma":0.00019856736,"threshold_uncertainty_score":0.41744405},"labels":[],"label_agreement":null},{"id":"W2408503479","doi":"10.1158/1538-7445.sabcs15-p4-14-01","title":"Abstract P4-14-01: Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Capecitabine; Lapatinib; Trastuzumab emtansine; Medicine; Taxane; Trastuzumab; Interim analysis; Internal medicine; Metastatic breast cancer; Gastroenterology; Confidence interval; Hazard ratio; Breast cancer; Cancer; Oncology; Randomized controlled trial","score_opus":0.07246694683704773,"score_gpt":0.4110668480894483,"score_spread":0.3385999012524006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2408503479","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823774,0.0007490593,0.0000028397146,0.0042712423,0.00038161592,0.0058267512,0.005695973,0.00008283571,0.00061225134],"genre_scores_gemma":[0.995156,0.0010546073,0.000028655733,0.00006543592,0.00065305654,0.001555479,0.00029117384,0.00015422858,0.0010413904],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9914957,0.00079990964,0.00096798287,0.0016007071,0.003275925,0.0018597665],"domain_scores_gemma":[0.9935454,0.0023498351,0.00024096295,0.001413643,0.001832861,0.00061728933],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018169577,0.00060992874,0.0010020387,0.0003320386,0.00035596648,0.00011732257,0.00081993925,0.0002088823,0.0011416655],"category_scores_gemma":[0.0009904696,0.00034982467,0.0001247121,0.0013577219,0.000734516,0.00038422283,0.00026667517,0.0015733773,0.000053239437],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45121086,0.0063637663,0.23645912,0.00022007742,0.0011481588,0.00082162215,0.006681642,0.000080374586,0.02005894,0.000006554071,0.0054202457,0.27152866],"study_design_scores_gemma":[0.1354842,0.007533088,0.85030806,0.0020592224,0.00010080898,0.0000025970228,0.00092645345,0.00003115796,0.002359649,0.00000817607,0.0007403882,0.00044618556],"about_ca_topic_score_codex":0.063254856,"about_ca_topic_score_gemma":0.05291028,"teacher_disagreement_score":0.6138489,"about_ca_system_score_codex":0.005190004,"about_ca_system_score_gemma":0.0036915678,"threshold_uncertainty_score":0.9998954},"labels":[],"label_agreement":null},{"id":"W2409578170","doi":"10.1038/modpathol.2008.131","title":"Letter to the Editor","year":2008,"lang":"en","type":"letter","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Pathology; Medicine; Medical physics","score_opus":0.054108918829823174,"score_gpt":0.3420044143705634,"score_spread":0.28789549554074023,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409578170","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046054422,0.0005270433,0.0015090855,0.9833954,0.008133207,0.0009323248,0.00008063131,0.00009828381,0.0048634736],"genre_scores_gemma":[0.00031083974,0.0000829296,0.00034257406,0.7798648,0.18979307,0.0003315447,0.0001247445,0.00011792168,0.0290316],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968173,0.00031408572,0.0003203881,0.00077549234,0.0008579881,0.00091473816],"domain_scores_gemma":[0.99789476,0.00018600661,0.00006757024,0.0015520047,0.00016860575,0.00013102722],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003509082,0.00033978283,0.0006091988,0.00023557035,0.00012719085,0.000021292533,0.0005866033,0.0013538497,0.0004810774],"category_scores_gemma":[0.00021819805,0.00022624404,0.0001964355,0.00016017274,0.0002747301,0.000018826702,0.00027167026,0.0045751412,0.0035357003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003483881,0.000018230427,0.00009380437,0.00009071406,0.000033241544,0.012985833,0.0005398618,0.0000041207527,0.00031774506,6.7534825e-7,0.98247373,0.0034072115],"study_design_scores_gemma":[0.0003192625,0.00026147786,0.00020750698,0.000060803814,0.000041288902,0.0015697352,0.0000020395596,0.000044711913,0.00010514314,0.00006861072,0.9971074,0.00021205378],"about_ca_topic_score_codex":0.00004033695,"about_ca_topic_score_gemma":0.00001504974,"teacher_disagreement_score":0.20353062,"about_ca_system_score_codex":0.00023874982,"about_ca_system_score_gemma":0.00032718905,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W2410015475","doi":"","title":"AR47A6.4.2, a functional naked monoclonal antibody targeting Trop-2, demonstrates in vivo efficacy in human pancreatic, colon, breast and prostate cancer models","year":2007,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Pancreatic cancer; In vivo; Cancer research; Monoclonal antibody; Cancer; Cytotoxicity; Antibody; Signal transduction; Prostate cancer; Colorectal cancer; Biology; In vitro; Immunology; Medicine; Internal medicine; Cell biology; Biochemistry","score_opus":0.041043055824262084,"score_gpt":0.36784482769629,"score_spread":0.3268017718720279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410015475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484975,0.010634826,0.0011228309,0.0014569365,0.00010931541,0.0011503154,0.00007528448,0.000052690637,0.00054803723],"genre_scores_gemma":[0.9959936,0.0018144579,0.0006264129,0.00087069336,0.0001534318,0.00020785182,0.000043124317,0.00009442063,0.000196019],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969558,0.00013738824,0.0006499093,0.00063361344,0.00070133334,0.00092195603],"domain_scores_gemma":[0.9990167,0.00010566431,0.00013042921,0.0002813674,0.00022766738,0.00023816047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079020456,0.0003622435,0.0005523955,0.0003724781,0.00012334311,0.00005850806,0.00014652338,0.00021254338,0.00019673021],"category_scores_gemma":[0.000016125867,0.00034986367,0.000091450565,0.0007199071,0.00028042792,0.00011490849,0.000070517766,0.00071619067,0.0000020066361],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015046021,0.0004550621,0.234239,0.00020471947,0.0002406958,0.00047927906,0.0010386949,0.0034194107,0.7442846,0.00035781623,0.000056462923,0.013719688],"study_design_scores_gemma":[0.028467847,0.0014168425,0.6172762,0.003013006,0.0005962345,0.00038490357,0.0015266697,0.049604267,0.28672168,0.0024423434,0.006471777,0.002078214],"about_ca_topic_score_codex":0.0023903577,"about_ca_topic_score_gemma":0.0013367815,"teacher_disagreement_score":0.4575629,"about_ca_system_score_codex":0.00072542264,"about_ca_system_score_gemma":0.000661239,"threshold_uncertainty_score":0.99989533},"labels":[],"label_agreement":null},{"id":"W2414802120","doi":"10.1038/sj.gt.3301712","title":"Intratumoral administration of an adenovirus expressing a kinase dead form of ErbB-2 inhibits tumor growth","year":2002,"lang":"en","type":"article","venue":"Gene Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Breast Cancer Society of Canada","keywords":"Immune system; Cancer research; Biology; ErbB; Receptor; Immunology","score_opus":0.07684677624089369,"score_gpt":0.3485078335019935,"score_spread":0.2716610572610998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2414802120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564004,0.0024901994,0.000065327025,0.00031320265,0.00006240831,0.00044932045,0.000023181186,0.00003495339,0.0009213833],"genre_scores_gemma":[0.996448,0.00046873075,0.0024480172,0.00021961262,0.0002226814,0.00002466934,0.000018379964,0.00003661791,0.000113335496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998443,0.00007787746,0.0004092384,0.00024631745,0.00052302855,0.00030051876],"domain_scores_gemma":[0.9990284,0.000031871117,0.0001552658,0.00039420466,0.00022028758,0.00016998188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003006806,0.00015069832,0.00033034978,0.00015002138,0.00004580561,0.000017042492,0.00015276596,0.00007057046,0.00048875797],"category_scores_gemma":[0.000051297837,0.00013269842,0.000075220385,0.0003011429,0.00014424027,0.0001535595,0.00002127505,0.00019296267,0.000010536813],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011745603,0.00055310695,0.0012861383,0.00014522063,0.000033477612,0.00009851575,0.0017855169,0.0000011140895,0.9358755,0.000066384186,0.00034105324,0.058639433],"study_design_scores_gemma":[0.0021138636,0.0028181558,0.0034751855,0.00014504636,0.000012503277,0.00010701652,0.00013657038,0.00030348322,0.9900679,0.00029637176,0.00040732673,0.00011659825],"about_ca_topic_score_codex":0.000079635065,"about_ca_topic_score_gemma":0.000024808518,"teacher_disagreement_score":0.058522835,"about_ca_system_score_codex":0.00007248963,"about_ca_system_score_gemma":0.00019978847,"threshold_uncertainty_score":0.54112846},"labels":[],"label_agreement":null},{"id":"W2418561090","doi":"10.1186/s12885-016-2385-z","title":"HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer","year":2016,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Pertuzumab; Anthracycline; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Vinorelbine; Cardiotoxicity; Chemotherapy; Cancer","score_opus":0.02509831432039076,"score_gpt":0.3684742946253877,"score_spread":0.34337598030499694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2418561090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98703104,0.0014782224,0.00069035724,0.00050806015,0.00042543883,0.008360045,0.0010702064,0.000058989885,0.00037763905],"genre_scores_gemma":[0.9930308,0.0027337556,0.0004414088,0.00016933892,0.00037627073,0.0023893383,0.000057598078,0.00017806079,0.0006234335],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99454045,0.0005353856,0.0014880284,0.00094280473,0.0015430714,0.0009502486],"domain_scores_gemma":[0.99594504,0.0012028262,0.0008942185,0.0007646115,0.0008530853,0.00034021208],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000632346,0.00066919375,0.002792123,0.0003804949,0.00006562121,0.00001879589,0.00029457678,0.00017246947,0.0008218769],"category_scores_gemma":[0.00028079448,0.0004401036,0.0004483113,0.001021253,0.0008663177,0.00032857846,0.000053672848,0.00038841384,0.000007657238],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86212945,0.003186422,0.0037638792,0.0006748433,0.00079000014,0.000025221163,0.000589327,0.00038099813,0.0013701185,0.0000058756727,0.00026385547,0.12682001],"study_design_scores_gemma":[0.96617997,0.0055405833,0.014695621,0.00474198,0.0006119825,0.000006532166,0.0001197974,0.0004773036,0.006874633,0.000008982853,0.00023293137,0.00050966046],"about_ca_topic_score_codex":0.0051072184,"about_ca_topic_score_gemma":0.0032054156,"teacher_disagreement_score":0.12631035,"about_ca_system_score_codex":0.002942145,"about_ca_system_score_gemma":0.0036978126,"threshold_uncertainty_score":0.9998051},"labels":[],"label_agreement":null},{"id":"W2435490795","doi":"10.1200/jco.2014.32.15_suppl.2530","title":"A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Adverse effect; Nausea; Gastroenterology; Cancer; Vomiting; Paclitaxel; Oncology; Discontinuation; Pharmacology","score_opus":0.11987352055479122,"score_gpt":0.4955037543018407,"score_spread":0.37563023374704946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2435490795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958003,0.0001258374,0.000018144901,0.0017904933,0.0005616537,0.0010064085,0.000008657712,0.000004144695,0.0006843214],"genre_scores_gemma":[0.9982065,0.000050597537,0.00039606076,0.00072692777,0.00033230914,0.000032359592,5.036456e-7,0.00003068161,0.000224084],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509764,0.0009935979,0.0021911762,0.00028705617,0.0010843291,0.00034618526],"domain_scores_gemma":[0.99503696,0.0011681482,0.0020135546,0.0004809425,0.0009449821,0.0003554395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029723803,0.00017874477,0.001565992,0.00013117213,0.000035961915,0.000007350642,0.00037345738,0.00020187139,0.000051672556],"category_scores_gemma":[0.00078957697,0.000088639295,0.00016530616,0.0003796662,0.00038619738,0.000092628834,0.00010132732,0.001276138,0.0000024827455],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032046616,0.031724308,0.8350182,0.00012377824,0.00017027625,0.00013617489,0.00081569643,0.000038676935,0.00011100583,0.0000037433247,0.0007544245,0.09905708],"study_design_scores_gemma":[0.13846304,0.23148575,0.6152222,0.00086802663,0.00025668158,0.000019065932,0.0015043404,0.00003290622,0.00049841113,0.000009885243,0.011501848,0.00013782691],"about_ca_topic_score_codex":0.000055990567,"about_ca_topic_score_gemma":0.0006959904,"teacher_disagreement_score":0.219796,"about_ca_system_score_codex":0.0003148879,"about_ca_system_score_gemma":0.0029051136,"threshold_uncertainty_score":0.55442554},"labels":[],"label_agreement":null},{"id":"W2442066587","doi":"10.1016/j.clbc.2016.06.004","title":"Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer","year":2016,"lang":"en","type":"review","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Breast cancer; Hormone; Blockade; Internal medicine; Oncology; Cancer; Hormone receptor; Gynecology; Endocrinology; Receptor","score_opus":0.07345930812789521,"score_gpt":0.42714991484241327,"score_spread":0.3536906067145181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2442066587","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045064986,0.9279253,0.0000016684486,0.00096248556,0.00061865884,0.005572472,0.019217247,0.000052225147,0.00058498955],"genre_scores_gemma":[0.02717349,0.9693309,0.00010984058,0.00008063205,0.0011027417,0.0013685258,0.00011832271,0.00024412351,0.00047143176],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9927317,0.0004864744,0.002682434,0.0014579911,0.001589708,0.0010517074],"domain_scores_gemma":[0.99360764,0.0013831373,0.0015304537,0.0010760045,0.0017751909,0.0006275735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000773916,0.000988792,0.0048751775,0.00046659715,0.00005362994,0.00002426765,0.0005790567,0.0009211845,0.00085027417],"category_scores_gemma":[0.00028724808,0.0006146308,0.0008855711,0.0010045453,0.0014911685,0.00019049033,0.00039296976,0.0016237327,0.000047607253],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020443752,0.0011565497,0.057008788,0.006799184,0.002290116,0.000077628036,0.00013595725,0.0000010998177,0.0000026610685,0.000008009398,0.0008285701,0.9112477],"study_design_scores_gemma":[0.02641931,0.0048813913,0.83617854,0.096856385,0.0035015664,0.000077935874,0.00005027534,0.000003173424,0.000016899796,0.000016885375,0.03081547,0.001182183],"about_ca_topic_score_codex":0.0032076498,"about_ca_topic_score_gemma":0.0005916424,"teacher_disagreement_score":0.9100655,"about_ca_system_score_codex":0.001527901,"about_ca_system_score_gemma":0.0039731767,"threshold_uncertainty_score":0.9996305},"labels":[],"label_agreement":null},{"id":"W2463246825","doi":"10.1159/000394715","title":"The Differentiation and Organization of Tumors in vitro","year":2015,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"In vitro; Biology; Cell biology; Genetics","score_opus":0.04487894248190542,"score_gpt":0.3180234379174945,"score_spread":0.27314449543558905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2463246825","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020559877,0.002046475,0.00019727579,0.0026132546,0.00020155168,0.0014244743,0.000024655865,0.00005080216,0.9728816],"genre_scores_gemma":[0.4753085,0.00079359266,0.00006876176,0.000045816778,0.00011664501,0.0000049407154,0.0001101717,0.000053192653,0.52349836],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992088,0.000012284904,0.00020542055,0.00012483814,0.00036021596,0.00008843899],"domain_scores_gemma":[0.9993579,0.000058164664,0.00006914111,0.00018563117,0.00027444778,0.00005475615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022290729,0.00008607571,0.00019832404,0.00010121071,0.000017786295,0.000009886646,0.000052343265,0.00011073614,0.0003476377],"category_scores_gemma":[0.00015705176,0.000054635002,0.000014307621,0.000043117663,0.000073467534,0.000015668169,0.000052077863,0.0001969697,0.00001585264],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017103413,0.0002710527,0.057589985,0.0035269188,0.0006069684,0.00014180389,0.0029012228,0.000005239678,0.06447178,0.41925895,0.07987034,0.3696454],"study_design_scores_gemma":[0.015345182,0.0021055592,0.15467033,0.005580228,0.00072588766,0.00024388373,0.0009419838,0.002098176,0.14280142,0.078248344,0.5952035,0.0020354674],"about_ca_topic_score_codex":0.000064056396,"about_ca_topic_score_gemma":0.000053452903,"teacher_disagreement_score":0.5153332,"about_ca_system_score_codex":0.00013133891,"about_ca_system_score_gemma":0.00019939418,"threshold_uncertainty_score":0.3806389},"labels":[],"label_agreement":null},{"id":"W2465741927","doi":"","title":"[Her-2/neu analysis--new data?].","year":2006,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CISH; Lapatinib; Pertuzumab; Trastuzumab; Breast cancer; Medicine; Internal medicine; Oncology; Cancer; Fish <Actinopterygii>; Immunohistochemistry; Antibody; Biology; Immunology; Gene; Messenger RNA","score_opus":0.137500939092921,"score_gpt":0.366092862524219,"score_spread":0.22859192343129803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2465741927","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25292158,0.0063796747,0.0033276747,0.03080487,0.0009372578,0.004717098,0.00025664165,0.00073589757,0.6999193],"genre_scores_gemma":[0.94691277,0.0000509996,0.00063779304,0.00050633337,0.0012327154,0.00031285215,0.0003538961,0.000030553503,0.0499621],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9980152,0.000045522058,0.0002550687,0.00045138606,0.0006430592,0.0005897392],"domain_scores_gemma":[0.99814034,0.000065547814,0.00004505216,0.0013459349,0.00006465511,0.00033849681],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066054956,0.00011608767,0.00031082585,0.00027760843,0.00004077029,0.000048755006,0.00039875845,0.00007578643,0.0005708398],"category_scores_gemma":[0.0002116491,0.00009997814,0.000098536424,0.0012055516,0.00006190541,0.00010042446,0.00017523565,0.00023058297,0.00017070118],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000892427,0.00017535465,0.24224013,0.00005940842,0.0005760275,0.00014434454,0.000019987616,0.000038728464,0.00007742641,0.00025137022,0.43418953,0.32213846],"study_design_scores_gemma":[0.0005668649,0.000012152686,0.73910517,0.0000040525338,0.00036378164,0.000008326216,0.0000056141944,0.00022933011,0.00027804542,0.00017881554,0.25916022,0.000087644454],"about_ca_topic_score_codex":0.0028439316,"about_ca_topic_score_gemma":0.0007364049,"teacher_disagreement_score":0.6939912,"about_ca_system_score_codex":0.00014800817,"about_ca_system_score_gemma":0.00017862498,"threshold_uncertainty_score":0.6250295},"labels":[],"label_agreement":null},{"id":"W2468868288","doi":"10.1007/s10555-016-9631-3","title":"Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review","year":2016,"lang":"en","type":"review","venue":"Cancer and Metastasis Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Metastasis; Oncology; Metastatic breast cancer; Progesterone receptor; Estrogen receptor; Estrogen; Internal medicine; Breast cancer; Cancer","score_opus":0.14047034859132446,"score_gpt":0.44881871120596106,"score_spread":0.3083483626146366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2468868288","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002079215,0.9874025,0.000035943725,0.0014581839,0.00019236522,0.00865587,0.0019338847,0.000051308674,0.00024913583],"genre_scores_gemma":[9.406234e-7,0.9911138,0.0015665741,0.0007974295,0.0006215729,0.0040748324,0.00029109285,0.00021099372,0.0013227978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99330413,0.0011627395,0.0021384293,0.0017065454,0.000714056,0.00097411365],"domain_scores_gemma":[0.99608964,0.0003696706,0.0010530619,0.0011788916,0.00018240836,0.0011263158],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002715646,0.0012988431,0.008769535,0.00027027802,0.0001721571,0.00012045511,0.0003708132,0.0002005013,0.00043928475],"category_scores_gemma":[0.00025471984,0.00077294506,0.0006885057,0.0006908213,0.0006110989,0.00026802396,0.00043532622,0.0009535569,0.000107393964],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000011861224,0.000029897288,0.0002408472,0.28364506,0.00040583537,0.000020181136,0.0000122626125,3.1247516e-10,0.0000021269936,0.000030528696,0.007671238,0.70793015],"study_design_scores_gemma":[0.0004895186,0.0001598602,0.00011360679,0.26693955,0.0067169266,0.0006766988,0.0000033780102,3.2918454e-8,0.000003171811,0.000006212223,0.72435707,0.000533979],"about_ca_topic_score_codex":0.00004746456,"about_ca_topic_score_gemma":0.000011046277,"teacher_disagreement_score":0.71668583,"about_ca_system_score_codex":0.00044794398,"about_ca_system_score_gemma":0.0011789238,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W2469000447","doi":"10.1093/jnci/djw111","title":"RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer","year":2016,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science Foundation Ireland; Irish Cancer Society; Health Research Board; GlaxoSmithKline","keywords":"Trastuzumab; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Biomarker; Epidermal growth factor receptor; Medicine; Pathological; Cancer research; Internal medicine; Cancer; Neoadjuvant therapy; Biology","score_opus":0.12292834570016804,"score_gpt":0.41298595279302047,"score_spread":0.29005760709285244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2469000447","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27570593,0.0007951671,0.000049224866,0.70910066,0.0026785445,0.0012248512,0.009396283,0.000023393077,0.0010259117],"genre_scores_gemma":[0.9094563,0.0008683471,0.00014032397,0.07889439,0.008448948,0.00018075595,0.00016491166,0.000114362265,0.0017316543],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9920111,0.0016118834,0.001682971,0.000549259,0.0034748355,0.00066998636],"domain_scores_gemma":[0.9938068,0.00083999144,0.0017177876,0.0003193222,0.0030912182,0.00022487917],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00245302,0.00054762914,0.0012755156,0.00092885084,0.00020375896,0.000048882423,0.0008173122,0.0008233801,0.0024277915],"category_scores_gemma":[0.0015113773,0.00032771565,0.00066594774,0.0007679485,0.00085785723,0.0003945302,0.00018208435,0.0030657798,0.000020539852],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021320656,0.0003811074,0.016679892,0.0005715921,0.0013398145,0.0021514706,0.000613483,0.0000619942,0.15827034,0.000065312386,0.7878843,0.010660061],"study_design_scores_gemma":[0.007862476,0.0011422903,0.7753147,0.008962355,0.0003913073,0.0018636244,0.000038200462,0.00005293394,0.006473463,0.00048887165,0.19664335,0.0007664279],"about_ca_topic_score_codex":0.0012520754,"about_ca_topic_score_gemma":0.00026228663,"teacher_disagreement_score":0.7586348,"about_ca_system_score_codex":0.0068757352,"about_ca_system_score_gemma":0.0041968324,"threshold_uncertainty_score":0.9999175},"labels":[],"label_agreement":null},{"id":"W2482099568","doi":"10.3390/ijms17081200","title":"Non-Ligand-Induced Dimerization is Sufficient to Initiate the Signalling and Endocytosis of EGF Receptor","year":2016,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Endocytosis; Cell biology; ERBB3; Autophosphorylation; Epidermal growth factor; Proto-oncogene tyrosine-protein kinase Src; Internalization; Epidermal growth factor receptor; Endosome; Receptor tyrosine kinase; Tyrosine kinase; Protein kinase B; Chemistry; Phosphorylation; Biology; Endocytic cycle; Signal transduction; Receptor; Biochemistry; Intracellular; Protein kinase A","score_opus":0.051410785751539546,"score_gpt":0.37464456138699725,"score_spread":0.3232337756354577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2482099568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97340184,0.00016435202,0.013139057,0.012566576,0.0003245285,0.00011161568,0.0000050271096,0.0000022685,0.00028470182],"genre_scores_gemma":[0.99792826,0.0001972243,0.0009026968,0.00083815836,0.00010415276,0.0000027153344,2.1301659e-7,0.0000054646466,0.000021140722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810123,0.00004189018,0.00032522218,0.00013038673,0.00127148,0.0001297714],"domain_scores_gemma":[0.99881375,0.0001278737,0.00020192254,0.00007293104,0.0006799618,0.00010356195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009138904,0.00006529252,0.0001313125,0.0002545737,0.000048100803,0.000048038375,0.00038793296,0.000023943185,0.00007270674],"category_scores_gemma":[0.00034592472,0.000034105364,0.00006420594,0.00025767018,0.00017202717,0.00010700631,0.00007979704,0.00008626938,0.0000064636115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008047632,0.000039190472,0.0042692497,0.0000049575765,0.000056522185,0.000023326951,0.0007372977,0.000047552407,0.9814073,0.00016925689,0.0001161196,0.013048781],"study_design_scores_gemma":[0.000509965,0.00070479506,0.0032537447,0.000460001,0.000015801186,0.00008123971,0.00019956082,0.00017303269,0.99387795,0.00017343728,0.00050063786,0.000049858205],"about_ca_topic_score_codex":0.000030759762,"about_ca_topic_score_gemma":0.0000014361639,"teacher_disagreement_score":0.024526361,"about_ca_system_score_codex":0.00006529097,"about_ca_system_score_gemma":0.0002909161,"threshold_uncertainty_score":0.13907763},"labels":[],"label_agreement":null},{"id":"W2491668168","doi":"10.1158/1538-7445.am2016-3940","title":"Abstract 3940: Baseline molecular markers and risk of distant relapse in the NeoSphere study","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Oncology; Breast cancer; Trastuzumab; Cancer; CD8; Immune system; Immunology","score_opus":0.06699181598170728,"score_gpt":0.44153113491877855,"score_spread":0.37453931893707126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2491668168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884191,0.0035309887,0.00002708789,0.0041698306,0.000051489067,0.0016678639,0.00006394865,0.000012103021,0.002057589],"genre_scores_gemma":[0.99369395,0.0050641303,0.00005707726,0.000048138307,0.0000897879,0.00037303945,0.0000018405663,0.00003763852,0.00063441606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957579,0.0010228482,0.00039009145,0.0004838668,0.0017097809,0.00063551846],"domain_scores_gemma":[0.99722666,0.0012357755,0.00006341808,0.00087896234,0.0003815858,0.00021358309],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00829354,0.00014757045,0.00031348865,0.00018925505,0.000095024036,0.000029845914,0.00038690178,0.00008502812,0.0011380446],"category_scores_gemma":[0.001728059,0.00007825284,0.000060423525,0.00080626016,0.0005436699,0.00006619146,0.00017294544,0.00090092194,0.000026008527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044170143,0.001071376,0.75539184,0.0005832534,0.00029573456,0.001467929,0.0028950109,0.000012286595,0.06908973,0.00016726906,0.014713555,0.14989501],"study_design_scores_gemma":[0.00957094,0.002608324,0.9426674,0.0017401874,0.00009995396,0.000025130728,0.011601506,0.00008154665,0.012550008,0.0007908988,0.01794656,0.00031753868],"about_ca_topic_score_codex":0.0069910823,"about_ca_topic_score_gemma":0.0019947505,"teacher_disagreement_score":0.18727557,"about_ca_system_score_codex":0.0003564133,"about_ca_system_score_gemma":0.0006562562,"threshold_uncertainty_score":0.99977505},"labels":[],"label_agreement":null},{"id":"W2501964380","doi":"10.1007/978-1-907673-94-8","title":"Handbook of HER2-targeted agents in breast cancer","year":2013,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Cancer; Medicine; Oncology; Quarter (Canadian coin); Internal medicine; History","score_opus":0.057967900286424255,"score_gpt":0.3935470452836446,"score_spread":0.33557914499722036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2501964380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9571335,0.0012248527,0.00003520631,0.008132844,0.00013745276,0.0009980103,0.000021827425,0.00004346494,0.032272857],"genre_scores_gemma":[0.9862148,0.0004622772,0.00040967047,0.0007861184,0.00007650297,0.00014150194,0.0000048190536,0.000019858988,0.011884417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989845,0.000030441903,0.00021276667,0.00016089932,0.00034053993,0.00027083885],"domain_scores_gemma":[0.9994254,0.000023766856,0.000026936998,0.00022994952,0.00015352832,0.00014038988],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012171823,0.00007832814,0.00020882854,0.00011761316,0.000010627773,0.0000069985613,0.000093028524,0.00006146817,0.038866073],"category_scores_gemma":[0.000022863269,0.000059657017,0.00003802295,0.00022854128,0.00006623244,0.00005413624,0.000043955675,0.00015614911,0.00035543137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009494054,0.00021478748,0.7809838,0.00025066105,0.000048073158,0.00002297976,0.00027753285,0.0000071317113,0.035477545,0.000024892317,0.14703138,0.035566274],"study_design_scores_gemma":[0.0016884942,0.00008546383,0.9594956,0.00055215834,0.000009236214,0.000014727609,0.0001048918,0.0007505958,0.031149,0.00006861352,0.0059840214,0.000097184115],"about_ca_topic_score_codex":0.020964041,"about_ca_topic_score_gemma":0.00051449816,"teacher_disagreement_score":0.17851181,"about_ca_system_score_codex":0.00015953895,"about_ca_system_score_gemma":0.00022223376,"threshold_uncertainty_score":0.98555547},"labels":[],"label_agreement":null},{"id":"W2511312089","doi":"10.1093/ajcp/aqw117","title":"Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer","year":2016,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Fluorescence in situ hybridization; Human Epidermal Growth Factor Receptor 2; Fish <Actinopterygii>; Breast cancer; Biology; Cohort; In situ hybridization; Copy-number variation; Pathology; Cancer; Oncology; Medicine; Internal medicine; Chromosome; Genetics; Gene; Fishery; Gene expression","score_opus":0.08438104769738537,"score_gpt":0.507046366395642,"score_spread":0.4226653186982567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511312089","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883441,0.0002435521,0.00012543472,0.010889498,0.00017154266,0.00011883013,0.000008171278,0.0000029419027,0.00009597161],"genre_scores_gemma":[0.9966132,0.0018504921,0.0009850675,0.00034030294,0.00017665741,0.0000045118345,3.683388e-7,0.0000125482475,0.00001685426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971475,0.00060460734,0.0015023786,0.00020401718,0.00029239824,0.0002490706],"domain_scores_gemma":[0.997608,0.0010167595,0.000764488,0.00016190055,0.0002594754,0.00018938204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019695095,0.00009379017,0.001082224,0.00023440142,0.000009081245,0.000002778696,0.0001084033,0.000080933845,0.00006915345],"category_scores_gemma":[0.0013975133,0.00006159311,0.000080593665,0.0003410949,0.0011088944,0.00006690405,0.000053801417,0.0005003451,0.0000036430959],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011541167,0.00027835337,0.74419856,0.000018707657,0.000012238168,0.00033533628,0.00015174437,0.0000053854533,0.018691996,0.00001162652,0.00016830386,0.23497361],"study_design_scores_gemma":[0.002633538,0.0022287315,0.99219733,0.0005101881,0.000019648329,0.0005450565,0.00022744242,0.00004514206,0.001251849,0.00005361663,0.00022396228,0.00006350568],"about_ca_topic_score_codex":0.00015291203,"about_ca_topic_score_gemma":0.00020763822,"teacher_disagreement_score":0.24799873,"about_ca_system_score_codex":0.00009298337,"about_ca_system_score_gemma":0.00046984828,"threshold_uncertainty_score":0.40857676},"labels":[],"label_agreement":null},{"id":"W2511927825","doi":"10.1038/srep32259","title":"A-Disintegrin and Metalloproteinase (ADAM) 17 Enzymatically Degrades Interferon-gamma","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"First Quantum Minerals (Canada)","funders":"National Institute of Dental and Craniofacial Research; Japan Science and Technology Agency; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Ministry of Education, Culture, Sports, Science and Technology; Japan Society for the Promotion of Science; Astellas Pharma","keywords":"Disintegrin; Metalloproteinase; Cancer research; Interferon gamma; Osteolysis; Cytokine; Cancer cell; Immune system; Cell culture; Interferon; Cancer; Chemistry; Biology; Immunology; Matrix metalloproteinase; Medicine; Biochemistry","score_opus":0.037022784823903636,"score_gpt":0.32472471828609584,"score_spread":0.2877019334621922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511927825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788071,0.0011367161,0.001076695,0.005820899,0.0020588506,0.0009979086,0.000004720153,0.00014207939,0.009955063],"genre_scores_gemma":[0.9257422,0.0000435058,0.0020537938,0.000082811806,0.000118385586,0.00008307064,0.000007657632,0.000032517415,0.071836054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967833,0.00007578696,0.0006117825,0.00094102276,0.0010433596,0.0005447509],"domain_scores_gemma":[0.99770194,0.00010588012,0.00014648624,0.0012355453,0.00031073875,0.0004993781],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00254822,0.00020051838,0.00036311484,0.00026996763,0.00017218682,0.00023626005,0.00014521006,0.00009872385,0.0016645432],"category_scores_gemma":[0.001419001,0.00011666719,0.0001117136,0.00036121556,0.0009458895,0.0001885401,0.00019798763,0.00021244619,0.00013344192],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019401909,0.0002718666,0.016226204,0.0003589062,0.0001244667,0.005412366,0.00045802386,1.758053e-7,0.7086116,0.00060333736,0.15357839,0.114160635],"study_design_scores_gemma":[0.0011602042,0.0006950977,0.008888312,0.0017613377,0.000114564784,0.004892919,0.00024910044,0.000047050813,0.49450332,0.014357809,0.47282848,0.00050180824],"about_ca_topic_score_codex":0.000049736263,"about_ca_topic_score_gemma":0.00006706995,"teacher_disagreement_score":0.31925008,"about_ca_system_score_codex":0.0001705285,"about_ca_system_score_gemma":0.00044389983,"threshold_uncertainty_score":0.9992481},"labels":[],"label_agreement":null},{"id":"W2512472999","doi":"10.1371/journal.pone.0161219","title":"HER3, but Not HER4, Plays an Essential Role in the Clinicopathology and Prognosis of Gastric Cancer: A Meta-Analysis","year":2016,"lang":"en","type":"review","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Meta-analysis; Medicine; Pathology; Internal medicine","score_opus":0.41513450105349264,"score_gpt":0.46032270942430625,"score_spread":0.04518820837081361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512472999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004505962,0.9917821,0.000005419053,0.000701856,0.000018992643,0.0022167547,0.0005487272,0.000019570069,0.00020060314],"genre_scores_gemma":[0.003926085,0.9925223,0.0004036791,0.00012189052,0.00032706524,0.002194173,0.00007065583,0.00006615696,0.00036796712],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948733,0.0014685661,0.0012200212,0.00080617605,0.0011053623,0.0005266116],"domain_scores_gemma":[0.99713033,0.0008156822,0.0005699108,0.0010641087,0.00023131208,0.00018863115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022600444,0.0004152199,0.0058341227,0.00082283164,0.000045299188,0.000028434137,0.0005594435,0.00040040058,0.0011328637],"category_scores_gemma":[0.00037916578,0.0002244348,0.0012058757,0.0014831298,0.0002860183,0.00005856666,0.00015838482,0.00086142396,0.00003316845],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003337429,0.008620094,0.007032256,0.050880834,0.2643977,0.0004832659,0.00066599116,5.874126e-7,0.0002984547,0.00003718695,0.00017279327,0.66707706],"study_design_scores_gemma":[0.0012386247,0.0016677845,0.000628608,0.006217175,0.9464649,0.00009332742,0.00010487101,0.000041301722,0.0002921008,0.00002469691,0.042707156,0.00051948125],"about_ca_topic_score_codex":0.00065180106,"about_ca_topic_score_gemma":0.00045032703,"teacher_disagreement_score":0.68206716,"about_ca_system_score_codex":0.00014121553,"about_ca_system_score_gemma":0.0008097351,"threshold_uncertainty_score":0.99978024},"labels":[],"label_agreement":null},{"id":"W2513036042","doi":"10.21873/anticanres.11017","title":"Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer","year":2016,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec; Université Laval","keywords":"Concordance; Tissue microarray; Breast cancer; Fluorescence in situ hybridization; Gene duplication; Oncology; Pathology; Cancer; Microarray; Medicine; Biopsy; Internal medicine; Biology; Gene; Gene expression; Genetics","score_opus":0.23726570701125313,"score_gpt":0.5396638585272922,"score_spread":0.302398151516039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513036042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78031474,0.0055188243,0.0012145033,0.20069896,0.00034008516,0.009124754,0.00048184049,0.000038241455,0.0022680585],"genre_scores_gemma":[0.9907234,0.0034565814,0.00021334869,0.000222664,0.00030355388,0.0023228573,0.0000049873265,0.000041152463,0.002711508],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960896,0.00021883013,0.00040332196,0.00047001714,0.0021391374,0.0006791134],"domain_scores_gemma":[0.9956639,0.00075899315,0.00006959092,0.0008272317,0.0025855193,0.000094813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008079826,0.00011907976,0.0002668009,0.00028502505,0.00013111036,0.000030266257,0.0003517749,0.00011044749,0.0027758104],"category_scores_gemma":[0.000641062,0.00006901127,0.000063922686,0.0009719436,0.0004606684,0.00011511919,0.00008140508,0.00030411658,0.00008706735],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012640251,0.0002286366,0.10528807,0.0004392512,0.00009366072,0.0000020803461,0.0006916947,0.000014044556,0.28940392,0.00057640247,0.054423373,0.5475748],"study_design_scores_gemma":[0.006462975,0.00047002765,0.4962093,0.0020568483,0.00012796176,0.00001953886,0.0004469835,0.002654135,0.35677856,0.0020852657,0.13242516,0.0002632315],"about_ca_topic_score_codex":0.004504427,"about_ca_topic_score_gemma":0.0005703539,"teacher_disagreement_score":0.5473116,"about_ca_system_score_codex":0.0010574101,"about_ca_system_score_gemma":0.0022007045,"threshold_uncertainty_score":0.9981358},"labels":[],"label_agreement":null},{"id":"W2513447495","doi":"10.1038/modpathol.2016.151","title":"Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort","year":2016,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Calgary Laboratory Services; Alberta Health Services","funders":"Breast Cancer Society of Canada; Calgary Laboratory Services","keywords":"Concordance; Progesterone receptor; Breast cancer; Immunohistochemistry; Medicine; Oncology; Tamoxifen; Pathology; Internal medicine; Cohort; Estrogen receptor; Cancer; Companion diagnostic; Lymph node; Gynecology","score_opus":0.11420820221566332,"score_gpt":0.381436496236264,"score_spread":0.2672282940206007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513447495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215996,0.00036691997,0.0007187226,0.0041500884,0.00015094671,0.0012323967,0.00015986842,0.000038532336,0.0010225761],"genre_scores_gemma":[0.9987414,0.00005898216,0.00021366609,0.0001090093,0.0001345305,0.00051805674,0.000024105644,0.000039293496,0.00016095077],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974034,0.0005007478,0.00039087294,0.00042221567,0.0008689364,0.0004138381],"domain_scores_gemma":[0.99854386,0.0000816587,0.0001155608,0.0004498601,0.0007050034,0.000104043764],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022134536,0.00015619672,0.00045147655,0.00019911262,0.000026211894,0.0000050026388,0.00013360268,0.00022890489,0.0010190674],"category_scores_gemma":[0.00026820152,0.000113167094,0.000050948893,0.00021627675,0.00024864718,0.00006765094,0.00007683851,0.00019092725,0.000049823575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030527313,0.00029305895,0.5535831,0.000030699826,0.000034257784,0.000027561233,0.00019938039,0.000008134469,0.21464789,0.000006752407,0.00030324562,0.23056066],"study_design_scores_gemma":[0.0047489735,0.00048960635,0.9712081,0.00038518687,0.00016299644,0.00014242774,0.000009057134,0.0013182091,0.020650579,0.0005973561,0.00013981848,0.00014771534],"about_ca_topic_score_codex":0.0005755068,"about_ca_topic_score_gemma":0.003448882,"teacher_disagreement_score":0.41762498,"about_ca_system_score_codex":0.0009177245,"about_ca_system_score_gemma":0.00052372564,"threshold_uncertainty_score":0.99989414},"labels":[],"label_agreement":null},{"id":"W2517870508","doi":"10.1200/jco.2010.28.15_suppl.1095","title":"Correlation of GPNMB expression with outcome in breast cancer (BC) patients treated with the antibody–drug conjugate (ADC), CDX-011 (CR011-vcMMAE).","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Antibody-drug conjugate; Breast cancer; Oncology; Correlation; Conjugate; Drug; Internal medicine; Cancer; Antibody; Monoclonal antibody; Immunology; Pharmacology","score_opus":0.08273252036991065,"score_gpt":0.494299588317368,"score_spread":0.41156706794745734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517870508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761976,0.000048126898,0.000044048786,0.0100658,0.00060811214,0.00045109415,0.000017669567,0.0000074069508,0.0011380021],"genre_scores_gemma":[0.9978116,0.0001893002,0.00043659078,0.0006986171,0.0004618415,0.0000114045115,0.000007097799,0.000031487012,0.0003520732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959275,0.0005931866,0.0020205367,0.00024344683,0.00088472536,0.0003306214],"domain_scores_gemma":[0.9943759,0.0017512386,0.0019750204,0.00033536195,0.00122215,0.00034032145],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030417785,0.00018755134,0.0013391216,0.00019421095,0.000051818162,0.000010681044,0.000293666,0.00034245607,0.0004535488],"category_scores_gemma":[0.0008857134,0.000089093875,0.00018257154,0.00033166344,0.0006176334,0.00017279264,0.000061919476,0.0026880717,0.000010811215],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013123608,0.0013024865,0.96986884,0.00004873604,0.000122048514,0.00018667516,0.00015595445,0.000081022255,0.0009973027,0.000012354891,0.0019762742,0.012124713],"study_design_scores_gemma":[0.012483822,0.005494671,0.9749657,0.0004965317,0.00017959507,0.00015566725,0.00010918276,0.00025625396,0.00036803292,0.000013360147,0.0053747823,0.000102380116],"about_ca_topic_score_codex":0.001344718,"about_ca_topic_score_gemma":0.002052733,"teacher_disagreement_score":0.012022332,"about_ca_system_score_codex":0.0001747113,"about_ca_system_score_gemma":0.0017748801,"threshold_uncertainty_score":0.99961275},"labels":[],"label_agreement":null},{"id":"W2518302135","doi":"10.5858/arpa.2016-0119-ra","title":"Diagnostic Immunohistochemistry: What Can Go Wrong and How to Prevent It","year":2016,"lang":"en","type":"review","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Context (archaeology); Immunohistochemistry; Computer science; Epitope; Vendor; Antibody; Task (project management); Primary and secondary antibodies; Process (computing); Medicine; Pathology; Immunology; Biology","score_opus":0.0343991355478382,"score_gpt":0.3853445796393571,"score_spread":0.3509454440915189,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2518302135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058033847,0.98535866,0.000037786398,0.010345623,0.00051972177,0.0019421155,0.00030939624,0.000043549833,0.00086280826],"genre_scores_gemma":[0.00025115066,0.9949054,0.00035380188,0.00067130994,0.0008059315,0.00055537006,0.00015478022,0.00012698256,0.0021752499],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99616027,0.0006894267,0.00083577895,0.0010058054,0.0005798874,0.0007288436],"domain_scores_gemma":[0.99371994,0.0034562922,0.00048072258,0.0014072796,0.00020062242,0.00073515653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009174156,0.00067321566,0.0032051709,0.0005654915,0.00008127332,0.000015960979,0.00054064224,0.00037725296,0.00024280665],"category_scores_gemma":[0.0053024776,0.0004541938,0.00020439642,0.00047161858,0.002155291,0.00007286427,0.00040409845,0.00093178276,0.0000352587],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000062113475,0.00012962612,0.000080977494,0.029300073,0.0003354261,0.0020903202,0.0015691179,2.3129806e-8,0.0045643533,0.000064991924,0.012552969,0.94925],"study_design_scores_gemma":[0.0008707737,0.0011960863,0.00012017312,0.11957435,0.00088468427,0.0005257535,0.00035175128,1.659091e-7,0.0002232551,0.000043221575,0.8758672,0.000342568],"about_ca_topic_score_codex":0.000010748656,"about_ca_topic_score_gemma":0.000011982444,"teacher_disagreement_score":0.94890743,"about_ca_system_score_codex":0.00023568669,"about_ca_system_score_gemma":0.0019062985,"threshold_uncertainty_score":0.99979097},"labels":[],"label_agreement":null},{"id":"W2520503678","doi":"10.1111/bcpt.12675","title":"Use of a Target‐Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of <scp>GC</scp>1118, an Anti‐epidermal Growth Factor Receptor Antibody","year":2016,"lang":"en","type":"article","venue":"Basic & Clinical Pharmacology & Toxicology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Pharmacokinetics; Cetuximab; Chemistry; Epidermal growth factor receptor; Volume of distribution; Pharmacology; Receptor; Monoclonal antibody; Antibody; Biochemistry; Biology; Immunology","score_opus":0.1078287518249041,"score_gpt":0.45242553987766054,"score_spread":0.34459678805275645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2520503678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853317,0.00020613013,0.0009258749,0.008703399,0.001305646,0.0022665875,0.0010669939,0.000108585555,0.00008509658],"genre_scores_gemma":[0.98927593,0.0010070076,0.001984809,0.005834079,0.0010069505,0.00016822045,0.00013966391,0.000094249706,0.00048909173],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9932335,0.001997606,0.001985654,0.0010741459,0.0006218294,0.0010872673],"domain_scores_gemma":[0.991432,0.0055869315,0.00065069844,0.00061679067,0.000738115,0.00097542506],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019744032,0.000482908,0.0015506818,0.00036566562,0.00017682237,0.000015137944,0.0006466843,0.0005707686,0.0009441395],"category_scores_gemma":[0.002591464,0.00029892087,0.00030030988,0.00048183554,0.002132708,0.00029296544,0.0004766008,0.0010982073,0.000044837503],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069699687,0.0018122034,0.2723801,0.00014748974,0.0003742612,0.000043627784,0.00031727165,0.000029507168,0.67558223,0.00006428124,0.047365855,0.0011861451],"study_design_scores_gemma":[0.013988258,0.0075184973,0.56588715,0.00023634592,0.0009389022,0.000066933135,0.0000866139,0.0070116837,0.38517636,0.0003669419,0.018327707,0.000394616],"about_ca_topic_score_codex":0.00004884212,"about_ca_topic_score_gemma":0.0000103835555,"teacher_disagreement_score":0.293507,"about_ca_system_score_codex":0.00013907767,"about_ca_system_score_gemma":0.0006947976,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W2522392425","doi":"10.1007/s10549-016-3979-5","title":"Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer","year":2016,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"National Institute for Health and Care Research; AstraZeneca; Pfizer","keywords":"Anastrozole; Medicine; Internal medicine; Tolerability; Placebo; Breast cancer; Rash; Combination therapy; Adverse effect; Oncology; Gastroenterology; Cancer; Aromatase; Pathology","score_opus":0.041784829547201,"score_gpt":0.392317485535919,"score_spread":0.35053265598871797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2522392425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913511,0.0008755698,0.000032152268,0.0019438837,0.000009961879,0.005429579,0.00019677509,0.000027292264,0.00013364456],"genre_scores_gemma":[0.98918796,0.0032016423,0.0001957707,0.00003576218,0.00006127053,0.0070607373,0.000017565038,0.00006920378,0.00017011775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959387,0.00054644136,0.00044608137,0.00089971005,0.0012114187,0.00095762557],"domain_scores_gemma":[0.9982258,0.0001891149,0.00014376477,0.00039796758,0.0005587842,0.00048457473],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010131681,0.0004039329,0.0010479206,0.0006475464,0.00016431135,0.000053172225,0.0000972306,0.00006368788,0.00020007309],"category_scores_gemma":[0.0000135562,0.00021268816,0.000029016372,0.0009602336,0.0008478596,0.0004045105,0.000061047576,0.00030452767,6.823905e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.52341926,0.010690017,0.14061189,0.00016087464,0.0005326819,0.00034537626,0.0043974114,0.000051876676,0.005624927,0.000039864135,0.0000037014336,0.3141221],"study_design_scores_gemma":[0.7670376,0.04728293,0.16472915,0.0027726793,0.000093352784,0.00039901398,0.007818547,0.00018783218,0.009069453,0.00010581562,0.000050207997,0.00045344263],"about_ca_topic_score_codex":0.019437807,"about_ca_topic_score_gemma":0.0066485987,"teacher_disagreement_score":0.31366867,"about_ca_system_score_codex":0.001784132,"about_ca_system_score_gemma":0.0012011682,"threshold_uncertainty_score":0.98709184},"labels":[],"label_agreement":null},{"id":"W2525265150","doi":"10.1093/annonc/mdw434","title":"Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; National Institutes of Health; Breast Cancer Research Foundation; Yale University; U.S. Department of Health and Human Services","keywords":"Lapatinib; Trastuzumab; Medicine; RHOA; Gene; Mutation; Internal medicine; Oncology; Proportional hazards model; Cancer; Cancer research; Genetics; Breast cancer; Biology; Signal transduction","score_opus":0.2949287766874463,"score_gpt":0.4705472389473932,"score_spread":0.17561846225994687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2525265150","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88148105,0.00039779078,0.00013949123,0.115334205,0.00016255458,0.0012469579,0.000079421094,0.000015991995,0.0011425507],"genre_scores_gemma":[0.9955157,0.00013522147,0.00040884232,0.0021474864,0.00022836174,0.0004661008,0.0000091862985,0.000021998474,0.0010670875],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971162,0.0014138841,0.000503148,0.00025437967,0.00033331552,0.00037908228],"domain_scores_gemma":[0.99732935,0.0018523686,0.00009027296,0.00039249085,0.00023859205,0.000096934775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026041882,0.00012585813,0.00035432435,0.00039511517,0.00005263685,0.000012923201,0.00023598895,0.00014438246,0.0003090707],"category_scores_gemma":[0.0017681615,0.00007469055,0.00008107387,0.0005196254,0.0001904997,0.00007783691,0.000042728057,0.00017880293,0.000041808482],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11525254,0.0041948757,0.0148387635,0.000048764985,0.0001689497,0.000338871,0.034980677,0.0000739634,0.50792515,0.0006218661,0.018335894,0.3032197],"study_design_scores_gemma":[0.059033163,0.04195344,0.2679591,0.00048541193,0.00003258429,0.00007172674,0.0049973303,0.000054501415,0.08561249,0.0026316051,0.53676635,0.00040230874],"about_ca_topic_score_codex":0.0003235836,"about_ca_topic_score_gemma":0.0029969753,"teacher_disagreement_score":0.5184305,"about_ca_system_score_codex":0.00012894353,"about_ca_system_score_gemma":0.0011278292,"threshold_uncertainty_score":0.3384107},"labels":[],"label_agreement":null},{"id":"W2527179162","doi":"10.1016/j.jasc.2016.07.018","title":"Toward Standard Controls for Her2 Immunohistochemistry","year":2016,"lang":"en","type":"article","venue":"Journal of the American Society of Cytopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology","score_opus":0.034992448729536406,"score_gpt":0.37849243487914186,"score_spread":0.3434999861496055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2527179162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9362697,0.00091932673,0.010696747,0.051122162,0.00026363524,0.00032966235,0.00006924929,0.00000957163,0.0003199478],"genre_scores_gemma":[0.98533225,0.000635854,0.010794138,0.0018535547,0.00041692256,0.000012575612,3.328339e-7,0.00002596982,0.00092838967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849033,0.00009938886,0.00052984484,0.00012902822,0.0004569456,0.00029447224],"domain_scores_gemma":[0.9975276,0.00037468167,0.00097612926,0.00035893606,0.0006547381,0.000107891836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011099708,0.00011536179,0.000765557,0.000027373228,0.000051124614,0.000004639223,0.00038624756,0.00006812475,0.000055142555],"category_scores_gemma":[0.0005690358,0.00006037777,0.0008505954,0.00014039676,0.0013624813,0.000035507288,0.00007737956,0.00028857906,0.000001598612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001794751,0.00005872857,0.00782175,0.00010306841,0.00015464028,0.000014000301,0.0003301428,8.232757e-7,0.92789096,0.000024491246,0.039909247,0.02189741],"study_design_scores_gemma":[0.019165806,0.013092658,0.057424407,0.0013642281,0.0006670671,0.005782593,0.0041089067,0.000021787617,0.6310842,0.0028275154,0.2640072,0.00045361102],"about_ca_topic_score_codex":0.000008831354,"about_ca_topic_score_gemma":1.9624912e-7,"teacher_disagreement_score":0.29680675,"about_ca_system_score_codex":0.0003709888,"about_ca_system_score_gemma":0.0006996502,"threshold_uncertainty_score":0.5020119},"labels":[],"label_agreement":null},{"id":"W2528319239","doi":"10.1038/ncomms12991","title":"Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers","year":2016,"lang":"en","type":"article","venue":"Nature Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Research Resources; Stand Up To Cancer; National Cancer Institute; Cancer Research UK; National Institutes of Health; Nancy Owens Memorial Foundation; Congressionally Directed Medical Research Programs; National Institute of Allergy and Infectious Diseases; Breast Cancer Research Foundation; BC Cancer Agency; Susan G. Komen for the Cure","keywords":"Cancer research; Breast cancer; Kinase; Ectopic expression; Biology; Cancer; Cell cycle; Apoptosis; Medicine; Internal medicine; Oncology; Gene; Cell biology; Genetics","score_opus":0.05021994215550371,"score_gpt":0.36579579989605654,"score_spread":0.31557585774055286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528319239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89405113,0.020895468,0.00016753611,0.070183836,0.00096080796,0.001796479,0.0014823411,0.00009229853,0.010370102],"genre_scores_gemma":[0.9973462,0.0008266963,0.00033431087,0.00076377153,0.000064374944,0.00010158644,0.00009162575,0.000015885693,0.0004555292],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838305,0.00027333785,0.00033129705,0.00023955671,0.0005338276,0.00023891368],"domain_scores_gemma":[0.9959475,0.0006468415,0.0002367613,0.0023482982,0.00071533985,0.00010527439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019194983,0.00013281318,0.00033850735,0.00041121664,0.00015287753,0.0000099251865,0.00085154525,0.00021576544,0.0003013376],"category_scores_gemma":[0.0002844053,0.000081266706,0.00022317232,0.001981441,0.0006252356,0.000058794285,0.00035235911,0.00094737083,0.000011873161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010667412,0.0010211038,0.8206882,0.00015294584,0.003986724,0.000044002012,0.0014530843,0.00034795696,0.07640987,0.012610636,0.051980127,0.03023864],"study_design_scores_gemma":[0.0012382303,0.000043973792,0.9605753,0.0003805397,0.0005000174,0.000035479374,0.0003047299,0.00025477543,0.0006845342,0.000113318114,0.03574467,0.00012443122],"about_ca_topic_score_codex":0.0010037837,"about_ca_topic_score_gemma":0.008478093,"teacher_disagreement_score":0.13988714,"about_ca_system_score_codex":0.0007605121,"about_ca_system_score_gemma":0.00071978575,"threshold_uncertainty_score":0.47309747},"labels":[],"label_agreement":null},{"id":"W2528759573","doi":"10.20381/ruor-4859","title":"The combination of pan-ErbB tyrosine kinase inhibitor CI-1033 and lovastatin: A potential novel therapeutic approach in squamous cell carcinoma of the head and neck","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"ErbB; Head and neck; Tyrosine-kinase inhibitor; Cancer research; Tyrosine kinase; Head and neck squamous-cell carcinoma; Medicine; Basal cell; Lovastatin; Oncology; Internal medicine; Head and neck cancer; Cancer; Receptor; Surgery","score_opus":0.008760140810670305,"score_gpt":0.19491737962453248,"score_spread":0.18615723881386217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528759573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97573763,0.0034386653,0.0000066442813,0.00055773085,0.00015354146,0.0007304151,0.0003456618,0.0000021379763,0.019027572],"genre_scores_gemma":[0.9961437,0.0003030397,0.00013529648,0.00012232288,0.000029916066,0.000017856859,0.000060403505,0.000033148684,0.0031543365],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973699,0.000099037345,0.00045845433,0.0002761685,0.0015354017,0.00026107195],"domain_scores_gemma":[0.99905306,0.00020350944,0.00032654166,0.00027571528,0.0000058007627,0.00013537261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000045716053,0.00022527136,0.00040028803,0.000050952123,0.00011709113,0.000014989252,0.00018544728,0.00007013962,0.0000072550647],"category_scores_gemma":[0.0000086208765,0.00015759803,0.000036325324,0.00013021946,0.00021739303,0.000086437445,0.00009595078,0.00033416876,7.141733e-10],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017256463,0.0017498126,0.37013695,0.02141183,0.00037113955,0.0001418457,0.006192608,0.000032677362,0.4717944,0.032936662,0.00096099376,0.077014595],"study_design_scores_gemma":[0.0026680508,0.000496266,0.8226568,0.00046117388,0.00009071307,0.000011942121,0.00651957,0.0010519956,0.16502963,0.00029551378,0.0005153779,0.0002029522],"about_ca_topic_score_codex":0.01265855,"about_ca_topic_score_gemma":0.035887457,"teacher_disagreement_score":0.45251986,"about_ca_system_score_codex":0.000016896463,"about_ca_system_score_gemma":0.0022068394,"threshold_uncertainty_score":0.9939162},"labels":[],"label_agreement":null},{"id":"W2528766886","doi":"10.1093/annonc/mdv336.24","title":"First line trastuzumab-based therapy in her2-positive metastatic breast cancer patients presenting with de novo or recurrent disease","year":2015,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Proportional hazards model; Retrospective cohort study; Adjuvant therapy; Cohort; Cancer; Stage (stratigraphy)","score_opus":0.19802956454535903,"score_gpt":0.4781728379178396,"score_spread":0.2801432733724806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2528766886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98203963,0.0006122966,0.000060813592,0.015534443,0.00009106209,0.0010185918,0.00022315352,0.000017267626,0.00040272324],"genre_scores_gemma":[0.9970663,0.0005517288,0.00036934376,0.0014354091,0.00010698535,0.00028896146,0.00004629216,0.00003453837,0.000100420795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99799955,0.00029392992,0.00037687493,0.0003073223,0.000503729,0.00051857193],"domain_scores_gemma":[0.99805206,0.00026290666,0.00016866752,0.00022643287,0.00080798566,0.00048197538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005949195,0.0001754309,0.0004959593,0.00019777934,0.00003320691,0.000008814202,0.0001502974,0.000064697706,0.00023010162],"category_scores_gemma":[0.0003223517,0.00012150056,0.00006397333,0.00041263862,0.0002048011,0.00006939856,0.0000388402,0.00028170066,0.0000060933453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035438444,0.008624769,0.8296197,0.00049102516,0.00029728524,0.00095750595,0.002292566,0.0013763107,0.000042859025,0.00000993313,0.004885891,0.1159637],"study_design_scores_gemma":[0.020273661,0.025659634,0.93294066,0.0010807383,0.00012330805,0.000046204612,0.00029128164,0.0031332718,0.0017358572,0.000108708526,0.014280999,0.0003256709],"about_ca_topic_score_codex":0.0012797763,"about_ca_topic_score_gemma":0.0026262465,"teacher_disagreement_score":0.115638025,"about_ca_system_score_codex":0.0004193325,"about_ca_system_score_gemma":0.0035477604,"threshold_uncertainty_score":0.62935746},"labels":[],"label_agreement":null},{"id":"W2529742963","doi":"","title":"First-in-class GnRH analog for cancer therapy","year":2016,"lang":"en","type":"article","venue":"Journal of Cancer Science & Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Monoclonal antibody; Ovarian cancer; Gonadotropin-releasing hormone; Receptor; Peptide; Gonadotropin-releasing hormone receptor; Pharmacology; Cancer cell; Cancer; Antibody; Cancer research; Biology; Chemistry; Biochemistry; Hormone; Medicine; Immunology; Internal medicine; Luteinizing hormone","score_opus":0.08549783948216659,"score_gpt":0.44408235902671456,"score_spread":0.35858451954454795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2529742963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9072617,0.027466077,0.0007671778,0.06125834,0.001751752,0.00089074636,0.000024860834,0.000018248238,0.0005610889],"genre_scores_gemma":[0.8977423,0.096636385,0.0006263452,0.0025391502,0.0012495528,0.00016710203,1.2671927e-7,0.000038393813,0.0010006696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672383,0.000047272893,0.0006064952,0.00037156264,0.0014711721,0.00077965466],"domain_scores_gemma":[0.9974949,0.00022852102,0.00036669412,0.0003847732,0.00113657,0.0003885926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023163052,0.0002041405,0.00052960054,0.00059699075,0.00016885577,0.00007147022,0.0008111346,0.000087242115,0.00096618506],"category_scores_gemma":[0.00015588396,0.00011179225,0.00022135806,0.001176426,0.00068506354,0.0005214457,0.000030041334,0.00029335858,0.0000054134903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030742476,0.00021349019,0.13413608,0.00003460933,0.000101678204,0.00004144724,0.00093219103,0.00009021356,0.1787283,0.00017801517,0.0062688272,0.6762009],"study_design_scores_gemma":[0.01349735,0.0030606058,0.15386526,0.0013013737,0.000019609,0.000068857466,0.00013285523,0.00025082796,0.10705687,0.0013342166,0.71908164,0.0003305103],"about_ca_topic_score_codex":0.00040978595,"about_ca_topic_score_gemma":0.0007210677,"teacher_disagreement_score":0.71281284,"about_ca_system_score_codex":0.0013888332,"about_ca_system_score_gemma":0.0042260587,"threshold_uncertainty_score":0.9999471},"labels":[],"label_agreement":null},{"id":"W2533474121","doi":"10.1016/j.breast.2016.09.014","title":"Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors","year":2016,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation Cancer; Fondation du cancer du sein du Québec; Université Laval","keywords":"Breast cancer; Medicine; Oncology; Internal medicine; Single-nucleotide polymorphism; Lymphovascular invasion; Carcinogenesis; Genotype; Cancer; CA15-3; Pathology; Metastasis; Gene; Biology; Genetics","score_opus":0.044005681133845204,"score_gpt":0.31511709530617416,"score_spread":0.271111414172329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2533474121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99030334,0.0005861428,0.000010471938,0.0068768077,0.000068524445,0.0011025448,0.00072328455,0.000046273984,0.00028260399],"genre_scores_gemma":[0.9991926,0.00006414038,0.000023577728,0.00005839763,0.00036242252,0.000091640315,0.000015554851,0.00007066342,0.000120999604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973361,0.00039490248,0.0003746936,0.0004514634,0.0008980002,0.0005448462],"domain_scores_gemma":[0.9983825,0.0002771143,0.0001940184,0.0003720859,0.00051136105,0.00026293338],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010076138,0.00033269287,0.00049514417,0.00019112403,0.00013369079,0.00004152051,0.00019615269,0.0000891777,0.0011834864],"category_scores_gemma":[0.00010061246,0.00016514212,0.00004858354,0.000292283,0.0006873462,0.00026653215,0.000120744146,0.00026721458,0.00000924089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005700326,0.0002125065,0.79221827,0.0001487664,0.00013373076,0.0000093616745,0.0018343357,0.00000129009,0.07246528,0.000029370005,0.000094782416,0.1322823],"study_design_scores_gemma":[0.0025642938,0.0004480013,0.98026127,0.0011659327,0.00013350135,0.0010083604,0.00044220153,0.00009909652,0.013539438,0.00006332538,0.000038667804,0.00023592693],"about_ca_topic_score_codex":0.0035597202,"about_ca_topic_score_gemma":0.0010237837,"teacher_disagreement_score":0.18804301,"about_ca_system_score_codex":0.00032173927,"about_ca_system_score_gemma":0.00037511787,"threshold_uncertainty_score":0.9997296},"labels":[],"label_agreement":null},{"id":"W2546973056","doi":"10.1001/jamaoncol.2016.4884","title":"Association of Polymorphisms in <i>FCGR2A</i> and <i>FCGR3A</i> With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer","year":2016,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Breast cancer; Regimen; Cyclophosphamide; Cohort; Cancer; Chemotherapy","score_opus":0.02793474528304624,"score_gpt":0.3318939157411339,"score_spread":0.3039591704580877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2546973056","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711885,0.0010631984,0.0000065199306,0.024313819,0.000044535118,0.0007416399,0.00032716163,0.0000044635185,0.002310183],"genre_scores_gemma":[0.9976174,0.0014483844,0.000116197865,0.00025389215,0.00006672521,0.00015947058,0.00000618041,0.000017626375,0.0003140823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982821,0.00024522466,0.00047320852,0.00024829133,0.00042789977,0.00032327182],"domain_scores_gemma":[0.99829406,0.00083710474,0.0003322582,0.00023957816,0.00023269931,0.00006432464],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005692937,0.00014942966,0.0007055716,0.00018542317,0.00001528827,0.000002735006,0.000116298936,0.0001997057,0.00009169342],"category_scores_gemma":[0.00006718426,0.000079240825,0.000057062527,0.0003580609,0.0002414685,0.000064724096,0.000027204445,0.00014680577,0.000001267809],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024980595,0.0010770693,0.61506015,0.000062503954,0.00014647689,0.0000697398,0.003012909,0.000003652409,0.023773814,0.000102970414,0.00038248353,0.35381016],"study_design_scores_gemma":[0.0099445665,0.0058112727,0.9570828,0.00058071624,0.0001170373,0.000098436474,0.0004956083,0.000012027896,0.024562027,0.00007899087,0.0011316946,0.0000848032],"about_ca_topic_score_codex":0.010088302,"about_ca_topic_score_gemma":0.024033098,"teacher_disagreement_score":0.35372534,"about_ca_system_score_codex":0.001727168,"about_ca_system_score_gemma":0.0006964933,"threshold_uncertainty_score":0.9965036},"labels":[],"label_agreement":null},{"id":"W2547090396","doi":"10.1080/19420862.2016.1255389","title":"Development and preclinical studies of <sup>64</sup>Cu-NOTA-pertuzumab F(ab′)<sub>2</sub> for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT","year":2016,"lang":"en","type":"article","venue":"mAbs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"","keywords":"Pertuzumab; Trastuzumab; Biodistribution; Medicine; Nuclear medicine; Breast cancer; Cancer; Cancer research; Chemistry; Internal medicine; Biochemistry; In vitro","score_opus":0.06149780428111189,"score_gpt":0.37061000100646496,"score_spread":0.30911219672535306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2547090396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905343,0.0009556621,0.00006721355,0.0068686325,0.00004452023,0.0013733386,0.00007221239,0.00005644686,0.00002769082],"genre_scores_gemma":[0.99669707,0.00015823358,0.0015048936,0.00036675204,0.00005068564,0.0007021756,0.000012733493,0.00006754955,0.00043990853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972344,0.00028892246,0.00056405197,0.0006187563,0.00066842145,0.00062544225],"domain_scores_gemma":[0.99702454,0.0019268477,0.00014340121,0.0003304055,0.0003209554,0.0002538341],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002064373,0.0002802696,0.00071736745,0.00026936238,0.00010608615,0.000019433905,0.00016168432,0.000028537886,0.000026287085],"category_scores_gemma":[0.004089165,0.00018023449,0.00005004481,0.00028820848,0.00021494356,0.00008651273,0.00018437362,0.00020686496,0.00000841053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021942327,0.0008380682,0.038992476,0.0007917294,0.0003617826,0.00079118006,0.0064181895,0.000006782809,0.8004961,0.000005277145,0.022847317,0.10650876],"study_design_scores_gemma":[0.013340184,0.0028053683,0.041888203,0.008636273,0.00008707557,0.00015597018,0.0042401897,0.00022163722,0.9119188,0.00003345235,0.016077714,0.00059513754],"about_ca_topic_score_codex":0.000020707008,"about_ca_topic_score_gemma":0.00021890392,"teacher_disagreement_score":0.11142269,"about_ca_system_score_codex":0.0008689192,"about_ca_system_score_gemma":0.00049117283,"threshold_uncertainty_score":0.7349749},"labels":[],"label_agreement":null},{"id":"W2554303407","doi":"10.1038/bjc.2016.360","title":"Adjuvant chemotherapy and HER-2-directed therapy for early-stage breast cancer in the elderly","year":2016,"lang":"en","type":"review","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical trial; Systemic therapy; Oncology; Internal medicine; Population; Intensive care medicine; Adjuvant therapy; Randomized controlled trial; Cancer; Stage (stratigraphy); Adjuvant; Chemotherapy","score_opus":0.053753720127942994,"score_gpt":0.4222511520062968,"score_spread":0.3684974318783538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554303407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001450991,0.99265045,0.000012033679,0.0020807828,0.0004548792,0.0020986048,0.0010834326,0.00001736242,0.00015149268],"genre_scores_gemma":[0.00019020414,0.99500614,0.00009361945,0.00050288346,0.0018645532,0.00062594627,0.0000053577583,0.00014941925,0.0015618537],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99672973,0.00031965505,0.0010670258,0.0003966245,0.0008705017,0.0006164763],"domain_scores_gemma":[0.9977455,0.00037615228,0.0007425137,0.00030383878,0.0005903301,0.00024167229],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013539937,0.0004023149,0.0021066207,0.000265024,0.00009565586,0.00017337991,0.0005243403,0.00033810604,0.001406769],"category_scores_gemma":[0.00007393535,0.00025408855,0.000588258,0.00042085166,0.00020262058,0.00014561812,0.000027004751,0.001158992,0.0000027177969],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037224387,0.00009569008,0.00039190755,0.0036671709,0.00045369106,0.00036926987,0.00012474578,1.3680352e-7,0.0000051979437,0.0000023023856,0.008445163,0.9860725],"study_design_scores_gemma":[0.0041525173,0.00055581355,0.0062846937,0.07227549,0.00020034381,0.0035548036,0.000024752857,0.0000013347064,0.000004206326,0.000022931983,0.9126552,0.0002679424],"about_ca_topic_score_codex":0.002047231,"about_ca_topic_score_gemma":0.001412588,"teacher_disagreement_score":0.98580456,"about_ca_system_score_codex":0.00061104127,"about_ca_system_score_gemma":0.0025274672,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W2556607246","doi":"10.5858/arpa.2016-0331-cp","title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Guideline; Clinical Oncology; Internal medicine; Adenocarcinoma; Biomarker; Clinical pathology; Oncology; Pathology; Cancer","score_opus":0.1289693971999853,"score_gpt":0.4916737082039777,"score_spread":0.3627043110039924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556607246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98075086,0.0024162515,0.0044160127,0.009933052,0.00026413135,0.0010151629,0.0011298797,0.00003361133,0.000041033858],"genre_scores_gemma":[0.77976704,0.0068222806,0.20927663,0.0032883433,0.00071981305,0.000046509038,0.000019041712,0.00005259483,0.000007766879],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98995167,0.0028455793,0.0046587763,0.0012913011,0.00050727424,0.00074540684],"domain_scores_gemma":[0.94421047,0.05078294,0.002919839,0.0010456044,0.0006372222,0.00040393393],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.012187365,0.0004241397,0.00372298,0.00016427318,0.00010218359,0.0000023988084,0.0005421095,0.00031181597,0.000016216252],"category_scores_gemma":[0.02150605,0.00025723604,0.0005524485,0.00085636997,0.03919664,0.000055368262,0.0006102401,0.0012595685,7.0660684e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019924373,0.0004192155,0.67118925,0.00006563627,0.00016469229,0.00030930262,0.0005455489,3.5931694e-7,0.004143559,0.0000298702,0.003374159,0.31776598],"study_design_scores_gemma":[0.00876329,0.017959325,0.9639792,0.00075456913,0.00036821715,0.00015102986,0.005177975,0.00041866035,0.00007095744,0.00052802276,0.0016465589,0.0001822022],"about_ca_topic_score_codex":0.00037823754,"about_ca_topic_score_gemma":0.00032942314,"teacher_disagreement_score":0.31758377,"about_ca_system_score_codex":0.000070076785,"about_ca_system_score_gemma":0.0014196351,"threshold_uncertainty_score":0.99998796},"labels":[],"label_agreement":null},{"id":"W2559761169","doi":"10.1093/ajcp/aqw206","title":"<i>HER2</i>Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma","year":2016,"lang":"en","type":"review","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Guideline; Medicine; Targeted therapy; Clinical trial; Medical physics; Oncology; Internal medicine; Biomarker; Intensive care medicine; Pathology; Cancer","score_opus":0.21422844248419573,"score_gpt":0.5662473226282525,"score_spread":0.3520188801440568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559761169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016718524,0.9802609,0.0005321821,0.0003095089,0.0012959086,0.0005400568,0.000017479912,0.00001756375,0.00030785808],"genre_scores_gemma":[0.010501626,0.9590736,0.026661213,0.0006117921,0.002999511,0.000010184871,0.0000015539248,0.00011098589,0.000029529801],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859648,0.0041058357,0.007460843,0.0008779167,0.0007613284,0.00082929834],"domain_scores_gemma":[0.9644243,0.028958615,0.0045737037,0.00073542394,0.00047441156,0.00083355635],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014260973,0.00050882396,0.008015185,0.00069533364,0.000047500875,0.000027854976,0.0006437922,0.0006696401,0.00010243294],"category_scores_gemma":[0.03311369,0.00032721116,0.0014017987,0.00072786125,0.0023078604,0.00008247187,0.00041493666,0.004920721,0.000075301716],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045394202,0.00018462205,0.17308696,0.0006371953,0.00011519025,0.010387055,0.000010146825,6.610412e-8,1.1849177e-7,0.0000034526988,0.00026342968,0.81485784],"study_design_scores_gemma":[0.007071919,0.032354042,0.33968022,0.13328214,0.001980454,0.0517098,0.00007966936,0.000014224121,9.9421094e-8,0.00060924527,0.43246222,0.00075597013],"about_ca_topic_score_codex":0.000008482866,"about_ca_topic_score_gemma":0.000007234943,"teacher_disagreement_score":0.8141019,"about_ca_system_score_codex":0.00020876391,"about_ca_system_score_gemma":0.0025630489,"threshold_uncertainty_score":0.999918},"labels":[],"label_agreement":null},{"id":"W2559964267","doi":"10.1200/jco.2011.29.27_suppl.286","title":"The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.","year":2011,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Trastuzumab; Cohort; Internal medicine; Oncology; Cancer; Gynecology","score_opus":0.12100030117918352,"score_gpt":0.5276321636059318,"score_spread":0.40663186242674826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559964267","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978356,0.0006665996,0.00003044803,0.0077266297,0.0011453034,0.0004827882,0.000010067205,0.000004910639,0.011577234],"genre_scores_gemma":[0.9965762,0.0018342511,0.0002569215,0.0006374,0.00049821637,0.000017775736,3.5421468e-7,0.000020755784,0.0001581456],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99545074,0.0013807742,0.0020182743,0.00018960742,0.0006062831,0.00035429906],"domain_scores_gemma":[0.9909728,0.006920099,0.0010719964,0.0002446275,0.00046017344,0.00033028558],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006749764,0.00014392716,0.0014366426,0.00011922847,0.0000375143,0.0000037807686,0.00033664415,0.0003131009,0.00023708983],"category_scores_gemma":[0.003392391,0.00007783572,0.0003949796,0.00023163234,0.00055591244,0.000057941714,0.00005277445,0.0019113196,0.00001659311],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05706421,0.0010519462,0.14130612,0.000057856072,0.00026407032,0.0008213698,0.00020910548,0.000024445646,0.0002442481,0.00007133037,0.0012187179,0.7976666],"study_design_scores_gemma":[0.013251209,0.09324263,0.88207996,0.00091577746,0.00013854308,0.00038722053,0.00013235945,0.00005673307,0.0026830083,0.00014884873,0.0068755364,0.00008814781],"about_ca_topic_score_codex":0.00025056332,"about_ca_topic_score_gemma":0.00047365346,"teacher_disagreement_score":0.79757845,"about_ca_system_score_codex":0.0005251306,"about_ca_system_score_gemma":0.0023764374,"threshold_uncertainty_score":0.8303839},"labels":[],"label_agreement":null},{"id":"W2560641415","doi":"10.1016/j.jmb.2016.12.006","title":"Systematic Identification of Oncogenic EGFR Interaction Partners","year":2016,"lang":"en","type":"article","venue":"Journal of Molecular Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University Health Network","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council","keywords":"Epidermal growth factor receptor; Cyclin-dependent kinase 8; ERBB3; Signal transduction; Biology; Small hairpin RNA; Cell biology; Receptor tyrosine kinase; Protein kinase B; Tyrosine kinase; Gene knockdown; Cancer research; Epidermal growth factor; Receptor; Cell culture; Biochemistry; Genetics; Notch signaling pathway","score_opus":0.040649225039150895,"score_gpt":0.4500055448296283,"score_spread":0.4093563197904774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560641415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9690412,0.0014779201,0.025781611,0.002638264,0.00048397164,0.00027474712,0.0000028437491,0.000005603048,0.00029380588],"genre_scores_gemma":[0.99914485,0.00021953072,0.00028932505,0.00008150614,0.00008403792,0.0000060533675,0.0000010830541,0.000009890687,0.00016374994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985397,0.00025375315,0.00076938845,0.000091454094,0.00021877012,0.00012693292],"domain_scores_gemma":[0.9985292,0.0001201389,0.0006392409,0.00021004137,0.00041972072,0.000081667036],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001028474,0.00006422253,0.0003534133,0.0002210198,0.000010494121,0.000004015853,0.00012178126,0.00008547505,0.00006877014],"category_scores_gemma":[0.0010616749,0.000036978465,0.0001643059,0.000112621645,0.00007937233,0.000040761544,0.00002096789,0.00012840018,0.000031574764],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014480551,0.00004883042,0.0009465938,0.0010024828,0.00019179801,0.00004235233,0.00004047174,0.0000016795043,0.9945854,0.0003297915,0.00021368038,0.002452102],"study_design_scores_gemma":[0.001419422,0.0012963917,0.0011849931,0.0040149093,0.00022022742,0.0011288978,0.00014021184,0.000026901735,0.9885516,0.0008112458,0.0011318708,0.000073307165],"about_ca_topic_score_codex":0.000004679455,"about_ca_topic_score_gemma":8.6287014e-7,"teacher_disagreement_score":0.03010359,"about_ca_system_score_codex":0.00018543884,"about_ca_system_score_gemma":0.00017742216,"threshold_uncertainty_score":0.1507938},"labels":[],"label_agreement":null},{"id":"W2563445076","doi":"10.1021/acs.molpharmaceut.6b00963","title":"<sup>64</sup>Cu-Labeled Trastuzumab Fab-PEG<sub>24</sub>-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents","year":2017,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto","keywords":"Biodistribution; Trastuzumab; Chemistry; Pharmacokinetics; Cancer research; In vitro; Pharmacology; Cancer; Medicine; Breast cancer; Biochemistry; Internal medicine","score_opus":0.0501293980763969,"score_gpt":0.38584092137977055,"score_spread":0.33571152330337367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563445076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97723395,0.011518516,0.0022103596,0.0046760654,0.00032650566,0.0031640786,0.000630091,0.00009427625,0.00014617495],"genre_scores_gemma":[0.99424773,0.0027494899,0.0010491797,0.0010152768,0.00016139496,0.00027348657,0.00028595253,0.00013847333,0.00007901124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960183,0.00018297853,0.0008495757,0.0010592636,0.000703772,0.0011860919],"domain_scores_gemma":[0.997644,0.00013151545,0.000248145,0.00086734665,0.00034095594,0.0007680319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008388394,0.0005945203,0.000872847,0.00033453843,0.0005420113,0.0005076224,0.00055662345,0.00010152825,0.00006411213],"category_scores_gemma":[0.00030171638,0.00064942136,0.00013370154,0.00030105206,0.0005174285,0.00019372278,0.0003440677,0.000813455,0.000036659312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010578978,0.0006772232,0.049574118,0.0006609563,0.0003034524,0.0008459548,0.00086655066,0.0001670125,0.8672678,0.00004270994,0.043191083,0.035345234],"study_design_scores_gemma":[0.013095638,0.0003687428,0.004979635,0.00031286274,0.00033945276,0.00025453782,0.00051872904,0.07889264,0.74575204,0.000065530796,0.15464225,0.00077793683],"about_ca_topic_score_codex":0.0000942554,"about_ca_topic_score_gemma":0.000010203644,"teacher_disagreement_score":0.121515766,"about_ca_system_score_codex":0.00060015346,"about_ca_system_score_gemma":0.00018723478,"threshold_uncertainty_score":0.9995957},"labels":[],"label_agreement":null},{"id":"W2566727384","doi":"","title":"進行・再発の薬物療法Pertuzumab（パージェタ(R)）を用いた進行乳癌症例１ Trastuzumab＋Pertuzumab＋DTX（1st line）（臨床報告）","year":2014,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Trastuzumab; Medicine; Internal medicine","score_opus":0.06880277521345375,"score_gpt":0.39063594190029527,"score_spread":0.32183316668684153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566727384","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2702847,0.09015407,0.009466096,0.17586413,0.045224145,0.013613138,0.0013577082,0.0041531837,0.3898828],"genre_scores_gemma":[0.93060386,0.0139192855,0.0006788666,0.011004586,0.018123383,0.00052806834,0.00034149457,0.0006705892,0.024129858],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9816457,0.0017158387,0.002856967,0.0029641155,0.006241408,0.004575974],"domain_scores_gemma":[0.9871807,0.0025068203,0.00069611106,0.0033412173,0.0010135465,0.0052616135],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0056830994,0.001925593,0.0030302363,0.001143687,0.00093628804,0.00035369358,0.0029322694,0.0012885768,0.045314286],"category_scores_gemma":[0.006367383,0.0017578546,0.0010150424,0.002064749,0.0021801258,0.00055471255,0.0009688608,0.005294008,0.015315326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014931348,0.002198935,0.0014520254,0.0032038032,0.0013826165,0.0013748033,0.0053566345,0.000040942272,0.016252775,0.0005398654,0.44736594,0.51933855],"study_design_scores_gemma":[0.0127925,0.003884974,0.0009055,0.0029866172,0.0011414007,0.00058267196,0.0010005997,0.039872143,0.012679218,0.00021392832,0.9220701,0.001870337],"about_ca_topic_score_codex":0.0010944286,"about_ca_topic_score_gemma":0.000095072726,"teacher_disagreement_score":0.66031915,"about_ca_system_score_codex":0.0028159684,"about_ca_system_score_gemma":0.003989598,"threshold_uncertainty_score":0.99934876},"labels":[],"label_agreement":null},{"id":"W2566808867","doi":"10.1007/s40262-016-0496-y","title":"A Phase I Pharmacokinetic Study of Trastuzumab Emtansine (T-DM1) in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function","year":2016,"lang":"en","type":"article","venue":"Clinical Pharmacokinetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab emtansine; Medicine; Internal medicine; Pharmacokinetics; Metastatic breast cancer; Breast cancer; Gastroenterology; Endocrinology; Cancer","score_opus":0.08172419646481328,"score_gpt":0.4483246871888897,"score_spread":0.3666004907240764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2566808867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949438,0.00011166078,0.000092676986,0.000878567,0.00036167612,0.0029295073,0.0005815899,0.00004896197,0.000051558276],"genre_scores_gemma":[0.99819624,0.00045288607,0.00015729059,0.00035001605,0.00032695383,0.00018692679,0.000039063976,0.00009947523,0.00019116212],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952248,0.00064397417,0.0016475972,0.00082900614,0.0009873888,0.00066725345],"domain_scores_gemma":[0.9968616,0.00094556744,0.0004430245,0.000371576,0.0007784434,0.0005998199],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006407059,0.00046459818,0.0011488001,0.00033533596,0.00008904174,0.000021293916,0.00021922641,0.00010779102,0.0022332263],"category_scores_gemma":[0.000367483,0.00028586065,0.00011233244,0.0006720896,0.0005223487,0.00021403572,0.00013171429,0.0006546531,0.000012655229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047113054,0.03309375,0.65971875,0.0007968929,0.0014040958,0.00021530244,0.000870335,0.000008487916,0.027381148,0.0000034613645,0.0014512517,0.22794347],"study_design_scores_gemma":[0.10365732,0.02668233,0.8616557,0.00071825646,0.0012639717,0.0000179563,0.00013503575,0.00020581968,0.0051119043,0.000008153685,0.000114112925,0.00042941913],"about_ca_topic_score_codex":0.00016949972,"about_ca_topic_score_gemma":0.000080813246,"teacher_disagreement_score":0.22751406,"about_ca_system_score_codex":0.00027688968,"about_ca_system_score_gemma":0.0003924067,"threshold_uncertainty_score":0.99995935},"labels":[],"label_agreement":null},{"id":"W2569849644","doi":"10.1016/j.jtho.2016.11.1504","title":"P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC","year":2017,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cancer; Oncology; Chemotherapy; Monoclonal antibody; Neuregulin; Lung cancer; In situ hybridization; Phases of clinical research; Cancer research; Pathology; Antibody; Receptor; Messenger RNA; Immunology","score_opus":0.06833756263630814,"score_gpt":0.51890546857189,"score_spread":0.4505679059355819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2569849644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857592,0.00074637606,0.0006805836,0.009618375,0.00042378,0.0017097002,0.000012501593,0.000014000374,0.0010354605],"genre_scores_gemma":[0.9870903,0.0010514022,0.008827129,0.0011206523,0.0003726153,0.000043445034,0.0000034209756,0.00008504688,0.0014060121],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957663,0.0006188401,0.001556677,0.0004096418,0.0010264708,0.0006221043],"domain_scores_gemma":[0.995547,0.00048843364,0.0017942362,0.0009098345,0.0008588186,0.00040170382],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002734733,0.00035430072,0.0021410405,0.00055232213,0.00014523084,0.000044986697,0.00087592023,0.00021742843,0.0007426347],"category_scores_gemma":[0.0007231589,0.0002632805,0.00024811452,0.00035260274,0.00042603532,0.0003162094,0.00010904112,0.0011783636,0.000018159337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12817235,0.014177874,0.005218819,0.00039688224,0.0011814394,0.007006118,0.0055046487,0.0001036808,0.022408247,0.000006723576,0.0019847476,0.8138385],"study_design_scores_gemma":[0.3428176,0.27576616,0.16184908,0.0056412085,0.001820442,0.0079727955,0.018563746,0.0025906565,0.12370665,0.0007968313,0.056779984,0.0016948399],"about_ca_topic_score_codex":0.00017225475,"about_ca_topic_score_gemma":0.0005092581,"teacher_disagreement_score":0.8121436,"about_ca_system_score_codex":0.0011400321,"about_ca_system_score_gemma":0.0026279045,"threshold_uncertainty_score":0.99998194},"labels":[],"label_agreement":null},{"id":"W2571057012","doi":"10.1158/1078-0432.ccr-16-1496","title":"Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC)","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":160,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Internal medicine; Rash; Gastroenterology; Nausea; Cohort; Anemia; Metastatic breast cancer; Pharmacokinetics; Diarrhea; Vomiting; Neutropenia; Breast cancer; Cancer; Toxicity","score_opus":0.18753899173105087,"score_gpt":0.5709110171428204,"score_spread":0.38337202541176957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2571057012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198097,0.00025582864,0.0000038111682,0.00097170105,0.00019173231,0.006181102,0.00016738649,0.000036887755,0.00021059644],"genre_scores_gemma":[0.9962891,0.00043974366,0.00021776008,0.00011459969,0.0003005383,0.0021419667,0.00003421227,0.00016540707,0.00029670703],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9893198,0.0015838173,0.0017730126,0.0016949826,0.004015847,0.0016125648],"domain_scores_gemma":[0.9935072,0.0005326508,0.000516418,0.0025281007,0.0019261908,0.0009894167],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006181791,0.000495707,0.0019227545,0.0006676975,0.00033650704,0.00013611195,0.0011138429,0.0002091668,0.0005169245],"category_scores_gemma":[0.0010326224,0.0003606832,0.000113380825,0.0011860424,0.0014980742,0.00063728885,0.00050036877,0.0029980275,0.000015849517],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03307132,0.021993479,0.88279307,0.0003911526,0.00021583219,0.0006117907,0.0009782274,0.00011280914,0.00013342273,0.0000025318159,0.00023989605,0.059456468],"study_design_scores_gemma":[0.051866103,0.031625446,0.9101379,0.0031788696,0.00008426544,0.000006702971,0.0017972414,0.00028872772,0.00042353716,0.000024052542,0.00017317015,0.0003940011],"about_ca_topic_score_codex":0.059950996,"about_ca_topic_score_gemma":0.112648055,"teacher_disagreement_score":0.059062466,"about_ca_system_score_codex":0.0014711567,"about_ca_system_score_gemma":0.0044925725,"threshold_uncertainty_score":0.9998845},"labels":[],"label_agreement":null},{"id":"W2577984904","doi":"10.12788/j.cmonc.0037","title":"When is an answer not an answer?","year":2013,"lang":"en","type":"article","venue":"Community Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto","funders":"","keywords":"Computer science","score_opus":0.22753971955614408,"score_gpt":0.4586631591440516,"score_spread":0.23112343958790751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2577984904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93986094,0.00009317362,0.000050974304,0.023601204,0.00032952364,0.0007571531,0.000019171446,0.00015356208,0.035134293],"genre_scores_gemma":[0.9757421,0.00007055233,0.0034275274,0.017403426,0.00039226995,0.0001455983,0.000108260996,0.000053696534,0.002656583],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965768,0.0018939063,0.00032588636,0.00025131187,0.00035206656,0.0006000648],"domain_scores_gemma":[0.99633586,0.00042016836,0.000070759976,0.0021317692,0.0004255631,0.00061589165],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013093113,0.00019610391,0.00050855207,0.00017940074,0.00038955218,0.000048932445,0.00087736035,0.0003806833,0.012004941],"category_scores_gemma":[0.00025897656,0.00018229165,0.00007473366,0.00018574792,0.00043375688,0.00030763142,0.00036204094,0.0020950318,0.0013886695],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005539434,0.0046567176,0.04132562,0.00025048296,0.00016466588,0.0001303348,0.05485986,0.0000018537646,0.03378352,0.00038670583,0.31696266,0.54692364],"study_design_scores_gemma":[0.0028789714,0.010464028,0.11741758,0.00006404429,0.000064058586,0.0002025477,0.0075892513,0.0008451734,0.004078987,0.0036656074,0.8523665,0.00036324502],"about_ca_topic_score_codex":0.017449446,"about_ca_topic_score_gemma":0.004598704,"teacher_disagreement_score":0.5465604,"about_ca_system_score_codex":0.00049525296,"about_ca_system_score_gemma":0.00063629664,"threshold_uncertainty_score":0.9993889},"labels":[],"label_agreement":null},{"id":"W2582500594","doi":"10.1200/jco.2005.23.16_suppl.6070","title":"Patterns of trastuzumab use and cost in a single Canadian cancer institute","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Pharmacy; Metastatic breast cancer; Cancer; Breast cancer; Chemotherapy; Internal medicine; Family medicine","score_opus":0.4083267166461031,"score_gpt":0.5638005249704544,"score_spread":0.15547380832435131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582500594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97789866,0.00042414467,0.000027272625,0.020062579,0.00053523097,0.00019253528,0.000016708143,0.0000016759335,0.00084118237],"genre_scores_gemma":[0.9935569,0.0017581823,0.0010410583,0.0025753486,0.00085830275,0.0000045272186,9.0522684e-7,0.000011004067,0.00019375741],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976081,0.00020589487,0.0015006639,0.0001271736,0.0002825098,0.0002756553],"domain_scores_gemma":[0.9975873,0.00080253225,0.00048234494,0.000121210855,0.00032056312,0.0006860174],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019138913,0.00007912408,0.0009106212,0.0002700304,0.000015762893,0.000008053719,0.00011455581,0.0002635196,0.0002537956],"category_scores_gemma":[0.0030300096,0.000061976665,0.00011946763,0.00013035338,0.00018036508,0.00017224473,0.000026552949,0.0009826735,0.0000035546793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006165936,0.0005196952,0.6404718,0.000030082689,0.00006551943,0.0005799245,0.00015117816,0.000039598162,0.00013813264,0.00002329271,0.0019273071,0.35543683],"study_design_scores_gemma":[0.004232125,0.0031125008,0.6133567,0.00025474836,0.000047510635,0.00018517488,0.00005258856,0.00007766839,0.00008952374,0.000013540711,0.378532,0.00004593754],"about_ca_topic_score_codex":0.06454043,"about_ca_topic_score_gemma":0.7029676,"teacher_disagreement_score":0.6384272,"about_ca_system_score_codex":0.000972045,"about_ca_system_score_gemma":0.0070790243,"threshold_uncertainty_score":0.99854994},"labels":[],"label_agreement":null},{"id":"W2586584461","doi":"10.1007/978-1-4939-6759-9_5","title":"Using Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Signal Transduction","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tissue microarray; DNA microarray; Protein microarray; Computational biology; Transduction (biophysics); Signal transduction; Throughput; Immunohistochemistry; Biology; Cell biology; Computer science; Biophysics; Biochemistry; Gene expression; Gene; Immunology","score_opus":0.20833832949128106,"score_gpt":0.5520613957039319,"score_spread":0.3437230662126508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586584461","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029615598,0.0005757994,0.9673822,0.0010099004,0.00016920321,0.0009783764,0.00003670917,0.000007997365,0.00022421038],"genre_scores_gemma":[0.23427051,0.000026399992,0.7655374,0.000023525234,0.000037130125,0.00004680339,0.00001528068,0.00002490212,0.00001805405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752253,0.0010756189,0.00056063005,0.00035814237,0.00019999324,0.00028308673],"domain_scores_gemma":[0.9976834,0.00080495904,0.00038250457,0.00063321827,0.000446916,0.00004897732],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034673421,0.0001502154,0.0005193366,0.000187401,0.000079395344,0.000020013667,0.00034530525,0.00018694079,0.00002375425],"category_scores_gemma":[0.004007764,0.00011717319,0.00012833007,0.00018247489,0.0005996245,0.000051773368,0.00006672967,0.00022776682,5.005381e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042768253,0.00008972895,0.00034027366,0.00022146363,0.00009847378,0.0000039998254,0.00070429995,0.0001845513,0.95302165,0.0038209176,0.0000025380903,0.041084398],"study_design_scores_gemma":[0.000903158,0.0009387042,0.00033655448,0.00010686356,0.00008369418,0.000025144489,0.0004702644,0.003587906,0.98543847,0.0070539815,0.00095607305,0.000099190795],"about_ca_topic_score_codex":0.00037012683,"about_ca_topic_score_gemma":0.000020392303,"teacher_disagreement_score":0.20465492,"about_ca_system_score_codex":0.00007276699,"about_ca_system_score_gemma":0.00019650807,"threshold_uncertainty_score":0.47979575},"labels":[],"label_agreement":null},{"id":"W2586974551","doi":"10.1074/mcp.m116.061267","title":"Effects of ErbB2 Overexpression on the Proteome and ErbB Ligand-specific Phosphosignaling in Mammary Luminal Epithelial Cells","year":2017,"lang":"en","type":"article","venue":"Molecular & Cellular Proteomics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council Canada; Association for International Cancer Research; Cancer Research UK; National Institute for Health and Care Research; National Institute for Social Care and Health Research","keywords":"Stable isotope labeling by amino acids in cell culture; ErbB; Biology; Cancer research; Signal transduction; Epidermal growth factor receptor; Cell biology; Epidermal growth factor; Phosphorylation; Receptor; Proteomics; Genetics","score_opus":0.015341490539569777,"score_gpt":0.2663836283510436,"score_spread":0.25104213781147383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586974551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917598,0.0010140389,0.0018185511,0.0008891885,0.00012494986,0.0039253356,0.000022133741,0.000021768425,0.0004242799],"genre_scores_gemma":[0.9952616,0.00035849476,0.0034467743,0.00014600575,0.00014429033,0.00031927094,0.000010846827,0.00007362513,0.00023908533],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976193,0.00020988095,0.00039522926,0.0005551655,0.0007262181,0.00049423345],"domain_scores_gemma":[0.99811345,0.00014903433,0.00026342593,0.0012042453,0.0000958156,0.00017399981],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083103,0.0002994331,0.0004638006,0.00014301343,0.00023984094,0.00013477883,0.000566868,0.00023177928,0.000048583614],"category_scores_gemma":[0.0002671151,0.00022684006,0.00014225098,0.00012303292,0.00031505452,0.00008875938,0.0003731049,0.00079939316,0.000022879896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005211983,0.00017973414,0.00017655165,0.0006600208,0.00003206966,0.00069578516,0.00026771723,0.000011158379,0.9956482,0.00030632733,0.00024654705,0.0012546848],"study_design_scores_gemma":[0.0018869952,0.00050296076,0.0014304351,0.0018429516,0.000022696064,0.000016512404,0.000022687442,0.00041221819,0.9920277,0.0005251575,0.0010930098,0.00021666325],"about_ca_topic_score_codex":0.000111883615,"about_ca_topic_score_gemma":0.0000010250327,"teacher_disagreement_score":0.0036204928,"about_ca_system_score_codex":0.00013118837,"about_ca_system_score_gemma":0.0001861957,"threshold_uncertainty_score":0.9250269},"labels":[],"label_agreement":null},{"id":"W2588395233","doi":"10.1093/annonc/mdw365.94","title":"HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Anthracycline; Internal medicine; Metastatic breast cancer; Trastuzumab emtansine; Taxane; Oncology; Clinical endpoint; Capecitabine; Vinorelbine; Breast cancer; Epirubicin; Chemotherapy; Cancer; Clinical trial","score_opus":0.0772610085246743,"score_gpt":0.4431137932374388,"score_spread":0.3658527847127645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588395233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876701,0.000735531,0.00025371776,0.002951823,0.000054322118,0.0073003736,0.00023344035,0.000026084654,0.0007746013],"genre_scores_gemma":[0.99407005,0.0031057305,0.0006668198,0.00077087013,0.00009618045,0.0009382001,0.000049016446,0.00009619465,0.00020693534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99577886,0.00073913933,0.0011919364,0.00079858163,0.0007012802,0.00079020543],"domain_scores_gemma":[0.99605274,0.0012888693,0.0008846642,0.0004330386,0.0010220448,0.00031864966],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091041176,0.00051373156,0.003306858,0.00031070338,0.00008113069,0.000023736839,0.00032730403,0.0001606046,0.00012063173],"category_scores_gemma":[0.00022027726,0.00031508112,0.00012331821,0.00061949994,0.0012933539,0.00039284222,0.000121970974,0.0003820428,0.000002431186],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.767844,0.007456395,0.002941711,0.00030519904,0.00093693286,0.00014975201,0.0014434686,0.000066394045,0.0016667212,0.000012581104,0.00020693627,0.21696986],"study_design_scores_gemma":[0.94305146,0.03894016,0.007023792,0.0037573213,0.0002939145,0.00009948843,0.00026875964,0.00093151693,0.004839536,0.000032305146,0.00036557447,0.00039616556],"about_ca_topic_score_codex":0.0037406061,"about_ca_topic_score_gemma":0.0017703051,"teacher_disagreement_score":0.2165737,"about_ca_system_score_codex":0.00082954945,"about_ca_system_score_gemma":0.0023358797,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2588570873","doi":"10.1016/j.ejca.2017.08.019","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Universitätsklinikum Hamburg-Eppendorf; Centre Léon Bérard; Assistance publique-Hôpitaux de Paris; Baskent Üniversitesi; Gaziantep Üniversitesi; Ege Üniversitesi; Institut Bergonié; University of Sussex; F. Hoffmann-La Roche; Roche","keywords":"Trastuzumab; Medicine; Breast cancer; Adjuvant; Oncology; Internal medicine; Adjuvant therapy; Cancer","score_opus":0.028440997345682596,"score_gpt":0.3521403557355309,"score_spread":0.32369935838984826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588570873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206805,0.00440801,0.000043711047,0.00059168995,0.0001696978,0.0017846309,0.00029804365,0.0000033333608,0.00063284696],"genre_scores_gemma":[0.99462825,0.0047163414,0.000045194985,0.000041871663,0.0002673659,0.000021309,0.0000014378217,0.00005119239,0.00022705228],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996888,0.0005838855,0.0010773455,0.00030010962,0.0008526583,0.00029804852],"domain_scores_gemma":[0.9966318,0.00028542016,0.0014091324,0.0005286256,0.00094227615,0.00020271617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019138473,0.00024710162,0.0012996813,0.00020451033,0.00018572618,0.000040376093,0.000452214,0.00003662748,0.0001743371],"category_scores_gemma":[0.00016906078,0.00015789266,0.00034938185,0.00022888524,0.0005749318,0.00009383882,0.0000837159,0.00038379926,2.3220758e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16262214,0.0015865077,0.3491071,0.00022189466,0.015782554,0.00033476582,0.011850166,0.0006127415,0.009162734,0.000008665618,0.00021423404,0.44849652],"study_design_scores_gemma":[0.04130117,0.0060156058,0.9445041,0.00072600343,0.0033986634,0.00024719824,0.0003467731,0.000061372404,0.0028099453,0.0000045560832,0.00044464692,0.0001399777],"about_ca_topic_score_codex":0.001128948,"about_ca_topic_score_gemma":0.00028813086,"teacher_disagreement_score":0.595397,"about_ca_system_score_codex":0.00016895539,"about_ca_system_score_gemma":0.00062767783,"threshold_uncertainty_score":0.6438676},"labels":[],"label_agreement":null},{"id":"W2588914509","doi":"10.1016/j.jtho.2017.01.007","title":"HER2 Transmembrane Domain Mutations: Rare New Target for Non–Small Cell Lung Cancer Therapy","year":2017,"lang":"en","type":"letter","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Medicine; Lung cancer; Breast cancer; ErbB; Targeted therapy; Cancer; Cancer research; Oncology; Internal medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Receptor","score_opus":0.06442857875986661,"score_gpt":0.4781557608819319,"score_spread":0.4137271821220653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588914509","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007298348,0.020065144,0.0047940137,0.95594954,0.004271838,0.002947325,0.00023176901,0.000027946253,0.0044140867],"genre_scores_gemma":[0.0026508302,0.019973364,0.13180517,0.59618264,0.10487252,0.0009956968,0.00053820835,0.0008795276,0.14210205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959605,0.00045397176,0.0012597854,0.00049998215,0.0008990397,0.00092673296],"domain_scores_gemma":[0.99519175,0.00084512227,0.0017503322,0.0007276857,0.001039347,0.00044577883],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0017001345,0.00052064256,0.002019822,0.0006487025,0.00023950885,0.0000968983,0.0010566706,0.0017971778,0.001823763],"category_scores_gemma":[0.00019970088,0.000410659,0.0008911458,0.00017199162,0.00023357166,0.00015651845,0.000044057986,0.0047457465,0.00001959259],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027622427,0.00018714556,0.00022240412,0.0023082055,0.0006921437,0.005115024,0.0009658137,0.000029628485,0.0015579757,5.7794983e-7,0.8937351,0.09242374],"study_design_scores_gemma":[0.0045732576,0.0038524,0.00013453972,0.001348351,0.0006916506,0.0013169555,0.000107947024,0.00006699116,0.0027533686,0.0006010367,0.9841975,0.0003560197],"about_ca_topic_score_codex":0.00021216272,"about_ca_topic_score_gemma":0.0000913812,"teacher_disagreement_score":0.3597669,"about_ca_system_score_codex":0.0015778571,"about_ca_system_score_gemma":0.011993536,"threshold_uncertainty_score":0.99983454},"labels":[],"label_agreement":null},{"id":"W2589233229","doi":"10.1200/jco.2012.30.15_suppl.tps658","title":"HALT MBC: HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Metastatic breast cancer; Internal medicine; Discontinuation; Oncology; Clinical endpoint; Breast cancer; Chemotherapy; Blockade; Cancer; Adverse effect; Clinical trial; Receptor","score_opus":0.1545185930237691,"score_gpt":0.5411181389432805,"score_spread":0.3865995459195114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2589233229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9526122,0.0004537161,0.00025387283,0.043249648,0.0006875102,0.0006202057,0.00009662822,0.0000048052198,0.0020214142],"genre_scores_gemma":[0.9938547,0.00030215265,0.002087041,0.0023835988,0.0010958912,0.00004190095,0.000004598318,0.000024898949,0.00020521398],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99556434,0.0013230015,0.0016758256,0.00017387472,0.00082519965,0.0004377466],"domain_scores_gemma":[0.99456435,0.0028693348,0.0010872493,0.0002273591,0.00070859294,0.0005431118],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052810735,0.00015262494,0.0012860369,0.0001757941,0.00003868515,0.0000070306287,0.00023459348,0.00019080903,0.0014847164],"category_scores_gemma":[0.001440268,0.00008119261,0.00022474887,0.00036652214,0.0003135378,0.0001742024,0.000064389984,0.0014307357,0.000024680032],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035405166,0.009842263,0.27275577,0.00029761778,0.001072721,0.0007036737,0.004215984,0.0002946949,0.0023994897,0.00014758202,0.084792204,0.58807284],"study_design_scores_gemma":[0.007381929,0.01517101,0.93719935,0.0012150506,0.00038259482,0.0008540798,0.0012131884,0.00006741636,0.0012017239,0.00005181009,0.03513112,0.00013072116],"about_ca_topic_score_codex":0.0003659826,"about_ca_topic_score_gemma":0.0007374395,"teacher_disagreement_score":0.66444355,"about_ca_system_score_codex":0.000462597,"about_ca_system_score_gemma":0.001909368,"threshold_uncertainty_score":0.99942803},"labels":[],"label_agreement":null},{"id":"W2590097386","doi":"10.1200/jco.2012.30.34_suppl.166","title":"Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Bone and Joint Health Institute; Princess Margaret Cancer Centre; University of Toronto; Cancer Care Ontario; McMaster University; Sunnybrook Health Science Centre; University of Calgary; Institute for Clinical Evaluative Sciences","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Oncology; Cohort; Breast cancer; Odds ratio; Population; Cancer; Cancer registry; Medical record; Exact test","score_opus":0.5359880732810848,"score_gpt":0.5793496880569081,"score_spread":0.04336161477582334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2590097386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99634194,0.0006806875,0.000015977552,0.0013769676,0.00045811044,0.00031269138,0.0000031495663,0.000004980769,0.0008054714],"genre_scores_gemma":[0.9825226,0.0003155839,0.016011147,0.00028130694,0.00069319195,0.000006037674,9.943899e-7,0.000016086882,0.0001530397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9929201,0.0003630002,0.005494822,0.00022218085,0.00039579533,0.000604101],"domain_scores_gemma":[0.9927968,0.0023368166,0.0030617684,0.00014004186,0.0006603435,0.0010042745],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0047283135,0.00016224608,0.0017610195,0.0001562555,0.000038258815,0.000008559643,0.00007958373,0.00022488323,0.00021801902],"category_scores_gemma":[0.034812596,0.0001137029,0.00014762777,0.00013708699,0.00017456667,0.00013364782,0.00007761494,0.0008379876,0.000001356496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005869779,0.0005201565,0.7689328,0.000034231096,0.000067751724,0.00014761201,0.000854731,0.0000022079007,0.0012670376,0.00000731766,0.00022982304,0.22734931],"study_design_scores_gemma":[0.0037609916,0.022300927,0.9678252,0.00032554867,0.00007678514,0.00029529372,0.00029077608,0.00001548352,0.0005088043,0.00005287967,0.0044562276,0.00009112421],"about_ca_topic_score_codex":0.029533094,"about_ca_topic_score_gemma":0.02402384,"teacher_disagreement_score":0.22725819,"about_ca_system_score_codex":0.00091986614,"about_ca_system_score_gemma":0.0029855885,"threshold_uncertainty_score":0.9937852},"labels":[],"label_agreement":null},{"id":"W2591046956","doi":"10.1634/theoncologist.2016-0265","title":"Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"U.S. Food and Drug Administration; Eli Lilly and Company","keywords":"Medicine; Ramucirumab; Capecitabine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Clinical endpoint; Phases of clinical research; Cancer; Randomized controlled trial; Confidence interval; Oncology; Chemotherapy; Colorectal cancer","score_opus":0.051736645608612145,"score_gpt":0.408330866346466,"score_spread":0.35659422073785385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591046956","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98891515,0.00007089614,0.000022034761,0.0010959059,0.000043600365,0.009430049,0.000037780017,0.000025415658,0.00035914854],"genre_scores_gemma":[0.9970621,0.00008245041,0.0001917395,0.000062352214,0.000015935471,0.0015563157,0.000021820928,0.000039636754,0.0009676574],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972031,0.00061212626,0.00064845354,0.00038774306,0.00072517176,0.0004234215],"domain_scores_gemma":[0.99760807,0.0004310566,0.0005529641,0.00085676357,0.00044859527,0.0001025267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014714467,0.0002647377,0.0013206742,0.00019149666,0.00020135644,0.000033149292,0.0004341512,0.00005648376,0.00033675515],"category_scores_gemma":[0.0007681215,0.00011558262,0.00004146208,0.0004528445,0.00075279915,0.00016582078,0.00012054826,0.0003701422,0.0000025472277],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.847567,0.015221726,0.0712094,0.0001468837,0.00030598167,0.00025690324,0.0024620327,0.00021114419,0.000032763575,0.000008308796,0.00005916362,0.06251866],"study_design_scores_gemma":[0.82426274,0.03221455,0.14033847,0.0008267986,0.00033557523,0.000016550888,0.0010796249,0.0006211613,0.00008850764,0.000009453064,0.000036436286,0.0001701138],"about_ca_topic_score_codex":0.0092335045,"about_ca_topic_score_gemma":0.06360273,"teacher_disagreement_score":0.069129065,"about_ca_system_score_codex":0.00081220997,"about_ca_system_score_gemma":0.0010029355,"threshold_uncertainty_score":0.9973641},"labels":[],"label_agreement":null},{"id":"W2591342011","doi":"10.1200/jco.2015.33.28_suppl.117","title":"Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Placebo; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Population; Breast cancer; Trastuzumab; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.14825902496273938,"score_gpt":0.4963269494320232,"score_spread":0.3480679244692838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591342011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94610095,0.0036306747,0.0000376453,0.03592451,0.00534146,0.0068797185,0.00004140106,0.000025596619,0.002018063],"genre_scores_gemma":[0.9822364,0.007600511,0.00019836884,0.0034417599,0.004054964,0.00061095215,0.000008737528,0.00007647939,0.0017718333],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9843545,0.0061878394,0.005788076,0.00056941935,0.0021407215,0.0009594725],"domain_scores_gemma":[0.9735736,0.019306777,0.0029505289,0.00090368866,0.0011706313,0.002094744],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.030537385,0.00047300494,0.0067379046,0.0002825398,0.00012004125,0.00008731245,0.001073975,0.0005434579,0.0009482005],"category_scores_gemma":[0.03446165,0.0002643938,0.002310342,0.00039301356,0.000658227,0.00025300565,0.00018008695,0.002684424,0.000019413177],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9415326,0.003691396,0.0035918609,0.00001872321,0.0018136048,0.0037946638,0.00064909377,0.00012617782,0.000069307804,0.00019880118,0.002105543,0.042408235],"study_design_scores_gemma":[0.96921855,0.012559374,0.008869652,0.0003068335,0.00076131255,0.000095978,0.00054890354,0.000526028,0.000030128516,0.001586208,0.005238852,0.00025817897],"about_ca_topic_score_codex":0.0015452408,"about_ca_topic_score_gemma":0.0015996865,"teacher_disagreement_score":0.042150058,"about_ca_system_score_codex":0.00073713926,"about_ca_system_score_gemma":0.017659858,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W2591351447","doi":"10.1200/jco.2008.26.15_suppl.6615","title":"Review of utilization of trastuzumab in the adjuvant treatment of breast cancer in four university-teaching hospitals in Quebec, Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Adjuvant; Taxane; Regimen; Anthracycline; Metastatic breast cancer; Cancer","score_opus":0.20308625434264685,"score_gpt":0.4986246580019878,"score_spread":0.2955384036593409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2591351447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97243506,0.012969407,0.0000061721307,0.013453337,0.00014870787,0.00034898435,0.000016864324,5.370961e-7,0.0006209049],"genre_scores_gemma":[0.89069784,0.108730756,0.000083145336,0.00033873718,0.00007300366,0.0000015001161,9.5020016e-7,0.0000051575435,0.000068891095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99616885,0.0012521872,0.0018806707,0.00010568111,0.0004339473,0.0001586627],"domain_scores_gemma":[0.99694914,0.0014598077,0.0010837169,0.00014812902,0.00026957245,0.000089608024],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002790149,0.00008046842,0.001424284,0.00018015545,0.000010229266,4.6167176e-7,0.00018264218,0.000121098325,0.000097276505],"category_scores_gemma":[0.001182155,0.0000525445,0.00016816483,0.0003304609,0.00015694975,0.000054784672,0.000018610122,0.0005407262,1.3143284e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016007842,0.0019230436,0.73850876,0.00091179257,0.00009727053,0.0015617122,0.0008993417,0.00010109682,0.000047744157,0.00002533381,0.0026316391,0.2516915],"study_design_scores_gemma":[0.004887543,0.0029998694,0.97439235,0.004719051,0.00007277583,0.00013040371,0.00055196084,0.000048023834,0.000028291994,0.000007896149,0.012122574,0.00003926642],"about_ca_topic_score_codex":0.56951755,"about_ca_topic_score_gemma":0.86593956,"teacher_disagreement_score":0.29642195,"about_ca_system_score_codex":0.0016652767,"about_ca_system_score_gemma":0.010708551,"threshold_uncertainty_score":0.9948998},"labels":[],"label_agreement":null},{"id":"W2592670291","doi":"10.3747/co.24.3413","title":"Trastuzumab in Metastatic Breast Cancer after Complete Remission: An Expensive Commitment for an Entire Life?","year":2017,"lang":"en","type":"letter","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Complete remission; Cancer; Bioinformatics; Chemotherapy","score_opus":0.40544019414483634,"score_gpt":0.5395140546614471,"score_spread":0.13407386051661074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592670291","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03385963,0.013827068,0.00014655096,0.92321706,0.010828234,0.0109799085,0.0059496686,0.0001432669,0.0010486422],"genre_scores_gemma":[0.16734995,0.0057980223,0.003515047,0.68110484,0.06683113,0.04687239,0.020222126,0.0013704876,0.0069360365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99511063,0.0007750571,0.0008432927,0.0012480351,0.0008087158,0.0012142397],"domain_scores_gemma":[0.9964293,0.00034781883,0.00046656784,0.0015292084,0.00058280467,0.00064427324],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006596438,0.00063784485,0.0018396003,0.0004384959,0.00018758413,0.00007872301,0.00076662,0.0007213964,0.001972518],"category_scores_gemma":[0.00018947924,0.00054979685,0.00028583786,0.00011415448,0.00046918236,0.00016803328,0.00021362651,0.0030387472,0.000054457043],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013389173,0.0009854161,0.003164465,0.0019399313,0.00019623713,0.0015008731,0.0010809908,0.0000012241433,0.000056196495,0.0000033108595,0.8640376,0.12569484],"study_design_scores_gemma":[0.0051858434,0.0025236225,0.0069779553,0.0015724228,0.00040179433,0.00034234583,0.00023136173,0.0003582292,0.000013362352,0.00008753893,0.98180085,0.0005046724],"about_ca_topic_score_codex":0.00047854986,"about_ca_topic_score_gemma":0.0010020516,"teacher_disagreement_score":0.24211222,"about_ca_system_score_codex":0.0028166934,"about_ca_system_score_gemma":0.0033678538,"threshold_uncertainty_score":0.99969536},"labels":[],"label_agreement":null},{"id":"W2592770830","doi":"10.1158/1538-7445.sabcs16-p3-07-03","title":"Abstract P3-07-03: GPNMB activates EGFR to overcome Mek-inhibition: Implications for the development of rational targeted therapy combinations in triple negative breast cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Occupational Cancer Research Centre","funders":"","keywords":"Triple-negative breast cancer; MAPK/ERK pathway; Medicine; Cancer research; Targeted therapy; Breast cancer; Melanoma; Oncology; Cancer; Internal medicine; Signal transduction; Biology; Cell biology","score_opus":0.2165357930011002,"score_gpt":0.5071941370836902,"score_spread":0.29065834408259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592770830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87166446,0.0010691938,0.00040032834,0.11766074,0.00027402138,0.0063449778,0.001262281,0.000033652297,0.0012903204],"genre_scores_gemma":[0.98739433,0.00066009135,0.000644606,0.00019886359,0.00029214815,0.009539528,0.000059178365,0.00004573398,0.0011655446],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99723965,0.00011250746,0.0005123963,0.00047786842,0.0009954976,0.000662055],"domain_scores_gemma":[0.9956605,0.001053332,0.00016157562,0.0008175707,0.0020591817,0.00024784767],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018603757,0.00018417125,0.00034121363,0.00038606662,0.0012682083,0.00014326215,0.0006084758,0.00011465412,0.0018389991],"category_scores_gemma":[0.0007258083,0.00014039996,0.00009637668,0.00063041964,0.0004480913,0.0002694548,0.00017847627,0.0006210675,0.00003731541],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005891187,0.002027032,0.07659571,0.0006507029,0.00078696216,0.0000073709216,0.011774977,0.00035214477,0.6505403,0.005616671,0.05580945,0.18994752],"study_design_scores_gemma":[0.0035406358,0.00014626398,0.8901727,0.00037070262,0.000007846481,0.0000024784897,0.00044269804,0.00007893792,0.09761251,0.0013555157,0.0061188424,0.00015084755],"about_ca_topic_score_codex":0.0036486674,"about_ca_topic_score_gemma":0.0048673167,"teacher_disagreement_score":0.813577,"about_ca_system_score_codex":0.001662104,"about_ca_system_score_gemma":0.0043905904,"threshold_uncertainty_score":0.99907345},"labels":[],"label_agreement":null},{"id":"W2593203574","doi":"10.1158/1538-7445.sabcs16-p6-07-06","title":"Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Metastatic breast cancer; Taxane; Breast cancer; Univariate analysis; Proportional hazards model; Multivariate analysis; Cancer; Oncology; Gastroenterology","score_opus":0.07355459369102431,"score_gpt":0.430158884603077,"score_spread":0.3566042909120527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2593203574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915389,0.00020665867,5.6152805e-7,0.00255388,0.000068062305,0.0039407467,0.00085872965,0.00003238036,0.0008001211],"genre_scores_gemma":[0.9966229,0.0004968249,0.000027750233,0.000043002972,0.000062713916,0.0015390242,0.000052925185,0.00014388729,0.0010109342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99431735,0.00048450712,0.00074611657,0.0010331435,0.0020414863,0.0013774148],"domain_scores_gemma":[0.9964657,0.000928665,0.00035630833,0.001137796,0.0005713365,0.00054018886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021353364,0.000554463,0.0013835906,0.0009122474,0.0003153496,0.00014637197,0.0006053312,0.00020169368,0.0010174806],"category_scores_gemma":[0.000604101,0.0003582338,0.000080574624,0.0010705733,0.0010277521,0.00031401985,0.00019634188,0.0014799117,0.000027267548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045296572,0.0010744808,0.92530483,0.002624019,0.00039538057,0.0007010936,0.00047982912,0.00006847141,0.00043506434,0.0000019860502,0.0005442973,0.023073949],"study_design_scores_gemma":[0.025096033,0.009680797,0.95423645,0.0044372533,0.000080521386,0.000024596493,0.00016980356,0.00020404455,0.005522427,0.0000030957244,0.00017704394,0.00036790685],"about_ca_topic_score_codex":0.063794084,"about_ca_topic_score_gemma":0.111325696,"teacher_disagreement_score":0.04753161,"about_ca_system_score_codex":0.0019528458,"about_ca_system_score_gemma":0.0015701492,"threshold_uncertainty_score":0.99989575},"labels":[],"label_agreement":null},{"id":"W2594604923","doi":"10.1158/1538-7445.sabcs16-p4-21-23","title":"Abstract P4-21-23: A retrospective evaluation of cardiovascular recovery and oncologic outcomes associated with interrupted and continuous adjuvant trastuzumab in the setting of mild left ventricular dysfunction","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Medicine; Ejection fraction; Breast cancer; Internal medicine; Asymptomatic; Oncology; Cancer; Adjuvant therapy; Cardiac function curve; Cardiology; Metastatic breast cancer; Surgery; Heart failure","score_opus":0.13438231319708782,"score_gpt":0.43730653060470037,"score_spread":0.30292421740761255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594604923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916052,0.005023607,0.0000078412,0.00069799635,0.00006578061,0.0018293837,0.00003143409,0.000008261274,0.000730446],"genre_scores_gemma":[0.99876225,0.0008723264,0.000016699105,0.000015756117,0.000049515613,0.00019425192,0.000013193778,0.00002052004,0.000055465174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957418,0.00077858113,0.00035694093,0.00041410048,0.0023054252,0.00040319026],"domain_scores_gemma":[0.9971755,0.00048225018,0.00023134373,0.0006172698,0.0014138735,0.000079737576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009788614,0.00014535802,0.0006794593,0.00028727952,0.00020670025,0.00006340395,0.00023004439,0.00014507923,0.000055834844],"category_scores_gemma":[0.004621276,0.00009452098,0.00010907514,0.0002893104,0.00050286925,0.00014084941,0.00011511798,0.00079058454,8.3621643e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008455056,0.00021159134,0.95274466,0.00032600635,0.0010351768,0.0000901829,0.001828244,0.0001441223,0.0032371914,0.0000058301234,0.00024162559,0.03928985],"study_design_scores_gemma":[0.0043654293,0.0010848613,0.9885516,0.0010009143,0.00024348599,0.000018661816,0.0017832613,0.000356278,0.0023299817,0.00011321362,0.000062845975,0.00008944714],"about_ca_topic_score_codex":0.004127968,"about_ca_topic_score_gemma":0.0025675388,"teacher_disagreement_score":0.039200407,"about_ca_system_score_codex":0.0012660482,"about_ca_system_score_gemma":0.0007347224,"threshold_uncertainty_score":0.6240281},"labels":[],"label_agreement":null},{"id":"W2596210945","doi":"10.1200/jco.2012.30.15_suppl.e11061","title":"Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Trastuzumab; Medicine; Bioluminescence imaging; In vivo; Breast cancer; Cancer research; Cancer; Lymph node; Chemotherapy; Metastatic breast cancer; Metastasis; Oncology; Internal medicine; Pathology; Cell culture; Luciferase; Biology; Transfection","score_opus":0.47719018676011143,"score_gpt":0.5664286975740835,"score_spread":0.0892385108139721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596210945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321735,0.0021393052,0.00014251904,0.0023035791,0.0004523493,0.00043875922,0.00003296244,0.0000056717427,0.0012674901],"genre_scores_gemma":[0.98847663,0.0014900668,0.008375157,0.00064913684,0.00074689847,0.00001605718,0.0000012520647,0.000033870714,0.00021093432],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948512,0.00064089324,0.002726938,0.00029694007,0.0009639916,0.00052006263],"domain_scores_gemma":[0.99402505,0.0025959301,0.0014347745,0.00029778673,0.00051291805,0.00113354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007758732,0.0002142204,0.0020992926,0.00022621306,0.000066637745,0.000010021352,0.00027983024,0.00049827644,0.0002960208],"category_scores_gemma":[0.00097456755,0.00015786916,0.00025127598,0.00013914447,0.00053478015,0.00022643567,0.0002695488,0.0011200085,0.0000022915285],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017243747,0.0038481066,0.6603331,0.00060734665,0.001057477,0.00012333826,0.0064599426,0.000021480217,0.012586014,0.00020176504,0.002968888,0.2945488],"study_design_scores_gemma":[0.008924099,0.008132606,0.9495722,0.0010654764,0.0003455861,0.0007881401,0.0009280176,0.000042882013,0.005923901,0.0002687423,0.023774648,0.00023369756],"about_ca_topic_score_codex":0.00012915434,"about_ca_topic_score_gemma":0.00021309257,"teacher_disagreement_score":0.2943151,"about_ca_system_score_codex":0.00027613202,"about_ca_system_score_gemma":0.0026238726,"threshold_uncertainty_score":0.64377177},"labels":[],"label_agreement":null},{"id":"W2597431707","doi":"10.1200/jco.2012.30.15_suppl.3027","title":"Rational molecularly targeted combinations: A parallel-arm phase I trial of the humanized anti-IGF-1R antibody dalotuzumab (D) in combination with the allosteric AKT inhibitor MK-2206 or the gamma secretase inhibitor MK-0752, in patients with advanced solid tumors.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rash; Neutropenia; Febrile neutropenia; Adverse effect; Internal medicine; Leukopenia; Pharmacology; Oncology; Toxicity; Gastroenterology","score_opus":0.06951995384007696,"score_gpt":0.45923291073914174,"score_spread":0.38971295689906477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597431707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98675907,0.00017597975,0.0002162142,0.008966163,0.0008132068,0.0029319767,0.000019114987,0.0000082745155,0.000109977875],"genre_scores_gemma":[0.9974597,0.00006958717,0.000645302,0.0010400721,0.0005327633,0.00009547573,0.000049550836,0.000042462023,0.00006508586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99208784,0.0025217428,0.0028889363,0.0002885836,0.0016904668,0.00052240724],"domain_scores_gemma":[0.99260324,0.0027568978,0.002618257,0.00048391125,0.0012801649,0.000257553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0060578506,0.00028329183,0.0015321526,0.00028570453,0.00014908468,0.00003499997,0.0005381301,0.00028145133,0.00011147705],"category_scores_gemma":[0.005063606,0.00011692585,0.0002735905,0.00094048656,0.0007493527,0.00042184963,0.00013686705,0.0019431501,0.000004500702],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63984305,0.076372795,0.24977173,0.00020831198,0.00093620055,0.00047797104,0.0027336897,0.00037229335,0.004012206,0.00066047464,0.002315678,0.02229563],"study_design_scores_gemma":[0.48995855,0.07261138,0.430179,0.00070415233,0.00031530377,0.000106522595,0.00060212635,0.00062620983,0.0007886547,0.00016232478,0.0036692603,0.00027651543],"about_ca_topic_score_codex":0.000031773296,"about_ca_topic_score_gemma":0.0001570302,"teacher_disagreement_score":0.18040726,"about_ca_system_score_codex":0.00048245693,"about_ca_system_score_gemma":0.003665246,"threshold_uncertainty_score":0.84421283},"labels":[],"label_agreement":null},{"id":"W2597614090","doi":"10.1007/s10549-017-4203-y","title":"Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute; F. Hoffmann-La Roche","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Metastatic breast cancer; Chemotherapy; Cardiotoxicity; Oncology; Cancer; Gastroenterology; Surgery","score_opus":0.061904357849037736,"score_gpt":0.37300700441964424,"score_spread":0.3111026465706065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597614090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97448665,0.001323886,0.000010640893,0.013748475,0.00007528381,0.0064035943,0.0038469397,0.0000098811,0.000094641466],"genre_scores_gemma":[0.9977784,0.0008122228,0.000022080587,0.000019637899,0.00011156074,0.0010135848,0.000025743066,0.00004732155,0.00016945049],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99470204,0.0010558867,0.0006019093,0.0006908923,0.0022130487,0.00073623034],"domain_scores_gemma":[0.99705243,0.00039852894,0.00036571673,0.0012456386,0.00065727433,0.00028038296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028559961,0.0003819182,0.00090120744,0.00010567721,0.0010128231,0.00011252613,0.00043885718,0.00006737573,0.00006423207],"category_scores_gemma":[0.00005976595,0.00016967813,0.00007099701,0.0003953804,0.0013099051,0.000120421224,0.00028328894,0.000499143,8.052223e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23651262,0.0075672716,0.6077786,0.00016872108,0.0057713846,0.00023215197,0.0360448,0.00042672775,0.0021809272,0.000050498547,0.00015445302,0.10311184],"study_design_scores_gemma":[0.049885515,0.00992065,0.931064,0.0007753874,0.00032779688,0.000036013374,0.006872399,0.00012396571,0.000696531,0.000024348565,0.000104931794,0.00016846029],"about_ca_topic_score_codex":0.09710294,"about_ca_topic_score_gemma":0.03426282,"teacher_disagreement_score":0.3232854,"about_ca_system_score_codex":0.0021174802,"about_ca_system_score_gemma":0.0017690208,"threshold_uncertainty_score":0.98335934},"labels":[],"label_agreement":null},{"id":"W2598244667","doi":"10.1200/jco.2014.32.15_suppl.647","title":"Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Breast cancer; Adjuvant; Oncology; Internal medicine; Quality of life (healthcare); Cancer","score_opus":0.20429124569115753,"score_gpt":0.5118660664074929,"score_spread":0.30757482071633535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598244667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944242,0.00010569373,0.000024363411,0.003608401,0.00015027654,0.0009684292,0.000020640708,0.0000069485714,0.00069103664],"genre_scores_gemma":[0.99722207,0.00047229836,0.00033376936,0.0012210775,0.00053257216,0.000054000615,0.0000025828563,0.000031581283,0.00013006182],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923808,0.0028032653,0.002765813,0.00036497333,0.0012738061,0.00041135892],"domain_scores_gemma":[0.9914305,0.0045968387,0.0020710616,0.00042052317,0.0009812537,0.0004997963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007941048,0.00024122503,0.0022712655,0.0001057508,0.0000531593,0.00001526039,0.00038788308,0.00025812996,0.00013030472],"category_scores_gemma":[0.0034895584,0.00011200258,0.0001498659,0.00040522072,0.0006918498,0.000111742746,0.000059814964,0.0015536115,0.0000032988403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02370337,0.006226272,0.8646332,0.0001082932,0.00033912947,0.00014315838,0.00076630036,0.000028448074,0.000003882133,0.0000045951006,0.00068993797,0.10335344],"study_design_scores_gemma":[0.027182708,0.04647066,0.92223436,0.00045917797,0.00019299301,0.00005648818,0.0012585011,0.000073114476,0.000005028865,0.000009518214,0.0019317998,0.0001256661],"about_ca_topic_score_codex":0.004187406,"about_ca_topic_score_gemma":0.029507577,"teacher_disagreement_score":0.10322777,"about_ca_system_score_codex":0.00026956078,"about_ca_system_score_gemma":0.0029424403,"threshold_uncertainty_score":0.9882014},"labels":[],"label_agreement":null},{"id":"W2598547790","doi":"10.2196/resprot.7289","title":"Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility","year":2017,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; University of Louisville; Takeda Oncology; Virginia Commonwealth University; Moffitt Cancer Center; Quest Diagnostics","keywords":"Brentuximab vedotin; Medicine; Clinical trial; Oncology; Cancer; Medical physics; Internal medicine; CD30; Lymphoma","score_opus":0.6744726766871684,"score_gpt":0.6790201270023464,"score_spread":0.004547450315178003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598547790","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44271937,0.000005062865,0.00014038607,0.0010150736,0.00006792048,0.55573946,0.0002435452,0.000028452858,0.000040719162],"genre_scores_gemma":[0.47321764,1.6078012e-7,0.0008980678,0.00004375712,0.00030273543,0.525251,0.000004860415,0.000057869198,0.00022391602],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.98959166,0.002624397,0.0016119323,0.0013954621,0.0034045319,0.0013720092],"domain_scores_gemma":[0.9890722,0.0016555089,0.00047751723,0.0028736913,0.0050241086,0.0008969935],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011520474,0.0003742443,0.0012301706,0.00030209555,0.0012108408,0.0004107519,0.0012736704,0.00011116891,0.0000277821],"category_scores_gemma":[0.010608541,0.00025994412,0.00041013068,0.0004785181,0.00035837415,0.00017352952,0.0019755259,0.00092921243,0.000012624044],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7296566,0.017429803,0.109870546,0.008618026,0.00062881276,0.00004409108,0.019104324,0.0002967788,0.005150471,0.000053943964,0.010998703,0.09814793],"study_design_scores_gemma":[0.19463801,0.45635423,0.27443656,0.02754842,0.0001311369,0.000008925639,0.015775533,0.0025034104,0.017055264,0.000039942006,0.010654659,0.0008539133],"about_ca_topic_score_codex":0.0027464372,"about_ca_topic_score_gemma":0.00087239983,"teacher_disagreement_score":0.53501856,"about_ca_system_score_codex":0.002322938,"about_ca_system_score_gemma":0.003025059,"threshold_uncertainty_score":0.9999853},"labels":[],"label_agreement":null},{"id":"W2598916155","doi":"10.1200/jco.2004.22.90140.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Epitope; Cancer; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2598916155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393661,0.0016878415,0.00031632674,0.054018542,0.0014406288,0.00038268228,0.000013390329,0.0000146613,0.0027598378],"genre_scores_gemma":[0.9863661,0.0027280967,0.0025635879,0.005414544,0.0027121515,0.000013231006,0.0000023170123,0.000038827162,0.00016113755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948683,0.0007288536,0.0026810865,0.00032396193,0.00080652646,0.00059131376],"domain_scores_gemma":[0.99558836,0.0016953927,0.0011891604,0.00020992177,0.0007324998,0.0005846338],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005358683,0.00021150864,0.0017031835,0.0002552645,0.000053752345,0.000017287382,0.00033028977,0.0004932882,0.0009476503],"category_scores_gemma":[0.0023477008,0.00015439065,0.00049270596,0.00046536932,0.00044196303,0.00016851531,0.00008297834,0.0030321013,0.000043176093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01275529,0.004804071,0.6852301,0.00014841942,0.00087409955,0.0044901855,0.0008684942,0.0008250019,0.0045863865,0.00038788226,0.0029884805,0.28204164],"study_design_scores_gemma":[0.021582188,0.009439007,0.93448555,0.0009440861,0.00022198119,0.0015859054,0.0006428962,0.00016375571,0.0006023139,0.0044919923,0.025569187,0.0002711543],"about_ca_topic_score_codex":0.0011260009,"about_ca_topic_score_gemma":0.0006424463,"teacher_disagreement_score":0.28177047,"about_ca_system_score_codex":0.0014418387,"about_ca_system_score_gemma":0.007918887,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W2599026586","doi":"10.1016/j.ejcb.2017.03.006","title":"PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression","year":2017,"lang":"en","type":"article","venue":"European Journal of Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke; Centre Hospitalier Universitaire de Sherbrooke","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Canadian Cancer Society; Heart and Stroke Foundation of Canada","keywords":"Cancer research; Breast cancer; Estrogen receptor; Tumor progression; Cancer; Medicine; Cell growth; Estrogen; Internal medicine; Biology","score_opus":0.029916881052933348,"score_gpt":0.35842537930141255,"score_spread":0.3285084982484792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2599026586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995362,0.0009082746,0.000023917724,0.0015544625,0.00019437392,0.00024098795,0.00006282295,0.00000519363,0.0016479583],"genre_scores_gemma":[0.99723536,0.0009599316,0.00094681955,0.00015726073,0.00054739666,0.00000209233,0.0000075884923,0.000026753109,0.00011680287],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984832,0.00041550247,0.0004777934,0.0001955367,0.00020667516,0.00022129696],"domain_scores_gemma":[0.99816585,0.000020870899,0.00082554045,0.00027414298,0.0004635117,0.00025006663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010133144,0.00012731712,0.00032656325,0.00009432911,0.00012449952,0.00003169955,0.00020882653,0.000040723844,0.00025969232],"category_scores_gemma":[0.00006966049,0.0000872885,0.000065308945,0.000036865033,0.00032801332,0.00013417419,0.00008632865,0.00032738992,0.000008476501],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011913084,0.00014269192,0.4314571,0.00007183977,0.00007478575,0.0003002566,0.00079739036,4.836437e-7,0.5269619,0.000017619315,0.000839923,0.038144674],"study_design_scores_gemma":[0.0038777385,0.006861901,0.5305371,0.0008641894,0.00013467242,0.0012663521,0.00021944803,0.00010815857,0.44345763,0.000030980336,0.012412526,0.00022927055],"about_ca_topic_score_codex":0.000018510473,"about_ca_topic_score_gemma":0.0000029002967,"teacher_disagreement_score":0.099080026,"about_ca_system_score_codex":0.000054592307,"about_ca_system_score_gemma":0.00023582135,"threshold_uncertainty_score":0.35595217},"labels":[],"label_agreement":null},{"id":"W2600462870","doi":"10.1200/jco.2012.30.15_suppl.531","title":"A randomized phase II study (VEG108838) of lapatanib plus pazopanib (L+P) versus lapatanib (L) in patients with ErbB2+ inflammatory breast cancer (IBC).","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Neutropenia; Clinical endpoint; Cohort; Placebo; Population; Randomized controlled trial; Pazopanib; Surgery; Cancer; Toxicity; Pathology","score_opus":0.1521543493657456,"score_gpt":0.5263324141883701,"score_spread":0.3741780648226245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600462870","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99368036,0.0005613408,0.000012302198,0.0012168081,0.0020163048,0.001789165,0.000043789998,0.0000122040365,0.0006677254],"genre_scores_gemma":[0.9974038,0.00034952955,0.00031360894,0.0003215081,0.0013967471,0.000068250934,0.000005611594,0.000052359395,0.00008856304],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9911304,0.002134812,0.004181354,0.00031153238,0.0015416195,0.00070026424],"domain_scores_gemma":[0.99057037,0.004083374,0.002614294,0.00047950554,0.0013640164,0.0008884229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012559292,0.00030375615,0.004005727,0.00037838196,0.000059954797,0.000009134063,0.00042061447,0.0004221371,0.0007683317],"category_scores_gemma":[0.005121302,0.0001975572,0.00049109204,0.00044824192,0.0006294779,0.00033862708,0.00020460594,0.002055637,0.000014911761],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5478909,0.0135716535,0.4103056,0.00007162976,0.0008838458,0.00022422985,0.001093286,0.0000118409625,0.00001584672,0.000023276481,0.0006984783,0.025209406],"study_design_scores_gemma":[0.6384742,0.030876847,0.32552347,0.0003012354,0.0007455149,0.000042357897,0.00066906644,0.00003403543,0.000014218885,0.000009298231,0.0031532226,0.0001565365],"about_ca_topic_score_codex":0.0002263935,"about_ca_topic_score_gemma":0.00049117696,"teacher_disagreement_score":0.09058327,"about_ca_system_score_codex":0.0009349018,"about_ca_system_score_gemma":0.004615228,"threshold_uncertainty_score":0.89308345},"labels":[],"label_agreement":null},{"id":"W2600507632","doi":"10.2217/ebo.13.381","title":"EGF receptor inhibitors: patient selection and clinical outcomes","year":2013,"lang":"en","type":"other","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"HEC Montréal","funders":"","keywords":"Miami; Medicine; Clinical Oncology; Internal medicine; Breast cancer; Oncology; Pharmacy; Family medicine; Cancer; Library science","score_opus":0.04510780986228854,"score_gpt":0.4086447254697415,"score_spread":0.363536915607453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2600507632","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0064411485,0.0007531925,0.000040644583,0.002231428,0.0017276853,0.001995218,0.000017368124,0.00042254428,0.98637074],"genre_scores_gemma":[0.0009326446,0.0011872513,0.0023631733,0.0007199471,0.0014798776,0.000079288315,0.0000278305,0.00035866178,0.9928513],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983361,0.000100368634,0.00039301073,0.00043123518,0.00046466058,0.00027464028],"domain_scores_gemma":[0.999115,0.000113012844,0.00010954106,0.00028715728,0.00008916785,0.00028611312],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022878309,0.0002145906,0.0005256008,0.0002134777,0.000022207434,0.000030461006,0.000057747016,0.00053331174,0.04367676],"category_scores_gemma":[0.00031225572,0.00014845896,0.000119674405,0.000118029544,0.00009915737,0.000022884356,0.00007903229,0.00058463484,0.0019206953],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015104054,0.000098958124,0.11321848,0.000108840395,0.00012658614,0.000002280849,0.000013428408,5.2179345e-9,0.000012154829,0.000022923588,0.83919775,0.04718347],"study_design_scores_gemma":[0.00065728655,0.0007093149,0.0049141217,0.00031107996,0.000041489646,0.000006395717,0.00003129836,0.000013108311,0.00008236692,0.000004647128,0.99307054,0.00015837465],"about_ca_topic_score_codex":0.0019815452,"about_ca_topic_score_gemma":0.00033281086,"teacher_disagreement_score":0.15387274,"about_ca_system_score_codex":0.00012195043,"about_ca_system_score_gemma":0.00019016041,"threshold_uncertainty_score":0.9988564},"labels":[],"label_agreement":null},{"id":"W2601086841","doi":"10.1200/jco.2014.32.15_suppl.8051","title":"A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Oncology; ERBB3; Progression-free survival; Log-rank test; Epidermal growth factor receptor; Cancer; Chemotherapy; Survival analysis","score_opus":0.12330918582681002,"score_gpt":0.5359127661219609,"score_spread":0.4126035802951509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601086841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993249,0.0000884234,0.00018228362,0.002495848,0.00079858245,0.0013952535,0.0000017479549,0.000006255347,0.0017826095],"genre_scores_gemma":[0.9965062,0.00014724075,0.002083422,0.0004024903,0.0007446156,0.000016846443,0.000021221816,0.000026796079,0.00005115907],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904707,0.0033346314,0.004587224,0.0002705072,0.00095992343,0.00037701547],"domain_scores_gemma":[0.9893995,0.0061338083,0.0027784281,0.00021516153,0.0011562011,0.00031690672],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022346865,0.0001813362,0.0031738013,0.0005266825,0.0000321895,0.000010321739,0.0002553663,0.0004081517,0.00013690302],"category_scores_gemma":[0.025910469,0.000126434,0.00039063577,0.0004765582,0.00047219647,0.0001346731,0.00005980082,0.0018044249,0.0000047962108],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8792655,0.012059442,0.07852249,0.00007236067,0.00017202321,0.00016781228,0.00024180797,0.000027403483,0.0006009666,0.0002084728,0.0004575294,0.0282042],"study_design_scores_gemma":[0.90055954,0.064692065,0.029244497,0.00044737442,0.00014899585,0.000019308623,0.000061251645,0.00072713784,0.00008492719,0.0004675935,0.0034368967,0.00011041354],"about_ca_topic_score_codex":0.00014186942,"about_ca_topic_score_gemma":0.00012460233,"teacher_disagreement_score":0.052632622,"about_ca_system_score_codex":0.00028246792,"about_ca_system_score_gemma":0.0020166845,"threshold_uncertainty_score":0.9822947},"labels":[],"label_agreement":null},{"id":"W2602586354","doi":"10.1021/acsami.6b15987","title":"A New Spin on Antibody–Drug Conjugates: Trastuzumab-Fulvestrant Colloidal Drug Aggregates Target HER2-Positive Cells","year":2017,"lang":"en","type":"article","venue":"ACS Applied Materials & Interfaces","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; Natural Sciences and Engineering Research Council of Canada; Canadian Cancer Society Research Institute","keywords":"Trastuzumab; Fulvestrant; Materials science; Drug; Conjugate; Antibody-drug conjugate; Colloid; Nanotechnology; Combinatorial chemistry; Pharmacology; Antibody; Cancer; Monoclonal antibody; Chemical engineering; Medicine; Breast cancer; Tamoxifen; Immunology; Internal medicine; Chemistry","score_opus":0.017780271233533304,"score_gpt":0.33513220597890825,"score_spread":0.31735193474537493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602586354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830279,0.0004130633,0.000022779705,0.002748471,0.001197219,0.001988559,0.0004370894,0.0001734324,0.0099915145],"genre_scores_gemma":[0.99182606,0.0008473859,0.0010794313,0.000505748,0.0007988059,0.00014336375,0.000112567155,0.00014395417,0.0045427154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99619704,0.000121491925,0.00081167324,0.0010158395,0.0008528769,0.0010010711],"domain_scores_gemma":[0.9974616,0.00018318655,0.00051632215,0.0012489588,0.00016359054,0.00042632266],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00083433377,0.00065871165,0.001189265,0.00026492044,0.00048082302,0.0009028893,0.0010270199,0.00021505468,0.0025053013],"category_scores_gemma":[0.00010445127,0.0005532765,0.00007164435,0.00013697913,0.0005128516,0.0002125306,0.0003554918,0.00047863516,0.0013816446],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002179849,0.00023370844,0.00010550871,0.00035031728,0.00024268401,0.00014054528,0.00136398,0.00001645209,0.9690196,0.00035746314,0.024400333,0.0015895492],"study_design_scores_gemma":[0.002523042,0.0006291223,0.0008996756,0.0012872309,0.00010270113,0.000028463837,0.00058155315,0.000001804324,0.9891327,0.00066608243,0.0036297643,0.0005178422],"about_ca_topic_score_codex":0.0028337908,"about_ca_topic_score_gemma":0.00010098132,"teacher_disagreement_score":0.020770568,"about_ca_system_score_codex":0.00021709877,"about_ca_system_score_gemma":0.0004568445,"threshold_uncertainty_score":0.99969184},"labels":[],"label_agreement":null},{"id":"W2603167024","doi":"10.1200/jco.2014.32.15_suppl.617","title":"Effect of serum HER2, TIMP-1, and CAIX on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: NCIC CTG MA.31.","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Taxane; Metastatic breast cancer; Oncology; Breast cancer; Multivariate analysis; Univariate analysis; Cancer","score_opus":0.08082417327815228,"score_gpt":0.4823661614697947,"score_spread":0.40154198819164244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603167024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99434733,0.000054772485,0.000005592729,0.004180886,0.0001732234,0.0008936268,0.00004442605,0.000007460117,0.00029269813],"genre_scores_gemma":[0.99847454,0.00018535192,0.00025125465,0.0006463015,0.00014415856,0.000041641302,0.0000054117054,0.000044724795,0.00020661396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946054,0.0014183752,0.0024232175,0.0003376437,0.000762725,0.00045259873],"domain_scores_gemma":[0.9924605,0.0049807327,0.0014321902,0.00025711616,0.00042295078,0.00044653733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004623549,0.00029738536,0.0028450687,0.00035763532,0.000028876235,0.000009938832,0.00020053252,0.00027190967,0.00026412794],"category_scores_gemma":[0.002699914,0.00015476877,0.0001407579,0.0005310948,0.00035774524,0.000091810994,0.00004570959,0.0015170042,0.00000528807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07537517,0.0027776046,0.8299889,0.00044984516,0.00025353298,0.00064746145,0.000109759625,0.00013984917,0.0000050298117,0.000001982457,0.00018862021,0.09006227],"study_design_scores_gemma":[0.048516415,0.165604,0.7828324,0.0011921091,0.00030776975,0.00019413703,0.00003084239,0.00045949843,0.00007333382,0.000005017684,0.00065549737,0.00012897656],"about_ca_topic_score_codex":0.0009862763,"about_ca_topic_score_gemma":0.012457258,"teacher_disagreement_score":0.16282639,"about_ca_system_score_codex":0.00052428315,"about_ca_system_score_gemma":0.0011577958,"threshold_uncertainty_score":0.69514424},"labels":[],"label_agreement":null},{"id":"W2604129376","doi":"10.5772/66437","title":"Cardiac Toxicity of HER2-Directed Therapy in Women with Breast Cancer: Epidemiology, Etiology, Risk Factors, and Management","year":2017,"lang":"en","type":"book-chapter","venue":"InTech eBooks","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Lapatinib; Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Neratinib; Oncology; Breast cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Metastatic breast cancer; Targeted therapy; Cancer","score_opus":0.054806164819263814,"score_gpt":0.35238366588232156,"score_spread":0.29757750106305775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604129376","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44315502,0.009456835,0.00006092726,0.0020456447,0.00087629043,0.008003949,0.003259481,0.00043480156,0.53270704],"genre_scores_gemma":[0.7823138,0.051395703,0.0005715776,0.00043309704,0.0004294547,0.0010212149,0.000064105705,0.00027875087,0.16349228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975123,0.00020584764,0.00059639144,0.00075220194,0.00031917,0.00061413384],"domain_scores_gemma":[0.99763507,0.00033882883,0.0005322065,0.0010304148,0.0002231919,0.00024027696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012853841,0.0005133337,0.0017229593,0.0003950001,0.000082502454,0.000011267094,0.00035133408,0.000660158,0.00029073548],"category_scores_gemma":[0.000078032026,0.00036429655,0.00013188658,0.000016575406,0.0013180407,0.000021833333,0.00023092577,0.0013502772,0.000006364302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009183966,0.00015771986,0.3825053,0.0022157186,0.006002989,0.00034489474,0.002024604,0.0000011508168,0.0030809303,0.0017858293,0.0040142396,0.58868265],"study_design_scores_gemma":[0.006338006,0.004638972,0.47384524,0.010761839,0.00045775177,0.000103591905,0.00035096778,0.000009566838,0.010381749,0.012085815,0.4794213,0.0016052212],"about_ca_topic_score_codex":0.0053609554,"about_ca_topic_score_gemma":0.0010514468,"teacher_disagreement_score":0.58707744,"about_ca_system_score_codex":0.0006799608,"about_ca_system_score_gemma":0.00029316638,"threshold_uncertainty_score":0.9998809},"labels":[],"label_agreement":null},{"id":"W2604499807","doi":"10.1021/acschembio.6b00990","title":"Structure-Directed and Tailored Diversity Synthetic Antibody Libraries Yield Novel Anti-EGFR Antagonists","year":2017,"lang":"en","type":"article","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Toronto","funders":"Canadian Institutes of Health Research; Western Economic Diversification Canada; Government of Canada","keywords":"Antibody; Computational biology; Yield (engineering); Diversity (politics); Biology; Immunology; Political science","score_opus":0.04756236875923106,"score_gpt":0.3427056118638686,"score_spread":0.2951432431046376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604499807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937249,0.0003286874,0.00002598339,0.0039628083,0.00021398968,0.0002415572,0.00011009837,0.000111572226,0.0012804267],"genre_scores_gemma":[0.9982437,0.0001920638,0.0007627485,0.00034148942,0.00021075107,0.0000036677984,0.00011212619,0.000018749173,0.00011472152],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986439,0.000029258284,0.00019085224,0.0005084318,0.00016427523,0.00046332114],"domain_scores_gemma":[0.998659,0.00023152979,0.00010043422,0.0006839335,0.00009065768,0.00023445314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000116901516,0.00019403589,0.00047083411,0.0000634795,0.0004135937,0.00007111116,0.00045662594,0.00037802945,0.00025754678],"category_scores_gemma":[0.0015547451,0.00015689548,0.00005310954,0.00007080398,0.0014309704,0.00010360023,0.001305182,0.00044404395,0.000015213131],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018350051,0.000050766448,0.20399421,0.00006534895,0.000064604574,0.000028650762,0.000072225674,1.553271e-8,0.79269046,0.00041097697,0.00074069906,0.0016985366],"study_design_scores_gemma":[0.0014096268,0.0001966157,0.1119909,0.0000962792,0.00006763053,0.00013318023,0.000028280938,0.000047589812,0.8803676,0.0009891185,0.004428746,0.00024447168],"about_ca_topic_score_codex":0.00035522316,"about_ca_topic_score_gemma":0.000009019314,"teacher_disagreement_score":0.092003316,"about_ca_system_score_codex":0.000047132733,"about_ca_system_score_gemma":0.00010607719,"threshold_uncertainty_score":0.6398012},"labels":[],"label_agreement":null},{"id":"W2604691720","doi":"10.1200/jco.2012.30.15_suppl.517","title":"Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Immunohistochemistry; Oncology; Breast cancer; Internal medicine; Hazard ratio; Proportional hazards model; Univariate; Algorithm; Univariate analysis; Cancer; Gynecology; Multivariate analysis; Multivariate statistics; Confidence interval; Machine learning; Computer science","score_opus":0.5361192643362197,"score_gpt":0.5720454570989529,"score_spread":0.03592619276273323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604691720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925702,0.00088338234,0.005035859,0.00035792132,0.00054499926,0.0002897721,0.00025796986,0.0000010516917,0.000058852012],"genre_scores_gemma":[0.9777522,0.00084879226,0.020963503,0.000013031691,0.00039687642,0.0000066340335,0.000004414591,0.0000081405105,0.000006371619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970106,0.00050924544,0.0018233863,0.000107736116,0.00039293847,0.00015611366],"domain_scores_gemma":[0.9946287,0.0022717994,0.0021509344,0.00007902881,0.0007245534,0.0001449736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0068754284,0.00006890268,0.0008603301,0.00018259177,0.000013783204,0.0000016531519,0.00007147996,0.00021183261,0.000040194842],"category_scores_gemma":[0.0027974956,0.000054815086,0.00017804992,0.00017131898,0.00038156752,0.00017478145,0.000026822536,0.00048822924,1.5442882e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037360778,0.0011805975,0.94651943,0.00023988911,0.00022326446,0.000001640776,0.0005663956,0.00009491966,0.000704005,0.00024173404,0.00009176293,0.046400305],"study_design_scores_gemma":[0.0052229855,0.0041648266,0.98368233,0.00049688324,0.0002706003,0.000051339703,0.00030043197,0.00415422,0.0010722508,0.00036146413,0.00018423285,0.00003842949],"about_ca_topic_score_codex":0.0002327895,"about_ca_topic_score_gemma":0.00001846171,"teacher_disagreement_score":0.046361875,"about_ca_system_score_codex":0.00014537224,"about_ca_system_score_gemma":0.0012311905,"threshold_uncertainty_score":0.33490658},"labels":[],"label_agreement":null},{"id":"W2606271249","doi":"","title":"A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer","year":2016,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Oncology; Cancer therapy; Internal medicine; Cancer research; Cancer","score_opus":0.03887320266124419,"score_gpt":0.37596619975551926,"score_spread":0.3370929970942751,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606271249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.978468,0.00012023434,0.0020040313,0.015411554,0.000014909248,0.0013059522,0.000022143482,0.000019598006,0.0026335602],"genre_scores_gemma":[0.9976759,0.00051832217,0.00026107734,0.00009594079,0.000021698788,0.00056377985,0.000004385058,0.000013331723,0.0008455875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992702,0.000018659932,0.00015902173,0.00017388056,0.0002301755,0.0001480598],"domain_scores_gemma":[0.9995805,0.00004629525,0.000038741946,0.00019984896,0.00009084956,0.00004374463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001367322,0.00007549692,0.0001629767,0.00014871603,0.0000066263356,0.0000025239774,0.000047818194,0.000041043,0.00021901532],"category_scores_gemma":[0.0000043247915,0.0000393389,0.000015541707,0.00028933314,0.000049219194,0.000045824025,0.0000069827697,0.000043020904,0.0000080537475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071469013,0.00104027,0.54772925,0.000028998727,0.000015872429,0.000002396316,0.00024555024,0.000004309341,0.09284382,0.00090826594,0.00004606653,0.35642052],"study_design_scores_gemma":[0.01459475,0.00074285397,0.9483248,0.0002656016,0.0000054887587,0.000013481153,0.000073840965,0.00030686508,0.03366372,0.00010235342,0.0018235664,0.000082708815],"about_ca_topic_score_codex":0.0139108775,"about_ca_topic_score_gemma":0.0051892884,"teacher_disagreement_score":0.40059552,"about_ca_system_score_codex":0.0007545315,"about_ca_system_score_gemma":0.00025231118,"threshold_uncertainty_score":0.9926556},"labels":[],"label_agreement":null},{"id":"W2607754295","doi":"10.1200/jco.2016.70.5319","title":"Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Guideline; Cancer; Immunohistochemistry; Metastatic breast cancer; Biomarker; Gynecology; Pathology","score_opus":0.47689772601224484,"score_gpt":0.6404764171538218,"score_spread":0.16357869114157692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607754295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9513592,0.000081036145,0.00015096285,0.04658877,0.00042086496,0.00035428238,0.00048000773,0.0000051357324,0.0005597288],"genre_scores_gemma":[0.94478035,0.0016446625,0.051383104,0.0013984627,0.00071557314,0.00001240327,0.00000829281,0.000016859298,0.000040318315],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98946,0.001758276,0.0073647466,0.00043545084,0.00055763166,0.00042391926],"domain_scores_gemma":[0.97532254,0.009498002,0.011222186,0.00047581474,0.0028609252,0.0006205178],"candidate_categories":["metaresearch","sts"],"consensus_categories":[],"category_scores_codex":[0.012250638,0.00022560963,0.006027276,0.0004982785,0.00011428382,0.0000074740797,0.00057213736,0.00033021948,0.0003372873],"category_scores_gemma":[0.01396277,0.00017770169,0.0008989936,0.0009858003,0.003056703,0.00015923494,0.00036382672,0.0017195508,0.0000016318785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016350676,0.0014824289,0.81612533,0.000041393683,0.0013869506,0.000033432476,0.0002603401,0.00004596174,0.0013918161,0.000009273993,0.021691931,0.15589608],"study_design_scores_gemma":[0.0035610392,0.011241202,0.9749068,0.00023219858,0.0008032638,0.000029993258,0.0025745865,0.0010277613,0.00011541466,0.000020673298,0.005349479,0.00013757759],"about_ca_topic_score_codex":0.006857608,"about_ca_topic_score_gemma":0.0025280968,"teacher_disagreement_score":0.1587815,"about_ca_system_score_codex":0.00041251985,"about_ca_system_score_gemma":0.0031125161,"threshold_uncertainty_score":0.9997558},"labels":[],"label_agreement":null},{"id":"W2608357984","doi":"10.3390/cancers9050040","title":"HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance","year":2017,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Alberta; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Lapatinib; Trastuzumab; Cancer research; Cancer stem cell; Medicine; Epithelial–mesenchymal transition; Wnt signaling pathway; Breast cancer; Tumor microenvironment; Cancer; Biology; Internal medicine; Metastasis; Signal transduction; Cell biology","score_opus":0.17106005455353648,"score_gpt":0.466605342863232,"score_spread":0.2955452883096955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608357984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000031296975,0.97280973,0.0000035246856,0.0009003502,0.0011529278,0.003073759,0.0013102693,0.000082208106,0.020635923],"genre_scores_gemma":[0.00012251693,0.9684957,0.000083375206,0.00019965445,0.001218139,0.0028109318,0.000067703295,0.00026069162,0.026741272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945164,0.00035174852,0.0011444127,0.0014415982,0.0012407481,0.0013051307],"domain_scores_gemma":[0.99620235,0.00018679695,0.0007650355,0.0018378918,0.0004167229,0.00059118634],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000763094,0.0009595118,0.004130002,0.0005469205,0.00020378167,0.0001509332,0.0011776637,0.00073595013,0.0016852882],"category_scores_gemma":[0.00025880526,0.00080844824,0.00070826325,0.0010053668,0.0007047995,0.00020528208,0.00020853223,0.002109846,0.00019168179],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00028435708,0.000033868047,0.000073070456,0.048114844,0.00041129254,0.00046212773,0.0003466946,0.0000051229495,4.9861177e-7,0.00001833622,0.026129615,0.9241202],"study_design_scores_gemma":[0.0014684228,0.00007274003,0.00043963385,0.11480227,0.0005257873,0.000092971124,0.00017061958,0.000008295252,0.0000031999077,0.000019410056,0.88174045,0.0006562177],"about_ca_topic_score_codex":0.010760875,"about_ca_topic_score_gemma":0.008944419,"teacher_disagreement_score":0.92346394,"about_ca_system_score_codex":0.029427797,"about_ca_system_score_gemma":0.03423905,"threshold_uncertainty_score":0.9994366},"labels":[],"label_agreement":null},{"id":"W2609600658","doi":"10.1200/jco.2009.27.15_suppl.1067","title":"A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC)","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Rash; Taxane; Gastroenterology; Mucositis; Metastatic breast cancer; Cancer; Chemotherapy; Oncology; Surgery","score_opus":0.14103104228452873,"score_gpt":0.5760817173539257,"score_spread":0.43505067506939693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609600658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464554,0.0001228724,0.000042321135,0.0033454802,0.00036516946,0.0011467139,0.000026197898,0.000009354568,0.0002963479],"genre_scores_gemma":[0.9958004,0.00032453114,0.0017769135,0.0015933933,0.0002964937,0.00001468167,0.000004848165,0.000030579013,0.00015819498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99354464,0.0010886869,0.0033632754,0.00037472355,0.0011469655,0.00048168993],"domain_scores_gemma":[0.99441075,0.0010243481,0.0018807547,0.00040061414,0.0015700886,0.00071341393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003687989,0.0002464678,0.0025237575,0.00034439447,0.00005081883,0.000010042726,0.00038835863,0.00016957364,0.00041265716],"category_scores_gemma":[0.0015897162,0.0001495454,0.00018673122,0.00059092895,0.00029469756,0.0003064255,0.00006393597,0.0016053072,0.000004051486],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1224123,0.12093161,0.24797924,0.00009584285,0.00051712483,0.0026490134,0.0009200488,0.00023583634,0.0003789263,0.0000076204005,0.00086684263,0.5030056],"study_design_scores_gemma":[0.119729675,0.39353508,0.48226947,0.0006219501,0.00039887457,0.00020024288,0.0009225625,0.00018586213,0.000065517714,0.000046879584,0.0018540759,0.00016981806],"about_ca_topic_score_codex":0.00029721693,"about_ca_topic_score_gemma":0.0021967567,"teacher_disagreement_score":0.5028358,"about_ca_system_score_codex":0.00039869462,"about_ca_system_score_gemma":0.004827454,"threshold_uncertainty_score":0.8563696},"labels":[],"label_agreement":null},{"id":"W2610975296","doi":"10.5430/jst.v7n2p28","title":"A phase II trial of neoadjuvant doxorubicin plus cyclophosphamide followed by lapatinib plus docetaxel sequential with adjuvant trastuzumab for treatment of early HER2 positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Journal of Solid Tumors","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Lapatinib; Docetaxel; Breast cancer; Internal medicine; Oncology; Pertuzumab; Population; Anemia; Cyclophosphamide; Lumpectomy; Phases of clinical research; Gastroenterology; Surgery; Chemotherapy; Cancer; Mastectomy","score_opus":0.035304341008534315,"score_gpt":0.38008501407414963,"score_spread":0.34478067306561533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610975296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932582,0.0007846582,0.00031685337,0.00091343984,0.0005547899,0.0023243967,0.0015036749,0.000011107044,0.00033291234],"genre_scores_gemma":[0.9973485,0.00033742655,0.00076664204,0.00003803731,0.000694857,0.000099962694,0.000027831013,0.00008306348,0.00060371],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.995974,0.000106933156,0.0015116788,0.00037738896,0.0013452759,0.00068474025],"domain_scores_gemma":[0.99520534,0.00015809557,0.0024764314,0.00061323284,0.0009960856,0.00055084133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067099853,0.0004328119,0.0021611517,0.0002674361,0.00030136175,0.000045896373,0.00046079417,0.00013877933,0.00007926992],"category_scores_gemma":[0.00017544636,0.00030403398,0.0006434859,0.00016642004,0.00053198467,0.0002872109,0.00006192701,0.0003186658,0.0000013380103],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.83863884,0.007693755,0.0014197539,0.00051396573,0.00337682,0.0024789467,0.009841199,0.00054267276,0.091301985,0.000029948233,0.0040033767,0.040158715],"study_design_scores_gemma":[0.5539663,0.2053298,0.0032436755,0.0028794338,0.0015714857,0.0016058988,0.0012984824,0.0006623402,0.22810219,0.000040174487,0.00082533143,0.00047487573],"about_ca_topic_score_codex":0.004131002,"about_ca_topic_score_gemma":0.00025779265,"teacher_disagreement_score":0.28467256,"about_ca_system_score_codex":0.0023011996,"about_ca_system_score_gemma":0.0050877947,"threshold_uncertainty_score":0.9999412},"labels":[],"label_agreement":null},{"id":"W2611085088","doi":"10.71781/29231","title":"Effet de la signalisation de ErbB2 et ErbB3 sur l'activité transcriptionnelle des récepteurs des estrogènes et sur la prolifération cellulaire","year":2003,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Chemistry","score_opus":0.06920749747848025,"score_gpt":0.3975885247861963,"score_spread":0.328381027307716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611085088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523149,0.004061473,0.004078213,0.0003645235,0.00043196214,0.002902244,0.00016108074,0.000016385704,0.035669204],"genre_scores_gemma":[0.94625,0.0017831005,0.0110093085,0.00012119038,0.0002785583,0.00073499844,0.0023543169,0.00023111595,0.03723736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.991413,0.004806998,0.00080903585,0.00097640365,0.0009450065,0.0010495587],"domain_scores_gemma":[0.9965311,0.0014366683,0.00037895062,0.00051830383,0.00060949347,0.00052546297],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006646842,0.00071040913,0.00082674786,0.00033429518,0.0005050812,0.00092967466,0.0006078244,0.0010615396,0.0044933213],"category_scores_gemma":[0.0016785623,0.00076422875,0.00026945877,0.0006222,0.0006245541,0.0012017428,0.000050943694,0.0014434642,0.0002753892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024327224,0.002265879,0.06953021,0.003729886,0.00044297753,0.00044720416,0.090829745,0.004031197,0.48789412,0.0009325648,0.0020266743,0.33543682],"study_design_scores_gemma":[0.010963824,0.0025572588,0.15328886,0.013088614,0.0017487158,0.0006604429,0.031911936,0.0069248234,0.6819225,0.003213164,0.0913781,0.0023417547],"about_ca_topic_score_codex":0.006692247,"about_ca_topic_score_gemma":0.012720491,"teacher_disagreement_score":0.33309504,"about_ca_system_score_codex":0.0013316402,"about_ca_system_score_gemma":0.0060105133,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W2612557208","doi":"10.1007/s10549-017-4273-x","title":"Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab)","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"Canadian Cancer Society Research Institute; GlaxoSmithKline; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Metastatic breast cancer","score_opus":0.13082130753244084,"score_gpt":0.49038875891903344,"score_spread":0.35956745138659263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612557208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771132,0.0009900434,0.0000029661214,0.005688808,0.00012274958,0.0033206146,0.012241968,0.000028810948,0.0004908456],"genre_scores_gemma":[0.99292517,0.0022388003,0.00009078224,0.000059972048,0.00025945838,0.0020131853,0.0000698765,0.00009522765,0.0022475568],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959041,0.00015463494,0.00054808875,0.0008816894,0.0012169629,0.0012945306],"domain_scores_gemma":[0.9966037,0.00030647928,0.00023711134,0.0009499071,0.00094747334,0.00095529767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006234116,0.00049654726,0.0010051955,0.00035021306,0.0006793649,0.00020806988,0.00030643705,0.00012655741,0.00077959953],"category_scores_gemma":[0.00012081105,0.00033392673,0.0002537186,0.00021401451,0.0007319544,0.00022833695,0.00018061939,0.00039376208,0.000015506886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0069033005,0.0020431718,0.7488776,0.0005606088,0.0012088203,0.000062201805,0.00036831046,0.000005065493,0.00010618162,0.000052701744,0.0017200916,0.23809196],"study_design_scores_gemma":[0.012672938,0.00886801,0.97554386,0.0006319213,0.00022265088,0.000096882985,0.000109722416,0.00013799842,0.0005071795,0.00010669514,0.0008365754,0.00026554603],"about_ca_topic_score_codex":0.04879302,"about_ca_topic_score_gemma":0.0039859354,"teacher_disagreement_score":0.23782642,"about_ca_system_score_codex":0.0023186873,"about_ca_system_score_gemma":0.0015804555,"threshold_uncertainty_score":0.99991125},"labels":[],"label_agreement":null},{"id":"W2613907595","doi":"10.1016/j.ejca.2017.03.033","title":"HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Tamoxifen; Medicine; Exemestane; Hazard ratio; Oncology; Internal medicine; Clinical trial; Breast cancer; Adjuvant therapy; Confidence interval; Cancer","score_opus":0.19449919099568974,"score_gpt":0.41727949380375684,"score_spread":0.2227803028080671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613907595","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00083524844,0.99154985,0.00029747077,0.00021008356,0.0003583373,0.0016597203,0.004158212,0.000012624032,0.000918444],"genre_scores_gemma":[0.0028099753,0.9932623,0.0011176809,0.00016678119,0.00074678886,0.000061170285,0.00021151609,0.00024099983,0.0013827924],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941085,0.00065353827,0.0021500147,0.00066726276,0.0016638672,0.00075682014],"domain_scores_gemma":[0.9936749,0.00027942032,0.002846196,0.0010240037,0.001308847,0.0008666476],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014998349,0.0007324612,0.006576857,0.00076029374,0.000120837845,0.00013266885,0.0007882968,0.00014283716,0.0005373178],"category_scores_gemma":[0.00026785917,0.0004512705,0.0027435948,0.0003487981,0.00025478107,0.00018672802,0.00009593327,0.0009799191,0.0000031066536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00097618456,0.0002057928,0.002471983,0.004947051,0.14206685,0.00022207406,0.00044217875,0.000026592657,0.0000021415244,6.583516e-7,0.0025196255,0.84611887],"study_design_scores_gemma":[0.0028349326,0.0017896978,0.0053734095,0.004927042,0.2700114,0.00001640208,0.0000132639,0.000017582108,0.000006243286,0.0000018557446,0.7147114,0.00029673154],"about_ca_topic_score_codex":0.00039561072,"about_ca_topic_score_gemma":0.0011457576,"teacher_disagreement_score":0.84582216,"about_ca_system_score_codex":0.00043185562,"about_ca_system_score_gemma":0.0017618742,"threshold_uncertainty_score":0.9997939},"labels":[],"label_agreement":null},{"id":"W2614328947","doi":"10.3969/j.issn.1008-7125.2013.12.003","title":"Role of epidermal growth factor and its receptor in regulating proliferation of colon cancer stem cells","year":2013,"lang":"en","type":"article","venue":"Weichangbingxue","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Epidermal growth factor receptor; Colorectal cancer; Cancer research; Epidermal growth factor; Stem cell; Growth factor receptor inhibitor; Cancer; Cancer stem cell; Cell biology; Biology; Receptor; Oncology; Internal medicine; Chemistry; Medicine","score_opus":0.0405483809262111,"score_gpt":0.322165437905933,"score_spread":0.2816170569797219,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614328947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674493,0.0011073147,0.0000067998362,0.00068871427,0.00007465644,0.0010469524,0.000025971347,0.000015106803,0.00028957042],"genre_scores_gemma":[0.998729,0.00014880828,0.0002515648,0.000052935273,0.00011806844,0.00017168082,0.0000040718455,0.000023943834,0.0004999491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987324,0.00009485236,0.0003738169,0.00021672812,0.0003222462,0.00025997424],"domain_scores_gemma":[0.99922585,0.00009299684,0.00015024599,0.00013829084,0.00028960293,0.000103036306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026304548,0.00011072093,0.00033489155,0.00017503965,0.000024954932,0.0000096266485,0.00006589845,0.0001102359,0.00038617916],"category_scores_gemma":[0.00007733856,0.00010019859,0.000031036074,0.00025001192,0.000054623415,0.00013132382,0.0000548035,0.00017191176,0.000011651439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008127194,0.00005621841,0.058853354,0.0007461583,0.000019451581,9.367339e-7,0.002128188,0.000013367344,0.9272988,0.00013101757,0.00031703594,0.01035424],"study_design_scores_gemma":[0.0008444604,0.00025834082,0.026506413,0.00058850256,0.000010339888,0.0000023872492,0.0003688933,0.0059932554,0.96510303,0.000049572973,0.00018213816,0.00009266171],"about_ca_topic_score_codex":0.0012996903,"about_ca_topic_score_gemma":0.0001853769,"teacher_disagreement_score":0.037804276,"about_ca_system_score_codex":0.00012688617,"about_ca_system_score_gemma":0.00015261577,"threshold_uncertainty_score":0.4228391},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","score_opus":0.1471450445887598,"score_gpt":0.43954737622099455,"score_spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616596696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98494554,0.00013448857,0.000016429623,0.00258871,0.00038989837,0.0046955883,0.0046465998,0.000024572506,0.0025581955],"genre_scores_gemma":[0.996963,0.0003407483,0.00041817423,0.00012329427,0.00039244283,0.00064687256,0.0007915624,0.000045144032,0.0002787554],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959414,0.00097457494,0.00089181674,0.00076327624,0.00068284996,0.0007461075],"domain_scores_gemma":[0.99553156,0.0014321563,0.0008806374,0.0012990611,0.0006509746,0.00020558393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013818458,0.00037678983,0.0026592202,0.00022181869,0.00021390764,0.00006149373,0.00096286,0.00020483423,0.00030803186],"category_scores_gemma":[0.0012220845,0.00024946325,0.00013051505,0.00058935577,0.0006024683,0.00021982324,0.00025843916,0.00064328586,0.0000047213593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96454495,0.0030293334,0.009050699,0.000028708904,0.002948453,0.00017453752,0.003082528,0.00015446664,0.00032376943,0.000010182299,0.0004710185,0.01618137],"study_design_scores_gemma":[0.78597236,0.012271999,0.19764684,0.00031986594,0.0019914757,0.0000021570988,0.00021550198,0.00095877744,0.00013612276,0.000008775104,0.00025493436,0.00022118169],"about_ca_topic_score_codex":0.027265567,"about_ca_topic_score_gemma":0.055466086,"teacher_disagreement_score":0.18859614,"about_ca_system_score_codex":0.0019199827,"about_ca_system_score_gemma":0.0017509408,"threshold_uncertainty_score":0.99999577},"labels":[],"label_agreement":null},{"id":"W2617889858","doi":"10.1016/j.breast.2017.05.004","title":"Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial","year":2017,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Trastuzumab; Tolerability; Discontinuation; Adverse effect; Cohort; Internal medicine; Adjuvant; Syringe; Oncology; Breast cancer; Cancer","score_opus":0.05830078814096429,"score_gpt":0.3442258103662161,"score_spread":0.2859250222252518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617889858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95979005,0.00017926333,0.000041024457,0.026990868,0.00025355926,0.0010929015,0.0004412349,0.000049155453,0.011161919],"genre_scores_gemma":[0.9958018,0.000088730216,0.00004563097,0.0001670175,0.002871848,0.000015685131,0.000027008819,0.00003517716,0.00094711356],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9983098,0.00018998979,0.00029051318,0.00032803474,0.00050405227,0.00037762715],"domain_scores_gemma":[0.9973753,0.0008765547,0.00015199326,0.0013871122,0.000052931246,0.00015608197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012840605,0.00016413147,0.00031258943,0.000019326244,0.0008759196,0.00019631184,0.00063138123,0.000100640485,0.000091797716],"category_scores_gemma":[0.00048822505,0.00008420003,0.000069199166,0.000044481752,0.0002999861,0.000059760765,0.00023780277,0.0006491692,0.00005952265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10340393,0.00012746228,0.008812403,0.000031889795,0.000412679,0.00025277352,0.0063198754,0.0000024780484,0.0010859728,0.00010404324,0.0040487153,0.8753978],"study_design_scores_gemma":[0.054351803,0.0013956005,0.9169766,0.00049734063,0.00042715797,0.0015765501,0.0006180007,0.00016166561,0.00034219076,0.0016369034,0.021668902,0.00034729196],"about_ca_topic_score_codex":0.0048634186,"about_ca_topic_score_gemma":0.00032740162,"teacher_disagreement_score":0.9081642,"about_ca_system_score_codex":0.000112645386,"about_ca_system_score_gemma":0.00020487925,"threshold_uncertainty_score":0.73520666},"labels":[],"label_agreement":null},{"id":"W2619487615","doi":"10.1097/pai.0000000000000525","title":"Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Testing in Breast Cancer: Assessing the Value of Repeated Centralized Testing in Excision Specimens","year":2017,"lang":"en","type":"article","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Association of Occupational Therapists","funders":"","keywords":"Progesterone receptor; Estrogen receptor; Biopsy; Breast cancer; Immunohistochemistry; Medicine; Human Epidermal Growth Factor Receptor 2; Receptor; Hormone receptor; Fluorescence in situ hybridization; Estrogen; Epidermal growth factor receptor; Cancer; Pathology; Internal medicine; Gynecology; Oncology; Biology; Gene","score_opus":0.03757101817127356,"score_gpt":0.36035404963979445,"score_spread":0.3227830314685209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619487615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99449503,0.0011027482,0.000026014395,0.0013029109,0.0001292777,0.0011407267,0.00005173229,0.000058997764,0.0016925326],"genre_scores_gemma":[0.9935577,0.00008948802,0.0055790134,0.000113773574,0.00010677175,0.00029318235,0.000096464166,0.00010552191,0.00005811971],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99612933,0.00023963291,0.0011120803,0.0009987714,0.0005541785,0.00096599036],"domain_scores_gemma":[0.99699575,0.0003083109,0.00080046494,0.0013831751,0.0003134862,0.00019884139],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009973189,0.00048477115,0.000948404,0.00016272129,0.00040890017,0.00010077886,0.0007206369,0.00040828402,0.00026346813],"category_scores_gemma":[0.0011283543,0.00045113094,0.00009652485,0.00043852304,0.0009985351,0.000117486656,0.000514627,0.0012368081,0.000007666476],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022884326,0.00017336664,0.12032181,0.00025434504,0.000061513005,0.00012989498,0.00018997463,0.00001012103,0.87346274,0.000079193946,0.00010214491,0.004986081],"study_design_scores_gemma":[0.0039462307,0.00013594254,0.22850636,0.0009892753,0.000058330766,0.00038044684,0.00020262603,0.00006696929,0.7651203,0.00008553711,0.00006959463,0.00043838972],"about_ca_topic_score_codex":0.004039953,"about_ca_topic_score_gemma":0.00000192366,"teacher_disagreement_score":0.10834241,"about_ca_system_score_codex":0.0009507217,"about_ca_system_score_gemma":0.0005042625,"threshold_uncertainty_score":0.99979407},"labels":[],"label_agreement":null},{"id":"W2620843145","doi":"10.1016/j.ejca.2017.04.028","title":"Getting under the skin","year":2017,"lang":"en","type":"letter","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Pertuzumab; Lapatinib; Medicine; Trastuzumab; Trastuzumab emtansine; Breast cancer; Oncology; Internal medicine; Metastatic breast cancer; Capecitabine; Cancer; Colorectal cancer","score_opus":0.08659865713768121,"score_gpt":0.4007143997159772,"score_spread":0.314115742578296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2620843145","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00090301636,0.012051203,0.000083035025,0.9110861,0.002132294,0.0002048152,0.000014194252,0.000012378103,0.07351301],"genre_scores_gemma":[0.010889311,0.002754422,0.00026187414,0.82145864,0.08889827,0.0000062276617,0.0000069966964,0.0003159955,0.07540825],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963426,0.0007302375,0.00065909134,0.00023613665,0.001527162,0.0005047462],"domain_scores_gemma":[0.99703515,0.00016975058,0.0010954628,0.00087123725,0.0006750111,0.0001533977],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025608405,0.0002736949,0.0005528475,0.00017892066,0.00023072098,0.00019759218,0.001164558,0.00012790738,0.0014288801],"category_scores_gemma":[0.00027417598,0.0001591895,0.00040186016,0.000083085884,0.00029649874,0.00008264619,0.00016471978,0.005799234,0.00020745963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051720457,0.000007932044,0.00014291702,0.00015054329,0.0003128559,0.007916368,0.00016479101,0.000012096439,0.00010814964,0.000002187347,0.94103616,0.050094277],"study_design_scores_gemma":[0.00082309643,0.0002122244,0.0050322865,0.0018186774,0.0002373191,0.0009958098,0.00004480158,0.0000040305663,0.00013715278,0.00002279206,0.99050504,0.00016676617],"about_ca_topic_score_codex":0.000046262605,"about_ca_topic_score_gemma":0.000006919757,"teacher_disagreement_score":0.08962741,"about_ca_system_score_codex":0.00038436893,"about_ca_system_score_gemma":0.0010726716,"threshold_uncertainty_score":0.99948394},"labels":[],"label_agreement":null},{"id":"W2726739357","doi":"10.1158/1078-0432.ccr-17-0900","title":"Neratinib Efficacy and Circulating Tumor DNA Detection of <i>HER2</i> Mutations in <i>HER2</i> Nonamplified Metastatic Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":191,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Puma Biotechnology","keywords":"Neratinib; Metastatic breast cancer; Breast cancer; Circulating tumor DNA; Cancer; Medicine; Oncology; Trastuzumab; Cancer research; Internal medicine; Biology","score_opus":0.3070330761576317,"score_gpt":0.5647289912994085,"score_spread":0.25769591514177675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2726739357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897965,0.0010568409,0.000054592165,0.005432061,0.00036433557,0.001661185,0.00015993003,0.000035305424,0.0014392154],"genre_scores_gemma":[0.99660516,0.0010652096,0.00026793737,0.0002601653,0.0006400277,0.0006817181,0.000010200407,0.00007677731,0.0003928278],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99448013,0.000877032,0.0012898702,0.0009229042,0.0014900691,0.0009399622],"domain_scores_gemma":[0.99493855,0.0018939076,0.00036885642,0.00117031,0.0010547255,0.00057367596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058668125,0.00025508052,0.00090572744,0.00036154347,0.0006100952,0.00018995118,0.00052445167,0.0001771446,0.0005109431],"category_scores_gemma":[0.004641225,0.00023043052,0.00016491098,0.00065991847,0.0017203668,0.00024851953,0.00038898186,0.0020350958,0.000028511127],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034432462,0.001461157,0.45222336,0.001851092,0.00037091173,0.0003545384,0.00086545426,0.00015991628,0.09006707,0.00021110251,0.0010621486,0.44792998],"study_design_scores_gemma":[0.00893107,0.0007930194,0.9745264,0.0016633142,0.00011643617,0.00007761574,0.00036283483,0.0028422978,0.007861794,0.0004504242,0.0020416018,0.00033319008],"about_ca_topic_score_codex":0.013578699,"about_ca_topic_score_gemma":0.007450227,"teacher_disagreement_score":0.52230304,"about_ca_system_score_codex":0.00043929243,"about_ca_system_score_gemma":0.0019918522,"threshold_uncertainty_score":0.99298996},"labels":[],"label_agreement":null},{"id":"W2735826756","doi":"10.3821/1913-701x-143.sp1.s7","title":"Le traitement du cancer du sein au trastuzumab","year":2010,"lang":"fr","type":"article","venue":"Canadian Pharmacists Journal / Revue des Pharmaciens du Canada","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Gynecology; Breast cancer; Cancer; Internal medicine","score_opus":0.051851486151688025,"score_gpt":0.3415804289907829,"score_spread":0.2897289428390949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735826756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8842,0.020208765,0.00021609268,0.015716923,0.06005528,0.0019585106,0.004560333,0.00007532749,0.013008778],"genre_scores_gemma":[0.92923015,0.030638319,0.00018437563,0.0069702044,0.023759313,0.00015065071,0.0000670024,0.00028878707,0.008711196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99010265,0.0005985426,0.0016198739,0.0011313839,0.0018456911,0.0047018435],"domain_scores_gemma":[0.9840595,0.00030338668,0.0005080944,0.0007208996,0.0017215982,0.012686505],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027985293,0.0010798727,0.0011795155,0.00093590317,0.0025384515,0.00055492605,0.0017222321,0.00035640964,0.023002805],"category_scores_gemma":[0.0007057676,0.0012510698,0.0005086582,0.0015431009,0.0013437156,0.0007265153,0.00013758794,0.0051014386,0.00015437545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00029860227,0.0003296332,0.008365339,0.0014817092,0.0010428368,0.24676797,0.0054159747,0.0014201252,0.015934225,0.00058294693,0.2778266,0.44053403],"study_design_scores_gemma":[0.0048171245,0.00013564512,0.00020137412,0.00023697416,0.00045680118,0.35462278,0.00007604183,0.008721725,0.0048742867,0.000033997872,0.6248925,0.00093078834],"about_ca_topic_score_codex":0.6746294,"about_ca_topic_score_gemma":0.91948247,"teacher_disagreement_score":0.43960324,"about_ca_system_score_codex":0.022707656,"about_ca_system_score_gemma":0.11909661,"threshold_uncertainty_score":0.99899393},"labels":[],"label_agreement":null},{"id":"W2735832888","doi":"10.1021/acs.jmedchem.7b00396","title":"A Kinome-Wide Selective Radiolabeled TrkB/C Inhibitor for in Vitro and in Vivo Neuroimaging: Synthesis, Preclinical Evaluation, and First-in-Human","year":2017,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Jewish General Hospital; University of Toronto; Montreal Neurological Institute and Hospital; McGill University; Douglas Mental Health University Institute; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Canada Foundation for Innovation; National Institute of Biomedical Imaging and Bioengineering; Weston Brain Institute; U.S. Department of Energy","keywords":"Kinome; Chemistry; In vivo; In vitro; Pharmacology; Neuroimaging; Neuroscience; Biochemistry; Kinase","score_opus":0.062075990788290965,"score_gpt":0.4165301395666692,"score_spread":0.3544541487783782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735832888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989222,0.0020690453,0.0000060641405,0.0076716505,0.00007579055,0.0004585486,0.000004124186,0.000003088015,0.0004897271],"genre_scores_gemma":[0.99855524,0.00034753082,0.00025064894,0.000116482945,0.00059063605,0.000053353513,0.0000010058219,0.000021133643,0.00006396854],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779075,0.00009572965,0.0008050286,0.0002967388,0.00068975135,0.00032202038],"domain_scores_gemma":[0.9976211,0.0011390309,0.00040614212,0.0002455709,0.0003153389,0.0002727861],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004143527,0.00016040352,0.0006661153,0.00017620386,0.00009016291,0.00004080809,0.00019887215,0.00014491496,0.000050679835],"category_scores_gemma":[0.014851686,0.00013815278,0.00006135758,0.00010094748,0.00026867917,0.0001367033,0.000055914843,0.0009510556,1.3628586e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004818936,0.00034926957,0.55897224,0.0012220326,0.000060045608,0.0005244398,0.00065794145,0.000005989162,0.423957,6.698102e-7,0.001628934,0.0078024883],"study_design_scores_gemma":[0.024576625,0.00077321776,0.47770792,0.004866012,0.00024917163,0.0011814538,0.00051956833,0.003668838,0.4838079,0.0004405968,0.0019221395,0.00028654936],"about_ca_topic_score_codex":0.00006648019,"about_ca_topic_score_gemma":0.000073537594,"teacher_disagreement_score":0.08126432,"about_ca_system_score_codex":0.00045413282,"about_ca_system_score_gemma":0.00067674543,"threshold_uncertainty_score":0.99344665},"labels":[],"label_agreement":null},{"id":"W2738212876","doi":"10.1161/hyp.60.suppl_1.a244","title":"Abstract 244: Vascular Induction of Adam17 in vitro and in Vivo By Angiotensin Ii: Potential Involvement of a Hypoxia Responsible Element","year":2012,"lang":"en","type":"article","venue":"Hypertension","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Angiotensin II; In vivo; Internal medicine; Endocrinology; Renin–angiotensin system; Biology; In vitro; Hypoxia (environmental); Chemistry; Medicine; Receptor; Biochemistry","score_opus":0.04903374367959088,"score_gpt":0.2951052024496921,"score_spread":0.2460714587701012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738212876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954625,0.003118759,0.000007860943,0.00062842236,0.00011518322,0.0005577899,0.00002555588,0.000009592783,0.000074366864],"genre_scores_gemma":[0.9980326,0.00045394924,0.0011787603,0.00014324862,0.00006708001,0.000018305374,0.000038024955,0.000022809987,0.000045169927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814785,0.00009827254,0.00048990484,0.0002508118,0.00063202914,0.00038114807],"domain_scores_gemma":[0.9992297,0.000044132234,0.00010654709,0.00031963884,0.00015977945,0.00014019423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010491313,0.00014125949,0.0004311148,0.00041229784,0.000031022635,0.000004087148,0.00005705948,0.00014873367,0.00013903322],"category_scores_gemma":[0.0001575258,0.00012569588,0.00006910926,0.00034928095,0.00007343565,0.000121119156,0.00011405017,0.0002542773,0.0000032715707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010810725,0.0006826134,0.0048549497,0.00015515952,0.000030320001,0.000024336066,0.00025339946,0.000010627356,0.983508,0.000002542996,0.005424723,0.0039722524],"study_design_scores_gemma":[0.0027696334,0.00033294197,0.16232502,0.00047446942,0.00004168169,0.000033654833,0.00033843826,0.0003065667,0.82897127,0.000016717895,0.0042693685,0.000120221324],"about_ca_topic_score_codex":0.0014635074,"about_ca_topic_score_gemma":0.00006302609,"teacher_disagreement_score":0.15747008,"about_ca_system_score_codex":0.00016270512,"about_ca_system_score_gemma":0.00015236992,"threshold_uncertainty_score":0.5125729},"labels":[],"label_agreement":null},{"id":"W2738553575","doi":"10.1200/jco.2017.35.15_suppl.e13078","title":"Relationship between survival to breast cancer and level of HER2 expression by immunohistochemistry.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Immunohistochemistry; Breast cancer; Trastuzumab; Internal medicine; Oncology; Cancer; Retrospective cohort study; Gynecology","score_opus":0.5335075287104397,"score_gpt":0.6202554639857291,"score_spread":0.08674793527528935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2738553575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97161067,0.00045278302,0.00013473339,0.024361715,0.00053686695,0.00013407815,0.00008849976,0.000002790052,0.0026778816],"genre_scores_gemma":[0.99531066,0.00021696094,0.0013298335,0.00018394514,0.0011484503,0.0000041958165,0.0000016592583,0.000014693806,0.0017896225],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974808,0.00020763297,0.0014573737,0.00016601352,0.0004944365,0.00019371032],"domain_scores_gemma":[0.9948571,0.0022899355,0.0014238545,0.00037230656,0.0005489794,0.00050782313],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0037065514,0.00009470915,0.0010432939,0.000055580447,0.000105218234,0.00001313886,0.0003258553,0.00036207313,0.00017184137],"category_scores_gemma":[0.008551613,0.00007134363,0.00016981192,0.0000461015,0.00038237966,0.000089556306,0.00015578183,0.0010753624,0.0000052184887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015546497,0.00020897517,0.90324754,0.000069480186,0.0000683878,0.0000355122,0.000051925334,5.8734565e-7,0.009987629,0.00000822687,0.02265691,0.06211017],"study_design_scores_gemma":[0.0031227686,0.0015249909,0.9726839,0.00033037097,0.00009445591,0.00006595924,0.00003970391,0.0000018280616,0.0018268554,0.00010648623,0.020139575,0.00006312506],"about_ca_topic_score_codex":0.00029618526,"about_ca_topic_score_gemma":0.000018352377,"teacher_disagreement_score":0.069436334,"about_ca_system_score_codex":0.00019611552,"about_ca_system_score_gemma":0.0015953915,"threshold_uncertainty_score":0.9997998},"labels":[],"label_agreement":null},{"id":"W2739675795","doi":"","title":"EGFR遺伝子変異陽性の肺癌患者におけるirreversible ErbB family blockerアファチニブの有用性","year":2012,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Neuregulin; Medicine; Internal medicine; Receptor","score_opus":0.091182672881219,"score_gpt":0.4042391389252187,"score_spread":0.31305646604399967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739675795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33762014,0.25998867,0.0005436575,0.04270953,0.035497982,0.004824899,0.0004948368,0.001002158,0.3173181],"genre_scores_gemma":[0.9324252,0.014711517,0.00094904756,0.010250857,0.014031805,0.000112714966,0.00010192196,0.0002563728,0.02716054],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98996013,0.0006030774,0.0012506618,0.00093967706,0.003682888,0.0035635643],"domain_scores_gemma":[0.99308115,0.0006181162,0.00030790933,0.0014133861,0.00038234048,0.0041971006],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004311734,0.00079356396,0.001183833,0.00054927217,0.00039994874,0.00008342554,0.0011145006,0.00057555496,0.039275132],"category_scores_gemma":[0.0010827582,0.00074488664,0.00042791723,0.0013955572,0.0008521191,0.0005351078,0.0006525648,0.0026881485,0.021382585],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048507669,0.0014412221,0.016391758,0.0013780639,0.00075278076,0.00044614766,0.0052823112,0.0000012661405,0.01857282,0.000105884006,0.8641102,0.0910325],"study_design_scores_gemma":[0.0054437118,0.0004029108,0.005162938,0.0009761453,0.00078063423,0.00021648337,0.001961955,0.0007328733,0.012885716,0.000022156692,0.97068393,0.0007305573],"about_ca_topic_score_codex":0.0003620385,"about_ca_topic_score_gemma":0.000004123136,"teacher_disagreement_score":0.59480506,"about_ca_system_score_codex":0.000981384,"about_ca_system_score_gemma":0.0017620975,"threshold_uncertainty_score":0.9996127},"labels":[],"label_agreement":null},{"id":"W2739843036","doi":"10.1158/1538-7445.am2017-5868","title":"Abstract 5868: Role of STAT3 vs AKT in cellular survival","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Focal adhesion; Protein kinase B; Cell biology; PI3K/AKT/mTOR pathway; Proto-oncogene tyrosine-protein kinase Src; Integrin; Cell adhesion; Phosphorylation; Chemistry; Cell migration; Kinase; Biology; Signal transduction; Cell; Biochemistry","score_opus":0.20821498026634186,"score_gpt":0.5194455924197172,"score_spread":0.31123061215337533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2739843036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94659114,0.0024316339,0.0000028829054,0.0027434449,0.00027571406,0.0007866757,0.000061416285,0.000019632354,0.04708744],"genre_scores_gemma":[0.99394506,0.0011944385,0.000054572432,0.0000241769,0.0005662599,0.00020062664,0.000010007166,0.00005909198,0.003945754],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956869,0.0001937783,0.00041593047,0.00052098016,0.0021086743,0.0010737568],"domain_scores_gemma":[0.9969547,0.00027070113,0.000105374784,0.0015782594,0.00069863274,0.0003923396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036661406,0.00016319737,0.00050159876,0.00045419578,0.00025372003,0.00010042325,0.0009280797,0.0001756908,0.0024801677],"category_scores_gemma":[0.0010197872,0.00015043403,0.00009880191,0.00035615158,0.00080508046,0.0001655816,0.000411809,0.001428404,0.0001997841],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019694064,0.00039191244,0.3213555,0.0011689349,0.00008824825,0.00037643735,0.0009820958,0.00002049386,0.61448276,0.0007083607,0.009322389,0.049133506],"study_design_scores_gemma":[0.003354335,0.0005491176,0.47192818,0.0010853781,0.0000123012605,0.000003969323,0.0009685882,0.00012196082,0.4336801,0.0011561454,0.08688027,0.00025965864],"about_ca_topic_score_codex":0.021643175,"about_ca_topic_score_gemma":0.0021874977,"teacher_disagreement_score":0.18080264,"about_ca_system_score_codex":0.00067715824,"about_ca_system_score_gemma":0.001986387,"threshold_uncertainty_score":0.9984317},"labels":[],"label_agreement":null},{"id":"W2741665883","doi":"10.1038/nrclinonc.2017.96","title":"HER2-positive breast cancer is lost in translation: time for patient-centered research","year":2017,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Breast cancer; Biomarker; Translational research; Disease; Drug development; Biomarker discovery; Cancer; Translational science; Oncology; Clinical research; Trastuzumab; Internal medicine; Bioinformatics; Drug; Pathology; Proteomics","score_opus":0.5935254299144336,"score_gpt":0.6815331907619722,"score_spread":0.08800776084753859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741665883","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000014250015,0.95967877,0.0000024854996,0.013282722,0.0013601846,0.015054855,0.0015591198,0.00002108322,0.009039366],"genre_scores_gemma":[0.0000031003176,0.9869764,0.0008285487,0.00216047,0.0031244208,0.002753942,0.00051761186,0.0001636956,0.0034718004],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9855313,0.0059635984,0.0042642606,0.0018427351,0.0010761489,0.0013219981],"domain_scores_gemma":[0.9870272,0.0076692607,0.0015610066,0.00182314,0.0012123839,0.00070699607],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.013857173,0.00075158005,0.009613588,0.0005888638,0.00019812565,0.000059253183,0.0011807092,0.00580609,0.0024183483],"category_scores_gemma":[0.0053632976,0.00053098635,0.0026351486,0.0008534751,0.00084375136,0.00010622105,0.00029652458,0.011922317,0.0017562337],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005086616,0.0007986436,0.000079985744,0.022198757,0.00027456685,0.00015926686,0.000053325,6.940489e-9,1.5948466e-7,0.000015357717,0.12501729,0.850894],"study_design_scores_gemma":[0.0021858567,0.0021594518,0.00011267405,0.07580116,0.00086649845,0.00017595403,0.0000037920372,0.000007503453,2.7274965e-7,0.000035717094,0.91827476,0.00037639134],"about_ca_topic_score_codex":0.00008107893,"about_ca_topic_score_gemma":0.00028412888,"teacher_disagreement_score":0.8505176,"about_ca_system_score_codex":0.0023098206,"about_ca_system_score_gemma":0.0077729234,"threshold_uncertainty_score":0.9997142},"labels":[],"label_agreement":null},{"id":"W2742539909","doi":"10.1007/978-1-4939-7219-7_6","title":"Dimerization Assessment of Epithelial Growth Factor Family of Receptor Tyrosine Kinases by Using Cross-Linking Reagent","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Receptor tyrosine kinase; Tyrosine kinase; Kinase; Reagent; Cell biology; Chemistry; Receptor; Cancer research; Biochemistry; Biology; Organic chemistry","score_opus":0.1107430438792326,"score_gpt":0.5423649582831309,"score_spread":0.4316219144038983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2742539909","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5446489,0.0004003225,0.453994,0.00007488551,0.0002615269,0.00028621525,0.00007263081,0.000007469603,0.00025406],"genre_scores_gemma":[0.43378377,0.00020737361,0.5657769,0.00006549848,0.000048067086,0.00001630443,0.000048919403,0.00002758738,0.000025585998],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99753,0.00097263046,0.0005730456,0.00037364595,0.00024351173,0.0003071598],"domain_scores_gemma":[0.9983964,0.00019962434,0.00041919804,0.0006343012,0.00027593542,0.000074517746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016368798,0.00016160382,0.00058128394,0.00018511432,0.00007680334,0.000017759434,0.0003141747,0.00023556771,0.000086787935],"category_scores_gemma":[0.0018880919,0.00014484556,0.0001081097,0.00015494636,0.0005247877,0.00003948147,0.00021650629,0.0002713648,6.012784e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007837143,0.00009989931,0.13221905,0.00016047402,0.000047200167,0.0000074543655,0.000036251462,0.0000104669,0.85246205,0.00033005766,0.0000066911048,0.0145420125],"study_design_scores_gemma":[0.000944618,0.00044410088,0.05003848,0.0002137082,0.000026983713,0.0000030686485,0.000014873165,0.0008866335,0.94656324,0.00032713223,0.00042273046,0.000114433715],"about_ca_topic_score_codex":0.000755501,"about_ca_topic_score_gemma":0.0000024493768,"teacher_disagreement_score":0.11178287,"about_ca_system_score_codex":0.00015462379,"about_ca_system_score_gemma":0.00026173744,"threshold_uncertainty_score":0.590663},"labels":[],"label_agreement":null},{"id":"W2743114779","doi":"10.1007/978-1-4939-7219-7_7","title":"Application of Immunofluorescence Staining to Study ErbB Family of Receptor Tyrosine Kinases","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Immunofluorescence; Staining; ErbB; Receptor tyrosine kinase; Intracellular; Cell biology; Phosphorylation; Receptor; Kinase; Biology; Tyrosine kinase; Signal transduction; Molecular biology; Chemistry; Antibody; Biochemistry; Immunology; Genetics","score_opus":0.07838037049551468,"score_gpt":0.5294343681556881,"score_spread":0.45105399766017346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2743114779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5724307,0.0006586402,0.42528242,0.0002567062,0.00009069412,0.00092480995,0.000008589138,0.00000927525,0.00033819157],"genre_scores_gemma":[0.55693334,0.00003906995,0.44282785,0.000064262844,0.00001765435,0.00008364859,0.0000045474562,0.000014250351,0.000015396097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793124,0.0008260262,0.00044765283,0.00035991025,0.0001779266,0.0002572535],"domain_scores_gemma":[0.99812704,0.00019812906,0.0002102765,0.0011541215,0.00024158924,0.00006885597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002712024,0.00011924912,0.00049696356,0.00021736394,0.000048389502,0.0000063025386,0.00047995284,0.00011231422,0.000025032768],"category_scores_gemma":[0.0030641775,0.00010766147,0.000057599358,0.00023325016,0.00025705868,0.00001653175,0.00030654747,0.00021249338,0.000003962812],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021833969,0.00019685617,0.078329116,0.00004982748,0.00003320393,0.0000072814464,0.00028516803,0.000004938764,0.767293,0.0003156421,0.000009196569,0.15325743],"study_design_scores_gemma":[0.0009636998,0.0017744419,0.11620801,0.0000957287,0.00002318343,0.0000021262867,0.00046264415,0.00009226973,0.8789827,0.0004111682,0.0008865864,0.00009742789],"about_ca_topic_score_codex":0.0010681519,"about_ca_topic_score_gemma":0.000010503239,"teacher_disagreement_score":0.15315999,"about_ca_system_score_codex":0.00007200389,"about_ca_system_score_gemma":0.000119689714,"threshold_uncertainty_score":0.43903077},"labels":[],"label_agreement":null},{"id":"W2744282918","doi":"10.1007/978-1-4939-7219-7_4","title":"Targeting HER2 in Advanced Breast Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Clinical trial; Cancer; Targeted therapy; Disease","score_opus":0.18600482413268593,"score_gpt":0.6291759151960609,"score_spread":0.44317109106337493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744282918","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000047159638,0.97841454,0.017668108,0.00027185318,0.0006289878,0.0015450822,0.00006770325,0.000029421903,0.0013696133],"genre_scores_gemma":[7.0472083e-7,0.7472702,0.25116867,0.00013241883,0.00017099394,0.00083294424,0.00006696363,0.00009818059,0.00025894024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930331,0.0037527818,0.0010123927,0.0010584799,0.00019923286,0.00094400847],"domain_scores_gemma":[0.9977092,0.00045031498,0.00040251593,0.001163995,0.00010379512,0.00017013952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00417935,0.00052854983,0.0032505316,0.00071944995,0.000049975202,0.000020110163,0.00074126775,0.0010118507,0.00033420912],"category_scores_gemma":[0.0020728551,0.00043362172,0.0004039168,0.0005322252,0.00029208124,0.000025552044,0.00040554156,0.001993827,0.000028696308],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003119398,0.000049587787,0.0004915783,0.0072057014,0.00008728796,0.00051864673,0.000020191845,0.0000034463944,0.0010971574,0.000076419725,0.000047026046,0.99037176],"study_design_scores_gemma":[0.0006414755,0.00009067903,0.0000585469,0.014100542,0.00012471844,0.0001667603,0.000008539551,0.000023697405,0.00009173701,0.0002731338,0.9840348,0.00038536647],"about_ca_topic_score_codex":0.00072490127,"about_ca_topic_score_gemma":0.00008129173,"teacher_disagreement_score":0.9899864,"about_ca_system_score_codex":0.00084829296,"about_ca_system_score_gemma":0.0013508128,"threshold_uncertainty_score":0.99981153},"labels":[],"label_agreement":null},{"id":"W2744674968","doi":"10.1007/978-1-4939-7219-7_19","title":"Isolation of Human Mesenchymal Stem Cells for Studying ErbB Receptor Signaling","year":2017,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"ErbB; Mesenchymal stem cell; Carcinogenesis; Cancer research; Signal transduction; Biology; Receptor; Cell biology; Cancer; Biochemistry; Genetics","score_opus":0.1837056690886039,"score_gpt":0.544444254645198,"score_spread":0.3607385855565941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744674968","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.32276377,0.00028930375,0.6751798,0.00024040297,0.00026960947,0.0007540633,0.000007859912,0.00001285205,0.00048234613],"genre_scores_gemma":[0.34066963,0.0000128678,0.6589366,0.000055858316,0.000085659936,0.000059641472,0.000007266449,0.00002474408,0.00014771071],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793047,0.0008240062,0.00041728775,0.00036241006,0.00012973574,0.0003361121],"domain_scores_gemma":[0.99858034,0.00034729188,0.00022070772,0.00061958755,0.00016374061,0.0000683225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0037275185,0.00012843883,0.00046835095,0.00018637053,0.00013723162,0.00001573532,0.0003005194,0.00021039874,0.00006364873],"category_scores_gemma":[0.0005490402,0.000118428245,0.00011738603,0.00008711129,0.00019489684,0.000026038504,0.00014455289,0.00025673036,0.000002601267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009526056,0.00004989803,0.010698089,0.00014263018,0.00004788962,0.0000064483243,0.00023853382,0.000012475138,0.96073806,0.000824875,0.000024944891,0.027120866],"study_design_scores_gemma":[0.0011597963,0.0008107146,0.00059142645,0.00011032143,0.000029368124,0.00000215813,0.00017320432,0.0005880313,0.99400127,0.0015520968,0.00087259285,0.0001090388],"about_ca_topic_score_codex":0.000092110866,"about_ca_topic_score_gemma":0.000007282812,"teacher_disagreement_score":0.03326316,"about_ca_system_score_codex":0.0000952422,"about_ca_system_score_gemma":0.000096855736,"threshold_uncertainty_score":0.48293638},"labels":[],"label_agreement":null},{"id":"W2744689594","doi":"10.1007/s12032-017-1018-y","title":"Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single “real-world” setting","year":2017,"lang":"en","type":"article","venue":"Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"Genentech","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Anthracycline; Oncology; Cardiotoxicity; Incidence (geometry); Population; Ejection fraction; Cancer; Surgery; Chemotherapy; Heart failure","score_opus":0.054160820954944164,"score_gpt":0.42862162170200696,"score_spread":0.3744608007470628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744689594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973882,0.000026980268,0.00008668022,0.0012343258,0.00025944473,0.000635038,0.00018125797,0.000009670669,0.00017842941],"genre_scores_gemma":[0.9993977,0.00014310195,0.00012164022,0.000042386713,0.00015480028,0.00009063622,0.000019322139,0.000015957401,0.00001447081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792075,0.00022786985,0.0006303961,0.0003188966,0.0006135954,0.0002884635],"domain_scores_gemma":[0.99778926,0.0007013119,0.0005493145,0.0003699419,0.00032368803,0.00026647825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016408908,0.00011145969,0.00059919525,0.0001732318,0.00010058734,0.000009496265,0.00026434122,0.0002223823,0.00009456795],"category_scores_gemma":[0.004760246,0.00009446053,0.000060240975,0.000121130026,0.00046890805,0.00011961333,0.00010460228,0.00033261144,5.2179894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026966017,0.0005580988,0.87848306,0.00021590246,0.000036569498,0.000007730594,0.0012715063,0.0000017848207,0.015359009,0.000014659975,0.00010066506,0.10368133],"study_design_scores_gemma":[0.0021236602,0.0008579122,0.98393023,0.00025647864,0.0000557136,0.000004362432,0.00023210575,0.00066414877,0.011596117,0.00006690511,0.00013959127,0.00007278288],"about_ca_topic_score_codex":0.015392583,"about_ca_topic_score_gemma":0.013793218,"teacher_disagreement_score":0.10544714,"about_ca_system_score_codex":0.0006441003,"about_ca_system_score_gemma":0.0009998876,"threshold_uncertainty_score":0.991164},"labels":[],"label_agreement":null},{"id":"W2745112655","doi":"10.1007/978-1-4939-7219-7_1","title":"ErbB Receptors and Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"ErbB; Receptor tyrosine kinase; ERBB3; ERBB4; Cancer research; Receptor; Epidermal growth factor receptor; Biology; Epidermal growth factor; Signal transduction; Neuregulin; Tyrosine kinase; Growth factor receptor; Cell biology; Biochemistry","score_opus":0.3336806821133151,"score_gpt":0.6622974962907782,"score_spread":0.3286168141774631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745112655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.95926e-7,0.9770463,0.017538648,0.00022713467,0.00074804906,0.0010451103,0.000021050211,0.000022573638,0.0033501377],"genre_scores_gemma":[4.1016825e-8,0.75821453,0.24017811,0.0001032252,0.00016086614,0.0002920371,0.000031725485,0.00006550002,0.00095395494],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953271,0.0026562589,0.00055139634,0.00079118856,0.00013292662,0.0005411152],"domain_scores_gemma":[0.9981341,0.00037448748,0.00024278571,0.0009990713,0.00006454291,0.0001850363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025650107,0.00038989005,0.002471951,0.00044852585,0.000053578427,0.000020668887,0.0004132527,0.0009612399,0.0003162133],"category_scores_gemma":[0.0017937965,0.0002979865,0.0002891895,0.00023276375,0.0005699458,0.000011158873,0.00026660293,0.0012220829,0.000020319032],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008995346,0.00002183198,0.00007478434,0.0055359104,0.00013305963,0.0001146091,0.000022468203,2.3475973e-8,0.00017965083,0.0002921179,0.00026669778,0.99334985],"study_design_scores_gemma":[0.00026691417,0.00013945765,0.0000055335863,0.010400766,0.00029663637,0.00010728873,0.000003441812,0.0000023707566,0.00012792685,0.0006414335,0.98775923,0.00024897893],"about_ca_topic_score_codex":0.00022049226,"about_ca_topic_score_gemma":0.0000148709505,"teacher_disagreement_score":0.9931009,"about_ca_system_score_codex":0.00035923359,"about_ca_system_score_gemma":0.00094852684,"threshold_uncertainty_score":0.99994725},"labels":[],"label_agreement":null},{"id":"W2746712977","doi":"10.1016/j.ctrv.2017.08.001","title":"Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Oncology; Meta-analysis; Confidence interval; Randomized controlled trial; Odds ratio; Cancer","score_opus":0.47897338594908834,"score_gpt":0.54750043717925,"score_spread":0.06852705123016167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746712977","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004872499,0.9494011,0.00000789157,0.00085262785,0.00027655065,0.02342404,0.025623122,0.000011636636,0.0003543205],"genre_scores_gemma":[0.00030028008,0.9814419,0.00011078684,0.000031269057,0.00044620398,0.015462192,0.0013052839,0.00007844279,0.00082362664],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9792472,0.009826184,0.008294339,0.0011848274,0.0010032282,0.00044422245],"domain_scores_gemma":[0.9821563,0.0056513017,0.009186146,0.002048348,0.00044042105,0.00051751],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.009649669,0.0012156424,0.05782837,0.00047758492,0.00007097647,0.00006022476,0.00043848137,0.00030322978,0.0007922301],"category_scores_gemma":[0.010813495,0.00057984336,0.00973872,0.00027016908,0.00040144147,0.00013354835,0.00010179746,0.0003527837,0.000004915592],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11784868,0.0005336195,0.000043767162,0.012943467,0.055496138,0.00007698745,0.00016730593,0.0000026052244,0.000009114387,0.000015439016,0.00072734983,0.8121355],"study_design_scores_gemma":[0.3648906,0.0002957665,0.000211711,0.061984647,0.36742562,0.0000064001983,0.000009171366,0.000023677314,0.000022696271,0.00007250869,0.20457236,0.00048484092],"about_ca_topic_score_codex":0.03449089,"about_ca_topic_score_gemma":0.0024482424,"teacher_disagreement_score":0.8116507,"about_ca_system_score_codex":0.0016998794,"about_ca_system_score_gemma":0.0042559304,"threshold_uncertainty_score":0.9996653},"labels":[],"label_agreement":null},{"id":"W2754755063","doi":"10.1007/s11095-017-2259-3","title":"Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer","year":2017,"lang":"en","type":"review","venue":"Pharmaceutical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Pharmacokinetics; Antibody-drug conjugate; Drug; Cancer; Distribution (mathematics); Payload (computing); Medicine; Pharmacology; Monoclonal antibody; Cancer research; Antibody; Chemistry; Internal medicine; Immunology; Computer science","score_opus":0.8113589362850359,"score_gpt":0.7279344229882478,"score_spread":0.08342451329678802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754755063","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009552621,0.9694842,0.000017915152,0.0071354713,0.00079504173,0.009776233,0.0009950966,0.00012677643,0.011659674],"genre_scores_gemma":[0.00021654305,0.9796444,0.0003458521,0.0005727424,0.0026753058,0.006367442,0.0003408784,0.00029753198,0.009539287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99109435,0.00124914,0.0012081933,0.0014990501,0.0024774638,0.0024718144],"domain_scores_gemma":[0.9866112,0.0082272375,0.0002312409,0.0014907982,0.0016965263,0.0017429943],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0056795776,0.0007486625,0.0028757511,0.0009817247,0.0012518562,0.00054679665,0.0010252419,0.0004897824,0.004174068],"category_scores_gemma":[0.0073397863,0.0006045017,0.0009720262,0.0006060755,0.0017605458,0.00014834115,0.00069667905,0.0048507224,0.0010718206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014335693,0.00029287094,0.000022960623,0.063326575,0.0007282185,0.00037038958,0.0000474942,7.4005516e-7,0.00018063816,0.0007294802,0.09830269,0.8358546],"study_design_scores_gemma":[0.0020053897,0.00013389831,0.0000024450676,0.019403456,0.0011516864,0.00008871792,0.000010745819,0.0007120289,0.00049707684,0.00039219568,0.9750863,0.0005160823],"about_ca_topic_score_codex":0.00012399541,"about_ca_topic_score_gemma":0.000023156235,"teacher_disagreement_score":0.8767836,"about_ca_system_score_codex":0.0011118357,"about_ca_system_score_gemma":0.0085397875,"threshold_uncertainty_score":0.999706},"labels":[],"label_agreement":null},{"id":"W2754815061","doi":"10.1186/s12885-017-3641-6","title":"A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer","year":2017,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; National Institutes of Health; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Pharmacodynamics; Oncology; Tolerability; Pharmacokinetics; Cancer; Surgical oncology; Esophagus; Adverse effect","score_opus":0.06740690104374676,"score_gpt":0.41182605596332345,"score_spread":0.3444191549195767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754815061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950672,0.0014713212,0.0000042352444,0.000118766584,0.00013212605,0.0029210893,0.0002066586,0.000005376021,0.00007325721],"genre_scores_gemma":[0.9991402,0.000064399064,0.0001890122,0.00004212084,0.000063413696,0.0001676049,0.0000033008919,0.000042437627,0.00028752832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797493,0.0001451078,0.0004006047,0.00046697573,0.00066525344,0.0003471541],"domain_scores_gemma":[0.99827486,0.00009075254,0.00047019133,0.00079534843,0.00025023278,0.00011861396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020864382,0.00023593812,0.0005161052,0.00008230291,0.00027230356,0.0000794016,0.00046461207,0.000073606876,0.00007627216],"category_scores_gemma":[0.000091916016,0.000121126184,0.000026491392,0.00034330797,0.00030370956,0.000269094,0.00045885963,0.0002842305,2.0345142e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008881237,0.002710979,0.9713252,0.00039335436,0.00002447502,0.00000807762,0.00079314795,0.00010167804,0.0018533977,5.727854e-7,0.000050768598,0.013857087],"study_design_scores_gemma":[0.04992237,0.0020885419,0.9442681,0.0009567155,0.00008956379,0.00000962148,0.00026692124,0.00079017284,0.001454919,0.0000015841385,0.000014198103,0.0001372937],"about_ca_topic_score_codex":0.013440893,"about_ca_topic_score_gemma":0.011392294,"teacher_disagreement_score":0.041041132,"about_ca_system_score_codex":0.00022529945,"about_ca_system_score_gemma":0.0010569601,"threshold_uncertainty_score":0.9931287},"labels":[],"label_agreement":null},{"id":"W2755901387","doi":"10.1136/annrheumdis-2017-eular.4594","title":"THU0064 ADAM-10 as a tocilizumab treatment predictive factor in rheumatoid arthritis","year":2017,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; St. Olavs Hospital Universitetssykehuset i Trondheim","keywords":"Tocilizumab; Medicine; Rheumatoid arthritis; Adalimumab; Internal medicine; CX3CL1; Rheumatology; Cytokine; Tumor necrosis factor alpha; Gastroenterology; Receptor; Immunology; Chemokine; Chemokine receptor","score_opus":0.09281284942180426,"score_gpt":0.40234021715342017,"score_spread":0.30952736773161593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755901387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9794289,0.0061036455,0.000002869526,0.005883112,0.00016730372,0.0013855761,0.000416072,0.000041530984,0.006570996],"genre_scores_gemma":[0.9855991,0.012002131,0.000020652205,0.00013431326,0.00003393701,0.0002617023,0.000012583858,0.00003340956,0.0019021718],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997753,0.00014864684,0.00050458434,0.00033004262,0.00079989544,0.00046381372],"domain_scores_gemma":[0.99732286,0.0002602931,0.00031532958,0.001592377,0.0002021099,0.00030701305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018536272,0.00025000045,0.0006605656,0.000114397175,0.0002342758,0.000081981285,0.00058431795,0.00007808116,0.0016482655],"category_scores_gemma":[0.0025491454,0.00016348202,0.00034823598,0.00011254537,0.00042137306,0.00019032315,0.00022064718,0.00013723834,0.00014905604],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031657366,0.0036982084,0.239465,0.0011070832,0.0012829828,0.00017769892,0.004447883,0.000045829656,0.00010251846,0.0007428471,0.028598076,0.7171661],"study_design_scores_gemma":[0.0047255675,0.0017538028,0.9747203,0.0073504415,0.00005178316,0.00003397905,0.000675685,0.0004203908,0.003442963,0.003822834,0.002744867,0.00025740714],"about_ca_topic_score_codex":0.0032026495,"about_ca_topic_score_gemma":0.0003370339,"teacher_disagreement_score":0.7352553,"about_ca_system_score_codex":0.00015288198,"about_ca_system_score_gemma":0.0008326122,"threshold_uncertainty_score":0.99926436},"labels":[],"label_agreement":null},{"id":"W2761835480","doi":"10.1186/s13058-017-0900-z","title":"Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers","year":2017,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Genentech; Queen's University; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Trastuzumab; Surgical oncology; Medicine; Breast cancer; Internalization; Oncology; Internal medicine; Cancer; Receptor","score_opus":0.08054531900090665,"score_gpt":0.4435854263303194,"score_spread":0.3630401073294127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2761835480","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.963145,0.0005182375,0.00017508135,0.031094195,0.00016972616,0.002807021,0.0005888962,0.000058270154,0.0014435459],"genre_scores_gemma":[0.9969706,0.0006204316,0.000108880515,0.00045911004,0.00057169463,0.000676695,0.000024424724,0.000096157004,0.00047199967],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995001,0.00073207053,0.0003828426,0.0010068478,0.0016794705,0.0011977779],"domain_scores_gemma":[0.99688447,0.0002508647,0.000107247324,0.0009872139,0.0010746213,0.00069555826],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028594981,0.00033487706,0.00056998926,0.0006498786,0.0005252924,0.0003573984,0.00036771505,0.00018936179,0.0004965054],"category_scores_gemma":[0.00033463494,0.0003032535,0.00009133932,0.0006204325,0.0007764504,0.0002707601,0.0002935951,0.00109381,0.00004270991],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009856896,0.0006600608,0.46603128,0.0005119801,0.00018965165,0.0013341816,0.0022666638,0.00019487923,0.042404912,0.00013381765,0.0016694237,0.47474626],"study_design_scores_gemma":[0.0043871943,0.0008566798,0.96760166,0.0023578338,0.000013565113,0.0006137594,0.0002542454,0.0029445807,0.01948737,0.0001157278,0.0010049829,0.000362374],"about_ca_topic_score_codex":0.112051144,"about_ca_topic_score_gemma":0.025387494,"teacher_disagreement_score":0.5015704,"about_ca_system_score_codex":0.0027948183,"about_ca_system_score_gemma":0.0026611302,"threshold_uncertainty_score":0.99994195},"labels":[],"label_agreement":null},{"id":"W2762364343","doi":"10.1186/s13643-017-0588-2","title":"Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis","year":2017,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; St. Michael's Hospital; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Observational study; Internal medicine; Randomized controlled trial; Meta-analysis; Cochrane Library; Clinical trial; Systematic review; MEDLINE; Cancer","score_opus":0.47108867253015685,"score_gpt":0.5680127958106302,"score_spread":0.0969241232804734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762364343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[3.906006e-9,0.5276244,0.000072459545,0.000112938375,0.00002842207,0.47165692,0.00023220267,0.000023861345,0.00024880405],"genre_scores_gemma":[1.7173399e-7,0.49923015,0.00027825768,0.00013268813,0.00013747082,0.49804893,0.00004148114,0.00011935541,0.0020114994],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9740313,0.0115305325,0.0099634845,0.0018277891,0.0014399943,0.0012068658],"domain_scores_gemma":[0.9827379,0.0022357148,0.009529145,0.004077243,0.00086045195,0.00055952795],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.023195712,0.0019787238,0.064436786,0.00069719396,0.00028746558,0.00033092333,0.0012315777,0.00061606406,0.0005903252],"category_scores_gemma":[0.003849117,0.001033722,0.010108502,0.0021106482,0.0002170689,0.00022068089,0.00027733148,0.0011424839,0.00025515733],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000012574714,0.00008119392,0.0000053819517,0.9102188,0.08484532,0.000030709292,0.00015465796,5.59363e-7,4.2020343e-9,0.000023723871,0.0015488402,0.0030782477],"study_design_scores_gemma":[0.00027886464,0.00011463715,0.0000029765727,0.54073495,0.3955809,0.00018442096,0.00000954842,0.000016399912,4.319095e-9,0.000007818706,0.06262919,0.00044027998],"about_ca_topic_score_codex":0.00048381003,"about_ca_topic_score_gemma":0.00033998702,"teacher_disagreement_score":0.36948383,"about_ca_system_score_codex":0.0015003692,"about_ca_system_score_gemma":0.0011123983,"threshold_uncertainty_score":0.99980503},"labels":[],"label_agreement":null},{"id":"W2762812042","doi":"10.1093/annonc/mdx362.001","title":"Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Trastuzumab; Oncology; Adjuvant; Internal medicine; Breast cancer; Stage (stratigraphy); Adjuvant therapy; Cancer","score_opus":0.1519478025427769,"score_gpt":0.5029018058917327,"score_spread":0.3509540033489558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762812042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869511,0.00039553922,0.000008404767,0.009605079,0.0002549367,0.0010128923,0.00037875172,0.00000829231,0.0013849995],"genre_scores_gemma":[0.9968362,0.0010209436,0.00004709046,0.0010244009,0.00024336576,0.00027509857,0.000012585955,0.000026292777,0.00051401247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99752384,0.00038628138,0.00070342905,0.00037184064,0.00055908307,0.000455502],"domain_scores_gemma":[0.9976219,0.00019405592,0.00050206814,0.0011433532,0.0003916657,0.00014693406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011644398,0.00019374731,0.0011350438,0.00035116656,0.00008887867,0.000021063,0.00052167184,0.00022581877,0.0024884155],"category_scores_gemma":[0.00017428881,0.00013165628,0.00043357877,0.00046322774,0.00058094185,0.0000808585,0.000085747575,0.0004016863,0.000004501216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.30349448,0.0068066334,0.33987758,0.00014476327,0.002741754,0.00028469157,0.0023453254,0.00035850384,0.005297549,0.000067993074,0.0053804778,0.33320025],"study_design_scores_gemma":[0.11353684,0.008634131,0.8507398,0.00015355177,0.0003435422,0.0000030061249,0.00013328147,0.0010125638,0.009526142,0.000021220501,0.015708063,0.00018790377],"about_ca_topic_score_codex":0.015276616,"about_ca_topic_score_gemma":0.008811958,"teacher_disagreement_score":0.5108622,"about_ca_system_score_codex":0.0001315723,"about_ca_system_score_gemma":0.0015455306,"threshold_uncertainty_score":0.99842346},"labels":[],"label_agreement":null},{"id":"W2762949878","doi":"10.1590/1678-4324-2017160733","title":"Gene Expression Analyses of HER-2/neu and ESR1 in Patients with Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Brazilian Archives of Biology and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Tabriz; Tabriz University of Medical Sciences","keywords":"Breast cancer; Pathological; Gene; Estrogen receptor alpha; Lymph node; Cancer; Biology; Gene expression; Oncology; Internal medicine; Cancer research; Medicine; Pathology; Genetics; Estrogen receptor","score_opus":0.019419365488782862,"score_gpt":0.36091302432139455,"score_spread":0.3414936588326117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762949878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711907,0.00076208275,0.000014411827,0.001344354,0.000018579813,0.00021427184,0.00007535361,0.0000125328415,0.00043932488],"genre_scores_gemma":[0.9978809,0.000837324,0.0011763115,0.000017834886,0.000011631066,0.000018607592,0.0000084678695,0.000008476845,0.000040496394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992398,0.00003634505,0.00018955828,0.00027111298,0.000059530066,0.00020363358],"domain_scores_gemma":[0.9992819,0.000056345678,0.00014900735,0.00041492144,0.000043447148,0.000054417644],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000060586,0.000102814796,0.00037620007,0.0003896832,0.000068956266,0.0000027746203,0.00017870564,0.0001536242,0.000029785784],"category_scores_gemma":[0.00008149293,0.00007146792,0.000018417824,0.00008695342,0.0022595066,0.000032037304,0.00022082594,0.00020753317,4.0216295e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058351737,0.00008844314,0.78482425,0.00009160155,0.000041260446,0.0000048336183,0.000043217995,1.3758472e-7,0.09559589,0.00009875477,0.000008600431,0.118619524],"study_design_scores_gemma":[0.0019915034,0.00060433475,0.90672994,0.0002922258,0.000018492932,0.000014090069,0.000030404151,0.000013011109,0.089152485,0.0010113744,0.00008009199,0.00006203148],"about_ca_topic_score_codex":0.00023598479,"about_ca_topic_score_gemma":0.00014981376,"teacher_disagreement_score":0.12190574,"about_ca_system_score_codex":0.0000064168435,"about_ca_system_score_gemma":0.000065960885,"threshold_uncertainty_score":0.8325246},"labels":[],"label_agreement":null},{"id":"W2762963596","doi":"10.1093/annonc/mdx362.009","title":"Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Lapatinib; Breast cancer; Trastuzumab; Confidence interval; Adjuvant; Gynecology; Cancer; Oncology; Gastroenterology","score_opus":0.1485413740334905,"score_gpt":0.43702328293874504,"score_spread":0.28848190890525455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762963596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870639,0.000493505,0.000003536257,0.00834579,0.00025488235,0.0017503541,0.00067797105,0.000016708029,0.00139338],"genre_scores_gemma":[0.9961055,0.0023432206,0.0000344468,0.00052387395,0.00046426617,0.00021939506,0.00010639806,0.000048219335,0.0001546885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966399,0.00070548244,0.0005802445,0.00070458645,0.0006849168,0.0006848704],"domain_scores_gemma":[0.9971688,0.0005248731,0.0005316346,0.0009468679,0.00056252663,0.00026530234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000772978,0.0003639915,0.0013998259,0.00022086703,0.00023957172,0.00007539372,0.00043618403,0.00026559486,0.00024387855],"category_scores_gemma":[0.000112694244,0.00022928762,0.00015788566,0.00036072763,0.0005099173,0.00015321116,0.00013730023,0.00041049096,0.0000122527335],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036525883,0.002280574,0.7512379,0.000013554201,0.0031217798,0.00011652545,0.003024542,0.000006912852,0.0014368907,0.0000052348964,0.00030200597,0.20192814],"study_design_scores_gemma":[0.043881163,0.02042756,0.93110263,0.00012823411,0.00045180082,0.000004495826,0.00034394645,0.000035565863,0.0018789374,0.000027958504,0.0015022137,0.00021546376],"about_ca_topic_score_codex":0.12014898,"about_ca_topic_score_gemma":0.045797184,"teacher_disagreement_score":0.20171268,"about_ca_system_score_codex":0.00033294797,"about_ca_system_score_gemma":0.00096793345,"threshold_uncertainty_score":0.97161454},"labels":[],"label_agreement":null},{"id":"W2766013741","doi":"10.3389/fpsyt.2017.00225","title":"Peripheral Transcription of NRG-ErbB Pathway Genes Are Upregulated in Treatment-Resistant Schizophrenia","year":2017,"lang":"en","type":"article","venue":"Frontiers in Psychiatry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Health and Medical Research Council; Medical Research Council; Macquarie Group Foundation; Neuroscience Research Australia; NSW Ministry of Health; University of New South Wales; National Alliance for Research on Schizophrenia and Depression","keywords":"ERBB4; ErbB; Downregulation and upregulation; Neuregulin 1; Clozapine; PI3K/AKT/mTOR pathway; Peripheral blood mononuclear cell; Signal transduction; ERBB3; Biology; Internal medicine; Endocrinology; Medicine; Gene; Schizophrenia (object-oriented programming); Cancer research; Receptor; Genetics; In vitro; Epidermal growth factor receptor; Psychiatry","score_opus":0.024365082173259563,"score_gpt":0.3092000873199102,"score_spread":0.28483500514665067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766013741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98004514,0.010570691,0.00013198658,0.0018617822,0.005045431,0.0007143529,0.00006337674,0.00003520026,0.0015320474],"genre_scores_gemma":[0.9857691,0.00075396296,0.012060991,0.000047877285,0.00027844415,0.000057454607,0.0000243016,0.000049827144,0.0009580406],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981119,0.00010290616,0.00050283974,0.00044027946,0.0003913775,0.00045072113],"domain_scores_gemma":[0.99866253,0.0000072828516,0.00019880524,0.00092805526,0.000057267127,0.00014603465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026129512,0.00024300408,0.0006083788,0.00034123316,0.00011886346,0.00004004882,0.00031554932,0.00023065496,0.000115468196],"category_scores_gemma":[0.00003503908,0.00021838737,0.0001703718,0.00021328467,0.0002519223,0.00014448624,0.000025073128,0.0002849742,0.0000041938624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004725249,0.00067550037,0.9280901,0.0003727267,0.0001221193,0.00007216403,0.0007536671,0.000029228222,0.014095977,0.00010751843,0.007330198,0.043625563],"study_design_scores_gemma":[0.013435215,0.00085923093,0.97014284,0.0012465245,0.0000611578,0.000011280415,0.001457078,0.0009939193,0.0051503233,0.0012854888,0.0050460147,0.00031091296],"about_ca_topic_score_codex":0.0007003504,"about_ca_topic_score_gemma":0.0021144282,"teacher_disagreement_score":0.04331465,"about_ca_system_score_codex":0.0005072344,"about_ca_system_score_gemma":0.00052917696,"threshold_uncertainty_score":0.8905579},"labels":[],"label_agreement":null},{"id":"W2766249538","doi":"10.1016/j.ctrv.2017.10.008","title":"Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis","year":2017,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Queen's University","funders":"","keywords":"Medicine; Breast cancer; Meta-analysis; Oncology; Internal medicine; Hazard ratio; Epidermal growth factor receptor; Triple-negative breast cancer; Cancer; Confidence interval","score_opus":0.32236565591717875,"score_gpt":0.5041202922561302,"score_spread":0.18175463633895145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766249538","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006651663,0.97820026,8.367237e-7,0.0013668993,0.00006148267,0.017806368,0.0024364323,0.000031245814,0.000089806366],"genre_scores_gemma":[0.000007292761,0.96470547,0.00008495149,0.00037747985,0.00008933402,0.030236052,0.00010595271,0.00011125501,0.0042821863],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99280524,0.0016612367,0.0026573185,0.0015195826,0.0006371269,0.00071948336],"domain_scores_gemma":[0.9946604,0.0003957934,0.0021149504,0.0020544343,0.00016576558,0.0006086987],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010962108,0.001472753,0.030140743,0.00058743684,0.0001625536,0.00015742579,0.00043670813,0.00037335436,0.0018299973],"category_scores_gemma":[0.00035206173,0.0007323931,0.0041800495,0.0007199388,0.00017203004,0.00021367421,0.00020421104,0.0005747667,0.00007104022],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008178262,0.000107152664,0.0014978306,0.80705434,0.06959364,0.000033357635,0.00006668424,8.148913e-9,1.2342805e-7,0.0000024501142,0.0005209585,0.121115275],"study_design_scores_gemma":[0.00035751206,0.0000827144,0.00019968893,0.24757078,0.4791995,0.00004137371,0.0000014592857,3.0185737e-7,2.6085831e-7,8.3320344e-7,0.27218488,0.00036069832],"about_ca_topic_score_codex":0.004465402,"about_ca_topic_score_gemma":0.0005112851,"teacher_disagreement_score":0.5594836,"about_ca_system_score_codex":0.0019088265,"about_ca_system_score_gemma":0.0008059929,"threshold_uncertainty_score":0.9998022},"labels":[],"label_agreement":null},{"id":"W2766565770","doi":"10.1097/md.0000000000008437","title":"Clinicopathological factors associated with HER2-positive gastric cancer","year":2017,"lang":"en","type":"review","venue":"Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Cancer; Cochrane Library; Oncology; Odds ratio; Chemotherapy; Meta-analysis; Clinical trial; Breast cancer","score_opus":0.5193196599766069,"score_gpt":0.5682100767777455,"score_spread":0.04889041680113859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766565770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020282478,0.98806536,0.000016264556,0.0011382893,0.00071664795,0.0022241578,0.00023665803,0.0001381066,0.007261667],"genre_scores_gemma":[0.0003737018,0.9893116,0.00002386754,0.00027456068,0.0016950467,0.00038832077,0.00082081364,0.00016615685,0.006945939],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99475455,0.00058683124,0.0010565293,0.0010654508,0.0015622699,0.0009743483],"domain_scores_gemma":[0.99542904,0.001152001,0.0009933383,0.0012488868,0.0004716283,0.00070513535],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001635642,0.00085647195,0.0052158306,0.00048534432,0.00023853198,0.000033078577,0.0006833083,0.0008632763,0.002394388],"category_scores_gemma":[0.0043757805,0.0004439235,0.00043642276,0.0007197116,0.0011859519,0.000051751165,0.00018151688,0.0026001488,0.00010662354],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071022056,0.00023844742,0.007118177,0.0065548946,0.00060836796,0.0017729411,0.00015095125,8.117111e-8,7.8910904e-7,0.0000066954162,0.016067265,0.9674104],"study_design_scores_gemma":[0.001560349,0.0028856997,0.008022494,0.115829475,0.003273198,0.00015855643,0.00004149446,0.0000015695337,0.0000011201045,0.000004550925,0.8678355,0.00038594013],"about_ca_topic_score_codex":0.00041735766,"about_ca_topic_score_gemma":0.00011934174,"teacher_disagreement_score":0.96702445,"about_ca_system_score_codex":0.0012737777,"about_ca_system_score_gemma":0.0021693185,"threshold_uncertainty_score":0.9998013},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","score_opus":0.09179359523436297,"score_gpt":0.4422125994061898,"score_spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768649895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.962174,0.00048137346,0.00002469492,0.02392821,0.0007957061,0.0076175556,0.00042731198,0.00005918563,0.004491955],"genre_scores_gemma":[0.9933774,0.0014462597,0.0004870856,0.0016280047,0.0013054729,0.00095723785,0.0000874663,0.000120957026,0.00059012603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576676,0.0006100551,0.00070551207,0.00095026643,0.0007471818,0.001220228],"domain_scores_gemma":[0.99641323,0.0009439858,0.0005173766,0.0013212246,0.00040359545,0.0004005923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001228867,0.0005741048,0.002064518,0.00014998257,0.000655012,0.00025647972,0.0011903433,0.00030262227,0.00050095294],"category_scores_gemma":[0.00056171115,0.0003693966,0.00008591436,0.00022767205,0.0010881653,0.00030360115,0.00035952148,0.0010881908,0.000020451464],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85918576,0.0037418848,0.0039152834,0.000104014594,0.00048037744,0.00035257402,0.0028362728,0.0000075218773,0.00011568796,0.000035909037,0.003260805,0.12596393],"study_design_scores_gemma":[0.8948277,0.015718453,0.078963086,0.0004696586,0.0003081653,0.00010292238,0.00042301894,0.0013531379,0.000060846258,0.000017359871,0.0073090256,0.00044657246],"about_ca_topic_score_codex":0.0043462273,"about_ca_topic_score_gemma":0.004473965,"teacher_disagreement_score":0.12551735,"about_ca_system_score_codex":0.002941645,"about_ca_system_score_gemma":0.0025102806,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","score_opus":0.09916280515671266,"score_gpt":0.4624950642930083,"score_spread":0.36333225913629563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768980003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97413385,0.00074785936,0.00006236865,0.014821355,0.0003595762,0.0060447026,0.00031656734,0.000026457623,0.0034872908],"genre_scores_gemma":[0.991768,0.00074808294,0.00011389345,0.0012137842,0.0013877923,0.004362972,0.000043733773,0.00004102296,0.0003206895],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9963283,0.0010440797,0.0008247164,0.0005159047,0.00058079936,0.00070622866],"domain_scores_gemma":[0.9968558,0.0008126576,0.00056521414,0.0012714689,0.00031284033,0.00018200849],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003355339,0.00031464038,0.0028018306,0.00041633865,0.00017913547,0.00006395772,0.0006490671,0.0002711853,0.0020875307],"category_scores_gemma":[0.0002038683,0.0001940339,0.0005494572,0.00045235822,0.0006231558,0.00007957287,0.0000755382,0.0007271996,0.000016226715],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9646903,0.0014215796,0.005973177,0.000033778204,0.002384654,0.00017481571,0.0008515592,0.0003357587,0.0011915093,0.000030247813,0.00061758055,0.022294996],"study_design_scores_gemma":[0.9722398,0.003379461,0.016510552,0.00011121165,0.0013976252,0.000012416141,0.00011106795,0.0037510223,0.0008788596,0.000018104736,0.0013976514,0.00019226511],"about_ca_topic_score_codex":0.0031479276,"about_ca_topic_score_gemma":0.0060423156,"teacher_disagreement_score":0.022102732,"about_ca_system_score_codex":0.00053375494,"about_ca_system_score_gemma":0.0016197104,"threshold_uncertainty_score":0.9988247},"labels":[],"label_agreement":null},{"id":"W2770903255","doi":"10.1016/j.clbc.2017.11.012","title":"Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients","year":2017,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval; Hôtel-Dieu de Québec; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Cancer Society","keywords":"Medicine; Trastuzumab; Breast cancer; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Genotype; Cancer; Gynecology; Confidence interval","score_opus":0.06898295181947652,"score_gpt":0.4281602336921043,"score_spread":0.3591772818726278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2770903255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820267,0.00011209245,0.000005767865,0.014713901,0.00031763082,0.0011038632,0.0016091998,0.000021494825,0.000089376845],"genre_scores_gemma":[0.9967352,0.00057374005,0.00009611366,0.0010132481,0.00027617704,0.00023594296,0.000017119306,0.000050596936,0.0010018465],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968816,0.0004087634,0.0007375016,0.0006540686,0.000800552,0.0005175012],"domain_scores_gemma":[0.9970518,0.00064444635,0.00050775486,0.0005833632,0.00075479544,0.00045785963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013657291,0.00024839496,0.0007217783,0.0001564328,0.00014084905,0.00008861047,0.00022616285,0.00029477105,0.0004786013],"category_scores_gemma":[0.0008626202,0.00020834178,0.00010080493,0.0001917197,0.0003804437,0.00030422336,0.00015050313,0.00057194487,0.000025443824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019413352,0.00052219897,0.9102797,0.00005075226,0.00018415567,0.000023970528,0.00019789883,0.000006060123,0.0003932884,0.0000032934647,0.0013205721,0.067604795],"study_design_scores_gemma":[0.0070298193,0.0007034667,0.9893896,0.00155782,0.0001262342,0.000023873823,0.000029986099,0.000022772605,0.00021586932,0.0000044702765,0.0006721763,0.0002239357],"about_ca_topic_score_codex":0.010194618,"about_ca_topic_score_gemma":0.006038086,"teacher_disagreement_score":0.079109915,"about_ca_system_score_codex":0.0013809467,"about_ca_system_score_gemma":0.00082978,"threshold_uncertainty_score":0.9963966},"labels":[],"label_agreement":null},{"id":"W2773416496","doi":"10.1016/j.ejca.2017.10.037","title":"A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer","year":2017,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Calgary","funders":"Canadian Institutes of Health Research","keywords":"Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Cancer; Intensive care medicine; Metastatic breast cancer; Epidermal growth factor receptor; Targeted therapy; Value (mathematics); Oncology; Internal medicine; Computer science","score_opus":0.14677084885074435,"score_gpt":0.4564360463690129,"score_spread":0.3096651975182686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773416496","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018581287,0.99316585,9.779963e-7,0.002509631,0.00084115734,0.0010193152,0.00043441734,0.0000061497813,0.0018366779],"genre_scores_gemma":[0.0006373939,0.99663746,0.000051990493,0.00042927035,0.0013254564,0.000029908206,0.0000057254474,0.00017042203,0.00071234297],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926835,0.0026617586,0.0026001183,0.0003350167,0.0012602742,0.00045939177],"domain_scores_gemma":[0.99289626,0.00015761252,0.0045004017,0.00095885573,0.0012470996,0.00023978834],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031209965,0.000510292,0.0036379276,0.00035675993,0.00008971282,0.000025219217,0.0016083131,0.00011583661,0.0036042333],"category_scores_gemma":[0.00057189463,0.00028927712,0.0014026188,0.00049671583,0.00045032232,0.0001312433,0.00022836572,0.0018056103,0.000012792717],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007418376,0.00010518056,0.0017113008,0.13689794,0.0008645223,0.00007909229,0.00028112883,4.1541878e-7,0.000090717534,0.000012895809,0.020964656,0.838918],"study_design_scores_gemma":[0.00060994225,0.00014910845,0.007893062,0.3550937,0.00056637754,0.00011073144,0.00000945691,1.3782847e-7,0.00004203376,0.000002612073,0.6353566,0.00016622953],"about_ca_topic_score_codex":0.0004448141,"about_ca_topic_score_gemma":0.00004035694,"teacher_disagreement_score":0.83875173,"about_ca_system_score_codex":0.00066699897,"about_ca_system_score_gemma":0.0030987503,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W2773743704","doi":"10.1038/s41398-017-0041-2","title":"Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients","year":2017,"lang":"en","type":"article","venue":"Translational Psychiatry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Health and Medical Research Council; Macquarie Group Foundation; Ramsay Health Care; University of New South Wales; Australian Schizophrenia Research Bank; Sylvia and Charles Viertel Charitable Foundation; Australian Government; Neuroscience Research Australia; Murdoch Children's Research Institute; Pratt Foundation; National Alliance for Research on Schizophrenia and Depression; Medical Research Council; NSW Ministry of Health; Children’s Hospital of Wisconsin Research Institute","keywords":"Neuregulin 1; Clozapine; Schizophrenia (object-oriented programming); Neuregulin; Peripheral; Gene isoform; Psychosis; Medicine; Internal medicine; Pharmacology; Psychology; Psychiatry; Biology; Receptor; Genetics; Gene","score_opus":0.02501492277253212,"score_gpt":0.3361033545480111,"score_spread":0.31108843177547896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773743704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926045,0.00037675642,0.00004552144,0.0031445008,0.00045526936,0.0006047822,0.000077284014,0.00003840375,0.0026530037],"genre_scores_gemma":[0.9958358,0.00006037145,0.003192612,0.00011956307,0.0002572205,0.000027922339,0.00018317088,0.000040612824,0.00028273652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795634,0.00005043476,0.0005441511,0.00035735255,0.0007587053,0.00033304858],"domain_scores_gemma":[0.99881625,0.000027364451,0.00018757101,0.0006018686,0.00020707947,0.00015988665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020367856,0.0002042437,0.00034633806,0.00019477775,0.00017617784,0.000029039578,0.00030052333,0.00018768682,0.00061129883],"category_scores_gemma":[0.000055537916,0.00017237487,0.00013659646,0.00017553905,0.00018036498,0.0002205228,0.000027231064,0.00041248734,0.00002753721],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034726146,0.0005520354,0.97878104,0.000209273,0.000029418634,0.0000043345995,0.0001721817,0.00005446946,0.010367147,0.0003479468,0.0010882637,0.004921259],"study_design_scores_gemma":[0.010087396,0.00030199328,0.98313427,0.00048128908,0.000021486923,0.0000035524804,0.000014642224,0.0006062405,0.0031618897,0.0012231998,0.00079832174,0.00016574103],"about_ca_topic_score_codex":0.00014529427,"about_ca_topic_score_gemma":0.00018735968,"teacher_disagreement_score":0.0072052567,"about_ca_system_score_codex":0.0000517894,"about_ca_system_score_gemma":0.00040342915,"threshold_uncertainty_score":0.7029244},"labels":[],"label_agreement":null},{"id":"W2774227900","doi":"10.1016/j.ejca.2017.10.021","title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"F. Hoffmann-La Roche; Roche","keywords":"Pertuzumab; Anthracycline; Trastuzumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer","score_opus":0.02363119783183756,"score_gpt":0.37978011214785656,"score_spread":0.356148914316019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774227900","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99307084,0.0028023352,0.000054072523,0.0017847524,0.00020281874,0.0015772951,0.0003471153,0.000007642526,0.00015312001],"genre_scores_gemma":[0.9975265,0.001786866,0.000104186365,0.00009144741,0.0003052286,0.0000148905565,0.0000041982444,0.000085252475,0.00008139956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954165,0.00097225077,0.0011648015,0.0004866115,0.0015047368,0.00045510472],"domain_scores_gemma":[0.9959635,0.00025719788,0.0015387157,0.00086922926,0.0010650035,0.00030634482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029329043,0.00037790128,0.0016515935,0.00034225747,0.00058032986,0.00012617013,0.00054580334,0.000047721256,0.00010850918],"category_scores_gemma":[0.0004384793,0.0002377097,0.00029014377,0.00039421782,0.0006151546,0.00030651668,0.00026150752,0.00076986826,1.6281716e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0806468,0.0006203529,0.6994997,0.000048768932,0.0031113506,0.0001579506,0.008824017,0.00025340333,0.00040178516,2.8743764e-7,0.000030872718,0.2064047],"study_design_scores_gemma":[0.15086105,0.00690232,0.83696014,0.0017245476,0.0023260738,0.000018535216,0.0004957706,0.0002483084,0.00022659227,4.888959e-7,0.000025134219,0.00021103259],"about_ca_topic_score_codex":0.0006312401,"about_ca_topic_score_gemma":0.00045343454,"teacher_disagreement_score":0.20619367,"about_ca_system_score_codex":0.0006893111,"about_ca_system_score_gemma":0.0008224472,"threshold_uncertainty_score":0.969352},"labels":[],"label_agreement":null},{"id":"W2774414712","doi":"10.18632/oncotarget.22958","title":"FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition","year":2017,"lang":"en","type":"article","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Royal University Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Epithelial–mesenchymal transition; Cancer research; Biology; Kinome; Cell growth; Cell migration; Signal transduction; Vimentin; Mesenchymal stem cell; Cell biology; Cell culture; Downregulation and upregulation; Immunology; Gene","score_opus":0.023451253549584283,"score_gpt":0.33013123874951367,"score_spread":0.3066799851999294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2774414712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98051465,0.0014696737,0.00010546232,0.014001515,0.00021563213,0.00036468907,0.00030096027,0.000037853348,0.002989572],"genre_scores_gemma":[0.9957935,0.0015789631,0.0004100333,0.00039825792,0.00046678114,0.000039565857,0.00009794746,0.000033980617,0.0011809482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863064,0.00006123911,0.00020262513,0.00035413823,0.00043161653,0.00031971917],"domain_scores_gemma":[0.99912095,0.000029804014,0.000103048165,0.00039381973,0.00012326191,0.0002291019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029285956,0.0001573531,0.0002401062,0.00004494761,0.00039828251,0.00014068837,0.000111722264,0.00014632127,0.00063525094],"category_scores_gemma":[0.00003973833,0.00013825789,0.000050679908,0.000045851175,0.0001473418,0.00040428204,0.000050983857,0.00025594345,0.000029927638],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002927971,0.00015423728,0.07632129,0.00029467305,0.000018859715,0.000030224612,0.0012438248,0.00000437887,0.8751273,0.000005765486,0.034472752,0.012033859],"study_design_scores_gemma":[0.0045251194,0.0004184829,0.24338922,0.0011509439,0.000114277274,0.00012448993,0.00031607674,0.002685502,0.6957888,0.00013369646,0.050894834,0.0004585787],"about_ca_topic_score_codex":0.005555594,"about_ca_topic_score_gemma":0.0012879767,"teacher_disagreement_score":0.17933856,"about_ca_system_score_codex":0.00019751066,"about_ca_system_score_gemma":0.00021578764,"threshold_uncertainty_score":0.83984333},"labels":[],"label_agreement":null},{"id":"W2779273646","doi":"10.1038/labinvest.2017.131","title":"Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer","year":2017,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health and Social Care Research and Development Division; Public Health Agency; Queen's University Belfast; Queen's University; European Commission; Cancer Research UK; Friends of the Cancer Centre; Invest Northern Ireland","keywords":"Tissue microarray; Concordance; Breast cancer; Medicine; Digital pathology; Cutoff; Receiver operating characteristic; Biomarker; Pathology; Immunohistochemistry; Cancer; Oncology; Bioinformatics; Internal medicine; Biology","score_opus":0.0499341235382879,"score_gpt":0.34217540971966565,"score_spread":0.29224128618137774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779273646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908074,0.0005930892,0.000014658324,0.007370279,0.00016029183,0.000839499,0.00005029479,0.00013412182,0.000030340128],"genre_scores_gemma":[0.9973132,0.00016232212,0.0014496482,0.0006862144,0.00008278812,0.00018982361,0.00003380086,0.000023631446,0.000058542882],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99862206,0.0001124881,0.00033971452,0.00043569147,0.00027645216,0.00021361515],"domain_scores_gemma":[0.99875927,0.00003307009,0.00018088071,0.00038898582,0.00029271952,0.00034506855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046393325,0.00016165969,0.00022135515,0.00026792375,0.00019819161,0.00026356438,0.000120507706,0.00008257514,0.000013438234],"category_scores_gemma":[0.0006160014,0.00014450749,0.00001068133,0.00037574218,0.00035398084,0.00041253897,0.000083107174,0.00016366933,0.00000797282],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001356553,0.000025647249,0.5979533,0.000292028,0.00003207696,0.000038616006,0.002081585,0.0000064781802,0.39219692,0.00008970583,0.0027856608,0.0043622777],"study_design_scores_gemma":[0.001062921,0.00007390456,0.93891823,0.0010588361,0.000027116555,0.0000070285532,0.00055913493,0.002779549,0.05444936,0.00019934664,0.00070136425,0.0001632128],"about_ca_topic_score_codex":0.003937072,"about_ca_topic_score_gemma":0.002115872,"teacher_disagreement_score":0.34096488,"about_ca_system_score_codex":0.00031230933,"about_ca_system_score_gemma":0.0008430003,"threshold_uncertainty_score":0.5951702},"labels":[],"label_agreement":null},{"id":"W2779627475","doi":"10.1021/acs.jmedchem.7b01607","title":"Identification of [<sup>18</sup>F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging","year":2017,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Montreal Neurological Institute and Hospital; McGill University; Douglas Mental Health University Institute; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Canada Foundation for Innovation; National Institute of Biomedical Imaging and Bioengineering; Weston Brain Institute; U.S. Department of Energy","keywords":"Trk receptor; Chemistry; Tropomyosin receptor kinase A; Pharmacophore; In vivo; Radioligand; Receptor; Tropomyosin; HEK 293 cells; Biochemistry; Neurotrophin","score_opus":0.03909447434663377,"score_gpt":0.3800916285491597,"score_spread":0.3409971542025259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2779627475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775494,0.0014724944,0.00030038468,0.008220836,0.0004646503,0.0004488623,0.000050658855,0.000018179257,0.0012690062],"genre_scores_gemma":[0.99102813,0.0003246784,0.0018215678,0.00009233152,0.0039993264,0.00003037735,0.000021261774,0.000057150282,0.002625204],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963171,0.00004948656,0.0013945604,0.00032205513,0.0014556365,0.00046117857],"domain_scores_gemma":[0.99540895,0.00021787889,0.0015304965,0.00079157087,0.0015341181,0.0005169663],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023685382,0.00025687655,0.0007708419,0.00014638671,0.0002175307,0.00007509788,0.00064835715,0.00012496924,0.0011309051],"category_scores_gemma":[0.0049212547,0.00021689764,0.0003168893,0.00012792929,0.00044083467,0.00025849894,0.000086379325,0.00089889695,0.00001024777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016533758,0.0003082642,0.00405566,0.001869936,0.00013155604,0.0002782878,0.00023141767,0.0000047673943,0.9334789,0.000004847679,0.0486132,0.009369771],"study_design_scores_gemma":[0.0076660854,0.0004883959,0.0011927438,0.0024395608,0.0003339299,0.0013270938,0.0011589811,0.0011472157,0.96780384,0.00009373415,0.016140886,0.00020751287],"about_ca_topic_score_codex":0.000028212786,"about_ca_topic_score_gemma":8.8497376e-7,"teacher_disagreement_score":0.034324944,"about_ca_system_score_codex":0.0004593852,"about_ca_system_score_gemma":0.0009750142,"threshold_uncertainty_score":0.9997822},"labels":[],"label_agreement":null},{"id":"W2789664849","doi":"10.1158/1078-0432.ccr-17-3473","title":"Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study","year":2018,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institute for Health and Care Research","keywords":"Trastuzumab; Medicine; Tissue microarray; Hazard ratio; Internal medicine; Breast cancer; Cyclin D1; Oncology; Clinical endpoint; Proportional hazards model; Cancer; Clinical trial; Cell cycle; Confidence interval","score_opus":0.14554333420835522,"score_gpt":0.5289420088485274,"score_spread":0.3833986746401722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2789664849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005437,0.0025461072,0.0000033301887,0.0041411673,0.00019846464,0.0022072436,0.00060668343,0.000020373114,0.0002222653],"genre_scores_gemma":[0.99029994,0.0070990864,0.000069316455,0.00007077615,0.00077426236,0.00062678574,0.000013454393,0.000047772188,0.0009986024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99502736,0.0008911798,0.00092982745,0.0009606467,0.0014630508,0.0007279235],"domain_scores_gemma":[0.99648154,0.0016400033,0.00015453382,0.00044808397,0.0007890194,0.00048683674],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030994166,0.00024389796,0.00095375074,0.00026385058,0.00016016563,0.00005905662,0.00019619569,0.00032060037,0.0007179419],"category_scores_gemma":[0.00031230733,0.00019380951,0.000105555846,0.00057128165,0.00063258957,0.0001259352,0.00015496521,0.0010259631,0.000011767645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048433277,0.0016494247,0.83570266,0.000059132206,0.00024160359,0.000048559865,0.004739661,9.599429e-7,0.0028928656,0.000002608222,0.0003512282,0.14946799],"study_design_scores_gemma":[0.010055056,0.007281224,0.9770231,0.0009119156,0.000106431406,0.0000025274667,0.0011597297,0.00013085768,0.002541415,0.0001816507,0.00044466113,0.00016138164],"about_ca_topic_score_codex":0.07317,"about_ca_topic_score_gemma":0.03253352,"teacher_disagreement_score":0.14930661,"about_ca_system_score_codex":0.0015320451,"about_ca_system_score_gemma":0.00079751445,"threshold_uncertainty_score":0.98512024},"labels":[],"label_agreement":null},{"id":"W2790006193","doi":"10.1093/annonc/mdy023","title":"Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Gastroenterology; Adverse effect; Population; Ovarian cancer; Confidence interval; Cancer; Pharmacology","score_opus":0.0897298999838671,"score_gpt":0.46234936169323504,"score_spread":0.37261946170936794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2790006193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876961,0.00029138717,0.000007887288,0.0026414387,0.00015485246,0.0067092264,0.0001248883,0.000035384834,0.0023388271],"genre_scores_gemma":[0.99802184,0.00009520501,0.000389399,0.0006280631,0.000117264826,0.00036108404,0.00008536106,0.00008002084,0.0002217509],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99446493,0.0012834856,0.0014154409,0.00087987445,0.00093910826,0.001017156],"domain_scores_gemma":[0.99658513,0.00049043796,0.0006530323,0.0006938198,0.0012527779,0.00032481886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002738113,0.00046815144,0.0030072134,0.00069039856,0.00016252579,0.000044566474,0.00062389125,0.00018604872,0.00063578767],"category_scores_gemma":[0.0003700684,0.00034009854,0.00005594026,0.0013436617,0.0010112431,0.00023986572,0.00039633908,0.0007394483,0.00001851929],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.697211,0.02818426,0.2492703,0.00017209999,0.0010326394,0.0009852989,0.007606222,0.000067624605,0.005801899,0.000038400703,0.0013017906,0.008328408],"study_design_scores_gemma":[0.7701317,0.08103573,0.14022335,0.0015304367,0.0002126421,0.000016696038,0.0008980176,0.0012347249,0.0029280288,0.0000205975,0.0012928644,0.00047517745],"about_ca_topic_score_codex":0.012693472,"about_ca_topic_score_gemma":0.02263868,"teacher_disagreement_score":0.10904696,"about_ca_system_score_codex":0.0003307452,"about_ca_system_score_gemma":0.0023768793,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W2794142549","doi":"10.1007/s10549-018-4734-x","title":"Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; McMaster University; Health Sciences Centre; CancerCare Manitoba; University of Toronto; Institute of Health Services and Policy Research; Western University","funders":"Canadian Cancer Society; Canadian Institutes of Health Research; Sunnybrook Research Institute","keywords":"Medicine; Hazard ratio; Internal medicine; Trastuzumab; Proportional hazards model; Breast cancer; Metastatic breast cancer; Oncology; Confidence interval; Cancer; Metastasis","score_opus":0.06202613288929283,"score_gpt":0.3763758606711169,"score_spread":0.3143497277818241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794142549","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936104,0.00030409894,0.000007436042,0.0007873375,0.00004787116,0.0022308892,0.0021519782,0.00007585572,0.00078415073],"genre_scores_gemma":[0.9971054,0.00033821023,0.000049302347,0.000036158384,0.00025514635,0.0010364515,0.00013541502,0.00011931626,0.00092458475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503285,0.00029704304,0.00032418908,0.0010002917,0.0019075613,0.0014380588],"domain_scores_gemma":[0.996301,0.00019322407,0.00010490901,0.000531149,0.0018266689,0.0010430275],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028829658,0.00056887657,0.0007601818,0.00043322935,0.0005693994,0.00016249772,0.00017589098,0.00009755485,0.0010677201],"category_scores_gemma":[0.000013672825,0.00032070166,0.00007670972,0.0011230042,0.0015303069,0.0002888425,0.00009171627,0.00045843594,0.000021159984],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071015665,0.0013026696,0.9540946,0.000106306936,0.0015597026,0.00018446131,0.0013461766,0.000004973454,0.000092005925,0.000012424252,0.00012221023,0.034072928],"study_design_scores_gemma":[0.0081374375,0.007982874,0.9788064,0.0009909219,0.00028495074,0.000077923614,0.0009988254,0.000032021373,0.00217769,0.000006686305,0.00017033957,0.00033393246],"about_ca_topic_score_codex":0.08735868,"about_ca_topic_score_gemma":0.023584092,"teacher_disagreement_score":0.063774586,"about_ca_system_score_codex":0.00330787,"about_ca_system_score_gemma":0.0016837845,"threshold_uncertainty_score":0.9999245},"labels":[],"label_agreement":null},{"id":"W2802296799","doi":"10.1200/jco.2012.30.15_suppl.596","title":"Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Hazard ratio; Internal medicine; Clinical endpoint; Breast cancer; Population; Hormone receptor; Subgroup analysis; Randomization; Oncology; Intention-to-treat analysis; Placebo; Trastuzumab; Gastroenterology; Randomized controlled trial; Cancer; Confidence interval; Pathology","score_opus":0.08460041507953373,"score_gpt":0.4613426568447472,"score_spread":0.3767422417652134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802296799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907649,0.00018116235,0.000008698076,0.0069457274,0.0005149549,0.0009807236,0.00009123923,0.000002180729,0.00051042135],"genre_scores_gemma":[0.9982447,0.0003245399,0.00014595807,0.00045387013,0.0003981865,0.00003836621,0.0000014038409,0.00002222609,0.00037075757],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993043,0.0026668059,0.0025391371,0.000207403,0.0011454481,0.0003981961],"domain_scores_gemma":[0.99250513,0.00253876,0.003193845,0.00053181266,0.00096082437,0.00026962312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006492645,0.00018298432,0.0019794148,0.00024613063,0.000051774325,0.000005209359,0.0005674183,0.0003000477,0.00029234466],"category_scores_gemma":[0.0035177616,0.00007886646,0.00061305787,0.0016758796,0.00065320916,0.00011923445,0.0002140243,0.0014791831,0.0000014585395],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060381114,0.0018850481,0.9103617,0.00003552536,0.0013487594,0.0000036952385,0.0040691756,0.0001280672,0.0007860938,0.000028259326,0.0004799373,0.020492617],"study_design_scores_gemma":[0.014671111,0.00631132,0.9747232,0.0004244964,0.00097283424,0.000009234601,0.0016000863,0.000028637376,0.00072720257,0.000022880506,0.00043326567,0.00007568817],"about_ca_topic_score_codex":0.0065605347,"about_ca_topic_score_gemma":0.003320874,"teacher_disagreement_score":0.064361535,"about_ca_system_score_codex":0.0010112395,"about_ca_system_score_gemma":0.0012868244,"threshold_uncertainty_score":0.99176097},"labels":[],"label_agreement":null},{"id":"W2802334461","doi":"10.15761/cpb.1000119","title":"Antibody microarray and immunoblotting analyses of the EGF signaling phosphorylation network in human A431 epidermoid carcinoma cells","year":2017,"lang":"en","type":"article","venue":"Clinical Proteomics and Bioinformatics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kinexus Bioinformatics Corporation (Canada); University of British Columbia","funders":"","keywords":"A431 cells; Phosphorylation; Epidermoid carcinoma; Antibody; Cancer research; Biology; Carcinoma; Epidermal growth factor; Pathology; Medicine; Immunology; Cancer; Receptor; Cell biology; Molecular medicine; Genetics","score_opus":0.11968787697014388,"score_gpt":0.4536997581995993,"score_spread":0.3340118812294554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802334461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713445,0.00036183692,0.00035023998,0.00042800792,0.00014334754,0.00081466424,0.0000072093853,0.0000069956336,0.00075326534],"genre_scores_gemma":[0.9859547,0.00040461766,0.013279931,0.00014596587,0.00015031995,0.000006615967,0.000008643755,0.0000132740915,0.000035953035],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980768,0.00008280772,0.0011805772,0.00016741056,0.00021286911,0.00027953926],"domain_scores_gemma":[0.9982876,0.00025315088,0.00067422487,0.0005685711,0.00011060511,0.00010583465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002355709,0.0001392428,0.0004879067,0.000051150204,0.00038439172,0.00010223932,0.00023525998,0.00017819456,0.0000058294077],"category_scores_gemma":[0.0006564915,0.000094328185,0.00011387593,0.00009751116,0.0005706158,0.000120329205,0.00030655466,0.000528591,0.0000014046548],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015306391,0.00017676664,0.8475536,0.00089423906,0.00007597113,0.0000059351987,0.0006739881,0.000046080906,0.13925914,0.00008727743,0.00012322894,0.010950716],"study_design_scores_gemma":[0.007216527,0.0007470124,0.79046375,0.0018686081,0.00017275957,0.00002123856,0.00047286614,0.06776385,0.12941334,0.0011918931,0.00030869816,0.00035949107],"about_ca_topic_score_codex":0.0002404504,"about_ca_topic_score_gemma":0.000016869164,"teacher_disagreement_score":0.06771777,"about_ca_system_score_codex":0.000030228428,"about_ca_system_score_gemma":0.0001353602,"threshold_uncertainty_score":0.38465917},"labels":[],"label_agreement":null},{"id":"W2803726086","doi":"10.1186/s12885-018-4143-x","title":"The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2","year":2018,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cure Brain Cancer Foundation; Canadian Cancer Society; Canadian Institutes of Health Research; Women and Children's Health Research Institute","keywords":"Trastuzumab; Antibody-dependent cell-mediated cytotoxicity; Chinese hamster ovary cell; Cancer research; Cytotoxicity; Phosphorylation; Cell culture; Receptor; Cancer cell; Signal transduction; Cell; Breast cancer; Cell biology; Cancer; In vitro; Chemistry; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.036347423481242064,"score_gpt":0.3707843810947666,"score_spread":0.33443695761352454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2803726086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991443,0.0015665577,0.000041120933,0.00014823943,0.00053800247,0.0010744311,0.000008721142,0.000038161477,0.005141789],"genre_scores_gemma":[0.9965951,0.00020244393,0.000119488475,0.00019966945,0.00062797935,0.0002476673,0.0000036921704,0.00005652647,0.0019474332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979371,0.00018821842,0.00036124623,0.00034685698,0.0006270304,0.0005395789],"domain_scores_gemma":[0.9983918,0.0007472234,0.00012357667,0.0004553493,0.00013678607,0.00014526457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005234127,0.00018365026,0.00033179615,0.0001315456,0.00017031598,0.00003204833,0.0002371129,0.000119665245,0.00037712455],"category_scores_gemma":[0.00016853574,0.00013332866,0.00008600507,0.00037326472,0.0003120999,0.000041085932,0.00005557831,0.0004070692,0.00005634439],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043182116,0.00022223307,0.011497832,0.0010160446,0.000025248459,0.00002586299,0.0015731507,0.000060951217,0.9711973,0.000009502074,0.006660407,0.007279657],"study_design_scores_gemma":[0.0025927406,0.0008302421,0.011192976,0.0019017635,0.000025990064,0.0000010339814,0.00020917202,0.00026898444,0.9704615,0.0000252726,0.012333269,0.00015704217],"about_ca_topic_score_codex":0.0017149408,"about_ca_topic_score_gemma":0.0014127418,"teacher_disagreement_score":0.007122615,"about_ca_system_score_codex":0.0005056452,"about_ca_system_score_gemma":0.00049187575,"threshold_uncertainty_score":0.5436985},"labels":[],"label_agreement":null},{"id":"W2807161544","doi":"10.1093/jnci/djy094","title":"Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients","year":2018,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Genentech; Novartis Pharma; Astellas Pharma; European Society for Medical Oncology; Alliance for Clinical Trials in Oncology Foundation; Teva Pharmaceutical Industries; Novartis; GlaxoSmithKline; Eli Lilly and Company","keywords":"Lapatinib; Trastuzumab; Medicine; Oncology; Internal medicine; Hazard ratio; Breast cancer; Interquartile range; Cohort; Gynecology; Cancer; Confidence interval","score_opus":0.05072946608820937,"score_gpt":0.37832727657369003,"score_spread":0.32759781048548064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807161544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901683,0.0011785517,0.0000028350535,0.004111405,0.0022169356,0.0005783118,0.00032634256,0.000008999466,0.0014083679],"genre_scores_gemma":[0.9956139,0.0019531166,0.000047534195,0.000491134,0.0012899704,0.000037749523,0.0000069199727,0.000030165396,0.0005295488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972242,0.00015605423,0.00059909566,0.00025925855,0.001414639,0.00034676536],"domain_scores_gemma":[0.99749625,0.000068887224,0.00038099792,0.0001314963,0.0017302947,0.0001920501],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00051063136,0.00023155249,0.00044877388,0.00025104717,0.00017918606,0.000050018487,0.0002508935,0.000119007724,0.00032516784],"category_scores_gemma":[0.000088624794,0.000147318,0.000105501356,0.000530956,0.00043740505,0.0003783706,0.000066266846,0.00046418988,0.000008238199],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025168906,0.000865308,0.9522266,0.00003669314,0.00075764226,0.00003999213,0.0018531932,0.000212815,0.005122789,0.00012911182,0.0018320759,0.034406934],"study_design_scores_gemma":[0.0071484116,0.0013600822,0.98117894,0.0006410975,0.0000749995,0.000105729574,0.000026126696,0.0000855992,0.0027532082,0.00014164996,0.006328623,0.00015552605],"about_ca_topic_score_codex":0.004208021,"about_ca_topic_score_gemma":0.0019994776,"teacher_disagreement_score":0.034251407,"about_ca_system_score_codex":0.0022137132,"about_ca_system_score_gemma":0.0020598038,"threshold_uncertainty_score":0.6361297},"labels":[],"label_agreement":null},{"id":"W2807192583","doi":"10.1186/s13000-018-0696-x","title":"Physical basis of the ‘magnification rule’ for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer","year":2018,"lang":"en","type":"article","venue":"Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Magnification; Immunohistochemistry; Pathology; Breast cancer; Biopsy; Cancer; Medicine; Intensity (physics); Nuclear medicine; Internal medicine; Physics; Optics","score_opus":0.02379823563574092,"score_gpt":0.3652826096877164,"score_spread":0.3414843740519755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807192583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99727696,0.0004546686,0.00028399003,0.0010427538,0.000108902794,0.00055241265,0.00014256041,0.000006109395,0.00013162976],"genre_scores_gemma":[0.9988633,0.00020680671,0.00047917463,0.000048211143,0.00014122023,0.00022848215,0.000005356933,0.000013349441,0.000014093802],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991009,0.000077134064,0.00023338677,0.00020398064,0.0001789451,0.00020563035],"domain_scores_gemma":[0.99850893,0.0008608427,0.00009115764,0.00026582935,0.00022942529,0.000043834607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031113278,0.000079805905,0.00031255413,0.00008182291,0.000026022966,0.0000020637115,0.00010297976,0.00006639016,0.000028022258],"category_scores_gemma":[0.0019054285,0.000060296097,0.000054728596,0.00023939925,0.00057110225,0.000017803406,0.00006285817,0.00013823221,0.000001135415],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064786366,0.00028103788,0.40457135,0.00041976606,0.000025687057,0.000010681632,0.0009637235,0.0000022110592,0.55926466,0.00021834201,0.00034414968,0.03325052],"study_design_scores_gemma":[0.002266226,0.0003668076,0.80512995,0.00042094672,0.000078867066,0.0000836282,0.000086299726,0.00016761471,0.19079942,0.00042597586,0.00010553187,0.00006874387],"about_ca_topic_score_codex":0.00017988158,"about_ca_topic_score_gemma":0.000020188174,"teacher_disagreement_score":0.40055856,"about_ca_system_score_codex":0.000117094656,"about_ca_system_score_gemma":0.00021794545,"threshold_uncertainty_score":0.24588035},"labels":[],"label_agreement":null},{"id":"W2807205027","doi":"10.1139/cjpp-2018-0005","title":"Breast cancer drug trastuzumab induces cardiac toxicity: evaluation of human epidermal growth factor receptor 2 as a potential diagnostic and prognostic marker","year":2018,"lang":"en","type":"review","venue":"Canadian Journal of Physiology and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Trastuzumab; Breast cancer; Medicine; Cancer; Metastatic breast cancer; Epidermal growth factor receptor; Oncology; Toxicity; Doxorubicin; Cancer research; Internal medicine; Pharmacology; Human Epidermal Growth Factor Receptor 2; Chemotherapy","score_opus":0.06798067259086966,"score_gpt":0.4170400817295677,"score_spread":0.34905940913869804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807205027","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41231486,0.5848199,1.6699879e-7,0.00032248552,0.001172736,0.00085281814,0.00047654167,0.0000026782568,0.000037783626],"genre_scores_gemma":[0.39531088,0.60263896,0.0000060365664,0.00011618249,0.0016893145,0.00012809686,0.00004093082,0.00003658293,0.000033036853],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958195,0.0019654143,0.0008648605,0.00041599953,0.0003496126,0.0005845821],"domain_scores_gemma":[0.9963077,0.00079024513,0.0007327397,0.00013570783,0.0010759659,0.0009576683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012983365,0.0003905912,0.0020592308,0.00063469034,0.00019305143,0.000015604202,0.00023361246,0.00046448602,0.008778127],"category_scores_gemma":[0.0004149153,0.00031619202,0.0003034597,0.00023626258,0.0010134755,0.00009807682,0.00005049887,0.0011191996,0.000009601612],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004998871,0.0002715789,0.0042955177,0.035102475,0.0071999114,0.0004203216,0.0014543686,0.0000021746312,0.02454545,0.000026264932,0.051421512,0.8747605],"study_design_scores_gemma":[0.021827444,0.014360496,0.24449264,0.053823754,0.09358223,0.018088877,0.00086844485,0.00008894099,0.016090177,0.0021316628,0.5299824,0.004662952],"about_ca_topic_score_codex":0.0022935376,"about_ca_topic_score_gemma":0.000604369,"teacher_disagreement_score":0.8700976,"about_ca_system_score_codex":0.00052400475,"about_ca_system_score_gemma":0.009219846,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W2809727906","doi":"10.1136/esmoopen-2018-eacr25.104","title":"PO-060 ErbB2/Her2-dependent downregulation of a transcription factor IRF6 in breast cancer cells is required for their three-dimensional growth","year":2018,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Downregulation and upregulation; Transcription factor; Cancer research; Breast cancer; Cancer; Oncology; Medicine; Internal medicine; Biology; Gene; Genetics","score_opus":0.07786127573367449,"score_gpt":0.37090880091018413,"score_spread":0.29304752517650967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809727906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839678,0.00013493001,0.0005885042,0.009021531,0.00038489542,0.003553419,0.0010095236,0.00003056863,0.0013088406],"genre_scores_gemma":[0.99720126,0.000044774646,0.0005933716,0.0004936661,0.00029881723,0.0002852512,0.00005764663,0.00004615675,0.0009790428],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813557,0.000076160664,0.0004302477,0.0004444202,0.00053168944,0.00038193667],"domain_scores_gemma":[0.9988492,0.000072529074,0.00011918606,0.0003764803,0.00044235672,0.0001402252],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058084156,0.00018791902,0.00041021145,0.00016162352,0.000075818476,0.00003874506,0.0003389624,0.00016079676,0.00372124],"category_scores_gemma":[0.000022675571,0.00015237983,0.0001017368,0.00025857234,0.00015123622,0.00027077334,0.00010363742,0.00017512136,0.00004153597],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010633833,0.0010710905,0.052700154,0.0008702147,0.0003674171,0.00001956635,0.0053914404,0.00004437016,0.8301825,0.00040014196,0.026556704,0.07176259],"study_design_scores_gemma":[0.0056280256,0.00066989346,0.53969836,0.0008173535,0.000047856796,0.0000189568,0.00010332553,0.0018461811,0.44655824,0.0012825953,0.0030621304,0.00026709063],"about_ca_topic_score_codex":0.017884275,"about_ca_topic_score_gemma":0.008065229,"teacher_disagreement_score":0.4869982,"about_ca_system_score_codex":0.00035391905,"about_ca_system_score_gemma":0.00049405236,"threshold_uncertainty_score":0.9971895},"labels":[],"label_agreement":null},{"id":"W2810215276","doi":"10.1016/j.jval.2018.04.115","title":"Long-Term Epidemiological Impact of Pertuzumab+Trastuzmab on Metastatic Breast Cancer Incidence in Canada","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Pertuzumab; Breast cancer; Incidence (geometry); Population; Internal medicine; Trastuzumab; Epidemiology; Cancer registry; Oncology; Cancer; Demography; Environmental health","score_opus":0.15389497500984478,"score_gpt":0.4715576909005265,"score_spread":0.31766271589068173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810215276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253553,0.0011266948,0.000015992107,0.005130082,0.00016681246,0.0007601372,0.00011737082,0.00001060184,0.00013678407],"genre_scores_gemma":[0.9973242,0.000884567,0.0001818207,0.0013409692,0.00014882928,0.000060742626,0.0000069176494,0.00002326631,0.000028686372],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964109,0.00079101,0.00085619447,0.000428441,0.0006595719,0.00085386465],"domain_scores_gemma":[0.9979051,0.0008999488,0.00019207604,0.0004285186,0.00013886015,0.0004355241],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002100933,0.00020256091,0.0008446553,0.00025230853,0.000040578594,0.0000045858205,0.00022807311,0.000062451516,0.00083472615],"category_scores_gemma":[0.00090005464,0.00014559523,0.00007971408,0.00066876743,0.00018602386,0.000046594603,0.000056170386,0.0006171806,0.0000143201105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004986718,0.00016019578,0.9835529,0.00055231515,0.000025905361,0.00016417331,0.0002896105,0.001648312,0.00007228235,0.00003772775,0.0010632899,0.011934649],"study_design_scores_gemma":[0.00095829414,0.0014848805,0.9896837,0.0019085687,0.0000055833934,0.00011430399,0.00005606607,0.0055264183,0.00006239712,0.00007535265,0.000017929771,0.00010652853],"about_ca_topic_score_codex":0.9929209,"about_ca_topic_score_gemma":0.89848727,"teacher_disagreement_score":0.094433606,"about_ca_system_score_codex":0.010804138,"about_ca_system_score_gemma":0.019561281,"threshold_uncertainty_score":0.99299324},"labels":[],"label_agreement":null},{"id":"W2810295565","doi":"10.1021/acs.molpharmaceut.8b00392","title":"Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with <sup>89</sup>Zr-Labeled Trastuzumab-DM1: A Comparison with <sup>89</sup>Zr-Labeled Trastuzumab","year":2018,"lang":"en","type":"article","venue":"Molecular Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Ontario Institute for Cancer Research; University of Toronto; Terry Fox Foundation","keywords":"Trastuzumab; Chemistry; Immunoconjugate; Positron emission tomography; Trastuzumab emtansine; Breast cancer; Nuclear medicine; Cancer; Medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.023633541708159896,"score_gpt":0.36119830935695424,"score_spread":0.33756476764879434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810295565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874238,0.00337658,0.0017510337,0.0020102516,0.00012100672,0.0035379943,0.00045271323,0.00020374278,0.0011228897],"genre_scores_gemma":[0.9944725,0.00045473856,0.002476062,0.0011229172,0.00033310818,0.00035931074,0.00022037812,0.00032697496,0.0002340055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9915447,0.0007743998,0.0013491325,0.0015821253,0.0026817196,0.0020679105],"domain_scores_gemma":[0.99566656,0.00018610452,0.0004940529,0.0010715971,0.0013889121,0.0011927468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086123863,0.0011773255,0.0017795886,0.0010419197,0.0003132008,0.00012550846,0.00083911215,0.00047206576,0.0005088839],"category_scores_gemma":[0.000051721105,0.0010015746,0.00033979226,0.003339216,0.0012399516,0.00028018065,0.0002619114,0.0019747447,0.000037761863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02993923,0.009756057,0.2265998,0.0028716372,0.0051017464,0.0025391148,0.020048331,0.008573194,0.66167897,0.00006942422,0.004529992,0.028292514],"study_design_scores_gemma":[0.03281611,0.00770925,0.013594979,0.005102818,0.0024633494,0.0010111672,0.002892341,0.08281327,0.84183055,0.000019302639,0.00774426,0.0020026304],"about_ca_topic_score_codex":0.0015119348,"about_ca_topic_score_gemma":0.000265988,"teacher_disagreement_score":0.21300481,"about_ca_system_score_codex":0.0013444765,"about_ca_system_score_gemma":0.0014475056,"threshold_uncertainty_score":0.99924344},"labels":[],"label_agreement":null},{"id":"W2810342468","doi":"10.1001/jamaoncol.2018.1812","title":"Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced <i>ERBB2/HER2</i>-Positive Metastatic Breast Cancer","year":2018,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":165,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Bausch Health (Canada); London Health Sciences Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Metastatic breast cancer; Taxane; Internal medicine; Adverse effect; Breast cancer; Pharmacokinetics; Oncology; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Capecitabine; Gastroenterology; Pharmacology; Progressive disease; Chemotherapy; Colorectal cancer","score_opus":0.025182949452053863,"score_gpt":0.39367988303731133,"score_spread":0.3684969335852575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810342468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.932335,0.00040425564,0.0001684881,0.03979486,0.0005104773,0.0019408838,0.00019647439,0.00010961136,0.024539918],"genre_scores_gemma":[0.9876527,0.00018845411,0.004045174,0.005353951,0.0005134426,0.00056333054,0.00005509436,0.000086782275,0.0015410371],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9969932,0.00036976812,0.00052181503,0.0006676789,0.0005530389,0.0008945319],"domain_scores_gemma":[0.9976542,0.00052411464,0.00018283055,0.0005234793,0.0007594021,0.0003559607],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000597553,0.00032375872,0.0008998061,0.00029993473,0.00010190244,0.000027153705,0.00025946417,0.00019381143,0.0020930823],"category_scores_gemma":[0.00024414787,0.0002570119,0.00007123583,0.0010043958,0.00072909123,0.00017950199,0.00010457508,0.0008035024,0.00019737238],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06176285,0.0073985797,0.12509087,0.0010619501,0.00126712,0.00644448,0.011533351,0.00008649291,0.03291227,0.0012425234,0.04656032,0.7046392],"study_design_scores_gemma":[0.03933163,0.034757126,0.82554257,0.002024311,0.00040053684,0.0025084186,0.002980037,0.0008116039,0.009208158,0.0003481608,0.08122258,0.0008648823],"about_ca_topic_score_codex":0.001896861,"about_ca_topic_score_gemma":0.012250034,"teacher_disagreement_score":0.70377433,"about_ca_system_score_codex":0.0018917193,"about_ca_system_score_gemma":0.0032712289,"threshold_uncertainty_score":0.9999882},"labels":[],"label_agreement":null},{"id":"W2883651613","doi":"10.1188/18.cjon.e103-e114","title":"Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events","year":2018,"lang":"en","type":"review","venue":"Clinical journal of oncology nursing","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Brentuximab vedotin; Adverse effect; Clinical trial; Neutropenia; Oncology; Internal medicine; Intensive care medicine; Lymphoma; Hodgkin lymphoma; Chemotherapy","score_opus":0.45245779199719316,"score_gpt":0.6617095147735645,"score_spread":0.20925172277637138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883651613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014120151,0.9705782,0.00002150684,0.0025094105,0.0028960996,0.0011196071,0.00001328147,0.000010983946,0.02143889],"genre_scores_gemma":[0.00053868734,0.99575615,0.0018769393,0.000106882806,0.0012236426,0.0000071859736,0.0000059849385,0.00006555579,0.00041898488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936346,0.0019222161,0.0025415192,0.00052537944,0.0008939754,0.0004823143],"domain_scores_gemma":[0.9885285,0.0027286792,0.0068506086,0.00036715085,0.0010751743,0.000449897],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0051049944,0.00037144704,0.003529158,0.0004910928,0.00010726573,0.000010833436,0.00037800783,0.00085631345,0.00006254471],"category_scores_gemma":[0.003823577,0.0002915709,0.0009242937,0.0004297313,0.0011964611,0.000115485265,0.000073256706,0.0027058115,0.000032219992],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011629189,0.006245313,0.00018835935,0.00326471,0.0021717404,0.00085705676,0.00035891458,1.8188715e-7,2.5363403e-7,0.000080915364,0.0035968695,0.9820728],"study_design_scores_gemma":[0.0059017623,0.019904764,0.0008148482,0.38508675,0.011582841,0.0017053307,0.002736997,0.000009619891,0.0000010022218,0.00032268767,0.571667,0.00026635334],"about_ca_topic_score_codex":0.000008580616,"about_ca_topic_score_gemma":0.0000022838747,"teacher_disagreement_score":0.9818064,"about_ca_system_score_codex":0.00445402,"about_ca_system_score_gemma":0.0027639135,"threshold_uncertainty_score":0.9999536},"labels":[],"label_agreement":null},{"id":"W2885940108","doi":"10.1158/1538-7445.am2018-3161","title":"Abstract 3161: The macrolide toxin mycalolide B disrupts actin-driven invasion and metastasis of HER2-positive cancers","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Cancer research; Metastasis; Trastuzumab; Cancer; Medicine; Cancer cell; Actin cytoskeleton; Breast cancer; Biology; Cell; Internal medicine; Cytoskeleton","score_opus":0.13896822554050128,"score_gpt":0.47725381539821765,"score_spread":0.3382855898577164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885940108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97618765,0.0023482232,0.000017194669,0.00912371,0.0002334053,0.001457985,0.0001846891,0.00003323233,0.010413916],"genre_scores_gemma":[0.99339217,0.003422029,0.000184369,0.0003678002,0.0007589516,0.00033683833,0.000012198517,0.00007143359,0.0014542161],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954363,0.00044016328,0.0004516507,0.00069347257,0.0018896365,0.0010887568],"domain_scores_gemma":[0.9963475,0.0009133908,0.00012150339,0.0008811233,0.0012328335,0.0005036783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024266548,0.0002520987,0.00051679555,0.00035444426,0.00044943645,0.00008704023,0.0005369668,0.0001652122,0.0018627259],"category_scores_gemma":[0.0007459291,0.00017311514,0.00012797583,0.0011177447,0.002342917,0.00015901972,0.0004623243,0.0012817852,0.00010386477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005393456,0.00033514,0.026838593,0.0015863104,0.0010034313,0.00043716046,0.009357513,0.000036125348,0.65667623,0.00064794044,0.07551554,0.22217256],"study_design_scores_gemma":[0.0024962723,0.0016971144,0.122672625,0.0017312012,0.00012564569,0.00010024491,0.0028914034,0.00018281132,0.8069651,0.0004489114,0.060314994,0.0003736385],"about_ca_topic_score_codex":0.01899517,"about_ca_topic_score_gemma":0.0046174317,"teacher_disagreement_score":0.22179893,"about_ca_system_score_codex":0.0012250573,"about_ca_system_score_gemma":0.0020600494,"threshold_uncertainty_score":0.9990497},"labels":[],"label_agreement":null},{"id":"W2887078648","doi":"10.1158/1538-7445.am2018-3465","title":"Abstract 3465: Biased signaling downstream of epidermal growth factor receptor regulates proliferative versus apoptotic response to ligand","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; Epidermal growth factor receptor; Signal transduction; Phosphorylation; MAPK/ERK pathway; Biology; Cell biology; ERBB3; EGFR inhibitors; Receptor tyrosine kinase; Cancer","score_opus":0.16573674846723718,"score_gpt":0.46068769895449674,"score_spread":0.29495095048725956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887078648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893903,0.000399477,0.000012930469,0.006328651,0.0004019714,0.0019999207,0.00020446834,0.00007341456,0.0011888307],"genre_scores_gemma":[0.9957665,0.00012993936,0.00062115025,0.00012412683,0.0012860685,0.00042532268,0.000017642053,0.00009569652,0.0015335045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941504,0.00069282384,0.00065734156,0.00086717674,0.0022545964,0.0013776371],"domain_scores_gemma":[0.9926395,0.0023309414,0.00011675538,0.0008329005,0.0031565353,0.0009234013],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035040216,0.00031637022,0.0006583007,0.0009408999,0.00032482445,0.00009317529,0.0005282711,0.0002480024,0.0035256888],"category_scores_gemma":[0.006730308,0.00027121836,0.00015064985,0.0018426282,0.0010774003,0.00017532836,0.00025085645,0.0010530909,0.00053733686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04396143,0.00018954014,0.0028304749,0.00045459502,0.00019103571,0.000047361482,0.0026499552,0.000011199593,0.93274397,0.000029089339,0.011786296,0.005105052],"study_design_scores_gemma":[0.0033140567,0.003925722,0.017076796,0.0011704685,0.000021096743,0.000004999458,0.00061598216,0.000030699517,0.9688555,0.000040622763,0.0046910103,0.0002530637],"about_ca_topic_score_codex":0.0011527519,"about_ca_topic_score_gemma":0.00013492996,"teacher_disagreement_score":0.040647376,"about_ca_system_score_codex":0.0012254592,"about_ca_system_score_gemma":0.0031237216,"threshold_uncertainty_score":0.999974},"labels":[],"label_agreement":null},{"id":"W2887131751","doi":"10.18632/oncotarget.25739","title":"Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results","year":2018,"lang":"en","type":"review","venue":"Oncotarget","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Oncology; Breast cancer; Internal medicine; Cancer; Clinical trial","score_opus":0.25996172392567307,"score_gpt":0.4952517428112211,"score_spread":0.235290018885548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887131751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010109484,0.98796487,0.00008794913,0.00086373376,0.0009146065,0.0034240128,0.0023154595,0.00007418771,0.003344246],"genre_scores_gemma":[0.0013023335,0.99181294,0.0009825764,0.000077878365,0.00414801,0.00013152257,0.00045321946,0.00020714136,0.000884368],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936515,0.00077747507,0.0021962584,0.0013072629,0.0012295741,0.00083791104],"domain_scores_gemma":[0.99574775,0.001484674,0.0010409242,0.0006794203,0.00047548916,0.0005717517],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00273115,0.000749406,0.0039580464,0.00032940193,0.00018534024,0.00006267225,0.00025697498,0.0007334349,0.00033138317],"category_scores_gemma":[0.00079543213,0.0005170975,0.00056342187,0.00070911966,0.0011129989,0.00011052999,0.00019190458,0.0015311913,0.000022055889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23777737,0.0030540014,0.0014391269,0.08011278,0.008143893,0.002802974,0.0024589477,0.0000017791788,0.0000077934865,0.00033107886,0.1619912,0.50187904],"study_design_scores_gemma":[0.047329362,0.009518679,0.00025245047,0.07237812,0.0029269983,0.0008142128,0.0004394138,0.00003285638,0.000003581622,0.000026509646,0.8653889,0.0008889572],"about_ca_topic_score_codex":0.00052925624,"about_ca_topic_score_gemma":0.00022418887,"teacher_disagreement_score":0.7033977,"about_ca_system_score_codex":0.0020058153,"about_ca_system_score_gemma":0.005640742,"threshold_uncertainty_score":0.99999636},"labels":[],"label_agreement":null},{"id":"W2887351902","doi":"10.1002/cjp2.112","title":"Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients","year":2018,"lang":"en","type":"article","venue":"The Journal of Pathology Clinical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Cancer; Biomarker; Ductal carcinoma; Progesterone receptor; Gynecology; Estrogen receptor; Biology","score_opus":0.4502120533375113,"score_gpt":0.618210457192407,"score_spread":0.16799840385489567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887351902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996655,0.00020323218,0.00019377944,0.0015708777,0.00011860085,0.00045264722,0.0006596737,0.0000032115863,0.0001430099],"genre_scores_gemma":[0.99482363,0.00043319922,0.004135816,0.00011502132,0.00038291753,0.00002075894,0.00006752004,0.000013155073,0.000008002243],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9910683,0.0033547573,0.0031671356,0.00042755855,0.0015404979,0.00044172045],"domain_scores_gemma":[0.96808326,0.026456017,0.0010837511,0.00049173937,0.0036209137,0.00026430315],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.06729332,0.00013152734,0.0009045579,0.00053870695,0.00009052698,0.000019258277,0.00043010354,0.00022546331,0.000067713976],"category_scores_gemma":[0.043850202,0.00009522872,0.0002006821,0.00096227485,0.0016038312,0.00008896059,0.00031074134,0.0018179325,0.0000016527505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024105478,0.0007637433,0.94273084,0.000039076207,0.0005488192,0.00006199955,0.00018419311,0.0000063568286,0.019934108,0.000006906748,0.00025545526,0.011363005],"study_design_scores_gemma":[0.009844062,0.0013824896,0.98436004,0.00050958205,0.00017170314,0.000029914308,0.00033383706,0.0025300672,0.0004593324,0.00028640113,0.000014926884,0.00007764362],"about_ca_topic_score_codex":0.0010668974,"about_ca_topic_score_gemma":0.00069985254,"teacher_disagreement_score":0.041629184,"about_ca_system_score_codex":0.00044782175,"about_ca_system_score_gemma":0.0022299543,"threshold_uncertainty_score":0.96420383},"labels":[],"label_agreement":null},{"id":"W2887806952","doi":"10.1158/1538-7445.am2018-756","title":"Abstract 756: Development of next-generation antibody-drug conjugates for resistant HER2-positive tumors","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Antibody-drug conjugate; Cytotoxic T cell; Cancer research; Antibody; Cancer; Chemistry; Cancer cell; Drug delivery; In vivo; Pharmacology; In vitro; Medicine; Biology; Biochemistry; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.22731882205759396,"score_gpt":0.49274887540770745,"score_spread":0.2654300533501135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887806952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898303,0.0015937284,0.00018055702,0.0021967452,0.00022509937,0.0020707126,0.00011520079,0.000038283557,0.0037493529],"genre_scores_gemma":[0.9921828,0.00031603986,0.0031191267,0.000111684385,0.0012125054,0.0006307189,0.00013296312,0.00007018352,0.0022239913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99624014,0.00014946287,0.0006006465,0.0006033646,0.0014948574,0.00091155566],"domain_scores_gemma":[0.995889,0.00035404915,0.00010841581,0.0004902717,0.002822112,0.00033616612],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002988444,0.00019810388,0.0004250835,0.00039781714,0.00045334577,0.00008337597,0.000326232,0.00011571852,0.0009882429],"category_scores_gemma":[0.000545469,0.0001740907,0.000091616545,0.00066180085,0.0008017914,0.00014543107,0.00013846264,0.0004963267,0.00009865482],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015117759,0.00016464584,0.0013969844,0.00079535134,0.00011392816,0.000022210113,0.0021663145,0.0000020789394,0.95527315,0.00026477638,0.019121496,0.019167317],"study_design_scores_gemma":[0.0012320288,0.00068510993,0.016723754,0.0011642558,0.000014567427,0.000003743658,0.0007176148,0.00022791179,0.94683164,0.000103680846,0.03210995,0.00018571029],"about_ca_topic_score_codex":0.0011650842,"about_ca_topic_score_gemma":0.0011702392,"teacher_disagreement_score":0.018981608,"about_ca_system_score_codex":0.000930249,"about_ca_system_score_gemma":0.0038814272,"threshold_uncertainty_score":0.999925},"labels":[],"label_agreement":null},{"id":"W2888555396","doi":"10.1016/j.bbamcr.2018.08.013","title":"The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis","year":2018,"lang":"en","type":"article","venue":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Cancer research; Cell biology; Transgene; Genetically modified mouse; Biology; Carcinogenesis; Oncogene; Cell; Cancer; Cell cycle; Gene","score_opus":0.06951604189795799,"score_gpt":0.3693132207436446,"score_spread":0.2997971788456866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888555396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97144645,0.0002733284,0.00005045079,0.017950842,0.00015808958,0.0028428924,0.000036356538,0.00011929797,0.0071222656],"genre_scores_gemma":[0.9953586,0.00022925873,0.000909981,0.00016306968,0.00053717295,0.00069698534,0.00006613512,0.00020010746,0.0018386925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99051255,0.0019809392,0.0007664085,0.0014575688,0.002983592,0.002298965],"domain_scores_gemma":[0.9955434,0.0006011154,0.00017278561,0.002302867,0.000678865,0.0007009636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039822436,0.0005708269,0.0006556149,0.00086344825,0.0010242148,0.0007013026,0.0018502269,0.00035147398,0.00007403627],"category_scores_gemma":[0.000703594,0.0004441036,0.00033412743,0.0029164683,0.0015225504,0.00017589353,0.001078087,0.002069266,0.0005394393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007603086,0.0005470511,0.000044090157,0.00021857895,0.000075209195,0.00055145635,0.0004939697,1.3831992e-7,0.9913181,0.0004527396,0.0022530693,0.0032852683],"study_design_scores_gemma":[0.0013924798,0.0016182027,0.0028426007,0.0004042344,0.000022588461,0.000013260328,0.00038346535,0.00013819714,0.9845503,0.0007295496,0.007450626,0.00045451266],"about_ca_topic_score_codex":0.0005245473,"about_ca_topic_score_gemma":0.00022935627,"teacher_disagreement_score":0.02391212,"about_ca_system_score_codex":0.00073533703,"about_ca_system_score_gemma":0.0022107465,"threshold_uncertainty_score":0.9998011},"labels":[],"label_agreement":null},{"id":"W2890098568","doi":"10.1007/s10585-018-9929-3","title":"Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment","year":2018,"lang":"en","type":"article","venue":"Clinical & Experimental Metastasis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Trastuzumab; Medicine; In vivo; Immunohistochemistry; Pathology; Cancer; Cancer research; Breast cancer; Internal medicine; Biology","score_opus":0.038091256455284744,"score_gpt":0.3937615804408038,"score_spread":0.355670323985519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890098568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463636,0.003729237,0.00002161482,0.00017792996,0.00013738807,0.00078120676,0.00039468272,0.0000075246007,0.00011408047],"genre_scores_gemma":[0.9988816,0.00013560748,0.00060935837,0.00015883963,0.000089117,0.000056268214,0.000031521908,0.00002311856,0.000014607434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737114,0.00048723645,0.00091635314,0.0004287689,0.00048001908,0.00031650742],"domain_scores_gemma":[0.99887073,0.0001788193,0.00022666494,0.0004740242,0.000062910665,0.00018682155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007816878,0.00019306462,0.0006588079,0.00005582837,0.00005887285,0.000008859814,0.00019496752,0.00007206714,0.00024727033],"category_scores_gemma":[0.00020304749,0.00013907313,0.0002749497,0.00025271703,0.0015352388,0.000046293793,0.0002879486,0.00024950638,0.000011104628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004570095,0.011489312,0.18058546,0.00025506417,0.0011567591,0.000106248466,0.0026130131,0.000007847631,0.7303885,0.00023177204,0.00081053696,0.06778537],"study_design_scores_gemma":[0.0018078819,0.0030939754,0.07663421,0.000192133,0.00013739917,0.000052653035,0.0013140887,0.00004356948,0.914513,0.000031679996,0.0020680847,0.000111316185],"about_ca_topic_score_codex":0.00023177596,"about_ca_topic_score_gemma":0.000025823798,"teacher_disagreement_score":0.18412448,"about_ca_system_score_codex":0.0002005253,"about_ca_system_score_gemma":0.00009320272,"threshold_uncertainty_score":0.5671238},"labels":[],"label_agreement":null},{"id":"W2890440333","doi":"10.1093/dote/doy089.ps02.153","title":"PS02.153: HER2 PATHWAY CONTROL SENSITIVITY TO CISPLATIN IN ESOPHAGEAL ADENOCARCINOMA CELL LINES","year":2018,"lang":"en","type":"article","venue":"Diseases of the Esophagus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Cisplatin; Medicine; Cancer research; Adenocarcinoma; Cell culture; Esophageal cancer; Chemotherapy; Downregulation and upregulation; Cell growth; Oncology; Cancer; Esophagus; Cell; Internal medicine; Biology; Gene; Genetics","score_opus":0.014250424507458932,"score_gpt":0.2992810073715946,"score_spread":0.28503058286413563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890440333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779845,0.01683877,0.00006475222,0.0021212017,0.00050039525,0.0015002625,0.00052615925,0.00006521086,0.00039874573],"genre_scores_gemma":[0.9967429,0.000009187967,0.00015061136,0.0012390516,0.00083955855,0.00006321734,0.000011309352,0.000051944004,0.00089221366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973842,0.0003443855,0.0004417551,0.00047531904,0.000781917,0.0005724336],"domain_scores_gemma":[0.99778277,0.0003582966,0.000120367775,0.0009787164,0.00031059876,0.00044927845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004703112,0.00026027352,0.00055076065,0.00019163224,0.00010028606,0.00002391737,0.00034215482,0.00011236682,0.00028533133],"category_scores_gemma":[0.00083392084,0.00019375615,0.0002533034,0.00059289916,0.00032692787,0.00006824043,0.00022868573,0.00029398588,0.00017039957],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013954587,0.000557586,0.9886815,0.00026604286,0.000044212462,0.00043485776,0.0003570438,0.00006978088,0.0017959815,0.000051773754,0.0033180169,0.0030277616],"study_design_scores_gemma":[0.0026227466,0.0005841021,0.94135684,0.00022494211,0.00008438206,0.000020185294,0.00007003085,0.0011036401,0.053581223,0.00010996074,0.0000771992,0.00016475703],"about_ca_topic_score_codex":0.00060631527,"about_ca_topic_score_gemma":0.00020657279,"teacher_disagreement_score":0.05178524,"about_ca_system_score_codex":0.0001813258,"about_ca_system_score_gemma":0.0004871631,"threshold_uncertainty_score":0.7901146},"labels":[],"label_agreement":null},{"id":"W2891579961","doi":"10.3390/cancers10100342","title":"Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer","year":2018,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Pertuzumab; Trastuzumab; Medicine; Breast cancer; Oncology; Docetaxel; Cancer; Adjuvant; Monoclonal antibody; Internal medicine; Metastatic breast cancer; Regimen; Pharmacology; Antibody; Immunology","score_opus":0.12397561589420557,"score_gpt":0.4352357693218751,"score_spread":0.3112601534276695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891579961","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010245419,0.9963792,0.00006956977,0.00029696766,0.00033537843,0.0013161569,0.00015546835,0.000020112022,0.00040259532],"genre_scores_gemma":[0.014036495,0.98497146,0.00010253283,0.000084095795,0.00015290352,0.0003399113,0.000023153028,0.000082189064,0.00020727918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977878,0.00023907873,0.0005149041,0.0005792447,0.00043282149,0.0004461832],"domain_scores_gemma":[0.9988392,0.00027319213,0.00029088458,0.00029045242,0.00014637095,0.00015990675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061608764,0.00036596626,0.001243144,0.00023479376,0.0001382306,0.00003600584,0.0001635033,0.00029621396,0.00013699374],"category_scores_gemma":[0.00007411503,0.00025071285,0.00014256091,0.0004557859,0.00042828848,0.000080619655,0.000103777544,0.0007566159,0.0000024730077],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008256535,0.000013169587,0.00001446145,0.01615458,0.00027568405,0.000025617777,0.00092563056,0.000005211582,0.00010055596,0.00010339381,0.0007373323,0.9815618],"study_design_scores_gemma":[0.0032810401,0.0015431757,0.002671515,0.19934906,0.0032796338,0.0014856003,0.007509429,0.0012307939,0.00015772793,0.00042301987,0.7773951,0.001673889],"about_ca_topic_score_codex":0.0057616592,"about_ca_topic_score_gemma":0.0007644185,"teacher_disagreement_score":0.9798879,"about_ca_system_score_codex":0.0048670587,"about_ca_system_score_gemma":0.0031321007,"threshold_uncertainty_score":0.9999945},"labels":[],"label_agreement":null},{"id":"W2892311857","doi":"10.1200/jco.2018.36.15_suppl.2500","title":"Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Medicine; Pertuzumab; Lapatinib; Trastuzumab; Internal medicine; Oncology; Adverse effect; Cancer; Breast cancer","score_opus":0.2772677226377683,"score_gpt":0.5580802764934101,"score_spread":0.2808125538556418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892311857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863534,0.00068310107,0.000121480676,0.004199671,0.0015360407,0.00035005456,0.000007791392,0.00001443604,0.006734009],"genre_scores_gemma":[0.9938654,0.0008010548,0.002849951,0.00048287972,0.0016778318,0.000004262501,0.000002349788,0.000037563612,0.00027874045],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943783,0.0012238533,0.0026224162,0.0003623405,0.0008664144,0.0005466665],"domain_scores_gemma":[0.9944823,0.0016786974,0.0018048821,0.00042007965,0.00107064,0.00054342666],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0049111717,0.00020751361,0.0020691662,0.00038803654,0.000049645518,0.00001559486,0.00033022623,0.0006010054,0.0007649817],"category_scores_gemma":[0.004693663,0.00016192737,0.00044024416,0.00065608154,0.0009804006,0.0001561314,0.00012121087,0.0017797173,0.000023591687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02141426,0.0072501507,0.42268378,0.00027193013,0.0005414296,0.002181062,0.0007797768,0.000029358007,0.23308824,0.000012627592,0.011988714,0.29975864],"study_design_scores_gemma":[0.0123000285,0.045369867,0.7668623,0.0017320989,0.00019131837,0.00031111072,0.00023307701,0.0005305505,0.058678754,0.0001252479,0.11341407,0.00025162325],"about_ca_topic_score_codex":0.0008580101,"about_ca_topic_score_gemma":0.0008587572,"teacher_disagreement_score":0.34417847,"about_ca_system_score_codex":0.0012930656,"about_ca_system_score_gemma":0.004775215,"threshold_uncertainty_score":0.84710264},"labels":[],"label_agreement":null},{"id":"W2892343964","doi":"10.1007/s10549-018-4967-8","title":"Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials","year":2018,"lang":"en","type":"review","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Breast cancer; Hazard ratio; Oncology; Meta-analysis; Odds ratio; Randomized controlled trial; Population; Adjuvant; Confidence interval; Cancer","score_opus":0.3371883552928294,"score_gpt":0.5253974729976785,"score_spread":0.18820911770484905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892343964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006324172,0.9655148,0.0000061707296,0.00049234496,0.000061634004,0.016249418,0.01120094,0.0000128022675,0.00013774486],"genre_scores_gemma":[0.03130458,0.9458209,0.00009867232,0.000002399081,0.00022677208,0.021304637,0.0002757797,0.00008280121,0.00088345096],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9839476,0.006126837,0.005427561,0.0011735,0.0023658138,0.0009587349],"domain_scores_gemma":[0.98899645,0.005061752,0.0024905792,0.0010896054,0.0018538071,0.00050778943],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_broad"],"category_scores_codex":[0.008968138,0.0009944969,0.042458296,0.0037264174,0.00008687896,0.00005019928,0.0002953974,0.00043024987,0.0025645392],"category_scores_gemma":[0.00042486348,0.000504301,0.010227982,0.0027956946,0.00124817,0.00009135427,0.00008714177,0.00033234,0.0000046092873],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1915562,0.002906701,0.00028396436,0.004384237,0.45838907,0.00006919823,0.0005725269,0.0000168163,0.00001380037,0.000037980422,0.000035610086,0.34173387],"study_design_scores_gemma":[0.28391412,0.005957509,0.00084186584,0.0051180176,0.69854987,0.00009712546,0.00011854141,0.00017649781,0.00016047838,0.00001452282,0.0046403115,0.00041117906],"about_ca_topic_score_codex":0.058873937,"about_ca_topic_score_gemma":0.0040567336,"teacher_disagreement_score":0.34132272,"about_ca_system_score_codex":0.0032033725,"about_ca_system_score_gemma":0.0063697016,"threshold_uncertainty_score":0.99974084},"labels":[],"label_agreement":null},{"id":"W2896257009","doi":"","title":"The combi-targeting concept: a new cell signaling-based model for the selective targeting of the epidermal growth factor receptor (EGFR)- and Her2-expressing solid tumor cells by the complex combi-molecule RB24 (NSC 741279)","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Health Canada","funders":"","keywords":"Transfection; Comet assay; DNA damage; Apoptosis; Biology; Epidermal growth factor receptor; Cancer cell; Cell biology; Cancer research; Annexin; Epidermal growth factor; Molecular biology; DNA; Cell culture; Receptor; Cancer; Biochemistry; Genetics","score_opus":0.08819268868269484,"score_gpt":0.4062163210851354,"score_spread":0.3180236324024406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896257009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8569578,0.036991514,0.036450226,0.048352968,0.0010450064,0.01704018,0.0012357363,0.00019379852,0.0017327516],"genre_scores_gemma":[0.9953723,0.00027557556,0.00067072915,0.0011687,0.0005558607,0.00039825478,0.000027466667,0.00015001945,0.0013810865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99299765,0.0011297787,0.0009016339,0.00078695413,0.002197257,0.0019867485],"domain_scores_gemma":[0.98808134,0.008566416,0.00039290806,0.0008325169,0.0016669928,0.00045982815],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.006756672,0.00042916427,0.0006176407,0.00012150315,0.002691855,0.00028190875,0.0014627618,0.00017436837,0.00019553026],"category_scores_gemma":[0.0017706258,0.00022131698,0.00028509114,0.0010015123,0.002279714,0.00010830391,0.0004995725,0.0022256554,0.0000064438896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012150098,0.00013953313,0.0011253805,0.00039848886,0.00013596012,0.000004120529,0.0038620967,0.0019436077,0.8083559,0.00008409737,0.18104175,0.0016940524],"study_design_scores_gemma":[0.0028277214,0.00038436087,0.0003107305,0.00038678088,0.000060070095,0.000003259985,0.0027811583,0.07902195,0.9008181,0.00022906373,0.01289408,0.00028271604],"about_ca_topic_score_codex":0.0026406415,"about_ca_topic_score_gemma":0.00024521997,"teacher_disagreement_score":0.16814767,"about_ca_system_score_codex":0.0007384296,"about_ca_system_score_gemma":0.0027129035,"threshold_uncertainty_score":0.9986065},"labels":[],"label_agreement":null},{"id":"W2897175439","doi":"10.1007/s00280-018-3689-2","title":"Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer","year":2018,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Afatinib; Internal medicine; Rash; Trastuzumab; Diarrhea; Metastatic breast cancer; Cancer; Adverse effect; Oncology; Gastroenterology; Breast cancer; Surgery; Epidermal growth factor receptor; Erlotinib","score_opus":0.028446106103640956,"score_gpt":0.4090134797091505,"score_spread":0.3805673736055095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897175439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952203,0.0006878667,0.00007797287,0.0012180322,0.00017466703,0.0021742573,0.00009096567,0.000013091478,0.00034284854],"genre_scores_gemma":[0.99489015,0.0022555059,0.0008116034,0.0011691354,0.00023699748,0.00044095496,0.000013160568,0.000040425446,0.00014207943],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99851257,0.00010767273,0.00027646765,0.0004219015,0.0002902288,0.00039115813],"domain_scores_gemma":[0.99934775,0.00006418871,0.00012620137,0.000119540164,0.00017009303,0.00017223854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020299277,0.00022123246,0.0005310777,0.00015836337,0.000059250917,0.000010123873,0.000079071186,0.000059386115,0.00090317323],"category_scores_gemma":[0.000002304351,0.00016398421,0.000024205272,0.00029879072,0.0006315771,0.0000732341,0.000024955425,0.00022390194,7.293919e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5995837,0.00644902,0.059679523,0.0012334227,0.0033693996,0.00015322122,0.0065627005,0.000041798507,0.008073529,0.0000298866,0.0029774886,0.31184635],"study_design_scores_gemma":[0.7659966,0.047355924,0.07284305,0.00060899963,0.00087097473,0.000016984208,0.00040572876,0.0006453528,0.1048363,0.000015458732,0.0058654207,0.0005392349],"about_ca_topic_score_codex":0.00030229316,"about_ca_topic_score_gemma":0.000083804916,"teacher_disagreement_score":0.3113071,"about_ca_system_score_codex":0.0001620407,"about_ca_system_score_gemma":0.0002709208,"threshold_uncertainty_score":0.98891133},"labels":[],"label_agreement":null},{"id":"W2898173867","doi":"10.1007/s40261-018-0719-0","title":"Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials","year":2018,"lang":"en","type":"review","venue":"Clinical Drug Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Neratinib; Medicine; Oncology; Internal medicine; Adverse effect; Diarrhea; Breast cancer; Clinical trial; Hazard ratio; Nausea; Cancer; Trastuzumab; Confidence interval","score_opus":0.5943309892068062,"score_gpt":0.6027997922926437,"score_spread":0.008468803085837528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898173867","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000048286307,0.9836679,0.0000256129,0.0005920761,0.000098554774,0.014961203,0.0004205334,0.000028236887,0.00015761507],"genre_scores_gemma":[0.00003663808,0.99588126,0.0013734769,0.00042321594,0.00022674013,0.0007383878,0.00035550425,0.00005876804,0.0009060015],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9679076,0.016542144,0.0132111525,0.0011667745,0.0009011268,0.00027120308],"domain_scores_gemma":[0.9581511,0.029987607,0.007973894,0.001788882,0.001359182,0.00073934766],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.064098865,0.00054274994,0.03039439,0.00041180354,0.00006210569,0.000028795605,0.00030192136,0.0006759672,0.00026768201],"category_scores_gemma":[0.13287017,0.0003212018,0.0050735855,0.0017316132,0.0020649007,0.000076655844,0.000224237,0.0011733471,0.000031439038],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005975957,0.00019725024,0.00019641439,0.8652211,0.12575871,0.0000027283947,0.000072356466,6.09068e-8,1.3036632e-7,0.00019810315,0.0018082141,0.0064851698],"study_design_scores_gemma":[0.00082702585,0.0005953925,0.000246961,0.11326942,0.8771928,0.000008109566,0.000010993115,0.00006706677,0.000002371525,0.00007526181,0.0074718106,0.00023281698],"about_ca_topic_score_codex":0.000024046209,"about_ca_topic_score_gemma":0.000012688859,"teacher_disagreement_score":0.7519517,"about_ca_system_score_codex":0.000083575054,"about_ca_system_score_gemma":0.0014254351,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W2898265596","doi":"10.1093/annonc/mdy424.001","title":"PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Cost-effectiveness analysis; Adjuvant; Internal medicine; Cost effectiveness; Oncology; Surgery; Cancer","score_opus":0.06745822084552353,"score_gpt":0.43022346759668556,"score_spread":0.36276524675116206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898265596","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99235934,0.0001306985,0.0000140017055,0.00089109124,0.0001696876,0.0010280331,0.00077153475,0.000011956327,0.0046236473],"genre_scores_gemma":[0.9992844,0.00015153701,0.000068589965,0.00012574451,0.00010319708,0.000115259754,0.00006558291,0.00002914732,0.000056559908],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972661,0.00050050137,0.0005505749,0.0005102239,0.00063424086,0.00053834106],"domain_scores_gemma":[0.9968923,0.00055655336,0.00031876302,0.00043789213,0.0015830166,0.00021152088],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088665745,0.00021832343,0.0011001811,0.00057277665,0.000044513163,0.000005542132,0.000199527,0.0002155731,0.00019241958],"category_scores_gemma":[0.00022425361,0.00017809276,0.00016891217,0.0012782217,0.00068855315,0.0000996573,0.000076495686,0.0003219741,0.000013455492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1565852,0.0031177101,0.7006858,0.00019239508,0.0033197668,0.0001336219,0.004857458,0.00019475997,0.0010662393,0.000016954913,0.0010763918,0.12875372],"study_design_scores_gemma":[0.016089668,0.025224905,0.95020616,0.0003569516,0.00042800241,0.000004615502,0.00036865278,0.000101980535,0.0064831567,0.000003295545,0.0005806126,0.00015199448],"about_ca_topic_score_codex":0.020286985,"about_ca_topic_score_gemma":0.011422443,"teacher_disagreement_score":0.24952038,"about_ca_system_score_codex":0.0005824976,"about_ca_system_score_gemma":0.0009287196,"threshold_uncertainty_score":0.986237},"labels":[],"label_agreement":null},{"id":"W2898304683","doi":"10.1093/annonc/mdy270.187","title":"Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Internal medicine; Oncology; Docetaxel; Population; Pertuzumab; Trastuzumab; Chemotherapy; Breast cancer; Cancer","score_opus":0.1758411817290713,"score_gpt":0.5024193249183248,"score_spread":0.3265781431892535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898304683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97392845,0.0021261019,0.0000069327566,0.017812598,0.00012091223,0.0006193861,0.0001170298,0.0000208071,0.0052478076],"genre_scores_gemma":[0.99649864,0.0015154091,0.0003445892,0.00077372923,0.00034393772,0.00011073618,0.000011430089,0.000034094857,0.00036745783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996232,0.0012787589,0.00056317216,0.00038158914,0.0008888633,0.0006556208],"domain_scores_gemma":[0.9967857,0.0008249249,0.00016053508,0.0007287628,0.0011743297,0.00032574873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003927975,0.00014163268,0.0005622717,0.00064850296,0.000050738872,0.000006050939,0.00027846056,0.00023136745,0.0010007819],"category_scores_gemma":[0.0022396126,0.00011797501,0.0001088555,0.0006867095,0.0025997504,0.000068198424,0.000137451,0.0006632841,0.000068677895],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018225785,0.0024936912,0.86721015,0.0006612915,0.00022444951,0.0008140144,0.0024190615,0.000016674227,0.003320332,0.000247236,0.07198377,0.032383554],"study_design_scores_gemma":[0.0028956744,0.0101229735,0.9044827,0.0005175186,0.000036699344,0.0000037205464,0.0003143217,0.00011775745,0.014616434,0.0016864712,0.0650938,0.0001119225],"about_ca_topic_score_codex":0.00088168675,"about_ca_topic_score_gemma":0.0006081949,"teacher_disagreement_score":0.03727256,"about_ca_system_score_codex":0.00009318455,"about_ca_system_score_gemma":0.0020145052,"threshold_uncertainty_score":0.99991244},"labels":[],"label_agreement":null},{"id":"W2898439681","doi":"10.4049/jimmunol.1701556","title":"Structural and Functional Analyses of the Shedding Protease ADAM17 in HoxB8-Immortalized Macrophages and Dendritic-like Cells","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Exzellenzclusters Entzündungsforschung; Wellcome Trust","keywords":"Cell biology; Biology; Transfection; Embryonic stem cell; Metalloproteinase; Cell culture; Immune system; Immunology; Matrix metalloproteinase; Biochemistry; Genetics; Gene","score_opus":0.0530488482860415,"score_gpt":0.37016246966107225,"score_spread":0.31711362137503074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898439681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993022,0.005323912,0.000018577883,0.0010638798,0.00028860345,0.00019724377,0.000003656911,0.0000021833994,0.00007993986],"genre_scores_gemma":[0.9988812,0.00054793985,0.00016215535,0.00010985954,0.00013065708,0.0000020413506,2.708103e-7,0.000009350546,0.00015647797],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987743,0.0003211587,0.00036954586,0.000083078936,0.00025986973,0.00019205973],"domain_scores_gemma":[0.9991179,0.00020102116,0.00021453733,0.00019643537,0.00022576019,0.00004432093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006748396,0.000091930604,0.00030017277,0.00015073801,0.00009612473,0.000010571537,0.00015074383,0.00006288675,0.00023473095],"category_scores_gemma":[0.00023371726,0.00004659189,0.000051773164,0.00018607503,0.0009261268,0.000060936454,0.00012530995,0.00043893763,0.0000013150433],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017808487,0.00002810201,0.0211991,0.000057449473,0.00026618503,0.000038409442,0.0007368161,0.000008947228,0.9735401,0.000042047064,0.00018547181,0.0021165072],"study_design_scores_gemma":[0.0036934633,0.0012120934,0.6449504,0.00033960774,0.00023116422,0.0028579165,0.0014026884,0.00017859958,0.34420103,0.00051217753,0.0003339828,0.00008686791],"about_ca_topic_score_codex":0.00019690295,"about_ca_topic_score_gemma":0.000044404078,"teacher_disagreement_score":0.6293391,"about_ca_system_score_codex":0.000051028284,"about_ca_system_score_gemma":0.00018642578,"threshold_uncertainty_score":0.34123528},"labels":[],"label_agreement":null},{"id":"W2900133605","doi":"10.1093/neuonc/noy148.1115","title":"TMOD-02. DIFFUSE GLIOMATOSIS IN MOUSE MODEL OF GFAP TISSUE SPECIFIC KNOCK IN OF EGFRvIII AND KNOCK OUT OF p19 ARF","year":2018,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pathology; Immunohistochemistry; Biology; NeuN; Synaptophysin; Glioma; Nestin; Glial fibrillary acidic protein; Genetically modified mouse; Parenchyma; Leptomeninges; Cancer research; Transgene; Medicine; Neural stem cell; Stem cell; Central nervous system; Cell biology","score_opus":0.07303066409905097,"score_gpt":0.3795410821435967,"score_spread":0.30651041804454576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900133605","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99260014,0.00031674246,0.000065904875,0.0008972311,0.00019464272,0.00072175224,0.000051368446,0.00001747549,0.0051347194],"genre_scores_gemma":[0.99759376,0.000782105,0.0009823131,0.00017119906,0.0001157348,0.000043119886,0.0000040869027,0.000050708877,0.00025699704],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974377,0.0002780579,0.00089977734,0.00048356433,0.00043253053,0.0004683606],"domain_scores_gemma":[0.99819034,0.00046888518,0.00024851007,0.0006624507,0.0002512901,0.00017851821],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050831534,0.00020613718,0.001029383,0.000690258,0.000018100889,0.0000040043574,0.00028123104,0.00031468156,0.0001483378],"category_scores_gemma":[0.0004250596,0.00019904735,0.00006174883,0.0005069614,0.0007082739,0.00006736335,0.00026277817,0.00044798892,0.000022772656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010022864,0.0010872683,0.028911171,0.00038442973,0.000019636085,0.00007119395,0.0025216632,0.000054782802,0.9557093,0.00018278396,0.0015082192,0.008547288],"study_design_scores_gemma":[0.008220419,0.0052865194,0.0062401188,0.00020314743,0.00003387749,0.000047349196,0.00039116884,0.006507268,0.96014535,0.00034672164,0.012376249,0.0002017855],"about_ca_topic_score_codex":0.00043983263,"about_ca_topic_score_gemma":0.001006353,"teacher_disagreement_score":0.022671053,"about_ca_system_score_codex":0.00022317166,"about_ca_system_score_gemma":0.00046920485,"threshold_uncertainty_score":0.8116916},"labels":[],"label_agreement":null},{"id":"W2900581547","doi":"10.1038/s41598-018-35284-9","title":"Effects of Modulating Actin Dynamics on HER2 Cancer Cell Motility and Metastasis","year":2018,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Queen's University; Government of Canada","keywords":"Metastasis; Cancer research; Cancer; Motility; Cancer cell; Trastuzumab; Cortactin; Medicine; Biology; Cell; Breast cancer; Internal medicine; Cell biology; Cytoskeleton; Biochemistry","score_opus":0.025379370454895262,"score_gpt":0.3559277230747027,"score_spread":0.3305483526198075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900581547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920011,0.00036729086,0.00005946466,0.00013258411,0.0022139137,0.00056181214,0.0000059414356,0.000031115134,0.0046267323],"genre_scores_gemma":[0.9962873,0.000014212496,0.00065401546,0.000027972676,0.00009999473,0.000026357671,0.0000071781715,0.000019771078,0.00286321],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977353,0.00007364828,0.0003808866,0.0006771919,0.00080881105,0.00032413047],"domain_scores_gemma":[0.9983842,0.00010841393,0.00022259666,0.00075117714,0.0003408058,0.00019280368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016880131,0.00012601857,0.0002914877,0.000110078596,0.00016760603,0.000053145326,0.000068749396,0.000065283726,0.0002495764],"category_scores_gemma":[0.0005095081,0.000104304774,0.000066521105,0.0004015958,0.00052626466,0.000058399917,0.00009403238,0.00015976132,0.000006373],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026364042,0.0009885828,0.28997108,0.005081265,0.00020001344,0.0010605315,0.0024921438,0.00007326558,0.4365761,0.00005033247,0.012478842,0.25076422],"study_design_scores_gemma":[0.00042663427,0.00036367206,0.063622065,0.00043242972,0.00009869488,0.0000713636,0.00014783387,0.006806981,0.9245975,0.0005503073,0.002743264,0.0001392277],"about_ca_topic_score_codex":0.0012172795,"about_ca_topic_score_gemma":0.00046916388,"teacher_disagreement_score":0.48802143,"about_ca_system_score_codex":0.0002768371,"about_ca_system_score_gemma":0.00028438275,"threshold_uncertainty_score":0.42534253},"labels":[],"label_agreement":null},{"id":"W2901691660","doi":"10.1186/s13058-018-1064-1","title":"Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Breast Cancer Ireland; Trinity College Dublin; Science Foundation Ireland; Health Research Board","keywords":"Lapatinib; Gene silencing; Trastuzumab; Breast cancer; Cancer research; Medicine; Epidermal growth factor receptor; Cancer; Protein kinase B; Metastatic breast cancer; Internal medicine; Biology; Signal transduction; Cell biology","score_opus":0.03564888088784328,"score_gpt":0.3661277690871291,"score_spread":0.3304788881992858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901691660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9581028,0.0014597791,0.000016369604,0.03654838,0.00011096004,0.0013237005,0.0007914099,0.000024918938,0.0016216616],"genre_scores_gemma":[0.9952306,0.00028515828,0.00014695004,0.00043679832,0.00029119293,0.0003132236,0.000006753327,0.0000851517,0.0032041573],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99401146,0.0006344637,0.0005689668,0.00069407484,0.0031101154,0.0009809462],"domain_scores_gemma":[0.9963125,0.00022758689,0.00020442676,0.00084966887,0.0021427912,0.00026305168],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027024532,0.00026471523,0.00058607967,0.00048320877,0.00023245742,0.0000339333,0.0006405146,0.00019396993,0.0015761608],"category_scores_gemma":[0.00014642121,0.00018296702,0.00012238884,0.0032114,0.0012889531,0.000112208145,0.00026861113,0.00090900715,0.000019077108],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008792834,0.00074839225,0.48827076,0.0007774419,0.00038524592,0.00007465154,0.0045241155,0.000014532098,0.42916024,0.0002620231,0.061385784,0.00560398],"study_design_scores_gemma":[0.0024349303,0.0003215097,0.85800105,0.0050003384,0.000028386554,0.000046921596,0.0008223102,0.00003322577,0.12743983,0.00012480335,0.0055232714,0.00022342568],"about_ca_topic_score_codex":0.0072535872,"about_ca_topic_score_gemma":0.005080403,"teacher_disagreement_score":0.3697303,"about_ca_system_score_codex":0.0011525701,"about_ca_system_score_gemma":0.0022572703,"threshold_uncertainty_score":0.9993572},"labels":[],"label_agreement":null},{"id":"W2901824468","doi":"10.2967/jnumed.118.220921","title":"Measuring Estrogen Receptor Functionality Using Progesterone Receptor PET Imaging: Rising to the (Estradiol) Challenge!","year":2018,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Progesterone receptor; Estrogen receptor; Estrogen; Receptor; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Epidermal growth factor receptor; Estrogen receptor beta; Endocrinology; Estrogen-related receptor gamma; Medicine; Cancer research; Chemistry; Cancer","score_opus":0.15688124416527063,"score_gpt":0.3730962132279249,"score_spread":0.21621496906265428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901824468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8807764,0.0018737102,0.000281081,0.112843946,0.002016128,0.0005442309,0.000006174348,0.000045302673,0.0016129946],"genre_scores_gemma":[0.97610945,0.0002669037,0.007749413,0.002792134,0.012815047,0.0000038157477,0.0000028716122,0.000108111744,0.000152236],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963705,0.00024610714,0.0008527677,0.00030518536,0.0017087078,0.0005167344],"domain_scores_gemma":[0.99718463,0.00010493094,0.00040826426,0.0004956937,0.0011655231,0.0006409732],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033303716,0.00024136173,0.00059939135,0.00030342964,0.00029600895,0.000042621847,0.00039620802,0.00006265828,0.0020535097],"category_scores_gemma":[0.0012602424,0.00015172995,0.00014909422,0.00047867067,0.00044234173,0.00018707331,0.000104713596,0.0009059669,0.00019921517],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056360727,0.0007933654,0.015779642,0.00059787155,0.0010748461,0.0006936938,0.012863065,0.000051162304,0.50844485,0.0002911496,0.33500382,0.118770435],"study_design_scores_gemma":[0.004250179,0.005798664,0.012178914,0.0043832315,0.00042022683,0.0067762886,0.005098298,0.000818976,0.0025114836,0.0000915497,0.9573122,0.00035997946],"about_ca_topic_score_codex":0.00010559442,"about_ca_topic_score_gemma":0.0000067767005,"teacher_disagreement_score":0.6223084,"about_ca_system_score_codex":0.0007087002,"about_ca_system_score_gemma":0.00040842767,"threshold_uncertainty_score":0.99885875},"labels":[],"label_agreement":null},{"id":"W2901939101","doi":"10.1186/s13643-018-0854-y","title":"Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis","year":2018,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Ottawa Public Health; St. Michael's Hospital; Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Meta-analysis; Anthracycline; Randomized controlled trial; Chemotherapy; Cancer","score_opus":0.27067337043976175,"score_gpt":0.48490405594176067,"score_spread":0.21423068550199892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901939101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[2.2955649e-7,0.90759975,0.00006409447,0.000196304,0.00012415159,0.09099785,0.00029334638,0.000055989578,0.00066827866],"genre_scores_gemma":[0.000006403837,0.94374865,0.00033142456,0.0005427285,0.00033127388,0.051433887,0.00010608167,0.00021902316,0.0032805102],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9652446,0.019029992,0.010630927,0.0019790053,0.0018356338,0.0012798598],"domain_scores_gemma":[0.9866356,0.0020987573,0.006229254,0.0035420882,0.00081375643,0.00068054174],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.022525527,0.0020951726,0.068117075,0.0009445394,0.00016695075,0.00020606878,0.0010057555,0.0006540767,0.0016526595],"category_scores_gemma":[0.0024499253,0.0011204216,0.009231758,0.006334609,0.00029845792,0.00018840394,0.00033836922,0.0014253092,0.0013287166],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000039801275,0.00006337229,0.0000081405915,0.8827674,0.11387284,0.00006220568,0.0002858322,4.0273764e-7,4.8097415e-9,0.000018066718,0.0019593423,0.00095844443],"study_design_scores_gemma":[0.00009935885,0.000085598345,0.0000049988134,0.52487427,0.4591387,0.00036941556,0.000020285901,0.000011173878,3.77287e-9,0.0000050449994,0.014937495,0.0004536426],"about_ca_topic_score_codex":0.0007946253,"about_ca_topic_score_gemma":0.00044402873,"teacher_disagreement_score":0.35789308,"about_ca_system_score_codex":0.0018212111,"about_ca_system_score_gemma":0.00083784404,"threshold_uncertainty_score":0.99944884},"labels":[],"label_agreement":null},{"id":"W2904586743","doi":"10.1186/s13058-018-1080-1","title":"ErbB2-driven downregulation of the transcription factor Irf6 in breast epithelial cells is required for their 3D growth","year":2018,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Faculty of Medicine, Dalhousie University; Canadian Institutes of Health Research; Dalhousie University; Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute; Cancer Research Institute","keywords":"Anoikis; Lapatinib; Cancer research; Trastuzumab; Downregulation and upregulation; Breast cancer; HER2/neu; Biology; Cancer cell; Medicine; Cancer; Internal medicine","score_opus":0.09643598774559511,"score_gpt":0.3982481477689688,"score_spread":0.30181216002337363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904586743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696966,0.00016835635,0.0002545969,0.021067493,0.000462424,0.0035087916,0.0038381526,0.000043158587,0.0009604525],"genre_scores_gemma":[0.99655855,0.00020050204,0.00016310581,0.00016967677,0.0011838926,0.0005033054,0.000020426514,0.000073414056,0.0011271118],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99589527,0.00042859768,0.00052318524,0.00061194866,0.0015809679,0.00096001563],"domain_scores_gemma":[0.9969912,0.00020903589,0.00010613129,0.00074562005,0.0017151455,0.00023283604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014086481,0.00023378631,0.00043000974,0.00045782866,0.00023623805,0.000047899655,0.00058202574,0.00023491497,0.001537082],"category_scores_gemma":[0.00007285629,0.00016182517,0.00021074977,0.0012505456,0.0009129841,0.00019700271,0.00013548501,0.00061089307,0.00004326221],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041267443,0.00027677522,0.0181127,0.00065687404,0.00007306521,0.0000028459528,0.0031842825,0.00000792898,0.91380244,0.00016167526,0.0055189687,0.054075688],"study_design_scores_gemma":[0.004641828,0.00053235143,0.6333859,0.0010210334,0.00003100931,0.00007013972,0.00038874167,0.0026579958,0.34915152,0.00066274125,0.007198585,0.00025814204],"about_ca_topic_score_codex":0.0051454226,"about_ca_topic_score_gemma":0.0011354757,"teacher_disagreement_score":0.61527324,"about_ca_system_score_codex":0.0009597088,"about_ca_system_score_gemma":0.0013527108,"threshold_uncertainty_score":0.99937564},"labels":[],"label_agreement":null},{"id":"W2906141260","doi":"10.1016/j.cjca.2018.12.026","title":"Statins in Cardio-oncology: Holy Grail or Epiphenomenon","year":2018,"lang":"en","type":"letter","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Epiphenomenon; Medicine; Holy Grail; Internal medicine; Oncology; Intensive care medicine; Cardiology; Epistemology","score_opus":0.08610786503211194,"score_gpt":0.36956553495169553,"score_spread":0.2834576699195836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906141260","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0073213633,0.0042956453,0.0002557421,0.8662535,0.00717175,0.0011044326,0.0005678838,0.00001892582,0.11301079],"genre_scores_gemma":[0.08468203,0.0026594123,0.0017803666,0.75593215,0.13706169,0.00012639475,0.00036100554,0.00052537525,0.016871577],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951967,0.0010941706,0.0011344566,0.00047226626,0.0005769777,0.0015254257],"domain_scores_gemma":[0.9962881,0.0005049789,0.0004633595,0.0006842063,0.00089065114,0.0011686661],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.002055802,0.00042718754,0.0025577084,0.0021345522,0.00009139932,0.000037625596,0.00069405854,0.0018216321,0.0006281469],"category_scores_gemma":[0.0012016108,0.0003479398,0.0005418472,0.00050596317,0.0010501759,0.000068474794,0.000045199144,0.005901637,0.00014666453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00021640227,0.0000018838841,0.00623552,0.00015729801,0.00065501954,0.05945235,0.00039243238,0.00002551134,0.000022902916,0.0000037583745,0.924635,0.008201934],"study_design_scores_gemma":[0.0018207958,0.0028167982,0.0052181864,0.0003756033,0.00027686937,0.00925143,0.00018210785,0.0000013699986,0.0000068401523,0.0001489553,0.97961265,0.0002884174],"about_ca_topic_score_codex":0.005458942,"about_ca_topic_score_gemma":0.01534169,"teacher_disagreement_score":0.12988994,"about_ca_system_score_codex":0.004433387,"about_ca_system_score_gemma":0.031273097,"threshold_uncertainty_score":0.99989724},"labels":[],"label_agreement":null},{"id":"W2907374233","doi":"10.3390/ph12010007","title":"Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging","year":2019,"lang":"en","type":"review","venue":"Pharmaceuticals","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Addiction and Mental Health; Jewish General Hospital; Douglas Mental Health University Institute; McGill University; University of Toronto; SickKids Foundation; Montreal Neurological Institute and Hospital; Hospital for Sick Children; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society; Weston Brain Institute; U.S. Department of Energy","keywords":"Positron emission tomography; Tropomyosin; Trk receptor; Medicine; Positron Emission Tomography-Computed Tomography; Radioligand; Nuclear medicine; Receptor; Internal medicine; Chemistry; Biochemistry; Neurotrophin; Actin","score_opus":0.21234201172078415,"score_gpt":0.5322720071699203,"score_spread":0.31992999544913614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907374233","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012779492,0.9887142,0.00018282552,0.0012435856,0.0010746688,0.005957726,0.0003344792,0.00018039155,0.0022993055],"genre_scores_gemma":[0.000033976095,0.99137455,0.0012477875,0.0006629334,0.0016290651,0.00093953084,0.00056537805,0.0002860882,0.0032606635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99529487,0.00037005526,0.0010692164,0.0011198361,0.00086949725,0.0012765359],"domain_scores_gemma":[0.9966247,0.0008738987,0.00027053896,0.00093330326,0.0002634328,0.0010341017],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013630202,0.0007775426,0.0028660977,0.0006953371,0.00015007083,0.00010556705,0.0005361478,0.0004057472,0.00134075],"category_scores_gemma":[0.00041433677,0.0006040049,0.0016006099,0.00081984146,0.00020289348,0.00010005482,0.00018947001,0.0014221553,0.00048237675],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022355559,0.00019460155,0.00007015292,0.058585625,0.00033640207,0.000037948914,0.000027523765,3.9497206e-8,0.0009912039,0.000050855673,0.060986213,0.8784959],"study_design_scores_gemma":[0.0019750746,0.00021066668,0.0000013066881,0.021680033,0.0028078428,0.0001249321,0.000009279413,0.00010960995,0.0026656545,0.00002191941,0.96982914,0.000564536],"about_ca_topic_score_codex":0.000008785727,"about_ca_topic_score_gemma":1.10346946e-7,"teacher_disagreement_score":0.9088429,"about_ca_system_score_codex":0.0007095905,"about_ca_system_score_gemma":0.0010448714,"threshold_uncertainty_score":0.9996411},"labels":[],"label_agreement":null},{"id":"W2910682218","doi":"10.2967/jnumed.118.220095","title":"Preclinical Evaluation of<sup>111</sup>In-Labeled PEGylated Maytansine Nimotuzumab Drug Conjugates in EGFR-Positive Cancer Models","year":2019,"lang":"en","type":"article","venue":"Journal of Nuclear Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Nimotuzumab; Biodistribution; In vivo; Chemistry; PEG ratio; Ex vivo; Pharmacokinetics; Antibody-drug conjugate; DOTA; Monoclonal antibody; Epidermal growth factor receptor; In vitro; Pharmacology; Antibody; Medicine; Receptor; Biochemistry; Immunology","score_opus":0.09107480338629023,"score_gpt":0.4276933108519808,"score_spread":0.33661850746569055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910682218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97179806,0.004092829,0.000004392979,0.019403324,0.00030916565,0.0010060486,0.000008565026,0.000011783727,0.0033658305],"genre_scores_gemma":[0.9963884,0.0017537909,0.00023995555,0.00082159357,0.00046314695,0.0000069311104,0.000007810097,0.00006466689,0.00025374175],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9946043,0.0005554557,0.0016983359,0.00033144953,0.0023708995,0.00043957628],"domain_scores_gemma":[0.9964226,0.0005192617,0.0005911495,0.00037150408,0.0018009109,0.00029460472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0058103297,0.00024307145,0.0012859863,0.0007285184,0.00002453318,0.00001025093,0.00028067883,0.00020460834,0.0033131589],"category_scores_gemma":[0.0012447835,0.00018277066,0.00013513981,0.0007531997,0.00025413444,0.00027204605,0.00006555489,0.0013066207,0.000036432004],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063481376,0.0068725403,0.27434483,0.0038668695,0.00312743,0.0026502076,0.08507474,0.17428616,0.16369198,0.0012424852,0.07956297,0.1417984],"study_design_scores_gemma":[0.066861816,0.008853049,0.12570465,0.019821594,0.0010843049,0.0005306492,0.0065627443,0.7638811,0.0017270476,0.0016750271,0.002791012,0.00050702685],"about_ca_topic_score_codex":0.00071852194,"about_ca_topic_score_gemma":0.00010902704,"teacher_disagreement_score":0.5895949,"about_ca_system_score_codex":0.0011833514,"about_ca_system_score_gemma":0.0012058157,"threshold_uncertainty_score":0.99759793},"labels":[],"label_agreement":null},{"id":"W2911042793","doi":"10.6026/97320630014482","title":"Molecular docking analysis of Cianidanol from Ginkgo biloba with HER2+ breast cancer target","year":2018,"lang":"en","type":"article","venue":"Bioinformation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ebro Foods (Canada)","funders":"","keywords":"Lapatinib; Ginkgo biloba; Trastuzumab emtansine; Trastuzumab; Medicine; Breast cancer; Pharmacology; Docking (animal); Cancer; Internal medicine","score_opus":0.014443804886816151,"score_gpt":0.31743929710637303,"score_spread":0.3029954922195569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911042793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98460644,0.00013168537,0.0063481326,0.00089012814,0.000078292665,0.00034630203,0.00025387446,0.00005768342,0.0072874804],"genre_scores_gemma":[0.9969479,0.00003128737,0.0023006264,0.00032921517,0.00013406579,0.000024113415,0.0001883608,0.000013298839,0.000031126783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998726,0.000022216887,0.0003105689,0.00014057459,0.0005815619,0.0002190399],"domain_scores_gemma":[0.9989373,0.000017153532,0.00016515433,0.00034358804,0.0004335471,0.000103244005],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017434073,0.00011204456,0.0002746376,0.00039984807,0.000049613613,0.00002675068,0.00010626854,0.000076192046,0.0014047016],"category_scores_gemma":[0.000023575776,0.00008579034,0.00008056437,0.0013097455,0.000106598796,0.0002332304,0.00003313947,0.000100047895,0.00005751378],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018700461,0.0002566807,0.7770591,0.0005910511,0.006285229,0.000033733926,0.008023596,0.004227431,0.04279442,0.00043065834,0.0050875577,0.1533405],"study_design_scores_gemma":[0.0018604178,0.00050773146,0.7135015,0.0004989172,0.0013498599,0.000015743057,0.000693027,0.1583907,0.11413175,0.000041682124,0.008675276,0.00033339125],"about_ca_topic_score_codex":0.0026205026,"about_ca_topic_score_gemma":0.00035129,"teacher_disagreement_score":0.15416327,"about_ca_system_score_codex":0.00019758168,"about_ca_system_score_gemma":0.00024538193,"threshold_uncertainty_score":0.99950814},"labels":[],"label_agreement":null},{"id":"W2911072167","doi":"10.1136/jclinpath-2018-205672","title":"Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes","year":2019,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"Memorial Sloan-Kettering Cancer Center","keywords":"Tropomyosin; Biology; Tropomyosin receptor kinase B; Tyrosine kinase; Gene; Fusion gene; Neurotrophin; Cancer research; Immunohistochemistry; Fusion protein; Receptor tyrosine kinase; Tropomyosin receptor kinase C; Trk receptor; Cell biology; Receptor; Kinase; Neurotrophic factors; Immunology; Actin; Signal transduction; Genetics; Platelet-derived growth factor receptor","score_opus":0.48134786745023955,"score_gpt":0.5904580397059904,"score_spread":0.10911017225575087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911072167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007650116,0.98961157,0.000045434117,0.0015898074,0.0064288503,0.0010944242,0.000055549266,0.000023096396,0.00038627148],"genre_scores_gemma":[0.00001855215,0.9844886,0.0022310994,0.0009350067,0.008003059,0.000024027382,0.00002466772,0.0001723684,0.0041026124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889691,0.0030022382,0.0056026797,0.0007010031,0.0009981426,0.00072685524],"domain_scores_gemma":[0.99071485,0.003300324,0.0032292714,0.001112689,0.0008251538,0.0008176887],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.005003839,0.00059148215,0.008146336,0.00061466463,0.00005365963,0.000037014197,0.0008594702,0.0015573249,0.0024404654],"category_scores_gemma":[0.010329362,0.00034801287,0.0027489993,0.0005657918,0.00058559474,0.000078293015,0.00026451587,0.0053627314,0.0012569136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013261188,0.00059908855,0.00034109238,0.012226971,0.000296098,0.010100427,0.0000063941293,4.0422267e-7,0.000019927616,0.000019885398,0.023453183,0.9516104],"study_design_scores_gemma":[0.0025370696,0.0084949825,0.00029845352,0.013136757,0.001887236,0.009435302,0.000004091973,0.0000020847192,0.000002959908,0.00002056594,0.96390504,0.000275454],"about_ca_topic_score_codex":0.0000025317393,"about_ca_topic_score_gemma":0.000001999712,"teacher_disagreement_score":0.95133495,"about_ca_system_score_codex":0.00024215301,"about_ca_system_score_gemma":0.0056919875,"threshold_uncertainty_score":0.9999448},"labels":[],"label_agreement":null},{"id":"W2911209161","doi":"10.18433/jpps29891","title":"Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors","year":2019,"lang":"en","type":"review","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pharmacology; Tyrosine kinase; Solid lipid nanoparticle; Cetuximab; Drug delivery; Monoclonal antibody; Medicine; Chemistry; Drug; Cancer research; Signal transduction; Biochemistry; Immunology; Antibody","score_opus":0.5152280653806227,"score_gpt":0.5376442910074799,"score_spread":0.02241622562685719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911209161","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00089612446,0.9938747,0.00035578583,0.0006456377,0.0015646564,0.0019941805,0.000110648376,0.0000136896515,0.0005445457],"genre_scores_gemma":[0.003785082,0.99180704,0.0025428028,0.0001740489,0.0014476295,0.000042368567,0.000007192208,0.000059528193,0.00013428781],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940915,0.0002249976,0.002032553,0.0005682513,0.0022427472,0.0008399333],"domain_scores_gemma":[0.9958241,0.0012252346,0.0012714108,0.00026476235,0.0006362941,0.00077821803],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004706325,0.00050770614,0.0025183994,0.00085081294,0.0001440654,0.00007763531,0.0010538126,0.00016852179,0.00030104915],"category_scores_gemma":[0.0005209349,0.00032697932,0.0015077654,0.0014226093,0.00110619,0.00017640431,0.00024905187,0.0013365028,0.0000264563],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003291073,0.0009644661,0.000050485094,0.03027539,0.00029985988,0.000037810045,0.000052895663,0.00011655791,0.0015376436,0.00011038587,0.0020775856,0.9641478],"study_design_scores_gemma":[0.0029323834,0.0007281341,0.0000022792053,0.010326311,0.0026299665,0.00058899046,0.00004719052,0.0047732773,0.0049329796,0.000004889069,0.9727293,0.00030429757],"about_ca_topic_score_codex":0.000014430806,"about_ca_topic_score_gemma":3.641558e-7,"teacher_disagreement_score":0.97065175,"about_ca_system_score_codex":0.00045906275,"about_ca_system_score_gemma":0.0041157384,"threshold_uncertainty_score":0.9999182},"labels":[],"label_agreement":null},{"id":"W2911757824","doi":"10.1002/jbm4.10177","title":"EGFR Signaling: Friend or Foe for Cartilage?","year":2019,"lang":"en","type":"review","venue":"JBMR Plus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","keywords":"Endochondral ossification; Osteoarthritis; Cartilage; Medicine; Signal transduction; Epidermal growth factor receptor; Neuroscience; Bioinformatics; Receptor; Cancer research; Cell biology; Biology; Pathology; Internal medicine; Anatomy","score_opus":0.3890660332608632,"score_gpt":0.5283927576351763,"score_spread":0.13932672437431315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911757824","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026341156,0.9845093,0.00014621275,0.00026136794,0.00096556725,0.0053932406,0.0002486935,0.00010047146,0.008372518],"genre_scores_gemma":[0.0000072712032,0.9138716,0.00060185615,0.0001809579,0.0017196058,0.0010636012,0.00028436637,0.0002169978,0.08205375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996715,0.000123094,0.0007732178,0.0007875347,0.0007664995,0.0008346649],"domain_scores_gemma":[0.99719864,0.00083214504,0.00025188428,0.0011082563,0.00023579331,0.00037327615],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00074616185,0.00051281863,0.0027751757,0.00029294202,0.0000844578,0.00006515089,0.00045955493,0.0006319881,0.0017360253],"category_scores_gemma":[0.0007430379,0.00030608062,0.0008658777,0.00046091573,0.00009017703,0.00004870988,0.00015970255,0.0008368267,0.0015046445],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000169601,0.000047975198,0.0000018177603,0.10867042,0.00019270538,0.00017964075,0.00012762198,8.487585e-7,0.0000069228413,0.00010954541,0.06900659,0.8214863],"study_design_scores_gemma":[0.0011072119,0.00049710565,1.8887633e-7,0.017000038,0.0012642919,0.00013553863,0.00003753503,0.00003053655,0.000038332357,0.000024261448,0.9795115,0.00035347167],"about_ca_topic_score_codex":0.000036898095,"about_ca_topic_score_gemma":0.000020911328,"teacher_disagreement_score":0.9105049,"about_ca_system_score_codex":0.0011662083,"about_ca_system_score_gemma":0.0050206757,"threshold_uncertainty_score":0.99993914},"labels":[],"label_agreement":null},{"id":"W2912108694","doi":"10.1093/annonc/mdz016","title":"Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Neratinib; Breast cancer; Oncology; Quality of life (healthcare); Stage (stratigraphy); Internal medicine; Randomized controlled trial; Gynecology; Cancer; Trastuzumab; Nursing","score_opus":0.15561644541174927,"score_gpt":0.5094365783830779,"score_spread":0.35382013297132864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912108694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98671025,0.00137133,0.000012527566,0.0077102394,0.00013477875,0.003336617,0.00031561,0.000008711171,0.00039993247],"genre_scores_gemma":[0.9974902,0.0009022734,0.000039382772,0.0010462527,0.00010669039,0.00027298724,0.000026915708,0.000020496109,0.000094794326],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99406505,0.003127318,0.0013911031,0.00037123097,0.0006092765,0.00043605035],"domain_scores_gemma":[0.9921635,0.005687783,0.0011097053,0.000419516,0.00041476227,0.00020477403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039684675,0.00020249572,0.0028305526,0.00017794075,0.00003080361,0.0000051504576,0.00020979664,0.00017648329,0.00050489046],"category_scores_gemma":[0.00081679155,0.00012394745,0.00018267252,0.00046164735,0.0005434713,0.000051101062,0.000054571006,0.0004699001,0.000003902716],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96987313,0.002410228,0.0076934025,0.00031479276,0.0013030403,0.000030864125,0.003371842,0.0001495859,0.004389795,0.00006781553,0.00056914164,0.009826381],"study_design_scores_gemma":[0.8168931,0.026162624,0.14676584,0.0008199825,0.00009607559,0.000002636485,0.0004862929,0.00009576349,0.008404844,0.000059600505,0.000084784435,0.00012847564],"about_ca_topic_score_codex":0.09074892,"about_ca_topic_score_gemma":0.0019186296,"teacher_disagreement_score":0.15298003,"about_ca_system_score_codex":0.00018457288,"about_ca_system_score_gemma":0.0019883993,"threshold_uncertainty_score":0.91530585},"labels":[],"label_agreement":null},{"id":"W2912202910","doi":"10.7150/thno.30835","title":"Near infrared imaging of epidermal growth factor receptor positive xenografts in mice with domain I/II specific antibody fragments","year":2019,"lang":"en","type":"article","venue":"Theranostics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Canadian Cancer Society Research Institute","keywords":"Epidermal growth factor receptor; Antibody; Cancer research; Monoclonal antibody; Nimotuzumab; Chemistry; Epitope; Antigen; Cetuximab; Epidermal growth factor; Molecular biology; EGFR inhibitors; Receptor; Medicine; Biology; Immunology","score_opus":0.014968737696984676,"score_gpt":0.30432931586403905,"score_spread":0.28936057816705435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912202910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940617,0.0005047135,0.0003088426,0.00074437406,0.00021564704,0.0010307604,0.000089294816,0.000074135205,0.0029705444],"genre_scores_gemma":[0.9915498,0.00033879105,0.0071908035,0.00028119428,0.00013507486,0.000009345709,0.000064780535,0.00012314443,0.00030706168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795514,0.00015013167,0.00039435504,0.00034639428,0.00064805895,0.0005059144],"domain_scores_gemma":[0.9988178,0.00027146112,0.00012362315,0.00037413786,0.00026108968,0.00015188816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027903696,0.00022921068,0.00048501368,0.00035095174,0.00004449354,0.000026029767,0.0002055589,0.000090395784,0.00039065332],"category_scores_gemma":[0.000083138104,0.00019029387,0.00006046945,0.000790369,0.00022786479,0.00011333003,0.000091806185,0.0004414247,0.0000764998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018910182,0.000380082,0.5034616,0.0002529437,0.000116073104,0.0001255957,0.0062508853,0.000017075368,0.4853348,0.00018086111,0.00095302355,0.0010360306],"study_design_scores_gemma":[0.0138521455,0.0027559216,0.70644456,0.0030570512,0.00006153051,0.00007558088,0.0017687869,0.0003966734,0.25473386,0.00038118786,0.015708912,0.00076377555],"about_ca_topic_score_codex":0.00025950317,"about_ca_topic_score_gemma":0.000006885504,"teacher_disagreement_score":0.23060095,"about_ca_system_score_codex":0.00017691473,"about_ca_system_score_gemma":0.0002399611,"threshold_uncertainty_score":0.7759959},"labels":[],"label_agreement":null},{"id":"W2912998652","doi":"10.1038/s41586-019-0974-0","title":"Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers","year":2019,"lang":"en","type":"erratum","venue":"Nature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Genentech; EMD Serono; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Eli Lilly and Company; Chinese University of Hong Kong; Juno Therapeutics; Eisai; Daiichi-Sankyo; Puma Biotechnology; Aminex Therapeutics; Symphogen; Pfizer; Incyte; Ipsen; Five Prime Therapeutics; Les Laboratories Pierre Fabre; BioMarin Pharmaceutical; Sanofi; Sierra Oncology; Genomic Health; Clovis Oncology; Varian Medical Systems; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Spectrum Pharmaceuticals; Jounce Therapeutics; Celgene; Servier; Foghorn Therapeutics; AstraZeneca; Bristol-Myers Squibb","keywords":"Mutant; Cancer research; Kinase; Internal medicine; Biology; Oncology; Medicine; Genetics; Gene","score_opus":0.010367093851211704,"score_gpt":0.31070624403118363,"score_spread":0.3003391501799719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912998652","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57444835,0.03657255,0.000012652081,0.021259407,0.1922932,0.012956049,0.0010219476,0.00048966164,0.16094619],"genre_scores_gemma":[0.37360692,0.00072108075,0.00011641786,0.0033531114,0.0035332723,0.00020150261,0.0021737847,0.00029421173,0.6159997],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973168,0.00009158369,0.00026463516,0.0006969439,0.0011694856,0.0004605969],"domain_scores_gemma":[0.9987386,0.000040670333,0.00013854096,0.0004776476,0.0003920503,0.00021248354],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0002445806,0.00036573544,0.00058482663,0.0003528674,0.00005760748,0.000046915688,0.00008039983,0.003737946,0.0004490747],"category_scores_gemma":[0.00016809948,0.00028757646,0.000059341026,0.0005960502,0.00011170728,0.000088369154,0.00006817269,0.011550068,0.000039518396],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092746265,0.000102960825,0.024966417,0.0008051371,0.000055507015,0.00021568773,0.00020045631,0.000004654456,0.0000123506925,0.0000044197095,0.96725184,0.0054530827],"study_design_scores_gemma":[0.0035670996,0.0012891907,0.0996258,0.005561488,0.000078025936,0.000040319337,0.00011961327,0.0000923491,0.0001161346,0.000011201334,0.88908345,0.0004153264],"about_ca_topic_score_codex":0.00063025503,"about_ca_topic_score_gemma":0.0015782772,"teacher_disagreement_score":0.4550535,"about_ca_system_score_codex":0.0018323219,"about_ca_system_score_gemma":0.0015797641,"threshold_uncertainty_score":0.9999576},"labels":[],"label_agreement":null},{"id":"W2913513847","doi":"10.1097/md.0000000000014261","title":"The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer","year":2019,"lang":"en","type":"review","venue":"Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; PTEN; Tensin; Oncology; Breast cancer; Internal medicine; Lapatinib; Hazard ratio; Trastuzumab; Neoadjuvant therapy; Cochrane Library; Odds ratio; Meta-analysis; Confidence interval; Cancer; PI3K/AKT/mTOR pathway","score_opus":0.051905256061697144,"score_gpt":0.3797236229295417,"score_spread":0.32781836686784455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913513847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.023529932,0.96425396,0.0000010250288,0.0073076263,0.00027665735,0.0035507975,0.00085584266,0.000019818426,0.0002043573],"genre_scores_gemma":[0.02058547,0.9777376,0.0000397387,0.0008266406,0.00022425925,0.00028212054,0.00007049473,0.00007200509,0.00016165922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946162,0.0018163562,0.0011034056,0.00070983026,0.00091789424,0.0008362765],"domain_scores_gemma":[0.99600565,0.0022505696,0.00036944554,0.00093021104,0.00020700431,0.00023711773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036778287,0.0004958858,0.0025658805,0.0003374156,0.00011185194,0.000017650118,0.00047387468,0.00030834388,0.000081186656],"category_scores_gemma":[0.0011831721,0.00022842291,0.00015252388,0.0010873706,0.0010814712,0.000037170255,0.0004620878,0.0015591593,0.000008063634],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017864681,0.0001311664,0.045809466,0.003373342,0.00012567455,0.00040959593,0.0020064947,0.0000021039696,0.00025155782,0.00002650373,0.00053449377,0.9455431],"study_design_scores_gemma":[0.0022776506,0.0009892174,0.37616035,0.054808706,0.00031386994,0.0005750562,0.0011251742,0.000026526868,0.000016308453,0.000025732577,0.5634153,0.00026610598],"about_ca_topic_score_codex":0.0031134454,"about_ca_topic_score_gemma":0.00043386727,"teacher_disagreement_score":0.94527704,"about_ca_system_score_codex":0.00074050884,"about_ca_system_score_gemma":0.0012634876,"threshold_uncertainty_score":0.9314816},"labels":[],"label_agreement":null},{"id":"W2917182113","doi":"10.3747/co.26.4220","title":"A Multidisciplinary Perspective on the Subcutaneous Administration of Trastuzumab in HER2-Positive Breast Cancer","year":2019,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; University Health Network; Roche (Canada); Memorial University of Newfoundland; Impact; Université Laval; Fluidigm (Canada); Dr. H. Bliss Murphy Cancer Centre; Princess Margaret Cancer Centre; Canadian Breast Cancer Network","funders":"","keywords":"Medicine; Trastuzumab; Dosing; Breast cancer; Pharmacokinetics; Quality of life (healthcare); Intensive care medicine; Health care; Drug administration; Metastatic breast cancer; Clinical trial; Multidisciplinary approach; Food and drug administration; Cancer; Oncology; Pharmacology; Internal medicine; Nursing","score_opus":0.2926029293163404,"score_gpt":0.569392238596131,"score_spread":0.27678930927979056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917182113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004959065,0.9790044,0.0000024580868,0.0015417769,0.0007551142,0.0037665614,0.000469034,0.000019303301,0.013945443],"genre_scores_gemma":[0.0072076204,0.9907227,0.000009835953,0.000016490541,0.00036697654,0.0007226198,0.00006950841,0.00008572789,0.000798519],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973308,0.0006697164,0.00059743755,0.00059549336,0.00041210192,0.00039446424],"domain_scores_gemma":[0.9980601,0.00073048496,0.00039016324,0.00046383514,0.00024326584,0.00011214142],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039035632,0.0003645886,0.0017627049,0.0003279682,0.00003851812,0.00000743061,0.00028268364,0.00037643613,0.00096813997],"category_scores_gemma":[0.00012660134,0.00023432334,0.00034119835,0.00047090056,0.00030354332,0.000018222205,0.00011004406,0.0014027236,0.00018098955],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076404284,0.0017111142,0.00014102363,0.008492399,0.00019513907,0.00034903488,0.001019367,9.1380707e-7,0.000001823932,0.0007954837,0.0012789199,0.9852507],"study_design_scores_gemma":[0.0014739955,0.006984306,0.0015700066,0.05089005,0.0010807313,0.002459541,0.0016022802,0.00005615621,0.0000062678264,0.00005644941,0.9333733,0.0004469336],"about_ca_topic_score_codex":0.00018723984,"about_ca_topic_score_gemma":0.00042676085,"teacher_disagreement_score":0.9848038,"about_ca_system_score_codex":0.004894155,"about_ca_system_score_gemma":0.0052286047,"threshold_uncertainty_score":0.9999451},"labels":[],"label_agreement":null},{"id":"W2917891638","doi":"10.1158/1078-0432.ccr-18-2599","title":"Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"Hellenic Cooperative Oncology Group; National Cancer Institute; National Center for Advancing Translational Sciences; National Human Genome Research Institute; National Institute of General Medical Sciences; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cytotoxic T cell; Medicine; Cancer research; Mass cytometry; CD8; PI3K/AKT/mTOR pathway; Antibody; Immune system; Internal medicine; Oncology; Cancer; Immunology; Breast cancer; Biology; Signal transduction; Cell biology; Phenotype","score_opus":0.3013185643104747,"score_gpt":0.5159816777818874,"score_spread":0.2146631134714127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917891638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948581,0.001798973,0.000042136846,0.0001931117,0.000267431,0.0023028294,0.000054248238,0.000028067705,0.0004551044],"genre_scores_gemma":[0.9979281,0.00053049845,0.0009567487,0.000087199085,0.00018199829,0.000097429845,0.00001106137,0.00008294591,0.00012400569],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923411,0.0010613869,0.0013356962,0.0009729372,0.0031107136,0.0011781821],"domain_scores_gemma":[0.99577665,0.0011240495,0.00018666442,0.0006532119,0.001713199,0.0005462487],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008977371,0.00027130745,0.000961677,0.0009055065,0.00010035534,0.000050419487,0.00035746174,0.0002341553,0.0010337282],"category_scores_gemma":[0.0018617553,0.00024542338,0.00017165462,0.0015127683,0.0005714693,0.00014131005,0.0002986577,0.0017510789,0.000047806025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009814305,0.00035455628,0.5755311,0.00045779324,0.000054905297,0.00003301521,0.00009064583,0.000059696133,0.41688398,0.0000011310891,0.00020337058,0.005348318],"study_design_scores_gemma":[0.018048313,0.0019516218,0.60344243,0.003801576,0.00007352586,0.0000038329467,0.0006129326,0.0113854585,0.35890418,0.00007100735,0.0011398381,0.00056527054],"about_ca_topic_score_codex":0.0022350803,"about_ca_topic_score_gemma":0.00012051358,"teacher_disagreement_score":0.057979815,"about_ca_system_score_codex":0.0016722522,"about_ca_system_score_gemma":0.0013162567,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W2920257759","doi":"10.1039/c9sc00285e","title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","year":2019,"lang":"en","type":"article","venue":"Chemical Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Centre National de la Recherche Scientifique; Bpifrance","keywords":"Conjugate; Pharmacokinetics; Linker; Drug; Potency; In vivo; Dispersity; Chemistry; Antibody-drug conjugate; Pharmacology; Combinatorial chemistry; Antibody; In vitro; Medicine; Monoclonal antibody; Computer science; Biochemistry; Organic chemistry; Mathematics; Biology; Immunology","score_opus":0.017916338028028944,"score_gpt":0.347806761276972,"score_spread":0.3298904232489431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2920257759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9837089,0.00020488582,0.00002030574,0.0047739367,0.00019786322,0.00040761655,0.000006551226,0.000105976535,0.0105739245],"genre_scores_gemma":[0.99697584,0.000012037572,0.00077130005,0.0011828676,0.0001176832,0.000012759545,0.000011330507,0.000018200464,0.00089798943],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973252,0.00001767417,0.00021800083,0.0006277115,0.0010937551,0.0007176647],"domain_scores_gemma":[0.9984833,0.000120374476,0.000043714786,0.00061798043,0.00019738168,0.0005372545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055260403,0.0001564595,0.00027105602,0.00013477943,0.00008152851,0.000070656824,0.0005667951,0.00006977634,0.0008196316],"category_scores_gemma":[0.00039952603,0.0001222693,0.00008210013,0.0010608736,0.001183895,0.00015019423,0.00015492114,0.00034045213,0.0011327815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007324308,0.0000866848,0.019721815,0.00006509725,0.000003337118,0.000016345104,0.00005908436,0.0000029188031,0.97760737,0.00020392075,0.0012611641,0.0008989964],"study_design_scores_gemma":[0.0010095235,0.0000723274,0.002481227,0.00015272904,0.000009307333,0.000012825698,0.000046517926,0.0027514726,0.98823303,0.000045475907,0.005024434,0.00016112007],"about_ca_topic_score_codex":0.00019729506,"about_ca_topic_score_gemma":0.0000011527105,"teacher_disagreement_score":0.01724059,"about_ca_system_score_codex":0.00030913175,"about_ca_system_score_gemma":0.0008326445,"threshold_uncertainty_score":0.99964494},"labels":[],"label_agreement":null},{"id":"W2921213784","doi":"10.3390/cancers11030375","title":"The Effects of Pertuzumab and Its Combination with Trastuzumab on HER2 Homodimerization and Phosphorylation","year":2019,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Cure Brain Cancer Foundation; Canadian Institutes of Health Research; Women and Children's Health Research Institute","keywords":"Pertuzumab; Trastuzumab; Phosphorylation; Chemistry; Chinese hamster ovary cell; Apoptosis; Molecular biology; Cancer research; Biochemistry; Biology; Receptor; Cancer; Breast cancer; Genetics","score_opus":0.00902042721348332,"score_gpt":0.2752201647484832,"score_spread":0.26619973753499987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921213784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950279,0.0024264506,0.000026235606,0.00031960895,0.000118942124,0.00084196415,0.00000169597,0.000013675259,0.0012235357],"genre_scores_gemma":[0.998467,0.0007923707,0.0000127105095,0.00007516125,0.000017423452,0.000042556163,0.0000054966326,0.000015903264,0.0005713477],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99930936,0.000035538556,0.000090837086,0.00016385166,0.0002774107,0.00012302713],"domain_scores_gemma":[0.9994672,0.00019272734,0.00005360809,0.00013124273,0.000098333076,0.000056913468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011680399,0.00007764527,0.00013124027,0.000045239063,0.000067134824,0.00001468265,0.000033343444,0.000042465745,0.0000135345035],"category_scores_gemma":[0.00008338831,0.000051571526,0.000011517202,0.000144582,0.00007869851,0.00005381454,0.000010171581,0.00010999218,0.0000036328347],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013321465,0.00039668696,0.12549993,0.009957435,0.00078629964,0.000046275185,0.015646793,0.002109878,0.31154835,0.02571396,0.0028482266,0.4921247],"study_design_scores_gemma":[0.018359385,0.023156175,0.4157415,0.002961814,0.00020589097,0.000047272973,0.0015119106,0.052821506,0.47761655,0.0002536002,0.006796846,0.0005275449],"about_ca_topic_score_codex":0.000096375814,"about_ca_topic_score_gemma":0.000017355911,"teacher_disagreement_score":0.49159715,"about_ca_system_score_codex":0.0005228657,"about_ca_system_score_gemma":0.00029427384,"threshold_uncertainty_score":0.21030258},"labels":[],"label_agreement":null},{"id":"W2923651250","doi":"10.1093/jnci/djz032","title":"Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer","year":2019,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Yonsei University College of Medicine; University of Florida Health; Cancer Institute, University of Pittsburgh; Weill Cornell Medical College; Peter MacCallum Cancer Centre; Yonsei University; Department of Medicine, Georgetown University; KU Leuven; NRG Oncology; University of Ottawa; Allegheny Health Network; VCU Massey Cancer Center; Virginia Commonwealth University; National Cancer Institute; Kaiser Permanente; Breast Cancer Research Foundation; Pennsylvania Department of Health; AstraZeneca; Georgetown University; Genentech; University of Pittsburgh; Amgen","keywords":"Trastuzumab; Medicine; Internal medicine; Oncology; Breast cancer; Hazard ratio; Confidence interval; Concordance; Stage (stratigraphy); Cancer","score_opus":0.0748041909655118,"score_gpt":0.42729085140462797,"score_spread":0.35248666043911614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923651250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98299897,0.0007349423,0.000020974443,0.0067525785,0.0044886223,0.0016321667,0.00076047436,0.000010889124,0.0026003956],"genre_scores_gemma":[0.99195856,0.00025001957,0.00048558388,0.0016502555,0.0041196262,0.00020396238,0.000007454701,0.00003604383,0.001288492],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657845,0.00013311439,0.0009020927,0.0002932319,0.0016285637,0.00046455383],"domain_scores_gemma":[0.99704474,0.0003424326,0.00073345355,0.00016820728,0.001516243,0.00019494664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014794614,0.00023349666,0.00064301206,0.00029045108,0.00014761808,0.000055597233,0.00047464317,0.00014781716,0.0003758601],"category_scores_gemma":[0.0004934858,0.00016579236,0.00034259207,0.00047035853,0.00020450601,0.00046319902,0.00009133162,0.00081701606,0.0000110425235],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32620114,0.0023729303,0.49084455,0.0013364718,0.0024632297,0.0005518423,0.003651523,0.036115542,0.035247896,0.0035206315,0.04920832,0.04848591],"study_design_scores_gemma":[0.19622083,0.004331125,0.651139,0.004583799,0.0003594643,0.0014290755,0.00051529723,0.00295813,0.014339938,0.0005591898,0.1228095,0.00075465394],"about_ca_topic_score_codex":0.0019305828,"about_ca_topic_score_gemma":0.0013482632,"teacher_disagreement_score":0.16029443,"about_ca_system_score_codex":0.0063989866,"about_ca_system_score_gemma":0.011986327,"threshold_uncertainty_score":0.99741524},"labels":[],"label_agreement":null},{"id":"W2923800831","doi":"10.1186/s13058-019-1115-2","title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Chugai Pharmaceutical; Genentech; Eisai; MacroGenics; Puma Biotechnology; Daiichi-Sankyo; Teva Pharmaceutical Industries; Wyeth; Sanofi; GlaxoSmithKline; Amgen; Pfizer; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Neratinib; Placebo; Surgical oncology; Double blind; Medicine; Randomized controlled trial; Oncology; Internal medicine; Breast cancer; Alternative medicine; Pathology; Cancer","score_opus":0.0792212121238377,"score_gpt":0.436616696189183,"score_spread":0.35739548406534527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923800831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613961,0.002537505,0.0002299338,0.016741654,0.00019932607,0.014469078,0.00043045208,0.00005801007,0.0039379466],"genre_scores_gemma":[0.9807453,0.00086352526,0.00015318193,0.00034325782,0.0017204324,0.0072964807,0.0002052535,0.00007475121,0.008597828],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938304,0.0008216854,0.00077473494,0.0010058808,0.0025666084,0.0010007202],"domain_scores_gemma":[0.994103,0.002761744,0.00016583763,0.0012948716,0.0011328044,0.0005417325],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0052754693,0.00036262948,0.0017608042,0.0006507475,0.0005584953,0.00053917756,0.0004852304,0.00018001003,0.006976122],"category_scores_gemma":[0.00016185765,0.00020374922,0.0003818018,0.0020809502,0.00072573434,0.00021382475,0.00021722131,0.0013245874,0.000118116215],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.98394704,0.00035847147,0.0017073129,0.000035453028,0.0036337483,0.00003250602,0.0006455376,0.00035953193,0.00045503367,0.0006590045,0.0015211169,0.0066452688],"study_design_scores_gemma":[0.9858366,0.0007133361,0.00043777472,0.00017094502,0.0014093809,0.000036915553,0.00036880703,0.008643086,0.00020578492,0.00012293234,0.001817639,0.0002367611],"about_ca_topic_score_codex":0.025311511,"about_ca_topic_score_gemma":0.006862377,"teacher_disagreement_score":0.019349195,"about_ca_system_score_codex":0.00035483946,"about_ca_system_score_gemma":0.0015410021,"threshold_uncertainty_score":0.99393165},"labels":[],"label_agreement":null},{"id":"W2941033195","doi":"","title":"Effect of siRNA-mediated EGF receptor knockdown on cell growth and inhibitor response in A549 lung adenocarcinoma cells.","year":2005,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"A549 cell; Cell growth; Transfection; Epidermal growth factor receptor; Epidermal growth factor; Gene knockdown; Cancer research; Cell culture; Biology; Signal transduction; Growth inhibition; MTT assay; Cell biology; Growth factor receptor; Receptor; Chemistry; Biochemistry","score_opus":0.008810122317115547,"score_gpt":0.2967409756605052,"score_spread":0.2879308533433897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2941033195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98934066,0.0012080073,0.0000039670836,0.0018619592,0.00013585048,0.0011036023,0.000022158567,0.000061363215,0.006262403],"genre_scores_gemma":[0.9959939,0.00028129242,0.00038495846,0.00026379488,0.0002611198,0.00006016946,0.000013643048,0.00005592727,0.0026852025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997141,0.00069546635,0.0004780779,0.00049119076,0.00066639244,0.0005278526],"domain_scores_gemma":[0.9971989,0.0018641016,0.00007962896,0.00041685082,0.00008834165,0.00035222585],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017391451,0.00026611207,0.00054485624,0.0005323683,0.000037789632,0.000017669297,0.00015163493,0.00023017559,0.0010394877],"category_scores_gemma":[0.0008166847,0.00020746126,0.00008227654,0.00061886763,0.00016197511,0.00008311767,0.00010249065,0.000587772,0.00024439758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021080192,0.0003628996,0.05630084,0.0010691185,0.000025890118,0.00009627358,0.0006286458,0.0000057612756,0.895785,0.000010174902,0.021358067,0.003277145],"study_design_scores_gemma":[0.006004856,0.0061433385,0.01828165,0.00035032068,0.000028275626,0.000011558035,0.000055659173,0.0004821315,0.9657075,0.0000013070563,0.0027385335,0.00019490518],"about_ca_topic_score_codex":0.00021587044,"about_ca_topic_score_gemma":0.000024991197,"teacher_disagreement_score":0.06992247,"about_ca_system_score_codex":0.00033422836,"about_ca_system_score_gemma":0.0002507962,"threshold_uncertainty_score":0.9998737},"labels":[],"label_agreement":null},{"id":"W2944436740","doi":"10.1158/1538-7445.sabcs18-ot2-07-03","title":"Abstract OT2-07-03: Trastuzumab deruxtecan (DS-8201a) vs ado-trastuzumab emtansine (T-DM1) for subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized study","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Trastuzumab emtansine; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Antibody-drug conjugate; Population; Breast cancer; Cancer; Antibody; Immunology; Monoclonal antibody","score_opus":0.061201817016351676,"score_gpt":0.4287969098125477,"score_spread":0.367595092796196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944436740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9600579,0.007433372,0.00014307119,0.0031981268,0.00020583092,0.026996424,0.0011347965,0.00015620209,0.0006742435],"genre_scores_gemma":[0.9739064,0.00686515,0.0005010337,0.0002411048,0.00044535234,0.011659885,0.00011336837,0.00038983315,0.005877904],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98818946,0.0016797134,0.0013455916,0.0024925324,0.003234022,0.0030587066],"domain_scores_gemma":[0.99043196,0.0039140536,0.00040502506,0.0013313077,0.0023829618,0.0015346791],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006671468,0.0011009924,0.0033998883,0.0011273645,0.0007692787,0.00054426916,0.0007155894,0.00030048707,0.0033082967],"category_scores_gemma":[0.0011487615,0.0007938383,0.00029908036,0.001867568,0.0015790723,0.0006397345,0.00030987037,0.002177374,0.00005790012],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85409534,0.0067043225,0.008849496,0.009737543,0.0052656536,0.0015542445,0.016663566,0.00011320079,0.020611849,0.00004991555,0.0071362774,0.069218576],"study_design_scores_gemma":[0.8576787,0.043279182,0.04197618,0.012847302,0.0026390508,0.0016085531,0.020324722,0.0028676842,0.009628211,0.00019077933,0.0042501246,0.0027094749],"about_ca_topic_score_codex":0.019346494,"about_ca_topic_score_gemma":0.014329076,"teacher_disagreement_score":0.066509105,"about_ca_system_score_codex":0.0026890566,"about_ca_system_score_gemma":0.0068794643,"threshold_uncertainty_score":0.9994513},"labels":[],"label_agreement":null},{"id":"W2944662988","doi":"10.1093/jncics/pkz033","title":"Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"JNCI Cancer Spectrum","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Oncology; Breast cancer; Cardiotoxicity; Odds ratio; Confidence interval; Heart failure; Estrogen receptor; Subgroup analysis; Cancer; Chemotherapy","score_opus":0.13459750571490264,"score_gpt":0.4460231361980427,"score_spread":0.31142563048314004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944662988","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000481048,0.98656476,0.000016545933,0.0022126692,0.00020436385,0.006429935,0.003573608,0.00007776598,0.0008722455],"genre_scores_gemma":[0.0012308072,0.9882493,0.000045781828,0.00060148333,0.00038656208,0.0035845307,0.0001263407,0.00024387428,0.005531333],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9923039,0.00085123203,0.002130557,0.0019554254,0.0013923595,0.001366529],"domain_scores_gemma":[0.9963172,0.0002762363,0.0011288045,0.0015143614,0.00022394743,0.00053944683],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014469723,0.0012695239,0.014712291,0.0011052979,0.00010718387,0.000115538685,0.0005945903,0.00054888043,0.005330497],"category_scores_gemma":[0.0000661412,0.0009294007,0.003272445,0.0037023441,0.00017152594,0.00016501993,0.00030115596,0.0022431365,0.000119707365],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009761884,0.00018910051,0.0032373734,0.49004766,0.20676242,0.00069208426,0.00042626896,0.000025742516,0.0000011654429,0.00007158399,0.0013470653,0.2971019],"study_design_scores_gemma":[0.00071409385,0.0002149155,0.0015813814,0.05522653,0.7712862,0.0005720581,0.00004596719,0.000051206447,0.000002186368,0.000003854425,0.16918258,0.0011190429],"about_ca_topic_score_codex":0.024707444,"about_ca_topic_score_gemma":0.006209461,"teacher_disagreement_score":0.56452376,"about_ca_system_score_codex":0.00490602,"about_ca_system_score_gemma":0.00325511,"threshold_uncertainty_score":0.99991536},"labels":[],"label_agreement":null},{"id":"W2944776474","doi":"10.1158/1538-7445.sabcs18-ot3-04-02","title":"Abstract OT3-04-02: Neoadjuvant Her2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Pembrolizumab; Internal medicine; Oncology; Breast cancer; Pertuzumab; Regimen; Lapatinib; Taxane; Blockade; Metastatic breast cancer; Neoadjuvant therapy; Cancer; Immunotherapy; Receptor","score_opus":0.17144214421042142,"score_gpt":0.5137250226387211,"score_spread":0.3422828784282997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944776474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95632356,0.009226697,0.000013333249,0.0043054787,0.0005621564,0.018478857,0.00011203714,0.00016075825,0.010817107],"genre_scores_gemma":[0.96548235,0.011220661,0.00038233722,0.00084160594,0.0011831059,0.005539835,0.00017116361,0.00035022863,0.014828694],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9900093,0.0017168493,0.0010288018,0.0015475267,0.0035921775,0.0021053643],"domain_scores_gemma":[0.9938608,0.0009451636,0.00025179097,0.002445937,0.0015549145,0.0009414385],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009044817,0.000627701,0.0021373737,0.00070566754,0.00066454115,0.0005587746,0.002171673,0.00039768906,0.025328975],"category_scores_gemma":[0.0003414705,0.00043682952,0.00022484365,0.0014921287,0.0010145096,0.00065880927,0.00045443478,0.0026077605,0.0004161763],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7702948,0.0034998828,0.00011194999,0.00013500066,0.00062651874,0.00017127836,0.0013352876,0.000011962953,0.12437898,0.00014255191,0.0043208166,0.09497096],"study_design_scores_gemma":[0.8809517,0.025007268,0.00028696915,0.000542383,0.000032677428,0.000025572981,0.00031876168,0.00030795083,0.025976302,0.00020769598,0.065803245,0.0005394653],"about_ca_topic_score_codex":0.009574483,"about_ca_topic_score_gemma":0.0004145404,"teacher_disagreement_score":0.110656895,"about_ca_system_score_codex":0.0011720151,"about_ca_system_score_gemma":0.0059157982,"threshold_uncertainty_score":0.9998084},"labels":[],"label_agreement":null},{"id":"W2944967705","doi":"10.1097/pai.0000000000000773","title":"Chromogenic and Silver in Situ Hybridization for Identification of HER 2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CISH; Chromogenic in situ hybridization; Confidence interval; Medicine; Meta-analysis; Concordance; Oncology; Breast cancer; Internal medicine; Cancer; In situ hybridization; Biology; Genetics","score_opus":0.03241972078852673,"score_gpt":0.3696589229634074,"score_spread":0.3372392021748807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2944967705","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022668433,0.9907423,0.00008575487,0.000056569654,0.000013374818,0.006488183,0.00029324,0.000007963952,0.000045769644],"genre_scores_gemma":[0.025726095,0.96692145,0.00006420881,0.00015669451,0.00000687519,0.005802466,0.0010597695,0.00007533497,0.00018713136],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.996608,0.00019402133,0.0017131532,0.00084879517,0.00033586237,0.00030017778],"domain_scores_gemma":[0.9975632,0.00012468178,0.0010678276,0.0009570504,0.00021779678,0.00006943475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006765556,0.0004448333,0.0055195405,0.00036702576,0.00002209868,0.000012889812,0.00023011511,0.0003893551,0.00012479654],"category_scores_gemma":[0.00013893156,0.00037424744,0.00069320813,0.0007837098,0.00013419415,0.000031522482,0.00014136438,0.0003754579,0.0000037407901],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000031653242,0.00013293429,0.0000062709532,0.7524152,0.011417781,0.0000074434906,0.00002043967,0.0000019909849,0.2353307,0.000006891542,0.0000593438,0.0005693669],"study_design_scores_gemma":[0.0023521527,0.000091772505,0.000084432606,0.09753383,0.8899623,0.00020767961,0.000021229187,0.00001545119,0.008175292,0.000019739673,0.00059129356,0.0009448018],"about_ca_topic_score_codex":0.00008096342,"about_ca_topic_score_gemma":5.455489e-7,"teacher_disagreement_score":0.87854457,"about_ca_system_score_codex":0.00054456864,"about_ca_system_score_gemma":0.00027318718,"threshold_uncertainty_score":0.99987096},"labels":[],"label_agreement":null},{"id":"W2945268366","doi":"10.1093/annonc/mdz100.045","title":"Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs T-DM1 for HER2-positive breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Pertuzumab; Metastatic breast cancer; Oncology; Clinical endpoint; Breast cancer; Taxane; Population; Antibody-drug conjugate; Phases of clinical research; Cancer; Clinical trial; Immunology; Antibody","score_opus":0.12893878878310253,"score_gpt":0.5177291619702629,"score_spread":0.38879037318716037,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945268366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402137,0.00045726498,0.000043685388,0.0070999144,0.00032164837,0.0029884174,0.00040413145,0.00002242495,0.004641168],"genre_scores_gemma":[0.99678504,0.00027026143,0.00012423572,0.0010045604,0.0002521852,0.000342916,0.000025692669,0.000047555768,0.0011475579],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99762547,0.00020448574,0.0006422795,0.0004530919,0.0004941487,0.0005805206],"domain_scores_gemma":[0.9974361,0.00042909634,0.0003143797,0.0004862311,0.0011037257,0.00023044233],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008077376,0.0002123503,0.0011100052,0.00024428236,0.000048281476,0.000005485991,0.00027813844,0.00020912889,0.001032005],"category_scores_gemma":[0.00009512549,0.00018872292,0.00018018851,0.0003094857,0.0002219901,0.00007616262,0.000093963245,0.00031051238,0.000023918847],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05281807,0.043530267,0.051519834,0.0014894656,0.0029066498,0.00019430328,0.013352922,0.00007374646,0.056127723,0.0003386713,0.07142926,0.7062191],"study_design_scores_gemma":[0.15739883,0.3623817,0.1920404,0.0012647226,0.0010050099,0.0003583621,0.016287366,0.00061829796,0.1257364,0.00047908208,0.14139606,0.001033769],"about_ca_topic_score_codex":0.00264091,"about_ca_topic_score_gemma":0.0010392946,"teacher_disagreement_score":0.7051853,"about_ca_system_score_codex":0.00022076587,"about_ca_system_score_gemma":0.0013579971,"threshold_uncertainty_score":0.9998812},"labels":[],"label_agreement":null},{"id":"W2947440045","doi":"10.1200/jco.2019.37.15_suppl.554","title":"Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Exome sequencing; Internal medicine; Cancer; Digital polymerase chain reaction; Copy number analysis; Exome; Chemotherapy; Population; Cohort; Mutation; Copy-number variation; Genetics; Gene; Genome; Biology; Polymerase chain reaction","score_opus":0.046394274262798976,"score_gpt":0.45771201654683535,"score_spread":0.4113177422840364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947440045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879767,0.000336672,0.000009409659,0.010058078,0.00058348884,0.00039349584,0.000018409288,0.0000031356935,0.0006206231],"genre_scores_gemma":[0.994627,0.0010671327,0.00076735055,0.002116489,0.00079889194,0.000019938105,3.6492878e-7,0.000030558243,0.00057228975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997049,0.0001887107,0.0017366457,0.00022760939,0.00042342595,0.00037462063],"domain_scores_gemma":[0.99799275,0.00038685906,0.0005677921,0.00022531734,0.00034581852,0.0004814444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028968037,0.00013830357,0.0015571548,0.00018742618,0.000009122995,0.000007306344,0.00016509993,0.00037822503,0.0012829154],"category_scores_gemma":[0.00030443963,0.00010347181,0.0001801572,0.00019503303,0.00015995969,0.00007381281,0.0000712528,0.0010369682,0.000012857438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013811044,0.00049669965,0.8064897,0.00012929508,0.00018351935,0.00019348598,0.0024206068,0.00003355118,0.00096879754,0.0000041854073,0.00036765158,0.17490144],"study_design_scores_gemma":[0.010251316,0.011162822,0.96856856,0.00023780852,0.00003252509,0.00048981747,0.00057322707,0.000056829656,0.00008908042,0.00007590703,0.0083757965,0.0000862987],"about_ca_topic_score_codex":0.00014637077,"about_ca_topic_score_gemma":0.0010126142,"teacher_disagreement_score":0.17481513,"about_ca_system_score_codex":0.0014080259,"about_ca_system_score_gemma":0.0031421082,"threshold_uncertainty_score":0.99963003},"labels":[],"label_agreement":null},{"id":"W2947469974","doi":"10.1200/jco.2019.37.15_suppl.500","title":"Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Internal medicine; Oncology; Trastuzumab emtansine; Taxane; Docetaxel; Breast cancer; Regimen; Chemotherapy; Carboplatin; Cancer; Cisplatin","score_opus":0.17629281528993362,"score_gpt":0.5137821301172162,"score_spread":0.33748931482728256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947469974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9614625,0.0005350732,0.0000138027135,0.0347909,0.0012109741,0.0012200132,0.00038811678,0.0000151606,0.00036349113],"genre_scores_gemma":[0.9941573,0.0015592267,0.00031207505,0.0016613106,0.0019130361,0.000019147677,0.000023654004,0.000058727317,0.00029552006],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992639,0.0012897287,0.0037680555,0.0007191418,0.0009526671,0.0006314124],"domain_scores_gemma":[0.9887299,0.008062184,0.0015433498,0.0004163123,0.000614609,0.0006336715],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003970052,0.00042902646,0.0027486496,0.00020047989,0.00014174898,0.000051067655,0.0004008832,0.00047474814,0.0012168195],"category_scores_gemma":[0.002666686,0.00027398628,0.00033284942,0.00029016822,0.00063265115,0.00022083899,0.00014248688,0.0028057164,0.000012802249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2141978,0.008102491,0.49348944,0.00006747232,0.001399631,0.001587486,0.004596338,0.0000074505083,0.0010868117,0.000013848994,0.0054704566,0.2699808],"study_design_scores_gemma":[0.14098868,0.029831447,0.8226999,0.0002707746,0.0002669458,0.00024970167,0.0015049983,0.0001654012,0.000060889004,0.00002584607,0.0036919566,0.00024343781],"about_ca_topic_score_codex":0.003923988,"about_ca_topic_score_gemma":0.0026742436,"teacher_disagreement_score":0.3292105,"about_ca_system_score_codex":0.0010283509,"about_ca_system_score_gemma":0.0021820762,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W2948116664","doi":"10.1177/1078155219850299","title":"Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario","year":2019,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Ontario Institute for Cancer Research; Public Health Ontario; Institute for Clinical Evaluative Sciences; Alberta Bone and Joint Health Institute; University of Calgary; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network; University of Toronto; Sunnybrook Health Science Centre; Hospital for Sick Children; Cancer Care Ontario; McMaster University; St. Joseph’s Healthcare Hamilton; Canadian Centre for Applied Research in Cancer Control","funders":"Ontario Institute for Cancer Research; Ontario Ministry of Health and Long-Term Care","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Epidermal growth factor receptor; Immunohistochemistry; Gynecology","score_opus":0.31022023476033067,"score_gpt":0.5294626497073359,"score_spread":0.21924241494700525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948116664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9760568,0.00050220994,0.000014003201,0.014231389,0.0005518802,0.0007222738,0.000003212536,0.000011445731,0.007906779],"genre_scores_gemma":[0.9716389,0.000442218,0.023035219,0.0026116043,0.0004831803,0.00002394972,0.0000013959329,0.000031546184,0.0017319712],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972823,0.0004411247,0.0010926301,0.0002987521,0.00045580338,0.00042933717],"domain_scores_gemma":[0.9953501,0.0021723362,0.000665499,0.0001689207,0.001192671,0.0004504385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017751945,0.0002189638,0.0007573773,0.0003289213,0.00006707327,0.00003295043,0.00018035248,0.000087431996,0.0016179628],"category_scores_gemma":[0.0048092613,0.00017149156,0.000083288694,0.00026754627,0.000056380493,0.0005731203,0.00008026162,0.0011510083,0.000095987176],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042659696,0.0011857346,0.6255597,0.00007531318,0.00029042902,0.0020162899,0.0029721805,0.000038224618,0.10014212,0.000012524927,0.005802374,0.25763914],"study_design_scores_gemma":[0.02343905,0.031401463,0.1794452,0.00054319977,0.0004055029,0.008270529,0.0011853977,0.00014736211,0.011188075,0.000042768395,0.74356735,0.00036411072],"about_ca_topic_score_codex":0.036265675,"about_ca_topic_score_gemma":0.008993416,"teacher_disagreement_score":0.73776495,"about_ca_system_score_codex":0.003283943,"about_ca_system_score_gemma":0.003477005,"threshold_uncertainty_score":0.9992947},"labels":[],"label_agreement":null},{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","score_opus":0.1404453096150034,"score_gpt":0.5111550693327782,"score_spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948405934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96343225,0.0004641885,0.000019589037,0.033400454,0.0010406079,0.0010818272,0.0001749524,0.00001132262,0.00037478414],"genre_scores_gemma":[0.9958166,0.0005235019,0.00020363594,0.0016438952,0.0015675627,0.00001644173,0.00000855366,0.000040886607,0.00017893394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99429977,0.0011462411,0.0027559667,0.00045156112,0.00086497545,0.00048151385],"domain_scores_gemma":[0.9911066,0.006241063,0.001151577,0.0003616072,0.00063507224,0.00050403323],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034261756,0.0002881139,0.0025935643,0.000157617,0.000095294214,0.000030109359,0.00040178062,0.00033146844,0.0027928618],"category_scores_gemma":[0.0023542023,0.00016612884,0.000360578,0.0002320464,0.0003952222,0.00016385982,0.0001707346,0.002491365,0.00002720403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009358034,0.0045532277,0.8904425,0.000021629387,0.00066073687,0.00077374565,0.0010581682,0.0000019722563,0.00049058284,0.000020141308,0.00215957,0.090459675],"study_design_scores_gemma":[0.047185685,0.019012177,0.9301007,0.00022165896,0.0002506569,0.0001361813,0.0013637769,0.000080059865,0.00003176516,0.00007322067,0.0013865205,0.00015763615],"about_ca_topic_score_codex":0.0029565115,"about_ca_topic_score_gemma":0.0031674004,"teacher_disagreement_score":0.09030204,"about_ca_system_score_codex":0.0007087806,"about_ca_system_score_gemma":0.0023228468,"threshold_uncertainty_score":0.9998099},"labels":[],"label_agreement":null},{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","score_opus":0.05371163214208088,"score_gpt":0.3732203289132454,"score_spread":0.31950869677116456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948726637","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9763303,0.0002257549,0.000042396096,0.0034560012,0.0010893582,0.0055175787,0.010235596,0.00003190494,0.0030711193],"genre_scores_gemma":[0.9971461,0.00018993429,0.00013229028,0.00006139255,0.0015870362,0.00034079104,0.00008101645,0.00004715267,0.00041424655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974186,0.00023548517,0.00057972304,0.00038918768,0.00084235717,0.00053467706],"domain_scores_gemma":[0.996875,0.000983323,0.0002712002,0.0012712465,0.00036899542,0.00023025637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014320732,0.00023162877,0.0012849665,0.00007627533,0.000056935383,0.000017569619,0.00054454134,0.00010103365,0.00023650522],"category_scores_gemma":[0.0006811037,0.00016035872,0.0003372109,0.00021703453,0.00025745723,0.00007567597,0.00010617412,0.00032457386,0.000014930413],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.97977394,0.0005680963,0.0021916886,0.00038463375,0.00045136778,0.000010903733,0.0013816841,0.000017699487,0.004968294,0.000045734017,0.007070489,0.0031354446],"study_design_scores_gemma":[0.94284934,0.004190405,0.0463495,0.00052214385,0.00042308794,0.0000015280353,0.00041333548,0.000713841,0.0033598554,0.00006540883,0.0009003314,0.00021122521],"about_ca_topic_score_codex":0.0031995506,"about_ca_topic_score_gemma":0.0003438628,"teacher_disagreement_score":0.04415781,"about_ca_system_score_codex":0.00022060823,"about_ca_system_score_gemma":0.00085523527,"threshold_uncertainty_score":0.65392387},"labels":[],"label_agreement":null},{"id":"W2949261725","doi":"10.1089/bio.2019.0039","title":"The Importance of Human Tissue Bioresources in Advancing Biomedical Research","year":2019,"lang":"en","type":"article","venue":"Biopreservation and Biobanking","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Personalized medicine; Precision medicine; Medicine; Biotechnology; Business; Computational biology; Bioinformatics; Pathology; Biology","score_opus":0.08483540331221695,"score_gpt":0.4416111439184968,"score_spread":0.35677574060627987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949261725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156255,0.0013493586,0.000005248947,0.0046712444,0.00006150756,0.0005162712,0.0000027624671,0.000017103974,0.0018139797],"genre_scores_gemma":[0.9984842,0.00027288296,0.00018475755,0.00009659963,0.00010474635,0.000020108064,0.0000132721525,0.00001314715,0.000810314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980655,0.000114662726,0.00036824378,0.00025989496,0.00080409826,0.00038765543],"domain_scores_gemma":[0.9990151,0.00025577494,0.000074321906,0.00035072866,0.00021314324,0.00009090975],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027232843,0.00008195604,0.0001855553,0.00028206734,0.00015734705,0.00004010977,0.00019750824,0.00010197693,0.00017194367],"category_scores_gemma":[0.00042582038,0.000055158165,0.00002368866,0.00074450107,0.00032965207,0.000078594465,0.00017699407,0.00034601375,0.000014803645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006379726,0.00004042568,0.75177604,0.00017942548,0.000006889942,0.000007694719,0.00028316822,2.7317327e-7,0.237351,0.0012958365,0.00075404096,0.008241436],"study_design_scores_gemma":[0.001662233,0.0008676565,0.787383,0.00085953175,0.0000066560274,0.000012866937,0.0017829618,0.00082810625,0.045286335,0.00157408,0.15957369,0.00016284146],"about_ca_topic_score_codex":0.00047058656,"about_ca_topic_score_gemma":0.00038100575,"teacher_disagreement_score":0.19206466,"about_ca_system_score_codex":0.00009303779,"about_ca_system_score_gemma":0.00010813375,"threshold_uncertainty_score":0.22492847},"labels":[],"label_agreement":null},{"id":"W2949384952","doi":"10.1158/0008-5472.can-19-0989","title":"A Tribute to John Mendelsohn: A Pioneer in Targeted Cancer Therapy","year":2019,"lang":"en","type":"review","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Tribute; Cancer; Cancer therapy; Medicine; Art; Internal medicine; Art history","score_opus":0.522667861932053,"score_gpt":0.6135850359263461,"score_spread":0.09091717399429311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949384952","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016933146,0.977898,0.0000055468386,0.007186185,0.00087290583,0.011012308,0.00066378404,0.00009181956,0.0021001224],"genre_scores_gemma":[0.000030739353,0.9303817,0.000084455605,0.00047081895,0.0014808358,0.017173411,0.00016501549,0.00038544013,0.049827553],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9886168,0.0014503889,0.0012917687,0.001969482,0.0037861702,0.0028853747],"domain_scores_gemma":[0.99453527,0.00076978287,0.00017555301,0.00208374,0.0012765217,0.0011591184],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004565364,0.0008696228,0.0038702684,0.003198717,0.00016786816,0.00016576056,0.0014807802,0.0009544145,0.008277593],"category_scores_gemma":[0.0006305366,0.0006787317,0.00068143394,0.00690661,0.00028073695,0.00012732508,0.00066173583,0.0053166235,0.0021657888],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004506358,0.00017126511,0.00008557341,0.018517295,0.00038029498,0.00024593557,0.00031498456,0.0000054538846,0.00011821798,0.000023933339,0.18603346,0.79365295],"study_design_scores_gemma":[0.0019224256,0.00059421547,0.00004820998,0.036171086,0.0001095185,0.0000241276,0.000047718415,0.000008760294,0.00011518371,0.000025308866,0.9603297,0.00060374866],"about_ca_topic_score_codex":0.0074509135,"about_ca_topic_score_gemma":0.0014502319,"teacher_disagreement_score":0.7930492,"about_ca_system_score_codex":0.008384349,"about_ca_system_score_gemma":0.017579354,"threshold_uncertainty_score":0.9995664},"labels":[],"label_agreement":null},{"id":"W2952744834","doi":"","title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update","year":2018,"lang":"en","type":"article","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Clinical Oncology; Guideline; Medicine; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Internal medicine; Clinical Practice; Cancer; Gynecology; Pathology; Family medicine","score_opus":0.22644169620457952,"score_gpt":0.548833630365114,"score_spread":0.32239193416053447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952744834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93590325,0.00006560856,0.00033064734,0.05617894,0.00041957447,0.0011052852,0.0007862835,0.00012855677,0.0050818375],"genre_scores_gemma":[0.77261704,0.00060976984,0.21687612,0.008043313,0.0015494606,0.000053471143,0.000022316775,0.000068299785,0.00016020284],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99072033,0.0018022978,0.004634944,0.0009970757,0.0009849656,0.00086039497],"domain_scores_gemma":[0.9891083,0.0038955077,0.0025788595,0.0008546449,0.0029965444,0.0005661246],"candidate_categories":["metaresearch","metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0087313885,0.00035729562,0.0024841805,0.0001811747,0.000101301215,0.0000077855075,0.00054562604,0.00032534593,0.0011825628],"category_scores_gemma":[0.012125009,0.00029092783,0.0005056836,0.0017598317,0.006295588,0.00018040782,0.00041546096,0.0015395706,0.000038825976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012325938,0.0016479368,0.64045995,0.000098124954,0.00020190266,0.000062027946,0.00013092853,8.458604e-7,0.0025458816,0.000051598145,0.09591501,0.2576532],"study_design_scores_gemma":[0.0060225967,0.009620766,0.9133586,0.00025099286,0.00016887442,0.0001017289,0.0018614724,0.0010696398,0.0013508688,0.000032621007,0.065742664,0.00041915276],"about_ca_topic_score_codex":0.01850421,"about_ca_topic_score_gemma":0.0011287327,"teacher_disagreement_score":0.27289867,"about_ca_system_score_codex":0.00045612332,"about_ca_system_score_gemma":0.0030355824,"threshold_uncertainty_score":0.9999543},"labels":[],"label_agreement":null},{"id":"W2953389360","doi":"10.1016/j.pneurobio.2019.101643","title":"Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair","year":2019,"lang":"en","type":"review","venue":"Progress in Neurobiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":142,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Canadian Institutes of Health Research; Multiple Sclerosis Society of Canada","keywords":"Neuregulin; ErbB; Neuroscience; Neuregulin 1; Biology; Nervous system; Receptor tyrosine kinase; Remyelination; Central nervous system; Signal transduction; Myelin; Cell biology","score_opus":0.10506675705289172,"score_gpt":0.44379408326948694,"score_spread":0.33872732621659524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953389360","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004432941,0.99119616,0.0000015362301,0.000054586675,0.0011755215,0.0027558897,0.000047949477,0.00018754735,0.00014784357],"genre_scores_gemma":[0.004687552,0.9934793,0.00040620682,0.00006314557,0.00069790415,0.0002771783,0.000108230815,0.00016886077,0.00011161205],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951143,0.0012468147,0.0013169196,0.0011661914,0.00025657716,0.0008991786],"domain_scores_gemma":[0.9975141,0.0002577333,0.0005797956,0.0012897756,0.00013423545,0.00022435833],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010532028,0.00055390224,0.0033561045,0.00046811329,0.000046375833,0.000016049818,0.000448395,0.00076270045,0.000022828177],"category_scores_gemma":[0.000100978075,0.0004449609,0.0003563678,0.000644166,0.00045475678,0.000053935226,0.00049218663,0.001312801,0.000018971408],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012217178,0.00010386233,0.0076118587,0.10882643,0.0001443038,0.00023397506,0.00003997521,0.0000071152476,0.0000022042902,0.0002693145,0.00042429502,0.8822145],"study_design_scores_gemma":[0.00074954255,0.0025848078,0.0013122681,0.037920736,0.0007380209,0.0011814645,0.00002450598,0.00092672143,0.0000038770536,0.000011340773,0.9539522,0.00059454044],"about_ca_topic_score_codex":0.000021088223,"about_ca_topic_score_gemma":0.000007499118,"teacher_disagreement_score":0.95352787,"about_ca_system_score_codex":0.00016778051,"about_ca_system_score_gemma":0.00055056193,"threshold_uncertainty_score":0.9998002},"labels":[],"label_agreement":null},{"id":"W2954367118","doi":"10.1158/1538-7445.am2019-218","title":"Abstract 218: AVID100 is an anti-EGFR ADC that promotes DM1-meditated cytotoxicity on cancer cells but not on normal cells","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Cytotoxicity; Cancer research; Epidermal growth factor receptor; EGFR inhibitors; Cytotoxic T cell; Antibody-drug conjugate; Cancer cell; Chemistry; Antibody; Cancer; In vivo; Cell culture; In vitro; Biology; Receptor; Monoclonal antibody; Immunology; Medicine; Internal medicine; Biochemistry","score_opus":0.1687449514968752,"score_gpt":0.4478875337279058,"score_spread":0.2791425822310306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954367118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789781,0.00052415056,0.0000017981725,0.0054370947,0.0013284783,0.003887981,0.0009934496,0.0001846135,0.008664313],"genre_scores_gemma":[0.9786894,0.002364584,0.000054997876,0.0020830396,0.0014487131,0.000863656,0.00007080992,0.00025038375,0.01417446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9889493,0.00051969476,0.00066968537,0.0018636219,0.005268823,0.0027288622],"domain_scores_gemma":[0.9945292,0.0007707264,0.00018289083,0.0020550145,0.0012377513,0.0012244356],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002921322,0.0006654312,0.0010119611,0.0009406669,0.00042615345,0.00026023207,0.0012572536,0.00059025333,0.021972157],"category_scores_gemma":[0.00018181134,0.0005676514,0.00023313661,0.0013199049,0.0007411454,0.00042924914,0.000340763,0.0040169572,0.0054645063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029816038,0.0010488832,0.009158114,0.001229752,0.00018172918,0.000372936,0.0011568132,0.00015584247,0.92798406,0.000022286435,0.04441983,0.011288129],"study_design_scores_gemma":[0.0032661478,0.0026492332,0.03842595,0.0015442453,0.000028556215,0.000007709183,0.00032715825,0.00042192306,0.93164426,0.000019096284,0.021098852,0.0005668395],"about_ca_topic_score_codex":0.012412319,"about_ca_topic_score_gemma":0.00052431994,"teacher_disagreement_score":0.029267834,"about_ca_system_score_codex":0.0026574954,"about_ca_system_score_gemma":0.003352351,"threshold_uncertainty_score":0.9996775},"labels":[],"label_agreement":null},{"id":"W2963723783","doi":"10.1136/esmoopen-2019-000532","title":"A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Carboplatin; Paclitaxel; Lung cancer; Medicine; Oncology; Internal medicine; Cancer research; Chemotherapy; Cisplatin","score_opus":0.02520585020919555,"score_gpt":0.3661034264544797,"score_spread":0.34089757624528416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963723783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887448,0.00013892625,0.0000049117175,0.000103568666,0.000031689357,0.010461624,0.000023501976,0.000009020796,0.00048196278],"genre_scores_gemma":[0.9973544,0.00003642522,0.0007208894,0.000034124027,0.0000072732682,0.0009787974,0.000053580356,0.000050762614,0.00076374057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981337,0.00012854996,0.00044196646,0.0004845985,0.0004622181,0.00034893738],"domain_scores_gemma":[0.9990029,0.00016348745,0.00020149621,0.00034912888,0.00016363154,0.00011938448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003761239,0.0002455963,0.0006786212,0.00020607049,0.000059749917,0.000027936174,0.0001662228,0.0000428989,0.00019558534],"category_scores_gemma":[0.00006283243,0.0001627426,0.000016952108,0.000503008,0.000039708404,0.00018120088,0.00013866478,0.00021840414,0.0000025837355],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011286919,0.011540663,0.9503987,0.0005228255,0.00011259037,0.00013741803,0.015931834,0.0009764199,0.000074958494,0.0000012355567,0.000013288032,0.009003192],"study_design_scores_gemma":[0.28896052,0.12786871,0.5633522,0.0017572386,0.0002827538,0.0000044096887,0.0075832275,0.0074757463,0.0020905593,0.000008098212,0.000127054,0.00048947165],"about_ca_topic_score_codex":0.03534264,"about_ca_topic_score_gemma":0.03906905,"teacher_disagreement_score":0.38704646,"about_ca_system_score_codex":0.0006849712,"about_ca_system_score_gemma":0.0005490684,"threshold_uncertainty_score":0.97846544},"labels":[],"label_agreement":null},{"id":"W2966607539","doi":"10.14740/cr888","title":"Trastuzumab-Induced Cardiomyopathy and Intermittent Left Bundle Branch Block","year":2019,"lang":"en","type":"article","venue":"Cardiology Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Asymptomatic; Cardiology; Internal medicine; Left bundle branch block; Cardiomyopathy; Breast cancer; Bundle branch block; Heart failure; Cancer; Electrocardiography","score_opus":0.09741754072748693,"score_gpt":0.4148566247322922,"score_spread":0.31743908400480525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2966607539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95566,0.0020106488,0.000017976108,0.0018082059,0.0005176354,0.001459913,0.000013918781,0.000075045486,0.038436685],"genre_scores_gemma":[0.9934358,0.00045041853,0.000038184608,0.00016659292,0.00076762855,0.000108830696,0.000015793088,0.00006756217,0.0049491697],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538785,0.00094453566,0.00035657288,0.0009270998,0.0010662443,0.0013176836],"domain_scores_gemma":[0.99709344,0.0005503051,0.000031691772,0.0011359501,0.0006659943,0.0005226227],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003492163,0.0002478969,0.0010910743,0.00057024625,0.00017918237,0.000056348934,0.00037650747,0.0003898081,0.0002953028],"category_scores_gemma":[0.00059565646,0.00021505487,0.00023266599,0.00044564434,0.0006002339,0.000072671945,0.00055781426,0.0019156943,0.0011389308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007090176,0.0001125146,0.73136705,0.0006291176,0.000608188,0.00033859786,0.00090333924,0.000011540326,0.21744297,0.00021489427,0.01791537,0.029747399],"study_design_scores_gemma":[0.0069443067,0.009215746,0.7764019,0.00053940696,0.00013819382,0.0071179355,0.0022581383,0.00030572774,0.022320837,0.00065074954,0.17327976,0.00082729437],"about_ca_topic_score_codex":0.00012687106,"about_ca_topic_score_gemma":0.0000103848,"teacher_disagreement_score":0.19512214,"about_ca_system_score_codex":0.00044265573,"about_ca_system_score_gemma":0.00068211317,"threshold_uncertainty_score":0.9996388},"labels":[],"label_agreement":null},{"id":"W2968994994","doi":"10.1016/j.scr.2019.101538","title":"Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness","year":2019,"lang":"en","type":"article","venue":"Stem Cell Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Iran Nanotechnology Initiative Council; Consejo Nacional de Ciencia y Tecnología","keywords":"Biology; Prolactin; Hormone; Cancer research; Breast cancer; Cancer; Mammary gland; Internal medicine; Endocrinology; Genetics","score_opus":0.050077471872063586,"score_gpt":0.38531601513218466,"score_spread":0.3352385432601211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2968994994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839343,0.0034093147,0.0000257998,0.00032114267,0.0002695539,0.0034102146,0.000025610954,0.00003816214,0.008565911],"genre_scores_gemma":[0.9910958,0.00056884845,0.00012752617,0.000022230013,0.00019683466,0.00023286416,0.000009648339,0.00009544673,0.007650805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940639,0.00085185346,0.0006020984,0.0007795597,0.0025274341,0.0011751573],"domain_scores_gemma":[0.9972195,0.0006804645,0.0001603126,0.0010100164,0.00069630845,0.00023341012],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025888314,0.00026257412,0.00073224807,0.0005186752,0.00010760999,0.000069422655,0.00038877342,0.0002568753,0.00077455194],"category_scores_gemma":[0.000028600303,0.0002309704,0.000117325166,0.0015744406,0.00022221518,0.00037208595,0.0002839212,0.001142915,0.00021624012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002078517,0.00039284627,0.040449392,0.005294222,0.000032267773,0.0000740685,0.0011846387,0.00014983682,0.93838286,0.000045735604,0.0017021926,0.010213391],"study_design_scores_gemma":[0.0034261134,0.00053168513,0.26859525,0.0025296283,0.000016497987,0.00001986465,0.00063759566,0.00084527116,0.7218037,0.000084943276,0.0012727476,0.0002367056],"about_ca_topic_score_codex":0.0015771935,"about_ca_topic_score_gemma":0.000045895827,"teacher_disagreement_score":0.22814585,"about_ca_system_score_codex":0.0009612772,"about_ca_system_score_gemma":0.0012043926,"threshold_uncertainty_score":0.94187},"labels":[],"label_agreement":null},{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.37189936812377367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969017474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876633,0.00011494247,0.000023906976,0.0044504963,0.00014344066,0.0031240436,0.00008192358,0.000016504366,0.004381408],"genre_scores_gemma":[0.998541,0.000080562335,0.000093265575,0.00015659635,0.000057559853,0.000375214,0.00002200162,0.000025360323,0.00064843916],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978405,0.0004951544,0.00043292367,0.00028477353,0.0005963234,0.00035031018],"domain_scores_gemma":[0.9988879,0.0003526602,0.00018259081,0.0003486449,0.00015807139,0.00007013085],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014391551,0.00016179318,0.00058797555,0.00021196499,0.000029710425,0.000014249267,0.00021922159,0.00008072417,0.00042948133],"category_scores_gemma":[0.00012895152,0.00010218353,0.000055696368,0.0007204659,0.0003655858,0.00008136027,0.000052253716,0.00052039616,0.00002901439],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61182743,0.03997851,0.06717616,0.0012155832,0.0007212221,0.0009163432,0.013416724,0.00083722,0.009461508,0.002148534,0.0015879701,0.25071278],"study_design_scores_gemma":[0.71137464,0.046402566,0.2257129,0.0018267084,0.0003125333,0.00022401719,0.0049155,0.0030311698,0.0041812556,0.000616808,0.0009084901,0.0004934141],"about_ca_topic_score_codex":0.009825579,"about_ca_topic_score_gemma":0.0063539958,"teacher_disagreement_score":0.25021935,"about_ca_system_score_codex":0.0013740386,"about_ca_system_score_gemma":0.0012358011,"threshold_uncertainty_score":0.99676806},"labels":[],"label_agreement":null},{"id":"W2969950347","doi":"10.1007/s10549-019-05398-3","title":"Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Georgetown University; GlaxoSmithKline; Breast Cancer Research Foundation","keywords":"Trastuzumab; Lapatinib; Medicine; Oncology; Internal medicine; Breast cancer; Chemotherapy; Estrogen receptor; Proportional hazards model; Neoadjuvant therapy; Cancer","score_opus":0.05395772915114432,"score_gpt":0.38805740147013806,"score_spread":0.33409967231899373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969950347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97920024,0.0009162889,0.0000018474417,0.014301891,0.00003253419,0.005258513,0.0001497249,0.000014242615,0.00012473868],"genre_scores_gemma":[0.9938593,0.003272301,0.00004468132,0.000105745705,0.00002943857,0.0012797274,0.00001560567,0.000025930736,0.0013672556],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997028,0.0009998176,0.00035252125,0.00040851336,0.0007610387,0.0004501231],"domain_scores_gemma":[0.9973345,0.0018522118,0.00009202467,0.00035307347,0.00021271434,0.00015551779],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022206528,0.00021179594,0.0008719998,0.00023441139,0.00009265019,0.000044836353,0.00010696852,0.00007581419,0.00022505858],"category_scores_gemma":[0.0001408543,0.00008840888,0.000063020394,0.00039477795,0.0006992248,0.00005326151,0.000048811136,0.00027441492,0.000005159356],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85436326,0.0009699459,0.05395409,0.000065409215,0.00020843635,0.000069090376,0.0012181002,6.9509184e-7,0.0006536144,0.000047522622,0.000108586086,0.088341266],"study_design_scores_gemma":[0.71410155,0.01157973,0.2714373,0.00024216533,0.000041183695,0.000095609605,0.0006569552,0.00008677786,0.0006894336,0.00010867378,0.0008400882,0.00012053054],"about_ca_topic_score_codex":0.00478689,"about_ca_topic_score_gemma":0.0008850228,"teacher_disagreement_score":0.2174832,"about_ca_system_score_codex":0.00045308057,"about_ca_system_score_gemma":0.00065330503,"threshold_uncertainty_score":0.72363776},"labels":[],"label_agreement":null},{"id":"W2978627448","doi":"10.1093/annonc/mdz268.096","title":"Targeting NRG1-fusions in multiple tumour types: Afatinib as a novel potential treatment option","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Afatinib; Medicine; Oncology; Cancer research; Computational biology; Internal medicine; Cancer; Gefitinib","score_opus":0.1542739538545159,"score_gpt":0.4589318350192664,"score_spread":0.30465788116475045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978627448","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.983596,0.00025672303,0.0000585143,0.0054796175,0.0002416955,0.00073440926,0.000017169985,0.000019990024,0.009595879],"genre_scores_gemma":[0.9961392,0.00046038983,0.001448253,0.00047866776,0.00016845956,0.00005817402,0.000039987623,0.000020055193,0.0011867653],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99868053,0.00009313623,0.00035579802,0.00026023987,0.00024839622,0.00036187502],"domain_scores_gemma":[0.99916065,0.00019950155,0.000113730806,0.00020543802,0.00020344665,0.00011720899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046707847,0.00011456345,0.0004086918,0.00020244787,0.000030668176,0.0000045993106,0.000094457464,0.00016222619,0.0007665622],"category_scores_gemma":[0.00042756696,0.000097850825,0.000093213,0.00020366868,0.00006513542,0.000046045065,0.0000648709,0.00020184452,0.0003741369],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024566392,0.0042095976,0.054612204,0.00021340253,0.00018271251,0.0003023652,0.0021302977,0.0023040338,0.8705391,0.0005808347,0.003871453,0.058597337],"study_design_scores_gemma":[0.045641012,0.06649336,0.25208545,0.001198374,0.00020617411,0.00046313606,0.0053720875,0.041399367,0.18906684,0.0009267807,0.3961545,0.0009929327],"about_ca_topic_score_codex":0.0014665731,"about_ca_topic_score_gemma":0.0001669543,"teacher_disagreement_score":0.6814723,"about_ca_system_score_codex":0.00018781617,"about_ca_system_score_gemma":0.000657243,"threshold_uncertainty_score":0.8393318},"labels":[],"label_agreement":null},{"id":"W2978854127","doi":"10.1093/annonc/mdz394.008","title":"Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Veliparib; Medicine; Carboplatin; Paclitaxel; Oncology; Metastatic breast cancer; PARP inhibitor; Internal medicine; Breast cancer; Cancer; Chemotherapy; Cisplatin; Poly ADP ribose polymerase","score_opus":0.09477682576886066,"score_gpt":0.47934025473107505,"score_spread":0.3845634289622144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978854127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944241,0.00041395324,0.0000014058985,0.001575879,0.00005544423,0.0014914618,0.000119063,0.000009917645,0.0019087789],"genre_scores_gemma":[0.9988461,0.00029961581,0.00012375957,0.00025769774,0.000017827206,0.0001281084,0.000007605061,0.000025113708,0.0002941851],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980407,0.0003059394,0.00052522257,0.00033550864,0.00040998112,0.0003826778],"domain_scores_gemma":[0.9983302,0.0004004532,0.0003351264,0.00026846392,0.0005280813,0.00013767116],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073433475,0.00016634392,0.0009896578,0.00022950066,0.000019664456,0.0000033272363,0.000105515406,0.00009142511,0.00027933484],"category_scores_gemma":[0.00020751139,0.00013369347,0.00003695916,0.00052341516,0.00021550948,0.000078412566,0.000066047505,0.00033937622,0.0000036904257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02262781,0.02387866,0.7036175,0.00084285246,0.0016670725,0.0004542642,0.024198852,0.0003623374,0.011843156,0.00006810403,0.0016050765,0.20883428],"study_design_scores_gemma":[0.10232467,0.07828344,0.7912093,0.0011618853,0.00023353919,0.00006678799,0.020274475,0.0005826876,0.0045154006,0.00022515628,0.00076193584,0.00036072297],"about_ca_topic_score_codex":0.0073462543,"about_ca_topic_score_gemma":0.007283806,"teacher_disagreement_score":0.20847355,"about_ca_system_score_codex":0.00015210574,"about_ca_system_score_gemma":0.0007666585,"threshold_uncertainty_score":0.9992639},"labels":[],"label_agreement":null},{"id":"W2978938554","doi":"10.21873/anticanres.13727","title":"Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients","year":2019,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Internal medicine; Oncology; Pathological; Cohort; Human Epidermal Growth Factor Receptor 2; Cancer; HER2 negative; Gastroenterology; Pathology","score_opus":0.3407760826680046,"score_gpt":0.5048778119201074,"score_spread":0.1641017292521028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978938554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852078,0.000089946996,6.307184e-7,0.0038351775,0.000105700616,0.0033454993,0.000116785435,0.0000079388055,0.007290526],"genre_scores_gemma":[0.9992707,0.000043375818,0.0000037591135,0.00018834372,0.00008377677,0.00019907852,0.0000018875029,0.00003221087,0.00017688057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99373335,0.0013176407,0.00055058044,0.00047306533,0.0031898932,0.0007354813],"domain_scores_gemma":[0.99608886,0.0015824009,0.00010867285,0.0012297677,0.0009007776,0.00008953021],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0062263436,0.00016358096,0.0004496297,0.00024760317,0.00011647024,0.000026511823,0.0007644334,0.000044092358,0.002279986],"category_scores_gemma":[0.000608188,0.00009185018,0.00007334896,0.0015863917,0.00048831647,0.00006930389,0.00026420134,0.0012427671,0.000053054064],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006414531,0.0023144607,0.9858022,0.00032984663,0.00007347278,0.000010510382,0.0022756362,0.000005531568,0.0027491327,0.00015163288,0.0006752829,0.00497087],"study_design_scores_gemma":[0.0016437944,0.0029903713,0.98913234,0.00058257824,0.000013166292,0.000002356196,0.0032828783,0.00039045935,0.0017112979,0.000094254145,0.00007756604,0.00007895515],"about_ca_topic_score_codex":0.012953563,"about_ca_topic_score_gemma":0.0010396211,"teacher_disagreement_score":0.014062892,"about_ca_system_score_codex":0.00023365128,"about_ca_system_score_gemma":0.0008398611,"threshold_uncertainty_score":0.9986321},"labels":[],"label_agreement":null},{"id":"W2979515484","doi":"10.1634/theoncologist.2019-0446","title":"De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Breast cancer; Pertuzumab; Clinical endpoint; Oncology; Proportional hazards model; Metastasis; Trastuzumab; Confidence interval; Cancer; Chemotherapy; Cancer registry; Progression-free survival; Clinical trial","score_opus":0.05891216506106133,"score_gpt":0.37614151386067546,"score_spread":0.3172293487996141,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979515484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797112,0.0013582802,0.0000070565256,0.012386159,0.0009814736,0.0011500297,0.0012192917,0.000037060243,0.0031494936],"genre_scores_gemma":[0.9965105,0.0017102091,0.000056102897,0.00043935128,0.0003396144,0.00017529921,0.00006547668,0.000030605155,0.0006728252],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9982873,0.0004341767,0.00023887517,0.00033059664,0.0003099093,0.00039914326],"domain_scores_gemma":[0.9978916,0.0010978729,0.00016362268,0.0005901649,0.000107852786,0.00014885937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043071073,0.00020894433,0.0004033241,0.000020332885,0.00015417412,0.00006695794,0.00022671102,0.00006707442,0.00045330066],"category_scores_gemma":[0.00013836352,0.00010780604,0.00008049235,0.00011926879,0.00046877915,0.000029688275,0.00010089859,0.00033222456,0.00008613988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02363884,0.0017621779,0.36519197,0.00031151707,0.0031064833,0.0006207976,0.011621795,0.000031869735,0.0033095975,0.00077074626,0.010340463,0.5792937],"study_design_scores_gemma":[0.013092078,0.009863459,0.86100155,0.0010823183,0.0016046492,0.00036980957,0.01272623,0.0005864356,0.000946547,0.00012340797,0.09796723,0.0006362979],"about_ca_topic_score_codex":0.01270134,"about_ca_topic_score_gemma":0.0013235445,"teacher_disagreement_score":0.57865745,"about_ca_system_score_codex":0.0015533908,"about_ca_system_score_gemma":0.0006325571,"threshold_uncertainty_score":0.9938732},"labels":[],"label_agreement":null},{"id":"W2981000307","doi":"10.1200/jgo.2019.5.suppl.110","title":"Afatinib as a novel potential treatment option for <i>NRG1</i> fusion-positive tumors.","year":2019,"lang":"en","type":"article","venue":"Journal of Global Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Afatinib; Medicine; Oncology; KRAS; Internal medicine; Adenocarcinoma; Lung cancer; Epidermal growth factor receptor; Colorectal cancer; Cancer; Erlotinib","score_opus":0.02958158023751304,"score_gpt":0.4123533889199466,"score_spread":0.38277180868243355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981000307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676282,0.00038874912,0.002352284,0.009772778,0.0014994675,0.0012106582,0.000088620676,0.0000130664575,0.01704617],"genre_scores_gemma":[0.98955566,0.0001652961,0.00709367,0.0011155531,0.0011046163,0.000022526783,0.000012218327,0.00001776485,0.0009126958],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983209,0.00008271764,0.0005536298,0.00019725447,0.00047904334,0.00036650355],"domain_scores_gemma":[0.99833244,0.0001543351,0.0004036416,0.00015853252,0.00065744616,0.00029359368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00050246366,0.00015442239,0.0006319445,0.000081468796,0.000052418316,0.000017381493,0.00013812282,0.00018825164,0.000309554],"category_scores_gemma":[0.00017296676,0.00011442647,0.00031201256,0.00017156929,0.00007008722,0.00008720424,0.000045953035,0.00023606108,0.00012772165],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07771072,0.013984617,0.045989927,0.00049378054,0.0028232553,0.0056088427,0.0013449809,0.0009996106,0.43082598,0.011774393,0.06147636,0.34696755],"study_design_scores_gemma":[0.087789565,0.24927938,0.12316877,0.0013567203,0.0015395955,0.043313544,0.002069603,0.0021967627,0.018250689,0.0037383894,0.46655083,0.00074616564],"about_ca_topic_score_codex":0.0001288924,"about_ca_topic_score_gemma":0.000027814183,"teacher_disagreement_score":0.41257527,"about_ca_system_score_codex":0.0032364817,"about_ca_system_score_gemma":0.0024077303,"threshold_uncertainty_score":0.8463287},"labels":[],"label_agreement":null},{"id":"W2982402876","doi":"10.21873/anticanres.11701","title":"Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Anticancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"Fonds de Recherche du Québec - Santé; Fondation du cancer du sein du Québec; Université Laval","keywords":"Concordance; Immunohistochemistry; Tissue microarray; Fluorescence in situ hybridization; Breast cancer; Pathology; In situ hybridization; Medicine; Cancer; Biology; Oncology; Internal medicine; Gene expression; Gene","score_opus":0.08115000927052714,"score_gpt":0.486531928542941,"score_spread":0.40538191927241385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982402876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926166,0.0024385795,0.0000187918,0.0024583193,0.000076481454,0.0006248267,0.000030380295,0.000008222913,0.0017277957],"genre_scores_gemma":[0.99523324,0.0037022356,0.00045877372,0.000031109743,0.00012949585,0.00007007669,0.000003983506,0.00003493734,0.00033614683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99737597,0.0001352085,0.0004126545,0.0005285376,0.00085563044,0.0006920034],"domain_scores_gemma":[0.9982556,0.000119696284,0.00011871443,0.0008517675,0.00049561786,0.00015857579],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014598396,0.00015324733,0.00043906405,0.0002926553,0.0001899737,0.00007411954,0.00044198774,0.00011934884,0.00017704016],"category_scores_gemma":[0.0004314343,0.00015539782,0.000029052506,0.00046291214,0.0013486097,0.00020172024,0.0002958925,0.0007915611,0.0000061581454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040244186,0.00007785684,0.3247362,0.0005332775,0.000010241362,0.000097535514,0.00023769149,0.000006698704,0.662691,0.000023641505,0.00013739643,0.011046024],"study_design_scores_gemma":[0.001696491,0.00008038746,0.5244765,0.0025785177,0.00000788521,0.00006869663,0.00020635262,0.0008858251,0.4694808,0.00005710082,0.00030077,0.00016061973],"about_ca_topic_score_codex":0.031464193,"about_ca_topic_score_gemma":0.0011162106,"teacher_disagreement_score":0.19974032,"about_ca_system_score_codex":0.00081431307,"about_ca_system_score_gemma":0.0013672642,"threshold_uncertainty_score":0.97498536},"labels":[],"label_agreement":null},{"id":"W2982411421","doi":"10.1158/1541-7786.mcr-19-0582","title":"Antibody–Drug Conjugates: A Comprehensive Review","year":2019,"lang":"en","type":"review","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":770,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Antibody-drug conjugate; Drug; Payload (computing); Monoclonal antibody; Cytotoxic T cell; Immunotherapy; Computational biology; Cancer immunotherapy; Cancer research; Medicine; Pharmacology; Cancer; Antibody; Chemistry; Biology; Computer science; Immunology; In vitro; Biochemistry; Internal medicine","score_opus":0.354517806902707,"score_gpt":0.6034749384917816,"score_spread":0.24895713158907457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982411421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000054614675,0.9782403,0.000017473672,0.0018524767,0.00042412922,0.011240283,0.00026465123,0.00011086796,0.007844351],"genre_scores_gemma":[0.0000023602329,0.9855567,0.00010205553,0.0016898379,0.00048438623,0.002989158,0.0008456002,0.00045390893,0.007875947],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.98695344,0.0027003486,0.0013950992,0.002002971,0.004723622,0.0022245424],"domain_scores_gemma":[0.99244213,0.0007543925,0.00032240228,0.003151791,0.0024137287,0.0009155821],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0029047814,0.0009875,0.005468871,0.0012354378,0.00021365818,0.00015858593,0.0015441749,0.0005724538,0.0037841466],"category_scores_gemma":[0.00069802644,0.00079649704,0.001630912,0.0035338781,0.0007303553,0.00008042498,0.0011136521,0.005567105,0.00583615],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036306374,0.00007977643,0.00000687442,0.47351155,0.00068264635,0.0015763486,0.000024358136,3.227889e-7,0.00018863294,0.00006441402,0.050650403,0.47317836],"study_design_scores_gemma":[0.0004591561,0.0001939705,0.0000013767212,0.30227372,0.00091660523,0.00020950216,0.000011419864,0.00000374759,0.00005435497,0.000013949759,0.6954015,0.00046071617],"about_ca_topic_score_codex":0.001026199,"about_ca_topic_score_gemma":0.000014981443,"teacher_disagreement_score":0.6447511,"about_ca_system_score_codex":0.0021226618,"about_ca_system_score_gemma":0.010673883,"threshold_uncertainty_score":0.9994486},"labels":[],"label_agreement":null},{"id":"W2984163037","doi":"10.1182/blood-2019-123449","title":"Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Jewish General Hospital; Spinal Cord Injury BC","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Internal medicine; Refractory (planetary science); Phases of clinical research; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Clinical trial","score_opus":0.014116232482786045,"score_gpt":0.3040344386412057,"score_spread":0.2899182061584197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984163037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897529,0.0009658763,0.000006666386,0.00018474125,0.00012557583,0.004465839,0.0001775993,0.00010356024,0.0042172787],"genre_scores_gemma":[0.99639463,0.00006360952,0.0002950473,0.00008089028,0.00009938108,0.00015562064,0.00017890311,0.000102953934,0.0026289492],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955451,0.0005718496,0.0011502295,0.0008012601,0.0011513089,0.0007802471],"domain_scores_gemma":[0.99730814,0.00046538355,0.0003870318,0.0012381654,0.0003056113,0.0002956721],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001957974,0.00040711014,0.0018373735,0.0005509393,0.00007801807,0.00002107344,0.00035132043,0.00020906825,0.00022382473],"category_scores_gemma":[0.0006757367,0.00030994075,0.00017585163,0.00092153257,0.00016462318,0.00009935851,0.00023963708,0.00062093505,0.00010389948],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.616103,0.34822497,0.0075993137,0.0006097293,0.0007999713,0.0015637169,0.008365246,0.0000070779047,0.014954546,0.000029018269,0.0010288602,0.00071453926],"study_design_scores_gemma":[0.97990686,0.006986747,0.0013909767,0.00040430028,0.0005443062,0.000044376997,0.001248464,0.00074184587,0.0067547862,0.000005573764,0.0016608421,0.00031090758],"about_ca_topic_score_codex":0.0010554497,"about_ca_topic_score_gemma":0.00031873363,"teacher_disagreement_score":0.36380386,"about_ca_system_score_codex":0.00028940284,"about_ca_system_score_gemma":0.0011952156,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W2990808969","doi":"","title":"Stromal mast cells as a favorable prognostic marker in early breast cancer","year":2004,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Breast cancer; Tissue microarray; Oncology; Stromal cell; Internal medicine; Lymph node; Immunohistochemistry; Antibody; Adjuvant; Mast cell; Pathology; Cohort; Cancer; Immunology","score_opus":0.07651018433685033,"score_gpt":0.4339942106875084,"score_spread":0.357484026350658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990808969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97823256,0.0022952934,0.000009452249,0.0084158,0.00029382174,0.0022494101,0.00018727865,0.000081946826,0.008234421],"genre_scores_gemma":[0.98595065,0.0014196818,0.00015904372,0.00027019688,0.00069795985,0.0021572437,0.0000109409575,0.00013403333,0.0092002405],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934709,0.0003222563,0.0004825063,0.0009772055,0.0025769996,0.0021701504],"domain_scores_gemma":[0.9972228,0.00021403829,0.000056461733,0.00080505485,0.00087264006,0.0008290391],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018813764,0.00031916494,0.0005412097,0.00082367344,0.00021775514,0.00017159822,0.00059176615,0.0002604811,0.0066696843],"category_scores_gemma":[0.00023339184,0.00029181765,0.00012282196,0.0023445615,0.00059953704,0.00024068386,0.00033317602,0.0022689293,0.0010716283],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052335146,0.0014409474,0.76292807,0.0020321116,0.00028974714,0.0037292459,0.0032566683,0.0008222303,0.17204024,0.0007848234,0.018081972,0.029360404],"study_design_scores_gemma":[0.011358768,0.0018238284,0.91126496,0.0055437493,0.00006454632,0.00028399462,0.0012718557,0.00013238474,0.045991484,0.0013486131,0.02006398,0.00085185614],"about_ca_topic_score_codex":0.055358674,"about_ca_topic_score_gemma":0.0049202535,"teacher_disagreement_score":0.14833684,"about_ca_system_score_codex":0.003675806,"about_ca_system_score_gemma":0.0068394085,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W2991090638","doi":"10.1093/annonc/mdz420.002","title":"NRG1-fusion-driven solid tumours: A case series indicating the therapeutic potential of afatinib","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System; University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Afatinib; Series (stratigraphy); Oncology; Cancer research; Internal medicine; Cancer","score_opus":0.10946429398928428,"score_gpt":0.4602900680415992,"score_spread":0.35082577405231496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991090638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97487617,0.0005962487,0.000017543494,0.016062021,0.00018646843,0.00062373996,0.000018046865,0.000015889724,0.0076038516],"genre_scores_gemma":[0.99742454,0.00037016615,0.00032160923,0.0012408164,0.00016304172,0.00003339374,0.00000608971,0.000022129385,0.00041821026],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834853,0.0002697114,0.00044584178,0.00020924612,0.00037696288,0.0003496946],"domain_scores_gemma":[0.99841034,0.00033654907,0.00031620002,0.0004599664,0.0003832,0.00009376121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008779777,0.000116149065,0.00048367295,0.00012836381,0.00006575804,0.0000059895588,0.00024012686,0.00014996738,0.000922659],"category_scores_gemma":[0.00022907028,0.00007896947,0.00013007494,0.00023898733,0.0004034497,0.00005756369,0.00015715972,0.0003608214,0.00005998374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039534434,0.002203183,0.11203202,0.0015283731,0.0012644383,0.0045073675,0.017142573,0.00030312894,0.44785056,0.0029187682,0.015338834,0.3909573],"study_design_scores_gemma":[0.017145632,0.08112713,0.15507224,0.0022060776,0.0009752761,0.04926144,0.04054616,0.0052467245,0.44666678,0.005537419,0.19485597,0.0013591541],"about_ca_topic_score_codex":0.00024835265,"about_ca_topic_score_gemma":0.00006688745,"teacher_disagreement_score":0.38959816,"about_ca_system_score_codex":0.000033551307,"about_ca_system_score_gemma":0.000711582,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W2994601580","doi":"10.1186/s13058-019-1240-y","title":"Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer","year":2020,"lang":"en","type":"erratum","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Trastuzumab; Neratinib; Medicine; Surgical oncology; Paclitaxel; Oncology; Breast cancer; Internal medicine; Chemotherapy; Neoadjuvant therapy; Cancer","score_opus":0.043530157859972565,"score_gpt":0.42125467691721774,"score_spread":0.3777245190572452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994601580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40042454,0.04310744,0.0003479946,0.39205596,0.034756083,0.09390112,0.022496024,0.00083982456,0.012071016],"genre_scores_gemma":[0.47337973,0.062421363,0.00044949076,0.006962426,0.017783994,0.048080638,0.0018284697,0.0018218288,0.38727206],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9874354,0.00221798,0.0015076855,0.002783653,0.003780679,0.002274629],"domain_scores_gemma":[0.99455625,0.0009151435,0.00033868363,0.0008985236,0.0014527225,0.0018386573],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0034872445,0.0013653237,0.0041077784,0.0011941368,0.00075600593,0.00050542864,0.0006175907,0.0009376118,0.0030034753],"category_scores_gemma":[0.0007535901,0.0009806511,0.00034285,0.0027721752,0.0014365645,0.0003390692,0.0003935136,0.0066917595,0.000018414357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4716319,0.0009829246,0.00006276053,0.0003751176,0.0005087208,0.00026005608,0.003203537,0.0000032056653,0.0008868095,0.000003323306,0.43655273,0.08552892],"study_design_scores_gemma":[0.8313703,0.017764635,0.000846252,0.0072524254,0.00034302575,0.0013158242,0.0020087482,0.0023195904,0.0002601495,0.000010040448,0.13509905,0.0014099394],"about_ca_topic_score_codex":0.042430993,"about_ca_topic_score_gemma":0.016859131,"teacher_disagreement_score":0.3850935,"about_ca_system_score_codex":0.003944185,"about_ca_system_score_gemma":0.013282587,"threshold_uncertainty_score":0.99990976},"labels":[],"label_agreement":null},{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","score_opus":0.11634704752836855,"score_gpt":0.5119909698977256,"score_spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994917610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792491,0.00015078193,0.0003948582,0.013836232,0.0006837374,0.0052722716,0.000078236575,0.000013858769,0.00032093402],"genre_scores_gemma":[0.9853699,0.0036775086,0.0043085134,0.003983763,0.0014332408,0.0003539623,0.000007446339,0.0000786366,0.0007870182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932959,0.0017272197,0.0030848156,0.0005645449,0.00069019437,0.0006373273],"domain_scores_gemma":[0.978784,0.016363325,0.0030673041,0.00027397208,0.0008435893,0.00066778046],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072255502,0.0003804981,0.006812479,0.00023918707,0.00007073997,0.000028588642,0.0002978554,0.0005492732,0.0006504876],"category_scores_gemma":[0.0030574563,0.00019295144,0.0003261389,0.0003337946,0.0010322432,0.00020511427,0.0000549136,0.0022542744,0.0000032074852],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8663756,0.003339153,0.023943312,0.00011207422,0.0015480513,0.00037937606,0.0008076338,0.000030260633,0.000061562176,0.0000047625867,0.0049753534,0.098422825],"study_design_scores_gemma":[0.87484634,0.10620879,0.005531505,0.0007299162,0.000787838,0.0008107586,0.00083051296,0.0007684319,0.00015079178,0.00004537087,0.009049068,0.00024065896],"about_ca_topic_score_codex":0.001440587,"about_ca_topic_score_gemma":0.01289879,"teacher_disagreement_score":0.10286963,"about_ca_system_score_codex":0.0009853957,"about_ca_system_score_gemma":0.011968663,"threshold_uncertainty_score":0.99363256},"labels":[],"label_agreement":null},{"id":"W2995808512","doi":"10.1056/nejmoa1914609","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1313,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Seattle Genetics","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Cancer; Colorectal cancer","score_opus":0.03135860786207033,"score_gpt":0.37047147226077715,"score_spread":0.3391128643987068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995808512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9030551,0.00846918,0.00092023495,0.08323563,0.0012340645,0.0011370048,0.00007963588,0.000014504474,0.0018546506],"genre_scores_gemma":[0.98771214,0.001558489,0.0016257489,0.0012666261,0.0049021407,0.00001360602,0.000011000534,0.000045208883,0.0028650307],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99809253,0.0000895812,0.0005723202,0.00020376775,0.00070564105,0.00033614202],"domain_scores_gemma":[0.9978073,0.000607042,0.0002594774,0.00017510132,0.00057782995,0.00057325116],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012457225,0.00019133379,0.00079133286,0.00024378447,0.00004146555,0.000012794678,0.0001239061,0.000051475334,0.001644206],"category_scores_gemma":[0.0003240816,0.0001202175,0.00008456768,0.00020905699,0.00014150878,0.000097184726,0.0000205433,0.00045853807,0.000007109278],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008041342,0.00036972045,0.05632061,0.0011720269,0.0010776569,0.00034211084,0.0062308237,0.00003156857,0.02337299,0.00031027896,0.06903319,0.8336977],"study_design_scores_gemma":[0.33962017,0.02618566,0.2827309,0.009460465,0.0024395774,0.026735466,0.0041170716,0.00093542645,0.0032085506,0.0016615489,0.30222315,0.00068201154],"about_ca_topic_score_codex":0.00046120095,"about_ca_topic_score_gemma":0.000076743665,"teacher_disagreement_score":0.8330157,"about_ca_system_score_codex":0.00018484287,"about_ca_system_score_gemma":0.0007432235,"threshold_uncertainty_score":0.9992684},"labels":[],"label_agreement":null},{"id":"W2998482686","doi":"10.1158/1541-7786.mcr-19-0856","title":"Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1","year":2020,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Vetenskapsrådet; Cancerfonden","keywords":"Internalization; Cancer research; Trastuzumab; Cytotoxicity; Endocytosis; Trastuzumab emtansine; Phosphorylation; Biology; Flow cytometry; Breast cancer; Pharmacology; Chemistry; Cancer; In vitro; Cell biology; Cell; Molecular biology; Biochemistry","score_opus":0.10406138963881843,"score_gpt":0.4044872859441323,"score_spread":0.30042589630531386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998482686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9701524,0.009525068,0.001747998,0.013642749,0.00007969611,0.0018449683,0.00040400095,0.00010918287,0.0024939375],"genre_scores_gemma":[0.995946,0.0021255638,0.0005312328,0.0005582841,0.00021938165,0.00022342382,0.000120706645,0.00010214596,0.00017328018],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99430895,0.00040721495,0.00071838,0.0010054534,0.002388114,0.0011718938],"domain_scores_gemma":[0.9971519,0.00018663215,0.00012009145,0.0006401661,0.0012168989,0.00068428623],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011346253,0.00036191614,0.0008050005,0.00019833393,0.00022682235,0.00006685332,0.0004004329,0.00030026952,0.00058907096],"category_scores_gemma":[0.0011606243,0.00034542635,0.00018360312,0.0018928406,0.00097047776,0.00013623026,0.00030297085,0.0014738089,0.00004127179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019394708,0.0002412498,0.0014923658,0.0010407745,0.00029417168,0.0007974516,0.0016014369,0.00004306603,0.9769917,0.00053525355,0.007287975,0.0077350438],"study_design_scores_gemma":[0.0035837516,0.0022325725,0.009778522,0.0005457437,0.00010980797,0.0000660569,0.0005901056,0.0019009388,0.9710976,0.00047583695,0.009253845,0.00036523247],"about_ca_topic_score_codex":0.0021299748,"about_ca_topic_score_gemma":0.000084545405,"teacher_disagreement_score":0.025793582,"about_ca_system_score_codex":0.0008692216,"about_ca_system_score_gemma":0.0017123697,"threshold_uncertainty_score":0.99989974},"labels":[],"label_agreement":null},{"id":"W2998888159","doi":"10.1002/jcla.23187","title":"Genetic variation in NRG 1 gene and risk of post‐traumatic stress disorders in patients with hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Laboratory Analysis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Genotype; Internal medicine; Hepatocellular carcinoma; Cognition; Medicine; Neuregulin 1; Clinical psychology; Gastroenterology; Montreal Cognitive Assessment; Oncology; Psychiatry; Gene; Cognitive impairment; Biology; Genetics; Receptor","score_opus":0.028810753936203637,"score_gpt":0.33848294256660566,"score_spread":0.309672188630402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998888159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985378,0.00045480588,0.0003121531,0.00039364473,0.000024203247,0.00020725136,0.000059393013,0.0000021606,0.000008602055],"genre_scores_gemma":[0.99784356,0.00053009595,0.0014296689,0.00010403486,0.00006961307,0.0000022718107,0.0000058660294,0.000013883793,0.0000010139881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965856,0.0007046031,0.0016254414,0.00021957516,0.0007014635,0.00016330261],"domain_scores_gemma":[0.99756557,0.00038250728,0.00086909847,0.00021067688,0.0006755783,0.00029656317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015220246,0.000119624485,0.001003075,0.00043309212,0.000016690596,0.000012137447,0.00013049415,0.00011764833,0.00007716907],"category_scores_gemma":[0.0018192423,0.00009047495,0.00017674264,0.001949889,0.00010394051,0.000096848744,0.000030141908,0.0006347213,0.0000011252158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00123432,0.0005431174,0.9939452,0.00013412652,0.00085947866,0.00005289246,0.00057232357,0.0012880586,0.0000644558,0.0000011063689,0.0000049866926,0.0012999296],"study_design_scores_gemma":[0.003858984,0.0017940357,0.9835196,0.000086716034,0.001497352,3.2283418e-7,0.0001778293,0.008898203,0.000062997446,0.0000104777,0.000014593212,0.000078859186],"about_ca_topic_score_codex":0.00027374973,"about_ca_topic_score_gemma":0.00063101813,"teacher_disagreement_score":0.010425574,"about_ca_system_score_codex":0.00005551689,"about_ca_system_score_gemma":0.0004435442,"threshold_uncertainty_score":0.36894614},"labels":[],"label_agreement":null},{"id":"W2999581422","doi":"10.1016/s0923-7534(20)34201-0","title":"Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Medicine; Docetaxel; Trastuzumab; Metastatic breast cancer; Bevacizumab; Oncology; Internal medicine; HER2 negative; Breast cancer; Phases of clinical research; Chemotherapy; Cancer","score_opus":0.22965652475487,"score_gpt":0.5029663557028642,"score_spread":0.2733098309479942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999581422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919526,0.0054538837,0.0011934863,0.043719657,0.0022321795,0.006197615,0.01793243,0.000050017767,0.003694779],"genre_scores_gemma":[0.9937402,0.0016856903,0.00068358425,0.0012627166,0.0012338127,0.00043592256,0.00051728036,0.00006404549,0.0003767728],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99557525,0.00065759604,0.0014898387,0.0005370986,0.0007842727,0.00095595693],"domain_scores_gemma":[0.9939871,0.0028225258,0.0008122382,0.0007197816,0.0012579542,0.0004004191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026882754,0.00035977637,0.001345627,0.0001976639,0.0001152163,0.000012744128,0.00045497753,0.00028016517,0.00059768884],"category_scores_gemma":[0.0012622309,0.0002558636,0.0004349741,0.0004709885,0.0007017571,0.00016115751,0.0001414235,0.00050319824,0.000023989118],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42474425,0.0077867853,0.00012237502,0.00019933099,0.0015329059,0.000030200303,0.0025663914,0.000007709357,0.004663404,0.00012372492,0.06882152,0.4894014],"study_design_scores_gemma":[0.67927915,0.060678773,0.009606458,0.001790165,0.002185562,0.00024011442,0.0022924098,0.0017079101,0.05811625,0.00083309214,0.1823339,0.0009362314],"about_ca_topic_score_codex":0.003520055,"about_ca_topic_score_gemma":0.0005947901,"teacher_disagreement_score":0.4884652,"about_ca_system_score_codex":0.00032076865,"about_ca_system_score_gemma":0.001831279,"threshold_uncertainty_score":0.99998933},"labels":[],"label_agreement":null},{"id":"W2999743029","doi":"10.1002/ijc.32859","title":"Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"McGill University; Israel Cancer Research Fund; Breast Cancer Research Foundation","keywords":"Trastuzumab; Breast cancer; Stroma; Oncology; Medicine; Internal medicine; Mammary gland; Cancer; Cancer research; Immunohistochemistry","score_opus":0.025397180332142045,"score_gpt":0.38695985745350214,"score_spread":0.3615626771213601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999743029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9336465,0.00619695,0.000065970286,0.05777006,0.0003971129,0.00017401081,0.00025326447,0.000007261739,0.0014888496],"genre_scores_gemma":[0.9953521,0.0016198732,0.00021678928,0.001418941,0.0011774463,0.0000188171,0.000001708862,0.000022448927,0.00017188795],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982277,0.000054544314,0.0003951666,0.0001952774,0.0009337465,0.0001935206],"domain_scores_gemma":[0.9985225,0.00006614716,0.00022933738,0.00006304152,0.000880271,0.00023868591],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017066517,0.00012290708,0.00029611305,0.00016151958,0.000019400262,0.00004557668,0.00021549642,0.000059039434,0.00043914502],"category_scores_gemma":[0.00008087641,0.00010696821,0.00007800909,0.00018513814,0.00010069059,0.00024715302,0.00004625091,0.00054955506,0.000003863315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02036971,0.000329741,0.84244215,0.00014852383,0.0018904351,0.0028218704,0.010092558,0.00015646826,0.021534557,0.0008927681,0.009055112,0.09026613],"study_design_scores_gemma":[0.0032446862,0.00028525852,0.9858962,0.0013152935,0.000055955028,0.0001895616,0.00028420065,0.00006289734,0.0025570532,0.00014495899,0.0058462014,0.00011771845],"about_ca_topic_score_codex":0.0010827038,"about_ca_topic_score_gemma":0.0009226151,"teacher_disagreement_score":0.14345409,"about_ca_system_score_codex":0.0010449333,"about_ca_system_score_gemma":0.000748283,"threshold_uncertainty_score":0.480833},"labels":[],"label_agreement":null},{"id":"W2999808793","doi":"10.1016/s0923-7534(20)32799-x","title":"Meta-Analysis of HER3 Expression and Prognosis in Solid Tumors","year":2012,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Oncology; Expression (computer science); Solid tumor; Internal medicine; Cancer research; Pathology; Cancer; Programming language","score_opus":0.5046343515644572,"score_gpt":0.5479802251370528,"score_spread":0.04334587357259556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999808793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870487,0.006114467,0.0000063311463,0.003526081,0.000022983759,0.00028598218,0.000013128419,0.000005767036,0.0029765521],"genre_scores_gemma":[0.99831235,0.00041391738,0.00058755634,0.00038138192,0.000032076758,0.000074454765,0.0000056490617,0.000009091614,0.00018354687],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985864,0.00022731342,0.00045065465,0.0001574795,0.00027269148,0.00030546868],"domain_scores_gemma":[0.9990138,0.00027172858,0.00017128423,0.00020992347,0.00018410145,0.00014919757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013919825,0.00008618683,0.0012703108,0.00048327702,0.000010982506,0.0000015666405,0.000082481114,0.00011703277,0.0007141609],"category_scores_gemma":[0.0002372451,0.000063283725,0.00028926414,0.000576282,0.00015773445,0.00006211718,0.00008196589,0.00015520494,0.000003840159],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006981227,0.0027530722,0.8336287,0.0005152101,0.04859105,0.000069647125,0.00473025,0.000036191996,0.06999062,0.00013213484,0.0068186093,0.03203639],"study_design_scores_gemma":[0.001410093,0.004214283,0.5050117,0.000073135576,0.046634704,0.000029372715,0.00072215986,0.00015640334,0.42500266,0.00014750296,0.016391654,0.00020638309],"about_ca_topic_score_codex":0.00022010118,"about_ca_topic_score_gemma":0.00006179392,"teacher_disagreement_score":0.35501203,"about_ca_system_score_codex":0.000022875232,"about_ca_system_score_gemma":0.00012374784,"threshold_uncertainty_score":0.78195614},"labels":[],"label_agreement":null},{"id":"W3002686079","doi":"10.1080/07357907.2020.1720223","title":"Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry","year":2020,"lang":"en","type":"article","venue":"Cancer Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Essar Steel Algoma (Canada); Sault Area Hospital; NOSM University","funders":"","keywords":"Chromosome 17 (human); Breast cancer; Internal medicine; Biology; Immunohistochemistry; Chromosome; Medicine; Fluorescence in situ hybridization; Cancer; Pathology; Genetics; Gene","score_opus":0.026211123835748643,"score_gpt":0.3091500376235991,"score_spread":0.28293891378785047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3002686079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99188316,0.0010313526,0.000019083887,0.0055555827,0.000044680753,0.0006190012,0.0006053633,0.000021779919,0.0002200092],"genre_scores_gemma":[0.99837005,0.00022296299,0.00019131151,0.00044332715,0.00008799037,0.00020044929,0.00036091424,0.00003285646,0.00009012006],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99833506,0.000042782027,0.00048291823,0.00034475865,0.0005704624,0.00022401712],"domain_scores_gemma":[0.99868935,0.000025294383,0.00033255905,0.0002750218,0.00046949263,0.00020828359],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000101935926,0.00015099456,0.00033976737,0.00006508014,0.000025224339,0.0000073620704,0.00015115063,0.0001063284,0.0003325486],"category_scores_gemma":[0.00007994883,0.0001400255,0.000037153237,0.0006704499,0.0003126317,0.000112979935,0.00002907065,0.0002519921,0.000002779632],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006379005,0.00010186646,0.44129664,0.0009587744,0.00004766351,9.729423e-7,0.001086702,0.000095176096,0.54396355,0.000011229866,0.009108523,0.0026909867],"study_design_scores_gemma":[0.004128776,0.00029159008,0.6921998,0.0016906213,0.0000697863,0.0000017513927,0.000147427,0.00048303723,0.29969227,0.000025839707,0.0010497177,0.0002193645],"about_ca_topic_score_codex":0.002400914,"about_ca_topic_score_gemma":0.00002608338,"teacher_disagreement_score":0.2509032,"about_ca_system_score_codex":0.000622822,"about_ca_system_score_gemma":0.0008084618,"threshold_uncertainty_score":0.5710074},"labels":[],"label_agreement":null},{"id":"W3003660073","doi":"10.1016/j.amjcard.2020.01.029","title":"Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"The American Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Women's College Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Cardiotoxicity; Medicine; Metastatic breast cancer; Breast cancer; Internal medicine; Oncology; Cardiology; Cancer; Chemotherapy","score_opus":0.011490205173424318,"score_gpt":0.3000320926430055,"score_spread":0.2885418874695812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003660073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930738,0.0019854554,0.00005369608,0.0039423914,0.00008483651,0.0004165394,0.00014467536,0.000007481752,0.00029108],"genre_scores_gemma":[0.998607,0.00048906147,0.00009713967,0.0005293305,0.00022626422,0.000012090662,0.000004875249,0.000030100404,0.00000416749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777055,0.0008322902,0.0003778971,0.00021484791,0.00046226318,0.00034213127],"domain_scores_gemma":[0.99860793,0.00017569054,0.00029012427,0.00018125122,0.00047020227,0.00027476915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038424434,0.00018158274,0.0012882135,0.00011098171,0.00004915048,0.00001082305,0.00016583593,0.000033231325,0.000013156595],"category_scores_gemma":[0.000068199,0.000107225474,0.00018381285,0.00051066594,0.0007683225,0.00005615885,0.000056364282,0.0007442057,0.0000022631161],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050219228,0.000021573096,0.9381831,0.000043146854,0.0019745384,0.0002687216,0.0036090752,0.00093218096,0.00024153762,0.0000061585815,0.00027244914,0.04942559],"study_design_scores_gemma":[0.0022139053,0.004736755,0.9882279,0.000116859504,0.00052739115,0.00033278647,0.0033375719,0.000012741713,0.00006644814,0.0000065042173,0.00030218496,0.00011893684],"about_ca_topic_score_codex":0.00026085856,"about_ca_topic_score_gemma":0.0000059274844,"teacher_disagreement_score":0.05004481,"about_ca_system_score_codex":0.00032226538,"about_ca_system_score_gemma":0.00047164192,"threshold_uncertainty_score":0.43725282},"labels":[],"label_agreement":null},{"id":"W3005632677","doi":"10.1158/1538-7445.sabcs19-p3-08-52","title":"Abstract P3-08-52: Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Toxicity; Trastuzumab; Internal medicine; Oncology; Cancer; Antibody-drug conjugate; Breast cancer; Antibody; Immunology; Monoclonal antibody","score_opus":0.13632153337005212,"score_gpt":0.44626065717162655,"score_spread":0.3099391238015744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005632677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97086686,0.010622084,0.000019596078,0.014061363,0.00018502247,0.002162202,0.0012070527,0.0000903443,0.0007854591],"genre_scores_gemma":[0.99424165,0.0027319782,0.000081851314,0.00044658018,0.00054466235,0.0011160792,0.000017657216,0.00014038922,0.00067916507],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9924448,0.0010303581,0.0011054522,0.0009362603,0.0029887056,0.0014943881],"domain_scores_gemma":[0.9960474,0.0010484817,0.0001744154,0.0007686761,0.0011009848,0.0008600459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039544334,0.000388083,0.0011459275,0.00082887796,0.00013515208,0.00007189255,0.00072376407,0.00014446584,0.005113899],"category_scores_gemma":[0.0014536752,0.00034462838,0.00019069537,0.00257686,0.00085102674,0.00022609891,0.00025131847,0.0018847965,0.00012341522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06463379,0.0008336449,0.040917054,0.016973801,0.0006918339,0.0044617937,0.009556429,0.0013642509,0.8073823,0.000090378904,0.034859072,0.018235693],"study_design_scores_gemma":[0.026641823,0.010078587,0.676255,0.0343973,0.00033951545,0.0015020866,0.028374415,0.0053622085,0.19693868,0.00024522826,0.017671317,0.0021938402],"about_ca_topic_score_codex":0.0070902514,"about_ca_topic_score_gemma":0.0010309208,"teacher_disagreement_score":0.63533795,"about_ca_system_score_codex":0.0025030691,"about_ca_system_score_gemma":0.0077217575,"threshold_uncertainty_score":0.9999006},"labels":[],"label_agreement":null},{"id":"W3005905875","doi":"10.1158/1538-7445.sabcs19-p6-13-02","title":"Abstract P6-13-02: Subcutaneous trastuzumab for the treatment of HER2+ breast cancer in Canada: A cost-minimization study","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Roche (Canada)","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Metastatic breast cancer; Internal medicine; Health care; Clinical trial; Cancer; Drug; Intensive care medicine; Pharmacology","score_opus":0.16501558405181768,"score_gpt":0.4549794697304116,"score_spread":0.2899638856785939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3005905875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96570027,0.003919451,0.000014992237,0.020709664,0.00020034732,0.008162822,0.0010633968,0.000020881818,0.00020817317],"genre_scores_gemma":[0.98995405,0.0042845546,0.000010461087,0.00017985622,0.00050256384,0.004675283,0.000018038514,0.000072162446,0.00030303723],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99616474,0.00018676663,0.0005322314,0.0005983406,0.0016159121,0.0009020356],"domain_scores_gemma":[0.9973736,0.0008545158,0.000087661785,0.0004995863,0.0007817289,0.00040292545],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005559686,0.00023415107,0.00056523073,0.00016784038,0.0001703594,0.000036715646,0.0003965536,0.00007969145,0.0017384262],"category_scores_gemma":[0.00016723387,0.00016477816,0.00009586018,0.0011400804,0.00018584728,0.000054323456,0.00005659145,0.0005010345,0.0000072875177],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017816765,0.0028249891,0.2796374,0.0014605215,0.001031075,0.0012180434,0.020354547,0.0086976485,0.008473087,0.000015901653,0.021613969,0.636856],"study_design_scores_gemma":[0.017989863,0.010291244,0.8794374,0.00073532475,0.00027091685,0.00007776408,0.023530837,0.010391682,0.012492142,0.000019204805,0.0441312,0.00063241716],"about_ca_topic_score_codex":0.9223114,"about_ca_topic_score_gemma":0.9563795,"teacher_disagreement_score":0.6362236,"about_ca_system_score_codex":0.0076830843,"about_ca_system_score_gemma":0.014250693,"threshold_uncertainty_score":0.9991741},"labels":[],"label_agreement":null},{"id":"W3006656146","doi":"10.1186/s13058-020-1252-7","title":"HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates","year":2020,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; CRIS Cancer Foundation","keywords":"Trastuzumab; Trastuzumab emtansine; Antibody-drug conjugate; Medicine; Breast cancer; Surgical oncology; Drug resistance; Drug development; Drug; Cancer; Computational biology; Oncology; Pharmacology; Internal medicine; Antibody; Monoclonal antibody; Immunology; Biology","score_opus":0.1406654208036132,"score_gpt":0.5094523079334535,"score_spread":0.3687868871298403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006656146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00053894805,0.9797429,0.000005398026,0.010092002,0.00036026447,0.0048531634,0.001804244,0.00016369851,0.0024394146],"genre_scores_gemma":[0.00048616872,0.9909749,0.00027523236,0.0003917234,0.0024160533,0.0015077137,0.00014745892,0.00036929708,0.0034314704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98954207,0.0014359755,0.001126979,0.0024013822,0.0032855237,0.0022080706],"domain_scores_gemma":[0.993976,0.00067407236,0.00020317374,0.0017043863,0.001194615,0.002247733],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002895291,0.0009427505,0.0037160823,0.00095597154,0.00046638915,0.00038987448,0.0012173924,0.0005302414,0.0009003768],"category_scores_gemma":[0.00051793363,0.00078912626,0.0005269596,0.0032638907,0.00088037405,0.00014805839,0.0013987692,0.0034978718,0.0010239447],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005944754,0.00019946034,0.0020054965,0.08807478,0.00072270306,0.0014443394,0.00020926213,2.9384796e-7,0.00014138175,0.0001502491,0.08456407,0.8218935],"study_design_scores_gemma":[0.0006807122,0.00016134002,0.0014509611,0.0413678,0.0002551834,0.0005239502,0.00005117353,0.0000028787229,0.000088680004,0.000021360564,0.95475626,0.00063967705],"about_ca_topic_score_codex":0.0027850922,"about_ca_topic_score_gemma":0.0015401329,"teacher_disagreement_score":0.8701922,"about_ca_system_score_codex":0.0017560602,"about_ca_system_score_gemma":0.005773622,"threshold_uncertainty_score":0.99986273},"labels":[],"label_agreement":null},{"id":"W3007877035","doi":"10.1016/j.ygyno.2020.01.037","title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"ImmunoGen","keywords":"Medicine; Bevacizumab; Ovarian cancer; Adverse effect; Internal medicine; Gastroenterology; Combination therapy; Oncology; Pharmacology; Cancer; Chemotherapy","score_opus":0.029979538483348143,"score_gpt":0.36143151902576276,"score_spread":0.3314519805424146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007877035","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918165,0.00015416057,0.000026155298,0.0030615465,0.00016641161,0.004058216,0.00007830602,0.00006514177,0.0005735548],"genre_scores_gemma":[0.9975169,0.000049895905,0.0012554857,0.00051939284,0.000048577298,0.00032938152,0.00017771499,0.000058804722,0.000043899254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958949,0.00074717833,0.0010271345,0.0008395578,0.000713551,0.0007776493],"domain_scores_gemma":[0.99785256,0.0005237007,0.0005268204,0.00032944276,0.0005046332,0.00026281312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009810947,0.00037648078,0.0013186061,0.00036936277,0.00009191405,0.000019424784,0.00028950028,0.00025033584,0.0006162657],"category_scores_gemma":[0.0007343756,0.0002896686,0.000043103348,0.0013202943,0.00022761589,0.00016107707,0.00013667082,0.00090356247,0.000015400932],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03514999,0.02172833,0.90685475,0.0004126655,0.00029482986,0.000994665,0.009606511,0.00023990321,0.006972606,0.000057482823,0.0007617205,0.016926566],"study_design_scores_gemma":[0.18995503,0.13512728,0.6640524,0.00041092664,0.00020361766,0.000005538083,0.0045662774,0.0018435188,0.0009847786,0.000048353075,0.0021937948,0.0006084651],"about_ca_topic_score_codex":0.0019586347,"about_ca_topic_score_gemma":0.0077171503,"teacher_disagreement_score":0.24280229,"about_ca_system_score_codex":0.0012888138,"about_ca_system_score_gemma":0.0012752902,"threshold_uncertainty_score":0.99995553},"labels":[],"label_agreement":null},{"id":"W3008959887","doi":"10.1096/fj.201902649r","title":"Substrate‐selective protein ectodomain shedding by ADAM17 and iRhom2 depends on their juxtamembrane and transmembrane domains","year":2020,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Ectodomain; Disintegrin; Metalloproteinase; Epidermal growth factor; Cell biology; Transmembrane domain; Epidermal growth factor receptor; Mutant; Transmembrane protein; Biology; Chemistry; Receptor; Biochemistry; Matrix metalloproteinase; Gene","score_opus":0.029448935846276243,"score_gpt":0.2900757147255682,"score_spread":0.260626778879292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3008959887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786926,0.0018376105,0.00030135637,0.015732896,0.000042238567,0.00073795224,0.000043663247,0.00004379358,0.0025678966],"genre_scores_gemma":[0.9971703,0.000760441,0.00014957419,0.0011904535,0.00041220261,0.000026376792,0.0000058042747,0.000055890985,0.00022890014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977903,0.0003377909,0.00034658323,0.00035362272,0.00061792927,0.0005538215],"domain_scores_gemma":[0.99870557,0.0002662812,0.0001040951,0.00020056365,0.000083928106,0.0006395378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010537893,0.0002761773,0.00042656317,0.000096394484,0.00044217793,0.00015825607,0.00021907949,0.00011462617,0.000245237],"category_scores_gemma":[0.00016391787,0.00017072771,0.00009257883,0.0003185722,0.00028317075,0.00012488374,0.00004040529,0.0015635637,0.000013199488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024710956,0.000083667204,0.00093160185,0.00016496232,0.00019558292,0.0003466054,0.0031886513,0.0000140676175,0.97923934,0.00012438008,0.0012346283,0.012005421],"study_design_scores_gemma":[0.006202929,0.0029565012,0.004400449,0.00049127126,0.00011629769,0.0023631968,0.0018842494,0.00071483804,0.97766095,0.0005607727,0.0023168756,0.0003316543],"about_ca_topic_score_codex":0.00003554666,"about_ca_topic_score_gemma":0.000023511699,"teacher_disagreement_score":0.018477764,"about_ca_system_score_codex":0.00012426551,"about_ca_system_score_gemma":0.00026254397,"threshold_uncertainty_score":0.6962074},"labels":[],"label_agreement":null},{"id":"W3009135015","doi":"10.1158/1535-7163.targ-19-b001","title":"Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Capecitabine; Medicine; Trastuzumab; Internal medicine; Oncology; Cancer; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Metastatic breast cancer; Paclitaxel; Breast cancer; Phases of clinical research; Colorectal cancer","score_opus":0.0167205724280495,"score_gpt":0.3281169170133715,"score_spread":0.31139634458532195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009135015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935234,0.0033022806,0.000578951,0.0005156351,0.000045123597,0.0019136104,0.00003214387,0.000021299289,0.000067553374],"genre_scores_gemma":[0.99572366,0.0017781028,0.0017805246,0.00045978252,0.000011170532,0.00006936525,0.000038180013,0.00009689031,0.000042342723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976878,0.00011093715,0.0004686277,0.00053267257,0.00070926646,0.0004906807],"domain_scores_gemma":[0.9989749,0.00008524063,0.00021303286,0.00037195385,0.0002293824,0.00012549736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002572091,0.00032611424,0.00066106,0.0002680604,0.000035338497,0.00003264003,0.00012948374,0.00009280492,0.00013731573],"category_scores_gemma":[0.000009897345,0.00024259149,0.00003667815,0.0006208411,0.00022855174,0.00012527185,0.000033972126,0.0004278423,9.00432e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02440039,0.0011242292,0.7975185,0.00089321804,0.000373813,0.0001196158,0.0013127468,0.0021964845,0.053616807,0.000020951988,0.0000019619074,0.11842131],"study_design_scores_gemma":[0.031411406,0.0021754368,0.9472937,0.002064629,0.00007695855,0.000005086585,0.00015971086,0.0010618988,0.015101232,0.000013032929,0.00035527046,0.00028165974],"about_ca_topic_score_codex":0.0005420914,"about_ca_topic_score_gemma":0.00040767092,"teacher_disagreement_score":0.1497752,"about_ca_system_score_codex":0.00034436843,"about_ca_system_score_gemma":0.00046642162,"threshold_uncertainty_score":0.98925936},"labels":[],"label_agreement":null},{"id":"W3010753547","doi":"10.1177/1078155220910252","title":"Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Nodular regenerative hyperplasia; Internal medicine; Breast cancer; Oncology; Cirrhosis; Surgery; Gastroenterology; Cancer; Portal hypertension","score_opus":0.10711538175138427,"score_gpt":0.4658162816026355,"score_spread":0.3587008998512512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010753547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89172244,0.0017296227,0.0009281076,0.09518294,0.0008648166,0.00080053735,0.000028698427,0.00002563374,0.00871723],"genre_scores_gemma":[0.9824621,0.00080391706,0.009540509,0.0053463327,0.0016033544,0.000021559514,0.0000043527357,0.000062576786,0.00015531266],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99513495,0.0011082741,0.0019049193,0.00041521885,0.0009738932,0.0004627632],"domain_scores_gemma":[0.9932248,0.001586401,0.0018894785,0.00034634926,0.0021748936,0.000778056],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028154943,0.0003042719,0.0012060514,0.00024921494,0.00010951485,0.000023254064,0.00024130705,0.00018924747,0.000915779],"category_scores_gemma":[0.0075983712,0.00025631688,0.0003437122,0.000652873,0.00019665045,0.0007751638,0.000098936136,0.0023093333,0.000032552463],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031873878,0.0015084152,0.00089254143,0.00023016158,0.0014194322,0.8321664,0.0046757925,0.000044689667,0.09526591,0.000015048674,0.01252921,0.019378535],"study_design_scores_gemma":[0.010201372,0.005808093,0.00024456155,0.000114725124,0.0014161719,0.6324582,0.0025934686,0.0002951207,0.04153271,0.0000052994037,0.30515838,0.00017188083],"about_ca_topic_score_codex":0.00009420445,"about_ca_topic_score_gemma":0.00002350037,"teacher_disagreement_score":0.29262918,"about_ca_system_score_codex":0.0011293415,"about_ca_system_score_gemma":0.006324484,"threshold_uncertainty_score":0.9999975},"labels":[],"label_agreement":null},{"id":"W3010907432","doi":"10.1200/jco.2013.31.15_suppl.518","title":"A phase Ib study of an anti-HER2 inhibitor, lapatinib, in combination with a c-MET and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198.","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care South East; McGill University; Royal Victoria Hospital; Queen's University; Cancer Care Ontario; Interior Health; BC Cancer Agency","funders":"","keywords":"Lapatinib; Medicine; Internal medicine; Metastatic breast cancer; Tyrosine-kinase inhibitor; Oncology; Pharmacokinetics; Phases of clinical research; Regimen; Breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Pharmacology; Gastroenterology; Toxicity; Trastuzumab","score_opus":0.10205888868964136,"score_gpt":0.4980479330769425,"score_spread":0.39598904438730115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010907432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940856,0.00018743615,0.000009452377,0.00346638,0.00036269292,0.0015819487,0.000121949175,0.000007762606,0.00017679622],"genre_scores_gemma":[0.99708897,0.00022352657,0.0016205239,0.00043794245,0.00046837513,0.00007770178,0.00002099011,0.00004079276,0.000021157519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99210995,0.0022075868,0.003725071,0.0005046369,0.0010158648,0.00043686843],"domain_scores_gemma":[0.9929798,0.0030059647,0.0020569456,0.00032739888,0.0010927897,0.0005370576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005235115,0.00027261509,0.002304665,0.00056444167,0.000037348527,0.000030251664,0.00024075933,0.000345943,0.00013468755],"category_scores_gemma":[0.0025708426,0.00019866017,0.00012695069,0.0006797326,0.00046260693,0.00043816652,0.000108353066,0.0019977305,0.0000047098433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04321798,0.07078044,0.6013108,0.00014951236,0.00068430055,0.0025067946,0.009542464,0.00005889409,0.0020588213,0.000014590878,0.0008279284,0.2688475],"study_design_scores_gemma":[0.10815804,0.09759741,0.7859658,0.0012756424,0.00025713682,0.00018123085,0.004784813,0.0006595572,0.00047934236,0.0002607138,0.00018737839,0.00019290668],"about_ca_topic_score_codex":0.00911182,"about_ca_topic_score_gemma":0.009576298,"teacher_disagreement_score":0.26865458,"about_ca_system_score_codex":0.00046226426,"about_ca_system_score_gemma":0.0019953593,"threshold_uncertainty_score":0.9974866},"labels":[],"label_agreement":null},{"id":"W3012129470","doi":"10.1158/1538-7445.sabcs19-ot1-07-01","title":"Abstract OT1-07-01: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Lapatinib; Antibody-drug conjugate; Phases of clinical research; Cancer; Breast cancer; Antibody; Clinical trial; Immunology; Monoclonal antibody","score_opus":0.08177458749404355,"score_gpt":0.4152758576420249,"score_spread":0.33350127014798137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012129470","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95901906,0.010102485,0.00013958437,0.013704883,0.00017314948,0.014941326,0.00096267887,0.00020818,0.00074864493],"genre_scores_gemma":[0.9779148,0.011929146,0.0005450649,0.0006111107,0.00090781535,0.0066070515,0.00012978236,0.00037712976,0.0009780618],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9859886,0.0026097442,0.0017709978,0.0026775412,0.003638732,0.0033143917],"domain_scores_gemma":[0.9913041,0.0033147684,0.0004623315,0.0009913356,0.0014139992,0.0025134697],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054121944,0.0012487264,0.003821257,0.001171023,0.00056544284,0.0005634276,0.0007987932,0.00041995005,0.0037605267],"category_scores_gemma":[0.0026375833,0.00094966835,0.0003123417,0.003218833,0.0024917193,0.000700537,0.00038401227,0.0036989702,0.000049844657],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.92763984,0.0018307397,0.0011895071,0.0037191396,0.00118456,0.0031786968,0.0066753756,0.00008331627,0.009810969,0.000023354345,0.0030631134,0.0416014],"study_design_scores_gemma":[0.9517777,0.015022817,0.009037315,0.007918765,0.0008975428,0.0013315425,0.0029166723,0.0024652854,0.0053075543,0.000098233235,0.0016939102,0.0015326709],"about_ca_topic_score_codex":0.027676718,"about_ca_topic_score_gemma":0.016268367,"teacher_disagreement_score":0.040068727,"about_ca_system_score_codex":0.0028213863,"about_ca_system_score_gemma":0.009834454,"threshold_uncertainty_score":0.9992954},"labels":[],"label_agreement":null},{"id":"W3012233653","doi":"10.1200/jco.2012.30.15_suppl.634","title":"Evaluation of Ile655Val HER2 polymorphism associated with cardiac toxicity following the administration of trastuzumab in women with breast cancer.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Centre hospitalier universitaire de Québec","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Metastatic breast cancer; Population; Internal medicine; Oncology; Toxicity; Genotyping; Genotype; Cancer; Gastroenterology; Biology; Genetics","score_opus":0.18276055988397144,"score_gpt":0.5201602895009736,"score_spread":0.33739972961700215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012233653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938302,0.0005040312,0.000015575024,0.0039432626,0.00043649002,0.0004113216,0.000015492695,0.0000027901092,0.00084082625],"genre_scores_gemma":[0.99895954,0.00011113762,0.00012908278,0.00018052915,0.0005504743,0.000027774637,0.0000014216508,0.000015920054,0.000024106845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941299,0.0019434283,0.0016108524,0.00012313855,0.0018534604,0.0003392173],"domain_scores_gemma":[0.9950123,0.0017195651,0.0016471598,0.00018025933,0.0011800601,0.00026066718],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024742626,0.000114286995,0.0012558283,0.000110925066,0.000028520546,0.0000041348308,0.00015230927,0.00025056873,0.00015719206],"category_scores_gemma":[0.003097875,0.00006345381,0.00019988946,0.00037013312,0.00027048137,0.00015933844,0.000021956826,0.0008829816,6.69574e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022274042,0.0035555225,0.79230654,0.000045225803,0.0019236155,0.000063731444,0.0017681275,0.00014829448,0.0015611382,0.000014483779,0.00034175583,0.17599753],"study_design_scores_gemma":[0.0071050003,0.012970622,0.976688,0.00042846912,0.0007782034,0.00008990827,0.0009271065,0.000120183,0.00061405543,0.000030993673,0.00018221149,0.000065201624],"about_ca_topic_score_codex":0.00017998593,"about_ca_topic_score_gemma":0.00043918553,"teacher_disagreement_score":0.1843815,"about_ca_system_score_codex":0.0014548835,"about_ca_system_score_gemma":0.009502772,"threshold_uncertainty_score":0.9961124},"labels":[],"label_agreement":null},{"id":"W3013826160","doi":"10.1101/2020.03.24.006379","title":"Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Lapatinib; Cancer research; Trastuzumab; Breast cancer; Pertuzumab; Gene silencing; Cancer; Medicine; Downregulation and upregulation; Receptor tyrosine kinase; Tyrosine kinase; Biology; Internal medicine; Receptor; Gene","score_opus":0.021497249528566527,"score_gpt":0.28597440801122803,"score_spread":0.2644771584826615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013826160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845899,0.00271808,0.00013881628,0.008922432,0.0003909059,0.0024931736,0.0005192703,0.00021387835,0.000013550511],"genre_scores_gemma":[0.9929942,0.00037219163,0.004145123,0.00062953733,0.0006100263,0.0009775835,6.0776046e-7,0.00023582684,0.00003492978],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953319,0.00023925265,0.0010034344,0.001447525,0.0010910942,0.0008868375],"domain_scores_gemma":[0.99644613,0.00006376794,0.0003311277,0.0015268661,0.0009029103,0.000729222],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006635258,0.00063454447,0.0011777479,0.00073222746,0.00008963499,0.00009011551,0.0006508119,0.00035757606,0.0002895405],"category_scores_gemma":[0.00030263368,0.0006883663,0.00017333824,0.0019462607,0.00013160885,0.00008253604,0.00054495333,0.0010038587,0.000071550414],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089200144,0.0001370689,0.10975551,0.0027303873,0.00012256046,0.00014436422,0.00015890818,0.0006018322,0.88498414,0.000033467564,0.0004317117,0.0000080566815],"study_design_scores_gemma":[0.0006546558,0.000068421345,0.67033154,0.0029157996,0.00004439906,3.621537e-8,0.000009000145,0.000044102573,0.3243961,0.0000013629241,0.0010960029,0.0004386085],"about_ca_topic_score_codex":0.0007439594,"about_ca_topic_score_gemma":0.00026322913,"teacher_disagreement_score":0.56058806,"about_ca_system_score_codex":0.0014829669,"about_ca_system_score_gemma":0.0017353155,"threshold_uncertainty_score":0.9995568},"labels":[],"label_agreement":null},{"id":"W3014809226","doi":"10.1007/s10549-020-05614-5","title":"Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Institute for Clinical Evaluative Sciences; Sunnybrook Hospital; Canadian Centre for Applied Research in Cancer Control; Health Sciences Centre; Sunnybrook Health Science Centre; St. Michael's Hospital; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research","keywords":"Pertuzumab; Medicine; Trastuzumab; Cohort; Internal medicine; Metastatic breast cancer; Population; Breast cancer; Trastuzumab emtansine; Oncology; Randomized controlled trial; Cohort study; Cancer","score_opus":0.23654628794184537,"score_gpt":0.5262910221048149,"score_spread":0.28974473416296953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014809226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894399,0.00049296126,0.0000033767287,0.006042637,0.00006589036,0.0032066985,0.0006861306,0.000018152614,0.000044270815],"genre_scores_gemma":[0.99787825,0.0008733249,0.0001403824,0.00009867099,0.00007770619,0.00077678834,0.00006477954,0.00004562715,0.000044439417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958377,0.00048928004,0.0009849294,0.0005993797,0.0015182723,0.00057045417],"domain_scores_gemma":[0.9976381,0.00070000696,0.00025339605,0.00036361217,0.0005907527,0.0004541534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072675035,0.0002892644,0.0015753609,0.00028638373,0.00007876298,0.00002738102,0.00016337188,0.00008705129,0.0003391065],"category_scores_gemma":[0.00012362708,0.00018027265,0.00016612995,0.0006997158,0.00032297548,0.00008173849,0.000053161122,0.00038332614,0.0000024673184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042126257,0.0047186036,0.9048035,0.00018991577,0.0008422684,0.000018573746,0.0002920482,0.0000491038,0.000023881157,0.0000051171955,0.00005707064,0.046873674],"study_design_scores_gemma":[0.06546339,0.005598538,0.9276864,0.0003432572,0.00009338939,0.000002104573,0.00010712795,0.00029362366,0.00023090822,0.000005191551,0.00004415414,0.00013193044],"about_ca_topic_score_codex":0.035562612,"about_ca_topic_score_gemma":0.0039383937,"teacher_disagreement_score":0.046741743,"about_ca_system_score_codex":0.00059279613,"about_ca_system_score_gemma":0.0013642071,"threshold_uncertainty_score":0.97085965},"labels":[],"label_agreement":null},{"id":"W3018446798","doi":"10.1007/s00432-020-03220-y","title":"Afatinib is active in osteosarcoma in osteosarcoma cell lines","year":2020,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Afatinib; Osteosarcoma; Cancer research; Viability assay; Medicine; ErbB; Cell culture; Motility; Oncology; Internal medicine; Biology; Cancer; Cell biology; Gefitinib","score_opus":0.34528108718722733,"score_gpt":0.6026386473651789,"score_spread":0.2573575601779516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3018446798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86404914,0.0046339794,0.000003025006,0.1266401,0.00021455628,0.00054373,0.000015104299,0.0000054322454,0.0038949247],"genre_scores_gemma":[0.9739324,0.019701697,0.00047354016,0.0038113308,0.0016352003,0.00003984114,0.0000016655456,0.000033230423,0.0003710834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99447113,0.0012742536,0.0017443255,0.00044485417,0.0012408259,0.0008246134],"domain_scores_gemma":[0.99394053,0.0034002142,0.00036155514,0.00021960436,0.0009445199,0.0011335488],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004970819,0.0001758048,0.001251754,0.0005006925,0.00005246667,0.000031764816,0.0004268945,0.00043017828,0.0008114646],"category_scores_gemma":[0.0031664008,0.00013743677,0.00020182539,0.001074465,0.0007162105,0.00015649748,0.00029911016,0.004686978,0.00003446364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02339193,0.0019501058,0.56523657,0.00037818978,0.00013879138,0.004504711,0.0020202158,0.0000037426612,0.003488064,0.000034710836,0.019024309,0.37982866],"study_design_scores_gemma":[0.037114173,0.06967332,0.53563344,0.0011662608,0.00008243592,0.00023745652,0.004873856,0.00052965514,0.011620964,0.0014401856,0.33725396,0.00037427925],"about_ca_topic_score_codex":0.0006264167,"about_ca_topic_score_gemma":0.0019143986,"teacher_disagreement_score":0.37945437,"about_ca_system_score_codex":0.0006703282,"about_ca_system_score_gemma":0.0047898646,"threshold_uncertainty_score":0.99760926},"labels":[],"label_agreement":null},{"id":"W3020654673","doi":"10.1093/jnci/djaa054","title":"Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Queen's University; McMaster University; Ottawa Hospital; University of Ottawa","funders":"Ontario Ministry of Health and Long-Term Care","keywords":"Medicine; Trastuzumab; Hazard ratio; Internal medicine; Breast cancer; Cardiotoxicity; Discontinuation; Population; Confidence interval; Retrospective cohort study; Cancer; Oncology; Surgery; Chemotherapy","score_opus":0.09539194288725586,"score_gpt":0.39898250008616615,"score_spread":0.30359055719891026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020654673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932808,0.00013676667,0.00000488642,0.005394964,0.0004749297,0.00047158243,0.00012505206,0.000002463867,0.00010851041],"genre_scores_gemma":[0.9989673,0.000008494246,0.00003706364,0.0005743416,0.0003421069,0.000023858214,0.0000029473747,0.000013691027,0.00003018356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969872,0.000093321294,0.0007424,0.00015987344,0.0017918256,0.00022537088],"domain_scores_gemma":[0.998571,0.00006968493,0.00039111022,0.00009710422,0.00070036476,0.00017076868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045416507,0.00014163718,0.0004354091,0.00025127636,0.000047928064,0.000015574757,0.00031515496,0.000048599923,0.0002707728],"category_scores_gemma":[0.00024927704,0.00010131573,0.00014932417,0.00080387294,0.000036882007,0.00019684891,0.000035285175,0.00081507646,2.8372855e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0009180155,0.00017286067,0.90068895,0.000038659713,0.00011878563,0.000052076095,0.0008177491,0.09558749,0.00024010778,0.0000057322563,0.0007149216,0.00064467057],"study_design_scores_gemma":[0.0035187302,0.00028052865,0.9944702,0.00047429066,0.000034817298,0.00002433975,0.000057677287,0.0007155152,0.000048974845,0.000013457474,0.0002752249,0.00008626907],"about_ca_topic_score_codex":0.98661166,"about_ca_topic_score_gemma":0.9950032,"teacher_disagreement_score":0.094871975,"about_ca_system_score_codex":0.01447635,"about_ca_system_score_gemma":0.035651095,"threshold_uncertainty_score":0.9893069},"labels":[],"label_agreement":null},{"id":"W3020879346","doi":"10.1016/j.humpath.2009.10.006","title":"HER-2 amplification is highly homogenous in gastric cancer","year":2009,"lang":"en","type":"letter","venue":"Human Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Cancer; Medicine; Pathology; Internal medicine","score_opus":0.08778048155360492,"score_gpt":0.3900565801647532,"score_spread":0.3022760986111483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020879346","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.080635406,0.006455039,0.000057207533,0.89726925,0.0007035896,0.002012902,0.00021777666,0.00021045776,0.012438384],"genre_scores_gemma":[0.028968323,0.0015126795,0.00038623638,0.9369136,0.0072663273,0.00072095,0.0009987612,0.00019654045,0.023036553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99666876,0.00028246842,0.00058537105,0.0009286521,0.0005726988,0.0009620272],"domain_scores_gemma":[0.99835527,0.000064744636,0.00019795462,0.0010872397,0.00018702226,0.00010777703],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00036735056,0.00038259893,0.000833824,0.0009087585,0.0000966133,0.000027991251,0.000399529,0.0013402936,0.0020400835],"category_scores_gemma":[0.00004910615,0.00038194493,0.00014746196,0.0004848289,0.00022917124,0.00003179121,0.00006887247,0.003333863,0.00052904576],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027610637,0.0001038497,0.0042746733,0.0003193014,0.00002595828,0.008799617,0.0005068104,8.854847e-7,0.0032815938,0.000021251546,0.97012305,0.012515388],"study_design_scores_gemma":[0.0010825287,0.0006954242,0.04904708,0.00029821118,0.000084812855,0.0008299706,0.000014616034,0.0000028926324,0.00026128668,0.0005421251,0.94678926,0.00035178356],"about_ca_topic_score_codex":0.0007643897,"about_ca_topic_score_gemma":0.0002052059,"teacher_disagreement_score":0.051667087,"about_ca_system_score_codex":0.00096030894,"about_ca_system_score_gemma":0.0005163034,"threshold_uncertainty_score":0.9999562},"labels":[],"label_agreement":null},{"id":"W3021570777","doi":"10.1158/1078-0432.ccr-20-0152","title":"NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute","keywords":"Breast cancer; Oncology; Trastuzumab; Medicine; Internal medicine; Estrogen receptor; Proportional hazards model; Cancer; Biology; Cancer research","score_opus":0.49011177305954695,"score_gpt":0.5634234850545039,"score_spread":0.07331171199495695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021570777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9257446,0.010221117,0.000046668156,0.05778149,0.00020266349,0.0050689285,0.00010915534,0.00016974872,0.00065565633],"genre_scores_gemma":[0.9869486,0.0054548006,0.0003251998,0.0039586136,0.0009909401,0.0011504219,0.000025839343,0.000098313314,0.001047279],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9843787,0.009875239,0.0011618313,0.0011922529,0.0022603506,0.0011316446],"domain_scores_gemma":[0.9774397,0.01920848,0.00021445254,0.0006644411,0.0011726809,0.0013002465],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.024061235,0.00032318535,0.0019803713,0.00023447847,0.0002965376,0.00013699052,0.00048383753,0.0004789707,0.00086407026],"category_scores_gemma":[0.0443049,0.00021144607,0.00033471352,0.0012156793,0.0030693866,0.0000748284,0.00045199544,0.0032222252,0.00007442014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.96652067,0.0003099462,0.0031164004,0.00013088815,0.0003374583,0.001305395,0.00034820844,0.000009791777,0.0027897656,0.00005580522,0.012035609,0.013040071],"study_design_scores_gemma":[0.9239476,0.015264655,0.015470735,0.0007400778,0.00023263096,0.000025466905,0.00031546966,0.0020767949,0.0005428323,0.00037398294,0.040540896,0.00046891536],"about_ca_topic_score_codex":0.00024621165,"about_ca_topic_score_gemma":0.00010860631,"teacher_disagreement_score":0.061204024,"about_ca_system_score_codex":0.00027465686,"about_ca_system_score_gemma":0.0021795405,"threshold_uncertainty_score":0.9996437},"labels":[],"label_agreement":null},{"id":"W3023558472","doi":"10.1093/annonc/mdw364.65","title":"Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PrefHer study","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Trastuzumab; Population; Cohort; Adverse effect; Breast cancer; Internal medicine; Confidence interval; Surgery; Cancer","score_opus":0.056440000735117485,"score_gpt":0.40708711098821365,"score_spread":0.35064711025309614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023558472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924942,0.0012616327,0.00003151047,0.0018524863,0.00005797395,0.003348785,0.0005937747,0.000005840388,0.00035377828],"genre_scores_gemma":[0.9958184,0.0036636232,0.000032925385,0.000094101735,0.000059386286,0.00016998885,0.000005127881,0.000025452462,0.0001309878],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973943,0.0004691808,0.00089856354,0.00040270263,0.00047612915,0.00035910134],"domain_scores_gemma":[0.9966567,0.0014751252,0.0005408846,0.00041427978,0.0007779525,0.00013504495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012046171,0.00021411237,0.0016410858,0.0002334283,0.000055282355,0.0000036361112,0.00021376989,0.00013790949,0.000180041],"category_scores_gemma":[0.00018834759,0.00012480117,0.00026957833,0.00042880632,0.00081811537,0.000040490802,0.00006761321,0.00015826373,2.7978376e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18897976,0.0046286364,0.17460178,0.00019235282,0.011420479,0.000047206293,0.006744603,0.000042567557,0.022750013,0.000052443265,0.0002214242,0.59031874],"study_design_scores_gemma":[0.04996477,0.03164463,0.8967075,0.00029803975,0.0020728565,0.00013038819,0.0004571327,0.000033239598,0.017983424,0.00005871274,0.0005006799,0.00014864586],"about_ca_topic_score_codex":0.0022608733,"about_ca_topic_score_gemma":0.0006446513,"teacher_disagreement_score":0.7221057,"about_ca_system_score_codex":0.00010132963,"about_ca_system_score_gemma":0.0007835255,"threshold_uncertainty_score":0.5089244},"labels":[],"label_agreement":null},{"id":"W3027663151","doi":"10.1016/j.annonc.2020.05.012","title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Sunnybrook Hospital","funders":"National Cancer Institute; National Institutes of Health; Puma Biotechnology; American Society of Clinical Oncology","keywords":"Medicine; Neratinib; Tolerability; Oncology; Breast cancer; Internal medicine; Stage (stratigraphy); Metastatic breast cancer; Cancer; Trastuzumab; Adverse effect","score_opus":0.07013071804840221,"score_gpt":0.40395035431116005,"score_spread":0.33381963626275785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027663151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9615331,0.00006806348,0.000012234798,0.035180498,0.000076415796,0.0019243605,0.00034957274,0.000007699162,0.0008479995],"genre_scores_gemma":[0.9967229,0.000033887078,0.0000353872,0.002864599,0.00016712298,0.00012642294,0.00000900104,0.000014635955,0.000026062065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99822503,0.0003997225,0.00049063796,0.00025825735,0.00033210142,0.00029426618],"domain_scores_gemma":[0.9983855,0.00035236048,0.00023490677,0.0002521075,0.0006333676,0.00014179236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005853677,0.00012032465,0.0006733725,0.000042763684,0.000025648158,0.0000046519613,0.00017002001,0.00011975833,0.0003388728],"category_scores_gemma":[0.0002849328,0.00007605879,0.00008226469,0.00025630288,0.00035336846,0.000048102487,0.000048006044,0.00038418928,0.000001994674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28002214,0.0019564424,0.65993404,0.00019077724,0.0002893461,0.000021950305,0.0027920709,0.000052686995,0.0014020615,0.000061816245,0.0013775313,0.051899146],"study_design_scores_gemma":[0.0907827,0.034140013,0.8695524,0.000082650025,0.000046486926,0.0000012565248,0.00018578376,0.00033605006,0.002982181,0.000013075557,0.0017745066,0.00010289456],"about_ca_topic_score_codex":0.0038080295,"about_ca_topic_score_gemma":0.00071789854,"teacher_disagreement_score":0.20961837,"about_ca_system_score_codex":0.00008012859,"about_ca_system_score_gemma":0.000932429,"threshold_uncertainty_score":0.5756627},"labels":[],"label_agreement":null},{"id":"W3032274390","doi":"10.1200/jco.2020.38.15_suppl.e13079","title":"A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Infectious Diseases Centre","funders":"","keywords":"Medicine; Eribulin; Cyclophosphamide; Internal medicine; Docetaxel; Breast cancer; Toxicity; Metastatic breast cancer; Cancer; Gastroenterology; Oncology; Surgery; Chemotherapy","score_opus":0.11389035408599417,"score_gpt":0.517889981634441,"score_spread":0.4039996275484468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032274390","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899889,0.00015539334,0.000022198536,0.008306071,0.00025506155,0.00082936336,0.000024362187,0.000008789097,0.00040983272],"genre_scores_gemma":[0.99631375,0.0002570788,0.0009305868,0.0019175082,0.00047001892,0.000027475035,0.0000020860418,0.000038868115,0.00004260515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995057,0.0006647087,0.0025190865,0.0003161407,0.0010610005,0.0003820704],"domain_scores_gemma":[0.9953471,0.0008814865,0.0016703416,0.00025882912,0.001101999,0.0007402883],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001987647,0.00020629942,0.0020942965,0.00013640184,0.00004747527,0.000005243821,0.0003108189,0.000213635,0.00029993913],"category_scores_gemma":[0.0016852067,0.00012857375,0.00015045282,0.00060490373,0.00029994655,0.00013821226,0.00011098134,0.002297613,0.0000054100915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10446409,0.026388139,0.67635614,0.00009894875,0.00042056473,0.0010994674,0.0014312812,0.00026791063,0.0000764968,0.000001905443,0.00088871893,0.18850634],"study_design_scores_gemma":[0.10477135,0.29062638,0.59619194,0.0004264707,0.00023131118,0.00006856672,0.0010960747,0.00005528825,0.00006813688,0.0000064139736,0.0063326233,0.00012547689],"about_ca_topic_score_codex":0.00023631287,"about_ca_topic_score_gemma":0.00066587643,"teacher_disagreement_score":0.26423824,"about_ca_system_score_codex":0.00034297918,"about_ca_system_score_gemma":0.0035798233,"threshold_uncertainty_score":0.9982113},"labels":[],"label_agreement":null},{"id":"W3032425473","doi":"10.1186/s12964-020-00575-0","title":"CAMKK2-CAMK4 signaling regulates transferrin trafficking, turnover, and iron homeostasis","year":2020,"lang":"en","type":"article","venue":"Cell Communication and Signaling","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Boniface Hospital","funders":"School of Medicine, Indiana University","keywords":"Cell biology; Transferrin receptor; HEK 293 cells; Biology; Receptor; Downregulation and upregulation; Ferroportin; Chemistry; Biochemistry; Metabolism; Gene; Iron homeostasis","score_opus":0.0528266430946191,"score_gpt":0.3033934389698981,"score_spread":0.250566795875279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032425473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96727514,0.025273949,0.00036812847,0.004488452,0.000018746076,0.00039713882,0.0000075863486,0.00010704686,0.0020638104],"genre_scores_gemma":[0.99340737,0.0037237443,0.0017761163,0.0008205075,0.00006556882,0.000016226844,0.00004417886,0.000039465027,0.00010681718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986002,0.00018811475,0.00033939697,0.00031669592,0.00029158682,0.00026399817],"domain_scores_gemma":[0.99884856,0.000257966,0.000063996216,0.00040894916,0.00009236617,0.00032816245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004812172,0.00017716084,0.00031216885,0.00008649777,0.0002581086,0.00009740462,0.00020545474,0.000118292905,0.00025969808],"category_scores_gemma":[0.000072423805,0.00017320129,0.000060354367,0.00023501461,0.00017623117,0.00009600995,0.00010048027,0.0005046517,0.000009937836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006609303,0.00024562737,0.0074841557,0.0022240346,0.000116760864,0.000036506557,0.03349639,0.0007711176,0.8749119,0.00051526714,0.0015743317,0.077962995],"study_design_scores_gemma":[0.008628214,0.0012754278,0.0025502688,0.0015396615,0.00044115118,0.00008720891,0.011972085,0.039577518,0.8881371,0.00036411828,0.0442453,0.0011819476],"about_ca_topic_score_codex":0.00006586296,"about_ca_topic_score_gemma":0.000012419186,"teacher_disagreement_score":0.07678105,"about_ca_system_score_codex":0.000048874957,"about_ca_system_score_gemma":0.00008196838,"threshold_uncertainty_score":0.70629436},"labels":[],"label_agreement":null},{"id":"W3034998325","doi":"10.1158/1535-7163.mct-19-0993","title":"Patient Selection Strategies to Maximize Therapeutic Index of Antibody–Drug Conjugates: Prior Approaches and Future Directions","year":2020,"lang":"en","type":"review","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Clinical trial; Selection (genetic algorithm); Antibody-drug conjugate; Drug development; Medicine; Biomarker; Drug; Expression (computer science); Computational biology; Computer science; Pharmacology; Antibody; Machine learning; Internal medicine; Monoclonal antibody; Biology; Immunology","score_opus":0.0828555232670809,"score_gpt":0.3865256745269056,"score_spread":0.3036701512598247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3034998325","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017952784,0.9934795,0.0011051374,0.0013766563,0.00032891464,0.0028943745,0.00011338656,0.00009731727,0.0004252222],"genre_scores_gemma":[0.0016316441,0.99571395,0.0005537888,0.0007702654,0.00039319228,0.00060773356,0.00005858252,0.00019929564,0.00007156464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99677134,0.00037061019,0.0007604543,0.00081279455,0.0007743058,0.00051052484],"domain_scores_gemma":[0.9984877,0.00007794551,0.00034197315,0.000528299,0.00026604964,0.00029803163],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020504463,0.00066124526,0.0019070011,0.0003666331,0.00012481761,0.00010671406,0.00024451967,0.00039422556,0.000092395756],"category_scores_gemma":[0.000008944893,0.00054094364,0.00042660002,0.0012801673,0.0001911858,0.000062567255,0.0001240752,0.0010308217,0.00000875759],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001339931,0.0001227655,0.000056366982,0.011709534,0.0017530086,0.000030035204,0.0012299201,0.000012673314,0.00037095882,0.0002051809,0.0000349546,0.9843406],"study_design_scores_gemma":[0.00046812135,0.00048399175,0.00005052098,0.0038602368,0.0020605724,0.00008012027,0.0005480475,0.00013383647,0.00039087268,0.00007070772,0.99139583,0.00045714335],"about_ca_topic_score_codex":0.00016089198,"about_ca_topic_score_gemma":0.000044888042,"teacher_disagreement_score":0.9913609,"about_ca_system_score_codex":0.00044630747,"about_ca_system_score_gemma":0.002146882,"threshold_uncertainty_score":0.9997042},"labels":[],"label_agreement":null},{"id":"W3036172594","doi":"10.1016/bs.acr.2020.04.004","title":"In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches","year":2020,"lang":"en","type":"review","venue":"Advances in cancer research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Breast cancer; In vivo; Cancer research; Epidermal growth factor receptor; Medicine; Metastasis; Cancer; Human Epidermal Growth Factor Receptor 2; Oncology; Biology; Internal medicine; Genetics","score_opus":0.3671908909486335,"score_gpt":0.5569368107235614,"score_spread":0.18974591977492788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036172594","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00048288208,0.9912247,0.0000034837678,0.0025516795,0.00020262957,0.003873126,0.0001332595,0.000012988018,0.0015152218],"genre_scores_gemma":[0.010330858,0.9849787,0.00007479552,0.00008791563,0.00028219985,0.003998439,0.0000036896404,0.00012057148,0.00012284143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934793,0.0011888199,0.0011173781,0.001134604,0.0019549076,0.0011249953],"domain_scores_gemma":[0.9981257,0.00050760765,0.00020370711,0.00075719756,0.00020071323,0.00020510201],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0023950257,0.00047710608,0.0020509586,0.000982182,0.00008182555,0.00003811065,0.0009255048,0.0004077419,0.00012588294],"category_scores_gemma":[0.00014425862,0.00031084983,0.000192903,0.0040726042,0.00071643677,0.00022222652,0.0006978965,0.0037363202,0.0000033782571],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029803746,0.00016534294,0.0045700516,0.033487324,0.0000438326,0.00007333207,0.0004983966,0.00053688965,0.000025277539,0.00012589169,0.000066291504,0.96010935],"study_design_scores_gemma":[0.001642709,0.00016636525,0.00028139944,0.108764,0.000075226926,0.000045031178,0.0005012336,0.008521919,0.000039613016,0.00042955973,0.87910104,0.00043188556],"about_ca_topic_score_codex":0.0037835166,"about_ca_topic_score_gemma":0.0036134261,"teacher_disagreement_score":0.95967746,"about_ca_system_score_codex":0.0019221607,"about_ca_system_score_gemma":0.004149706,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W3036364287","doi":"10.1074/jbc.ra119.010925","title":"The guanine nucleotide exchange factor VAV3 participates in ERBB4-mediated cancer cell migration","year":2020,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Turun Yliopistollinen Keskussairaala; Academy of Finland","keywords":"Guanine nucleotide exchange factor; ERBB4; ERBB3; Receptor tyrosine kinase; Epidermal growth factor receptor; Cell biology; Cancer research; Biology; ErbB; Signal transduction; Epidermal growth factor; Tyrosine phosphorylation; Tyrosine kinase; Receptor; Biochemistry","score_opus":0.12745283606116675,"score_gpt":0.3662935132493659,"score_spread":0.23884067718819912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3036364287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767402,0.0049208426,0.000005488677,0.01761768,0.000057853584,0.000114703675,0.00001980234,0.000013196177,0.00051027664],"genre_scores_gemma":[0.9930196,0.0052764486,0.000053469696,0.0006829708,0.00080915884,0.000013899543,0.000006959033,0.000010283435,0.00012724847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986962,0.00006123425,0.00047514142,0.00015013383,0.0003171823,0.0003000746],"domain_scores_gemma":[0.99896723,0.00025304453,0.00020656161,0.00010645406,0.00016533263,0.00030140474],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031481124,0.000121076555,0.0002974312,0.000010447906,0.000041075145,0.00002304683,0.00020212903,0.00014851835,0.0018413048],"category_scores_gemma":[0.0010264415,0.0000642016,0.00010496474,0.00018694201,0.0001070831,0.00004096056,0.00005488327,0.00057758094,0.000014352702],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054274267,0.000107912434,0.07328499,0.00013874097,0.000028815599,0.00014082603,0.0003194891,0.000007994586,0.91803443,3.4219403e-7,0.0053642713,0.0020294634],"study_design_scores_gemma":[0.001921599,0.0008462739,0.05842398,0.00017436601,0.000030002388,0.000030532505,0.00069445453,0.00065040897,0.86909145,0.000023711535,0.06794319,0.00017000956],"about_ca_topic_score_codex":0.000055578625,"about_ca_topic_score_gemma":0.000026145943,"teacher_disagreement_score":0.06257892,"about_ca_system_score_codex":0.00019175174,"about_ca_system_score_gemma":0.00016489356,"threshold_uncertainty_score":0.9990711},"labels":[],"label_agreement":null},{"id":"W3037008990","doi":"10.1371/journal.pone.0234991","title":"Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines","year":2020,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval; Centre hospitalier de l'Université Laval","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research","keywords":"Trastuzumab; Medicine; Breast cancer; Immunohistochemistry; Oncology; Cancer research; Internal medicine; Biomarker; Cancer; Cell growth; Biology; Genetics","score_opus":0.06255074206964746,"score_gpt":0.314305918201733,"score_spread":0.25175517613208553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037008990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864973,0.0005971765,0.000010864277,0.00757004,0.000052153435,0.0012681525,0.00005321277,0.000082773025,0.0038683284],"genre_scores_gemma":[0.9965337,0.00053481234,0.0004234509,0.0012593239,0.0005149216,0.00024407185,0.000016413906,0.00005987169,0.00041344098],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980278,0.00011093268,0.0002526701,0.00043217774,0.0008039465,0.00037245898],"domain_scores_gemma":[0.9990672,0.00021643267,0.00006344776,0.00022305519,0.0001485376,0.00028134932],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00014824535,0.00019746996,0.0004287799,0.000067702305,0.000042421023,0.000020895477,0.0001257045,0.000120937235,0.0009947635],"category_scores_gemma":[0.00023522378,0.00018167836,0.000054530687,0.00042191177,0.000045241333,0.0000889401,0.000044073884,0.00051868364,0.00025431882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013739094,0.019618487,0.3230427,0.015078227,0.001358672,0.0012979221,0.020017693,0.0005957758,0.51220953,0.000092409406,0.0076522226,0.08529727],"study_design_scores_gemma":[0.0048609152,0.001660243,0.17808454,0.0022178038,0.00015273556,0.0000038079968,0.00026546788,0.0049519725,0.80727893,0.00004593676,0.00016827043,0.00030938676],"about_ca_topic_score_codex":0.0031580848,"about_ca_topic_score_gemma":0.0015039957,"teacher_disagreement_score":0.2950694,"about_ca_system_score_codex":0.0006123351,"about_ca_system_score_gemma":0.00027226697,"threshold_uncertainty_score":0.99991846},"labels":[],"label_agreement":null},{"id":"W3037873371","doi":"10.1001/jamaoncol.2020.1796","title":"Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer","year":2020,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Capecitabine; Medicine; Metastatic breast cancer; Trastuzumab emtansine; Internal medicine; Trastuzumab; Oncology; Phases of clinical research; Breast cancer; Cancer; Gastroenterology; Chemotherapy","score_opus":0.019962352137295275,"score_gpt":0.31567226766944956,"score_spread":0.2957099155321543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037873371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.976393,0.00080430525,0.00013056574,0.018006684,0.000071432914,0.0031326425,0.00062936515,0.00006430553,0.0007677307],"genre_scores_gemma":[0.99639094,0.0005926936,0.00088032836,0.0013284737,0.0001713966,0.00016013208,0.0002610987,0.00010176206,0.0001131734],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961264,0.00047616241,0.0009826928,0.0008417552,0.0007511175,0.0008218833],"domain_scores_gemma":[0.997464,0.00065154635,0.0003153099,0.00037579058,0.0006153281,0.0005780063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038127328,0.00047855603,0.0018430821,0.00028588687,0.000077606106,0.000021623693,0.00021454626,0.0002473359,0.00067594467],"category_scores_gemma":[0.00038842633,0.00037951165,0.00009172335,0.0012499149,0.00053699047,0.00017890136,0.00011295895,0.00079636154,0.000014466671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2847766,0.009736181,0.35574818,0.0036019057,0.0031813455,0.0044986173,0.023660978,0.0007460331,0.0042304303,0.000100291894,0.005845745,0.30387372],"study_design_scores_gemma":[0.06494399,0.016027534,0.9139944,0.0009316159,0.0006164306,0.00019106014,0.00039416552,0.0006532123,0.0005233336,0.000005931086,0.0013503291,0.00036804576],"about_ca_topic_score_codex":0.0022298105,"about_ca_topic_score_gemma":0.0031778095,"teacher_disagreement_score":0.5582462,"about_ca_system_score_codex":0.00209347,"about_ca_system_score_gemma":0.0022096252,"threshold_uncertainty_score":0.99986565},"labels":[],"label_agreement":null},{"id":"W3041329672","doi":"10.1007/s10637-020-00958-7","title":"Subcellular distribution and mechanism of action of AL906, a novel and potent EGFR inhibitor rationally designed to be green fluorescent","year":2020,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"Canadian Institutes of Health Research","keywords":"Moiety; EGFR inhibitors; Quinazoline; Gefitinib; Chemistry; Transfection; Small molecule; Potency; Mechanism of action; Epidermal growth factor receptor; Penetration (warfare); Biophysics; Biochemistry; Phosphorylation; In vitro; Receptor; Biology; Stereochemistry","score_opus":0.0797261951099458,"score_gpt":0.30861932225513944,"score_spread":0.22889312714519364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041329672","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90940917,0.00012598097,0.021754079,0.06762002,0.000053788728,0.00076751894,0.00020616545,0.00002288584,0.00004039595],"genre_scores_gemma":[0.98863536,0.000024045958,0.009114805,0.0015711521,0.00022688574,0.000019857289,0.0002941419,0.000015882137,0.00009785253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841756,0.00004321957,0.00035780724,0.000273022,0.00076486217,0.00014352708],"domain_scores_gemma":[0.9988815,0.00008946591,0.00011130743,0.000106921114,0.00030323144,0.00050757476],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025341037,0.00012070332,0.00022767001,0.00007323685,0.00004710565,0.000012864791,0.000061352504,0.00007964174,0.00003770391],"category_scores_gemma":[0.00038285973,0.00011937233,0.00003848311,0.00026531875,0.00014511209,0.000092419825,0.0000723112,0.00012784702,0.000003393691],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002987695,0.000062572035,0.0013308531,0.00030160078,0.000046002868,0.0000033334459,0.0012012067,0.00004288273,0.9711321,0.020738415,0.0026789245,0.002163344],"study_design_scores_gemma":[0.0025388726,0.0009466962,0.01666018,0.00026485077,0.00007685968,0.000023359624,0.00025784085,0.004973786,0.9673684,0.004234887,0.0024776198,0.00017661219],"about_ca_topic_score_codex":0.00038496358,"about_ca_topic_score_gemma":0.000015192864,"teacher_disagreement_score":0.07922621,"about_ca_system_score_codex":0.00011154182,"about_ca_system_score_gemma":0.0006933131,"threshold_uncertainty_score":0.48678622},"labels":[],"label_agreement":null},{"id":"W3042132061","doi":"10.1016/s1470-2045(20)30326-0","title":"Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial","year":2020,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McMaster University; Juravinski Cancer Centre","funders":"Merck Sharp and Dohme; MacroGenics","keywords":"Pembrolizumab; Gastro-; Medicine; Internal medicine; Adenocarcinoma; Gastroenterology; Oncology; Cancer; Immunotherapy; Reflux; Disease","score_opus":0.07346060626970793,"score_gpt":0.3594422757535952,"score_spread":0.28598166948388726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3042132061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769991,0.00053653505,0.00006382979,0.012143461,0.00021645924,0.0041780164,0.00012946573,0.00013281836,0.0056003183],"genre_scores_gemma":[0.9930853,0.000051967752,0.00047252176,0.003780975,0.0017152183,0.00039788953,0.00017629845,0.00009237432,0.00022744623],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9956459,0.0010057763,0.000615057,0.0007450034,0.0007401691,0.0012481364],"domain_scores_gemma":[0.9980675,0.0003759349,0.00024081094,0.0006503909,0.00021786329,0.00044751723],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00065237185,0.00040947212,0.0014898216,0.00014746664,0.00012007915,0.000041833144,0.0005511676,0.0002588271,0.00043463844],"category_scores_gemma":[0.00032276163,0.0002764652,0.00013733245,0.0006356877,0.00042437523,0.00010511181,0.0002087242,0.0012231936,0.0001366548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84753036,0.011064887,0.09510067,0.00034819785,0.00041325204,0.0034193718,0.0062986156,0.000031680785,0.0002798356,0.00009564063,0.015508526,0.019908983],"study_design_scores_gemma":[0.7851749,0.13840075,0.060500804,0.00026999175,0.00038698787,0.00021227692,0.00037908315,0.000628896,0.00070396625,0.000046665285,0.012842107,0.00045357685],"about_ca_topic_score_codex":0.0003152516,"about_ca_topic_score_gemma":0.0001745089,"teacher_disagreement_score":0.12733586,"about_ca_system_score_codex":0.0016427606,"about_ca_system_score_gemma":0.0010900233,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W3044214090","doi":"10.1016/j.clon.2020.07.006","title":"Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK","year":2020,"lang":"en","type":"editorial","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Daiichi Sankyo Company; National Institute on Handicapped Research; Merck Sharp and Dohme; Health Technology Assessment Programme; Eisai; AstraZeneca France; Daiichi-Sankyo; National Institute for Health and Care Research; Puma Biotechnology; Les Laboratories Pierre Fabre; Genomic Health; Elsevier Foundation; Sanofi; Novartis; Celgene; Roche; Oncolytics Biotech; Cancer Research UK; Intas Pharmaceuticals; Department for Culture, Heritage and the Gaeltacht, Ireland; Amgen; Novartis Pharmaceuticals Corporation; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Neratinib; Breast cancer; Internal medicine; Adjuvant therapy; Adjuvant; Cancer; Surgery; Oncology","score_opus":0.12727869513434384,"score_gpt":0.5247389173070323,"score_spread":0.3974602221726884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044214090","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.070902705,0.0021809696,0.000024226054,0.09703597,0.82180476,0.0032138217,0.00046942054,0.00003211889,0.0043360107],"genre_scores_gemma":[0.32650447,0.0031122144,0.00010913254,0.0012309577,0.6684028,0.00029013527,0.000089898786,0.00005669942,0.0002037188],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99415976,0.0017481985,0.0019017075,0.0005622985,0.0011393667,0.0004886742],"domain_scores_gemma":[0.98734444,0.011090707,0.00052386924,0.00054977403,0.00034978666,0.0001414348],"candidate_categories":["research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.006019677,0.00022668639,0.001386247,0.00013333674,0.00004368731,0.000021232236,0.0007312664,0.0015188764,0.00031511593],"category_scores_gemma":[0.00796966,0.00012883368,0.00024869008,0.0005917713,0.00065381837,0.000033782933,0.00017765339,0.0052141626,0.0000285377],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026144902,0.00052423024,0.020382084,0.00019207913,0.000090623565,0.00039305573,0.0015075308,0.000026000489,0.00002572052,0.000019072357,0.90622705,0.06799808],"study_design_scores_gemma":[0.0055741584,0.004036556,0.27473894,0.00085320516,0.00019899762,0.000024437128,0.0005222066,0.0002541067,0.000006764548,0.000088097324,0.71350944,0.00019307394],"about_ca_topic_score_codex":0.0031737513,"about_ca_topic_score_gemma":0.005067379,"teacher_disagreement_score":0.25560176,"about_ca_system_score_codex":0.00094260875,"about_ca_system_score_gemma":0.0072483635,"threshold_uncertainty_score":0.9997774},"labels":[],"label_agreement":null},{"id":"W3044478606","doi":"10.1016/s2055-6640(20)31142-0","title":"Selection of the R263K and H51Y resistance substitutions for DTG causes diminished integration and explains the lack of clinically significant drug resistance to this compound","year":2016,"lang":"en","type":"article","venue":"Journal of Virus Eradication","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Drug; Selection (genetic algorithm); Drug resistance; Resistance (ecology); Pharmacology; Computational biology; Medicine; Biology; Computer science; Genetics; Artificial intelligence; Ecology","score_opus":0.09224462931416175,"score_gpt":0.4000524584154449,"score_spread":0.3078078291012831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3044478606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519934,0.0006315069,0.009231021,0.03662608,0.00017406842,0.00094224204,0.000054339504,0.000007273504,0.00034006435],"genre_scores_gemma":[0.9945931,0.0012486966,0.0031577821,0.00020472275,0.00012743371,0.000027522434,0.0000012888712,0.000010669456,0.0006287797],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983188,0.00018985468,0.00079721585,0.00014431133,0.0004305634,0.00011924645],"domain_scores_gemma":[0.9973194,0.0009301233,0.0007075377,0.00023955134,0.00071089814,0.00009250974],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017736136,0.00008643588,0.00025877295,0.000105750965,0.00015965762,0.000019140778,0.0001529304,0.000058273505,0.000022221657],"category_scores_gemma":[0.0019222547,0.000043264627,0.00006780542,0.00025610527,0.00037668546,0.00012372568,0.000019947094,0.0001909169,6.4622424e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039721583,0.00027514782,0.022285141,0.00030501382,0.00015166464,0.000001714758,0.003330238,0.000005286387,0.9177638,0.0073959846,0.04043225,0.0040815617],"study_design_scores_gemma":[0.005591018,0.0015910945,0.35126418,0.004639566,0.0005740566,0.0000784421,0.0013163689,0.0001877744,0.5503453,0.005723189,0.078381844,0.0003071593],"about_ca_topic_score_codex":0.00002796666,"about_ca_topic_score_gemma":0.0006389537,"teacher_disagreement_score":0.36741853,"about_ca_system_score_codex":0.000154897,"about_ca_system_score_gemma":0.00038222154,"threshold_uncertainty_score":0.23012573},"labels":[],"label_agreement":null},{"id":"W3046257387","doi":"10.1016/j.clon.2020.07.013","title":"Effectiveness of Trastuzumab in Routine Clinical Practice: A Population-based Study of Patients with HER-2-positive Oesophageal, Gastroesophageal and Gastric Cancer","year":2020,"lang":"en","type":"article","venue":"Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"Queen's University","keywords":"Medicine; Trastuzumab; Internal medicine; Cancer; Population; Cohort; Clinical trial; Oncology; Gastroenterology; Breast cancer","score_opus":0.07581011858358351,"score_gpt":0.48774804402756294,"score_spread":0.41193792544397945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046257387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99626786,0.00016362805,0.000109046414,0.00076299394,0.00013208835,0.0024090891,0.000055864584,0.000015676425,0.00008377196],"genre_scores_gemma":[0.9978723,0.000031887554,0.0012212595,0.00051460264,0.00016927415,0.000112398004,0.000042581254,0.000032711312,0.000002998166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932243,0.0034295153,0.0017529331,0.000670438,0.00058865035,0.00033412845],"domain_scores_gemma":[0.9888825,0.009135491,0.00069062447,0.0002714962,0.000619359,0.0004005688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032037753,0.00020440752,0.0016516787,0.00012815071,0.000030016205,0.0000048882985,0.00014920124,0.00027338497,0.00006682701],"category_scores_gemma":[0.0063707354,0.00016081813,0.00011617181,0.00063055893,0.00033265192,0.00007897084,0.00010092323,0.0010453967,0.0000023782954],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027628224,0.011289675,0.9440976,0.0003249171,0.0002470188,0.0002434947,0.00021133584,0.00010372574,0.0000071131067,0.00000531766,0.000030980525,0.015810605],"study_design_scores_gemma":[0.029118374,0.06913202,0.90052855,0.00021610432,0.0003070732,0.0000024818971,0.00021370918,0.00035411108,0.000020668625,0.00000422281,0.00002031671,0.00008237575],"about_ca_topic_score_codex":0.0005890098,"about_ca_topic_score_gemma":0.00013748158,"teacher_disagreement_score":0.05784235,"about_ca_system_score_codex":0.00030089502,"about_ca_system_score_gemma":0.0013500989,"threshold_uncertainty_score":0.76268256},"labels":[],"label_agreement":null},{"id":"W3052318948","doi":"10.1016/j.ijpharm.2020.119786","title":"The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT","year":2020,"lang":"en","type":"article","venue":"International Journal of Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"Canadian Cancer Society; University Health Network","keywords":"Trastuzumab; Biodistribution; Chemistry; High-performance liquid chromatography; Chromatography; Medicine; Cancer; Breast cancer; Biochemistry; In vitro; Internal medicine","score_opus":0.04466126435502655,"score_gpt":0.42241515929937823,"score_spread":0.3777538949443517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3052318948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721067,0.006582913,0.00013933291,0.020136354,0.00026015812,0.00029589687,0.00026693268,0.00002185865,0.00018984202],"genre_scores_gemma":[0.99584156,0.0022638044,0.0002208518,0.0010731558,0.00049033284,0.0000074861173,0.000014224748,0.00003498749,0.000053576336],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971282,0.00014907787,0.0007931407,0.0002621261,0.0013501408,0.00031730172],"domain_scores_gemma":[0.99805105,0.00031952505,0.0002003342,0.00013486012,0.0008084774,0.0004857373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087041955,0.0002203454,0.0003929806,0.00008436112,0.00007643217,0.000121983474,0.00046894702,0.000047438087,0.0003450998],"category_scores_gemma":[0.0002294765,0.00015970576,0.00018604881,0.0001577011,0.00036314531,0.00017797037,0.00021792165,0.0011831576,0.000002343103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023860743,0.00031716056,0.12508422,0.00011330251,0.00041373953,0.0012543567,0.00023582255,8.81167e-7,0.8483023,0.000010279562,0.011869287,0.010012543],"study_design_scores_gemma":[0.001575608,0.0002180649,0.0026038422,0.00013917562,0.00021058485,0.0015771416,0.00014038046,0.0027098192,0.90750295,0.000011165799,0.08315313,0.00015815815],"about_ca_topic_score_codex":0.0000038796597,"about_ca_topic_score_gemma":0.0000012582279,"teacher_disagreement_score":0.12248038,"about_ca_system_score_codex":0.00060510525,"about_ca_system_score_gemma":0.00028235928,"threshold_uncertainty_score":0.65126115},"labels":[],"label_agreement":null},{"id":"W30545388","doi":"10.1186/s13058-018-1080-1","title":"統合教育現場における聴覚障害児の「当事者性」の涵養 : ろう者モデルの提示をめぐる関係者の語りの分析(IV-1部会 【テーマ部会】ニューカマーと近接領域,研究発表IV,一般研究報告)","year":2009,"lang":"ja","type":"article","venue":"日本教育社会学会大会発表要旨集録","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine, Dalhousie University; Canadian Institutes of Health Research; Breast Cancer Society of Canada; Beatrice Hunter Cancer Research Institute","keywords":"Computer science","score_opus":0.06410206263565742,"score_gpt":0.41650894046566245,"score_spread":0.352406877830005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W30545388","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3032194,0.064208955,0.0013342429,0.09613692,0.012864099,0.010458083,0.0010792925,0.0028909396,0.5078081],"genre_scores_gemma":[0.88657767,0.005944982,0.0010925035,0.010946603,0.008599006,0.00022923674,0.0002820092,0.0005234347,0.08580458],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9816667,0.0010430083,0.0030206174,0.003578061,0.0050290097,0.005662649],"domain_scores_gemma":[0.9884765,0.00095212285,0.00079007,0.005037929,0.0012679201,0.0034754244],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0036938174,0.002348206,0.0031834545,0.0015319736,0.0011472694,0.0007169041,0.002857665,0.001927029,0.01724218],"category_scores_gemma":[0.0022613665,0.0023562398,0.0014213054,0.0035216229,0.0013169105,0.00086036325,0.000783207,0.0050936965,0.022719972],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035992162,0.005071429,0.008534492,0.0019013732,0.001418285,0.007385477,0.0076755984,0.00012530354,0.043094885,0.0053252834,0.54796624,0.3679024],"study_design_scores_gemma":[0.01391115,0.008287216,0.048175972,0.0042704316,0.0013623927,0.0010226727,0.002836939,0.0029887026,0.018232526,0.0025017904,0.89226323,0.004146988],"about_ca_topic_score_codex":0.0008098756,"about_ca_topic_score_gemma":0.00016154394,"teacher_disagreement_score":0.5833582,"about_ca_system_score_codex":0.002396172,"about_ca_system_score_gemma":0.0029478432,"threshold_uncertainty_score":0.99936867},"labels":[],"label_agreement":null},{"id":"W3080952862","doi":"10.1634/theoncologist.2020-0379","title":"Therapeutic Potential of Afatinib in<i>NRG1</i>Fusion-Driven Solid Tumors: A Case Series","year":2020,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; William Osler Health System; University of Toronto","funders":"National Cancer Institute","keywords":"Afatinib; Series (stratigraphy); Fusion; Computer science; Computational biology; Cancer research; Medicine; Biology; Internal medicine; Cancer","score_opus":0.08401261259245403,"score_gpt":0.391276329499115,"score_spread":0.307263716906661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080952862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9519199,0.00052038283,0.00009977168,0.039873514,0.0001396433,0.0009874549,0.000028941338,0.00007121366,0.006359145],"genre_scores_gemma":[0.9969335,0.00016979185,0.00036102536,0.0018720522,0.00030877005,0.00006200618,0.0000058028745,0.00002455803,0.0002624911],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984466,0.0002324352,0.00038345854,0.0002392306,0.00036836314,0.00032993944],"domain_scores_gemma":[0.99911684,0.00016545098,0.00011411992,0.00035724207,0.00010639364,0.00013995357],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004458724,0.00013820852,0.00042133665,0.000052380994,0.00008671461,0.000016365697,0.0002668863,0.000089249865,0.0005554445],"category_scores_gemma":[0.0003233141,0.00008910133,0.00009292184,0.00038964103,0.00058588164,0.00004907972,0.00019950945,0.00046815723,0.00006678515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017837463,0.0030437242,0.07944156,0.0030361416,0.00076995045,0.110645846,0.039773356,0.0028915694,0.5688971,0.0033831298,0.034145743,0.13613437],"study_design_scores_gemma":[0.05617683,0.07729437,0.16912164,0.004069704,0.0020136335,0.08738582,0.10249637,0.059682783,0.23536924,0.008606142,0.19376612,0.0040173647],"about_ca_topic_score_codex":0.00053608435,"about_ca_topic_score_gemma":0.0003204407,"teacher_disagreement_score":0.3335279,"about_ca_system_score_codex":0.00013321832,"about_ca_system_score_gemma":0.00050208525,"threshold_uncertainty_score":0.6081728},"labels":[],"label_agreement":null},{"id":"W3081708016","doi":"10.1101/2020.08.28.273029","title":"Ontogeny and Vulnerabilities of Drug-Tolerant Persisters in HER2+ Breast Cancer","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Institutes of Health; University of Toronto","keywords":"Biology; Transcriptome; Cancer research; Breast cancer; Population; Cancer; Genetics; Medicine; Gene; Gene expression","score_opus":0.030010849726923413,"score_gpt":0.28534996269393487,"score_spread":0.25533911296701145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081708016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876659,0.0051068496,0.000019276737,0.004662347,0.00048721547,0.0011840144,0.00072050694,0.00012000646,0.000033905846],"genre_scores_gemma":[0.99655664,0.0013534438,0.0007921913,0.00039354654,0.00040724798,0.0003453441,3.3616368e-7,0.00013675365,0.000014498394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657077,0.0002175224,0.0007226674,0.0011083616,0.00074756495,0.00063309347],"domain_scores_gemma":[0.9976106,0.000085947664,0.00025253525,0.0010223745,0.0005225711,0.00050596026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074043183,0.00051337184,0.0011499812,0.00037260007,0.0000627929,0.000073699965,0.00037679385,0.0003826905,0.00023300402],"category_scores_gemma":[0.00018600789,0.0005263731,0.00018268763,0.0005330308,0.0004242772,0.00008553227,0.00054498465,0.0013620323,0.000010753031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007751287,0.00042212155,0.56952715,0.013867071,0.00058342004,0.00040362446,0.0007272741,0.00010980962,0.41199806,0.00023151188,0.0013123017,0.000042528052],"study_design_scores_gemma":[0.0022746439,0.00013379709,0.92550707,0.004831648,0.0002419207,2.1420222e-7,0.00014484097,0.0008800585,0.062614225,0.0000030226504,0.0025287059,0.0008398284],"about_ca_topic_score_codex":0.003865225,"about_ca_topic_score_gemma":0.00015137799,"teacher_disagreement_score":0.35597992,"about_ca_system_score_codex":0.0008968301,"about_ca_system_score_gemma":0.0022108178,"threshold_uncertainty_score":0.9997188},"labels":[],"label_agreement":null},{"id":"W3081807968","doi":"10.3310/hta24400","title":"Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT","year":2020,"lang":"en","type":"article","venue":"Health Technology Assessment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"National Institute for Health and Care Research; Cancer Research UK; Eli Lilly and Company; AstraZeneca; National Cancer Research Institute; Daiichi Sankyo Europe; Health Technology Assessment Programme; Genentech; Servier; Pfizer; Eisai; Cancer Research Institute","keywords":"Trastuzumab; Medicine; Breast cancer; Clinical endpoint; Internal medicine; Randomized controlled trial; Oncology; Metastatic breast cancer; Adjuvant; Cancer; Surgery","score_opus":0.025793146387843965,"score_gpt":0.37273332795000214,"score_spread":0.34694018156215817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081807968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8482097,0.00041171515,0.000140365,0.14724123,0.00023626292,0.0029503258,0.00018263808,0.00017687939,0.0004509238],"genre_scores_gemma":[0.99617434,0.0003978679,0.0006512181,0.0019221547,0.000100821635,0.0006494609,0.00003124734,0.000054230648,0.00001863864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968278,0.0001674235,0.000504751,0.00068966276,0.0008422602,0.0009681127],"domain_scores_gemma":[0.99851036,0.00009889852,0.00019943413,0.00058966497,0.00024472486,0.00035692507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041723554,0.0003173923,0.00072491175,0.00022996156,0.00025430712,0.000022284228,0.00036362893,0.00026850053,0.00016044303],"category_scores_gemma":[0.000044275133,0.00022537977,0.00006323211,0.001035132,0.00040672216,0.00008834496,0.00018872897,0.0018605341,0.000030203688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003246557,0.00069371786,0.9274959,0.00023776204,0.00016633891,0.00009334595,0.0015466635,0.000019363204,0.0000459606,0.0001607196,0.0011077805,0.0651859],"study_design_scores_gemma":[0.008789921,0.0070246365,0.97975147,0.00035366713,0.000038860642,0.000009938109,0.0020171767,0.00032519168,0.00007757741,0.00000778436,0.0014034364,0.00020035794],"about_ca_topic_score_codex":0.005775564,"about_ca_topic_score_gemma":0.0027110982,"teacher_disagreement_score":0.1479647,"about_ca_system_score_codex":0.0026588968,"about_ca_system_score_gemma":0.0028594555,"threshold_uncertainty_score":0.91907203},"labels":[],"label_agreement":null},{"id":"W3083872932","doi":"10.1002/cncr.33149","title":"Higher serum PD‐L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial","year":2020,"lang":"en","type":"article","venue":"Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Queen's University","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Hazard ratio; Oncology; Proportional hazards model; Biomarker; Population; Cancer; Breast cancer; Gastroenterology; Confidence interval","score_opus":0.24914493463437037,"score_gpt":0.4245487594532483,"score_spread":0.17540382481887795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083872932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719728,0.0004654048,0.000026461646,0.013668696,0.0009851088,0.0020201104,0.00048748156,0.000084256855,0.0102896495],"genre_scores_gemma":[0.9930363,0.00010924076,0.00007617352,0.0025529324,0.002624538,0.0005308575,0.00006970072,0.00006360758,0.0009366228],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99716216,0.00024795826,0.00035417516,0.0005114335,0.0011279316,0.0005963395],"domain_scores_gemma":[0.9986522,0.00031880784,0.000089271285,0.00045096842,0.00012762452,0.00036112138],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049611833,0.0002701347,0.00049047143,0.000072474075,0.000074859374,0.0000504625,0.00036064538,0.00013853693,0.002119071],"category_scores_gemma":[0.0002479283,0.0001790906,0.000092971975,0.0005464848,0.0001610337,0.00010825929,0.000059634975,0.0007479924,0.000055172008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7855492,0.0017817097,0.016625162,0.00074908836,0.0007003658,0.0013511679,0.0068757464,0.00012266281,0.0027402022,0.00039558025,0.15998825,0.023120843],"study_design_scores_gemma":[0.6206767,0.012452702,0.081259005,0.00046359887,0.00032775188,0.000011033243,0.00074083643,0.0009051949,0.0016385005,0.000029609899,0.2808785,0.0006165867],"about_ca_topic_score_codex":0.001625113,"about_ca_topic_score_gemma":0.000668324,"teacher_disagreement_score":0.16487254,"about_ca_system_score_codex":0.0005215192,"about_ca_system_score_gemma":0.0017183624,"threshold_uncertainty_score":0.9987931},"labels":[],"label_agreement":null},{"id":"W3083874242","doi":"10.3389/fgene.2020.01016","title":"Pathway-Based Drug Response Prediction Using Similarity Identification in Gene Expression","year":2020,"lang":"en","type":"article","venue":"Frontiers in Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Princess Margaret Cancer Centre; Institute of Cancer Research; Ontario Institute for Cancer Research; University of Toronto","funders":"Ontario Institute for Cancer Research; Canadian Institutes of Health Research; Government of Ontario; Cancer Research Society; Genome Canada","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Logistic regression; Concordance; Univariate; Internal medicine; Cancer; Computational biology; Machine learning; Biology; Multivariate statistics; Computer science","score_opus":0.059988346184270326,"score_gpt":0.3287130958285926,"score_spread":0.26872474964432225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083874242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94419926,0.001239975,0.051322833,0.0018714526,0.0005246725,0.0007087641,0.000053507094,0.000047019053,0.000032486656],"genre_scores_gemma":[0.93738174,0.00015035288,0.06171604,0.00040177332,0.0001716361,0.000037224065,0.00005216373,0.000038213315,0.00005087967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785995,0.00039071668,0.0004638745,0.0004274371,0.0005483689,0.00030966676],"domain_scores_gemma":[0.99920106,0.00004585152,0.00008246818,0.00038466568,0.000093582596,0.0001923823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009284549,0.00013783919,0.00024766443,0.0002940194,0.00005000222,0.000026757723,0.00016205834,0.00015644747,0.000025506048],"category_scores_gemma":[0.0004607713,0.00015177391,0.00004967873,0.00062614825,0.00008136092,0.000054567023,0.000060437982,0.00041733778,0.0000056145013],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023865132,0.00013410946,0.46586877,0.00017309189,0.0000074193435,0.00008212086,0.0012860926,0.011375571,0.50847226,4.1942045e-7,0.0066820323,0.0035315703],"study_design_scores_gemma":[0.0020268448,0.0001545451,0.12639059,0.00020675476,0.000017009032,0.0000025805768,0.00039349266,0.3170338,0.54988766,0.00006306812,0.0036748308,0.00014880935],"about_ca_topic_score_codex":0.000025391897,"about_ca_topic_score_gemma":0.000007838973,"teacher_disagreement_score":0.3394782,"about_ca_system_score_codex":0.00055046636,"about_ca_system_score_gemma":0.0006068176,"threshold_uncertainty_score":0.6189161},"labels":[],"label_agreement":null},{"id":"W3084151679","doi":"10.1101/2020.09.09.290122","title":"Structural and dynamic characterization of the C-terminal tail of ErbB2: disordered but not random","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"French Infrastructure for Integrated Structural Biology; Centre National de la Recherche Scientifique; Université Paris-Sud; Agence Nationale de la Recherche","keywords":"Small-angle X-ray scattering; Protein kinase domain; Receptor tyrosine kinase; Signal transducing adaptor protein; Biophysics; Signal transduction; Protein tertiary structure; Intrinsically disordered proteins; Tyrosine kinase; Tyrosine; Protein structure; Biology; Chemistry; Cell biology; Biochemistry; Mutant; Physics; Scattering","score_opus":0.02044600539116284,"score_gpt":0.2665999173037357,"score_spread":0.24615391191257288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084151679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99570453,0.00030445395,0.00020758664,0.0011353866,0.0005178622,0.0013979418,0.00066747074,0.00006118818,0.0000035768626],"genre_scores_gemma":[0.99878174,0.00032726617,0.00042851703,0.00011128237,0.00016755248,0.00008416994,0.0000017579866,0.00008740537,0.000010280849],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99747527,0.00018695263,0.000677173,0.00063400506,0.0006931519,0.00033343912],"domain_scores_gemma":[0.99764055,0.00006873068,0.0005786464,0.0010006716,0.0005073529,0.00020405973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036453851,0.00036521695,0.0008658295,0.00015764397,0.00007728947,0.000046179153,0.0004343173,0.00034191858,0.000060705137],"category_scores_gemma":[0.00045636698,0.00029503417,0.0001730232,0.0004064226,0.0003838199,0.000068185655,0.00062808703,0.00082171924,0.0000033555427],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053006713,0.000037506994,0.01854223,0.0025521806,0.00013543064,0.000022913307,0.000037876318,0.0000029923958,0.97805864,0.000050858,0.000009543035,0.00001975099],"study_design_scores_gemma":[0.0019668362,0.000097701886,0.60801476,0.00092072575,0.00018059966,1.1488256e-7,0.0000045083148,0.002341222,0.38606486,0.000001641253,0.0001701323,0.0002369272],"about_ca_topic_score_codex":0.00008223924,"about_ca_topic_score_gemma":0.000003600554,"teacher_disagreement_score":0.5919938,"about_ca_system_score_codex":0.00016288635,"about_ca_system_score_gemma":0.0010176991,"threshold_uncertainty_score":0.9999502},"labels":[],"label_agreement":null},{"id":"W3084860251","doi":"10.1017/s1460396920000746","title":"A review of clinical and emerging biomarkers for breast cancers: towards precision medicine for patients","year":2020,"lang":"en","type":"review","venue":"Journal of Radiotherapy in Practice","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Guelph; Grand River Hospital; University of Waterloo","funders":"","keywords":"Medicine; Breast cancer; Malignancy; Disease; Precision medicine; Oncology; Cancer; Internal medicine; Intensive care medicine; Pathology","score_opus":0.154204515137662,"score_gpt":0.5709382007861928,"score_spread":0.41673368564853086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3084860251","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000002757162,0.9847135,0.00061810855,0.009827663,0.0008916694,0.003713103,0.00011086633,0.000004183163,0.00011813821],"genre_scores_gemma":[0.0000011403193,0.9781328,0.018400645,0.0016297591,0.0016093275,0.000102310936,0.00001484165,0.00008974804,0.000019462279],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397796,0.0009027713,0.003637407,0.00038476774,0.0008032194,0.00029389808],"domain_scores_gemma":[0.98757786,0.006155356,0.0041238638,0.00032467872,0.001459722,0.00035854656],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.010165618,0.00034522312,0.004575009,0.00043001675,0.000032402975,0.000014255832,0.00033838066,0.00029512678,0.00009699012],"category_scores_gemma":[0.022266747,0.0002294569,0.00080717896,0.0006369546,0.0001869786,0.00026360818,0.000033935557,0.0010277446,3.1885142e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029126047,0.00017283304,0.00007095271,0.13383703,0.0014134302,0.000026468742,0.0001056882,6.091185e-8,5.4129e-7,0.0000043915225,0.030825945,0.83063006],"study_design_scores_gemma":[0.004541057,0.0040327287,0.000022664344,0.26470003,0.002048741,0.00076518586,0.000043984062,0.000025091571,1.8177784e-7,0.000007041663,0.72369355,0.00011976364],"about_ca_topic_score_codex":0.00005255404,"about_ca_topic_score_gemma":0.0000030088606,"teacher_disagreement_score":0.8305103,"about_ca_system_score_codex":0.00066805526,"about_ca_system_score_gemma":0.003603166,"threshold_uncertainty_score":0.9859691},"labels":[],"label_agreement":null},{"id":"W3087853974","doi":"10.1016/j.annonc.2020.08.454","title":"352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Pertuzumab; Hazard ratio; Trastuzumab; Internal medicine; Taxane; Breast cancer; Oncology; Clinical endpoint; PI3K/AKT/mTOR pathway; Metastatic breast cancer; Placebo; Cancer; Clinical trial; Confidence interval; Pathology; Signal transduction","score_opus":0.06491574675293652,"score_gpt":0.4117682651337963,"score_spread":0.34685251838085973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087853974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897517,0.00033027245,0.000017411088,0.0056401193,0.000044648128,0.0030144837,0.00030441987,0.000038983573,0.0008579824],"genre_scores_gemma":[0.9966899,0.000779393,0.00012588201,0.0018197049,0.00007926351,0.00029800978,0.000060828246,0.00009049521,0.00005652224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960477,0.00050717714,0.0009248751,0.0008886298,0.00082502246,0.0008066061],"domain_scores_gemma":[0.9968749,0.00027796894,0.0005652142,0.00036917042,0.0014364284,0.0004762924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034533662,0.0004767132,0.0015998901,0.00027821996,0.00010486148,0.000013887419,0.00030873553,0.00020100926,0.0005623577],"category_scores_gemma":[0.00015434621,0.000349584,0.00008731308,0.00081762223,0.00063893676,0.00027441312,0.00010161637,0.0006930217,0.0000042473657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17301553,0.030047275,0.43352813,0.00058644614,0.0020960958,0.0010170772,0.055551354,0.00010996708,0.013188547,0.000069553505,0.0025164965,0.2882735],"study_design_scores_gemma":[0.1466756,0.23358645,0.5932944,0.0008815548,0.00013443296,0.00010440827,0.007734641,0.00014789929,0.015678642,0.000024729214,0.0010323237,0.0007049504],"about_ca_topic_score_codex":0.004231403,"about_ca_topic_score_gemma":0.0010390646,"teacher_disagreement_score":0.28756857,"about_ca_system_score_codex":0.00040929238,"about_ca_system_score_gemma":0.001063213,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W3087905898","doi":"10.1016/j.annonc.2020.08.2239","title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Puma Biotechnology; Syndax Pharmaceuticals; F. Hoffmann-La Roche; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Atezolizumab; Taxane; Internal medicine; Clinical endpoint; Anthracycline; Cyclophosphamide; Breast cancer; Oncology; Triple-negative breast cancer; Chemotherapy; Phases of clinical research; Placebo; Neoadjuvant therapy; Doxorubicin; Gastroenterology; Surgery; Cancer; Randomized controlled trial; Pathology; Immunotherapy; Pembrolizumab","score_opus":0.16364009510904998,"score_gpt":0.48364156771962136,"score_spread":0.3200014726105714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087905898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585097,0.00037434712,0.000006980215,0.036881763,0.00014632913,0.0016725232,0.0009241092,0.000029761399,0.0014544906],"genre_scores_gemma":[0.99619985,0.0009107703,0.0001117271,0.0020850734,0.00031811188,0.00015598032,0.000030945324,0.000045030214,0.00014249916],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99643147,0.0004263084,0.0012576528,0.0006484994,0.0006798034,0.00055624667],"domain_scores_gemma":[0.99744695,0.00051064783,0.0005370513,0.00049451843,0.0006112172,0.0003996137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006359616,0.00027330068,0.0014351789,0.0002592247,0.000038558115,0.0000076141578,0.0003695549,0.000259071,0.0008524531],"category_scores_gemma":[0.00049272936,0.00022999266,0.00015510852,0.0008416207,0.00025741977,0.00010351144,0.00013858124,0.0006432803,0.00001843346],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21990429,0.018366767,0.027301416,0.00019497314,0.0013037205,0.001802246,0.102199554,0.000057865935,0.03773342,0.000022540777,0.052419234,0.53869396],"study_design_scores_gemma":[0.29773235,0.091194116,0.5245763,0.00091012515,0.00019092893,0.0000439274,0.011763063,0.0013033866,0.05085581,0.0003289518,0.020456191,0.00064481725],"about_ca_topic_score_codex":0.036883574,"about_ca_topic_score_gemma":0.0021111856,"teacher_disagreement_score":0.53804916,"about_ca_system_score_codex":0.00021335753,"about_ca_system_score_gemma":0.0013870342,"threshold_uncertainty_score":0.9695299},"labels":[],"label_agreement":null},{"id":"W3088305507","doi":"10.1016/j.annonc.2020.08.343","title":"221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"European Society for Medical Oncology; Pfizer Japan; Meso Scale Diagnostics; Novartis; AstraZeneca","keywords":"Medicine; Trastuzumab; Internal medicine; Breast cancer; Lapatinib; Clinical endpoint; Anthracycline; Oncology; Median follow-up; Cancer; Gastroenterology; Surgery; Chemotherapy; Randomized controlled trial","score_opus":0.1255883365181992,"score_gpt":0.45173019833508016,"score_spread":0.326141861816881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088305507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670653,0.00011390489,0.000009642279,0.029112777,0.00007423956,0.00072378287,0.00014688875,0.000013685328,0.0027398232],"genre_scores_gemma":[0.9957701,0.00019595918,0.00019837891,0.0034421508,0.00007100792,0.000082839055,0.000019694684,0.00003044373,0.00018941975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99805254,0.00016473276,0.00054027484,0.0003231567,0.00051009975,0.00040917512],"domain_scores_gemma":[0.99835837,0.0002722057,0.00025376063,0.0002637764,0.000612186,0.00023968765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024698186,0.0001808246,0.0009850767,0.00016844689,0.000018891875,0.0000033107558,0.00021988689,0.00013875785,0.0013659067],"category_scores_gemma":[0.00020898142,0.0001362702,0.000099325305,0.0004587406,0.0002882658,0.000073718,0.00010890528,0.00033193198,0.000020552752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031276892,0.00084321044,0.973557,0.00030284206,0.00025882307,0.00006804418,0.00086427777,0.000025506497,0.00014121956,0.0000135002065,0.0022853778,0.018512528],"study_design_scores_gemma":[0.006717626,0.0029141803,0.98707706,0.00016671386,0.0000357391,0.0000025602699,0.000082979015,0.000024559082,0.0020890415,0.000019383546,0.00075611717,0.00011403242],"about_ca_topic_score_codex":0.002034059,"about_ca_topic_score_gemma":0.0010364926,"teacher_disagreement_score":0.02870485,"about_ca_system_score_codex":0.000107343556,"about_ca_system_score_gemma":0.00086687435,"threshold_uncertainty_score":0.999547},"labels":[],"label_agreement":null},{"id":"W3090447719","doi":"10.1016/j.cjca.2020.07.126","title":"CHALLENGES IN USING A DEEP LEARNING NETWORK TO PREDICT TRASTUZUMAB INDUCED CARDIOTOXICITY","year":2020,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Cardiotoxicity; Asymptomatic; Internal medicine; Breast cancer; Oncology; Monoclonal antibody; Cardiology; Cancer; Antibody; Chemotherapy; Immunology","score_opus":0.1800084144554361,"score_gpt":0.3507374176590548,"score_spread":0.1707290032036187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090447719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96865547,0.0075047957,0.0022398727,0.010278583,0.0006404556,0.0004588844,0.000004859772,0.0000136189365,0.010203439],"genre_scores_gemma":[0.9947819,0.0003354796,0.00037546403,0.00065888365,0.0038041428,0.0000052018017,0.0000010608222,0.00003307771,0.0000047864114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99782854,0.0004823899,0.0004506827,0.00024737124,0.00026916535,0.00072186586],"domain_scores_gemma":[0.9976254,0.00010047344,0.00009664679,0.0001607475,0.0002266823,0.0017900486],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010325038,0.00015123657,0.0008786959,0.00035083506,0.00007256453,0.000015447513,0.000223345,0.00021189562,0.000026786065],"category_scores_gemma":[0.0011630141,0.00014872149,0.00019564525,0.00045562835,0.00007028355,0.00005107926,0.000029123978,0.0012743567,0.000009438141],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075578754,0.000006868645,0.4246417,0.00021316869,0.0010193139,0.009724725,0.0071223215,0.39621636,0.0048263664,0.00008443699,0.005511271,0.14987767],"study_design_scores_gemma":[0.004945752,0.007830862,0.62753254,0.0010470628,0.00037062156,0.006773184,0.0043255603,0.0039405385,0.0005349904,0.00012912258,0.3418785,0.0006912365],"about_ca_topic_score_codex":0.0008422372,"about_ca_topic_score_gemma":0.0041374834,"teacher_disagreement_score":0.39227584,"about_ca_system_score_codex":0.00086233165,"about_ca_system_score_gemma":0.0027628986,"threshold_uncertainty_score":0.6064687},"labels":[],"label_agreement":null},{"id":"W3090684381","doi":"10.1007/s40265-020-01411-y","title":"Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars","year":2020,"lang":"en","type":"review","venue":"Drugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Trastuzumab; Pertuzumab; Lapatinib; Medicine; Biosimilar; Neratinib; Trastuzumab emtansine; Metastatic breast cancer; Breast cancer; Oncology; Targeted therapy; Internal medicine; Cancer; Pharmacology","score_opus":0.05352402178422109,"score_gpt":0.3772090738336325,"score_spread":0.3236850520494114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090684381","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003361546,0.9895042,3.4770483e-7,0.008130469,0.00017552213,0.0014627782,0.00007530428,0.000020417141,0.00029480894],"genre_scores_gemma":[0.0005944364,0.9981077,0.00009120777,0.00014245191,0.0005398564,0.0002778914,0.00007455746,0.000047716883,0.00012418692],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981926,0.00021706709,0.0005370312,0.00043103797,0.00035544796,0.00026681824],"domain_scores_gemma":[0.9992365,0.00017097972,0.0002054391,0.00023175988,0.000060957736,0.00009431807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00054401904,0.00029055873,0.0013207983,0.00017744073,0.00004961928,0.000016321284,0.00011465543,0.00012766448,0.00007296966],"category_scores_gemma":[0.00009844833,0.00016589202,0.000119917866,0.0005147506,0.00013307242,0.000025485637,0.0000669347,0.00043710324,0.000015245488],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000110687084,0.000028925613,0.0002682915,0.0072251554,0.00020716403,0.00003252092,0.0013070572,0.0000052684372,0.0000066191315,0.000016227037,0.0017392155,0.9890529],"study_design_scores_gemma":[0.0012307254,0.00007858114,0.000065633445,0.010491379,0.00026035236,0.00005663903,0.00020204234,0.00003943335,0.000040798783,0.000004105729,0.9873838,0.00014650669],"about_ca_topic_score_codex":0.00093690405,"about_ca_topic_score_gemma":0.000025772428,"teacher_disagreement_score":0.9889064,"about_ca_system_score_codex":0.0028887296,"about_ca_system_score_gemma":0.0016268037,"threshold_uncertainty_score":0.75539273},"labels":[],"label_agreement":null},{"id":"W3092280067","doi":"10.1016/j.clbc.2020.09.014","title":"Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Eli Lilly Japan; Chugai Pharmaceutical; PharmaMar; AstraZeneca Australia; Kyowa Hakko Kirin; Astellas Pharma; Eisai; GlaxoSmithKline Australia; Puma Biotechnology; Genentech; Seattle Genetics; Genomic Health; AbbVie; Mount Sylvia Diatomite; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Pfizer Australia; Celgene; Novartis; Merck; GlaxoSmithKline; British Microcirculation Society; Amgen; Ontario Brain Institute; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company","keywords":"Neratinib; Medicine; Breast cancer; Oncology; Hormone receptor; Internal medicine; Stage (stratigraphy); Gynecology; Cancer; Trastuzumab","score_opus":0.12503202366143637,"score_gpt":0.45440523439789093,"score_spread":0.32937321073645454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092280067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.916825,0.0013044694,0.00003795495,0.058240756,0.0007568712,0.0025520248,0.019610548,0.00006016671,0.0006122183],"genre_scores_gemma":[0.98585486,0.0020119296,0.00013726758,0.0043495484,0.006368305,0.00036891742,0.0003214319,0.00008919363,0.00049857085],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9937054,0.0010193479,0.0020843078,0.0012683882,0.0011353178,0.00078725786],"domain_scores_gemma":[0.9949683,0.002265969,0.00058263086,0.0007755082,0.0006133549,0.000794233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014480464,0.0004668491,0.0014375176,0.00007315601,0.00013069333,0.00006431602,0.0006124309,0.00042115286,0.002405925],"category_scores_gemma":[0.0009995273,0.0003411882,0.00046702442,0.0008961946,0.0009459919,0.00016079837,0.00028486756,0.0020136205,0.00008677054],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.72036326,0.0029770923,0.018561654,0.000054152068,0.0007022086,0.00023382706,0.0030395149,0.0000964979,0.004264358,0.000030045916,0.04858436,0.201093],"study_design_scores_gemma":[0.27892834,0.004133756,0.7041625,0.0012595265,0.00030692475,0.000016398395,0.00036027396,0.0007885921,0.0011932096,0.000011556472,0.008337277,0.0005016863],"about_ca_topic_score_codex":0.025830435,"about_ca_topic_score_gemma":0.00096486934,"teacher_disagreement_score":0.6856008,"about_ca_system_score_codex":0.00042842492,"about_ca_system_score_gemma":0.002001949,"threshold_uncertainty_score":0.99990404},"labels":[],"label_agreement":null},{"id":"W3092474336","doi":"10.3390/cancers12102929","title":"Drug Resistance and Novel Therapies in Cancers","year":2020,"lang":"en","type":"editorial","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Drug resistance; Medicine; Drug; Pharmacology; Intensive care medicine; Bioinformatics; Biology; Microbiology","score_opus":0.02930812947669069,"score_gpt":0.3517981079342054,"score_spread":0.3224899784575147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3092474336","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001433201,0.050765567,0.000029299541,0.009175785,0.918949,0.0018044516,0.0008905073,0.00017942215,0.016772745],"genre_scores_gemma":[0.005635775,0.021961134,0.0007230615,0.0011480646,0.94028467,0.00063174847,0.00026414255,0.00029603086,0.029055398],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99660206,0.000065075335,0.00043699954,0.00093641673,0.0013026582,0.000656794],"domain_scores_gemma":[0.99824476,0.00045432398,0.00015703712,0.00052789116,0.00023213556,0.00038385906],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041176446,0.0004259899,0.0009186395,0.00023148737,0.0000728772,0.00006386164,0.00033994,0.00051984546,0.00019351998],"category_scores_gemma":[0.0008015339,0.0004157931,0.00010363051,0.0005640685,0.00042139727,0.00007320428,0.000109862296,0.0020661666,0.00001862206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00078277325,0.000006206579,0.00022475305,0.0013586249,0.000116795665,0.00011882449,0.0016398293,0.000013971647,0.00023778752,0.00003470808,0.99421954,0.0012461727],"study_design_scores_gemma":[0.0024556532,0.000088459026,0.00013865046,0.0018789585,0.000053833814,0.0000012975282,0.00045275342,0.00003792569,0.00011746027,0.000052338688,0.994358,0.00036465298],"about_ca_topic_score_codex":0.0067711654,"about_ca_topic_score_gemma":0.015320674,"teacher_disagreement_score":0.02880443,"about_ca_system_score_codex":0.0113579715,"about_ca_system_score_gemma":0.014277782,"threshold_uncertainty_score":0.9998428},"labels":[],"label_agreement":null},{"id":"W3093476204","doi":"10.1016/j.ctrv.2020.102113","title":"National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study","year":2020,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Food and drug administration; Metastatic breast cancer; Cancer; Breast cancer; Drug; Cancer drugs; Oncology; Drug approval; Drug administration; Internal medicine; Intensive care medicine; Pharmacology","score_opus":0.2736387104802975,"score_gpt":0.5247481558783833,"score_spread":0.25110944539808583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093476204","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030482173,0.9720892,0.000015102172,0.0016021968,0.00071099965,0.020104192,0.005020108,0.000048860624,0.00010457001],"genre_scores_gemma":[0.00029585868,0.9270014,0.00077126105,0.00031441392,0.0016670077,0.06790805,0.001294875,0.00013139403,0.0006156917],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99442333,0.0007358426,0.001959512,0.0014700894,0.00074868987,0.00066255475],"domain_scores_gemma":[0.9972267,0.00045264515,0.0009577773,0.00043760863,0.00052546145,0.00039977184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000784745,0.0009591407,0.0038012727,0.00027246567,0.00029299274,0.00017809958,0.00023943468,0.00017777662,0.0005042692],"category_scores_gemma":[0.00006115446,0.00072481524,0.00068727497,0.0009957224,0.00015674166,0.00016644792,0.00008912734,0.00060572085,0.000019931498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00029621762,0.00073619117,0.025074415,0.017790437,0.0019363703,0.000014543952,0.00037133126,0.000027263563,1.3462737e-7,0.00003340701,0.00651537,0.9472043],"study_design_scores_gemma":[0.0037673353,0.00096612325,0.0027890662,0.012178623,0.002561439,0.00009129438,0.000059806873,0.00008038731,5.0920664e-7,0.000024032295,0.97697383,0.0005075369],"about_ca_topic_score_codex":0.0017005402,"about_ca_topic_score_gemma":0.00588075,"teacher_disagreement_score":0.97045845,"about_ca_system_score_codex":0.0057561253,"about_ca_system_score_gemma":0.007139547,"threshold_uncertainty_score":0.9995203},"labels":[],"label_agreement":null},{"id":"W3093752709","doi":"10.1016/j.breast.2020.10.003","title":"Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; University of Toronto; Mount Sinai Hospital; Western University","funders":"Janssen Canada; Novartis; Bayer","keywords":"Trastuzumab; Medicine; Breast cancer; Meta-analysis; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Randomized controlled trial; Subgroup analysis; Cancer; Surgery","score_opus":0.10818742444388223,"score_gpt":0.39569247456465007,"score_spread":0.2875050501207678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093752709","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026211733,0.98462677,0.0000065875215,0.0022129584,0.00001225161,0.0066937874,0.0061543817,0.00002480583,0.00026585461],"genre_scores_gemma":[0.00047206573,0.99705666,0.000037665563,0.00045453876,0.000063598,0.0010846881,0.0002333526,0.000116249284,0.00048120055],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99524957,0.0010432113,0.001157336,0.00072071195,0.0013984119,0.00043075136],"domain_scores_gemma":[0.9965836,0.0002552372,0.0010116047,0.0012702863,0.0005378336,0.00034145656],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096005236,0.00065174414,0.011201581,0.00021675233,0.000060164763,0.000039729537,0.00052144384,0.00015939037,0.0013093026],"category_scores_gemma":[0.00006844008,0.00030678965,0.0016557885,0.0015572887,0.00026464995,0.00007869028,0.00019880965,0.00067550485,0.000053010008],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000067858186,0.00015503452,0.00002449297,0.7654708,0.21859147,0.00002236534,0.00017604318,1.3842838e-7,4.9529206e-8,0.000017376351,0.00022912057,0.015245241],"study_design_scores_gemma":[0.00031947342,0.00018703249,0.00022622007,0.16463861,0.8278189,0.00029838475,0.00002889583,9.4629354e-7,9.89171e-8,0.0000015546419,0.0062096063,0.00027029266],"about_ca_topic_score_codex":0.00045568298,"about_ca_topic_score_gemma":0.00006285952,"teacher_disagreement_score":0.6092274,"about_ca_system_score_codex":0.00040833463,"about_ca_system_score_gemma":0.0006765826,"threshold_uncertainty_score":0.9999384},"labels":[],"label_agreement":null},{"id":"W3093782821","doi":"10.1007/s10549-020-05976-w","title":"A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer","year":2020,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); University of Toronto; Sunnybrook Health Science Centre; Mount Sinai Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Lumpectomy; Breast cancer; Trastuzumab; Stage (stratigraphy); Population; Internal medicine; Cancer; Oncology; Cancer registry; Health care; Gynecology; Mastectomy; Environmental health","score_opus":0.10140654018881648,"score_gpt":0.41887150982277555,"score_spread":0.3174649696339591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3093782821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719744,0.0030939498,0.000033483026,0.0069977553,0.000023120101,0.0038043587,0.013907712,0.000032455282,0.00013279087],"genre_scores_gemma":[0.9943779,0.0008337584,0.00008405651,0.00016387875,0.00011222411,0.0023789424,0.000968012,0.00006934037,0.001011888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972763,0.00014005051,0.00035734475,0.0007579986,0.0007953461,0.0006729287],"domain_scores_gemma":[0.9978002,0.00020946046,0.00014161879,0.00026987956,0.00084835483,0.000730527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012202547,0.0003536604,0.00068318995,0.00015536645,0.00030815857,0.00006928559,0.00009312221,0.00010579575,0.00051070977],"category_scores_gemma":[0.000014693021,0.0002522041,0.000066313165,0.00044155077,0.00028941073,0.000098295015,0.000043768083,0.0001952122,0.000001264846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011225669,0.0011493519,0.87900263,0.00021661888,0.0005167203,0.0000063463717,0.001321559,0.000069972586,0.000088357505,0.00001663808,0.0014527504,0.1049334],"study_design_scores_gemma":[0.015136072,0.0075263954,0.95882446,0.0007134931,0.00022848946,0.000004520067,0.0003532287,0.0009875726,0.001964573,0.0000029757582,0.013996995,0.00026125307],"about_ca_topic_score_codex":0.44794068,"about_ca_topic_score_gemma":0.19313402,"teacher_disagreement_score":0.25480664,"about_ca_system_score_codex":0.005269216,"about_ca_system_score_gemma":0.0022114955,"threshold_uncertainty_score":0.999993},"labels":[],"label_agreement":null},{"id":"W3095550184","doi":"10.1038/s41598-020-75279-z","title":"Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer","year":2020,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Insulin-like growth factor; Drug; Conjugate; Pharmacology; Cancer; Growth factor; Medicine; Cancer research; Receptor; Oncology; Internal medicine","score_opus":0.15934996027989135,"score_gpt":0.4128545193625031,"score_spread":0.25350455908261177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095550184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996187,0.0007985323,0.000031574564,0.0011057736,0.0004448901,0.0010205852,0.000025341205,0.0000132747955,0.00037304487],"genre_scores_gemma":[0.99743253,0.0000514108,0.0021042028,0.000051841107,0.000031684336,0.00008724296,0.000036764875,0.0000147467445,0.00018956873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99648696,0.00012856034,0.0009767644,0.000648387,0.0015332636,0.00022609062],"domain_scores_gemma":[0.99797904,0.00008779716,0.00034752683,0.00027822278,0.001094829,0.00021255587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003199902,0.00012089646,0.00040135457,0.00016398473,0.00004723349,0.00002534489,0.00008109988,0.00007357461,0.00025899636],"category_scores_gemma":[0.0018252233,0.00010513043,0.000050446102,0.0005075221,0.0003279351,0.000099286015,0.00010845299,0.00020478579,0.000003520314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001206139,0.00092472037,0.33881173,0.0020567838,0.0002637724,0.00011223274,0.07413468,0.0014519343,0.49111947,0.000075794,0.008595398,0.08124736],"study_design_scores_gemma":[0.002194791,0.00017175026,0.040612534,0.0010923218,0.00009102081,0.0000146601515,0.0007605501,0.06240029,0.8907107,0.0008371574,0.0008658814,0.0002483075],"about_ca_topic_score_codex":0.00015317654,"about_ca_topic_score_gemma":0.00013057694,"teacher_disagreement_score":0.39959127,"about_ca_system_score_codex":0.00025397504,"about_ca_system_score_gemma":0.0034881209,"threshold_uncertainty_score":0.6187777},"labels":[],"label_agreement":null},{"id":"W3095704533","doi":"10.1182/blood-2020-137078","title":"Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study and Preliminary Results of a Single-Arm Extension","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Bendamustine; Rituximab; Medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Phases of clinical research; Lymphoma; Internal medicine; Oncology; Chemotherapy; Materials science","score_opus":0.032755742784233016,"score_gpt":0.3085714796981534,"score_spread":0.27581573691392036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095704533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911311,0.004305256,0.0000053702074,0.0007883028,0.000051285177,0.0028151656,0.00038499013,0.00006232794,0.00045618435],"genre_scores_gemma":[0.9986539,0.000344075,0.0004311509,0.00010089306,0.000080076374,0.000049196817,0.00014493556,0.00006360013,0.00013215997],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576324,0.0006199306,0.0015073756,0.0008653608,0.0007565656,0.0004875046],"domain_scores_gemma":[0.9973947,0.0007874785,0.0004975043,0.0006414915,0.00029310407,0.00038573632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016759298,0.00035290755,0.0016841178,0.00036499597,0.000085345346,0.000015705316,0.00017699078,0.00021363105,0.0000121657895],"category_scores_gemma":[0.003924275,0.00030294468,0.00011568144,0.00065715687,0.00029678512,0.00008946628,0.00046251493,0.0004351054,0.0000024428603],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7339652,0.17041485,0.0002390691,0.0007414269,0.00022471051,0.0010563991,0.015008768,0.0000013577636,0.075544246,0.0000032647552,0.00068110495,0.0021196094],"study_design_scores_gemma":[0.9492881,0.023947923,0.001040131,0.0005847712,0.0006409735,0.000054903874,0.0016882344,0.0029196704,0.019190786,0.000007930001,0.00039996632,0.000236632],"about_ca_topic_score_codex":0.00051686174,"about_ca_topic_score_gemma":0.00006207671,"teacher_disagreement_score":0.21532288,"about_ca_system_score_codex":0.0000942897,"about_ca_system_score_gemma":0.00041238955,"threshold_uncertainty_score":0.99994224},"labels":[],"label_agreement":null},{"id":"W3096107020","doi":"10.1182/blood-2020-142859","title":"A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Adverse effect; Population; Internal medicine; Gastroenterology; Phases of clinical research; Pharmacodynamics; Refractory (planetary science); Antibody-drug conjugate; Diffuse large B-cell lymphoma; Toxicity; Pharmacology; Lymphoma; Urology; Antibody; Immunology; Monoclonal antibody","score_opus":0.02164718382084827,"score_gpt":0.31118856560637054,"score_spread":0.28954138178552224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096107020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582136,0.00015608063,0.0000086519685,0.00027118283,0.000040103143,0.0020063857,0.000066305736,0.000032989275,0.0015969414],"genre_scores_gemma":[0.99934065,0.0000616848,0.00015983901,0.0001382373,0.0000927892,0.000049467897,0.00005453914,0.000045949753,0.00005685661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99765295,0.00016604537,0.0005967123,0.0005135176,0.00076102786,0.00030974403],"domain_scores_gemma":[0.9989194,0.00012577599,0.00017578085,0.00033556166,0.00015681305,0.00028664386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034032646,0.00020872845,0.0004377323,0.0001724713,0.000042909694,0.000012856952,0.00013068366,0.00008561164,0.000050768493],"category_scores_gemma":[0.00014638626,0.00017598229,0.00003401762,0.0005867367,0.00007543696,0.00009758133,0.000084752566,0.00028164854,0.000011440919],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05690696,0.08120144,0.7523614,0.0009558801,0.00032675825,0.0004093961,0.015229051,0.000050095226,0.0158091,0.0000011714709,0.0010461423,0.075702555],"study_design_scores_gemma":[0.32295108,0.023438124,0.6443825,0.00023189846,0.0002747274,0.0000039497604,0.00050047046,0.0005515712,0.0064812577,0.0000012051655,0.0009640498,0.00021920641],"about_ca_topic_score_codex":0.00016479609,"about_ca_topic_score_gemma":0.000030871917,"teacher_disagreement_score":0.2660441,"about_ca_system_score_codex":0.00008266568,"about_ca_system_score_gemma":0.00020184407,"threshold_uncertainty_score":0.717635},"labels":[],"label_agreement":null},{"id":"W3101556373","doi":"10.3390/ijms21228732","title":"Role of iRhoms 1 and 2 in Endochondral Ossification","year":2020,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"National Institute of General Medical Sciences; National Institutes of Health; Deutsche Forschungsgemeinschaft","keywords":"Endochondral ossification; Cell biology; Chemistry; Cartilage; Chondrocyte; Ossification; Transforming growth factor; Bone growth; Intramembranous ossification; Internal medicine; Endocrinology; Biology; Anatomy; Medicine","score_opus":0.04461041628779224,"score_gpt":0.3859035092801751,"score_spread":0.34129309299238286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101556373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881015,0.0012864259,0.00035322597,0.008682011,0.00007812662,0.000048952534,0.0000016110777,0.0000016053272,0.0014465544],"genre_scores_gemma":[0.9974791,0.00014513014,0.001955259,0.0003411339,0.00007045681,5.2646413e-7,3.6656957e-7,0.000002459007,0.0000056166314],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987822,0.00003195307,0.00024889616,0.000086687694,0.00077784737,0.000072372735],"domain_scores_gemma":[0.9994867,0.0000326789,0.00012688011,0.00003361082,0.00023883603,0.000081316415],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003422694,0.00003650113,0.000104790306,0.00017309525,0.000009589066,0.000024074021,0.00024468446,0.000017679475,0.00004523107],"category_scores_gemma":[0.00031279193,0.000029075569,0.000036826605,0.00019309859,0.00016927427,0.00010308798,0.00003751736,0.00011913408,0.0000017387722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001851959,0.000059967242,0.069603115,0.00001418612,0.00003092545,0.00017314142,0.0010740928,0.00018964996,0.89834946,0.0011055433,0.000064334556,0.02915038],"study_design_scores_gemma":[0.0028321748,0.0014611857,0.1816537,0.00046677658,0.000027075166,0.0009411365,0.002741202,0.0068383017,0.7948828,0.0035144885,0.004490516,0.0001506787],"about_ca_topic_score_codex":0.000019525954,"about_ca_topic_score_gemma":0.0000025363165,"teacher_disagreement_score":0.11205058,"about_ca_system_score_codex":0.00003199094,"about_ca_system_score_gemma":0.00022577011,"threshold_uncertainty_score":0.11856673},"labels":[],"label_agreement":null},{"id":"W310270586","doi":"","title":"[Prognostic role of human epidermal growth factor receptor 2 in resectable gastric cancer: a meta-analysis].","year":2015,"lang":"en","type":"article","venue":"PubMed","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Meta-analysis; Cochrane Library; Internal medicine; Oncology; Cancer; MEDLINE; Web of science; Gastroenterology","score_opus":0.21101581042050882,"score_gpt":0.37390667580121845,"score_spread":0.16289086538070963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W310270586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97495383,0.011160471,0.000015754264,0.002236928,0.000101594975,0.0023522845,0.00015891681,0.00006796714,0.008952251],"genre_scores_gemma":[0.9935587,0.00007478265,0.00015067619,0.000098148135,0.00014705726,0.003991915,0.000032549073,0.000035495028,0.0019106733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967402,0.00029290718,0.0006132506,0.00046157034,0.001038527,0.0008535141],"domain_scores_gemma":[0.9980748,0.00020578563,0.00016883871,0.00050161703,0.00045202748,0.00059689145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014939738,0.00020505523,0.0012835552,0.00090927636,0.000033805547,0.000024569803,0.0002899485,0.000115818,0.0014057227],"category_scores_gemma":[0.0016545533,0.00016537921,0.0004661254,0.0025504709,0.00010851468,0.00012399559,0.000115379764,0.00041196798,0.000023149827],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028483974,0.0003768199,0.9654839,0.00019537944,0.020104367,0.000038823175,0.00052985334,0.000059245354,0.0010941182,0.000083352905,0.0045842915,0.0071650296],"study_design_scores_gemma":[0.0018790474,0.00022803439,0.9619648,0.000010133515,0.022482753,0.0000067852425,0.0002535925,0.0001234039,0.009688449,0.00026401284,0.0028529016,0.0002461285],"about_ca_topic_score_codex":0.008595813,"about_ca_topic_score_gemma":0.0016128153,"teacher_disagreement_score":0.01860487,"about_ca_system_score_codex":0.00050052424,"about_ca_system_score_gemma":0.0003728541,"threshold_uncertainty_score":0.9995071},"labels":[],"label_agreement":null},{"id":"W3105819471","doi":"10.1021/acs.jpclett.0c02327","title":"Phosphorylation-Dependent Conformations of the Disordered Carboxyl-Terminus Domain in the Epidermal Growth Factor Receptor","year":2020,"lang":"en","type":"article","venue":"The Journal of Physical Chemistry Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Canadian Institute for Advanced Research; Richard and Susan Smith Family Foundation; National Cancer Institute; Arnold and Mabel Beckman Foundation; Alfred P. Sloan Foundation","keywords":"Autophosphorylation; Phosphorylation; Epidermal growth factor receptor; Biophysics; Tyrosine; Epidermal growth factor; Chemistry; Docking (animal); Tyrosine phosphorylation; Receptor tyrosine kinase; Cell biology; Tyrosine kinase; Protein kinase domain; Signal transduction; Receptor; Biochemistry; Biology; Protein kinase A; Mutant","score_opus":0.021964697882905435,"score_gpt":0.28512667786527696,"score_spread":0.2631619799823715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105819471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9183097,0.000041040377,0.00007275956,0.08096114,0.000033103996,0.00021620539,0.000020718711,0.0000037532175,0.00034160772],"genre_scores_gemma":[0.99746495,0.0000145601725,0.000020086705,0.0019994436,0.00046888035,0.000005573207,0.000002573999,0.000011969473,0.000011932363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998291,0.00016722495,0.00043131763,0.00007902489,0.00083056267,0.00020084213],"domain_scores_gemma":[0.9988206,0.00041471323,0.0003059573,0.00025472362,0.00010749165,0.00009648849],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037389342,0.00012333965,0.00026679068,0.000014080329,0.00006921763,0.000016550044,0.00058784045,0.00003690033,0.00009864435],"category_scores_gemma":[0.0003186076,0.000058703925,0.00019460797,0.00024955688,0.00023596565,0.00007723857,0.00006736964,0.0008074539,0.000005495851],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025749838,0.000116129275,0.002147613,0.00016930104,0.000060729904,0.000012518921,0.011293353,0.00016015932,0.98221844,0.000017810606,0.0032523817,0.00029404555],"study_design_scores_gemma":[0.0029594454,0.00018858675,0.023188638,0.00028635634,0.00014679549,0.00014252882,0.0045422814,0.000774564,0.96623886,0.00021088372,0.0011202035,0.00020086595],"about_ca_topic_score_codex":0.00003093849,"about_ca_topic_score_gemma":0.0000012147426,"teacher_disagreement_score":0.0791553,"about_ca_system_score_codex":0.00010118166,"about_ca_system_score_gemma":0.00015978399,"threshold_uncertainty_score":0.35080302},"labels":[],"label_agreement":null},{"id":"W3107784614","doi":"10.1021/acs.bioconjchem.0c00563","title":"Rapid, High-Yielding Solid-Phase Synthesis of Cathepsin-B Cleavable Linkers for Targeted Cancer Therapeutics","year":2020,"lang":"en","type":"article","venue":"Bioconjugate Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Linker; Chemistry; Combinatorial chemistry; Solid-phase synthesis; Conjugate; Protecting group; Peptide synthesis; Peptide; Biochemistry; Organic chemistry","score_opus":0.09069001897675098,"score_gpt":0.39973601750512205,"score_spread":0.30904599852837106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107784614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97412694,0.0050522857,0.00037866042,0.016147409,0.00022334929,0.0014237084,0.00077715126,0.0001955753,0.0016749416],"genre_scores_gemma":[0.9942012,0.0013999403,0.0013934553,0.0014476293,0.0006912936,0.00032437732,0.000056098663,0.0000892636,0.00039676076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99816614,0.000023176397,0.00046029766,0.0004763324,0.00036333702,0.0005107138],"domain_scores_gemma":[0.99858165,0.00020352313,0.00017269468,0.00041470752,0.00027764382,0.0003497913],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024087609,0.0002508862,0.00056203594,0.000033450713,0.00008253396,0.000023763412,0.00027141106,0.00026246565,0.0011028047],"category_scores_gemma":[0.00036330993,0.00023389421,0.00020154293,0.00026884236,0.00018748923,0.00004178136,0.00006688273,0.0003063161,0.000014044206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010131788,0.00015564986,0.00025135395,0.002382104,0.00031856884,0.000014780104,0.00028804562,0.000012055522,0.9710827,0.0000060293874,0.0051981388,0.019277414],"study_design_scores_gemma":[0.0022499254,0.00023228004,0.000021530806,0.00029838594,0.00021263702,0.000004142393,0.00027237454,0.0014755155,0.9541893,0.000018359458,0.040806428,0.00021910286],"about_ca_topic_score_codex":0.00011301442,"about_ca_topic_score_gemma":0.0000014088281,"teacher_disagreement_score":0.035608288,"about_ca_system_score_codex":0.0001733108,"about_ca_system_score_gemma":0.00060232735,"threshold_uncertainty_score":0.99981034},"labels":[],"label_agreement":null},{"id":"W3111242120","doi":"10.1101/2020.12.08.417006","title":"A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Extracellular; Transmembrane protein; Epidermal growth factor; Receptor tyrosine kinase; Epidermal growth factor receptor; Cell biology; Tyrosine kinase; Transforming growth factor; Ligand (biochemistry); Chemistry; Transmembrane domain; Intracellular; Receptor; Signal transduction; Biophysics; Growth factor receptor; Biology; Biochemistry","score_opus":0.04844546252924644,"score_gpt":0.28581171924563425,"score_spread":0.2373662567163878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111242120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8708326,0.0020647051,0.10367745,0.013837049,0.0022413516,0.0052754967,0.0018673555,0.00020016424,0.0000037874356],"genre_scores_gemma":[0.9947942,0.0005356284,0.0010812127,0.0008515519,0.0013597943,0.0011721522,0.0000039757288,0.00018836772,0.0000131198285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962673,0.0002595494,0.0007421077,0.0009680944,0.001155579,0.0006073309],"domain_scores_gemma":[0.9965321,0.00023250394,0.0004578069,0.0013399131,0.0011146606,0.00032301055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006159556,0.00054915063,0.0007690366,0.00011999344,0.00022383995,0.00017351158,0.0008544597,0.0005145846,0.00009099443],"category_scores_gemma":[0.0010260773,0.0003737813,0.00038287428,0.00028685448,0.00017225002,0.000056201552,0.0005819716,0.0011657155,0.000023890401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014396061,0.00012012812,0.0002873347,0.0007393594,0.0004989902,0.000011415862,0.000037922226,0.000005722178,0.99150395,0.0031322476,0.003510584,0.000008356351],"study_design_scores_gemma":[0.0010664728,0.00021546787,0.0016830121,0.00022861669,0.00033770155,3.571178e-8,0.000006058587,0.0022840006,0.9924231,0.00001054671,0.0013881482,0.00035680475],"about_ca_topic_score_codex":0.0001411684,"about_ca_topic_score_gemma":0.0000029674027,"teacher_disagreement_score":0.12396156,"about_ca_system_score_codex":0.00034451942,"about_ca_system_score_gemma":0.0010339044,"threshold_uncertainty_score":0.99987143},"labels":[],"label_agreement":null},{"id":"W3112085252","doi":"10.1186/s13046-020-01797-3","title":"Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study","year":2020,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Pertuzumab; Trastuzumab; Trastuzumab emtansine; Medicine; Taxane; Oncology; Internal medicine; Breast cancer; Cancer; Pharmacology; Cancer research","score_opus":0.1485700922824443,"score_gpt":0.5444483581006178,"score_spread":0.3958782658181734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112085252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805527,0.0053944616,0.0000013325617,0.011614821,0.00009643915,0.0019935272,0.00007513453,0.00001310477,0.0002584989],"genre_scores_gemma":[0.99664396,0.0014790887,0.00009037504,0.0006144378,0.00079209445,0.00016460042,0.0000029653845,0.000086233464,0.00012624782],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925437,0.0016431392,0.0015894352,0.0006828335,0.002715618,0.0008252603],"domain_scores_gemma":[0.99553365,0.001295127,0.0004467417,0.00044451206,0.0012095239,0.0010704793],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030724443,0.00035659163,0.0012735146,0.00023555913,0.00016452433,0.000072197094,0.00052193686,0.00018515394,0.0010974114],"category_scores_gemma":[0.00054934074,0.00021954514,0.00024600307,0.0014097997,0.0013760943,0.00021532417,0.0003303748,0.0026864063,0.000007066219],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053613055,0.008352569,0.8848359,0.00015378358,0.0011228139,0.0021390785,0.0054984237,0.00009832648,0.029867852,0.000007710597,0.0013394492,0.012971052],"study_design_scores_gemma":[0.031467736,0.022546364,0.89092994,0.0018246291,0.0001870796,0.0003337811,0.01630393,0.00015964954,0.03501352,0.0000057273032,0.0008784294,0.00034919378],"about_ca_topic_score_codex":0.0049505383,"about_ca_topic_score_gemma":0.0006953656,"teacher_disagreement_score":0.022145322,"about_ca_system_score_codex":0.0007726415,"about_ca_system_score_gemma":0.0020198422,"threshold_uncertainty_score":0.9998157},"labels":[],"label_agreement":null},{"id":"W3114182039","doi":"10.1111/cge.13900","title":"Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review","year":2020,"lang":"en","type":"review","venue":"Clinical Genetics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; Women's College Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Subtyping; Breast cancer; Computational biology; Cancer; Biology; Genetics; Oncology; Medicine; Bioinformatics; Computer science; Programming language","score_opus":0.4118269879179667,"score_gpt":0.5911137378199902,"score_spread":0.17928674990202353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114182039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005606794,0.9902067,0.0000071306713,0.0035173537,0.0021666728,0.00339382,0.00015184672,0.00006989948,0.0004304762],"genre_scores_gemma":[0.000007741517,0.99171245,0.00053483836,0.004778534,0.0023132032,0.00027972562,0.00012610377,0.00020405164,0.000043374686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98907423,0.0027895144,0.0047726748,0.0016116145,0.0009121264,0.0008398409],"domain_scores_gemma":[0.9923479,0.0035663967,0.0008298645,0.0015852449,0.00050233287,0.0011682627],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0021995145,0.00074981747,0.007257272,0.00018079455,0.000046355646,0.00003384217,0.0008915158,0.0012099564,0.00038070677],"category_scores_gemma":[0.0031702165,0.0006510116,0.00217586,0.0014355669,0.0006350031,0.000019369525,0.000810787,0.0059601786,0.00074650184],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021011075,0.00021379133,0.00082204345,0.076051615,0.00049752096,0.0011744723,0.0000042207807,5.1546283e-7,7.901833e-8,0.000008092838,0.009991751,0.91102576],"study_design_scores_gemma":[0.0021203558,0.00062863197,0.0006761666,0.12307545,0.0024527465,0.00010958093,0.0000046950045,0.000023671037,1.4767654e-7,0.000005272322,0.8704418,0.00046148602],"about_ca_topic_score_codex":0.000029447536,"about_ca_topic_score_gemma":0.000013811319,"teacher_disagreement_score":0.9105643,"about_ca_system_score_codex":0.00050345727,"about_ca_system_score_gemma":0.0055319224,"threshold_uncertainty_score":0.9995941},"labels":[],"label_agreement":null},{"id":"W3115087778","doi":"10.3390/cancers13010044","title":"HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes","year":2020,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"Leids Universitair Medisch Centrum; National Institute for Health and Care Research; Universiteit Leiden; Cancer Research UK","keywords":"Oncology; Medicine; Internal medicine; Endometrial cancer; Bioinformatics; Gynecology; Cancer; Biology","score_opus":0.10741671877125591,"score_gpt":0.40010839891139355,"score_spread":0.29269168014013763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115087778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055576,0.0013080073,0.00046972738,0.00451542,0.00031953584,0.0009622815,0.00006246438,0.00007940886,0.0017273988],"genre_scores_gemma":[0.9955035,0.0012919878,0.0014092715,0.001216835,0.00020544785,0.00010649558,0.000035116373,0.00005210903,0.00017924295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757546,0.00020355792,0.00058114127,0.00060637377,0.0005806321,0.00045283625],"domain_scores_gemma":[0.99815285,0.0004996357,0.00019527553,0.0003900719,0.0001527907,0.000609395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005364814,0.00019880479,0.0005411429,0.00021002325,0.00007191137,0.000025769836,0.00013000096,0.00016518499,0.00016111182],"category_scores_gemma":[0.0023364855,0.00017124038,0.00008189731,0.0010399612,0.00037629416,0.00008529967,0.000036172914,0.0008617252,0.000023188277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011641551,0.000015190465,0.98904073,0.00006593388,0.00012300187,0.00009658996,0.00028227692,0.0003327015,0.000042049418,0.00034006956,0.0022461964,0.0062511237],"study_design_scores_gemma":[0.007890261,0.00095686933,0.9694319,0.000076680546,0.00015038151,0.0000042332063,0.00038272433,0.00082730316,0.000052964573,0.00007621845,0.01993183,0.00021864816],"about_ca_topic_score_codex":0.010113243,"about_ca_topic_score_gemma":0.0023995198,"teacher_disagreement_score":0.019608825,"about_ca_system_score_codex":0.0034781634,"about_ca_system_score_gemma":0.004108043,"threshold_uncertainty_score":0.9964785},"labels":[],"label_agreement":null},{"id":"W3115666250","doi":"10.1016/j.ejca.2020.11.023","title":"Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne","funders":"","keywords":"Pertuzumab; Medicine; Rash; Internal medicine; Hazard ratio; Metastatic breast cancer; Cohort; Proportional hazards model; Breast cancer; Oncology; Cohort study; Cancer; Confidence interval","score_opus":0.03363012525165893,"score_gpt":0.3112171129630532,"score_spread":0.2775869877113943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115666250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860769,0.0010052688,0.000026381487,0.01150924,0.00012813673,0.0003672803,0.00083922385,0.000007751194,0.00003983053],"genre_scores_gemma":[0.99851763,0.00033427737,0.000024977762,0.0006539113,0.00036278617,0.000009678582,0.000022311307,0.000038436654,0.000035981273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608755,0.0018150185,0.0005545917,0.00023438307,0.0010552106,0.00025326468],"domain_scores_gemma":[0.9980076,0.00053450663,0.0006200195,0.00010903667,0.00046915066,0.00025966755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015656,0.00017802004,0.00078165124,0.00012533739,0.000102223465,0.00007009511,0.00015634594,0.000023838404,0.00008937307],"category_scores_gemma":[0.00033912936,0.00011398228,0.00011786024,0.00060686335,0.00007251567,0.00014358124,0.00007676712,0.00065419014,0.0000013588407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004265817,0.00009042869,0.9804759,0.000010410065,0.0041351463,0.00005416594,0.0028138736,0.00006311946,0.000008957568,2.0570462e-7,0.00044088505,0.0076411124],"study_design_scores_gemma":[0.027520778,0.00087807345,0.9681295,0.00012488905,0.0024672756,4.2282446e-7,0.00052540173,0.00004481758,0.000009109072,0.0000019018734,0.0001800281,0.00011781035],"about_ca_topic_score_codex":0.00067137915,"about_ca_topic_score_gemma":0.0007020017,"teacher_disagreement_score":0.02325496,"about_ca_system_score_codex":0.0006655,"about_ca_system_score_gemma":0.00034478202,"threshold_uncertainty_score":0.46480623},"labels":[],"label_agreement":null},{"id":"W3116148769","doi":"10.3747/co.27.6517","title":"Economic Evaluation of Adjuvant Trastuzumab Emtansine in Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease after Neoadjuvant Taxane and Trastuzumab–Based Treatment in Canada","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McGill University Health Centre; Roche (Canada); Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Hazard ratio; Oncology; Internal medicine; Breast cancer; Taxane; Confidence interval; Clinical trial; Cancer","score_opus":0.055360135410148364,"score_gpt":0.3608170115498937,"score_spread":0.30545687613974537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116148769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913429,0.0023324324,0.0000015270734,0.0031959317,0.00010614794,0.0018381522,0.0011610588,0.0000047075914,0.000017145905],"genre_scores_gemma":[0.9988937,0.00026282464,0.000018740293,0.00013583292,0.00006873019,0.0004452503,0.00014937588,0.000023460587,0.0000021145004],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980495,0.0002800126,0.00040341323,0.0004945535,0.00043572928,0.00033678397],"domain_scores_gemma":[0.99896675,0.00016303376,0.00013459615,0.00014513722,0.00019739459,0.00039310794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017943562,0.00022632291,0.0005912238,0.00014480021,0.000020939213,0.000007775764,0.000054584187,0.00005506597,0.00014041524],"category_scores_gemma":[0.00006715533,0.00018530956,0.000022957734,0.00015332625,0.00016538329,0.00007130662,0.000035696252,0.00021657297,0.000001298034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0066535054,0.00050673576,0.89296716,0.00018936236,0.00005500768,0.00013422985,0.0012906701,0.0002554717,0.000017631764,9.818201e-7,0.0000835075,0.097845756],"study_design_scores_gemma":[0.015443824,0.003062926,0.97825134,0.0005377525,0.0002423884,0.0000039230204,0.00027862738,0.0018269778,0.00009953038,0.0000035716357,0.00009125887,0.00015790189],"about_ca_topic_score_codex":0.24794737,"about_ca_topic_score_gemma":0.8506478,"teacher_disagreement_score":0.6027005,"about_ca_system_score_codex":0.006693576,"about_ca_system_score_gemma":0.01440736,"threshold_uncertainty_score":0.99711955},"labels":[],"label_agreement":null},{"id":"W3120020809","doi":"10.1007/s10549-020-06048-9","title":"HER2 fluorescent in situ hybridization signal degradation: a 10-year retrospective study","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"","keywords":"In situ hybridization; In situ; Fluorescence in situ hybridization; Breast cancer; Degradation (telecommunications); Fluorescence; Medicine; Retrospective cohort study; Biology; Pathology; Internal medicine; Chemistry; Genetics; Cancer; Computer science; Telecommunications; Chromosome; Optics; Physics; Gene expression","score_opus":0.07400740665816091,"score_gpt":0.40829915614598367,"score_spread":0.33429174948782275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120020809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999786,0.0014747265,0.000008609196,0.004281667,0.00004546966,0.0016787157,0.00010654892,0.00003323192,0.0023731904],"genre_scores_gemma":[0.9930002,0.0015200699,0.00008848068,0.00002649239,0.00026039284,0.0008095185,0.000077772274,0.000034091878,0.0041829995],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99683535,0.00033828276,0.00026154588,0.00070824707,0.0012238226,0.00063276093],"domain_scores_gemma":[0.9982937,0.00006722946,0.000031261792,0.00039302587,0.00084245903,0.00037233782],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052675285,0.00019341228,0.00035843527,0.0002899193,0.00018352237,0.00010785897,0.00007932281,0.00006249532,0.0020205562],"category_scores_gemma":[0.00006061605,0.00015955449,0.000051723433,0.0010651334,0.0001466649,0.00009853039,0.00011721493,0.000327401,0.00006675186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002508927,0.004851598,0.9155902,0.000083808765,0.00030414102,0.0022175156,0.0009301374,0.0000067649385,0.0035771993,0.00017679657,0.0015138215,0.06823907],"study_design_scores_gemma":[0.0075458065,0.0028253545,0.9739504,0.0002573404,0.00004094418,0.00018163497,0.0020017368,0.00006171588,0.011344448,0.0001061763,0.0015274285,0.00015702963],"about_ca_topic_score_codex":0.004414155,"about_ca_topic_score_gemma":0.00844033,"teacher_disagreement_score":0.06808204,"about_ca_system_score_codex":0.003122182,"about_ca_system_score_gemma":0.0016520488,"threshold_uncertainty_score":0.9988917},"labels":[],"label_agreement":null},{"id":"W3125841806","doi":"10.1007/s11307-020-01571-z","title":"Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex","year":2021,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Government of Ontario; Genentech; University of Toronto; Canadian Cancer Society; Terry Fox Foundation","keywords":"Pertuzumab; Biodistribution; Chemistry; Molecular biology; Peptide; Biochemistry; Cancer; Medicine; Metastatic breast cancer; In vitro; Biology; Breast cancer; Internal medicine","score_opus":0.01644187833566498,"score_gpt":0.30140612448920623,"score_spread":0.28496424615354127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125841806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98531395,0.005625595,0.00061647437,0.0057937806,0.000025380927,0.0003845298,0.000029955552,0.000042215783,0.0021681236],"genre_scores_gemma":[0.9945464,0.000114171016,0.0038471166,0.001114303,0.000029642906,0.00003402499,0.00016262368,0.000047006484,0.000104700106],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980311,0.00025302425,0.00034687345,0.00061296124,0.00020497006,0.0005511037],"domain_scores_gemma":[0.99888045,0.00014178628,0.00010912128,0.0003539802,0.00037908772,0.00013558584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002763729,0.00027087753,0.00063003023,0.00024687612,0.000069514186,0.00002904106,0.00013472905,0.00005096055,0.0000638661],"category_scores_gemma":[0.0001461448,0.00020618412,0.00005522306,0.0005790168,0.00068158226,0.000042207263,0.00014048516,0.00041254875,0.000004563577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000498825,0.00014566442,0.23466413,0.00013697882,0.00010685047,0.0021301112,0.00030888445,0.000006665807,0.7588099,0.00012399878,0.000095748524,0.0029722087],"study_design_scores_gemma":[0.017217709,0.0025722317,0.20234199,0.0029545333,0.00039886645,0.008287704,0.0038753457,0.00886565,0.746786,0.00030391177,0.005047954,0.0013481105],"about_ca_topic_score_codex":0.0016853849,"about_ca_topic_score_gemma":0.00010818368,"teacher_disagreement_score":0.032322142,"about_ca_system_score_codex":0.00014890324,"about_ca_system_score_gemma":0.0004144075,"threshold_uncertainty_score":0.84079444},"labels":[],"label_agreement":null},{"id":"W3127832917","doi":"10.1007/s00428-021-03034-4","title":"Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry","year":2021,"lang":"en","type":"article","venue":"Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Guideline; Medicine; Immunohistochemistry; Breast cancer; Fluorescence in situ hybridization; Pathology; Internal medicine; Cancer; Fish <Actinopterygii>; Staining; Oncology; Biology","score_opus":0.06921580976706479,"score_gpt":0.4775608253405975,"score_spread":0.40834501557353275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127832917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93706083,0.02355473,0.004327561,0.02348583,0.0009853558,0.0023990595,0.0032058358,0.00020764983,0.0047731283],"genre_scores_gemma":[0.9700599,0.006294508,0.014032511,0.005822302,0.0008648092,0.00043964526,0.0014078334,0.00014978992,0.0009287212],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930574,0.00092075317,0.0017749622,0.0015679031,0.0011974673,0.001481459],"domain_scores_gemma":[0.99103934,0.0046152873,0.00060751976,0.0020553372,0.0011074139,0.0005750903],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019879532,0.00080330804,0.0017328243,0.00016569332,0.0006000262,0.000057123994,0.0010187817,0.0005452737,0.0010295967],"category_scores_gemma":[0.005392268,0.00056608376,0.00063457893,0.0006426172,0.0036087537,0.00013685497,0.0010945927,0.0016781356,0.000027023176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014003919,0.0010362967,0.0040241685,0.0010470224,0.0009745055,0.0010535821,0.0002540275,0.00013119623,0.91804534,0.0012069625,0.06718065,0.003645842],"study_design_scores_gemma":[0.018273935,0.006351639,0.019353433,0.0047357655,0.005463817,0.003926153,0.010220259,0.013610452,0.83082134,0.010023579,0.07404118,0.0031784747],"about_ca_topic_score_codex":0.001434833,"about_ca_topic_score_gemma":0.00011574094,"teacher_disagreement_score":0.08722405,"about_ca_system_score_codex":0.00069635926,"about_ca_system_score_gemma":0.0052259127,"threshold_uncertainty_score":0.9998836},"labels":[],"label_agreement":null},{"id":"W3128947316","doi":"10.26443/mjm.v4i1.673","title":"HER2/neu Oncogene and Sensitivity to the DNA-Interactive Drug Doxorubicin","year":2020,"lang":"en","type":"article","venue":"McGill Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Doxorubicin; Oncogene; Cell culture; IC50; Sulforhodamine B; Molecular biology; Cancer research; Cell; Medicine; Drug resistance; Cancer; In vitro; Chemistry; Biology; Internal medicine; Cytotoxicity; Cell cycle; Chemotherapy; Biochemistry; Genetics","score_opus":0.06253521179347514,"score_gpt":0.37345508086361673,"score_spread":0.3109198690701416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128947316","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3904495,0.00091143424,0.00028902962,0.60394,0.00048051748,0.00045822887,0.00002033692,0.000018849798,0.0034321018],"genre_scores_gemma":[0.9479031,0.00037700695,0.00029268302,0.048879795,0.0021686305,0.0000032120586,0.0000014573013,0.000031902997,0.00034220557],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997444,0.00033045214,0.00056016224,0.0002457088,0.0010917133,0.00032797543],"domain_scores_gemma":[0.99753803,0.00058010884,0.00023199878,0.00024359302,0.00052927446,0.00087700743],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020210827,0.00019675339,0.00068051333,0.00015603579,0.00013423886,0.000011095673,0.00014339334,0.0000539398,0.00028897027],"category_scores_gemma":[0.002157056,0.00010892743,0.00009579432,0.00042855946,0.0001899801,0.000089164896,0.00013009606,0.00091352715,0.000044245906],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046096807,0.0001967845,0.0026018778,0.00030963085,0.00056734245,0.007896379,0.008786909,0.00006972825,0.39273036,0.00008478606,0.44820818,0.13393833],"study_design_scores_gemma":[0.006786126,0.005397249,0.012719321,0.0017428757,0.0003849625,0.0066363458,0.0044798665,0.0004885688,0.07441549,0.00006151714,0.88665056,0.00023714745],"about_ca_topic_score_codex":0.00018224123,"about_ca_topic_score_gemma":0.00007165903,"teacher_disagreement_score":0.55745363,"about_ca_system_score_codex":0.00018662153,"about_ca_system_score_gemma":0.00012899231,"threshold_uncertainty_score":0.44419318},"labels":[],"label_agreement":null},{"id":"W3130005770","doi":"10.1007/s10549-021-06109-7","title":"The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Institute for Health and Care Research; Pfizer","keywords":"Trastuzumab; Medicine; Enzalutamide; Internal medicine; Oncology; Metastatic breast cancer; Breast cancer; Response Evaluation Criteria in Solid Tumors; Regimen; Adverse effect; Androgen receptor; Cancer; Clinical endpoint; Progressive disease; Phases of clinical research; Prostate cancer; Clinical trial; Chemotherapy","score_opus":0.027840409809214116,"score_gpt":0.35712052906739994,"score_spread":0.32928011925818584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130005770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98721343,0.0061754603,0.0000058248143,0.0033896107,0.000017202208,0.0019643807,0.0010969995,0.000011141923,0.00012596867],"genre_scores_gemma":[0.985625,0.012826823,0.00023953705,0.000039095255,0.000038668302,0.0006612039,0.000041940653,0.000048390655,0.00047933447],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99709123,0.0002903076,0.00030696412,0.00064644916,0.0009459227,0.0007191133],"domain_scores_gemma":[0.99785167,0.00051704916,0.00007376044,0.00033919798,0.00077185663,0.00044644537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003523798,0.0002887108,0.00055153307,0.00013864803,0.00027504517,0.00007112079,0.00008369813,0.0000526826,0.00015557311],"category_scores_gemma":[0.00003438877,0.00014829377,0.00002628795,0.000683034,0.00085604296,0.0001187713,0.00010273802,0.00031474035,0.0000011749505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07005524,0.0012163144,0.42422447,0.00026842582,0.0009932894,0.00027964596,0.0008816873,0.000022848939,0.00022437677,0.000049507198,0.000040974588,0.50174326],"study_design_scores_gemma":[0.026031628,0.0058088796,0.9616592,0.0019277566,0.00013589463,0.0003500019,0.00108957,0.000027688146,0.0020845835,0.000016442973,0.0006649951,0.00020334421],"about_ca_topic_score_codex":0.0046853004,"about_ca_topic_score_gemma":0.012773007,"teacher_disagreement_score":0.53743476,"about_ca_system_score_codex":0.0009829615,"about_ca_system_score_gemma":0.002115119,"threshold_uncertainty_score":0.7127638},"labels":[],"label_agreement":null},{"id":"W3132376902","doi":"10.1038/s41523-021-00220-0","title":"Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; University of Toronto","funders":"University of Toronto","keywords":"Trastuzumab; Medicine; Internal medicine; Oncology; Incidence (geometry); Breast cancer; Meta-analysis; Randomized controlled trial; Targeted therapy; Observational study; Metastatic breast cancer; Surgery; Cancer","score_opus":0.16813124575614494,"score_gpt":0.43838207818789926,"score_spread":0.2702508324317543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3132376902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010040268,0.9935162,0.000030989868,0.0009572845,0.00007775764,0.0036354063,0.0017143503,0.000022629374,0.000035362664],"genre_scores_gemma":[0.00022478017,0.99658966,0.00018957183,0.00026775757,0.000092300405,0.0021272555,0.00019530926,0.00007327196,0.00024007645],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99485403,0.0010528931,0.0015824703,0.00088012376,0.0012347111,0.00039576544],"domain_scores_gemma":[0.99657327,0.00050850434,0.0008775915,0.00093580835,0.00057884236,0.00052600814],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012358571,0.0006138219,0.010033371,0.00039643535,0.000062926345,0.0000698871,0.00013053665,0.00012161322,0.0025828131],"category_scores_gemma":[0.0005963487,0.00042413085,0.00174417,0.0015730619,0.00024144487,0.00011640549,0.00020621844,0.00049106457,0.000011387462],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041469902,0.000099931625,0.0000038937956,0.88933796,0.0921531,0.000404914,0.00002469499,5.6462903e-7,5.685745e-7,0.000014674967,0.00019376185,0.017724486],"study_design_scores_gemma":[0.0003576453,0.000068214,0.000015987704,0.19124672,0.8013568,0.0005536755,0.000016465669,0.0000096422955,5.735229e-7,0.0000028311044,0.0060934345,0.000278014],"about_ca_topic_score_codex":0.00036012277,"about_ca_topic_score_gemma":0.00018653856,"teacher_disagreement_score":0.70920366,"about_ca_system_score_codex":0.0006063011,"about_ca_system_score_gemma":0.0012853162,"threshold_uncertainty_score":0.99982107},"labels":[],"label_agreement":null},{"id":"W3134342541","doi":"10.1007/s10549-021-06103-z","title":"Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Taxane; Pertuzumab; Breast cancer; Cancer registry; Trastuzumab; Oncology; Cancer; Odds ratio; Chemotherapy","score_opus":0.04727928516653658,"score_gpt":0.3718786086865928,"score_spread":0.3245993235200562,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134342541","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97561085,0.0018796679,0.000005728521,0.015693152,0.000034487013,0.0017974495,0.004879815,0.000012304522,0.00008655314],"genre_scores_gemma":[0.9858718,0.011274884,0.000031432694,0.00015185424,0.00014639445,0.0017055272,0.00028020644,0.0000483127,0.0004895841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967164,0.00047603066,0.00035103253,0.00072556984,0.0009178544,0.0008131331],"domain_scores_gemma":[0.9982446,0.00032296192,0.00007130226,0.00051651255,0.00048799563,0.00035663997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000489883,0.0003521319,0.00058688584,0.00023271047,0.00017740678,0.0001259228,0.00011084138,0.000071680835,0.00036141064],"category_scores_gemma":[0.000028561408,0.00020482179,0.000050439878,0.0006311141,0.00028411354,0.000093819996,0.00007232016,0.00036362294,0.000004785323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032750592,0.0028622753,0.8505214,0.00026602633,0.00033940596,0.0016408368,0.0011426755,0.000010429062,0.000012000903,0.000013098798,0.00005121278,0.13986558],"study_design_scores_gemma":[0.009834651,0.0021707485,0.9841205,0.0015078589,0.00011835417,0.00034407584,0.0008544751,0.00014126932,0.00012163387,0.000010512609,0.00059253443,0.00018341359],"about_ca_topic_score_codex":0.03896036,"about_ca_topic_score_gemma":0.042125035,"teacher_disagreement_score":0.13968216,"about_ca_system_score_codex":0.0023860873,"about_ca_system_score_gemma":0.0011008242,"threshold_uncertainty_score":0.97535366},"labels":[],"label_agreement":null},{"id":"W3134813321","doi":"10.1186/s12885-021-08003-3","title":"Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"review","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Western Economic Diversification Canada","keywords":"Nimotuzumab; Medicine; Pharmacokinetics; Monoclonal antibody; Toxicity; Pharmacology; Epidermal growth factor receptor; Antibody; Oncology; Internal medicine; Cancer; Immunology","score_opus":0.3541460664967972,"score_gpt":0.5736643055672753,"score_spread":0.21951823907047813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134813321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019531639,0.9917299,0.00003611982,0.000038825507,0.0006043778,0.0047077383,0.00024219562,0.000036656205,0.00065099116],"genre_scores_gemma":[0.00122086,0.9958903,0.00020473104,0.000037450132,0.0009123992,0.00048503585,0.0000937081,0.000104026636,0.0010514886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99495316,0.0007699035,0.001942198,0.00094051176,0.00097602094,0.00041818462],"domain_scores_gemma":[0.99664176,0.00089290505,0.000487703,0.0010265328,0.0006191993,0.0003318855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00157156,0.00043163184,0.0030752853,0.0001670493,0.000062959756,0.00002901947,0.00027301768,0.0003486827,0.0028549698],"category_scores_gemma":[0.00070317235,0.00035064708,0.000413306,0.00062888494,0.00017960044,0.000051126415,0.00043039973,0.0009721373,0.000009797961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021327299,0.00085553445,0.022038743,0.042719517,0.000625696,0.000017925495,0.0002902685,0.0000025948002,5.2603275e-7,0.000009570616,0.003799783,0.92942655],"study_design_scores_gemma":[0.0029558823,0.0007239986,0.0060285428,0.011551838,0.0023334804,0.000021330472,0.00010670644,0.000038302067,0.00000488108,0.000004560624,0.97593474,0.00029573395],"about_ca_topic_score_codex":0.0006776219,"about_ca_topic_score_gemma":0.0011147737,"teacher_disagreement_score":0.97213495,"about_ca_system_score_codex":0.0006449601,"about_ca_system_score_gemma":0.0044306517,"threshold_uncertainty_score":0.99989456},"labels":[],"label_agreement":null},{"id":"W3134994882","doi":"10.1111/hae.14292","title":"Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study","year":2021,"lang":"en","type":"article","venue":"Haemophilia","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact; McMaster University; University of Waterloo","funders":"","keywords":"Vial; Dosing; Medicine; Pharmacokinetics; Regimen; Nuclear medicine; Pharmacology; Surgery; Chromatography; Chemistry","score_opus":0.07041949286454836,"score_gpt":0.429097122988103,"score_spread":0.35867763012355464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134994882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903449,0.00010484682,0.00056196173,0.0030877267,0.00015901893,0.0010082027,0.000030236426,0.000058849593,0.0046442845],"genre_scores_gemma":[0.99838966,0.000006861944,0.00040746122,0.0005395249,0.00021071434,0.000053016796,0.000023065817,0.000030258987,0.00033944435],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99847955,0.00012817669,0.0003193127,0.00032850032,0.00051725766,0.00022721186],"domain_scores_gemma":[0.99842507,0.00045217044,0.00006757839,0.00057375664,0.00035741192,0.0001240121],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002388205,0.00012028711,0.0002633449,0.00010928744,0.000071029586,0.000014777547,0.00009963966,0.000054382403,0.0010518995],"category_scores_gemma":[0.0006127902,0.00011827855,0.00008324076,0.0005759158,0.00005475071,0.000029041243,0.000044400316,0.00023644594,0.00004139403],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030471173,0.009943992,0.17323777,0.0010687085,0.00037782578,0.00065368164,0.0025516236,0.0820227,0.5800335,0.00017282709,0.004909743,0.14198053],"study_design_scores_gemma":[0.015476041,0.002436786,0.6802703,0.0006388696,0.0005551989,0.000049437458,0.0004585765,0.1675141,0.12602697,0.00046728688,0.0056511564,0.00045527756],"about_ca_topic_score_codex":0.000033805823,"about_ca_topic_score_gemma":0.000010072181,"teacher_disagreement_score":0.5070325,"about_ca_system_score_codex":0.00018603382,"about_ca_system_score_gemma":0.00041235823,"threshold_uncertainty_score":0.9998613},"labels":[],"label_agreement":null},{"id":"W3136212749","doi":"10.1016/j.ejca.2021.01.053","title":"Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Cancer Society; National Institutes of Health; Novartis Pharmaceuticals Corporation; GlaxoSmithKline","keywords":"Lapatinib; Medicine; Trastuzumab; Internal medicine; Hazard ratio; Breast cancer; Chemotherapy; Oncology; Gastroenterology; Confidence interval; Cancer","score_opus":0.11838979315974739,"score_gpt":0.41610397808041366,"score_spread":0.29771418492066626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136212749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8279341,0.012116598,0.000392236,0.098639116,0.008512754,0.000496739,0.0005146719,0.00003824148,0.051355537],"genre_scores_gemma":[0.9470206,0.006625859,0.00084382825,0.005958047,0.018828351,0.00000550781,0.00013239053,0.00008961769,0.020495813],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996784,0.00051904557,0.00091456214,0.0002690687,0.0012413318,0.00027200658],"domain_scores_gemma":[0.99751824,0.00025698956,0.00047498877,0.00043925914,0.0010524913,0.00025804926],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018489639,0.00015283855,0.00033384623,0.000052488875,0.00008373012,0.00011314516,0.00059900235,0.00003053335,0.0025869997],"category_scores_gemma":[0.0013737918,0.00010338696,0.0002030393,0.00027563627,0.00010763722,0.000101655074,0.000134977,0.0008230987,0.00013605488],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08705505,0.00039738644,0.00035292262,0.000010716819,0.00075903453,0.005205392,0.0012584798,0.000094029936,0.015321104,0.00002355838,0.72588104,0.16364132],"study_design_scores_gemma":[0.118325606,0.00046818124,0.0024062195,0.00050304737,0.00010232682,0.000109539455,0.0002274011,0.00007041006,0.005318761,0.00002023886,0.8723416,0.00010670931],"about_ca_topic_score_codex":0.00008116994,"about_ca_topic_score_gemma":0.00010119006,"teacher_disagreement_score":0.16353461,"about_ca_system_score_codex":0.00027790954,"about_ca_system_score_gemma":0.0015094709,"threshold_uncertainty_score":0.99832475},"labels":[],"label_agreement":null},{"id":"W3137776366","doi":"10.1007/s10549-021-06164-0","title":"Tumor levels of the mediators of ErbB2-driven anoikis resistance correlate with breast cancer relapse in patients receiving trastuzumab-based therapies","year":2021,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Moncton Hospital; Saint John Regional Hospital; Nova Scotia Health Authority; Dalhousie University","funders":"Canadian Institutes of Health Research; Beatrice Hunter Cancer Research Institute","keywords":"Trastuzumab; Anoikis; Medicine; Breast cancer; Oncology; Cancer; Immunohistochemistry; Internal medicine; Epidermal growth factor receptor; Apoptosis; Cancer research; Cancer cell; Biology","score_opus":0.03670378781311591,"score_gpt":0.34039308619681263,"score_spread":0.30368929838369674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137776366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887654,0.003494589,0.000001993046,0.004522374,0.00008738801,0.0011256147,0.0016670334,0.000013295803,0.0003223012],"genre_scores_gemma":[0.99667007,0.0016629397,0.00012303944,0.00004728124,0.000062976826,0.0005220176,0.000014024465,0.000053940563,0.0008437037],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963172,0.0004065947,0.00045685048,0.0005832966,0.0015306844,0.00070537446],"domain_scores_gemma":[0.9975556,0.0002833954,0.00016744038,0.00058334984,0.001128412,0.00028176667],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040154258,0.00027556843,0.0006156927,0.00025621676,0.00015571341,0.000026891146,0.00019821068,0.00008935712,0.000511373],"category_scores_gemma":[0.000060409726,0.00016789441,0.00010327462,0.0013101238,0.00074906874,0.00008973179,0.00009969778,0.00044831834,0.0000018080443],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005343011,0.0012693215,0.954791,0.000451166,0.00036196865,0.0001188614,0.0012229662,0.000041542975,0.0012012656,0.000034570938,0.00020456107,0.034959726],"study_design_scores_gemma":[0.008158197,0.0007061875,0.97961974,0.0028980235,0.000063553074,0.000029102106,0.00047782267,0.000039764407,0.007510968,0.000031844385,0.0003196034,0.0001451888],"about_ca_topic_score_codex":0.0050727287,"about_ca_topic_score_gemma":0.017626602,"teacher_disagreement_score":0.03481454,"about_ca_system_score_codex":0.0015747778,"about_ca_system_score_gemma":0.0036069397,"threshold_uncertainty_score":0.9836058},"labels":[],"label_agreement":null},{"id":"W3139363653","doi":"10.11159/nddte19.102","title":"Half-Chain Trastuzumab Nanoconjugates Enhance Antitumor Activityin HER2+ breast cancer","year":2019,"lang":"en","type":"article","venue":"Proceedings of the World Congress on Recent Advances in Nanotechnology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Breast cancer; Cancer research; Cancer; Oncology; Medicine; Internal medicine","score_opus":0.010128694441214435,"score_gpt":0.32333386655248897,"score_spread":0.3132051721112745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139363653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521844,0.005168228,0.0000015391918,0.03259993,0.0024256862,0.0021285866,0.00003519461,0.00018630103,0.0052701533],"genre_scores_gemma":[0.9776539,0.013779286,0.00024618185,0.00035173932,0.00009031602,0.00035243935,0.0000013538377,0.00006589889,0.0074588703],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970167,0.000027062324,0.0005917076,0.00083085574,0.00071201957,0.0008216167],"domain_scores_gemma":[0.99835646,0.00016002022,0.00047478802,0.00047833697,0.00043449018,0.000095923446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046351473,0.0003834857,0.0008610182,0.00074393005,0.00008732134,0.000027381155,0.0009925275,0.0002452924,0.00045491426],"category_scores_gemma":[0.00027729545,0.00028798886,0.00013610638,0.0020158794,0.00068288913,0.00033926876,0.0003603305,0.0012145742,0.000039681123],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031251316,0.0010211112,0.2749245,0.0017776147,0.0001303012,0.000020767719,0.00010718975,0.00010018081,0.32723805,0.010782228,0.0014440265,0.37932894],"study_design_scores_gemma":[0.0018010819,0.000395122,0.0030601248,0.002944758,0.000027642534,0.00006607514,0.00019285928,0.00015630898,0.83283824,0.0010797122,0.15710948,0.00032857698],"about_ca_topic_score_codex":0.00006701136,"about_ca_topic_score_gemma":0.0005494504,"teacher_disagreement_score":0.5056002,"about_ca_system_score_codex":0.0006541706,"about_ca_system_score_gemma":0.00022108066,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W3148173154","doi":"10.3390/cancers13071688","title":"Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Prostate cancer; Oncology; Prostate; Medicine; Internal medicine; Cancer","score_opus":0.037529794219627356,"score_gpt":0.400819810740704,"score_spread":0.3632900165210766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148173154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822877,0.008020689,0.000009575095,0.00021768088,0.00024195279,0.00070895656,0.00013364271,0.000024807234,0.008354963],"genre_scores_gemma":[0.9938437,0.004682666,0.00037529322,0.000115480085,0.00006897768,0.00013453573,0.000020872028,0.000030086216,0.0007284413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980887,0.00010580234,0.00035283016,0.00040719908,0.00074640586,0.00029905193],"domain_scores_gemma":[0.9986788,0.00006403529,0.00018354418,0.00037845332,0.0004562519,0.00023890375],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031044093,0.00015408882,0.00042145108,0.000079436875,0.00004374459,0.000007693404,0.00008558392,0.00011046411,0.00040193496],"category_scores_gemma":[0.00018245558,0.00013026895,0.00007725806,0.00036346875,0.00043929674,0.00008792944,0.000113548296,0.00024611133,9.525384e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066306703,0.00011293498,0.33823642,0.004210484,0.00042416918,0.00019430388,0.0035622478,0.00057547423,0.588478,0.000041344796,0.011447407,0.046086535],"study_design_scores_gemma":[0.0027074644,0.0012828452,0.13481645,0.004610116,0.00018971696,0.000015244743,0.004171209,0.00079922774,0.8455217,0.00009961457,0.0055708108,0.00021563971],"about_ca_topic_score_codex":0.0017744037,"about_ca_topic_score_gemma":0.000105420135,"teacher_disagreement_score":0.25704366,"about_ca_system_score_codex":0.0007712513,"about_ca_system_score_gemma":0.0033439547,"threshold_uncertainty_score":0.5932032},"labels":[],"label_agreement":null},{"id":"W3148214373","doi":"10.3390/cancers13071726","title":"Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement; Université Laval","funders":"","keywords":"Ductal carcinoma; In situ; Biomarker; Oncology; Medicine; Breast cancer; Pathology; Transcriptome; Cancer research; Downregulation and upregulation; Internal medicine; Biology; Cancer; Gene expression; Chemistry; Gene","score_opus":0.052245894604464174,"score_gpt":0.361034075551956,"score_spread":0.30878818094749183,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3148214373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813281,0.0023430432,0.000020623667,0.0024520112,0.00032299352,0.000916319,0.000054566593,0.00003028791,0.012532004],"genre_scores_gemma":[0.99366397,0.00008672124,0.00048994715,0.0012368186,0.00034391313,0.00046949228,0.000036994188,0.000044761524,0.003627378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984572,0.000042232517,0.00021845504,0.00043701666,0.00032833597,0.0005167486],"domain_scores_gemma":[0.9990158,0.0001235082,0.00003131244,0.00037207245,0.00022711509,0.00023017367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019863366,0.00014317849,0.00028671444,0.00010737485,0.000039437033,0.000022174929,0.00009448045,0.00009139822,0.0006273502],"category_scores_gemma":[0.00036199784,0.00014356637,0.0001108758,0.00044595622,0.00009325004,0.00004574225,0.000052217052,0.0002594496,0.000031701187],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001148937,0.00011577036,0.84248596,0.002088416,0.00017912294,0.0035370388,0.0037477459,0.000063666244,0.052469518,0.00018577946,0.08240212,0.01157592],"study_design_scores_gemma":[0.014091522,0.0012336838,0.6491548,0.0017378461,0.0002728247,0.0005269863,0.0043415437,0.006130577,0.13453403,0.0004465445,0.18654051,0.0009891103],"about_ca_topic_score_codex":0.0007239747,"about_ca_topic_score_gemma":0.0010002787,"teacher_disagreement_score":0.19333117,"about_ca_system_score_codex":0.0022163151,"about_ca_system_score_gemma":0.004080081,"threshold_uncertainty_score":0.7237888},"labels":[],"label_agreement":null},{"id":"W3149083586","doi":"10.1111/his.14381","title":"Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer","year":2021,"lang":"en","type":"article","venue":"Histopathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Leids Universitair Medisch Centrum; Unicancer; KWF Kankerbestrijding; Universiteit Leiden","keywords":"Immunohistochemistry; Medicine; Confidence interval; Kappa; Concordance; Human Epidermal Growth Factor Receptor 2; Cancer; Gold standard (test); Internal medicine; Pathology; Gynecology; Breast cancer; Oncology; Mathematics","score_opus":0.10201119053040816,"score_gpt":0.3671584360928934,"score_spread":0.26514724556248526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149083586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97788954,0.007847154,0.0023384239,0.0005927658,0.0022627378,0.0007592562,0.00012971135,0.00007096107,0.008109425],"genre_scores_gemma":[0.84171766,0.0015247171,0.14349926,0.00048420645,0.003201209,0.000606051,0.0000777207,0.00011207791,0.008777085],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834394,0.00008357944,0.00040976406,0.0003868855,0.00030793936,0.00046789576],"domain_scores_gemma":[0.9984314,0.00034581494,0.000119271135,0.000378683,0.00060357293,0.0001212741],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00056867045,0.00013904675,0.00050129736,0.00022360412,0.00008835198,0.0000060305983,0.00012825945,0.00013576516,0.00060728565],"category_scores_gemma":[0.00070021395,0.00013882304,0.00011305211,0.00063092,0.00022100765,0.000044453434,0.00008189164,0.00028928116,0.00002460425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009377686,0.00033997383,0.12578686,0.0009331577,0.000021559159,0.0010084233,0.00051198876,0.000030218062,0.2383733,0.00012767751,0.007191911,0.62473714],"study_design_scores_gemma":[0.013635656,0.0047425404,0.2168094,0.0005958941,0.0002030834,0.0036073136,0.00022967416,0.0084239645,0.12461522,0.000082875194,0.62644714,0.0006072146],"about_ca_topic_score_codex":0.00007206344,"about_ca_topic_score_gemma":0.000015961916,"teacher_disagreement_score":0.62412995,"about_ca_system_score_codex":0.00033190387,"about_ca_system_score_gemma":0.00083528704,"threshold_uncertainty_score":0.66493523},"labels":[],"label_agreement":null},{"id":"W3149876840","doi":"10.1093/jnci/djp403","title":"Response: Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2009,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Queen's University; University of Toronto; University of Calgary; University of British Columbia; Sunnybrook Health Science Centre; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital; BC Cancer Agency","funders":"","keywords":"Topoisomerase; Breast cancer; Adjuvant; Oncology; Medicine; Internal medicine; Adjuvant chemotherapy; Chemotherapy; Alpha (finance); Cancer; Pharmacology; Biology; DNA; Surgery; Genetics","score_opus":0.05730616838911928,"score_gpt":0.42148059456968884,"score_spread":0.36417442618056955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3149876840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82427627,0.0020648837,0.00002483002,0.17210133,0.0008020774,0.00033171845,0.00016705775,0.0000061602736,0.00022566303],"genre_scores_gemma":[0.98503834,0.0011027161,0.00044241868,0.011011,0.0009885144,0.000018260995,9.690247e-7,0.000017342181,0.0013804492],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9972912,0.0001428181,0.0005618282,0.00018920495,0.0015785408,0.0002364103],"domain_scores_gemma":[0.9972106,0.00012798038,0.00034692982,0.00019269939,0.001875924,0.0002458365],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014449812,0.00015973284,0.00041495892,0.00033874228,0.00016978694,0.000019570256,0.00033652748,0.0000862224,0.00026824986],"category_scores_gemma":[0.000656603,0.0001081145,0.00014805129,0.00067069975,0.00018185019,0.00022409609,0.00006728941,0.00040905937,0.0000014563726],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09295692,0.00070452626,0.018533424,0.00022524138,0.0006578827,0.00015623064,0.0028338442,0.004064122,0.5653349,0.00096101343,0.15925325,0.15431862],"study_design_scores_gemma":[0.0044185594,0.0009564613,0.71649116,0.0015172296,0.0000839706,0.000779289,0.00005959556,0.00005704776,0.040871747,0.00046969054,0.23410112,0.0001941035],"about_ca_topic_score_codex":0.00014812314,"about_ca_topic_score_gemma":0.00009965412,"teacher_disagreement_score":0.69795775,"about_ca_system_score_codex":0.0010203852,"about_ca_system_score_gemma":0.003394514,"threshold_uncertainty_score":0.60217226},"labels":[],"label_agreement":null},{"id":"W3154532546","doi":"10.1002/ijc.33597","title":"Systemic toxicities of trastuzumab‐emtansine predict tumor response in <scp>HER2</scp>+ metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Alberta","funders":"National Institute of General Medical Sciences; Agencia de Innovación y Desarrollo de Andalucía","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Trastuzumab; Breast cancer; Toxicity; Cancer; Clinical endpoint; Biomarker; Clinical trial; Gastroenterology; Biology","score_opus":0.029030348334815867,"score_gpt":0.3842017598161571,"score_spread":0.35517141148134124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154532546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.967096,0.025183886,0.0001369572,0.0050201714,0.0014728511,0.00019892641,0.000552759,0.000009977559,0.00032850608],"genre_scores_gemma":[0.99227744,0.0051807505,0.00024255968,0.0005222229,0.00079949683,0.000041633262,0.000005611543,0.00004099621,0.0008892771],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961937,0.000303875,0.0010994152,0.00022230732,0.0018652832,0.00031539323],"domain_scores_gemma":[0.9956629,0.00079130527,0.000557646,0.00019732007,0.002592245,0.00019855186],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001047657,0.00019061766,0.00064754224,0.0005750636,0.000021135593,0.000042731237,0.00038625373,0.000058052643,0.00095986854],"category_scores_gemma":[0.0012056355,0.00016327096,0.0002225415,0.0004345869,0.00015176191,0.00021787509,0.00007208221,0.000527914,0.000005242986],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025152843,0.0024654479,0.3852873,0.0026259192,0.008570375,0.026310956,0.010480886,0.017952608,0.43072703,0.0005955721,0.03350514,0.05632588],"study_design_scores_gemma":[0.01752005,0.0015897749,0.75080067,0.027851254,0.0006357345,0.025982615,0.010384812,0.0015651189,0.14233941,0.0003712924,0.020636564,0.0003227106],"about_ca_topic_score_codex":0.0005693295,"about_ca_topic_score_gemma":0.0005201323,"teacher_disagreement_score":0.36551332,"about_ca_system_score_codex":0.0017084144,"about_ca_system_score_gemma":0.0051835617,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W3156985612","doi":"10.1056/nejmoa2028485","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1543,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Vinorelbine; Metastatic breast cancer; Oncology; Breast cancer; Chemotherapy; Eribulin; Gemcitabine; Cancer; Gastroenterology; Surgery; Confidence interval","score_opus":0.051532004151187895,"score_gpt":0.38854795709070733,"score_spread":0.3370159529395194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3156985612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75778955,0.019929387,0.0010170053,0.21010795,0.0025906987,0.00068304705,0.00006524195,0.000028185743,0.00778894],"genre_scores_gemma":[0.98686296,0.0030158805,0.0010315158,0.0015996122,0.00439097,0.000006679406,0.00000603126,0.00003500155,0.0030513376],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99719095,0.00028639237,0.00079805945,0.00020812152,0.0011398179,0.0003766839],"domain_scores_gemma":[0.9977866,0.00045393946,0.00026674237,0.00023733727,0.00065768685,0.0005977053],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014632873,0.00018627945,0.0008872419,0.0004051657,0.000032642805,0.000012849303,0.00015290244,0.00005865903,0.0040938114],"category_scores_gemma":[0.0015586271,0.00012440816,0.00010028896,0.00086160866,0.00016025986,0.00010750412,0.000033210552,0.0009810838,0.000008501912],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056485226,0.00039580683,0.055236448,0.0004883573,0.00068939594,0.016383704,0.0059129135,0.00011596094,0.016269784,0.0002682555,0.057647783,0.8409431],"study_design_scores_gemma":[0.4266547,0.0052910717,0.300932,0.012874517,0.0012741948,0.053553965,0.0054100845,0.00048875355,0.012033354,0.0054482315,0.17540732,0.0006318215],"about_ca_topic_score_codex":0.0017290273,"about_ca_topic_score_gemma":0.0016371193,"teacher_disagreement_score":0.8403112,"about_ca_system_score_codex":0.0005319994,"about_ca_system_score_gemma":0.0027369522,"threshold_uncertainty_score":0.9968166},"labels":[],"label_agreement":null},{"id":"W3157870687","doi":"10.3390/curroncol28030150","title":"HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features","year":2021,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pathology; HER2 negative; Invasive lobular carcinoma; Invasive ductal carcinoma; Breast cancer; Internal medicine; Cancer","score_opus":0.22356879943461647,"score_gpt":0.5105782300579937,"score_spread":0.28700943062337725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157870687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715284,0.017928874,0.00003316614,0.003446948,0.0010621794,0.00054750626,0.00004080919,0.000029356026,0.005382772],"genre_scores_gemma":[0.9966928,0.001450036,0.0007501622,0.00028761363,0.0003165887,0.000030880237,0.00007640183,0.000021554677,0.0003739729],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976495,0.0006734309,0.00045308596,0.00050948164,0.0003359816,0.0003785135],"domain_scores_gemma":[0.99729687,0.0011825868,0.00017941643,0.0003165003,0.0007774169,0.0002472066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034470132,0.00019205686,0.00089617446,0.0001039743,0.0000656514,0.000012195767,0.00012408613,0.0002901342,0.00023822795],"category_scores_gemma":[0.0020620907,0.0001648347,0.00010379775,0.00036747675,0.0006792651,0.00003783183,0.00025588326,0.0009954054,0.000035906414],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015062694,0.0029951746,0.8005383,0.00075740763,0.00019763604,0.0014097606,0.005545261,0.0000054688685,0.008368138,0.0011746767,0.032279916,0.14522198],"study_design_scores_gemma":[0.005325306,0.010393079,0.84098846,0.0007621644,0.00037176916,0.0006359166,0.005778692,0.00019407904,0.058349907,0.0009679618,0.07586127,0.00037142358],"about_ca_topic_score_codex":0.000043279975,"about_ca_topic_score_gemma":0.00027713453,"teacher_disagreement_score":0.14485055,"about_ca_system_score_codex":0.00033725408,"about_ca_system_score_gemma":0.0015323967,"threshold_uncertainty_score":0.67217636},"labels":[],"label_agreement":null},{"id":"W3164370300","doi":"10.1038/s41388-021-01841-2","title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","year":2021,"lang":"en","type":"review","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":201,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Receptor tyrosine kinase; Biology; Receptor Protein-Tyrosine Kinases; Cancer research; Tyrosine kinase; Cancer; Signal transduction; Receptor; Kinase; Targeted therapy; Bioinformatics; Computational biology; Cell biology; Genetics","score_opus":0.25863309324506767,"score_gpt":0.42782301358025915,"score_spread":0.16918992033519148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164370300","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008829896,0.9968509,0.000030229708,0.00044149658,0.00030576778,0.0014280422,0.00020529942,0.00006276826,0.00058716175],"genre_scores_gemma":[0.000041958072,0.99329585,0.0015395078,0.00020442244,0.00066697074,0.0007016036,0.00023479939,0.0001833316,0.0031315847],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969711,0.0003039211,0.0005668533,0.0010020799,0.00058691617,0.0005691544],"domain_scores_gemma":[0.99833935,0.00022716282,0.00020730733,0.00067359465,0.000118920114,0.00043365065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005301963,0.0006007458,0.0024973475,0.00022852595,0.00012917639,0.000087320965,0.00019815403,0.0005081004,0.0008412964],"category_scores_gemma":[0.000089409805,0.000469812,0.0003235613,0.00054697535,0.00021737357,0.000032532167,0.00027909235,0.0006889906,0.000040041497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019485115,0.000089793095,0.000008466953,0.016152414,0.0005638865,0.00008083031,0.000048302765,6.130012e-8,0.0006217534,0.00025884015,0.0008159032,0.9813403],"study_design_scores_gemma":[0.0005702816,0.00033964182,0.0000024243152,0.014801853,0.0018772454,0.00048802956,0.00005340274,0.000008655376,0.0006109779,0.000040772284,0.98077637,0.00043033925],"about_ca_topic_score_codex":0.00013490078,"about_ca_topic_score_gemma":0.000028381157,"teacher_disagreement_score":0.98090994,"about_ca_system_score_codex":0.0004876299,"about_ca_system_score_gemma":0.0018572969,"threshold_uncertainty_score":0.99977535},"labels":[],"label_agreement":null},{"id":"W3166496575","doi":"10.1200/jco.2021.39.15_suppl.3015","title":"A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AbbVie","keywords":"Medicine; Nausea; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Taxane; Vomiting; Diarrhea; Tolerability; Chills; Surgery; Cancer; Breast cancer","score_opus":0.13510556123169,"score_gpt":0.5069815495929816,"score_spread":0.37187598836129154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166496575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927024,0.00040526217,0.000004900831,0.0054881102,0.00012723822,0.0006825959,0.0000011644969,0.000003820497,0.0005844783],"genre_scores_gemma":[0.9973604,0.0016317675,0.00034014674,0.00037684685,0.00014934457,0.000018990624,0.0000025062657,0.000021934584,0.00009806296],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99466085,0.0012905392,0.0029071728,0.00029587332,0.0006077686,0.00023778567],"domain_scores_gemma":[0.995521,0.0022318335,0.0013331828,0.0002571992,0.00048242885,0.00017436822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058138724,0.00013769744,0.0014227614,0.00045460957,0.000023646013,0.000010446244,0.00013091009,0.00031473732,0.0000630771],"category_scores_gemma":[0.0026192728,0.00010522089,0.00009147764,0.0005236893,0.0001763641,0.00011689538,0.000034929548,0.001645715,0.0000013968549],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061262883,0.027678713,0.805192,0.00007845926,0.0001809261,0.0059314673,0.0046599316,0.00055662537,0.0014438313,0.000044533426,0.00019809556,0.092772566],"study_design_scores_gemma":[0.07939788,0.06380761,0.85217375,0.0005267963,0.000018795416,0.00014291337,0.0016611067,0.00040670935,0.00018242683,0.0003564218,0.0012397883,0.00008578143],"about_ca_topic_score_codex":0.00043965367,"about_ca_topic_score_gemma":0.0059209885,"teacher_disagreement_score":0.09268679,"about_ca_system_score_codex":0.00046682724,"about_ca_system_score_gemma":0.0018876238,"threshold_uncertainty_score":0.71499044},"labels":[],"label_agreement":null},{"id":"W3167002996","doi":"","title":"モノクローナル抗体Trastuzumab(Herceptin)をめぐって 2 乳癌におけるHER2(c-erbB-2)のamplification & overexpression","year":2000,"lang":"ja","type":"article","venue":"Pharma Medica","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab; ErbB; Cancer research; Virology; Biology; Medicine; Internal medicine; Receptor; Cancer; Breast cancer","score_opus":0.07202902031683282,"score_gpt":0.4115252189068889,"score_spread":0.3394961985900561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167002996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6941254,0.02398463,0.00033910948,0.029036865,0.003954735,0.004964844,0.00044321298,0.0010158388,0.24213535],"genre_scores_gemma":[0.9198511,0.023747426,0.0005213428,0.0035557132,0.0061776284,0.0002227824,0.0003097928,0.00026541424,0.0453488],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900086,0.0008293603,0.0015190466,0.0016506138,0.0038672355,0.0021251275],"domain_scores_gemma":[0.9947184,0.00054697116,0.0003268892,0.0018110493,0.00037173787,0.002224974],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023869597,0.0008603326,0.0010985467,0.00037058536,0.0005256891,0.00015741572,0.0012335529,0.00068884675,0.31955776],"category_scores_gemma":[0.00069647696,0.00080108806,0.000394158,0.0011277739,0.00081694283,0.0004051998,0.00022231671,0.0026109337,0.023719661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012404454,0.0010023952,0.001460323,0.00089439715,0.0002498204,0.00033526076,0.0045919507,0.000021186039,0.062179167,0.000020072646,0.28387326,0.6441317],"study_design_scores_gemma":[0.00733882,0.000746001,0.0064590513,0.003503399,0.00041053025,0.00026747806,0.0009141492,0.0034924755,0.017357538,0.00009849047,0.958513,0.0008990451],"about_ca_topic_score_codex":0.0007098784,"about_ca_topic_score_gemma":0.000008606239,"teacher_disagreement_score":0.67463976,"about_ca_system_score_codex":0.0011899832,"about_ca_system_score_gemma":0.0015257737,"threshold_uncertainty_score":0.99969006},"labels":[],"label_agreement":null},{"id":"W3168005110","doi":"10.1055/s-0041-1730167","title":"IMpassion031: Efficacy, safety and patient (pts)-reported outcomes/quality of life (QoL) - Results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemo in early stage triple-negative breast cancer (eTNBC)","year":2021,"lang":"en","type":"article","venue":"Senologie - Zeitschrift für Mammadiagnostik und -therapie","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Atezolizumab; Placebo; Oncology; Medicine; Paclitaxel; Breast cancer; Internal medicine; Doxorubicin; Cyclophosphamide; Quality of life (healthcare); Stage (stratigraphy); Triple-negative breast cancer; Chemotherapy; Cancer; Pembrolizumab; Immunotherapy; Nursing","score_opus":0.0626525346854209,"score_gpt":0.39185394507235083,"score_spread":0.32920141038692996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168005110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98047096,0.006150181,0.000010917319,0.004772826,0.00045988287,0.003343106,0.003899679,0.00012651064,0.00076594175],"genre_scores_gemma":[0.9949417,0.0033588451,0.0003363699,0.00038989514,0.00011986105,0.00020031334,0.00020133816,0.00011735846,0.00033432824],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908871,0.0012366164,0.003307988,0.0017044896,0.0017006212,0.0011631498],"domain_scores_gemma":[0.99031895,0.0045788637,0.0014097258,0.0019115178,0.0010952967,0.0006856514],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012548354,0.00080446387,0.0026582854,0.0005148228,0.0001665208,0.00006054548,0.00048744486,0.00059514825,0.0006914031],"category_scores_gemma":[0.00859968,0.0006646875,0.00032020925,0.0014908707,0.0006289351,0.00021891388,0.0005885481,0.0014135019,0.000017375536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026118051,0.008422855,0.8179635,0.00033098535,0.004376023,0.002206525,0.01655502,0.00034105167,0.0051174117,0.0001126212,0.0007121978,0.1177438],"study_design_scores_gemma":[0.04078511,0.0024834624,0.94021046,0.0007587646,0.00030248045,0.000021844106,0.005456445,0.00009785962,0.006746248,0.00003950673,0.0024865514,0.00061125314],"about_ca_topic_score_codex":0.087654404,"about_ca_topic_score_gemma":0.009958864,"teacher_disagreement_score":0.12224702,"about_ca_system_score_codex":0.00030042467,"about_ca_system_score_gemma":0.0025567424,"threshold_uncertainty_score":0.9997513},"labels":[],"label_agreement":null},{"id":"W3168045009","doi":"10.3390/cancers13122922","title":"Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Breast Cancer Society of Canada; Dalhousie Medical Research Foundation","keywords":"PI3K/AKT/mTOR pathway; Breast cancer; Medicine; Glycolysis; Cancer research; Cancer; Internal medicine; Discovery and development of mTOR inhibitors; Protein kinase B; Oncology; Signal transduction; Biology; Metabolism; Biochemistry","score_opus":0.05457637850732933,"score_gpt":0.4224668694947123,"score_spread":0.36789049098738297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168045009","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006218713,0.9963938,0.0000033591434,0.00032330997,0.0004029198,0.0011680821,0.00049613917,0.000030697283,0.0011195025],"genre_scores_gemma":[0.000063990105,0.9961982,0.00010486336,0.00023207159,0.00085400045,0.0009294558,0.0001583742,0.00012095544,0.0013381141],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99713296,0.0002463961,0.0005872152,0.00086005457,0.0005097236,0.00066365924],"domain_scores_gemma":[0.9987003,0.0001598898,0.0001907443,0.00039690651,0.0002019696,0.00035019772],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039675325,0.00045169969,0.002295664,0.0003230874,0.0000701034,0.000055536886,0.00018358833,0.00037306873,0.0014859485],"category_scores_gemma":[0.00013079098,0.00039752468,0.00030310592,0.0011260431,0.00019293794,0.00006105092,0.00016181078,0.0010973372,0.000024586961],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000030995965,0.000014255465,0.00031094646,0.018299706,0.0003646021,0.0005068148,0.00019970015,0.00001045436,0.0000038865787,0.000009259549,0.007584636,0.9726647],"study_design_scores_gemma":[0.0004716605,0.00004026706,0.00009249549,0.061241705,0.0006429316,0.0001676029,0.00018615466,0.00003358141,0.0000035640094,0.0000010252545,0.9367521,0.00036690893],"about_ca_topic_score_codex":0.0058152075,"about_ca_topic_score_gemma":0.00051079673,"teacher_disagreement_score":0.97229785,"about_ca_system_score_codex":0.009799238,"about_ca_system_score_gemma":0.009021277,"threshold_uncertainty_score":0.99984765},"labels":[],"label_agreement":null},{"id":"W3168166940","doi":"10.1200/jco.2021.39.15_suppl.524","title":"The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et de Services Sociaux des Laurentides; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"","keywords":"Medicine; Lapatinib; Internal medicine; Trastuzumab; Breast cancer; Stage (stratigraphy); Oncology; Receiver operating characteristic; Confidence interval; Cancer; Adjuvant therapy","score_opus":0.07048322028907646,"score_gpt":0.4645412224529246,"score_spread":0.3940580021638482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168166940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098796,0.00039465484,0.000006374325,0.0059057865,0.0005723953,0.00038462828,0.000029063378,0.000004097961,0.0017150204],"genre_scores_gemma":[0.9957261,0.0022353951,0.0002825012,0.00052740943,0.0005346591,0.000019757188,0.000002537645,0.000024192237,0.00064741017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583995,0.0007127137,0.0018826616,0.00022294758,0.0009460354,0.00039568997],"domain_scores_gemma":[0.993848,0.0025639043,0.0011218467,0.00026668012,0.001866858,0.00033268795],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029144476,0.00014078579,0.0010671354,0.00008740226,0.000055779663,0.000013286442,0.0002618195,0.00026411473,0.00023715045],"category_scores_gemma":[0.0023000105,0.00008050102,0.00019569996,0.00038373165,0.00054752687,0.000120283126,0.00010258757,0.001758951,0.000008687992],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007963082,0.0017882338,0.9063845,0.00009220156,0.0002552337,0.0004575547,0.00016473523,0.000045825578,0.000017041368,0.000011771099,0.00069273025,0.082127064],"study_design_scores_gemma":[0.0073214523,0.018367302,0.9647605,0.0009221064,0.00013158249,0.00013901418,0.0001371706,0.0001530004,0.00015102694,0.000009116291,0.007833129,0.00007464021],"about_ca_topic_score_codex":0.00017337292,"about_ca_topic_score_gemma":0.00052411924,"teacher_disagreement_score":0.082052425,"about_ca_system_score_codex":0.0003923432,"about_ca_system_score_gemma":0.005652931,"threshold_uncertainty_score":0.9999841},"labels":[],"label_agreement":null},{"id":"W3173791032","doi":"10.1096/fasebj.2019.33.1_supplement.250.6","title":"Association between genome‐wide DNA methylation pattern and response to trastuzumab in HER2‐positive breast cancer patients","year":2019,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"Fonds de Recherche du Québec - Santé","keywords":"Breast cancer; Trastuzumab; DNA methylation; Epigenetics; Methylation; Oncology; Cancer; Medicine; Internal medicine; Cancer research; Bioinformatics; Biology; Gene; Genetics; Gene expression","score_opus":0.01880126149840886,"score_gpt":0.32115654239431973,"score_spread":0.30235528089591085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173791032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892556,0.00007868885,0.00008501357,0.009616744,0.00012362582,0.0005786044,0.00013088103,0.000007524613,0.00012333627],"genre_scores_gemma":[0.9984123,0.00006476336,0.000018716022,0.0005710358,0.00025694165,0.000014584284,0.000012268479,0.000022857384,0.000626537],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99793375,0.00058341515,0.00029512285,0.00017057553,0.0006824189,0.00033470718],"domain_scores_gemma":[0.99885964,0.00042115527,0.00014867014,0.00013651286,0.00023761202,0.0001964092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021547077,0.00011331469,0.0002373044,0.00020366641,0.000095188145,0.00005997672,0.00011235115,0.00007843031,0.0003282358],"category_scores_gemma":[0.00022174451,0.00008205713,0.000045906807,0.00025884676,0.000018912702,0.00011704071,0.000050755378,0.00057182217,0.00007072134],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009872062,0.00004278048,0.9484917,0.000013337457,0.0001056787,0.000009597997,0.0027151927,0.00002585834,0.021458987,1.4893682e-7,0.0001976833,0.025951855],"study_design_scores_gemma":[0.001854949,0.0004112289,0.99263066,0.0001901555,0.000054849614,0.000018547487,0.00023866798,0.000034933077,0.004240377,0.000019410967,0.00021824661,0.000088002584],"about_ca_topic_score_codex":0.0003371093,"about_ca_topic_score_gemma":0.00010847062,"teacher_disagreement_score":0.044138957,"about_ca_system_score_codex":0.0020963124,"about_ca_system_score_gemma":0.00026305433,"threshold_uncertainty_score":0.5481784},"labels":[],"label_agreement":null},{"id":"W3175466915","doi":"10.1096/fasebj.27.1_supplement.1087.12","title":"Association of HER2 Ile655Val and Ala1170Pro polymorphisms with breast cancer prognosis factors","year":2013,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Breast cancer; Oncology; Medicine; Internal medicine; Genotyping; Lymphovascular invasion; Carcinogenesis; CA15-3; Cancer; Genotype; Metastasis; Biology; Gene; Genetics","score_opus":0.022679191979553343,"score_gpt":0.29491062935611845,"score_spread":0.2722314373765651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175466915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854718,0.000326015,0.000012841418,0.0132914,0.0000831532,0.0003818707,0.0000290233,0.000012304642,0.00039161654],"genre_scores_gemma":[0.99759144,0.0002931027,0.00008470522,0.00016042254,0.00029795524,0.000030980096,0.0000018370599,0.0000225442,0.0015170118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853045,0.00010308787,0.00021701242,0.00011371509,0.00072409003,0.00031164594],"domain_scores_gemma":[0.99897754,0.000099957906,0.00021402023,0.00013367985,0.0003674381,0.0002073683],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047934704,0.0001140737,0.00022545633,0.00007976503,0.00013317412,0.00006139148,0.000115454146,0.000064166015,0.0017904941],"category_scores_gemma":[0.000054385095,0.00005862832,0.00005358449,0.00018134496,0.000116064235,0.00013718105,0.00003209519,0.0004749864,0.000012200774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011028115,0.000063797175,0.94253296,0.00003313167,0.00025065418,0.000007782779,0.0007021561,0.0000036559152,0.043053806,0.0000053502135,0.0047125802,0.008523851],"study_design_scores_gemma":[0.001116708,0.0003322775,0.95834285,0.0002698741,0.00014922272,0.00041972974,0.0005752995,0.000103192375,0.038313687,0.00004533702,0.00024193169,0.000089908375],"about_ca_topic_score_codex":0.0015184097,"about_ca_topic_score_gemma":0.000075917145,"teacher_disagreement_score":0.015809879,"about_ca_system_score_codex":0.00028329444,"about_ca_system_score_gemma":0.00030664878,"threshold_uncertainty_score":0.999122},"labels":[],"label_agreement":null},{"id":"W3178119289","doi":"10.3390/cancers13143540","title":"Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Action (physics); Cancer; Internal medicine; Bioinformatics; Biology","score_opus":0.3822447179344954,"score_gpt":0.5475082367344839,"score_spread":0.16526351879998852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178119289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00013543363,0.993917,0.00006467378,0.00011262469,0.00054680044,0.001959606,0.00031178354,0.000022733986,0.0029293732],"genre_scores_gemma":[0.00027696686,0.9943522,0.00042948432,0.000034244546,0.00042315302,0.00048248234,0.0000766286,0.000115997,0.003808814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957658,0.00039811834,0.0007870275,0.00065110606,0.0017501656,0.00064777496],"domain_scores_gemma":[0.996992,0.00045218188,0.00020308406,0.0010417388,0.0008869741,0.0004240467],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001380287,0.00027219395,0.0022115444,0.0009088189,0.00004280546,0.000015860813,0.00048458079,0.0003831604,0.0013634604],"category_scores_gemma":[0.00083319965,0.00026555266,0.0005201033,0.002415187,0.00025511612,0.000032928507,0.00023811268,0.0012283402,0.00008833366],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000052446998,0.00003590843,0.0000011289018,0.032072913,0.00044166544,0.00012905487,0.0002810812,0.0000049594714,0.00014934951,0.00094900985,0.01786441,0.9480181],"study_design_scores_gemma":[0.00035364003,0.0005297936,0.0000041896515,0.03399124,0.00028768048,0.00004624951,0.00030615053,0.000004299395,0.00064074417,0.000034458622,0.9636256,0.00017594433],"about_ca_topic_score_codex":0.0017346861,"about_ca_topic_score_gemma":0.00016634168,"teacher_disagreement_score":0.9478421,"about_ca_system_score_codex":0.0061457087,"about_ca_system_score_gemma":0.017981838,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W3179982079","doi":"10.1016/j.cjco.2021.06.019","title":"Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis","year":2021,"lang":"en","type":"review","venue":"CJC Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Population Health Research Institute; McMaster University; Hamilton Health Sciences; Impact","funders":"","keywords":"Pertuzumab; Medicine; Internal medicine; Trastuzumab; Relative risk; Placebo; Breast cancer; Meta-analysis; Asymptomatic; Oncology; Adverse effect; Randomized controlled trial; Cardiotoxicity; Cancer; Confidence interval; Chemotherapy; Pathology","score_opus":0.1463421792317762,"score_gpt":0.46422019880430915,"score_spread":0.3178780195725329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179982079","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000021628607,0.98048836,0.000002808695,0.00024091089,0.000016642673,0.017410021,0.00052418903,0.000009885272,0.0013050446],"genre_scores_gemma":[0.000020081327,0.9891809,0.000097394295,0.0006248859,0.00001965348,0.007067444,0.00035832514,0.00007981764,0.00255149],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9947306,0.0017245975,0.00116411,0.0010238796,0.0009334479,0.00042336588],"domain_scores_gemma":[0.9969787,0.00029017418,0.000503746,0.0014397202,0.0005027884,0.00028488226],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001529191,0.0005950918,0.02266542,0.00033031058,0.00006520397,0.00017219133,0.0006604318,0.00021419437,0.0011628113],"category_scores_gemma":[0.0003915818,0.00034187792,0.0015476358,0.002309842,0.00009023211,0.000109564615,0.00062131527,0.0007432748,0.000026611655],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009640138,0.00009289582,0.000112704,0.80991197,0.18518189,0.00014353581,0.000046238285,2.442821e-7,1.1359542e-9,0.0000042439538,0.0004834999,0.004013124],"study_design_scores_gemma":[0.00034547344,0.00012887866,0.000044450906,0.2550064,0.7109314,0.000022994978,0.000011893977,7.0572736e-7,1.0500271e-7,2.8930904e-7,0.033220038,0.00028735373],"about_ca_topic_score_codex":0.0019819262,"about_ca_topic_score_gemma":0.0006163615,"teacher_disagreement_score":0.5549056,"about_ca_system_score_codex":0.0012067922,"about_ca_system_score_gemma":0.0016947048,"threshold_uncertainty_score":0.9999033},"labels":[],"label_agreement":null},{"id":"W3180426532","doi":"10.1001/jamaoncol.2021.2140","title":"Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of <i>ERBB2</i>-Positive Metastatic Breast Cancer","year":2021,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; CancerCare Manitoba; Queen's University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Metastatic breast cancer; Oncology; Breast cancer; Cancer; Internal medicine; Intensive care medicine","score_opus":0.08597336018157553,"score_gpt":0.4605725266895825,"score_spread":0.37459916650800695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180426532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86272746,0.0041381097,0.0018324855,0.123783715,0.00053126283,0.0025136317,0.0033695046,0.000015505859,0.0010883246],"genre_scores_gemma":[0.98594284,0.0040941346,0.0045574517,0.003389159,0.0001404586,0.0005413147,0.0000563248,0.00003133233,0.0012469703],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998875,0.00015052974,0.0002985591,0.00021666811,0.0002357739,0.0002234708],"domain_scores_gemma":[0.99631894,0.0025676885,0.00019014985,0.00024150853,0.0005974944,0.00008420957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028217872,0.000115506715,0.00052380055,0.00004851344,0.000040808703,0.0000069466237,0.00006574087,0.000071373375,0.00024574515],"category_scores_gemma":[0.0004215123,0.00007213205,0.0001029985,0.00013435434,0.0001357646,0.000051600673,0.000040648913,0.000103675084,0.000001117466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057470165,0.014228267,0.32354346,0.0012473973,0.009413215,0.00057286536,0.012842532,0.00007210813,0.034840614,0.00071778253,0.006771328,0.59000343],"study_design_scores_gemma":[0.016225064,0.004542766,0.8159953,0.00014880692,0.0019928447,0.000498781,0.0042687696,0.0008143598,0.026843775,0.000021989075,0.12851158,0.00013601576],"about_ca_topic_score_codex":0.00240499,"about_ca_topic_score_gemma":0.00074652705,"teacher_disagreement_score":0.5898674,"about_ca_system_score_codex":0.000348127,"about_ca_system_score_gemma":0.0007587509,"threshold_uncertainty_score":0.36356413},"labels":[],"label_agreement":null},{"id":"W3186846250","doi":"10.1111/cas.15086","title":"TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Science","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal; Theratechnologies (Canada)","funders":"Québec Consortium for Drug Discovery","keywords":"Docetaxel; Cancer research; Triple-negative breast cancer; In vivo; Breast cancer; Gene silencing; Medicine; Cancer; Internalization; Apoptosis; Receptor; Internal medicine; Biology","score_opus":0.07158712367629191,"score_gpt":0.4232752614865087,"score_spread":0.3516881378102168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186846250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78866166,0.0687514,0.005097557,0.108005114,0.004964227,0.010611074,0.003965831,0.00018401253,0.009759147],"genre_scores_gemma":[0.96839726,0.012716652,0.0012149586,0.0013696033,0.0008853169,0.0012356004,0.000007023672,0.000040481686,0.014133104],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997457,0.0000456026,0.00033856227,0.0006709822,0.0008285875,0.0006592132],"domain_scores_gemma":[0.9972699,0.0003799132,0.00015557565,0.00061112235,0.001205576,0.0003778708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038606985,0.00021430635,0.00044737253,0.0000984974,0.00031337872,0.00006940665,0.00037259026,0.00005431977,0.0007719147],"category_scores_gemma":[0.0002240568,0.00013652713,0.00018536621,0.0013719405,0.0012907132,0.00018340068,0.000073267394,0.0001463811,0.000009508849],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033999472,0.00095211004,0.02217351,0.00036711205,0.0008598274,0.00013631996,0.016924351,0.0007489381,0.17729874,0.0014759188,0.015980473,0.7596828],"study_design_scores_gemma":[0.006368072,0.0011255476,0.09336929,0.0006675611,0.00035772612,0.00008802904,0.0014185372,0.003241214,0.8698734,0.00041666857,0.022765052,0.0003089089],"about_ca_topic_score_codex":0.0059238835,"about_ca_topic_score_gemma":0.0021143295,"teacher_disagreement_score":0.75937384,"about_ca_system_score_codex":0.0012449007,"about_ca_system_score_gemma":0.010426153,"threshold_uncertainty_score":0.9951838},"labels":[],"label_agreement":null},{"id":"W3194861850","doi":"10.3390/jpm11080808","title":"Breast Cancer Treatments: Updates and New Challenges","year":2021,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":473,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Cancer; Immunotherapy; Oncology; Targeted therapy; Radiation therapy; Triple-negative breast cancer; Internal medicine; Epidermal growth factor receptor; Bioinformatics; Cancer research; Biology","score_opus":0.26747323684843194,"score_gpt":0.49935521943700617,"score_spread":0.23188198258857423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194861850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009913727,0.97703844,0.000005181877,0.021014296,0.00061934517,0.00048717012,0.000054113254,0.000013433278,0.0007581014],"genre_scores_gemma":[0.0000014957867,0.9856116,0.00042097236,0.00032396123,0.005856038,0.00002634029,0.00003555215,0.00010485841,0.0076191826],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612767,0.0002894251,0.0012423622,0.0004516819,0.0014225977,0.00046628766],"domain_scores_gemma":[0.99660677,0.00037420238,0.00090738176,0.0003761765,0.00061235414,0.0011231159],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097380416,0.00058006094,0.004840652,0.00059672416,0.00005754263,0.000022989332,0.0002477902,0.00036032833,0.006068522],"category_scores_gemma":[0.0003322357,0.00033742888,0.0006396256,0.00043217983,0.00035501894,0.00009301974,0.00007987545,0.0012366896,0.000012800257],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001288102,0.00011110913,0.000020176893,0.015564171,0.0023912243,0.0016267707,0.0005699721,2.1690237e-8,0.000004405748,0.00007478909,0.039894063,0.9396145],"study_design_scores_gemma":[0.004064869,0.0006725148,0.00004344796,0.13094226,0.006689158,0.023999896,0.0004474685,5.693417e-7,8.402169e-7,0.000019175557,0.83292896,0.0001908509],"about_ca_topic_score_codex":0.00018893952,"about_ca_topic_score_gemma":0.000015728696,"teacher_disagreement_score":0.9394236,"about_ca_system_score_codex":0.000803501,"about_ca_system_score_gemma":0.004382044,"threshold_uncertainty_score":0.9999078},"labels":[],"label_agreement":null},{"id":"W3195543529","doi":"10.3390/life11090868","title":"Epigenetic Silencing of HER2 Expression during Epithelial-Mesenchymal Transition Leads to Trastuzumab Resistance in Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Life","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; University of Alberta","funders":"Canadian Institutes of Health Research; Women and Children's Health Research Institute; Children's Health Research Institute","keywords":"Lapatinib; Gene silencing; Cancer research; Trastuzumab; Breast cancer; Epigenetics; Epithelial–mesenchymal transition; Cancer; Biology; Chromatin; Gene; Metastasis; Genetics","score_opus":0.021159398207756013,"score_gpt":0.3219307502491696,"score_spread":0.3007713520414136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195543529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99163955,0.0017735485,0.00018577842,0.005219146,0.00013234543,0.00032449543,0.00008096268,0.000025912293,0.0006182316],"genre_scores_gemma":[0.9972292,0.00040249454,0.00089756085,0.00033524996,0.00030252512,0.000091843714,0.000006978122,0.000035036217,0.00069908134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803376,0.00012986241,0.00042057686,0.00039984117,0.00060188817,0.0004140909],"domain_scores_gemma":[0.9990739,0.0000630456,0.000052496755,0.00035683572,0.0001781197,0.00027558388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024218009,0.00014205422,0.0003729666,0.0001610902,0.000051456107,0.000011807295,0.00010423156,0.00009951487,0.0007191367],"category_scores_gemma":[0.0001416652,0.00014110011,0.00007740362,0.0006012337,0.000050068506,0.00006543464,0.000041507043,0.0002801067,0.000017713395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006462756,0.00012817625,0.018327285,0.00089311216,0.0000130944345,0.00018009594,0.0035401853,0.00056251924,0.9742308,0.0000076524675,0.0002842123,0.001186536],"study_design_scores_gemma":[0.0011945915,0.000055224835,0.36562535,0.0026702934,0.00001537944,0.000020897007,0.00070044294,0.0000496702,0.6293439,0.000017604218,0.00017856149,0.00012805135],"about_ca_topic_score_codex":0.0004385793,"about_ca_topic_score_gemma":0.0010164846,"teacher_disagreement_score":0.34729806,"about_ca_system_score_codex":0.00037154066,"about_ca_system_score_gemma":0.0007298695,"threshold_uncertainty_score":0.78740424},"labels":[],"label_agreement":null},{"id":"W3197219028","doi":"10.3390/ijms22179569","title":"Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting","year":2021,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Canadian Institutes of Health Research; McGill University","keywords":"Potency; Kinase; IC50; Pharmacology; In vitro; Drug; Chemistry; Small molecule; Combinatorial chemistry; Biochemistry; Medicine","score_opus":0.024508568542378976,"score_gpt":0.3675815611742724,"score_spread":0.3430729926318934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197219028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895865,0.005503554,0.0006557913,0.0037141016,0.00019045264,0.00009267029,0.000019329222,0.0000010820334,0.00023657594],"genre_scores_gemma":[0.99743384,0.00013848822,0.0022744967,0.00012284843,0.000013194915,0.0000015114362,0.000002743736,0.000004186021,0.000008706724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973539,0.00034122943,0.0006578631,0.00013598004,0.0013890596,0.000121929465],"domain_scores_gemma":[0.997256,0.0004266109,0.00063174486,0.00012330696,0.0015179095,0.0000444354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015422856,0.00007647324,0.00032039502,0.00044482967,0.00005536177,0.000028114126,0.00050478056,0.000023597117,0.000019632156],"category_scores_gemma":[0.0017133397,0.000048269645,0.0002003267,0.0014339273,0.00085999485,0.00011668314,0.00017695715,0.00022972451,7.6629306e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007089145,0.00021789968,0.03013354,0.000022358068,0.0005031187,0.000087081346,0.0025801756,0.004467422,0.95273423,0.007975894,0.000026711627,0.0011806712],"study_design_scores_gemma":[0.001235186,0.00018928491,0.024422983,0.0005214591,0.00019798835,0.00003263793,0.0070885126,0.011610473,0.9529933,0.0016211293,0.000020052239,0.00006700256],"about_ca_topic_score_codex":0.00032601043,"about_ca_topic_score_gemma":0.000060275383,"teacher_disagreement_score":0.007847381,"about_ca_system_score_codex":0.00006286686,"about_ca_system_score_gemma":0.00056195323,"threshold_uncertainty_score":0.3168687},"labels":[],"label_agreement":null},{"id":"W3197623252","doi":"10.1503/jpn.200166","title":"Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation","year":2021,"lang":"en","type":"article","venue":"Journal of Psychiatry and Neuroscience","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"National Science Fund for Distinguished Young Scholars; National Key Research and Development Program of China","keywords":"Neuregulin 1; White matter; Neuregulin; Psychology; Psychiatry; Neuroscience; Medicine; Clinical psychology; Internal medicine; Magnetic resonance imaging","score_opus":0.04579744722907405,"score_gpt":0.3689059528014966,"score_spread":0.32310850557242254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197623252","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683707,0.000983053,0.00015616021,0.028916702,0.0012113049,0.00012811604,0.000058069756,0.0000063733482,0.00016955692],"genre_scores_gemma":[0.9947615,0.001972776,0.001441574,0.0013488607,0.0003718953,0.0000014354781,0.000004997903,0.0000113735305,0.00008555719],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979246,0.00031735998,0.00085358083,0.00028505645,0.00037832762,0.0002410507],"domain_scores_gemma":[0.9986587,0.00041586193,0.00037012162,0.00015046865,0.00016432113,0.00024049607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008098684,0.00012832318,0.0003925902,0.00011188636,0.00012087571,0.000054537766,0.0001376436,0.000111257315,0.000062667474],"category_scores_gemma":[0.00039283134,0.00010368885,0.00013624314,0.00034769689,0.00037055215,0.00020509413,0.000034044202,0.0005914199,0.0000014951557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006100693,0.0002795802,0.99776685,0.000112341455,0.000014066151,0.000020771977,0.000055829143,0.000004945495,0.00039431028,0.00022038215,0.00075915176,0.0003107826],"study_design_scores_gemma":[0.00096631754,0.0012626795,0.99465173,0.00015606983,0.00012867966,0.00039977324,0.00015695531,0.00002534239,0.0000915748,0.0019181358,0.00015626651,0.000086459746],"about_ca_topic_score_codex":0.0000061276032,"about_ca_topic_score_gemma":0.00005616217,"teacher_disagreement_score":0.027567841,"about_ca_system_score_codex":0.000010772174,"about_ca_system_score_gemma":0.0005462955,"threshold_uncertainty_score":0.42283088},"labels":[],"label_agreement":null},{"id":"W3198257986","doi":"10.21203/rs.3.rs-841103/v1","title":"Definitive Results of a Phase III Adjuvant Trial Comparing Six Cycles of FEC-100 to Four Cycles of AC in Women with Operable Node-negative Breast Cancer: The NSABP B-36 Trial (NRG Oncology)","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal","funders":"National Institutes of Health","keywords":"Breast cancer; Medicine; Adjuvant; Oncology; Internal medicine; Node (physics); Gynecology; Cancer; Physics","score_opus":0.18937807339919693,"score_gpt":0.49025522985159664,"score_spread":0.3008771564523997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198257986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9780735,0.0006816376,0.000018472922,0.003579247,0.00024762377,0.010995716,0.0025398354,0.00002558435,0.0038383955],"genre_scores_gemma":[0.9928949,0.0015315291,0.00052121107,0.00004422547,0.0005708585,0.004085948,0.00009807384,0.00010144912,0.00015180756],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98766524,0.003491675,0.0020975047,0.0013614523,0.0038116707,0.0015724505],"domain_scores_gemma":[0.98872733,0.0044302656,0.00075847487,0.00171437,0.003756983,0.00061255804],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009741491,0.00055721746,0.0031968385,0.0012977283,0.00018927321,0.00008201314,0.0012721549,0.0005688056,0.00035630292],"category_scores_gemma":[0.004577251,0.0003974098,0.00032022796,0.0022049337,0.0014235204,0.00012396651,0.0021993574,0.003944374,0.0000060449497],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.934832,0.0040473235,0.0012199245,0.0028034002,0.00095364003,0.00038011614,0.021861015,0.0021901368,0.0024416668,0.00003064451,0.00073804724,0.028502136],"study_design_scores_gemma":[0.8336499,0.027635325,0.02499081,0.028188905,0.00022927888,0.000045182678,0.05789214,0.0012936252,0.024515344,0.00019538296,0.00063646736,0.00072766846],"about_ca_topic_score_codex":0.04951673,"about_ca_topic_score_gemma":0.012057712,"teacher_disagreement_score":0.10118208,"about_ca_system_score_codex":0.0032089895,"about_ca_system_score_gemma":0.014369646,"threshold_uncertainty_score":0.99984777},"labels":[],"label_agreement":null},{"id":"W3199342822","doi":"10.30683/1929-2279.2019.08.01","title":"HER2 Expression Discordance between Ductal Carcinoma In situ and Invasive Breast Carcinoma. How to Analyze Oncotype DX","year":2019,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Ductal carcinoma; Breast cancer; Oncology; Progesterone receptor; Stage (stratigraphy); Hormone receptor; Internal medicine; Invasive ductal carcinoma; Medicine; Breast carcinoma; In situ hybridization; Pathology; Cancer; Cancer research; Biology; Gene expression; Gene; Estrogen receptor","score_opus":0.05139895220199545,"score_gpt":0.4067404122457482,"score_spread":0.3553414600437527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199342822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97445357,0.004628563,0.0000067398228,0.019222151,0.00018851314,0.00085630984,0.00006169066,0.000008467635,0.0005739704],"genre_scores_gemma":[0.9963223,0.0011567984,0.00034347264,0.0001344072,0.001095823,0.000041791434,0.000009865277,0.00006174092,0.0008338558],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504745,0.0004796755,0.00061859854,0.0005448751,0.002293498,0.0010159027],"domain_scores_gemma":[0.99646765,0.0005706415,0.00022303016,0.00054909626,0.0012368459,0.0009527096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023791408,0.00027074444,0.0008788916,0.0012300159,0.00010991289,0.00018032237,0.00058475614,0.00015215059,0.00039212842],"category_scores_gemma":[0.000582388,0.00020779349,0.00013201013,0.0013173057,0.00026902716,0.0005423866,0.0004673021,0.0018544254,0.000047987138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013083775,0.000074938675,0.78761625,0.00033714168,0.00006246152,0.00057947775,0.0006394129,0.000014354543,0.1992538,0.000010402799,0.0060224505,0.004080911],"study_design_scores_gemma":[0.0024762615,0.0015220724,0.8889725,0.0016432421,0.00003311687,0.0002982238,0.0013686069,0.000019002855,0.09979418,0.00012399933,0.0035333165,0.00021543964],"about_ca_topic_score_codex":0.0017336118,"about_ca_topic_score_gemma":0.001870935,"teacher_disagreement_score":0.10135625,"about_ca_system_score_codex":0.0011374169,"about_ca_system_score_gemma":0.0022463854,"threshold_uncertainty_score":0.8473573},"labels":[],"label_agreement":null},{"id":"W3200858465","doi":"10.1002/pbc.29316","title":"Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma","year":2021,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Institute for Health and Care Research; Brain Tumour Charity; Boehringer Ingelheim","keywords":"ErbB; Medulloblastoma; Ependymoma; Neuroblastoma; Epidermal growth factor receptor; Rhabdomyosarcoma; Medicine; Cancer research; Glioma; EGFR inhibitors; Pathology; Oncology; Internal medicine; Sarcoma; Biology; Receptor; Cell culture","score_opus":0.025577329739935158,"score_gpt":0.30539863850700044,"score_spread":0.2798213087670653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200858465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384043,0.059121575,0.000006124203,0.0007561387,0.00039085117,0.0005317094,0.00013676395,0.0000397097,0.00061281247],"genre_scores_gemma":[0.9846773,0.013434898,0.000205169,0.00027109234,0.0009794021,0.00010467207,0.00001701693,0.00004361596,0.00026684423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99686754,0.00029725285,0.0007180812,0.0006304692,0.0009412407,0.0005454465],"domain_scores_gemma":[0.9978965,0.0003355646,0.0002570156,0.00072304404,0.0005479443,0.00023991922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033202494,0.00026497242,0.00096587674,0.0007175698,0.00008752611,0.000028590084,0.00027229494,0.00015851612,0.00017116097],"category_scores_gemma":[0.00016056097,0.00020779892,0.00029508158,0.0067593353,0.00010472779,0.000057368852,0.00027179203,0.000573117,0.000009225772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008250296,0.00019827505,0.9917783,0.0025085658,0.0004896354,0.00015543953,0.00045901904,0.00018691187,0.0011240374,0.000058267102,0.0018392367,0.0011197935],"study_design_scores_gemma":[0.002017216,0.00011000097,0.98840636,0.00013043587,0.0059105675,0.00003568555,0.0008509131,0.00039267156,0.00078160665,0.000006764405,0.0011223895,0.00023541221],"about_ca_topic_score_codex":0.0021571368,"about_ca_topic_score_gemma":0.00047274327,"teacher_disagreement_score":0.046272974,"about_ca_system_score_codex":0.00023077166,"about_ca_system_score_gemma":0.001379016,"threshold_uncertainty_score":0.8473794},"labels":[],"label_agreement":null},{"id":"W3202236569","doi":"10.1158/1078-0432.ccr-21-1181","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Nivolumab; Maximum tolerated dose; Clinical trial; Solid tumor; Immunotherapy; Phases of clinical research; Cytotoxic T cell","score_opus":0.14198669748668777,"score_gpt":0.559179952943152,"score_spread":0.41719325545646424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202236569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994075,0.00028437155,0.00001529737,0.0017430076,0.00019057651,0.0032598716,0.00009350176,0.000030805728,0.00030757493],"genre_scores_gemma":[0.9967209,0.0010386829,0.00046558256,0.00019612037,0.0002154651,0.00034365468,0.0002290838,0.00009896249,0.00069153594],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99131846,0.0019053859,0.0017433604,0.0011534652,0.0027766072,0.0011027025],"domain_scores_gemma":[0.9942938,0.0013591697,0.00029302962,0.0010760658,0.002414386,0.00056354055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061661736,0.00029803065,0.0015086611,0.000643865,0.00010205536,0.000057631416,0.00046567063,0.00022526542,0.0007845024],"category_scores_gemma":[0.0030453352,0.00022032617,0.00010545052,0.0027724775,0.0010937267,0.00033669884,0.00021372289,0.0021680456,0.000020426089],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42115337,0.024596613,0.5117179,0.0006555646,0.00012712885,0.0011163111,0.0004590781,0.00008540271,0.0017704631,0.000039673498,0.0005393014,0.03773921],"study_design_scores_gemma":[0.5910782,0.050065637,0.3415013,0.0037255164,0.000046832465,0.00001032217,0.00078426616,0.0008759049,0.010085095,0.00009330082,0.0012514195,0.00048220478],"about_ca_topic_score_codex":0.001685918,"about_ca_topic_score_gemma":0.0066113574,"teacher_disagreement_score":0.17021662,"about_ca_system_score_codex":0.00061278313,"about_ca_system_score_gemma":0.0063776877,"threshold_uncertainty_score":0.99925524},"labels":[],"label_agreement":null},{"id":"W3203662700","doi":"10.1186/s12967-021-03081-0","title":"Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma","year":2021,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Immunohistochemistry; Proportional hazards model; Medicine; Oncology; Cancer; Internal medicine; Epidermal growth factor receptor; Laryngeal Neoplasm; Survival analysis; Pathology; Cancer research","score_opus":0.014668160104112695,"score_gpt":0.28565917043076733,"score_spread":0.2709910103266546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203662700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876286,0.0018349783,0.00038418022,0.008583977,0.00013841454,0.00048528248,0.000023109402,0.000005514702,0.00091598614],"genre_scores_gemma":[0.9973192,0.00003419939,0.0020272317,0.00018369069,0.0002704152,0.000005311971,0.000058257167,0.000025953907,0.00007570317],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99757135,0.00014108408,0.0006114928,0.00016505855,0.0013379323,0.000173105],"domain_scores_gemma":[0.9972983,0.0004388017,0.0003806033,0.00019848344,0.0015286537,0.00015516568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035501883,0.000136247,0.0003528064,0.00010730022,0.00007857572,0.000008279587,0.00013135855,0.000066147935,0.00027247018],"category_scores_gemma":[0.00023460314,0.00007628871,0.00008221339,0.00028583294,0.0002030868,0.0001478932,0.000010246107,0.00043942808,0.0000015320735],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008653304,0.002058359,0.3217692,0.0011399729,0.00017068551,0.0003034593,0.0069129234,0.0003200251,0.6294354,0.0003073035,0.001502036,0.027427295],"study_design_scores_gemma":[0.0073654577,0.0039415555,0.95405984,0.0007629829,0.0002424446,0.00009203858,0.00096882903,0.0001622076,0.031652495,0.00015875546,0.0004986214,0.00009479075],"about_ca_topic_score_codex":0.000009301666,"about_ca_topic_score_gemma":0.00000664532,"teacher_disagreement_score":0.6322906,"about_ca_system_score_codex":0.000061489285,"about_ca_system_score_gemma":0.0005388251,"threshold_uncertainty_score":0.31109634},"labels":[],"label_agreement":null},{"id":"W3204588330","doi":"10.1016/j.annonc.2021.08.1489","title":"1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Princess Margaret Cancer Centre","funders":"Astellas Pharma; Natera; Pharmacyclics; MacroGenics; BeiGene; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb; Incyte; Amgen","keywords":"Medicine; Internal medicine; Hypokalemia; Oxaliplatin; Gastroenterology; Vomiting; Nausea; Capecitabine; Adverse effect; Cancer; Colorectal cancer","score_opus":0.16177578153297198,"score_gpt":0.4767629339354125,"score_spread":0.3149871524024406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204588330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861605,0.0023279611,0.000050958737,0.006570379,0.00013991713,0.00071985996,0.00004160955,0.000023881437,0.001509395],"genre_scores_gemma":[0.9965077,0.00054552837,0.0010236852,0.0010764085,0.00025985864,0.00006107274,0.000047873826,0.000051338116,0.00042651745],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969248,0.0003146063,0.0009286894,0.000569953,0.00062589813,0.0006360546],"domain_scores_gemma":[0.99781716,0.00027674157,0.00029594658,0.0008115501,0.0005764193,0.0002222025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092832564,0.00024519578,0.0011418406,0.00029792992,0.00007490803,0.000009519046,0.00032750863,0.00022791972,0.0011365825],"category_scores_gemma":[0.0004379507,0.00024312481,0.00014301392,0.0006430386,0.00022625855,0.00010769803,0.00028553835,0.0005541551,0.000009457138],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012041784,0.069839805,0.31037015,0.001482713,0.0010083565,0.009467173,0.01872245,0.00017732172,0.21473493,0.000055726883,0.027574155,0.33452544],"study_design_scores_gemma":[0.07482397,0.08647568,0.20267747,0.00096171204,0.00019159532,0.0006084811,0.0072548594,0.00080413907,0.59262305,0.0002269961,0.032813385,0.00053864846],"about_ca_topic_score_codex":0.00045244073,"about_ca_topic_score_gemma":0.0004989855,"teacher_disagreement_score":0.37788814,"about_ca_system_score_codex":0.00015644432,"about_ca_system_score_gemma":0.0009591588,"threshold_uncertainty_score":0.99977654},"labels":[],"label_agreement":null},{"id":"W3204658474","doi":"10.1016/j.annonc.2021.08.1962","title":"1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Refractory (planetary science); Oncology; Lung cancer; Cancer; non-small cell lung cancer (NSCLC); Antibody-drug conjugate; Antibody; Breast cancer; Monoclonal antibody; Immunology","score_opus":0.09043951009908645,"score_gpt":0.4486056378400373,"score_spread":0.35816612774095086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204658474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905705,0.001298306,0.00007023551,0.002012192,0.00022045184,0.0024841721,0.00009442071,0.00004542212,0.0032043254],"genre_scores_gemma":[0.9961181,0.0003078505,0.0009942396,0.0009941049,0.00008778381,0.0005390925,0.00008268428,0.00010552515,0.0007706002],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954667,0.00071288744,0.0010213965,0.0008748834,0.0008592013,0.0010649427],"domain_scores_gemma":[0.9966468,0.0004428861,0.00037398352,0.00070222147,0.0013735321,0.0004605313],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010232405,0.00043339017,0.0014195326,0.00044649563,0.00012033881,0.000021842228,0.00034832384,0.0001878765,0.0009364082],"category_scores_gemma":[0.0003956231,0.0003802472,0.00014373795,0.0014124234,0.000243365,0.00011073465,0.00022620196,0.0008372557,0.000018779838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011274072,0.07273239,0.6533732,0.002059733,0.0020123357,0.00822277,0.020039517,0.00048040872,0.008016906,0.00000934558,0.013035263,0.20874408],"study_design_scores_gemma":[0.19000539,0.2276051,0.44358456,0.0032053979,0.0024684016,0.00025693487,0.014025887,0.0030285474,0.08924492,0.000118954544,0.02429521,0.0021607024],"about_ca_topic_score_codex":0.0032949308,"about_ca_topic_score_gemma":0.007749074,"teacher_disagreement_score":0.20978862,"about_ca_system_score_codex":0.0005711029,"about_ca_system_score_gemma":0.004510092,"threshold_uncertainty_score":0.9999769},"labels":[],"label_agreement":null},{"id":"W3207977249","doi":"10.2217/fon-2021-0753","title":"Alliance A011801 (compassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients with Residual HER2-Positive Invasive Breast Cancer","year":2021,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Breast cancer; Oncology; Placebo; Randomized controlled trial; Cancer; Pathology","score_opus":0.015681021701659328,"score_gpt":0.3375341293603767,"score_spread":0.3218531076587174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3207977249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91118807,0.0019306097,0.000007266065,0.07021521,0.0011990875,0.0017419744,0.00047432844,0.00007339235,0.013170065],"genre_scores_gemma":[0.9823472,0.0010141588,0.002266835,0.0073107975,0.0026868444,0.00065525906,0.0005041093,0.00015025637,0.00306455],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963145,0.0006394681,0.0004947261,0.0008863491,0.0007588301,0.00090610376],"domain_scores_gemma":[0.99738306,0.0004071369,0.00019292682,0.000608436,0.0010200749,0.00038838433],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039613908,0.00037085626,0.0008729729,0.00014363922,0.00010730826,0.000029942259,0.00027725066,0.00042612912,0.002357787],"category_scores_gemma":[0.0001818849,0.00030874237,0.00007709822,0.0007468939,0.00027247006,0.00011931375,0.00018034961,0.0012458189,0.00014702666],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010259191,0.0024698174,0.8467549,0.00036669624,0.00040407528,0.003564176,0.0028631776,0.000038074217,0.0010060072,0.00020047737,0.08439041,0.04768297],"study_design_scores_gemma":[0.0100707635,0.0018665749,0.9242729,0.000782846,0.00008981108,0.00030314896,0.0013195631,0.0000072176204,0.0016632008,0.000021307018,0.05924932,0.00035337172],"about_ca_topic_score_codex":0.0008689594,"about_ca_topic_score_gemma":0.014890985,"teacher_disagreement_score":0.07751795,"about_ca_system_score_codex":0.0019776842,"about_ca_system_score_gemma":0.0050058705,"threshold_uncertainty_score":0.99993646},"labels":[],"label_agreement":null},{"id":"W3209164903","doi":"10.1093/ajcp/aqab191.053","title":"HER2 testing in metastatic breast cancer – is reflex in situ hybridization necessary in cases that are equivocal by immunohistochemistry?","year":2021,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Immunohistochemistry; Pathology; Metastatic breast cancer; Metastasis; In situ hybridization; Breast cancer; Incidence (geometry); Cancer; Oncology; Internal medicine; Biology","score_opus":0.155043225926168,"score_gpt":0.5059862879618359,"score_spread":0.35094306203566783,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209164903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887532,0.002266989,0.000062854546,0.0082707135,0.00019653214,0.00011664792,0.000032912692,0.0000062624854,0.00029387747],"genre_scores_gemma":[0.9943043,0.00126536,0.0015986382,0.0025418429,0.00017069733,0.000014996799,0.000010070215,0.000031241696,0.000062875326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958869,0.0010236134,0.0017482578,0.00040705717,0.00046558818,0.00046853384],"domain_scores_gemma":[0.99610865,0.002000593,0.0009704395,0.00030144127,0.0003843,0.0002345757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002337208,0.00018177573,0.001352902,0.000218165,0.000021644004,0.000014532617,0.00021089379,0.000104569655,0.0001986269],"category_scores_gemma":[0.0051948526,0.00016726795,0.00014906102,0.0010672306,0.00060577894,0.000107780295,0.000102815364,0.0015753455,0.0000044785916],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084081996,0.0006594663,0.82999015,0.00008979354,0.000036020825,0.025941724,0.00019219368,0.00004668656,0.028305544,6.17101e-7,0.0009670993,0.11292989],"study_design_scores_gemma":[0.005151216,0.0015169899,0.96792567,0.0018756615,0.00008057339,0.014137805,0.0034368464,0.00014940964,0.004889874,0.000118940705,0.00043585786,0.00028115322],"about_ca_topic_score_codex":0.000824806,"about_ca_topic_score_gemma":0.00039073077,"teacher_disagreement_score":0.13793552,"about_ca_system_score_codex":0.00042118414,"about_ca_system_score_gemma":0.001568688,"threshold_uncertainty_score":0.68441796},"labels":[],"label_agreement":null},{"id":"W3214083702","doi":"10.1158/0008-5472.can-21-3360","title":"HER3 Is an Actionable Target in Advanced Prostate Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute; Wellcome Trust Centre for Mitochondrial Research; Daiichi Sankyo Company; Imperial Experimental Cancer Medicine Centre; Stand Up To Cancer; National Institute for Health and Care Research; Prostate Cancer UK; Mark Foundation For Cancer Research; National Institutes of Health; Prostate Cancer Foundation; Cancer Research UK; Academy of Medical Sciences; Wellcome Trust; Chordoma Foundation","keywords":"Prostate cancer; Prostate; Cancer; PCA3; ErbB; Antibody; Immunotherapy","score_opus":0.15372566243138425,"score_gpt":0.5247178831692222,"score_spread":0.37099222073783794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214083702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9560919,0.012336384,0.000007075186,0.021463271,0.00039781045,0.001249143,0.00014314508,0.0000741915,0.008237113],"genre_scores_gemma":[0.8896722,0.014862399,0.00095762353,0.0016658636,0.0008890477,0.003664875,0.00008493955,0.00016206644,0.08804095],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99487096,0.00040143487,0.00037675814,0.0009866032,0.0018995142,0.0014647457],"domain_scores_gemma":[0.9967391,0.0001336782,0.000042027845,0.00090603577,0.0015755888,0.000603588],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014027142,0.0002145026,0.00044200377,0.00044420833,0.00022464294,0.000105370505,0.00032280275,0.00017857576,0.019092312],"category_scores_gemma":[0.00034156404,0.00020965407,0.00008198742,0.0024447853,0.00027720496,0.00035873163,0.00023596098,0.0016965041,0.00020809381],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00295891,0.001084365,0.2759699,0.0019109822,0.00019192684,0.00216361,0.0055766627,0.00092242257,0.4405973,0.00034391994,0.116266795,0.15201324],"study_design_scores_gemma":[0.0037945705,0.0004672678,0.03423371,0.0009882633,0.00001253871,0.00003780718,0.0023757287,0.000540673,0.38592523,0.0012519143,0.5699959,0.0003764109],"about_ca_topic_score_codex":0.0051440336,"about_ca_topic_score_gemma":0.00389355,"teacher_disagreement_score":0.45372906,"about_ca_system_score_codex":0.002379015,"about_ca_system_score_gemma":0.0066741966,"threshold_uncertainty_score":0.99895704},"labels":[],"label_agreement":null},{"id":"W3217635890","doi":"10.7554/elife.73218","title":"A molecular mechanism for the generation of ligand-dependent differential outputs by the epidermal growth factor receptor","year":2021,"lang":"en","type":"article","venue":"eLife","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; Canada Excellence Research Chairs, Government of Canada; VGH and UBC Hospital Foundation","keywords":"Extracellular; Epidermal growth factor; Transmembrane protein; Epidermal growth factor receptor; Tyrosine kinase; Receptor tyrosine kinase; Transmembrane domain; Intracellular; Receptor","score_opus":0.061377380090935844,"score_gpt":0.33700611762329374,"score_spread":0.2756287375323579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217635890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8985049,0.0015684894,0.07707945,0.02068731,0.0007634251,0.001072551,0.00018608046,0.000026959084,0.00011080908],"genre_scores_gemma":[0.99606836,0.00028726648,0.00027176007,0.0014176024,0.00059315446,0.00016755566,0.00006936465,0.000030067087,0.0010948874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99844295,0.00011591444,0.00025172625,0.00022757165,0.00071879337,0.0002430614],"domain_scores_gemma":[0.9988671,0.00018115467,0.00006708914,0.00036102976,0.00043507185,0.0000885857],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025598353,0.000113540795,0.00020200737,0.000023828274,0.00011336432,0.000034297653,0.0001624427,0.000080361315,0.00027168158],"category_scores_gemma":[0.0006192049,0.00006509443,0.00013536937,0.000095590665,0.00004763583,0.000025849384,0.0000808458,0.00020074302,0.000016624197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006029808,0.00007965389,0.00017065588,0.00006363428,0.00012799603,0.000005661732,0.00031268678,0.0000019937647,0.97513974,0.003473176,0.018472359,0.0020921412],"study_design_scores_gemma":[0.0008773934,0.00013325052,0.0002789043,0.000027202459,0.000058313297,0.000008950245,0.00010598543,0.0011294284,0.9936635,0.00008665318,0.003563314,0.00006713995],"about_ca_topic_score_codex":0.00007038016,"about_ca_topic_score_gemma":0.00002103415,"teacher_disagreement_score":0.09756342,"about_ca_system_score_codex":0.00006571179,"about_ca_system_score_gemma":0.00023888075,"threshold_uncertainty_score":0.29747227},"labels":[],"label_agreement":null},{"id":"W3217700626","doi":"10.1002/1878-0261.13141","title":"The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial","year":2021,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Saint-Sacrement","funders":"Associazione Italiana per la Ricerca sul Cancro; International Breast Cancer Research Foundation; F. Hoffmann-La Roche; Breast Cancer Research Foundation","keywords":"Oncology; Breast cancer; Medicine; Internal medicine; Neoadjuvant therapy; Bioinformatics; Gynecology; Cancer; Biology","score_opus":0.02953605829063439,"score_gpt":0.37249265669463144,"score_spread":0.34295659840399706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217700626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9523996,0.0012846772,0.0006675148,0.042420536,0.00021884232,0.0022128313,0.0005934804,0.000018183624,0.00018429711],"genre_scores_gemma":[0.9866682,0.0005368575,0.00037727752,0.010600595,0.00025977165,0.0011587859,0.00014192914,0.000051539537,0.00020503666],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9940998,0.0034966322,0.0004566556,0.0007885866,0.0006067407,0.00055160397],"domain_scores_gemma":[0.9972159,0.0009903639,0.00009840255,0.0006621543,0.0006281337,0.0004050156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009477461,0.0002736591,0.00066633796,0.00012464619,0.00021616975,0.00008432505,0.00029046502,0.00021857215,0.00025046547],"category_scores_gemma":[0.0004513535,0.00017463545,0.00016384544,0.001496765,0.00023670038,0.000094125884,0.00018374252,0.00054692547,0.0000111449735],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43676865,0.0022283765,0.025371544,0.000006456748,0.0041442504,0.0030762742,0.03469991,0.00054591295,0.086018145,0.000083310944,0.0030715165,0.40398565],"study_design_scores_gemma":[0.045166418,0.016549582,0.8666567,0.00015583457,0.0007391301,0.000034861616,0.008376731,0.00065170357,0.0365076,0.00013248679,0.024534162,0.0004947564],"about_ca_topic_score_codex":0.0030547315,"about_ca_topic_score_gemma":0.00859999,"teacher_disagreement_score":0.84128517,"about_ca_system_score_codex":0.0009083763,"about_ca_system_score_gemma":0.0014265096,"threshold_uncertainty_score":0.7121427},"labels":[],"label_agreement":null},{"id":"W4200093061","doi":"10.1002/cam4.4449","title":"What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"National Center for Advancing Translational Sciences; Ministero della Salute","keywords":"microRNA; Breast cancer; Cancer; Oncology; Exploratory research; Exploratory analysis; Medicine; Internal medicine; Biology; Genetics; Computer science; Gene; Data science","score_opus":0.030898679600262283,"score_gpt":0.37358260290346085,"score_spread":0.3426839233031986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200093061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94887453,0.028407225,0.0000067820274,0.019855069,0.0013941621,0.0010004542,0.00030892764,0.000024974273,0.00012788734],"genre_scores_gemma":[0.984097,0.009753183,0.00001568967,0.00273448,0.0023048029,0.00047817625,0.00026071837,0.000057060362,0.00029886197],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99584854,0.00058709196,0.0007381341,0.00080141006,0.0015068846,0.0005179344],"domain_scores_gemma":[0.9968907,0.00020474842,0.00022669614,0.0010797638,0.0011985673,0.00039949844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064591825,0.00034476587,0.0011932914,0.0003609572,0.00009606618,0.000033845823,0.0003976676,0.0001494168,0.0037611227],"category_scores_gemma":[0.00007787433,0.00022075263,0.000150659,0.0028889896,0.00034328518,0.00035531,0.00015222377,0.00074211205,0.0000067209667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073275703,0.0011228621,0.8958577,0.00010494908,0.0016388823,0.0003026708,0.03362497,0.00007207754,0.0011661111,0.0000046214027,0.003465523,0.061906904],"study_design_scores_gemma":[0.0050604767,0.00060977065,0.8978933,0.0012591446,0.0015541535,0.0000037451891,0.09006804,0.0001424724,0.00094603887,0.00002231088,0.0022348945,0.00020561145],"about_ca_topic_score_codex":0.014412711,"about_ca_topic_score_gemma":0.043657195,"teacher_disagreement_score":0.06170129,"about_ca_system_score_codex":0.000810085,"about_ca_system_score_gemma":0.000991566,"threshold_uncertainty_score":0.9971496},"labels":[],"label_agreement":null},{"id":"W4200320387","doi":"10.1158/1535-7163.targ-21-p196","title":"Abstract P196: Novel hydrophilic drug linkers enable exatecan-based antibody-drug conjugates with promising physiochemical properties and in vivo activity","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Profound Medical (Canada)","funders":"","keywords":"In vivo; Conjugate; Linker; Pharmacokinetics; Chemistry; Camptothecin; Drug; Potency; Pharmacology; Combinatorial chemistry; Pharmacodynamics; In vitro; Biochemistry; Medicine; Biology","score_opus":0.04894244771709914,"score_gpt":0.32794026793012554,"score_spread":0.2789978202130264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200320387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98801786,0.0062003443,0.00012371782,0.0043509137,0.000055603366,0.0007467279,0.000024874202,0.000059760107,0.00042019266],"genre_scores_gemma":[0.9970359,0.00056679366,0.00043496097,0.0014228902,0.00007935292,0.00012050711,0.000012177566,0.00009811313,0.00022926719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779713,0.00007666575,0.00025592328,0.00063870824,0.0006406141,0.00059098325],"domain_scores_gemma":[0.9989396,0.000052155618,0.000088413544,0.0004977505,0.00023786479,0.00018422399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002298485,0.00032542326,0.00048435258,0.00010974227,0.00009084905,0.000092601906,0.00014051334,0.00012082841,0.0000724924],"category_scores_gemma":[0.000025597396,0.00026813868,0.00007769192,0.00045193272,0.0003951632,0.000088087545,0.00006567536,0.0006642178,0.0000023476007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083965325,0.0003905725,0.0033148509,0.00086139137,0.00017885641,0.00023498951,0.00046553471,0.0006448909,0.99061334,0.0000041876983,0.000029623749,0.0024220836],"study_design_scores_gemma":[0.0028044041,0.00009494337,0.0015587771,0.001292553,0.00009456316,0.000024466053,0.00017259101,0.0042386265,0.9873518,0.000023832512,0.0020135795,0.0003298949],"about_ca_topic_score_codex":0.0011535619,"about_ca_topic_score_gemma":0.000309692,"teacher_disagreement_score":0.009018072,"about_ca_system_score_codex":0.00036831913,"about_ca_system_score_gemma":0.0015193387,"threshold_uncertainty_score":0.99997705},"labels":[],"label_agreement":null},{"id":"W4200511560","doi":"10.1038/s41416-021-01676-4","title":"No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer","year":2021,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Princess Margaret Cancer Centre; University of Alberta; St. Michael's Hospital","funders":"","keywords":"Medicine; Internal medicine; Metastatic breast cancer; Trastuzumab; Oncology; Hazard ratio; Breast cancer; Taxane; Proportional hazards model; Radiation therapy; Lapatinib; Chemotherapy; Cancer; Surgery; Confidence interval","score_opus":0.07852426429881962,"score_gpt":0.4304724511525911,"score_spread":0.3519481868537715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200511560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84291893,0.1403709,0.00011903366,0.013924957,0.00078386796,0.000904068,0.00095420313,0.000009907075,0.000014142333],"genre_scores_gemma":[0.92639345,0.06992348,0.000498351,0.0009692775,0.00093536807,0.00026018717,0.000019335237,0.00007647344,0.00092405855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967825,0.00022616699,0.00085077644,0.00039010175,0.0012176029,0.0005328519],"domain_scores_gemma":[0.99585867,0.0005060392,0.00029894142,0.00033307404,0.0020088784,0.0009943879],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007870119,0.00021029708,0.00067101495,0.0002537688,0.00007271397,0.00007150206,0.00030620513,0.000052684878,0.0021070156],"category_scores_gemma":[0.0017527678,0.00022099855,0.0002868401,0.0006774913,0.00013865819,0.0002756567,0.00006643341,0.00042168325,0.0000039111724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3175881,0.0018305946,0.35351646,0.00524325,0.0013621104,0.014298903,0.000523171,0.005256193,0.0047465474,0.000009911412,0.026352918,0.26927185],"study_design_scores_gemma":[0.013354981,0.001201932,0.959907,0.018554626,0.00036331758,0.00015726581,0.00006075826,0.00008713984,0.0018140385,0.000045187753,0.0041540987,0.000299673],"about_ca_topic_score_codex":0.0015834798,"about_ca_topic_score_gemma":0.008467875,"teacher_disagreement_score":0.60639054,"about_ca_system_score_codex":0.00076531543,"about_ca_system_score_gemma":0.005413647,"threshold_uncertainty_score":0.99880517},"labels":[],"label_agreement":null},{"id":"W4200592628","doi":"10.1158/1535-7163.targ-21-p062","title":"Abstract P062: The CL2A-SN38 linker-payload system conjugated to trastuzumab results in improved cellular cytotoxicity over time relative to T-DM1","year":2021,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Linker; Cytotoxicity; Chemistry; Conjugate; Trastuzumab; Conjugated system; Antibody-drug conjugate; Internalization; Prodrug; Endosome; Cancer cell; Biophysics; Combinatorial chemistry; Biochemistry; Monoclonal antibody; Cancer; In vitro; Antibody; Biology; Intracellular; Cell","score_opus":0.03613944612334209,"score_gpt":0.33726379957734026,"score_spread":0.3011243534539982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200592628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97085804,0.003392355,0.0019091427,0.015001409,0.00043299684,0.00338002,0.00038174944,0.00017619657,0.004468105],"genre_scores_gemma":[0.98976445,0.00013099816,0.00049872854,0.00738805,0.00022100846,0.00036107903,0.000060605842,0.00013826959,0.0014368381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99575293,0.00039886124,0.0008671614,0.000967906,0.0010629378,0.00095019204],"domain_scores_gemma":[0.9972752,0.00022253687,0.00015883101,0.0013374271,0.000558812,0.00044722078],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083406497,0.00046060665,0.00072018884,0.00020894877,0.00014456184,0.00011473592,0.0004690175,0.000345786,0.00023844665],"category_scores_gemma":[0.00018725355,0.00037516418,0.00023623618,0.001462406,0.000120465455,0.00007480767,0.00020943763,0.0011628036,0.00027423436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001614352,0.00020244764,0.00036169883,0.00018820797,0.00047361932,0.0010761678,0.0024600194,0.0006396246,0.9871453,0.00010469342,0.0005199067,0.005213941],"study_design_scores_gemma":[0.0056000976,0.00079334684,0.016587993,0.0013282446,0.00027194273,0.00004300064,0.00063811726,0.005520478,0.9278391,0.000059392063,0.040587462,0.00073084806],"about_ca_topic_score_codex":0.001092164,"about_ca_topic_score_gemma":0.00041366986,"teacher_disagreement_score":0.05930624,"about_ca_system_score_codex":0.0020848156,"about_ca_system_score_gemma":0.0013136828,"threshold_uncertainty_score":0.99987},"labels":[],"label_agreement":null},{"id":"W4205118191","doi":"10.51731/cjht.2022.240","title":"Tucatinib (Tukysa)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Capecitabine; Trastuzumab; Pertuzumab; Medicine; Trastuzumab emtansine; Oncology; Internal medicine; Breast cancer; Cancer; Political science; Colorectal cancer","score_opus":0.08428908766939776,"score_gpt":0.38703315185344067,"score_spread":0.3027440641840429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205118191","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.27710187,0.15944164,0.000102796264,0.5556741,0.0017116709,0.000891306,0.00008341288,0.00026132344,0.0047318856],"genre_scores_gemma":[0.99684167,0.0003178554,0.0006894852,0.0017192949,0.000022210788,0.000024272602,0.000002383307,0.00002089064,0.0003619281],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982708,0.00009953731,0.00049454387,0.00012518596,0.00041947706,0.00059045403],"domain_scores_gemma":[0.99899167,0.000054533743,0.0002558295,0.00033200707,0.00016135735,0.00020462235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014540955,0.000089629604,0.00034839477,0.00096257596,0.00045619832,0.000017777618,0.00046075945,0.00006213489,0.0006350797],"category_scores_gemma":[0.0008354833,0.0000823739,0.000077706594,0.0006509264,0.00020784141,0.00004003197,0.000059648868,0.0013047134,0.00001297581],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035243895,0.00003621535,0.020864494,0.0001759088,0.00004119192,0.0009388498,0.000631968,0.000020715648,0.00006649089,0.0011918959,0.13920315,0.8367939],"study_design_scores_gemma":[0.0004752898,0.0014344205,0.00675892,0.000100001394,0.000006837724,0.0020758454,0.00848246,0.000007998116,0.00023535528,0.0015740265,0.9787717,0.000077173],"about_ca_topic_score_codex":0.0054758587,"about_ca_topic_score_gemma":0.0014152686,"teacher_disagreement_score":0.83956856,"about_ca_system_score_codex":0.0017982105,"about_ca_system_score_gemma":0.014461689,"threshold_uncertainty_score":0.9911254},"labels":[],"label_agreement":null},{"id":"W4205404910","doi":"10.1038/s41598-022-05209-8","title":"Efficacy of adjuvant trastuzumab in women with HER2-positive T1a or bN0M0 breast cancer: a population-based cohort study","year":2022,"lang":"en","type":"article","venue":"Scientific Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Cancer Agency","keywords":"Trastuzumab; Medicine; Breast cancer; Hazard ratio; Internal medicine; Oncology; Adjuvant; Cohort; Proportional hazards model; Population; Gynecology; Concordance; Cancer; Confidence interval","score_opus":0.01860266590587352,"score_gpt":0.33582704513284545,"score_spread":0.31722437922697194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205404910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950009,0.0000624047,0.0000059390895,0.00034720404,0.0008699264,0.003342004,0.00006323212,0.000043489526,0.00026492524],"genre_scores_gemma":[0.9968847,0.0000015257552,0.00005047583,0.000048387585,0.000041033647,0.0013091909,0.00008409546,0.000039420196,0.0015411425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99508005,0.00024522378,0.00076137116,0.0010214173,0.0023439557,0.0005479664],"domain_scores_gemma":[0.9979987,0.00010542017,0.00034507384,0.0010029762,0.000311219,0.00023660297],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003245089,0.00019066097,0.0005793336,0.00052452885,0.0002904558,0.000057068326,0.00017128141,0.000034093315,0.0025963904],"category_scores_gemma":[0.00012520456,0.00014595705,0.00005583711,0.0021914844,0.00020889615,0.000071882685,0.00011207889,0.00037479703,0.0000026177718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029574672,0.0022142406,0.9782239,0.00008206415,0.00009689591,0.0034133524,0.0026843844,0.0024713022,0.0006551176,7.417449e-7,0.00086195004,0.0063385535],"study_design_scores_gemma":[0.002222846,0.0012758861,0.99219537,0.0001967199,0.00005532893,0.00046324346,0.002153968,0.000269138,0.0004031285,0.000014406403,0.0005832121,0.00016677483],"about_ca_topic_score_codex":0.0069799027,"about_ca_topic_score_gemma":0.001587458,"teacher_disagreement_score":0.013971417,"about_ca_system_score_codex":0.0021935403,"about_ca_system_score_gemma":0.0030559478,"threshold_uncertainty_score":0.9996327},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","score_opus":0.053771382150858645,"score_gpt":0.4747381370782596,"score_spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205813526","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017827857,0.99058783,0.000009665972,0.0051391074,0.001378048,0.0020792529,0.00009825947,0.000028462826,0.0005010656],"genre_scores_gemma":[0.00034214524,0.9961335,0.00007811446,0.00073549536,0.001183982,0.0013382903,0.00008217014,0.000083192266,0.00002309159],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942975,0.0017029959,0.0013008518,0.00075437943,0.0012208216,0.0007234372],"domain_scores_gemma":[0.99668247,0.0019249856,0.00051796495,0.00053042674,0.000100274076,0.00024388939],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002064392,0.00053306646,0.0029602258,0.00043395476,0.00009538966,0.000008070926,0.0007205194,0.0005535769,0.0025898332],"category_scores_gemma":[0.00014757931,0.0003230261,0.0002541678,0.0013963019,0.00083218503,0.0000922792,0.0002651295,0.0035131196,0.0000026598868],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006390557,0.00043739405,0.00066486903,0.003933098,0.00013294817,0.00018240816,0.00065144344,0.000003884583,0.0000010680999,0.00010510591,0.000042436743,0.99320626],"study_design_scores_gemma":[0.002482198,0.0009977864,0.0006097439,0.007690889,0.0001501441,0.00037822372,0.0005722809,0.000053774547,0.0000012097769,0.00017386352,0.9866175,0.0002723619],"about_ca_topic_score_codex":0.00007537144,"about_ca_topic_score_gemma":0.00029976422,"teacher_disagreement_score":0.9929339,"about_ca_system_score_codex":0.00082086545,"about_ca_system_score_gemma":0.003330751,"threshold_uncertainty_score":0.99992216},"labels":[],"label_agreement":null},{"id":"W4210879173","doi":"10.1007/s10549-021-06449-4","title":"Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial","year":2022,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"Boehringer Ingelheim","keywords":"Vinorelbine; Medicine; Afatinib; Lapatinib; Internal medicine; Oncology; Trastuzumab; Breast cancer; Metastatic breast cancer; Clinical endpoint; Rash; Cancer; Chemotherapy; Clinical trial; Gefitinib; Epidermal growth factor receptor","score_opus":0.07544896408578985,"score_gpt":0.4259875661619342,"score_spread":0.3505386020761443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210879173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784501,0.0003255498,6.6405283e-7,0.004528202,0.000045267036,0.012199453,0.0043751,0.00003280372,0.000042858588],"genre_scores_gemma":[0.9850956,0.0008186143,0.00015789844,0.00009188103,0.00010316008,0.012509964,0.00041490005,0.00010628701,0.0007016923],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9944965,0.0008063531,0.000555648,0.0013355934,0.001689428,0.0011164246],"domain_scores_gemma":[0.9977595,0.00029861368,0.0001810177,0.00048749056,0.00053385657,0.000739524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008165706,0.00054024346,0.00097148126,0.0006115262,0.0006881583,0.0002381771,0.00026638957,0.00010487625,0.0008624666],"category_scores_gemma":[0.00004147729,0.00031547615,0.000020521153,0.0012456459,0.00052625657,0.00043987783,0.0003918608,0.00074124226,0.0000012456393],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5948973,0.034524046,0.11547418,0.00015816648,0.00026698122,0.0005636121,0.0015868059,0.000003036363,0.000037125166,0.000007821033,0.00007261014,0.25240833],"study_design_scores_gemma":[0.39809215,0.16327734,0.43476313,0.0014376374,0.00008373157,0.00019702673,0.0011266401,0.000382681,0.00011339158,0.000003992125,0.00018532347,0.00033696747],"about_ca_topic_score_codex":0.018540453,"about_ca_topic_score_gemma":0.03389572,"teacher_disagreement_score":0.31928894,"about_ca_system_score_codex":0.0028354807,"about_ca_system_score_gemma":0.0022480022,"threshold_uncertainty_score":0.9999297},"labels":[],"label_agreement":null},{"id":"W4211157853","doi":"10.3389/fonc.2021.667397","title":"Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches","year":2022,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; University of Toronto","keywords":"Medicine; Minimal residual disease; Disease; Breast cancer; Clinical trial; Oncology; Bone marrow; Internal medicine; Cancer; Stage (stratigraphy); Bioinformatics","score_opus":0.1652289853562642,"score_gpt":0.4071593561355931,"score_spread":0.2419303707793289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211157853","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031966722,0.99158794,0.000009543983,0.004173688,0.00059765624,0.0025469845,0.00036505223,0.000013815095,0.00038566478],"genre_scores_gemma":[0.0001333697,0.9957607,0.0021272148,0.000074330834,0.00030590245,0.0011444575,0.00011099764,0.000067998364,0.00027507686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99609315,0.0011609267,0.00082286727,0.0008556086,0.0004436734,0.00062374945],"domain_scores_gemma":[0.99853003,0.00036648297,0.000306431,0.00033067272,0.000033534096,0.00043284474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011550362,0.00039690707,0.0022625478,0.00068801583,0.000038755003,0.0000075281373,0.00037797604,0.00032012066,0.00013777068],"category_scores_gemma":[0.0002077081,0.0003627354,0.00015856452,0.00052086374,0.00021364323,0.000048961927,0.00036658312,0.0011851917,0.0000027939816],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010462533,0.00040188374,0.00063444994,0.0064357505,0.00020351361,0.0001203839,0.002310217,0.0000048469483,0.0000010145939,0.000024932395,0.007411907,0.98140484],"study_design_scores_gemma":[0.0010501532,0.0013643468,0.004152773,0.0077498374,0.00041653306,0.000029820467,0.0010682166,0.000031623866,0.0000014547569,0.00010099597,0.983643,0.00039124503],"about_ca_topic_score_codex":0.00029767223,"about_ca_topic_score_gemma":0.000120893805,"teacher_disagreement_score":0.9810136,"about_ca_system_score_codex":0.002325543,"about_ca_system_score_gemma":0.0042945365,"threshold_uncertainty_score":0.99988246},"labels":[],"label_agreement":null},{"id":"W4212796650","doi":"10.5306/wjco.v13.i2.135","title":"Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas","year":2022,"lang":"en","type":"article","venue":"World Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Breast cancer; Medicine; Receptor tyrosine kinase; Cancer research; Tyrosine kinase; Cancer; Oncology; Internal medicine; Bioinformatics; Receptor; Biology","score_opus":0.0986459385811777,"score_gpt":0.43283005071646263,"score_spread":0.3341841121352849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212796650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97243357,0.0028862578,0.0000061568994,0.015728187,0.0024619333,0.00039445108,0.000021768454,0.000012199644,0.006055469],"genre_scores_gemma":[0.9894786,0.0010882197,0.00073892693,0.005035829,0.001622747,0.0000288659,0.0000060162697,0.000050553488,0.0019502623],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944825,0.0015940673,0.0021268518,0.00040013282,0.0008835749,0.0005128852],"domain_scores_gemma":[0.9959906,0.0018062262,0.0007937679,0.00034554215,0.00028275448,0.00078114076],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005972367,0.00020668644,0.0014390909,0.00069327216,0.00011264045,0.000012927727,0.00035687585,0.00017163553,0.002301212],"category_scores_gemma":[0.0010093421,0.00018554986,0.00032362103,0.0006759749,0.00054892787,0.00009175395,0.00034923674,0.0040137484,0.00001672425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016645318,0.0021311473,0.7760028,0.00020746827,0.00022693898,0.010807966,0.00044853947,0.00017210489,0.0073920405,0.00013311509,0.08103807,0.10479445],"study_design_scores_gemma":[0.007854671,0.0064602373,0.58038473,0.00012098225,0.00008376065,0.0012080341,0.0002567356,0.00019929906,0.000020349442,0.00005556152,0.40320805,0.00014756683],"about_ca_topic_score_codex":0.00017087697,"about_ca_topic_score_gemma":0.00021111844,"teacher_disagreement_score":0.32217,"about_ca_system_score_codex":0.000824023,"about_ca_system_score_gemma":0.0031371347,"threshold_uncertainty_score":0.9986108},"labels":[],"label_agreement":null},{"id":"W4212829434","doi":"10.1093/jnci/djv244","title":"Response","year":2015,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Computer science","score_opus":0.23137384200923772,"score_gpt":0.46457669080654057,"score_spread":0.23320284879730285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212829434","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027680919,0.0020744514,0.000012108492,0.97912234,0.009271958,0.00035196947,0.00023279032,0.000012227161,0.0061540417],"genre_scores_gemma":[0.0037864195,0.00036309467,0.00044149096,0.9146588,0.04312136,0.000038652015,0.000022960447,0.00007837902,0.037488855],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931125,0.00032455492,0.00073676056,0.00021476203,0.005267364,0.00034403193],"domain_scores_gemma":[0.99393463,0.00023072235,0.0007656469,0.00030266063,0.004581613,0.00018475164],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0028035024,0.000253891,0.00056052103,0.00047794648,0.000116266645,0.000056423592,0.00086387136,0.0005238647,0.00041740297],"category_scores_gemma":[0.003274756,0.00015891746,0.00044637095,0.0005077791,0.00032900914,0.00020794843,0.00014364373,0.004322663,0.00006074448],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014777969,0.000026831089,0.0002011384,0.00012069842,0.0002820243,0.00052183017,0.00007406172,0.00018894619,0.00030566915,0.00001731377,0.99604833,0.00073533604],"study_design_scores_gemma":[0.0013978776,0.00018816063,0.00097157864,0.0009930743,0.0001543898,0.0016520726,0.0000045054667,0.000014734438,0.0003728243,0.0006298118,0.9934686,0.00015239342],"about_ca_topic_score_codex":0.00007591677,"about_ca_topic_score_gemma":0.000024946894,"teacher_disagreement_score":0.06446357,"about_ca_system_score_codex":0.0046713543,"about_ca_system_score_gemma":0.019569153,"threshold_uncertainty_score":0.99914956},"labels":[],"label_agreement":null},{"id":"W4212868198","doi":"10.1007/978-3-662-46875-3_1933","title":"Epidermal Growth Factor-like Ligands","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Epidermal growth factor; Computer science; Medicine; Internal medicine; Programming language; Receptor","score_opus":0.0645098071193837,"score_gpt":0.3399901661483824,"score_spread":0.2754803590289987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4212868198","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011341863,0.00055357546,0.00031633256,0.0024935745,0.00051875744,0.0005519878,0.0000360495,0.0002031112,0.9952132],"genre_scores_gemma":[0.022596758,0.0006681596,0.00023581646,0.0029104992,0.0016666641,0.000018588378,0.000084567444,0.00018382767,0.9716351],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973235,0.000013633512,0.0004598398,0.0006078418,0.0010527306,0.0005424343],"domain_scores_gemma":[0.9980564,0.00018461367,0.000104500585,0.00081441767,0.00031543773,0.0005246022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028420606,0.0004434746,0.00084645837,0.0002925174,0.000060715633,0.00003499929,0.00027185402,0.0006760838,0.02411581],"category_scores_gemma":[0.00011496749,0.00035196953,0.0003160968,0.000034170393,0.00018931387,0.000030946056,0.00017604335,0.0011654741,0.004337956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023698571,0.00004914683,0.0019604303,0.0017869743,0.00060278916,0.00074851216,0.00015113853,1.8657911e-7,0.00055032613,0.20889182,0.7288249,0.05619677],"study_design_scores_gemma":[0.0007902463,0.00042276515,0.00051899557,0.0005141845,0.00008561735,0.00011138562,0.0000035470557,0.000016990363,0.0014556411,0.0023494784,0.99332887,0.00040230143],"about_ca_topic_score_codex":0.00012389907,"about_ca_topic_score_gemma":0.000038583108,"teacher_disagreement_score":0.26450393,"about_ca_system_score_codex":0.00026274563,"about_ca_system_score_gemma":0.0004696909,"threshold_uncertainty_score":0.99989325},"labels":[],"label_agreement":null},{"id":"W4214522566","doi":"10.1016/j.clbc.2022.02.008","title":"Characteristics, Clinical Differences and Outcomes of Breast Cancer Patients with Negative or Low HER2 Expression","year":2022,"lang":"en","type":"article","venue":"Clinical Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital; Algoma University","funders":"","keywords":"Medicine; Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Trastuzumab; Cancer; Stage (stratigraphy)","score_opus":0.067916034245382,"score_gpt":0.43671123553147156,"score_spread":0.36879520128608956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214522566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99010044,0.00012636022,0.000006644483,0.0043324884,0.0009796119,0.00082802534,0.0035129515,0.00004088652,0.00007259187],"genre_scores_gemma":[0.9954163,0.0010403153,0.000121058794,0.0014823835,0.00058416574,0.0003919634,0.000031220512,0.000059397247,0.00087322615],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956937,0.0005404863,0.0013396771,0.00081796205,0.0011139018,0.00049429707],"domain_scores_gemma":[0.9964122,0.0013562033,0.00058011303,0.00051731674,0.0005693865,0.0005647757],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084313157,0.00031630864,0.0013664418,0.00009116416,0.00018741011,0.00002598974,0.0003247537,0.00017092978,0.006882189],"category_scores_gemma":[0.00046017053,0.00019363673,0.00020140018,0.00031808237,0.0010101051,0.00010670445,0.00048687655,0.0011750044,0.000007665744],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007994101,0.0014983943,0.9024532,0.00018609944,0.0002494389,0.000025384104,0.0001316875,8.611502e-7,0.000012841643,0.000003925002,0.0017924419,0.08565163],"study_design_scores_gemma":[0.005797598,0.0012849445,0.99073786,0.0006422433,0.0001650385,0.000020809583,0.00014378747,0.00006740467,0.000016354978,0.000014942089,0.0008584802,0.0002505465],"about_ca_topic_score_codex":0.0008820645,"about_ca_topic_score_gemma":0.00016041222,"teacher_disagreement_score":0.08828465,"about_ca_system_score_codex":0.00022008542,"about_ca_system_score_gemma":0.0011743604,"threshold_uncertainty_score":0.99402565},"labels":[],"label_agreement":null},{"id":"W4214616073","doi":"10.1001/jamaoncol.2021.8049","title":"Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer","year":2022,"lang":"en","type":"article","venue":"JAMA Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Pertuzumab; Medicine; Trastuzumab; Metastatic breast cancer; Breast cancer; Oncology; Internal medicine; Cost effectiveness; Population; Chemotherapy; Cancer; Environmental health","score_opus":0.048287472551245374,"score_gpt":0.3967369460307583,"score_spread":0.34844947347951294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214616073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99581474,0.00009842639,0.000085503794,0.0011348247,0.000056943292,0.0014940875,0.0004028268,0.000015816784,0.0008968488],"genre_scores_gemma":[0.99764377,0.0000142050385,0.00021682656,0.0003316331,0.000019278916,0.0015482854,0.000114058465,0.000028381924,0.00008356092],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99736995,0.000733299,0.00030570937,0.0004034756,0.0007877576,0.0003997878],"domain_scores_gemma":[0.9986073,0.00043816163,0.00016000628,0.00033762303,0.00032520713,0.00013171276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000687716,0.00016417728,0.0009398167,0.0007859421,0.00007025062,0.000006910883,0.00017055744,0.000053761763,0.0021835114],"category_scores_gemma":[0.000051403807,0.0001199648,0.00008649702,0.0026026778,0.00019162496,0.00006515582,0.0000985568,0.00055436714,0.0000023223301],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013920778,0.0020145047,0.91100687,0.00016817052,0.0021877403,0.00023546946,0.0010516606,0.00644254,0.00007288745,0.00003542304,0.00016925411,0.06269471],"study_design_scores_gemma":[0.011779701,0.0062904563,0.97514284,0.00006515715,0.0013558378,0.00004538129,0.0007508266,0.0011172774,0.00005740611,0.0000041906696,0.003259597,0.00013135893],"about_ca_topic_score_codex":0.0037557501,"about_ca_topic_score_gemma":0.0030265118,"teacher_disagreement_score":0.06413595,"about_ca_system_score_codex":0.003990684,"about_ca_system_score_gemma":0.0017596497,"threshold_uncertainty_score":0.9998328},"labels":[],"label_agreement":null},{"id":"W4214692750","doi":"10.3390/curroncol13050019","title":"Receptor Tyrosine Kinases: Role in Cancer Progression","year":2006,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Receptor tyrosine kinase; Medicine; Tyrosine kinase; Kinase; Cancer research; Receptor; Receptor Protein-Tyrosine Kinases; Cancer; Protein-Serine-Threonine Kinases; Bioinformatics; Computational biology; Cell biology; Biology; Internal medicine; Protein kinase A","score_opus":0.13165655459075395,"score_gpt":0.5191632641784624,"score_spread":0.3875067095877084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214692750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94706863,0.031888794,0.000017873434,0.006129615,0.002014679,0.0011223096,0.000027198706,0.000095486685,0.01163544],"genre_scores_gemma":[0.99280596,0.0020858012,0.000529413,0.00017019517,0.001987571,0.0009173564,0.0001363747,0.000047091187,0.0013202246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984338,0.00012285793,0.00031411936,0.00033658175,0.00032079648,0.00047184082],"domain_scores_gemma":[0.999369,0.000070014044,0.00007325365,0.00022865231,0.00013066952,0.00012836914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030619043,0.0001338868,0.00033679843,0.00019284617,0.000038998438,0.00000949594,0.000122024896,0.00014838307,0.0014673824],"category_scores_gemma":[0.00009832913,0.00011126722,0.000052525174,0.0003912718,0.00013970428,0.00004254266,0.000081779894,0.00049145357,0.00017352797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033185925,0.0015415289,0.36602575,0.000206371,0.0000066109696,0.000046829155,0.00013027992,0.0000073667634,0.010532002,0.00017840623,0.079377465,0.54161555],"study_design_scores_gemma":[0.0022278612,0.0007325234,0.058791988,0.0005239761,0.00001606704,0.000013061282,0.000060376955,0.00021779054,0.0061479723,0.0001420505,0.93100595,0.00012038696],"about_ca_topic_score_codex":0.00054224906,"about_ca_topic_score_gemma":0.0007218305,"teacher_disagreement_score":0.8516285,"about_ca_system_score_codex":0.0011676569,"about_ca_system_score_gemma":0.0007152259,"threshold_uncertainty_score":0.99944544},"labels":[],"label_agreement":null},{"id":"W4220811973","doi":"10.1158/1538-7445.sabcs21-p2-13-07","title":"Abstract P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): Results from a phase 1 study","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Jewish General Hospital; University of Ottawa; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pertuzumab; Vinorelbine; Capecitabine; Trastuzumab; Internal medicine; Tolerability; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Toxicity; Phases of clinical research; Chemotherapy; Adverse effect; Cisplatin","score_opus":0.08425191162979943,"score_gpt":0.4665428208257864,"score_spread":0.38229090919598696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220811973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96657795,0.0011130361,0.000034657867,0.012815759,0.0002859313,0.008376871,0.010034752,0.000105919986,0.00065513595],"genre_scores_gemma":[0.9875562,0.00085394393,0.000119557226,0.00028180264,0.0005728163,0.0070807273,0.0019925656,0.00022308757,0.0013192554],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9916975,0.0006982792,0.0008617348,0.0017576233,0.0033877182,0.0015971324],"domain_scores_gemma":[0.9957692,0.0008432333,0.00023430966,0.0012603435,0.0014074354,0.00048545448],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036274013,0.00048399603,0.00089345337,0.0009637432,0.00069302256,0.00018961712,0.0008857398,0.00017101901,0.0060141706],"category_scores_gemma":[0.0002107065,0.0004483366,0.00014082152,0.002794608,0.0004467537,0.00027658363,0.0003527938,0.0024103972,0.000046418903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27657586,0.041555602,0.16677529,0.0011542314,0.0023587176,0.002942831,0.03188609,0.0006758716,0.20976281,0.000094192554,0.091893464,0.17432503],"study_design_scores_gemma":[0.1462672,0.013316491,0.73746276,0.0017114842,0.00013751705,0.000066028144,0.0193458,0.0021262432,0.036346573,0.00022599557,0.041636154,0.0013577485],"about_ca_topic_score_codex":0.104792655,"about_ca_topic_score_gemma":0.009836237,"teacher_disagreement_score":0.5706875,"about_ca_system_score_codex":0.004618765,"about_ca_system_score_gemma":0.0033979777,"threshold_uncertainty_score":0.9998911},"labels":[],"label_agreement":null},{"id":"W4220980555","doi":"10.3390/curroncol29010026","title":"Immune Effective Score as a Predictor of Response to Neoadjuvant Trastuzumab Therapy and a Prognostic Indicator for HER2-Positive Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Neoadjuvant therapy; Cancer; Immune system; Immunology","score_opus":0.07569433129261209,"score_gpt":0.44758842209662436,"score_spread":0.37189409080401226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220980555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97818553,0.0076341084,0.0000634548,0.005205254,0.0006456325,0.006933037,0.0012516582,0.000035041834,0.00004630375],"genre_scores_gemma":[0.98848224,0.00036257296,0.00008504367,0.00023362933,0.00020484372,0.01046757,0.00004583094,0.000046245368,0.00007200924],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99753004,0.0006985704,0.00036042297,0.00049332716,0.00045503755,0.00046260282],"domain_scores_gemma":[0.99781,0.0012357387,0.00015982377,0.00025046617,0.00025036986,0.00029361065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010661947,0.00020112812,0.0006280881,0.00032073923,0.0001610695,0.000008120554,0.00019016885,0.000085343185,0.0004568246],"category_scores_gemma":[0.0004555721,0.00017568136,0.000111356494,0.00039068676,0.00026232103,0.00003058327,0.00021684018,0.00052054063,0.0000059276344],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10026215,0.0033484583,0.1462998,0.00054458366,0.00047260008,0.0001014033,0.012537208,0.000011141321,0.03316535,0.000090057,0.0038666732,0.6993006],"study_design_scores_gemma":[0.010502381,0.032380983,0.88769656,0.0004566624,0.00014314357,0.000382638,0.00092414685,0.0001317646,0.0035232396,0.00007516217,0.06357114,0.0002121504],"about_ca_topic_score_codex":0.0001559126,"about_ca_topic_score_gemma":0.000018183979,"teacher_disagreement_score":0.7413968,"about_ca_system_score_codex":0.0013703837,"about_ca_system_score_gemma":0.0021233198,"threshold_uncertainty_score":0.7164078},"labels":[],"label_agreement":null},{"id":"W4221069651","doi":"10.3390/curroncol29030154","title":"Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis—The Adjuvant Role of Lifestyle Changes","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Breast cancer; Internal medicine; Docetaxel; Cancer; Oncology; Gastroenterology; Surgery","score_opus":0.05094887773735504,"score_gpt":0.41298838487317246,"score_spread":0.36203950713581745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221069651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96511894,0.008922207,0.00011823817,0.016718987,0.0013343516,0.004232931,0.0014441037,0.00003109977,0.0020791134],"genre_scores_gemma":[0.9962244,0.00052453484,0.00015189177,0.00015563465,0.00014604346,0.0026195904,0.000044435204,0.000026849168,0.00010659534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99850184,0.00015746123,0.00025346587,0.00026687825,0.00049167516,0.0003286764],"domain_scores_gemma":[0.999114,0.00007960887,0.00019514984,0.00026322095,0.0002627134,0.00008531879],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031231507,0.00012546477,0.00037875614,0.00010058034,0.00010254162,0.0000031670832,0.00018265012,0.000031900163,0.00043315216],"category_scores_gemma":[0.0000065361073,0.00008789775,0.00007521889,0.00024425314,0.00014260897,0.000015877107,0.0002515832,0.000263727,0.000001379405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072482727,0.004038983,0.04468937,0.0019162989,0.0009906548,0.00008007188,0.01384511,0.00023429583,0.0013390903,0.0011611993,0.039305206,0.88515145],"study_design_scores_gemma":[0.011546657,0.02867185,0.14678961,0.0013867986,0.0014337556,0.0005600511,0.05973577,0.0016735714,0.010690365,0.00024807866,0.73668444,0.0005790474],"about_ca_topic_score_codex":0.00039131512,"about_ca_topic_score_gemma":0.00022204132,"teacher_disagreement_score":0.8845724,"about_ca_system_score_codex":0.00059249793,"about_ca_system_score_gemma":0.0003163806,"threshold_uncertainty_score":0.47427124},"labels":[],"label_agreement":null},{"id":"W4221092886","doi":"10.1016/j.esmoop.2022.100419","title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","year":2022,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Merck Sharp and Dohme; Genentech; Novartis Farmacéutica; Servier; Oncolytics Biotech; Else Kröner-Fresenius-Stiftung; Cancer Research UK; AstraZeneca España; Tessa Therapeutics; Eli Lilly and Company; Boehringer Ingelheim España; Novartis; Celgene; Roche España; F. Hoffmann-La Roche; Roche; NordForsk; Ernst Schering Foundation; GlaxoSmithKline España; Wilhelm Sander-Stiftung; Amgen; Pfizer; Bristol-Myers Squibb; Sanofi; MedImmune; Merck","keywords":"Medicine; Atezolizumab; Internal medicine; Clinical endpoint; Interim analysis; Hazard ratio; Lung cancer; Oncology; Surgery; Cancer; Confidence interval; Clinical trial; Gastroenterology; Pembrolizumab; Immunotherapy","score_opus":0.09255978133815697,"score_gpt":0.4642404448781073,"score_spread":0.37168066353995033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221092886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246633,0.00012891779,0.0000060954867,0.0004543081,0.00018078192,0.004504402,0.000042625292,0.000024252495,0.0021922833],"genre_scores_gemma":[0.9957134,0.000069771275,0.00034069002,0.00026518747,0.00003678665,0.0018220902,0.000025597683,0.000052453626,0.0016739878],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997814,0.00020442647,0.0004623233,0.00045717775,0.0006620917,0.0003999702],"domain_scores_gemma":[0.9989221,0.00008431572,0.00011097208,0.00066508894,0.00008050343,0.00013703774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068317266,0.00016029604,0.0005500162,0.00020901617,0.00022412204,0.00001661394,0.0006710341,0.000034876026,0.002237116],"category_scores_gemma":[0.00011125757,0.00015969895,0.000051759525,0.0005669905,0.00006156642,0.00012013267,0.00075788697,0.00047007858,0.000008962208],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042043272,0.04586055,0.35490444,0.00021885932,0.0008407053,0.0014273631,0.06591828,0.02081599,0.027686188,0.000041176525,0.008383836,0.4318593],"study_design_scores_gemma":[0.4072911,0.09151485,0.14377347,0.0004207419,0.00016023515,0.00007509437,0.05664677,0.035336837,0.048847195,0.00011661231,0.21443143,0.0013856542],"about_ca_topic_score_codex":0.04076487,"about_ca_topic_score_gemma":0.00866337,"teacher_disagreement_score":0.4304737,"about_ca_system_score_codex":0.0010427617,"about_ca_system_score_gemma":0.0007204586,"threshold_uncertainty_score":0.998675},"labels":[],"label_agreement":null},{"id":"W4221120760","doi":"10.1158/1538-7445.sabcs21-p2-03-04","title":"Abstract P2-03-04: Characteristics and clinical differences of breast cancer patients with negative or low HER2 expression","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Algoma University; Sault Area Hospital","funders":"","keywords":"Medicine; Breast cancer; Immunohistochemistry; Internal medicine; Oncology; Cancer; Trastuzumab; Stage (stratigraphy); Biology","score_opus":0.13593175903646715,"score_gpt":0.479460287434435,"score_spread":0.3435285283979678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221120760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99532056,0.0003225463,0.0000017586394,0.0013094465,0.00022823205,0.001198514,0.0012626625,0.00002333511,0.00033292393],"genre_scores_gemma":[0.99578786,0.0017448689,0.000054634525,0.000111561545,0.0003431975,0.0007696369,0.0000343704,0.00005844006,0.0010954413],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509233,0.00048515073,0.00057562534,0.00067189144,0.0024451362,0.0007298712],"domain_scores_gemma":[0.99695724,0.00085082307,0.00019739964,0.00048447668,0.0010342693,0.00047580493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013338998,0.00021731036,0.0006346691,0.00025975332,0.00037618334,0.000048107653,0.00039504914,0.00011099393,0.008358863],"category_scores_gemma":[0.00036539766,0.0001451247,0.00006858774,0.0007278939,0.0009606063,0.00011326195,0.00055358186,0.0017674409,0.000010220269],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0092995055,0.0009194599,0.9409123,0.00073578826,0.00014304192,0.00008138204,0.00075254904,0.0000021221056,0.0033155233,0.000006496502,0.004449966,0.039381832],"study_design_scores_gemma":[0.0029975066,0.0016653707,0.9900446,0.0010267452,0.000028048746,0.000007540739,0.00059704075,0.00004115795,0.0020483031,0.00002027379,0.0013473124,0.00017613344],"about_ca_topic_score_codex":0.002540885,"about_ca_topic_score_gemma":0.00030800077,"teacher_disagreement_score":0.04913223,"about_ca_system_score_codex":0.00060757605,"about_ca_system_score_gemma":0.0021673676,"threshold_uncertainty_score":0.99254763},"labels":[],"label_agreement":null},{"id":"W4223510214","doi":"10.1101/2022.04.11.487842","title":"The ADAM17 sheddase complex regulator iTAP modulates inflammation, epithelial repair, and tumor growth","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação para a Ciência e a Tecnologia; Queen's University; Queen's University Belfast","keywords":"Cell biology; Biology; Cytokine; Cancer research; Cell; Immunology; Biochemistry","score_opus":0.023913963058486018,"score_gpt":0.27124518293336775,"score_spread":0.2473312198748817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223510214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881834,0.0027983696,0.000056815854,0.004100695,0.0010425987,0.0024892613,0.0004512213,0.0008186827,0.000058993148],"genre_scores_gemma":[0.9929031,0.00089354295,0.0031766507,0.00037718957,0.0013907439,0.0009206022,0.0000024916178,0.00025284718,0.00008278968],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99486405,0.00046321485,0.0009725943,0.0013834791,0.0013874174,0.00092921825],"domain_scores_gemma":[0.9950718,0.00033742117,0.00047750687,0.0023941707,0.0010932165,0.0006258807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023725822,0.00068133796,0.00086681335,0.00034428915,0.000877979,0.0003411068,0.00074275985,0.00032675263,0.00047163252],"category_scores_gemma":[0.0016750956,0.0005881826,0.00028565607,0.00067065627,0.00056925253,0.00014045472,0.0016434238,0.0017913107,0.00005838798],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012183242,0.00040307164,0.08852256,0.005559645,0.0015368845,0.0012677764,0.00014234702,0.00014363769,0.8657682,0.00997002,0.025427712,0.00003981916],"study_design_scores_gemma":[0.0027987366,0.00045827118,0.6838284,0.0010429857,0.00046977398,8.8459285e-7,0.000044245266,0.007000636,0.124358475,0.000069249516,0.17831498,0.0016133465],"about_ca_topic_score_codex":0.00028002402,"about_ca_topic_score_gemma":0.000011713278,"teacher_disagreement_score":0.7414097,"about_ca_system_score_codex":0.00088980753,"about_ca_system_score_gemma":0.0018156839,"threshold_uncertainty_score":0.999657},"labels":[],"label_agreement":null},{"id":"W4224091336","doi":"10.3390/curroncol29040222","title":"Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of British Columbia; University of Alberta; Fluidigm (Canada); Memorial University of Newfoundland; McGill University; Jewish General Hospital","funders":"AstraZeneca Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Context (archaeology); Oncology; Taxane; Trastuzumab emtansine; Capecitabine; Metastatic breast cancer; Internal medicine; Clinical trial; Breast cancer; Regimen; Intensive care medicine; Cancer","score_opus":0.30072225588401286,"score_gpt":0.5542062625307176,"score_spread":0.25348400664670473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224091336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000053587128,0.98161745,0.000022789225,0.002932256,0.001807341,0.006204331,0.006465835,0.000018024019,0.0009266397],"genre_scores_gemma":[0.00002514542,0.98780775,0.00007897129,0.00005853362,0.00073838263,0.010624346,0.00023739802,0.000084532345,0.00034491814],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977309,0.00022875611,0.00048451175,0.0005946763,0.00032186654,0.0006392855],"domain_scores_gemma":[0.99703807,0.0014153852,0.00033145802,0.00051867665,0.0004078111,0.000288631],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002730477,0.00043304198,0.0020294802,0.00033293752,0.00023976855,0.000010167809,0.00036115223,0.00020899848,0.0014083396],"category_scores_gemma":[0.00008050918,0.00026963776,0.0007492876,0.00046032824,0.00034669877,0.000020954072,0.000050872648,0.00057163986,0.000007704082],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00018574359,0.00092374894,0.000021802127,0.0025050277,0.001216715,0.000014762066,0.002551952,0.0000012283373,7.199856e-7,0.000413221,0.0012787837,0.9908863],"study_design_scores_gemma":[0.0016190867,0.0031088558,0.000076120814,0.0022666804,0.0017834587,0.00019820301,0.0019072829,0.000010189075,0.0000010896221,0.000020312396,0.98880297,0.00020577802],"about_ca_topic_score_codex":0.0739337,"about_ca_topic_score_gemma":0.087409705,"teacher_disagreement_score":0.9906805,"about_ca_system_score_codex":0.018198414,"about_ca_system_score_gemma":0.014016909,"threshold_uncertainty_score":0.99997556},"labels":[],"label_agreement":null},{"id":"W4224238498","doi":"10.1016/j.anndiagpath.2022.151953","title":"HER2 testing in metastatic breast cancer – Is reflex ISH testing necessary on HER2 IHC-equivocal (2+) cases?","year":2022,"lang":"en","type":"article","venue":"Annals of Diagnostic Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"","keywords":"Medicine; Immunohistochemistry; Context (archaeology); Breast cancer; Pathology; Metastasis; Biopsy; Cancer; Metastatic breast cancer; Oncology; Internal medicine; Biology","score_opus":0.2816990791093923,"score_gpt":0.4717600769175204,"score_spread":0.19006099780812813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224238498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772399,0.002082314,0.000009834972,0.015294098,0.00032284055,0.00077963027,0.00074913446,0.000076084536,0.0034461569],"genre_scores_gemma":[0.98863876,0.00029482992,0.00088356907,0.009030692,0.0002204952,0.0006439475,0.000034384,0.00008070491,0.00017263566],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575245,0.0007497014,0.0008364659,0.0007628119,0.0008708253,0.0010277656],"domain_scores_gemma":[0.9865922,0.011702244,0.00031609746,0.00064071635,0.0004606187,0.00028816],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001904166,0.0003206701,0.0008617154,0.00049464306,0.00018544942,0.000016623488,0.0003797663,0.000109164976,0.0017549585],"category_scores_gemma":[0.020949902,0.00032452846,0.00011956134,0.001520357,0.00031167385,0.000091776266,0.00040727164,0.0010223195,0.000039359365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007238303,0.0023816586,0.6485865,0.0009912753,0.0001627392,0.043507256,0.0016819235,0.0017293269,0.0051836804,0.00011825873,0.03041541,0.26451814],"study_design_scores_gemma":[0.004755337,0.010233224,0.94922864,0.0030108795,0.00026657997,0.013337877,0.0026875315,0.0020672882,0.0064967917,0.0020050101,0.004881977,0.0010288542],"about_ca_topic_score_codex":0.0044512325,"about_ca_topic_score_gemma":0.00026399444,"teacher_disagreement_score":0.30064216,"about_ca_system_score_codex":0.00023212207,"about_ca_system_score_gemma":0.0009675758,"threshold_uncertainty_score":0.99992067},"labels":[],"label_agreement":null},{"id":"W4224299878","doi":"10.32388/sgz7ro","title":"Review of: \"Blocking Gi/o-coupled signaling eradicates cancer stem cells and sensitizes breast tumors to HER2-targeted therapies to inhibit tumor relapse\"","year":2022,"lang":"en","type":"peer-review","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Blocking (statistics); Cancer research; Breast cancer; Cancer; Medicine; Oncology; Internal medicine; Computer science","score_opus":0.0409102015812574,"score_gpt":0.3492797994662499,"score_spread":0.30836959788499246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224299878","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0046934756,0.81656474,0.000016531621,0.16837168,0.0009245045,0.0070143268,0.001378384,0.00020783761,0.0008285177],"genre_scores_gemma":[0.0050367434,0.76681906,0.0019146994,0.119844966,0.001372325,0.0028437045,0.00056454504,0.0006460824,0.10095787],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99256146,0.000456459,0.0018965385,0.0015649111,0.0024014248,0.0011191856],"domain_scores_gemma":[0.99534965,0.0005481028,0.00062525616,0.0012491996,0.0012696967,0.0009581109],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003302151,0.00097425655,0.0035651415,0.0006601016,0.00024041857,0.00007112284,0.00060284766,0.00019158318,0.016014325],"category_scores_gemma":[0.00033279296,0.0008052917,0.00047548153,0.0019907157,0.00022272437,0.000071643786,0.0007527566,0.0016379254,0.00008497345],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016993258,0.000095730116,0.00009411689,0.17103809,0.00047887315,0.00027687332,0.0005059678,0.000021394895,0.015402044,0.000008626545,0.79365695,0.01825138],"study_design_scores_gemma":[0.00054902374,0.00042644405,0.000031941367,0.2766966,0.0005843146,0.0003595819,0.00029266646,0.000035729685,0.00901046,0.000005079609,0.7112548,0.0007533888],"about_ca_topic_score_codex":0.0049378388,"about_ca_topic_score_gemma":0.0002534711,"teacher_disagreement_score":0.105658494,"about_ca_system_score_codex":0.00090939575,"about_ca_system_score_gemma":0.0019152382,"threshold_uncertainty_score":0.9994398},"labels":[],"label_agreement":null},{"id":"W4224311311","doi":"10.2217/fon-2022-0045","title":"A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ <i>PIK3CA</i> -mutated breast cancer","year":2022,"lang":"en","type":"article","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Trastuzumab; Medicine; Fulvestrant; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; Estrogen receptor","score_opus":0.03373686270539864,"score_gpt":0.405549785522902,"score_spread":0.37181292281750333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676818,0.0011424931,0.000019535517,0.019319264,0.0036485007,0.0026606305,0.0005486474,0.000087682194,0.0048913946],"genre_scores_gemma":[0.9940339,0.0008403607,0.00018030634,0.0011147232,0.002113022,0.0010661196,0.00014415332,0.00009417443,0.00041325568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99598217,0.00061860005,0.00090651016,0.00068884745,0.00096318586,0.000840676],"domain_scores_gemma":[0.99848807,0.00023387806,0.00027842287,0.0005369681,0.00016633091,0.00029631006],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011146184,0.00035427176,0.001236585,0.0004070307,0.00013456504,0.00001099496,0.00043451868,0.00031336778,0.0065104333],"category_scores_gemma":[0.000044199474,0.00033409445,0.00025916155,0.0012198652,0.00026180962,0.00007151088,0.00010472402,0.0014767476,0.000009070069],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6796848,0.01260008,0.00015944194,0.00016354163,0.0004214453,0.001027281,0.0045396145,0.0001150018,0.013327626,0.000115296745,0.023600336,0.2642455],"study_design_scores_gemma":[0.70637417,0.030401336,0.00094785116,0.00007256244,0.0001685039,0.0005405919,0.004477333,0.00044355416,0.0015750931,0.000025155543,0.25459933,0.0003745366],"about_ca_topic_score_codex":0.001720948,"about_ca_topic_score_gemma":0.0013106656,"teacher_disagreement_score":0.26387098,"about_ca_system_score_codex":0.0030166944,"about_ca_system_score_gemma":0.0041809576,"threshold_uncertainty_score":0.9999111},"labels":[],"label_agreement":null},{"id":"W4224313646","doi":"10.3390/curroncol29040208","title":"Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Oncology; Breast cancer; Lapatinib; Cancer; Systemic therapy; Antibody-drug conjugate; Internal medicine; Hormone receptor; Disease; Antibody; Immunology; Monoclonal antibody","score_opus":0.427164784705476,"score_gpt":0.5917821791165028,"score_spread":0.1646173944110268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224313646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[9.867226e-7,0.9866342,0.0000023612422,0.00074761023,0.0007004326,0.005223113,0.00028530875,0.000010574184,0.0063954154],"genre_scores_gemma":[0.0000015389605,0.99245656,0.00016178556,0.00030850107,0.000075147,0.006438415,0.00034444986,0.00004377103,0.00016983115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954352,0.0015523038,0.0011267499,0.0005261872,0.00087162305,0.00048794728],"domain_scores_gemma":[0.99832845,0.00041149513,0.00050431135,0.00055522734,0.000096654716,0.000103843915],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021093679,0.0003677602,0.0026199212,0.0002910554,0.00005456999,0.0000061067103,0.00071589946,0.00008304657,0.0019832803],"category_scores_gemma":[0.000040120703,0.0002390379,0.00037130743,0.0013436901,0.00014169389,0.000021522672,0.00042739738,0.0012923038,0.00006067717],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016155962,0.0005302079,0.000026303653,0.22996187,0.00045765442,0.0003064211,0.000121897174,4.056434e-8,4.5526996e-9,0.00010857702,0.0066963634,0.7617745],"study_design_scores_gemma":[0.0004619147,0.00018182592,0.00014617518,0.14404662,0.002382111,0.00042091467,0.000092906754,3.2111478e-7,3.2226904e-8,0.000005933694,0.85211116,0.00015005337],"about_ca_topic_score_codex":0.00006630135,"about_ca_topic_score_gemma":0.00002358526,"teacher_disagreement_score":0.8454148,"about_ca_system_score_codex":0.0026234426,"about_ca_system_score_gemma":0.0026563052,"threshold_uncertainty_score":0.998929},"labels":[],"label_agreement":null},{"id":"W4225002517","doi":"10.51731/cjht.2022.320","title":"Pertuzumab (Perjeta)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Reimbursement; Trastuzumab; Medicine; Breast cancer; Oncology; Family medicine; Internal medicine; Cancer; Political science; Health care","score_opus":0.0735274290851781,"score_gpt":0.364587629344771,"score_spread":0.2910602002595929,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225002517","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24703893,0.22778709,0.00012854052,0.51876897,0.0014438101,0.0007952286,0.00007740951,0.00024886092,0.0037111882],"genre_scores_gemma":[0.9968634,0.00047510248,0.00049136014,0.0016955897,0.00002048702,0.000020198815,0.0000022266506,0.000021334696,0.00041028977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822336,0.0000992284,0.00047540944,0.00013389248,0.0004562066,0.00061188854],"domain_scores_gemma":[0.9990348,0.00004666316,0.00021279116,0.00033513125,0.00017030048,0.00020028371],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012595166,0.00009631079,0.0003758201,0.0009955862,0.0005306091,0.000019507761,0.00045855175,0.000067678586,0.00070231914],"category_scores_gemma":[0.0007181506,0.00008595147,0.0000935105,0.0005835826,0.00021726757,0.000046354202,0.00006342153,0.0013367538,0.000012375305],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050059523,0.000035381054,0.012928544,0.00017750931,0.000053637876,0.0017046967,0.0005993816,0.000032423104,0.000083131556,0.0011733432,0.10639037,0.8767715],"study_design_scores_gemma":[0.0005328892,0.0017785701,0.0039360076,0.000095256175,0.0000082579745,0.003087137,0.008224581,0.000020386287,0.00016749933,0.0010877787,0.9809788,0.000082828185],"about_ca_topic_score_codex":0.005897423,"about_ca_topic_score_gemma":0.0015189135,"teacher_disagreement_score":0.8766887,"about_ca_system_score_codex":0.0027229246,"about_ca_system_score_gemma":0.01434429,"threshold_uncertainty_score":0.9912435},"labels":[],"label_agreement":null},{"id":"W4229028760","doi":"10.1016/j.jmoldx.2022.04.002","title":"Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to Determine Human Epidermal Growth Factor Receptor 2 Low Status for Breast Cancer","year":2022,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Toronto; Ontario Institute for Cancer Research","funders":"Cancer Research UK; BioTheranostics; Government of Ontario; Breast Cancer Society of Canada; Ontario Institute for Cancer Research","keywords":"Immunohistochemistry; Breast cancer; Epidermal growth factor receptor; Tyrosine kinase; Cancer research; Receptor tyrosine kinase; Human Epidermal Growth Factor Receptor 2; Receptor; Internal medicine; Biology; Oncology; Medicine; Cancer","score_opus":0.02415254706952066,"score_gpt":0.3498008022656732,"score_spread":0.3256482551961526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229028760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98261786,0.0052622943,0.0015994621,0.005994087,0.00047808918,0.000816118,0.003190311,0.000016936066,0.000024833382],"genre_scores_gemma":[0.99177855,0.0014336285,0.004447884,0.0007641736,0.0009861739,0.0001909639,0.00009833394,0.00011659081,0.00018367628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701124,0.00012725485,0.00081989035,0.00037046554,0.0009901772,0.0006809789],"domain_scores_gemma":[0.99720323,0.0005056463,0.0004501958,0.00036566984,0.0006841194,0.0007911191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045245775,0.0003095778,0.0007135714,0.00022283262,0.00027578595,0.000058263096,0.00035396713,0.00009104689,0.0008166067],"category_scores_gemma":[0.0016024243,0.00029986617,0.00022699649,0.00032578286,0.00014125332,0.00009450545,0.000283622,0.000857554,0.000003773415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010439388,0.0004259512,0.068708085,0.0007872068,0.0003294271,0.0005306679,0.00033929784,0.00008589471,0.8660451,0.000018171844,0.033030417,0.028655844],"study_design_scores_gemma":[0.010896171,0.006265396,0.18950786,0.0020552059,0.00078748295,0.0008703056,0.00037277138,0.00006771115,0.737475,0.00017952891,0.050267756,0.0012548633],"about_ca_topic_score_codex":0.000115086135,"about_ca_topic_score_gemma":0.0000042255374,"teacher_disagreement_score":0.12857014,"about_ca_system_score_codex":0.0010625923,"about_ca_system_score_gemma":0.0006577242,"threshold_uncertainty_score":0.99994534},"labels":[],"label_agreement":null},{"id":"W4229046548","doi":"10.1055/s-0042-1746156","title":"Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB)","year":2022,"lang":"de","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Gynecology","score_opus":0.044023793344331874,"score_gpt":0.34594898073692804,"score_spread":0.30192518739259616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229046548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5872861,0.32610393,0.00074878347,0.021517355,0.019282151,0.01925723,0.008630273,0.00086459564,0.016309572],"genre_scores_gemma":[0.9744688,0.0041347924,0.0011615858,0.0015983118,0.00194837,0.0032125523,0.0059897443,0.0009028015,0.0065830173],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9771502,0.0050160424,0.0036467942,0.0038107398,0.0058626365,0.0045135813],"domain_scores_gemma":[0.9895407,0.002933632,0.0014114613,0.0030884026,0.0010413082,0.001984529],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0058479607,0.002282223,0.0031934436,0.0027340758,0.001706609,0.00065632456,0.0025014884,0.001006494,0.008311334],"category_scores_gemma":[0.0018324023,0.0026027283,0.0010601736,0.0048968755,0.0010634143,0.000917683,0.0017470202,0.005545225,0.0016134363],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11916481,0.04711795,0.06681555,0.0074188146,0.08131,0.022241294,0.08441252,0.014583997,0.009251181,0.010624955,0.28196532,0.2550936],"study_design_scores_gemma":[0.086829424,0.022383003,0.03910494,0.0022034436,0.023453236,0.00015275528,0.020424321,0.008735451,0.0044138953,0.0022077996,0.78326285,0.0068288776],"about_ca_topic_score_codex":0.009971604,"about_ca_topic_score_gemma":0.0039357725,"teacher_disagreement_score":0.50129753,"about_ca_system_score_codex":0.009332566,"about_ca_system_score_gemma":0.0036918835,"threshold_uncertainty_score":0.999593},"labels":[],"label_agreement":null},{"id":"W4230568286","doi":"10.1200/edbk_175630","title":"Optimal Management of Early and Advanced HER2 Breast Cancer","year":2017,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Disease; Breast cancer; Oncology; Internal medicine; Intensive care medicine; Adjuvant chemotherapy; Cancer; Chemotherapy; Adjuvant","score_opus":0.26462721998985017,"score_gpt":0.6238183746282034,"score_spread":0.35919115463835327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230568286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00055141374,0.9786962,0.0000070946153,0.012122745,0.00039268078,0.0012205591,0.00018396153,0.000011147354,0.0068141436],"genre_scores_gemma":[0.00007129628,0.96261686,0.016740318,0.0009265213,0.0006729717,0.00041552164,0.000047711277,0.000047936846,0.01846087],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648994,0.00026210284,0.0017230108,0.00063569995,0.0005475399,0.00034172874],"domain_scores_gemma":[0.99414814,0.0019811506,0.0023635803,0.0006911393,0.0004547691,0.0003612279],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0011823529,0.0003030952,0.0037196698,0.00005503106,0.00008173744,0.000007687547,0.00045382575,0.00036116006,0.0008891188],"category_scores_gemma":[0.00014885372,0.00025382568,0.0012175336,0.00016850213,0.00426197,0.00006566266,0.0002587967,0.0009435349,0.000022545946],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013089723,0.0006147062,0.0017726388,0.008707713,0.0015106625,0.0000037173866,0.00008133465,5.155921e-7,1.7768335e-7,0.00015902251,0.01673999,0.9702786],"study_design_scores_gemma":[0.0007663246,0.0010389558,0.036622554,0.006840464,0.0012027335,0.000034764606,0.00015174135,0.000002407344,1.3652837e-7,0.000018284158,0.9531448,0.00017685759],"about_ca_topic_score_codex":0.00035181388,"about_ca_topic_score_gemma":0.0000037874295,"teacher_disagreement_score":0.9701018,"about_ca_system_score_codex":0.0004333583,"about_ca_system_score_gemma":0.008990312,"threshold_uncertainty_score":0.9999914},"labels":[],"label_agreement":null},{"id":"W4230918009","doi":"10.1200/jco.2004.22.90140.581","title":"Intratumoral and plasma concentrations of gefitinib in breast cancer patients: Preliminary results from a presurgical investigatory study (BCIRG 103)","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Gefitinib; Medicine; Breast cancer; Pharmacokinetics; Lung cancer; Adenocarcinoma; Cancer; Internal medicine; Colorectal cancer; Oncology; Urology; Epidermal growth factor receptor","score_opus":0.14831609006630797,"score_gpt":0.48750950387369624,"score_spread":0.33919341380738827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230918009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845714,0.0002686808,0.000001824143,0.009457051,0.00060182717,0.0005515142,0.0001607316,0.00000586946,0.00049536314],"genre_scores_gemma":[0.9973455,0.0005942558,0.00073419866,0.00061601383,0.0006505777,0.000015145489,0.000008545325,0.000015408998,0.00002036426],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947932,0.0007607155,0.0031804207,0.0003040799,0.0006735688,0.00028806418],"domain_scores_gemma":[0.9948031,0.002469732,0.0012552612,0.00020956207,0.0006438021,0.0006185621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025856316,0.00014802604,0.0013263623,0.00014593585,0.00003058895,0.0000098715645,0.00019278345,0.00033093742,0.00009086655],"category_scores_gemma":[0.0049506417,0.00011342236,0.0001523055,0.00022755374,0.00069668447,0.00015329002,0.00010449066,0.0015891779,0.0000030956153],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03159426,0.008777791,0.94087195,0.00003608258,0.00023206937,0.001080526,0.001348892,0.0001135346,0.00009480638,0.000050118015,0.002187704,0.013612237],"study_design_scores_gemma":[0.039546635,0.023106936,0.9341145,0.00048652652,0.00016099204,0.000096253956,0.00050826767,0.00010140201,0.00006025362,0.00024906074,0.0014794135,0.00008975811],"about_ca_topic_score_codex":0.0008887728,"about_ca_topic_score_gemma":0.00054123445,"teacher_disagreement_score":0.014329145,"about_ca_system_score_codex":0.00036873698,"about_ca_system_score_gemma":0.0051861536,"threshold_uncertainty_score":0.9200014},"labels":[],"label_agreement":null},{"id":"W4232358903","doi":"10.1158/1538-7445.am2019-1556","title":"Abstract 1556: Preclinical development of antibody drug conjugates targetting EGFRvIII","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; In vivo; Epidermal growth factor receptor; Conjugate; Cancer; Chemistry; Monoclonal antibody; Molecular biology; Medicine; Biology; Immunology; Internal medicine; Genetics","score_opus":0.1575404227938784,"score_gpt":0.5331337627656179,"score_spread":0.3755933399717395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4232358903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97822255,0.003437479,0.000009217192,0.0019151096,0.00032488944,0.0014341999,0.000021803658,0.000053546955,0.014581221],"genre_scores_gemma":[0.99125063,0.00075346336,0.0013763739,0.00010847117,0.00038708744,0.00017955154,0.000038578983,0.00007274189,0.005833068],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947712,0.00021404706,0.0008435281,0.0007106579,0.0023206568,0.0011399146],"domain_scores_gemma":[0.9965875,0.0009092262,0.00012552523,0.0007851718,0.0011375899,0.0004549711],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005353857,0.00021055662,0.0006208322,0.00039156774,0.00017184214,0.000048965165,0.0005458275,0.00017690271,0.007109741],"category_scores_gemma":[0.00080333214,0.00018135697,0.00012897575,0.00076744263,0.00042688937,0.00012165115,0.0003940092,0.0015663531,0.0011158976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000986347,0.00043064982,0.22609544,0.0033764686,0.00024864968,0.00006647607,0.0023248815,0.000020257785,0.7124685,0.00017739757,0.014413305,0.039391637],"study_design_scores_gemma":[0.0033353325,0.00040248394,0.15926215,0.00313956,0.000020106076,0.000010032941,0.0012472548,0.00014911202,0.64527655,0.00013988519,0.18662025,0.00039729232],"about_ca_topic_score_codex":0.00059730734,"about_ca_topic_score_gemma":0.0000872513,"teacher_disagreement_score":0.17220694,"about_ca_system_score_codex":0.0005726268,"about_ca_system_score_gemma":0.004110252,"threshold_uncertainty_score":0.99966186},"labels":[],"label_agreement":null},{"id":"W4233227002","doi":"10.12688/f1000research.9417.1","title":"Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning","year":2016,"lang":"en","type":"preprint","venue":"F1000Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; University of Windsor","funders":"","keywords":"Medicine; Breast cancer; Oncology; Internal medicine; Biology; Cancer","score_opus":0.04348960773477192,"score_gpt":0.37474096455814815,"score_spread":0.33125135682337625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233227002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831123,0.0047758953,0.000114877155,0.0074999197,0.00007167514,0.003006538,0.0006121511,0.00002758023,0.00077909784],"genre_scores_gemma":[0.9954763,0.0027442533,0.00016101368,0.00009715425,0.00009849779,0.0009118184,0.000065167435,0.000065829336,0.00037997685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954385,0.00058142125,0.00080816104,0.0006540672,0.002025321,0.00049250876],"domain_scores_gemma":[0.9977213,0.00054117717,0.0003130792,0.0006879991,0.00057955197,0.00015685402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027842682,0.00030492988,0.0008437131,0.0004949946,0.00004848345,0.000044165987,0.00091888726,0.00022308416,0.0002916752],"category_scores_gemma":[0.00066136447,0.00020171372,0.00014291513,0.00035113684,0.0005329751,0.000046479556,0.0010429969,0.0016717294,0.000002065816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007380205,0.00068616105,0.91110575,0.00025033546,0.0006766087,0.000037820137,0.0005417809,0.000007166045,0.07770049,0.000012774521,0.0007783408,0.0074647716],"study_design_scores_gemma":[0.006413999,0.0005616782,0.96728814,0.0005843825,0.00009957673,0.000025000458,0.0008854511,0.0015133593,0.020307986,0.00006082874,0.0019757946,0.0002838347],"about_ca_topic_score_codex":0.0055414964,"about_ca_topic_score_gemma":0.00005607165,"teacher_disagreement_score":0.0573925,"about_ca_system_score_codex":0.0002838924,"about_ca_system_score_gemma":0.0005773716,"threshold_uncertainty_score":0.83771217},"labels":[],"label_agreement":null},{"id":"W4234549590","doi":"10.1016/s0021-9258(19)61439-0","title":"Superagonistic Activation of ErbB-1 by EGF-related Growth Factors with Enhanced Association and Dissociation Rate Constants","year":2000,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Biotechnology Research Institute","funders":"Stichting de Drie Lichten","keywords":"ErbB; Chemistry; Dissociation (chemistry); Dissociation rate; Biochemistry; Receptor; Physical chemistry","score_opus":0.01755594530503023,"score_gpt":0.28725033365545005,"score_spread":0.2696943883504198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234549590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770045,0.000121038414,0.000035801146,0.0004062178,0.000015203456,0.00009137114,0.0000230754,0.0000089074065,0.0015979578],"genre_scores_gemma":[0.9987825,0.00053973205,0.00004362137,0.000029834973,0.00004811139,0.0000012043477,0.00003746889,0.000006879698,0.00051063346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989144,0.00007114588,0.00039724144,0.00012429974,0.00032517864,0.00016774156],"domain_scores_gemma":[0.99880606,0.00031669167,0.0003703004,0.0000572334,0.0003310587,0.00011864071],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004294644,0.0001046314,0.00033046835,0.000020270749,0.00004190684,0.000014019867,0.000057519825,0.00023630344,0.00072987704],"category_scores_gemma":[0.0010125141,0.0000661112,0.00005261919,0.0001572367,0.00009790916,0.00006597743,0.000007964034,0.00037411047,0.000001178525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005193561,0.000116825664,0.12762363,0.000053197437,0.00011034549,0.0000048982674,0.00009249774,0.0000015758785,0.8699613,0.0000025022212,0.00018291785,0.001330948],"study_design_scores_gemma":[0.0014159284,0.0004886963,0.07821604,0.00017197854,0.000042689157,0.000017307417,0.00014469273,0.0000152390685,0.9191185,0.00012389034,0.00016492173,0.00008007233],"about_ca_topic_score_codex":0.000009205574,"about_ca_topic_score_gemma":1.787012e-7,"teacher_disagreement_score":0.049407598,"about_ca_system_score_codex":0.00033525235,"about_ca_system_score_gemma":0.00012476218,"threshold_uncertainty_score":0.7991642},"labels":[],"label_agreement":null},{"id":"W4234834979","doi":"10.3390/curroncol16050001","title":"Erratum","year":2009,"lang":"en","type":"erratum","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Oncology; Medical physics; Bioinformatics; Internal medicine; Cancer; Biology","score_opus":0.22260729816970312,"score_gpt":0.5184633407299551,"score_spread":0.295856042560252,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4234834979","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055803685,0.052968934,0.00002622043,0.008299539,0.14537857,0.0010048978,0.000051619867,0.0001977481,0.7920167],"genre_scores_gemma":[0.00029146177,0.027762238,0.00026904757,0.0016328257,0.029108493,0.000259065,0.0022985644,0.00017509775,0.9382032],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653184,0.0002349445,0.0005804163,0.000814327,0.00086561125,0.0009728599],"domain_scores_gemma":[0.9977862,0.000093538576,0.00022393605,0.00094208197,0.00041525735,0.0005389519],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.00051113573,0.00045700656,0.0013051885,0.0004681581,0.00008630053,0.000027771788,0.0004713784,0.0014598293,0.0021477053],"category_scores_gemma":[0.0005052461,0.00041077405,0.00032425977,0.0004102316,0.00027828795,0.00003310294,0.0001865877,0.005762372,0.0015968547],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000082213424,0.00049088267,0.00018607055,0.00057369703,0.000049298407,0.00030120806,0.00007262556,6.156902e-8,0.000011215761,0.00008956257,0.73853475,0.25960842],"study_design_scores_gemma":[0.0011226576,0.0020262625,0.0016156088,0.00095657335,0.00018931448,0.00021396813,0.000024797562,0.00004180323,0.00000849421,0.0005043288,0.992976,0.00032015363],"about_ca_topic_score_codex":0.000019341522,"about_ca_topic_score_gemma":0.00005623176,"teacher_disagreement_score":0.25928825,"about_ca_system_score_codex":0.0019225096,"about_ca_system_score_gemma":0.0060467888,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W4235487124","doi":"10.3410/f.1032827.554251","title":"Faculty Opinions recommendation of An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor.","year":2007,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Allosteric regulation; Epidermal growth factor receptor; Mechanism (biology); Domain (mathematical analysis); Chemistry; Factor (programming language); Epidermal growth factor; Cell biology; Cancer research; Computational biology; Receptor; Computer science; Biology; Biochemistry; Mathematics; Physics","score_opus":0.06663620951716587,"score_gpt":0.4145805635379009,"score_spread":0.34794435402073504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235487124","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037081423,0.0002090587,0.00026976783,0.124222726,0.00077666837,0.003584492,0.87085676,0.00001968287,0.000023779836],"genre_scores_gemma":[0.00013849598,0.00024242331,0.0036085767,0.002669238,0.000375201,0.000329935,0.9923702,0.00004807733,0.00021788648],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99328256,0.0007940593,0.0023710707,0.0006841833,0.0024141434,0.0004539988],"domain_scores_gemma":[0.98321927,0.0004938077,0.0026212242,0.0018882498,0.011422756,0.00035467892],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027104851,0.0005236089,0.0013735767,0.00055752404,0.00017829634,0.0000411244,0.0016454895,0.0009136133,0.00046807172],"category_scores_gemma":[0.0155751975,0.00031241818,0.00087390374,0.0025014752,0.0005218044,0.00033590605,0.00045428608,0.0011323104,0.0000061016513],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001442505,0.00071899965,0.000009208952,0.019361222,0.00018213918,1.2216005e-7,0.0002452672,3.8610594e-8,0.00034857658,0.0010001044,0.9744121,0.003578002],"study_design_scores_gemma":[0.0015876903,0.0005307989,0.0017165171,0.015871037,0.0001906233,0.000020707643,0.000085821295,0.000007989311,0.0043060947,0.00016851348,0.9752638,0.00025045214],"about_ca_topic_score_codex":0.00014648703,"about_ca_topic_score_gemma":0.000009938093,"teacher_disagreement_score":0.12155349,"about_ca_system_score_codex":0.0002840933,"about_ca_system_score_gemma":0.0011662677,"threshold_uncertainty_score":0.99993277},"labels":[],"label_agreement":null},{"id":"W4235681351","doi":"10.1200/jco.2004.22.14_suppl.2622","title":"ARH460–16-2: a therapeutic monoclonal antibody targeting CD44 in Her2/neu negative breast cancer","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Arius3D (Canada)","funders":"","keywords":"Immunohistochemistry; CD44; Medicine; Breast cancer; Monoclonal antibody; Cancer; Epitope; Antigen; Cancer research; HER2/neu; Antibody; Pathology; Internal medicine; Immunology; Biology; Cell","score_opus":0.18380388789095847,"score_gpt":0.5762637421299914,"score_spread":0.39245985423903296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235681351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393661,0.0016878415,0.00031632674,0.054018542,0.0014406288,0.00038268228,0.000013390329,0.0000146613,0.0027598378],"genre_scores_gemma":[0.9863661,0.0027280967,0.0025635879,0.005414544,0.0027121515,0.000013231006,0.0000023170123,0.000038827162,0.00016113755],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948683,0.0007288536,0.0026810865,0.00032396193,0.00080652646,0.00059131376],"domain_scores_gemma":[0.99558836,0.0016953927,0.0011891604,0.00020992177,0.0007324998,0.0005846338],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005358683,0.00021150864,0.0017031835,0.0002552645,0.000053752345,0.000017287382,0.00033028977,0.0004932882,0.0009476503],"category_scores_gemma":[0.0023477008,0.00015439065,0.00049270596,0.00046536932,0.00044196303,0.00016851531,0.00008297834,0.0030321013,0.000043176093],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01275529,0.004804071,0.6852301,0.00014841942,0.00087409955,0.0044901855,0.0008684942,0.0008250019,0.0045863865,0.00038788226,0.0029884805,0.28204164],"study_design_scores_gemma":[0.021582188,0.009439007,0.93448555,0.0009440861,0.00022198119,0.0015859054,0.0006428962,0.00016375571,0.0006023139,0.0044919923,0.025569187,0.0002711543],"about_ca_topic_score_codex":0.0011260009,"about_ca_topic_score_gemma":0.0006424463,"teacher_disagreement_score":0.28177047,"about_ca_system_score_codex":0.0014418387,"about_ca_system_score_gemma":0.007918887,"threshold_uncertainty_score":0.9999656},"labels":[],"label_agreement":null},{"id":"W4235748407","doi":"10.1097/pai.0000000000000163","title":"Standardization of Positive Controls in Diagnostic Immunohistochemistry","year":2014,"lang":"en","type":"review","venue":"Applied immunohistochemistry & molecular morphology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Standardization; Immunohistochemistry; Harmonization; Medicine; Computer science; Pathology; Medical physics","score_opus":0.014024258154765623,"score_gpt":0.3609952550895327,"score_spread":0.3469709969347671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235748407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012663419,0.980416,0.0032082421,0.000048172034,0.00017518792,0.0027938343,0.00023518139,0.000067561676,0.011789481],"genre_scores_gemma":[0.027021606,0.966484,0.0007934914,0.0001651777,0.00014150143,0.0019817497,0.0026673188,0.00030483928,0.00044028892],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943791,0.00024214892,0.0023130854,0.0013025227,0.00082179357,0.0009413712],"domain_scores_gemma":[0.9950623,0.0010424106,0.0011979537,0.0020929384,0.00036472973,0.00023966041],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008665847,0.0009990452,0.0047558667,0.0003757136,0.000071981536,0.000022716102,0.00081580767,0.001531445,0.00040143653],"category_scores_gemma":[0.0018098288,0.0010553098,0.00087834697,0.0007833658,0.0008801679,0.000022499346,0.00033221787,0.0019713843,0.0000807331],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002728631,0.00029326623,0.0000029863256,0.023726203,0.0005530344,0.00073340704,0.000047723686,0.000014414248,0.87431484,0.00020076858,0.0005612334,0.09927925],"study_design_scores_gemma":[0.012436414,0.0011538658,0.000033406173,0.057915386,0.006663851,0.0045295763,0.00011046746,0.000012721663,0.27815393,0.00037873842,0.63480353,0.0038080907],"about_ca_topic_score_codex":0.00007636321,"about_ca_topic_score_gemma":7.331737e-8,"teacher_disagreement_score":0.6342423,"about_ca_system_score_codex":0.0022365027,"about_ca_system_score_gemma":0.0019731438,"threshold_uncertainty_score":0.9997648},"labels":[],"label_agreement":null},{"id":"W4235904818","doi":"10.1007/s40278-015-3201-2","title":"Trastuzumab emtansine: lower AE-related costs in Canada","year":2015,"lang":"en","type":"article","venue":"Reactions Weekly","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Medicine; Trastuzumab; Internal medicine; Breast cancer; Cancer","score_opus":0.04215747184043541,"score_gpt":0.32872668504274083,"score_spread":0.28656921320230544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235904818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8715275,0.00045781743,0.000023269225,0.011860343,0.0011733818,0.00057641906,0.000025074161,0.000084074025,0.11427215],"genre_scores_gemma":[0.9893803,0.00006976336,0.00009551275,0.00022129921,0.000107098465,0.000035913516,0.000026548421,0.000033458688,0.01003012],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983414,0.00006260591,0.0003316883,0.00025709995,0.00061117765,0.00039605866],"domain_scores_gemma":[0.99882984,0.000106049694,0.0000452799,0.00040241343,0.00020098728,0.00041545727],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029597865,0.00012854305,0.0002437279,0.00019405935,0.00004225367,0.000015042683,0.00010069328,0.00009144215,0.00046992596],"category_scores_gemma":[0.0004442769,0.00012318071,0.000041520507,0.0007526106,0.000048655136,0.000086465574,0.00002533475,0.00056694064,0.00024537518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00083961384,0.0011681527,0.090989426,0.0002053004,0.00027780613,0.0048304475,0.00074995524,0.000508592,0.008839125,0.00071930105,0.83128333,0.05958892],"study_design_scores_gemma":[0.00523708,0.0005850508,0.15977,0.00055432745,0.00006948599,0.00084010354,0.0027383731,0.001647258,0.001163109,0.00011980211,0.82684684,0.00042858985],"about_ca_topic_score_codex":0.9153748,"about_ca_topic_score_gemma":0.92114043,"teacher_disagreement_score":0.11785281,"about_ca_system_score_codex":0.0073337783,"about_ca_system_score_gemma":0.00997965,"threshold_uncertainty_score":0.9964769},"labels":[],"label_agreement":null},{"id":"W4236472457","doi":"10.5858/133.4.597","title":"Practice Evolution: Decentralized Computer-Assisted Immunohistochemical Image Analysis","year":2009,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Computer science; Pathology; Medicine","score_opus":0.015740116940510303,"score_gpt":0.3631940186392202,"score_spread":0.3474539016987099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236472457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8291994,0.022406181,0.06947248,0.05222095,0.0008102734,0.0017040991,0.00015713242,0.00043400234,0.023595525],"genre_scores_gemma":[0.9374699,0.0007572219,0.058206674,0.0028125287,0.00041511757,0.000022668017,0.00017159409,0.00002928056,0.00011500149],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9967485,0.0006660627,0.0008127863,0.000580693,0.0006448854,0.00054706703],"domain_scores_gemma":[0.9969399,0.00085469533,0.00033362518,0.00096288644,0.0005311541,0.00037773722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085096236,0.00027646797,0.0011156085,0.00072262774,0.00009512907,0.0000059164745,0.00033114647,0.00015965932,0.00036003836],"category_scores_gemma":[0.001681079,0.00023274863,0.00020908142,0.0018066636,0.0017087413,0.00011068451,0.00007723531,0.0006428164,0.000021686708],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002161126,0.00094300724,0.0075508757,0.00014137808,0.0009516354,0.0028160908,0.0021215603,0.0000073770148,0.96311134,0.0015561666,0.005248882,0.013390535],"study_design_scores_gemma":[0.017112073,0.009151464,0.8995589,0.00092690415,0.007692536,0.0018049566,0.0016607667,0.0019400012,0.02344316,0.0011847483,0.034729496,0.0007950125],"about_ca_topic_score_codex":0.000047259677,"about_ca_topic_score_gemma":0.000005445732,"teacher_disagreement_score":0.9396682,"about_ca_system_score_codex":0.00017688794,"about_ca_system_score_gemma":0.0005968773,"threshold_uncertainty_score":0.94912136},"labels":[],"label_agreement":null},{"id":"W4236939410","doi":"10.1007/978-3-662-46875-3_1932","title":"Epidermal Growth Factor Receptor","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Epidermal growth factor receptor; Factor (programming language); Biology; Receptor; Computer science; Genetics; Programming language","score_opus":0.07684365104587398,"score_gpt":0.34825861066300934,"score_spread":0.27141495961713535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236939410","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000042439828,0.0003879456,0.000333759,0.004202389,0.00053051306,0.00065928564,0.00006775689,0.00019058444,0.99358535],"genre_scores_gemma":[0.0021418247,0.0005985261,0.0009855966,0.0020235104,0.0020898033,0.000022505765,0.00011423815,0.00018100167,0.991843],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756956,0.00002657883,0.00042606436,0.00056877127,0.0009305394,0.00047850987],"domain_scores_gemma":[0.9981876,0.00019293603,0.00010249973,0.00070811657,0.00032023725,0.0004885869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00025353473,0.00039236055,0.0007600276,0.0002404662,0.000049316845,0.000026533962,0.00024026388,0.00061121286,0.10113691],"category_scores_gemma":[0.00022518531,0.00031135158,0.00028220422,0.000027374095,0.00017398864,0.000026791255,0.0001379237,0.0010614168,0.012841871],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014187647,0.000022961041,0.00042646483,0.0008685029,0.0002554057,0.000105166066,0.000055456178,3.641502e-8,0.00043942477,0.1475095,0.79965174,0.050523486],"study_design_scores_gemma":[0.00054909236,0.0003388578,0.0001509131,0.0004295819,0.000046829995,0.000036831385,0.0000027139304,0.0000062835215,0.0010172252,0.0012762208,0.995826,0.00031944778],"about_ca_topic_score_codex":0.00009675182,"about_ca_topic_score_gemma":0.000020059148,"teacher_disagreement_score":0.19617428,"about_ca_system_score_codex":0.00032885183,"about_ca_system_score_gemma":0.00043413416,"threshold_uncertainty_score":0.99993384},"labels":[],"label_agreement":null},{"id":"W4237424163","doi":"10.1007/978-3-642-27841-9_1933-2","title":"Epidermal Growth Factor-like Ligands","year":2014,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Epidermal growth factor; Chemistry; Computer science; Programming language; Biochemistry","score_opus":0.0645098071193837,"score_gpt":0.3399901661483824,"score_spread":0.2754803590289987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237424163","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011341863,0.00055357546,0.00031633256,0.0024935745,0.00051875744,0.0005519878,0.0000360495,0.0002031112,0.9952132],"genre_scores_gemma":[0.022596758,0.0006681596,0.00023581646,0.0029104992,0.0016666641,0.000018588378,0.000084567444,0.00018382767,0.9716351],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973235,0.000013633512,0.0004598398,0.0006078418,0.0010527306,0.0005424343],"domain_scores_gemma":[0.9980564,0.00018461367,0.000104500585,0.00081441767,0.00031543773,0.0005246022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028420606,0.0004434746,0.00084645837,0.0002925174,0.000060715633,0.00003499929,0.00027185402,0.0006760838,0.02411581],"category_scores_gemma":[0.00011496749,0.00035196953,0.0003160968,0.000034170393,0.00018931387,0.000030946056,0.00017604335,0.0011654741,0.004337956],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023698571,0.00004914683,0.0019604303,0.0017869743,0.00060278916,0.00074851216,0.00015113853,1.8657911e-7,0.00055032613,0.20889182,0.7288249,0.05619677],"study_design_scores_gemma":[0.0007902463,0.00042276515,0.00051899557,0.0005141845,0.00008561735,0.00011138562,0.0000035470557,0.000016990363,0.0014556411,0.0023494784,0.99332887,0.00040230143],"about_ca_topic_score_codex":0.00012389907,"about_ca_topic_score_gemma":0.000038583108,"teacher_disagreement_score":0.26450393,"about_ca_system_score_codex":0.00026274563,"about_ca_system_score_gemma":0.0004696909,"threshold_uncertainty_score":0.99989325},"labels":[],"label_agreement":null},{"id":"W4238539811","doi":"10.1007/978-3-540-47648-1_1933","title":"Epidermal Growth Factor-like Ligands","year":2008,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Computer science; Programming language","score_opus":0.08436577679503883,"score_gpt":0.3410091998712522,"score_spread":0.2566434230762134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238539811","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023343199,0.0017797359,0.000036625974,0.0018912784,0.00043176193,0.00060121226,0.00005568267,0.00021615998,0.99475414],"genre_scores_gemma":[0.011106491,0.0063242964,0.0002538769,0.0021624553,0.0012922463,0.000018892202,0.00009463499,0.00018687705,0.9785602],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997163,0.000009836752,0.0004733559,0.0006137944,0.0011760942,0.0005639322],"domain_scores_gemma":[0.99818504,0.00013534309,0.000094710995,0.0007361717,0.00032333628,0.0005253821],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013507974,0.00045960982,0.00082121004,0.00032757263,0.000085465545,0.000021460892,0.00025256746,0.0006835935,0.02030422],"category_scores_gemma":[0.00008012047,0.00037450853,0.00034724356,0.000046662262,0.00025554962,0.00005233362,0.0001639294,0.0012849768,0.0032746748],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001786718,0.000061440805,0.0014150885,0.0006744207,0.00043500372,0.0028800115,0.00023949644,1.2929577e-7,0.00023892606,0.012718637,0.96198463,0.019173542],"study_design_scores_gemma":[0.0008349559,0.00037409426,0.0008819539,0.00040549206,0.000060559694,0.0005130877,0.0000050180347,0.0000071080417,0.0015835001,0.000520224,0.99439585,0.00041812568],"about_ca_topic_score_codex":0.00015461305,"about_ca_topic_score_gemma":0.000029510982,"teacher_disagreement_score":0.032411247,"about_ca_system_score_codex":0.00034200886,"about_ca_system_score_gemma":0.00080211705,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W4239258335","doi":"10.1200/jco.2012.30.18_suppl.lba506","title":"Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Neoadjuvant therapy; Exact test; Clinical endpoint; Gastroenterology; Oncology; Cancer; Gynecology; Clinical trial","score_opus":0.45636250260094796,"score_gpt":0.651772909540381,"score_spread":0.19541040693943307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239258335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94013697,0.00091584394,0.00008974701,0.012276723,0.0012081746,0.04212932,0.00004195896,0.0000070123288,0.0031942797],"genre_scores_gemma":[0.9838424,0.00048173394,0.0027831194,0.0008897895,0.0021485768,0.009691785,0.0000022954962,0.00003328781,0.00012705813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936948,0.0013379408,0.0028573277,0.000158161,0.0015871547,0.0003646521],"domain_scores_gemma":[0.99112034,0.0018459149,0.0022361148,0.0002704108,0.0040997355,0.00042748955],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.024644936,0.00013708453,0.0016154298,0.00013298602,0.000032825636,0.0000043454224,0.0002488505,0.0003251904,0.0016335975],"category_scores_gemma":[0.0034152688,0.000091467584,0.00048161933,0.0001625422,0.0002609333,0.00013134308,0.000045521723,0.0007153476,0.0000077601535],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020236887,0.006634393,0.09463601,0.0002627431,0.00066728826,0.000008745417,0.0003462345,0.00011119784,0.005010878,0.00008480216,0.008060211,0.8639406],"study_design_scores_gemma":[0.0700965,0.05195431,0.5099943,0.0012002937,0.0008726258,0.00049257034,0.00036410222,0.0022832728,0.010746404,0.0006732101,0.35109973,0.00022263138],"about_ca_topic_score_codex":0.00033248847,"about_ca_topic_score_gemma":0.00004430386,"teacher_disagreement_score":0.863718,"about_ca_system_score_codex":0.00045304434,"about_ca_system_score_gemma":0.007840122,"threshold_uncertainty_score":0.999279},"labels":[],"label_agreement":null},{"id":"W4243113348","doi":"10.1200/jco.2017.35.15_suppl.502","title":"Updated results from the phase III ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L+T) in the adjuvant treatment of HER2-positive early breast cancer.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Lapatinib; Trastuzumab; Internal medicine; Tolerability; Clinical endpoint; Gastroenterology; Surgery; Breast cancer; Clinical trial; Cancer; Adverse effect","score_opus":0.3334326856360255,"score_gpt":0.5070968932165508,"score_spread":0.1736642075805253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243113348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98020977,0.0005650212,0.000028753528,0.016056286,0.0004529611,0.0017895281,0.0005192509,0.00000796138,0.00037047226],"genre_scores_gemma":[0.991173,0.0069241044,0.00027814612,0.0003461262,0.001088054,0.00004246767,0.00005492319,0.00003624645,0.000056888664],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99330556,0.0018225679,0.0030388066,0.00041876014,0.0009801674,0.0004341466],"domain_scores_gemma":[0.9888585,0.004729877,0.004244,0.0009252595,0.0010107734,0.00023158526],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0051129744,0.0003259769,0.00282913,0.000092785696,0.00018377946,0.000045900437,0.00097072567,0.00033552534,0.00009150694],"category_scores_gemma":[0.0009078152,0.00014605928,0.00038674474,0.0002783359,0.0012617077,0.00019101675,0.00006976386,0.0012063382,0.0000032935334],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6356883,0.019926824,0.05029601,0.000024162458,0.002036168,0.0004381153,0.00867768,0.000057422712,0.0030376713,0.000029027802,0.0005701836,0.27921844],"study_design_scores_gemma":[0.3224868,0.061033484,0.607914,0.00096137787,0.00029775576,0.000090029105,0.0015078848,0.00031194984,0.0036619783,0.00010339875,0.0014649743,0.00016642957],"about_ca_topic_score_codex":0.009266893,"about_ca_topic_score_gemma":0.00537571,"teacher_disagreement_score":0.55761796,"about_ca_system_score_codex":0.00051168393,"about_ca_system_score_gemma":0.0034276298,"threshold_uncertainty_score":0.9973305},"labels":[],"label_agreement":null},{"id":"W4243385540","doi":"10.1200/jco.2012.30.18_suppl.lba1","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Gastroenterology; Refractory (planetary science); Tolerability; Breast cancer; Oncology; Cancer; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243385540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W4243460686","doi":"10.1186/s13058-019-1196-y","title":"NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer","year":2019,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Trastuzumab; Medicine; Neratinib; Oncology; Internal medicine; Breast cancer; Cyclophosphamide; Chemotherapy; Gastroenterology; Cancer","score_opus":0.03781533341049981,"score_gpt":0.4208535751548812,"score_spread":0.3830382417443814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243460686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95295894,0.0036938144,0.000019919358,0.030715318,0.00020194692,0.0103365835,0.0012717097,0.00007261297,0.00072913826],"genre_scores_gemma":[0.9820841,0.0046636066,0.00014714348,0.000805282,0.0005532495,0.004674239,0.000054124153,0.00019621692,0.0068220655],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99189514,0.0013689202,0.0009521304,0.0015986476,0.0023901984,0.0017949471],"domain_scores_gemma":[0.99660844,0.0007350704,0.00016876552,0.00076411164,0.00081777014,0.0009058536],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037251501,0.0007024889,0.0021999346,0.00064661645,0.00042613162,0.00026810917,0.0003937518,0.00034565033,0.004813338],"category_scores_gemma":[0.00017055363,0.00046766404,0.00018758257,0.0014577552,0.0012858737,0.00040835323,0.00021923827,0.0019150295,0.000021968102],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8538592,0.0019285611,0.0028364807,0.00031486913,0.00047982394,0.0001805911,0.004288785,0.0000064352894,0.014143963,0.000048530837,0.007121743,0.11479101],"study_design_scores_gemma":[0.9721302,0.00989844,0.004758208,0.0017304952,0.000108496344,0.00089375,0.0020848631,0.0015217263,0.0013233477,0.000027396169,0.0047868732,0.00073624897],"about_ca_topic_score_codex":0.020136554,"about_ca_topic_score_gemma":0.003727931,"teacher_disagreement_score":0.118270956,"about_ca_system_score_codex":0.0015898077,"about_ca_system_score_gemma":0.004438045,"threshold_uncertainty_score":0.9997775},"labels":[],"label_agreement":null},{"id":"W4243654865","doi":"10.1093/jnci/djx242","title":"Response","year":2017,"lang":"en","type":"letter","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Computer science","score_opus":0.20334903797934395,"score_gpt":0.473213058432316,"score_spread":0.26986402045297203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243654865","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030435268,0.0014032412,0.000010313046,0.9771735,0.010411041,0.0003379197,0.0002246372,0.000009555681,0.007386264],"genre_scores_gemma":[0.0097366385,0.00065870857,0.0003979305,0.86372834,0.058133744,0.00004798558,0.000019330699,0.000089428715,0.06718792],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944424,0.00023786834,0.0006657097,0.00022968762,0.0040750527,0.0003492679],"domain_scores_gemma":[0.99522316,0.0002422581,0.0011984742,0.0004916579,0.0027114004,0.00013303723],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002091526,0.00025677198,0.00057380466,0.00041015956,0.00032268284,0.00011274263,0.0013579928,0.0005388426,0.00047288663],"category_scores_gemma":[0.0038031759,0.00016170355,0.00056749966,0.00019333484,0.00047595098,0.00026579434,0.00017347839,0.004502772,0.000051568262],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011650171,0.000022711125,0.0003198082,0.00015108568,0.0003236769,0.0008970107,0.000044867025,0.00006664799,0.00045441088,0.000018913186,0.99540716,0.0011287006],"study_design_scores_gemma":[0.0012011471,0.0001347591,0.0040181293,0.0015507917,0.00016150743,0.001890027,0.0000017662913,0.000010057019,0.00061305496,0.00042358288,0.98984146,0.00015374184],"about_ca_topic_score_codex":0.00009842135,"about_ca_topic_score_gemma":0.000028833221,"teacher_disagreement_score":0.113445185,"about_ca_system_score_codex":0.0028388118,"about_ca_system_score_gemma":0.01275025,"threshold_uncertainty_score":0.99779385},"labels":[],"label_agreement":null},{"id":"W4244123106","doi":"10.1097/01.pas.0000169497.11907.3a","title":"Description of a Novel System for Grading of Endometrial Carcinoma and Comparison With Existing Grading Systems","year":2005,"lang":"en","type":"article","venue":"The American Journal of Surgical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Grading (engineering); Medicine; Carcinoma; General surgery; Radiology; Oncology; Pathology; Biology","score_opus":0.14336739730510878,"score_gpt":0.37683670121627433,"score_spread":0.23346930391116555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4244123106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902038,0.0012200654,0.007578225,0.00032916915,0.00013994091,0.000340582,0.000010519866,0.0000065201693,0.00017115867],"genre_scores_gemma":[0.9951122,0.000050501003,0.004307516,0.000008791217,0.00048027496,0.0000089239265,8.3947924e-7,0.000019095425,0.000011904877],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99804854,0.00028835743,0.0008519386,0.00013835564,0.0004056806,0.00026714682],"domain_scores_gemma":[0.99691695,0.0012154649,0.0012340816,0.00015780282,0.00034072401,0.00013497428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023780747,0.000118325195,0.0011286279,0.0003351267,0.000060024533,0.000010831218,0.0001444852,0.00003905162,0.0000017334877],"category_scores_gemma":[0.00021821141,0.000070570255,0.00011958435,0.00037896703,0.000677056,0.00005225813,0.00003182348,0.0003163748,1.7651891e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04437535,0.0011152591,0.50012505,0.0033470895,0.0008787248,0.0011835438,0.0062865703,0.0025488297,0.34853464,0.0054449723,0.00023077003,0.08592918],"study_design_scores_gemma":[0.13365024,0.1259092,0.17358682,0.015392514,0.004229916,0.27975026,0.099154785,0.082848236,0.073668994,0.00011035741,0.009985548,0.0017131361],"about_ca_topic_score_codex":0.000101874844,"about_ca_topic_score_gemma":0.00000230012,"teacher_disagreement_score":0.32653826,"about_ca_system_score_codex":0.00016093857,"about_ca_system_score_gemma":0.000116212075,"threshold_uncertainty_score":0.28777716},"labels":[],"label_agreement":null},{"id":"W4245612590","doi":"10.1111/j.1471-0528.2007.01357.x","title":"What’s new in the other journals?","year":2007,"lang":"en","type":"article","venue":"BJOG An International Journal of Obstetrics & Gynaecology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.09633261367511584,"score_gpt":0.4452345611641628,"score_spread":0.348901947489047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245612590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9066616,0.013658133,0.0038170274,0.024472497,0.03474567,0.00048642288,0.00000613169,0.00001816277,0.016134331],"genre_scores_gemma":[0.9901603,0.0013084678,0.0014494952,0.004361755,0.0017734478,0.0000019598294,0.0000026468852,0.000027324884,0.00091461267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968168,0.00019557554,0.0009152854,0.0001625297,0.0015151661,0.00039462253],"domain_scores_gemma":[0.99600714,0.00192227,0.0004507689,0.00024491045,0.0010758089,0.00029911153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036547217,0.0001340086,0.00031223655,0.0014520403,0.000039949213,0.00018693456,0.0010500252,0.00017312432,0.0032897743],"category_scores_gemma":[0.004377004,0.00009376652,0.00016246898,0.0006870909,0.00009252467,0.0005949591,0.0000585341,0.0010821694,0.000047958194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044822835,0.00088614214,0.31906697,0.000012639324,0.0002601863,0.009174073,0.002921195,0.0001555004,0.00032270953,0.001869946,0.0060044243,0.65887797],"study_design_scores_gemma":[0.0038545688,0.0011729798,0.81909376,0.000057645117,0.000036782993,0.0027368523,0.0023745687,0.000063525484,0.0002560341,0.0016519462,0.1685845,0.000116805604],"about_ca_topic_score_codex":0.00006926336,"about_ca_topic_score_gemma":0.00012330392,"teacher_disagreement_score":0.65876114,"about_ca_system_score_codex":0.00094275735,"about_ca_system_score_gemma":0.00088155444,"threshold_uncertainty_score":0.99762136},"labels":[],"label_agreement":null},{"id":"W4247991125","doi":"10.1200/edbk_159161","title":"A Value-Based Approach to Treatment of HER2-Positive Breast Cancer: Examining the Evidence","year":2016,"lang":"en","type":"review","venue":"American Society of Clinical Oncology Educational Book","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Breast cancer; Medicine; Value (mathematics); Oncology; Cancer; Family medicine; Intensive care medicine; Internal medicine; Computer science","score_opus":0.3712633474379659,"score_gpt":0.5953295001663849,"score_spread":0.22406615272841895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247991125","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006947626,0.93999094,0.00017776812,0.05178701,0.0003252413,0.0028038768,0.00035594104,0.00001605448,0.004473699],"genre_scores_gemma":[0.00015940401,0.97723806,0.008381178,0.0053917384,0.001623997,0.0019420175,0.0000525107,0.000059283277,0.0051518143],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994536,0.001400081,0.0019845918,0.0008354736,0.0008008744,0.0004429873],"domain_scores_gemma":[0.9724144,0.023756938,0.0018297767,0.00081278733,0.00074445043,0.00044165642],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0020361966,0.00041069504,0.0039322344,0.000078342244,0.000091979025,0.0000066342313,0.00055755035,0.00036748243,0.00050738343],"category_scores_gemma":[0.0009608869,0.00023134472,0.001775487,0.0005747618,0.0036335364,0.000041359133,0.00010299886,0.00059420336,0.000050750466],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019589771,0.00206148,0.0011980516,0.0019027075,0.0010789003,8.762913e-7,0.00042169946,0.0000036310794,0.0000012778497,0.00010081698,0.019927692,0.973107],"study_design_scores_gemma":[0.00063472916,0.004454077,0.007801735,0.012926275,0.0012852937,0.000033746375,0.0002831909,0.000012818677,0.0000022137488,0.000010357498,0.9723501,0.00020543428],"about_ca_topic_score_codex":0.001011276,"about_ca_topic_score_gemma":0.000004789953,"teacher_disagreement_score":0.9729015,"about_ca_system_score_codex":0.0023716358,"about_ca_system_score_gemma":0.03812396,"threshold_uncertainty_score":0.999078},"labels":[],"label_agreement":null},{"id":"W4248017765","doi":"10.1177/117955490800200202","title":"Biological Markers Predictive of Invasive Recurrence in DCIS","year":2008,"lang":"en","type":"article","venue":"Clinical medicine Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Hazard ratio; Univariate analysis; Breast cancer; Oncology; Internal medicine; Immunohistochemistry; Multivariate analysis; Ductal carcinoma; Pathology; Confidence interval; Proportional hazards model; Cancer","score_opus":0.3741225147348614,"score_gpt":0.5492625681031179,"score_spread":0.1751400533682565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248017765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9389453,0.0012009463,0.00009093929,0.013201485,0.0011122699,0.0010045312,0.000011592617,0.000041354975,0.044391595],"genre_scores_gemma":[0.9849329,0.01077737,0.0009207759,0.0021601513,0.0007895809,0.000090267924,0.000020672964,0.000017157568,0.00029109733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99600065,0.0009369389,0.001514268,0.000594486,0.00046918876,0.00048449243],"domain_scores_gemma":[0.9907026,0.0077368477,0.0002869777,0.00046402912,0.00035053483,0.00045899936],"candidate_categories":["metaresearch","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030085223,0.00018476267,0.0014295197,0.00026491305,0.000035884426,6.0094004e-7,0.0003049978,0.0005798143,0.0013162243],"category_scores_gemma":[0.030649865,0.00012811419,0.00014416224,0.00065987895,0.004273644,0.000031762174,0.00016857176,0.0013663652,0.00006974819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038762896,0.0009795984,0.90166473,0.000104364306,0.00007668739,0.0015649253,0.0006047139,0.0000012012698,0.0004600996,0.00010521451,0.040059038,0.050503146],"study_design_scores_gemma":[0.007952756,0.03619528,0.9211459,0.00083830615,0.00005202174,0.00041468698,0.00073415734,0.00009809619,0.0002118875,0.00056117657,0.031656895,0.00013884294],"about_ca_topic_score_codex":0.00017291598,"about_ca_topic_score_gemma":0.00008045963,"teacher_disagreement_score":0.0503643,"about_ca_system_score_codex":0.00031467975,"about_ca_system_score_gemma":0.0017660134,"threshold_uncertainty_score":0.9995967},"labels":[],"label_agreement":null},{"id":"W4249293748","doi":"10.5858/2008-132-61-htiaps","title":"HER2 Testing in a Population-Based Study of Patients With Metastatic Breast Cancer Treated With Trastuzumab","year":2008,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; Lunenfeld-Tanenbaum Research Institute; University of Toronto; BC Cancer Agency","funders":"","keywords":"Trastuzumab; Concordance; Medicine; Immunohistochemistry; Breast cancer; Oncology; Internal medicine; Context (archaeology); Metastatic breast cancer; Fish <Actinopterygii>; Cancer; Population; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.03244274009161618,"score_gpt":0.32535604436669985,"score_spread":0.29291330427508366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249293748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980791,0.00017122526,0.000030231675,0.00020900555,0.000021939983,0.0011820607,0.00015178842,0.000028936116,0.00012567481],"genre_scores_gemma":[0.99830914,0.000011288938,0.0012681055,0.00011634894,0.000033507582,0.00013630101,0.000065228305,0.000045807275,0.000014265984],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755365,0.0004141477,0.00061924057,0.00041833206,0.00064722553,0.0003473846],"domain_scores_gemma":[0.9980576,0.00059685495,0.00031384127,0.0004388258,0.00043177776,0.00016111377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026382547,0.00024908446,0.0009183504,0.00059443305,0.00005926213,0.0000010037421,0.0001429848,0.000041300085,0.000085172964],"category_scores_gemma":[0.00027586124,0.00016078124,0.000021870204,0.0013042304,0.00072369695,0.000051940508,0.000022927925,0.00033588856,5.9091e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025118128,0.0020252499,0.98709464,0.00025838646,0.00011688005,0.0010274281,0.0033647635,0.0002637535,0.001713338,0.0000024525943,0.000010429866,0.0016108515],"study_design_scores_gemma":[0.0150301615,0.008557118,0.97380686,0.0009445852,0.00020182898,0.000045482,0.000912922,0.00014991968,0.00021748155,0.0000043348023,0.0000039408264,0.00012535711],"about_ca_topic_score_codex":0.0025859608,"about_ca_topic_score_gemma":0.0014363634,"teacher_disagreement_score":0.0132877845,"about_ca_system_score_codex":0.00010097693,"about_ca_system_score_gemma":0.00082566624,"threshold_uncertainty_score":0.6556469},"labels":[],"label_agreement":null},{"id":"W4250006491","doi":"10.5858/2008-132-1635-coqiwc","title":"Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer","year":2008,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"National Center for Research Resources; National Institute of General Medical Sciences; National Cancer Institute","keywords":"Immunohistochemistry; Tissue microarray; Trastuzumab; Breast cancer; Medicine; Internal medicine; Cancer; Fish <Actinopterygii>; Context (archaeology); Oncology; Pathology; Biology","score_opus":0.13129772062697326,"score_gpt":0.4896196454963863,"score_spread":0.35832192486941306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4250006491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718757,0.002031628,0.019440204,0.004444693,0.00006304654,0.0018047016,0.00022856148,0.000023907312,0.00008754055],"genre_scores_gemma":[0.72985756,0.00009625861,0.2691387,0.00037169468,0.000037430098,0.0004023959,0.000011043931,0.000044236785,0.000040680683],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996406,0.0013277975,0.0007703421,0.00053596904,0.00049813796,0.00046175093],"domain_scores_gemma":[0.99352777,0.004694465,0.0002950672,0.00045558423,0.00077635975,0.0002507671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020285354,0.00027347446,0.0012238859,0.00077770377,0.00008517049,0.0000021390865,0.00026927138,0.00004864472,0.00006576756],"category_scores_gemma":[0.0019925295,0.00018824938,0.000048154405,0.0014940519,0.0016584381,0.000054946217,0.000046393758,0.00037690587,0.000001334071],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064564995,0.00056303636,0.18492739,0.00026452928,0.00020398808,0.00035940812,0.01885063,0.0002238582,0.7189294,0.000182528,0.00018914192,0.010741092],"study_design_scores_gemma":[0.009403269,0.032788172,0.8849931,0.0027281365,0.00010381157,0.00038020758,0.0044679535,0.00033332477,0.063884065,0.00007871214,0.00059138006,0.00024787476],"about_ca_topic_score_codex":0.00033192182,"about_ca_topic_score_gemma":0.00019740601,"teacher_disagreement_score":0.70006573,"about_ca_system_score_codex":0.00011917638,"about_ca_system_score_gemma":0.0019615088,"threshold_uncertainty_score":0.7676587},"labels":[],"label_agreement":null},{"id":"W4251289754","doi":"10.1007/978-3-642-16483-5_1933","title":"Epidermal Growth Factor–Like Ligands","year":2011,"lang":"en","type":"book-chapter","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Factor (programming language); Computer science; Programming language","score_opus":0.11157145975790331,"score_gpt":0.34298060869531616,"score_spread":0.23140914893741285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251289754","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009708942,0.00094484695,0.00007930052,0.00092637376,0.0005067585,0.000582786,0.00004902954,0.00019692525,0.9966169],"genre_scores_gemma":[0.015360304,0.0014373461,0.00023662389,0.0016620563,0.0009964318,0.000021099924,0.00006406186,0.00018733679,0.98003477],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99752265,0.000009880142,0.00045170618,0.0005975991,0.000869674,0.00054846006],"domain_scores_gemma":[0.9981578,0.00009520631,0.000102090766,0.0007922301,0.00032372912,0.00052895746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020566118,0.0004467086,0.0007676594,0.00031413024,0.000055479137,0.000023182816,0.0002848637,0.0006970228,0.058790937],"category_scores_gemma":[0.00007040957,0.00035424158,0.00031517458,0.000035257395,0.00020909295,0.00005501186,0.0001971266,0.0011944736,0.004868963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000495285,0.00014578333,0.0038164,0.00189272,0.0010747266,0.0023028557,0.0006066034,3.408609e-8,0.00057184877,0.2700528,0.6628674,0.05617356],"study_design_scores_gemma":[0.00082486373,0.0005532998,0.0010467973,0.0005621567,0.00012539058,0.00016578443,0.0000061319347,0.0000026950036,0.0031232242,0.008517554,0.9845642,0.00050790596],"about_ca_topic_score_codex":0.0002912206,"about_ca_topic_score_gemma":0.000051306295,"teacher_disagreement_score":0.3216968,"about_ca_system_score_codex":0.00023915678,"about_ca_system_score_gemma":0.00058640615,"threshold_uncertainty_score":0.999891},"labels":[],"label_agreement":null},{"id":"W4251422122","doi":"10.1159/000423687","title":"Tyrosine Protein Kinases in T Lymphocytes","year":2015,"lang":"en","type":"book-chapter","venue":"Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Tyrosine kinase; Protein tyrosine phosphatase; Cell biology; Receptor tyrosine kinase; Kinase; Biology; Signal transduction","score_opus":0.03309474698557992,"score_gpt":0.3030187165639056,"score_spread":0.2699239695783257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251422122","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33254886,0.557132,0.000008505687,0.0058997953,0.0010712306,0.003909932,0.00014295608,0.00079612934,0.09849058],"genre_scores_gemma":[0.72257483,0.112569965,0.0053146547,0.0028710673,0.002341844,0.0052810432,0.005836179,0.0023795823,0.14083081],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.98928344,0.00023072958,0.0029716752,0.003237367,0.0012455062,0.003031281],"domain_scores_gemma":[0.9950185,0.0004309855,0.000747021,0.002337775,0.0007179396,0.0007477989],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0008627436,0.0023532452,0.0039728587,0.0017538253,0.00016542581,0.00012041834,0.0017362243,0.0059411344,0.0018990533],"category_scores_gemma":[0.0005811111,0.0023822836,0.0006631398,0.00064413477,0.0055912803,0.00030825307,0.0024842946,0.006347963,0.00024169277],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.045193423,0.009662974,0.0045671035,0.0033569057,0.026776806,0.03622696,0.002098454,0.000022334667,0.43861637,0.16127616,0.050127506,0.22207502],"study_design_scores_gemma":[0.030895911,0.0021976782,0.0010945026,0.009688807,0.00028212453,0.00463394,0.00032721017,0.00025636022,0.10684684,0.022358075,0.8155309,0.0058876704],"about_ca_topic_score_codex":0.0002882453,"about_ca_topic_score_gemma":0.00016922315,"teacher_disagreement_score":0.7654034,"about_ca_system_score_codex":0.0015321763,"about_ca_system_score_gemma":0.0016127669,"threshold_uncertainty_score":0.99901336},"labels":[],"label_agreement":null},{"id":"W4252392529","doi":"10.5858/2010-0038-oa.1","title":"Immunohistochemical Expression of Neurotrophic Tyrosine Kinase Receptors 1 and 2 in Lung Carcinoma: Potential Discriminators Between Squamous and Nonsquamous Subtypes","year":2011,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunohistochemistry; Tissue microarray; Adenocarcinoma; Pathology; Lung cancer; Carcinoma; Immunostaining; Medicine; Receptor tyrosine kinase; Cancer; Cancer research; Internal medicine; Receptor","score_opus":0.02190539495490347,"score_gpt":0.2921123080271221,"score_spread":0.27020691307221867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4252392529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070174,0.007918494,0.000055956465,0.00032971214,0.0001552014,0.00047624653,0.000044757697,0.000020995598,0.0002969145],"genre_scores_gemma":[0.99824303,0.00048678837,0.000980229,0.0000543438,0.00011266658,0.000028934155,0.00003072453,0.00004019149,0.000023110497],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.997776,0.00037062223,0.0006640226,0.0004949049,0.0003167627,0.00037772526],"domain_scores_gemma":[0.9986275,0.00032803678,0.00021176104,0.0004612865,0.00010790838,0.0002635483],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.00043943973,0.00025334247,0.00083994615,0.0005419648,0.00005017281,0.0000015929215,0.00017822726,0.00016932395,0.00007557997],"category_scores_gemma":[0.00065201224,0.00020535385,0.000045318036,0.00031076535,0.0028403627,0.000060821552,0.00021098147,0.0005692561,6.563573e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009497382,0.00013230783,0.3874089,0.000606241,0.000010314283,0.0005923296,0.0035483136,1.7822789e-7,0.60561705,0.000046017125,0.00008105574,0.0010075144],"study_design_scores_gemma":[0.003709596,0.0018269535,0.80569243,0.00059175014,0.00017577452,0.0001097726,0.0006437907,0.000028762692,0.18680826,0.00020915309,0.00003832445,0.00016544735],"about_ca_topic_score_codex":0.0002177778,"about_ca_topic_score_gemma":0.000009852554,"teacher_disagreement_score":0.41880882,"about_ca_system_score_codex":0.000034018114,"about_ca_system_score_gemma":0.00019406565,"threshold_uncertainty_score":0.99987334},"labels":[],"label_agreement":null},{"id":"W4253408104","doi":"10.1200/jco.2012.30.27_suppl.98","title":"Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Trastuzumab emtansine; Lapatinib; Capecitabine; Taxane; Trastuzumab; Metastatic breast cancer; Internal medicine; Interim analysis; Adverse effect; Refractory (planetary science); Gastroenterology; Pertuzumab; Breast cancer; Cancer; Oncology; Clinical trial","score_opus":0.12002997400766796,"score_gpt":0.48375085071599894,"score_spread":0.363720876708331,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253408104","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942012,0.0019666222,0.000042958327,0.0013223616,0.00023029612,0.0017039474,0.0002467417,0.000010570448,0.00027530038],"genre_scores_gemma":[0.99424976,0.002383856,0.0024667967,0.00026524335,0.00040675362,0.000061287734,0.000021477239,0.000048426336,0.00009642373],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9934989,0.0011873767,0.0033739232,0.00048868824,0.00085595855,0.0005951606],"domain_scores_gemma":[0.99086356,0.0053097066,0.0019090315,0.00031622365,0.0007603456,0.0008411157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032309147,0.00035688566,0.0031006548,0.00027361466,0.000050072318,0.000012633763,0.00018367368,0.00025049088,0.00014467101],"category_scores_gemma":[0.0024290823,0.00022776477,0.00013483106,0.00049582607,0.0005594547,0.00029397378,0.00008639996,0.0013843793,0.000001080625],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5207486,0.02438756,0.05873552,0.00018235228,0.0018934886,0.0029618798,0.0060076504,0.000033075852,0.000839036,0.0000013177698,0.00028505063,0.38392445],"study_design_scores_gemma":[0.29844466,0.15140864,0.5389225,0.0014589467,0.0018579497,0.0009180638,0.005868028,0.00014962952,0.00013057211,0.000004965116,0.0005585541,0.00027752077],"about_ca_topic_score_codex":0.0023609905,"about_ca_topic_score_gemma":0.008142427,"teacher_disagreement_score":0.48018694,"about_ca_system_score_codex":0.00081570173,"about_ca_system_score_gemma":0.003592645,"threshold_uncertainty_score":0.9287978},"labels":[],"label_agreement":null},{"id":"W4254075956","doi":"10.3410/f.717999671.793528402","title":"Faculty Opinions recommendation of Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Morphogen; Scaffold; Wnt signaling pathway; Computational biology; Cell biology; World Wide Web; Biology; Computer science; Engineering; Genetics; Signal transduction; Biomedical engineering","score_opus":0.11208554817992725,"score_gpt":0.44306380982439864,"score_spread":0.3309782616444714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254075956","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000045086567,0.0015108179,0.00009015759,0.15227468,0.00086267345,0.0045477,0.8405957,0.000032874537,0.000080844606],"genre_scores_gemma":[0.00003722338,0.0015013086,0.002486428,0.0011156444,0.0004923046,0.000968029,0.9907356,0.000064314234,0.0025991309],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926147,0.0005706636,0.0028333522,0.0009329979,0.0025125823,0.00053570274],"domain_scores_gemma":[0.9774099,0.00038574784,0.0037087605,0.0026773016,0.015365147,0.00045312857],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0042915614,0.00062600424,0.0018619226,0.0006244174,0.00029859747,0.00012297647,0.0021135097,0.0010649782,0.00069439516],"category_scores_gemma":[0.02943885,0.00042354144,0.0009615353,0.0015902669,0.00064033445,0.00035257553,0.0006686582,0.0009761201,0.0000327952],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009368113,0.00057594304,0.000057081223,0.035057284,0.0002898973,1.8178096e-7,0.00010371397,2.805313e-7,0.00010447513,0.000294118,0.96085006,0.0025733053],"study_design_scores_gemma":[0.001508499,0.0004647836,0.0019519886,0.027243381,0.00037441493,0.000022332599,0.00003543145,0.000017563212,0.00052470557,0.000032798267,0.96749234,0.00033174723],"about_ca_topic_score_codex":0.000110012516,"about_ca_topic_score_gemma":0.000013651236,"teacher_disagreement_score":0.15115903,"about_ca_system_score_codex":0.00037296236,"about_ca_system_score_gemma":0.0019767117,"threshold_uncertainty_score":0.99982166},"labels":[],"label_agreement":null},{"id":"W4281640394","doi":"10.1056/nejmoa2203690","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2548,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; First Hospital of Jilin University; West China Hospital, Sichuan University; University of California, San Francisco; Kyungpook National University; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Peking Union Medical College; Cleveland Clinic; Samsung; Universitat de Barcelona; Seoul National University Hospital; College of Medicine, Seoul National University; Memorial Sloan-Kettering Cancer Center; Yonsei University; Chinese Academy of Medical Sciences; Tel Aviv University; Seoul National University; Jilin University; Liaoning Cancer Hospital and Institute; Sichuan University; Sun Yat-sen University; Queen Mary University of London; Cleveland Clinic Foundation; University of Ulsan; Institute of Genetics; AstraZeneca; Cancer Research Institute","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","score_opus":0.0217942489314834,"score_gpt":0.3451216111915363,"score_spread":0.3233273622600529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281640394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95265234,0.008107225,0.000044741788,0.036683053,0.00070089987,0.00053749245,0.000020313595,0.000023855664,0.0012300762],"genre_scores_gemma":[0.99212176,0.0023501643,0.00015996522,0.0009858848,0.002677353,0.000034620633,0.0000095015375,0.00004855472,0.0016121964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967423,0.00030730068,0.0008207479,0.00024402695,0.0013820959,0.00050354353],"domain_scores_gemma":[0.9983967,0.0001893469,0.00030487878,0.00026172923,0.00024873024,0.0005986206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001688593,0.00021715234,0.00081979774,0.00054709084,0.000088530345,0.000007888812,0.0002865231,0.00005516574,0.0054201856],"category_scores_gemma":[0.00026110074,0.00015568745,0.00009975309,0.0008311516,0.00011728273,0.00008634453,0.000058425423,0.0013376847,0.000003294654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007018264,0.00035615408,0.08655889,0.00018783515,0.00016042886,0.0028620563,0.0035685957,0.0008496847,0.007847135,0.000012193325,0.016599175,0.87397957],"study_design_scores_gemma":[0.30815527,0.01711253,0.29426762,0.00551377,0.00055701355,0.030233914,0.0037901306,0.0004613597,0.0017474622,0.00047806645,0.33706677,0.0006161053],"about_ca_topic_score_codex":0.002004672,"about_ca_topic_score_gemma":0.00072625926,"teacher_disagreement_score":0.8733635,"about_ca_system_score_codex":0.0011176638,"about_ca_system_score_gemma":0.0014169454,"threshold_uncertainty_score":0.995489},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","score_opus":0.06037269198487216,"score_gpt":0.3976504848924063,"score_spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281722441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906309,0.00007477202,0.000003218423,0.0016511341,0.00019860028,0.0063306736,0.00006467061,0.000013501083,0.0010325073],"genre_scores_gemma":[0.9966329,0.0000040278837,0.000051359795,0.0006831027,0.00006991305,0.0024320998,0.000038543272,0.00002430003,0.000063750354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617904,0.0018996149,0.0005330911,0.00032485378,0.00068455364,0.00037882314],"domain_scores_gemma":[0.9985084,0.00055676745,0.00017356996,0.0006203688,0.00008485038,0.00005604618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025104578,0.00014350632,0.0004946864,0.00022288856,0.00013729121,0.0000082435145,0.0004163508,0.00005549452,0.0006613979],"category_scores_gemma":[0.0002563814,0.00008481225,0.000053988842,0.0007316454,0.00020816714,0.00003737838,0.0001551904,0.00087557203,0.000006332511],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19881319,0.08735282,0.6199746,0.000087227265,0.00035738945,0.00042434444,0.07346888,0.0010145821,0.0024228997,0.0000929484,0.008171339,0.007819805],"study_design_scores_gemma":[0.20789321,0.05190501,0.7054503,0.000017719438,0.000087709355,0.000004907346,0.02772318,0.00050949486,0.000072777424,0.00006678484,0.0061079375,0.00016095542],"about_ca_topic_score_codex":0.0008565953,"about_ca_topic_score_gemma":0.0010228639,"teacher_disagreement_score":0.08547573,"about_ca_system_score_codex":0.0006614012,"about_ca_system_score_gemma":0.0012227546,"threshold_uncertainty_score":0.7241843},"labels":[],"label_agreement":null},{"id":"W4281746025","doi":"10.3390/curroncol29060329","title":"Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Oncology; Anthracycline; Internal medicine; Adjuvant therapy; Stage (stratigraphy); Targeted therapy; Neoadjuvant therapy; Systemic therapy; Clinical trial; Disease; Trastuzumab; Cancer","score_opus":0.14555198247840234,"score_gpt":0.4902207322631705,"score_spread":0.34466874978476814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281746025","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009043296,0.98778087,5.404759e-7,0.00020906706,0.0008241678,0.002711325,0.003657156,0.000024070436,0.0038884585],"genre_scores_gemma":[0.0021201896,0.9955416,0.0000144125215,0.000025555519,0.00044703844,0.0014602339,0.00019151536,0.000110286004,0.00008920147],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99541825,0.0014452896,0.0007833627,0.00084265287,0.00059232995,0.0009181214],"domain_scores_gemma":[0.997283,0.00064807315,0.0005482201,0.0005623779,0.00043167942,0.00052665337],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087720226,0.000486678,0.0025987434,0.0012614989,0.00012586209,0.000018580096,0.0005251882,0.00041026983,0.005569722],"category_scores_gemma":[0.00031068776,0.00044195552,0.00047878732,0.0012423168,0.000292708,0.000059672457,0.00017608759,0.0030527967,0.000031639647],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015943177,0.0004392427,0.009514992,0.0018193586,0.0003367192,0.00017701053,0.005116519,9.861359e-7,3.6658997e-7,0.00011941605,0.00081190054,0.9815041],"study_design_scores_gemma":[0.0011989787,0.0010463197,0.00825749,0.0052076657,0.00031048805,0.000077025856,0.0024193968,0.000017657076,7.682142e-7,0.000052135532,0.98108965,0.0003224191],"about_ca_topic_score_codex":0.6538461,"about_ca_topic_score_gemma":0.32349706,"teacher_disagreement_score":0.9811816,"about_ca_system_score_codex":0.019346442,"about_ca_system_score_gemma":0.019548902,"threshold_uncertainty_score":0.99980325},"labels":[],"label_agreement":null},{"id":"W4281764145","doi":"10.1200/jco.2022.40.16_suppl.tps9137","title":"Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; non-small cell lung cancer (NSCLC); Trastuzumab; KRAS; Metastatic breast cancer; Phases of clinical research; Cancer; Lung cancer; Clinical trial; Breast cancer; Colorectal cancer","score_opus":0.24050476738856874,"score_gpt":0.5669676579238045,"score_spread":0.3264628905352358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281764145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98462147,0.0008883552,0.0008526207,0.0015845574,0.0008849748,0.010797661,0.00006568087,0.000018564999,0.0002861235],"genre_scores_gemma":[0.97504824,0.0007618559,0.01884325,0.00082627,0.0003096525,0.0025958975,0.000028441402,0.00011549884,0.0014708737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98788357,0.004103699,0.0045728013,0.00077969994,0.0018084766,0.0008517576],"domain_scores_gemma":[0.9802392,0.014157096,0.0029036,0.0005276387,0.0012255304,0.00094693626],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011440985,0.0004870117,0.0037780132,0.0004995962,0.00037331437,0.00007961785,0.00084547367,0.0001365182,0.001894327],"category_scores_gemma":[0.011345438,0.00030331902,0.00027242114,0.0009796162,0.0002512277,0.00031592327,0.0004455522,0.0020591721,0.0000067177166],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.71539456,0.06462712,0.059914105,0.00025227893,0.0015682002,0.004458996,0.0016869439,0.0139152855,0.000050574952,7.027214e-7,0.00013016995,0.13800104],"study_design_scores_gemma":[0.7399327,0.22731811,0.004396537,0.0006803905,0.0025025066,0.0000963129,0.0023128963,0.021091523,0.000034180743,0.000011472314,0.0013285176,0.00029482835],"about_ca_topic_score_codex":0.0025266642,"about_ca_topic_score_gemma":0.013018596,"teacher_disagreement_score":0.162691,"about_ca_system_score_codex":0.0039829346,"about_ca_system_score_gemma":0.019750057,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4281936531","doi":"10.1200/jco.2022.40.16_suppl.105","title":"Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Cancer; Phases of clinical research; Internal medicine; Oncology; Population; Response Evaluation Criteria in Solid Tumors; Antibody; Stage (stratigraphy); Clinical trial; Cancer research; Immunology","score_opus":0.15167348230874803,"score_gpt":0.5658398469977208,"score_spread":0.41416636468897283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281936531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804522,0.003503502,0.00006720963,0.010541207,0.0020510089,0.00051849673,0.000047124722,0.000014802387,0.0028044756],"genre_scores_gemma":[0.98361075,0.010370845,0.002421713,0.0016201625,0.0012352894,0.00000953883,0.000009084844,0.00004684232,0.0006757839],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99377006,0.0010253799,0.003073339,0.00039813633,0.001189983,0.00054308784],"domain_scores_gemma":[0.9927945,0.0036690226,0.0018742228,0.00043087723,0.0006120173,0.0006193421],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007576654,0.00020004499,0.0020660954,0.00014343207,0.00021617157,0.000011690359,0.00043728307,0.0003061757,0.0015279227],"category_scores_gemma":[0.003919177,0.00016143145,0.00044442306,0.0004930735,0.00065732736,0.000107638916,0.0005434818,0.002719431,0.000010050087],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06468201,0.0024655997,0.07475891,0.00021147325,0.00053241267,0.002196904,0.0012126295,0.00041357154,0.008665208,0.00012276146,0.017108334,0.82763016],"study_design_scores_gemma":[0.023147615,0.026913924,0.2527313,0.0002668854,0.00012328605,0.0009348489,0.0011806892,0.00010522826,0.00018511165,0.00010590749,0.6941483,0.00015693097],"about_ca_topic_score_codex":0.00018158427,"about_ca_topic_score_gemma":0.0001265033,"teacher_disagreement_score":0.8274733,"about_ca_system_score_codex":0.0011542992,"about_ca_system_score_gemma":0.0046953782,"threshold_uncertainty_score":0.99958134},"labels":[],"label_agreement":null},{"id":"W4282940254","doi":"10.1158/1538-7445.am2022-819","title":"Abstract 819: ERBB4 mediates IL10-induced growth of EGFR-independent colon tumors","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"ERBB4; Downregulation and upregulation; ErbB; Cancer research; Colorectal cancer; ERBB3; Biology; Medicine; Receptor; Cancer; Internal medicine; Epidermal growth factor receptor; Receptor tyrosine kinase; Gene; Genetics","score_opus":0.14543979386801828,"score_gpt":0.46036240678029816,"score_spread":0.31492261291227985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282940254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779117,0.001706908,0.000001490348,0.0075658676,0.00045350552,0.0016085082,0.00017258895,0.00007506778,0.010504361],"genre_scores_gemma":[0.99445045,0.0004649948,0.000044132496,0.00024206712,0.0006382399,0.0016680672,0.000045226076,0.00010660695,0.0023402087],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9915198,0.0005253894,0.00064715423,0.00079139555,0.005133964,0.0013822638],"domain_scores_gemma":[0.99655104,0.0006470446,0.00014588569,0.00087098184,0.0011362421,0.00064879283],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047451607,0.0002520216,0.0006330049,0.00090060657,0.0004896671,0.000046297617,0.0009687916,0.000141523,0.013375256],"category_scores_gemma":[0.0009342805,0.0002427884,0.00018270484,0.0019038222,0.00042687912,0.00010848661,0.0009008404,0.0028563032,0.00015039851],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027896112,0.00095820474,0.036766488,0.0018453792,0.00029854928,0.0012787217,0.002226171,0.00006170628,0.86121863,0.0009381372,0.07896559,0.012652808],"study_design_scores_gemma":[0.0064684716,0.0041275555,0.123755954,0.0007314485,0.000069773014,0.0001379878,0.0047602756,0.00019169267,0.82379127,0.0012384767,0.034019586,0.0007075002],"about_ca_topic_score_codex":0.0072425716,"about_ca_topic_score_gemma":0.0002764958,"teacher_disagreement_score":0.08698947,"about_ca_system_score_codex":0.0026623227,"about_ca_system_score_gemma":0.0043805493,"threshold_uncertainty_score":0.9994441},"labels":[],"label_agreement":null},{"id":"W4282968322","doi":"10.3390/curroncol29060337","title":"A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Occupational Cancer Research Centre","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Biosimilar; Stage (stratigraphy); Chemotherapy; Regimen; Cancer","score_opus":0.4092377757126683,"score_gpt":0.5581179420768986,"score_spread":0.1488801663642303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282968322","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004629674,0.99161166,3.6529275e-7,0.00067514903,0.0013302923,0.0026457591,0.0012484615,0.000025431766,0.001999925],"genre_scores_gemma":[0.00014268437,0.9980308,0.000041862237,0.00008227479,0.00012993703,0.0011799664,0.00019977105,0.000083153165,0.000109589484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945759,0.0008532352,0.002092391,0.00090538827,0.0008540189,0.00071906805],"domain_scores_gemma":[0.9964709,0.0011520067,0.001050103,0.0007995087,0.00022338073,0.00030405362],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012610451,0.0006347342,0.005919531,0.0009768612,0.000047515397,0.000007087225,0.0006000266,0.00032154538,0.0018952035],"category_scores_gemma":[0.00032248232,0.00050994655,0.00053742237,0.0015614759,0.0004918945,0.000057811067,0.00042659405,0.002089159,0.00000873304],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002893314,0.00059296296,0.0028373864,0.16025704,0.0002741056,0.000056775167,0.0001375373,6.439845e-8,3.8357365e-7,0.00004340909,0.0036453623,0.83186567],"study_design_scores_gemma":[0.002419298,0.0013821825,0.0050638733,0.1132717,0.0014262996,0.00007412469,0.00004228603,0.0000014801623,4.1132617e-7,0.0000044724757,0.87600726,0.0003066261],"about_ca_topic_score_codex":0.0011450575,"about_ca_topic_score_gemma":0.0014519305,"teacher_disagreement_score":0.8723619,"about_ca_system_score_codex":0.0032714645,"about_ca_system_score_gemma":0.005780667,"threshold_uncertainty_score":0.99985564},"labels":[],"label_agreement":null},{"id":"W4284959551","doi":"10.1371/journal.pone.0271090","title":"Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis","year":2022,"lang":"en","type":"article","venue":"PLoS ONE","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Cancer Agency; University of Saskatchewan","keywords":"Breast cancer; Metastasis; Cancer research; Cancer; Medicine; Triple-negative breast cancer; Cell; Internal medicine; Biology; Biochemistry","score_opus":0.03333294983593834,"score_gpt":0.29248249797600695,"score_spread":0.25914954814006863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284959551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917877,0.0013643379,0.00005103315,0.0046748095,0.00005910503,0.0015064126,0.00033729384,0.00002683569,0.00019248156],"genre_scores_gemma":[0.9961262,0.00068610645,0.00097510073,0.00034525222,0.0001026024,0.0010882557,0.000020744297,0.000030911073,0.00062485004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977832,0.00023888907,0.0003183327,0.0005210802,0.0007499632,0.00038855357],"domain_scores_gemma":[0.99908864,0.00014070493,0.00008454427,0.00021998228,0.00019711217,0.00026898534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004239768,0.00018018889,0.00047254286,0.00030121248,0.00016959546,0.000042701056,0.00011145977,0.000055248416,0.0005152494],"category_scores_gemma":[0.00014214082,0.00017414558,0.00003102896,0.00057841686,0.00006789074,0.00010132961,0.00023062817,0.00044352346,0.0000046555656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013834052,0.0009527536,0.006886039,0.00031275503,0.00009066714,0.000035072288,0.0022549161,0.000007704651,0.9857357,0.0000028449806,0.0015237895,0.00081431697],"study_design_scores_gemma":[0.0032109013,0.00043502712,0.022418825,0.00035750004,0.00012282007,0.000006905824,0.0013312071,0.00012255063,0.9716986,0.000053066757,0.00007740766,0.0001651933],"about_ca_topic_score_codex":0.0013485086,"about_ca_topic_score_gemma":0.00037595027,"teacher_disagreement_score":0.015532787,"about_ca_system_score_codex":0.00036002987,"about_ca_system_score_gemma":0.00025422827,"threshold_uncertainty_score":0.71014506},"labels":[],"label_agreement":null},{"id":"W4285196366","doi":"10.1007/978-1-0716-2376-3_11","title":"Flow Cytometry Analysis to Detect Lapatinib-Induced Modulation of Constitutive and IFN-γ-Induced HLA Class I Expression in HER2-Positive Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Lapatinib; Flow cytometry; Downregulation and upregulation; Cancer research; Immune system; Cancer; Human leukocyte antigen; Biology; Cancer cell; Immunology; Breast cancer; Trastuzumab; Antigen; Genetics; Gene","score_opus":0.0402782762195107,"score_gpt":0.45619999057676763,"score_spread":0.41592171435725694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285196366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8074843,0.00020011811,0.19073167,0.0003162507,0.00013525994,0.0007480181,0.00015251219,0.000012595059,0.00021923753],"genre_scores_gemma":[0.8085134,0.000021821354,0.19084728,0.0002569061,0.000019604167,0.00028699957,0.0000255902,0.000019152345,0.000009252938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949576,0.0032257496,0.0004909043,0.0006442655,0.0002902825,0.0003911757],"domain_scores_gemma":[0.99879897,0.00038877653,0.00013940854,0.00038376727,0.00015004088,0.00013905489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021588004,0.00019985746,0.0007535084,0.0014829178,0.000061149876,0.0000065992613,0.00017244206,0.00020329536,0.00019501954],"category_scores_gemma":[0.0004018932,0.00019511963,0.00011392508,0.0028418517,0.00012732271,0.000023957513,0.00034511398,0.00061121164,8.4944963e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004655285,0.00007857736,0.02441401,0.000028715533,0.00017476203,0.00007057267,0.00062136137,0.002744395,0.9058084,0.00002178642,0.0000042452134,0.06556768],"study_design_scores_gemma":[0.0011869835,0.0005717187,0.08431433,0.00007787834,0.00011710704,0.000018652061,0.00031643952,0.01110117,0.9018804,0.00018490499,0.000038224938,0.00019218316],"about_ca_topic_score_codex":0.0016687742,"about_ca_topic_score_gemma":0.0002412728,"teacher_disagreement_score":0.0653755,"about_ca_system_score_codex":0.00051052636,"about_ca_system_score_gemma":0.0002777834,"threshold_uncertainty_score":0.79567474},"labels":[],"label_agreement":null},{"id":"W4285285895","doi":"10.1007/978-1-0716-2376-3_14","title":"Western Blot Analysis of Lapatinib-Mediated Inhibition of the Epidermal Growth Factor Receptor 2 (HER2) Pathway in Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Lapatinib; Western blot; Phosphorylation; Blot; Epidermal growth factor receptor; Molecular biology; Signal transduction; Receptor tyrosine kinase; Tyrosine-kinase inhibitor; Chemistry; Cancer research; Cancer; Tyrosine phosphorylation; Biology; Breast cancer; Receptor; Cell biology; Biochemistry; Trastuzumab","score_opus":0.040004353161672446,"score_gpt":0.41591909066818633,"score_spread":0.3759147375065139,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285285895","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98961663,0.00048782598,0.007073071,0.0012196439,0.0002381671,0.0004955624,0.0007903593,0.000009843499,0.0000689155],"genre_scores_gemma":[0.97522247,0.000092278446,0.023678316,0.00056836643,0.000031087442,0.00025082717,0.00009676169,0.000030081397,0.000029786574],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99385905,0.0044795997,0.0006514511,0.0003382002,0.0002993766,0.00037229748],"domain_scores_gemma":[0.9986706,0.00047786804,0.0002577329,0.00040086516,0.00012302451,0.00006991096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002139436,0.00015176595,0.00071051164,0.0006620056,0.000027230597,0.0000020010289,0.00022774638,0.0001479481,0.0013304576],"category_scores_gemma":[0.00038821506,0.00011995193,0.00021073829,0.0025351355,0.0002185745,0.00001592634,0.00029614344,0.0005623519,0.000001237453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010663487,0.00015643626,0.35178757,0.000055324024,0.00015157624,0.000006970599,0.00038644363,0.00012941516,0.64398503,0.000032544332,0.00001057214,0.003191488],"study_design_scores_gemma":[0.00093832484,0.00017677895,0.21203776,0.00004854135,0.000110949564,0.0000051016614,0.00014512178,0.00034930737,0.7855439,0.00006813424,0.00045350194,0.0001225741],"about_ca_topic_score_codex":0.0026977502,"about_ca_topic_score_gemma":0.00024686148,"teacher_disagreement_score":0.14155887,"about_ca_system_score_codex":0.00028412422,"about_ca_system_score_gemma":0.0002641441,"threshold_uncertainty_score":0.99958247},"labels":[],"label_agreement":null},{"id":"W4285992942","doi":"10.1038/s41523-022-00452-8","title":"PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer","year":2022,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Hôpital Charles-Le Moyne; Université de Sherbrooke","funders":"Novartis Pharma; National Cancer Institute; National Institutes of Health; Amis de l'Institut Bordet; Ministero della Salute; Associazione Italiana per la Ricerca sul Cancro; National Institute for Health and Care Research; American Society of Clinical Oncology; GlaxoSmithKline","keywords":"Lapatinib; Trastuzumab; Medicine; Internal medicine; Breast cancer; Oncology; Stage (stratigraphy); Chemotherapy; Population; Cancer","score_opus":0.019051291407503723,"score_gpt":0.31597203856608413,"score_spread":0.2969207471585804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285992942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728263,0.0004399906,0.000038300164,0.0034510868,0.000522977,0.0012039033,0.019059133,0.0001034582,0.002354852],"genre_scores_gemma":[0.9967354,0.000096924,0.000067898385,0.00031216413,0.00028624004,0.00070419256,0.00016071717,0.00011725904,0.0015191885],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996254,0.00017968997,0.00038282963,0.0006111551,0.0018588692,0.00071341265],"domain_scores_gemma":[0.9981393,0.00009483608,0.00021154033,0.00053029,0.000676628,0.0003473873],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028120895,0.00032510658,0.0005813064,0.00018589738,0.00023656718,0.000029104871,0.00033016893,0.00008393777,0.014462773],"category_scores_gemma":[0.000013820256,0.00027330246,0.000114519695,0.00065811374,0.00034324647,0.00014965495,0.00028798755,0.0006678763,0.000013725577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004023259,0.000576176,0.9828213,0.00029963756,0.000390787,0.000049837574,0.0004317662,0.00075535546,0.00017086235,0.00005980349,0.0022116909,0.008209558],"study_design_scores_gemma":[0.0035400377,0.00059030624,0.99214906,0.00037648802,0.0001525704,0.000045877423,0.00025265958,0.00024272053,0.00032843841,0.000011862065,0.0020286967,0.0002812692],"about_ca_topic_score_codex":0.021826698,"about_ca_topic_score_gemma":0.0010243643,"teacher_disagreement_score":0.023909118,"about_ca_system_score_codex":0.0014006819,"about_ca_system_score_gemma":0.0014513774,"threshold_uncertainty_score":0.9999719},"labels":[],"label_agreement":null},{"id":"W4288431972","doi":"10.1021/acsomega.2c03407","title":"Toward the Development of GE11-Based Radioligands for Imaging of Epidermal Growth Factor Receptor-Positive Tumors","year":2022,"lang":"en","type":"article","venue":"ACS Omega","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bundesministerium für Bildung und Forschung","keywords":"Epidermal growth factor receptor; Chemistry; Cancer research; In vivo; Peptide; Positron emission tomography; Ligand (biochemistry); Rational design; Biophysics; Receptor; Computational biology; Medicine; Nuclear medicine; Biochemistry; Nanotechnology; Materials science; Biology","score_opus":0.05339359974201312,"score_gpt":0.3354542421718758,"score_spread":0.2820606424298627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288431972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904635,0.0003750534,0.0014638639,0.00562316,0.00017054583,0.001032489,0.0001949458,0.000025750545,0.000650675],"genre_scores_gemma":[0.99621266,0.000006298032,0.0027618567,0.00041566283,0.000076803895,0.00029018486,0.00006517815,0.000033126482,0.00013823665],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982486,0.000103107406,0.00043795482,0.00022792094,0.00064156536,0.00034087236],"domain_scores_gemma":[0.99874777,0.00049220264,0.00015271067,0.0002545034,0.00025911714,0.00009368675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008086092,0.00012917044,0.00034186206,0.00015526451,0.00015470688,0.0000071049503,0.00028814684,0.000023717525,0.00011581901],"category_scores_gemma":[0.00033637744,0.000098715835,0.000109250126,0.0003344838,0.00014313043,0.00004177181,0.00014358439,0.00026098857,0.000002818947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054804743,0.001276127,0.32413203,0.0038172973,0.0010792478,0.00009879837,0.064571865,0.00021753869,0.45284128,0.0015323745,0.03504307,0.10990992],"study_design_scores_gemma":[0.0025926232,0.00047834398,0.043722812,0.00017181526,0.000041073057,0.000019428217,0.0024195577,0.00037490358,0.94095165,0.00008854872,0.008953902,0.0001853496],"about_ca_topic_score_codex":0.000060640567,"about_ca_topic_score_gemma":0.000002423575,"teacher_disagreement_score":0.48811036,"about_ca_system_score_codex":0.00034868094,"about_ca_system_score_gemma":0.0011019389,"threshold_uncertainty_score":0.40255147},"labels":[],"label_agreement":null},{"id":"W4288749431","doi":"10.1186/s13550-022-00915-w","title":"Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases","year":2022,"lang":"en","type":"article","venue":"EJNMMI Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atuka (Canada); University Health Network; McGill University; Montreal Neurological Institute and Hospital; University of Alberta","funders":"University of Alberta; Weston Brain Institute; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Medicine; In vivo; Kinase; Peripheral; Tropomyosin; Receptor; Internal medicine; Cell biology; Actin; Genetics; Biology","score_opus":0.14741915073502457,"score_gpt":0.4392329236631014,"score_spread":0.29181377292807686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288749431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874052,0.0005959579,0.0000063031407,0.0059099137,0.00026042695,0.0023658962,0.00016687607,0.000031238298,0.0032581983],"genre_scores_gemma":[0.987912,0.000060073224,0.0009716057,0.000066725675,0.00028584732,0.0007183757,0.000023452869,0.00008370497,0.009878232],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9926487,0.0010880514,0.00074222434,0.00068083673,0.0036630763,0.0011770903],"domain_scores_gemma":[0.9974346,0.0005041027,0.00010310153,0.00074699457,0.0007884743,0.00042268855],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004703581,0.00021791247,0.0007196124,0.001972693,0.00018990302,0.000032216067,0.00068188034,0.000091079375,0.009815937],"category_scores_gemma":[0.0021843559,0.00021408031,0.00014627927,0.0044756434,0.00039777881,0.0001063495,0.0008793434,0.0017220228,0.00004791467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037596843,0.0014378058,0.02502738,0.0013186139,0.000071290626,0.00030176007,0.0045822114,0.000096599746,0.8667751,0.0002555172,0.08840417,0.007969887],"study_design_scores_gemma":[0.0032869328,0.005777325,0.0013953331,0.0006218077,0.000010592561,0.00003399304,0.0069676572,0.00019065004,0.8896711,0.000050414998,0.091740794,0.00025343877],"about_ca_topic_score_codex":0.0013046273,"about_ca_topic_score_gemma":0.00017050821,"teacher_disagreement_score":0.023632046,"about_ca_system_score_codex":0.0016700382,"about_ca_system_score_gemma":0.0016764702,"threshold_uncertainty_score":0.9910892},"labels":[],"label_agreement":null},{"id":"W4290993146","doi":"10.1016/j.esmoop.2022.100553","title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","year":2022,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Lilly Deutschland; Merck Sharp and Dohme; Eisai; Clovis Oncology; Boehringer Ingelheim; Ariad Pharmaceuticals; Roche; Daiichi-Sankyo; Teva Pharmaceutical Industries; Novartis; Merck; Sanofi-Aventis Deutschland; Pfizer; Queen Mary University of London; Bristol-Myers Squibb; AstraZeneca; Gilead Sciences","keywords":"Medicine; Breast cancer; Trastuzumab; Internal medicine; Pneumonitis; Nausea; Context (archaeology); Neutropenia; Oncology; Metastatic breast cancer; Cancer; Chemotherapy; Lung","score_opus":0.33804201657331107,"score_gpt":0.5932876732972931,"score_spread":0.2552456567239821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290993146","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001432475,0.9530732,0.0000052670234,0.00046226094,0.0002583239,0.0053669736,0.00023378567,0.000010095363,0.040575765],"genre_scores_gemma":[0.00003649796,0.99092776,0.004930607,0.000055777717,0.000100055935,0.0019212011,0.000091671456,0.000082972765,0.0018534778],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99569625,0.0008122235,0.0017021935,0.00065524917,0.0007540502,0.0003800311],"domain_scores_gemma":[0.9973365,0.0006869261,0.0007745457,0.00094719586,0.00008995891,0.00016485517],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002458106,0.0003377872,0.0028128757,0.00026266262,0.00004135132,0.000023923863,0.00087528053,0.00017692294,0.0046294043],"category_scores_gemma":[0.000109041284,0.0002690715,0.00045592966,0.0007494318,0.0001146076,0.00010280728,0.0009208563,0.0007353676,0.000015771198],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031154425,0.001241117,0.0001032527,0.015185115,0.0014601959,0.00054117816,0.00016586021,0.000008033049,1.9976424e-8,0.00006925586,0.0006479766,0.98026645],"study_design_scores_gemma":[0.0018850697,0.00074399885,0.00043868064,0.019760313,0.0019893495,0.000134647,0.00042949742,0.0000049396663,0.0000010493527,0.0000030174501,0.9744275,0.00018194229],"about_ca_topic_score_codex":0.011864519,"about_ca_topic_score_gemma":0.00039882807,"teacher_disagreement_score":0.98008454,"about_ca_system_score_codex":0.002138154,"about_ca_system_score_gemma":0.00245074,"threshold_uncertainty_score":0.99997616},"labels":[],"label_agreement":null},{"id":"W4292121937","doi":"10.1007/s00432-022-04189-6","title":"Triple negative breast cancer: approved treatment options and their mechanisms of action","year":2022,"lang":"en","type":"article","venue":"Journal of Cancer Research and Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Triple-negative breast cancer; Epirubicin; Olaparib; Breast cancer; Oncology; Docetaxel; Paclitaxel; Internal medicine; Adverse effect; Cancer; Pharmacology","score_opus":0.3171317950564267,"score_gpt":0.5861197862775303,"score_spread":0.26898799122110356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292121937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9392458,0.0061377767,0.00012907734,0.05182256,0.0007313423,0.0009798958,0.00027504432,0.0000081678845,0.00067033817],"genre_scores_gemma":[0.93480307,0.06259411,0.00036538878,0.00023756943,0.0006070541,0.00022532212,0.0000025220322,0.000020353396,0.0011446265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967444,0.0010955745,0.0008225517,0.0002567077,0.0007011206,0.00037962396],"domain_scores_gemma":[0.9965059,0.0015669437,0.0004064793,0.00017069482,0.0008524588,0.00049750763],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037738835,0.000118578355,0.0008053797,0.0003019506,0.00024313506,0.000014896366,0.00015706297,0.00012921728,0.0009814936],"category_scores_gemma":[0.00033269136,0.00008013048,0.00017114259,0.00041070612,0.00061376666,0.00007909962,0.00018449748,0.0014428524,7.490255e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023775721,0.0033302936,0.01737482,0.0001503117,0.0013811915,0.00016095152,0.00091733295,0.00003170242,0.016778126,0.00084659655,0.007034665,0.9282183],"study_design_scores_gemma":[0.06564298,0.25676855,0.23128374,0.00069577934,0.0008484695,0.0031978285,0.031061634,0.0022153931,0.024084093,0.035521865,0.3480898,0.0005898664],"about_ca_topic_score_codex":0.0022301355,"about_ca_topic_score_gemma":0.0014044323,"teacher_disagreement_score":0.9276284,"about_ca_system_score_codex":0.0014765463,"about_ca_system_score_gemma":0.0042083943,"threshold_uncertainty_score":0.99993175},"labels":[],"label_agreement":null},{"id":"W4292265152","doi":"10.3390/curroncol29080458","title":"Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Breast cancer; Trastuzumab; Internal medicine; Chemotherapy; Neoadjuvant therapy; Capecitabine; Disease; Stage (stratigraphy); Cancer; Taxane; Colorectal cancer","score_opus":0.24325960886720419,"score_gpt":0.5219915138139263,"score_spread":0.27873190494672206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292265152","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004405732,0.9851645,0.000004782705,0.00032608298,0.0011954698,0.0066433847,0.0019505175,0.000052087493,0.00025744882],"genre_scores_gemma":[0.00035912648,0.9886826,0.000046417645,0.00003671388,0.0004954994,0.00853517,0.001177734,0.00015342169,0.0005132923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99676675,0.0003202189,0.00065020827,0.00085862906,0.0006129519,0.00079126324],"domain_scores_gemma":[0.99838966,0.0003047479,0.0002890598,0.00055274036,0.000088428314,0.00037536997],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025256476,0.0005838803,0.0022275846,0.00037058868,0.00011561464,0.000039764964,0.000284664,0.00019677545,0.0012403042],"category_scores_gemma":[0.000032721862,0.0004094294,0.0005023761,0.00037840006,0.00011335307,0.00006718399,0.00009336041,0.0007113636,0.000010188525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014634422,0.00182397,0.02242723,0.008666461,0.00038996214,0.00016968262,0.00024876083,0.0000027704268,1.8744359e-8,0.00003725694,0.0007180821,0.9640524],"study_design_scores_gemma":[0.008291932,0.0030321337,0.008050397,0.0049486104,0.00093993684,0.000005785983,0.00008898267,0.0000052096466,5.290097e-8,0.000011377614,0.9742703,0.00035529805],"about_ca_topic_score_codex":0.00031661542,"about_ca_topic_score_gemma":0.00022722923,"teacher_disagreement_score":0.9735522,"about_ca_system_score_codex":0.0058188722,"about_ca_system_score_gemma":0.009012596,"threshold_uncertainty_score":0.9998357},"labels":[],"label_agreement":null},{"id":"W4292634632","doi":"10.47102/annals-acadmedsg.v44n10p360","title":"Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer","year":2015,"lang":"en","type":"article","venue":"Annals of the Academy of Medicine Singapore","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"NIH Clinical Center; National University Cancer Institute, Singapore; University of Toronto; National Cancer Centre of Singapore","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Internal medicine; Cancer; Stage (stratigraphy); Adjuvant; Workgroup","score_opus":0.4128579596647815,"score_gpt":0.5084332479875551,"score_spread":0.09557528832277357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292634632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70188737,0.017940367,0.000035832913,0.27631104,0.0005662831,0.0020416698,0.00085237366,0.00004031768,0.00032476775],"genre_scores_gemma":[0.9740618,0.0057334057,0.0005860307,0.013970706,0.0028167316,0.00017827928,0.000035138244,0.00012844404,0.0024895072],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9950996,0.0002533516,0.0014704529,0.00058236177,0.00164186,0.0009523976],"domain_scores_gemma":[0.9958311,0.00043085948,0.00079709105,0.0004856239,0.0019641188,0.0004912319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030749722,0.0004279085,0.0013637913,0.0002798628,0.000099543664,0.000012832732,0.0006869214,0.00035176525,0.00013520001],"category_scores_gemma":[0.002056907,0.00027914357,0.00027330272,0.0010456102,0.0010570303,0.000253356,0.00020779399,0.00096199557,0.0000013567483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049690143,0.0003018824,0.21866962,0.0009936518,0.00058126246,0.000030981584,0.004437183,0.0026177848,0.0024389848,0.0004238176,0.70621413,0.058321666],"study_design_scores_gemma":[0.014054125,0.0026715468,0.7934111,0.028822813,0.00068079674,0.00013946276,0.0029369753,0.0023485445,0.02202857,0.0028459462,0.12919162,0.00086849806],"about_ca_topic_score_codex":0.01854644,"about_ca_topic_score_gemma":0.00096349366,"teacher_disagreement_score":0.57702255,"about_ca_system_score_codex":0.00030025613,"about_ca_system_score_gemma":0.0012378627,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W4293029338","doi":"10.3390/curroncol29090476","title":"Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China; China Medical Board","keywords":"Capecitabine; Lapatinib; Medicine; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; China; Cancer; Trastuzumab; Colorectal cancer","score_opus":0.16749156255611966,"score_gpt":0.4809945161196087,"score_spread":0.313502953563489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293029338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9702455,0.011902852,0.0008305366,0.0013729989,0.001071883,0.0068069836,0.0076718736,0.00001291685,0.00008449158],"genre_scores_gemma":[0.9920929,0.0030930508,0.000077212324,0.000023529423,0.000059542075,0.004238102,0.0003554194,0.000033970715,0.000026262802],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958973,0.0014156213,0.0010140965,0.0004943929,0.00064394635,0.0005346338],"domain_scores_gemma":[0.9954597,0.0027665184,0.00073093566,0.0004898085,0.00042605697,0.00012699858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017132836,0.0002799849,0.002139998,0.00058427127,0.00013157746,0.0000038824423,0.00027011894,0.0000558416,0.00044999318],"category_scores_gemma":[0.0001791753,0.00021366571,0.0003972168,0.0020213556,0.00035554895,0.000040985822,0.000107889,0.00035905797,5.697114e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057267774,0.013875847,0.24867038,0.003788436,0.007904433,0.00004794302,0.01934594,0.112932034,0.0009822313,0.00030993493,0.00021581132,0.5346592],"study_design_scores_gemma":[0.041443504,0.015494516,0.9116289,0.00041394777,0.0017015265,0.000016811457,0.0016248804,0.022062462,0.00069493125,0.000018252249,0.0046736933,0.00022659817],"about_ca_topic_score_codex":0.009549861,"about_ca_topic_score_gemma":0.005514676,"teacher_disagreement_score":0.6629585,"about_ca_system_score_codex":0.006548718,"about_ca_system_score_gemma":0.003339978,"threshold_uncertainty_score":0.997265},"labels":[],"label_agreement":null},{"id":"W4293395719","doi":"10.1158/0008-5472.18.65.1","title":"The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":183,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Sylvester Comprehensive Cancer Center, University of Miami Health Systems; U.S. Department of Defense","keywords":"Tamoxifen; Lapatinib; Estrogen receptor; Antiestrogen; Cancer research; Breast cancer; Cyclin D1; Cancer; Medicine; Biology; Internal medicine; Endocrinology; Pharmacology; Cell cycle; Trastuzumab","score_opus":0.03860283302467069,"score_gpt":0.3709254548999244,"score_spread":0.3323226218752537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293395719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724487,0.011239859,0.000016734768,0.012308312,0.00011269473,0.0030685526,0.0002742352,0.000057866087,0.0004730184],"genre_scores_gemma":[0.98610854,0.004299512,0.00063349673,0.00038817181,0.0012876381,0.0031587805,0.000022671178,0.00013219146,0.003969018],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937946,0.000478984,0.00065976847,0.001046854,0.002450192,0.0015696037],"domain_scores_gemma":[0.99688256,0.00029590627,0.000095992684,0.0008192049,0.0010810863,0.00082527724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019160733,0.0004028228,0.00051806774,0.00044594266,0.00072457537,0.000391188,0.00039553884,0.00020331223,0.00049783644],"category_scores_gemma":[0.0001530829,0.0002656125,0.000055591063,0.001249341,0.0005550089,0.00027527873,0.0004411492,0.0013441497,0.000064871165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007664386,0.00046603425,0.115093514,0.0003919672,0.000085773114,0.00023208189,0.002434289,0.00058714085,0.8332018,0.00007978539,0.02150717,0.018256033],"study_design_scores_gemma":[0.0050638174,0.001108091,0.016869193,0.0013701031,0.000028642256,0.00010956534,0.0010446877,0.00025720993,0.9374916,0.000017586914,0.036141492,0.00049800106],"about_ca_topic_score_codex":0.0023066804,"about_ca_topic_score_gemma":0.008227347,"teacher_disagreement_score":0.10428978,"about_ca_system_score_codex":0.0013851845,"about_ca_system_score_gemma":0.0035211977,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W4294992606","doi":"10.1139/bcb-2022-0099","title":"HER2 induces cell scattering and invasion through ∆Np63α and E-cadherin","year":2022,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cell migration; Metastasis; Cancer research; Cell growth; Transfection; Cell; Biology; Downregulation and upregulation; Cancer; Cell culture; Genetics; Gene","score_opus":0.040440815122009116,"score_gpt":0.31292957342054534,"score_spread":0.27248875829853625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294992606","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98272973,0.008316231,0.0000022335653,0.0007176642,0.00006319817,0.00012375851,0.000021734602,0.000019201932,0.008006264],"genre_scores_gemma":[0.99563515,0.0019264295,0.00016760422,0.00038686677,0.00010628693,0.00003566498,0.00003511455,0.000011983014,0.0016948788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991203,0.00004883199,0.00013169048,0.00038405848,0.00008299524,0.00023213886],"domain_scores_gemma":[0.9996171,0.00005056458,0.000039354018,0.00016632404,0.00001534977,0.00011128545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018126046,0.00011962694,0.00017941617,0.000020887992,0.0001645671,0.000013306577,0.000069489695,0.00012271722,0.0003217037],"category_scores_gemma":[0.000016121547,0.00010977162,0.000017844954,0.000072005954,0.00023641073,0.000018584431,0.0003770881,0.00031160595,0.0000027481676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000078243815,0.000045432327,0.009699493,0.00039677066,0.0000093652925,0.000019955673,0.00020964659,1.1889067e-7,0.98475325,0.000005270975,0.00054586586,0.0042365673],"study_design_scores_gemma":[0.00077247125,0.00036881142,0.0007723145,0.00002278282,0.000016129434,0.00012269973,0.00086514256,0.000008790116,0.95159787,0.000078782876,0.045244843,0.00012939035],"about_ca_topic_score_codex":0.00010461566,"about_ca_topic_score_gemma":0.0000011575505,"teacher_disagreement_score":0.044698976,"about_ca_system_score_codex":0.000035017667,"about_ca_system_score_gemma":0.000068114736,"threshold_uncertainty_score":0.4476357},"labels":[],"label_agreement":null},{"id":"W4295679167","doi":"10.1007/s00280-022-04471-x","title":"Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Dosing; Pharmacokinetics; Medicine; Population; Body surface area; Cancer; Internal medicine; Pharmacology; Oncology","score_opus":0.035151670659454175,"score_gpt":0.43091332078514066,"score_spread":0.3957616501256865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295679167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562675,0.0018232105,0.000015844298,0.0007570333,0.00036922135,0.0011403738,0.00020838717,0.000022854643,0.000036352027],"genre_scores_gemma":[0.9926193,0.0040062238,0.00026371353,0.002256364,0.00010706772,0.00040579648,0.00014722664,0.00004860949,0.00014570884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833703,0.00018849668,0.0003391076,0.00040758812,0.00036368956,0.00036405819],"domain_scores_gemma":[0.9993444,0.000053445587,0.00016454683,0.00018021953,0.00011480573,0.00014255873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000201416,0.00019795769,0.000515098,0.00020936738,0.000090319,0.00000677188,0.00015684387,0.000040784522,0.0070447605],"category_scores_gemma":[0.000004528067,0.00016207567,0.000029327946,0.0005906221,0.0001258724,0.00012104441,0.000054287313,0.0003726584,5.1959967e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008387147,0.00093195547,0.8444846,0.00047730506,0.00025197474,0.00003416666,0.0007417893,0.0015162954,0.076067396,0.000008515529,0.0007094312,0.06638942],"study_design_scores_gemma":[0.036239434,0.0041049854,0.8556602,0.00012042033,0.00028855767,0.000014424231,0.00018089994,0.00242734,0.07057238,0.00002581352,0.029933065,0.0004324522],"about_ca_topic_score_codex":0.00069802656,"about_ca_topic_score_gemma":0.00010696693,"teacher_disagreement_score":0.065956965,"about_ca_system_score_codex":0.0002467742,"about_ca_system_score_gemma":0.00033524964,"threshold_uncertainty_score":0.9938629},"labels":[],"label_agreement":null},{"id":"W4295837361","doi":"10.1016/j.annonc.2022.07.1858","title":"274TiP Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Chemotherapy; Oncology; Metastatic breast cancer; Internal medicine; Breast cancer; Drug; Cancer; Gynecology; Pharmacology","score_opus":0.06520598839853473,"score_gpt":0.41253695573535093,"score_spread":0.34733096733681623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295837361","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9661043,0.0020843265,0.000010209858,0.02581558,0.00018268412,0.0028235563,0.001704584,0.000065590015,0.0012091412],"genre_scores_gemma":[0.98430014,0.0060972306,0.001252384,0.0055334647,0.0001950087,0.0010329167,0.00038182907,0.00015028639,0.0010567305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99283344,0.0021215298,0.001493929,0.0010372659,0.0012271792,0.0012866325],"domain_scores_gemma":[0.99579793,0.0010851681,0.0007844808,0.00089350506,0.0008705029,0.0005684339],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015706514,0.00062275183,0.0022272512,0.0007847137,0.00022380766,0.000030563842,0.0008948868,0.00021741507,0.0039509386],"category_scores_gemma":[0.0005055765,0.0005452758,0.00030123975,0.002296654,0.0009259878,0.0003158069,0.00029424776,0.0012608251,0.000028060882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05911284,0.0214047,0.36572447,0.0038418719,0.005023566,0.0028396887,0.031052928,0.00035115116,0.16920687,0.00069699617,0.20394926,0.13679567],"study_design_scores_gemma":[0.061923508,0.06270431,0.38296968,0.0026366322,0.0011300276,0.0035742172,0.012537634,0.0010666165,0.19320562,0.0009267658,0.27445692,0.0028680866],"about_ca_topic_score_codex":0.040911123,"about_ca_topic_score_gemma":0.0032576078,"teacher_disagreement_score":0.13392758,"about_ca_system_score_codex":0.0008838284,"about_ca_system_score_gemma":0.004260346,"threshold_uncertainty_score":0.9996999},"labels":[],"label_agreement":null},{"id":"W4295872731","doi":"10.5858/arpa.2022-0031-ra","title":"A Consortium for Analytic Standardization in Immunohistochemistry","year":2022,"lang":"en","type":"review","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Health Quality Council; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health","keywords":"Standardization; Immunohistochemistry; Pathology; Medicine; Computer science","score_opus":0.06853813911439628,"score_gpt":0.44192988354096086,"score_spread":0.3733917444265646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295872731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011436221,0.9930143,0.00035686602,0.00020309651,0.00030086856,0.0019519635,0.00073879276,0.000034001783,0.0032857775],"genre_scores_gemma":[0.00013396514,0.9963055,0.00068013335,0.0001351393,0.00025321043,0.0008918343,0.0010747511,0.00009631123,0.00042913156],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964231,0.00055398804,0.0013616197,0.00068674027,0.0004999061,0.00047462678],"domain_scores_gemma":[0.9964352,0.0017215288,0.0006106751,0.0009200006,0.00013769789,0.00017488355],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014172292,0.00040378256,0.0030759482,0.0009336004,0.000070429145,0.00000261421,0.00038698773,0.00025560785,0.00079471467],"category_scores_gemma":[0.0028216923,0.00034099672,0.0003024041,0.0009884383,0.00132349,0.000023422252,0.00015003404,0.0010558892,0.000003045889],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077756465,0.0004102482,0.00042694923,0.120315716,0.0006248474,0.0023945132,0.0017785355,0.0000043526693,0.0032488615,0.0006088716,0.0045889826,0.86482054],"study_design_scores_gemma":[0.0021166245,0.0010604031,0.000047291454,0.011950537,0.0010477299,0.00020412618,0.00025150136,0.00001154133,0.000042581843,0.00013727463,0.98290265,0.00022776834],"about_ca_topic_score_codex":0.000013322782,"about_ca_topic_score_gemma":0.0000051027273,"teacher_disagreement_score":0.9783136,"about_ca_system_score_codex":0.00040965166,"about_ca_system_score_gemma":0.003874936,"threshold_uncertainty_score":0.9999042},"labels":[],"label_agreement":null},{"id":"W4296246565","doi":"10.3390/pharmaceutics14091917","title":"Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates","year":2022,"lang":"en","type":"article","venue":"Pharmaceutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Nimotuzumab; Monoclonal antibody; Epitope; Epidermal growth factor receptor; Biodistribution; Conjugate; Chemistry; Antibody; Cancer research; Antibody-drug conjugate; Pharmacology; Immunohistochemistry; Molecular biology; Receptor; Medicine; In vitro; Immunology; Biochemistry; Biology","score_opus":0.11598252000600795,"score_gpt":0.42953738690281595,"score_spread":0.313554866896808,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296246565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9707355,0.023240604,0.00014877037,0.0034300978,0.000901892,0.00090694736,0.00019137133,0.00015866663,0.00028617372],"genre_scores_gemma":[0.9759565,0.020313418,0.0008871634,0.0019610832,0.0005417358,0.000023227843,0.00005910002,0.000106357395,0.0001514249],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997233,0.0002897452,0.00040833413,0.00054236886,0.00079018367,0.00073641434],"domain_scores_gemma":[0.9984905,0.0004882248,0.000114741335,0.00032162154,0.00021580672,0.00036910022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005130463,0.00029868513,0.0004566566,0.00021823835,0.000527212,0.00009609431,0.000245896,0.00004742775,0.0024239342],"category_scores_gemma":[0.00012747502,0.00029369417,0.0000959666,0.0004239568,0.0002561804,0.00013266916,0.0003030707,0.00094714476,0.00003274325],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042633348,0.0002612759,0.10887559,0.00017009379,0.00012058355,0.0006182973,0.0010677011,0.00024179209,0.8306668,0.000035902078,0.0017482215,0.055767417],"study_design_scores_gemma":[0.0045801005,0.00026725468,0.0013942149,0.00007592863,0.00006446126,0.0006899165,0.0008282682,0.06741116,0.2189773,0.000043284654,0.7050971,0.00057099643],"about_ca_topic_score_codex":0.00007640821,"about_ca_topic_score_gemma":3.1552045e-7,"teacher_disagreement_score":0.7033489,"about_ca_system_score_codex":0.00033998422,"about_ca_system_score_gemma":0.00022826117,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4299117194","doi":"","title":"Trastuzumab (T) and everolimus (E) pharmacokinetics (PK) in HER2 positive (+) primary breast cancer (BC) patients (pts): Unicancer RADHER trial results","year":2013,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Trastuzumab; Everolimus; Medicine; Breast cancer; Pharmacokinetics; Oncology; Internal medicine; Cancer; Gynecology","score_opus":0.02166874102913106,"score_gpt":0.3020995897932127,"score_spread":0.28043084876408164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299117194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9394803,0.0019000251,0.0002615224,0.021353336,0.00067539903,0.0044082673,0.001296309,0.00015709228,0.030467762],"genre_scores_gemma":[0.9786227,0.0079593435,0.0029140504,0.000528017,0.00018643968,0.000744585,0.0012848877,0.00014278904,0.0076172086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9911211,0.004397736,0.0011327727,0.0013984018,0.0011836055,0.00076636364],"domain_scores_gemma":[0.9927504,0.001038594,0.0006133724,0.0019415033,0.0031403739,0.0005157468],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003763473,0.0005846449,0.00093611644,0.000405397,0.00018553219,0.00026727477,0.0009112045,0.0005246992,0.00047678055],"category_scores_gemma":[0.0008078426,0.00058276433,0.00021323463,0.00058724266,0.0005412199,0.00016931901,0.0016114258,0.0019191761,0.00004072777],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04376217,0.014282398,0.08485539,0.0038685137,0.0015435122,0.00015265423,0.039485764,0.00031680975,0.0027412956,0.0016993165,0.040464584,0.7668276],"study_design_scores_gemma":[0.15347733,0.000038089285,0.76553255,0.019764766,0.000578684,0.000057091533,0.00025966164,0.009592193,0.013700033,0.00076188176,0.033991583,0.0022461158],"about_ca_topic_score_codex":0.020120686,"about_ca_topic_score_gemma":0.0030856633,"teacher_disagreement_score":0.7645815,"about_ca_system_score_codex":0.0016646066,"about_ca_system_score_gemma":0.0016010108,"threshold_uncertainty_score":0.9996624},"labels":[],"label_agreement":null},{"id":"W4300137879","doi":"","title":"Activation of P38MAP kinase in estrogen-positive invasive breast cancers: Relation with HER2 and downstream signaling phosphorylated proteins expression","year":2013,"lang":"en","type":"preprint","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre d'expertise et de recherche en infrastructures urbaines","funders":"","keywords":"Phosphorylation; Cancer research; Kinase; Estrogen; Downstream (manufacturing); Protein kinase A; Signal transduction; Cell biology; Chemistry; Biology; Internal medicine; Medicine","score_opus":0.015341786391121565,"score_gpt":0.2559631362785085,"score_spread":0.2406213498873869,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300137879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864051,0.0007045789,0.005217178,0.0023239953,0.00003143539,0.002309969,0.000076194854,0.000069977286,0.0028615717],"genre_scores_gemma":[0.98208195,0.00047243683,0.015955057,0.000025644986,0.000017778138,0.0003724929,0.0005860989,0.000053933134,0.00043459702],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9956931,0.002031902,0.00055535126,0.0007413557,0.0006505079,0.00032780948],"domain_scores_gemma":[0.9947887,0.00076285563,0.0006175873,0.0010682107,0.002547763,0.00021488688],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019269715,0.00031970697,0.0004923671,0.00034409086,0.00013410096,0.00011433353,0.00030976985,0.000358257,0.00013989705],"category_scores_gemma":[0.00079733983,0.0002957281,0.00007839047,0.00051882584,0.0003137295,0.00021161475,0.00046725236,0.0009709794,0.0000052127402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012202258,0.0017468676,0.11642141,0.0029127023,0.0003631307,0.00005087302,0.035337806,0.0014424032,0.76115304,0.0031812089,0.00023743964,0.0759329],"study_design_scores_gemma":[0.0015887113,0.0000070688766,0.03221917,0.025886416,0.000052352472,0.000024893166,0.0005356941,0.0040721,0.9348725,0.00038589042,0.00005861652,0.00029655642],"about_ca_topic_score_codex":0.015864868,"about_ca_topic_score_gemma":0.0014525186,"teacher_disagreement_score":0.1737195,"about_ca_system_score_codex":0.0007025982,"about_ca_system_score_gemma":0.0013630453,"threshold_uncertainty_score":0.99994946},"labels":[],"label_agreement":null},{"id":"W4304127970","doi":"10.1016/j.jaad.2022.10.005","title":"Prognostic factors for the development of acneiform eruptions in patients on epidermal growth factor receptor inhibitors","year":2022,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Dermatology; Epidermal growth factor receptor; Receptor; Internal medicine","score_opus":0.0506189236224899,"score_gpt":0.3628806373907033,"score_spread":0.31226171376821343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304127970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98259795,0.00008515067,0.00003218931,0.016235312,0.00024305255,0.0007298218,0.00004929674,0.000003936218,0.00002331454],"genre_scores_gemma":[0.9986155,0.000036327518,0.0006624717,0.00054466934,0.000047081652,0.000050327413,0.0000027445456,0.000022167542,0.000018725115],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973547,0.00029019977,0.0011006967,0.0001332776,0.00078477437,0.000336384],"domain_scores_gemma":[0.9969309,0.0012711162,0.0014235197,0.00012834802,0.00014494282,0.00010120158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041075682,0.00014596908,0.0006468769,0.0003692134,0.00016598319,0.0000032433998,0.00057634985,0.000054512835,0.00006442569],"category_scores_gemma":[0.001121375,0.00008390981,0.00023425934,0.0005697672,0.0004193903,0.00005340033,0.00020413166,0.0010147843,0.0000013922602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008894504,0.00043586834,0.9850054,0.00011195171,0.0001933436,0.0000017378978,0.001993364,0.00004318807,0.0015201339,0.000052343705,0.004104012,0.005649255],"study_design_scores_gemma":[0.0015996031,0.0008623997,0.9607044,0.00012934962,0.00006129498,0.000089145535,0.0016779061,0.000027912054,0.025503518,0.00006618696,0.009181151,0.00009715991],"about_ca_topic_score_codex":0.000017948845,"about_ca_topic_score_gemma":0.0000029272796,"teacher_disagreement_score":0.024300978,"about_ca_system_score_codex":0.00036094722,"about_ca_system_score_gemma":0.0005083359,"threshold_uncertainty_score":0.44087896},"labels":[],"label_agreement":null},{"id":"W4306155108","doi":"10.1016/j.ccell.2022.09.016","title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","year":2022,"lang":"en","type":"article","venue":"Cancer Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Drug; Therapeutic window; Conjugate; Maximum tolerated dose; Pharmacology; Antibody; Medicine; Antibody-drug conjugate; Computational biology; Pharmacokinetics; Immunology; Monoclonal antibody; Biology","score_opus":0.026803969198095252,"score_gpt":0.3725866003387929,"score_spread":0.3457826311406976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306155108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9295642,0.058495987,0.000008463094,0.0025221035,0.00031007893,0.0009990756,0.000040531537,0.000014641878,0.008044912],"genre_scores_gemma":[0.9918186,0.00607471,0.000017396309,0.0003097408,0.00005616971,0.00007432708,0.000007206774,0.000023857881,0.0016179717],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984714,0.00018331606,0.00035127858,0.00019107778,0.00054594263,0.00025702157],"domain_scores_gemma":[0.99904346,0.0002193297,0.0001316475,0.0004399817,0.00010766253,0.000057931647],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007979923,0.00009454826,0.00029982172,0.00007013639,0.00007518071,0.00000587299,0.00026478007,0.000027307595,0.0012043738],"category_scores_gemma":[0.000030033507,0.00006786023,0.00007988647,0.0004555736,0.00015102733,0.000027855403,0.00012847695,0.0003297666,0.0000040378377],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002425851,0.0006161346,0.15741347,0.0022816602,0.00013514176,0.000060709604,0.008994577,0.0004770776,0.7398043,0.00047978203,0.010194518,0.07711676],"study_design_scores_gemma":[0.009715169,0.0017399327,0.036038272,0.0013606162,0.00015257738,0.000016877379,0.01482801,0.0019495594,0.40756392,0.00046028208,0.5257619,0.00041286208],"about_ca_topic_score_codex":0.0021759775,"about_ca_topic_score_gemma":0.00013356803,"teacher_disagreement_score":0.5155674,"about_ca_system_score_codex":0.00030790552,"about_ca_system_score_gemma":0.0005388894,"threshold_uncertainty_score":0.99970865},"labels":[],"label_agreement":null},{"id":"W4306739715","doi":"10.1016/j.breast.2022.10.007","title":"Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":133,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"EMD Serono; Genentech; PharmaMar; G1 Therapeutics; MacroGenics; Pfizer; Incyte; NuCana; Seagen; Relay Therapeutics; Plexxikon; Ontario Brain Institute; Syndax Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Radius Health; Gilead Sciences; Merck; Mersana Therapeutics; Novartis; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Roche; Astellas Pharma US","keywords":"Medicine; Metastatic breast cancer; Antibody-drug conjugate; Drug; Cancer; Antibody; Breast cancer; Oncology; Conjugate; Drug development; Cancer research; Internal medicine; Pharmacology; Immunology; Monoclonal antibody","score_opus":0.05927251587468007,"score_gpt":0.42484980232567876,"score_spread":0.3655772864509987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306739715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97334516,0.0016365697,0.000028888564,0.022177473,0.0004260775,0.0008752143,0.00019230183,0.00007500453,0.0012433205],"genre_scores_gemma":[0.996557,0.00018009721,0.00044661202,0.0009842545,0.00028186108,0.00029982504,0.00008478352,0.000050827537,0.0011147626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969601,0.0006160837,0.00060384563,0.00039754616,0.0008261753,0.00059621833],"domain_scores_gemma":[0.9989088,0.00030955623,0.00012192153,0.00037086985,0.00009817028,0.00019064483],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00319642,0.00018758197,0.00044969493,0.00012477927,0.0003057956,0.00002929089,0.0003933816,0.000025870671,0.0039921794],"category_scores_gemma":[0.0000819266,0.00013231218,0.000101671016,0.0005288474,0.0001984994,0.00005285258,0.000405596,0.0009591613,0.00010140995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001885627,0.0011164142,0.83146536,0.00033028354,0.0004281122,0.0005576372,0.0037500968,0.0003409297,0.004863751,0.00025108166,0.016241373,0.13876936],"study_design_scores_gemma":[0.0052015577,0.00020271173,0.8857522,0.0004175714,0.00013651373,0.0024664847,0.0042239623,0.0017510366,0.0006309401,0.00012611465,0.09859248,0.0004984242],"about_ca_topic_score_codex":0.001266238,"about_ca_topic_score_gemma":0.00019424957,"teacher_disagreement_score":0.13827093,"about_ca_system_score_codex":0.00049295556,"about_ca_system_score_gemma":0.0012121855,"threshold_uncertainty_score":0.9969183},"labels":[],"label_agreement":null},{"id":"W4308016405","doi":"10.1186/s12885-022-10206-1","title":"Prevalence of Her2-neu status and its clinicopathological association in newly diagnosed gastric cancer patients","year":2022,"lang":"en","type":"article","venue":"BMC Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Roche Canada","keywords":"Surgical oncology; Medicine; Internal medicine; Cancer; Oncology; Association (psychology); General surgery","score_opus":0.06354620483384012,"score_gpt":0.3958588212015545,"score_spread":0.3323126163677144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308016405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911637,0.00658852,0.00000224968,0.00030260938,0.00036942455,0.0008870709,0.00041554577,0.000020857107,0.0002500722],"genre_scores_gemma":[0.98876375,0.008072072,0.00007244188,0.00031476343,0.00011894317,0.0010703288,0.000013170887,0.000023082119,0.0015514411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744326,0.00033256834,0.00043359047,0.00040553423,0.0009051854,0.00047988276],"domain_scores_gemma":[0.99885994,0.00036856395,0.00023689108,0.00017702459,0.00020271007,0.00015489096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007118333,0.00013019751,0.0003367755,0.00015710059,0.00006418157,0.000009123029,0.00012761075,0.000086601554,0.0023043088],"category_scores_gemma":[0.0009935626,0.0001246563,0.00005770485,0.00056317775,0.00004151597,0.00006319426,0.00019603677,0.0004934066,0.000005073178],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035227175,0.00032409615,0.9886021,0.00046823305,0.000010431547,0.00001376956,0.00038120354,0.00025032958,0.00026964658,0.0000056161125,0.0019400874,0.00738219],"study_design_scores_gemma":[0.0033440704,0.00067673787,0.99227196,0.0001688476,0.000041327738,0.0000012317108,0.000079945276,0.0003355973,0.00022816517,0.000013529942,0.002728152,0.00011042963],"about_ca_topic_score_codex":0.0019319912,"about_ca_topic_score_gemma":0.0008895626,"teacher_disagreement_score":0.00727176,"about_ca_system_score_codex":0.0018344808,"about_ca_system_score_gemma":0.00091872783,"threshold_uncertainty_score":0.9986077},"labels":[],"label_agreement":null},{"id":"W4308254239","doi":"10.1200/jco.21.02937","title":"Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Regional Municipality of Durham; Lakeridge Health","funders":"MacroGenics; University of Washington","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Internal medicine; Overall survival; Randomized controlled trial; Cancer","score_opus":0.1259646493750785,"score_gpt":0.49088681888886,"score_spread":0.3649221695137815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98637676,0.00029084654,0.0000144222595,0.0065408405,0.002746196,0.002388209,0.0007599599,0.00001459058,0.0008681607],"genre_scores_gemma":[0.9963772,0.0004919127,0.0006135613,0.000530442,0.0013992972,0.00017941091,0.00014472395,0.00005135143,0.00021207689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98878026,0.004553455,0.0038788556,0.00055149157,0.0016399833,0.00059593096],"domain_scores_gemma":[0.9857798,0.009928395,0.002535134,0.00034216058,0.00082899735,0.0005854835],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007288229,0.000308475,0.0039615575,0.0002762503,0.00010020337,0.000017409116,0.00036930587,0.00028407158,0.0011857679],"category_scores_gemma":[0.005524334,0.00021936196,0.000712285,0.00041889772,0.0003961465,0.0001639788,0.0001396899,0.002836173,0.000005514202],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.909203,0.013476157,0.0068646227,0.000012110549,0.0011095814,0.0013282464,0.00028264787,0.00018547503,0.000008276739,0.0000052505216,0.0012335295,0.06629109],"study_design_scores_gemma":[0.8586609,0.075942405,0.06062006,0.00018511574,0.0006355839,0.00003159595,0.00009915153,0.00018257988,0.0000071712434,0.00004109848,0.0034108078,0.0001835732],"about_ca_topic_score_codex":0.0012553356,"about_ca_topic_score_gemma":0.0004404641,"teacher_disagreement_score":0.06610751,"about_ca_system_score_codex":0.0021405246,"about_ca_system_score_gemma":0.0059270244,"threshold_uncertainty_score":0.9997273},"labels":[],"label_agreement":null},{"id":"W4309412600","doi":"10.1016/s1470-2045(22)00621-0","title":"Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Trastuzumab; Adverse effect; Bispecific antibody; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Phases of clinical research; Cancer; Monoclonal antibody; Antibody; Breast cancer; Immunology","score_opus":0.2538568129815828,"score_gpt":0.5097609920992456,"score_spread":0.25590417911766283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309412600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795477,0.0015043119,0.005485368,0.005449549,0.00039389642,0.0070872093,0.00032583563,0.00005580044,0.00015036837],"genre_scores_gemma":[0.9913887,0.0014322358,0.0031908245,0.00045509922,0.00034416493,0.0024337866,0.00007865323,0.000051367122,0.0006251877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976741,0.00044802928,0.00048208237,0.00045000823,0.00047423688,0.00047153144],"domain_scores_gemma":[0.9968846,0.0018722998,0.000261278,0.0007549152,0.00013500494,0.00009190082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012704653,0.00022184751,0.00084647647,0.00010024682,0.0004484542,0.000027264832,0.00030872817,0.000045558645,0.00042279012],"category_scores_gemma":[0.00019121676,0.00010929429,0.00007494701,0.00043649413,0.0002744471,0.00006208597,0.00014342328,0.00026389695,0.0000018529952],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14326152,0.013373197,0.0021299112,0.0005763394,0.0012029634,0.00029257406,0.025038078,0.0022142287,0.14956397,0.0001701153,0.0032141623,0.6589629],"study_design_scores_gemma":[0.16815011,0.15988615,0.015039213,0.00036175875,0.0017185003,0.0005825471,0.06411113,0.031605393,0.005417978,0.00018113804,0.5523329,0.0006131993],"about_ca_topic_score_codex":0.0007162091,"about_ca_topic_score_gemma":0.0012900116,"teacher_disagreement_score":0.65834975,"about_ca_system_score_codex":0.00089330925,"about_ca_system_score_gemma":0.0011391059,"threshold_uncertainty_score":0.46292552},"labels":[],"label_agreement":null},{"id":"W4311302338","doi":"10.1016/j.breast.2022.12.003","title":"Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer","year":2022,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Loperamide; Diarrhea; Internal medicine; Incidence (geometry); Discontinuation; Gastroenterology; Tolerability; Oncology; Breast cancer; Adverse effect; Cancer; Trastuzumab","score_opus":0.02128492988764032,"score_gpt":0.31009708585149054,"score_spread":0.28881215596385024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311302338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98020643,0.00008556712,0.000004400746,0.014943253,0.000080120364,0.0019604152,0.002598559,0.000014818778,0.00010643975],"genre_scores_gemma":[0.99857134,0.000011345286,0.000005796434,0.00070751144,0.00008963183,0.00038908247,0.000024659204,0.000023957227,0.00017667726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753696,0.00073863077,0.00025738435,0.0002858708,0.0008385283,0.00034259984],"domain_scores_gemma":[0.9985495,0.0006562703,0.00013394364,0.00038905395,0.00018404581,0.00008718208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011327713,0.0001686927,0.00033000475,0.00003959382,0.00035311145,0.000073393734,0.0003921915,0.000036785706,0.00030484982],"category_scores_gemma":[0.00010470448,0.00008493403,0.00004266069,0.0004897761,0.0003134097,0.000098875884,0.00020408366,0.0006789518,0.0000020965588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055978246,0.00039172982,0.92809933,0.000017499073,0.00023099256,0.00002094886,0.010687289,0.00028399852,0.00029911514,0.000093019014,0.0012936046,0.0026042112],"study_design_scores_gemma":[0.0153114,0.00068006146,0.9814105,0.00016698986,0.0000620683,0.000016672953,0.0019878757,0.00010331842,0.00006970992,0.00003542452,0.000054486984,0.00010146493],"about_ca_topic_score_codex":0.042419642,"about_ca_topic_score_gemma":0.00369088,"teacher_disagreement_score":0.05331118,"about_ca_system_score_codex":0.00030552203,"about_ca_system_score_gemma":0.0006124752,"threshold_uncertainty_score":0.96395695},"labels":[],"label_agreement":null},{"id":"W4311497732","doi":"10.1016/j.jval.2022.09.242","title":"CO166 Clinical Outcomes of Patients With Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion Cancer Treated With Non-Tropomyosin Recepter Kinase Inhibitors: A Systematic Literature Review","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bayer (Canada)","funders":"","keywords":"Trk receptor; Medicine; Fusion gene; Tropomyosin receptor kinase B; Tropomyosin receptor kinase C; Tyrosine kinase; Oncology; Receptor tyrosine kinase; Clinical trial; Internal medicine; Kinase; Tropomyosin receptor kinase A; Neurotrophin; Bioinformatics; Cancer research; Gene; Receptor; Biology; Neurotrophic factors; Genetics; Platelet-derived growth factor receptor","score_opus":0.050287907902456706,"score_gpt":0.3700510836361082,"score_spread":0.31976317573365154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311497732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9384205,0.047577653,0.0000057783363,0.005212421,0.0003862736,0.007962181,0.00036139233,0.00005449594,0.000019328969],"genre_scores_gemma":[0.9290903,0.05956921,0.0014328769,0.005963794,0.0002568219,0.0024638246,0.0005439584,0.0002227805,0.00045640158],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.9927065,0.0022308934,0.0019336625,0.00079865614,0.0016450923,0.00068519573],"domain_scores_gemma":[0.9967952,0.00032830916,0.00084853463,0.0010205777,0.00052685087,0.00048056175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022036687,0.00041960017,0.0019876678,0.0004092119,0.00017208725,0.000024079396,0.00027782345,0.000118545824,0.00040171857],"category_scores_gemma":[0.00046122976,0.00027305595,0.00017504297,0.0020518685,0.00015967364,0.00009323953,0.00016753472,0.0012906044,0.0000104394885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00268025,0.0019098042,0.82451844,0.16315131,0.00013265556,0.00025499935,0.00044471605,0.00021341941,0.00013378642,0.0000073172064,0.0050064544,0.0015468438],"study_design_scores_gemma":[0.020454926,0.024952695,0.43614715,0.51135945,0.00048430418,0.00008656326,0.00014229566,0.0008292048,0.0003491495,0.0000047862327,0.0042785048,0.0009109465],"about_ca_topic_score_codex":0.0021458457,"about_ca_topic_score_gemma":0.000056584395,"teacher_disagreement_score":0.38837132,"about_ca_system_score_codex":0.0011392751,"about_ca_system_score_gemma":0.0013577335,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W4311621345","doi":"10.3390/curroncol29120778","title":"Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Ottawa Hospital; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Breast cancer; Neoadjuvant therapy; Oncology; Internal medicine; Adverse effect; Chemotherapy; Stage (stratigraphy); Guideline; Cancer; Pathology","score_opus":0.12635178229933344,"score_gpt":0.46221414231616426,"score_spread":0.3358623600168308,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311621345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94502306,0.00058361585,0.00009011193,0.046623897,0.001909132,0.0031338448,0.0022733044,0.000028997309,0.00033402749],"genre_scores_gemma":[0.9897299,0.000050603958,0.00009786887,0.0033973549,0.0004910735,0.005924843,0.000119631375,0.00005195146,0.00013678068],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99712,0.00029613345,0.00042670273,0.0006410635,0.00063191005,0.00088413863],"domain_scores_gemma":[0.9982074,0.00038489827,0.000101356796,0.00030924834,0.00038013564,0.00061698025],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044352023,0.00023220791,0.0006208028,0.0003213846,0.00019599238,0.000026778327,0.0004962486,0.00005680033,0.0011456218],"category_scores_gemma":[0.00042101578,0.0002219662,0.00006852349,0.00088460813,0.000040781102,0.00006165285,0.0006843469,0.0006250347,0.000009577654],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057816114,0.0012304437,0.18356153,0.00024309602,0.00008514358,0.00054870086,0.002969642,0.0011321735,0.0011758215,0.000102838974,0.19545256,0.60771644],"study_design_scores_gemma":[0.0037577208,0.001799577,0.47686613,0.00030025316,0.000047694848,0.0003065969,0.0016815482,0.0009327117,0.00021865872,0.000012242434,0.5137246,0.00035226083],"about_ca_topic_score_codex":0.7461605,"about_ca_topic_score_gemma":0.8993362,"teacher_disagreement_score":0.6073642,"about_ca_system_score_codex":0.02223063,"about_ca_system_score_gemma":0.012165968,"threshold_uncertainty_score":0.9997675},"labels":[],"label_agreement":null},{"id":"W4312069235","doi":"10.21203/rs.3.rs-2322502/v1","title":"Development of DHES0815A; a novel HER2-directed antibody-drug conjugate comprised of a reduced potency mono-alkylating agent linked to a domain I binding HER2 antibody","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"Genentech; MacroGenics; Pfizer","keywords":"Conjugate; Potency; Antibody; Chemistry; Antibody-drug conjugate; Pharmacology; Drug; Medicine; Biochemistry; Monoclonal antibody; Immunology; In vitro; Mathematics","score_opus":0.12340316379014168,"score_gpt":0.4697713062184486,"score_spread":0.34636814242830694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312069235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98265505,0.000818821,0.0010333363,0.0016592696,0.00040608036,0.008911548,0.0006670998,0.0002897268,0.0035590816],"genre_scores_gemma":[0.9139602,0.00047091872,0.08045025,0.000046882953,0.0002998016,0.0012676504,0.001800619,0.00033463296,0.0013690325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9841003,0.0015064306,0.0028550434,0.0022104636,0.0069887876,0.0023390192],"domain_scores_gemma":[0.99120915,0.0010749786,0.00086506497,0.002565588,0.0030578533,0.0012273607],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011376372,0.00088653096,0.0025315841,0.003357617,0.0006843391,0.00013983106,0.0018014851,0.000584196,0.0019780016],"category_scores_gemma":[0.0029019506,0.0008986233,0.00060231617,0.0038585654,0.00049894623,0.00009045661,0.006126284,0.0054061725,0.00007764116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021839414,0.0019187401,0.0072308066,0.014507787,0.0008680482,0.0004281687,0.02011955,0.00047321746,0.9443068,0.000086622735,0.00097489404,0.006901434],"study_design_scores_gemma":[0.027278088,0.0066107414,0.30464286,0.10227883,0.00048817007,0.00019954052,0.056931283,0.015931986,0.42368048,0.00083029794,0.055276174,0.0058515593],"about_ca_topic_score_codex":0.0038326958,"about_ca_topic_score_gemma":0.00025603024,"teacher_disagreement_score":0.5206263,"about_ca_system_score_codex":0.0030957034,"about_ca_system_score_gemma":0.009313348,"threshold_uncertainty_score":0.99934644},"labels":[],"label_agreement":null},{"id":"W4312194612","doi":"10.3390/cells11244093","title":"A Novel Mechanism Underlying the Inhibitory Effects of Trastuzumab on the Growth of HER2-Positive Breast Cancer Cells","year":2022,"lang":"en","type":"article","venue":"Cells","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Inhibitory postsynaptic potential; Mechanism (biology); Breast cancer; Cancer; Cancer research; Medicine; Pharmacology; Internal medicine","score_opus":0.03168771625906569,"score_gpt":0.303700326435653,"score_spread":0.2720126101765873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312194612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851003,0.00062268355,0.00044709773,0.005266783,0.001148392,0.0027340935,0.0003872184,0.00003502987,0.0042583817],"genre_scores_gemma":[0.9980825,0.00008041397,0.000037612837,0.0008308323,0.00008832176,0.00023707573,0.0000029564305,0.00004339977,0.00059687736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979577,0.00027314114,0.00025848966,0.0002690207,0.0009206217,0.00032104366],"domain_scores_gemma":[0.99821323,0.0009892186,0.00014926751,0.00042316373,0.00014395658,0.000081176746],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064629235,0.00016282198,0.00030716442,0.00009415004,0.000204506,0.000009464447,0.00033690757,0.0000530308,0.00053231436],"category_scores_gemma":[0.000030783627,0.00010028526,0.00014371361,0.00040269908,0.00021158723,0.000023159948,0.00018583788,0.00063541817,0.000011742483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022301511,0.00039368772,0.000035749075,0.00042914445,0.00012611452,0.00002156739,0.0025973,0.000054663407,0.9903885,0.0017456261,0.0026626415,0.0013219579],"study_design_scores_gemma":[0.001018455,0.000816858,0.0021731195,0.00039213576,0.000089149544,0.000023415281,0.0013541583,0.00016805992,0.99337953,0.0002572987,0.0002258375,0.00010197572],"about_ca_topic_score_codex":0.0013716973,"about_ca_topic_score_gemma":0.00002070815,"teacher_disagreement_score":0.01298219,"about_ca_system_score_codex":0.00043387845,"about_ca_system_score_gemma":0.00045916782,"threshold_uncertainty_score":0.58284694},"labels":[],"label_agreement":null},{"id":"W4316511360","doi":"10.1101/2023.01.13.523972","title":"Death by a Thousand Cuts – Combining Kinase Inhibitors for Selective Target Inhibition and Rational Polypharmacology","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of North Carolina at Chapel Hill; Genentech; Ontario Genomics; National Institutes of Health; UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Deutschen Konsortium für Translationale Krebsforschung; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; McGill University; Memorial Sloan-Kettering Cancer Center; Pfizer; Genome Canada; Damon Runyon Cancer Research Foundation","keywords":"Pharmacology; Computational biology; Biology","score_opus":0.03258838149492683,"score_gpt":0.31382389745023226,"score_spread":0.28123551595530544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316511360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98686904,0.0017795544,0.0021819053,0.0021631669,0.001422289,0.003745869,0.0013742553,0.00044755774,0.000016362726],"genre_scores_gemma":[0.99068385,0.0004351035,0.0049388143,0.0005793873,0.0011198103,0.0019138892,0.000012409378,0.00025943381,0.000057281384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99656546,0.00020818567,0.0005835009,0.001254775,0.0006027962,0.0007852647],"domain_scores_gemma":[0.9975578,0.00028663804,0.00029740017,0.00048439088,0.0008708575,0.0005028807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011432226,0.00053262594,0.0007323362,0.0004895921,0.00028868453,0.00014389871,0.00016578687,0.0006581991,0.000035182722],"category_scores_gemma":[0.0006389704,0.0005923947,0.00014405661,0.0005082661,0.00020564294,0.00007987425,0.00041437344,0.0011514814,0.000024893132],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047575956,0.00024148583,0.026040856,0.0011092772,0.00033963128,0.000115173876,0.000032268792,0.000023846214,0.9206433,0.00027783957,0.050697442,0.000003071512],"study_design_scores_gemma":[0.0044098375,0.00069934136,0.041836165,0.0010520882,0.00030072156,2.6877842e-7,0.000009341039,0.0015206404,0.9351067,0.000035050587,0.014176001,0.00085384806],"about_ca_topic_score_codex":0.00009828517,"about_ca_topic_score_gemma":0.0000029495332,"teacher_disagreement_score":0.036521442,"about_ca_system_score_codex":0.00066390226,"about_ca_system_score_gemma":0.0018865274,"threshold_uncertainty_score":0.99965274},"labels":[],"label_agreement":null},{"id":"W4317934829","doi":"10.51731/cjht.2023.551","title":"Trastuzumab Deruxtecan (Enhertu)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Reimbursement; Medicine; Regimen; Adjuvant; Oncology; Breast cancer; Internal medicine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Cancer; Health care","score_opus":0.10286531305846934,"score_gpt":0.398326580389078,"score_spread":0.2954612673306086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317934829","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4534305,0.07818354,0.00028851244,0.4622791,0.0013700528,0.00093901774,0.00005155147,0.00089609943,0.0025616023],"genre_scores_gemma":[0.99657834,0.001651867,0.0005112512,0.00070659065,0.0000343797,0.000010789737,0.0000032276985,0.000030926112,0.00047264638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979847,0.00005862126,0.0005687961,0.0001560058,0.00036351054,0.0008683832],"domain_scores_gemma":[0.998843,0.00007875373,0.00019698631,0.00034753606,0.00024115283,0.00029254146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012865202,0.0001256626,0.0004479542,0.0015642556,0.00022855078,0.00003117623,0.00039489398,0.00017437682,0.00011679921],"category_scores_gemma":[0.0013587706,0.00010568794,0.00009811665,0.0012958992,0.00030268822,0.000064057094,0.000026637737,0.0008709455,0.000109812805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001695462,0.000010002983,0.007698179,0.00021004921,0.000039021477,0.0011076189,0.00032599355,0.0000066025386,0.00008385337,0.00029446595,0.0763762,0.91383106],"study_design_scores_gemma":[0.00091086404,0.0016173312,0.040787008,0.00078299496,0.000015904803,0.0013449255,0.007961091,0.000036219943,0.0012374488,0.004319933,0.94081736,0.00016893017],"about_ca_topic_score_codex":0.0054456326,"about_ca_topic_score_gemma":0.0065215207,"teacher_disagreement_score":0.91366214,"about_ca_system_score_codex":0.0012033251,"about_ca_system_score_gemma":0.010888831,"threshold_uncertainty_score":0.9947185},"labels":[],"label_agreement":null},{"id":"W4318696356","doi":"10.26508/lsa.202201644","title":"The ADAM17 sheddase complex regulator iTAP/Frmd8 modulates inflammation and tumor growth","year":2023,"lang":"en","type":"article","venue":"Life Science Alliance","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Queen's University; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; “la Caixa” Foundation; Queen's University Belfast; Worldwide Cancer Research","keywords":"Cell biology; Cancer research; Biology","score_opus":0.060158230119526986,"score_gpt":0.36024009416225755,"score_spread":0.3000818640427306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318696356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715942,0.00037425346,0.000027673668,0.0256458,0.00021998296,0.0005550588,0.0000071947543,0.00015860768,0.0014171881],"genre_scores_gemma":[0.9960925,0.00043916143,0.00062403496,0.00054127624,0.0002468306,0.00006535734,0.00000486553,0.000017960137,0.001968007],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99743193,0.000045224515,0.0002702094,0.000476815,0.0011354769,0.00064036064],"domain_scores_gemma":[0.9984608,0.00021504144,0.0000792123,0.0005309979,0.00031332573,0.00040060282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017174009,0.00013284464,0.00018115727,0.00010466171,0.000710511,0.00021397985,0.00047434922,0.000033055047,0.00005183883],"category_scores_gemma":[0.002155323,0.00009260081,0.000033960627,0.0017771071,0.0014763647,0.00035642934,0.0002131592,0.00020230525,0.00030208353],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048276235,0.000096769036,0.14899822,0.00095088437,0.00007920145,0.0002873254,0.00287923,0.0004764494,0.6496614,0.03173411,0.10733826,0.057015356],"study_design_scores_gemma":[0.0009007972,0.0002265507,0.83979696,0.0002935838,0.000014763407,0.000039657123,0.0005912371,0.08706657,0.030499496,0.0033645434,0.03691588,0.00028994158],"about_ca_topic_score_codex":0.000064948894,"about_ca_topic_score_gemma":0.000028626966,"teacher_disagreement_score":0.69079876,"about_ca_system_score_codex":0.00011684364,"about_ca_system_score_gemma":0.00056099327,"threshold_uncertainty_score":0.54647475},"labels":[],"label_agreement":null},{"id":"W4318926335","doi":"10.1158/1078-0432.ccr-22-1989","title":"Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Adjuvant; Biomarker; Internal medicine; Adjuvant therapy; Neoadjuvant therapy; Cancer; Biology","score_opus":0.5670680553339,"score_gpt":0.6237006534623429,"score_spread":0.0566325981284429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318926335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9251647,0.0051926333,0.00002877383,0.01971531,0.00092986977,0.0112236645,0.037624825,0.00007588407,0.000044328353],"genre_scores_gemma":[0.9731987,0.00893465,0.000058192756,0.0005020146,0.0028342821,0.011634754,0.0017553815,0.00019121147,0.0008908267],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9918769,0.0012703526,0.001361095,0.0018078033,0.0022774525,0.0014063909],"domain_scores_gemma":[0.98012537,0.014142146,0.00023408863,0.002732961,0.0019109457,0.00085447694],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006860819,0.00042159017,0.001155841,0.00024822005,0.00040998348,0.00010071856,0.0017694108,0.00022671546,0.0016543095],"category_scores_gemma":[0.0032295373,0.00028181507,0.00035251156,0.0012550994,0.0012621799,0.00016208449,0.0011316333,0.0011597576,0.000043142736],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40267673,0.0068808617,0.050640464,0.00037435137,0.0028806054,0.00033353042,0.0023047011,0.000015501493,0.0011796891,0.00001168735,0.27015042,0.26255146],"study_design_scores_gemma":[0.13165727,0.017679874,0.7690491,0.0015614318,0.0007944045,0.0000032167843,0.007828035,0.0031727217,0.00078255066,0.00030747685,0.066468686,0.0006952224],"about_ca_topic_score_codex":0.0112012,"about_ca_topic_score_gemma":0.00991831,"teacher_disagreement_score":0.71840864,"about_ca_system_score_codex":0.0005161459,"about_ca_system_score_gemma":0.004781779,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W4319164392","doi":"10.1016/j.trecan.2023.01.003","title":"Antibody–drug conjugates: in search of partners of choice","year":2023,"lang":"en","type":"review","venue":"Trends in cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":200,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"University of Toronto; Conquer Cancer Foundation","keywords":"Drug; Antibody-drug conjugate; Computational biology; Pharmacology; Medicine; Antibody; Cancer research; Monoclonal antibody; Immunology; Biology","score_opus":0.36880977156407213,"score_gpt":0.6077878399316997,"score_spread":0.23897806836762758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319164392","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00045268663,0.99212134,3.5387464e-7,0.00018906649,0.00024835148,0.0006604278,0.00029616896,0.00002890252,0.00600272],"genre_scores_gemma":[0.00042051866,0.992324,0.000032545566,0.000022274817,0.00022591469,0.00034159064,0.0002518383,0.00012404287,0.0062573086],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99597543,0.00032708846,0.0013859225,0.0006172286,0.0010067172,0.0006876112],"domain_scores_gemma":[0.9979024,0.00071764254,0.00030269075,0.0007608208,0.00015218476,0.00016426155],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013385746,0.00038239744,0.0030273243,0.0016178528,0.000012607967,0.0000074992836,0.00048117668,0.00031715696,0.0016830531],"category_scores_gemma":[0.00020874088,0.00032022528,0.00039913814,0.004255703,0.00034057538,0.00004390562,0.00018960144,0.0012788787,0.00004708266],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000051199047,0.00015005437,0.0064522615,0.074311174,0.00020096912,0.00010682479,0.00043359562,0.000019930847,0.000011098898,0.000024285951,0.0026858589,0.91555274],"study_design_scores_gemma":[0.0012587332,0.00013993104,0.0015575261,0.09546016,0.00023927382,0.0000065724116,0.00008286688,0.00003834304,0.000060152404,0.0000068983622,0.90086865,0.000280872],"about_ca_topic_score_codex":0.012764696,"about_ca_topic_score_gemma":0.006245499,"teacher_disagreement_score":0.9152719,"about_ca_system_score_codex":0.00088367343,"about_ca_system_score_gemma":0.0018743299,"threshold_uncertainty_score":0.99992496},"labels":[],"label_agreement":null},{"id":"W4319922981","doi":"10.1016/j.ejca.2023.02.002","title":"Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Chugai Pharmaceutical; PharmaMar; Daiichi Sankyo Europe; Servier; Sanofi; Kyowa Hakko Kirin; Astellas Pharma; Eisai; Genomic Health; Fondation ARC pour la Recherche sur le Cancer; Seagen; Genentech; Veracyte; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Medpace; Puma Biotechnology; Regeneron Pharmaceuticals; Samsung; Bristol-Myers Squibb; Eli Lilly and Company; Kræftens Bekæmpelse; European Commission; Exelixis; Amgen; Pfizer; Celgene","keywords":"Neratinib; Trastuzumab; Medicine; Placebo; Oncology; Breast cancer; Internal medicine; Pertuzumab; Adjuvant; Adjuvant therapy; Double blind; Cancer; Alternative medicine; Pathology","score_opus":0.0521616362129542,"score_gpt":0.38182823190836057,"score_spread":0.32966659569540635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319922981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98305863,0.0036681937,0.00014075445,0.006102722,0.0010428295,0.0038354346,0.00015296042,0.000047747137,0.0019507083],"genre_scores_gemma":[0.9910945,0.0023586492,0.00008203492,0.0009691576,0.0032535254,0.0006101033,0.000015219582,0.00018840464,0.001428354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9942933,0.001461751,0.0013188121,0.00048590318,0.0016425395,0.0007977149],"domain_scores_gemma":[0.997339,0.00031722712,0.00060885935,0.00036874635,0.0008274446,0.0005387394],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038363547,0.00048065893,0.0014848753,0.0006333779,0.00009569678,0.00014068924,0.00035067895,0.00007477766,0.0020512512],"category_scores_gemma":[0.00007712314,0.00031616839,0.00046736977,0.0007713653,0.00020164726,0.00021372683,0.00003891519,0.0011547062,0.00004012928],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93735856,0.00069102785,0.0017677513,0.00005251472,0.0007266706,0.004834051,0.0008678191,0.0027567935,0.0013839353,0.0000021334097,0.002468398,0.04709037],"study_design_scores_gemma":[0.97586286,0.0059865355,0.009231945,0.0013793039,0.00023559568,0.0001278071,0.00012661262,0.0006860642,0.0008087153,0.0000022424888,0.0051929955,0.00035931097],"about_ca_topic_score_codex":0.00038868122,"about_ca_topic_score_gemma":0.00053071073,"teacher_disagreement_score":0.04673106,"about_ca_system_score_codex":0.0006496776,"about_ca_system_score_gemma":0.0026138052,"threshold_uncertainty_score":0.999929},"labels":[],"label_agreement":null},{"id":"W4322760569","doi":"10.1158/1538-7445.sabcs22-p2-01-06","title":"Abstract P2-01-06: Real-world outcome and cost analysis of the addition of pertuzumab to neoadjuvant therapy in localized HER2 positive breast cancer: a single center experience","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Neoadjuvant therapy; Trastuzumab; Oncology; Internal medicine; Clinical endpoint; Cancer; Perioperative; Exact test; Clinical trial; Surgery","score_opus":0.15228257007957094,"score_gpt":0.48874254072948536,"score_spread":0.3364599706499144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322760569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891253,0.00041887828,0.0000038423527,0.006327656,0.00008299473,0.0016177492,0.0014661457,0.000024147543,0.00093330053],"genre_scores_gemma":[0.994582,0.0029966792,0.000014223181,0.00023824051,0.000087957014,0.00092087185,0.00006318253,0.000041749605,0.0010550857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99605006,0.00032590338,0.00061536435,0.0005828731,0.0016469839,0.00077882496],"domain_scores_gemma":[0.99772626,0.000449091,0.00011990637,0.0006834342,0.0007260928,0.00029521124],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012153257,0.00019659127,0.00071450695,0.001444815,0.00012355256,0.000037630296,0.00041270332,0.0000976202,0.0017374564],"category_scores_gemma":[0.00018918765,0.00014155377,0.00017536305,0.0068882806,0.0006254427,0.00010194183,0.00026179227,0.0006089947,0.00001207799],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031755413,0.00046620442,0.82501316,0.00030637186,0.0005363779,0.00007976909,0.0071323817,0.000476728,0.0960985,0.000042575124,0.0058402973,0.06083209],"study_design_scores_gemma":[0.0021146687,0.00025683842,0.9743514,0.0009958878,0.00004589939,0.000004560047,0.0016281719,0.00062202255,0.016561357,0.000011984901,0.0032589084,0.00014830974],"about_ca_topic_score_codex":0.05094047,"about_ca_topic_score_gemma":0.02666423,"teacher_disagreement_score":0.14933822,"about_ca_system_score_codex":0.0015004342,"about_ca_system_score_gemma":0.00074593385,"threshold_uncertainty_score":0.9991751},"labels":[],"label_agreement":null},{"id":"W4322769277","doi":"10.1158/1538-7445.sabcs22-p5-07-08","title":"Abstract P5-07-08: Evaluating the risk of cardiotoxicity associated with concurrent trastuzumab emtansine (TDM1) and radiation therapy in patients with early-stage HER2 positive breast cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Cardiotoxicity; Internal medicine; Oncology; Breast cancer; Trastuzumab; Ejection fraction; Trastuzumab emtansine; Radiation therapy; Adjuvant therapy; Cardiology; Heart failure; Cancer; Chemotherapy","score_opus":0.0851732530163475,"score_gpt":0.44099505400862105,"score_spread":0.35582180099227356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322769277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993478,0.001430704,0.0000029121707,0.0008225279,0.0000706773,0.0027949035,0.0011806887,0.000037174,0.00018238525],"genre_scores_gemma":[0.9934819,0.005333427,0.000004810293,0.000034287135,0.00013155668,0.0006436447,0.00007360368,0.00007120516,0.00022558562],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99460924,0.0008749999,0.0003941782,0.0005846823,0.0026725417,0.00086436],"domain_scores_gemma":[0.9966909,0.0009432496,0.00020754492,0.00041475013,0.0015217526,0.0002217851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036062193,0.00025103503,0.0005281121,0.00036505386,0.00028029334,0.000068952024,0.00022926975,0.00013178501,0.00045164672],"category_scores_gemma":[0.00043083343,0.00015619608,0.000062168,0.0018913051,0.0006524172,0.00015728288,0.00008653781,0.0013463562,0.000009559556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003396539,0.00019940594,0.9063001,0.00015345555,0.0005226709,0.000030756062,0.0029953355,0.0004950124,0.0011110351,0.000004350404,0.0005281691,0.08426314],"study_design_scores_gemma":[0.0070940135,0.0023586587,0.986401,0.0011906431,0.000045572557,0.000001334143,0.00047697686,0.0004524405,0.0017454803,0.000008661381,0.00005539772,0.00016979277],"about_ca_topic_score_codex":0.019679222,"about_ca_topic_score_gemma":0.0036882814,"teacher_disagreement_score":0.08409335,"about_ca_system_score_codex":0.0016660184,"about_ca_system_score_gemma":0.0020463096,"threshold_uncertainty_score":0.98684883},"labels":[],"label_agreement":null},{"id":"W4324132274","doi":"10.1016/s0960-9776(23)00123-6","title":"P004 Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer : a multicenter, open-label, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Trastuzumab; Open label; Oncology; Adjuvant; Breast cancer; Internal medicine; Adjuvant therapy; Clinical trial; Cancer","score_opus":0.04864517656838026,"score_gpt":0.3922865478377956,"score_spread":0.34364137126941535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324132274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853463,0.00010620952,0.00000793748,0.006735173,0.00024116822,0.005799182,0.0013974434,0.000094992145,0.00027159136],"genre_scores_gemma":[0.99568516,0.000060363695,0.000036631445,0.0011782607,0.0003096202,0.001983523,0.00016786522,0.0001083805,0.00047018417],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99694616,0.00034293605,0.00038402152,0.0005799853,0.0009464143,0.0008004785],"domain_scores_gemma":[0.99849266,0.00017208159,0.00012028305,0.00066632597,0.00027689818,0.00027175917],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068752386,0.0003497575,0.00055315567,0.00021398025,0.00012793097,0.00010686888,0.0005463847,0.000100513025,0.0010980058],"category_scores_gemma":[0.000026339441,0.00021011417,0.000069012116,0.0009921237,0.0002745666,0.00016246889,0.00015639185,0.0005458721,0.00014754897],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6766312,0.009649857,0.11446324,0.0000891168,0.00028838505,0.0002625784,0.0018257683,0.000028710128,0.0003325153,0.000004013367,0.0028362197,0.19358839],"study_design_scores_gemma":[0.38496748,0.004540281,0.6071829,0.001045739,0.00006668635,0.000023682274,0.00018483726,0.00083685655,0.0003040338,0.00000592733,0.00054097874,0.000300582],"about_ca_topic_score_codex":0.0020854068,"about_ca_topic_score_gemma":0.00052459416,"teacher_disagreement_score":0.49271968,"about_ca_system_score_codex":0.0004902542,"about_ca_system_score_gemma":0.0007885969,"threshold_uncertainty_score":0.9998151},"labels":[],"label_agreement":null},{"id":"W4353015178","doi":"10.1007/s10549-023-06881-8","title":"Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-41","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; NSABP Foundation; GlaxoSmithKline; U.S. Department of Health and Human Services","keywords":"Medicine; Lapatinib; Breast cancer; Trastuzumab; Internal medicine; Neoadjuvant therapy; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval; Cohort; Cancer","score_opus":0.16420894382315235,"score_gpt":0.45441019810179134,"score_spread":0.29020125427863896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353015178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98783237,0.0022001623,3.8379252e-7,0.0076785935,0.00008415565,0.0013147453,0.00022263508,0.000110380315,0.0005565744],"genre_scores_gemma":[0.9854151,0.01014767,0.000026548212,0.0000450824,0.00013932427,0.0007276037,0.00005584425,0.000054148073,0.0033886775],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967818,0.00020494036,0.0003555197,0.0005480066,0.0011272578,0.000982444],"domain_scores_gemma":[0.9984452,0.0002888886,0.0000467349,0.00048515337,0.00032919343,0.00040482348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005620773,0.00024934649,0.00061627803,0.0006727233,0.00010941481,0.000045557324,0.00012970324,0.00011103277,0.00064191857],"category_scores_gemma":[0.000049913513,0.0001749979,0.00010101963,0.0012713254,0.00037659385,0.00006771732,0.00011912549,0.00030873797,0.00006606032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002484524,0.0012604343,0.73143923,0.00010423357,0.00026828083,0.00078887003,0.00047137597,0.0000025720994,0.0030743445,0.000016284772,0.0006482175,0.25944164],"study_design_scores_gemma":[0.0065864,0.0030634047,0.98129433,0.00034649827,0.000014514296,0.000069405505,0.00013119949,0.00003808749,0.0074476143,0.00005321812,0.0008231488,0.00013217724],"about_ca_topic_score_codex":0.011946781,"about_ca_topic_score_gemma":0.004539076,"teacher_disagreement_score":0.25930947,"about_ca_system_score_codex":0.0009918112,"about_ca_system_score_gemma":0.0007513623,"threshold_uncertainty_score":0.9946328},"labels":[],"label_agreement":null},{"id":"W4361190864","doi":"10.1158/1078-0432.ccr-22-2535","title":"A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Saskatchewan Cancer Agency; Centre hospitalier de l'Université Laval; Saskatoon Medical Imaging; University of Saskatchewan; Centre hospitalier universitaire de Québec; Royal University Hospital","funders":"National Institute of Neurological Disorders and Stroke; Canadian Institutes of Health Research; Saskatchewan Health Research Foundation; National Cancer Institute; Genome Canada","keywords":"Bispecific antibody; EPH receptor A2; Cancer; Medicine; Antibody; Cancer therapy; Epidermal growth factor receptor; Cancer research; Antibody therapy; Oncology; Internal medicine; Immunology; Monoclonal antibody; Receptor","score_opus":0.700667143084389,"score_gpt":0.6785639125598978,"score_spread":0.022103230524491257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361190864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707557,0.001682598,0.00007156829,0.0058290297,0.0005213379,0.0040633287,0.00011493269,0.000116852716,0.00052479963],"genre_scores_gemma":[0.9870713,0.0066012223,0.00048305787,0.00019106954,0.00082089985,0.0024470887,0.00021136271,0.00010667287,0.0020673631],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99327135,0.0010640095,0.0014102607,0.0009003414,0.0021913538,0.001162698],"domain_scores_gemma":[0.99296725,0.002924127,0.00020719829,0.001006644,0.0024582632,0.00043653417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0142568825,0.00025903582,0.0007478258,0.0004399376,0.00055047474,0.00010127282,0.00087501446,0.00029160068,0.00072882907],"category_scores_gemma":[0.0016974361,0.00017798443,0.00023419021,0.0020241952,0.0010860076,0.00014032752,0.0002056713,0.0012118235,0.000070018825],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046964693,0.0018094361,0.09765708,0.00082885916,0.00050636684,0.000037125734,0.0018332853,0.00014016965,0.056581058,0.0003145171,0.03017615,0.8054195],"study_design_scores_gemma":[0.013517522,0.0034088593,0.78426677,0.00080089184,0.000042306896,0.0000025308755,0.0023007232,0.009907722,0.057984672,0.000586378,0.12673528,0.00044637325],"about_ca_topic_score_codex":0.0011874913,"about_ca_topic_score_gemma":0.0014341845,"teacher_disagreement_score":0.8049731,"about_ca_system_score_codex":0.00053711585,"about_ca_system_score_gemma":0.0052620033,"threshold_uncertainty_score":0.9334568},"labels":[],"label_agreement":null},{"id":"W4361249370","doi":"10.1158/0008-5472.22367729","title":"Supplementary Figure 5 from Distinct ErbB-2–Coupled Signaling Pathways Promote Mammary Tumors with Unique Pathologic and Transcriptional Profiles","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"ErbB; Cancer research; Signal transduction; Biology; Mammary tumor; Cell biology; Computational biology; Genetics; Cancer; Breast cancer","score_opus":0.07118641295120709,"score_gpt":0.3134633758700232,"score_spread":0.24227696291881612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361249370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971905,0.0007209914,0.006326913,0.007515113,0.00023044027,0.004532075,0.007591147,0.00056897354,0.00060935033],"genre_scores_gemma":[0.93471235,0.0003778242,0.037708476,0.00047720698,0.00059756765,0.0010311347,0.022778552,0.00019687541,0.0021199915],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9957722,0.00023273163,0.0006810612,0.0014540628,0.0011547676,0.0007051678],"domain_scores_gemma":[0.9981327,0.00023035827,0.00016969735,0.00081967417,0.0002429278,0.00040465585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000868686,0.0006407889,0.0009241606,0.00027241497,0.00015696704,0.00013679657,0.0004220996,0.00044033193,0.0045978953],"category_scores_gemma":[0.00010108555,0.00047287502,0.00017309525,0.00024014905,0.0002694575,0.000073529125,0.000607413,0.0019221753,0.000026181773],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007892915,0.0026681677,0.30846515,0.024925964,0.0043684165,0.073162,0.014922055,0.0006170323,0.51254755,0.0060273083,0.02684355,0.017559886],"study_design_scores_gemma":[0.025965603,0.011466861,0.6413587,0.036267493,0.0029567266,0.002366672,0.007833661,0.036941342,0.12439145,0.089912646,0.011856146,0.008682722],"about_ca_topic_score_codex":0.0034613528,"about_ca_topic_score_gemma":0.0005269664,"teacher_disagreement_score":0.3881561,"about_ca_system_score_codex":0.00035035243,"about_ca_system_score_gemma":0.0014940621,"threshold_uncertainty_score":0.9997723},"labels":[],"label_agreement":null},{"id":"W4361822765","doi":"10.1158/0008-5472.c.6500066.v1","title":"Data from β&lt;sub&gt;1&lt;/sub&gt;-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of California, Los Angeles; Alberta Cancer Foundation; Cancer Research Institute","keywords":"Trastuzumab; Cancer research; Protein kinase B; Breast cancer; Integrin; Epidermal growth factor receptor; Metastatic breast cancer; PI3K/AKT/mTOR pathway; Growth factor receptor; Cancer; Medicine; Internal medicine; Biology; Receptor; Signal transduction; Cell biology","score_opus":0.08616599863725775,"score_gpt":0.3870258860101897,"score_spread":0.30085988737293196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361822765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605685,0.0013880935,0.0005448966,0.004788167,0.0019431602,0.006518863,0.022610761,0.00026161608,0.0013759264],"genre_scores_gemma":[0.9893906,0.0022991204,0.0001386924,0.00038246412,0.0014466229,0.001015361,0.0044166604,0.00028875857,0.00062171195],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9905727,0.0014958926,0.0016208042,0.0025830679,0.0023701368,0.0013574344],"domain_scores_gemma":[0.99277806,0.0020680695,0.0006441135,0.0031474463,0.0008469755,0.000515349],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014394299,0.0011294682,0.0023527727,0.0006688085,0.00022737012,0.00014877344,0.0026309437,0.0009409973,0.001735112],"category_scores_gemma":[0.0010597736,0.00083234976,0.00042575342,0.0008678912,0.00070885086,0.00029173013,0.0040299,0.004007888,0.00022653311],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036274677,0.0033372182,0.2249672,0.0093762735,0.007906564,0.0014703637,0.011644576,0.00012176276,0.60956424,0.00073123415,0.094824865,0.032428227],"study_design_scores_gemma":[0.0042262594,0.0004509011,0.75067705,0.008123313,0.00041673612,0.000028727665,0.00039338562,0.0011117187,0.23263378,0.0006835904,0.0002610555,0.0009935057],"about_ca_topic_score_codex":0.02071065,"about_ca_topic_score_gemma":0.010951578,"teacher_disagreement_score":0.5257098,"about_ca_system_score_codex":0.0020282746,"about_ca_system_score_gemma":0.0023699251,"threshold_uncertainty_score":0.9994127},"labels":[],"label_agreement":null},{"id":"W4361954460","doi":"10.1158/1078-0432.c.6533189.v1","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Biomarker; Medicine; Internal medicine; Adjuvant; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954460","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4420923,0.0045352266,0.0007870849,0.007575537,0.0014311139,0.014887704,0.52853477,0.00012343042,0.00003284235],"genre_scores_gemma":[0.80997884,0.004724426,0.0011606759,0.0007546026,0.0034305798,0.010296073,0.1680818,0.0005297993,0.0010432074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9922521,0.00047455102,0.001351049,0.003327572,0.0016473181,0.00094742584],"domain_scores_gemma":[0.98411334,0.004719282,0.0005428286,0.009183787,0.0008431743,0.00059760746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014350985,0.0009607426,0.001780271,0.00019311521,0.0002087831,0.00017080105,0.004319464,0.00034974574,0.0026616305],"category_scores_gemma":[0.00081945036,0.0006414896,0.00030283886,0.00030843186,0.00042811965,0.00022261927,0.006487492,0.00093404815,0.000027668273],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41454682,0.011533886,0.010492664,0.0008593496,0.019736426,0.0006507926,0.0056420686,0.000049468523,0.0017521993,0.000005562155,0.44740555,0.087325215],"study_design_scores_gemma":[0.26785615,0.010577106,0.59280986,0.008128889,0.012590402,0.000009609467,0.027325887,0.026336743,0.0017439959,0.0010174221,0.048192237,0.0034117033],"about_ca_topic_score_codex":0.07271902,"about_ca_topic_score_gemma":0.055571362,"teacher_disagreement_score":0.5823172,"about_ca_system_score_codex":0.00051808386,"about_ca_system_score_gemma":0.0040313257,"threshold_uncertainty_score":0.9996036},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"not_applicable","genre":"dataset","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4361954621","doi":"10.1158/1078-0432.c.6533189","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Biomarker; Internal medicine; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361954621","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4420923,0.0045352266,0.0007870849,0.007575537,0.0014311139,0.014887704,0.52853477,0.00012343042,0.00003284235],"genre_scores_gemma":[0.80997884,0.004724426,0.0011606759,0.0007546026,0.0034305798,0.010296073,0.1680818,0.0005297993,0.0010432074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9922521,0.00047455102,0.001351049,0.003327572,0.0016473181,0.00094742584],"domain_scores_gemma":[0.98411334,0.004719282,0.0005428286,0.009183787,0.0008431743,0.00059760746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014350985,0.0009607426,0.001780271,0.00019311521,0.0002087831,0.00017080105,0.004319464,0.00034974574,0.0026616305],"category_scores_gemma":[0.00081945036,0.0006414896,0.00030283886,0.00030843186,0.00042811965,0.00022261927,0.006487492,0.00093404815,0.000027668273],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41454682,0.011533886,0.010492664,0.0008593496,0.019736426,0.0006507926,0.0056420686,0.000049468523,0.0017521993,0.000005562155,0.44740555,0.087325215],"study_design_scores_gemma":[0.26785615,0.010577106,0.59280986,0.008128889,0.012590402,0.000009609467,0.027325887,0.026336743,0.0017439959,0.0010174221,0.048192237,0.0034117033],"about_ca_topic_score_codex":0.07271902,"about_ca_topic_score_gemma":0.055571362,"teacher_disagreement_score":0.5823172,"about_ca_system_score_codex":0.00051808386,"about_ca_system_score_gemma":0.0040313257,"threshold_uncertainty_score":0.9996036},"labels":[],"label_agreement":null},{"id":"W4362536143","doi":"10.1158/1538-7445.am2023-2641","title":"Abstract 2641: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Camptothecin; Antibody; Cytotoxicity; Humanized antibody; DU145; Cancer research; Conjugate; Chemistry; Cell culture; Monoclonal antibody; Molecular biology; Cancer cell; Cancer; Biology; Medicine; Immunology; In vitro; Biochemistry; Internal medicine","score_opus":0.127248917654099,"score_gpt":0.4785073000761052,"score_spread":0.35125838242200624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362536143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98027265,0.0022144879,0.000019623461,0.009908688,0.00068181154,0.0016096256,0.00014915258,0.0004241203,0.004719826],"genre_scores_gemma":[0.9865945,0.0023110048,0.00019895013,0.0003266968,0.0022371265,0.00072309974,0.00014451171,0.00018399731,0.007280138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9925068,0.00020006082,0.0007096783,0.001148126,0.0030435899,0.0023917172],"domain_scores_gemma":[0.996163,0.0007735614,0.0000990356,0.0009546248,0.0010646511,0.00094509503],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.005066281,0.00036721068,0.0006454591,0.001113773,0.00065662747,0.00026105,0.00063192693,0.00023619899,0.0022905502],"category_scores_gemma":[0.0015977637,0.00033732128,0.00021400557,0.0031614222,0.0005703211,0.00027324434,0.0006920463,0.0027716309,0.0022029863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050139555,0.00020655394,0.016476013,0.001245715,0.00013000458,0.00080289965,0.0015415476,0.000060599406,0.9005085,0.00009843261,0.06800931,0.010419023],"study_design_scores_gemma":[0.0095647555,0.0006991018,0.09624818,0.0048094057,0.0000753389,0.00006657152,0.0054980717,0.0022933001,0.5465047,0.0003813497,0.33243492,0.0014243571],"about_ca_topic_score_codex":0.0060538948,"about_ca_topic_score_gemma":0.00025259133,"teacher_disagreement_score":0.35400385,"about_ca_system_score_codex":0.0010763031,"about_ca_system_score_gemma":0.0019902117,"threshold_uncertainty_score":0.9999079},"labels":[],"label_agreement":null},{"id":"W4365509978","doi":"10.1158/1078-0432.c.6533189.v2","title":"Data from Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Trastuzumab; Breast cancer; Oncology; Medicine; Biomarker; Internal medicine; Adjuvant; Cancer; Biology; Genetics","score_opus":0.3330609675641214,"score_gpt":0.48522905722732396,"score_spread":0.15216808966320255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365509978","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4420923,0.0045352266,0.0007870849,0.007575537,0.0014311139,0.014887704,0.52853477,0.00012343042,0.00003284235],"genre_scores_gemma":[0.80997884,0.004724426,0.0011606759,0.0007546026,0.0034305798,0.010296073,0.1680818,0.0005297993,0.0010432074],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9922521,0.00047455102,0.001351049,0.003327572,0.0016473181,0.00094742584],"domain_scores_gemma":[0.98411334,0.004719282,0.0005428286,0.009183787,0.0008431743,0.00059760746],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014350985,0.0009607426,0.001780271,0.00019311521,0.0002087831,0.00017080105,0.004319464,0.00034974574,0.0026616305],"category_scores_gemma":[0.00081945036,0.0006414896,0.00030283886,0.00030843186,0.00042811965,0.00022261927,0.006487492,0.00093404815,0.000027668273],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41454682,0.011533886,0.010492664,0.0008593496,0.019736426,0.0006507926,0.0056420686,0.000049468523,0.0017521993,0.000005562155,0.44740555,0.087325215],"study_design_scores_gemma":[0.26785615,0.010577106,0.59280986,0.008128889,0.012590402,0.000009609467,0.027325887,0.026336743,0.0017439959,0.0010174221,0.048192237,0.0034117033],"about_ca_topic_score_codex":0.07271902,"about_ca_topic_score_gemma":0.055571362,"teacher_disagreement_score":0.5823172,"about_ca_system_score_codex":0.00051808386,"about_ca_system_score_gemma":0.0040313257,"threshold_uncertainty_score":0.9996036},"labels":[],"label_agreement":null},{"id":"W4365512223","doi":"10.1158/1538-7445.am2023-ct229","title":"Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"","keywords":"Medicine; Cohort; Internal medicine; Oncology; Cancer; Response Evaluation Criteria in Solid Tumors; ErbB; Adenocarcinoma; Cancer research; Phases of clinical research; Chemotherapy","score_opus":0.076277487442443,"score_gpt":0.4803886962775271,"score_spread":0.4041112088350841,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308485,0.00012532626,0.000004955822,0.00073503,0.00009606986,0.0054009687,0.00019469674,0.000075666816,0.00028241216],"genre_scores_gemma":[0.9970988,0.0003151,0.00006803408,0.000085444124,0.000077763085,0.0014082376,0.000092787246,0.00012303647,0.00073077815],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9929835,0.0004928252,0.00081098056,0.0009265239,0.0034378883,0.0013482644],"domain_scores_gemma":[0.99553496,0.0005914306,0.000168546,0.00084040564,0.0023605141,0.0005041263],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015559032,0.00033921408,0.00087796606,0.0012673328,0.00019205984,0.000046793204,0.000497821,0.00009256274,0.00063205825],"category_scores_gemma":[0.0010138085,0.00024731347,0.00007271446,0.00422497,0.00044468904,0.00022648163,0.0003163651,0.0014251878,0.00008669142],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.24766558,0.038622446,0.2067718,0.007961452,0.0013696229,0.020774718,0.032786414,0.0048309024,0.100466534,0.00006464887,0.009370341,0.32931554],"study_design_scores_gemma":[0.07238759,0.040707707,0.8392854,0.0057992814,0.00010580247,0.000024523693,0.012809084,0.0013461832,0.026510911,0.000055188953,0.00029415727,0.0006741873],"about_ca_topic_score_codex":0.0028472908,"about_ca_topic_score_gemma":0.0037350503,"teacher_disagreement_score":0.6325136,"about_ca_system_score_codex":0.00084145204,"about_ca_system_score_gemma":0.0026590687,"threshold_uncertainty_score":0.9999979},"labels":[],"label_agreement":null},{"id":"W4366427874","doi":"10.3389/fimmu.2023.1181014","title":"Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"Health Canada; Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Mitacs; University of Ottawa; Ovarian Cancer Canada; Terry Fox Research Institute; Australian Government; Natural Sciences and Engineering Research Council of Canada; Ottawa Hospital Research Institute","keywords":"Oncolytic virus; Immune system; Trastuzumab emtansine; Trastuzumab; Immunotherapy; Cancer research; Medicine; Vesicular stomatitis virus; Cancer; Immunology; Breast cancer; Antibody; Virus; Internal medicine","score_opus":0.09414800290936359,"score_gpt":0.39520593003516635,"score_spread":0.30105792712580276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366427874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98784626,0.0026349444,0.0042660087,0.0018424328,0.00033347376,0.0026710106,0.00022943682,0.000038283404,0.00013813545],"genre_scores_gemma":[0.99607104,0.00055914384,0.0015748641,0.00004273149,0.00002345702,0.0009378196,0.000042691212,0.00005137564,0.0006968845],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99804264,0.0002058014,0.00048729122,0.00027274492,0.0005934639,0.000398045],"domain_scores_gemma":[0.9985172,0.00019322734,0.00019008786,0.00052748306,0.00053297775,0.000038984563],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013641039,0.00016552983,0.00065689645,0.0004363292,0.00007276708,0.000005037384,0.00023148068,0.000093641545,0.000058827627],"category_scores_gemma":[0.00016886971,0.000117395015,0.0000854277,0.00070373877,0.0004971753,0.000051716084,0.000050500512,0.00025087286,0.0000019936263],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030448548,0.0029149468,0.03846422,0.0038473988,0.009958223,0.000041714487,0.01130835,0.16359569,0.4490163,0.0012733856,0.041622616,0.24750859],"study_design_scores_gemma":[0.030599039,0.006168724,0.07075549,0.0007957421,0.0023921754,0.000046147983,0.006393038,0.83132535,0.047682434,0.0031731413,0.00020645351,0.00046224686],"about_ca_topic_score_codex":0.00079696777,"about_ca_topic_score_gemma":0.0008417788,"teacher_disagreement_score":0.6677297,"about_ca_system_score_codex":0.0006901469,"about_ca_system_score_gemma":0.0013925349,"threshold_uncertainty_score":0.478723},"labels":[],"label_agreement":null},{"id":"W4366485651","doi":"10.1055/s-0043-1766335","title":"Untersuchung von monomeren Radioliganden ausgehend von publizierten EGFR-spezifischen Peptiden hinsichtlich ihrer Eignung für die Theranostik maligner Transformationen","year":2023,"lang":"de","type":"article","venue":"Nuklearmedizin - NuclearMedicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemistry; Epidermal growth factor receptor; Receptor; Biochemistry","score_opus":0.04559089352838608,"score_gpt":0.34648343989692104,"score_spread":0.30089254636853496,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366485651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5032594,0.12817472,0.0004485493,0.22551566,0.023854537,0.015181244,0.0011820366,0.0051580765,0.09722577],"genre_scores_gemma":[0.8814019,0.06084402,0.0006148524,0.007289174,0.020020775,0.00053555093,0.0026267574,0.0015263237,0.02514063],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9819234,0.0010797576,0.0034212351,0.0028671739,0.005818233,0.0048902244],"domain_scores_gemma":[0.99003386,0.0012071175,0.0008477192,0.0037038585,0.0011091388,0.0030983242],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0056176414,0.002171723,0.003374409,0.0031450773,0.0010727542,0.0006725342,0.0031259195,0.001693775,0.010298064],"category_scores_gemma":[0.0014968353,0.001942849,0.000950874,0.004465645,0.002384313,0.0015547109,0.0009814849,0.004450962,0.027565012],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052954876,0.001196483,0.018710155,0.0048319944,0.007759583,0.0038310462,0.052071888,0.00010534463,0.034124132,0.00075771275,0.72812086,0.14319533],"study_design_scores_gemma":[0.018039782,0.003564947,0.028539639,0.0048438003,0.0035802603,0.00017105528,0.010314949,0.0139060225,0.002457298,0.0003292335,0.91182846,0.0024245575],"about_ca_topic_score_codex":0.0014975701,"about_ca_topic_score_gemma":0.00013239143,"teacher_disagreement_score":0.3781425,"about_ca_system_score_codex":0.002202388,"about_ca_system_score_gemma":0.0016128466,"threshold_uncertainty_score":0.99960226},"labels":[],"label_agreement":null},{"id":"W4366496702","doi":"10.1016/j.ejca.2023.04.007","title":"Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial","year":2023,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Boehringer Ingelheim","keywords":"Afatinib; Refractory (planetary science); Medicine; Oncology; Internal medicine; Pediatrics; Cancer; Gefitinib; Epidermal growth factor receptor","score_opus":0.04850224767936248,"score_gpt":0.3747968129093108,"score_spread":0.32629456522994826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366496702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956053,0.0012526205,0.0000052514156,0.0005976361,0.0007867086,0.0005492089,0.00007194346,0.000021624599,0.0011097391],"genre_scores_gemma":[0.99749964,0.00101038,0.00010365258,0.000048095884,0.0009379696,0.000004040258,0.000027664813,0.00006544529,0.0003031057],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99629647,0.0006556882,0.0011499752,0.00023576619,0.0012966581,0.00036545243],"domain_scores_gemma":[0.9976901,0.00015959538,0.00081309286,0.00028232692,0.00078747334,0.0002674597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023677351,0.0001786809,0.0005059654,0.00077489286,0.000031259955,0.000016390415,0.0002369436,0.000038969018,0.00015078108],"category_scores_gemma":[0.0008664818,0.0001283122,0.0001258108,0.0014241809,0.0000956751,0.0001404452,0.00006108537,0.0007014537,0.000028257438],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42619795,0.0026842777,0.03321975,0.00031843575,0.0002369496,0.0019290075,0.003640005,0.0003662772,0.0033827035,0.0000015687942,0.062751755,0.46527132],"study_design_scores_gemma":[0.50758535,0.028565746,0.4148127,0.004074782,0.0002598562,0.000022117005,0.0003375973,0.00021362992,0.0016839537,0.000007923985,0.042062033,0.00037433373],"about_ca_topic_score_codex":0.000026767131,"about_ca_topic_score_gemma":0.000017988481,"teacher_disagreement_score":0.46489698,"about_ca_system_score_codex":0.00024586267,"about_ca_system_score_gemma":0.00074359495,"threshold_uncertainty_score":0.52324194},"labels":[],"label_agreement":null},{"id":"W4366597244","doi":"10.3390/curroncol30040330","title":"‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Trastuzumab; Lung cancer; Cancer; Drug; Oncology; Targeted therapy; Cancer research; Internal medicine; Breast cancer; Pharmacology","score_opus":0.16381891991469927,"score_gpt":0.5315866527994902,"score_spread":0.367767732884791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366597244","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001882697,0.987979,0.000008926385,0.0006589963,0.001940878,0.0083260145,0.00021827208,0.000196681,0.00048298275],"genre_scores_gemma":[0.000006519983,0.9916257,0.0001582637,0.00031463866,0.00053893385,0.0025680207,0.003349311,0.00028068435,0.001157893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99387914,0.0009312517,0.0018519856,0.001429858,0.00055043405,0.0013573212],"domain_scores_gemma":[0.9965503,0.00049965794,0.00089354726,0.0010606063,0.00043615184,0.0005597141],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0019614298,0.0009848727,0.0062049767,0.0006447477,0.00008682415,0.00003622841,0.0008660018,0.00053478644,0.0006905798],"category_scores_gemma":[0.00027487287,0.00068261055,0.00046846442,0.0015351253,0.00024498795,0.00008000941,0.00037989003,0.0029069975,0.0002584364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005637654,0.000717588,0.006957309,0.4001242,0.00035293156,0.0005293179,0.00015736285,8.0578366e-7,0.000006951425,0.0000042919305,0.044955187,0.5461377],"study_design_scores_gemma":[0.0016156917,0.00049970445,0.00010419588,0.13250796,0.0019545727,0.000040139214,0.000038038597,0.00015479492,0.0000021238204,0.0000015311452,0.8624935,0.0005877111],"about_ca_topic_score_codex":0.00069580093,"about_ca_topic_score_gemma":0.0009027812,"teacher_disagreement_score":0.8175383,"about_ca_system_score_codex":0.0020227588,"about_ca_system_score_gemma":0.0065290206,"threshold_uncertainty_score":0.9995625},"labels":[],"label_agreement":null},{"id":"W4366815856","doi":"10.1038/s41416-023-02272-4","title":"Biparatopic anti-HER2 drug radioconjugates as breast cancer theranostics","year":2023,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"CIHR Skin Research Training Centre; Canadian Institutes of Health Research; Government of Canada","keywords":"Medicine; Breast cancer; Drug; Oncology; Cancer; Internal medicine; Pharmacology","score_opus":0.022176495954511766,"score_gpt":0.37173380882424717,"score_spread":0.3495573128697354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366815856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94053996,0.044199403,0.0000075972753,0.011763351,0.0015189858,0.00033862566,0.00018029548,0.000062293686,0.0013894778],"genre_scores_gemma":[0.8839374,0.104163,0.00007591167,0.0014548934,0.0028512238,0.00005019036,0.000005614906,0.00008393039,0.007377822],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99747,0.00010239635,0.00058901997,0.00024383703,0.0010217004,0.0005730379],"domain_scores_gemma":[0.998261,0.000120751334,0.00023878513,0.00020718074,0.0007679095,0.00040442162],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060849864,0.00018062023,0.0005862105,0.00023405894,0.00013231783,0.00013753827,0.00030795185,0.00010776929,0.0039736126],"category_scores_gemma":[0.00014732625,0.00017908592,0.00021801876,0.0007523657,0.00018233086,0.000179802,0.00005691943,0.00075806386,0.00013046442],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005340739,0.00015897719,0.16023351,0.0004279331,0.00068139174,0.006780368,0.0004516259,0.00028944516,0.00860276,0.000039341925,0.28858256,0.533218],"study_design_scores_gemma":[0.0045547243,0.0003026893,0.59055704,0.005044753,0.00027078186,0.011505464,0.00034075527,0.0001568707,0.009501795,0.00034948133,0.37701428,0.00040138903],"about_ca_topic_score_codex":0.004606738,"about_ca_topic_score_gemma":0.0008274241,"teacher_disagreement_score":0.53281665,"about_ca_system_score_codex":0.00036200418,"about_ca_system_score_gemma":0.0015967473,"threshold_uncertainty_score":0.9969369},"labels":[],"label_agreement":null},{"id":"W4366982735","doi":"10.3233/bd-220052","title":"Efficacy and safety of antibody-drug conjugates in triple-negative and HER-2 positive breast cancer: A systematic review and meta-analysis of clinical trials","year":2023,"lang":"en","type":"review","venue":"Breast Disease","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Internal medicine; Trastuzumab; Breast cancer; Randomized controlled trial; Oncology; Chemotherapy; Meta-analysis; Cancer; Gastroenterology","score_opus":0.2870142338148702,"score_gpt":0.5635373667569885,"score_spread":0.27652313294211833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366982735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011582827,0.9631263,0.000001452786,0.0010743268,0.000029203811,0.011456377,0.02415574,0.0000202881,0.000020471458],"genre_scores_gemma":[0.00081327115,0.9974216,0.000022046272,0.00012920664,0.00004733589,0.0008943476,0.0003593505,0.0000765767,0.0002362697],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98498285,0.007212122,0.0055099363,0.001070938,0.0008281857,0.0003959677],"domain_scores_gemma":[0.98512954,0.009843838,0.0026789345,0.00088892115,0.00051990646,0.0009388564],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.011796835,0.00069584354,0.027343227,0.0008325943,0.000047469708,0.000033859003,0.00024182729,0.0002264083,0.0002697187],"category_scores_gemma":[0.008034867,0.00043674064,0.0028313678,0.0022011637,0.0006849606,0.0000837834,0.00026841278,0.0005884117,0.0000045339348],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010091781,0.00029522745,0.00040353445,0.8453507,0.13842581,0.000118125834,0.00006955079,3.1314005e-7,1.4060629e-7,0.000025066895,0.0000923687,0.014209991],"study_design_scores_gemma":[0.0020904038,0.00006308048,0.009068941,0.25555322,0.73264855,0.00007823738,0.000041192794,0.000037026093,9.6159454e-8,0.000009329944,0.00013882043,0.00027106656],"about_ca_topic_score_codex":0.0011288264,"about_ca_topic_score_gemma":0.00012091801,"teacher_disagreement_score":0.5942228,"about_ca_system_score_codex":0.00011733439,"about_ca_system_score_gemma":0.0015550667,"threshold_uncertainty_score":0.99980843},"labels":[],"label_agreement":null},{"id":"W4376645278","doi":"10.3390/curroncol30050381","title":"Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University Health Network; Ottawa Hospital; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Dilemma; Cancer; Internal medicine; Trastuzumab; Epistemology","score_opus":0.12050075996441456,"score_gpt":0.48514988563745276,"score_spread":0.3646491256730382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376645278","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14396232,0.0062897424,0.000090359244,0.8308883,0.0026048208,0.013757109,0.0018470964,0.00013263628,0.00042761312],"genre_scores_gemma":[0.2531257,0.019731445,0.00014341094,0.6798848,0.0013407429,0.044473812,0.0007796262,0.00029868432,0.00022177392],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930412,0.0009236434,0.0012338632,0.0014943145,0.0015923663,0.0017146021],"domain_scores_gemma":[0.99426764,0.0017295693,0.0003356401,0.0011593322,0.0012331728,0.0012746362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002096977,0.00072402897,0.0016649662,0.00051456,0.0003805879,0.000097074604,0.0013841827,0.00014967259,0.000370712],"category_scores_gemma":[0.00223031,0.0005418681,0.00018791389,0.0026787198,0.000103369755,0.00017065021,0.0007793708,0.0013264407,0.00007675167],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002461965,0.0008542655,0.004665995,0.00082733826,0.00008191685,0.00020956696,0.0028594723,0.00024151265,0.00007870314,0.00003238273,0.82802826,0.15965861],"study_design_scores_gemma":[0.003633427,0.0024902483,0.023833426,0.010740875,0.00007952803,0.000068397036,0.0023584103,0.00043395712,0.00037892477,0.000008848284,0.9553474,0.00062652596],"about_ca_topic_score_codex":0.4208791,"about_ca_topic_score_gemma":0.62428725,"teacher_disagreement_score":0.20340815,"about_ca_system_score_codex":0.013311697,"about_ca_system_score_gemma":0.008279801,"threshold_uncertainty_score":0.9997033},"labels":[],"label_agreement":null},{"id":"W4376956449","doi":"10.3390/curroncol30050380","title":"The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Pertuzumab; Medicine; Breast cancer; Dilemma; Cancer; Family medicine; Trastuzumab; Oncology; Internal medicine","score_opus":0.12885039517155653,"score_gpt":0.49870845031395566,"score_spread":0.3698580551423991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376956449","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11730189,0.014558448,0.000063541505,0.8494433,0.0034367128,0.012926326,0.0015495935,0.00013784891,0.00058231986],"genre_scores_gemma":[0.47484803,0.09801309,0.00012683836,0.36043504,0.0019634366,0.062567934,0.0011876071,0.00043403334,0.00042399933],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99397063,0.0008316335,0.0010582928,0.001130311,0.0013809231,0.0016281784],"domain_scores_gemma":[0.9947487,0.0020466412,0.00031846567,0.00082481804,0.0011136276,0.0009477576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019372687,0.0006093456,0.0013852797,0.00034750812,0.0004504904,0.00009698682,0.0011364368,0.00014276088,0.00021163172],"category_scores_gemma":[0.001679382,0.00044454754,0.00016448388,0.0018548449,0.00012556244,0.00015007642,0.0006130527,0.001210302,0.000049899747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019269432,0.00066375325,0.0042922567,0.00076059275,0.00007523328,0.0001571956,0.0016564071,0.000110498244,0.00007205423,0.000047983624,0.77633315,0.21390393],"study_design_scores_gemma":[0.003618032,0.0017873124,0.022962924,0.010026895,0.000064479274,0.00008637558,0.0018799801,0.0007160087,0.00026194102,0.000010780897,0.9580541,0.00053115725],"about_ca_topic_score_codex":0.26464194,"about_ca_topic_score_gemma":0.6501089,"teacher_disagreement_score":0.48900828,"about_ca_system_score_codex":0.013534729,"about_ca_system_score_gemma":0.009085315,"threshold_uncertainty_score":0.9998006},"labels":[],"label_agreement":null},{"id":"W4379282852","doi":"10.1200/jco.2023.41.16_suppl.tps3153","title":"TROPION-PanTumor03: Phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced/metastatic solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Prostate cancer; Internal medicine; Oncology; Cancer; Combination therapy; Bevacizumab; Cancer research; Immunotherapy; Chemotherapy","score_opus":0.139887455660775,"score_gpt":0.5423854401283179,"score_spread":0.4024979844675429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379282852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997433,0.000058110858,0.000031694373,0.0010957421,0.00016240933,0.001152115,0.0000057497073,0.0000070347332,0.000054133725],"genre_scores_gemma":[0.9981279,0.0006650956,0.0006793529,0.00037643744,0.0000513655,0.000030097643,0.000005654943,0.00003373355,0.000030390524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570805,0.0006823279,0.0021134436,0.00030833564,0.00083387544,0.0003539823],"domain_scores_gemma":[0.9967336,0.001126731,0.0011626285,0.00023706027,0.00046428625,0.00027569267],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001958447,0.00017503182,0.001551975,0.0005373468,0.000026025813,0.000010282724,0.00018016019,0.00009082345,0.00006634484],"category_scores_gemma":[0.0014279262,0.000117257965,0.00006514731,0.0006421987,0.00021820772,0.00018729077,0.000058089303,0.0008844517,0.0000054022375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032054365,0.018510206,0.85917526,0.00010897778,0.00020765516,0.0018056735,0.00089939695,0.00013390562,0.000052888674,0.000003885254,0.00010635402,0.086941406],"study_design_scores_gemma":[0.117394485,0.08059835,0.7981028,0.00063925196,0.00009384136,0.000036648977,0.0013730905,0.0011585681,0.00009251937,0.00007230382,0.00033447353,0.00010366916],"about_ca_topic_score_codex":0.0001171046,"about_ca_topic_score_gemma":0.0006489973,"teacher_disagreement_score":0.08683774,"about_ca_system_score_codex":0.0002670426,"about_ca_system_score_gemma":0.0012177739,"threshold_uncertainty_score":0.4781641},"labels":[],"label_agreement":null},{"id":"W4379285655","doi":"10.1200/jco.2023.41.16_suppl.e13113","title":"Efficacy of antibody-drug conjugates in breast cancer: A systematic review and meta-analysis of randomized clinical trials.","year":2023,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer; Metastatic breast cancer; Meta-analysis; Randomized controlled trial; Antibody-drug conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.6540924356858592,"score_gpt":0.6992106650388575,"score_spread":0.04511822935299836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379285655","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000046456717,0.9867222,0.000007652381,0.005453005,0.00049985334,0.006939455,0.00025007717,0.000007661029,0.00007367019],"genre_scores_gemma":[0.00007467786,0.99801415,0.00021705066,0.0006609893,0.00045052578,0.00024174768,0.000022035952,0.00006576434,0.0002530419],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.87486756,0.07184647,0.05065355,0.0006661664,0.0015210679,0.00044516256],"domain_scores_gemma":[0.6777756,0.27409887,0.044061024,0.0010833688,0.0021399872,0.00084114354],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaresearch","metaepi_broad"],"category_scores_codex":[0.31317115,0.0005845967,0.16453372,0.0016380941,0.00001838409,0.000013402826,0.00079094496,0.0012740085,0.0008064193],"category_scores_gemma":[0.2579738,0.00029282665,0.033809472,0.0024640895,0.0012867355,0.000062598905,0.0002438536,0.0038411105,0.000013018162],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011469788,0.0009885022,0.0000955271,0.5622572,0.39761338,0.0002653845,0.000016217575,0.0000011283274,5.267221e-8,0.000020833928,0.0010265002,0.026245521],"study_design_scores_gemma":[0.046348207,0.0007690238,0.000085923566,0.16938838,0.77217305,0.00017888052,0.000011684093,0.000021832846,4.443287e-8,0.000017285614,0.010855988,0.00014969116],"about_ca_topic_score_codex":0.0002324811,"about_ca_topic_score_gemma":0.000094801144,"teacher_disagreement_score":0.39286882,"about_ca_system_score_codex":0.00023303897,"about_ca_system_score_gemma":0.009092478,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","score_opus":0.13996570816914805,"score_gpt":0.5367814479793399,"score_spread":0.39681573981019186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379383902","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003983862,0.9937808,0.00008090686,0.0018742908,0.0009420016,0.0025413341,0.00007117543,0.00013889889,0.00053073955],"genre_scores_gemma":[0.00014602467,0.9943541,0.00045620496,0.0006221038,0.00089276594,0.0029178194,0.00015640163,0.00021334006,0.00024122262],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917804,0.0021563962,0.0019736271,0.0012041201,0.0013703188,0.0015151621],"domain_scores_gemma":[0.99523425,0.0027782961,0.00046229752,0.00069663214,0.000080774014,0.00074772886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029042133,0.0007944117,0.004872832,0.00082198204,0.00007898566,0.000023313924,0.00076259667,0.00080930325,0.0027249262],"category_scores_gemma":[0.00048563644,0.00057335576,0.0003494075,0.0016784094,0.00065358455,0.00020500667,0.0001562882,0.002269163,0.0001810645],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013886298,0.00096279365,0.00030885614,0.011137751,0.00027788512,0.0033362473,0.00034821316,0.00003074787,3.8912646e-7,0.000109321954,0.000043264372,0.9833057],"study_design_scores_gemma":[0.0025870749,0.0014602459,0.00008755859,0.0261721,0.00055968715,0.00061922305,0.00025365988,0.0012610762,3.1023225e-7,0.00068160327,0.96584195,0.0004755306],"about_ca_topic_score_codex":0.00093107607,"about_ca_topic_score_gemma":0.003384941,"teacher_disagreement_score":0.9828301,"about_ca_system_score_codex":0.0065296646,"about_ca_system_score_gemma":0.008106926,"threshold_uncertainty_score":0.9996718},"labels":[],"label_agreement":null},{"id":"W4379984937","doi":"10.1158/1538-7445.am2023-1837","title":"Abstract 1837: E7386, a selective inhibitor of the interaction between β-catenin and CREB-binding protein (CBP), enhances antitumor activity in combination with lenvatinib (LEN), and LEN + anti-PD-1 antibody in a preclinical tumor model","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"","keywords":"Cancer research; Population; Medicine; Chemistry; Pharmacology","score_opus":0.16830660519183713,"score_gpt":0.49233501208204594,"score_spread":0.32402840689020884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379984937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99482864,0.0001235724,0.000013486719,0.0019288461,0.00004293207,0.0027421073,0.00004817954,0.000033391247,0.00023886641],"genre_scores_gemma":[0.99865127,0.00031255113,0.00006232917,0.000009784974,0.00009714572,0.00056155754,0.000015551268,0.000046111443,0.00024372835],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99643606,0.00049214385,0.0004957804,0.00071324705,0.0011680817,0.00069468893],"domain_scores_gemma":[0.9982556,0.0007246606,0.00018098365,0.0003007941,0.00038304745,0.00015492675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003516291,0.00021166762,0.00057996146,0.0008474952,0.00016508246,0.00006843177,0.00022347867,0.0001454376,0.000017419477],"category_scores_gemma":[0.00095459085,0.00015926188,0.000044360713,0.0022041514,0.00063597766,0.00042539075,0.00028859157,0.0018785888,0.000004667916],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016160482,0.00025656962,0.3667827,0.0010569784,0.00004737584,0.000037108963,0.0011371855,0.00008142836,0.6238809,0.000027085038,0.00008449822,0.0049921223],"study_design_scores_gemma":[0.0025822036,0.0006560674,0.5775108,0.0026352208,0.000012468217,0.0000059558797,0.00051113666,0.0039907983,0.41177937,0.0001479891,0.000021552227,0.00014646753],"about_ca_topic_score_codex":0.0036108573,"about_ca_topic_score_gemma":0.0016405989,"teacher_disagreement_score":0.21210152,"about_ca_system_score_codex":0.0005643665,"about_ca_system_score_gemma":0.0013935437,"threshold_uncertainty_score":0.8161638},"labels":[],"label_agreement":null},{"id":"W4380086049","doi":"10.1158/1538-7445.am2023-1538","title":"Abstract 1538: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Tolerability; Medicine; Drug; Antibody-drug conjugate; Therapeutic index; Pharmacology; Payload (computing); Linker; Cancer research; Antibody; Monoclonal antibody; Adverse effect; Immunology; Computer science","score_opus":0.22548872914863063,"score_gpt":0.4925144957504283,"score_spread":0.26702576660179766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380086049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9424962,0.02535282,0.000002309292,0.028673206,0.00007513998,0.0016438084,0.0003169468,0.000021769976,0.0014178461],"genre_scores_gemma":[0.9579457,0.041320797,0.00001853065,0.000047863563,0.00035545757,0.00010580411,0.00003996772,0.00003808785,0.00012779143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953263,0.0006538805,0.0007903715,0.0005549173,0.0019806987,0.00069386285],"domain_scores_gemma":[0.9910541,0.004934261,0.0002517734,0.0023618112,0.0012764768,0.00012153067],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.016927455,0.00017852374,0.0005954706,0.00017941164,0.0003378655,0.00004254434,0.0014542018,0.000080912374,0.0004961538],"category_scores_gemma":[0.0020118358,0.00008805152,0.000113703616,0.0012093368,0.0027228324,0.00014587629,0.0017109932,0.0012684964,0.000009501943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007408985,0.00041617185,0.13695803,0.025720216,0.0017917189,0.000088492285,0.04233613,0.0001535342,0.33386523,0.0074807494,0.008765451,0.4350153],"study_design_scores_gemma":[0.016300177,0.00087993545,0.5694162,0.015442424,0.00059413916,0.00003210565,0.070971616,0.014374332,0.26198643,0.0062100994,0.042834673,0.0009578456],"about_ca_topic_score_codex":0.008469409,"about_ca_topic_score_gemma":0.00037341414,"teacher_disagreement_score":0.43405744,"about_ca_system_score_codex":0.0001122346,"about_ca_system_score_gemma":0.0008298515,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W4380303043","doi":"10.1021/acs.jmedchem.3c00760","title":"Structure–Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody–Drug Conjugate Payloads","year":2023,"lang":"en","type":"article","venue":"Journal of Medicinal Chemistry","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Linker; Conjugate; Chemistry; In vivo; In vitro; Cytotoxicity; Peptide; Combinatorial chemistry; Antibody-drug conjugate; Intercalation (chemistry); Conjugated system; Drug; Payload (computing); Antibody; Stereochemistry; Biochemistry; Pharmacology; Monoclonal antibody; Immunology; Biology; Organic chemistry","score_opus":0.03054896719663998,"score_gpt":0.3614380745643872,"score_spread":0.33088910736774724,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380303043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99507076,0.0005988507,0.0002997199,0.002476654,0.000063955194,0.00012573625,0.000012740296,0.00001923666,0.00133233],"genre_scores_gemma":[0.998675,0.00029436406,0.00016343393,0.000043180888,0.0004930157,0.0000023684597,0.000012777982,0.000020120666,0.0002957592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983497,0.0000726516,0.0005288071,0.00017086379,0.000646599,0.00023133447],"domain_scores_gemma":[0.9981944,0.00048373098,0.00047536418,0.00021735198,0.0003716726,0.00025746462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015450658,0.00014370798,0.0004393492,0.00012382654,0.00008455148,0.000012563425,0.0001388695,0.000113645474,0.00010227718],"category_scores_gemma":[0.0012576744,0.00010270969,0.00009182394,0.00036126224,0.0002278961,0.0000867748,0.000061553306,0.0010467577,0.000003214914],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002830728,0.00003183911,0.05924445,0.0007643052,0.00008441574,0.000051082447,0.0006375377,0.000011644044,0.93014127,0.000009194607,0.0007920533,0.007949161],"study_design_scores_gemma":[0.0019691861,0.0003101569,0.09702978,0.001835072,0.00013436697,0.0018965631,0.0033763438,0.0017287128,0.8889756,0.0010112803,0.0015745908,0.00015834768],"about_ca_topic_score_codex":0.000044142715,"about_ca_topic_score_gemma":0.00000348585,"teacher_disagreement_score":0.041165646,"about_ca_system_score_codex":0.00011012859,"about_ca_system_score_gemma":0.00037363404,"threshold_uncertainty_score":0.45476994},"labels":[],"label_agreement":null},{"id":"W4380323763","doi":"10.1186/s13058-023-01649-w","title":"XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Medicine; Everolimus; Internal medicine; Breast cancer; Hazard ratio; Tolerability; Placebo; Oncology; Metastatic breast cancer; Clinical endpoint; Aromatase inhibitor; Cancer; Clinical trial; Adverse effect; Confidence interval; Aromatase; Pathology","score_opus":0.054923355716337066,"score_gpt":0.3966304399903068,"score_spread":0.34170708427396973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380323763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98784685,0.0006580889,0.0000045126844,0.002721531,0.00009030184,0.0075829267,0.0009734645,0.000032275548,0.00009002762],"genre_scores_gemma":[0.9936924,0.0029997497,0.000065013315,0.000028804074,0.00010611041,0.0025677653,0.00018802934,0.00010493691,0.0002471653],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941999,0.00057331607,0.00069111126,0.0010634958,0.0023273067,0.0011448903],"domain_scores_gemma":[0.99679905,0.0006074145,0.00020744774,0.0004490822,0.0011378407,0.0007991783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018115571,0.00047304865,0.0010589026,0.0012942741,0.00025346858,0.00010155913,0.00020272423,0.00013026081,0.00013470379],"category_scores_gemma":[0.00013755583,0.0003745259,0.00005512126,0.0025551505,0.0010626377,0.0004385566,0.0002855758,0.00091869716,0.000002521122],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93124926,0.002373331,0.034916196,0.00058364205,0.0003554421,0.00022973953,0.0017277083,0.00004729106,0.00043452636,0.000019894844,0.00022060327,0.027842393],"study_design_scores_gemma":[0.61073995,0.00710141,0.3791557,0.0011689755,0.00013548716,0.000016910299,0.00038842525,0.00081246975,0.00014758739,0.000024551307,0.000018659211,0.0002898638],"about_ca_topic_score_codex":0.013760516,"about_ca_topic_score_gemma":0.0026328473,"teacher_disagreement_score":0.3442395,"about_ca_system_score_codex":0.0011842735,"about_ca_system_score_gemma":0.0019758064,"threshold_uncertainty_score":0.99987066},"labels":[],"label_agreement":null},{"id":"W4383162923","doi":"10.1016/j.esmoop.2023.101592","title":"Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Astellas Pharma; Eisai; Seagen; Gilead Sciences; Servier; Instituto de Salud Carlos III; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Medicine; Internal medicine; Oncology; Hazard ratio; Breast cancer; Confidence interval; Meta-analysis; Odds ratio; Hormone receptor; Cancer","score_opus":0.26727533271768683,"score_gpt":0.5170282764841014,"score_spread":0.2497529437664146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383162923","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.053806e-7,0.9800712,9.497492e-7,0.0008372303,0.000026781845,0.017697724,0.00090473524,0.000021941582,0.0004386485],"genre_scores_gemma":[0.000008339712,0.9859412,0.00008146412,0.00022239154,0.000022808676,0.010126105,0.00016081825,0.00010851521,0.003328363],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9941734,0.0015151524,0.0020537658,0.0008014118,0.00089020364,0.00056607235],"domain_scores_gemma":[0.996442,0.00080151885,0.0008365086,0.0013614311,0.00024883222,0.00030969884],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037848311,0.0005213364,0.016932769,0.000688976,0.000033703098,0.00008454538,0.0008590144,0.00021494659,0.0018523758],"category_scores_gemma":[0.0009395924,0.00032764673,0.0015263727,0.003994373,0.00010577991,0.000081271246,0.0006873399,0.00065996486,0.00012407177],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000045659162,0.00006147973,0.000112594396,0.89690226,0.09879481,0.00010266676,0.00003685433,7.8646167e-7,3.7902077e-9,0.000023313662,0.00072560785,0.003235066],"study_design_scores_gemma":[0.0001468897,0.000038351187,0.00011778072,0.34992856,0.6304096,0.000054822696,0.000012695714,0.000007476841,4.2389594e-8,0.0000054609322,0.019080797,0.00019752282],"about_ca_topic_score_codex":0.019630916,"about_ca_topic_score_gemma":0.0022038522,"teacher_disagreement_score":0.5469737,"about_ca_system_score_codex":0.00045597224,"about_ca_system_score_gemma":0.0020707916,"threshold_uncertainty_score":0.99991757},"labels":[],"label_agreement":null},{"id":"W4383553191","doi":"10.3390/curroncol30070474","title":"Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Trastuzumab emtansine; Breast cancer; Trastuzumab; Cancer; Antibody-drug conjugate; Metastatic breast cancer; Clinical trial; Drug; Oncology; Internal medicine; Pharmacology; Immunology; Antibody; Monoclonal antibody","score_opus":0.29384681142776564,"score_gpt":0.5896260345667751,"score_spread":0.29577922313900945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383553191","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017567882,0.98487794,0.0000016315536,0.0072240937,0.0020127636,0.0045492337,0.0005263674,0.000083078856,0.0007073279],"genre_scores_gemma":[8.7217643e-7,0.9953166,0.00004724589,0.00070077076,0.0008455879,0.0018191738,0.00051593524,0.0001221185,0.00063169276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99545336,0.00068173243,0.0012989903,0.0010566497,0.0005663173,0.00094296946],"domain_scores_gemma":[0.9973944,0.0007070129,0.00032388084,0.0006194227,0.00027158984,0.0006836903],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017402889,0.00059466437,0.0041498328,0.0006667593,0.000060391056,0.000024639214,0.0004259975,0.0003131294,0.0006876103],"category_scores_gemma":[0.00059789413,0.0004787251,0.00030913285,0.0017107141,0.00021789115,0.000037614373,0.0005605588,0.0016954123,0.0010974378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018320312,0.0001606542,0.0008671508,0.18727557,0.00008023858,0.00023776556,0.000039928986,6.758573e-8,6.953317e-7,0.000016642278,0.07680069,0.73450226],"study_design_scores_gemma":[0.00043267696,0.00015114412,0.0002832814,0.24026826,0.0006555621,0.00039630223,0.000014484365,0.0000032751107,1.4002372e-7,0.000010981562,0.75749433,0.0002895763],"about_ca_topic_score_codex":0.00031453447,"about_ca_topic_score_gemma":0.0004109616,"teacher_disagreement_score":0.7342127,"about_ca_system_score_codex":0.0019051553,"about_ca_system_score_gemma":0.003915975,"threshold_uncertainty_score":0.99976647},"labels":[],"label_agreement":null},{"id":"W4384009290","doi":"10.1055/s-0043-1769867","title":"TROP-2 expression in vulval carcinoma – as a possible target for the treatment approach with antibody drug conjugates (ADC)","year":2023,"lang":"en","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Antibody; Antibody-drug conjugate; Cancer research; Cervical carcinoma; Antigen; Medicine; Drug; Carcinoma; Cancer; Pathology; Immunology; Internal medicine; Cervical cancer; Monoclonal antibody; Pharmacology","score_opus":0.04100265128176192,"score_gpt":0.36674009025587423,"score_spread":0.32573743897411234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384009290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9758369,0.0052566943,0.0014268723,0.004539455,0.00028330364,0.0046350975,0.00010274498,0.0003156538,0.007603292],"genre_scores_gemma":[0.9819925,0.0011036798,0.0038630173,0.00031800818,0.00055443024,0.0015504342,0.00042446167,0.00015774363,0.010035751],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99651074,0.00015351534,0.0004637076,0.0008688457,0.00083114445,0.0011720583],"domain_scores_gemma":[0.9977336,0.00066932174,0.00011106398,0.0009793834,0.00016717061,0.0003394581],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074617664,0.00045835512,0.00066773925,0.00042080163,0.00038365935,0.0001348635,0.00039324965,0.00018700166,0.00018446201],"category_scores_gemma":[0.00012677463,0.00027144354,0.00019899418,0.001126339,0.00033545576,0.00014243908,0.0001041956,0.00045057276,0.00015458796],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019519474,0.0072900043,0.723282,0.0032844753,0.0025042729,0.0034007165,0.03387798,0.0071395487,0.07241873,0.004756223,0.07520373,0.047322895],"study_design_scores_gemma":[0.047533244,0.021251896,0.21233808,0.0017671316,0.0011761656,0.0005130474,0.019277096,0.05133588,0.15770757,0.0063905194,0.47805592,0.0026534693],"about_ca_topic_score_codex":0.0012714692,"about_ca_topic_score_gemma":0.00016634681,"teacher_disagreement_score":0.5109439,"about_ca_system_score_codex":0.000512882,"about_ca_system_score_gemma":0.00078465446,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4384076785","doi":"10.20960/revcancer.00025","title":"Beyond the first line of HER2+ metastatic breast cancer","year":2023,"lang":"es","type":"article","venue":"Revisiones en Cáncer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Metastatic breast cancer; Breast cancer; Oncology; Medicine; Internal medicine; Cancer","score_opus":0.052102977007611,"score_gpt":0.41777546711219415,"score_spread":0.36567249010458314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384076785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3919662,0.20669374,0.000152911,0.37476322,0.0049614706,0.007069877,0.0040600444,0.00050898764,0.009823567],"genre_scores_gemma":[0.8304397,0.1583995,0.00008627611,0.0011888986,0.00209273,0.00028404908,0.000050655493,0.00015914286,0.007299054],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99570054,0.0003723875,0.0009196321,0.0006139981,0.0015732513,0.0008201801],"domain_scores_gemma":[0.9962853,0.001441818,0.0002874209,0.0012318346,0.00048635463,0.00026723393],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002119247,0.00040441414,0.00097592856,0.0003086323,0.00025140226,0.00008619651,0.00072749826,0.00016310519,0.0076105874],"category_scores_gemma":[0.00047760337,0.00024832037,0.0003502893,0.0023609167,0.00043945917,0.00012177608,0.0004911096,0.00071352755,0.0018262406],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006026539,0.0005299841,0.05957717,0.014612778,0.0015434432,0.000356551,0.0033678594,0.0011560651,0.0017401505,0.002543401,0.20415637,0.7098136],"study_design_scores_gemma":[0.0023464512,0.00053284515,0.18912028,0.010505972,0.0011141272,0.00012590572,0.0008322321,0.004483791,0.0012634029,0.0005907066,0.7884903,0.0005939603],"about_ca_topic_score_codex":0.001338885,"about_ca_topic_score_gemma":0.00013402863,"teacher_disagreement_score":0.70921963,"about_ca_system_score_codex":0.00029866106,"about_ca_system_score_gemma":0.00070951943,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W4385173573","doi":"10.1016/j.esmoop.2023.101613","title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","year":2023,"lang":"en","type":"review","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Daiichi Sankyo Europe; Daiichi-Sankyo","keywords":"Medicine; Internal medicine; Breast cancer; Incidence (geometry); Asymptomatic; Cardiotoxicity; Oncology; Gastroenterology; Lung cancer; Cancer; Chemotherapy","score_opus":0.15007037871251086,"score_gpt":0.4438841884306995,"score_spread":0.2938138097181886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385173573","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00005011231,0.98837924,0.0000126554005,0.00022950459,0.000020135352,0.010276948,0.0009359617,0.0000141216115,0.00008132784],"genre_scores_gemma":[0.0030547043,0.9928483,0.000037661834,0.0001462236,0.00002238746,0.0035477595,0.00010051939,0.000072523384,0.00016994441],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99587464,0.0008863678,0.0012987831,0.0008014793,0.00079369504,0.00034501473],"domain_scores_gemma":[0.9975537,0.00033232538,0.00063762267,0.00081249885,0.00028105424,0.00038280588],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015366981,0.00048848224,0.009260753,0.0005113717,0.00004755442,0.00009828954,0.00054986536,0.00011555218,0.00027959683],"category_scores_gemma":[0.00045392042,0.00030241584,0.00073335785,0.0018570814,0.00021550826,0.00015975986,0.0006200779,0.00046827944,0.0000037002424],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006140503,0.00016517469,0.0009108498,0.93147016,0.06333018,0.00012534784,0.00008519596,8.7518043e-7,1.2920631e-8,0.0000030338756,0.00012177176,0.0037259967],"study_design_scores_gemma":[0.0003847027,0.00016420978,0.0006809692,0.41208407,0.5857162,0.000038268485,0.00002240574,0.000015230709,1.339316e-7,0.0000021051765,0.0006117361,0.00027996372],"about_ca_topic_score_codex":0.007439215,"about_ca_topic_score_gemma":0.004370385,"teacher_disagreement_score":0.522386,"about_ca_system_score_codex":0.0007633747,"about_ca_system_score_gemma":0.0010544196,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W4385547758","doi":"10.1158/2767-9764.c.6773851","title":"Data from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens","year":2023,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Sanofi","keywords":"Pharmacokinetics; Medicine; Dosing; Internal medicine; Chemistry; Gastroenterology; Animal science; Biology","score_opus":0.1697949845590386,"score_gpt":0.4671297690045865,"score_spread":0.29733478444554795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385547758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171436,0.00012586352,0.0010576759,0.00017583428,0.00030834595,0.0039708237,0.0024760582,0.00007214485,0.00009888072],"genre_scores_gemma":[0.9952916,0.00024737432,0.0031965235,0.00002985141,0.00017198123,0.000028900167,0.0008459415,0.00012824652,0.000059564354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550676,0.00030277987,0.0008047251,0.0015539711,0.0013064259,0.0005253452],"domain_scores_gemma":[0.99670976,0.00028089236,0.0005191587,0.0018157283,0.00044365707,0.00023081532],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068404817,0.0005067962,0.0014139841,0.00052381883,0.00006590137,0.000055060053,0.0005948542,0.000119944554,0.00009606128],"category_scores_gemma":[0.00030348022,0.00043454673,0.00003868977,0.00045716017,0.00023145275,0.00024374112,0.0030951402,0.0012739674,0.0000031014379],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05985925,0.03527202,0.77566004,0.0036800124,0.0044344985,0.002885186,0.007775217,0.010672502,0.04111531,0.000004400737,0.0005904637,0.05805108],"study_design_scores_gemma":[0.16156267,0.009359264,0.57258326,0.015322388,0.00161646,0.000014207026,0.0036949252,0.19590792,0.03775173,0.00013993736,0.0001340594,0.0019132012],"about_ca_topic_score_codex":0.0085170595,"about_ca_topic_score_gemma":0.001028678,"teacher_disagreement_score":0.20307682,"about_ca_system_score_codex":0.00048669925,"about_ca_system_score_gemma":0.0005820313,"threshold_uncertainty_score":0.99981064},"labels":[],"label_agreement":null},{"id":"W4385651875","doi":"10.1016/j.esmoop.2023.101615","title":"Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer","year":2023,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"AstraZeneca","keywords":"Concordance; Medicine; Immunohistochemistry; Internal medicine; Trastuzumab; Oncology; Breast cancer; Cancer","score_opus":0.09067429760705649,"score_gpt":0.4811611636940519,"score_spread":0.3904868660869954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385651875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728186,0.000056702826,8.257934e-7,0.009057585,0.00011569241,0.0028713455,0.00022227659,0.00002441749,0.00036928328],"genre_scores_gemma":[0.9950495,0.00070095016,0.000053456475,0.00031172016,0.00004553047,0.0004416371,0.000004067203,0.000019957832,0.0033732273],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984415,0.00025564482,0.0002749724,0.00040773686,0.00035297195,0.0002671317],"domain_scores_gemma":[0.99894965,0.00021191464,0.00008527408,0.0004875368,0.00014112952,0.00012448906],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013697722,0.00015063927,0.0004316645,0.000038964085,0.0001790782,0.00008697207,0.00038455476,0.00004074793,0.00030139845],"category_scores_gemma":[0.00054668775,0.000072927025,0.000031097334,0.00027064516,0.0002638711,0.00006476301,0.00073102105,0.00023979787,0.000034997276],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032151237,0.00022007513,0.9865823,0.000054293578,0.000090168876,0.00006494735,0.0025674712,5.0107917e-7,0.000026761172,0.000013181692,0.00059364055,0.009465175],"study_design_scores_gemma":[0.000982305,0.0008009247,0.9968019,0.00016594428,0.00012715218,0.000028317523,0.0007740252,0.000035185785,0.000031745396,0.000051547242,0.0001251524,0.00007581044],"about_ca_topic_score_codex":0.0021890562,"about_ca_topic_score_gemma":0.00055608805,"teacher_disagreement_score":0.010219618,"about_ca_system_score_codex":0.00011452164,"about_ca_system_score_gemma":0.00010388793,"threshold_uncertainty_score":0.3309213},"labels":[],"label_agreement":null},{"id":"W4386688264","doi":"10.51731/cjht.2023.734","title":"Trastuzumab Deruxtecan (Enhertu)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Reimbursement; Metastatic breast cancer; Oncology; Chemotherapy; Breast cancer; Internal medicine; Disease; Adjuvant; Cancer; Intensive care medicine; Health care","score_opus":0.10286531305846934,"score_gpt":0.398326580389078,"score_spread":0.2954612673306086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386688264","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4534305,0.07818354,0.00028851244,0.4622791,0.0013700528,0.00093901774,0.00005155147,0.00089609943,0.0025616023],"genre_scores_gemma":[0.99657834,0.001651867,0.0005112512,0.00070659065,0.0000343797,0.000010789737,0.0000032276985,0.000030926112,0.00047264638],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979847,0.00005862126,0.0005687961,0.0001560058,0.00036351054,0.0008683832],"domain_scores_gemma":[0.998843,0.00007875373,0.00019698631,0.00034753606,0.00024115283,0.00029254146],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012865202,0.0001256626,0.0004479542,0.0015642556,0.00022855078,0.00003117623,0.00039489398,0.00017437682,0.00011679921],"category_scores_gemma":[0.0013587706,0.00010568794,0.00009811665,0.0012958992,0.00030268822,0.000064057094,0.000026637737,0.0008709455,0.000109812805],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001695462,0.000010002983,0.007698179,0.00021004921,0.000039021477,0.0011076189,0.00032599355,0.0000066025386,0.00008385337,0.00029446595,0.0763762,0.91383106],"study_design_scores_gemma":[0.00091086404,0.0016173312,0.040787008,0.00078299496,0.000015904803,0.0013449255,0.007961091,0.000036219943,0.0012374488,0.004319933,0.94081736,0.00016893017],"about_ca_topic_score_codex":0.0054456326,"about_ca_topic_score_gemma":0.0065215207,"teacher_disagreement_score":0.91366214,"about_ca_system_score_codex":0.0012033251,"about_ca_system_score_gemma":0.010888831,"threshold_uncertainty_score":0.9947185},"labels":[],"label_agreement":null},{"id":"W4386779326","doi":"10.3390/curroncol30090615","title":"Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"California State University, Fresno","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Lapatinib; Metastatic breast cancer; Internal medicine; Meta-analysis; Cancer","score_opus":0.3205140542993283,"score_gpt":0.5329883481369438,"score_spread":0.21247429383761557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386779326","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000055605127,0.9864052,0.000760973,0.0008443732,0.00038408843,0.006630342,0.004809688,0.000048199065,0.0000615493],"genre_scores_gemma":[0.00025712766,0.99519247,0.0005879547,0.00008105735,0.00044693265,0.0020038984,0.0011550912,0.00013964328,0.00013581915],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99422747,0.0017099858,0.0014651582,0.0012053533,0.00052466535,0.000867389],"domain_scores_gemma":[0.9936255,0.0038221758,0.0009509115,0.0005713211,0.0005940766,0.00043597879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018320656,0.0007807461,0.009749416,0.0006944849,0.0001717447,0.000032640728,0.00028914312,0.00039988605,0.00043688796],"category_scores_gemma":[0.00017569566,0.00055564597,0.0020028956,0.002141883,0.00059063267,0.000051616433,0.00020620323,0.0009285176,0.0000066567613],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006833725,0.00046984063,0.00015642686,0.011028959,0.17999016,0.000046881785,0.0003242462,0.000013794204,8.619911e-7,0.00006996334,0.0017137962,0.8055017],"study_design_scores_gemma":[0.0031171525,0.0015653208,0.0019596298,0.0031696584,0.382126,0.00012107599,0.000049154747,0.0002129041,0.000002499114,0.00006379634,0.60710734,0.0005054827],"about_ca_topic_score_codex":0.00034021935,"about_ca_topic_score_gemma":0.0002601186,"teacher_disagreement_score":0.8049962,"about_ca_system_score_codex":0.0005748064,"about_ca_system_score_gemma":0.0017630303,"threshold_uncertainty_score":0.9996895},"labels":[],"label_agreement":null},{"id":"W4387338086","doi":"10.1016/j.cjca.2023.06.322","title":"INTERRUPTIONS IN TRASTUZUMAB THERAPY FOR BREAST CANCER ARE ASSOCIATED WITH ADVERSE CARDIOVASCULAR AND ONCOLOGIC OUTCOMES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Internal medicine; Adjuvant; Oncology; Limiting; Cancer; Adjuvant therapy; Adverse effect","score_opus":0.07536772514643893,"score_gpt":0.35635336037631493,"score_spread":0.280985635229876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387338086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899713,0.0020733697,0.00010923975,0.006342097,0.00034949102,0.0005089507,0.00028676487,0.000011726784,0.00034705165],"genre_scores_gemma":[0.9982778,0.0009281635,0.000024553356,0.00026074154,0.0002835508,0.00006829216,0.000007744997,0.00002394308,0.00012521064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99875927,0.0001762581,0.00026762774,0.00016801305,0.0001760716,0.000452776],"domain_scores_gemma":[0.99879926,0.00018063393,0.00009570296,0.0001554733,0.0003479476,0.0004209919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009074672,0.00012429841,0.0008113711,0.0005667321,0.0000685444,0.000009178884,0.00011247671,0.00014797652,0.000029118646],"category_scores_gemma":[0.0002972932,0.00009001592,0.00028544196,0.0003763819,0.00020512492,0.00004595256,0.000008437586,0.0003677054,0.0000019885995],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022322756,0.0000048265965,0.96875924,0.000022570423,0.001965212,0.0011024638,0.00031009916,0.0025492413,0.000025003026,0.000008852217,0.004857809,0.020171486],"study_design_scores_gemma":[0.003807024,0.00056764303,0.9705128,0.00017865376,0.00014291613,0.0006121283,0.0008638729,0.000028101344,0.0000037945297,0.00003993183,0.023152538,0.00009060794],"about_ca_topic_score_codex":0.0019514662,"about_ca_topic_score_gemma":0.02530663,"teacher_disagreement_score":0.023355164,"about_ca_system_score_codex":0.0009380086,"about_ca_system_score_gemma":0.0023406406,"threshold_uncertainty_score":0.99247897},"labels":[],"label_agreement":null},{"id":"W4387809682","doi":"10.1016/j.annonc.2023.10.011","title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Seagen; Genentech; Hope Foundation; AstraZeneca; Breast Cancer Research Foundation; Pfizer; Bristol-Myers Squibb; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy; Breast cancer; Adjuvant chemotherapy; Internal medicine; Gynecology; Cancer; Immunotherapy","score_opus":0.12724318332632856,"score_gpt":0.4865900282985598,"score_spread":0.35934684497223124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768841,0.001209723,0.00009652746,0.0115279555,0.0006028009,0.0066406876,0.0023166533,0.00023360064,0.0004879293],"genre_scores_gemma":[0.9620383,0.018059973,0.0002997702,0.002193984,0.00053643476,0.0021904712,0.00019974187,0.00029905967,0.014182303],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9928911,0.0007513157,0.0018607206,0.0013217226,0.0013861682,0.0017889886],"domain_scores_gemma":[0.9937915,0.0017865811,0.0010936324,0.0014124019,0.0012868909,0.00062894356],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020837341,0.0008316427,0.0029372422,0.00069688493,0.00022452355,0.00003853401,0.00090663956,0.00046232127,0.0038496135],"category_scores_gemma":[0.0005224079,0.000615599,0.0005262626,0.0014769594,0.00047366432,0.0002297792,0.00025723985,0.0009394621,0.000040060793],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33938563,0.015460821,0.008947152,0.00083691924,0.0036231473,0.0009974134,0.007394823,0.00011954382,0.06729037,0.000044434502,0.19438757,0.36151218],"study_design_scores_gemma":[0.4152745,0.1229393,0.042870447,0.00065929303,0.0007180333,0.00028357943,0.0056864386,0.0014307797,0.12355572,0.00012795311,0.28489733,0.0015566382],"about_ca_topic_score_codex":0.016763372,"about_ca_topic_score_gemma":0.0038579926,"teacher_disagreement_score":0.35995555,"about_ca_system_score_codex":0.00040718363,"about_ca_system_score_gemma":0.002969789,"threshold_uncertainty_score":0.99962956},"labels":[],"label_agreement":null},{"id":"W4387810529","doi":"10.1016/j.annonc.2023.09.2538","title":"1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Oncology; Pemetrexed; Carboplatin; Chemotherapy; Combination therapy; Phases of clinical research; non-small cell lung cancer (NSCLC); Lung cancer; Cisplatin","score_opus":0.08150752208758626,"score_gpt":0.4458721133865545,"score_spread":0.36436459129896825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387810529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417794,0.0009896689,0.000056430694,0.00026991326,0.000027075148,0.004342086,0.000075265845,0.000018802728,0.0000428225],"genre_scores_gemma":[0.9913488,0.005921415,0.0017089042,0.00014441914,0.000018237975,0.000597585,0.000018294575,0.00007671044,0.00016563678],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99775803,0.00019397704,0.0006881834,0.00050261983,0.00038472447,0.00047246792],"domain_scores_gemma":[0.9981603,0.00046594298,0.0004503371,0.0003851949,0.00036694857,0.00017124701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030603187,0.00034654912,0.0012676859,0.00034558531,0.000054135737,0.0000066178595,0.00012555468,0.000096559554,0.0001063217],"category_scores_gemma":[0.000042304855,0.00020518327,0.00004564541,0.0005321013,0.00026033644,0.00008313121,0.00004133424,0.00016569516,4.2269994e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14217606,0.0252567,0.55296767,0.0016811722,0.0007916452,0.00020914972,0.02253959,0.00033724253,0.011378564,2.0630186e-7,0.00010855934,0.24255347],"study_design_scores_gemma":[0.31561762,0.3649114,0.219398,0.003417923,0.0004933792,0.00002922746,0.007317201,0.005111426,0.08158801,0.000005282831,0.0015187435,0.00059175876],"about_ca_topic_score_codex":0.002438912,"about_ca_topic_score_gemma":0.0074188635,"teacher_disagreement_score":0.3396547,"about_ca_system_score_codex":0.00018571576,"about_ca_system_score_gemma":0.00066822907,"threshold_uncertainty_score":0.83671314},"labels":[],"label_agreement":null},{"id":"W4387811438","doi":"10.1016/j.annonc.2023.09.1878","title":"692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Centre Léon Bérard; PharmaMar; Basilea Pharmaceutica; Eisai; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Memorial Sloan-Kettering Cancer Center; Genentech; Institut Gustave-Roussy; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Pfizer; Incyte; Boston Pharmaceuticals; F. Hoffmann-La Roche; Seagen; Agios Pharmaceuticals; Roche; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Folate receptor; Anemia; Internal medicine; Regimen; Adverse effect; Toxicity; Gastroenterology; Conjugate; Pharmacology; Cancer; Cancer cell","score_opus":0.09242421790982693,"score_gpt":0.432836990109584,"score_spread":0.3404127721997571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99552554,0.00014684876,2.5157618e-7,0.0015018028,0.000071473216,0.00105809,0.000009805723,0.00004647137,0.0016396894],"genre_scores_gemma":[0.99914163,0.00008549867,0.000055214277,0.0001765577,0.00004551039,0.00012919126,0.00001057247,0.000041965068,0.00031385155],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972936,0.0003536199,0.0007710133,0.00040418413,0.00047954015,0.0006980566],"domain_scores_gemma":[0.9985532,0.00035704963,0.00025001675,0.0004080258,0.0002668558,0.0001648255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013761459,0.00017983452,0.00091901846,0.00054780766,0.000057460467,0.000008382309,0.0001872505,0.00010939955,0.00017499029],"category_scores_gemma":[0.0003473261,0.00015852568,0.000055762743,0.0012565664,0.00022430433,0.00010782364,0.00014446596,0.00038308057,0.000026386635],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004214496,0.005085363,0.48099953,0.0006965581,0.0002149325,0.0016094942,0.023275923,0.00074368675,0.46700254,0.000058047564,0.013253031,0.0028464163],"study_design_scores_gemma":[0.018884663,0.033313423,0.41273516,0.0018800128,0.000049911218,0.000036027457,0.011483751,0.000831357,0.5162466,0.00036779852,0.003731862,0.00043941516],"about_ca_topic_score_codex":0.0023100022,"about_ca_topic_score_gemma":0.005478575,"teacher_disagreement_score":0.06826436,"about_ca_system_score_codex":0.00013265567,"about_ca_system_score_gemma":0.0005076084,"threshold_uncertainty_score":0.64644897},"labels":[],"label_agreement":null},{"id":"W4387836897","doi":"10.1016/j.annonc.2023.09.563","title":"386MO Trastuzumab duocarmazine versus physician's choice therapy in pre-treated HER2-positive metastatic breast cancer: Final results of the phase III TULIP trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"AstraZeneca","keywords":"Medicine; Trastuzumab; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Cancer","score_opus":0.215818782700106,"score_gpt":0.5112288047317133,"score_spread":0.29541002203160727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785149,0.00035542238,0.0000011316429,0.015628457,0.00043988632,0.0018165208,0.00078914675,0.00003483313,0.0024196838],"genre_scores_gemma":[0.9963064,0.0019233509,0.000015207838,0.0005583109,0.00037556936,0.00026207298,0.00008217659,0.000034845634,0.00044204303],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99695593,0.00066058175,0.00078933634,0.0004029241,0.0006188749,0.0005723776],"domain_scores_gemma":[0.9972645,0.0012583742,0.0003957017,0.0004558744,0.00049877836,0.00012678567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00104152,0.00022940879,0.00095595064,0.00027322033,0.00005617006,0.000006034567,0.00034127655,0.00013846773,0.00010264307],"category_scores_gemma":[0.00038269436,0.00016570426,0.00023851002,0.0015758667,0.00042829098,0.000074590964,0.000090223715,0.000467965,0.00001229746],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5884726,0.0051287767,0.0006567332,0.00015003982,0.0010291093,0.00021586817,0.0031376604,0.00022979066,0.018837638,0.000031118205,0.026703022,0.35540763],"study_design_scores_gemma":[0.68703353,0.058522712,0.112307504,0.0008134126,0.00032122812,0.00003788327,0.00075269176,0.0010258517,0.1099832,0.0001098536,0.028708711,0.0003834427],"about_ca_topic_score_codex":0.007978094,"about_ca_topic_score_gemma":0.0014862345,"teacher_disagreement_score":0.3550242,"about_ca_system_score_codex":0.00025289544,"about_ca_system_score_gemma":0.0014804323,"threshold_uncertainty_score":0.99862784},"labels":[],"label_agreement":null},{"id":"W4387836902","doi":"10.1016/j.annonc.2023.09.556","title":"379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Santé Montérégie; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; London Health Sciences Centre; Western University","funders":"Daiichi-Sankyo; Daiichi Sankyo Europe; AstraZeneca","keywords":"Medicine; Internal medicine; Tolerability; Oncology; Adverse effect; Gastroenterology","score_opus":0.1913055246931296,"score_gpt":0.5132972358923467,"score_spread":0.32199171119921705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387836902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9365632,0.0008141214,0.00013367826,0.039104324,0.00053723966,0.007322744,0.014073987,0.00023411524,0.001216604],"genre_scores_gemma":[0.98401684,0.0031215223,0.001046158,0.0012103989,0.00039808475,0.0027775594,0.0021711593,0.00015495419,0.0051033013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941622,0.00055458315,0.0015588197,0.0013702604,0.00095023523,0.0014039129],"domain_scores_gemma":[0.9941214,0.0018408715,0.0006252794,0.0012555375,0.0015145087,0.0006424098],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013981122,0.0006074297,0.0018929185,0.00063255976,0.00040140937,0.00003095384,0.0005578153,0.0002615973,0.0011531996],"category_scores_gemma":[0.0018299597,0.00052234804,0.00031730783,0.0017261097,0.0004106582,0.00023341771,0.0003219174,0.00048083256,0.00015470866],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13089164,0.026312808,0.0019232286,0.00038962293,0.005821954,0.002833846,0.009422798,0.0012893084,0.0048116753,0.000060841397,0.11106996,0.7051723],"study_design_scores_gemma":[0.3280743,0.23584497,0.012435074,0.0013138058,0.0021440815,0.00029863886,0.00878179,0.010889167,0.05240064,0.0053216023,0.34083745,0.0016584612],"about_ca_topic_score_codex":0.01763586,"about_ca_topic_score_gemma":0.018528365,"teacher_disagreement_score":0.70351386,"about_ca_system_score_codex":0.0008445803,"about_ca_system_score_gemma":0.0038097203,"threshold_uncertainty_score":0.99975985},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","score_opus":0.16127771494674698,"score_gpt":0.5034432526818972,"score_spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387865238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931667,0.000114297305,0.000019537503,0.0050256113,0.00040877974,0.0007727908,0.00005661087,0.0000117441405,0.0004239492],"genre_scores_gemma":[0.9968565,0.0002679252,0.0012532031,0.0004551395,0.0010680418,0.0000061402166,0.000026200798,0.000027813681,0.00003901472],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9939156,0.0011156189,0.0034036005,0.00030302457,0.00087999227,0.00038211656],"domain_scores_gemma":[0.9861416,0.01095005,0.0017932979,0.0003393481,0.00040596182,0.00036974385],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0070592784,0.00016646921,0.0017003256,0.00016714302,0.00009474322,0.000012879208,0.00030034324,0.00024495117,0.000041014755],"category_scores_gemma":[0.014887613,0.00009589279,0.00017045574,0.00041790985,0.0006147417,0.00009530571,0.00017908461,0.0016623155,0.0000038688813],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6577554,0.0069367224,0.04236623,0.000041240088,0.00022709426,0.0005646164,0.00088508043,0.000046090776,0.00026963142,0.000002465625,0.0032335988,0.28767186],"study_design_scores_gemma":[0.31613505,0.061380845,0.6166926,0.0010224745,0.0001291059,0.000021785152,0.00014757055,0.00007495884,0.00007253753,0.00006735818,0.0041697407,0.00008599097],"about_ca_topic_score_codex":0.00010454838,"about_ca_topic_score_gemma":0.000054712054,"teacher_disagreement_score":0.57432634,"about_ca_system_score_codex":0.00024600577,"about_ca_system_score_gemma":0.0033193324,"threshold_uncertainty_score":0.9934104},"labels":[],"label_agreement":null},{"id":"W4387934295","doi":"10.1016/j.jcjd.2023.10.325","title":"INTERRUPTIONS IN TRASTUZUMAB THERAPY FOR BREAST CANCER ARE ASSOCIATED WITH ADVERSE CARDIOVASCULAR AND ONCOLOGIC OUTCOMES","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Diabetes","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Medicine; Trastuzumab; Adverse effect; Breast cancer; Oncology; Internal medicine; Cancer; Intensive care medicine","score_opus":0.05743949454727167,"score_gpt":0.33392838100517425,"score_spread":0.2764888864579026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387934295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179924,0.0024340327,0.0000018772171,0.0049566342,0.00013524578,0.0003669761,0.00024780512,0.000009325331,0.000048846494],"genre_scores_gemma":[0.9991306,0.00020210443,0.000025992966,0.00033708877,0.000088085384,0.000059945585,0.0000059640865,0.000024847182,0.00012536286],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989139,0.000069255846,0.0002282891,0.00013146386,0.00022422585,0.00043285618],"domain_scores_gemma":[0.9988748,0.00017217874,0.00009277704,0.000119636265,0.00028295122,0.00045766967],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006710574,0.000113052556,0.0004901367,0.0005137522,0.000071615126,0.000020514071,0.00010106559,0.00007833301,0.00009121652],"category_scores_gemma":[0.00029186433,0.00008123854,0.00017293134,0.00044548756,0.000120521734,0.00007387397,0.000006069252,0.00027034208,0.0000017368769],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018350047,0.000020492475,0.9799557,0.0000365599,0.00070866797,0.00010388907,0.00036018598,0.000139772,0.000031579588,0.000002282176,0.0013701116,0.017252427],"study_design_scores_gemma":[0.0030662154,0.00044623134,0.9925493,0.00056999933,0.00008774345,0.000011773628,0.0008543425,0.00007723934,0.000025020785,0.000034823173,0.0021883883,0.00008893811],"about_ca_topic_score_codex":0.0012298144,"about_ca_topic_score_gemma":0.05351156,"teacher_disagreement_score":0.052281745,"about_ca_system_score_codex":0.00079107133,"about_ca_system_score_gemma":0.0017456867,"threshold_uncertainty_score":0.96375936},"labels":[],"label_agreement":null},{"id":"W4388495210","doi":"10.1136/ijgc-2023-igcs.288","title":"EP206/#943  The spectrum of HER2 expression in endometrial carcinoma","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Immunohistochemistry; Medicine; Internal medicine; Oncology; Serous carcinoma; Serous fluid; Endometrial cancer; Trastuzumab; Carcinoma; Cancer; Breast cancer; Ovarian cancer","score_opus":0.08222163464780835,"score_gpt":0.4235963263892816,"score_spread":0.3413746917414732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388495210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793894,0.00069576025,0.00003300101,0.016031373,0.0019649405,0.000223464,0.000020125211,0.000010131952,0.0016317645],"genre_scores_gemma":[0.9969488,0.0009891695,0.00010277178,0.00036911978,0.0011360068,0.0000245829,0.000002722507,0.0000115468,0.00041532423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975221,0.00014957417,0.0006511036,0.0001462954,0.0012758289,0.00025510218],"domain_scores_gemma":[0.99790037,0.0011306984,0.0003058277,0.00013297371,0.00042075137,0.00010939353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012306559,0.000101689024,0.0003493639,0.00050039456,0.000026131464,0.000020159452,0.00054572365,0.000102640915,0.003461961],"category_scores_gemma":[0.0022890836,0.000057460984,0.00019853593,0.00061509176,0.00014493159,0.00007656994,0.00016349243,0.0005948849,0.000026323465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004545313,0.0005260396,0.8857705,0.00005962554,0.0002577788,0.0026469808,0.0005541666,0.00091193203,0.03842904,0.0004636897,0.026253704,0.03958124],"study_design_scores_gemma":[0.004490337,0.0010327619,0.9407371,0.0002609705,0.000023822604,0.00012900177,0.0002382023,0.00024972446,0.02759463,0.0014043271,0.023750266,0.00008881269],"about_ca_topic_score_codex":0.00016048731,"about_ca_topic_score_gemma":0.00011115134,"teacher_disagreement_score":0.054966655,"about_ca_system_score_codex":0.00057162275,"about_ca_system_score_gemma":0.00047142938,"threshold_uncertainty_score":0.997449},"labels":[],"label_agreement":null},{"id":"W4388498898","doi":"10.1007/s11912-023-01469-3","title":"Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan","year":2023,"lang":"en","type":"review","venue":"Current Oncology Reports","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"NOSM University; Health Sciences North","funders":"","keywords":"Medicine; Trastuzumab; Breast cancer; Oncology; Cancer; Lung cancer; Vinorelbine; Clinical trial; Chemotherapy; Immunotherapy; Antibody-drug conjugate; Biomarker; Internal medicine; Antibody; Immunology; Monoclonal antibody","score_opus":0.8062497559473588,"score_gpt":0.575193570234524,"score_spread":0.23105618571283482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388498898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000025401772,0.99332565,0.000046242625,0.0006475981,0.0019691985,0.0031054858,0.000064373984,0.000096895936,0.000719127],"genre_scores_gemma":[0.00003237865,0.9967212,0.000086853775,0.000013074503,0.00031626257,0.00177167,0.00047339755,0.000099849574,0.00048531158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968545,0.0002504694,0.0014219668,0.0007058378,0.00032691992,0.00044032652],"domain_scores_gemma":[0.99660325,0.0011969774,0.001055793,0.0005419257,0.0003606834,0.00024137877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012297865,0.00037598514,0.0028306362,0.0006050565,0.000071181996,0.0000061066794,0.00011157333,0.00059610145,0.0000487078],"category_scores_gemma":[0.0019801315,0.00032297126,0.0003346032,0.00020272325,0.0004903321,0.000029839304,0.00012947258,0.00048329448,0.0000042816014],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015372128,0.00020566517,0.000019808946,0.12284972,0.00019871996,0.00066192495,0.00018526208,4.3187327e-8,1.5911516e-7,0.0001778912,0.0042241365,0.87146133],"study_design_scores_gemma":[0.0003148162,0.0011282836,0.00004133347,0.017693188,0.0017798119,0.0034094108,0.00014443572,0.0000040771406,9.803309e-7,0.00028870624,0.97502065,0.00017432483],"about_ca_topic_score_codex":0.000008066104,"about_ca_topic_score_gemma":0.00003927787,"teacher_disagreement_score":0.9707965,"about_ca_system_score_codex":0.0006619867,"about_ca_system_score_gemma":0.0047562867,"threshold_uncertainty_score":0.9999222},"labels":[],"label_agreement":null},{"id":"W4388796117","doi":"10.1080/14712598.2023.2285996","title":"The endosomal-lysosomal system in ADC design and cancer therapy","year":2023,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research","keywords":"Endosome; Rab; Transferrin receptor; Epidermal growth factor receptor; Computational biology; Cancer; Cancer research; Medicine; GTPase; Biology; Transferrin; Cell biology; Biochemistry; Internal medicine; Intracellular","score_opus":0.4938790619789927,"score_gpt":0.5135073950707947,"score_spread":0.019628333091802008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388796117","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040443578,0.9929979,0.000016479413,0.000878068,0.0011252522,0.004338571,0.000024875675,0.00024276129,0.00033567156],"genre_scores_gemma":[0.000048090493,0.9927924,0.000087345994,0.00051099254,0.0013731999,0.004876543,0.00004655016,0.00011855216,0.00014630084],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99496037,0.0017986381,0.00086285133,0.0009900889,0.0005767222,0.0008113034],"domain_scores_gemma":[0.9961557,0.0025600935,0.00022772222,0.00072978844,0.00007312344,0.00025358863],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014866347,0.0006799805,0.0019608333,0.00024347914,0.00024457264,0.00009052467,0.0005693337,0.00081601675,0.00015154149],"category_scores_gemma":[0.00015020052,0.00030782763,0.00041970698,0.00070704264,0.0003488702,0.000026609096,0.000106124484,0.0010748382,0.00013734763],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006940017,0.00010126947,0.000035118876,0.0003060949,0.0002027732,0.000052768708,0.00008324095,5.230285e-7,0.000022792978,0.0005791196,0.0023275209,0.9955948],"study_design_scores_gemma":[0.0013976743,0.0016812158,0.00010658977,0.010801955,0.0000011614484,0.00005192365,0.00007610505,0.00002443667,0.000027701779,0.000031196985,0.98546433,0.00033569543],"about_ca_topic_score_codex":0.00014038573,"about_ca_topic_score_gemma":0.0000021451604,"teacher_disagreement_score":0.9952591,"about_ca_system_score_codex":0.0005699676,"about_ca_system_score_gemma":0.00049076165,"threshold_uncertainty_score":0.99993736},"labels":[],"label_agreement":null},{"id":"W4389020371","doi":"10.1096/fasebj.31.1_supplement.775.2","title":"Targeting Cancer Progression Genes Upregulated in CREB3L1‐Deficient Breast Cancer Cells","year":2017,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"Breast cancer; Cancer research; Downregulation and upregulation; Microarray analysis techniques; Cancer; Metastasis; Carcinogenesis; Gene; Cancer cell; Biology; Gene expression; Medicine; Internal medicine; Genetics","score_opus":0.04526489795576984,"score_gpt":0.3945698354451919,"score_spread":0.3493049374894221,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389020371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806783,0.00691064,0.00002245758,0.0102752885,0.0009213411,0.0004589969,0.000037075177,0.000022314365,0.0006735713],"genre_scores_gemma":[0.99375975,0.003664863,0.00014070609,0.00018332902,0.0011916822,0.000053535347,0.0000021098874,0.000040297782,0.00096371834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977415,0.00015664747,0.00037706987,0.00024327164,0.0008321832,0.0006492865],"domain_scores_gemma":[0.9985806,0.000041157396,0.00031720108,0.00051823194,0.00027347452,0.00026934646],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013295226,0.00018052002,0.00028970971,0.00012065277,0.00084481825,0.0002353873,0.0005602956,0.000096716125,0.00173803],"category_scores_gemma":[0.00006731434,0.00010618209,0.000096891185,0.00014458223,0.00025015173,0.00014066367,0.00018556922,0.0009269855,0.00003352306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000530718,0.00013290209,0.15379708,0.00008897807,0.00006956545,0.00030045467,0.0007266078,0.0015007588,0.7278498,0.000004765434,0.00510393,0.10989447],"study_design_scores_gemma":[0.0048297113,0.00023460065,0.33247882,0.0045934897,0.00015668175,0.0011070626,0.00066845835,0.012813777,0.6361066,0.00008240531,0.006457805,0.000470592],"about_ca_topic_score_codex":0.0014215519,"about_ca_topic_score_gemma":0.00014514,"teacher_disagreement_score":0.17868175,"about_ca_system_score_codex":0.00052880845,"about_ca_system_score_gemma":0.00074151246,"threshold_uncertainty_score":0.99917454},"labels":[],"label_agreement":null},{"id":"W4389203459","doi":"10.3390/curroncol30120743","title":"Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab emtansine; Trastuzumab; Breast cancer; Antibody-drug conjugate; Adverse effect; Clinical trial; Pertuzumab; Oncology; Cancer; Metastatic breast cancer; Human Epidermal Growth Factor Receptor 2; Internal medicine; Immunology; Antibody; Monoclonal antibody","score_opus":0.23401407147636205,"score_gpt":0.49557800240253663,"score_spread":0.2615639309261746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389203459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727059,0.0055191587,0.0000031743073,0.0170693,0.0031871302,0.0004339847,0.000051006584,0.00020227344,0.0008280585],"genre_scores_gemma":[0.9678739,0.028212091,0.00004070658,0.00018550373,0.002867999,0.00048472124,0.00009486592,0.000050795774,0.00018945729],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99805105,0.00015113111,0.00033769506,0.00042109317,0.0003493705,0.0006896686],"domain_scores_gemma":[0.9991653,0.00015206441,0.00006459136,0.00027067057,0.00013634277,0.00021104192],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006344663,0.00017646553,0.00046382478,0.00041911568,0.00007407039,0.000016712698,0.00018924697,0.00010549542,0.00036107004],"category_scores_gemma":[0.0000654843,0.00015924926,0.00007205645,0.00087858643,0.00012530248,0.00011589849,0.00015830321,0.0007756172,0.00024841257],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021344399,0.00017370135,0.6389731,0.0007286856,0.000042893233,0.0005544359,0.00418663,0.0000776303,0.014363025,0.00024233418,0.018575765,0.32186833],"study_design_scores_gemma":[0.004435367,0.00031036482,0.36989307,0.002206468,0.00007003638,0.00027271832,0.012215375,0.003045882,0.0040498977,0.0002622799,0.6027434,0.00049515057],"about_ca_topic_score_codex":0.00036105452,"about_ca_topic_score_gemma":0.00061149517,"teacher_disagreement_score":0.5841676,"about_ca_system_score_codex":0.0013984756,"about_ca_system_score_gemma":0.0011265838,"threshold_uncertainty_score":0.64939964},"labels":[],"label_agreement":null},{"id":"W4389227449","doi":"10.1158/1535-7163.targ-23-ia003","title":"Abstract IA003: Refining our understanding of ADCs: Drug development insights from 40 years of data","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Magic bullet; Medicine; Drug; Linker; Pharmacology; Computational biology; Computer science; Bioinformatics; Biology","score_opus":0.2877227097958665,"score_gpt":0.4243710880456244,"score_spread":0.1366483782497579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901151,0.0060378374,0.001004832,0.0010538124,0.00030373674,0.0002818237,0.00015466507,0.00007999422,0.0009681894],"genre_scores_gemma":[0.99611074,0.0010395864,0.0020377047,0.00032662915,0.00006870446,0.000018322968,0.00018003969,0.00006732268,0.00015097561],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978875,0.000056757966,0.0004606581,0.00039372267,0.0008814063,0.0003199467],"domain_scores_gemma":[0.99863225,0.00008544927,0.00016821783,0.00090014224,0.00010894522,0.000105021296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035020342,0.00016000734,0.00038012085,0.00022678205,0.000044500564,0.000014412632,0.00047130464,0.00010224007,0.00006129438],"category_scores_gemma":[0.0000309809,0.0001611246,0.00006273716,0.0006178939,0.000089951915,0.00006886126,0.0002597878,0.00029848222,0.000023588023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079683185,0.00027693703,0.00760868,0.0010927368,0.0028696163,0.00063340703,0.014717038,0.00056809647,0.7672162,0.00050473225,0.0024973452,0.20121835],"study_design_scores_gemma":[0.0066019096,0.00029489884,0.090419516,0.0050244993,0.00072446954,0.000007740806,0.01782934,0.0032368156,0.67577326,0.0020866033,0.19686203,0.0011389337],"about_ca_topic_score_codex":0.0005395096,"about_ca_topic_score_gemma":0.00021377477,"teacher_disagreement_score":0.20007941,"about_ca_system_score_codex":0.00037884028,"about_ca_system_score_gemma":0.0009457488,"threshold_uncertainty_score":0.65704703},"labels":[],"label_agreement":null},{"id":"W4389306890","doi":"10.1097/coc.0000000000001068","title":"Long-term Survival Among Patients With De Novo Human Epidermal Growth Receptor 2–Positive Metastatic Breast Cancer in Manitoba","year":2023,"lang":"en","type":"article","venue":"American Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"George & Fay Yee Centre for Healthcare Innovation; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Metastatic breast cancer; Internal medicine; Univariate analysis; Odds ratio; Cohort; Proportional hazards model; Oncology; Breast cancer; Cancer; Survival analysis; Multivariate analysis","score_opus":0.09528721805467023,"score_gpt":0.48239477823000837,"score_spread":0.38710756017533815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389306890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931394,0.000025830108,0.000055440425,0.0053835227,0.0005116691,0.00036909332,0.000059853952,0.000019336918,0.00043586444],"genre_scores_gemma":[0.99711573,0.00034929853,0.00066117593,0.000926799,0.0007693311,0.000028636441,0.00001637743,0.000055817363,0.000076818316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947071,0.0016781988,0.0017346352,0.00034338623,0.00080735894,0.00072929304],"domain_scores_gemma":[0.9944893,0.002496644,0.0012188347,0.00021639295,0.00085832557,0.0007205118],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034546475,0.00022147482,0.0017547576,0.0004035431,0.000063630134,0.000016013979,0.00033112007,0.00011718407,0.0005121917],"category_scores_gemma":[0.001059059,0.00016388805,0.00026036246,0.0009730757,0.0014600814,0.00014720597,0.00010492913,0.0016320851,0.000039618255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003317818,0.0009760643,0.8630997,0.000040161958,0.00043570952,0.0021623094,0.00018619979,0.000016878948,0.00003135393,0.000009539961,0.00040247265,0.1293218],"study_design_scores_gemma":[0.006822547,0.011020321,0.98058236,0.00036896407,0.00020835789,0.00020819294,0.00046073654,0.000012801955,0.000024286179,0.000024181525,0.00010802532,0.00015923574],"about_ca_topic_score_codex":0.0016141617,"about_ca_topic_score_gemma":0.003661747,"teacher_disagreement_score":0.12916256,"about_ca_system_score_codex":0.0008763781,"about_ca_system_score_gemma":0.0020825912,"threshold_uncertainty_score":0.7090688},"labels":[],"label_agreement":null},{"id":"W4389516076","doi":"10.1096/fj.202301209r","title":"Different <scp>EGF</scp> ‐induced receptor dimer conformations for signaling and internalization","year":2023,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Région Occitanie Pyrénées-Méditerranée; Laboratoire d'Excellence MAbImprove; Centre National de la Recherche Scientifique; Ligue Contre le Cancer; Institute of Genetics; Fondation pour la Recherche Médicale; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"Internalization; Erlotinib; Chemistry; Dimer; Epidermal growth factor receptor; Signal transduction; Tyrosine kinase; Epidermal growth factor; Cell biology; Receptor; Gefitinib; Cancer research; Biochemistry; Biology","score_opus":0.08137704500790463,"score_gpt":0.3611804125892828,"score_spread":0.27980336758137814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389516076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094194,0.00013461495,0.0056285025,0.0018481526,0.00041668274,0.00046696543,0.0000178313,0.00004583017,0.00049948896],"genre_scores_gemma":[0.99640214,0.00027901336,0.00010852105,0.00030455797,0.00058708334,0.000043401884,0.00003395599,0.0000255861,0.0022157524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885994,0.0000801125,0.00028678667,0.00009715445,0.00037987725,0.00029610383],"domain_scores_gemma":[0.99893504,0.0004349012,0.00011049372,0.0001377256,0.00019353477,0.00018829643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081356545,0.000101419304,0.00016416649,0.0001699618,0.00031370923,0.00011890576,0.0001303039,0.00005338922,0.00015040404],"category_scores_gemma":[0.00055997085,0.00006269331,0.00007754051,0.00020072925,0.000052850017,0.000100887846,0.00005303229,0.0003775058,0.00007081948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010155496,0.000057209272,0.008016029,0.00018683326,0.00025867668,0.000012250456,0.006386849,0.00009003351,0.92845154,0.000619014,0.041856248,0.013963764],"study_design_scores_gemma":[0.006685264,0.0015059833,0.016869847,0.0013867256,0.00034758222,0.00070330006,0.00955597,0.02925115,0.8893106,0.0028971585,0.041279,0.00020739842],"about_ca_topic_score_codex":0.000009166708,"about_ca_topic_score_gemma":0.0000034682812,"teacher_disagreement_score":0.039140917,"about_ca_system_score_codex":0.00010175215,"about_ca_system_score_gemma":0.000108671185,"threshold_uncertainty_score":0.2556559},"labels":[],"label_agreement":null},{"id":"W4389555553","doi":"10.30683/1929-2279.2023.12.9","title":"A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting","year":2023,"lang":"en","type":"article","venue":"Journal of cancer research updates","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Trastuzumab emtansine; Trastuzumab; Medicine; Metastatic breast cancer; Oncology; Breast cancer; Internal medicine; Cancer; Disease; Population; Human Epidermal Growth Factor Receptor 2; Lapatinib","score_opus":0.08048723051552804,"score_gpt":0.4850504688383424,"score_spread":0.4045632383228144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389555553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950926,0.0025873305,0.0000054324764,0.04483203,0.00026770166,0.0010547041,0.00012752424,0.000047490834,0.00015177345],"genre_scores_gemma":[0.9934058,0.003706208,0.00027356186,0.00019126183,0.00082512473,0.00037506432,0.00000999824,0.000108537126,0.0011044019],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99262255,0.0010075734,0.001101051,0.0006151022,0.0033037364,0.0013499979],"domain_scores_gemma":[0.99486744,0.0011485167,0.00043618112,0.0006429033,0.002265852,0.0006391154],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.010762078,0.00031114626,0.000764509,0.0019353079,0.00023557416,0.000106099,0.00037938068,0.00013845216,0.0004350376],"category_scores_gemma":[0.002314966,0.00022211368,0.00013863109,0.0034221585,0.00038698583,0.00033094513,0.0001423977,0.0028696847,0.000030968127],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11190576,0.0005891594,0.06274765,0.0007707551,0.00034773382,0.7066839,0.0017161646,0.0010755602,0.010381058,0.000014755917,0.026857007,0.07691053],"study_design_scores_gemma":[0.02086079,0.016203756,0.44970647,0.025678286,0.00022082917,0.38220808,0.005331861,0.0020526983,0.02540032,0.00030139284,0.07086497,0.0011705615],"about_ca_topic_score_codex":0.0007481824,"about_ca_topic_score_gemma":0.0029904225,"teacher_disagreement_score":0.3869588,"about_ca_system_score_codex":0.0028599312,"about_ca_system_score_gemma":0.0066693146,"threshold_uncertainty_score":0.9994307},"labels":[],"label_agreement":null},{"id":"W4389684245","doi":"10.3389/jpps.2023.12078","title":"Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada","year":2023,"lang":"en","type":"article","venue":"Journal of Pharmacy & Pharmaceutical Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; Ottawa Hospital; Health Sciences Centre; Jewish General Hospital; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire de Sherbrooke; Centre hospitalier universitaire de Québec; Aegera Therapeutics (Canada); Moncton Hospital; Innovation and Economic Development Trois Rivières; Horizon Health Network; Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Dr. Georges-L.-Dumont University Hospital Centre; IGNIS Innovation (Canada)","funders":"Université de Montréal; Jewish General Hospital","keywords":"Lapatinib; Metastatic breast cancer; Trastuzumab; Medicine; Cohort; Neratinib; Real world evidence; Breast cancer; Retrospective cohort study; Cancer; Oncology; Internal medicine","score_opus":0.22791909789375314,"score_gpt":0.529580517470613,"score_spread":0.3016614195768598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389684245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856086,0.0004850934,0.00000858179,0.011951164,0.00021155726,0.0003726285,0.001049417,0.0000083409195,0.00030465156],"genre_scores_gemma":[0.98948514,0.00982307,0.000098014716,0.00035496138,0.0001354565,0.000015335258,0.000019259855,0.000013205853,0.00005557475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954962,0.00039281003,0.0010681552,0.00047493086,0.0018789949,0.0006889194],"domain_scores_gemma":[0.9980258,0.0005266572,0.00039869722,0.0002790772,0.00028732617,0.00048244064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028135297,0.00022127978,0.0010681846,0.0016702791,0.00006359986,0.000032595577,0.0007325142,0.000014829762,0.0007594501],"category_scores_gemma":[0.00013920956,0.00015735936,0.00015945631,0.009082677,0.00036003222,0.00031984673,0.00019692267,0.0005824983,0.0000028815516],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005659749,0.00040017813,0.959451,0.00006633969,0.00087967963,0.0013545925,0.0003239983,0.0018497973,0.0015358051,0.0000146639595,0.00031935837,0.033238616],"study_design_scores_gemma":[0.0029995162,0.00029687455,0.8816259,0.00027277853,0.0013076818,0.0000538335,0.0007032106,0.10621814,0.005380937,0.000015461548,0.0009796266,0.00014606389],"about_ca_topic_score_codex":0.8725314,"about_ca_topic_score_gemma":0.9306452,"teacher_disagreement_score":0.10436834,"about_ca_system_score_codex":0.0036111535,"about_ca_system_score_gemma":0.0055074673,"threshold_uncertainty_score":0.977001},"labels":[],"label_agreement":null},{"id":"W4389858628","doi":"10.1093/ajcp/aqad167","title":"<i>HER2/ERBB2</i> copy number analysis by targeted next-generation sequencing in breast cancer","year":2023,"lang":"en","type":"article","venue":"American Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"National Cancer Institute; Gilead Sciences; Eisai; National Comprehensive Cancer Network; Daiichi Sankyo Europe; Sanofi; Pfizer; Genentech; Dana-Farber/Harvard Cancer Center; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Breast cancer; Fluorescence in situ hybridization; Oncology; Immunohistochemistry; Internal medicine; Medicine; Fish <Actinopterygii>; Clinical Oncology; Copy-number variation; Cancer; Pathology; Biology; Genetics; Gene; Genome","score_opus":0.15449250155855102,"score_gpt":0.4836317958463231,"score_spread":0.3291392942877721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389858628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98761666,0.00020180926,0.000361603,0.010833121,0.0004953363,0.00013192461,0.00005537815,0.000027813747,0.00027636797],"genre_scores_gemma":[0.99125886,0.0029164373,0.0010330187,0.003530345,0.0009499044,0.00001607533,0.000035986584,0.000036260197,0.00022310353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954429,0.0011251708,0.0018624895,0.00039623896,0.0006327132,0.000540432],"domain_scores_gemma":[0.9971692,0.0007169555,0.0008687893,0.00033284782,0.0004817069,0.0004304915],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039222077,0.00018203708,0.0015236015,0.00046389922,0.000047069505,0.000023117605,0.00024987443,0.00017105759,0.00094623177],"category_scores_gemma":[0.00094384555,0.00015143336,0.00047294682,0.0031902248,0.0006342551,0.00012736562,0.00006266041,0.0012442452,0.00010665791],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050164806,0.00011754127,0.9000938,0.00001384855,0.00042285176,0.00146603,0.0001995522,0.00054636644,0.017543908,0.000004620092,0.022827284,0.056262556],"study_design_scores_gemma":[0.004505439,0.0023994232,0.9715831,0.00019703884,0.0011318407,0.0015641542,0.0014260978,0.0077776117,0.0014045286,0.000107414286,0.0074412427,0.0004620544],"about_ca_topic_score_codex":0.0010758777,"about_ca_topic_score_gemma":0.00026852827,"teacher_disagreement_score":0.071489364,"about_ca_system_score_codex":0.0003927412,"about_ca_system_score_gemma":0.0012345017,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W4389924284","doi":"10.3390/curroncol30120763","title":"Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"McMaster University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Clinical trial; Stage (stratigraphy); Hormonal therapy; Adjuvant therapy; Internal medicine; Cancer; Oncology; Family medicine","score_opus":0.08536906940342316,"score_gpt":0.45939691896454926,"score_spread":0.3740278495611261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389924284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864065,0.00040333625,0.00007687853,0.007910909,0.000552368,0.0024839586,0.0009412837,0.00005205526,0.0011727137],"genre_scores_gemma":[0.99700093,0.0011530126,0.000026257041,0.0002186657,0.0004212657,0.00077714643,0.00010729624,0.000039624214,0.00025579229],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985922,0.00012659232,0.00021544565,0.00032521703,0.0003562651,0.00038429134],"domain_scores_gemma":[0.9982147,0.00025304552,0.0001227623,0.00028296025,0.0010357705,0.00009076325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018501541,0.0001576538,0.00036082027,0.00012044886,0.00014816297,0.000012843774,0.00016705514,0.0000731928,0.00011769051],"category_scores_gemma":[0.000033424727,0.00009843184,0.000104498504,0.0005400653,0.000354661,0.000064737185,0.000046286164,0.00030415584,0.000022649278],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026075416,0.003116209,0.76364267,0.00016945417,0.0007054047,0.000012289977,0.011675253,0.000033775512,0.0004876908,0.001459556,0.029693734,0.18639645],"study_design_scores_gemma":[0.0030747494,0.0022674424,0.95775896,0.00014494239,0.00007346915,0.0000023328018,0.0018454735,0.00016555916,0.00040545457,0.000085844214,0.034050636,0.00012513342],"about_ca_topic_score_codex":0.00047194766,"about_ca_topic_score_gemma":0.0002672135,"teacher_disagreement_score":0.19411632,"about_ca_system_score_codex":0.00048909354,"about_ca_system_score_gemma":0.00063510926,"threshold_uncertainty_score":0.40139338},"labels":[],"label_agreement":null},{"id":"W4390233924","doi":"10.1016/j.jtho.2023.12.019","title":"Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC","year":2023,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Brigham and Women's Hospital","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.1175471607756235,"score_gpt":0.4995437960313276,"score_spread":0.3819966352557041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390233924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908494,0.0017041797,0.00023852568,0.0064179064,0.00024069232,0.00020192648,0.0000044525236,0.000008779069,0.00033418843],"genre_scores_gemma":[0.99573374,0.0011578588,0.002381397,0.00012655671,0.00017677846,0.0000068153176,0.0000013789813,0.000013462715,0.00040203342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984749,0.00026922446,0.0005692209,0.00012569485,0.00034487018,0.00021609287],"domain_scores_gemma":[0.998707,0.00043941342,0.00035433492,0.0001358391,0.00026585712,0.000097566786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025857938,0.00007333527,0.00037720904,0.00039658343,0.000023990728,0.000005776755,0.00013670178,0.00011997427,0.00008841545],"category_scores_gemma":[0.00057396386,0.000059166865,0.00004670106,0.00045248045,0.00011889488,0.00005459976,0.000048577003,0.0004503523,0.000012778438],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022177557,0.00036378021,0.19252247,0.0015515883,0.0001157937,0.00036397303,0.0020200484,0.00009482312,0.12095847,0.00020761267,0.002808324,0.67677534],"study_design_scores_gemma":[0.0010035242,0.0019490313,0.97917503,0.00067311176,0.0000975778,0.0003628668,0.0005820303,0.00044817076,0.008912178,0.0017063227,0.005002045,0.00008810234],"about_ca_topic_score_codex":0.00003133106,"about_ca_topic_score_gemma":0.0000102761505,"teacher_disagreement_score":0.78665257,"about_ca_system_score_codex":0.00023612202,"about_ca_system_score_gemma":0.00049962563,"threshold_uncertainty_score":0.24127547},"labels":[],"label_agreement":null},{"id":"W4391229921","doi":"10.3390/cancers16030518","title":"Treatment Patterns and Health Outcomes among Patients with HER2 IHC0/-Low Metastatic or Recurrent Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cancers","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary","funders":"AstraZeneca Canada","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Oncology; Internal medicine; Cancer","score_opus":0.06547864330049104,"score_gpt":0.41366605153146385,"score_spread":0.34818740823097283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391229921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880873,0.0024933286,0.00004333872,0.005832138,0.0006838507,0.001602222,0.0009976414,0.0001181267,0.00014203302],"genre_scores_gemma":[0.9935471,0.0032265184,0.00009696261,0.00061491545,0.00013248998,0.0006193681,0.00006331038,0.00007281285,0.0016265619],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99808127,0.000057086258,0.0002727147,0.0005227247,0.0005306007,0.00053563365],"domain_scores_gemma":[0.99901366,0.00006321941,0.00006135113,0.00029927018,0.000092003145,0.00047051982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012583521,0.00027902264,0.0005062723,0.00014803838,0.00008530978,0.00006939019,0.00007541128,0.000036375426,0.0008139938],"category_scores_gemma":[0.000009364492,0.0001601058,0.00006856332,0.0002971928,0.00013378776,0.00010587424,0.000031395502,0.00021997694,0.0000142839945],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003013642,0.000066705914,0.78123355,0.001154567,0.00043580163,0.000104904706,0.000943316,0.000025464162,6.2707073e-7,0.000006847735,0.0026922787,0.21303459],"study_design_scores_gemma":[0.0029997607,0.0019413254,0.9836624,0.0022919825,0.00017590413,0.000027225005,0.00032153988,0.0006493566,0.000026732245,0.0000039808747,0.007673733,0.0002260077],"about_ca_topic_score_codex":0.026408302,"about_ca_topic_score_gemma":0.015549329,"teacher_disagreement_score":0.21280858,"about_ca_system_score_codex":0.0066688373,"about_ca_system_score_gemma":0.003179243,"threshold_uncertainty_score":0.9971444},"labels":[],"label_agreement":null},{"id":"W4391430175","doi":"10.1172/jci176454","title":"HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Eisai; Knight Cancer Institute, Oregon Health and Science University; G1 Therapeutics; MacroGenics; Puma Biotechnology; Incyte; National Cancer Institute; Natera; Genomic Health; Daiichi Sankyo Europe; Sanofi; Oregon Health and Science University; Gilead Sciences; University of Texas Southwestern Medical Center; Amgen; Pfizer; Susan G. Komen for the Cure; AstraZeneca; Eli Lilly and Company","keywords":"Breast cancer; Trastuzumab; Medicine; Pertuzumab; Lapatinib; Oncology; Internal medicine; KRAS; Neoadjuvant therapy; ErbB; Cancer research; Cancer; Colorectal cancer","score_opus":0.25934820909865275,"score_gpt":0.5403783004386817,"score_spread":0.281030091340029,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391430175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95783967,0.0009855087,0.0000035328744,0.039251953,0.00095297204,0.0008623131,0.000044842196,0.000011551599,0.000047630278],"genre_scores_gemma":[0.99439454,0.0023041563,0.00013611685,0.001090894,0.0019019662,0.00005227523,0.000007296697,0.000021801276,0.00009093874],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923057,0.0041119712,0.002311567,0.00032213135,0.00068651774,0.0002621066],"domain_scores_gemma":[0.99417984,0.004580426,0.0004475474,0.00019391668,0.00024109652,0.00035714108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015737036,0.00016736545,0.000771936,0.00022018525,0.00004079983,0.0000890507,0.00014247485,0.00033089353,0.000048483675],"category_scores_gemma":[0.0065240236,0.00010001372,0.0003106065,0.00052764564,0.00045711952,0.0001688051,0.00003224652,0.0013521174,0.0000069170205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07342274,0.0013367034,0.84551316,0.000066206696,0.00035684236,0.0008786658,0.0011785028,0.000019086203,0.00031130182,0.000048608366,0.0022145947,0.074653566],"study_design_scores_gemma":[0.021574613,0.005534036,0.9680168,0.001486914,0.00013902098,0.00012732176,0.00016831033,0.0008537507,0.00020268603,0.0003855653,0.0014155618,0.00009542706],"about_ca_topic_score_codex":0.00034713297,"about_ca_topic_score_gemma":0.0010351782,"teacher_disagreement_score":0.12250361,"about_ca_system_score_codex":0.00051715865,"about_ca_system_score_gemma":0.0025399677,"threshold_uncertainty_score":0.7810337},"labels":[],"label_agreement":null},{"id":"W4391486548","doi":"10.1158/1078-0432.ccr-23-3414","title":"Antibody–Drug Conjugates: Advancing from Magic Bullet to Biological Missile","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Magic bullet; Drug; Conjugate; Missile; Medicine; Antibody-drug conjugate; Virology; Antibody; Pharmacology; Immunology; Biology; Engineering; Monoclonal antibody; Bioinformatics","score_opus":0.39801736688730605,"score_gpt":0.6481958773268562,"score_spread":0.2501785104395502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391486548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8744975,0.032761615,0.000345655,0.073633485,0.0024516112,0.0021918325,0.0004098124,0.00044354473,0.013264971],"genre_scores_gemma":[0.9550888,0.014495746,0.0018437208,0.004568854,0.0062599634,0.0004469438,0.00020319354,0.00016108959,0.016931698],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927588,0.001033857,0.0010426643,0.0016420546,0.0018871696,0.0016354729],"domain_scores_gemma":[0.99166334,0.0047982363,0.000038807702,0.0010284049,0.00071544887,0.0017557767],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.007553097,0.00030017365,0.0008630058,0.0004337872,0.0002008316,0.0002496694,0.00074146804,0.00034008356,0.01824127],"category_scores_gemma":[0.005499321,0.0002245801,0.00034855027,0.0015921838,0.00089736376,0.00009564758,0.00071709853,0.0035439413,0.007584492],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002692209,0.0005641281,0.10268682,0.00078346336,0.00035856635,0.0031503278,0.0006826918,0.000013856761,0.046910387,0.00035453023,0.7231647,0.11863832],"study_design_scores_gemma":[0.0011771822,0.0013342575,0.017452678,0.0022927453,0.000035824072,0.000018816609,0.0003892279,0.0008110654,0.0032823458,0.0014997991,0.9713779,0.00032812494],"about_ca_topic_score_codex":0.0035267926,"about_ca_topic_score_gemma":0.00025997023,"teacher_disagreement_score":0.24821323,"about_ca_system_score_codex":0.0006980226,"about_ca_system_score_gemma":0.002497063,"threshold_uncertainty_score":0.9987549},"labels":[],"label_agreement":null},{"id":"W4391532335","doi":"10.26226/morressier.5c8f909bb5d368000a26b3a0","title":"1357 - Short Link N Acts as a Disease Modifying Osteoarthritis Drug","year":2019,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Link (geometry); Osteoarthritis; Drug; Disease; Medicine; Internal medicine; Pharmacology; Computer science; Alternative medicine; Computer network; Pathology","score_opus":0.06437922146239913,"score_gpt":0.3887170902338482,"score_spread":0.3243378687714491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391532335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48571223,0.012556039,0.00046205742,0.034589086,0.0037647025,0.008821979,0.00042542574,0.000954124,0.45271435],"genre_scores_gemma":[0.93863744,0.0016658951,0.000776763,0.0017780117,0.0017184963,0.00047197854,0.0004827117,0.00016994361,0.054298736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99558854,0.00014023381,0.0005500863,0.0012377691,0.0016162879,0.00086707255],"domain_scores_gemma":[0.99589944,0.00017210873,0.000077808574,0.002187609,0.00036256821,0.0013004962],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00062570634,0.0005042734,0.00087656104,0.00033240544,0.00008473543,0.00017952739,0.00056164176,0.00043186493,0.004002975],"category_scores_gemma":[0.0006263475,0.00046323022,0.00041559662,0.0001872194,0.00014081005,0.00008662727,0.0017458042,0.0024575987,0.0028507332],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039451276,0.0010136396,0.1079845,0.025482815,0.0011423228,0.010472524,0.003044624,0.0017732807,0.0021675632,0.0020404567,0.17344943,0.6674837],"study_design_scores_gemma":[0.01030126,0.0015391345,0.041293006,0.02758049,0.0013496038,0.00031820693,0.00091342966,0.012174202,0.011121542,0.007361426,0.88163906,0.0044086436],"about_ca_topic_score_codex":0.0008314339,"about_ca_topic_score_gemma":0.00008958298,"teacher_disagreement_score":0.7081896,"about_ca_system_score_codex":0.00056836515,"about_ca_system_score_gemma":0.003497343,"threshold_uncertainty_score":0.9998438},"labels":[],"label_agreement":null},{"id":"W4391805157","doi":"10.1158/1535-7163.mct-23-0822","title":"Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Camptothecin; Drug; Conjugate; Pharmacology; Payload (computing); Antibody; Chemistry; Medicine; Immunology; Biochemistry; Computer science","score_opus":0.12025473286422184,"score_gpt":0.44940770754084514,"score_spread":0.3291529746766233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391805157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56003726,0.12712605,0.30102885,0.0060066176,0.0005342461,0.00464402,0.00013852392,0.00011286193,0.00037156208],"genre_scores_gemma":[0.99108195,0.0018874584,0.0053944644,0.00080885837,0.000101269936,0.00041282145,0.000024540186,0.00008093925,0.00020768092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828565,0.00011667256,0.00025914994,0.00034611352,0.00071226025,0.00028013758],"domain_scores_gemma":[0.9989359,0.00018554584,0.000048689777,0.00028776086,0.0004595486,0.00008258957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013782411,0.000167945,0.00027621366,0.0001409011,0.000043155167,0.000045079512,0.00009573036,0.00008612224,0.00009961308],"category_scores_gemma":[0.00003801166,0.00014257831,0.00008727746,0.00026407995,0.0001347995,0.000040860305,0.000028043154,0.00017012781,0.0000033099188],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025044655,0.00007808248,0.000355349,0.0007118469,0.0005192982,0.000008539226,0.0011269967,0.00053590746,0.89632916,0.00050031324,0.00023672213,0.09934735],"study_design_scores_gemma":[0.0035333028,0.00048713642,0.0004216894,0.0009454735,0.0013587588,0.000027049935,0.0001731471,0.26872447,0.6935044,0.0016707572,0.028873453,0.0002803643],"about_ca_topic_score_codex":0.00013890781,"about_ca_topic_score_gemma":0.000012014919,"teacher_disagreement_score":0.4310447,"about_ca_system_score_codex":0.00020957609,"about_ca_system_score_gemma":0.00088543963,"threshold_uncertainty_score":0.5814175},"labels":[],"label_agreement":null},{"id":"W4391839227","doi":"10.21203/rs.3.rs-3950210/v1","title":"Local Delivery of Accutox® Synergises With Immune-checkpoint Inhibitors at Disrupting Tumor Growth","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Immune system; Cancer research; Immune checkpoint; Medicine; Immunotherapy; Immunology","score_opus":0.06336038282571765,"score_gpt":0.4122147257744266,"score_spread":0.34885434294870893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391839227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9676636,0.015162507,0.00007252333,0.0035895305,0.00039764066,0.0033245103,0.00032922326,0.000270809,0.009189651],"genre_scores_gemma":[0.9931711,0.0014528288,0.00040465896,0.00003963619,0.0007093831,0.00073040475,0.00020004567,0.00030253406,0.0029894032],"study_design_codex":"systematic_review","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9891393,0.0007416066,0.0012669687,0.0016474972,0.0054075085,0.0017970852],"domain_scores_gemma":[0.99321514,0.001088923,0.00025204927,0.0018921224,0.0027426789,0.00080906646],"candidate_categories":["metaepi_narrow","open_science","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0043051983,0.00067095616,0.0013739492,0.0016148613,0.00028568096,0.00019056335,0.00089829805,0.00055132096,0.00083043874],"category_scores_gemma":[0.001571972,0.0005159789,0.00063212955,0.0016234937,0.0017694643,0.00008385216,0.008507673,0.006602257,0.00045853475],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025211768,0.0044886027,0.12001609,0.46018532,0.0067934776,0.049360693,0.013368756,0.0020617459,0.16998231,0.0030602904,0.07806003,0.06741091],"study_design_scores_gemma":[0.005118068,0.008018135,0.02121438,0.12962139,0.0006729622,0.0010897529,0.011886615,0.00702732,0.7949824,0.0029527962,0.01498813,0.0024280935],"about_ca_topic_score_codex":0.005019531,"about_ca_topic_score_gemma":0.0003285453,"teacher_disagreement_score":0.62500006,"about_ca_system_score_codex":0.0033224348,"about_ca_system_score_gemma":0.00516724,"threshold_uncertainty_score":0.99972916},"labels":[],"label_agreement":null},{"id":"W4391962054","doi":"10.1007/s00259-024-06648-3","title":"Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer","year":2024,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"Institute of Cancer Research","keywords":"Trastuzumab; Internalization; Flow cytometry; Monoclonal antibody; Immunoconjugate; Chemistry; In vitro; Medicine; Breast cancer; Pharmacology; Cancer research; Cancer; Antibody; Receptor; Internal medicine; Immunology; Biochemistry","score_opus":0.011050268542110267,"score_gpt":0.3207989335418847,"score_spread":0.30974866499977444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391962054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9097901,0.03446074,0.0012484045,0.029314598,0.0006730737,0.00048092415,0.000022051174,0.00005466997,0.023955453],"genre_scores_gemma":[0.9948764,0.0019311877,0.0001349208,0.0025685588,0.00035273455,0.000001024983,0.00000245872,0.000112519476,0.000020201103],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99770325,0.0006877119,0.00046109426,0.00024990106,0.0006299857,0.00026805946],"domain_scores_gemma":[0.99882126,0.00020524363,0.00013301214,0.00018286852,0.00037207874,0.00028552578],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018085528,0.00020081035,0.00048733415,0.00035614712,0.00005175395,0.000039105886,0.00015739261,0.00002052402,0.00016375957],"category_scores_gemma":[0.00023234871,0.0001450076,0.00014451967,0.00031561157,0.0003610718,0.00010481249,0.00007403775,0.00061362085,0.000018078641],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011166156,0.000100240366,0.0008923643,0.0015995435,0.0005978211,0.021605251,0.00344877,0.000014118556,0.8428063,0.00017536871,0.005260527,0.12238307],"study_design_scores_gemma":[0.036223922,0.015334875,0.2975812,0.26525348,0.0053375573,0.06792612,0.014478317,0.004689557,0.058952585,0.00055441604,0.23157191,0.0020960618],"about_ca_topic_score_codex":0.00006971215,"about_ca_topic_score_gemma":2.5255065e-7,"teacher_disagreement_score":0.7838537,"about_ca_system_score_codex":0.00013286964,"about_ca_system_score_gemma":0.00024167696,"threshold_uncertainty_score":0.5913238},"labels":[],"label_agreement":null},{"id":"W4392210732","doi":"10.2196/54178","title":"Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes","year":2024,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Universität Zürich; Swiss Tumor Institute","keywords":"Biosimilar; Trastuzumab; Medicine; Observational study; Breast cancer; Clinical trial; Human Epidermal Growth Factor Receptor 2; Oncology; Internal medicine; Cancer","score_opus":0.1278437417289211,"score_gpt":0.4706072347069483,"score_spread":0.3427634929780272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392210732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878816,0.0014754013,0.000013682937,0.0022534917,0.00007602638,0.00779009,0.00038324398,0.00002008074,0.00010639083],"genre_scores_gemma":[0.9961058,0.00022459084,0.00008472549,0.000025197842,0.00006354106,0.003246841,0.000038249393,0.00003577786,0.00017526674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970685,0.000101425336,0.0013431036,0.0004619134,0.00071864686,0.00030636718],"domain_scores_gemma":[0.9966087,0.0006855884,0.0012924465,0.0009198085,0.0004636265,0.000029882423],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000914986,0.00020465508,0.0007553838,0.00010019856,0.00008189005,0.00001529708,0.00030552488,0.000052972693,0.000026451651],"category_scores_gemma":[0.000161051,0.00009548671,0.00011613088,0.00083554536,0.00025610707,0.00006382635,0.000060792758,0.00020853936,2.0745407e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012916485,0.0009602349,0.97411674,0.00077301014,0.0009939881,0.000003041757,0.009747616,0.0001342779,0.00077448826,0.00005939657,0.00040796673,0.010737581],"study_design_scores_gemma":[0.0022338948,0.0019400071,0.98117286,0.0009469166,0.0005214148,0.0000077081095,0.0053477967,0.0032628973,0.0035198736,0.000038107584,0.0009118949,0.00009665307],"about_ca_topic_score_codex":0.008419657,"about_ca_topic_score_gemma":0.019657483,"teacher_disagreement_score":0.011237826,"about_ca_system_score_codex":0.0006745557,"about_ca_system_score_gemma":0.0014554899,"threshold_uncertainty_score":0.99823123},"labels":[],"label_agreement":null},{"id":"W4392433377","doi":"10.1016/j.jddst.2024.105519","title":"Intratumoral implantable drug delivery system for targeted localized chemotherapy in breast cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Drug Delivery Science and Technology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Drug delivery; Breast cancer; Drug; Medicine; Chemotherapy; Targeted drug delivery; Oncology; Internal medicine; Pharmacology; Cancer; Nanotechnology; Materials science","score_opus":0.011216440701605738,"score_gpt":0.30694541351492505,"score_spread":0.29572897281331934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392433377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745143,0.010423392,0.000040505896,0.013842756,0.00061534863,0.00036010687,0.000036909696,0.00006710631,0.00009955818],"genre_scores_gemma":[0.99592197,0.0029551175,0.0005559901,0.0002411593,0.00017365723,0.000026674994,9.0508377e-7,0.000019145855,0.00010537727],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979103,0.000026495418,0.0004830626,0.00033557942,0.00060373463,0.0006408125],"domain_scores_gemma":[0.99858963,0.00008366041,0.000119336444,0.00018368203,0.00082262553,0.00020103683],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019518783,0.00015425275,0.00047983284,0.0016005314,0.00012152106,0.000094537005,0.00038845307,0.00011538172,0.000032688105],"category_scores_gemma":[0.00005168995,0.00011584141,0.00006701484,0.0021808748,0.0006979411,0.00039842693,0.0000802054,0.00060050515,0.000004877772],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026609385,0.00030205498,0.06027979,0.0023431077,0.00027338098,0.002095337,0.0013221899,0.00003633953,0.5121058,0.0014357602,0.061095156,0.35605016],"study_design_scores_gemma":[0.020983648,0.0026251525,0.014905953,0.016001543,0.0004894119,0.040947475,0.022735344,0.06323362,0.7056049,0.0037893795,0.10709936,0.0015841846],"about_ca_topic_score_codex":0.0003808148,"about_ca_topic_score_gemma":0.00011121851,"teacher_disagreement_score":0.35446596,"about_ca_system_score_codex":0.00087789365,"about_ca_system_score_gemma":0.0028336253,"threshold_uncertainty_score":0.502673},"labels":[],"label_agreement":null},{"id":"W4392631941","doi":"10.1136/ijgc-2024-esgo.130","title":"85 Lymphovascular invasion in cervical squamous cell carcinoma is associated with mitogen-activated protein kinase (MAP kinase) pathway alterations","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lymphovascular invasion; Medicine; Pathology; MAPK/ERK pathway; Protein kinase A; Internal medicine; Oncology; Cancer; Cancer research; Kinase; Metastasis; Biology; Genetics","score_opus":0.03779154242643258,"score_gpt":0.325780249370875,"score_spread":0.28798870694444245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392631941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854148,0.0028303748,0.00013290883,0.009356676,0.0010133064,0.0005695125,0.00008242183,0.000037710306,0.0005622575],"genre_scores_gemma":[0.9969756,0.000097589334,0.0001992383,0.0009998253,0.00052793766,0.0001315668,0.000034583834,0.000040428313,0.0009932162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966437,0.00023754929,0.00072792184,0.0004025851,0.0015852305,0.00040296733],"domain_scores_gemma":[0.99780285,0.00040090698,0.00021163211,0.00018043297,0.0011106269,0.00029357467],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066613057,0.00024936296,0.0004682132,0.00046493477,0.000061665065,0.00014362717,0.00039662496,0.0002512678,0.0040893424],"category_scores_gemma":[0.00069573725,0.00017287166,0.0002591482,0.00052154774,0.00015109088,0.00023275072,0.00010753319,0.00093762006,0.000040055435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008970362,0.0063566887,0.20744282,0.0010380305,0.0018526978,0.07179301,0.0036353713,0.001891184,0.62103707,0.0009173895,0.022190837,0.05287457],"study_design_scores_gemma":[0.021893252,0.0075450093,0.28577468,0.004175258,0.0003296165,0.00084305555,0.00043733575,0.00611613,0.59788567,0.0012021789,0.072724305,0.0010735386],"about_ca_topic_score_codex":0.00037688419,"about_ca_topic_score_gemma":0.000393583,"teacher_disagreement_score":0.078331865,"about_ca_system_score_codex":0.002934279,"about_ca_system_score_gemma":0.0019406085,"threshold_uncertainty_score":0.99682105},"labels":[],"label_agreement":null},{"id":"W4393041772","doi":"10.3390/curroncol31030124","title":"Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Sunnybrook Health Science Centre; Cancer Care Ontario","funders":"Cancer Care Ontario","keywords":"Medicine; Trastuzumab; Internal medicine; Biosimilar; Breast cancer; Oncology; Hazard ratio; Discontinuation; Retrospective cohort study; Proportional hazards model; Adjuvant; Population; Cancer; Confidence interval","score_opus":0.2116304947401476,"score_gpt":0.5426354668958013,"score_spread":0.3310049721556537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393041772","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757821,0.015393619,0.000733261,0.0024610795,0.00097185455,0.003072349,0.0011818942,0.00003045425,0.000373409],"genre_scores_gemma":[0.9970187,0.0017838994,0.00021818679,0.00002165826,0.00016865518,0.00070705824,0.000021846367,0.000020520925,0.00003945692],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9987401,0.00016380595,0.00031568352,0.0003475271,0.00017114253,0.00026178826],"domain_scores_gemma":[0.9988334,0.00058681227,0.00005145811,0.00015582713,0.00020919976,0.00016327482],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002804832,0.00016305567,0.00083218253,0.00016268269,0.00002887547,0.000004512136,0.00006214126,0.00008422217,0.00021218507],"category_scores_gemma":[0.00002312167,0.0001225178,0.00011238015,0.0002500323,0.00020783782,0.00002344942,0.000035131794,0.000110085675,0.00000511796],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052294475,0.00147332,0.019040968,0.0031357396,0.00042008652,0.000015238456,0.0050463667,0.000038256232,0.016591363,0.000118652955,0.0031289812,0.94576156],"study_design_scores_gemma":[0.0106805125,0.02310875,0.6056214,0.0040129162,0.00069501164,0.00013816147,0.0013885433,0.0016501117,0.04403143,0.00010001767,0.30822822,0.0003448958],"about_ca_topic_score_codex":0.0001036442,"about_ca_topic_score_gemma":0.00016464593,"teacher_disagreement_score":0.9454167,"about_ca_system_score_codex":0.0012102028,"about_ca_system_score_gemma":0.0007981158,"threshold_uncertainty_score":0.49961308},"labels":[],"label_agreement":null},{"id":"W4393042534","doi":"10.14740/wjon1769","title":"The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Erlotinib; Dasatinib; Afatinib; Medicine; Cancer research; Lapatinib; Tyrosine kinase; Growth inhibition; Trastuzumab; Epidermal growth factor receptor; Hepatocyte Growth Factor Receptor; Growth factor receptor; Pharmacology; Cancer; Hepatocyte growth factor; Cell growth; Imatinib; Internal medicine; Biology; Receptor; C-Met; Breast cancer; Myeloid leukemia","score_opus":0.04696844984805061,"score_gpt":0.40109314676017704,"score_spread":0.35412469691212645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393042534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726101,0.0023259444,0.00015507292,0.016767459,0.0007019466,0.00053823384,0.000032434993,0.000010445995,0.0068583703],"genre_scores_gemma":[0.99746484,0.00092960714,0.0004515749,0.00008809383,0.00014169316,0.000017531209,0.0000031345912,0.000019666144,0.0008838755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978296,0.00029223046,0.0009587797,0.00013730575,0.00056639215,0.00021566307],"domain_scores_gemma":[0.9973065,0.0014197839,0.00045050713,0.00014303335,0.0005960635,0.000084091604],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017889728,0.0001031767,0.0004506398,0.0005144076,0.000032971147,0.000011939127,0.00012876959,0.00007239003,0.0001140793],"category_scores_gemma":[0.00039780026,0.000058300848,0.0000670251,0.0009544997,0.00028726985,0.00007697005,0.000023927594,0.0006161601,0.0000022045556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084840566,0.0033881625,0.017520372,0.0054109837,0.0011580435,0.0057893223,0.012244895,0.00091825356,0.51211303,0.009136565,0.059574567,0.28790522],"study_design_scores_gemma":[0.050405428,0.050957587,0.105970286,0.02460993,0.001070228,0.0012038647,0.0031691156,0.004272181,0.63938653,0.0038591141,0.11445292,0.00064281607],"about_ca_topic_score_codex":0.00031781517,"about_ca_topic_score_gemma":0.0040884325,"teacher_disagreement_score":0.2872624,"about_ca_system_score_codex":0.0005230309,"about_ca_system_score_gemma":0.0018766869,"threshold_uncertainty_score":0.3329162},"labels":[],"label_agreement":null},{"id":"W4393073328","doi":"10.1158/1538-7445.am2024-6599","title":"Abstract 6599: 3D genomic analysis reveals novel enhancer hijacking mechanisms caused by complex structural alterations that drive oncogene overexpression","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Enhancer; Oncogene; Biology; Cancer research; Cell biology; Cancer; Genetics; Computational biology; Gene; Gene expression","score_opus":0.18460482854299134,"score_gpt":0.48257775260103336,"score_spread":0.297972924058042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393073328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770799,0.006520024,0.0058277096,0.003678541,0.0005036017,0.0020278615,0.0015397537,0.00023672332,0.0025858863],"genre_scores_gemma":[0.99104595,0.0014692924,0.0013910955,0.00026957618,0.0007652671,0.00061535643,0.0005443478,0.0001384517,0.003760679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937379,0.00025636322,0.00063187955,0.0013116997,0.002641405,0.0014207747],"domain_scores_gemma":[0.99697727,0.0005533672,0.000100558704,0.0010379546,0.0006764822,0.00065439026],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016869017,0.00039956218,0.0007519948,0.0011843522,0.00060603506,0.0005275105,0.00058768754,0.00027816714,0.014213771],"category_scores_gemma":[0.0001648717,0.000342485,0.00033413226,0.0024172317,0.00033612785,0.00031638046,0.0003812936,0.0017006143,0.00023307372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014453736,0.00005561397,0.0008375956,0.0004917982,0.0010173125,0.000085993874,0.0007403914,0.00032674934,0.9660142,0.00035029493,0.024510823,0.0054246704],"study_design_scores_gemma":[0.0026530449,0.0004933833,0.03695368,0.0028359639,0.0007806909,0.000035787318,0.00070701254,0.0192611,0.8947479,0.0016205005,0.038840998,0.0010699005],"about_ca_topic_score_codex":0.0020903593,"about_ca_topic_score_gemma":0.0005118011,"teacher_disagreement_score":0.07126628,"about_ca_system_score_codex":0.003026087,"about_ca_system_score_gemma":0.0015126086,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4393075724","doi":"10.1158/1538-7445.am2024-6909","title":"Abstract 6909: KRASG12C inhibitor resistance in patient-derived non-small cell lung cancer models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Cancer; Lung cancer; Internal medicine; Oncology","score_opus":0.09395832323132718,"score_gpt":0.4287630284169272,"score_spread":0.3348047051856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393075724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8964657,0.06765151,0.000054504468,0.0047426596,0.00084259553,0.0024821034,0.00018438579,0.0001486595,0.027427834],"genre_scores_gemma":[0.97560656,0.010533633,0.00028422492,0.00023246171,0.0010500234,0.0029746997,0.000023293342,0.00020332242,0.00909177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933733,0.00023720975,0.00073771883,0.0013611721,0.0023179322,0.0019727105],"domain_scores_gemma":[0.9970269,0.00048065343,0.00006084849,0.0009604178,0.000766862,0.0007042957],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017861765,0.00040066094,0.00061004213,0.0010978018,0.0002323102,0.0002730445,0.00058520073,0.00034897742,0.002647309],"category_scores_gemma":[0.00015309844,0.00036922356,0.00018587263,0.0023928995,0.00039242065,0.00034941296,0.0003609854,0.00306609,0.0002993627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.002191305,0.0005663716,0.005868153,0.01597801,0.0002354629,0.0043858676,0.010213376,0.0011722259,0.65292406,0.0003742938,0.26986095,0.036229935],"study_design_scores_gemma":[0.00799629,0.0009327765,0.015060291,0.032273896,0.00014798906,0.000028221843,0.0031275896,0.019094976,0.7143442,0.0025226027,0.20234962,0.002121523],"about_ca_topic_score_codex":0.007086507,"about_ca_topic_score_gemma":0.005865593,"teacher_disagreement_score":0.07914083,"about_ca_system_score_codex":0.0039608665,"about_ca_system_score_gemma":0.0057486896,"threshold_uncertainty_score":0.99988776},"labels":[],"label_agreement":null},{"id":"W4393078914","doi":"10.1016/j.ejca.2024.113608","title":"Neoadjuvant pembrolizumab or placebo + chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: Results from the phase 3 KEYNOTE-756 study","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Stage (stratigraphy); Breast cancer; Oncology; Placebo; Chemotherapy; Internal medicine; Adjuvant; Adjuvant chemotherapy; Cancer; Immunotherapy; Pathology","score_opus":0.04050519310740351,"score_gpt":0.3783540340905074,"score_spread":0.33784884098310386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393078914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9364786,0.026687423,0.00092293596,0.016694235,0.0031503036,0.0052394224,0.009968844,0.00021762235,0.0006406115],"genre_scores_gemma":[0.943818,0.027667344,0.00023856485,0.0012396097,0.005664702,0.00030992183,0.00006565468,0.00054681156,0.02044943],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914417,0.0015651289,0.0021553396,0.0011887716,0.0022969847,0.001352037],"domain_scores_gemma":[0.99428195,0.0016467081,0.0010604239,0.0012719021,0.0009108832,0.0008281061],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031735387,0.0009529825,0.0016328577,0.0003452313,0.00044949452,0.00051996537,0.0014541504,0.00011340799,0.0042334828],"category_scores_gemma":[0.0005203978,0.0005295828,0.00066632836,0.0008527707,0.00031503994,0.00040328558,0.00019456986,0.0021735295,0.000067061505],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4388661,0.0011095968,0.001260128,0.000154176,0.0032143036,0.0053456104,0.008055466,0.00044707744,0.0033309131,0.000004056543,0.21143709,0.32677546],"study_design_scores_gemma":[0.2888669,0.017088516,0.015344292,0.0025789626,0.0012359335,0.0007414629,0.0021599915,0.0018292613,0.003688445,0.000015329406,0.6654174,0.0010335103],"about_ca_topic_score_codex":0.006867269,"about_ca_topic_score_gemma":0.0014777262,"teacher_disagreement_score":0.4539803,"about_ca_system_score_codex":0.0015933515,"about_ca_system_score_gemma":0.0037844449,"threshold_uncertainty_score":0.9997461},"labels":[],"label_agreement":null},{"id":"W4393085303","doi":"10.1158/1538-7445.am2024-6996","title":"Abstract 6996: A role for the cell adhesion molecule NCAM1 in regulating activity of the receptor tyrosine kinase RET in cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Saskatchewan; Queen's University","funders":"","keywords":"Receptor tyrosine kinase; Cancer; Tyrosine kinase; Cancer research; Cell adhesion molecule; ROR1; Neural cell adhesion molecule; Cell biology; Chemistry; Cell adhesion; Receptor; Biology; Kinase; Cell; Signal transduction; Biochemistry; Platelet-derived growth factor receptor; Genetics","score_opus":0.11762551135676212,"score_gpt":0.46308895044232273,"score_spread":0.3454634390855606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9679414,0.016800737,0.000006968097,0.011037156,0.0002978335,0.0024414253,0.00012499328,0.000023288798,0.0013262172],"genre_scores_gemma":[0.9932038,0.0017989636,0.00004852707,0.00006873869,0.00037706783,0.0018647604,0.000004590793,0.00007164951,0.0025619003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99663764,0.00030132942,0.00038509394,0.0005655641,0.0012812346,0.00082912354],"domain_scores_gemma":[0.99755955,0.0011764496,0.000062280305,0.0007333072,0.00033697626,0.0001314635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031639661,0.00017637465,0.00032910937,0.00035135448,0.00015476206,0.000066450266,0.00051199895,0.0001690386,0.00084116426],"category_scores_gemma":[0.0006871655,0.00010956019,0.00014183066,0.0020112423,0.00034620575,0.00011086422,0.00027533123,0.0016337895,0.000014060414],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011349706,0.00016077254,0.0069401287,0.0018491247,0.000025284211,0.000018023531,0.0011241337,0.00025296726,0.92418605,0.00006175453,0.012411525,0.05183526],"study_design_scores_gemma":[0.0013524807,0.00021883531,0.040053867,0.0035597996,0.000015474863,0.0000015866764,0.0004869365,0.0049478365,0.9298816,0.00016596592,0.019176424,0.00013921928],"about_ca_topic_score_codex":0.016416967,"about_ca_topic_score_gemma":0.006103285,"teacher_disagreement_score":0.051696043,"about_ca_system_score_codex":0.0016859702,"about_ca_system_score_gemma":0.0020470002,"threshold_uncertainty_score":0.9901328},"labels":[],"label_agreement":null},{"id":"W4393085675","doi":"10.1158/1538-7445.am2024-1862","title":"Abstract 1862: ZW191 - a FRα-targeting antibody drug conjugate with strong preclinical activity across multiple FRα-expressing indications","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Medicine; Drug; Conjugate; Antibody; Pharmacology; Cancer research; Immunology; Monoclonal antibody","score_opus":0.1774213273968225,"score_gpt":0.5574039194081839,"score_spread":0.3799825920113614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393085675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98394644,0.0045101484,0.00031875036,0.0055335313,0.0003298721,0.0017015593,0.0003446309,0.0003105729,0.0030045072],"genre_scores_gemma":[0.994089,0.0009406681,0.0005286209,0.000067961846,0.0012553293,0.0007683624,0.000100698766,0.00016577424,0.0020835677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932664,0.00045528766,0.00057910354,0.0013335012,0.0024610837,0.0019046463],"domain_scores_gemma":[0.99510163,0.0023021204,0.000101595266,0.00097550394,0.000725115,0.0007940368],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00488016,0.00034996972,0.00059397327,0.0004063793,0.00087992306,0.00066912017,0.000601439,0.00026323594,0.0014490595],"category_scores_gemma":[0.0014460587,0.0002839284,0.00017391673,0.0015018774,0.0012533283,0.00053353887,0.00046916824,0.0042405585,0.00034291545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035733737,0.001149689,0.18939705,0.005562051,0.0009902149,0.0015284658,0.0095807845,0.00035370298,0.6277462,0.00014518938,0.03551517,0.12445807],"study_design_scores_gemma":[0.0092325695,0.0014624152,0.31745732,0.017209398,0.00021424987,0.00012341871,0.0056295404,0.015228835,0.45050636,0.00032649434,0.18078896,0.0018204199],"about_ca_topic_score_codex":0.0042905794,"about_ca_topic_score_gemma":0.0008637061,"teacher_disagreement_score":0.17723987,"about_ca_system_score_codex":0.0011221353,"about_ca_system_score_gemma":0.003628581,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W4393088686","doi":"10.1158/1538-7445.am2024-684","title":"Abstract 684: DT-9045, a novel PAR2 inhibitor with best-in-class properties that reduces resistance to both EGFR-targeting therapies and immunotherapy in oncology models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada); Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Internal medicine; Cancer; Cancer research","score_opus":0.1920960856307969,"score_gpt":0.44219075160412197,"score_spread":0.2500946659733251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393088686","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88282895,0.08788749,0.000036635643,0.023557989,0.00016107343,0.0019566107,0.000028281971,0.000067840774,0.0034751561],"genre_scores_gemma":[0.9808235,0.012137507,0.00082933536,0.00026755143,0.0003880626,0.0019554358,0.000004081651,0.00013114295,0.0034633693],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.995469,0.0002546964,0.0004884199,0.0010114809,0.0014604058,0.001316003],"domain_scores_gemma":[0.9983881,0.00047221303,0.000045187742,0.00046865837,0.00031869224,0.00030711616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031242324,0.00031826706,0.0006186901,0.0009872516,0.0001726652,0.00024219835,0.00035446556,0.0002222717,0.0001809235],"category_scores_gemma":[0.00015082699,0.00023167333,0.000054527012,0.0014511816,0.0006534401,0.0003760644,0.00015927145,0.001801261,0.000025885838],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010606325,0.00062083174,0.0059593935,0.0028177132,0.0002615335,0.0010078402,0.03344935,0.00046312468,0.8459761,0.00073613954,0.009009803,0.08909182],"study_design_scores_gemma":[0.014398089,0.00638335,0.01779065,0.04394982,0.00005615623,0.00013099816,0.047338895,0.0039475537,0.32069004,0.0019143507,0.5411493,0.0022507661],"about_ca_topic_score_codex":0.0033563105,"about_ca_topic_score_gemma":0.006909746,"teacher_disagreement_score":0.53213954,"about_ca_system_score_codex":0.0022675223,"about_ca_system_score_gemma":0.0031583542,"threshold_uncertainty_score":0.9447364},"labels":[],"label_agreement":null},{"id":"W4393090873","doi":"10.1158/1538-7445.am2024-3127","title":"Abstract 3127: Development of three-dimensional cancer cell line spheroid models for the <i>in vitro</i> functional characterization of cytotoxic antibody-drug conjugates","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Spheroid; In vitro; Antibody-drug conjugate; Cytotoxic T cell; Cancer; Drug; Conjugate; Cell culture; Cancer cell lines; Cancer research; Antibody; Chemistry; Medicine; Biology; Cancer cell; Immunology; Pharmacology; Monoclonal antibody; Internal medicine; Biochemistry; Genetics; Mathematics","score_opus":0.12110038014965273,"score_gpt":0.4125313699256697,"score_spread":0.29143098977601695,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393090873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789596,0.013691595,0.0016381243,0.0022940075,0.0004485643,0.0021534672,0.0005033489,0.000031345367,0.00027995725],"genre_scores_gemma":[0.9941565,0.001952242,0.0005065441,0.000079439335,0.00043877875,0.0012969173,0.00022719994,0.00007145531,0.0012709216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965534,0.000069659094,0.00067449285,0.00051062583,0.0015685024,0.0006233064],"domain_scores_gemma":[0.997711,0.00070177927,0.0000914145,0.0003546152,0.000993161,0.00014801373],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021205314,0.0001972868,0.0004075566,0.00025072537,0.00014588656,0.000038377715,0.00027439976,0.00011993702,0.0012839492],"category_scores_gemma":[0.000060069855,0.00014331241,0.0001231726,0.0007443594,0.0003280972,0.00018864273,0.00014071584,0.000655823,0.000014849815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016815893,0.0001874888,0.0004354411,0.0024350015,0.00012715331,0.000009463135,0.00045789217,0.0016769296,0.9749223,0.00008550963,0.0011618193,0.016819442],"study_design_scores_gemma":[0.0011814613,0.00010141462,0.0064907405,0.00143547,0.000027149577,0.000002699176,0.000085502936,0.034957163,0.94982284,0.00018245423,0.0055684755,0.00014461532],"about_ca_topic_score_codex":0.0018938773,"about_ca_topic_score_gemma":0.0012160907,"teacher_disagreement_score":0.03328023,"about_ca_system_score_codex":0.0007847504,"about_ca_system_score_gemma":0.0049314187,"threshold_uncertainty_score":0.999629},"labels":[],"label_agreement":null},{"id":"W4393093045","doi":"10.1158/1538-7445.am2024-1030","title":"Abstract 1030: Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Concordance; Breast cancer; Cancer; Destiny (ISS module); Medicine; Immunohistochemistry; Oncology; Internal medicine","score_opus":0.2276398584926865,"score_gpt":0.5914306417682521,"score_spread":0.3637907832755656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9680827,0.0029957783,0.00008588803,0.012419376,0.00085472513,0.009340921,0.002957545,0.00009690087,0.0031661214],"genre_scores_gemma":[0.99129814,0.0012489944,0.0001843471,0.0001759798,0.002945304,0.003140235,0.000015435668,0.00013965975,0.0008518937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99193275,0.0012810696,0.0015556872,0.0013934582,0.0022327076,0.0016043485],"domain_scores_gemma":[0.98998773,0.0070674126,0.00025622477,0.000998184,0.0010741169,0.0006163504],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018456027,0.00043748118,0.0011060915,0.0003636035,0.00033116934,0.00028096547,0.00071432453,0.0002789338,0.0007208173],"category_scores_gemma":[0.0021697741,0.0003237627,0.0002675026,0.0018759764,0.0009161582,0.00032773276,0.0004397924,0.0024722414,0.000028263697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07089803,0.0043552713,0.83409226,0.0025407344,0.0010409765,0.0003907406,0.0020846215,0.000048541257,0.00023637475,0.00013421323,0.006684097,0.07749415],"study_design_scores_gemma":[0.14358157,0.00435952,0.74064106,0.00794214,0.0006207044,0.000055874814,0.0053664222,0.0050792648,0.0004306792,0.00015053028,0.09096621,0.0008060519],"about_ca_topic_score_codex":0.028742198,"about_ca_topic_score_gemma":0.050639,"teacher_disagreement_score":0.09345121,"about_ca_system_score_codex":0.0017845468,"about_ca_system_score_gemma":0.0027195017,"threshold_uncertainty_score":0.99992144},"labels":[],"label_agreement":null},{"id":"W4393166040","doi":"","title":"Amplification of cycline D1, c-myc and EGFR oncogenes in tumour samples of breast cancer patients","year":2013,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Biological Sciences","funders":"","keywords":"Breast cancer; Oncology; Cancer research; Gene duplication; Medicine; Internal medicine; Cancer; Biology; Gene; Genetics","score_opus":0.31373332295768513,"score_gpt":0.5966062829018832,"score_spread":0.2828729599441981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393166040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885157,0.00885131,0.00003019896,0.00058987155,0.00015438026,0.0010325139,0.00022403986,0.000009088443,0.0005929361],"genre_scores_gemma":[0.9825273,0.01669356,0.00027337673,0.00010644884,0.00011455604,0.000113802686,0.000026075291,0.00004473871,0.00010010721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969249,0.00021499346,0.0011966219,0.00037616247,0.00093835295,0.00034899116],"domain_scores_gemma":[0.99698603,0.00031041578,0.00086932315,0.00041068622,0.0011386407,0.00028491268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009692112,0.00023130725,0.0009394233,0.00085854897,0.000057647805,0.000139956,0.00091336784,0.00011159085,0.0077911303],"category_scores_gemma":[0.00042064508,0.00019598452,0.000101713624,0.0009035855,0.00025430438,0.00087130675,0.00043819743,0.00032746085,0.000006324976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002567593,0.00043626747,0.7297128,0.00040335103,0.00007825035,0.000002797005,0.00015590963,0.000019962035,0.23342863,0.000009641891,0.0041500833,0.031345565],"study_design_scores_gemma":[0.0012649322,0.00003294922,0.9379487,0.0013234834,0.00005166944,0.000007939011,0.000100227815,0.000048623016,0.05794935,0.00051269034,0.00059864967,0.000160772],"about_ca_topic_score_codex":0.023035636,"about_ca_topic_score_gemma":0.0005212085,"teacher_disagreement_score":0.20823593,"about_ca_system_score_codex":0.0001995501,"about_ca_system_score_gemma":0.00036412163,"threshold_uncertainty_score":0.9931159},"labels":[],"label_agreement":null},{"id":"W4393317592","doi":"10.21203/rs.3.rs-4165568/v1","title":"Backbone and methyl side-chain resonance assignments of the single chain Fab fragment of trastuzumab","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Canada","funders":"","keywords":"Trastuzumab; Fragment (logic); Chain (unit); Side chain; Chemistry; Resonance (particle physics); Stereochemistry; Computer science; Physics; Medicine; Algorithm; Internal medicine; Organic chemistry; Cancer; Polymer","score_opus":0.11143938424696605,"score_gpt":0.4332458645943632,"score_spread":0.3218064803473972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393317592","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91067964,0.058795962,0.00009739149,0.009886366,0.00055046746,0.0063668513,0.00075687293,0.000067916386,0.012798549],"genre_scores_gemma":[0.9899703,0.0025631674,0.00054721243,0.000037828737,0.0002562602,0.0004406682,0.000031705855,0.00011803358,0.0060348064],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9908496,0.0013691527,0.0009101404,0.0010803047,0.0047950777,0.0009957374],"domain_scores_gemma":[0.99567646,0.0009856498,0.00020680396,0.0018453695,0.00091437815,0.00037135658],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0060240016,0.00039254135,0.0010253298,0.0006874047,0.00014770684,0.00007137658,0.00077398017,0.0005202279,0.00032998068],"category_scores_gemma":[0.0019472196,0.00028260925,0.00033181816,0.0010944654,0.0012308958,0.000030129795,0.004356701,0.0038456374,0.000029459346],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028031026,0.004237523,0.019725505,0.10450874,0.0019638236,0.00082010933,0.01794903,0.00029809776,0.39692983,0.0042569675,0.0391552,0.40735206],"study_design_scores_gemma":[0.0068273414,0.008465343,0.100308515,0.08907415,0.00045953644,0.00009959908,0.01006223,0.0047790436,0.68507355,0.03424211,0.059117205,0.0014913689],"about_ca_topic_score_codex":0.0010647912,"about_ca_topic_score_gemma":0.00011706151,"teacher_disagreement_score":0.4058607,"about_ca_system_score_codex":0.0013681607,"about_ca_system_score_gemma":0.0021577524,"threshold_uncertainty_score":0.9999626},"labels":[],"label_agreement":null},{"id":"W4393989206","doi":"10.1158/1538-7445.am2024-ct265","title":"Abstract CT265: Trastuzumab emtansine in patients (pts) with <i>HER2</i> mutation-positive <i>(HER2</i>mut<i>)</i> tumors: TAPISTRY study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Mutation; Internal medicine; Oncology; Cancer; Cancer research; Breast cancer; Biology; Genetics; Gene","score_opus":0.048789231404111184,"score_gpt":0.4222173071015696,"score_spread":0.37342807569745845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393989206","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98455685,0.0021397814,0.000014394189,0.0021285464,0.00028657445,0.004022938,0.0002436366,0.0001748533,0.0064324494],"genre_scores_gemma":[0.99491626,0.00020823232,0.000059361333,0.00023519393,0.00057226256,0.0014901024,0.00010383499,0.00021037456,0.0022043518],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99203503,0.00044946306,0.00076516304,0.0014395865,0.0037050715,0.0016056563],"domain_scores_gemma":[0.99641347,0.0007399422,0.00007063494,0.00088155904,0.0012839984,0.0006104088],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022374238,0.00047560286,0.0007140521,0.000961504,0.00025830735,0.00035226828,0.0005377403,0.00020290198,0.001426464],"category_scores_gemma":[0.0003462526,0.000391671,0.000119940254,0.0034734937,0.0005624336,0.00041071378,0.00020320048,0.00290551,0.00041713467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013522774,0.013548145,0.6787761,0.00793497,0.0016966781,0.036487546,0.024478745,0.00042718512,0.012256502,0.00022958417,0.07857733,0.13206446],"study_design_scores_gemma":[0.01584063,0.013062777,0.92111146,0.011353993,0.00015935655,0.00013438636,0.00909489,0.00020176858,0.016291576,0.00022685403,0.011258939,0.0012633619],"about_ca_topic_score_codex":0.006777124,"about_ca_topic_score_gemma":0.0038401047,"teacher_disagreement_score":0.2423354,"about_ca_system_score_codex":0.0033085619,"about_ca_system_score_gemma":0.00450609,"threshold_uncertainty_score":0.9998535},"labels":[],"label_agreement":null},{"id":"W4393994610","doi":"10.1038/s41388-024-03023-2","title":"Correction: E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer","year":2024,"lang":"en","type":"erratum","venue":"Oncogene","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"National Cancer Institute; Johns Hopkins University","keywords":"Biology; Cadherin; MAPK/ERK pathway; Breast cancer; Cancer research; Carcinogenesis; Cancer; Internal medicine; Oncology; Bioinformatics; Cell biology; Signal transduction; Genetics; Cell","score_opus":0.06554297268671097,"score_gpt":0.3582832299099896,"score_spread":0.2927402572232787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393994610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7737444,0.009798645,0.00020550839,0.003710952,0.030924644,0.0039762487,0.0009932927,0.00015584595,0.17649044],"genre_scores_gemma":[0.93937105,0.0014184067,0.000413354,0.00006005438,0.0011647285,0.00024005678,0.00023970492,0.00014855836,0.056944113],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99745953,0.00010050549,0.00077011605,0.00054534856,0.00076056464,0.0003639411],"domain_scores_gemma":[0.99863416,0.00016854287,0.00030237992,0.00040808626,0.00038637166,0.00010046557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046551437,0.0002930247,0.0008521269,0.00071683014,0.000017099857,0.000013375891,0.0001760525,0.00041201315,0.00021365026],"category_scores_gemma":[0.00021879753,0.00025673138,0.00008933729,0.0011769236,0.00010416745,0.00012306469,0.000108796514,0.0016598236,0.00000761155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01129311,0.0015861859,0.023732722,0.01379191,0.0006585739,0.00052997144,0.007882399,0.018060785,0.17420201,0.000017308068,0.5916019,0.1566431],"study_design_scores_gemma":[0.017248131,0.0032440992,0.039459918,0.22110781,0.00045567242,0.0007209462,0.004446176,0.31998387,0.21658057,0.00014002794,0.17437494,0.0022378317],"about_ca_topic_score_codex":0.019357203,"about_ca_topic_score_gemma":0.010640948,"teacher_disagreement_score":0.417227,"about_ca_system_score_codex":0.0015019249,"about_ca_system_score_gemma":0.0021338651,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W4394071983","doi":"10.6084/m9.figshare.13154069","title":"Metadata record for the manuscript: Glembatumumab vedotin for patients with metastatic, gpNMB over-expressing, triplenegative breast cancer (“METRIC”): A Randomized Multicenter Study","year":2021,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Metadata; Oncology; Medicine; Internal medicine; Metric (unit); Breast cancer; Randomized controlled trial; Metastatic breast cancer; World Wide Web; Cancer; Computer science; Engineering","score_opus":0.079194503838024,"score_gpt":0.38363819325446313,"score_spread":0.3044436894164391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394071983","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028607083,0.0023364667,0.000030312209,0.00029460568,0.00052522053,0.027222417,0.9695074,0.000040953495,0.000014029808],"genre_scores_gemma":[0.000101221485,0.00013960249,0.0008402602,0.0005722228,0.0005910377,0.047146704,0.94928735,0.0001795353,0.0011420422],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939408,0.00073282834,0.0011181444,0.0014203099,0.0017789528,0.0010089828],"domain_scores_gemma":[0.98803765,0.00624353,0.0010355753,0.001974388,0.002366026,0.0003428176],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008523505,0.00093367463,0.0026882677,0.00046204738,0.0003874869,0.00056123023,0.0011157043,0.00024609594,0.079205476],"category_scores_gemma":[0.012747689,0.0005411939,0.00072132103,0.00081397814,0.00007773731,0.00035870748,0.000578109,0.0010515491,0.000068215784],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07147309,0.0015171297,0.000053251788,0.003076236,0.0041630184,0.000048040238,0.000119279546,0.0000027561307,5.651469e-7,1.0657369e-7,0.9139999,0.0055465833],"study_design_scores_gemma":[0.20371272,0.0008092597,0.0008017477,0.005905352,0.0036299136,0.000004585957,0.0002538126,0.00024621346,0.00002648746,0.0000017249879,0.7841118,0.00049636816],"about_ca_topic_score_codex":0.001457239,"about_ca_topic_score_gemma":0.0019503788,"teacher_disagreement_score":0.13223964,"about_ca_system_score_codex":0.00063195976,"about_ca_system_score_gemma":0.001631004,"threshold_uncertainty_score":0.99970394},"labels":[],"label_agreement":null},{"id":"W4394724801","doi":"10.1186/s40959-024-00223-3","title":"Cancer therapy related cardiac dysfunction as a result of Panitumumab","year":2024,"lang":"en","type":"article","venue":"Cardio-Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"Fondation Leducq","keywords":"Panitumumab; Medicine; Ejection fraction; Cardiology; Internal medicine; Heart failure; Colorectal cancer; Radiology; Oncology; Cancer; Cetuximab","score_opus":0.051955655534409256,"score_gpt":0.4218888970599156,"score_spread":0.36993324152550633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394724801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5926494,0.09431697,0.00005914571,0.009938736,0.008612148,0.001801692,0.00013715697,0.00044057268,0.2920442],"genre_scores_gemma":[0.97067,0.019356998,0.000082956125,0.00034938758,0.0011638917,0.00038347897,0.000047855516,0.00008209739,0.007863351],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99761575,0.0004186208,0.00046863285,0.0005059054,0.0005489854,0.00044210747],"domain_scores_gemma":[0.99849063,0.00033980003,0.00007032734,0.000533092,0.00036400522,0.00020215973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011469416,0.00019410437,0.0008144444,0.00027592503,0.000058502756,0.000017556336,0.0001322268,0.00044895106,0.00091484346],"category_scores_gemma":[0.0002482515,0.00016110178,0.00039529862,0.000730787,0.00026963113,0.00006743918,0.00006376725,0.0007964286,0.00035036227],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018482157,0.00013733678,0.0042347396,0.00045987408,0.0025069497,0.0010736516,0.0034245013,0.000063102736,0.121751174,0.0009921909,0.13496289,0.72854537],"study_design_scores_gemma":[0.0019411558,0.002044795,0.0032983273,0.00026303163,0.00024113097,0.00019662634,0.00054464827,0.00011527945,0.016417226,0.00030808445,0.9744727,0.00015699082],"about_ca_topic_score_codex":0.0009592016,"about_ca_topic_score_gemma":0.000018889727,"teacher_disagreement_score":0.83950984,"about_ca_system_score_codex":0.0015947195,"about_ca_system_score_gemma":0.00295307,"threshold_uncertainty_score":0.99999845},"labels":[],"label_agreement":null},{"id":"W4395464611","doi":"10.51731/cjht.2024.875","title":"Sacituzumab Govitecan (Trodelvy)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Immunohistochemistry; Medicine; Human Epidermal Growth Factor Receptor 2; Oncology; Metastatic breast cancer; Internal medicine; Family medicine; Cancer; Breast cancer; Political science","score_opus":0.060535617426535994,"score_gpt":0.3863126043444558,"score_spread":0.3257769869179198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464611","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0825678,0.5120998,0.0016446878,0.39631313,0.0020028863,0.00068153447,0.000065336775,0.0006385277,0.003986293],"genre_scores_gemma":[0.9964776,0.0014810578,0.00084507646,0.0006589232,0.000057534773,0.000007915099,0.0000018699851,0.00003265887,0.00043737225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981483,0.000045490477,0.00056918844,0.00018601691,0.00034304408,0.00070791616],"domain_scores_gemma":[0.9990177,0.00006646314,0.0001067289,0.00034340954,0.0001979806,0.0002677004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010556588,0.00013488086,0.0004169039,0.0014345456,0.000167252,0.000083905135,0.0003407404,0.0001823246,0.00017455465],"category_scores_gemma":[0.0007020153,0.00010781803,0.000119009914,0.0008052276,0.0003194364,0.000102653044,0.000022853357,0.001243236,0.000065704124],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000014782215,0.000007990403,0.0012849807,0.0006335129,0.00005934299,0.001832208,0.00024958642,0.0000048860798,0.00009554523,0.003547158,0.06497012,0.9272999],"study_design_scores_gemma":[0.00029504462,0.0009501741,0.0014074277,0.001506293,0.000017760736,0.0022600696,0.001481062,0.000078021905,0.0007395687,0.0044656885,0.9866872,0.00011171385],"about_ca_topic_score_codex":0.0059511685,"about_ca_topic_score_gemma":0.0042243944,"teacher_disagreement_score":0.92718816,"about_ca_system_score_codex":0.002106987,"about_ca_system_score_gemma":0.016153267,"threshold_uncertainty_score":0.9894242},"labels":[],"label_agreement":null},{"id":"W4395467322","doi":"10.1007/s10549-024-07302-0","title":"Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey","year":2024,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; McMaster University; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Breast cancer; Pertuzumab; Trastuzumab; Internal medicine; myalgia; Clinical trial; Cancer; Adverse effect; Oncology; Physical therapy","score_opus":0.07811656565937058,"score_gpt":0.42488924505717257,"score_spread":0.346772679397802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395467322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9765925,0.0095761465,0.000001954212,0.006158615,0.000085586515,0.0017697302,0.005010601,0.0000375239,0.00076736964],"genre_scores_gemma":[0.9571372,0.040367916,0.0000114976465,0.000034545574,0.00016941056,0.0012260616,0.000057925703,0.000059158174,0.00093627855],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965701,0.00045334123,0.0003441296,0.0008080531,0.0010677829,0.00075657456],"domain_scores_gemma":[0.99821943,0.0003344312,0.00003873932,0.00041762754,0.00062530057,0.00036445912],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005581811,0.00030158146,0.000491889,0.0006237532,0.00015066174,0.00012433162,0.0001188392,0.00011020594,0.00096528634],"category_scores_gemma":[0.000018575754,0.00021465255,0.00011034502,0.0010614534,0.00046119065,0.00013523627,0.00006728698,0.00050537946,0.000025999787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006696391,0.003359399,0.7145289,0.00020690744,0.001070448,0.0007664175,0.013583132,0.00002742045,0.0013577132,0.00043856495,0.0011525758,0.2568121],"study_design_scores_gemma":[0.001998015,0.003315362,0.9879938,0.0010555842,0.000019943165,0.0000802239,0.0017621071,0.00012213938,0.0025332554,0.000023735265,0.0009183445,0.00017749463],"about_ca_topic_score_codex":0.16580914,"about_ca_topic_score_gemma":0.017651182,"teacher_disagreement_score":0.27346486,"about_ca_system_score_codex":0.002189425,"about_ca_system_score_gemma":0.0015399131,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W4396228518","doi":"10.1111/febs.17143","title":"Can the <scp>HB‐EGF</scp>/<scp>EGFR</scp> pathway restore injured neurons?","year":2024,"lang":"en","type":"article","venue":"FEBS Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; Calouste Gulbenkian Foundation","keywords":"Cell biology; Chemistry; Neuroscience; Biology","score_opus":0.0475490130170152,"score_gpt":0.34178681163406627,"score_spread":0.29423779861705107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396228518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90413743,0.017017888,0.00012687758,0.019238187,0.005193831,0.0010084525,0.000115792,0.00035405895,0.052807465],"genre_scores_gemma":[0.9350173,0.001625467,0.00029374997,0.0026451224,0.006949726,0.00007388409,0.000023905315,0.0002356873,0.053135168],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994954,0.0005117535,0.00071416656,0.0005830343,0.0019278675,0.0013092108],"domain_scores_gemma":[0.9961436,0.0014664566,0.00016710242,0.00088721403,0.00038030854,0.000955358],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022245608,0.00041429535,0.00051410997,0.00048667338,0.0005851485,0.00068793964,0.0008104387,0.00026881418,0.00033316077],"category_scores_gemma":[0.0038430968,0.00027382807,0.00038450412,0.0010635388,0.00033085095,0.00021805259,0.00024949148,0.004028134,0.00068336003],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002436773,0.00013802988,0.00845314,0.00025180334,0.00030492543,0.005317537,0.004948146,0.000027476139,0.010337598,0.00081221055,0.9425321,0.026852662],"study_design_scores_gemma":[0.00096069183,0.0008522812,0.025772786,0.0007709701,0.00013762187,0.00496313,0.0017452281,0.00038931973,0.0043715113,0.0016674671,0.9583053,0.000063721425],"about_ca_topic_score_codex":0.00013923191,"about_ca_topic_score_gemma":0.0001540574,"teacher_disagreement_score":0.030879844,"about_ca_system_score_codex":0.00076199416,"about_ca_system_score_gemma":0.0026361058,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W4396586818","doi":"10.1158/1538-7445.sabcs23-ps17-07","title":"Abstract PS17-07: Interim analysis of giredestrant + inavolisib in MORPHEUS Breast Cancer: a Phase Ib/II study of giredestrant treatment combinations in estrogen receptor-positive, HER2-negative, locally advanced/metastatic breast cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Breast cancer; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Cancer; Estrogen receptor; Interim analysis; HER2 negative; Interim; Clinical trial","score_opus":0.09188087022298844,"score_gpt":0.48113297864485843,"score_spread":0.38925210842186997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396586818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800682,0.005173598,0.00001624612,0.0032253494,0.00021531867,0.0041712434,0.0067921,0.000056718334,0.0002812422],"genre_scores_gemma":[0.9885947,0.006517718,0.00011601844,0.00002263391,0.000093317925,0.0039665,0.000119545046,0.00012812906,0.00044141858],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99228525,0.0007570787,0.0017334148,0.001432038,0.0023651922,0.0014270287],"domain_scores_gemma":[0.9961667,0.0006051948,0.00025807373,0.0009546411,0.0014594803,0.00055588514],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001737993,0.0006278045,0.0019216045,0.003561303,0.00018288226,0.00009730412,0.0006811177,0.00018585632,0.004166304],"category_scores_gemma":[0.00012763876,0.0005512328,0.0003971892,0.008802692,0.0009211731,0.00038415298,0.00023886167,0.00142468,0.000016491302],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02108835,0.049519178,0.21179253,0.0051646126,0.014316768,0.0033869413,0.033584803,0.020841176,0.14825551,0.00029587102,0.0014830562,0.4902712],"study_design_scores_gemma":[0.042784706,0.015241015,0.842711,0.01917456,0.0027537963,0.00013183079,0.021278601,0.013639921,0.040148687,0.00021482835,0.0004919619,0.0014291322],"about_ca_topic_score_codex":0.17743188,"about_ca_topic_score_gemma":0.05578261,"teacher_disagreement_score":0.63091844,"about_ca_system_score_codex":0.006328926,"about_ca_system_score_gemma":0.0055537173,"threshold_uncertainty_score":0.99969393},"labels":[],"label_agreement":null},{"id":"W4396587235","doi":"10.1158/1538-7445.sabcs23-ps16-03","title":"Abstract PS16-03: Intratumoral dosing of INT230-6 in Early-Stage Breast Cancer Patients Induces Tumor Cell Necrosis and Immunomodulatory Effects: A Phase II Randomized Window-Of-Opportunity Study – the INVINCIBLE Trial","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Ontario Institute for Cancer Research; Institute of Cancer Research; Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Randomized controlled trial; Stage (stratigraphy); Dosing; Cancer; Necrosis; Window of opportunity; Oncology; Internal medicine; Therapeutic window; Pathology; Pharmacology; Biology","score_opus":0.08482277067803398,"score_gpt":0.436833172211823,"score_spread":0.35201040153378904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396587235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857692,0.0047050193,7.0709115e-7,0.0004410009,0.000623875,0.007835393,0.00026451045,0.000032516054,0.00032774167],"genre_scores_gemma":[0.9964267,0.00076849625,0.00000832027,0.000043374013,0.00033398918,0.0021200413,0.000012538582,0.00008125647,0.00020530829],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99378234,0.0014882489,0.0011240841,0.0007388936,0.001968346,0.0008980834],"domain_scores_gemma":[0.9963028,0.0016824114,0.00022401926,0.0006952874,0.00070076284,0.00039474227],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00795279,0.0003471132,0.0012787486,0.0009735759,0.00026674426,0.0001523117,0.00050878536,0.0001500606,0.00042350034],"category_scores_gemma":[0.0009361463,0.00023998648,0.00020436899,0.0017968497,0.001318244,0.0003081018,0.00052390277,0.0022403833,0.0000049587024],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7234604,0.008219141,0.044370227,0.0063011497,0.0009020839,0.00042109372,0.019969085,0.000021857806,0.1648665,0.000027096738,0.0010565021,0.030384872],"study_design_scores_gemma":[0.71778977,0.008278962,0.14890145,0.004682669,0.00030112872,0.000007680658,0.0023700972,0.0002633486,0.11645935,0.00015812802,0.00028132,0.00050607964],"about_ca_topic_score_codex":0.043340903,"about_ca_topic_score_gemma":0.00082456024,"teacher_disagreement_score":0.10453122,"about_ca_system_score_codex":0.0008710138,"about_ca_system_score_gemma":0.0037363784,"threshold_uncertainty_score":0.97863644},"labels":[],"label_agreement":null},{"id":"W4396588255","doi":"10.1158/1538-7445.sabcs23-gs01-10","title":"Abstract GS01-10: HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"","keywords":"Trastuzumab emtansine; Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Trastuzumab; Cancer; Double blind; Randomized controlled trial; Pathology; Alternative medicine","score_opus":0.1888228164544587,"score_gpt":0.5289525704182272,"score_spread":0.3401297539637685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396588255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9401313,0.028031407,0.00008443317,0.007443706,0.0005031127,0.01891281,0.0025387844,0.00011956886,0.0022348608],"genre_scores_gemma":[0.9688291,0.010625791,0.00015301014,0.000066630746,0.0012199065,0.01115921,0.0002040897,0.00019922915,0.007543057],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938933,0.00060090877,0.0011639175,0.0011463726,0.0018368092,0.0013586659],"domain_scores_gemma":[0.9935009,0.0032467528,0.00016694573,0.00064744597,0.0017306801,0.00070730835],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0058243917,0.0004796271,0.0017509431,0.00088934513,0.00023182387,0.00024379829,0.00035614145,0.0002232272,0.004701992],"category_scores_gemma":[0.00061492005,0.00036798345,0.00045289838,0.0015800674,0.001317776,0.00025212544,0.000121919285,0.0011769526,0.000037151516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90505093,0.0011643476,0.000023737617,0.004983843,0.0017155894,0.00020926948,0.0015609664,0.000012031823,0.009031756,0.00016749183,0.010962778,0.06511723],"study_design_scores_gemma":[0.95806503,0.0036570025,0.00012626174,0.0047951555,0.0009552456,0.00010654718,0.00044466255,0.00084058515,0.024994938,0.00019810324,0.005405298,0.00041116256],"about_ca_topic_score_codex":0.0070491955,"about_ca_topic_score_gemma":0.0009949997,"teacher_disagreement_score":0.06470607,"about_ca_system_score_codex":0.0012107394,"about_ca_system_score_gemma":0.005375626,"threshold_uncertainty_score":0.9998772},"labels":[],"label_agreement":null},{"id":"W4396591228","doi":"10.1158/1538-7445.sabcs23-po1-04-07","title":"Abstract PO1-04-07: Disitamab vedotin, a clinical stage HER2-directed antibody-drug conjugate, shows potent antitumor activity as a monotherapy and in combination with tucatinib in preclinical breast cancer models","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Antibody-drug conjugate; Cancer; Oncology; Stage (stratigraphy); Breast cancer; Drug; Internal medicine; Conjugate; Pharmacology; Antibody; Monoclonal antibody; Immunology; Biology","score_opus":0.1508340742934629,"score_gpt":0.5248850737820561,"score_spread":0.37405099948859316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396591228","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768092,0.0058581596,0.00001913257,0.012576566,0.00026957708,0.0029187943,0.00031405885,0.00015790004,0.0010766097],"genre_scores_gemma":[0.9768657,0.019572083,0.00008110243,0.0002024083,0.00032876074,0.0010538725,0.000036126057,0.00013974457,0.001720211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934429,0.0009857067,0.0009304499,0.0015326458,0.0018405379,0.0012677449],"domain_scores_gemma":[0.99654424,0.001368513,0.00011081891,0.0007145217,0.00064664904,0.0006152487],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005586109,0.00040084138,0.0009721146,0.00079056446,0.00013889282,0.00028644377,0.00039427556,0.00031450423,0.0011784589],"category_scores_gemma":[0.00030772615,0.00032860355,0.000128874,0.0016646323,0.00088773115,0.00052227586,0.00021593753,0.003582035,0.00005210525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029074576,0.005122551,0.71405655,0.0042513106,0.0005822473,0.0032618996,0.0030888217,0.0006449076,0.019430207,0.0004223205,0.0051279594,0.21493664],"study_design_scores_gemma":[0.009601012,0.0010588749,0.95192486,0.005924714,0.000035739748,0.00008093062,0.0004893428,0.025428684,0.0022815638,0.0003813991,0.0022527124,0.0005401782],"about_ca_topic_score_codex":0.034573924,"about_ca_topic_score_gemma":0.017497987,"teacher_disagreement_score":0.2378683,"about_ca_system_score_codex":0.0014388744,"about_ca_system_score_gemma":0.005183773,"threshold_uncertainty_score":0.9999166},"labels":[],"label_agreement":null},{"id":"W4396716435","doi":"10.14740/wjon1829","title":"Efficacy of First-Line Treatment With Pertuzumab and Trastuzumab in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Routine Clinical Practice","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Medicine; Trastuzumab; Taxane; Internal medicine; Metastatic breast cancer; Oncology; Clinical trial; Breast cancer; Cancer; Gynecology","score_opus":0.05443212531543985,"score_gpt":0.45939366738275805,"score_spread":0.4049615420673182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396716435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96181834,0.004358051,0.000028710994,0.03165097,0.00031202787,0.0006174675,0.00006241178,0.000010218306,0.0011418097],"genre_scores_gemma":[0.99312466,0.004457733,0.0013422759,0.00019817543,0.0005074747,0.00002771086,0.0000046113373,0.000036855734,0.00030050386],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971536,0.00049494754,0.0012381986,0.00033522156,0.00039918296,0.00037887113],"domain_scores_gemma":[0.99628055,0.0025411127,0.00039413423,0.00014397824,0.00038019696,0.00026000093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00105703,0.00021993181,0.0010847237,0.00061772583,0.000036392164,0.000014686985,0.000113774615,0.0001277583,0.0005098808],"category_scores_gemma":[0.0004353612,0.00015071544,0.00012838344,0.0006142042,0.0002812365,0.00021388517,0.0000419043,0.0010739322,0.000002817677],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030242426,0.0048489734,0.3015577,0.00031635808,0.0008085167,0.005777808,0.003669028,0.00011882391,0.0012533606,0.00013361213,0.0004940371,0.65077937],"study_design_scores_gemma":[0.03053327,0.03142048,0.8994763,0.0029635807,0.0003675219,0.0036436194,0.00065602193,0.00025189077,0.0007342399,0.000025938545,0.029683143,0.00024401362],"about_ca_topic_score_codex":0.0006895454,"about_ca_topic_score_gemma":0.005632996,"teacher_disagreement_score":0.65053535,"about_ca_system_score_codex":0.0026867578,"about_ca_system_score_gemma":0.0016833702,"threshold_uncertainty_score":0.7025778},"labels":[],"label_agreement":null},{"id":"W4396904404","doi":"10.1101/2024.05.10.593500","title":"G6b-B antibody-based cis-acting platelet receptor inhibitors (CAPRIs) as a new family of anti-thrombotic therapeutics","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Institut National de la Santé et de la Recherche Médicale; Etablissement Français du Sang; Agence Nationale de la Recherche","keywords":"Antibody; Platelet; Pharmacology; Chemistry; Receptor; Medicine; Immunology; Biochemistry","score_opus":0.04383900418984382,"score_gpt":0.32598727391547655,"score_spread":0.2821482697256327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396904404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98325014,0.006608662,0.0006913351,0.0022110397,0.0037304454,0.0022876011,0.00030185297,0.0007975837,0.00012134083],"genre_scores_gemma":[0.98775464,0.001387423,0.0075245686,0.0009100797,0.0017144589,0.00010787629,0.0000036277004,0.0005568343,0.000040510065],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9933295,0.00027337277,0.0014913928,0.0018256898,0.0018140709,0.0012659456],"domain_scores_gemma":[0.9945833,0.00027066632,0.0007063133,0.0024141856,0.0010091995,0.0010163499],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0014768611,0.0010864208,0.001851773,0.0010199419,0.00014778729,0.00028877478,0.00084596855,0.001305453,0.0003336418],"category_scores_gemma":[0.0007243066,0.0010970017,0.0005679818,0.0017739959,0.00039477544,0.00010600788,0.0008995961,0.0034315328,0.00058390194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002223417,0.0003119404,0.0041887886,0.004753544,0.00079327513,0.00033465325,0.00006070731,0.0001048876,0.9858387,0.00012316415,0.0031845067,0.00008346421],"study_design_scores_gemma":[0.0018292126,0.0005872507,0.008512297,0.008257565,0.0005991924,1.5928553e-7,0.000030569718,0.0011109264,0.94097453,0.000009442878,0.03688256,0.0012062647],"about_ca_topic_score_codex":0.0006421795,"about_ca_topic_score_gemma":0.0000025742834,"teacher_disagreement_score":0.04486417,"about_ca_system_score_codex":0.0009825686,"about_ca_system_score_gemma":0.011144366,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W4397007360","doi":"10.1016/j.esmoop.2024.103115","title":"127P Atezolizumab (A) + pertuzumab + trastuzumab (PH) + chemotherapy (CT) in HER2-positive early breast cancer (HER2+ eBC): Final results of the phase III IMpassion050 trial","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Pertuzumab; Atezolizumab; Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Cancer; Immunotherapy","score_opus":0.051704810733827496,"score_gpt":0.41411049754855733,"score_spread":0.36240568681472984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397007360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95598364,0.00067904766,0.000016998447,0.023829404,0.0010161501,0.0051207715,0.0010130437,0.00007188387,0.012269073],"genre_scores_gemma":[0.9876044,0.0003791358,0.000064726,0.00041865866,0.00068859465,0.0006075981,0.000055544973,0.00011342649,0.010067965],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99578756,0.00039444136,0.00097062363,0.0009109854,0.001159863,0.0007765058],"domain_scores_gemma":[0.99809897,0.00025547357,0.00018342867,0.000956159,0.00021999725,0.00028594537],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012281562,0.00041688734,0.0008944388,0.0002562385,0.00017089138,0.00023285075,0.0011582249,0.00018464387,0.0029748124],"category_scores_gemma":[0.00014855673,0.00028108357,0.00031545974,0.0011862752,0.00035415657,0.0003401297,0.00042345838,0.0011425456,0.000074837706],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43637872,0.0040132655,0.0018392247,0.00048563973,0.0010124579,0.0015793748,0.012471284,0.00004686016,0.004554007,0.00055433187,0.11295619,0.42410865],"study_design_scores_gemma":[0.6153115,0.0100652,0.18578105,0.010809216,0.0004089309,0.0010790341,0.0014643667,0.0030757503,0.033829723,0.0005321154,0.13624224,0.0014008782],"about_ca_topic_score_codex":0.065205,"about_ca_topic_score_gemma":0.003615269,"teacher_disagreement_score":0.42270777,"about_ca_system_score_codex":0.0016753853,"about_ca_system_score_gemma":0.0034267437,"threshold_uncertainty_score":0.9999641},"labels":[],"label_agreement":null},{"id":"W4399122010","doi":"10.1200/jco.2024.42.16_suppl.1005","title":"Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Triple negative; Cancer; Gynecology","score_opus":0.1377817727281921,"score_gpt":0.5451264201042444,"score_spread":0.4073446473760523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93946314,0.005955674,0.0000212871,0.045775335,0.0037770444,0.00072002714,0.00025963117,0.000021726275,0.004006134],"genre_scores_gemma":[0.98123354,0.013443392,0.00035702818,0.0011645115,0.0024808105,0.00004478759,0.0000023892126,0.000051775005,0.0012217495],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941801,0.00069215044,0.0031925638,0.0004464924,0.00093993865,0.0005487946],"domain_scores_gemma":[0.993878,0.0033108767,0.001011773,0.00026347965,0.0008543061,0.0006815409],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053212135,0.00026305264,0.002334462,0.00044174626,0.000036781952,0.000026718724,0.0002798578,0.00059474463,0.0027676767],"category_scores_gemma":[0.0018067625,0.0001923091,0.0004391945,0.00064676185,0.00077421207,0.00021400671,0.000095367985,0.002768139,0.000015816062],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009361668,0.0011987846,0.4714575,0.00069057243,0.0009795795,0.0036255042,0.0007607604,0.000048225305,0.00041145962,0.00014609196,0.026994381,0.48432547],"study_design_scores_gemma":[0.008434697,0.0039172173,0.9469662,0.0028538096,0.00041278757,0.0023060394,0.0003106329,0.00064230734,0.00022010122,0.00043854179,0.033294834,0.00020286908],"about_ca_topic_score_codex":0.006647034,"about_ca_topic_score_gemma":0.0049844133,"teacher_disagreement_score":0.4841226,"about_ca_system_score_codex":0.0010578857,"about_ca_system_score_gemma":0.012057471,"threshold_uncertainty_score":0.9999678},"labels":[],"label_agreement":null},{"id":"W4399122099","doi":"10.1200/jco.2024.42.16_suppl.1007","title":"Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eisai Canada","keywords":"Medicine; Pertuzumab; Trastuzumab; Eribulin; Taxane; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Paclitaxel; Anthracycline; Cancer","score_opus":0.11762713107934504,"score_gpt":0.5248258775869272,"score_spread":0.4071987465075822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96708935,0.0010857296,0.00090694404,0.024669986,0.000500458,0.005515408,0.00017899631,0.000011102572,0.000042007727],"genre_scores_gemma":[0.98476017,0.010322798,0.0033031395,0.0005159322,0.00030197954,0.0003970867,0.000019579438,0.000047763133,0.00033153288],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9940108,0.0008810529,0.0036797135,0.0004640686,0.0005391289,0.00042525973],"domain_scores_gemma":[0.9883208,0.009361271,0.0011976159,0.00020024442,0.0005716397,0.00034842445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005286548,0.00032035817,0.0035628318,0.00039330605,0.00003606792,0.00002595008,0.00014960027,0.00025698973,0.00014049637],"category_scores_gemma":[0.003463821,0.00017922717,0.00040622044,0.00044827678,0.00046951062,0.00017848452,0.00003079166,0.0008472663,0.0000014753867],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67592937,0.008344154,0.0001475017,0.0003403154,0.0008025427,0.0007905263,0.00084906706,0.00007488629,0.000116380834,0.0000062851805,0.000038996408,0.31255996],"study_design_scores_gemma":[0.8293004,0.14027199,0.0011944931,0.0022688063,0.00086541,0.00051272876,0.00022644152,0.022078369,0.00029540007,0.00006728755,0.0027607922,0.00015789102],"about_ca_topic_score_codex":0.0015008885,"about_ca_topic_score_gemma":0.006666228,"teacher_disagreement_score":0.31240207,"about_ca_system_score_codex":0.0013264411,"about_ca_system_score_gemma":0.0062170215,"threshold_uncertainty_score":0.9994168},"labels":[],"label_agreement":null},{"id":"W4399322695","doi":"10.1200/jco.2024.42.16_suppl.596","title":"Neoadjuvant pegylated liposomal doxorubicin-containing chemotherapy in combination with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer: A randomized phase II study (METIS).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pertuzumab; Trastuzumab; Oncology; Breast cancer; Chemotherapy; Internal medicine; Doxorubicin; Cancer","score_opus":0.036807645094533374,"score_gpt":0.4450239036082301,"score_spread":0.4082162585136967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399322695","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98999715,0.00061186973,0.000044740736,0.0068332097,0.0002683864,0.0020684607,0.000012051004,0.000015182604,0.00014896196],"genre_scores_gemma":[0.9985362,0.0004324607,0.00025371503,0.00038961536,0.00021847224,0.00006197702,0.000004569097,0.000047850084,0.00005509759],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9948876,0.0013722574,0.0021149071,0.00041568207,0.00081289164,0.00039664205],"domain_scores_gemma":[0.99585295,0.0023902045,0.0006618546,0.00014831385,0.0006179418,0.0003287197],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048650308,0.00025700152,0.002548275,0.0005438066,0.000054182565,0.00004269444,0.00014087906,0.00026331836,0.000105539686],"category_scores_gemma":[0.00055006536,0.00015557105,0.00016614523,0.00058255746,0.00037873813,0.0002514843,0.000046223187,0.0019885027,0.0000013309241],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.45182538,0.010360571,0.30157307,0.000038947524,0.0007165151,0.0019520737,0.0042506093,0.000012319804,0.00002081956,0.000010850085,0.00002869034,0.22921018],"study_design_scores_gemma":[0.38958612,0.12052673,0.48691496,0.0010529283,0.00024065819,0.0001938904,0.0005023156,0.0007641009,0.000009648665,0.000020535392,0.00007792579,0.000110206354],"about_ca_topic_score_codex":0.0011487063,"about_ca_topic_score_gemma":0.00094748545,"teacher_disagreement_score":0.22909997,"about_ca_system_score_codex":0.0009876211,"about_ca_system_score_gemma":0.0028559843,"threshold_uncertainty_score":0.8639165},"labels":[],"label_agreement":null},{"id":"W4399504365","doi":"10.1158/1538-8514.synthleth24-a013","title":"Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Microtubule; Microtubule polymerization; In vitro; Cancer research; Tubulin; Chemistry; Biophysics; Cell biology; Biology; Biochemistry","score_opus":0.046124812847405355,"score_gpt":0.3743399704367299,"score_spread":0.3282151575893245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399504365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.83210033,0.08926605,0.010646523,0.05195432,0.001072942,0.0017373088,0.00021064874,0.00062014256,0.012391746],"genre_scores_gemma":[0.99070966,0.0023614434,0.0004797887,0.004365011,0.00030951927,0.00012444145,0.000016903423,0.00019280285,0.0014404136],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972103,0.0000489286,0.00032209873,0.00064598426,0.0010807198,0.00069195597],"domain_scores_gemma":[0.99875027,0.00007746312,0.00004256026,0.00067866675,0.00020407248,0.00024695136],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022328897,0.0003661572,0.00041085345,0.00019380363,0.00007757781,0.00013994938,0.00024460355,0.00017992037,0.0015939737],"category_scores_gemma":[0.000008948334,0.00028756124,0.00018245167,0.00067897304,0.00028634013,0.000073627576,0.00004428048,0.00080739654,0.00017629165],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022128595,0.00083938375,0.0048193852,0.0061905747,0.0061304565,0.037392788,0.0061161155,0.00038920043,0.5286522,0.002017581,0.0099375425,0.3953019],"study_design_scores_gemma":[0.0039246613,0.0021009697,0.008718983,0.004945034,0.0016233958,0.0015849748,0.00043308164,0.0038733354,0.35777217,0.0007272146,0.612893,0.0014031818],"about_ca_topic_score_codex":0.0002524147,"about_ca_topic_score_gemma":0.000050513136,"teacher_disagreement_score":0.60295546,"about_ca_system_score_codex":0.0006441124,"about_ca_system_score_gemma":0.0014231082,"threshold_uncertainty_score":0.9999577},"labels":[],"label_agreement":null},{"id":"W4399803891","doi":"10.1016/j.ijbiomac.2024.133247","title":"HER-2 positive gastric cancer: Current targeted treatments","year":2024,"lang":"en","type":"review","venue":"International Journal of Biological Macromolecules","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Trastuzumab; Drug resistance; Cancer; Cancer research; Metastasis; Medicine; Drug; Pharmacology; Biology; Internal medicine; Breast cancer","score_opus":0.1302679898086728,"score_gpt":0.4882950427009865,"score_spread":0.35802705289231374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399803891","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035338316,0.99474686,0.00006390384,0.0005649294,0.0026673954,0.0004770507,0.0007456154,0.000027188713,0.00035369687],"genre_scores_gemma":[0.00073561136,0.99655426,0.00031713708,0.000093804214,0.0017688588,0.000063589876,0.0002148353,0.000048761758,0.00020312946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967623,0.000280227,0.0011430655,0.00042048874,0.0010248699,0.00036910237],"domain_scores_gemma":[0.99792224,0.00019572099,0.0006317585,0.00016242327,0.0007734271,0.00031442477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032046012,0.00046768572,0.0015811671,0.0006616855,0.00003122344,0.00010375624,0.0007290208,0.00030155698,0.00054287806],"category_scores_gemma":[0.00029462116,0.00025956408,0.0012898159,0.00038580102,0.00017007231,0.000044382225,0.00025254316,0.0013525119,0.000210667],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011428916,0.00033752376,0.00011512855,0.0011115201,0.0027739909,0.004208296,0.000016604265,2.7949275e-7,0.000056476187,0.00007825377,0.0029703346,0.9882173],"study_design_scores_gemma":[0.00060748024,0.0010716788,0.00022309458,0.034983307,0.0017408476,0.0044107866,0.000010870236,0.0000038728754,0.000051461113,0.0002481771,0.9563909,0.00025748467],"about_ca_topic_score_codex":0.000027446129,"about_ca_topic_score_gemma":0.000001305033,"teacher_disagreement_score":0.9879598,"about_ca_system_score_codex":0.0014313569,"about_ca_system_score_gemma":0.001164128,"threshold_uncertainty_score":0.99998564},"labels":[],"label_agreement":null},{"id":"W4399828028","doi":"10.32920/26052757.v1","title":"The Regulation of Epidermal Growth Factor Receptor Signaling","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epidermal growth factor receptor; Factor (programming language); Epidermal growth factor; Cell biology; Receptor; Biology; Computer science; Genetics","score_opus":0.08166949638005443,"score_gpt":0.3859924481226286,"score_spread":0.3043229517425742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399828028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80057764,0.010812381,0.0017825853,0.063806556,0.0060822517,0.005113562,0.00028061905,0.00065893016,0.110885456],"genre_scores_gemma":[0.9809349,0.0004122442,0.0016545659,0.00009017603,0.00087170396,0.00007993962,0.00005376498,0.000060156075,0.015842514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787277,0.00012588626,0.00051428785,0.00039535222,0.00080361945,0.00028805595],"domain_scores_gemma":[0.998345,0.00044474888,0.000117238495,0.0005839954,0.00038786666,0.00012112449],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007927954,0.00018734507,0.00036784555,0.00013819292,0.00005864652,0.000057999565,0.0002402371,0.0002760408,0.0023064925],"category_scores_gemma":[0.00056811905,0.000114533774,0.00021760425,0.00017455404,0.00014136684,0.000016476462,0.0006810792,0.0011641664,0.00020535137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011965134,0.00025802216,0.011078256,0.02307758,0.0021003757,0.000050433628,0.0036049644,0.0003348756,0.4598488,0.032974962,0.29967302,0.1658022],"study_design_scores_gemma":[0.0010567975,0.0004928446,0.017819159,0.0065534064,0.00035118742,0.000028348639,0.00057342096,0.007196853,0.8501733,0.049721062,0.06529257,0.00074107875],"about_ca_topic_score_codex":0.0003643853,"about_ca_topic_score_gemma":0.000017250532,"teacher_disagreement_score":0.39032447,"about_ca_system_score_codex":0.00027156755,"about_ca_system_score_gemma":0.00077465293,"threshold_uncertainty_score":0.99860555},"labels":[],"label_agreement":null},{"id":"W4399828159","doi":"10.32920/26052757","title":"The Regulation of Epidermal Growth Factor Receptor Signaling","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"","keywords":"Epidermal growth factor receptor; Cell biology; Epidermal growth factor; Factor (programming language); Receptor; Biology; Computer science; Genetics","score_opus":0.08166949638005443,"score_gpt":0.3859924481226286,"score_spread":0.3043229517425742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399828159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80057764,0.010812381,0.0017825853,0.063806556,0.0060822517,0.005113562,0.00028061905,0.00065893016,0.110885456],"genre_scores_gemma":[0.9809349,0.0004122442,0.0016545659,0.00009017603,0.00087170396,0.00007993962,0.00005376498,0.000060156075,0.015842514],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787277,0.00012588626,0.00051428785,0.00039535222,0.00080361945,0.00028805595],"domain_scores_gemma":[0.998345,0.00044474888,0.000117238495,0.0005839954,0.00038786666,0.00012112449],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007927954,0.00018734507,0.00036784555,0.00013819292,0.00005864652,0.000057999565,0.0002402371,0.0002760408,0.0023064925],"category_scores_gemma":[0.00056811905,0.000114533774,0.00021760425,0.00017455404,0.00014136684,0.000016476462,0.0006810792,0.0011641664,0.00020535137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011965134,0.00025802216,0.011078256,0.02307758,0.0021003757,0.000050433628,0.0036049644,0.0003348756,0.4598488,0.032974962,0.29967302,0.1658022],"study_design_scores_gemma":[0.0010567975,0.0004928446,0.017819159,0.0065534064,0.00035118742,0.000028348639,0.00057342096,0.007196853,0.8501733,0.049721062,0.06529257,0.00074107875],"about_ca_topic_score_codex":0.0003643853,"about_ca_topic_score_gemma":0.000017250532,"teacher_disagreement_score":0.39032447,"about_ca_system_score_codex":0.00027156755,"about_ca_system_score_gemma":0.00077465293,"threshold_uncertainty_score":0.99860555},"labels":[],"label_agreement":null},{"id":"W4399901966","doi":"10.1158/1535-7163.mct-23-0393","title":"Anti-Claudin-2 Antibody–Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McGill University","funders":"Institute of Cancer Research","keywords":"Metastasis; Colorectal cancer; Claudin; Cancer; Cancer research; Monoclonal antibody; Antibody; In vivo; Antibody-drug conjugate; Medicine; Liver cancer; Immunology; Biology; Internal medicine; Tight junction","score_opus":0.06740540409596586,"score_gpt":0.41211183557284087,"score_spread":0.344706431476875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399901966","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5420891,0.44204894,0.002443314,0.009104317,0.00093939074,0.0023719117,0.0006777824,0.000101707745,0.00022351141],"genre_scores_gemma":[0.8906509,0.1059026,0.00046860546,0.00087964797,0.0002576707,0.00092275685,0.00003199258,0.00010998397,0.0007758111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817145,0.00007811734,0.0003217245,0.00043216354,0.0005203002,0.00047622807],"domain_scores_gemma":[0.99883574,0.00031108406,0.00006889264,0.00039869637,0.00027872695,0.000106841115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023337359,0.00029118411,0.0005128777,0.0001283509,0.00010991216,0.00006347671,0.00020739547,0.000090417656,0.00045904735],"category_scores_gemma":[0.000009645069,0.00018444384,0.00040981107,0.00045600763,0.00029706047,0.000040168576,0.00002997343,0.00017823934,0.000012503267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007557618,0.00048551906,0.0042675133,0.001176994,0.0075111673,0.00022651358,0.0030106057,0.0004209065,0.6871908,0.00083857874,0.0016682339,0.29244745],"study_design_scores_gemma":[0.0011495162,0.00070351746,0.0009741515,0.00029135426,0.0018003859,0.000016085334,0.00012562884,0.009329237,0.62769306,0.00007864441,0.3576507,0.00018775479],"about_ca_topic_score_codex":0.0013807875,"about_ca_topic_score_gemma":0.00022167097,"teacher_disagreement_score":0.35598245,"about_ca_system_score_codex":0.00048555224,"about_ca_system_score_gemma":0.00079371367,"threshold_uncertainty_score":0.75214016},"labels":[],"label_agreement":null},{"id":"W4399984692","doi":"10.3389/fonc.2024.1395970","title":"Germline rare variants in HER2-positive breast cancer predisposition: a systematic review and meta-analysis","year":2024,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Germline; Meta-analysis; Breast cancer; Medicine; Oncology; Cancer; Genetic testing; Germline mutation; Bioinformatics; Internal medicine; Genetics; Gene; Biology; Mutation","score_opus":0.08222996412548599,"score_gpt":0.45784727354163207,"score_spread":0.3756173094161461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399984692","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[1.8253553e-7,0.9862575,0.00009360738,0.003571163,0.0004221602,0.0073113893,0.0016982707,0.000033188175,0.0006125308],"genre_scores_gemma":[0.00000551984,0.9876185,0.0008004385,0.0010040267,0.00015186846,0.0071498486,0.00033159752,0.0000917979,0.0028463746],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99348927,0.002196728,0.002015436,0.0011479959,0.0005300677,0.00062048127],"domain_scores_gemma":[0.99797344,0.00025816713,0.00050883775,0.00080057554,0.00019269869,0.0002662586],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021848336,0.00068458414,0.01659625,0.0017331113,0.000035798636,0.000038238835,0.00037431717,0.00076852186,0.0009430189],"category_scores_gemma":[0.0002103325,0.00046298112,0.0017184508,0.0034726125,0.00020606027,0.00007465602,0.00022875026,0.0016401219,0.000042767715],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029274108,0.00015525852,0.000041146828,0.8583793,0.10775597,0.0019763338,0.00012381266,7.206482e-7,1.1501796e-8,0.000012220025,0.019323517,0.012202421],"study_design_scores_gemma":[0.0002959145,0.00015079329,0.00003412475,0.17688537,0.76194584,0.0008878829,0.000041802447,0.00005053409,1.343439e-8,0.000023320581,0.059380013,0.0003043592],"about_ca_topic_score_codex":0.00036605142,"about_ca_topic_score_gemma":0.0005053556,"teacher_disagreement_score":0.68149394,"about_ca_system_score_codex":0.003404805,"about_ca_system_score_gemma":0.0019633656,"threshold_uncertainty_score":0.99997026},"labels":[],"label_agreement":null},{"id":"W4400350261","doi":"10.3390/biomedicines12071491","title":"Antibody-Drug Conjugates to Promote Immune Surveillance: Lessons Learned from Breast Cancer","year":2024,"lang":"en","type":"review","venue":"Biomedicines","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Medicine; Pembrolizumab; Atezolizumab; Immunotherapy; Trastuzumab; Immune system; Oncology; Breast cancer; Cancer; Cancer immunotherapy; Antibody-drug conjugate; Immunology; Chimeric antigen receptor; Cancer research; Antibody; Internal medicine; Monoclonal antibody","score_opus":0.14175747946290512,"score_gpt":0.49666867723443187,"score_spread":0.35491119777152674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400350261","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008894191,0.95810205,0.000007486942,0.02937905,0.00311093,0.0028706861,0.005609587,0.00037303896,0.00045820643],"genre_scores_gemma":[0.00008664668,0.98153,0.00011791404,0.00030172005,0.0053357817,0.00072593935,0.0033231173,0.00034326172,0.0082356185],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9943737,0.00025794643,0.00132768,0.0016157941,0.0013465675,0.0010783051],"domain_scores_gemma":[0.9967452,0.00029068856,0.00028569676,0.0014518794,0.0004152016,0.00081127585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010693733,0.0010462605,0.0043097776,0.0010366169,0.00012528224,0.00013040919,0.00076129596,0.0005324547,0.0017107642],"category_scores_gemma":[0.00027677155,0.0006785122,0.0006920862,0.0024945424,0.00044804433,0.000057370995,0.00048703884,0.0013475138,0.002164999],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007605271,0.000095833035,0.00012111921,0.046061758,0.0010775076,0.00050430227,0.00027366617,4.5393406e-8,0.0011148963,0.000010009109,0.04725825,0.90340656],"study_design_scores_gemma":[0.0005639795,0.00014403583,0.00027449473,0.11079418,0.0015377351,0.00022282769,0.00006577707,0.000006941634,0.000021930819,0.00003781236,0.88575965,0.0005706292],"about_ca_topic_score_codex":0.006568745,"about_ca_topic_score_gemma":0.00019062727,"teacher_disagreement_score":0.9028359,"about_ca_system_score_codex":0.0006892789,"about_ca_system_score_gemma":0.002597012,"threshold_uncertainty_score":0.9995666},"labels":[],"label_agreement":null},{"id":"W4400382953","doi":"10.14740/wjon1853","title":"Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs","year":2024,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Yunnan Provincial Science and Technology Department; Kunming Medical University","keywords":"Medicine; Triple-negative breast cancer; Conjugate; Antibody-drug conjugate; Drug; Breast cancer; Antibody; Drug development; Oncology; Cancer; Monoclonal antibody; Immunology; Internal medicine; Pharmacology","score_opus":0.20008682607938005,"score_gpt":0.4285066110945388,"score_spread":0.22841978501515875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400382953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71954435,0.081771135,0.00002631454,0.19341624,0.00070339727,0.00089974975,0.000043272674,0.000008501628,0.003587026],"genre_scores_gemma":[0.9470155,0.051267132,0.00032409487,0.0003537996,0.00034694342,0.000037414473,9.489149e-7,0.000011828648,0.00064234325],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894994,0.00015912061,0.0003581118,0.00009124525,0.00022698584,0.00021460226],"domain_scores_gemma":[0.9985028,0.0010553832,0.00015590948,0.00006804356,0.00015060695,0.00006728465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023968595,0.00009290288,0.00033552083,0.0005584845,0.00009442699,0.000021685457,0.0001276764,0.000032877408,0.000041626983],"category_scores_gemma":[0.000057995676,0.000049326492,0.000041574833,0.00025793078,0.00027915623,0.00008404478,0.0000642487,0.00032188193,2.4186224e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009907084,0.00011016766,0.0052010785,0.001297567,0.00043404673,0.00024972484,0.110998556,0.0000037084337,0.00057468686,0.0031519446,0.0016280115,0.8753598],"study_design_scores_gemma":[0.004441118,0.0010509616,0.058205012,0.002812597,0.00026709877,0.0014795006,0.17663504,0.0003156888,0.0007250183,0.0005182065,0.7533838,0.00016596839],"about_ca_topic_score_codex":0.000054424625,"about_ca_topic_score_gemma":0.0016168442,"teacher_disagreement_score":0.87519383,"about_ca_system_score_codex":0.00014428936,"about_ca_system_score_gemma":0.0008402442,"threshold_uncertainty_score":0.2011476},"labels":[],"label_agreement":null},{"id":"W4400810123","doi":"10.1002/1878-0261.13698","title":"<i>ERBB2</i> mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high ( <scp>MSI</scp> ‐H) molecular subtype","year":2024,"lang":"en","type":"article","venue":"Molecular Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Fonds de Recherche du Québec - Santé; Cycle for Survival; Ovarian Cancer Research Alliance; Breast Cancer Research Foundation","keywords":"Microsatellite instability; Biology; Cancer research; Mutation; Molecular biology; Wild type; Genetics; Microsatellite; Gene; Allele; Mutant","score_opus":0.015298773788025227,"score_gpt":0.29417872628802716,"score_spread":0.2788799525000019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400810123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853448,0.006617328,0.0011041841,0.0033897136,0.00025135692,0.0015113009,0.00016045826,0.00008428882,0.0015365366],"genre_scores_gemma":[0.9969886,0.00006125331,0.00135371,0.0005460174,0.00014006504,0.0002400619,0.00039347133,0.00008154381,0.00019526285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99655604,0.0007834046,0.00063129555,0.00064466376,0.00082125753,0.00056334474],"domain_scores_gemma":[0.99602026,0.0025843713,0.00018250979,0.00045600833,0.000540367,0.00021650881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422292,0.00030358668,0.0008090501,0.00044532694,0.00011074994,0.000067213696,0.00023232482,0.00022784946,0.000076286524],"category_scores_gemma":[0.0030087717,0.00022234439,0.00018446187,0.0015613681,0.0013174816,0.00006258395,0.00014893018,0.0006875554,0.000022383829],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035939547,0.0010067443,0.011243997,0.0013477015,0.0039212094,0.018450009,0.0074728713,0.0007060049,0.8589586,0.08445873,0.00093658094,0.007903566],"study_design_scores_gemma":[0.10351026,0.020556469,0.083673544,0.0021857787,0.0065718726,0.0057569016,0.0029967115,0.0050843568,0.65817046,0.043825597,0.06637584,0.0012922095],"about_ca_topic_score_codex":0.0017137498,"about_ca_topic_score_gemma":0.00022995379,"teacher_disagreement_score":0.20078817,"about_ca_system_score_codex":0.0005045288,"about_ca_system_score_gemma":0.0017344912,"threshold_uncertainty_score":0.90669405},"labels":[],"label_agreement":null},{"id":"W4400915869","doi":"10.17504/protocols.io.rm7vzj6rrlx1/v1","title":"Immunohistochemistry of free floating slices v1","year":2024,"lang":"en","type":"preprint","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Canadian Sleep & Circadian Network","funders":"","keywords":"Immunohistochemistry; Computer science; Chemistry; Pathology; Medicine","score_opus":0.04930180660465027,"score_gpt":0.4138150619434787,"score_spread":0.36451325533882845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400915869","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3805085,0.013958793,0.000053298463,0.0032718892,0.0008506417,0.0006911993,0.000112241796,0.00024019404,0.60031325],"genre_scores_gemma":[0.9210443,0.00047181014,0.012504805,0.00017107841,0.0011456748,0.000118933756,0.00011273379,0.00012528928,0.06430538],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99794394,0.000024378052,0.00049413985,0.0005019449,0.00075078104,0.00028479853],"domain_scores_gemma":[0.99793106,0.00009556419,0.000110335095,0.0014995907,0.00023705087,0.00012639935],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045658663,0.0002245328,0.0005267138,0.00013844432,0.000022895141,0.000033435335,0.0005460778,0.0003800595,0.0030446644],"category_scores_gemma":[0.00045131694,0.00019336787,0.00023755529,0.00015685035,0.00014107715,0.000009513412,0.0026751643,0.001783148,0.00013922066],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013677456,0.00015249,0.001204043,0.040604617,0.00073220144,0.00020599503,0.0013418824,0.000021196933,0.78017205,0.0006863573,0.15497833,0.019764068],"study_design_scores_gemma":[0.0010853286,0.00020841473,0.0006022034,0.011394181,0.00039818467,0.00007754495,0.0009933537,0.0012359952,0.95014733,0.009977354,0.023281328,0.000598784],"about_ca_topic_score_codex":0.0017455064,"about_ca_topic_score_gemma":0.000012534481,"teacher_disagreement_score":0.5405358,"about_ca_system_score_codex":0.00033913416,"about_ca_system_score_gemma":0.0012084573,"threshold_uncertainty_score":0.9978667},"labels":[],"label_agreement":null},{"id":"W4401831557","doi":"10.37349/etat.2024.00265","title":"Evaluation of HER2 immunohistochemistry expression in non-standard solid tumors from a Single-Institution Prospective Cohort","year":2024,"lang":"en","type":"article","venue":"Exploration of Targeted Anti-tumor Therapy","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; Western University","funders":"","keywords":"Medicine; Immunohistochemistry; Biomarker; Breast cancer; Internal medicine; Interquartile range; Oncology; Cancer; Prospective cohort study; Trastuzumab; Pathology; Biology","score_opus":0.052198028531590335,"score_gpt":0.3792982925428761,"score_spread":0.3271002640112858,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401831557","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98753476,0.004708626,0.003996994,0.00025064274,0.00038479653,0.0019390519,0.00008739756,0.00008114962,0.0010165981],"genre_scores_gemma":[0.9977333,0.00044748475,0.00091473496,0.00002208732,0.00018531317,0.00035524004,0.00026107678,0.000044406133,0.000036381647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966119,0.00019830563,0.0007593148,0.0004820667,0.0017115724,0.00023685941],"domain_scores_gemma":[0.99823296,0.0000594388,0.00023022055,0.00041851826,0.0009840316,0.000074815965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016837178,0.00022102999,0.0005490148,0.00032415375,0.000056787092,0.000034038323,0.00013855415,0.00011643453,0.00041451934],"category_scores_gemma":[0.00028286973,0.00020013348,0.00012933457,0.0006733092,0.00018316305,0.00051644933,0.00002824933,0.00034010684,0.000012851294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007679398,0.00039882024,0.006316689,0.00016140915,0.00011487955,0.000029492934,0.0021535624,0.00065422105,0.98328424,0.00002290955,0.00030862677,0.0057872357],"study_design_scores_gemma":[0.0025304505,0.0007002699,0.015379008,0.002102068,0.00005407655,0.000005194214,0.00064628205,0.009629769,0.9676095,0.000977041,0.00019499964,0.00017132069],"about_ca_topic_score_codex":0.00016431924,"about_ca_topic_score_gemma":0.000009468021,"teacher_disagreement_score":0.015674694,"about_ca_system_score_codex":0.00090236263,"about_ca_system_score_gemma":0.0011251966,"threshold_uncertainty_score":0.8161206},"labels":[],"label_agreement":null},{"id":"W4401994840","doi":"10.3390/cells13171452","title":"A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Cells","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Environmental Health Sciences","keywords":"Trastuzumab; ADAM10; Cancer research; Signal transduction; Cell growth; Cell biology; Breast cancer; Biology; Cancer; Medicine; Metalloproteinase; Matrix metalloproteinase; Biochemistry; Internal medicine; Disintegrin","score_opus":0.08228409039915346,"score_gpt":0.3902386193413681,"score_spread":0.30795452894221464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401994840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98243487,0.006796897,0.00025941702,0.0033529392,0.00045389766,0.0004705114,0.00003336671,0.00007810216,0.0061199856],"genre_scores_gemma":[0.9962037,0.00069593405,0.00029346507,0.00012680548,0.00023177385,0.00006662296,0.0000029956743,0.000039066523,0.002339607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998679,0.00004072391,0.0002182449,0.0003898288,0.00032541683,0.0003467968],"domain_scores_gemma":[0.99949265,0.00012355362,0.000020048843,0.00016993233,0.00004141699,0.00015238025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035781303,0.00012672455,0.00021839896,0.00014622888,0.000048511334,0.00007474228,0.00006497715,0.00010806165,0.00043428072],"category_scores_gemma":[0.000010016457,0.000115013354,0.00004606182,0.00038565925,0.000079691854,0.00009164138,0.000031326646,0.00050099345,0.00004421145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048500873,0.0001195927,0.006474006,0.0029273864,0.00008369068,0.0008378203,0.0020994635,0.000047203197,0.9247653,0.00027289358,0.004151659,0.05773601],"study_design_scores_gemma":[0.010791183,0.0009679986,0.20784609,0.034882184,0.00039301542,0.000643698,0.0053728884,0.015097647,0.5225949,0.0036894649,0.19533482,0.002386069],"about_ca_topic_score_codex":0.00045392488,"about_ca_topic_score_gemma":0.000837967,"teacher_disagreement_score":0.40217033,"about_ca_system_score_codex":0.0006650137,"about_ca_system_score_gemma":0.0008086165,"threshold_uncertainty_score":0.47550693},"labels":[],"label_agreement":null},{"id":"W4402250142","doi":"10.7759/cureus.68576","title":"Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects","year":2024,"lang":"en","type":"article","venue":"Cureus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor; Western University","funders":"","keywords":"Medicine; Trastuzumab; Denosumab; Metastatic breast cancer; Oncology; Human Epidermal Growth Factor Receptor 2; Breast cancer; Internal medicine; Cancer; Cancer research; Osteoporosis","score_opus":0.024915133658435045,"score_gpt":0.3520927106908752,"score_spread":0.32717757703244016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402250142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985526,0.009778141,0.00039053176,0.0011029924,0.0011454759,0.0010720952,0.00047481287,0.00013840641,0.00037154317],"genre_scores_gemma":[0.9973564,0.00085530744,0.00008328939,0.000091081405,0.0006975905,0.00015334321,0.00010388965,0.00010849725,0.00055059086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968559,0.00034526663,0.0004857748,0.00077728886,0.00073838956,0.000797357],"domain_scores_gemma":[0.99859935,0.00043539613,0.000064835884,0.00031074684,0.00015283424,0.00043684454],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003967874,0.00039886442,0.00074456807,0.0003056443,0.00013778408,0.00016394835,0.00018923657,0.00014808906,0.0010651028],"category_scores_gemma":[0.0001799436,0.00035513623,0.0001488732,0.0004469879,0.00029438542,0.0002385774,0.00013536372,0.0007495514,0.000061966384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020417639,0.0019792286,0.51726335,0.019564273,0.003182178,0.029894173,0.005394876,0.000025458025,0.232989,0.0037353502,0.00540587,0.17852445],"study_design_scores_gemma":[0.0028253952,0.0008024957,0.98514867,0.0022133035,0.00047921474,0.0008011626,0.00010116197,0.00026246058,0.0065803374,0.00015670022,0.00008389963,0.00054521236],"about_ca_topic_score_codex":0.0022484926,"about_ca_topic_score_gemma":0.0012047514,"teacher_disagreement_score":0.4678853,"about_ca_system_score_codex":0.0010156969,"about_ca_system_score_gemma":0.0006761481,"threshold_uncertainty_score":0.9998901},"labels":[],"label_agreement":null},{"id":"W4402267218","doi":"10.1158/1538-7445.pediatric24-b002","title":"Abstract B002: A novel NTRK2-activating internal tandem duplication characterizes a new mechanism of receptor tyrosine kinase activation","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tyrosine kinase; Receptor tyrosine kinase; Chemistry; Mechanism (biology); Cell biology; Cancer research; Receptor; Biochemistry; Biology; Philosophy","score_opus":0.16115813381259803,"score_gpt":0.4563875239758575,"score_spread":0.2952293901632595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9768669,0.0013363519,0.0048463107,0.012689944,0.0004846458,0.0014660836,0.00008675416,0.00016214966,0.0020608453],"genre_scores_gemma":[0.99263227,0.0009110657,0.0007821021,0.000100489895,0.001480251,0.00039506098,0.0000618609,0.00009383761,0.003543078],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965245,0.000081350154,0.00051232334,0.00064666476,0.0015697498,0.00066539977],"domain_scores_gemma":[0.9978749,0.00041883823,0.00011034866,0.00050840597,0.0007225089,0.00036497877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015724085,0.0002096422,0.00036765853,0.00064166303,0.00012908313,0.00015755187,0.0003212982,0.0001911778,0.003106777],"category_scores_gemma":[0.00084329344,0.00018809082,0.00011915389,0.0013149674,0.00017008629,0.00034434863,0.00017238723,0.0013088385,0.00012634452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047766438,0.00012090157,0.00024574233,0.0008542194,0.000096558884,0.000012050344,0.0006874779,0.0000022679105,0.89595276,0.0018824657,0.006133136,0.093534775],"study_design_scores_gemma":[0.0010532232,0.00037715904,0.008951449,0.004357962,0.000014713535,0.000013204779,0.00021797676,0.0007606614,0.9433947,0.0003891548,0.040290166,0.00017960566],"about_ca_topic_score_codex":0.0032808192,"about_ca_topic_score_gemma":0.00004323409,"teacher_disagreement_score":0.093355164,"about_ca_system_score_codex":0.0013813053,"about_ca_system_score_gemma":0.0023012424,"threshold_uncertainty_score":0.9978045},"labels":[],"label_agreement":null},{"id":"W4402472398","doi":"10.1200/jco.24.00920","title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":140,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Memorial Sloan-Kettering Cancer Center; AstraZeneca","keywords":"Medicine; Vinorelbine; Internal medicine; Metastatic breast cancer; Oncology; Chemotherapy; Eribulin; Gemcitabine; Breast cancer; Cancer","score_opus":0.12024444603652502,"score_gpt":0.47170743713032226,"score_spread":0.35146299109379725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402472398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9580866,0.0027376846,0.000034544624,0.033591185,0.0017933449,0.0010117751,0.0010722422,0.000056831013,0.0016157945],"genre_scores_gemma":[0.97790223,0.013087373,0.0032631068,0.0016175053,0.0032238264,0.000059678834,0.00017977838,0.000117876945,0.0005486258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99109715,0.0022355427,0.004030524,0.0008222608,0.0010209652,0.0007935424],"domain_scores_gemma":[0.988343,0.008120082,0.0012588381,0.00041635282,0.0009679166,0.00089378934],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034472437,0.00045892905,0.0027792782,0.0004907799,0.000099508405,0.00007055651,0.0004898338,0.000576355,0.0017262304],"category_scores_gemma":[0.0035460535,0.00034380407,0.00060126797,0.00083456544,0.0006010535,0.0004156925,0.000118613185,0.003489507,0.00008605754],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14872885,0.0045263246,0.025373753,0.00027608342,0.004194617,0.003241979,0.0035742295,0.000015170639,0.011976893,0.00005870188,0.047080897,0.7509525],"study_design_scores_gemma":[0.08217158,0.032093674,0.84937286,0.0027829066,0.0008426876,0.00046156874,0.0006690708,0.0002183022,0.003230744,0.00037116878,0.027063828,0.00072160806],"about_ca_topic_score_codex":0.0045723184,"about_ca_topic_score_gemma":0.0006976965,"teacher_disagreement_score":0.8239991,"about_ca_system_score_codex":0.0032753805,"about_ca_system_score_gemma":0.0065956106,"threshold_uncertainty_score":0.9999014},"labels":[],"label_agreement":null},{"id":"W4402561305","doi":"10.1016/j.annonc.2024.08.384","title":"437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Medicine; Antibody-drug conjugate; Open label; Conjugate; Trastuzumab; Drug; Oncology; Pharmacology; Phases of clinical research; Internal medicine; Antibody; Clinical trial; Monoclonal antibody; Adverse effect; Cancer; Immunology; Breast cancer","score_opus":0.14514835074140064,"score_gpt":0.5117613860980696,"score_spread":0.366613035356669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402561305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865478,0.00072781154,0.000016324742,0.0042775013,0.00011778902,0.007631412,0.000421825,0.00003797508,0.00022154035],"genre_scores_gemma":[0.9961147,0.0009927232,0.00040571656,0.00071213127,0.00006281639,0.00042204926,0.00007712618,0.000096760705,0.0011159991],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99513024,0.0011459091,0.0011643101,0.0008975409,0.00079312903,0.0008688765],"domain_scores_gemma":[0.9967186,0.001026508,0.0002704715,0.00062100106,0.00096844765,0.0003949862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036524558,0.00042329013,0.0014211716,0.00033723714,0.00017326135,0.00007458315,0.00061109033,0.000087475215,0.0009079719],"category_scores_gemma":[0.0006431367,0.0002384095,0.00004968462,0.0013398885,0.00033898925,0.00031827093,0.00046610952,0.0005267853,0.0000123051],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33983976,0.15484309,0.051589157,0.0042513288,0.004479103,0.0017612292,0.04363914,0.00080813165,0.023024872,0.000019848218,0.0074472395,0.36829713],"study_design_scores_gemma":[0.30793434,0.50183624,0.0915696,0.013069325,0.0025901587,0.00027853777,0.01261283,0.02599089,0.013237269,0.000019120844,0.02914628,0.001715399],"about_ca_topic_score_codex":0.021909436,"about_ca_topic_score_gemma":0.015181151,"teacher_disagreement_score":0.3665817,"about_ca_system_score_codex":0.0002711965,"about_ca_system_score_gemma":0.0016889743,"threshold_uncertainty_score":0.99416554},"labels":[],"label_agreement":null},{"id":"W4402826410","doi":"10.1007/s12032-024-02504-4","title":"Personalized treatment approach for HER2-positive metastatic breast cancer","year":2024,"lang":"en","type":"review","venue":"Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Science and Engineering Research Board","keywords":"Hematology; Internal medicine; Breast cancer; Metastatic breast cancer; Oncology; Medicine; Cancer; Trastuzumab","score_opus":0.20989891219432807,"score_gpt":0.5502231872662202,"score_spread":0.3403242750718921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402826410","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[5.2765495e-7,0.9798403,0.00055686675,0.0069464385,0.0008247381,0.0048974617,0.0014542763,0.00009416978,0.0053852554],"genre_scores_gemma":[0.0000014035005,0.9679553,0.0020037212,0.0008139793,0.0021010377,0.0122001665,0.0010476164,0.00017857231,0.013698226],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99525976,0.0007020435,0.0009165619,0.0010637444,0.0011572338,0.0009006541],"domain_scores_gemma":[0.9969474,0.0012177784,0.0001915051,0.00042269786,0.00018885842,0.001031741],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012034442,0.00067182636,0.0045996797,0.00033110494,0.000079308105,0.000025202711,0.0003559987,0.00093655044,0.0046953666],"category_scores_gemma":[0.00037271064,0.0003944188,0.0013087657,0.00051601673,0.0006993076,0.000019517991,0.00013996281,0.0012921733,0.0002921853],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00017714662,0.0009874769,0.0000013771876,0.03908578,0.0028614542,0.0011928458,0.00020558787,5.4267364e-8,1.1016169e-7,0.00029432809,0.035981387,0.91921246],"study_design_scores_gemma":[0.0023035135,0.0023604704,0.0000010683169,0.01178528,0.011298785,0.003398847,0.00007590568,0.00022010024,3.3107676e-7,0.000023496234,0.96824336,0.00028885432],"about_ca_topic_score_codex":0.0004749178,"about_ca_topic_score_gemma":0.000079857076,"teacher_disagreement_score":0.93226194,"about_ca_system_score_codex":0.0059933676,"about_ca_system_score_gemma":0.017024258,"threshold_uncertainty_score":0.99985075},"labels":[],"label_agreement":null},{"id":"W4402922378","doi":"10.3390/curroncol31090422","title":"Canadian Expert Recommendations on Safety Overview and Toxicity Management Strategies for Sacituzumab Govitecan Based on Use in Metastatic Triple-Negative Breast Cancer","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Toronto; University of British Columbia; University of Calgary; Saskatchewan Cancer Agency; University of Saskatchewan","funders":"Saskatchewan Health Research Foundation; Gilead Sciences","keywords":"Medicine; Triple-negative breast cancer; Metastatic breast cancer; Neutropenia; Adverse effect; Irinotecan; Internal medicine; Oncology; Breast cancer; Anemia; Tolerability; Febrile neutropenia; Cancer; Toxicity","score_opus":0.44193512524009676,"score_gpt":0.5652496553908358,"score_spread":0.12331453015073907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402922378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009716399,0.9760576,0.0001110385,0.0058418233,0.0017314068,0.0072681955,0.0070597986,0.000043160446,0.001877259],"genre_scores_gemma":[0.00007136129,0.9920102,0.00047771123,0.0006659461,0.00021154883,0.0053279507,0.00075871084,0.00008886499,0.00038771518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99638003,0.0007565601,0.00084885233,0.0009283901,0.0003457056,0.00074045814],"domain_scores_gemma":[0.99758595,0.0011035327,0.00020349397,0.0004924873,0.0001263842,0.00048812252],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008909129,0.0005779992,0.0019788868,0.0012823049,0.00011910996,0.000099320234,0.00023100886,0.00023943828,0.00061574584],"category_scores_gemma":[0.0001500182,0.00045559116,0.00031093165,0.00078348943,0.00013681124,0.000089670175,0.00007732844,0.0011031193,0.000034126802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016397914,0.0003316032,0.000009098784,0.025993712,0.0002928609,0.00009211555,0.00015409238,0.000004968687,4.443947e-8,0.0017297193,0.02514316,0.9460846],"study_design_scores_gemma":[0.0017659419,0.0007074469,0.00007806302,0.039395526,0.00096929097,0.000026002637,0.00023651849,0.00036030263,2.6864154e-7,0.0001731279,0.95594996,0.00033757294],"about_ca_topic_score_codex":0.0222793,"about_ca_topic_score_gemma":0.2594674,"teacher_disagreement_score":0.9457471,"about_ca_system_score_codex":0.013082165,"about_ca_system_score_gemma":0.007659667,"threshold_uncertainty_score":0.9997896},"labels":[],"label_agreement":null},{"id":"W4403173283","doi":"10.1200/jco.23.02768","title":"Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Trastuzumab; Immunohistochemistry; Oncology; Internal medicine; Lapatinib; Human Epidermal Growth Factor Receptor 2; Cohort; Stage (stratigraphy); Proportional hazards model; Cancer; Endometrial cancer; Breast cancer; Pathology; Biology","score_opus":0.30072103029406194,"score_gpt":0.566065639248905,"score_spread":0.265344608954843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403173283","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98009586,0.003213138,0.00031919978,0.0087241065,0.0067241723,0.00048426367,0.0002957017,0.000017210275,0.00012634209],"genre_scores_gemma":[0.96719813,0.023851626,0.0036157437,0.0012840417,0.0037151163,0.000014460071,0.000008266745,0.000056485056,0.00025610116],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99101686,0.002264851,0.0047654673,0.00047503444,0.0010260171,0.0004517523],"domain_scores_gemma":[0.9839879,0.0119130695,0.0021426324,0.0003026968,0.0007872051,0.0008664423],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008979123,0.00026802608,0.0032901347,0.00044843706,0.000054117903,0.00003792241,0.00032726035,0.00053083635,0.0032962107],"category_scores_gemma":[0.026409721,0.00017497249,0.00090978533,0.00044892353,0.00086999685,0.0001503402,0.00016577604,0.0033728797,0.000027709335],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010558908,0.0016602107,0.21648492,0.0009437702,0.0029449267,0.0022420567,0.00019098129,2.3485757e-7,0.0006811133,0.00019963722,0.023014309,0.7410789],"study_design_scores_gemma":[0.032697175,0.0731896,0.65751266,0.0027353424,0.0048891497,0.0006405283,0.00015260933,0.00023750892,0.004424662,0.0015900503,0.22132088,0.0006098097],"about_ca_topic_score_codex":0.00018548251,"about_ca_topic_score_gemma":0.000039164956,"teacher_disagreement_score":0.7404691,"about_ca_system_score_codex":0.00020907148,"about_ca_system_score_gemma":0.0038386178,"threshold_uncertainty_score":0.9989264},"labels":[],"label_agreement":null},{"id":"W4403284224","doi":"10.17615/hpyc-bg25","title":"Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Aptitude Health; Oncolytics Biotech; Seagen; Puma Biotechnology; Daiichi-Sankyo; Genentech; Veracyte; Pfizer; Incyte; Queen Mary University of London; Clovis Oncology; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Natera; Baxalta; Amgen; Ariad Pharmaceuticals; Servier; Gilead Sciences; Exelixis; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Les Laboratories Pierre Fabre","keywords":"Breast cancer; Stage (stratigraphy); Oncology; Internal medicine; Medicine; Gynecology; Cancer; Biology","score_opus":0.026881259007008367,"score_gpt":0.3289802243166732,"score_spread":0.3020989653096648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403284224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636529,0.00332464,0.00003778996,0.0015567547,0.0001078371,0.0011315251,0.029854644,0.000033017855,0.00030088364],"genre_scores_gemma":[0.99434304,0.00030260935,0.000182766,0.0002607436,0.000109718116,0.00017214168,0.004502597,0.000037753765,0.000088611094],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637246,0.00050644024,0.0008290739,0.00062121986,0.0010690528,0.0006017735],"domain_scores_gemma":[0.9977356,0.0009259964,0.00020116572,0.000748446,0.00024384915,0.00014494102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043795805,0.000313723,0.0012161098,0.0014211215,0.000058436595,0.00012395388,0.0005121792,0.00014011463,0.00055953703],"category_scores_gemma":[0.00006440821,0.00022881592,0.0003072752,0.011081339,0.0005140531,0.00039821633,0.00023834607,0.00053974654,0.000005294015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005850536,0.00031928992,0.9735968,0.0005192656,0.005573845,0.00015308218,0.004513179,0.008257836,0.000015521502,0.0017624426,0.0032206455,0.0014830048],"study_design_scores_gemma":[0.00066864095,0.0002217818,0.9845824,0.00077091577,0.0036710901,0.0000046289747,0.0008988514,0.00810788,0.00006614063,0.00018781672,0.00062591204,0.00019394445],"about_ca_topic_score_codex":0.07877917,"about_ca_topic_score_gemma":0.020285051,"teacher_disagreement_score":0.05849412,"about_ca_system_score_codex":0.0003038298,"about_ca_system_score_gemma":0.00088139245,"threshold_uncertainty_score":0.9975922},"labels":[],"label_agreement":null},{"id":"W4403410103","doi":"10.1016/j.jtho.2024.09.436","title":"P2.10A.01 Phase 2 Study of Disitamab Vedotin in Patients with HER2-Expressing Non-Small Cell Lung Cancer (DV-005; Trial in Progress)","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Oncology; Lung cancer; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.03779296339728983,"score_gpt":0.4926715589626017,"score_spread":0.45487859556531185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403410103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993418,0.0022868493,0.00002492805,0.0009139165,0.0008862337,0.0020354292,0.000010302443,0.000010775759,0.0004135837],"genre_scores_gemma":[0.99820083,0.00007649623,0.0008081509,0.000041347248,0.00059993495,0.000094972806,0.0000033277609,0.00005481551,0.00012011964],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99644125,0.0005868917,0.0012436571,0.00034529142,0.0008647906,0.0005181336],"domain_scores_gemma":[0.9984167,0.00029467806,0.0005313253,0.00027388718,0.0002864713,0.00019693302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019152014,0.00023233463,0.0010675378,0.000854197,0.000033654724,0.00004090348,0.00030047525,0.00020253958,0.00019226894],"category_scores_gemma":[0.00013066197,0.00016787443,0.00011332644,0.00079122203,0.00013140039,0.00017775717,0.00011060539,0.0014444325,0.0000028269026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16625808,0.021455947,0.61944497,0.0016374525,0.00031491922,0.0041041686,0.008068467,0.00024734272,0.0008068045,8.67467e-7,0.0014512533,0.1762097],"study_design_scores_gemma":[0.41893727,0.162346,0.37505463,0.01615471,0.0018669382,0.00018299434,0.008276855,0.004283561,0.005738144,0.00005187083,0.0062059234,0.0009011121],"about_ca_topic_score_codex":0.00024857395,"about_ca_topic_score_gemma":0.00066863024,"teacher_disagreement_score":0.25267917,"about_ca_system_score_codex":0.0013596526,"about_ca_system_score_gemma":0.0023116532,"threshold_uncertainty_score":0.68457204},"labels":[],"label_agreement":null},{"id":"W4403419652","doi":"10.1016/j.jtho.2024.09.543","title":"P3.02G.02 Integrin-Linked Kinase Facilitates Drug Tolerant Persister Cell Survival and EMT in Response to EGFR Targeted Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation","funders":"","keywords":"Medicine; Drug; Cancer research; Pharmacology; Multidrug tolerance; Oncology; Biology; Genetics; Bacteria","score_opus":0.05558787460023284,"score_gpt":0.4507780967487866,"score_spread":0.39519022214855376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403419652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483537,0.00965274,0.0000675079,0.039317522,0.0011755496,0.0004518677,0.00001797146,0.000024377463,0.0009387471],"genre_scores_gemma":[0.9915355,0.00087090925,0.0017823023,0.0007882294,0.0003650119,0.000018790675,0.0000026704354,0.000041565097,0.0045950483],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641645,0.0013456809,0.0008042099,0.00035545416,0.00057503843,0.00050314295],"domain_scores_gemma":[0.99738425,0.0014147958,0.0001244218,0.00026488173,0.0003367539,0.00047491462],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005264318,0.00023779544,0.00081400713,0.00092464057,0.00004972296,0.000066733235,0.00025073215,0.00021466843,0.00059422373],"category_scores_gemma":[0.0005852527,0.00017456766,0.00020174214,0.000555692,0.00017148156,0.00013728217,0.000103039965,0.0014601168,0.000081176346],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1166575,0.0013069689,0.009421679,0.0010562602,0.0003798688,0.018574048,0.04553066,0.00012024292,0.3950599,0.000016818956,0.027576435,0.38429958],"study_design_scores_gemma":[0.0059272414,0.020388005,0.06639586,0.0020257153,0.00019605315,0.0023384015,0.018160848,0.0015483059,0.02618737,0.00033359858,0.8558507,0.00064788316],"about_ca_topic_score_codex":0.0001211878,"about_ca_topic_score_gemma":0.00014143158,"teacher_disagreement_score":0.8282743,"about_ca_system_score_codex":0.0010450686,"about_ca_system_score_gemma":0.0013649683,"threshold_uncertainty_score":0.71186626},"labels":[],"label_agreement":null},{"id":"W4403455062","doi":"10.1016/j.esmoop.2024.103938","title":"Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kelowna General Hospital","funders":"National Cancer Institute; ECOG-ACRIN Cancer Research Group; National Institutes of Health; Meso Scale Diagnostics; Gilead Sciences; American College of Radiology Imaging Network; Roche; Canadian Cancer Society; GlaxoSmithKline; AstraZeneca; Novartis; Pfizer","keywords":"Lapatinib; Trastuzumab; Medicine; Breast cancer; Oncology; Internal medicine; Adjuvant; Cancer","score_opus":0.07178304164162665,"score_gpt":0.3880955706819111,"score_spread":0.31631252904028445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403455062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940227,0.00005804491,0.000010177147,0.0017263249,0.0000784832,0.003113333,0.00023451244,0.000010595606,0.00074583106],"genre_scores_gemma":[0.9982758,0.00004762751,0.000115588075,0.00013254849,0.000024689136,0.00059373403,0.000070370006,0.000033816315,0.0007058149],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974989,0.0003086933,0.00049315486,0.0005075809,0.00083014864,0.00036151955],"domain_scores_gemma":[0.9990271,0.00016473242,0.00012485517,0.00038849434,0.00021316131,0.00008168455],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00075147225,0.00019813646,0.0006544931,0.00040048547,0.00003423595,0.0000799472,0.00045273485,0.00008709348,0.00030747417],"category_scores_gemma":[0.00007149371,0.00011617777,0.000056882287,0.0039750626,0.00016742593,0.00026156474,0.00013137236,0.00054899446,0.000006276839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029898664,0.0008092867,0.94073844,0.00012925285,0.00032555067,0.00014976236,0.0032293664,0.00048203193,0.00001595277,0.000056871708,0.00009666804,0.024068182],"study_design_scores_gemma":[0.02433991,0.0017463658,0.9689511,0.0029325038,0.00018272409,0.0000032106414,0.00022198985,0.0011685179,0.00016108314,0.000016223283,0.00012345522,0.00015290116],"about_ca_topic_score_codex":0.066816345,"about_ca_topic_score_gemma":0.1445673,"teacher_disagreement_score":0.07775094,"about_ca_system_score_codex":0.0010763204,"about_ca_system_score_gemma":0.0015887772,"threshold_uncertainty_score":0.9393978},"labels":[],"label_agreement":null},{"id":"W4403602928","doi":"10.26685/urncst.606","title":"Mouse Models of HER2+ Human Breast Cancer: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Breast cancer; Human breast; Oncology; Internal medicine; Biology; Cancer; Medicine","score_opus":0.178777673544888,"score_gpt":0.5535555379536692,"score_spread":0.3747778644087812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602928","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003746537,0.9515281,5.5144943e-7,0.046253398,0.00024104796,0.0011844175,0.000053425636,0.000043197764,0.0003212441],"genre_scores_gemma":[0.0031303782,0.9949851,0.00010062441,0.00013567708,0.0003216295,0.00008098181,0.000007716403,0.000043675333,0.0011942424],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9922051,0.0006698411,0.0019445146,0.0012514518,0.0025193065,0.001409803],"domain_scores_gemma":[0.9956127,0.00051830924,0.0003947999,0.000660426,0.0020167392,0.0007970623],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.014596218,0.00048993324,0.0026991847,0.003244092,0.0005316112,0.00031511567,0.0013024502,0.0009831593,0.00003136153],"category_scores_gemma":[0.0013752829,0.0002821424,0.00040759688,0.010091099,0.0066879913,0.00037764895,0.0012775422,0.014399692,0.000016358268],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029848083,0.00017302003,0.00016209426,0.039259538,0.00016552645,0.0009499812,0.000009790785,3.778395e-8,0.000016194599,0.0035639536,0.006036543,0.9496335],"study_design_scores_gemma":[0.0012151158,0.0014263777,0.00003812829,0.54346454,0.0007429605,0.016191147,0.000074254924,0.00023488239,0.000006876345,0.06580969,0.37019256,0.00060345256],"about_ca_topic_score_codex":0.000087327346,"about_ca_topic_score_gemma":0.00008120575,"teacher_disagreement_score":0.94903004,"about_ca_system_score_codex":0.00077986467,"about_ca_system_score_gemma":0.0045409845,"threshold_uncertainty_score":0.99996305},"labels":[],"label_agreement":null},{"id":"W4403604899","doi":"10.58931/cot.2024.1222","title":"From Intractable to Treatable: Milestones and Horizons in the Management of HER2+ Breast Cancer","year":2024,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Breast cancer; Medicine; New horizons; Cancer; General surgery; Internal medicine; Engineering","score_opus":0.027025459900487908,"score_gpt":0.37526584115896766,"score_spread":0.3482403812584798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403604899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82215375,0.009070018,0.000008639941,0.12869881,0.0006870753,0.0011802454,0.0011001034,0.000028463304,0.037072882],"genre_scores_gemma":[0.9927078,0.0014957119,0.0003824842,0.0019736711,0.00032748727,0.00031847655,0.000029695042,0.00002781641,0.0027368772],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988142,0.00007454814,0.00019344219,0.00030873768,0.00017185403,0.00043719937],"domain_scores_gemma":[0.9991122,0.00014563592,0.000014942119,0.00029457515,0.00004122237,0.00039142536],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035085593,0.00011534249,0.00026365143,0.00029948165,0.00004694483,0.000025399593,0.00017621319,0.00012006081,0.0012828187],"category_scores_gemma":[0.0000136246235,0.00008796586,0.000026303172,0.0005880351,0.00012280556,0.000045417135,0.000039909886,0.00029910335,0.00004805498],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000176816,0.000119165576,0.027558224,0.00056118524,0.00038276947,0.0060503776,0.0049175085,0.000016923339,0.0006117059,0.002112479,0.2517593,0.70573354],"study_design_scores_gemma":[0.0006143341,0.00032489892,0.194177,0.00086714845,0.0001440687,0.00018284432,0.0028778417,0.00009093031,0.00012050428,0.00025552747,0.8002143,0.00013061796],"about_ca_topic_score_codex":0.55889714,"about_ca_topic_score_gemma":0.6270247,"teacher_disagreement_score":0.70560294,"about_ca_system_score_codex":0.0012354214,"about_ca_system_score_gemma":0.0018487669,"threshold_uncertainty_score":0.99963015},"labels":[],"label_agreement":null},{"id":"W4403665847","doi":"10.1200/jco.24.00529","title":"Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Medac","keywords":"Medicine; Metastatic breast cancer; Trastuzumab; Internal medicine; Trastuzumab emtansine; Oncology; Hazard ratio; Breast cancer; Clinical endpoint; Pertuzumab; Lapatinib; Cancer; Progression-free survival; Clinical trial; Surgery; Chemotherapy; Confidence interval","score_opus":0.2651344660519626,"score_gpt":0.5945402876781979,"score_spread":0.3294058216262353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403665847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742411,0.0016719068,0.00019510697,0.014583174,0.0033874244,0.004470543,0.00026498042,0.000048332575,0.0011374587],"genre_scores_gemma":[0.98823965,0.0038818025,0.0025858057,0.0012192695,0.0028204315,0.00028960343,0.000045789653,0.00010025285,0.0008173858],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9870741,0.0048989793,0.0056367465,0.0006828966,0.0009821609,0.0007251158],"domain_scores_gemma":[0.9869318,0.00912204,0.0015096763,0.00032970755,0.0009687425,0.0011380435],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011075283,0.0004206729,0.005584887,0.0005599049,0.00010240447,0.000110119276,0.0007197357,0.00045045605,0.0048146453],"category_scores_gemma":[0.007234652,0.00026553895,0.00051877263,0.0008339033,0.000733742,0.0008153813,0.00017907962,0.0031204624,0.00003407447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74774563,0.008920825,0.00014648345,0.00014305962,0.0014975939,0.004217531,0.00041155334,0.000005123169,0.0016446577,0.00008396988,0.00312562,0.23205794],"study_design_scores_gemma":[0.92104375,0.06854355,0.0009264947,0.001004869,0.0011071755,0.00096846797,0.00018756505,0.0008712982,0.00045599736,0.00020707527,0.0044078035,0.00027594453],"about_ca_topic_score_codex":0.0005870114,"about_ca_topic_score_gemma":0.0005547061,"teacher_disagreement_score":0.231782,"about_ca_system_score_codex":0.00147727,"about_ca_system_score_gemma":0.009231953,"threshold_uncertainty_score":0.9999797},"labels":[],"label_agreement":null},{"id":"W4403694618","doi":"10.1158/2159-8290.cd-24-0708","title":"The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development","year":2024,"lang":"en","type":"review","venue":"Cancer Discovery","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":186,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Drug development; Clinical trial; Medicine; Identification (biology); Modalities; Computational biology; Drug; Drug discovery; Bioinformatics; Pharmacology; Biology; Internal medicine","score_opus":0.2113580981287041,"score_gpt":0.491369090281659,"score_spread":0.2800109921529549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403694618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006601325,0.9951335,0.000011700768,0.00068413984,0.0010182789,0.0008369683,0.0008601842,0.000022931052,0.00077217264],"genre_scores_gemma":[0.0003163707,0.990557,0.000058468348,0.000043155524,0.0004641436,0.00020226666,0.00020755897,0.0001247894,0.008026209],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966878,0.00018787877,0.0011233806,0.0005774091,0.000958117,0.00046539112],"domain_scores_gemma":[0.9977548,0.00057699886,0.0004891076,0.00085271883,0.00016162785,0.00016474939],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000732404,0.00039107839,0.0020148477,0.00020928118,0.00006835789,0.00009644948,0.0006168303,0.00021212788,0.0002231398],"category_scores_gemma":[0.00019750382,0.00024905824,0.0006241359,0.00057972886,0.00042395218,0.000088281566,0.00033428453,0.0010326208,0.00010470297],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008031198,0.000053986223,0.000050056875,0.028024904,0.0016270259,0.00006293541,0.00047380492,0.0000014061667,0.000047922014,0.0001349363,0.0154922865,0.9539504],"study_design_scores_gemma":[0.0002652172,0.00003548591,0.00011190358,0.077314794,0.0012930001,0.0000066292064,0.00015658484,0.0000019644287,0.00022847821,0.00011132692,0.92026144,0.00021314852],"about_ca_topic_score_codex":0.0008683527,"about_ca_topic_score_gemma":0.00021250226,"teacher_disagreement_score":0.95373726,"about_ca_system_score_codex":0.00069366925,"about_ca_system_score_gemma":0.01031092,"threshold_uncertainty_score":0.9999962},"labels":[],"label_agreement":null},{"id":"W4403732678","doi":"10.3390/curroncol31110484","title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"St Joseph's Health Care; Princess Margaret Cancer Centre; Ottawa Hospital; Juravinski Cancer Centre; McGill University Health Centre; Sunnybrook Health Science Centre; Saskatchewan Cancer Agency; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; Jewish General Hospital","funders":"Canadian Institutes of Health Research; Genentech; Astellas Pharma; Seagen; Ipsen; BeiGene; McGill University; Helsinn; Eisai; Purdue University; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; Myriad Genetics; AstraZeneca; Eli Lilly and Company; University of Toronto; Genomic Health; GlaxoSmithKline","keywords":"Medicine; Breast cancer; Excellence; Metastatic breast cancer; Cancer; Family medicine; Oncology; Systemic therapy; Clinical trial; Internal medicine","score_opus":0.124020790390795,"score_gpt":0.48708459200591114,"score_spread":0.36306380161511614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403732678","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34098187,0.054839246,0.00042272618,0.54149145,0.0038866184,0.017131988,0.040808316,0.000054963082,0.0003827991],"genre_scores_gemma":[0.9931553,0.0011543382,0.00039805533,0.00025498497,0.00026761243,0.004534845,0.0000771552,0.000031652566,0.00012607024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987105,0.00015873766,0.0003212496,0.00026187455,0.00022663911,0.000320989],"domain_scores_gemma":[0.9967504,0.0022343204,0.00013151151,0.00013609038,0.0006386664,0.00010900926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006263288,0.00013227775,0.00025566638,0.0001335574,0.0001584036,0.000029053146,0.000083095016,0.00004191596,0.00007029895],"category_scores_gemma":[0.00016107103,0.00007289901,0.00004483302,0.00024807057,0.00016333995,0.000051809257,0.000014026533,0.00015884632,0.0000010269646],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013642798,0.0006764675,0.23177555,0.0017508086,0.0010909999,0.000012808829,0.005527026,0.00020584515,0.00002757378,0.0011350474,0.031481843,0.72495174],"study_design_scores_gemma":[0.006600823,0.0013276318,0.4089894,0.002175373,0.0008601758,0.00032403757,0.0018405723,0.009789425,0.000008851824,0.00009489045,0.5677737,0.00021512012],"about_ca_topic_score_codex":0.045000076,"about_ca_topic_score_gemma":0.13031036,"teacher_disagreement_score":0.72473663,"about_ca_system_score_codex":0.002537058,"about_ca_system_score_gemma":0.0048104185,"threshold_uncertainty_score":0.9613593},"labels":[],"label_agreement":null},{"id":"W4403789396","doi":"10.1016/j.ygyno.2024.10.013","title":"Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"ImmunoGen","keywords":"Medicine; Tolerability; Ovarian cancer; Oncology; Folate receptor; Internal medicine; Gynecology; Cancer; Adverse effect; Cancer cell","score_opus":0.05559084458819756,"score_gpt":0.40697704372038457,"score_spread":0.351386199132187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403789396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89391476,0.034463417,0.011411863,0.036730673,0.006202848,0.0086870985,0.0029615678,0.0007755054,0.0048522563],"genre_scores_gemma":[0.9188371,0.024065819,0.049350064,0.002027615,0.0010909062,0.0011291039,0.0011607799,0.00022449215,0.0021141453],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964635,0.00063021417,0.0010045717,0.00093108224,0.00027677044,0.0006939032],"domain_scores_gemma":[0.99694616,0.0016145578,0.00018668827,0.00050698523,0.00042168205,0.00032393055],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024300506,0.00034560458,0.0012288052,0.00023721764,0.00017391251,0.0000412026,0.00024463868,0.00058038486,0.0017702497],"category_scores_gemma":[0.00072489155,0.00027465884,0.00017189114,0.0004896633,0.000513273,0.00016532927,0.000107738466,0.00076846994,0.000007136069],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009015281,0.00078460237,0.0034327966,0.0007631968,0.0002827296,0.00005358326,0.0009076644,0.000023359074,0.018577531,0.0005770151,0.0053111645,0.96027106],"study_design_scores_gemma":[0.0067992266,0.013997864,0.014937632,0.00063529314,0.00021526038,0.000052390373,0.0004045323,0.0100696385,0.003383072,0.0014168294,0.9476672,0.000421057],"about_ca_topic_score_codex":0.0005615245,"about_ca_topic_score_gemma":0.0010059106,"teacher_disagreement_score":0.95985,"about_ca_system_score_codex":0.001827066,"about_ca_system_score_gemma":0.0022265618,"threshold_uncertainty_score":0.99997056},"labels":[],"label_agreement":null},{"id":"W4404321660","doi":"10.3390/curroncol31110522","title":"Antibody–Drug Conjugates: A Start of a New Era in Gynecological Cancers","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Antibody; Drug; Antibody-drug conjugate; Conjugate; Bioinformatics; Computational biology; Immunology; Pharmacology; Monoclonal antibody; Biology","score_opus":0.39152912207707863,"score_gpt":0.5939985891599726,"score_spread":0.20246946708289398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404321660","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015615951,0.99049205,0.000007041877,0.00055674504,0.0030760302,0.0023187636,0.00012576245,0.000059553284,0.0032079106],"genre_scores_gemma":[0.000041523894,0.99701715,0.00014041964,0.00007162449,0.00080413657,0.00035338366,0.00034887734,0.00007456314,0.0011483079],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995956,0.0005034678,0.0013699145,0.00086112606,0.0005276847,0.00078178797],"domain_scores_gemma":[0.9978203,0.0007396775,0.00031930066,0.0005425595,0.00014216744,0.0004359694],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00096942583,0.0005179706,0.004007851,0.00076381094,0.000021866066,0.000016186996,0.00045124668,0.0005893725,0.0018065433],"category_scores_gemma":[0.0006777363,0.0003721876,0.0006282614,0.0011003318,0.00037299265,0.000030721938,0.00033143352,0.003014327,0.00050263683],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000055032546,0.0003144398,0.00033777152,0.056431875,0.00019139075,0.00041335996,0.00031551238,3.4861995e-7,0.0000017274426,0.00009286375,0.06366237,0.8781833],"study_design_scores_gemma":[0.00095459376,0.00095633446,0.000038550173,0.036279466,0.0010057817,0.00012152987,0.00006249661,0.000021191185,9.606746e-7,0.00009053515,0.96021074,0.0002578087],"about_ca_topic_score_codex":0.00045687245,"about_ca_topic_score_gemma":0.00066093967,"teacher_disagreement_score":0.8965484,"about_ca_system_score_codex":0.0043153903,"about_ca_system_score_gemma":0.021165943,"threshold_uncertainty_score":0.999873},"labels":[],"label_agreement":null},{"id":"W4404367648","doi":"10.1016/j.ctrv.2024.102853","title":"Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer","year":2024,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Foundation; Spinal Cord Injury BC; BC Cancer Agency","funders":"Seagen; Pfizer","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Metastatic breast cancer; Breast cancer; Oncology; Cancer; Internal medicine; Epidermal growth factor receptor; Lapatinib; Cancer research; Trastuzumab","score_opus":0.3394679420235394,"score_gpt":0.5386860887968553,"score_spread":0.1992181467733159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404367648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012977066,0.9836787,0.0000070724614,0.0033235284,0.00077227707,0.009197165,0.002233796,0.00009361215,0.0005640515],"genre_scores_gemma":[0.00013525253,0.98063165,0.0003113353,0.00041427457,0.0012272691,0.014339766,0.0008914865,0.00026996786,0.0017789874],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919002,0.0019011575,0.0025715795,0.002093254,0.00048336122,0.0010504468],"domain_scores_gemma":[0.99682933,0.0007328927,0.00069658464,0.0008797464,0.00014982942,0.0007115992],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007927395,0.0016927148,0.0064467047,0.0007107217,0.00027240068,0.0001347516,0.00024846234,0.00040732374,0.0019729992],"category_scores_gemma":[0.000080111444,0.0010439474,0.0015693902,0.0007894149,0.00023226508,0.00016414473,0.00012046788,0.001124091,0.00026485615],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005259789,0.0006411179,0.00018925774,0.010011463,0.0021050824,0.0003112518,0.001311632,7.6545234e-7,0.0000037203627,0.000034753673,0.0026074576,0.9827309],"study_design_scores_gemma":[0.0017302153,0.0017850404,0.00011466747,0.13493828,0.0044198562,0.00015543547,0.00012536207,0.000021526075,0.000021206946,0.0000054505485,0.85590994,0.0007730319],"about_ca_topic_score_codex":0.006522052,"about_ca_topic_score_gemma":0.0014045893,"teacher_disagreement_score":0.98195785,"about_ca_system_score_codex":0.026079793,"about_ca_system_score_gemma":0.0027965636,"threshold_uncertainty_score":0.99958193},"labels":[],"label_agreement":null},{"id":"W4405050108","doi":"10.1182/blood-2024-198536","title":"Gemtuzumab Ozogamicin in Favorable and Intermediate Risk Acute Myeloid Leukemia: A Single-Center Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Myeloid leukemia; Calicheamicin; Leukemia; Internal medicine; Oncology; CD33; Biology","score_opus":0.024610560995963298,"score_gpt":0.3166875365898274,"score_spread":0.2920769755938641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929131,0.0026655332,0.00003584811,0.00031673413,0.00026315183,0.000433798,0.000038431735,0.00011415169,0.0032192357],"genre_scores_gemma":[0.99609184,0.0017035089,0.00031241312,0.00017637934,0.00019289013,0.0001015946,0.000010603834,0.00004473525,0.0013660577],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99830663,0.00006653577,0.00028378388,0.000504542,0.0003511193,0.0004873941],"domain_scores_gemma":[0.9993148,0.00009966084,0.000030146733,0.0003281075,0.000039415696,0.00018789785],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029085978,0.0001776781,0.00029140522,0.00026655308,0.000044008168,0.000100268655,0.00014455512,0.000120695346,0.00016896304],"category_scores_gemma":[0.00013314339,0.00015297267,0.000056548295,0.00041402446,0.00017203072,0.00014901363,0.00017170665,0.00065120857,0.00011774983],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013890356,0.0024829856,0.5198816,0.0026064555,0.00097139156,0.014663206,0.032555334,0.000007735094,0.22468258,0.00021404642,0.009351209,0.19119443],"study_design_scores_gemma":[0.06759973,0.015014506,0.17952737,0.017953223,0.0020444035,0.008378537,0.009595785,0.012095884,0.44422537,0.001604096,0.23861031,0.0033507722],"about_ca_topic_score_codex":0.00031915487,"about_ca_topic_score_gemma":0.00015434326,"teacher_disagreement_score":0.3403542,"about_ca_system_score_codex":0.00040248389,"about_ca_system_score_gemma":0.00035423366,"threshold_uncertainty_score":0.62380445},"labels":[],"label_agreement":null},{"id":"W4405182393","doi":"10.1158/1538-8514.cancerchem24-ia023","title":"Abstract IA023: Dual-drug ADC platform for effective and safe cancer treatment","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Antibody-drug conjugate; Tolerability; Drug; Cancer; Pharmacology; Cancer research; Drug resistance; Internal medicine; Antibody; Immunology; Biology; Adverse effect; Monoclonal antibody","score_opus":0.05581262807661499,"score_gpt":0.4060311569159849,"score_spread":0.35021852883936994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405182393","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7961105,0.18154296,0.0011045547,0.011572611,0.0012563753,0.0049927104,0.0006077225,0.00025503602,0.0025575403],"genre_scores_gemma":[0.9783249,0.013543864,0.00040499822,0.0018439587,0.00051904155,0.0029708592,0.000038519538,0.00015509753,0.0021987455],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99819744,0.000027353171,0.00025392984,0.00056232844,0.00041471966,0.0005442151],"domain_scores_gemma":[0.99906844,0.00019630657,0.000042065618,0.00034307383,0.00014097292,0.00020912898],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021347452,0.00033054128,0.00040393567,0.00014481964,0.0001056158,0.00009841808,0.00008305277,0.0001429308,0.00023589117],"category_scores_gemma":[0.000010633833,0.00025783354,0.00019843671,0.00025072528,0.00013345719,0.00006978819,0.000035625835,0.00029340343,0.000020585267],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007756874,0.00014886042,0.0012165796,0.0012959033,0.0020877083,0.00034561838,0.0020800945,0.000089639725,0.0990864,0.0006211677,0.0012794764,0.89097285],"study_design_scores_gemma":[0.0037425747,0.0010528433,0.0059613627,0.001124566,0.0010213074,0.000052639076,0.00018827569,0.0034539937,0.24768175,0.0008332671,0.73437893,0.00050845457],"about_ca_topic_score_codex":0.0010855129,"about_ca_topic_score_gemma":0.00039451726,"teacher_disagreement_score":0.8904644,"about_ca_system_score_codex":0.0012385576,"about_ca_system_score_gemma":0.00069278764,"threshold_uncertainty_score":0.99998736},"labels":[],"label_agreement":null},{"id":"W4405368113","doi":"10.1158/1078-0432.ccr-24-1779","title":"Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate","year":2024,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Canadian Nuclear Laboratories; University of Saskatchewan; Saskatoon Medical Imaging; Université Laval; Centre hospitalier de l'Université Laval; Hôtel-Dieu de Québec","funders":"Canadian Institutes of Health Research","keywords":"Trastuzumab; Biodistribution; Medicine; Pharmacology; Cancer; Internal medicine; Breast cancer; Chemistry; In vitro","score_opus":0.32613720757807146,"score_gpt":0.588059894922568,"score_spread":0.2619226873444966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405368113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96334475,0.017461969,0.0002462545,0.010706226,0.0012433823,0.0028745583,0.0008122826,0.00019501688,0.0031155648],"genre_scores_gemma":[0.98622465,0.0074180216,0.0010902772,0.00030127433,0.0017333021,0.0001614018,0.00010228272,0.00020155813,0.0027672532],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888843,0.0021316477,0.002034094,0.0016411906,0.003437111,0.0018716146],"domain_scores_gemma":[0.99197,0.0033024803,0.0001882167,0.0013337508,0.0017884679,0.0014170718],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009310997,0.00047762724,0.0016303811,0.0008598966,0.00047631827,0.0002084059,0.00084781396,0.00039986073,0.0016764634],"category_scores_gemma":[0.0019604089,0.00038988463,0.000738139,0.0028867344,0.002428602,0.00018471864,0.00062827306,0.00398588,0.00017394194],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007949171,0.0030352466,0.034787558,0.006688416,0.002605835,0.005501908,0.0020804233,0.00016444594,0.8153382,0.0009959093,0.06292464,0.057928246],"study_design_scores_gemma":[0.022035783,0.0140060065,0.19685291,0.063918926,0.0019243709,0.00064515346,0.003568763,0.062606856,0.11679101,0.002212512,0.5119876,0.003450079],"about_ca_topic_score_codex":0.005510885,"about_ca_topic_score_gemma":0.00024456283,"teacher_disagreement_score":0.6985472,"about_ca_system_score_codex":0.0013836225,"about_ca_system_score_gemma":0.005754994,"threshold_uncertainty_score":0.99988145},"labels":[],"label_agreement":null},{"id":"W4405602713","doi":"10.26434/chemrxiv-2024-v1sc1","title":"Large library docking and biophysical analysis of small molecule TMPRSS2 inhibitors","year":2024,"lang":"en","type":"preprint","venue":"ChemRxiv","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of British Columbia; University of Toronto","funders":"Canadian Institutes of Health Research; Genentech; Mitacs; Killam Trusts; Wellcome Trust; Ontario Genomics Institute; European Federation of Pharmaceutical Industries and Associations; American Foundation for Pharmaceutical Education; Merck KGaA; National Institutes of Health; Ontario Genomics; Genome Canada; Bayer; Natural Sciences and Engineering Research Council of Canada; Canadian Light Source; Pfizer; National Institute of Health Sciences","keywords":"Docking (animal); Computational biology; TMPRSS2; Small molecule; Chemistry; Biology; Medicine; Biochemistry; Coronavirus disease 2019 (COVID-19); Internal medicine","score_opus":0.03558635022213707,"score_gpt":0.33518207523741295,"score_spread":0.29959572501527587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405602713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873176,0.0035361107,0.000034010227,0.0012221452,0.00021063368,0.00035948164,0.000049733375,0.00013023279,0.0071400064],"genre_scores_gemma":[0.9970882,0.00047259335,0.00041872438,0.00014979104,0.00048512107,0.00005593532,0.00020833517,0.000082915016,0.0010383778],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99796456,0.000049123882,0.00042443656,0.000747161,0.00043945547,0.0003752508],"domain_scores_gemma":[0.9987453,0.00007822215,0.00010830993,0.000738294,0.00007538747,0.00025445665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024364864,0.00028400592,0.000901616,0.00075028447,0.000027951048,0.0000736453,0.0002198298,0.00036210875,0.00035668674],"category_scores_gemma":[0.00008644988,0.0002542014,0.0004809181,0.0012114,0.00016294153,0.00002674669,0.0020364902,0.0012767486,0.000027850403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010388531,0.0031309174,0.24524665,0.06774585,0.042871572,0.003980834,0.011630621,0.00040392517,0.53968215,0.008207777,0.060177248,0.015883578],"study_design_scores_gemma":[0.0014327683,0.00029439956,0.01767595,0.0047754557,0.010191921,0.000016267413,0.00038817158,0.045782447,0.90483415,0.0025629245,0.010973648,0.0010718866],"about_ca_topic_score_codex":0.000059949263,"about_ca_topic_score_gemma":0.0000061748465,"teacher_disagreement_score":0.365152,"about_ca_system_score_codex":0.00007462714,"about_ca_system_score_gemma":0.00041313333,"threshold_uncertainty_score":0.999991},"labels":[],"label_agreement":null},{"id":"W4405732807","doi":"10.3390/curroncol32010001","title":"The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Cancer; Internal medicine; Metastatic breast cancer","score_opus":0.12324691670883109,"score_gpt":0.47708145774799177,"score_spread":0.3538345410391607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405732807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991134,0.0026935455,0.0000035244398,0.0031531882,0.0006586026,0.0012201525,0.00029898196,0.000092936854,0.0007450693],"genre_scores_gemma":[0.99568695,0.0020468656,0.000053611726,0.00006434217,0.00011428852,0.00014014594,0.000079849684,0.00006364664,0.0017503017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970395,0.0005098176,0.0007478439,0.00058977713,0.00052125234,0.0005918387],"domain_scores_gemma":[0.9976532,0.0011054144,0.00016989588,0.00037321332,0.00034876334,0.00034950025],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047831403,0.00030083692,0.00086431816,0.00017622918,0.00012610915,0.00003604067,0.000160675,0.00010423206,0.00028250818],"category_scores_gemma":[0.00013350947,0.00017081488,0.0001521355,0.0006137032,0.0007217764,0.000055391105,0.00011940076,0.00054483966,0.00001889138],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011300098,0.0014307965,0.79243165,0.00043189625,0.0005374016,0.000066602275,0.00037965446,0.0000010635443,0.000030533818,0.000018191598,0.0035804918,0.19996169],"study_design_scores_gemma":[0.0045836903,0.0030751107,0.9519036,0.0010546624,0.00071142794,0.000040823095,0.00018130442,0.0003152317,0.00023131272,0.000019793062,0.03767218,0.00021087911],"about_ca_topic_score_codex":0.0011369621,"about_ca_topic_score_gemma":0.013637973,"teacher_disagreement_score":0.19975081,"about_ca_system_score_codex":0.0014254744,"about_ca_system_score_gemma":0.00085855584,"threshold_uncertainty_score":0.7610309},"labels":[],"label_agreement":null},{"id":"W4405987481","doi":"10.1101/2024.12.31.630944","title":"Structural conservation and divergence across the Receptor Tyrosine Kinase superfamily","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Haifa; Azrieli Foundation; Israel Science Foundation; International Development Research Centre; Council for Higher Education; United States-Israel Binational Science Foundation; National Science Foundation","keywords":"SUPERFAMILY; Tyrosine kinase; Receptor tyrosine kinase; Divergence (linguistics); ROR1; Platelet-derived growth factor receptor; Receptor; Cell biology; Biology; Kinase; Genetics","score_opus":0.03422649518746598,"score_gpt":0.3054845277984733,"score_spread":0.27125803261100734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405987481","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98725396,0.004346492,0.00008552656,0.004091526,0.001632913,0.0014596643,0.0008940398,0.00022259608,0.000013280949],"genre_scores_gemma":[0.99457425,0.0016250088,0.001544888,0.0012668311,0.00056452694,0.00026259845,0.0000017047219,0.00006899029,0.00009117701],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99687016,0.00020044723,0.00052589114,0.0010083502,0.0007045008,0.00069063384],"domain_scores_gemma":[0.9968346,0.00018156886,0.00019258824,0.0015011139,0.000975054,0.00031512737],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095713406,0.00049516285,0.0005964141,0.00013775591,0.00041703274,0.00025322707,0.00054766313,0.0004924987,0.00015065218],"category_scores_gemma":[0.0008415168,0.0003997242,0.00011904341,0.0006655368,0.00053286634,0.00011203025,0.0011495762,0.0013887665,0.000038154103],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036736066,0.000086875225,0.37420595,0.0027295474,0.0003218253,0.00008727449,0.00012790853,0.000021534088,0.61181915,0.00076254224,0.009418744,0.00005130537],"study_design_scores_gemma":[0.0011710775,0.00012940282,0.8035219,0.0015759879,0.00016530837,7.0524074e-8,0.000026804772,0.0011895993,0.16659813,0.0000036109086,0.024993116,0.0006250039],"about_ca_topic_score_codex":0.000719509,"about_ca_topic_score_gemma":0.000018894,"teacher_disagreement_score":0.445221,"about_ca_system_score_codex":0.0004632055,"about_ca_system_score_gemma":0.0013906169,"threshold_uncertainty_score":0.99984545},"labels":[],"label_agreement":null},{"id":"W4406206869","doi":"10.2139/ssrn.5087372","title":"New Standards in Her2-Low Testing: The Casi-01 Comparative Methods Study","year":2025,"lang":"en","type":"preprint","venue":"SSRN Electronic Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital","funders":"","keywords":"Computer science","score_opus":0.14338908652328425,"score_gpt":0.5266827475577621,"score_spread":0.3832936610344779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406206869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.58617955,0.113369584,0.15020892,0.033742487,0.0056851967,0.020423392,0.00021440857,0.00046417458,0.08971229],"genre_scores_gemma":[0.96410775,0.0050178687,0.010890393,0.00033393694,0.0020378407,0.00024306356,0.000013298174,0.00010925874,0.017246561],"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9907412,0.0024560944,0.0009991778,0.00074226,0.0018169711,0.0032442797],"domain_scores_gemma":[0.99665487,0.0008715254,0.0003828311,0.0009776432,0.0008102694,0.0003028629],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.020194352,0.0005268582,0.0012468621,0.00053244684,0.0002714776,0.00018599645,0.0011062411,0.00030585463,0.00020098093],"category_scores_gemma":[0.0018421161,0.00036677482,0.00027157363,0.001046994,0.00013064213,0.000054317537,0.0008014714,0.020937376,0.000010684227],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035483998,0.0024107131,0.07861596,0.0008078666,0.0059684054,0.0006916922,0.024775838,0.0031057238,0.00049229135,0.006488827,0.01735181,0.85574245],"study_design_scores_gemma":[0.034034446,0.02300017,0.086255446,0.01330387,0.003309226,0.0062759304,0.14871764,0.0068921354,0.0021313892,0.57705784,0.09527035,0.0037515596],"about_ca_topic_score_codex":0.0044463472,"about_ca_topic_score_gemma":0.013491588,"teacher_disagreement_score":0.85199094,"about_ca_system_score_codex":0.011799229,"about_ca_system_score_gemma":0.09601442,"threshold_uncertainty_score":0.9998784},"labels":[],"label_agreement":null},{"id":"W4406536614","doi":"10.1038/s41591-024-03462-0","title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"FUJIFILM Toyama Chemical; Bayer Yakuhin; MSD K.K.; Chugai Pharmaceutical; Eli Lilly Japan; Sierra Oncology; Sirtex Medical; Ono Pharmaceutical; Astellas Pharma; Swedish Orphan Biovitrum; Celgene; Yakult Honsha; Amgen; Coherus Biosciences; FibroGen; Puma Biotechnology; Seagen; Relay Therapeutics; Daiichi Sankyo Europe; European Society for Medical Oncology; Agios Pharmaceuticals; Veracyte; Foundation Medicine; GlaxoSmithKline; Advanced Accelerator Applications; BeiGene; PharmaMar; Array BioPharma; Nihon Medi-Physics; Clovis Oncology; Genentech; AstraZeneca; Novocure; Natera; Regeneron Pharmaceuticals; G1 Therapeutics; Lantheus Medical Imaging; Merck KGaA; Gilead Sciences; Taiho Pharmaceutical; Sumitomo Dainippon Pharma Oncology; Ipsen; Pancreatic Cancer Action Network; Mirati Therapeutics; Handok; F. Hoffmann-La Roche; Eisai; National Cancer Institute; Fondazione Beretta; Incyte; Servier; Halozyme; Exelixis; Apollomics; Sanofi; Miyarisan Pharmaceutical; Aptitude Health; Eli Lilly and Company; Bristol-Myers Squibb; Yuhan; Spectrum Pharmaceuticals; Pfizer","keywords":"Trastuzumab; Oncology; Metastatic breast cancer; Breast cancer; Medicine; Internal medicine; Clinical trial; Cancer; Cancer research","score_opus":0.025803389683979588,"score_gpt":0.4717154380101767,"score_spread":0.4459120483261971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406536614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88003236,0.01950289,0.00004741489,0.09005031,0.0013890677,0.0027216338,0.00013210546,0.00010268097,0.0060215476],"genre_scores_gemma":[0.99160546,0.0011766287,0.0001706525,0.0038687543,0.0006374581,0.00028848267,0.00007989705,0.000035861798,0.002136833],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99735147,0.00020774589,0.0005944872,0.0005610833,0.0007693484,0.0005158757],"domain_scores_gemma":[0.9986211,0.0003467799,0.0000892398,0.00040841958,0.00023580818,0.00029863598],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011637661,0.00028874684,0.0009020498,0.00069642544,0.000062454536,0.000015421429,0.00018272994,0.00027026623,0.0013790181],"category_scores_gemma":[0.0010473842,0.0002087191,0.00005949955,0.0016314423,0.00034565173,0.000059170896,0.000056128545,0.0018622597,0.0000063864372],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15675345,0.0038169953,0.016416786,0.0036835186,0.0010210553,0.0021205232,0.0043317573,0.0000053742942,0.014808259,0.001078745,0.16380677,0.6321567],"study_design_scores_gemma":[0.78512627,0.006384556,0.06551762,0.0095113795,0.0013320025,0.0008015751,0.0028025708,0.0020555642,0.00359543,0.0012057993,0.120921366,0.00074587995],"about_ca_topic_score_codex":0.001312141,"about_ca_topic_score_gemma":0.0005008324,"teacher_disagreement_score":0.6314109,"about_ca_system_score_codex":0.00046864376,"about_ca_system_score_gemma":0.001166616,"threshold_uncertainty_score":0.99953383},"labels":[],"label_agreement":null},{"id":"W4406584190","doi":"10.1016/j.ypat.2014.01.032","title":"10.1016/j.ypat.2014.01.032","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stage (stratigraphy); Fish <Actinopterygii>; Breast cancer; Cancer; Oncology; Internal medicine; Gynecology; Fishery; Biology","score_opus":0.017112444629831615,"score_gpt":0.2692044084067701,"score_spread":0.2520919637769385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584190","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012626819,0.00021716185,7.0798853e-7,0.0025805624,0.0000025110508,0.0004572322,0.000017040053,0.00017207615,0.99529004],"genre_scores_gemma":[0.0002896024,0.0000027014628,0.00019132844,0.00020712512,0.00043219418,0.000054864722,0.000021357639,0.000056857803,0.99874395],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840397,0.00005447993,0.00021426231,0.0003243878,0.0005094229,0.00049347075],"domain_scores_gemma":[0.99880624,0.000066837456,0.000018167771,0.00058805867,0.00008492109,0.00043579526],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00030331852,0.00015268185,0.0002669789,0.00012215745,0.000057954083,0.000030374584,0.00021549767,0.000096767486,0.99936265],"category_scores_gemma":[0.00010310362,0.00013855948,0.00007893031,0.00028990232,0.00006471896,0.00005290261,0.00005563003,0.00028611548,0.9984029],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019125588,0.00005175053,0.0000015933574,0.000021894062,0.000017318096,0.000037972633,0.000015754122,0.00000359414,0.0001822524,3.1019053e-7,0.5288738,0.47060248],"study_design_scores_gemma":[0.00064541685,0.000502834,0.0001822131,0.000075971395,0.000024187224,0.00004153383,0.0000011833141,0.000095814146,0.00071013544,0.0000050895437,0.99756813,0.00014751029],"about_ca_topic_score_codex":0.00014203154,"about_ca_topic_score_gemma":7.547466e-7,"teacher_disagreement_score":0.470455,"about_ca_system_score_codex":0.00015729299,"about_ca_system_score_gemma":0.00018626126,"threshold_uncertainty_score":0.5650292},"labels":[],"label_agreement":null},{"id":"W4406588304","doi":"10.1016/s1541-9800(08)70524-6","title":"10.1016/s1541-9800(08)70524-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.01764804893609909,"score_gpt":0.26796130889026404,"score_spread":0.2503132599541649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406588304","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013327268,0.00021410658,5.96125e-7,0.0024841574,0.0000025527913,0.0004981164,0.00001827933,0.00017328124,0.9952762],"genre_scores_gemma":[0.0003707951,0.0000021706198,0.00021321834,0.0002265961,0.00046168655,0.000057601235,0.00002264406,0.000057854657,0.9985874],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822485,0.00005687578,0.00023387857,0.00035168004,0.00059170136,0.0005410148],"domain_scores_gemma":[0.99871993,0.000069922375,0.000019183752,0.00061537744,0.000103621176,0.00047196285],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000321545,0.0001685389,0.00029145292,0.00013798941,0.000070167145,0.000034116205,0.0002359896,0.00010500937,0.99950826],"category_scores_gemma":[0.0001256168,0.00015452024,0.00008816722,0.00040739626,0.000073417024,0.000057674595,0.000060645867,0.00032057238,0.9985684],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019841157,0.00005986083,0.0000011401617,0.000025491252,0.000020519548,0.00004833746,0.000020382171,0.000005285052,0.00019286606,3.7823497e-7,0.5144194,0.48500794],"study_design_scores_gemma":[0.00073645776,0.00052547286,0.00017305475,0.00009410296,0.000026721527,0.00005092409,0.0000019128452,0.00010965743,0.00075254095,0.0000065530694,0.99735934,0.00016329433],"about_ca_topic_score_codex":0.00009267552,"about_ca_topic_score_gemma":5.523966e-7,"teacher_disagreement_score":0.48484465,"about_ca_system_score_codex":0.00017853704,"about_ca_system_score_gemma":0.00020293477,"threshold_uncertainty_score":0.6301153},"labels":[],"label_agreement":null},{"id":"W4406606700","doi":"10.1016/j.tranon.2025.102284","title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan","year":2025,"lang":"en","type":"article","venue":"Translational Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Syöpäjärjestöt; Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; Biocenter Finland; Helsingin Yliopisto","keywords":"Trastuzumab; Trastuzumab emtansine; Medicine; Oncology; Internal medicine; Breast cancer; Cancer","score_opus":0.04665332703341679,"score_gpt":0.4109207860228478,"score_spread":0.364267458989431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406606700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95094496,0.001862143,0.0047915904,0.03305434,0.00009449573,0.001414565,0.00038818756,0.000025790427,0.0074239257],"genre_scores_gemma":[0.99514645,0.00016235557,0.0038937316,0.00044137915,0.000048832986,0.00006847543,0.00003524579,0.00001767365,0.00018584213],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.998041,0.00019809412,0.00062917103,0.00045763256,0.00033655818,0.00033755708],"domain_scores_gemma":[0.9985252,0.0008414613,0.00006230221,0.00015262864,0.0002106638,0.00020776696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005503026,0.00017105197,0.00060761237,0.0004062175,0.000049598122,0.000009004615,0.00008951301,0.00018321289,0.00007810366],"category_scores_gemma":[0.000107730644,0.00016579813,0.000055005356,0.00062950136,0.00031229242,0.000069411406,0.000030948235,0.0003677005,0.0000014348077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05683575,0.0030827518,0.13205968,0.0019400851,0.00095592195,0.0006095412,0.0128671145,0.0069742706,0.020269379,0.017368233,0.0022762478,0.74476105],"study_design_scores_gemma":[0.008285288,0.0031503178,0.97693205,0.00075272354,0.00016729881,0.00015638162,0.000439608,0.0053850934,0.00030552398,0.0031543658,0.0010601614,0.0002111788],"about_ca_topic_score_codex":0.00079232006,"about_ca_topic_score_gemma":0.0050527523,"teacher_disagreement_score":0.8448724,"about_ca_system_score_codex":0.0006598173,"about_ca_system_score_gemma":0.002583634,"threshold_uncertainty_score":0.67610514},"labels":[],"label_agreement":null},{"id":"W4406690075","doi":"10.1159/000543554","title":"Trop2 Expression in Correlation to the Molecular Subtype in Vulvar Squamous Cell Carcinomas","year":2025,"lang":"en","type":"article","venue":"Pathobiology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver General Hospital; University of British Columbia","funders":"Universität Leipzig","keywords":"Immunohistochemistry; Medicine; Targeted therapy; Monoclonal antibody; Cancer; Cancer research; Vulvar cancer; Immunotherapy; Oncology; Antibody; Pathology; Internal medicine; Immunology","score_opus":0.017315386114867506,"score_gpt":0.3228786584515315,"score_spread":0.305563272336664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406690075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98562205,0.0012611032,0.0012546232,0.0022474537,0.00022588101,0.00079005875,0.0000048793972,0.0000156218,0.008578357],"genre_scores_gemma":[0.9976512,0.000021640988,0.00032639442,0.0013860217,0.000040544335,0.00013550585,0.000029520019,0.000009821098,0.00039930796],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99861836,0.00043436146,0.00023099149,0.00028898727,0.00011883594,0.00030848387],"domain_scores_gemma":[0.9993247,0.00019528269,0.000025975447,0.00036477702,0.000043403354,0.000045877252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060590316,0.00009762637,0.00020469012,0.00027964177,0.000025398818,0.000005665318,0.00017613023,0.00015918675,0.000070565075],"category_scores_gemma":[0.0003497794,0.00006986772,0.000032574626,0.00053736096,0.000036467998,0.000014001238,0.0000761591,0.00039125007,0.00010030733],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004322137,0.00021763907,0.55184346,0.00011053307,0.0000021971946,0.00049709564,0.00183536,0.0003780347,0.43741974,0.000517099,0.0030659158,0.0036806853],"study_design_scores_gemma":[0.00400461,0.0013353174,0.86813617,0.00024787392,0.000026414848,0.000046585166,0.0010244932,0.0014325414,0.08038273,0.0006495692,0.0424578,0.00025590337],"about_ca_topic_score_codex":0.0003037878,"about_ca_topic_score_gemma":0.00027683063,"teacher_disagreement_score":0.357037,"about_ca_system_score_codex":0.00016641687,"about_ca_system_score_gemma":0.00017877897,"threshold_uncertainty_score":0.2849123},"labels":[],"label_agreement":null},{"id":"W4406869258","doi":"10.1200/jco.2025.43.4_suppl.tps847","title":"A phase 1 dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors, including gastrointestinal (GI) cancers.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antibody-drug conjugate; Antibody; Conjugate; Cancer research; Monoclonal antibody; Internal medicine; Immunology","score_opus":0.07766651630289706,"score_gpt":0.5127989989166067,"score_spread":0.4351324826137097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406869258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99474174,0.00014861819,0.00022762603,0.0017011362,0.00044785926,0.0023451052,0.000014689734,0.000021098795,0.00035214814],"genre_scores_gemma":[0.99353987,0.00005516205,0.00549463,0.00041151384,0.00025413043,0.000054988104,0.000015970207,0.000039087805,0.00013463985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99179107,0.0014305135,0.004396589,0.00054573745,0.0011773595,0.000658725],"domain_scores_gemma":[0.9928527,0.0015980231,0.0027684935,0.00044684936,0.0018378579,0.0004960769],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004974535,0.00033644232,0.002699789,0.0006815025,0.00010144045,0.000015952033,0.00042683296,0.00022845974,0.00011985806],"category_scores_gemma":[0.008105027,0.00025086667,0.00026549274,0.0009777154,0.00048087115,0.00025520942,0.00024743553,0.002353172,0.0000041953494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057774305,0.020478701,0.8752242,0.00025577605,0.00032422296,0.0016993635,0.00049746805,0.00044857533,0.0065752026,0.000015049617,0.0006584929,0.036048695],"study_design_scores_gemma":[0.109288156,0.11726509,0.763734,0.0049614473,0.00028094935,0.00011223031,0.0011387233,0.0010692251,0.0010019958,0.00015583861,0.0007243195,0.00026806278],"about_ca_topic_score_codex":0.00042318122,"about_ca_topic_score_gemma":0.0006728272,"teacher_disagreement_score":0.11149018,"about_ca_system_score_codex":0.0011110491,"about_ca_system_score_gemma":0.006100522,"threshold_uncertainty_score":0.99999434},"labels":[],"label_agreement":null},{"id":"W4407162975","doi":"10.1056/nejmoa2405008","title":"Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer","year":2025,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Cancer; Fusion; Oncology; Internal medicine; Mathematics; Philosophy","score_opus":0.026742302585877658,"score_gpt":0.3892594150297424,"score_spread":0.3625171124438647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407162975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8978417,0.01869957,0.00041484105,0.05802049,0.0013454651,0.0004920392,0.0000071297227,0.000010968546,0.023167828],"genre_scores_gemma":[0.98998344,0.004091556,0.00029653046,0.001255206,0.0022340794,0.0000027067072,0.000003012342,0.000016816197,0.002116661],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9978376,0.00013842196,0.00081706315,0.00015412502,0.0007869786,0.0002657924],"domain_scores_gemma":[0.9982243,0.00058912137,0.00025585733,0.00021845973,0.00044114343,0.00027107532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013264308,0.00014413452,0.0007681841,0.000635699,0.000025795865,0.0000041075937,0.00020236177,0.000092391616,0.00073865533],"category_scores_gemma":[0.0011153877,0.00009500677,0.00008911856,0.00074443116,0.00017966516,0.00005013007,0.00004825466,0.0007626115,0.000002591441],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010189365,0.00032508868,0.06299643,0.0003986342,0.00032064322,0.0009755661,0.0034359682,0.00012392228,0.02653126,0.00039055475,0.07358943,0.8207231],"study_design_scores_gemma":[0.32199338,0.007035225,0.33105412,0.026993053,0.0007763002,0.0010408517,0.00096576323,0.00018058383,0.03068469,0.0015914609,0.27739343,0.00029112495],"about_ca_topic_score_codex":0.0012797833,"about_ca_topic_score_gemma":0.00023893647,"teacher_disagreement_score":0.820432,"about_ca_system_score_codex":0.00032402293,"about_ca_system_score_gemma":0.0015639294,"threshold_uncertainty_score":0.8087758},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","score_opus":0.01792386089167593,"score_gpt":0.41262272750791656,"score_spread":0.39469886661624065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407230737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817506,0.006836482,0.00027074805,0.0009770663,0.0006683488,0.007989002,0.0009069059,0.00004410062,0.00055673247],"genre_scores_gemma":[0.9936927,0.0037218987,0.00020455463,0.0001885561,0.00005750541,0.0016468219,0.00013905497,0.00006997171,0.00027896947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992521,0.0016982466,0.0018979016,0.00097141153,0.0019602485,0.00095120264],"domain_scores_gemma":[0.9952405,0.002310305,0.00068199274,0.00079082174,0.0005787491,0.00039760096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001042743,0.00062815327,0.0041743694,0.00058173295,0.00010016069,0.0000116196225,0.0005845389,0.00039896206,0.001128817],"category_scores_gemma":[0.00055367907,0.00041128302,0.00020725853,0.0014126974,0.0014608823,0.0002019363,0.00017066528,0.00089294586,0.0000020287264],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6742165,0.006190035,0.014797596,0.00029243357,0.0009429751,0.00031248428,0.0058389637,0.00006191218,0.0000173041,0.000039686627,0.000023233897,0.2972669],"study_design_scores_gemma":[0.9244431,0.04980676,0.00576666,0.0013801516,0.00083496235,0.000010089713,0.013224253,0.0006327107,0.00039658014,0.000062250816,0.00305905,0.00038341523],"about_ca_topic_score_codex":0.0058664796,"about_ca_topic_score_gemma":0.032550905,"teacher_disagreement_score":0.29688346,"about_ca_system_score_codex":0.004106665,"about_ca_system_score_gemma":0.0061634886,"threshold_uncertainty_score":0.9998339},"labels":[],"label_agreement":null},{"id":"W4408080074","doi":"10.1016/j.breast.2025.104432","title":"A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)","year":2025,"lang":"en","type":"article","venue":"The Breast","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Association of Schools and Colleges of Optometry; Breakthrough Cancer Research; Translational Breast Cancer Research Consortium; Susan G. Komen; AbbVie; Breast Cancer Research Foundation; National Cancer Institute; Conquer Cancer Foundation; Sidney Kimmel Comprehensive Cancer Center; Genentech; Susan G. Komen for the Cure","keywords":"Medicine; Pertuzumab; Trastuzumab; Breast cancer; Oncology; Biomarker; Internal medicine; Neoadjuvant therapy; Cancer","score_opus":0.015187110065405239,"score_gpt":0.34014640719778816,"score_spread":0.3249592971323829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408080074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9124891,0.00095907156,0.00008398993,0.08242516,0.00012530321,0.0020577982,0.0008358004,0.000078815356,0.00094495446],"genre_scores_gemma":[0.99402994,0.000067721565,0.00018579795,0.0032214418,0.00008609787,0.00027085847,0.000018883993,0.00006386232,0.0020553875],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968743,0.00059024047,0.00039670573,0.0007701778,0.0006133319,0.000755281],"domain_scores_gemma":[0.99803793,0.0004948114,0.00005424606,0.0006621376,0.0001984514,0.0005524384],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011873583,0.00039508205,0.0006182645,0.00053798745,0.00022282345,0.00012125497,0.00031324135,0.000033225322,0.00024095953],"category_scores_gemma":[0.000111035035,0.00029608613,0.000067058565,0.0011058389,0.0003422014,0.00008026034,0.00029739898,0.00046576356,0.000035762558],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14591774,0.0016586111,0.24011047,0.001219426,0.00087865704,0.009097365,0.0051498017,0.0003472329,0.12957904,0.00010404112,0.028368661,0.43756896],"study_design_scores_gemma":[0.0044479305,0.0006934076,0.9738538,0.002665759,0.00012685244,0.007030535,0.0005369514,0.0016320861,0.0022320824,0.000018076824,0.00642102,0.00034145475],"about_ca_topic_score_codex":0.0073739155,"about_ca_topic_score_gemma":0.0013495655,"teacher_disagreement_score":0.73374337,"about_ca_system_score_codex":0.0009491685,"about_ca_system_score_gemma":0.00093943777,"threshold_uncertainty_score":0.9999491},"labels":[],"label_agreement":null},{"id":"W4408245897","doi":"10.1200/po-24-00641","title":"Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Statistics Canada; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Hazard ratio; Oncology; Internal medicine; Metastatic breast cancer; Subgroup analysis; Population; Cancer; Cohort; Brain metastasis; Gynecology; Metastasis; Meta-analysis; Confidence interval","score_opus":0.01767704248195932,"score_gpt":0.36299924804994055,"score_spread":0.3453222055679812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408245897","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943474,0.000021264821,0.00005957652,0.0010387508,0.00008893999,0.003152273,0.00044929274,0.00003497912,0.00080750015],"genre_scores_gemma":[0.9965194,0.0000114800605,0.00094702246,0.00013431428,0.000059504015,0.00037218715,0.00012269522,0.000026192884,0.0018072181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968651,0.0005268466,0.0006430371,0.00057245075,0.0009401682,0.00045243074],"domain_scores_gemma":[0.99729294,0.0008316759,0.00030429623,0.00024910693,0.0010555869,0.00026637845],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013248082,0.00021086985,0.00093202776,0.00040242437,0.00015740251,0.000020470005,0.000135728,0.00016902832,0.0012591761],"category_scores_gemma":[0.0010869511,0.00016826355,0.000041143117,0.00056385377,0.00007996569,0.00011920253,0.00023608212,0.00034122402,0.000022315442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006378925,0.00070835487,0.9470504,0.00004665659,0.0008369052,0.0000030687654,0.0011084973,9.351812e-7,0.00032220592,0.0000023868836,0.007255263,0.04202745],"study_design_scores_gemma":[0.0035632793,0.0023353093,0.9893585,0.00018927766,0.0001688464,3.0228648e-7,0.00011087399,0.0000026746836,0.0011804957,0.0000116421015,0.0029378266,0.00014101095],"about_ca_topic_score_codex":0.000770636,"about_ca_topic_score_gemma":0.00069381617,"teacher_disagreement_score":0.042308077,"about_ca_system_score_codex":0.0040549105,"about_ca_system_score_gemma":0.0010160846,"threshold_uncertainty_score":0.9997683},"labels":[],"label_agreement":null},{"id":"W4408284710","doi":"10.5858/arpa.2024-0305-oa","title":"Breast Cancer Biopsies With Group 2 and Group 4 Human Epidermal Growth Factor Receptor 2 Fluorescence In Situ Hybridization Results Should Have Repeated Testing on Excision","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Breast cancer; Immunohistochemistry; Fluorescence in situ hybridization; Human Epidermal Growth Factor Receptor 2; Medicine; Context (archaeology); Group A; Group B; Internal medicine; In situ hybridization; Pathology; Fish <Actinopterygii>; Oncology; Clinical Oncology; Cancer; Biology","score_opus":0.039494407735406745,"score_gpt":0.34618099218674514,"score_spread":0.3066865844513384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408284710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906293,0.00080893,0.00015221126,0.0051692002,0.00014317773,0.00075004256,0.000256862,0.00008308958,0.0020071554],"genre_scores_gemma":[0.9966551,0.0006241111,0.0015052215,0.00068418804,0.00018706039,0.00007461836,0.00014602368,0.000039867376,0.00008378636],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969017,0.00051956304,0.0007936515,0.0008218269,0.00047911183,0.00048414042],"domain_scores_gemma":[0.99764764,0.0010578803,0.00027430503,0.00051464315,0.00030436856,0.00020116345],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077946595,0.0003296118,0.0007639572,0.0008831303,0.00014469576,0.000008749713,0.00020491504,0.00014934975,0.000033585722],"category_scores_gemma":[0.0016543469,0.0002445554,0.00002927298,0.0010108581,0.0016504577,0.00011168534,0.00012786855,0.00071470294,0.0000012815159],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029411498,0.00020634288,0.26487988,0.00050365354,0.00004660355,0.0005408046,0.0016342701,0.0000059690224,0.70992374,0.00037869407,0.00045268465,0.018486198],"study_design_scores_gemma":[0.0062064766,0.0023474891,0.956514,0.005018016,0.00006233161,0.00011110664,0.00069179403,0.00015231481,0.028412994,0.00012799527,0.00013538827,0.00022011672],"about_ca_topic_score_codex":0.00049141044,"about_ca_topic_score_gemma":0.0005235472,"teacher_disagreement_score":0.69163406,"about_ca_system_score_codex":0.00012582238,"about_ca_system_score_gemma":0.00026050577,"threshold_uncertainty_score":0.997268},"labels":[],"label_agreement":null},{"id":"W4408796472","doi":"10.1016/j.labinv.2024.102474","title":"250 Development and Clinical Performance of an LLM-Generated Application for Assessment of HER2 in Situ Hybridization in Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Laboratory Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital","funders":"","keywords":"In situ; In situ hybridization; Breast cancer; Medicine; Cancer; Oncology; Internal medicine; Medical physics; Cancer research; Biology; Chemistry; Genetics; Gene; Gene expression","score_opus":0.046106559356971964,"score_gpt":0.4193930743033043,"score_spread":0.37328651494633236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408796472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980183,0.00008005288,0.00035325953,0.0005620597,0.00005267612,0.000845177,0.000027789036,0.000010874263,0.00004979504],"genre_scores_gemma":[0.9938405,0.00011712175,0.0053450735,0.00021156514,0.000030593907,0.0002971091,0.00013372608,0.000009537899,0.000014738671],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987486,0.00010665312,0.00060379656,0.00023099672,0.00019453165,0.00011541731],"domain_scores_gemma":[0.99909556,0.000051691768,0.0001529215,0.00015996236,0.00047527146,0.00006456822],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010271855,0.00007996662,0.00023309894,0.00021953088,0.000023358847,0.000005831834,0.000054368513,0.00009403779,0.00000428652],"category_scores_gemma":[0.00007140629,0.00008203063,0.00001016455,0.00084200955,0.00010924823,0.00013176842,0.000017740196,0.0001303637,1.791329e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009974039,0.00016012929,0.87292147,0.0005755038,0.000013878671,3.137656e-7,0.0001626405,0.00030208778,0.10647284,0.00025697495,0.00004022785,0.018994192],"study_design_scores_gemma":[0.0011875057,0.00010801314,0.8192327,0.00038068581,0.000012415725,2.6613742e-7,0.000055051034,0.025632389,0.15309176,0.000032977925,0.0002116567,0.00005455132],"about_ca_topic_score_codex":0.0001320043,"about_ca_topic_score_gemma":0.0007433549,"teacher_disagreement_score":0.053688746,"about_ca_system_score_codex":0.00029242577,"about_ca_system_score_gemma":0.0022360736,"threshold_uncertainty_score":0.39666986},"labels":[],"label_agreement":null},{"id":"W4409127671","doi":"10.1200/po-24-00546","title":"Multiplex Spatial Proteomic Analysis of HER2–Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Cancer Institute; Translational Breast Cancer Research Consortium; Breakthrough Cancer Research; American Society of Clinical Oncology; Genentech; Breast Cancer Research Foundation","keywords":"Breast cancer; Trastuzumab; Pertuzumab; Immunohistochemistry; Immune system; Medicine; Oncology; Estrogen receptor; Stromal cell; Antibody; Internal medicine; Pathology; Cancer; Cancer research; Biology; Immunology","score_opus":0.015748799155744012,"score_gpt":0.36758629728602243,"score_spread":0.3518374981302784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409127671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99344844,0.00036169097,0.00044067492,0.0026791824,0.000036986585,0.0019357423,0.00013581461,0.000043750126,0.00091772276],"genre_scores_gemma":[0.9962364,0.00009403178,0.0014170659,0.00021003923,0.000011224457,0.00028997273,0.00007142016,0.00001976446,0.0016500881],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99658024,0.0017265334,0.0004705598,0.00053206505,0.00034146602,0.00034913048],"domain_scores_gemma":[0.9970504,0.0016384022,0.00024993913,0.00048264663,0.00045730715,0.00012129218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011943404,0.00024084463,0.0010973284,0.00089828245,0.00008388465,0.000015451307,0.00015058128,0.00036731586,0.00010959656],"category_scores_gemma":[0.0013833354,0.00016809406,0.00016539502,0.001271468,0.0003316132,0.000032057855,0.00013409973,0.00035448786,0.000002608271],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061064895,0.0021706335,0.16093414,0.00005959473,0.00789798,0.0013191878,0.0012847414,0.00027560384,0.6316139,0.000106121624,0.00038750307,0.13288571],"study_design_scores_gemma":[0.004284887,0.007702122,0.93458307,0.00043406177,0.0011598008,0.00008365098,0.00018138174,0.00040346358,0.050812338,0.00008962915,0.00012771582,0.00013789083],"about_ca_topic_score_codex":0.0018311316,"about_ca_topic_score_gemma":0.00084189087,"teacher_disagreement_score":0.7736489,"about_ca_system_score_codex":0.0015930601,"about_ca_system_score_gemma":0.0010893202,"threshold_uncertainty_score":0.68546766},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","score_opus":0.031952928587810535,"score_gpt":0.43753937024167455,"score_spread":0.40558644165386404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409528322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814369,0.0019822677,0.002463116,0.002405763,0.0006248378,0.010373609,0.00005618976,0.00005862646,0.00059868937],"genre_scores_gemma":[0.9916603,0.0032125828,0.0010143465,0.0010758158,0.00007546773,0.00251456,0.00002778434,0.000070486785,0.00034863752],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992877,0.0018915392,0.0015189461,0.00091695576,0.0019000008,0.00089557417],"domain_scores_gemma":[0.9952764,0.002699392,0.0004925244,0.000636412,0.0005379254,0.00035734635],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017543855,0.00057127787,0.0034545395,0.0006037645,0.000091706584,0.0000152695,0.0005811885,0.00023204953,0.002413876],"category_scores_gemma":[0.0006017924,0.0003093073,0.000090722824,0.0019371354,0.0015444166,0.00023149916,0.000112956295,0.001307926,0.0000034317593],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71285236,0.008599777,0.0068035326,0.0002867294,0.0010078498,0.00022796438,0.0026701135,0.00013897638,0.00000275156,0.00005858612,0.000018664035,0.2673327],"study_design_scores_gemma":[0.95106405,0.03041961,0.005763474,0.0019555495,0.0006645918,0.00004640246,0.0037737342,0.0046166815,0.000041402687,0.000111340545,0.0011727194,0.0003704306],"about_ca_topic_score_codex":0.002168591,"about_ca_topic_score_gemma":0.015469222,"teacher_disagreement_score":0.2669623,"about_ca_system_score_codex":0.002055371,"about_ca_system_score_gemma":0.008274933,"threshold_uncertainty_score":0.9999359},"labels":[],"label_agreement":null},{"id":"W4409625684","doi":"10.1158/1538-7445.am2025-1704","title":"Abstract 1704: Overcoming resistance in HER2-positive gastric and breast cancers: Efficacy of disitamab vedotin in preclinical models resistant to trastuzumab emtansine and trastuzumab deruxtecan","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Trastuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Oncology; Breast cancer; Cancer","score_opus":0.08495907479758326,"score_gpt":0.45098030383120075,"score_spread":0.3660212290336175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409625684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97815543,0.010945921,0.00009503394,0.005691827,0.00007020995,0.0022375118,0.0002437471,0.000024913801,0.0025354049],"genre_scores_gemma":[0.99525267,0.0029663714,0.0006003703,0.00011227955,0.00010154059,0.00038690004,0.0000108491195,0.00006060098,0.0005084171],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946498,0.00048222096,0.0010631006,0.0012355538,0.0012982312,0.0012710743],"domain_scores_gemma":[0.9965028,0.0016932322,0.00009997779,0.00067080726,0.00052057323,0.00051261135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030103072,0.00034893214,0.0010087063,0.0014954471,0.00014811965,0.000087046275,0.00038317774,0.00025125506,0.000081454404],"category_scores_gemma":[0.0011011501,0.00034518374,0.00008365984,0.003023169,0.0007120198,0.00020474433,0.00033797187,0.0016767582,0.000002370001],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13074714,0.004965471,0.25528798,0.016828777,0.0010013955,0.003279706,0.02546334,0.0034178146,0.17263554,0.004481028,0.0089386,0.3729532],"study_design_scores_gemma":[0.0077618835,0.00073087343,0.9737695,0.011127371,0.00003964924,0.000017471044,0.0015314212,0.00041782513,0.0028078773,0.0010628245,0.00040162943,0.000331697],"about_ca_topic_score_codex":0.01183914,"about_ca_topic_score_gemma":0.04816944,"teacher_disagreement_score":0.7184815,"about_ca_system_score_codex":0.003910915,"about_ca_system_score_gemma":0.0041271807,"threshold_uncertainty_score":0.9999129},"labels":[],"label_agreement":null},{"id":"W4409626158","doi":"10.1158/1538-7445.am2025-2874","title":"Abstract 2874: ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Conjugate; Antibody-drug conjugate; Topoisomerase; Drug; Antibody; Medicine; Pharmacology; Biology; Monoclonal antibody; Immunology; DNA; Genetics; Mathematics","score_opus":0.08370463835081471,"score_gpt":0.47499742427321706,"score_spread":0.39129278592240235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409626158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9518874,0.005920303,0.00009235477,0.0148188,0.0008195847,0.001916323,0.00010201903,0.00020700686,0.024236185],"genre_scores_gemma":[0.9848137,0.0019630154,0.0003871426,0.0007488528,0.0012182369,0.0006133168,0.000058082125,0.00010479488,0.010092882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9936959,0.00020857381,0.00077218685,0.0011528685,0.002162364,0.002008116],"domain_scores_gemma":[0.99620456,0.00070048653,0.00009547821,0.0010227015,0.0013015069,0.0006752461],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003937185,0.0003784984,0.0006989448,0.0010523549,0.0006482047,0.00028616106,0.0006771808,0.0002462761,0.0023466125],"category_scores_gemma":[0.0015982796,0.00034828542,0.00022200275,0.0022356268,0.0006452786,0.00025294514,0.00069347315,0.002836304,0.00038549665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009602421,0.0003891466,0.022849064,0.0020764743,0.00022488205,0.00034297063,0.0007457653,0.0000341572,0.9059218,0.00052617455,0.045857918,0.020071363],"study_design_scores_gemma":[0.008809649,0.00038909,0.04183742,0.0061206007,0.00008854769,0.000034047778,0.0026770846,0.0008302899,0.6049226,0.0004650873,0.33291706,0.00090850814],"about_ca_topic_score_codex":0.0066675725,"about_ca_topic_score_gemma":0.0003632658,"teacher_disagreement_score":0.30099925,"about_ca_system_score_codex":0.0015876743,"about_ca_system_score_gemma":0.003388106,"threshold_uncertainty_score":0.99994713},"labels":[],"label_agreement":null},{"id":"W4409627141","doi":"10.1158/1538-7445.am2025-1694","title":"Abstract 1694: Combination of inhibitors of RAD51 and FLT-3 and other tyrosine kinase inhibitors synergistically inhibits proliferation of cultured human leukemia cell lines","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre","funders":"","keywords":"Tyrosine kinase; Cancer research; Leukemia; Cell growth; Cell culture; Chemistry; Tyrosine-kinase inhibitor; Pharmacology; Biology; Cancer; Medicine; Biochemistry; Immunology; Internal medicine; Signal transduction; Genetics","score_opus":0.052923884148162306,"score_gpt":0.41336898773774405,"score_spread":0.36044510358958176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920957,0.00336919,0.000015797556,0.0008483869,0.00009156302,0.0011791184,0.00006145955,0.000017013092,0.002321783],"genre_scores_gemma":[0.99791765,0.0005846346,0.00014374345,0.000036267556,0.0001491293,0.0001120815,0.000021844597,0.00003245306,0.0010021679],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972934,0.00016905596,0.00073368364,0.00041184376,0.0010305487,0.0003614624],"domain_scores_gemma":[0.99759793,0.0002475181,0.00017533396,0.000341728,0.0014640222,0.0001734445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001381536,0.00018029775,0.00050860865,0.0006301555,0.00011677092,0.000029886827,0.00013740773,0.0002284031,0.00008491046],"category_scores_gemma":[0.00065066334,0.00015541853,0.000057964204,0.0008839438,0.00097467663,0.00009894449,0.00016894701,0.00055727904,0.0000011024435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005633193,0.00028832944,0.023564588,0.004806138,0.00005111418,0.0000058316937,0.0006094845,0.000020214664,0.96069795,0.0018141698,0.0035653594,0.004013519],"study_design_scores_gemma":[0.002721027,0.0005890889,0.025581207,0.0021456496,0.000037890753,0.0000016470008,0.00027574363,0.00013412458,0.9670971,0.0004153412,0.0008911762,0.00011000705],"about_ca_topic_score_codex":0.0015155798,"about_ca_topic_score_gemma":0.00018774273,"teacher_disagreement_score":0.0063991654,"about_ca_system_score_codex":0.00035419257,"about_ca_system_score_gemma":0.0010591319,"threshold_uncertainty_score":0.6337784},"labels":[],"label_agreement":null},{"id":"W4409628417","doi":"10.1158/1538-7445.am2025-1565","title":"Abstract 1565: Design and development of biparatopic antibody-drug conjugates against protein tyrosine kinase 7","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Conjugate; Antibody; Tyrosine kinase; Drug; Pharmacology; Tyrosine; Medicine; Biology; Immunology; Biochemistry; Signal transduction","score_opus":0.12732124567528805,"score_gpt":0.46816191315220906,"score_spread":0.340840667476921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409628417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98087674,0.010885191,0.00035765255,0.002502148,0.00008543924,0.0024421008,0.000014753641,0.000042717547,0.0027932485],"genre_scores_gemma":[0.98975843,0.0015386534,0.0035204063,0.00012249495,0.0000912222,0.00069649896,0.00001840734,0.000035638248,0.0042182207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99702555,0.00021344541,0.00048740994,0.0005275648,0.0010057242,0.00074033503],"domain_scores_gemma":[0.9980905,0.00028653574,0.00005911092,0.00048638997,0.0007978118,0.00027963912],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002437144,0.00019338254,0.00043661168,0.0005936425,0.00024136368,0.00006237575,0.0002871779,0.000119712684,0.00035419982],"category_scores_gemma":[0.0003753894,0.00016689383,0.000040562158,0.0009342179,0.00058564,0.000080274884,0.0002477606,0.0007624408,0.00004403058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069627224,0.00021085195,0.0087798815,0.002922573,0.00013232016,0.00009356196,0.00065608474,0.000018541463,0.90910715,0.0002925922,0.0067958524,0.07029433],"study_design_scores_gemma":[0.0017648758,0.00013280979,0.022390803,0.0028600835,0.000009693944,0.0000018349015,0.00028302328,0.00009705422,0.9302322,0.00013561772,0.041932248,0.00015975375],"about_ca_topic_score_codex":0.00040970443,"about_ca_topic_score_gemma":0.00007234583,"teacher_disagreement_score":0.07013457,"about_ca_system_score_codex":0.00047910574,"about_ca_system_score_gemma":0.004455418,"threshold_uncertainty_score":0.790372},"labels":[],"label_agreement":null},{"id":"W4409630451","doi":"10.1158/1538-7445.am2025-5533","title":"Abstract 5533: Drug tolerance mechanisms in patient-derived xenograft models with <i>epidermal growth factor receptor</i> mutated tumors treated with tyrosine kinase inhibitors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tyrosine kinase; Epidermal growth factor receptor; Cancer research; Receptor tyrosine kinase; Drug; Lapatinib; Tyrosine-kinase inhibitor; Medicine; Pharmacology; Biology; Receptor; Cancer; Internal medicine; Trastuzumab","score_opus":0.040799973165433046,"score_gpt":0.3462554423397977,"score_spread":0.30545546917436467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409630451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887586,0.0015480877,0.0001561744,0.0038771012,0.00012463854,0.0031071699,0.00017738387,0.00019799026,0.0020528466],"genre_scores_gemma":[0.99550337,0.0005514378,0.00059939665,0.00040286203,0.000114532464,0.0015639169,0.000101563724,0.00015652829,0.0010064145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99323076,0.00043723956,0.0007791134,0.0013108542,0.00232921,0.0019128221],"domain_scores_gemma":[0.9963561,0.00032727423,0.00014215164,0.0008750661,0.001634422,0.000664946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009085022,0.0005740778,0.00093254267,0.0013306573,0.00032590996,0.00015861106,0.00051284936,0.00023016901,0.0006062965],"category_scores_gemma":[0.00018061089,0.00043657736,0.00010860353,0.004287085,0.000737045,0.00044789675,0.000213108,0.0021934344,0.00004344228],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021751733,0.0017561398,0.03662246,0.0029611844,0.0004987576,0.003862614,0.0044185035,0.0030601863,0.8870728,0.0007385253,0.016024712,0.021232398],"study_design_scores_gemma":[0.008084276,0.0015083546,0.008951085,0.006018898,0.00003648294,0.000026975602,0.0013689763,0.000883323,0.971148,0.00034280494,0.0009904456,0.00064034644],"about_ca_topic_score_codex":0.013421613,"about_ca_topic_score_gemma":0.0023656015,"teacher_disagreement_score":0.08407525,"about_ca_system_score_codex":0.0019140177,"about_ca_system_score_gemma":0.0029097786,"threshold_uncertainty_score":0.9998086},"labels":[],"label_agreement":null},{"id":"W4409631957","doi":"10.1158/1538-7445.am2025-6748","title":"Abstract 6748: Comparison of activities and identification of predictive genomic biomarkers of response to trastuzumab and the trastuzumab deruxtecan ADC using the OncoPanel® platform","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Cancer; Breast cancer","score_opus":0.1297112918120443,"score_gpt":0.4849850739072937,"score_spread":0.3552737820952494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409631957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913046,0.004444785,0.00021487095,0.0016310599,0.00007299913,0.0018671913,0.0001364975,0.000007981562,0.00032005273],"genre_scores_gemma":[0.9989168,0.00059242203,0.00006333114,0.000017891522,0.00003801256,0.00018064272,0.0000027563296,0.000021539825,0.00016658001],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971403,0.00047184134,0.00066488964,0.0003438888,0.0009639463,0.00041512467],"domain_scores_gemma":[0.99625885,0.0024013652,0.00019847236,0.00054063735,0.00048739673,0.00011328601],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055434518,0.0001441044,0.0005339642,0.00057352893,0.0002431889,0.000037417358,0.00033611432,0.00010009701,0.000039743994],"category_scores_gemma":[0.00081766915,0.00009463075,0.0000705792,0.000911766,0.002320636,0.000090465626,0.0002380018,0.0005448598,4.4039027e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03756976,0.00014980008,0.011840903,0.0011818535,0.0004748095,0.0000024987137,0.014101615,0.00018662625,0.8964888,0.00015317845,0.00048379516,0.037366387],"study_design_scores_gemma":[0.0039776727,0.00088446646,0.4184524,0.0012606387,0.0001505661,0.000009204721,0.03591531,0.0025810366,0.5358235,0.00031326542,0.0005139604,0.000117960546],"about_ca_topic_score_codex":0.0034199608,"about_ca_topic_score_gemma":0.00040910544,"teacher_disagreement_score":0.4066115,"about_ca_system_score_codex":0.0007552619,"about_ca_system_score_gemma":0.0019683437,"threshold_uncertainty_score":0.855048},"labels":[],"label_agreement":null},{"id":"W4409644074","doi":"10.1158/1538-7445.am2025-5215","title":"Abstract 5215: IL-17RA expression by NSCLC is vital for restraining homeostatic tumor cell proliferation and baseline cytokine production","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Homeostasis; Cytokine; Cell growth; Baseline (sea); Cancer research; Immunology; Medicine; Biology; Internal medicine; Genetics","score_opus":0.0761928336317277,"score_gpt":0.44039412346696183,"score_spread":0.36420128983523414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409644074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96740586,0.0037346873,0.00089943496,0.021532107,0.00033750877,0.004264361,0.00044435417,0.000088723085,0.0012929796],"genre_scores_gemma":[0.9864492,0.0008988467,0.0009271081,0.00040943242,0.00071924564,0.002078837,0.00015983822,0.00006562113,0.008291915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965264,0.0001876125,0.00045558932,0.0008667707,0.0011350411,0.00082859426],"domain_scores_gemma":[0.9976668,0.00043142456,0.00007790197,0.00051416917,0.0010174582,0.00029226125],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029352168,0.0002216486,0.00035417374,0.00053877034,0.00042067887,0.00014069743,0.0001869022,0.0001315948,0.00032095387],"category_scores_gemma":[0.0014953743,0.00019789753,0.000063962856,0.0008215369,0.00029046548,0.00022738421,0.00012292824,0.00090998603,0.0000159995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016456094,0.00018255899,0.001633591,0.0022271422,0.00002876146,0.000016540202,0.0006607168,0.000009024843,0.76455146,0.00001721302,0.20099455,0.028032813],"study_design_scores_gemma":[0.0029076063,0.0006391395,0.001922968,0.001753152,0.00003231719,0.000010110689,0.0009253467,0.0007073838,0.9328028,0.00026554381,0.057819046,0.00021456242],"about_ca_topic_score_codex":0.0002527109,"about_ca_topic_score_gemma":0.00003707813,"teacher_disagreement_score":0.16825135,"about_ca_system_score_codex":0.00060039054,"about_ca_system_score_gemma":0.0015214153,"threshold_uncertainty_score":0.8070027},"labels":[],"label_agreement":null},{"id":"W4409689959","doi":"10.1158/1538-7445.am2025-1230","title":"Abstract 1230: High throughput quantitative molecular characterization of cytotoxic antibody-drug conjugates in spheroid models for improved functional characterization, screening and candidate selection","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Antibody-drug conjugate; Characterization (materials science); Cytotoxic T cell; Selection (genetic algorithm); High-throughput screening; Drug; Computational biology; Spheroid; Antibody; Chemistry; Biology; Pharmacology; Immunology; In vitro; Bioinformatics; Materials science; Nanotechnology; Monoclonal antibody; Computer science; Biochemistry","score_opus":0.06537420895556471,"score_gpt":0.4193367668752878,"score_spread":0.3539625579197231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409689959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94348043,0.0004048595,0.05096021,0.0024490585,0.0001267216,0.002151786,0.00030272926,0.00003237215,0.00009181036],"genre_scores_gemma":[0.9951823,0.0014237803,0.0008617288,0.00015540009,0.000100501245,0.00071357127,0.0009025177,0.000048524613,0.00061172957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761385,0.0001646585,0.0005165439,0.00059823954,0.00054286333,0.00056387676],"domain_scores_gemma":[0.9978857,0.00024486802,0.0001321376,0.00023873097,0.0013763882,0.00012216886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012748911,0.00019434915,0.00044121372,0.0006121324,0.00019341921,0.000076861164,0.0001340036,0.00014548874,0.00013868512],"category_scores_gemma":[0.0002689683,0.00019503827,0.000060122,0.0012506479,0.00028132746,0.00038125573,0.00009414103,0.00053134665,0.000001913782],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019463099,0.00010094188,0.00623776,0.00095214957,0.000116823496,0.000004085483,0.00028446683,0.00022696101,0.98397565,0.0021133074,0.00007415239,0.003967414],"study_design_scores_gemma":[0.0037749854,0.00036698743,0.19253491,0.0014406071,0.00003595644,0.000003560806,0.00021398459,0.04077674,0.7586797,0.0012835737,0.00066290965,0.00022610738],"about_ca_topic_score_codex":0.0021660745,"about_ca_topic_score_gemma":0.00030975006,"teacher_disagreement_score":0.22529596,"about_ca_system_score_codex":0.00040169674,"about_ca_system_score_gemma":0.0011909466,"threshold_uncertainty_score":0.795343},"labels":[],"label_agreement":null},{"id":"W4409708840","doi":"10.21203/rs.3.rs-6256038/v1","title":"A Machine Learning Platform for Interconnecting Antibody-Drug Conjugate Cytotoxic Design with Tumor Cell Biology","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Canadian Institutes of Health Research; Alliance de recherche numérique du Canada","keywords":"Cytotoxic T cell; Conjugate; Antibody-drug conjugate; Drug; Antibody; Computer science; Tumor cells; Computational biology; Cancer research; Biology; Immunology; Pharmacology; Monoclonal antibody; Mathematics; In vitro; Genetics","score_opus":0.12356467777840584,"score_gpt":0.4607400425210185,"score_spread":0.33717536474261267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409708840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75469595,0.021346923,0.10183086,0.009121934,0.0016455236,0.057090446,0.0027028543,0.0018928751,0.049672633],"genre_scores_gemma":[0.97469956,0.0012370668,0.009648773,0.00013452898,0.0006367351,0.002738119,0.0010564886,0.0002127749,0.009635959],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9927896,0.0012121102,0.0007801691,0.0017315467,0.0013305097,0.002156042],"domain_scores_gemma":[0.99146485,0.0044820076,0.0002487277,0.0012623538,0.001956958,0.0005851165],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007932378,0.0006544756,0.0013557202,0.0017059338,0.0006465196,0.0002455261,0.0009557246,0.0005085997,0.00042261253],"category_scores_gemma":[0.0036958272,0.0005272785,0.00034258422,0.00095205853,0.00054166635,0.00009379724,0.0020189665,0.0074576656,0.00008823151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07380003,0.0047984873,0.14282624,0.28763068,0.0055949036,0.006661057,0.021427367,0.024995262,0.30656812,0.0056555043,0.024863396,0.095178954],"study_design_scores_gemma":[0.026826812,0.027224889,0.0009306744,0.06438559,0.00060426444,0.0004094613,0.010680455,0.33953378,0.3943777,0.009576259,0.12163421,0.003815878],"about_ca_topic_score_codex":0.0018764965,"about_ca_topic_score_gemma":0.00019909642,"teacher_disagreement_score":0.31453854,"about_ca_system_score_codex":0.0013103345,"about_ca_system_score_gemma":0.00475026,"threshold_uncertainty_score":0.9997179},"labels":[],"label_agreement":null},{"id":"W4409713352","doi":"10.1002/ijc.35448","title":"Real‐world comparative effectiveness and safety of Pertuzumab in patients with HER2+ metastatic breast cancer: A pan‐Canadian population‐based cohort study","year":2025,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's College Hospital; Sunnybrook Health Science Centre; McGill University; Simon Fraser University; Hospital for Sick Children; University of Saskatchewan; University of New Brunswick; Dalhousie University; Newfoundland and Labrador Centre for Applied Health Research; OmniActive Health Technologies (Canada); University of Manitoba; Government of Manitoba; Centre for Addiction and Mental Health; University of Calgary; Health Sciences Centre; CancerCare Manitoba; Saskatchewan Cancer Agency; Canadian Centre for Applied Research in Cancer Control; University of Toronto; Public Health Ontario","funders":"Canadian Institutes of Health Research","keywords":"Pertuzumab; Medicine; Internal medicine; Propensity score matching; Febrile neutropenia; Metastatic breast cancer; Trastuzumab; Population; Breast cancer; Incidence (geometry); Cumulative incidence; Cohort; Cancer; Chemotherapy; Oncology; Surgery; Neutropenia","score_opus":0.020757184820117788,"score_gpt":0.4055644816163519,"score_spread":0.3848072967962341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409713352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99669945,0.0002637965,0.00003810481,0.001131593,0.00028448214,0.00096177007,0.00018849851,0.000003134775,0.00042915705],"genre_scores_gemma":[0.99946284,0.00009894228,0.00008899043,0.00013140964,0.000053862543,0.00007536542,0.000012850458,0.00001237941,0.00006337066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980186,0.00020461906,0.00051961164,0.00018070776,0.00090699823,0.00016946442],"domain_scores_gemma":[0.9977599,0.00021822921,0.00026657287,0.00011506745,0.0015037177,0.0001365565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005162375,0.00013651069,0.00054171367,0.0009115611,0.00003428012,0.000023571363,0.00018001402,0.000025377154,0.0002208639],"category_scores_gemma":[0.00004273021,0.00010470827,0.00005360756,0.00046550037,0.0000722973,0.00012766161,0.000025196192,0.00027832045,3.8593245e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054996065,0.0004178124,0.9817221,0.00008201412,0.0012002494,0.000042406435,0.00021394285,0.0011906514,0.000011973287,0.00004802251,0.00008122177,0.009489962],"study_design_scores_gemma":[0.008146254,0.000367667,0.9887996,0.0017741601,0.00018642875,0.0000051665597,0.0001126429,0.00025846306,0.000065697815,0.000033819266,0.00016909158,0.00008104809],"about_ca_topic_score_codex":0.23932974,"about_ca_topic_score_gemma":0.3184352,"teacher_disagreement_score":0.07910546,"about_ca_system_score_codex":0.0029339872,"about_ca_system_score_gemma":0.002248397,"threshold_uncertainty_score":0.7672275},"labels":[],"label_agreement":null},{"id":"W4409822066","doi":"10.1158/1538-7445.am2025-ct195","title":"Abstract CT195: A phase 1 dose escalation/expansion study of GSK5764227, a B7-homolog 3 protein targeted antibody-drug conjugate, in combination with standard of care in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Antibody-drug conjugate; Conjugate; Standard of care; Medicine; Antibody; Drug; Cancer research; Solid tumor; Cancer; Oncology; Pharmacology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.022690009711956734,"score_gpt":0.4296070132920876,"score_spread":0.4069170035801309,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409822066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990719,0.0004526003,0.000009721615,0.00022168843,0.00003350125,0.00809785,0.0001173052,0.000021709478,0.0003266134],"genre_scores_gemma":[0.9985295,0.000044931377,0.00011056927,0.000009798451,0.00001089646,0.0010228829,0.00012603424,0.0000438962,0.00010150631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955715,0.0004050996,0.0007577796,0.00061553216,0.002019344,0.00063076086],"domain_scores_gemma":[0.99641913,0.00015754286,0.00019397607,0.000588889,0.0024944276,0.00014605885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012446395,0.00023108964,0.0008072586,0.0013295515,0.00008676103,0.000020859014,0.0002758235,0.00010094194,0.00010941829],"category_scores_gemma":[0.00033207957,0.00018291338,0.000036023648,0.002804086,0.00038923824,0.00020435058,0.00012439427,0.00097197696,0.0000014911659],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.075172916,0.0069112116,0.8424975,0.0034035372,0.00012363635,0.0001759849,0.009480844,0.00087519205,0.04090972,0.000042845382,0.00007932887,0.020327274],"study_design_scores_gemma":[0.06097541,0.020533286,0.8202302,0.00743585,0.000023012282,5.23648e-7,0.008882475,0.000121087935,0.08145951,0.00005497372,0.000058498885,0.00022521432],"about_ca_topic_score_codex":0.0036736627,"about_ca_topic_score_gemma":0.0063285735,"teacher_disagreement_score":0.04054979,"about_ca_system_score_codex":0.001532476,"about_ca_system_score_gemma":0.0025848707,"threshold_uncertainty_score":0.74589914},"labels":[],"label_agreement":null},{"id":"W4410512952","doi":"10.3899/jrheum.2025-0390.pv254","title":"REAL-WORLD ASSESSMENT OF PATTERNS OF PAIN TREATMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: A PATHWAY VISUALIZATION STUDY USING EHR","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Systemic lupus; Lupus erythematosus; Visualization; Systemic disease; Dermatology; Internal medicine; Immunopathology; Immunology; Data mining; Disease","score_opus":0.04728678434799391,"score_gpt":0.41783211113072416,"score_spread":0.3705453267827302,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410512952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958475,0.00037640324,0.0023927507,0.00021641876,0.00020863247,0.0007681127,0.0000042748425,0.0000052739106,0.00018059839],"genre_scores_gemma":[0.99873424,0.0009845919,0.00013224778,0.000014163399,0.000005269799,0.000011851651,0.0000012585461,0.000015814176,0.000100572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962928,0.0016811382,0.0012818502,0.00011210547,0.0004177717,0.00021430582],"domain_scores_gemma":[0.9977626,0.0007773023,0.00078654336,0.0003316183,0.00029099593,0.000050935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034746414,0.00013600924,0.000963529,0.00070772745,0.000031418735,0.0000048142088,0.0001936363,0.00006252295,0.000037032376],"category_scores_gemma":[0.0001750812,0.00008511717,0.000097713426,0.000499001,0.00006779174,0.00003667535,0.000057943693,0.00021130126,3.5557173e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003635232,0.0009394568,0.98950326,0.00090798753,0.00033902546,0.000045144774,0.0030518626,0.00026057678,0.0026200486,0.0010343761,0.00003444147,0.0009003102],"study_design_scores_gemma":[0.05333015,0.024103716,0.6590445,0.05361625,0.0022415577,0.02567845,0.12804388,0.035970174,0.015625421,0.0011496834,0.00045264105,0.0007435919],"about_ca_topic_score_codex":0.0043508955,"about_ca_topic_score_gemma":0.0020112856,"teacher_disagreement_score":0.33045876,"about_ca_system_score_codex":0.0007012812,"about_ca_system_score_gemma":0.0010497549,"threshold_uncertainty_score":0.65772814},"labels":[],"label_agreement":null},{"id":"W4410708732","doi":"10.1038/s41523-025-00759-2","title":"Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis","year":2025,"lang":"en","type":"article","venue":"npj Breast Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Single Center; Breast cancer; Medicine; Oncology; Internal medicine; Center (category theory); Cancer","score_opus":0.024748921851020744,"score_gpt":0.37959586164959996,"score_spread":0.35484693979857923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410708732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853172,0.00019413323,0.00007539154,0.0066589788,0.00018578014,0.00084732915,0.00616593,0.000032417574,0.00052288815],"genre_scores_gemma":[0.9973988,0.00053177436,0.00006845611,0.0008124353,0.000101927406,0.00022140212,0.000118858996,0.000034775476,0.0007115488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99767727,0.00012658877,0.00054912904,0.00063689775,0.0005613535,0.00044879006],"domain_scores_gemma":[0.99834394,0.00014495557,0.00018200143,0.0004858705,0.000573195,0.00027001405],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012320488,0.0003165066,0.0010226488,0.00032050774,0.00006871424,0.000030892166,0.00013233192,0.0001375116,0.0009332304],"category_scores_gemma":[0.000012976164,0.00021534969,0.0002984448,0.0006694959,0.00026965488,0.00008058566,0.000094522016,0.00023172681,0.0000033597196],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017874253,0.001653276,0.8807208,0.00010284373,0.0054615405,0.000016889295,0.000119940094,0.00000733718,0.0000063273455,0.0000045089887,0.00022781595,0.10989132],"study_design_scores_gemma":[0.0064944318,0.0005354388,0.9890688,0.00047779627,0.002399108,0.000011862135,0.000078049015,0.00008272759,0.00007204658,0.0000018283339,0.0006012219,0.00017667156],"about_ca_topic_score_codex":0.027855523,"about_ca_topic_score_gemma":0.012039429,"teacher_disagreement_score":0.10971465,"about_ca_system_score_codex":0.0010825326,"about_ca_system_score_gemma":0.00061202666,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W4410803503","doi":"10.1200/jco.2025.43.16_suppl.1037","title":"Characterization of the immune microenvironment and spatial phenotypes across HER2 subtypes in advanced or metastatic breast cancer.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Breast cancer; Metastatic breast cancer; Immune system; Tumor microenvironment; Phenotype; Cancer; Cancer research; Oncology; Internal medicine; Immunology; Biology; Genetics; Gene","score_opus":0.07010473532947813,"score_gpt":0.4910602070998903,"score_spread":0.42095547177041215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810934,0.0007439127,0.0001371465,0.016948141,0.0006912334,0.00029475393,0.000023628187,0.0000016318087,0.000066123306],"genre_scores_gemma":[0.9945053,0.0038154223,0.0003218846,0.0007598373,0.00016173838,0.000008814734,0.0000012100933,0.000008718876,0.0004171039],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974819,0.00041065033,0.001530846,0.00013459231,0.00025630472,0.00018573151],"domain_scores_gemma":[0.9980101,0.000740384,0.0008508209,0.0001629291,0.00014920025,0.00008657306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019321365,0.000087145534,0.0009131583,0.000060022685,0.00003042592,0.0000054538946,0.00016130964,0.000118734315,0.00016929318],"category_scores_gemma":[0.001040655,0.000049426093,0.00013321097,0.00018943525,0.0003382013,0.000056566547,0.00011381384,0.000631097,0.0000012350131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009922213,0.0009149579,0.3157915,0.00019197431,0.00021147693,0.000067644265,0.00022730815,0.000023699728,0.045202944,0.000013913095,0.00004411003,0.62738824],"study_design_scores_gemma":[0.0049644047,0.0015803159,0.980448,0.0004788651,0.00010750683,0.00007147379,0.00012915766,0.00009646344,0.0043365727,0.0000493482,0.007697986,0.000039897626],"about_ca_topic_score_codex":0.0003094455,"about_ca_topic_score_gemma":0.0011280713,"teacher_disagreement_score":0.6646565,"about_ca_system_score_codex":0.00022372327,"about_ca_system_score_gemma":0.0014569183,"threshold_uncertainty_score":0.27418375},"labels":[],"label_agreement":null},{"id":"W4410803724","doi":"10.1200/jco.2025.43.16_suppl.1062","title":"Phase Ib study of inavolisib (INAVO) + weekly paclitaxel (wP) in patients (pts) with locally advanced/metastatic (LA/m) incurable solid tumors: Safety, pharmacokinetics (PK), and preliminary antitumor activity.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech","keywords":"Medicine; Pharmacokinetics; Paclitaxel; Pharmacology; Internal medicine; Oncology; Chemotherapy","score_opus":0.08265775153649609,"score_gpt":0.5225800354404776,"score_spread":0.4399222839039815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99319285,0.0005037717,0.00026631993,0.002627488,0.00036767407,0.0014245546,0.00001591738,0.00000934082,0.0015920781],"genre_scores_gemma":[0.99626493,0.0011587174,0.0017028442,0.00041442554,0.00013317398,0.000024961682,0.0000024584817,0.000034141678,0.0002643672],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933777,0.0015996973,0.0032002826,0.0004213145,0.0009188299,0.00048218627],"domain_scores_gemma":[0.9922868,0.0041164923,0.0017766797,0.00036416846,0.0010175571,0.0004382878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004629866,0.0002837725,0.002605881,0.0005840418,0.000057905843,0.00001776695,0.0003485095,0.00020264072,0.00004454132],"category_scores_gemma":[0.004649551,0.00021109938,0.00017526207,0.00070817256,0.0005996572,0.00028099134,0.00026638518,0.002215228,0.0000026918672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12291964,0.07181705,0.31642884,0.00093544775,0.0007719015,0.003892792,0.000635145,0.00029120815,0.0004087698,0.00002633016,0.0015896845,0.4802832],"study_design_scores_gemma":[0.14481193,0.2739815,0.56793946,0.0026288184,0.000788459,0.00024368535,0.001373604,0.0011117378,0.0004824604,0.00022922968,0.006157469,0.00025161033],"about_ca_topic_score_codex":0.00007347711,"about_ca_topic_score_gemma":0.00008312596,"teacher_disagreement_score":0.48003158,"about_ca_system_score_codex":0.0003588865,"about_ca_system_score_gemma":0.003381808,"threshold_uncertainty_score":0.96241874},"labels":[],"label_agreement":null},{"id":"W4410804527","doi":"10.1200/jco.2025.43.16_suppl.e13135","title":"Phase 1 study of the anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) + paclitaxel for previously untreated advanced triple negative breast cancer (TNBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Monoclonal antibody; Pembrolizumab; Triple-negative breast cancer; Antibody; Trastuzumab; Paclitaxel; Breast cancer; Cancer research; Virology; Cancer; Immunology; Immunotherapy; Immune system; Internal medicine","score_opus":0.11285010697904874,"score_gpt":0.5465878771365084,"score_spread":0.4337377701574596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410804527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778116,0.0023681964,0.0003272116,0.011001653,0.003637154,0.0035756016,0.00034769214,0.000022913346,0.00090798683],"genre_scores_gemma":[0.99280715,0.0021412482,0.00094567944,0.0014590124,0.00066601933,0.0001309328,0.000009831114,0.000052567495,0.0017875519],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9915359,0.0016604788,0.0044700126,0.00057188567,0.0010174909,0.0007442589],"domain_scores_gemma":[0.9904087,0.003541967,0.0023839776,0.0007349285,0.002478486,0.00045195056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0043109,0.00040497934,0.0033005264,0.00031706624,0.00019854141,0.000020545256,0.0009068742,0.0005493451,0.0003572793],"category_scores_gemma":[0.0039595854,0.00026015256,0.0012602025,0.0009717855,0.00068469887,0.00020048526,0.00014798883,0.002096998,0.0000039140587],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22005707,0.06229709,0.1359467,0.001035988,0.008004537,0.0007099472,0.0026214998,0.0004051068,0.01647335,0.00017390848,0.025115307,0.5271595],"study_design_scores_gemma":[0.32473752,0.08648759,0.5109277,0.0021531505,0.004118688,0.0005158619,0.0034793771,0.0011968294,0.00226933,0.0006229551,0.06298537,0.0005056264],"about_ca_topic_score_codex":0.00044700663,"about_ca_topic_score_gemma":0.00041269412,"teacher_disagreement_score":0.5266539,"about_ca_system_score_codex":0.0007336415,"about_ca_system_score_gemma":0.008742864,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W4410812638","doi":"10.1200/jco.2025.43.16_suppl.e15024","title":"Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacodynamics; Pharmacokinetics; Antibody-drug conjugate; Pharmacology; Drug; Conjugate; Antibody; Monoclonal antibody; Immunology","score_opus":0.11965148810061271,"score_gpt":0.5611931399788107,"score_spread":0.441541651878198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410812638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921567,0.0046482454,0.000020598463,0.0016877885,0.000616184,0.0006611607,0.000013084782,0.000005347833,0.00019093452],"genre_scores_gemma":[0.98689467,0.011992219,0.0003428769,0.00058442913,0.0001299805,0.0000023853631,0.0000021957103,0.000016267933,0.000034972833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99553126,0.0009072525,0.0024626527,0.00023938275,0.000544765,0.0003146858],"domain_scores_gemma":[0.9896566,0.0070934338,0.0018599605,0.00012611567,0.0010624294,0.00020145997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005129643,0.00021518933,0.0021522604,0.0006364793,0.00005424749,0.0000073140577,0.00022436566,0.00012030351,0.000029942152],"category_scores_gemma":[0.0025557494,0.00012156591,0.00014451623,0.0009843083,0.0010975152,0.000093560746,0.00020222664,0.0014828877,1.9034101e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072945934,0.0016162118,0.94909996,0.00069184485,0.0012370801,0.00013659301,0.0004883011,0.00010287708,0.0047221715,0.0000070679193,0.0005507722,0.034052514],"study_design_scores_gemma":[0.035786737,0.008293837,0.94286805,0.0006979719,0.0013032824,0.000039984225,0.0010314267,0.0012063541,0.0076032067,0.000050834173,0.0009774204,0.00014088846],"about_ca_topic_score_codex":0.000024624693,"about_ca_topic_score_gemma":0.000009421279,"teacher_disagreement_score":0.033911623,"about_ca_system_score_codex":0.00014676509,"about_ca_system_score_gemma":0.00086396426,"threshold_uncertainty_score":0.64424914},"labels":[],"label_agreement":null},{"id":"W4410872809","doi":"10.3389/fonc.2025.1564888","title":"Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting","year":2025,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Northern College","funders":"Chinese Society of Clinical Oncology; National Natural Science Foundation of China; Shanghai Municipal Health Commission","keywords":"Metastatic breast cancer; Medicine; Oncology; Breast cancer; Internal medicine; First line; Second line; Cancer; Line (geometry)","score_opus":0.012006504483170009,"score_gpt":0.33463157575941616,"score_spread":0.3226250712762461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410872809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911197,0.0011839941,0.00035609875,0.0040659397,0.00029627435,0.0014537245,0.00010837128,0.000012237783,0.0014036864],"genre_scores_gemma":[0.99430007,0.00023405736,0.004532381,0.00046760414,0.000031076564,0.00012418335,0.000035405308,0.000025776775,0.0002494298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978778,0.00029378044,0.00066346006,0.00044439637,0.00022835174,0.0004922436],"domain_scores_gemma":[0.9988962,0.00046795682,0.0001640463,0.00023070713,0.00014935904,0.000091754686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076366024,0.00020102177,0.0009049792,0.00071454875,0.000034479057,0.000006024366,0.00013075027,0.00015082542,0.00009306087],"category_scores_gemma":[0.00027186153,0.00018049922,0.000030091103,0.00077507086,0.00026427105,0.00007489092,0.000111601854,0.0006697918,7.0894146e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008294237,0.00055397267,0.9097344,0.00030913932,0.00014913947,0.000118604854,0.0015939736,0.0006993107,0.000015128636,0.00002119784,0.0007339001,0.07777694],"study_design_scores_gemma":[0.021853853,0.0018714999,0.97035086,0.0018749833,0.0000671546,0.000007946189,0.00089916063,0.0014820944,0.00011083212,0.000069228474,0.0012613753,0.00015101206],"about_ca_topic_score_codex":0.0013001784,"about_ca_topic_score_gemma":0.0069076745,"teacher_disagreement_score":0.07762593,"about_ca_system_score_codex":0.001720105,"about_ca_system_score_gemma":0.00093329663,"threshold_uncertainty_score":0.7360545},"labels":[],"label_agreement":null},{"id":"W4410952304","doi":"10.1016/s1470-2045(25)00287-6","title":"Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Jazz Pharmaceuticals","keywords":"Oxaliplatin; Medicine; Capecitabine; Regimen; Internal medicine; Tolerability; Chemotherapy; Gastroenterology; Dosing; Oncology; Adenocarcinoma; Adverse effect; Cancer; Colorectal cancer","score_opus":0.04556820725942549,"score_gpt":0.3980022265406252,"score_spread":0.3524340192811997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410952304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827899,0.00046817286,0.00019682485,0.005807636,0.00017809178,0.0073698075,0.0006391565,0.00005853551,0.0024919226],"genre_scores_gemma":[0.993867,0.00015554842,0.0024044944,0.0011064234,0.00027449962,0.0006658932,0.00037332525,0.00004459183,0.0011082586],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9976073,0.00027234078,0.00053667615,0.0005666037,0.00038614232,0.0006309622],"domain_scores_gemma":[0.997391,0.00097468373,0.0002714689,0.00083378406,0.00040369792,0.00012535656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004656738,0.00030428602,0.0011285045,0.00012662435,0.0001393372,0.000013043853,0.00033291374,0.0001116801,0.00004320843],"category_scores_gemma":[0.00022799423,0.00019087702,0.00009629117,0.00032181357,0.00025506722,0.000056323614,0.000100022466,0.00027076082,0.000008056421],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57886034,0.084385425,0.097573094,0.00072022603,0.0024686267,0.00041640183,0.013488793,0.00023439403,0.0014580463,0.000075365366,0.00400632,0.21631299],"study_design_scores_gemma":[0.52574223,0.25448158,0.1816354,0.00049617677,0.00092756574,0.000025999943,0.0020303156,0.0005064929,0.008165769,0.000071006456,0.02558662,0.00033080392],"about_ca_topic_score_codex":0.00028380528,"about_ca_topic_score_gemma":0.00035538248,"teacher_disagreement_score":0.21598218,"about_ca_system_score_codex":0.001843206,"about_ca_system_score_gemma":0.00088103476,"threshold_uncertainty_score":0.7783739},"labels":[],"label_agreement":null},{"id":"W4410954716","doi":"10.1016/j.critrevonc.2025.104787","title":"Adverse effect of trastuzumab deruxtecan in solid tumours: A systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North; NOSM University; Lakeshore General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Trastuzumab; Meta-analysis; Oncology; Adverse effect; Medicine; Systematic review; Internal medicine; MEDLINE; Cancer; Chemistry; Breast cancer","score_opus":0.1405847298912986,"score_gpt":0.5463202509195888,"score_spread":0.4057355210282902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410954716","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[8.009751e-7,0.98150873,0.00004486641,0.0014040164,0.000095097326,0.015557834,0.00006423332,0.000026436554,0.0012979853],"genre_scores_gemma":[0.000048548958,0.98573124,0.00051167636,0.001004422,0.000020530657,0.012335123,0.000055228807,0.00006250407,0.00023071443],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97618186,0.014022814,0.0066389577,0.0014911339,0.0005365444,0.0011286818],"domain_scores_gemma":[0.97729427,0.019059243,0.001035535,0.0018892757,0.00027411128,0.00044755396],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.012339171,0.0011495245,0.058592394,0.0022523825,0.000044005672,0.000010689932,0.0008044095,0.0013123727,0.0008520249],"category_scores_gemma":[0.056226674,0.00073006266,0.004978558,0.004162306,0.0009959553,0.000060435792,0.00042414194,0.002392018,0.00011225771],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021097527,0.00029690773,0.000022107643,0.963779,0.015599049,0.00095056044,0.000025710855,3.431319e-8,4.8818837e-8,0.0012010074,0.00051867386,0.017585836],"study_design_scores_gemma":[0.000402325,0.0006691672,8.8358524e-7,0.39479047,0.55992424,0.000999115,0.000010884771,0.000002685123,0.0000011589232,0.000061914696,0.042841785,0.00029535664],"about_ca_topic_score_codex":0.00003738585,"about_ca_topic_score_gemma":0.00024528423,"teacher_disagreement_score":0.5689885,"about_ca_system_score_codex":0.001139336,"about_ca_system_score_gemma":0.00194902,"threshold_uncertainty_score":0.99998415},"labels":[],"label_agreement":null},{"id":"W4411197152","doi":"10.1055/a-2549-4288","title":"HER2-positives Mammakarzinom: Ansprechen auf die neoadjuvante Chemotherapie","year":2025,"lang":"de","type":"article","venue":"Geburtshilfe und Frauenheilkunde","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gynecology","score_opus":0.027008713538358663,"score_gpt":0.3631233033884621,"score_spread":0.33611458985010345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411197152","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037105687,0.7058736,0.007463211,0.036430527,0.010334592,0.005042026,0.00055022887,0.0010324509,0.19616769],"genre_scores_gemma":[0.7164531,0.093740985,0.005112779,0.020852145,0.009880654,0.000712604,0.00064676726,0.00093371345,0.15166728],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899939,0.0007878157,0.0017569992,0.0024456494,0.0018676601,0.0031479886],"domain_scores_gemma":[0.9935147,0.0012017296,0.00041649368,0.0029502597,0.00074431277,0.0011724855],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0019842742,0.0015097399,0.0020654707,0.0011806355,0.0007980411,0.00058742915,0.0017230536,0.0014751885,0.0037428515],"category_scores_gemma":[0.00075072446,0.0015386392,0.0008378318,0.0019510031,0.0016177044,0.0003898273,0.0008148245,0.0031587894,0.0047052405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005206598,0.00513563,0.08298794,0.007931614,0.027348716,0.004111948,0.01097443,0.0001453172,0.0173366,0.017057119,0.23844494,0.5833191],"study_design_scores_gemma":[0.0066484716,0.0011096409,0.027686322,0.0046781925,0.003237811,0.000018330235,0.00080356543,0.00095311046,0.02621019,0.0070258416,0.92002994,0.0015985933],"about_ca_topic_score_codex":0.0017776414,"about_ca_topic_score_gemma":0.00029515653,"teacher_disagreement_score":0.681585,"about_ca_system_score_codex":0.0021299429,"about_ca_system_score_gemma":0.003040878,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W4411289858","doi":"10.1158/1557-3265.sabcs24-p3-07-03","title":"Abstract P3-07-03: Real-world comparison of safety and effectiveness of dose dense (2-weekly) versus weekly paclitaxel given with trastuzumab as neoadjuvant treatment in HER2-positive early stage breast cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Oncology; Breast cancer; Stage (stratigraphy); Internal medicine; Cancer","score_opus":0.14634287494718778,"score_gpt":0.5437414468488628,"score_spread":0.39739857190167505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411289858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847365,0.0024493074,0.000009644059,0.002631693,0.00022621619,0.003206314,0.00078347075,0.000028365714,0.005928468],"genre_scores_gemma":[0.99016494,0.006969022,0.000066511835,0.000025251575,0.0001443661,0.00060964527,0.000030233386,0.00006763817,0.0019224074],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99261326,0.001942155,0.0015285707,0.0011807706,0.001657198,0.0010780221],"domain_scores_gemma":[0.9897203,0.00723479,0.00029567815,0.0008984399,0.0012773928,0.0005734246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004996568,0.0004254795,0.0019771676,0.00074080867,0.00015733563,0.000046821926,0.0003978833,0.00032944034,0.00060173136],"category_scores_gemma":[0.00057479314,0.00033182206,0.0002403561,0.0017282732,0.0019851723,0.00014188551,0.00026872766,0.0018307312,0.000021640888],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17121254,0.0027575807,0.7495544,0.0018706896,0.000936685,0.00029753867,0.00088974735,0.00015179446,0.0012781194,0.00025952168,0.00029047905,0.07050089],"study_design_scores_gemma":[0.01992925,0.010568537,0.95682454,0.0054548015,0.00015949042,0.0000033659612,0.0011501345,0.00013184041,0.004357753,0.000058649908,0.0011116831,0.0002499352],"about_ca_topic_score_codex":0.18163635,"about_ca_topic_score_gemma":0.04271994,"teacher_disagreement_score":0.20727013,"about_ca_system_score_codex":0.003217291,"about_ca_system_score_gemma":0.0055133644,"threshold_uncertainty_score":0.9999134},"labels":[],"label_agreement":null},{"id":"W4411290570","doi":"10.1158/1557-3265.sabcs24-p2-11-15","title":"Abstract P2-11-15: Axillary Pathologic Complete Response in Triple-Negative Breast Cancer Patients with Mammary Pathologic Complete Response: A Systematic Review","year":2025,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Breast cancer; Complete response; Triple-negative breast cancer; Cancer; Triple negative; Pathology; Oncology; Internal medicine; Chemotherapy","score_opus":0.3170601579605599,"score_gpt":0.5545073676760174,"score_spread":0.23744720971545746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411290570","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012771143,0.9579853,0.000005074354,0.0048147817,0.00060211244,0.028264858,0.0065374905,0.00018376688,0.0003295343],"genre_scores_gemma":[0.0006484368,0.97551155,0.00018026574,0.002001061,0.00035850273,0.017977519,0.00045100096,0.0002884307,0.0025832169],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9431835,0.038065184,0.006748795,0.0037029928,0.0052325996,0.0030669367],"domain_scores_gemma":[0.95011425,0.038398158,0.0019223995,0.004446389,0.003724291,0.0013945147],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","metaepi_narrow","research_integrity"],"category_scores_codex":[0.050272465,0.0017894016,0.013168821,0.0024543947,0.00050186506,0.0002458037,0.0033501028,0.0018115409,0.001853368],"category_scores_gemma":[0.03871538,0.0011986239,0.0018034693,0.007267994,0.0024655655,0.0002753484,0.0020244394,0.010299982,0.00044965686],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021577612,0.0013064083,0.0021078861,0.89148897,0.0006779591,0.008204978,0.000087324006,9.677013e-7,0.0000016281015,0.000015776875,0.012484287,0.062046222],"study_design_scores_gemma":[0.0053608376,0.0028611706,0.03271747,0.85515815,0.0014903571,0.00033289703,0.000061449646,0.0000076084366,2.5885726e-7,0.000049736165,0.10079272,0.0011673216],"about_ca_topic_score_codex":0.00085136713,"about_ca_topic_score_gemma":0.0004980372,"teacher_disagreement_score":0.08830844,"about_ca_system_score_codex":0.005646314,"about_ca_system_score_gemma":0.021218894,"threshold_uncertainty_score":0.99948514},"labels":[],"label_agreement":null},{"id":"W4411290861","doi":"10.1158/1557-3265.sabcs24-p4-08-02","title":"Abstract P4-08-02: Identifying unique transcriptomes associated with HER2+ breast cancer recurrence at the single-cell level","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Medicine; Transcriptome; Cancer; Oncology; Internal medicine; Computational biology; Biology; Genetics; Gene; Gene expression","score_opus":0.45902800883359274,"score_gpt":0.5609312424808137,"score_spread":0.10190323364722098,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411290861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.919725,0.010624519,0.00008274561,0.047764454,0.0011197155,0.0026221785,0.0007632469,0.00016564883,0.017132478],"genre_scores_gemma":[0.9561416,0.006721347,0.000048809812,0.0013278852,0.0005354892,0.00093975774,0.00004241946,0.00010020277,0.034142513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99160755,0.0013627977,0.0011894912,0.0013232353,0.0027767408,0.0017401865],"domain_scores_gemma":[0.9915387,0.0041816267,0.00021190799,0.0012844219,0.0021438617,0.0006394534],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008930758,0.00040772452,0.0008991834,0.00038509752,0.00079729187,0.00024398202,0.0011674847,0.00051799865,0.0048699887],"category_scores_gemma":[0.0018137457,0.00027389728,0.00034369875,0.0027280173,0.0022832842,0.00019335753,0.00045630662,0.0046230527,0.000188626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007181105,0.0027474891,0.5244775,0.0022162392,0.0011747953,0.00045821452,0.0008913161,0.000058720296,0.02092348,0.00015694048,0.22669712,0.21301712],"study_design_scores_gemma":[0.0060585667,0.0008666828,0.92535734,0.0071591325,0.00021308877,0.000027432636,0.00051892863,0.00013103607,0.015202005,0.00031261047,0.043607403,0.0005457948],"about_ca_topic_score_codex":0.007876212,"about_ca_topic_score_gemma":0.019512897,"teacher_disagreement_score":0.40087986,"about_ca_system_score_codex":0.0030620773,"about_ca_system_score_gemma":0.005720969,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W4411306607","doi":"10.14740/wjon2552","title":"Co-expression of HER2/EGFRvIII/CD44 and Claudin 18.2/CD109 as Novel Prognostic Indicators in Stomach Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Stomach; Claudin; CD44; Adenocarcinoma; Internal medicine; Oncology; Cancer research; Gastroenterology; Cancer; Tight junction; Biochemistry; Cell","score_opus":0.03872907709233955,"score_gpt":0.4218318991536418,"score_spread":0.3831028220613022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411306607","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96478385,0.004998194,0.00007138884,0.0049322853,0.0003446281,0.00055072474,0.000006319541,0.000010141968,0.024302455],"genre_scores_gemma":[0.99577457,0.0004184532,0.0013861177,0.00065390044,0.00016235554,0.000017746905,0.000002665802,0.00002313474,0.0015610609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99744934,0.0002737215,0.0010163032,0.0002636697,0.0005786509,0.00041832624],"domain_scores_gemma":[0.9978871,0.0008203792,0.00052728277,0.00024946075,0.00023548158,0.00028031584],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015168098,0.00018472654,0.00089033926,0.0026418434,0.000053875334,0.000012722834,0.00029452002,0.00021665599,0.0004910269],"category_scores_gemma":[0.0008987282,0.00015349296,0.000108266075,0.0014509769,0.0003825748,0.000084133295,0.00011691427,0.001043444,0.000008037131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001857409,0.0010722005,0.89797556,0.0004348847,0.00011839114,0.00084896374,0.00060333504,0.000010252661,0.049014118,0.0005004096,0.015154897,0.03240959],"study_design_scores_gemma":[0.010845197,0.0049413186,0.8234076,0.0027072863,0.00020002612,0.0011422978,0.0006918193,0.000040231316,0.034839552,0.0004994592,0.120481156,0.00020407808],"about_ca_topic_score_codex":0.00009141142,"about_ca_topic_score_gemma":0.00017873436,"teacher_disagreement_score":0.10532626,"about_ca_system_score_codex":0.00062791293,"about_ca_system_score_gemma":0.0023143257,"threshold_uncertainty_score":0.62592614},"labels":[],"label_agreement":null},{"id":"W4411421224","doi":"10.1016/j.ard.2025.05.967","title":"POS0585 SEX DIFFERENCES IN THE SAFETY PROFILE OF JANUS KINASE INHIBITORS IN RHEUMATOID ARTHRITIS: RESULTS FROM THE JAK-POT INTERNATIONAL COLLABORATION","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"","keywords":"Medicine; Janus kinase; Rheumatoid arthritis; Janus kinase inhibitor; Tofacitinib; Dermatology; Janus; Internal medicine; Receptor","score_opus":0.03913187294183144,"score_gpt":0.34826958363718125,"score_spread":0.3091377106953498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411421224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95409966,0.00488347,0.000004394149,0.036209513,0.00028275725,0.001176597,0.001067875,0.000011623418,0.002264087],"genre_scores_gemma":[0.99419147,0.0048540127,0.000023670631,0.00048523565,0.00003136473,0.00012180476,0.000098937766,0.000008995929,0.00018452776],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997189,0.0005721246,0.00092246255,0.00023826574,0.0008596317,0.0002185389],"domain_scores_gemma":[0.99705356,0.0016778888,0.00029360937,0.0006636425,0.0002626136,0.00004870154],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010220476,0.00015055067,0.00039378268,0.00015012622,0.00007802686,0.00005002365,0.0007034239,0.00005968439,0.00009579675],"category_scores_gemma":[0.0044359853,0.00007935435,0.00012000763,0.0008565631,0.0003155479,0.000108685526,0.00017212443,0.00021811169,0.000004974396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049640443,0.002904773,0.6597156,0.00078794075,0.00058894284,0.000030758,0.019642083,0.0002448434,0.00039147487,0.0034244622,0.09149797,0.21580714],"study_design_scores_gemma":[0.002778013,0.00012142569,0.96832824,0.010090091,0.000022801387,0.0000017549612,0.009307841,0.0010944768,0.0027934585,0.0043941964,0.0009550383,0.00011264414],"about_ca_topic_score_codex":0.0024222042,"about_ca_topic_score_gemma":0.0010763395,"teacher_disagreement_score":0.3086127,"about_ca_system_score_codex":0.000058065278,"about_ca_system_score_gemma":0.00065309496,"threshold_uncertainty_score":0.53106093},"labels":[],"label_agreement":null},{"id":"W4411561109","doi":"10.1007/s10549-025-07749-9","title":"Adjunctive statistical standardization of quantitated adjuvant HER2 and ultra-low HER2 in Canadian Cancer Trials Group MA.27 trial of exemestane versus anastrozole","year":2025,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Essar Steel Algoma (Canada); North York General Hospital; London Health Sciences Centre; Queen's University; McMaster University; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; AstraZeneca; Government of Ontario; Strong; Pfizer","keywords":"Anastrozole; Exemestane; Medicine; Oncology; Breast cancer; Internal medicine; Adjuvant; Clinical trial; Cancer; Gynecology; Aromatase inhibitor; Tamoxifen","score_opus":0.09989953334003839,"score_gpt":0.47022284479665905,"score_spread":0.3703233114566207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411561109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97438115,0.0068805325,0.00017003286,0.0035704689,0.0004302089,0.0048934384,0.008373651,0.000018191313,0.0012823249],"genre_scores_gemma":[0.98879355,0.0098586865,0.00017064811,0.000015884943,0.0000889527,0.0006269316,0.00015964538,0.000025990536,0.000259716],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99649435,0.00064014655,0.00068570924,0.00052665995,0.0008578376,0.00079530897],"domain_scores_gemma":[0.99759245,0.0007857892,0.000111792135,0.00029902754,0.0006259957,0.0005849535],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018018996,0.0002361056,0.0010291246,0.0007635333,0.00010039354,0.000035971876,0.00009278359,0.0001335418,0.00037212542],"category_scores_gemma":[0.00047458496,0.00018517158,0.00006906729,0.0009315801,0.0005576176,0.000079575446,0.0000375017,0.00027942366,0.0000010152584],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4926398,0.0020295978,0.108450554,0.0012670413,0.0018325812,0.00037436708,0.00088968995,0.000078408586,0.0039841593,0.004559271,0.0019958713,0.38189864],"study_design_scores_gemma":[0.4310031,0.026769826,0.49999264,0.005034996,0.0007595302,0.00003533555,0.003099961,0.0010030824,0.01969645,0.0007204969,0.011233549,0.0006510337],"about_ca_topic_score_codex":0.6990206,"about_ca_topic_score_gemma":0.64475524,"teacher_disagreement_score":0.39154208,"about_ca_system_score_codex":0.002568036,"about_ca_system_score_gemma":0.0057145385,"threshold_uncertainty_score":0.99992216},"labels":[],"label_agreement":null},{"id":"W4411770375","doi":"10.14740/jmc5136","title":"Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Trastuzumab; Metastatic breast cancer; Human Epidermal Growth Factor Receptor 2; Oncology; Triple-negative breast cancer; Breast cancer; Internal medicine; Cancer; Cancer research","score_opus":0.03018995388442816,"score_gpt":0.3777845148453995,"score_spread":0.3475945609609713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411770375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202399,0.051475547,0.00023398129,0.026852513,0.00011269986,0.000980746,0.00007691651,0.000011588582,0.000016111751],"genre_scores_gemma":[0.97322536,0.023231383,0.00045375834,0.0025225852,0.0001323142,0.00012632951,0.0000103767625,0.000038284557,0.0002596199],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99584854,0.00083717576,0.0008784384,0.0003158263,0.0017317849,0.00038824894],"domain_scores_gemma":[0.9971246,0.0010084121,0.00039987333,0.00019288714,0.0007326302,0.0005415861],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013414548,0.0002910987,0.0009772106,0.00047466668,0.0001062311,0.000071612754,0.000179998,0.000113533206,0.0011945715],"category_scores_gemma":[0.0016305163,0.00017199323,0.00011568691,0.0010192795,0.00027891572,0.0002561664,0.00003061267,0.0011140839,7.929425e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1809226,0.0025071835,0.20728017,0.02326185,0.0032779507,0.2117603,0.014755326,0.000008900425,0.0008155433,0.00004706821,0.015551902,0.3398112],"study_design_scores_gemma":[0.047252674,0.015066443,0.64382815,0.20807183,0.0009778452,0.07890396,0.0017202616,0.000041742307,0.002770511,0.000071312475,0.0006190334,0.0006762176],"about_ca_topic_score_codex":0.0002011144,"about_ca_topic_score_gemma":0.0010781831,"teacher_disagreement_score":0.436548,"about_ca_system_score_codex":0.00059158343,"about_ca_system_score_gemma":0.0025121102,"threshold_uncertainty_score":0.9997185},"labels":[],"label_agreement":null},{"id":"W4412072814","doi":"10.1080/14796694.2025.2529151","title":"Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib","year":2025,"lang":"en","type":"review","venue":"Future Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Metastatic breast cancer; Oncology; Internal medicine; Breast cancer; Cancer; Trastuzumab","score_opus":0.029248126771143183,"score_gpt":0.4596720816154097,"score_spread":0.4304239548442665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412072814","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010546382,0.97969455,0.0000014605029,0.003669325,0.00059534,0.0030071563,0.0005530552,0.000016356495,0.012452222],"genre_scores_gemma":[0.000033955002,0.994793,0.00032455975,0.00020894673,0.0008966037,0.0021847447,0.00012719874,0.000047860394,0.0013831255],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99697953,0.00094761164,0.0007567417,0.0004895733,0.00029807878,0.0005284589],"domain_scores_gemma":[0.99770105,0.0010568135,0.0003618131,0.0005861127,0.00016411471,0.00013012424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005265289,0.0004113024,0.0028624288,0.0003531352,0.000052713196,0.000006769812,0.00032087349,0.00034842012,0.00056528335],"category_scores_gemma":[0.000094238465,0.00023503412,0.00042033682,0.0008601822,0.0001611564,0.00002163282,0.000111224435,0.00087000045,0.000025122661],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000090124704,0.000428445,0.000099525605,0.010003757,0.0004986886,0.00012958985,0.00056266284,0.0000010211264,0.0000018821011,0.00018660628,0.0012470863,0.9867506],"study_design_scores_gemma":[0.0007582447,0.0008219481,0.00014302396,0.015575246,0.0015770199,0.00034053496,0.0009040503,0.000002841725,0.000009037405,0.000038787446,0.9796882,0.00014104489],"about_ca_topic_score_codex":0.0022949448,"about_ca_topic_score_gemma":0.004380224,"teacher_disagreement_score":0.9866096,"about_ca_system_score_codex":0.00398903,"about_ca_system_score_gemma":0.010922685,"threshold_uncertainty_score":0.9998345},"labels":[],"label_agreement":null},{"id":"W4412163726","doi":"10.1158/1557-3265.aimachine-b043","title":"Abstract B043: Cellular localization as a prognostic indicator in invasive breast cancer","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Cancer; Breast cancer; Medicine; Oncology; Pathology; Internal medicine","score_opus":0.1948853610627769,"score_gpt":0.5672121022401246,"score_spread":0.37232674117734776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412163726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9552633,0.0056579513,0.000057310663,0.02556239,0.00069206546,0.0033204006,0.00011282198,0.00009507019,0.009238678],"genre_scores_gemma":[0.98498386,0.00801023,0.00003137359,0.001756976,0.0007627908,0.0017699114,0.000036698286,0.00006585824,0.0025823014],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99369454,0.00076229067,0.0012100557,0.0011298533,0.0019318266,0.0012714172],"domain_scores_gemma":[0.9949484,0.0023153352,0.00012764681,0.00085393456,0.0010734963,0.0006811816],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053837495,0.00026521896,0.0007385875,0.0009813525,0.00021003748,0.00010665928,0.00065232493,0.00053387415,0.005666531],"category_scores_gemma":[0.005187661,0.00023695226,0.0001936748,0.0028880548,0.0011098667,0.00013276341,0.0004369172,0.003141856,0.00060267514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016452469,0.0008339074,0.91596395,0.0013002165,0.00013898226,0.00045192792,0.00017498076,0.000048580347,0.0011463452,0.0003160206,0.028720157,0.04925966],"study_design_scores_gemma":[0.00411351,0.00045693247,0.95841396,0.0041563185,0.000059882852,0.000009506636,0.00029783905,0.00043166528,0.004211527,0.0012058897,0.026357213,0.00028578076],"about_ca_topic_score_codex":0.0095848525,"about_ca_topic_score_gemma":0.0029228362,"teacher_disagreement_score":0.04897388,"about_ca_system_score_codex":0.0016333679,"about_ca_system_score_gemma":0.012293924,"threshold_uncertainty_score":0.99915797},"labels":[],"label_agreement":null},{"id":"W4412662543","doi":"10.14740/wjon2583","title":"Clinical Utility of Targeted Next-Generation Sequencing for Determining Human Epidermal Growth Factor Receptor 2 Status and Optimizing Targeted Therapy in Breast Cancer","year":2025,"lang":"en","type":"article","venue":"World Journal of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Targeted therapy; Breast cancer; Epidermal growth factor receptor; Oncology; Cancer; DNA sequencing; Cancer research; Internal medicine; Gene; Genetics; Biology","score_opus":0.20033985539002883,"score_gpt":0.46555932314368786,"score_spread":0.265219467753659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412662543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929406,0.0021394903,0.00046350458,0.0030503548,0.0006667462,0.00048974296,0.00003664752,0.000007804984,0.00020510399],"genre_scores_gemma":[0.98588693,0.0019355756,0.011003274,0.0005695486,0.0004763232,0.000025822688,0.000008765422,0.000019190236,0.0000745883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99721456,0.0005130298,0.001372532,0.0002511204,0.00023783976,0.00041091352],"domain_scores_gemma":[0.9977706,0.00067432126,0.0005690658,0.00013519416,0.0006541061,0.00019668898],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019921865,0.00015213499,0.000882426,0.0005665362,0.000086131695,0.000017736711,0.00012584028,0.00017040056,0.00045093632],"category_scores_gemma":[0.0004812184,0.00012981797,0.0001509513,0.00038415802,0.000207454,0.0001659856,0.00004539236,0.00074326684,2.0286606e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018346757,0.000205807,0.57891935,0.00015542484,0.00018659451,0.00003381927,0.0006242503,0.000030056142,0.17546208,0.000029431589,0.001771056,0.24074742],"study_design_scores_gemma":[0.013290941,0.0030610478,0.936298,0.00070952816,0.00010119576,0.00007871967,0.0006005666,0.0056125405,0.033196744,0.00016016989,0.0066662356,0.00022432004],"about_ca_topic_score_codex":0.0003093215,"about_ca_topic_score_gemma":0.0007446096,"teacher_disagreement_score":0.3573786,"about_ca_system_score_codex":0.0007420538,"about_ca_system_score_gemma":0.002348768,"threshold_uncertainty_score":0.5293823},"labels":[],"label_agreement":null},{"id":"W4412956201","doi":"10.1158/1535-7163.mct-24-1176","title":"Preclinical Pharmacokinetic, Pharmacodynamic, and Safety Profile of OBI-992: A Novel TROP2-Targeted Antibody–Drug Conjugate","year":2025,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"FSD Pharma (Canada)","funders":"National Applied Research Laboratories","keywords":"Pharmacology; Medicine; Pharmacokinetics; In vivo; Toxicity; Pharmacodynamics; Drug; Antibody; Cancer research; Cell culture; Immunology; Internal medicine; Biology","score_opus":0.03920731020912873,"score_gpt":0.42594948924018755,"score_spread":0.38674217903105884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412956201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90547234,0.041219514,0.01803895,0.016969817,0.0009716292,0.0042980798,0.0007683085,0.00019834447,0.012062996],"genre_scores_gemma":[0.98102367,0.0076046996,0.0023087966,0.0075839325,0.000110941255,0.00016058396,0.000093649374,0.00007058016,0.0010431454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727166,0.00022564329,0.00068793254,0.00058027153,0.00069182436,0.00054266234],"domain_scores_gemma":[0.99863464,0.00016021887,0.00015610372,0.00051695155,0.00035317164,0.0001789168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059166056,0.00032862322,0.0006503995,0.00022691854,0.00007875745,0.00003000837,0.0003283532,0.00014958241,0.0004046004],"category_scores_gemma":[0.00003921828,0.00030260716,0.00019470428,0.0005987763,0.0003657597,0.00004986006,0.00012489097,0.0006576249,0.0000070024284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018350561,0.00053440465,0.0056396895,0.0009433854,0.00095726684,0.000072354305,0.00035513443,0.000044616663,0.951355,0.00048318197,0.00047633008,0.037303593],"study_design_scores_gemma":[0.017473415,0.00063225144,0.015114496,0.0010062307,0.0019327648,0.00005045443,0.00016329886,0.022525577,0.8083454,0.00030007196,0.13182706,0.000628984],"about_ca_topic_score_codex":0.00013995192,"about_ca_topic_score_gemma":0.000010422094,"teacher_disagreement_score":0.14300959,"about_ca_system_score_codex":0.00016589763,"about_ca_system_score_gemma":0.00075204764,"threshold_uncertainty_score":0.9999426},"labels":[],"label_agreement":null},{"id":"W4412974237","doi":"10.1158/2767-9764.crc-25-0019","title":"Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Alberta; Spinal Cord Injury BC; Ontario Institute for Cancer Research; Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"Merck Canada; National Cancer Institute; Incyte; Memorial Sloan-Kettering Cancer Center; BeiGene; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Internal medicine; Discontinuation; Nausea; Adverse effect; Oncology; Breast cancer; Metastatic breast cancer; Response Evaluation Criteria in Solid Tumors; Cancer; Clinical endpoint; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial","score_opus":0.3892141963931314,"score_gpt":0.6154104701398585,"score_spread":0.22619627374672713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412974237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98142564,0.0030458756,0.00003148985,0.0062540937,0.000025594129,0.002686421,0.000033297256,0.000028648281,0.006468934],"genre_scores_gemma":[0.9949704,0.00095168134,0.00042503062,0.00008557334,0.000013322975,0.0024533737,0.000014975334,0.0000284233,0.0010572214],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961445,0.0011464101,0.00059950695,0.0003440523,0.0010451262,0.0007204466],"domain_scores_gemma":[0.9949199,0.0009438841,0.000080255,0.0029221582,0.0009163863,0.0002173915],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025486022,0.00014111736,0.0005243769,0.00088416337,0.00022630891,0.000034864774,0.0011698998,0.000038304486,0.00022120171],"category_scores_gemma":[0.0010342408,0.00011961928,0.000041838168,0.00311514,0.00073728146,0.00009283978,0.0006501411,0.0011904008,0.00001980137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012236054,0.112747334,0.5958285,0.003792186,0.0030781936,0.0005054843,0.04623969,0.0010386292,0.045067426,0.009815471,0.0203794,0.14927165],"study_design_scores_gemma":[0.18068753,0.04287939,0.4033544,0.02201522,0.0013818125,0.000044670414,0.16781844,0.03963493,0.073683634,0.0042584646,0.062420785,0.0018206987],"about_ca_topic_score_codex":0.00673787,"about_ca_topic_score_gemma":0.013715127,"teacher_disagreement_score":0.19247408,"about_ca_system_score_codex":0.00070830766,"about_ca_system_score_gemma":0.0031812578,"threshold_uncertainty_score":0.9998763},"labels":[],"label_agreement":null},{"id":"W4413314398","doi":"10.7759/cureus.90253","title":"Exploring Human Epidermal Growth Factor Receptor 2 (HER2)-Low Early Breast Cancer in a Moroccan Population: Clinical Characteristics and Survival Outcomes","year":2025,"lang":"en","type":"article","venue":"Cureus","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Human Epidermal Growth Factor Receptor 2; Breast cancer; Oncology; Epidermal growth factor receptor; Internal medicine; Population; Epidermal growth factor; Cancer; Gynecology; Receptor; Environmental health","score_opus":0.19132457683614965,"score_gpt":0.44721974159378153,"score_spread":0.25589516475763185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413314398","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418485,0.00018401968,0.000010159353,0.0033654151,0.0011939515,0.00040775927,0.00016092743,0.00006521383,0.0004277095],"genre_scores_gemma":[0.99754685,0.0006768308,0.00008462899,0.00023977831,0.00061081664,0.00013053222,0.000032486078,0.00003559032,0.00064251013],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978827,0.00017618897,0.0006779144,0.00045526458,0.0003690825,0.0004388507],"domain_scores_gemma":[0.998925,0.0002319758,0.00009408905,0.00034662682,0.00015681454,0.00024552175],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047519253,0.00021429316,0.00067522883,0.00015300154,0.0000966182,0.0000531922,0.00016166162,0.00014624916,0.0006797733],"category_scores_gemma":[0.0004228601,0.00019382538,0.00009631386,0.0002841677,0.00011474606,0.00021870545,0.00013995897,0.00059353915,0.000014735409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000112901886,0.0001276522,0.97739345,0.00020504893,0.00007887444,0.000029020523,0.0002491438,2.2800778e-7,0.00021010372,0.00026741537,0.00020105862,0.021125099],"study_design_scores_gemma":[0.0013089186,0.00008867092,0.99731225,0.0003345565,0.000029569677,0.0000035749267,0.000081560655,0.000036988924,0.000063898086,0.000044974946,0.00053017325,0.00016485428],"about_ca_topic_score_codex":0.006458521,"about_ca_topic_score_gemma":0.0011572045,"teacher_disagreement_score":0.020960245,"about_ca_system_score_codex":0.00036924754,"about_ca_system_score_gemma":0.00020385183,"threshold_uncertainty_score":0.97633946},"labels":[],"label_agreement":null},{"id":"W4413372506","doi":"10.1016/j.ijgc.2025.102117","title":"Safety of antibody-drug conjugates in gynecologic cancers: current evidence and management approaches","year":2025,"lang":"en","type":"review","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Instituto de Salud Carlos III; Eisai; Seagen; Gilead Sciences; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Medicine; Antibody-drug conjugate; Gynecologic cancer; Drug; Antibody; Gynecology; Oncology; Pharmacology; Monoclonal antibody; Internal medicine; Ovarian cancer; Immunology; Cancer","score_opus":0.21986321063698808,"score_gpt":0.5025747878709089,"score_spread":0.2827115772339208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413372506","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041923532,0.99454045,0.000044685436,0.0010936386,0.0015377655,0.0011875809,0.00008599277,0.0000086602795,0.0010819773],"genre_scores_gemma":[0.0027381903,0.9959036,0.00038976507,0.00012634172,0.0003192946,0.00017805037,0.00001735336,0.000018652481,0.0003087625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99590206,0.00039225706,0.0017829473,0.000464914,0.0010990639,0.00035872712],"domain_scores_gemma":[0.9955152,0.00235072,0.001117686,0.00021792566,0.0006207401,0.00017770262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015277187,0.00037802637,0.0021728163,0.00084209215,0.00003088649,0.000042241412,0.00086895324,0.00024135057,0.0008021581],"category_scores_gemma":[0.0015468723,0.00025510383,0.00048650606,0.00048470142,0.00032785974,0.00015085508,0.00048026314,0.0011991232,0.000004189962],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033132522,0.00029648343,0.0038316639,0.024499219,0.00066369877,0.0006007151,0.0000440488,0.00003783862,0.0000013285226,0.0004152227,0.0013598239,0.96791863],"study_design_scores_gemma":[0.0015127909,0.00046344497,0.0070379237,0.14080483,0.00087789854,0.00016511044,0.00007828875,0.000040002757,0.00001057275,0.00023464867,0.8484836,0.00029089343],"about_ca_topic_score_codex":0.00007930349,"about_ca_topic_score_gemma":0.00017669197,"teacher_disagreement_score":0.96762776,"about_ca_system_score_codex":0.0030443869,"about_ca_system_score_gemma":0.002025593,"threshold_uncertainty_score":0.9999901},"labels":[],"label_agreement":null},{"id":"W4413417222","doi":"10.58931/cot.2025.2235","title":"Antibody-Drug Conjugates in Breast Cancer: Current Landscape and Future Targets","year":2025,"lang":"en","type":"article","venue":"Canadian oncology today.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Mount Sinai Hospital","funders":"University of Toronto; University of Ottawa","keywords":"Antibody-drug conjugate; Breast cancer; Antibody; Drug; Conjugate; Medicine; Cancer; Cancer drugs; Current (fluid); Immunology; Cancer research; Pharmacology; Monoclonal antibody; Internal medicine; Engineering","score_opus":0.011839490796647313,"score_gpt":0.3703987486551005,"score_spread":0.35855925785845316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413417222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.44610837,0.109995894,0.0000039729616,0.37715513,0.0038268054,0.0014466599,0.0005981013,0.000076431206,0.06078863],"genre_scores_gemma":[0.96647793,0.023093214,0.00007013705,0.0069221915,0.0011522225,0.00016761568,0.00015757377,0.00003394463,0.0019251544],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99849105,0.00010061553,0.00023915918,0.00038429562,0.0001294365,0.0006554256],"domain_scores_gemma":[0.99888027,0.00008301622,0.00003424411,0.00024361529,0.00012326382,0.00063561846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031237234,0.00016660392,0.0004243012,0.00056230533,0.00010097163,0.000019978219,0.00014561698,0.00020291233,0.0012449612],"category_scores_gemma":[0.00003833567,0.00015640086,0.00003837007,0.00047439657,0.00018454164,0.000046864912,0.0000480125,0.0006482152,0.000030399146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008662782,0.000050889244,0.72646964,0.000223336,0.000042100084,0.00041874725,0.0004086522,0.0000014128545,0.00021806326,0.00062716834,0.12816128,0.14329208],"study_design_scores_gemma":[0.001199237,0.000041410072,0.34339133,0.00023204899,0.000023189305,0.000060333856,0.00029813452,0.000097331664,0.000038107828,0.00008959591,0.6544292,0.00010006948],"about_ca_topic_score_codex":0.070508465,"about_ca_topic_score_gemma":0.47181764,"teacher_disagreement_score":0.52626795,"about_ca_system_score_codex":0.0013070601,"about_ca_system_score_gemma":0.006786799,"threshold_uncertainty_score":0.99966806},"labels":[],"label_agreement":null},{"id":"W4413835243","doi":"10.62110/sciencein.cbl.2025.v12.1271","title":"Synthesis and in-vitro anti-EGFR screening of new 1,2,3-triazole-benzimidazole hybrids and insilico studies","year":2025,"lang":"en","type":"article","venue":"Chemical Biology Letters","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Government of Manitoba","funders":"","keywords":"Benzimidazole; Triazole; In vitro; Chemistry; Pharmacology; Medicine; Biochemistry; Organic chemistry","score_opus":0.05006576369567979,"score_gpt":0.3667755083768124,"score_spread":0.3167097446811326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413835243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718965,0.004531144,0.00005022765,0.02308912,0.000054351254,0.00019249425,0.000007697531,0.000020919748,0.00015754228],"genre_scores_gemma":[0.9953798,0.00063907605,0.0009779983,0.0028684058,0.000074004114,0.00001899042,0.0000063286057,0.000009928625,0.00002544516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989057,0.000054744345,0.00029247892,0.00035068466,0.00008909368,0.0003072733],"domain_scores_gemma":[0.99897665,0.0006412295,0.000043217115,0.00019871826,0.00003692763,0.00010324373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024640164,0.00014446866,0.0005612746,0.00020648584,0.000026602236,0.0000058834316,0.000098776385,0.00012463213,0.000010032477],"category_scores_gemma":[0.0008815105,0.0001228799,0.000044297827,0.00024313868,0.0006966109,0.00002712127,0.00021486962,0.00031125275,0.0000012640395],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030903352,0.000021197686,0.070846744,0.00022546844,0.0001292641,0.000015666892,0.00009363962,4.815569e-7,0.89255154,0.000019840387,0.0025921997,0.033194907],"study_design_scores_gemma":[0.0011839741,0.000024020883,0.012291213,0.00031343295,0.000054989778,0.00001486537,0.0001277076,0.00004043717,0.98444116,0.000071735834,0.0013393658,0.00009708803],"about_ca_topic_score_codex":0.000089916415,"about_ca_topic_score_gemma":0.0000020915988,"teacher_disagreement_score":0.09188961,"about_ca_system_score_codex":0.00006380946,"about_ca_system_score_gemma":0.000066417226,"threshold_uncertainty_score":0.5010897},"labels":[],"label_agreement":null},{"id":"W4414145653","doi":"10.1101/2025.09.04.674072","title":"APOE+ Tumor-Associated Macrophages and CD4-DOCK4 T Cells Reveal Distinct Microenvironmental Features in HER2-Low and HER2-0 Hormone Receptor-Positive Breast Cancer","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação de Amparo à Pesquisa do Estado de São Paulo; Canadian Institutes of Health Research; Susan G. Komen","keywords":"Breast cancer; Estrogen; Cancer; Hormone; Human breast; Inflammation; Immune system; Mammary gland","score_opus":0.006999774018335251,"score_gpt":0.2476053088905238,"score_spread":0.24060553487218853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414145653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784947,0.011854486,0.000006214317,0.0014322477,0.00049173384,0.0019232433,0.005611505,0.00015306962,0.00003277949],"genre_scores_gemma":[0.99186134,0.005882879,0.00058498856,0.0004472454,0.000379851,0.00045841886,0.000006095576,0.00016362278,0.00021555864],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953301,0.00041332233,0.0007083187,0.0017616027,0.0007324098,0.0010542215],"domain_scores_gemma":[0.9977574,0.00014751763,0.0003675884,0.0008798926,0.0002566376,0.0005909872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007671559,0.0008919103,0.0012636199,0.00042208013,0.00021183702,0.00022329506,0.000387669,0.00069646357,0.00014797706],"category_scores_gemma":[0.00014813144,0.0009337873,0.00014464378,0.00061803724,0.00059375534,0.0001118668,0.0011141488,0.0022087984,0.000018929239],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007169796,0.00056876504,0.18041623,0.0019198648,0.00048296546,0.00064491644,0.00008508664,0.000007702794,0.8104493,0.000009995125,0.0046381988,0.00006000658],"study_design_scores_gemma":[0.0020968327,0.00013110279,0.8407324,0.0038476565,0.00018993074,5.689876e-7,0.000019983678,0.000038195634,0.15159775,7.9609106e-7,0.00062607025,0.00071868714],"about_ca_topic_score_codex":0.0026486618,"about_ca_topic_score_gemma":0.00012390576,"teacher_disagreement_score":0.66031617,"about_ca_system_score_codex":0.0021239924,"about_ca_system_score_gemma":0.0009307076,"threshold_uncertainty_score":0.99931127},"labels":[],"label_agreement":null},{"id":"W4414163609","doi":"10.1016/j.ebiom.2025.105919","title":"New standards in HER2-low testing: the CASI-01 comparative methods study","year":2025,"lang":"en","type":"article","venue":"EBioMedicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; Saskatchewan Health Authority","funders":"National Cancer Institute; National Institutes of Health","keywords":"Work (physics); MEDLINE; Cancer; Public health; Health policy","score_opus":0.1858812564281991,"score_gpt":0.5752051402724534,"score_spread":0.3893238838442543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414163609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.65224737,0.0113439,0.023181474,0.08947381,0.0031055561,0.011291014,0.00006270674,0.0004574932,0.20883669],"genre_scores_gemma":[0.9761356,0.000037078247,0.011221713,0.0014991008,0.00057103817,0.00013630779,0.000010419078,0.000030383486,0.010358351],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99679416,0.0006044207,0.000560026,0.00046584997,0.0010702198,0.00050534436],"domain_scores_gemma":[0.9974835,0.0010911514,0.000074885895,0.0007514553,0.00035484694,0.00024419706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004471135,0.00024137419,0.0007352635,0.0004741651,0.00011912978,0.000027644142,0.0003442107,0.00008456786,0.0006246883],"category_scores_gemma":[0.0020182831,0.00014731323,0.000053419204,0.0029890642,0.00030362714,0.000037223857,0.00018357753,0.0008135589,0.000023268987],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013888767,0.0014279375,0.17254144,0.00050279615,0.0005365803,0.0008632886,0.022122813,0.000020864685,0.0134206265,0.00029607132,0.34176192,0.4451168],"study_design_scores_gemma":[0.016936181,0.0055139326,0.55507,0.0025844197,0.0003187732,0.00009131641,0.024974575,0.0014237141,0.0053831604,0.0010050168,0.3863102,0.0003887476],"about_ca_topic_score_codex":0.0031663904,"about_ca_topic_score_gemma":0.00062800996,"teacher_disagreement_score":0.44472805,"about_ca_system_score_codex":0.0006643928,"about_ca_system_score_gemma":0.0020864874,"threshold_uncertainty_score":0.6839898},"labels":[],"label_agreement":null},{"id":"W4414167666","doi":"10.31557/apjcp.2025.26.9.3175","title":"Effect of HER3 Overexpression on Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Asian Pacific Journal of Cancer Prevention","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pancreatic cancer; Biomarker; Overall survival; Cancer; Survival analysis","score_opus":0.029516183761866845,"score_gpt":0.41493590106367617,"score_spread":0.38541971730180935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414167666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48891222,0.48286694,0.0003493119,0.007983841,0.0006622371,0.01255361,0.0005183105,0.000033166365,0.006120337],"genre_scores_gemma":[0.98896366,0.007942186,0.000039617935,0.00010907433,0.000017890166,0.00041152127,0.000010119775,0.000017824605,0.0024881025],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961879,0.0012867983,0.0012693517,0.00022969408,0.0008195719,0.00020668127],"domain_scores_gemma":[0.9979058,0.00041846812,0.000901972,0.00034293914,0.00032743881,0.00010340036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021903985,0.00022106571,0.0032958384,0.0006445302,0.000029093688,0.000017762079,0.00014012377,0.00008345947,0.00093950116],"category_scores_gemma":[0.00067086954,0.00013355169,0.0009547519,0.000932729,0.00004728501,0.00011845573,0.000032267126,0.0003388688,0.0000013363765],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012691729,0.0010532949,0.2922601,0.541499,0.15667365,0.000027940408,0.0004521864,0.000046508605,0.00027202713,0.00004057883,0.002121054,0.004284458],"study_design_scores_gemma":[0.004800339,0.0034057533,0.11992067,0.14577532,0.7236577,0.000006249499,0.00023209571,0.000031269054,0.0016420691,0.000156028,0.00008972724,0.00028276065],"about_ca_topic_score_codex":0.00015623521,"about_ca_topic_score_gemma":0.000096281896,"teacher_disagreement_score":0.56698406,"about_ca_system_score_codex":0.0003761511,"about_ca_system_score_gemma":0.00023125051,"threshold_uncertainty_score":0.9999738},"labels":[],"label_agreement":null},{"id":"W4414309670","doi":"10.1200/jco-25-01235","title":"Beyond the Guided Missile Paradigm: Embracing the Complexity of Antibody-Drug Conjugates","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Missile; Conjugate; Pandemic; Key (lock); Cancer","score_opus":0.3070645395625706,"score_gpt":0.579066841590274,"score_spread":0.27200230202770337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414309670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.581355,0.003518569,0.00020684488,0.34012222,0.0022055318,0.00052058545,0.0000081276785,0.000010790172,0.07205237],"genre_scores_gemma":[0.9859052,0.0009893831,0.0010398448,0.009720004,0.00095780345,0.0000036718786,0.0000016718723,0.000012152515,0.0013703067],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99497205,0.0012903347,0.0026905148,0.00016885277,0.0005821938,0.00029604213],"domain_scores_gemma":[0.9884099,0.008854018,0.0013764297,0.0004888751,0.00065330794,0.00021746606],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0108772265,0.00012471984,0.0013752764,0.00010097053,0.00013139386,0.000016894373,0.0006368383,0.00021314855,0.00037669728],"category_scores_gemma":[0.009004471,0.000058806585,0.00053078035,0.00032657737,0.002173808,0.000056150766,0.00016618882,0.0018454082,0.000014992944],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064966646,0.0028702572,0.17862163,0.00053533964,0.0022507985,0.00067619886,0.0010691766,0.000101729194,0.0055119228,0.06371095,0.6290655,0.10908982],"study_design_scores_gemma":[0.0087143835,0.004710035,0.34909388,0.0007373597,0.00072355976,0.00054205855,0.00089455146,0.0010332259,0.0033512758,0.08715213,0.5429039,0.00014362184],"about_ca_topic_score_codex":0.0001248677,"about_ca_topic_score_gemma":0.00007155045,"teacher_disagreement_score":0.4045502,"about_ca_system_score_codex":0.000121411365,"about_ca_system_score_gemma":0.0037563683,"threshold_uncertainty_score":0.9993431},"labels":[],"label_agreement":null},{"id":"W4414404323","doi":"10.1136/bmjopen-2025-100889","title":"Canadian real-world hybrid longitudinal cohort study of treatment discontinuations and modifications for patients with HER2+ and HER2-low metastatic breast cancer on trastuzumab deruxtecan enrolled in a patient support programme: the HER-TEMPO study protocol","year":2025,"lang":"en","type":"article","venue":"BMJ Open","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); University of Toronto; EVERSANA (Canada); Mount Sinai Hospital","funders":"Daiichi Sankyo Europe; AstraZeneca Canada; AstraZeneca","keywords":"Metastatic breast cancer; Trastuzumab; Breast cancer; Cohort study; Cohort; Epidemiology; Chemotherapy","score_opus":0.07744423486717573,"score_gpt":0.4562676566616243,"score_spread":0.37882342179444856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414404323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.60402316,0.0000018032516,0.0000030889362,0.0010644137,0.000011934617,0.3943295,0.00017466504,0.000006043654,0.0003854129],"genre_scores_gemma":[0.5521063,0.0000011623307,0.0000650589,0.000024327946,0.0000061216847,0.44729802,0.000027531714,0.000017334394,0.0004541131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976726,0.000290182,0.0006032672,0.0005801114,0.00044677593,0.0004070328],"domain_scores_gemma":[0.9984684,0.0001654198,0.00018075565,0.0006305278,0.0003232069,0.00023168696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077027193,0.00025200608,0.0006205725,0.0003214561,0.00025397088,0.000129052,0.00021152734,0.000019557148,0.000053273347],"category_scores_gemma":[0.00006331578,0.0001541358,0.00003446053,0.0005688153,0.00010152065,0.00009065207,0.000092508235,0.00012530987,4.846065e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027390034,0.0073162164,0.9531088,0.00015256433,0.0005935236,0.000023894565,0.0035614306,0.000035076595,6.162381e-7,0.000016957436,0.00020552485,0.032246403],"study_design_scores_gemma":[0.016712163,0.011045937,0.96500003,0.00033966807,0.00032183476,0.0000045572624,0.005893107,0.00020346143,0.000010514695,0.000016498427,0.00030446134,0.00014776477],"about_ca_topic_score_codex":0.4691939,"about_ca_topic_score_gemma":0.9250696,"teacher_disagreement_score":0.45587566,"about_ca_system_score_codex":0.0013875336,"about_ca_system_score_gemma":0.0029258847,"threshold_uncertainty_score":0.6285476},"labels":[],"label_agreement":null},{"id":"W4414891572","doi":"10.5858/arpa.2025-0074-oa","title":"Clinicopathologic Features and Genomic Profile of Human Epidermal Growth Factor Receptor 2–Low and Human Epidermal Growth Factor Receptor 2–Ultralow Invasive Breast Carcinomas","year":2025,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakeridge Health; Sunnybrook Health Science Centre; St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Immunohistochemistry; Epidermal growth factor receptor; Human Epidermal Growth Factor Receptor 2; Hormone receptor; Receptor; Hormone; Epidermal growth factor; Breast cancer","score_opus":0.027701960705590223,"score_gpt":0.33101573002568474,"score_spread":0.3033137693200945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414891572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987239,0.004698314,0.000033972334,0.0031296453,0.0003739262,0.001448795,0.0014242047,0.00009147131,0.0015606582],"genre_scores_gemma":[0.99431235,0.0013073867,0.0021523708,0.00086942484,0.00044810204,0.00011641051,0.00028131143,0.00007939752,0.00043327583],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946007,0.0013163177,0.0014855482,0.0012087361,0.000499446,0.00088923925],"domain_scores_gemma":[0.9956754,0.0017595596,0.00065370277,0.0008163258,0.00055465486,0.0005403818],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0009122117,0.0006556191,0.0020469942,0.0009848973,0.00029799502,0.000013806238,0.0004975558,0.0004424544,0.00069572154],"category_scores_gemma":[0.0022260677,0.000533532,0.00016970126,0.000570884,0.0053108856,0.00016334484,0.00033336764,0.0012732106,0.00000814599],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042886127,0.00017344185,0.39816055,0.001808527,0.00012656616,0.0002306782,0.002392839,9.114657e-8,0.59270406,0.001070592,0.0014962906,0.0014074895],"study_design_scores_gemma":[0.0044982643,0.002821235,0.8642716,0.0010268564,0.00018956636,0.00021591395,0.0010731944,0.0000021743776,0.12469471,0.0007680255,0.00010340832,0.00033508698],"about_ca_topic_score_codex":0.00020262008,"about_ca_topic_score_gemma":0.000067907466,"teacher_disagreement_score":0.46800938,"about_ca_system_score_codex":0.00010207747,"about_ca_system_score_gemma":0.0008558339,"threshold_uncertainty_score":0.99971163},"labels":[],"label_agreement":null},{"id":"W4415301317","doi":"10.3390/curroncol32100575","title":"Trastuzumab Deruxtecan-Associated Interstitial Lung Disease: Real-World Insights from a Tertiary Care Center","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Interstitial lung disease; Common Terminology Criteria for Adverse Events; Logistic regression; Lung cancer; Adverse effect; Univariate analysis; Tertiary care; Retrospective cohort study","score_opus":0.05646300562863377,"score_gpt":0.45100709929598465,"score_spread":0.3945440936673509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415301317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92758024,0.022772534,0.0006494144,0.006132073,0.009343886,0.0021505489,0.0005512986,0.00039308707,0.030426897],"genre_scores_gemma":[0.9960784,0.0006912068,0.000038425373,0.0006278604,0.0005752516,0.00023007754,0.00092248997,0.00003423164,0.00080206146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99766266,0.0003356024,0.00046284724,0.0006066899,0.0003874799,0.0005447431],"domain_scores_gemma":[0.99851656,0.0002620579,0.00009391111,0.00045971034,0.00027516606,0.0003925944],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000094611736,0.0002606097,0.0005430866,0.00043193833,0.00012486054,0.000026921065,0.00029120405,0.00016732958,0.0006119837],"category_scores_gemma":[0.00025828704,0.00023662523,0.0001909533,0.0004467558,0.0002753565,0.00006511961,0.0002553676,0.0008049456,0.00006932225],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013919346,0.0019794884,0.7127496,0.0007553664,0.00047851904,0.00061834854,0.003489079,0.0000030863757,0.00038238088,0.00029800765,0.12469182,0.15316235],"study_design_scores_gemma":[0.007191748,0.00030943708,0.53120595,0.002265562,0.00046912138,0.000002836303,0.0008250421,0.00096372503,0.00032239704,0.0004304051,0.45570046,0.00031332936],"about_ca_topic_score_codex":0.0005525675,"about_ca_topic_score_gemma":0.0045470526,"teacher_disagreement_score":0.3310086,"about_ca_system_score_codex":0.00422471,"about_ca_system_score_gemma":0.001966739,"threshold_uncertainty_score":0.9995979},"labels":[],"label_agreement":null},{"id":"W4415306169","doi":"10.1016/j.ctarc.2025.101021","title":"Retrospective database analysis to assess treatment patterns, clinical outcomes, and healthcare resource utilization in metastatic or recurrent HER2-positive breast cancer in Alberta","year":2025,"lang":"en","type":"article","venue":"Cancer Treatment and Research Communications","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Alberta Cancer Foundation; University of Calgary; Foothills Medical Centre","funders":"AstraZeneca","keywords":"Metastatic breast cancer; Breast cancer; Recurrent breast cancer; Health care; Medical diagnosis; Retrospective cohort study; Cancer treatment","score_opus":0.37454311074845226,"score_gpt":0.5960753306706257,"score_spread":0.22153221992217342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415306169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75041527,0.023940317,0.00010499173,0.21240044,0.00011443611,0.007482041,0.00435,0.000043416458,0.001149109],"genre_scores_gemma":[0.8748065,0.11870461,0.00025200128,0.00025033523,0.000025803325,0.0032327697,0.00047694292,0.000022438257,0.002228609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958793,0.0017706485,0.00062834664,0.0007398543,0.0004323132,0.0005495739],"domain_scores_gemma":[0.9960291,0.0015960789,0.000075266245,0.0014867657,0.00041880997,0.0003940029],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012061538,0.00025779064,0.0008266841,0.0012461318,0.00031496066,0.00008196995,0.0003042403,0.00009761664,0.00011992616],"category_scores_gemma":[0.00031160403,0.00018181698,0.000105885796,0.0030386709,0.0003366655,0.00009763055,0.0004308473,0.00055780984,0.0000027306314],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008154924,0.0013524299,0.88273335,0.00009703571,0.0011042121,0.000022626327,0.0014969528,0.000009851725,0.0000045514157,0.00042518307,0.00017670025,0.11176163],"study_design_scores_gemma":[0.0032894476,0.0009070629,0.98593915,0.0010154761,0.0004827926,0.0000033462902,0.0014550508,0.00149042,0.000028277778,0.000035389912,0.00521054,0.0001430283],"about_ca_topic_score_codex":0.18053855,"about_ca_topic_score_gemma":0.6380293,"teacher_disagreement_score":0.45749074,"about_ca_system_score_codex":0.0046421853,"about_ca_system_score_gemma":0.0016569679,"threshold_uncertainty_score":0.9991788},"labels":[],"label_agreement":null},{"id":"W4415321954","doi":"10.1016/j.annonc.2025.10.013","title":"Antibody–drug conjugates in combination therapy: defining the next chapter","year":2025,"lang":"en","type":"editorial","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Conjugate; Cancer","score_opus":0.1082992593934442,"score_gpt":0.4806774783455847,"score_spread":0.3723782189521405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415321954","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012901598,0.031945936,0.000011270484,0.07280208,0.76677775,0.0022266877,0.00017374038,0.00007156721,0.113089345],"genre_scores_gemma":[0.1579418,0.21062844,0.0002692393,0.010388853,0.60206264,0.00054624316,0.002848158,0.00023503753,0.015079553],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759436,0.00033967535,0.00059165107,0.0003679641,0.000694609,0.0004117472],"domain_scores_gemma":[0.99497736,0.0033539599,0.00028871026,0.00045420782,0.00085884286,0.00006694819],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002183925,0.00022543165,0.00086809235,0.00040411289,0.00005876785,0.000021637574,0.00039825344,0.00069375837,0.00029822526],"category_scores_gemma":[0.0018704634,0.00016337325,0.00015489609,0.00028990654,0.0003327554,0.000057271183,0.00014105262,0.001478422,0.00004101524],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069023477,0.00030640158,0.0007422465,0.0002588387,0.00015290458,0.00006747018,0.00063866377,0.0000014719873,0.00032702694,0.002303877,0.9160692,0.07844163],"study_design_scores_gemma":[0.002114255,0.0018524078,0.0005833654,0.0006768075,0.00002478479,0.0000029080156,0.00013166416,0.000028424194,0.0008247797,0.0010730274,0.9925714,0.0001161902],"about_ca_topic_score_codex":0.0010628408,"about_ca_topic_score_gemma":0.00024950868,"teacher_disagreement_score":0.1786825,"about_ca_system_score_codex":0.000116010386,"about_ca_system_score_gemma":0.0020086311,"threshold_uncertainty_score":0.6662168},"labels":[],"label_agreement":null},{"id":"W4415390112","doi":"10.1016/j.annonc.2025.10.019","title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"Daiichi Sankyo Europe; Allergan; Genentech; Servier; Astellas Pharma; Seagen; Eisai; Jazz Pharmaceuticals; Taiho Pharmaceutical; Gilead Sciences; Relay Therapeutics; Amgen; Pfizer; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Myriad Genetics; Les Laboratories Pierre Fabre; Nipro","keywords":"Pertuzumab; Trastuzumab; Neoadjuvant therapy; Breast cancer; Clinical trial; Chemotherapy","score_opus":0.08287070357006318,"score_gpt":0.4633421922553893,"score_spread":0.3804714886853261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415390112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95586133,0.0035691375,0.0007778614,0.020569539,0.00067708385,0.013548837,0.0038930168,0.00007922802,0.0010239902],"genre_scores_gemma":[0.9854166,0.0036224297,0.0015179515,0.0023474249,0.00039111768,0.0030724488,0.00019292823,0.000108701315,0.0033304219],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99440944,0.00088128564,0.0015721635,0.0011929839,0.00063018454,0.0013139682],"domain_scores_gemma":[0.99375683,0.0030770255,0.0006902111,0.00063892367,0.0011495398,0.00068745005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020400386,0.00063271594,0.0026532924,0.00039231917,0.0003805885,0.00010762125,0.0006338826,0.0005385898,0.00046459775],"category_scores_gemma":[0.0015047278,0.0005115619,0.00024854808,0.00067769206,0.0007286714,0.00027652245,0.00030436568,0.00073959905,0.000008281486],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5913251,0.0064632795,0.00034308078,0.00024402226,0.0013972024,0.00015707374,0.001028046,0.0000018398621,0.0038673403,0.000060575185,0.050928693,0.3441837],"study_design_scores_gemma":[0.92172605,0.04816916,0.0021070768,0.0009365706,0.0014468768,0.00017200848,0.000924173,0.00042972484,0.0063396194,0.0002640444,0.016903883,0.0005807981],"about_ca_topic_score_codex":0.014121786,"about_ca_topic_score_gemma":0.0021074482,"teacher_disagreement_score":0.34360293,"about_ca_system_score_codex":0.0007241469,"about_ca_system_score_gemma":0.004325539,"threshold_uncertainty_score":0.9997336},"labels":[],"label_agreement":null},{"id":"W4415755512","doi":"10.1016/j.atherosclerosis.2025.120567","title":"Loss of ADAM17 in smooth muscle cells enhances their transformation to macrophage-like cells leading to more severe atherosclerosis in mice","year":2025,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ted Rogers Centre for Heart Research; University of Alberta","funders":"Canadian Institutes of Health Research; University of Alberta; Canada Research Chairs; Heart and Stroke Foundation of Canada","keywords":"Smooth muscle; Transformation (genetics); Regulator; Function (biology); Vascular smooth muscle; Loss function","score_opus":0.026766718112091595,"score_gpt":0.3158507381304776,"score_spread":0.289084020018386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415755512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99272597,0.00017135672,0.0006834476,0.0022785424,0.0003532865,0.0019596764,0.000133334,0.00006825831,0.0016261304],"genre_scores_gemma":[0.99468523,0.000593427,0.0013496112,0.0018916889,0.00004804019,0.00032906828,0.000010236113,0.00007892923,0.0010137636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965354,0.00018543164,0.0009735212,0.0007456655,0.0006534582,0.00090649864],"domain_scores_gemma":[0.99848,0.00025981118,0.0001197254,0.0006738046,0.00017240578,0.00029425754],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095497473,0.00042384508,0.00086489134,0.00080753036,0.000091698406,0.00006013415,0.00057122554,0.00027785465,0.00021882272],"category_scores_gemma":[0.00007415085,0.00040384912,0.00020289666,0.002574947,0.00013717233,0.00023271362,0.00015212155,0.00052403344,0.00015003669],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023218017,0.0003584907,0.009451075,0.00053669536,0.000030386553,0.0000030986005,0.013707848,0.0008136002,0.9565359,0.000025202986,0.0010313977,0.01727417],"study_design_scores_gemma":[0.0021125283,0.00040701227,0.15162848,0.003002405,0.000030779567,5.5218004e-7,0.0028613722,0.00024374397,0.8340465,0.000031081076,0.0052587395,0.00037682086],"about_ca_topic_score_codex":0.0020704435,"about_ca_topic_score_gemma":0.0016616036,"teacher_disagreement_score":0.1421774,"about_ca_system_score_codex":0.00073273916,"about_ca_system_score_gemma":0.00026037867,"threshold_uncertainty_score":0.99984133},"labels":[],"label_agreement":null},{"id":"W4415820113","doi":"10.3390/curroncol32110606","title":"Idiosyncratic Drug-Induced Liver Injury and Trastuzumab Deruxtecan in Breast Cancer: A Case Report","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministero della Salute","keywords":"Trastuzumab; Liver injury; Breast cancer; Refractory (planetary science); Transaminase; Liver function; Liver function tests; Lung; Lung cancer","score_opus":0.09664931523836957,"score_gpt":0.4844381077683479,"score_spread":0.38778879252997833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415820113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98474556,0.004379337,0.000018235127,0.007168034,0.0011310976,0.00084139686,0.000028513707,0.000045657336,0.0016421493],"genre_scores_gemma":[0.9973679,0.0013562515,0.0000637072,0.00026576858,0.00021912767,0.00033646383,0.000008927375,0.000019400431,0.00036246373],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9980726,0.00022427866,0.0004941475,0.0005164948,0.00022306088,0.00046939377],"domain_scores_gemma":[0.9989859,0.00016642822,0.00009224755,0.00036799093,0.00016663858,0.00022083193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006488646,0.00018816681,0.0005477481,0.00040867698,0.00007899283,0.000016431657,0.00010136144,0.00015108066,0.00022200057],"category_scores_gemma":[0.0001889902,0.0001749052,0.00005632553,0.0005682626,0.00017367433,0.00005456488,0.00014399238,0.00075686106,0.000011774337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041053095,0.0006683417,0.12506045,0.0008701429,0.00006616425,0.05277662,0.0009621321,5.724873e-7,0.0010198319,0.00008735692,0.013088141,0.8049897],"study_design_scores_gemma":[0.014330807,0.001888277,0.5024907,0.004287328,0.00067820883,0.2136207,0.0029042552,0.0024965617,0.0030573125,0.0007114796,0.25246975,0.0010646338],"about_ca_topic_score_codex":0.001650071,"about_ca_topic_score_gemma":0.0038939426,"teacher_disagreement_score":0.8039251,"about_ca_system_score_codex":0.0015687792,"about_ca_system_score_gemma":0.0026223445,"threshold_uncertainty_score":0.7132427},"labels":[],"label_agreement":null},{"id":"W4415937477","doi":"10.1200/oa-25-00053","title":"Enfortumab Vedotin in Patients With Previously Treated Advanced Breast Cancer in the Phase II EV-202 Study","year":2025,"lang":"en","type":"article","venue":"JCO oncology advances.","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Rash; Maculopapular rash; Breast cancer; Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Toxicity; Metastatic breast cancer","score_opus":0.01476243486084391,"score_gpt":0.4208429098651232,"score_spread":0.4060804750042793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415937477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98493564,0.0017375846,0.0000085610245,0.0027060523,0.00024216926,0.004678895,0.000052783693,0.00005414051,0.005584194],"genre_scores_gemma":[0.9953705,0.00044394116,0.000107426065,0.0010315846,0.000060223545,0.0019423388,0.000034191595,0.000031357056,0.0009784481],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970761,0.00038750021,0.0006181594,0.000639177,0.0005421602,0.00073691754],"domain_scores_gemma":[0.998574,0.000279763,0.00016174177,0.0006395691,0.00023175812,0.000113142516],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072562613,0.0003055244,0.00076414715,0.00041553515,0.00014516588,0.000013117074,0.0004113187,0.00015244658,0.00030932287],"category_scores_gemma":[0.00015719431,0.00020120213,0.00005517465,0.0016464421,0.00023658274,0.0002222232,0.000104214654,0.00093892706,0.000011085113],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005162698,0.0068593915,0.64826685,0.00008895505,0.00006177343,0.00022959495,0.0015006233,0.00016837103,0.000028264554,0.000018580415,0.00041331665,0.3372016],"study_design_scores_gemma":[0.050358385,0.009402356,0.89362437,0.00057847594,0.0001132646,0.000014035002,0.0014057626,0.000083135325,0.00008179143,0.0000432047,0.04405978,0.00023542836],"about_ca_topic_score_codex":0.0007093491,"about_ca_topic_score_gemma":0.011730077,"teacher_disagreement_score":0.33696616,"about_ca_system_score_codex":0.0017296894,"about_ca_system_score_gemma":0.0014269905,"threshold_uncertainty_score":0.8204785},"labels":[],"label_agreement":null},{"id":"W4415939974","doi":"10.1016/j.annonc.2025.08.720","title":"291O DESTINY-Breast11: Neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Trastuzumab; Paclitaxel; Breast cancer; Chemotherapy","score_opus":0.06240779686711495,"score_gpt":0.42127854042782764,"score_spread":0.3588707435607127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415939974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9117401,0.0053639323,0.003116545,0.066199794,0.0013467616,0.0048457575,0.004089475,0.00032213997,0.0029754858],"genre_scores_gemma":[0.97907186,0.0031726714,0.002484374,0.003963175,0.0005976013,0.0015542799,0.00020476495,0.00020371003,0.008747592],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99275357,0.0006594136,0.0017610088,0.0015205853,0.001109844,0.0021956097],"domain_scores_gemma":[0.99374413,0.0018571217,0.00071501674,0.0012348081,0.0016014146,0.0008475307],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018162584,0.00088343787,0.0027330501,0.0007080644,0.00044879754,0.00007307354,0.0009465427,0.00094416854,0.0015007816],"category_scores_gemma":[0.001198446,0.0007505361,0.00070878665,0.0013207692,0.000926244,0.00027031644,0.0002735472,0.0012768432,0.000069415255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025630826,0.0037152157,0.01957833,0.0012087395,0.0022737945,0.00044186343,0.0017670394,0.000041419826,0.00786904,0.00048555838,0.31982005,0.6171681],"study_design_scores_gemma":[0.07464466,0.07860511,0.29908487,0.0041535776,0.004107665,0.0018165032,0.0036253089,0.0015763467,0.04638869,0.0065399623,0.47593015,0.0035271603],"about_ca_topic_score_codex":0.01830935,"about_ca_topic_score_gemma":0.005211411,"teacher_disagreement_score":0.61364096,"about_ca_system_score_codex":0.0015701618,"about_ca_system_score_gemma":0.0071071936,"threshold_uncertainty_score":0.99949455},"labels":[],"label_agreement":null},{"id":"W4415940538","doi":"10.1016/j.annonc.2025.08.978","title":"555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); McGill University Health Centre; Santé Montérégie","funders":"AstraZeneca","keywords":"Durvalumab; Begonia; Breast cancer; Cancer","score_opus":0.18474838880903363,"score_gpt":0.5169851682150306,"score_spread":0.33223677940599694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8830128,0.003115108,0.00044312136,0.092675894,0.00072531786,0.008663471,0.008358606,0.00008800075,0.0029176993],"genre_scores_gemma":[0.98421717,0.0023342818,0.0011132973,0.0024300267,0.0003635961,0.0024252024,0.00038240236,0.00007202687,0.0066620144],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99514437,0.00063377357,0.0013436495,0.0010975641,0.0007297047,0.0010509485],"domain_scores_gemma":[0.9928008,0.0037360664,0.00051772245,0.0012642458,0.0013502305,0.0003309341],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001376874,0.00052888936,0.0014910552,0.00029783102,0.0005439719,0.000035767516,0.00068418874,0.00020721162,0.0006600624],"category_scores_gemma":[0.0024158496,0.00037734353,0.00030915378,0.00093041087,0.0005428499,0.00016541012,0.0003105604,0.00054485846,0.000029184623],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10908505,0.021798775,0.0033889215,0.00031169155,0.0044654827,0.0006230704,0.0058918674,0.00070729345,0.0010612375,0.00028222162,0.07134992,0.78103447],"study_design_scores_gemma":[0.28924578,0.16377187,0.026924552,0.0021907045,0.0029869722,0.00021855695,0.010814853,0.0043333485,0.036550503,0.009994742,0.45175135,0.0012167513],"about_ca_topic_score_codex":0.01885821,"about_ca_topic_score_gemma":0.026426198,"teacher_disagreement_score":0.7798177,"about_ca_system_score_codex":0.00089264463,"about_ca_system_score_gemma":0.0052904105,"threshold_uncertainty_score":0.99986786},"labels":[],"label_agreement":null},{"id":"W4415940769","doi":"10.1016/j.annonc.2025.08.2572","title":"1948P Treatment outcomes in patients (pts) with advanced c-Met overexpressing (OE) EGFR wildtype (WT) nonsquamous (NSQ) NSCLC who had telisotuzumab vedotin (Teliso-V) dose modifications in the LUMINOSITY trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Phases of clinical research; Conjugate; Wild type; Overall survival; Adverse effect; Clinical trial","score_opus":0.09948266861913178,"score_gpt":0.44885699711055543,"score_spread":0.34937432849142364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97924006,0.0004865789,0.00001627912,0.007719784,0.00019130054,0.0028126321,0.00005115539,0.000024175657,0.009458018],"genre_scores_gemma":[0.9964387,0.00038441826,0.00042793865,0.00160759,0.000058833735,0.0005042369,0.000045666766,0.000023519842,0.0005091047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997075,0.00058838807,0.0007690235,0.0005125485,0.00046612532,0.00058887445],"domain_scores_gemma":[0.9976078,0.0009129811,0.00025173457,0.00081551255,0.00030367557,0.00010825587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000776213,0.00027929398,0.0009615146,0.00049398246,0.00011746757,0.000024729587,0.00038601694,0.00023796174,0.00005304736],"category_scores_gemma":[0.00070683245,0.00018957921,0.00014460161,0.0007365647,0.0003120845,0.00013304087,0.00009622991,0.0004809997,0.000013166263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06738844,0.018130714,0.5655941,0.0002459953,0.00035830747,0.00015204297,0.0046578837,0.00052778824,0.0007163963,0.00064084015,0.009512483,0.33207506],"study_design_scores_gemma":[0.13487118,0.029948,0.7741405,0.0008730981,0.00016112022,0.0000074078134,0.0011634218,0.00024016155,0.0024990672,0.00031028077,0.055401407,0.0003843932],"about_ca_topic_score_codex":0.0024170533,"about_ca_topic_score_gemma":0.0023517439,"teacher_disagreement_score":0.33169064,"about_ca_system_score_codex":0.0007467772,"about_ca_system_score_gemma":0.0014933483,"threshold_uncertainty_score":0.77308154},"labels":[],"label_agreement":null},{"id":"W4415940977","doi":"10.1016/j.annonc.2025.08.2574","title":"1950P Ocular surface disorders in patients with c-Met protein–overexpressing NSCLC treated with telisotuzumab vedotin in the LUMINOSITY study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"AbbVie","keywords":"Antibody-drug conjugate; Phases of clinical research; Conjugate; Adverse effect; Clinical trial; Brentuximab vedotin","score_opus":0.04071054316473132,"score_gpt":0.38936537763969814,"score_spread":0.3486548344749668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415940977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889049,0.00014125914,0.0000072599564,0.0021443302,0.00001624829,0.0033829692,0.000007704812,0.0000145439135,0.0053807655],"genre_scores_gemma":[0.9992132,0.000016757784,0.00017395572,0.00029538336,0.000009431201,0.0001375344,0.000013575578,0.000017589977,0.00012253645],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99757296,0.00072614703,0.00037179515,0.00037726006,0.0005176758,0.00043417787],"domain_scores_gemma":[0.9988855,0.00021472543,0.00012605451,0.0004863577,0.00023117379,0.00005620443],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001026861,0.00018292246,0.0005561195,0.0002371801,0.00005771834,0.000014417454,0.00027609267,0.000121224664,0.000029228964],"category_scores_gemma":[0.00020481688,0.00011406664,0.000038214373,0.0009649384,0.0002533788,0.00007715666,0.0000833662,0.0005013146,0.0000029219673],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037966843,0.004319725,0.97716814,0.000111931295,0.00010176244,0.00007858709,0.0016094184,0.00010605725,0.00018693769,0.000014384445,0.0003306934,0.0121757025],"study_design_scores_gemma":[0.00922896,0.013364263,0.97189647,0.0005367493,0.00003706609,0.0000012674992,0.0019676809,0.00003050176,0.0012864148,0.000031392254,0.0015041886,0.000115039584],"about_ca_topic_score_codex":0.00391954,"about_ca_topic_score_gemma":0.0044624656,"teacher_disagreement_score":0.012060663,"about_ca_system_score_codex":0.00017018522,"about_ca_system_score_gemma":0.0006939337,"threshold_uncertainty_score":0.5925198},"labels":[],"label_agreement":null},{"id":"W4415941146","doi":"10.1016/j.annonc.2025.08.690","title":"262eP Comprehensive HER2 isoform expression analysis reveals subgroup-specific profiles and implications for ADC resistance","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Gene isoform; Expression (computer science); Gene expression; Focus (optics)","score_opus":0.16175002698525984,"score_gpt":0.48723935820992287,"score_spread":0.32548933122466306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.828606,0.025179083,0.0063350284,0.1068595,0.0002116316,0.003815042,0.0004843106,0.00009459862,0.028414803],"genre_scores_gemma":[0.9788714,0.0053545204,0.0083563365,0.001982964,0.00012375084,0.00062584813,0.00011682126,0.000020193178,0.0045481334],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852353,0.0001063186,0.00047946224,0.00039586143,0.00015034493,0.00034448568],"domain_scores_gemma":[0.9974124,0.00081706094,0.00017931605,0.0005219791,0.00094570685,0.00012356525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043603545,0.00013030569,0.0006818664,0.0004215499,0.00012582989,0.000011075324,0.00016563165,0.00018344012,0.00009149468],"category_scores_gemma":[0.00022459372,0.00011516949,0.00016705913,0.00082698755,0.00027190216,0.000053244396,0.00009559676,0.00016988625,0.000003433199],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020648683,0.00069113384,0.089221016,0.0015168415,0.0011691136,0.000011669325,0.00058621337,0.000010350038,0.19773751,0.016935416,0.59280646,0.097249396],"study_design_scores_gemma":[0.0012807782,0.0009601834,0.366116,0.0002506404,0.00022055989,0.0000035014207,0.00041746235,0.000024019286,0.027094206,0.005769067,0.5977405,0.00012312664],"about_ca_topic_score_codex":0.000047175527,"about_ca_topic_score_gemma":0.000115783565,"teacher_disagreement_score":0.276895,"about_ca_system_score_codex":0.000085862666,"about_ca_system_score_gemma":0.00026302633,"threshold_uncertainty_score":0.46964753},"labels":[],"label_agreement":null},{"id":"W4415941485","doi":"10.1016/j.annonc.2025.08.1705","title":"1065MO First-in-human study of AZD5335, a folate receptor α (FRα)-targeted antibody-drug conjugate, in patients with platinum-resistant recurrent ovarian cancer","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Ovarian cancer; Conjugate; Folate receptor; Phases of clinical research; Topoisomerase; Chemotherapy","score_opus":0.05104004993616807,"score_gpt":0.4325312644285181,"score_spread":0.38149121449235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99195933,0.00057659595,0.0000015184938,0.0022837443,0.0002572298,0.0021755851,0.00007813707,0.000017717493,0.0026501107],"genre_scores_gemma":[0.99877536,0.0002540311,0.00009996433,0.00024155273,0.000034306508,0.00019571568,0.000054697302,0.000028834285,0.00031555936],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699265,0.00037616614,0.001022866,0.000511023,0.0005294747,0.0005678516],"domain_scores_gemma":[0.99812376,0.00025337376,0.0003550182,0.00048761585,0.0006485713,0.00013166509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093736674,0.00024153406,0.0010997633,0.00069448235,0.000056736244,0.0000068921318,0.0002781541,0.00016860195,0.00039170112],"category_scores_gemma":[0.00024819645,0.00020498251,0.000062686915,0.001035266,0.00019345134,0.00007133731,0.00014280324,0.00052885636,0.0000042451456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009591782,0.007908115,0.95659435,0.0006480133,0.0003679527,0.00007902066,0.0033880686,0.000055595083,0.002554067,0.00013377555,0.0060194745,0.012659802],"study_design_scores_gemma":[0.018020354,0.022162892,0.9413706,0.0017663559,0.00006547004,4.7132357e-7,0.0007962565,0.000048376183,0.0026437605,0.000105555446,0.01280605,0.00021386506],"about_ca_topic_score_codex":0.008410817,"about_ca_topic_score_gemma":0.026934728,"teacher_disagreement_score":0.018523911,"about_ca_system_score_codex":0.00034613235,"about_ca_system_score_gemma":0.0009746576,"threshold_uncertainty_score":0.99819225},"labels":[],"label_agreement":null},{"id":"W4415941514","doi":"10.1016/j.annonc.2025.08.3571","title":"2959eP EGFR-targeted monoclonal antibodies administered to patients with colon cancer can increase the risk of bone fracture","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada)","funders":"","keywords":"Monoclonal antibody; Colorectal cancer; Monoclonal; Risk factor; Antibody; Pathologic fracture; Cancer","score_opus":0.050522614143201895,"score_gpt":0.4299389961492394,"score_spread":0.3794163820060375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415941514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9635245,0.0013494745,0.000009406759,0.03076435,0.00012237209,0.00090284616,0.00039256632,0.000013701993,0.0029207827],"genre_scores_gemma":[0.9909823,0.00091512565,0.00031872335,0.006887487,0.000068433925,0.00011412494,0.000044276017,0.000018013634,0.00065154815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982038,0.0002733754,0.00044222292,0.0002811662,0.00042164166,0.00037775352],"domain_scores_gemma":[0.99770343,0.0004069933,0.00028345163,0.00044159067,0.0009865069,0.00017801963],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000513209,0.00016908991,0.0006795779,0.00022296341,0.00008281371,0.0000056483914,0.00021214734,0.00017039047,0.00026547274],"category_scores_gemma":[0.0007379304,0.00010628657,0.0000943856,0.0004639067,0.00033565646,0.000027706383,0.00013018175,0.00038949077,0.000004042946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074617844,0.0008136144,0.87678653,0.00027270135,0.0006485138,0.00003481743,0.0010092594,0.00007711281,0.0010409526,0.00004227603,0.07466471,0.03714771],"study_design_scores_gemma":[0.0023944627,0.0051821554,0.8241619,0.00030896874,0.00017407977,0.0000029236157,0.00016266365,0.000024443167,0.0144002475,0.00008843497,0.1529942,0.000105558596],"about_ca_topic_score_codex":0.011361928,"about_ca_topic_score_gemma":0.0059175347,"teacher_disagreement_score":0.07832949,"about_ca_system_score_codex":0.000116311436,"about_ca_system_score_gemma":0.0017691419,"threshold_uncertainty_score":0.9952215},"labels":[],"label_agreement":null},{"id":"W4415942079","doi":"10.1016/j.annonc.2025.08.2701","title":"2080eTiP A phase I/IIa, open-label, dose-finding study of the safety, pharmacokinetics, and preliminary efficacy of iza-bren (BL-B01D1) combinations in patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Centre Hospitalier de l’Université de Montréal","funders":"Bristol-Myers Squibb","keywords":"Lung cancer; Conjugate; Solid tumor; Phases of clinical research; Monoclonal antibody; Response Evaluation Criteria in Solid Tumors; Antibody; Cancer","score_opus":0.1152148650888674,"score_gpt":0.5120847254551094,"score_spread":0.396869860366242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99103296,0.00027301227,0.0000045336783,0.0030927083,0.00009637133,0.0030203278,0.00004259436,0.0000064433843,0.0024310448],"genre_scores_gemma":[0.9990988,0.00020784378,0.00013856252,0.00025363849,0.000009149861,0.00008577386,0.000013847579,0.000017557495,0.00017485583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99800223,0.00033103552,0.00071515,0.00029491945,0.0003701906,0.00028649755],"domain_scores_gemma":[0.99806666,0.0005334409,0.00035212422,0.0004139855,0.0005530318,0.00008074339],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066024304,0.00014738232,0.0007181404,0.0003427414,0.00006429161,0.0000053231124,0.00044894769,0.000075855525,0.00003949536],"category_scores_gemma":[0.0004984924,0.00011138336,0.000028660983,0.0007872551,0.00034713998,0.0000763857,0.0005361489,0.00030598903,5.9191126e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04371827,0.10908404,0.48739463,0.0010942648,0.00089124934,0.00006813891,0.0076941852,0.0003904246,0.0069754007,0.00045772537,0.0049302313,0.33730146],"study_design_scores_gemma":[0.10118171,0.05226992,0.83186597,0.0010502478,0.00017589086,0.0000034784582,0.0010234631,0.0001882229,0.010460791,0.000110183,0.0015357283,0.00013441606],"about_ca_topic_score_codex":0.00020254105,"about_ca_topic_score_gemma":0.00008728536,"teacher_disagreement_score":0.34447134,"about_ca_system_score_codex":0.000077951234,"about_ca_system_score_gemma":0.00060257065,"threshold_uncertainty_score":0.45420814},"labels":[],"label_agreement":null},{"id":"W4415942575","doi":"10.1016/j.annonc.2025.08.1043","title":"621TiP BNT323-03: A phase I/II trial of BNT323/DB-1303 (HER2 ADC) with BNT327 (PD-L1 x VEGF-A) in patients (pts) with advanced breast cancer (BC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Tolerability; Breast cancer; Limiting; Phases of clinical research; Cancer; Topoisomerase; Clinical trial","score_opus":0.07087206971817465,"score_gpt":0.4770906131229302,"score_spread":0.40621854340475555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415942575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747737,0.00048765063,0.000018835643,0.008353276,0.00036734415,0.0023676313,0.00020573064,0.00003814811,0.013387683],"genre_scores_gemma":[0.9953624,0.00072537945,0.0004496828,0.0014603776,0.00017617554,0.0005610887,0.000050391685,0.0000612027,0.0011533207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99616146,0.00031143412,0.001013091,0.0007146596,0.00090645713,0.00089291984],"domain_scores_gemma":[0.9968467,0.00031935587,0.0004986133,0.0007815936,0.0012633919,0.0002903743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078315684,0.00039149428,0.001534744,0.00067665346,0.00007848074,0.000009096263,0.00041835583,0.00034956337,0.0006258243],"category_scores_gemma":[0.00028288312,0.0003053196,0.00015682627,0.0013880106,0.0006382319,0.00017443311,0.0001876887,0.0007101487,0.000012938572],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4818868,0.016275385,0.077489994,0.00097349304,0.0007697932,0.00023134648,0.0012247984,0.00012621404,0.00128435,0.0002139547,0.014582863,0.40494102],"study_design_scores_gemma":[0.49469844,0.18774524,0.16260232,0.0044374773,0.00043073425,0.000050055118,0.0007413022,0.00013599281,0.014534544,0.0002341999,0.13358338,0.0008063347],"about_ca_topic_score_codex":0.0027773944,"about_ca_topic_score_gemma":0.0032798867,"teacher_disagreement_score":0.4041347,"about_ca_system_score_codex":0.00043519592,"about_ca_system_score_gemma":0.003652208,"threshold_uncertainty_score":0.9999399},"labels":[],"label_agreement":null},{"id":"W4416018995","doi":"10.1016/j.ijgc.2025.102238","title":"FIRST-LINE LENVATINIB + PEMBROLIZUMAB VERSUS CHEMOTHERAPY FOR ADVANCED OR RECURRENT ENDOMETRIAL CANCER: ADDITIONAL 1-YEAR FOLLOW-UP RESULTS FROM ENGOT-EN9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; Chemotherapy; MEDLINE; Compassionate Use","score_opus":0.09522776136698008,"score_gpt":0.43349187069703443,"score_spread":0.33826410933005435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416018995","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7666931,0.006430365,0.0020582618,0.11053871,0.05857279,0.004094021,0.044857305,0.00017945218,0.006575965],"genre_scores_gemma":[0.9465943,0.02041749,0.0068197506,0.00399713,0.011283743,0.0012839237,0.0014262936,0.00008570198,0.008091648],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613553,0.00010296635,0.0012863103,0.00051820575,0.0014749855,0.00048199712],"domain_scores_gemma":[0.98993236,0.006385176,0.00070912123,0.00023838032,0.0024580467,0.00027693235],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062634534,0.000313415,0.0007758587,0.0004773409,0.00013281773,0.00008126762,0.00075556966,0.00027242038,0.031451195],"category_scores_gemma":[0.01129396,0.0002293077,0.00047252217,0.0004692434,0.00017255603,0.00019061477,0.00012312262,0.00081156247,0.000020149984],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.399313,0.001092492,0.0009254939,0.00006772104,0.0020729823,0.00017212969,0.00013293597,0.00065910217,0.00065301853,0.00042373216,0.27596912,0.31851828],"study_design_scores_gemma":[0.13755137,0.004436755,0.008116511,0.00094295,0.00015776594,0.00001652014,0.000081749204,0.0005312068,0.0020957068,0.0009720534,0.84481996,0.00027744164],"about_ca_topic_score_codex":0.00022000632,"about_ca_topic_score_gemma":0.0011267415,"teacher_disagreement_score":0.5688509,"about_ca_system_score_codex":0.0025149593,"about_ca_system_score_gemma":0.00220716,"threshold_uncertainty_score":0.9970343},"labels":[],"label_agreement":null},{"id":"W4416019198","doi":"10.1016/j.ijgc.2025.102156","title":"PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier universitaire de Québec; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Bevacizumab; Pembrolizumab; Chemotherapy; Cervical cancer; Monoclonal","score_opus":0.103389803524005,"score_gpt":0.4244518838935613,"score_spread":0.3210620803695563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787752,0.00090000645,0.00019837588,0.017083857,0.0010815752,0.00071770675,0.0002494856,0.000028149532,0.0009656571],"genre_scores_gemma":[0.9904196,0.0021707807,0.0014974693,0.0022454206,0.00039618558,0.00018904814,0.000020640007,0.000038794406,0.0030220384],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99584967,0.0002232375,0.001076734,0.0005564888,0.0016553692,0.000638481],"domain_scores_gemma":[0.99668306,0.00088429725,0.00053097383,0.00028766607,0.0012460264,0.0003679496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060687325,0.00035154977,0.0010429928,0.00040110637,0.00006960949,0.000102804326,0.00070576504,0.00016239715,0.004733267],"category_scores_gemma":[0.0010785011,0.00018813815,0.00022066475,0.0006283039,0.00027703933,0.00019980228,0.00011118131,0.0010263904,0.000011548891],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6718808,0.0015112947,0.25038728,0.00018053388,0.004620073,0.004022446,0.0023250445,0.001818398,0.00032446318,0.00007112592,0.0077510276,0.05510756],"study_design_scores_gemma":[0.35516128,0.02862641,0.5100581,0.012681489,0.0025470408,0.0009296689,0.0071267113,0.012284227,0.0037334638,0.0005326358,0.06467613,0.0016428694],"about_ca_topic_score_codex":0.0022672394,"about_ca_topic_score_gemma":0.018686933,"teacher_disagreement_score":0.31671947,"about_ca_system_score_codex":0.0030730923,"about_ca_system_score_gemma":0.004561636,"threshold_uncertainty_score":0.9992195},"labels":[],"label_agreement":null},{"id":"W4416019222","doi":"10.1016/j.ijgc.2025.102160","title":"POST-(NEO)ADJUVANT THERAPY OUTCOMES WITH LENVATINIB PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER: RESULTS FROM STUDY 309/KEYNOTE-775 AND ENGOT-EN9/LEAP-001","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Pembrolizumab; Lenvatinib; MEDLINE; Compassionate Use; Nivolumab","score_opus":0.09727618982288361,"score_gpt":0.4481342611936658,"score_spread":0.3508580713707822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856094,0.0027757015,0.000033284126,0.008500459,0.0012378865,0.0012620649,0.00031200954,0.000022787224,0.0002464174],"genre_scores_gemma":[0.9918088,0.0054194834,0.00037095396,0.0012089633,0.0003829791,0.0003066005,0.000016806853,0.00002752944,0.0004579366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957876,0.00029678663,0.0011964227,0.0005630462,0.0016125564,0.000543573],"domain_scores_gemma":[0.995071,0.0023782044,0.000605539,0.00025744157,0.0014038614,0.00028393333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088932907,0.0003527572,0.0011057317,0.00057599467,0.00007699537,0.00009965628,0.0005398018,0.0001426193,0.0011204885],"category_scores_gemma":[0.002717108,0.00018994017,0.00010290017,0.00054853474,0.00022271862,0.00022601045,0.00014763299,0.0010236641,0.0000029923697],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22921132,0.0024696141,0.5006339,0.000028900738,0.0018358924,0.0022097505,0.0014216012,0.0009220767,0.0006145561,0.00002898674,0.00038468846,0.2602387],"study_design_scores_gemma":[0.10326541,0.012747465,0.87515247,0.0009523283,0.00016236486,0.0000465088,0.0011449829,0.0001998884,0.0007759811,0.000079886115,0.005185182,0.00028753854],"about_ca_topic_score_codex":0.0023900012,"about_ca_topic_score_gemma":0.010322475,"teacher_disagreement_score":0.37451854,"about_ca_system_score_codex":0.0016425271,"about_ca_system_score_gemma":0.0022528348,"threshold_uncertainty_score":0.99979264},"labels":[],"label_agreement":null},{"id":"W4416019250","doi":"10.1016/j.ijgc.2025.102732","title":"PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOT-OV65/KEYNOTE-B96 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Pembrolizumab; Bevacizumab; Placebo; Paclitaxel; Phases of clinical research; Monoclonal; Ovarian cancer","score_opus":0.07765121716790024,"score_gpt":0.45433611366968646,"score_spread":0.3766848965017862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92416877,0.0041251197,0.0015020819,0.056229137,0.0059017627,0.0030512111,0.003040356,0.000050297833,0.0019312402],"genre_scores_gemma":[0.9922591,0.001123427,0.00057755015,0.0020521358,0.0021884274,0.000594394,0.00005799578,0.00003130023,0.0011156602],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952257,0.0003829714,0.0015571621,0.00057394436,0.0017197981,0.00054040545],"domain_scores_gemma":[0.99225754,0.00437604,0.00076867506,0.0004208206,0.001892678,0.00028423517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017819934,0.00034694347,0.0008248902,0.0002600296,0.00023394614,0.00016910251,0.0012250489,0.00021899771,0.0017502836],"category_scores_gemma":[0.0059735905,0.00021840777,0.00037102238,0.00033782478,0.00020340564,0.00014834989,0.0002710777,0.0011931276,0.000008879609],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4734591,0.0050774403,0.021805385,0.0001306371,0.0060338005,0.0013200291,0.0038752826,0.0018091861,0.0023742171,0.0018187054,0.135121,0.3471752],"study_design_scores_gemma":[0.24184631,0.018218668,0.2591689,0.0026958538,0.0015030903,0.00008783098,0.0032607527,0.0058738505,0.0016780337,0.0049490593,0.4598638,0.00085385994],"about_ca_topic_score_codex":0.0016227617,"about_ca_topic_score_gemma":0.00244228,"teacher_disagreement_score":0.34632134,"about_ca_system_score_codex":0.0037566056,"about_ca_system_score_gemma":0.002767087,"threshold_uncertainty_score":0.99916226},"labels":[],"label_agreement":null},{"id":"W4416019293","doi":"10.1016/j.ijgc.2025.102245","title":"PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY","year":2025,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Pembrolizumab; Radiation therapy; Quality of life (healthcare); Chemotherapy; Adjuvant; Phases of clinical research","score_opus":0.08763137003118326,"score_gpt":0.4690589906847477,"score_spread":0.38142762065356445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416019293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95937353,0.00895113,0.0031875547,0.022667157,0.002195339,0.0028644707,0.000688818,0.00003210759,0.000039901242],"genre_scores_gemma":[0.98266757,0.009511478,0.0012798076,0.0041262126,0.0015567747,0.00047709848,0.000021593947,0.000047481928,0.00031197016],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99417967,0.0008728012,0.0020876424,0.00050980673,0.001850018,0.0005000749],"domain_scores_gemma":[0.9889971,0.006494685,0.0019180259,0.00039985863,0.0018354892,0.00035485966],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025811114,0.00037495414,0.0018497024,0.00035913297,0.00017339583,0.00008170111,0.0010449565,0.0002164803,0.003628125],"category_scores_gemma":[0.004467435,0.00020185387,0.00040259867,0.00066089473,0.00034236046,0.00013868266,0.00008295926,0.0010834549,0.00000148445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25310713,0.0044885348,0.44568598,0.00010323874,0.009384474,0.0001638958,0.0030726565,0.0017399007,0.0011980971,0.00014282322,0.011202806,0.26971045],"study_design_scores_gemma":[0.3598111,0.026710432,0.58004886,0.00105414,0.00062756403,0.000033008746,0.0020835928,0.0015314668,0.0016339988,0.0005677187,0.025357632,0.0005404836],"about_ca_topic_score_codex":0.02238369,"about_ca_topic_score_gemma":0.0063471757,"teacher_disagreement_score":0.26917,"about_ca_system_score_codex":0.0027544387,"about_ca_system_score_gemma":0.0062574814,"threshold_uncertainty_score":0.9993761},"labels":[],"label_agreement":null},{"id":"W4416088438","doi":"10.1136/jitc-2025-sitc2025.0057","title":"57 High-throughput quantitative characterization of cytotoxic antibody-drug conjugates using spheroid models reveals important considerations in potential molecular mechanisms of ADC resistance","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cytotoxic T cell; Conjugate; Spheroid; Cytotoxicity; Cell culture","score_opus":0.026555963767107112,"score_gpt":0.3195329329115008,"score_spread":0.2929769691443937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416088438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97252333,0.006446322,0.01584884,0.001747591,0.00062376825,0.0020577125,0.00060327665,0.00003427691,0.000114911134],"genre_scores_gemma":[0.981608,0.0019948077,0.015447692,0.00029780602,0.000057473753,0.000039286184,0.00018699322,0.00008842589,0.00027953202],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9932873,0.00066061964,0.002945718,0.0010922414,0.0011721537,0.000841935],"domain_scores_gemma":[0.99591017,0.00024065428,0.0013939064,0.00087775773,0.0010146014,0.00056292675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020852326,0.0006395962,0.0017035151,0.0006269256,0.00023742979,0.00012451355,0.0002576544,0.00048179948,0.000067718036],"category_scores_gemma":[0.0015751751,0.00070379226,0.00022455589,0.0010193071,0.001448248,0.00063409,0.0001843916,0.00069902994,0.0000020985456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002270034,0.0003126725,0.0021335026,0.0031711648,0.0003654949,0.00038510782,0.001063565,0.0028351196,0.9037129,0.08571519,0.00006257102,0.000015685891],"study_design_scores_gemma":[0.0023062886,0.00023237511,0.012671281,0.008315126,0.0004634503,0.00004391206,0.0008982397,0.011571251,0.8678126,0.09518549,0.000013276317,0.00048676904],"about_ca_topic_score_codex":0.0017543515,"about_ca_topic_score_gemma":0.00023095113,"teacher_disagreement_score":0.035900373,"about_ca_system_score_codex":0.00033838398,"about_ca_system_score_gemma":0.0036444587,"threshold_uncertainty_score":0.99954134},"labels":[],"label_agreement":null},{"id":"W4416138490","doi":"10.25259/ijmr_2009_2024","title":"Challenges &amp; recommendations for identification of human epidermal growth factor receptor -2 (HER2)-low metastatic breast cancer in India: Expert opinion statement","year":2025,"lang":"en","type":"review","venue":"The Indian Journal of Medical Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"AstraZeneca","keywords":"Metastatic breast cancer; Trastuzumab; Breast cancer; Human Epidermal Growth Factor Receptor 2; Immunohistochemistry; Cancer; Clinical trial; CA15-3; Statement (logic)","score_opus":0.3880157786016005,"score_gpt":0.5899644220023963,"score_spread":0.20194864340079577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416138490","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009046815,0.9348147,0.0000862528,0.060603607,0.0007394623,0.0028778613,0.0007079192,0.000006973791,0.00007276242],"genre_scores_gemma":[0.0007668852,0.9966624,0.0001526526,0.00007347299,0.00094673096,0.0008808549,0.00015572143,0.00006801649,0.00029331277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98674273,0.0037992836,0.0032314812,0.00046852356,0.0048591746,0.0008988076],"domain_scores_gemma":[0.99006337,0.0056419685,0.0012027166,0.00067408173,0.0017136494,0.0007042138],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025180606,0.0003547643,0.0020982753,0.0022683386,0.00022773158,0.0000678399,0.0017275987,0.00043665912,0.0030964776],"category_scores_gemma":[0.008163974,0.00022594498,0.0005539064,0.0013491941,0.00055849773,0.0001528156,0.0002981238,0.0037509291,0.000023213808],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012682079,0.00047592827,0.000016144715,0.033182032,0.0005554513,0.000042999167,0.0023785112,1.5341972e-7,0.000011297374,0.00020122707,0.02228012,0.9407293],"study_design_scores_gemma":[0.0023354823,0.00070384453,0.0005254393,0.13186687,0.00016827017,0.00028212892,0.0021774862,0.0000047711337,0.00007055737,0.0003985199,0.86118674,0.00027985885],"about_ca_topic_score_codex":0.000356159,"about_ca_topic_score_gemma":0.00021350684,"teacher_disagreement_score":0.9404495,"about_ca_system_score_codex":0.0017271859,"about_ca_system_score_gemma":0.010396837,"threshold_uncertainty_score":0.99854743},"labels":[],"label_agreement":null},{"id":"W4416254472","doi":"10.17615/4s15-x497","title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","year":2025,"lang":"","type":"article","venue":"UNC Libraries","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Society for Medical Oncology; Sociedad Española de Oncología Médica; Banco Bilbao Vizcaya Argentaria; Astellas Pharma; Università degli Studi di Padova; Fundación BBVA; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Celgene; Eli Lilly and Company; AstraZeneca; Oncolytics Biotech","keywords":"Trastuzumab; Breast cancer; Immunohistochemistry; Trastuzumab emtansine; Messenger RNA; Overall survival; Antibody; Cancer","score_opus":0.014004692194790924,"score_gpt":0.31111052610432377,"score_spread":0.2971058339095328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416254472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7233841,0.08084736,0.00078699604,0.05315928,0.0023435506,0.00883769,0.0019388141,0.00077811733,0.12792408],"genre_scores_gemma":[0.94532025,0.0024147232,0.0031496668,0.00222404,0.00065234164,0.0009874768,0.00017045264,0.00023182844,0.04484925],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942661,0.00054593204,0.0009583737,0.0014632646,0.0011579768,0.0016083535],"domain_scores_gemma":[0.9970054,0.0006307768,0.00024391862,0.0011523161,0.00043146222,0.0005361479],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033860607,0.00087349076,0.0013308855,0.0008346921,0.0003835453,0.00038650466,0.00066747755,0.00053917174,0.0041291635],"category_scores_gemma":[0.00017964144,0.00069734245,0.00016170955,0.0031457425,0.0012335913,0.0014539122,0.0005113064,0.0015674715,0.00008535341],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03530293,0.0021813565,0.72707283,0.0033627902,0.001060678,0.0019526865,0.008389595,0.0006702816,0.02404675,0.013352747,0.034096595,0.14851074],"study_design_scores_gemma":[0.021428075,0.0023575942,0.43480045,0.055527765,0.0005087631,0.00008293542,0.008022092,0.00092287885,0.43130502,0.0051438175,0.038062204,0.0018384061],"about_ca_topic_score_codex":0.0029561936,"about_ca_topic_score_gemma":0.00087277225,"teacher_disagreement_score":0.40725827,"about_ca_system_score_codex":0.0010918648,"about_ca_system_score_gemma":0.0046275547,"threshold_uncertainty_score":0.9995478},"labels":[],"label_agreement":null},{"id":"W4416391581","doi":"10.1016/j.annonc.2025.09.031","title":"LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Metastatic breast cancer; Chemotherapy; Immunotherapy; Breast cancer; Cancer; Chemotherapy regimen","score_opus":0.08251542603776353,"score_gpt":0.4295659143172496,"score_spread":0.3470504882794861,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93668437,0.00073493214,0.0012132614,0.046756323,0.0005670104,0.010869197,0.002978333,0.00003956342,0.0001570138],"genre_scores_gemma":[0.974842,0.005145589,0.0025764694,0.010950193,0.0006520426,0.003471055,0.0014229192,0.000114609655,0.0008251006],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9955805,0.00078001374,0.0014794826,0.0008081479,0.00065832847,0.0006935184],"domain_scores_gemma":[0.9948268,0.0023755624,0.00058485236,0.0008790703,0.0011289585,0.00020477122],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015522899,0.0004343787,0.001672604,0.00028012876,0.00024272925,0.00005393025,0.00054542685,0.00022585779,0.0004490366],"category_scores_gemma":[0.00057915016,0.00026749415,0.0002083367,0.00075686304,0.00050931016,0.00023864229,0.00007415809,0.00059820595,0.0000028881188],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.67921376,0.004501706,0.00034114544,0.00009500472,0.0008112621,0.000016531158,0.0014349398,0.000060341525,0.00015422919,0.000015996668,0.0034508577,0.3099042],"study_design_scores_gemma":[0.9172048,0.03003153,0.012630693,0.00090582954,0.0002579251,0.000009459805,0.0003661803,0.0009521572,0.0027975482,0.00023016958,0.034279473,0.0003342184],"about_ca_topic_score_codex":0.003916827,"about_ca_topic_score_gemma":0.0052352175,"teacher_disagreement_score":0.30956998,"about_ca_system_score_codex":0.00058030325,"about_ca_system_score_gemma":0.004472716,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W4416391787","doi":"10.1016/j.annonc.2025.09.028","title":"LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.147782217334356,"score_gpt":0.4590405512808375,"score_spread":0.3112583339464815,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416391787","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843241,0.0007837109,0.0006479549,0.0037687698,0.0001905117,0.0021426245,0.006755221,0.00003762482,0.0013494611],"genre_scores_gemma":[0.9922989,0.0005116193,0.004596087,0.000566057,0.00007782936,0.00086052786,0.0006782775,0.000081452774,0.00032926226],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952645,0.00037937707,0.0017419175,0.00085438084,0.00078149,0.0009783709],"domain_scores_gemma":[0.9938845,0.0017144101,0.0009263893,0.00066429016,0.002497711,0.0003126758],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064839085,0.0005505865,0.002157871,0.0012509581,0.00009153637,0.000012598267,0.0005708182,0.00028015836,0.0018769044],"category_scores_gemma":[0.0010108161,0.00047148005,0.00040101932,0.0014837496,0.0010273956,0.00023928208,0.00014828255,0.0005762929,0.0000043885752],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06138777,0.024708446,0.12732305,0.009195983,0.00395757,0.00032012022,0.0022893697,0.0011141424,0.013726315,0.0013366248,0.030823782,0.7238168],"study_design_scores_gemma":[0.05265128,0.083165735,0.7699033,0.013638526,0.0018360883,0.00071944343,0.0045535956,0.0022140208,0.045385957,0.0024860508,0.021742115,0.0017038684],"about_ca_topic_score_codex":0.002535484,"about_ca_topic_score_gemma":0.0055519,"teacher_disagreement_score":0.72211295,"about_ca_system_score_codex":0.0011278442,"about_ca_system_score_gemma":0.0043774447,"threshold_uncertainty_score":0.9997737},"labels":[],"label_agreement":null},{"id":"W4416410316","doi":"10.1016/j.annonc.2025.11.005","title":"Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Alberta","funders":"Seagen; Gilead Sciences; Roche; Novartis; Daiichi-Sankyo; Pfizer; Bristol-Myers Squibb","keywords":"Metastatic breast cancer; Trastuzumab emtansine; Trastuzumab; Phases of clinical research; Randomized controlled trial; Clinical endpoint","score_opus":0.033511208488277475,"score_gpt":0.4264416677257516,"score_spread":0.3929304592374741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416410316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654586,0.0015693182,0.0002459185,0.0045735743,0.0000636238,0.005903848,0.00053277495,0.000010186209,0.00055489084],"genre_scores_gemma":[0.9958367,0.0017670628,0.0005105461,0.000800506,0.000022263795,0.00067186455,0.00010933838,0.000019381827,0.00026238628],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9977209,0.0005238836,0.0007630999,0.00037075114,0.00030548754,0.00031588224],"domain_scores_gemma":[0.99630505,0.0018169425,0.00046182278,0.00029067232,0.0010041976,0.00012130198],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093928777,0.00020981173,0.0020889693,0.0003187254,0.000070284885,0.000007938263,0.0001227935,0.00009586921,0.000046034536],"category_scores_gemma":[0.00047881485,0.00012772878,0.0002476276,0.0009286379,0.0007451971,0.000058276146,0.000057837766,0.00016410195,7.2084546e-8],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8280082,0.0026118024,0.0035719238,0.0004747046,0.00675123,0.0000058826195,0.00069683784,0.000028235747,0.00025114836,0.00003745035,0.00039564288,0.15716697],"study_design_scores_gemma":[0.9428375,0.01427941,0.030981742,0.00064644567,0.008623587,0.0000063601788,0.00019762824,0.0005793138,0.0012027766,0.00006559189,0.00043199374,0.00014765734],"about_ca_topic_score_codex":0.0005193472,"about_ca_topic_score_gemma":0.0005770871,"teacher_disagreement_score":0.15701932,"about_ca_system_score_codex":0.00013004095,"about_ca_system_score_gemma":0.0013797509,"threshold_uncertainty_score":0.5208628},"labels":[],"label_agreement":null},{"id":"W4416592902","doi":"10.3390/curroncol32120658","title":"Real-World Outcomes of Subcutaneous PHESGO® in HER2-Positive Breast Cancer: Pathological Response, Sequencing, and Safety","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Taxane; Pathological; Blockade; Breast cancer; Neoadjuvant therapy; Prospective cohort study","score_opus":0.09665490570086571,"score_gpt":0.4812934815231594,"score_spread":0.3846385758222937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416592902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97949666,0.001624087,0.000017002294,0.009858963,0.00056116574,0.0007342181,0.00018030759,0.000039182458,0.0074884393],"genre_scores_gemma":[0.9945777,0.0036050468,0.00015591136,0.00027582582,0.00006468369,0.000104677514,0.000015449761,0.000014856818,0.0011858513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764585,0.00066879013,0.00054153695,0.00044675195,0.0002561876,0.00044085475],"domain_scores_gemma":[0.99832076,0.0009289105,0.00011267299,0.0002887571,0.00020323372,0.00014564862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009836528,0.00018861375,0.00081502734,0.00041190357,0.000049260463,0.0000063843527,0.00015159741,0.00018053524,0.00024815873],"category_scores_gemma":[0.00037146042,0.00015403122,0.00007873606,0.0005881774,0.0004920143,0.000028124286,0.00018701218,0.0006639519,0.0000063256284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008196092,0.0004265685,0.8605094,0.00025378476,0.00005761823,0.00092485215,0.00061165245,0.000005495586,0.0023231239,0.0007393565,0.0012844229,0.12466763],"study_design_scores_gemma":[0.0022135838,0.00087439094,0.97837114,0.00055573625,0.000064376814,0.000281649,0.00026010038,0.0000841424,0.0003951741,0.00021562548,0.016558444,0.00012565155],"about_ca_topic_score_codex":0.0012386196,"about_ca_topic_score_gemma":0.002625568,"teacher_disagreement_score":0.124541976,"about_ca_system_score_codex":0.0022512777,"about_ca_system_score_gemma":0.0017976791,"threshold_uncertainty_score":0.6281211},"labels":[],"label_agreement":null},{"id":"W4416738297","doi":"10.3390/curroncol32110603","title":"Predictors of Pathologic Complete Response and Its Prognostic Value in Early Breast Cancer: A Real-World Cohort Study","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Complete response; Surrogate endpoint; Clinical endpoint; Cohort; Cohort study; Value (mathematics); Disease; Event (particle physics)","score_opus":0.12626779724652026,"score_gpt":0.471336344793251,"score_spread":0.3450685475467307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416738297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99169415,0.0018770999,0.0000028760999,0.0014889983,0.0007349004,0.0032083103,0.00011990651,0.000043721662,0.00083006284],"genre_scores_gemma":[0.9978823,0.00090351584,0.000016504728,0.000045572855,0.00008477016,0.00076592853,0.0000088724355,0.000015656437,0.00027685333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970396,0.0011288823,0.0005500217,0.00050201535,0.00035872826,0.00042073216],"domain_scores_gemma":[0.9983087,0.00085121574,0.0001206886,0.0003126451,0.00025619814,0.00015053862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018561212,0.00017866358,0.00073650584,0.0006302061,0.000046794346,0.00000823776,0.00018221265,0.00010574899,0.00006903276],"category_scores_gemma":[0.00067040307,0.00015468996,0.000046476238,0.0009066569,0.0002444071,0.00003546816,0.00022696595,0.00058834616,0.0000065921245],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003084893,0.0014986068,0.9857377,0.00033428762,0.00008821388,0.00023407635,0.0009266245,0.000006473433,0.00057164807,0.000109841145,0.0006813077,0.0067263586],"study_design_scores_gemma":[0.0032889955,0.0021846232,0.9897544,0.0005467255,0.00016467586,0.00003080011,0.00018636844,0.00032689612,0.00003399287,0.000037081856,0.0033487242,0.000096751675],"about_ca_topic_score_codex":0.00091749046,"about_ca_topic_score_gemma":0.0010070492,"teacher_disagreement_score":0.006629607,"about_ca_system_score_codex":0.00078751077,"about_ca_system_score_gemma":0.0013189783,"threshold_uncertainty_score":0.6308074},"labels":[],"label_agreement":null},{"id":"W4417048935","doi":"10.1021/acsomega.5c08654","title":"Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics","year":2025,"lang":"en","type":"article","venue":"ACS Omega","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"PEGylation; Molecular dynamics; PEG ratio; Polyethylene glycol; Steric effects; Hydrogen bond; Monoclonal antibody; Dihedral angle; Tripeptide","score_opus":0.02737456954147662,"score_gpt":0.375535016196717,"score_spread":0.3481604466552404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417048935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518657,0.0019747869,0.00003793342,0.0017850449,0.00022482777,0.00031313382,0.000027142007,0.000023048102,0.00042749377],"genre_scores_gemma":[0.99707365,0.00023945194,0.0012770424,0.0002820212,0.000091611444,0.000014657198,0.000019931898,0.000014415215,0.0009872362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989947,0.000065933185,0.00017617112,0.00021623462,0.00035204107,0.0001949118],"domain_scores_gemma":[0.9989162,0.0006829042,0.000042244446,0.00016298651,0.00013491845,0.000060733848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017777461,0.00011785403,0.00029810183,0.00019295498,0.0000747528,0.000010249814,0.00007179585,0.000076211356,0.0000066904804],"category_scores_gemma":[0.0004404109,0.000096915865,0.000029673729,0.00026321606,0.00013550608,0.00002406632,0.0000968061,0.00022719201,0.0000032178566],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018025596,0.0007905007,0.426976,0.018234756,0.0031415645,0.00044415225,0.010145045,0.0035195448,0.12360525,0.022577839,0.04024502,0.34851778],"study_design_scores_gemma":[0.01658243,0.0044081737,0.47152156,0.006455754,0.0004452048,0.00006394146,0.0024932013,0.00646594,0.4631587,0.010014307,0.017583469,0.0008073267],"about_ca_topic_score_codex":0.000017573098,"about_ca_topic_score_gemma":0.000020838603,"teacher_disagreement_score":0.34771043,"about_ca_system_score_codex":0.00011303656,"about_ca_system_score_gemma":0.00009753583,"threshold_uncertainty_score":0.39521143},"labels":[],"label_agreement":null},{"id":"W4417156739","doi":"10.1038/s41416-025-03287-9","title":"Spatial molecular analyses reveal key features associated with response to KN026 in advanced HER2-positive breast cancer","year":2025,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"Natural Science Foundation of Heilongjiang Province; National Natural Science Foundation of China; Harbin Medical University","keywords":"Breast cancer; Endocrine system; Mammary gland; Oestrogen receptor; Key (lock); Cancer","score_opus":0.013944085488671354,"score_gpt":0.3942441363294163,"score_spread":0.3803000508407449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417156739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9703236,0.015889565,0.00020441892,0.0116632385,0.00026746927,0.00054774794,0.0003041128,0.000017283517,0.00078252825],"genre_scores_gemma":[0.99330604,0.0014433204,0.00038050732,0.0023200708,0.00020122882,0.00008741014,0.000006249071,0.000046650144,0.00220853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99706584,0.00045534072,0.0005792117,0.0003421466,0.0010238414,0.0005336419],"domain_scores_gemma":[0.9976596,0.00020177063,0.0002583828,0.00019232639,0.0013606397,0.00032722807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008769354,0.00021660393,0.00074321165,0.00051438867,0.00008103661,0.00009434454,0.00025798185,0.00014683582,0.00031078636],"category_scores_gemma":[0.0007782689,0.00021191598,0.00016159499,0.0013281208,0.00012159884,0.00014432293,0.000065607695,0.00095742836,0.0000017389366],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06494402,0.00081064977,0.17361134,0.00026015815,0.002385751,0.022361498,0.00087167724,0.0067021046,0.1366696,0.000010479821,0.029710174,0.56166255],"study_design_scores_gemma":[0.0050134147,0.00064095395,0.96014297,0.013575813,0.00023041418,0.00086882024,0.0001574962,0.00001770398,0.016382307,0.000024356234,0.0027222682,0.00022347555],"about_ca_topic_score_codex":0.0132601345,"about_ca_topic_score_gemma":0.028258117,"teacher_disagreement_score":0.7865316,"about_ca_system_score_codex":0.0018759056,"about_ca_system_score_gemma":0.0027589214,"threshold_uncertainty_score":0.99331063},"labels":[],"label_agreement":null},{"id":"W4417198347","doi":"10.1200/jco-25-02600","title":"HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Hospital","funders":"","keywords":"Pertuzumab; Trastuzumab; Metastatic breast cancer; Placebo; Maintenance therapy; Phases of clinical research; Chemotherapy; Clinical trial","score_opus":0.1733979768876252,"score_gpt":0.5582290306535705,"score_spread":0.38483105376594534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417198347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741904,0.00070501585,0.00024630313,0.021847589,0.0006112632,0.0020094204,0.000018161989,0.0000058057535,0.00036604883],"genre_scores_gemma":[0.99556154,0.0022215284,0.0007443919,0.0007591804,0.00016876745,0.0001670008,0.0000024919134,0.00002324662,0.00035183484],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9962677,0.0005177724,0.002100179,0.00029898167,0.00049866893,0.00031673885],"domain_scores_gemma":[0.99193853,0.0055021723,0.0011039012,0.00022122644,0.0010011296,0.00023302631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039267074,0.00018656018,0.0017687964,0.0003002374,0.000053385014,0.000011657329,0.00020723612,0.00016786248,0.000114222115],"category_scores_gemma":[0.0023017318,0.00012410045,0.0001715694,0.00041737498,0.00029704167,0.000100352176,0.000039298546,0.00091447035,6.234737e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4485508,0.034372807,0.028227353,0.0002970198,0.0016746846,0.00042566544,0.0017983819,0.000115248346,0.000054798635,0.00014555138,0.0029298917,0.4814078],"study_design_scores_gemma":[0.589039,0.27934954,0.1052106,0.0011727718,0.00073160714,0.00034057745,0.0062370677,0.0018789211,0.00007784405,0.00041919257,0.015343215,0.00019964209],"about_ca_topic_score_codex":0.00060001214,"about_ca_topic_score_gemma":0.003125145,"teacher_disagreement_score":0.48120815,"about_ca_system_score_codex":0.0006232319,"about_ca_system_score_gemma":0.0045107407,"threshold_uncertainty_score":0.80018604},"labels":[],"label_agreement":null},{"id":"W4417479984","doi":"10.1016/j.jval.2025.09.192","title":"CO90 Efficacy and Safety of Antibody-Drug Conjugates (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Non-Small Cell Lung Cancer (NSCLC): A Systematic Literature Review (SLR)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario","funders":"","keywords":"Lung cancer; Toxicity; Systematic review; Cytotoxic T cell; Conjugate; Cancer; Clinical trial","score_opus":0.0194310146393124,"score_gpt":0.3837935148397427,"score_spread":0.3643625002004303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417479984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10629334,0.88014615,0.00016365158,0.0029706715,0.00014872417,0.009326532,0.00008385102,0.000038465467,0.0008286175],"genre_scores_gemma":[0.28559119,0.71059406,0.0012839845,0.0013926085,0.00002332328,0.00039364945,0.000034133554,0.000051949537,0.00063510996],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9953651,0.001324324,0.0016513548,0.0005799739,0.0004598957,0.000619396],"domain_scores_gemma":[0.997122,0.0013982602,0.00036465752,0.00060880795,0.00025888236,0.0002474174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032305904,0.00032303992,0.0017461615,0.0005243901,0.000052590214,0.000027815879,0.00022195945,0.00011171479,0.000026917973],"category_scores_gemma":[0.00082881306,0.00026446453,0.00008283758,0.0020159741,0.00012552795,0.000079626516,0.000093509225,0.0008179367,0.0000031654324],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004701403,0.00032384341,0.02572166,0.96743083,0.0000732459,0.00016230014,0.0018738377,0.0007127753,0.00043104097,0.00012151958,0.0006572033,0.0020215823],"study_design_scores_gemma":[0.0056560906,0.0003091934,0.011069774,0.9715045,0.00012957827,0.000029780618,0.00015230279,0.010287125,0.0003740127,0.000030922838,0.00026239682,0.00019432374],"about_ca_topic_score_codex":0.0021366833,"about_ca_topic_score_gemma":0.00020208652,"teacher_disagreement_score":0.17929785,"about_ca_system_score_codex":0.000575301,"about_ca_system_score_gemma":0.002436028,"threshold_uncertainty_score":0.99998075},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"systematic_review","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4417480012","doi":"10.1016/j.jval.2025.09.317","title":"CO216 Safety and Efficacy of Antibody Drug Conjugate (ADCs) in Pretreated Locally Advanced/Metastatic (LA/m) Triple-Negative Breast Cancer (TNBC): Systematic Literature Review (SLR)","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agricultural Research Institute of Ontario","funders":"","keywords":"Breast cancer; Antibody-drug conjugate; Systematic review; Drug; Conjugate","score_opus":0.021433026575349914,"score_gpt":0.40031154003912167,"score_spread":0.37887851346377177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417480012","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07178023,0.89275795,0.00013358485,0.016016694,0.00034434287,0.01697178,0.00061602745,0.00008562675,0.0012937571],"genre_scores_gemma":[0.41382566,0.582449,0.00065464154,0.0017673079,0.000030183039,0.00034879646,0.00005278839,0.000054614622,0.00081695575],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99422425,0.0022170644,0.001795727,0.00059311604,0.00057814503,0.000591681],"domain_scores_gemma":[0.9965946,0.0017888638,0.0004344324,0.00057639315,0.00034745102,0.00025822938],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036718042,0.00032628738,0.001953097,0.0005714368,0.0000593505,0.000025088419,0.00020214163,0.00010133948,0.000056628523],"category_scores_gemma":[0.0016899467,0.00025930884,0.00009482628,0.002643166,0.00021322009,0.00012170237,0.00008163694,0.000840513,0.0000042968118],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019825564,0.00050569663,0.012671139,0.96980953,0.00017945598,0.00029479893,0.0028306968,0.0006354432,0.00013656249,0.00096752355,0.0005505991,0.009436012],"study_design_scores_gemma":[0.008773669,0.00032137107,0.046055235,0.9387275,0.00011258696,0.00011593956,0.00024448632,0.004965734,0.00009674265,0.00016743166,0.00020935215,0.00020995566],"about_ca_topic_score_codex":0.003320163,"about_ca_topic_score_gemma":0.00027292594,"teacher_disagreement_score":0.34204546,"about_ca_system_score_codex":0.00083812175,"about_ca_system_score_gemma":0.0022955963,"threshold_uncertainty_score":0.99998593},"labels":[],"label_agreement":null},{"id":"W4417481095","doi":"10.1016/j.jval.2025.09.1774","title":"HSD114 Treatment Characteristics of Breast Cancer Patients per HER2/HR Status in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2018-2022 Database Analysis","year":2025,"lang":"en","type":"article","venue":"Value in Health","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Canada","funders":"","keywords":"Breast cancer; Cancer; MEDLINE; Real world evidence","score_opus":0.08004581664081484,"score_gpt":0.41839420921166537,"score_spread":0.33834839257085053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417481095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751299,0.0017666871,0.000021707445,0.012282784,0.00013088589,0.0011278751,0.009438674,0.00001274063,0.00008874822],"genre_scores_gemma":[0.96005756,0.034792997,0.00015497507,0.0016358856,0.000043959808,0.00014519262,0.0030224137,0.000016789063,0.0001302316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99509656,0.0021897473,0.0011074793,0.0005156021,0.0003620192,0.00072857615],"domain_scores_gemma":[0.99654245,0.0020726242,0.00031157627,0.00067678146,0.0001814276,0.00021511884],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004189945,0.00021049779,0.0009581421,0.0010192312,0.000072357885,0.000009426154,0.00015140633,0.00009038351,0.000073963136],"category_scores_gemma":[0.0009451906,0.00014566194,0.00007016259,0.002418682,0.00020840012,0.00003701331,0.00007964709,0.00039570619,0.0000019913407],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011264334,0.00058550003,0.98470646,0.0005632099,0.00020780768,0.000014095707,0.0019402866,0.00062951335,0.0000039315737,0.000053947108,0.0018036194,0.00836522],"study_design_scores_gemma":[0.003032535,0.00054583803,0.97414196,0.0004010126,0.000067923735,0.000002098903,0.0005191917,0.009926963,0.0000022939043,0.000026398875,0.011241826,0.00009193438],"about_ca_topic_score_codex":0.31246483,"about_ca_topic_score_gemma":0.015884524,"teacher_disagreement_score":0.29658028,"about_ca_system_score_codex":0.001250188,"about_ca_system_score_gemma":0.0011893644,"threshold_uncertainty_score":0.8863937},"labels":[],"label_agreement":null},{"id":"W57864847","doi":"10.1007/978-1-59745-169-7_3","title":"Proteomic Profiling of Tyrosine Kinases as Pharmacological Endpoints for Targeted Cancer Therapy","year":2007,"lang":"en","type":"book-chapter","venue":"Humana Press eBooks","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Canadian Breast Cancer Research Alliance; Cancer Research Society","keywords":"Targeted therapy; Tyrosine kinase; Profiling (computer programming); Kinase; Proteomics; Cancer therapy; Computational biology; Cancer research; Bioinformatics; Medicine; Biology; Cancer; Gene; Signal transduction; Internal medicine; Biochemistry; Computer science","score_opus":0.3107914055341564,"score_gpt":0.4579386004752196,"score_spread":0.1471471949410632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W57864847","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011082492,0.05706193,0.00009586565,0.00010392403,0.00072185724,0.01756178,0.00064475223,0.00029078877,0.9124366],"genre_scores_gemma":[0.022628421,0.013831456,0.0026533504,0.0011432088,0.00340816,0.004429466,0.00031312968,0.0005883571,0.95100445],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968969,0.000041928153,0.00077281543,0.00075690844,0.0008674387,0.0006639663],"domain_scores_gemma":[0.99805665,0.00014854418,0.00041959534,0.00052879,0.00058473257,0.0002616863],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005300252,0.0005452302,0.001039734,0.00029950912,0.00011910777,0.00002638025,0.0003884452,0.0005763819,0.0016956924],"category_scores_gemma":[0.00006681407,0.00045360136,0.0003728548,0.000014012194,0.00046652395,0.000028965094,0.00013879042,0.00089920725,0.000013203379],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021179901,0.00057818467,0.0000549278,0.007932775,0.0045642555,0.0007594851,0.00091980875,0.00001718028,0.3060511,0.08846944,0.023306455,0.5461665],"study_design_scores_gemma":[0.0033357395,0.0012069157,0.000025039535,0.001071449,0.0003188849,0.000010949013,0.0000041811313,0.00003344895,0.6465083,0.001401581,0.3456885,0.00039503985],"about_ca_topic_score_codex":0.0003371023,"about_ca_topic_score_gemma":0.000022448394,"teacher_disagreement_score":0.5457715,"about_ca_system_score_codex":0.0003187507,"about_ca_system_score_gemma":0.0006275124,"threshold_uncertainty_score":0.99979156},"labels":[],"label_agreement":null},{"id":"W593708258","doi":"10.1200/jco.2005.23.16_suppl.500","title":"Clinical and molecular predictors of sustained response to trastuzumab in metastatic breast cancer","year":2005,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Trastuzumab; Oncology; Internal medicine; Breast cancer; Chemotherapy; Cancer; PTEN; Tissue microarray; Immunohistochemistry; Metastatic breast cancer; Hormonal therapy","score_opus":0.12459404427531262,"score_gpt":0.563880348099123,"score_spread":0.4392863038238104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W593708258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9378628,0.0006460128,0.00011778625,0.0602957,0.0004309889,0.0003750491,0.000015609945,0.000004750232,0.00025128282],"genre_scores_gemma":[0.9902487,0.0009101354,0.0048493217,0.0029837762,0.000790512,0.000010053881,4.0769848e-7,0.000024033256,0.00018310912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925089,0.0022434609,0.0039200797,0.00026858706,0.0006885827,0.0003704142],"domain_scores_gemma":[0.99234396,0.0049400046,0.00087811216,0.00024603587,0.0007064397,0.0008854657],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.016505862,0.00014330148,0.0019693743,0.0003839212,0.000014681368,0.0000060217776,0.00022623068,0.00030333185,0.0002634978],"category_scores_gemma":[0.014015624,0.00010660832,0.00036165255,0.0003755605,0.0004991493,0.000082751154,0.000100642384,0.0014911204,0.0000062528766],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0752704,0.0029704992,0.6124515,0.00011051407,0.000563282,0.0021913508,0.0003760918,0.00013709703,0.0012868594,0.000041550207,0.0059288503,0.29867202],"study_design_scores_gemma":[0.014279926,0.018475998,0.92003113,0.00031316507,0.00029238078,0.00058006146,0.00040767173,0.00020621522,0.00014682554,0.00008640734,0.045075655,0.00010456786],"about_ca_topic_score_codex":0.000063365565,"about_ca_topic_score_gemma":0.00017854091,"teacher_disagreement_score":0.30757964,"about_ca_system_score_codex":0.00039844704,"about_ca_system_score_gemma":0.006188361,"threshold_uncertainty_score":0.9994456},"labels":[],"label_agreement":null},{"id":"W6902013696","doi":"10.6084/m9.figshare.14211591.v1","title":"Additional file 9 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Listing (finance); Clinical trial; Subpoena; Data file","score_opus":0.14997297660444242,"score_gpt":0.4332336874999872,"score_spread":0.2832607108955448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902013696","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008161084,0.000099416,2.3246612e-7,0.000065395485,0.000019195515,0.0005806108,0.98809177,0.000016419424,0.0029658603],"genre_scores_gemma":[0.203448,0.000009589576,0.0003227337,0.00006352893,0.00017631275,0.0002967945,0.79490215,0.00002050876,0.00076038827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998303,0.0001290589,0.0005640298,0.00029079255,0.0005544485,0.00015864435],"domain_scores_gemma":[0.99600506,0.0024111753,0.00014200373,0.0003440471,0.00095591834,0.00014182295],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011421777,0.00009712083,0.00032883356,0.000046339865,0.000033570173,0.00000753405,0.00009323203,0.00007842749,0.9947042],"category_scores_gemma":[0.010146831,0.000093209645,0.00006849454,0.00024742284,0.000026878357,0.00005170019,0.0002212067,0.00024701882,0.00011193965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018372813,0.0007154367,0.0012812346,0.00057547376,0.00007230752,0.000017738663,0.00016462183,0.000002447064,0.000028002025,7.5233436e-7,0.9925192,0.0044390555],"study_design_scores_gemma":[0.002049375,0.0008343796,0.3400248,0.0017710227,0.00003100864,0.000014219331,0.00022485024,0.00043740906,0.0009247119,0.000017808869,0.65357774,0.000092661874],"about_ca_topic_score_codex":0.000009484501,"about_ca_topic_score_gemma":0.000046799432,"teacher_disagreement_score":0.99459225,"about_ca_system_score_codex":0.0000527139,"about_ca_system_score_gemma":0.00067417405,"threshold_uncertainty_score":0.9981911},"labels":[],"label_agreement":null},{"id":"W6902023125","doi":"10.6084/m9.figshare.14211570","title":"Additional file 2 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Schematic; Clinical trial; Event (particle physics); Troubleshooting; Table (database)","score_opus":0.14765557452903916,"score_gpt":0.43310266191126606,"score_spread":0.2854470873822269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902023125","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008038114,0.000100098914,2.2391455e-7,0.000064966334,0.000019295734,0.0005790161,0.9881556,0.000016405527,0.0030262934],"genre_scores_gemma":[0.19581129,0.000009704297,0.0003188928,0.00006342014,0.0001787875,0.00029881077,0.80253166,0.00002048289,0.0007669349],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830365,0.00012904895,0.0005638309,0.00029066618,0.000554219,0.00015857125],"domain_scores_gemma":[0.9960212,0.002395472,0.00014219235,0.00034387343,0.00095541903,0.00014180611],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011345404,0.00009709216,0.00032879182,0.000046301197,0.000033555003,0.000007532566,0.00009327808,0.00007844132,0.9948595],"category_scores_gemma":[0.010127669,0.00009318802,0.000068475434,0.000247273,0.000026869333,0.000051681873,0.00022134876,0.00024706958,0.00011218078],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018221108,0.00071396196,0.0012339597,0.0005742378,0.00007225342,0.000017932938,0.00016419646,0.0000024546157,0.000027083666,7.56941e-7,0.99246806,0.004542898],"study_design_scores_gemma":[0.0020141113,0.0008199572,0.3290142,0.0017182665,0.000030460727,0.000014021059,0.00021931116,0.00042508988,0.0008956884,0.000017438771,0.66474044,0.00009101037],"about_ca_topic_score_codex":0.000009683183,"about_ca_topic_score_gemma":0.00004647114,"teacher_disagreement_score":0.99474734,"about_ca_system_score_codex":0.00005271673,"about_ca_system_score_gemma":0.00067254226,"threshold_uncertainty_score":0.99821043},"labels":[],"label_agreement":null},{"id":"W6902125348","doi":"10.6084/m9.figshare.14211591","title":"Additional file 9 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Listing (finance); Clinical trial; Subpoena; Data file","score_opus":0.14997297660444242,"score_gpt":0.4332336874999872,"score_spread":0.2832607108955448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902125348","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008161084,0.000099416,2.3246612e-7,0.000065395485,0.000019195515,0.0005806108,0.98809177,0.000016419424,0.0029658603],"genre_scores_gemma":[0.203448,0.000009589576,0.0003227337,0.00006352893,0.00017631275,0.0002967945,0.79490215,0.00002050876,0.00076038827],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998303,0.0001290589,0.0005640298,0.00029079255,0.0005544485,0.00015864435],"domain_scores_gemma":[0.99600506,0.0024111753,0.00014200373,0.0003440471,0.00095591834,0.00014182295],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011421777,0.00009712083,0.00032883356,0.000046339865,0.000033570173,0.00000753405,0.00009323203,0.00007842749,0.9947042],"category_scores_gemma":[0.010146831,0.000093209645,0.00006849454,0.00024742284,0.000026878357,0.00005170019,0.0002212067,0.00024701882,0.00011193965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018372813,0.0007154367,0.0012812346,0.00057547376,0.00007230752,0.000017738663,0.00016462183,0.000002447064,0.000028002025,7.5233436e-7,0.9925192,0.0044390555],"study_design_scores_gemma":[0.002049375,0.0008343796,0.3400248,0.0017710227,0.00003100864,0.000014219331,0.00022485024,0.00043740906,0.0009247119,0.000017808869,0.65357774,0.000092661874],"about_ca_topic_score_codex":0.000009484501,"about_ca_topic_score_gemma":0.000046799432,"teacher_disagreement_score":0.99459225,"about_ca_system_score_codex":0.0000527139,"about_ca_system_score_gemma":0.00067417405,"threshold_uncertainty_score":0.9981911},"labels":[],"label_agreement":null},{"id":"W6920486473","doi":"10.6084/m9.figshare.14211567.v1","title":"Additional file 1 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Listing (finance); Table (database); Clinical trial; Data collection; Subpoena","score_opus":0.1531541678876461,"score_gpt":0.43397828516669323,"score_spread":0.2808241172790471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920486473","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008094751,0.0000983519,2.2921468e-7,0.000065314984,0.000019167863,0.0005799662,0.98817366,0.00001640487,0.0029521245],"genre_scores_gemma":[0.19841622,0.000009416664,0.000326178,0.00006331144,0.00017565025,0.00030468643,0.79992115,0.00002048027,0.00076291926],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983034,0.00012909647,0.0005635542,0.0002909036,0.00055436924,0.00015863475],"domain_scores_gemma":[0.9959803,0.0024332698,0.00014199734,0.00034464843,0.00095788884,0.00014185061],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011413399,0.00009712587,0.000328704,0.000046334306,0.00003355232,0.0000075147605,0.000093334784,0.000078440826,0.99496466],"category_scores_gemma":[0.010261427,0.000093221286,0.0000684899,0.00024748297,0.000026869739,0.000051643245,0.00022138275,0.00024713168,0.00011350185],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018334553,0.00071439316,0.0012783991,0.00056875416,0.00007227062,0.000017416442,0.0001640861,0.0000024424087,0.000028152763,7.428481e-7,0.9925601,0.0044098967],"study_design_scores_gemma":[0.0020154503,0.000826476,0.33623937,0.0017558502,0.00003083034,0.000014100949,0.00022358466,0.00043169566,0.0009091418,0.000017429089,0.6574441,0.0000919613],"about_ca_topic_score_codex":0.000009577775,"about_ca_topic_score_gemma":0.00004617277,"teacher_disagreement_score":0.9948512,"about_ca_system_score_codex":0.000052700252,"about_ca_system_score_gemma":0.00067582255,"threshold_uncertainty_score":0.99807554},"labels":[],"label_agreement":null},{"id":"W6920583159","doi":"10.6084/m9.figshare.14211588","title":"Additional file 8 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Listing (finance); Table (database); Key (lock); Subpoena; Data file","score_opus":0.1500435749855026,"score_gpt":0.43330015212976836,"score_spread":0.2832565771442658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920583159","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008199682,0.00009942502,2.3221608e-7,0.000065389766,0.00001919368,0.0005807607,0.9880352,0.000016298409,0.0029837915],"genre_scores_gemma":[0.20391929,0.000009459273,0.0003230141,0.00006349506,0.00017618254,0.0002989502,0.79442304,0.000020480878,0.00076606683],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830306,0.0001290644,0.00056403334,0.000290829,0.00055436936,0.00015865939],"domain_scores_gemma":[0.9960044,0.0024115846,0.00014202323,0.00034415754,0.00095598114,0.00014184353],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011424328,0.00009713346,0.00032889043,0.000046328016,0.000033568143,0.0000075356884,0.00009330521,0.000078441524,0.9947301],"category_scores_gemma":[0.010147389,0.00009322162,0.00006849633,0.00024727624,0.000026879025,0.000051692878,0.00022127216,0.0002471151,0.00011244937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018368707,0.00071522704,0.001270191,0.00057539315,0.00007230549,0.000017738403,0.0001645877,0.0000024469077,0.0000277586,7.636234e-7,0.99240804,0.0045618885],"study_design_scores_gemma":[0.0020557186,0.0008383145,0.33879334,0.0017758033,0.00003109495,0.000014258163,0.0002253908,0.00043856577,0.00094071217,0.000017852366,0.65477604,0.00009292715],"about_ca_topic_score_codex":0.00000968547,"about_ca_topic_score_gemma":0.0000468781,"teacher_disagreement_score":0.99461764,"about_ca_system_score_codex":0.000052725725,"about_ca_system_score_gemma":0.00067459204,"threshold_uncertainty_score":0.9981906},"labels":[],"label_agreement":null},{"id":"W6920611533","doi":"10.6084/m9.figshare.14211570.v1","title":"Additional file 2 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Schematic; Clinical trial; Event (particle physics); Troubleshooting; Table (database)","score_opus":0.14765557452903916,"score_gpt":0.43310266191126606,"score_spread":0.2854470873822269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920611533","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008038114,0.000100098914,2.2391455e-7,0.000064966334,0.000019295734,0.0005790161,0.9881556,0.000016405527,0.0030262934],"genre_scores_gemma":[0.19581129,0.000009704297,0.0003188928,0.00006342014,0.0001787875,0.00029881077,0.80253166,0.00002048289,0.0007669349],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830365,0.00012904895,0.0005638309,0.00029066618,0.000554219,0.00015857125],"domain_scores_gemma":[0.9960212,0.002395472,0.00014219235,0.00034387343,0.00095541903,0.00014180611],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011345404,0.00009709216,0.00032879182,0.000046301197,0.000033555003,0.000007532566,0.00009327808,0.00007844132,0.9948595],"category_scores_gemma":[0.010127669,0.00009318802,0.000068475434,0.000247273,0.000026869333,0.000051681873,0.00022134876,0.00024706958,0.00011218078],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018221108,0.00071396196,0.0012339597,0.0005742378,0.00007225342,0.000017932938,0.00016419646,0.0000024546157,0.000027083666,7.56941e-7,0.99246806,0.004542898],"study_design_scores_gemma":[0.0020141113,0.0008199572,0.3290142,0.0017182665,0.000030460727,0.000014021059,0.00021931116,0.00042508988,0.0008956884,0.000017438771,0.66474044,0.00009101037],"about_ca_topic_score_codex":0.000009683183,"about_ca_topic_score_gemma":0.00004647114,"teacher_disagreement_score":0.99474734,"about_ca_system_score_codex":0.00005271673,"about_ca_system_score_gemma":0.00067254226,"threshold_uncertainty_score":0.99821043},"labels":[],"label_agreement":null},{"id":"W6921037962","doi":"10.6084/m9.figshare.23505264","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","score_opus":0.040559955304512625,"score_gpt":0.35173738428798557,"score_spread":0.31117742898347295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921037962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93406975,0.000043603603,0.0000011774287,0.0002097473,0.000026756254,0.0044552023,0.060962845,0.000002266436,0.00022863896],"genre_scores_gemma":[0.98538953,0.00013568328,0.00077923184,0.000011989998,0.00002764034,0.0014755969,0.011748008,0.000038827246,0.00039346336],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9978064,0.00015346614,0.00048820925,0.00051093625,0.0007116462,0.00032937858],"domain_scores_gemma":[0.99805593,0.0008612424,0.00026880382,0.00020011037,0.00033472825,0.00027917055],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003639055,0.00025540503,0.00071108417,0.00037057133,0.00007705942,0.000042730688,0.00011110244,0.000062330284,0.018498424],"category_scores_gemma":[0.00020046598,0.00020516434,0.00002972344,0.0007423483,0.00038873195,0.000331377,0.00015027661,0.00022896078,0.0000029490334],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9673342,0.002095164,0.0010889291,0.000116707924,0.00024101259,0.00008503023,0.0011360401,0.000016568249,0.000083242354,0.0000014469314,0.005819747,0.021981904],"study_design_scores_gemma":[0.8669022,0.010904407,0.11881745,0.0014311265,0.0001894582,0.0000057838174,0.00037627542,0.00064680295,0.0001793159,0.0000104911505,0.00029220092,0.00024451248],"about_ca_topic_score_codex":0.00076320505,"about_ca_topic_score_gemma":0.0005568713,"teacher_disagreement_score":0.117728524,"about_ca_system_score_codex":0.00021833037,"about_ca_system_score_gemma":0.0008055473,"threshold_uncertainty_score":0.9823988},"labels":[],"label_agreement":null},{"id":"W6921278677","doi":"10.6084/m9.figshare.26710013","title":"Additional file 1 of NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Neratinib; Metastatic breast cancer; Breast cancer; Trastuzumab emtansine; Clinical trial; Phases of clinical research; Cancer","score_opus":0.08063681552332634,"score_gpt":0.41486271223250426,"score_spread":0.3342258967091779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921278677","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007964432,0.00021606896,9.162057e-7,0.00042741973,0.000025738242,0.001597353,0.98780286,0.00006945796,0.0018957607],"genre_scores_gemma":[0.07691124,0.0000042876777,0.0015245738,0.00033088002,0.00081911584,0.02080881,0.8949027,0.00015573029,0.004542661],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99703,0.00016536411,0.0004511122,0.00056536635,0.0012172468,0.00057088456],"domain_scores_gemma":[0.99721014,0.0015344674,0.00013788631,0.00028903573,0.00057853037,0.0002499152],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001818196,0.00030245256,0.0005621695,0.00026462701,0.00009689469,0.000067303794,0.00014913057,0.0000760751,0.99049795],"category_scores_gemma":[0.0013574387,0.00022316299,0.00006959701,0.0010000514,0.00006108329,0.00020192697,0.00007739415,0.0005536259,0.00041821794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028115297,0.0005550108,0.0000010906175,0.0010186483,0.00030286965,0.00065328967,0.0010304302,0.00005611429,0.00007183822,9.582416e-7,0.9421431,0.026051357],"study_design_scores_gemma":[0.14369743,0.060226183,0.0041006375,0.23338512,0.00043515392,0.0014838311,0.0026055144,0.01961463,0.0009449767,0.00003414815,0.5318728,0.0015995599],"about_ca_topic_score_codex":0.000105128245,"about_ca_topic_score_gemma":0.00032375765,"teacher_disagreement_score":0.99007976,"about_ca_system_score_codex":0.00082524645,"about_ca_system_score_gemma":0.004963897,"threshold_uncertainty_score":0.9100323},"labels":[],"label_agreement":null},{"id":"W6925137650","doi":"10.1594/pangaea.325075","title":"Water temperature real-time profiles from cruise 5188600 (DCQC)","year":2005,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cruise; Temperature measurement; Sea surface temperature; Ectotherm","score_opus":0.047459931808038855,"score_gpt":0.3465715143368315,"score_spread":0.2991115825287926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6925137650","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008023259,0.0010876537,9.590849e-10,0.0008764754,0.00014696625,0.0014564551,0.9945577,0.0001723919,0.0016221387],"genre_scores_gemma":[0.000004278206,0.00035965588,0.000059356847,0.0008255384,0.0053736456,0.0010873086,0.9798199,0.00013648736,0.012333807],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961643,0.0001338334,0.00049453013,0.0010167133,0.0012525575,0.0009380591],"domain_scores_gemma":[0.99693257,0.00016656282,0.0001171852,0.0018887089,0.00038022714,0.0005147417],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010907043,0.0006431344,0.0009185689,0.00026719103,0.00013088288,0.00018591485,0.0008040783,0.0013252799,0.9177327],"category_scores_gemma":[0.0006928409,0.0004533818,0.0002652113,0.00020427225,0.00002915112,0.00011036528,0.00038919196,0.0020069836,0.15446444],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011294481,0.00011022449,0.0000020729756,0.0014579914,0.00013474941,0.0009006923,0.00005044072,5.5912886e-7,0.0015126853,1.9384833e-8,0.9952696,0.00044803025],"study_design_scores_gemma":[0.00071899954,0.0001538843,0.00013889704,0.010198118,0.00009528891,0.00003880483,0.000007938826,0.0000046249,0.0064716605,0.0000026934579,0.9816609,0.0005081837],"about_ca_topic_score_codex":0.00048690275,"about_ca_topic_score_gemma":0.00011608712,"teacher_disagreement_score":0.7632683,"about_ca_system_score_codex":0.0004163771,"about_ca_system_score_gemma":0.00075949554,"threshold_uncertainty_score":0.9999712},"labels":[],"label_agreement":null},{"id":"W6927256940","doi":"10.25549/webster-c100-10089","title":"Toward Community-Oriented Policing, 1987-01","year":2021,"lang":"en","type":"dataset","venue":"University of Southern California Digital Library","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Commission; Newspaper; Economic Justice; Variety (cybernetics); Criminal justice; Government (linguistics)","score_opus":0.026216559793152655,"score_gpt":0.23964924562996395,"score_spread":0.2134326858368113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6927256940","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0038454095,0.00019727914,0.000013852252,0.0008110795,0.00006354639,0.00032112683,0.9885563,0.00012826569,0.006063103],"genre_scores_gemma":[0.00067806855,0.00025760333,0.000115419316,0.0004117384,0.00018512199,4.603372e-7,0.9951132,0.000067737776,0.0031706362],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978265,0.00020346552,0.00033002405,0.00039164675,0.00075986364,0.0004884727],"domain_scores_gemma":[0.9978045,0.00017570789,0.00022832243,0.0011761246,0.00012530277,0.0004900242],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00013275944,0.00038236048,0.0007960657,0.00040145643,0.00020915398,0.00009566386,0.000806659,0.00047099375,0.008357238],"category_scores_gemma":[0.00013527957,0.00040874069,0.00040553836,0.0005543263,0.0005492643,0.00018782665,0.0013443077,0.0016890573,0.008208425],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003457877,0.00042656352,0.003191817,0.0012649407,0.00023616974,0.00072974816,0.00020643562,7.710297e-7,0.000004879552,0.000001746204,0.99299943,0.000591733],"study_design_scores_gemma":[0.0010154295,0.00018436047,0.0000372996,0.0009639084,0.00015425104,0.000062232015,0.0054441066,0.00000467748,0.000049919516,0.000036109606,0.99173135,0.00031638864],"about_ca_topic_score_codex":0.002398889,"about_ca_topic_score_gemma":0.0000643764,"teacher_disagreement_score":0.0065568765,"about_ca_system_score_codex":0.00015952621,"about_ca_system_score_gemma":0.0011278351,"threshold_uncertainty_score":0.99983644},"labels":[],"label_agreement":null},{"id":"W6929426964","doi":"10.5061/dryad.44jk0","title":"Data from: Acute, delayed and chronic remote ischemic conditioning is associated with downregulation of mTOR and enhanced autophagy signaling","year":2014,"lang":"en","type":"dataset","venue":"Data Archiving and Networked Services (DANS)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Autophagy; Cardioprotection; PI3K/AKT/mTOR pathway; Ischemia; AMPK; Ischemic preconditioning; Signal transduction; Downregulation and upregulation","score_opus":0.029391244070330582,"score_gpt":0.32030643246463,"score_spread":0.2909151883942994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929426964","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.22658609,0.0022993165,0.0008191262,0.00006795336,0.00005757819,0.0004488097,0.7696447,0.000044707722,0.000031720097],"genre_scores_gemma":[0.05395584,0.003979465,0.0012615974,0.00021964891,0.0005144762,0.000008876128,0.93995374,0.000060789574,0.000045569348],"study_design_codex":"not_applicable","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9965409,0.00027126065,0.00061650673,0.0014005805,0.0006289555,0.0005418215],"domain_scores_gemma":[0.9956527,0.0008984544,0.00059812673,0.002467925,0.00010006536,0.00028273105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009769583,0.00048241447,0.0009812333,0.00015257955,0.000271859,0.00014638106,0.0011295347,0.00031080274,0.00010861134],"category_scores_gemma":[0.00007640084,0.00041690946,0.000026410478,0.00027344713,0.00033226574,0.00038751797,0.0018219756,0.0008184948,0.000004235048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019312577,0.00014965778,0.00063739705,0.0064807823,0.0051103695,0.00014906129,0.0015062189,0.00018387199,0.06549192,0.0000016953525,0.9016136,0.016744157],"study_design_scores_gemma":[0.007977586,0.0012908381,0.011809224,0.02980268,0.0055581173,0.00018331812,0.0003088455,0.775267,0.0029146075,0.0001215372,0.16305174,0.0017144768],"about_ca_topic_score_codex":0.0031793488,"about_ca_topic_score_gemma":0.0048883683,"teacher_disagreement_score":0.7750831,"about_ca_system_score_codex":0.000083889136,"about_ca_system_score_gemma":0.0002740488,"threshold_uncertainty_score":0.9998283},"labels":[],"label_agreement":null},{"id":"W6929572632","doi":"10.5061/dryad.ksn02v785","title":"Data from: Palaeobiology and taphonomy of the rangeomorph (Culmofrons plumosa)","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland","funders":"","keywords":"Taphonomy; Paleobiology; Paleoecology; Clade; Phylogenetic tree; Lineage (genetic); Tree of life (biology)","score_opus":0.28176754424813694,"score_gpt":0.4568649326875173,"score_spread":0.17509738843938039,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6929572632","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019107673,0.0005804459,4.587411e-7,0.0019145075,0.0004430138,0.0013644157,0.9930124,0.0000012234583,0.0007727117],"genre_scores_gemma":[0.000051395276,0.00080873055,0.00030584162,0.00013699692,0.00029731463,0.000053524054,0.99527085,0.000028007571,0.003047333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804366,0.00019403806,0.00037218403,0.00074673415,0.0003247459,0.0003186198],"domain_scores_gemma":[0.99609977,0.0004122335,0.00019087402,0.0030880945,0.000064076135,0.00014492529],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00076973817,0.00021899724,0.00069213356,0.00008397187,0.000073153766,0.000057261088,0.0026350648,0.00033116635,0.008734809],"category_scores_gemma":[0.0005264783,0.000150237,0.000050310366,0.00023845508,0.0005006165,0.000057928944,0.005188954,0.0007156937,0.0031966579],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009765625,0.000048609494,0.00032610606,0.00007844113,0.00019783073,0.00007145878,0.000027333743,7.3332e-8,0.00014338516,1.0495395e-7,0.9910015,0.008007515],"study_design_scores_gemma":[0.0010011398,0.00009112458,0.002352069,0.00044603602,0.00026066968,0.000020600266,0.00009334936,0.000009790971,0.00018039353,0.000006529705,0.9953993,0.00013902449],"about_ca_topic_score_codex":0.014921274,"about_ca_topic_score_gemma":0.010574878,"teacher_disagreement_score":0.007868491,"about_ca_system_score_codex":0.000055381293,"about_ca_system_score_gemma":0.0009829615,"threshold_uncertainty_score":0.99757946},"labels":[],"label_agreement":null},{"id":"W6930097254","doi":"10.5281/zenodo.11031626","title":"Canadian University of Nigeria, Abuja 2024/2025 Admission form is on sale Now☎07066280862} Dr ANITA {O7066280862} For Admission help NOW!!!","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Hospital admission; Work (physics); Government (linguistics); Public health","score_opus":0.03782249664164417,"score_gpt":0.29061488684134423,"score_spread":0.25279239019970007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930097254","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032681052,0.0008243383,0.0002492568,0.008655533,0.0006159822,0.0027280063,0.004691711,0.00077029655,0.98113805],"genre_scores_gemma":[0.0031381657,0.0012392333,0.0004149377,0.0003909999,0.00069155014,2.266387e-7,0.0032470988,0.0075236945,0.9833541],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963094,0.00024381622,0.00040764626,0.001080519,0.0010467329,0.00091187534],"domain_scores_gemma":[0.99643534,0.000051095092,0.00021467776,0.0011969089,0.00076713215,0.0013348404],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00088857725,0.00044966882,0.00062254,0.0014530617,0.0010043397,0.00025477854,0.0012409744,0.00053502433,0.16476783],"category_scores_gemma":[0.0007119008,0.0004722743,0.000260862,0.0008760941,0.00023051661,0.00009987728,0.000857384,0.0010463324,0.026720092],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005461294,0.00015924951,0.0000068034283,0.0017653868,0.0001900987,0.00014715051,0.00068330194,9.064298e-7,0.0009524463,0.00024776548,0.97182226,0.023478493],"study_design_scores_gemma":[0.0012432794,0.0013039166,0.000054198415,0.0021786503,0.00011256076,0.00006120814,0.0005476354,0.0001243964,0.00052744406,0.00011307447,0.99333376,0.0003998638],"about_ca_topic_score_codex":0.0043930486,"about_ca_topic_score_gemma":0.001051708,"teacher_disagreement_score":0.13804774,"about_ca_system_score_codex":0.0015505801,"about_ca_system_score_gemma":0.00034114197,"threshold_uncertainty_score":0.9997729},"labels":[],"label_agreement":null},{"id":"W6930217236","doi":"10.5281/zenodo.12732406","title":"Binding Lost Love Spells Specialist in USA UK Canada +27787407632South Africa UAE Indonesia Singapore Turkey Luxembourg Finland Norway German Spain Sweden Malta Brunei Japan Ireland Iceland Australia Qatar Croatia Austria Denmark Netherlands Romania Oman","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Spell; German; Wife; North west; Quarter (Canadian coin); Scots; Kingdom","score_opus":0.04770322174299311,"score_gpt":0.29405115386045017,"score_spread":0.24634793211745706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930217236","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07800505,0.0006276151,0.000021325415,0.0009406318,0.00075113104,0.0021331527,0.0026044408,0.00011792256,0.91479874],"genre_scores_gemma":[0.16159375,0.00020546437,0.000078087985,0.00007099214,0.0017251374,1.4329413e-7,0.0019962634,0.006059065,0.8282711],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935835,0.0007121545,0.00092607364,0.0015074674,0.0017571246,0.0015136738],"domain_scores_gemma":[0.9970285,0.00008104187,0.00042132937,0.0012652155,0.0003259676,0.0008779189],"candidate_categories":["metaepi_narrow","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.001426332,0.0008232138,0.001022408,0.0015570652,0.00037328195,0.0012065694,0.0015038252,0.0006342242,0.36413243],"category_scores_gemma":[0.0004075171,0.00081476645,0.00016678854,0.0018505915,0.00039112015,0.00011989979,0.0012121582,0.0021388007,0.19712564],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003170324,0.00013012346,0.0025001934,0.0010548744,0.00031524847,0.0021553955,0.001454474,0.000009056884,0.00071320374,0.00007886751,0.9901936,0.0010779477],"study_design_scores_gemma":[0.0021429085,0.00036911745,0.011191177,0.0016455331,0.00017359128,0.00036831675,0.00036663417,0.00007932584,0.000054161927,0.000018100443,0.98280025,0.00079087773],"about_ca_topic_score_codex":0.09901806,"about_ca_topic_score_gemma":0.02881893,"teacher_disagreement_score":0.16700679,"about_ca_system_score_codex":0.0018175867,"about_ca_system_score_gemma":0.00024248539,"threshold_uncertainty_score":0.99983025},"labels":[],"label_agreement":null},{"id":"W6930334914","doi":"10.5281/zenodo.11789149","title":"Iso 17556 pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Nucleofection; Limiting; Point (geometry)","score_opus":0.04781651636468972,"score_gpt":0.31114694003018595,"score_spread":0.26333042366549625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930334914","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016163038,0.0018679515,0.0002451869,0.001895253,0.00037447255,0.0010096065,0.00042641445,0.0022504623,0.9919145],"genre_scores_gemma":[0.0009167027,0.00091566733,0.00024515655,0.00031868287,0.0013472949,1.4498393e-7,0.0022265147,0.020581273,0.9734486],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99691373,0.00025407216,0.0003178921,0.00084795884,0.0010070085,0.00065932295],"domain_scores_gemma":[0.99800855,0.000015356682,0.000102335405,0.0010580843,0.00036683358,0.00044881148],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006871498,0.00031992773,0.00041125034,0.0009092011,0.0004636751,0.0006809177,0.0009758033,0.0003151016,0.5240149],"category_scores_gemma":[0.0005970496,0.00031532298,0.00015023569,0.00089144683,0.00030443995,0.00005445748,0.0014435592,0.0011140548,0.5506451],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000502935,0.000098915436,7.957385e-7,0.0009154031,0.0001743014,0.00022430619,0.00020648226,4.206015e-7,0.00041562069,0.0008875464,0.95777017,0.039255746],"study_design_scores_gemma":[0.000528983,0.0003714527,0.000018671622,0.00081661856,0.000079446305,0.0003562159,0.00010293935,0.0000361917,0.00009662304,0.00011256999,0.9972016,0.00027865585],"about_ca_topic_score_codex":0.00008255047,"about_ca_topic_score_gemma":0.0000013744184,"teacher_disagreement_score":0.03943146,"about_ca_system_score_codex":0.0004332618,"about_ca_system_score_gemma":0.00002560008,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W6930357843","doi":"10.5281/zenodo.12043003","title":"giochi di investigazione per bambini pdf","year":2024,"lang":"it","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Roller coaster; Girl; Child health; Fantasy","score_opus":0.051503107063154814,"score_gpt":0.29596890428221656,"score_spread":0.24446579721906175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930357843","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003954153,0.004039325,0.0004594491,0.005586419,0.0012402447,0.0022626424,0.00095165445,0.0017097169,0.9833551],"genre_scores_gemma":[0.010056675,0.003134983,0.0002806246,0.00071476394,0.0036290814,5.410403e-7,0.004489273,0.02510545,0.9525886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.991567,0.0012616683,0.0009764327,0.0020814291,0.002383591,0.0017298395],"domain_scores_gemma":[0.9947773,0.00007693645,0.00030248944,0.002166654,0.00121013,0.001466487],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023081156,0.00086566573,0.0009580817,0.0016207703,0.0018427279,0.002305987,0.0026620594,0.0007319556,0.7070415],"category_scores_gemma":[0.0025258772,0.0008890374,0.00035299663,0.0019055817,0.0013144953,0.00021024904,0.0042708297,0.0030502274,0.83361286],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017278023,0.0003481568,0.000007016082,0.002556935,0.0005455195,0.00041007804,0.001626056,0.000006187126,0.0037546519,0.002667002,0.95103204,0.03687358],"study_design_scores_gemma":[0.0013717155,0.00106858,0.00020854473,0.0022833953,0.00028026328,0.0005153904,0.00055624405,0.00024727857,0.0003286851,0.00034159652,0.99199986,0.0007984475],"about_ca_topic_score_codex":0.0001438788,"about_ca_topic_score_gemma":0.0000021142746,"teacher_disagreement_score":0.12657137,"about_ca_system_score_codex":0.0013014573,"about_ca_system_score_gemma":0.00010460903,"threshold_uncertainty_score":0.99945676},"labels":[],"label_agreement":null},{"id":"W6930545875","doi":"10.5281/zenodo.12501376","title":"slow carb list pdf","year":2024,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Taste; Cruciferous vegetables; Bitter taste; Feeding behavior; JAMS; Food supply; Food intake; Food products","score_opus":0.043613550974797174,"score_gpt":0.304145419622963,"score_spread":0.2605318686481658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930545875","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020691985,0.0029377702,0.00014005716,0.001593764,0.0004311379,0.0010337093,0.00054242095,0.0021357683,0.9911647],"genre_scores_gemma":[0.0012241543,0.00084742735,0.00020066193,0.00028931943,0.0014982339,1.7045215e-7,0.0025681073,0.020141603,0.9732303],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967496,0.00027463457,0.0003303879,0.00088941364,0.0010734876,0.00068250723],"domain_scores_gemma":[0.9978582,0.000016351114,0.00010722861,0.0011163099,0.0004125687,0.00048929756],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00069982884,0.00034035984,0.00043739763,0.0008902108,0.00049477856,0.0007808096,0.0010165182,0.00032603732,0.45697412],"category_scores_gemma":[0.00066816725,0.00033827272,0.00015796849,0.00093124714,0.00034135286,0.000054019834,0.0014448611,0.0011794058,0.38093963],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005149644,0.00009591778,0.0000011473878,0.0011851457,0.00017954657,0.00028528806,0.00019961296,3.901124e-7,0.00050662726,0.000587905,0.96014947,0.03675746],"study_design_scores_gemma":[0.0005383483,0.0003555589,0.000016589936,0.0008745934,0.00008848223,0.0003505122,0.00009354337,0.000044778724,0.00011308179,0.000071250215,0.99715716,0.00029610243],"about_ca_topic_score_codex":0.0001968815,"about_ca_topic_score_gemma":0.0000033553893,"teacher_disagreement_score":0.07603448,"about_ca_system_score_codex":0.00051615393,"about_ca_system_score_gemma":0.000029670164,"threshold_uncertainty_score":0.99990696},"labels":[],"label_agreement":null},{"id":"W6930549519","doi":"10.5281/zenodo.13620871","title":"Fig. 1 in New evidence on brain-endocranial cavity relationships in ornithischian dinosaurs","year":2005,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Holotype; Indeterminate; Theropoda; Taxonomy (biology); Fossil Record","score_opus":0.10814675137179994,"score_gpt":0.33357886766103384,"score_spread":0.2254321162892339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930549519","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015873087,0.00077330705,0.00012815934,0.018138045,0.00019675687,0.0022113987,0.00023599846,0.0009072979,0.97582173],"genre_scores_gemma":[0.08283177,0.0017314844,0.0007993195,0.001497581,0.0024617675,6.507374e-7,0.0023622361,0.0154598225,0.89285535],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99567485,0.0010872112,0.000508347,0.0008878276,0.0010940264,0.00074771413],"domain_scores_gemma":[0.9979554,0.00021571165,0.0001749603,0.0009900982,0.00018859514,0.00047524495],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015595725,0.00034595287,0.00047875298,0.0016914854,0.00047170007,0.00030519874,0.0010252614,0.00035624742,0.09405245],"category_scores_gemma":[0.0078018415,0.00036924094,0.00008459889,0.0015013192,0.00021009303,0.0001588957,0.0006477073,0.0023914187,0.020572195],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031400134,0.00021920711,0.00030890087,0.00022964433,0.000027261887,0.00020453476,0.00067323184,0.000020557056,0.00020267844,0.0007277142,0.9364052,0.060667098],"study_design_scores_gemma":[0.0016039201,0.00041707253,0.007073881,0.0022245785,0.000016041828,0.00010656264,0.00009459332,0.000068396024,0.000033488825,0.000038451934,0.9880154,0.00030761462],"about_ca_topic_score_codex":0.0008077172,"about_ca_topic_score_gemma":0.00022583571,"teacher_disagreement_score":0.08296636,"about_ca_system_score_codex":0.0011864182,"about_ca_system_score_gemma":0.000119741024,"threshold_uncertainty_score":0.9999101},"labels":[],"label_agreement":null},{"id":"W6930604239","doi":"10.5281/zenodo.14920013","title":"Diplocardia verrucosa Ude 1895","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Dorsum; Groove (engineering); Adult male; Apex (geometry); Sucker","score_opus":0.03872318634108398,"score_gpt":0.31411062854216404,"score_spread":0.2753874422010801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6930604239","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029221283,0.00061067403,0.003173345,0.0063178325,0.00034102538,0.0011746032,0.00014709329,0.0015824446,0.9574317],"genre_scores_gemma":[0.97993904,0.0004349865,0.00047683404,0.001146622,0.00035784033,2.1651076e-7,0.001012853,0.0016948291,0.014936762],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99769443,0.00030118463,0.0002926485,0.00051368854,0.00064807746,0.0005499441],"domain_scores_gemma":[0.99808216,0.000042341486,0.000049726033,0.0008090582,0.0007245724,0.00029217012],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008813744,0.00016567863,0.000259206,0.0004375425,0.0013275231,0.000427723,0.0007565148,0.00010221979,0.014285888],"category_scores_gemma":[0.0013268165,0.00016943908,0.00010574216,0.0011547089,0.0002542461,0.00012677778,0.0011913439,0.0005532457,0.012340749],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028329197,0.0002199273,0.000113168106,0.00033570494,0.0001691944,0.00009237046,0.00046608184,0.000016220245,0.009370337,0.008284747,0.76884824,0.21180072],"study_design_scores_gemma":[0.0010494139,0.00026227915,0.0045733848,0.00015458153,0.000038705333,0.0001055255,0.00018790606,0.00021439613,0.0021638125,0.00024931278,0.9908605,0.00014017275],"about_ca_topic_score_codex":0.0000322793,"about_ca_topic_score_gemma":3.372607e-7,"teacher_disagreement_score":0.95071775,"about_ca_system_score_codex":0.00046450563,"about_ca_system_score_gemma":0.000030766343,"threshold_uncertainty_score":0.99997264},"labels":[],"label_agreement":null},{"id":"W6931022459","doi":"10.5281/zenodo.16566502","title":"CITAC NEWS 2025","year":2025,"lang":"en","type":"report","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Traceability; Comparability; Key (lock); Standardization; Consistency (knowledge bases)","score_opus":0.11269136907180899,"score_gpt":0.3648266176713024,"score_spread":0.25213524859949343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931022459","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027963903,0.0015979562,0.00048269195,0.0034441291,0.0007819693,0.0016991221,0.0008531571,0.0013055222,0.98955584],"genre_scores_gemma":[0.021137912,0.025611373,0.0010069201,0.001781719,0.0052385307,0.0000011262288,0.03839812,0.013747829,0.8930765],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941262,0.0005007375,0.0007470192,0.0011563146,0.0025267084,0.0009429982],"domain_scores_gemma":[0.9932674,0.000073319236,0.00024716594,0.0017235245,0.0041098,0.000578768],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0021202478,0.00044059934,0.0007534639,0.0011373321,0.0017122725,0.00086844433,0.0016155504,0.00048904563,0.06953413],"category_scores_gemma":[0.0056733126,0.00045421455,0.0002807755,0.0015518788,0.00032549677,0.0001297033,0.0027649738,0.001928118,0.018954115],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010854644,0.00014388759,0.000012103128,0.0012467351,0.00019073533,0.00015810257,0.00012645082,0.0000021187095,0.00032567803,0.0002499306,0.7717927,0.22564301],"study_design_scores_gemma":[0.0008265948,0.000454428,0.00043288514,0.0009364544,0.000140609,0.0004766178,0.00014444275,0.000033068984,0.00016925225,0.00007763999,0.9959622,0.00034580549],"about_ca_topic_score_codex":0.00035247466,"about_ca_topic_score_gemma":0.0000027687308,"teacher_disagreement_score":0.2252972,"about_ca_system_score_codex":0.002147477,"about_ca_system_score_gemma":0.0003520341,"threshold_uncertainty_score":0.99979097},"labels":[],"label_agreement":null},{"id":"W6931161418","doi":"10.5281/zenodo.3866890","title":"Ommatoiulus imminutus","year":2017,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Research (Canada)","funders":"","keywords":"Schizophyllum commune; Distribution (mathematics); Process (computing); Identification (biology)","score_opus":0.07695822765553972,"score_gpt":0.3297608615452099,"score_spread":0.25280263388967017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931161418","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.054906774,0.00023486454,0.0007995739,0.007782751,0.00028853884,0.0009930307,0.00015126001,0.0010501721,0.933793],"genre_scores_gemma":[0.98839545,0.0002145495,0.00037639274,0.00026954492,0.0004540212,9.1281706e-8,0.00045587547,0.0017602829,0.008073762],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978631,0.00016398616,0.00025041524,0.00046566656,0.0006946933,0.00056212547],"domain_scores_gemma":[0.9971972,0.000018667813,0.00012468564,0.0015271509,0.000716697,0.00041556198],"candidate_categories":["sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00091525353,0.00015382626,0.00022629948,0.00020847678,0.0043647583,0.0012642021,0.0014202495,0.00009318501,0.019814761],"category_scores_gemma":[0.001999013,0.00015306863,0.000084956504,0.00020075803,0.0004215486,0.00024810198,0.0016898008,0.00047947242,0.022784395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030301698,0.00023341515,0.00015526701,0.00023873955,0.00009409697,0.00026633526,0.00076444744,0.0000031243626,0.008922878,0.003956144,0.48829743,0.4967651],"study_design_scores_gemma":[0.001090679,0.0003623181,0.008904534,0.00009010244,0.000019169554,0.00041362125,0.00014740678,0.0001839532,0.0021896202,0.0001515448,0.98629045,0.00015656641],"about_ca_topic_score_codex":0.00006978128,"about_ca_topic_score_gemma":6.4018894e-7,"teacher_disagreement_score":0.9334887,"about_ca_system_score_codex":0.00029655918,"about_ca_system_score_gemma":0.000016358654,"threshold_uncertainty_score":0.9997726},"labels":[],"label_agreement":null},{"id":"W6931360755","doi":"10.5281/zenodo.5555408","title":"stfxecutables/error-consistency: v0.3.2-alpha","year":2021,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Francis Xavier University","funders":"","keywords":"Process (computing); Identification (biology); Product (mathematics); Work (physics)","score_opus":0.07234457896070746,"score_gpt":0.3187038909340337,"score_spread":0.24635931197332622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931360755","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000102271275,0.0031945338,0.00030478663,0.0019054341,0.00033648437,0.0011864473,0.0004925215,0.0016491666,0.99082834],"genre_scores_gemma":[0.0037773827,0.0016986947,0.0009248372,0.0006535053,0.0013076729,3.4427612e-7,0.00871577,0.022080312,0.9608415],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563485,0.0005563311,0.00046846824,0.0010904332,0.0013330625,0.00091682986],"domain_scores_gemma":[0.99659,0.000035098587,0.00021078618,0.0015824283,0.00095116044,0.00063051755],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00085570576,0.00042799313,0.0006707292,0.0008244724,0.0010532036,0.00063296076,0.0011784456,0.00041791314,0.3693186],"category_scores_gemma":[0.0013363765,0.00045054228,0.00020559807,0.0011631435,0.0004400639,0.000066592074,0.0017206415,0.0011420882,0.021790506],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006774699,0.00022163377,0.000006372435,0.00088026817,0.00024820186,0.00039749083,0.00025748622,0.0000010114657,0.0011903485,0.00076540455,0.9480425,0.047921523],"study_design_scores_gemma":[0.001039735,0.0003545861,0.00012087489,0.0009270954,0.00008743907,0.00067350274,0.00031486817,0.000045262874,0.00022475726,0.000039990693,0.99577296,0.00039894175],"about_ca_topic_score_codex":0.00018473911,"about_ca_topic_score_gemma":0.000004775214,"teacher_disagreement_score":0.3475281,"about_ca_system_score_codex":0.00056881795,"about_ca_system_score_gemma":0.000088723405,"threshold_uncertainty_score":0.99979466},"labels":[],"label_agreement":null},{"id":"W6931538674","doi":"10.5281/zenodo.8249834","title":"Nobel Prize and Europe(s). Prix Nobel : un esprit européen ?","year":2019,"lang":"fr","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"General interest; Czech; Twenty-First Century","score_opus":0.0357360313191603,"score_gpt":0.28054597017727323,"score_spread":0.24480993885811292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6931538674","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09725926,0.021841735,0.001493974,0.029479083,0.0026533476,0.0052164434,0.0010920567,0.0019555995,0.8390085],"genre_scores_gemma":[0.59896475,0.024577342,0.002808311,0.0030770581,0.00438062,7.0912324e-7,0.0028553598,0.017510993,0.34582484],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99318236,0.0015176537,0.00074966473,0.0014038011,0.0014818315,0.0016646746],"domain_scores_gemma":[0.99518317,0.00015401102,0.00022871737,0.0015609475,0.0017479247,0.001125258],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0026739836,0.000516112,0.00061315123,0.0005385564,0.0018126605,0.0013312177,0.0016886507,0.00028568687,0.10876111],"category_scores_gemma":[0.002569217,0.0005668112,0.00012755334,0.0017837585,0.0008266133,0.000502742,0.0039794445,0.0016109052,0.14697881],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005947099,0.000839194,0.0003312118,0.002363014,0.00035544622,0.00049767515,0.002635264,0.00003266099,0.029018333,0.019240897,0.32475773,0.61933386],"study_design_scores_gemma":[0.0027907267,0.0015966448,0.0059349416,0.00069801405,0.0001052018,0.0009013015,0.00035894965,0.0012746557,0.0013638207,0.000109646826,0.9843299,0.0005362434],"about_ca_topic_score_codex":0.0001012239,"about_ca_topic_score_gemma":6.867289e-7,"teacher_disagreement_score":0.6595721,"about_ca_system_score_codex":0.0005807763,"about_ca_system_score_gemma":0.000067267305,"threshold_uncertainty_score":0.9997055},"labels":[],"label_agreement":null},{"id":"W6939471573","doi":"10.6084/m9.figshare.14211579.v1","title":"Additional file 5 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Toxicity; Alkaline phosphatase; Alanine aminotransferase; Glutamate dehydrogenase; Alanine; Aspartate Aminotransferases","score_opus":0.15003309822266772,"score_gpt":0.4333167021039686,"score_spread":0.2832836038813009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939471573","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008166533,0.00009924622,2.3161793e-7,0.0000652734,0.000019192921,0.0005807525,0.9880932,0.00001641847,0.0029591336],"genre_scores_gemma":[0.20339644,0.000009571818,0.00032256983,0.0000634242,0.00017606794,0.00029866397,0.7949563,0.00002049152,0.0007564594],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830294,0.00012906114,0.0005640342,0.00029083766,0.00055449246,0.00015863715],"domain_scores_gemma":[0.9960057,0.0024107103,0.00014200323,0.00034411933,0.00095563015,0.0001418234],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011424161,0.00009712888,0.00032888894,0.000046339,0.000033569275,0.000007532515,0.000093307106,0.000078444995,0.9947269],"category_scores_gemma":[0.010146259,0.00009321657,0.00006850114,0.00024743506,0.000026877316,0.00005169526,0.000221312,0.00024709967,0.00011145105],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018369958,0.00071533385,0.00128012,0.0005753088,0.000072293326,0.000017736045,0.00016437861,0.0000024415842,0.000028016562,7.6882657e-7,0.99246955,0.004490371],"study_design_scores_gemma":[0.0020501502,0.0008341783,0.3428379,0.0017700735,0.00003100654,0.000014216349,0.00022484911,0.00043374038,0.0009240058,0.000017700595,0.65076953,0.000092651935],"about_ca_topic_score_codex":0.000009698932,"about_ca_topic_score_gemma":0.00004691448,"teacher_disagreement_score":0.99461544,"about_ca_system_score_codex":0.00005271856,"about_ca_system_score_gemma":0.00067427417,"threshold_uncertainty_score":0.9981917},"labels":[],"label_agreement":null},{"id":"W6939613204","doi":"10.6084/m9.figshare.25143611","title":"Additional file 1 of Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments","year":2024,"lang":"en","type":"article","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Jewish General Hospital","funders":"","keywords":"Immunofluorescence; Antibody; Staining; Monoclonal antibody","score_opus":0.06469028045558681,"score_gpt":0.4069933686294916,"score_spread":0.34230308817390476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939613204","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24652047,0.00079345645,0.000010857013,0.0038504417,0.0005154876,0.0026622335,0.47618887,0.0000068858826,0.2694513],"genre_scores_gemma":[0.5565821,0.00008405312,0.024565874,0.0004446024,0.00097307516,0.0005564146,0.016113836,0.00013586646,0.4005442],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987817,0.00006543519,0.00034900242,0.00025423765,0.00037413763,0.00017550577],"domain_scores_gemma":[0.9989295,0.0005625794,0.00006672974,0.00032896874,0.000034932666,0.00007731402],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029148353,0.00007855384,0.00020931428,0.000036871585,0.000028688348,0.000025979105,0.00033849367,0.000033806315,0.9436436],"category_scores_gemma":[0.00036266824,0.000055193184,0.00010042522,0.00013868128,0.00022670848,0.000076044336,0.00043998804,0.000256001,0.0009986354],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053173295,0.00014046705,0.0012094309,0.000060842045,0.00005171266,0.000022189446,0.00006835383,0.0000016285766,0.002490493,8.048433e-7,0.9611059,0.034795024],"study_design_scores_gemma":[0.00035847587,0.000067219386,0.055490192,0.0011253234,0.00003082522,0.00002616021,0.000055754117,0.0003120507,0.0079773925,0.00003042348,0.9344736,0.000052627434],"about_ca_topic_score_codex":0.00005512328,"about_ca_topic_score_gemma":0.0000071805134,"teacher_disagreement_score":0.94264495,"about_ca_system_score_codex":0.00006171095,"about_ca_system_score_gemma":0.00037528176,"threshold_uncertainty_score":0.9997792},"labels":[],"label_agreement":null},{"id":"W6943188177","doi":"10.15468/dl.qxbq9d","title":"Occurrence Download","year":2022,"lang":"en","type":"dataset","venue":"Global Biodiversity Information Facility","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Download; Matching (statistics); Range (aeronautics); Task (project management); Reference data","score_opus":0.03529397703872908,"score_gpt":0.2980316917159591,"score_spread":0.26273771467723006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6943188177","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034237266,0.0000565855,9.672461e-7,0.000582362,0.0006504539,0.0007469427,0.99701834,0.000102391496,0.00049960427],"genre_scores_gemma":[0.000007051077,0.00022106689,0.0000013710073,0.0012119872,0.000002855786,0.000018528683,0.9985363,2.5799594e-8,8.345624e-7],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972494,0.00010543627,0.00044329473,0.0003011477,0.001461012,0.0004396584],"domain_scores_gemma":[0.9982303,0.000026671096,0.00021832301,0.00084405515,0.00033909743,0.0003415608],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000535743,0.00028508698,0.0004134312,0.00017158147,0.00037151997,0.00009232718,0.00054039015,0.00030855392,0.17465912],"category_scores_gemma":[0.00034738483,0.00029727162,0.00021649271,0.0005892249,0.0002292198,0.00042730177,0.0007734545,0.0008945243,0.13269065],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002447793,0.00007530857,0.0026615313,0.0006513761,0.00005517801,0.000022957436,0.000042490385,0.000003394054,5.9295548e-8,4.714734e-8,0.9935443,0.002698584],"study_design_scores_gemma":[0.0007277133,0.00018471718,0.00021715635,0.0000051032584,0.000087797016,0.000035500347,0.00020110766,1.13614405e-7,0.000002665122,3.1872935e-7,0.99829715,0.00024065071],"about_ca_topic_score_codex":0.0012636036,"about_ca_topic_score_gemma":0.000013065973,"teacher_disagreement_score":0.041968476,"about_ca_system_score_codex":0.0016821474,"about_ca_system_score_gemma":0.0008893685,"threshold_uncertainty_score":0.99994797},"labels":[],"label_agreement":null},{"id":"W6958178961","doi":"10.6084/m9.figshare.14211585","title":"Additional file 7 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Key (lock); File system; Data file; Data collection","score_opus":0.15007368053587383,"score_gpt":0.4332643322469285,"score_spread":0.2831906517110547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958178961","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008163672,0.000099331766,2.3196479e-7,0.00006529902,0.000019196596,0.0005806739,0.98809594,0.000016418871,0.0029592395],"genre_scores_gemma":[0.20245212,0.000009578792,0.0003220554,0.000063339816,0.0001758557,0.00029796286,0.795903,0.000020467134,0.0007555994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983029,0.00012902748,0.00056404487,0.00029087154,0.0005545008,0.00015866903],"domain_scores_gemma":[0.9960072,0.002409011,0.00014200219,0.00034414753,0.00095582125,0.00014184331],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000114239214,0.00009713658,0.00032889316,0.000046342524,0.000033570144,0.0000075368216,0.00009331843,0.000078442805,0.99464417],"category_scores_gemma":[0.010030739,0.00009322664,0.00006849698,0.00024743713,0.000026881735,0.000051702344,0.0002213309,0.00024712327,0.00011170932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018375032,0.00071568025,0.0012794371,0.0005811378,0.00007233673,0.000017746068,0.00016469818,0.0000024469825,0.000028107332,7.669745e-7,0.99243414,0.004519774],"study_design_scores_gemma":[0.0020553074,0.0008377601,0.33799043,0.0017935467,0.000031084415,0.000014248443,0.00022524066,0.00043802988,0.00093063444,0.00001783983,0.65557295,0.00009289941],"about_ca_topic_score_codex":0.000009705547,"about_ca_topic_score_gemma":0.00004693781,"teacher_disagreement_score":0.99453247,"about_ca_system_score_codex":0.000052728617,"about_ca_system_score_gemma":0.0006745132,"threshold_uncertainty_score":0.9983082},"labels":[],"label_agreement":null},{"id":"W6958297444","doi":"10.60692/q4x54-j6955","title":"Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies","year":2022,"lang":"en","type":"article","venue":"Greater South Information System","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Montréal","funders":"","keywords":"Downregulation and upregulation; Monoclonal antibody; Antibody; Polyclonal antibodies; Epitope; Receptor; Cytotoxicity","score_opus":0.057490557917117824,"score_gpt":0.3086334556016433,"score_spread":0.25114289768452547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958297444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99608076,0.00005427251,0.0002631466,0.00018699281,0.00014882367,0.0009349852,0.0001720598,0.000028902396,0.0021300842],"genre_scores_gemma":[0.9996921,0.0000020531193,0.00004460405,0.000010136631,0.000024828763,0.00005240792,0.0000658175,0.00001040887,0.00009767695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99780494,0.00030077668,0.00080858916,0.00011700592,0.000809509,0.0001592029],"domain_scores_gemma":[0.9985024,0.000088831184,0.0006160353,0.00045315476,0.00029200045,0.000047584388],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012272153,0.00013258032,0.00045513446,0.00035406917,0.00015048104,0.00002415419,0.000149878,0.000053731754,0.000044433626],"category_scores_gemma":[0.000057831163,0.00009252629,0.00009584398,0.0004411542,0.000142597,0.00019895186,0.00011896142,0.00014692469,0.000005228785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001231077,0.00002930504,0.9386828,0.006016176,0.00025429393,0.0000042846145,0.04451299,0.00012788753,0.005339664,0.001155204,0.00035102168,0.0022953202],"study_design_scores_gemma":[0.0046094987,0.0013609963,0.93666816,0.00058593915,0.00008976698,0.00013282194,0.0146384435,0.0012417068,0.04012215,0.0000026095622,0.0004094213,0.00013850258],"about_ca_topic_score_codex":0.00009643598,"about_ca_topic_score_gemma":5.281259e-7,"teacher_disagreement_score":0.034782488,"about_ca_system_score_codex":0.00011679917,"about_ca_system_score_gemma":0.000081493636,"threshold_uncertainty_score":0.37731126},"labels":[],"label_agreement":null},{"id":"W6958436557","doi":"10.6084/m9.figshare.21550986.v1","title":"Additional file 2 of The impact of facility-based transitional care programs on function and discharge destination for older adults with cognitive impairment: a systematic review","year":2022,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Transitional care; Cognition; Function (biology); Older people; MEDLINE; Aged care","score_opus":0.03563368801682821,"score_gpt":0.32996245237872124,"score_spread":0.29432876436189304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958436557","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003896494,0.0009348122,3.5238125e-7,0.000019760391,0.0000067350516,0.009722595,0.9892943,0.000009739095,0.00000784499],"genre_scores_gemma":[0.00022442646,0.0000067348738,0.0000072177636,0.00007708208,0.000024607702,0.036034856,0.9635944,0.000015922442,0.000014792747],"study_design_codex":"not_applicable","study_design_gemma":"systematic_review","domain_scores_codex":[0.9981457,0.00017080543,0.0003511366,0.00031009447,0.0008524238,0.00016986934],"domain_scores_gemma":[0.997247,0.0011123873,0.00041566193,0.00028078264,0.0008667956,0.000077373035],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000082747014,0.00022501647,0.00055522815,0.00009803714,0.00009153928,0.000010069273,0.000108939574,0.00009467664,0.95912486],"category_scores_gemma":[0.002270374,0.00013566868,0.00027442642,0.00026506782,0.00003287397,0.00003553074,0.000027837084,0.00031815207,0.000022727616],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038539956,0.00018665877,7.8511096e-7,0.38009995,0.00009456442,0.0000015244756,0.000025726922,8.6850946e-7,2.8773988e-8,2.0665789e-8,0.6191055,0.00009897296],"study_design_scores_gemma":[0.001566208,0.0031662611,0.0010599816,0.93450457,0.0004258411,0.000020108588,0.00015086171,0.000026442967,0.0000024205892,6.3831556e-7,0.05893455,0.00014213276],"about_ca_topic_score_codex":0.000016074426,"about_ca_topic_score_gemma":0.0000157303,"teacher_disagreement_score":0.9591021,"about_ca_system_score_codex":0.00025960346,"about_ca_system_score_gemma":0.0010839258,"threshold_uncertainty_score":0.55324084},"labels":[],"label_agreement":null},{"id":"W6958634373","doi":"10.6084/m9.figshare.c.3723055_d2.v1","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.16666382388697107,"score_gpt":0.3897621831193099,"score_spread":0.2230983592323388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958634373","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014361819,0.0005082104,6.600343e-8,0.00006703772,0.000007577904,0.0004911612,0.98437417,0.0000029175596,0.00018702052],"genre_scores_gemma":[0.7149737,0.000019357161,0.0006849789,0.000084028645,0.000021935006,0.0027140023,0.2812297,0.000013991699,0.00025834315],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986403,0.000140579,0.00036777207,0.00024833172,0.0004589088,0.00014413151],"domain_scores_gemma":[0.99694854,0.00161712,0.0005063172,0.00047765835,0.00039121098,0.000059174665],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000900179,0.00010388659,0.0006285227,0.00013563652,0.000039220282,0.00001435004,0.0002573965,0.000105225605,0.86368805],"category_scores_gemma":[0.016138358,0.000060228227,0.00034001673,0.00044635352,0.0000846356,0.00006176546,0.00015933967,0.0002494965,0.000005965383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098695265,0.0002824948,0.02115099,0.0005621959,0.0013242471,0.0000114590775,0.00012419293,0.000023862398,0.00013430824,2.3225664e-7,0.9752327,0.0010545917],"study_design_scores_gemma":[0.00038300164,0.0002737973,0.9830078,0.0042016604,0.0028000488,0.000001198862,0.00002114936,0.00012634422,0.001044941,0.000009190116,0.008052771,0.00007809781],"about_ca_topic_score_codex":0.000020993051,"about_ca_topic_score_gemma":0.000036732425,"teacher_disagreement_score":0.96717995,"about_ca_system_score_codex":0.0000307244,"about_ca_system_score_gemma":0.00015948684,"threshold_uncertainty_score":0.9921491},"labels":[],"label_agreement":null},{"id":"W6961280585","doi":"10.1371/journal.pone.0305485.t003","title":"Percent distribution of homeless individuals by episodes of homelessness, according to selected characteristics, Nipissing District, Ontario 2021.","year":2024,"lang":"en","type":"dataset","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Distribution (mathematics); Population; Statistical analysis","score_opus":0.03287647388166012,"score_gpt":0.3255246239496338,"score_spread":0.2926481500679736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6961280585","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010012358,0.000781893,0.0000020977477,0.00008603124,0.00023054227,0.0010627018,0.9877555,0.000036799098,0.000032126463],"genre_scores_gemma":[0.041548524,0.00012766733,0.000014612199,0.000020535259,0.00034674126,0.0002997805,0.95738536,0.000071219016,0.0001855625],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960431,0.000113244285,0.0010264515,0.00078678626,0.0013348206,0.0006955946],"domain_scores_gemma":[0.99700594,0.000253772,0.0004913455,0.00088281446,0.000976619,0.00038953582],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002300053,0.0005383104,0.0016629635,0.00038363226,0.000083112485,0.00013697373,0.00065955,0.0005639488,0.07449837],"category_scores_gemma":[0.0027263106,0.00051921624,0.00021829826,0.0013253111,0.000039972474,0.00009078365,0.0008610091,0.001228104,0.0020755406],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007843528,0.00021541731,0.0024783234,0.010464706,0.00021909885,0.00007344199,0.0001401705,4.6222334e-7,0.0001944904,2.2204098e-7,0.97848344,0.007651799],"study_design_scores_gemma":[0.0003772355,0.00028181018,0.027126016,0.02712744,0.00025584354,0.0000140775255,0.00014866494,0.0000059389577,0.0016475761,0.000001653272,0.9425836,0.00043014518],"about_ca_topic_score_codex":0.0045173992,"about_ca_topic_score_gemma":0.002092841,"teacher_disagreement_score":0.07242283,"about_ca_system_score_codex":0.0016694312,"about_ca_system_score_gemma":0.0022291832,"threshold_uncertainty_score":0.99972594},"labels":[],"label_agreement":null},{"id":"W6968976635","doi":"10.5281/zenodo.7224378","title":"FIGURES 4–10. Hydrocanthus debilis Sharp, 1882, instar I in Description and chaetotaxic analysis of the larval instars of Hydrocanthus debilis Sharp, 1882 (Coleoptera: Noteridae)","year":2022,"lang":"en","type":"other","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Instar; Dorsum; Seta; Larva; Predation","score_opus":0.03312751978464471,"score_gpt":0.26400192217898477,"score_spread":0.23087440239434007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968976635","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39340013,0.002840942,0.000080275866,0.00095900946,0.00029330113,0.0039582443,0.004424537,0.00060355506,0.59344],"genre_scores_gemma":[0.9341525,0.0021308926,0.0001593288,0.0002380188,0.0001786463,0.0000024803812,0.0031195919,0.004279129,0.055739436],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9952446,0.00075827417,0.00085136655,0.0009770385,0.001513027,0.0006556779],"domain_scores_gemma":[0.9973157,0.00008322314,0.0005239135,0.0013886088,0.00040866787,0.00027987084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011802575,0.00043009146,0.0010010926,0.0022832626,0.0005597827,0.00018235597,0.0014115071,0.00027841315,0.103724174],"category_scores_gemma":[0.0013493291,0.00039117946,0.0002813271,0.0035938055,0.00070865714,0.00015327401,0.002081353,0.0009387408,0.00024655677],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035222531,0.003209367,0.0087666735,0.008026886,0.00611494,0.00044173078,0.01473016,0.00080841687,0.021979945,0.0007676207,0.8310957,0.10053629],"study_design_scores_gemma":[0.0020102342,0.0009265086,0.019903693,0.00082387007,0.0006577569,0.00007390829,0.0006340197,0.0021876832,0.0006469904,0.000022959131,0.97164214,0.00047024508],"about_ca_topic_score_codex":0.002573053,"about_ca_topic_score_gemma":0.00057310885,"teacher_disagreement_score":0.54075235,"about_ca_system_score_codex":0.0007524271,"about_ca_system_score_gemma":0.00008917616,"threshold_uncertainty_score":0.999854},"labels":[],"label_agreement":null},{"id":"W6969419833","doi":"10.5281/zenodo.7246421","title":"Strange Quark as a probe for new physics in the Higgs sector","year":2022,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Higgs boson; Physics beyond the Standard Model; Top quark; Standard Model (mathematical formulation); Quark; Presentation (obstetrics)","score_opus":0.12336085945589462,"score_gpt":0.33110626193960085,"score_spread":0.20774540248370624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6969419833","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3720591,0.00234866,0.034485195,0.1036153,0.001214883,0.031385526,0.003117514,0.00398666,0.44778717],"genre_scores_gemma":[0.98684,0.00009909914,0.0007906797,0.001660862,0.0009849678,0.0000034027216,0.001896341,0.0022583345,0.0054662754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746656,0.00048255938,0.00024479174,0.00041309322,0.0008935759,0.00049940834],"domain_scores_gemma":[0.9988444,0.000073584706,0.000066591834,0.00056459755,0.00026689505,0.00018394254],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014073662,0.0001371806,0.0001840751,0.00017367386,0.0014395636,0.00028940762,0.0009947369,0.000039821025,0.018635858],"category_scores_gemma":[0.00058779796,0.00012254514,0.000084128515,0.0010139268,0.00010003725,0.00010622353,0.00063040294,0.0006459912,0.0014888623],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009345504,0.000675995,0.00009308207,0.00036156655,0.00007316253,0.000092739734,0.011121766,0.00013475446,0.0074335514,0.012351603,0.7939801,0.17274709],"study_design_scores_gemma":[0.0017304395,0.0014045426,0.00066080486,0.00003097443,0.000018152225,0.00017207906,0.001407705,0.00041207141,0.00040475413,0.00083987054,0.9927864,0.00013222058],"about_ca_topic_score_codex":0.00016658804,"about_ca_topic_score_gemma":0.0000016266382,"teacher_disagreement_score":0.6147809,"about_ca_system_score_codex":0.00043460907,"about_ca_system_score_gemma":0.000055820983,"threshold_uncertainty_score":0.9998604},"labels":[],"label_agreement":null},{"id":"W6976743783","doi":"10.6084/m9.figshare.25143611.v1","title":"Additional file 1 of Tunable PhenoCycler imaging of the murine pre-clinical tumour microenvironments","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; McGill University; Jewish General Hospital","funders":"","keywords":"Immunofluorescence; Antibody; Staining; Monoclonal antibody","score_opus":0.05643962261975415,"score_gpt":0.36165966343586975,"score_spread":0.3052200408161156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976743783","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042644228,0.00035769894,9.689031e-8,0.00027119945,0.000044036173,0.0002638573,0.9894061,0.000020659505,0.009209913],"genre_scores_gemma":[0.047385555,0.000009613346,0.00041523375,0.00032117273,0.00054333353,0.00068296626,0.9221299,0.000059925984,0.02845227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99880683,0.000046427802,0.00030117302,0.00021906718,0.00043543614,0.00019108028],"domain_scores_gemma":[0.9986407,0.0008497095,0.000066942135,0.00030262012,0.000060221762,0.00007979538],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000060946964,0.00008717708,0.00017889064,0.000044084394,0.000025767082,0.000010533667,0.00019384814,0.000043527758,0.9971413],"category_scores_gemma":[0.002034672,0.00006290337,0.00015715469,0.00015819473,0.00004641796,0.000048337988,0.00023561675,0.00031292858,0.0026014084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000015755404,0.00006963641,0.00017756404,0.000595281,0.00003448042,0.00002166929,0.000021726004,0.0000017351153,0.00029962967,4.2354122e-7,0.9962704,0.0024916884],"study_design_scores_gemma":[0.00018058496,0.000041430976,0.07991151,0.00864064,0.000011891162,0.000021571006,0.000012458896,0.00041555916,0.0018012008,0.00001813778,0.9088939,0.000051142953],"about_ca_topic_score_codex":0.000008973656,"about_ca_topic_score_gemma":0.000001561444,"teacher_disagreement_score":0.9945399,"about_ca_system_score_codex":0.0000663153,"about_ca_system_score_gemma":0.0002935759,"threshold_uncertainty_score":0.9981752},"labels":[],"label_agreement":null},{"id":"W6976866888","doi":"10.6084/m9.figshare.14211585.v1","title":"Additional file 7 of Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal University Hospital; University of Saskatchewan","funders":"","keywords":"Table (database); Key (lock); File system; Data file; Data collection","score_opus":0.15007368053587383,"score_gpt":0.4332643322469285,"score_spread":0.2831906517110547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976866888","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.008163672,0.000099331766,2.3196479e-7,0.00006529902,0.000019196596,0.0005806739,0.98809594,0.000016418871,0.0029592395],"genre_scores_gemma":[0.20245212,0.000009578792,0.0003220554,0.000063339816,0.0001758557,0.00029796286,0.795903,0.000020467134,0.0007555994],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983029,0.00012902748,0.00056404487,0.00029087154,0.0005545008,0.00015866903],"domain_scores_gemma":[0.9960072,0.002409011,0.00014200219,0.00034414753,0.00095582125,0.00014184331],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000114239214,0.00009713658,0.00032889316,0.000046342524,0.000033570144,0.0000075368216,0.00009331843,0.000078442805,0.99464417],"category_scores_gemma":[0.010030739,0.00009322664,0.00006849698,0.00024743713,0.000026881735,0.000051702344,0.0002213309,0.00024712327,0.00011170932],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018375032,0.00071568025,0.0012794371,0.0005811378,0.00007233673,0.000017746068,0.00016469818,0.0000024469825,0.000028107332,7.669745e-7,0.99243414,0.004519774],"study_design_scores_gemma":[0.0020553074,0.0008377601,0.33799043,0.0017935467,0.000031084415,0.000014248443,0.00022524066,0.00043802988,0.00093063444,0.00001783983,0.65557295,0.00009289941],"about_ca_topic_score_codex":0.000009705547,"about_ca_topic_score_gemma":0.00004693781,"teacher_disagreement_score":0.99453247,"about_ca_system_score_codex":0.000052728617,"about_ca_system_score_gemma":0.0006745132,"threshold_uncertainty_score":0.9983082},"labels":[],"label_agreement":null},{"id":"W6976952699","doi":"10.6084/m9.figshare.23505264.v1","title":"Additional file 1 of XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Boehringer Ingelheim (Canada); Centre hospitalier universitaire de Québec","funders":"","keywords":"Exemestane; Everolimus; Metastatic breast cancer; Breast cancer; Phases of clinical research; Placebo; Clinical trial","score_opus":0.03896974722991319,"score_gpt":0.32600910823917123,"score_spread":0.28703936100925803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976952699","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4600076,0.000056096567,1.0624099e-7,0.00008258145,0.000011137686,0.0021182445,0.53766286,0.000009951464,0.000051444673],"genre_scores_gemma":[0.68841904,0.00005760514,0.00009140157,0.000017358123,0.000033607055,0.0030036757,0.30821812,0.000039538296,0.00011963962],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9979317,0.00011557849,0.00041981193,0.00044391057,0.0007548889,0.0003340862],"domain_scores_gemma":[0.9977632,0.0010754839,0.00025430878,0.00018015374,0.0004541654,0.00027265665],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012286633,0.00025989613,0.0006108195,0.0003938424,0.00006829347,0.000022258084,0.0000730392,0.00006982904,0.121031284],"category_scores_gemma":[0.00060194306,0.00021249469,0.000037047474,0.00076028943,0.00012751987,0.0002340261,0.000096278825,0.00025149144,0.000005348737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87754387,0.0014198965,0.0003354858,0.0005690258,0.00019358762,0.00008973094,0.00058237393,0.000018575203,0.000021438254,9.308171e-7,0.115118966,0.0041061398],"study_design_scores_gemma":[0.81523037,0.008644392,0.16828051,0.0059828493,0.000104767874,0.0000051227867,0.00015025755,0.00084688584,0.000069403846,0.000007828869,0.00042438522,0.00025321313],"about_ca_topic_score_codex":0.00022336654,"about_ca_topic_score_gemma":0.00019917343,"teacher_disagreement_score":0.22944471,"about_ca_system_score_codex":0.00022079749,"about_ca_system_score_gemma":0.0006446868,"threshold_uncertainty_score":0.8797722},"labels":[],"label_agreement":null},{"id":"W6977638607","doi":"10.6084/m9.figshare.c.3723055_d2","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"en","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.16666382388697107,"score_gpt":0.3897621831193099,"score_spread":0.2230983592323388,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977638607","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014361819,0.0005082104,6.600343e-8,0.00006703772,0.000007577904,0.0004911612,0.98437417,0.0000029175596,0.00018702052],"genre_scores_gemma":[0.7149737,0.000019357161,0.0006849789,0.000084028645,0.000021935006,0.0027140023,0.2812297,0.000013991699,0.00025834315],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9986403,0.000140579,0.00036777207,0.00024833172,0.0004589088,0.00014413151],"domain_scores_gemma":[0.99694854,0.00161712,0.0005063172,0.00047765835,0.00039121098,0.000059174665],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000900179,0.00010388659,0.0006285227,0.00013563652,0.000039220282,0.00001435004,0.0002573965,0.000105225605,0.86368805],"category_scores_gemma":[0.016138358,0.000060228227,0.00034001673,0.00044635352,0.0000846356,0.00006176546,0.00015933967,0.0002494965,0.000005965383],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000098695265,0.0002824948,0.02115099,0.0005621959,0.0013242471,0.0000114590775,0.00012419293,0.000023862398,0.00013430824,2.3225664e-7,0.9752327,0.0010545917],"study_design_scores_gemma":[0.00038300164,0.0002737973,0.9830078,0.0042016604,0.0028000488,0.000001198862,0.00002114936,0.00012634422,0.001044941,0.000009190116,0.008052771,0.00007809781],"about_ca_topic_score_codex":0.000020993051,"about_ca_topic_score_gemma":0.000036732425,"teacher_disagreement_score":0.96717995,"about_ca_system_score_codex":0.0000307244,"about_ca_system_score_gemma":0.00015948684,"threshold_uncertainty_score":0.9921491},"labels":[],"label_agreement":null},{"id":"W6979865066","doi":"","title":"Amélioration de la résistance à la fissuration des bétons projetés : composition des mélanges et mise en place = Improving the cracking resistance of shotcrete : mix designs and placement","year":2021,"lang":"fr","type":"other","venue":"Corpus Université Laval (Université Laval)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université Laval","keywords":"Construction industry; Impact resistance; Steel frame","score_opus":0.022353169429925327,"score_gpt":0.2759333595517896,"score_spread":0.2535801901218643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6979865066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7512543,0.05562369,0.015185768,0.004038063,0.00044215473,0.0032438622,0.00043639826,0.0002352454,0.16954048],"genre_scores_gemma":[0.72682697,0.049907185,0.010726201,0.0001177524,0.00035235053,0.000024132534,0.00034295017,0.00031398592,0.21138847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99463123,0.0026868253,0.0003704637,0.00081350195,0.00078961044,0.00070834026],"domain_scores_gemma":[0.9960283,0.0019533024,0.00054118014,0.0006079036,0.00054909446,0.00032020238],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017018089,0.0005656507,0.0006807803,0.0004927003,0.0008505464,0.00017347555,0.00052940164,0.0006113658,0.00031142528],"category_scores_gemma":[0.00026780964,0.000591052,0.0002023525,0.0009073691,0.0013392217,0.00035474973,0.00037706445,0.0009619252,0.0000043906525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032409616,0.00036464114,0.020086266,0.006885347,0.00088619563,0.002044893,0.08677103,0.00080166484,0.82041585,0.018156527,0.002262778,0.03808385],"study_design_scores_gemma":[0.015650352,0.0025613108,0.118216746,0.0399515,0.0059402534,0.0010741545,0.17555879,0.007942812,0.32340083,0.0012594783,0.3049078,0.0035359492],"about_ca_topic_score_codex":0.006433428,"about_ca_topic_score_gemma":0.036392312,"teacher_disagreement_score":0.497015,"about_ca_system_score_codex":0.0032367697,"about_ca_system_score_gemma":0.0018132845,"threshold_uncertainty_score":0.9996541},"labels":[],"label_agreement":null},{"id":"W6982897497","doi":"","title":"La partecipazione digitale alla governance urbana attraverso i mapping collaborativi: approcci metodologici ed esempi","year":2023,"lang":"it","type":"article","venue":"Aisberg (University of Bergamo)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute on Governance","funders":"","keywords":"Corporate governance; Context (archaeology); Field (mathematics); Perspective (graphical); Work (physics)","score_opus":0.06905225047434815,"score_gpt":0.29495766296551534,"score_spread":0.2259054124911672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6982897497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8237553,0.005112458,0.00137152,0.014452136,0.0012956815,0.00237392,0.0013367432,0.0007170831,0.14958511],"genre_scores_gemma":[0.89487,0.007566702,0.00070287037,0.0001230195,0.0002535294,0.0000048184365,0.00017918654,0.00008793926,0.09621195],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99469656,0.0006210616,0.00053323864,0.001165302,0.0016082403,0.0013756177],"domain_scores_gemma":[0.9959081,0.0011308489,0.0005629526,0.0011516981,0.00063766923,0.0006087292],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016395118,0.0005582619,0.0012910066,0.00046562942,0.0005234048,0.00008258991,0.0011095321,0.0006748371,0.003975791],"category_scores_gemma":[0.0007252327,0.00069120486,0.00041903433,0.004211802,0.0012874398,0.0005976917,0.000925909,0.0010266582,0.0028497705],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015027701,0.0011067685,0.037995838,0.0025831598,0.0026878014,0.0056834635,0.023313446,0.0005075401,0.0097938245,0.004912766,0.8671091,0.04280351],"study_design_scores_gemma":[0.005746986,0.0010309491,0.12552845,0.0016345271,0.00046944688,0.000056295485,0.034977544,0.0021379876,0.0011016581,0.0003427757,0.82586944,0.0011039524],"about_ca_topic_score_codex":0.0019248091,"about_ca_topic_score_gemma":0.0008307324,"teacher_disagreement_score":0.08753261,"about_ca_system_score_codex":0.0008064271,"about_ca_system_score_gemma":0.0012313782,"threshold_uncertainty_score":0.9995539},"labels":[],"label_agreement":null},{"id":"W6986370126","doi":"","title":"Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations","year":2014,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pertuzumab; Trastuzumab; Breast cancer; Metastatic breast cancer; Disease; Clinical trial; Neratinib; Monoclonal antibody","score_opus":0.31423442667542384,"score_gpt":0.6089967220706151,"score_spread":0.2947622953951912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6986370126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490006,0.0038522736,0.00002812898,0.0049529914,0.0005868331,0.00091905566,0.00031822757,0.000029954705,0.004412473],"genre_scores_gemma":[0.987344,0.010209376,0.00017279529,0.0010366746,0.0007878818,0.00009920066,0.000019112898,0.000070792186,0.00026015725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99589926,0.0008817311,0.0014535708,0.00069762033,0.0005157761,0.00055201846],"domain_scores_gemma":[0.99650055,0.0014136778,0.0005315166,0.00047483997,0.0004165306,0.0006628686],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022354235,0.00033694998,0.0012989502,0.0007420526,0.00029974623,0.00067530165,0.0007644433,0.00021935851,0.03211706],"category_scores_gemma":[0.0009068632,0.00031300745,0.00019802699,0.00030771253,0.000604611,0.0012265183,0.00059353095,0.0010360989,0.0000362483],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036181285,0.0002586933,0.92979807,0.00011021937,0.00019951271,0.00004110148,0.00018009619,0.000014507555,0.011180926,0.00034518086,0.04336045,0.014149451],"study_design_scores_gemma":[0.0021981613,0.000060197366,0.9868447,0.0006886678,0.00006953156,0.00011385114,0.000049290444,0.00019727601,0.0052771675,0.0018281818,0.0023397538,0.0003332047],"about_ca_topic_score_codex":0.008369288,"about_ca_topic_score_gemma":0.0012798111,"teacher_disagreement_score":0.05704667,"about_ca_system_score_codex":0.0005280186,"about_ca_system_score_gemma":0.0009079878,"threshold_uncertainty_score":0.9999322},"labels":[],"label_agreement":null},{"id":"W6995824537","doi":"","title":"Profile of census tracts in Halifax, 2006 Census : map volume","year":2008,"lang":"en","type":"other","venue":"Bulletin of Miscellaneous Information (Royal Gardens Kew)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Census; Volume (thermodynamics); Field (mathematics); Population; Data collection","score_opus":0.013963267162930835,"score_gpt":0.24095674044900572,"score_spread":0.2269934732860749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6995824537","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021577808,0.0012001308,9.527915e-8,0.00046696028,0.00029730087,0.001306489,0.0014904452,0.00011451392,0.9949083],"genre_scores_gemma":[0.0011133325,0.0008968119,0.0013303006,0.00015171905,0.00024651093,0.000044736968,0.0009050362,0.00021409581,0.99509746],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99673283,0.000114711474,0.0011711566,0.00030606196,0.0010884082,0.00058682787],"domain_scores_gemma":[0.9979835,0.000105847575,0.00068188045,0.000646957,0.00033702952,0.00024477096],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003559131,0.0004192005,0.00094637467,0.00030280286,0.000033704648,0.000015052205,0.0003297185,0.00070638285,0.31281134],"category_scores_gemma":[0.00030190957,0.00041486626,0.00022119682,0.000030794985,0.00031378938,2.2198117e-7,0.000094934585,0.0007105025,0.007788632],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035693246,0.00019531697,0.0000850166,0.0031940502,0.000069372945,0.00025636578,0.00015068696,0.00005648003,0.0000019499787,0.0000053853023,0.9931883,0.0024401208],"study_design_scores_gemma":[0.001639803,0.00037210193,0.00020268974,0.0014453889,0.00004832377,0.00025059088,0.000100297024,0.000033350178,0.000064764405,0.0000017091171,0.9955169,0.0003240807],"about_ca_topic_score_codex":0.018378,"about_ca_topic_score_gemma":0.0018237884,"teacher_disagreement_score":0.30502272,"about_ca_system_score_codex":0.00021003463,"about_ca_system_score_gemma":0.0002297091,"threshold_uncertainty_score":0.9998303},"labels":[],"label_agreement":null},{"id":"W6998611194","doi":"","title":"Assessing the role of ADAM10 in Trastuzumab treatment and resistance","year":2012,"lang":"en","type":"dissertation","venue":"Oxford University Research Archive (ORA) (University of Oxford)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"University of Oxford","keywords":"ADAM10; Trastuzumab; Monoclonal antibody; Downregulation and upregulation; Gene knockdown; Cell; Extracellular; Cancer","score_opus":0.04010930535740649,"score_gpt":0.33180867554647137,"score_spread":0.2916993701890649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998611194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8195945,0.0017313976,0.000060242055,0.0005131964,0.000059160666,0.0013766122,0.00024962783,0.000024966714,0.1763903],"genre_scores_gemma":[0.965301,0.009737728,0.0020869672,0.0000042726842,0.000062096784,0.0000013766261,0.00048629518,0.000050660743,0.02226962],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960728,0.0007789061,0.00027692778,0.0006656057,0.0012578369,0.00094786496],"domain_scores_gemma":[0.99714124,0.0007990112,0.00029714662,0.0007774019,0.0005618635,0.00042335194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012057838,0.0003510772,0.00087738823,0.0015791286,0.00062572904,0.000034411503,0.00088462944,0.000324132,0.00027800148],"category_scores_gemma":[0.00013769946,0.00035532427,0.00028206862,0.0012443311,0.00122785,0.0004725951,0.000371553,0.0014170081,0.000003809105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034956917,0.005032021,0.40527236,0.008409745,0.002842673,0.0020788477,0.109261476,0.000024801962,0.043992687,0.028189635,0.004717549,0.3552213],"study_design_scores_gemma":[0.004295214,0.0013970947,0.4353601,0.0018779889,0.00034848187,0.000016916663,0.21988367,0.00024403557,0.0009709726,0.0018670395,0.3332776,0.00046087784],"about_ca_topic_score_codex":0.004760674,"about_ca_topic_score_gemma":0.028479459,"teacher_disagreement_score":0.3547604,"about_ca_system_score_codex":0.0011926477,"about_ca_system_score_gemma":0.0020046982,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W6998839979","doi":"","title":"Bank of Canada unveils 3 digital currency proposals from universities","year":2021,"lang":"en","type":"article","venue":"eYLS (Yale Law School)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Currency; Payment; Digital currency; Government (linguistics)","score_opus":0.01835721845225615,"score_gpt":0.27997114587339555,"score_spread":0.2616139274211394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6998839979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.871778,0.002638763,0.000026501817,0.0026673423,0.000517594,0.00030758017,0.00086025894,0.000055917015,0.12114804],"genre_scores_gemma":[0.9818032,0.00007023335,0.00033080517,0.00039740046,0.00027612373,0.000007439118,0.00016478085,0.000027859387,0.016922172],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980482,0.0000667294,0.00028918125,0.00034462044,0.00083286443,0.00041844265],"domain_scores_gemma":[0.99842393,0.00014291501,0.00006400944,0.0005533262,0.0004045099,0.00041128226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011378652,0.00015829706,0.0003776927,0.000045792993,0.00008727383,0.000056616434,0.00021169403,0.00008548399,0.004569296],"category_scores_gemma":[0.00021024453,0.00015464777,0.00008927302,0.000309169,0.0001687113,0.00021939841,0.0001510611,0.0003845303,0.0000815815],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010360914,0.0014339479,0.27029958,0.0027992763,0.0017959535,0.010298886,0.0021211016,0.000065139844,0.038105126,0.05406539,0.5892413,0.028738182],"study_design_scores_gemma":[0.0034317102,0.00037030684,0.015616534,0.0012537714,0.00012996365,0.00007327138,0.005801515,0.00007044345,0.14355099,0.0023423338,0.8267343,0.00062482746],"about_ca_topic_score_codex":0.35125646,"about_ca_topic_score_gemma":0.28219962,"teacher_disagreement_score":0.25468305,"about_ca_system_score_codex":0.00062900706,"about_ca_system_score_gemma":0.008680458,"threshold_uncertainty_score":0.9969394},"labels":[],"label_agreement":null},{"id":"W7000248523","doi":"","title":"ES1, a new lung carcinoma antibody - an immunohistochemical study.","year":2006,"lang":"en","type":"article","venue":"NPARC","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunohistochemistry; Antibody; Carcinoma; Lung cancer; Lung","score_opus":0.025273962201421446,"score_gpt":0.3831008264392179,"score_spread":0.3578268642377964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7000248523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94365346,0.00038157962,0.00014135317,0.0008826777,0.000118235184,0.0007015461,0.000004246287,0.000111601796,0.054005288],"genre_scores_gemma":[0.9919677,0.000005195923,0.0010223478,0.00013098808,0.0007885616,0.000025327914,0.000061849445,0.000048984053,0.005949089],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9981308,0.00006574245,0.00027768608,0.0004020555,0.0006615007,0.00046221292],"domain_scores_gemma":[0.9988282,0.00003529,0.000048603713,0.000706606,0.00009459202,0.0002867385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025575826,0.00016366933,0.00030550215,0.00011779944,0.00008355634,0.000037005855,0.0002408293,0.00009663328,0.0022595862],"category_scores_gemma":[0.000070256516,0.00015015768,0.0000771059,0.00027317237,0.00008936178,0.00007398758,0.00009200032,0.0004017399,0.00012578967],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002549699,0.00077479845,0.24468397,0.000060044003,0.00003161701,0.00036288062,0.00050865865,8.8570505e-7,0.6900693,0.00021011382,0.057712525,0.0053302543],"study_design_scores_gemma":[0.010816817,0.0033170877,0.8750045,0.00019085777,0.0002269077,0.00039966332,0.00083258376,0.0015319772,0.06204407,0.0022017644,0.04263979,0.0007940328],"about_ca_topic_score_codex":0.0023263763,"about_ca_topic_score_gemma":0.000040078543,"teacher_disagreement_score":0.6303205,"about_ca_system_score_codex":0.00032790448,"about_ca_system_score_gemma":0.00043683237,"threshold_uncertainty_score":0.99865246},"labels":[],"label_agreement":null},{"id":"W7009165784","doi":"","title":"Development and Evaluation of Novel Anti-HER2 Theranostics Against HER2-Positive Breast Cancer","year":2024,"lang":"en","type":"dissertation","venue":"University Library (University of Saskatchewan)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Atomic Energy of Canada Limited","keywords":"Trastuzumab; Breast cancer; Cancer; Disease; Epidermal growth factor receptor; Acquired resistance; Colorectal cancer; Metastatic breast cancer","score_opus":0.02319679075002021,"score_gpt":0.26628122636418283,"score_spread":0.24308443561416263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7009165784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868938,0.0006614608,0.000026387826,0.00088092365,0.00024026682,0.0007799428,0.0010939605,0.00007203224,0.009351248],"genre_scores_gemma":[0.9645391,0.0013471529,0.003766551,0.000047270816,0.00007110376,3.4332552e-7,0.0017407656,0.00006480609,0.028422918],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99778885,0.000102276405,0.0002141556,0.0005659391,0.001042814,0.00028594784],"domain_scores_gemma":[0.9985533,0.000077529105,0.00026901698,0.00030086783,0.0005725002,0.00022681268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002529479,0.00031710908,0.0006452256,0.00065137993,0.0001805196,0.000019503086,0.00033927974,0.0004414243,0.00073715684],"category_scores_gemma":[0.000008188053,0.000399334,0.00017737492,0.0006734548,0.00027124665,0.00048654986,0.00020809774,0.00054499507,0.000013739687],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008850667,0.0027257234,0.034648426,0.01622589,0.007679385,0.0012705958,0.61041236,0.00040570027,0.033733025,0.00042307808,0.009367576,0.27425757],"study_design_scores_gemma":[0.0072913948,0.0002872066,0.24067098,0.009100118,0.003357272,0.00002928653,0.7049546,0.0024875887,0.01653319,0.000054896285,0.014162466,0.0010709744],"about_ca_topic_score_codex":0.002119688,"about_ca_topic_score_gemma":0.0027678064,"teacher_disagreement_score":0.2731866,"about_ca_system_score_codex":0.0004517357,"about_ca_system_score_gemma":0.0049113273,"threshold_uncertainty_score":0.99984586},"labels":[],"label_agreement":null},{"id":"W7011675343","doi":"","title":"Novel mass spectrometry methods for characterizing antibodies and antibody-drug conjugates","year":2014,"lang":"en","type":"article","venue":"NPARC","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Glycosylation; Monoclonal antibody; Conjugate; Glycan; Antibody; Mass spectrometry; Sialic acid","score_opus":0.045948215495613974,"score_gpt":0.4220269215621523,"score_spread":0.37607870606653837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7011675343","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6104477,0.001022862,0.3313542,0.016142825,0.0006890413,0.0016107246,0.00007615091,0.00024655493,0.038409926],"genre_scores_gemma":[0.3716135,0.00041932313,0.6249461,0.0008144667,0.00057529146,0.00004461845,0.000035432306,0.000054886197,0.0014963399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859685,0.00007765425,0.0002429112,0.00038111565,0.00022735751,0.0004741246],"domain_scores_gemma":[0.9986552,0.00062676135,0.000067088746,0.0003219711,0.00013365968,0.00019529271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015253325,0.00017148248,0.00045171773,0.0001909829,0.00011572722,0.00006373682,0.00012106098,0.00007707576,0.00025962837],"category_scores_gemma":[0.0008038296,0.0001468824,0.00007812997,0.00017533399,0.00017427163,0.000088390916,0.00007486658,0.0002491279,0.000013319943],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009641911,0.0000388989,0.009005413,0.0004220977,0.000055445467,0.0000025096942,0.0001451205,3.7598234e-8,0.959346,0.0017161341,0.0008999369,0.028272007],"study_design_scores_gemma":[0.002706142,0.0005521693,0.0396487,0.00040789737,0.00010046446,0.00009506697,0.00016620236,0.0043194764,0.8377595,0.005501862,0.108391754,0.00035075325],"about_ca_topic_score_codex":0.000017440541,"about_ca_topic_score_gemma":0.0000015424831,"teacher_disagreement_score":0.29359195,"about_ca_system_score_codex":0.000053358635,"about_ca_system_score_gemma":0.0000696157,"threshold_uncertainty_score":0.59896904},"labels":[],"label_agreement":null},{"id":"W7019702876","doi":"","title":"Germline rare variants in HER2-positive breast cancer predisposition : a systematic review and meta-analysis","year":2024,"lang":"en","type":"article","venue":"Lume (Universidade Federal do Rio Grande do Sul)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Germline; Genetic testing; Breast cancer; Germline mutation; Cancer; Genetic association; Gene; Genetic variants; Phenotype; Genome-wide association study","score_opus":0.025101461603355094,"score_gpt":0.32037356921882987,"score_spread":0.2952721076154748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7019702876","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07524483,0.7928162,0.0014836335,0.10164891,0.00038391844,0.014538928,0.005141556,0.00059050904,0.008151465],"genre_scores_gemma":[0.980972,0.010066725,0.00010919588,0.0010177634,0.00007793988,0.00026266146,0.00018969164,0.0000608035,0.0072431993],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99696267,0.00046547482,0.0005291674,0.0008080218,0.00072326814,0.0005113842],"domain_scores_gemma":[0.99869984,0.00012977938,0.00011701397,0.00048723997,0.00023969065,0.00032640292],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00075403706,0.00037552937,0.0022173899,0.00075876416,0.00018001696,0.0003359888,0.00020091183,0.00018428717,0.003591729],"category_scores_gemma":[0.00004619591,0.00030289084,0.000792108,0.002233842,0.00011601818,0.00044171803,0.00011030508,0.0005825741,0.000051843122],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012416593,0.0006527666,0.005703185,0.71614736,0.24778678,0.008307783,0.00747251,0.00010441041,0.00066749274,0.0020033976,0.008711006,0.0012016246],"study_design_scores_gemma":[0.0043745884,0.00048047837,0.06574474,0.058078732,0.8612369,0.001590557,0.0019346173,0.0042785867,0.000044866854,0.00044371246,0.0004327294,0.0013595128],"about_ca_topic_score_codex":0.0025470557,"about_ca_topic_score_gemma":0.001382553,"teacher_disagreement_score":0.9057272,"about_ca_system_score_codex":0.00058477494,"about_ca_system_score_gemma":0.00024126418,"threshold_uncertainty_score":0.9999423},"labels":[],"label_agreement":null},{"id":"W7027053911","doi":"","title":"Bioanalytical investigation of type I and type II epidermal growth factor (EGFR)-DNA targeting combi-molecules in «in vitro» and «in vivo» tumour models","year":2011,"lang":"en","type":"other","venue":"Library and Archives Canada (Government of Canada)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"In vivo; In vitro; Potency; Epidermal growth factor receptor; Epidermal growth factor; Receptor; Ex vivo; Cell culture; DNA damage","score_opus":0.014952255332175944,"score_gpt":0.203483757017773,"score_spread":0.18853150168559704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7027053911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64993083,0.004271654,0.00001092816,0.0031083426,0.00014964941,0.00082282355,0.00033818348,0.000014180794,0.34135342],"genre_scores_gemma":[0.9890963,0.0011784369,0.00076156046,0.0003225059,0.00003784419,0.0000055160285,0.000020169438,0.000094097966,0.008483565],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978023,0.00011748564,0.0004156658,0.00034666504,0.0009814006,0.000336487],"domain_scores_gemma":[0.9992607,0.00015440215,0.00015153293,0.00014245808,0.0000023468049,0.00028856183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000040358656,0.00023681192,0.00057648384,0.00018612118,0.000026897465,0.00000746752,0.00011692703,0.00009455636,0.0001331777],"category_scores_gemma":[0.000031668096,0.00022862741,0.000015314086,0.00021388714,0.00022043532,0.00011537138,0.00017208523,0.00032983284,3.677884e-9],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028533216,0.00016263926,0.8991323,0.0050805155,0.00023579226,0.00091923244,0.0008329119,0.000026301122,0.051667094,0.023638966,0.012750584,0.0027003093],"study_design_scores_gemma":[0.0059943288,0.0013600339,0.8290059,0.0072088423,0.00014045698,0.000044870383,0.002482249,0.019445824,0.11512519,0.0064673554,0.011107075,0.0016179049],"about_ca_topic_score_codex":0.029461745,"about_ca_topic_score_gemma":0.064770974,"teacher_disagreement_score":0.33916548,"about_ca_system_score_codex":0.000026839736,"about_ca_system_score_gemma":0.0019525952,"threshold_uncertainty_score":0.97700113},"labels":[],"label_agreement":null},{"id":"W7034491428","doi":"","title":"The thorny issue of tight labour marketsWhat’s the significance of the ongoing recruitment and skills issues faced by Cumbrian businesses?","year":2024,"lang":"en","type":"other","venue":"Insight (University of Cumbria)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Economic shortage; Quarter (Canadian coin); Job loss; Affect (linguistics); Unemployment","score_opus":0.027155722814496793,"score_gpt":0.2997644452977361,"score_spread":0.2726087224832393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7034491428","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0277013,0.11824129,0.00012573594,0.06915338,0.0036779428,0.01094099,0.0013458553,0.00022878706,0.7685847],"genre_scores_gemma":[0.025275886,0.016355703,0.00021155023,0.0001262384,0.00028493637,0.000009871044,0.0000146977645,0.0002110491,0.95751005],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759114,0.0003103816,0.0003066865,0.00047440425,0.0009819504,0.0003354217],"domain_scores_gemma":[0.99760836,0.00030366617,0.0004953547,0.0011525633,0.0003324069,0.000107671476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000689386,0.00031092585,0.0007310891,0.00018352485,0.00018709883,0.00003896883,0.0008928506,0.00030572797,0.0014757246],"category_scores_gemma":[0.00017134601,0.00019482138,0.00018844522,0.000833366,0.0013283339,0.00006870979,0.00046924112,0.0005423347,0.000047378297],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019240858,0.00012098374,0.00047822628,0.0021050056,0.0006838458,0.000035319685,0.0023214514,9.488671e-7,0.0049333223,0.00079766527,0.97821856,0.010112253],"study_design_scores_gemma":[0.0006569102,0.00011451249,0.003027954,0.0022944112,0.0002746642,0.00000921464,0.0016486496,0.000019310484,0.002575497,0.0001284474,0.98906857,0.00018184855],"about_ca_topic_score_codex":0.005160932,"about_ca_topic_score_gemma":0.0017374476,"teacher_disagreement_score":0.18892536,"about_ca_system_score_codex":0.00012740595,"about_ca_system_score_gemma":0.0004650599,"threshold_uncertainty_score":0.99943703},"labels":[],"label_agreement":null},{"id":"W7066617335","doi":"","title":"Latent multi-state models for non-equidistant longitudinal observations with finite and infinite mixture model-based clustering","year":2019,"lang":"en","type":"dissertation","venue":"eScholarship@McGill (McGill)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cluster analysis; Markov chain Monte Carlo; Bayesian probability; Inference; Covariate; Markov chain; Bayesian inference; Trajectory; Statistical inference; Markov process","score_opus":0.09429552422286308,"score_gpt":0.3250005111047202,"score_spread":0.23070498688185714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7066617335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97206736,0.0005853462,0.0036896158,0.00018357746,0.0007343474,0.007306173,0.011239767,0.00031271833,0.003881075],"genre_scores_gemma":[0.94974047,0.00037807517,0.030720513,0.0006036279,0.00004914518,0.0011789814,0.0060332012,0.000521716,0.010774241],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99480975,0.000116713505,0.0010402494,0.0016085437,0.001246094,0.0011786453],"domain_scores_gemma":[0.9957825,0.00046002248,0.00053088396,0.0011465029,0.0014195979,0.0006604816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089807913,0.0010304422,0.0012827464,0.0006434017,0.00083834335,0.00016220137,0.00045526394,0.0007980873,0.00003581968],"category_scores_gemma":[0.00039708545,0.00094561675,0.00032236674,0.0006097624,0.00011669338,0.0006339212,0.0001398815,0.0019923672,0.000030768988],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025973363,0.002123969,0.0038588461,0.03493918,0.0028296441,0.000790818,0.00035759577,0.7755983,0.087554805,0.006733626,0.000070137656,0.059169725],"study_design_scores_gemma":[0.00988775,0.0013927158,0.003068778,0.0052412953,0.0008396525,0.000035561054,0.00015869364,0.9632074,0.008977647,0.0016594392,0.0038062087,0.0017248304],"about_ca_topic_score_codex":0.00028267922,"about_ca_topic_score_gemma":0.0023003218,"teacher_disagreement_score":0.18760914,"about_ca_system_score_codex":0.0009992241,"about_ca_system_score_gemma":0.00061685184,"threshold_uncertainty_score":0.9992994},"labels":[],"label_agreement":null},{"id":"W7086310305","doi":"10.17613/9wev-gj66","title":"How to be an ally with Kashmir: War stories from the kitchen","year":2019,"lang":"en","type":"article","venue":"Humanities Commons CORE (Modern Language Association / Columbia University)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Narrative; Face (sociological concept); Government (linguistics); Clothing","score_opus":0.04281105910540114,"score_gpt":0.2546347322204122,"score_spread":0.21182367311501107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7086310305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9722799,0.00010180074,0.00010100123,0.0040978654,0.00015002069,0.00094008027,0.00041891515,0.00021832825,0.021692112],"genre_scores_gemma":[0.8656784,0.000014519592,0.00024734973,0.0015245166,0.00021938952,0.000007778527,0.00031682104,0.00004961973,0.13194157],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978589,0.00022061085,0.00013846377,0.00040640568,0.00091708446,0.00045854447],"domain_scores_gemma":[0.9979903,0.00038107694,0.00016773594,0.0008019597,0.00047928272,0.00017963485],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027648552,0.00019032179,0.00037010157,0.00014467831,0.00046285993,0.0003325811,0.0005663116,0.00015510182,0.0008762402],"category_scores_gemma":[0.00016005118,0.0002025206,0.00009483498,0.00039263413,0.00009961389,0.00039891351,0.00021364626,0.00049878046,0.000045723402],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007740033,0.0003810035,0.78035975,0.00009394788,0.0009942704,0.0005921181,0.14855744,0.00003110671,0.003097694,0.0023621744,0.058824684,0.0039318213],"study_design_scores_gemma":[0.0040416406,0.0015595349,0.16945346,0.0002260957,0.00043706875,0.000011758672,0.21036294,0.0003231305,0.00022422675,0.00016095425,0.6124394,0.0007598024],"about_ca_topic_score_codex":0.01695941,"about_ca_topic_score_gemma":0.29596135,"teacher_disagreement_score":0.6109063,"about_ca_system_score_codex":0.0016375793,"about_ca_system_score_gemma":0.00036019436,"threshold_uncertainty_score":0.9895868},"labels":[],"label_agreement":null},{"id":"W7104928747","doi":"10.71781/28716","title":"Identification de nouvelles cibles thérapeutiques impliquées dans la formation de métastases dans le cancer du sein","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Breast cancer; Medical screening; Hair dyes","score_opus":0.0575694255113575,"score_gpt":0.4316993397871998,"score_spread":0.3741299142758423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104928747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94072115,0.0048595862,0.011337131,0.0025108976,0.0007237248,0.0026482968,0.0014346086,0.000017333314,0.035747264],"genre_scores_gemma":[0.9270494,0.010993205,0.0029211491,0.00011426267,0.0005443795,0.001400445,0.0044683367,0.0001031662,0.05240567],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99609864,0.00082198426,0.0009187204,0.00074143,0.0005937599,0.00082549616],"domain_scores_gemma":[0.997612,0.00050016795,0.00045719763,0.0006333654,0.00051676406,0.00028048412],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021750585,0.00047458443,0.0006126315,0.00040273933,0.0006123303,0.0007329332,0.0010679616,0.0005995482,0.0015575141],"category_scores_gemma":[0.00046346188,0.00050654507,0.00017401372,0.0006279367,0.0002257651,0.000783762,0.00021379543,0.0006660398,0.00017557266],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000760772,0.0006764462,0.01295359,0.0030786449,0.00053698116,0.00016160092,0.09463758,0.0006667865,0.38994554,0.002801155,0.008580573,0.48520032],"study_design_scores_gemma":[0.0011036065,0.00014912874,0.028232526,0.0050376696,0.00060704723,0.00007575262,0.09101233,0.0059766024,0.7877917,0.0003115349,0.079187624,0.00051443215],"about_ca_topic_score_codex":0.030184017,"about_ca_topic_score_gemma":0.070929565,"teacher_disagreement_score":0.4846859,"about_ca_system_score_codex":0.0024967403,"about_ca_system_score_gemma":0.011961957,"threshold_uncertainty_score":0.99973863},"labels":[],"label_agreement":null},{"id":"W7106485843","doi":"10.21203/rs.3.rs-8020339/v1","title":"Translational and Real-World Evidence of Trastuzumab Biosimilar CT-P6 Plus Pertuzumab in Neoadjuvant HER2-Positive Early Breast Cancer","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Purdue Pharma (Canada)","funders":"","keywords":"Pertuzumab; Trastuzumab; Biosimilar; Breast cancer; Clinical endpoint; Neoadjuvant therapy; Adverse effect; Clinical trial; Biomarker","score_opus":0.10511809782627815,"score_gpt":0.47284473067639543,"score_spread":0.3677266328501173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7106485843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.75932854,0.12087779,0.00023342013,0.06296344,0.0013434684,0.023339447,0.016324675,0.0001667552,0.015422481],"genre_scores_gemma":[0.88950133,0.102138005,0.00022832354,0.000098733675,0.0007279168,0.0018448448,0.00015525018,0.00015996206,0.005145625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9777015,0.0044474117,0.002756995,0.0035469662,0.0081719905,0.0033751514],"domain_scores_gemma":[0.9841691,0.006727444,0.00045623406,0.0022529822,0.004918606,0.0014756209],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.008940949,0.0013381944,0.003047644,0.005149902,0.0006289465,0.00034304117,0.0018808184,0.0008472429,0.003811974],"category_scores_gemma":[0.0013797366,0.0013380186,0.0006566723,0.0057350667,0.0032883864,0.00056020037,0.0020832538,0.008983991,0.000056319717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029591052,0.0032402808,0.58060765,0.07396476,0.0022719689,0.0038829665,0.036569454,0.003008565,0.0051878397,0.0022189654,0.004560909,0.25489557],"study_design_scores_gemma":[0.005932003,0.0022126748,0.82967967,0.1431467,0.00026460274,0.00010427471,0.0027529113,0.009913238,0.0031149173,0.0006119983,0.0011356631,0.0011313604],"about_ca_topic_score_codex":0.18439507,"about_ca_topic_score_gemma":0.037060644,"teacher_disagreement_score":0.2537642,"about_ca_system_score_codex":0.009774924,"about_ca_system_score_gemma":0.031682614,"threshold_uncertainty_score":0.99993694},"labels":[],"label_agreement":null},{"id":"W7108248980","doi":"","title":"Risk Signals of Antibody-Drug Conjugates in Bladder Cancer: A Real-World FAERS Study","year":2025,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacovigilance; Adverse Event Reporting System; Adverse effect; Odds ratio; Quarter (Canadian coin); Traditional Chinese medicine; Bladder cancer; Cancer","score_opus":0.24354764448475896,"score_gpt":0.6435171973427783,"score_spread":0.3999695528580194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108248980","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9541088,0.02406917,0.000019917868,0.00071372575,0.00047006106,0.0025017182,0.00012455558,0.000037300848,0.017954802],"genre_scores_gemma":[0.93889475,0.05720287,0.00006787353,0.0002933432,0.00013166758,0.00019587987,0.000010255382,0.000067921144,0.0031354153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942946,0.00094670657,0.0017952466,0.00074759254,0.0015015951,0.0007142562],"domain_scores_gemma":[0.99577504,0.0010854708,0.0009931482,0.0009368611,0.00084437727,0.00036511928],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042436696,0.0004360126,0.0018945007,0.0028680768,0.00017147005,0.00040708116,0.0023447028,0.00011737012,0.013051772],"category_scores_gemma":[0.0008777661,0.0003829704,0.00026420766,0.0040431707,0.0003589853,0.00084978604,0.0010846966,0.0011931155,0.00001440705],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010227498,0.0011996225,0.88438904,0.00044228235,0.0009278542,0.00015996126,0.0007032188,0.00029060253,0.053274207,0.000024164005,0.04710167,0.010464615],"study_design_scores_gemma":[0.0030061004,0.000060569357,0.93477374,0.003015729,0.00034587763,0.0000027509304,0.0008612885,0.00013639226,0.0519403,0.0009939282,0.0045353724,0.00032793896],"about_ca_topic_score_codex":0.07610229,"about_ca_topic_score_gemma":0.010104398,"teacher_disagreement_score":0.06599788,"about_ca_system_score_codex":0.00047972516,"about_ca_system_score_gemma":0.0014875858,"threshold_uncertainty_score":0.9998622},"labels":[],"label_agreement":null},{"id":"W7115819241","doi":"","title":"ECONOMIC EVALUATION OF HER2 TARGETED BREAST CANCER THERAPY","year":2014,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Trastuzumab; Economic evaluation; Breast cancer; Cost-effectiveness analysis; Cost–benefit analysis; Cohort; Cost effectiveness; Clinical trial; Cancer","score_opus":0.03405525428188679,"score_gpt":0.3169055184233334,"score_spread":0.28285026414144665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115819241","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26961693,0.0013741961,0.000014157091,0.0003301751,0.0009621653,0.0015296396,0.00024623738,0.00007410144,0.7258524],"genre_scores_gemma":[0.33132464,0.0013043932,0.000097499054,0.00009946983,0.000489278,0.000019230632,0.0007772922,0.00013328169,0.6657549],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976623,0.00027601988,0.0003188249,0.0005608552,0.0008196924,0.0003622766],"domain_scores_gemma":[0.99828535,0.00004435289,0.00033316758,0.00047563194,0.0006715677,0.00018992525],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044714945,0.000337526,0.00063089986,0.0003597749,0.000073918556,0.000023018976,0.00034643224,0.00041863945,0.352749],"category_scores_gemma":[0.000014909087,0.00035455215,0.0002377938,0.000346461,0.00008088912,0.000117801086,0.00003920857,0.000443232,0.00014898655],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022160185,0.00011735581,0.00998249,0.0005610276,0.00056274916,0.000017104983,0.0005362302,0.00023858361,0.0019688804,0.000119843426,0.005153331,0.9785264],"study_design_scores_gemma":[0.013739496,0.00070137595,0.16217905,0.0021115174,0.0016078366,0.000023237564,0.0040028687,0.0035469623,0.01324737,0.00012487106,0.7976111,0.0011042696],"about_ca_topic_score_codex":0.0026542011,"about_ca_topic_score_gemma":0.0049036653,"teacher_disagreement_score":0.9774221,"about_ca_system_score_codex":0.0013626327,"about_ca_system_score_gemma":0.0018989367,"threshold_uncertainty_score":0.9998906},"labels":[],"label_agreement":null},{"id":"W7116050106","doi":"10.3390/curroncol33010002","title":"Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric/Gastroesophageal Junction Cancer","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Cancer; Safety profile; Systemic therapy; First line; Adverse effect; Clinical trial","score_opus":0.09372716798261112,"score_gpt":0.47894800412537286,"score_spread":0.38522083614276176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116050106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98771083,0.00604044,0.00018934756,0.0012838066,0.0006825314,0.0011581876,0.000032661195,0.000015625841,0.0028865952],"genre_scores_gemma":[0.99161667,0.0074203005,0.00034212566,0.000029665178,0.00014584733,0.00016705565,0.000023509947,0.000012255561,0.00024254482],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99834937,0.00028233047,0.00048678243,0.00030730318,0.00025836803,0.00031584039],"domain_scores_gemma":[0.99886066,0.00048841216,0.00016418326,0.00031053068,0.000108488595,0.00006771776],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003191838,0.00015965625,0.0005463636,0.0002681179,0.000051670442,0.000005715733,0.000115813586,0.00007122531,0.00008442466],"category_scores_gemma":[0.000087303255,0.00011228431,0.00007162175,0.00056191644,0.0002332866,0.000037958667,0.000047427646,0.0002600218,0.0000011937898],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027908916,0.0022320328,0.2602979,0.00036701962,0.00007035061,0.000019786989,0.0012277352,0.00015995048,0.0037387195,0.00021911402,0.00074393157,0.72813255],"study_design_scores_gemma":[0.012929542,0.003259264,0.9210574,0.0011438673,0.00019421727,0.000009004757,0.00053229876,0.00039934032,0.0030419137,0.00006780077,0.057273176,0.000092177805],"about_ca_topic_score_codex":0.0005736647,"about_ca_topic_score_gemma":0.0007530363,"teacher_disagreement_score":0.7280404,"about_ca_system_score_codex":0.0010101709,"about_ca_system_score_gemma":0.0005809353,"threshold_uncertainty_score":0.45788214},"labels":[],"label_agreement":null},{"id":"W7116663774","doi":"10.1200/po-25-00221","title":"CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions","year":2025,"lang":"en","type":"article","venue":"JCO Precision Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"William Osler Health System","funders":"National Cancer Institute","keywords":"Monoclonal antibody; Solid tumor; Phase (matter); Cancer; Antibody; Tumor cells","score_opus":0.026661932388642968,"score_gpt":0.42918210070895435,"score_spread":0.4025201683203114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116663774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98896974,0.00027144732,0.000024997547,0.00558309,0.00025930107,0.002611891,0.000020985608,0.000013621499,0.002244907],"genre_scores_gemma":[0.9983457,0.00014140473,0.00014023861,0.00038231973,0.000040398634,0.000065754175,0.0000027172252,0.000019240084,0.000862233],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99718386,0.0006982777,0.00075005513,0.00042679434,0.0006200936,0.00032089523],"domain_scores_gemma":[0.9974754,0.0010547392,0.00024866828,0.00088233466,0.00024050208,0.00009834477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010200772,0.00018881712,0.00073850347,0.00021111504,0.00021684778,0.000006579759,0.0004934437,0.00015938937,0.0000941908],"category_scores_gemma":[0.00077681494,0.00009955046,0.000081101694,0.0011000499,0.0005496825,0.000038175356,0.00094707124,0.00074122916,0.0000012041527],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055727158,0.039594818,0.41245493,0.0005288325,0.0004981459,0.00040159302,0.01495572,0.0012845068,0.2132316,0.00059642585,0.0106678745,0.2500584],"study_design_scores_gemma":[0.039928652,0.02073255,0.90304476,0.001605349,0.00020761864,0.00017024598,0.0018423463,0.0009781234,0.011952962,0.00021655821,0.01913043,0.00019042742],"about_ca_topic_score_codex":0.00032588272,"about_ca_topic_score_gemma":0.0010845438,"teacher_disagreement_score":0.49058983,"about_ca_system_score_codex":0.00018181949,"about_ca_system_score_gemma":0.0014812093,"threshold_uncertainty_score":0.405955},"labels":[],"label_agreement":null},{"id":"W7116938074","doi":"10.1016/j.annonc.2025.10.727","title":"1016P Patient (pt) characteristics, HER2 testing, and treatment (Tx) patterns in advanced HER2 (ERBB2)-mutant (HER2m) NSCLC in real-world clinical practice","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"AstraZeneca","keywords":"Clinical Practice; Mutation; Chemotherapy; Clinical trial; MEDLINE","score_opus":0.20592206771403104,"score_gpt":0.5385735729854448,"score_spread":0.3326515052714138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116938074","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563652,0.0004937996,0.000007068756,0.017716192,0.00034889113,0.0011903611,0.000043713022,0.000030718304,0.023804002],"genre_scores_gemma":[0.9860883,0.006975127,0.0016239679,0.004217805,0.00013479311,0.00019829402,0.000021492444,0.000032211832,0.0007080263],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9964322,0.00057857914,0.0014319512,0.0006240418,0.0003182869,0.00061498175],"domain_scores_gemma":[0.99494815,0.003429945,0.00042587382,0.0005094417,0.00046077804,0.0002258067],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014798356,0.00025880785,0.0011053518,0.00044863598,0.00003639906,0.000013629071,0.00015107659,0.00025702544,0.00010337106],"category_scores_gemma":[0.0048470614,0.00022843677,0.000092697584,0.000603751,0.00023042117,0.00010418442,0.00016668065,0.0006222267,0.00001687371],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015984967,0.0023195816,0.49052927,0.00012290606,0.00007889164,0.0009052398,0.00036647537,0.0000026175117,0.00025911396,0.00008855831,0.0006757296,0.5030531],"study_design_scores_gemma":[0.004471123,0.01223505,0.8264913,0.0009934758,0.000057664067,0.000034748235,0.00048609785,0.0001441306,0.00095390156,0.000187105,0.15377015,0.00017527574],"about_ca_topic_score_codex":0.005938646,"about_ca_topic_score_gemma":0.00869066,"teacher_disagreement_score":0.50287783,"about_ca_system_score_codex":0.00056629226,"about_ca_system_score_gemma":0.0012586694,"threshold_uncertainty_score":0.9315381},"labels":[],"label_agreement":null},{"id":"W7116952014","doi":"10.1016/j.annonc.2025.10.923","title":"88MO Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of Asian patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): A DESTINY-Breast09 analysis","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Pertuzumab; Taxane; Trastuzumab; Breast cancer; Chemotherapy","score_opus":0.06237122466736459,"score_gpt":0.4233950909921288,"score_spread":0.3610238663247642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116952014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644886,0.002209926,0.0040347143,0.01940622,0.00030309753,0.004964741,0.0023894086,0.00016602142,0.002037263],"genre_scores_gemma":[0.98907316,0.0019886398,0.0047735674,0.00071025104,0.0001336253,0.0017178035,0.0003542137,0.00015066128,0.001098073],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99423987,0.0003340198,0.0016812002,0.0012904552,0.0010255161,0.0014289438],"domain_scores_gemma":[0.9940116,0.00090577034,0.0009076357,0.001176639,0.0024091823,0.0005892019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000533005,0.00084421283,0.0031926997,0.0015165042,0.00022847884,0.000026722539,0.0005422724,0.0003481189,0.0005155709],"category_scores_gemma":[0.00037923479,0.0006686156,0.00090041704,0.0027182968,0.0007715009,0.00019771398,0.0001041212,0.0003813646,0.000006757913],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022529453,0.014096766,0.074268416,0.0019667172,0.009523396,0.00019332336,0.0019331734,0.0019437688,0.0004451563,0.0001494073,0.0019356447,0.8710148],"study_design_scores_gemma":[0.08642462,0.21392356,0.5492282,0.0037653043,0.020103443,0.0006239379,0.004138251,0.0076199947,0.015758418,0.0009797453,0.09497569,0.0024588655],"about_ca_topic_score_codex":0.0038664495,"about_ca_topic_score_gemma":0.010728626,"teacher_disagreement_score":0.8685559,"about_ca_system_score_codex":0.0026085714,"about_ca_system_score_gemma":0.0042487285,"threshold_uncertainty_score":0.9995765},"labels":[],"label_agreement":null},{"id":"W7116955310","doi":"10.1016/j.annonc.2025.12.017","title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Daiichi Sankyo Europe; AstraZeneca","keywords":"Clinical endpoint; Chemotherapy; Overall survival; Phases of clinical research; Chemotherapy regimen; Hormone therapy; Hormone","score_opus":0.09547552410677164,"score_gpt":0.4617903217570697,"score_spread":0.36631479765029806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116955310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98688,0.0005658037,0.000016684638,0.008584193,0.00015933256,0.0018067467,0.00034439558,0.000016879623,0.0016259715],"genre_scores_gemma":[0.9965951,0.0019156616,0.000081137936,0.0004984538,0.000042943535,0.00021462802,0.000049626728,0.000024868265,0.0005776205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99625427,0.0011775796,0.0009050821,0.00054330536,0.0005680901,0.0005517014],"domain_scores_gemma":[0.9972806,0.0007569146,0.0003715875,0.0006592017,0.00079237967,0.0001393021],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010650064,0.0002951972,0.0016025921,0.00072301854,0.00008395645,0.000012229626,0.00043140785,0.00013984281,0.0006385411],"category_scores_gemma":[0.000255387,0.00022238013,0.00029596593,0.0031477034,0.00042173485,0.00008560872,0.00013527085,0.0005006977,0.000002202965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13600661,0.0292058,0.387873,0.00036640617,0.026912438,0.00019219308,0.011186005,0.0007375984,0.013380061,0.00026430597,0.008127395,0.38574818],"study_design_scores_gemma":[0.066681236,0.012955296,0.9022874,0.0003594827,0.0022756397,0.000008986481,0.002765394,0.0008100326,0.010036287,0.000055132994,0.0014794939,0.0002856099],"about_ca_topic_score_codex":0.029659597,"about_ca_topic_score_gemma":0.011069649,"teacher_disagreement_score":0.5144144,"about_ca_system_score_codex":0.00056518475,"about_ca_system_score_gemma":0.0018623925,"threshold_uncertainty_score":0.976802},"labels":[],"label_agreement":null},{"id":"W7116977830","doi":"10.1016/j.annonc.2025.10.1101","title":"664TiP BEHOLD-2: A phase I/II randomised study evaluating GSK5733584, a B7-H4-targeted antibody-drug conjugate, in combination with anti-cancer agents in patients with advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Abbotsford Veterinary Clinic; McGill University Health Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Phases of clinical research; Phase (matter); Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Cancer","score_opus":0.09961585291141915,"score_gpt":0.517144164483099,"score_spread":0.4175283115716798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116977830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912828,0.00024250508,0.000015356016,0.0017710014,0.0001361416,0.0056454204,0.00003162665,0.000031529176,0.0008435973],"genre_scores_gemma":[0.9978919,0.0001444683,0.0001994051,0.0007666914,0.00001929601,0.00064839056,0.00009895509,0.000040541643,0.00019036274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99620837,0.0007372875,0.0009267326,0.00062364375,0.00083009683,0.0006738686],"domain_scores_gemma":[0.997656,0.00030878032,0.00042729775,0.00040944244,0.0010543357,0.0001441392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020259866,0.0003023236,0.0012842229,0.00088301575,0.000099323115,0.000013513862,0.00024904657,0.00013033624,0.00012033434],"category_scores_gemma":[0.00060467183,0.00024695628,0.00006910976,0.0013830543,0.00022996454,0.00018979558,0.000119691525,0.0005568119,0.0000027116175],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060021255,0.01753058,0.88251776,0.00025708933,0.00033290352,0.00015300034,0.002774808,0.0006813178,0.004973748,0.000008756685,0.00056381786,0.030185],"study_design_scores_gemma":[0.31634778,0.03851592,0.6316991,0.0011936482,0.0001258782,0.0000017994946,0.0010825392,0.0012974004,0.009288825,0.000031444935,0.00016312003,0.00025255323],"about_ca_topic_score_codex":0.0006064737,"about_ca_topic_score_gemma":0.00080417056,"teacher_disagreement_score":0.25632653,"about_ca_system_score_codex":0.00031406627,"about_ca_system_score_gemma":0.00135926,"threshold_uncertainty_score":0.9999983},"labels":[],"label_agreement":null},{"id":"W7117293899","doi":"10.3390/biomedicines14010049","title":"HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management","year":2025,"lang":"en","type":"article","venue":"Biomedicines","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University; Queen's University","funders":"","keywords":"Liquid biopsy; Breast cancer; Biopsy; Histopathology; Narrative review; Standardization; Precision medicine; Targeted therapy; Cancer","score_opus":0.020049636351909483,"score_gpt":0.39522193475878387,"score_spread":0.3751722984068744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117293899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8411067,0.018886995,0.00023860254,0.13495725,0.0006630252,0.0010006911,0.000042323136,0.000073561954,0.0030308082],"genre_scores_gemma":[0.9851644,0.004931036,0.00017326715,0.00047125385,0.00008652698,0.00012576435,0.0000042487322,0.000013272996,0.009030225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99894017,0.000036379814,0.00024722418,0.00028681487,0.00026357727,0.00022584699],"domain_scores_gemma":[0.9992511,0.00007244896,0.000054282278,0.00041853587,0.00015085278,0.00005274948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034160982,0.000119433644,0.00028308044,0.000401555,0.00005360284,0.000004596215,0.00018572353,0.00011654094,0.00021505478],"category_scores_gemma":[0.000058327412,0.00006844007,0.000027331573,0.0008308262,0.00083634147,0.000015290778,0.00041833083,0.0001562059,0.0000106988155],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063102547,0.00014801258,0.08604023,0.001919787,0.00026776965,0.00020340955,0.0004905536,9.210689e-7,0.066245876,0.00032753797,0.08416244,0.75956243],"study_design_scores_gemma":[0.007547165,0.0012303884,0.3866158,0.009021908,0.00059809955,0.0011787371,0.0051010763,0.00024306886,0.12581639,0.0015454476,0.46073258,0.00036931923],"about_ca_topic_score_codex":0.000119962606,"about_ca_topic_score_gemma":0.000038737835,"teacher_disagreement_score":0.7591931,"about_ca_system_score_codex":0.00013286679,"about_ca_system_score_gemma":0.000078699704,"threshold_uncertainty_score":0.30815348},"labels":[],"label_agreement":null},{"id":"W7123335096","doi":"10.1093/cvr/cvaf256","title":"Temporal inhibition of ADAM17 in fibroblasts reduces stiffness and promotes vascularization following myocardial infarction","year":2025,"lang":"en","type":"article","venue":"Cardiovascular Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Alberta","funders":"Canadian Institutes of Health Research; Heart and Stroke Foundation of Canada","keywords":"Downregulation and upregulation; Myocardial infarction; Compliance (psychology); Limiting; Heart failure; Homeostasis; Stiffness","score_opus":0.04768868621588366,"score_gpt":0.3771006596338615,"score_spread":0.32941197341797784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7123335096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98816913,0.006957913,0.000563469,0.00054485706,0.00016950014,0.0016684674,0.0000047621843,0.000039704035,0.0018821855],"genre_scores_gemma":[0.9985908,0.000501922,0.00028788284,0.000013597441,0.00013714822,0.00020178534,0.000055421817,0.00003200499,0.00017939303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956877,0.00088512676,0.00044038094,0.0006078715,0.0018514955,0.00052742235],"domain_scores_gemma":[0.9983869,0.00017280731,0.000034044424,0.00066632504,0.000601073,0.00013882159],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054183295,0.00016923697,0.00065888994,0.0012852473,0.00015451244,0.00007025755,0.00012271901,0.00023688326,0.000014550514],"category_scores_gemma":[0.0014900089,0.00016765419,0.000519282,0.0022529021,0.0003035178,0.00020841464,0.00025486547,0.0007198706,0.0000059196723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00183774,0.0007425417,0.20103368,0.0070149517,0.0070925755,0.00072916265,0.0024599675,0.0010901276,0.34741998,0.0011269999,0.0018264336,0.42762583],"study_design_scores_gemma":[0.012647601,0.0006978552,0.77828294,0.007331006,0.0005637814,0.00008859141,0.0019697188,0.0022365467,0.18201111,0.0021579464,0.011408389,0.00060454046],"about_ca_topic_score_codex":0.0008849311,"about_ca_topic_score_gemma":0.000032724878,"teacher_disagreement_score":0.5772492,"about_ca_system_score_codex":0.00037895236,"about_ca_system_score_gemma":0.00076594495,"threshold_uncertainty_score":0.6836739},"labels":[],"label_agreement":null},{"id":"W7132891896","doi":"","title":"Comparison of HER2/neu Status Assessed by Quantitative Polymerase Chain Reaction and Immunohistochemistry","year":2001,"lang":"","type":"article","venue":"TSpace","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Toronto","keywords":"Immunohistochemistry; Polymerase chain reaction; Real-time polymerase chain reaction; Reverse transcription polymerase chain reaction; Antibody","score_opus":0.07489093250805003,"score_gpt":0.5009703699068477,"score_spread":0.4260794373987977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132891896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9175908,0.059387684,0.00047434602,0.0026664769,0.00033836305,0.00079331826,0.00006795436,0.000041320098,0.018639766],"genre_scores_gemma":[0.9724689,0.007962397,0.00043210268,0.00008302301,0.0001381057,0.000037607486,0.00009987942,0.00008213935,0.018695833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99616104,0.00032710575,0.0007996376,0.0007173781,0.0010087185,0.0009861322],"domain_scores_gemma":[0.99711686,0.00058603875,0.0005400606,0.00077849784,0.0003809594,0.00059757585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000721337,0.00043791268,0.001034843,0.00018434516,0.00017646738,0.000051580875,0.00020000194,0.00035407924,0.0019312501],"category_scores_gemma":[0.00065053557,0.00047886866,0.00011366523,0.0007288572,0.0007353371,0.00014672894,0.00012285938,0.0010817972,0.0000863828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021030828,0.0010352154,0.02147673,0.0009689689,0.00022926265,0.000046642057,0.010416594,0.0000033697063,0.94049114,0.00005762947,0.01580523,0.0073661236],"study_design_scores_gemma":[0.0066973134,0.003512296,0.009556755,0.0017731618,0.00034340593,0.000077869154,0.068190575,0.004035775,0.84467727,0.00002182585,0.06027843,0.00083535246],"about_ca_topic_score_codex":0.011460593,"about_ca_topic_score_gemma":0.00005749912,"teacher_disagreement_score":0.09581391,"about_ca_system_score_codex":0.0007539826,"about_ca_system_score_gemma":0.00084222783,"threshold_uncertainty_score":0.9997663},"labels":[],"label_agreement":null},{"id":"W7136033153","doi":"10.6084/m9.figshare.4776154.v1","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.17285375311511028,"score_gpt":0.3902435760244508,"score_spread":0.21738982290934053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136033153","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075212163,0.0035094903,1.07665734e-7,0.00010644167,0.000033344906,0.001288433,0.98732096,0.0000035414453,0.00021643615],"genre_scores_gemma":[0.61254334,0.0001188302,0.00040978554,0.00008553035,0.000052633317,0.004473249,0.3819188,0.00002882051,0.0003690553],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961381,0.0005824699,0.001104695,0.00064980786,0.0011272009,0.00039773952],"domain_scores_gemma":[0.9902793,0.005481717,0.0018482346,0.0011459661,0.0010796674,0.00016510517],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026000018,0.00030301363,0.0016759527,0.0003380471,0.00011939304,0.000051131632,0.0007749128,0.0003278738,0.9685704],"category_scores_gemma":[0.048313644,0.00018998528,0.00095036597,0.001189474,0.00029994323,0.00016171149,0.0005321684,0.000737518,0.000019753656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002553289,0.000795983,0.018035159,0.0019477041,0.0046901163,0.00002721885,0.0003737606,0.00007668619,0.00010944678,3.0517896e-7,0.9714871,0.0022012016],"study_design_scores_gemma":[0.00094573,0.0008654945,0.9469373,0.021759871,0.014078701,0.0000019845502,0.00008739259,0.0005193411,0.0012525598,0.00001495709,0.013288961,0.00024768477],"about_ca_topic_score_codex":0.0000524435,"about_ca_topic_score_gemma":0.00008380381,"teacher_disagreement_score":0.9685507,"about_ca_system_score_codex":0.00009538108,"about_ca_system_score_gemma":0.00058886484,"threshold_uncertainty_score":0.9597028},"labels":[],"label_agreement":null},{"id":"W7136061490","doi":"10.6084/m9.figshare.4776154","title":"Additional file 2: of The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature","year":2017,"lang":"","type":"article","venue":"Figshare","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer; Cohort; Expression (computer science); Scale (ratio); Cohort study; Clinical significance","score_opus":0.17285375311511028,"score_gpt":0.3902435760244508,"score_spread":0.21738982290934053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7136061490","genre_codex":"dataset","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075212163,0.0035094903,1.07665734e-7,0.00010644167,0.000033344906,0.001288433,0.98732096,0.0000035414453,0.00021643615],"genre_scores_gemma":[0.61254334,0.0001188302,0.00040978554,0.00008553035,0.000052633317,0.004473249,0.3819188,0.00002882051,0.0003690553],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9961381,0.0005824699,0.001104695,0.00064980786,0.0011272009,0.00039773952],"domain_scores_gemma":[0.9902793,0.005481717,0.0018482346,0.0011459661,0.0010796674,0.00016510517],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026000018,0.00030301363,0.0016759527,0.0003380471,0.00011939304,0.000051131632,0.0007749128,0.0003278738,0.9685704],"category_scores_gemma":[0.048313644,0.00018998528,0.00095036597,0.001189474,0.00029994323,0.00016171149,0.0005321684,0.000737518,0.000019753656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002553289,0.000795983,0.018035159,0.0019477041,0.0046901163,0.00002721885,0.0003737606,0.00007668619,0.00010944678,3.0517896e-7,0.9714871,0.0022012016],"study_design_scores_gemma":[0.00094573,0.0008654945,0.9469373,0.021759871,0.014078701,0.0000019845502,0.00008739259,0.0005193411,0.0012525598,0.00001495709,0.013288961,0.00024768477],"about_ca_topic_score_codex":0.0000524435,"about_ca_topic_score_gemma":0.00008380381,"teacher_disagreement_score":0.9685507,"about_ca_system_score_codex":0.00009538108,"about_ca_system_score_gemma":0.00058886484,"threshold_uncertainty_score":0.9597028},"labels":[],"label_agreement":null},{"id":"W7161972053","doi":"10.82308/47405","title":"Regulation of the MAFF transcription factor function in breast cancer cells","year":2023,"lang":"en","type":"dissertation","venue":"","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Breast cancer; Trastuzumab; Inflammatory breast cancer; Metastasis; Transcription factor","score_opus":0.043248764312501645,"score_gpt":0.35626865920340833,"score_spread":0.3130198948909067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7161972053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98825544,0.00019462383,0.000016171545,0.0012930646,0.0029999958,0.0014116274,0.00017235953,0.00007698901,0.0055797193],"genre_scores_gemma":[0.9170379,0.0003923737,0.000009447149,0.00004975609,0.00021321923,0.0001347539,0.00038611746,0.000062622465,0.08171378],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9982675,0.00007395861,0.00039926695,0.00029326355,0.00075095345,0.00021510993],"domain_scores_gemma":[0.99921757,0.00003267635,0.0001352239,0.0003185435,0.00024282215,0.000053191765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001848507,0.00016947805,0.00030389332,0.00029199178,0.00003373785,0.000011517464,0.000108849206,0.0003358267,0.0030688688],"category_scores_gemma":[0.000015924052,0.00012001985,0.00014877654,0.00069386105,0.000028836252,0.000058456008,0.000007639092,0.0004454697,0.00005062258],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013618091,0.00010745258,0.012071134,0.0022321886,0.000083416344,0.0000018589308,0.0015210976,0.00009032522,0.9320893,0.00007486341,0.009003432,0.041363113],"study_design_scores_gemma":[0.00060561555,0.000052803745,0.9319078,0.0010839853,0.00007651024,0.000001357337,0.0007697535,0.00022315886,0.064291604,0.00007905437,0.0008030476,0.000105325074],"about_ca_topic_score_codex":0.0044392147,"about_ca_topic_score_gemma":0.011096641,"teacher_disagreement_score":0.91983664,"about_ca_system_score_codex":0.0004220248,"about_ca_system_score_gemma":0.0005014188,"threshold_uncertainty_score":0.9978425},"labels":[],"label_agreement":null},{"id":"W846849520","doi":"10.71781/30168","title":"Growth factor activation of ErbB2/ErbB3 signaling pathways regulate the activity of Estrogen Receptors (ER)","year":2010,"lang":"en","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Université de Montréal; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Estrogen receptor; Signal transduction; Cell biology; Receptor; ERBB3; Cancer research; Chemistry; Biology; Internal medicine; Medicine; Cancer; Receptor tyrosine kinase; Breast cancer","score_opus":0.01479742512499417,"score_gpt":0.22475192343784642,"score_spread":0.20995449831285223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W846849520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882923,0.0013420345,0.00005030295,0.00024677574,0.0007074365,0.0007588197,0.00007222599,0.000055708075,0.008474398],"genre_scores_gemma":[0.9913538,0.00031312738,0.00030815124,0.000015341357,0.00023161892,0.000028642531,0.00030399254,0.000048220532,0.007397114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971756,0.00016493675,0.00047160938,0.000493723,0.0013320373,0.00036212467],"domain_scores_gemma":[0.9970989,0.000237103,0.00077434303,0.0005890814,0.0010678285,0.00023269808],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.00032289792,0.00036210817,0.0006020313,0.00037606832,0.0015174283,0.000018688841,0.00042040716,0.0006473152,0.0001003951],"category_scores_gemma":[0.00031475787,0.00032043812,0.00037409298,0.00055266265,0.00034869704,0.0002189852,0.00010096157,0.0010294428,0.000007329922],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030957523,0.00027198638,0.010312983,0.0009431768,0.00055474474,0.00012662087,0.013159054,0.00012079012,0.9597021,0.0029287958,0.00032184564,0.0084622],"study_design_scores_gemma":[0.00092895335,0.00022892671,0.06248187,0.00079874694,0.00029578837,0.00008842934,0.0046162587,0.00012583031,0.9252802,0.00020807875,0.0046553407,0.0002915855],"about_ca_topic_score_codex":0.016602522,"about_ca_topic_score_gemma":0.0010275196,"teacher_disagreement_score":0.052168887,"about_ca_system_score_codex":0.002518079,"about_ca_system_score_gemma":0.0037553126,"threshold_uncertainty_score":0.9999248},"labels":[],"label_agreement":null},{"id":"W97040042","doi":"10.1096/fasebj.20.5.lb72-c","title":"Acquired Capabilities of Cancer Cells Intersect at ADAM17 (TACE)","year":2006,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Autocrine signalling; Gene silencing; Epidermal growth factor receptor; Cancer research; Cancer cell; Cancer; Biology; Epidermal growth factor; Cell biology; Receptor","score_opus":0.03001105445655388,"score_gpt":0.32970453021344037,"score_spread":0.2996934757568865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W97040042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98689586,0.0026417521,0.00002876283,0.0021759735,0.00047014072,0.00022010655,0.000030838044,0.000015605712,0.0075209653],"genre_scores_gemma":[0.9869339,0.0003416985,0.00009088219,0.00018994258,0.000823494,0.000011295689,0.0000022848797,0.000026152678,0.0115803415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983369,0.00014441238,0.00037452218,0.00013101334,0.0006356795,0.00037744752],"domain_scores_gemma":[0.99902815,0.00015389036,0.00014951505,0.00032980894,0.00020579188,0.0001328497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069754437,0.00012699024,0.00027801533,0.00010149632,0.0001519114,0.000025947304,0.00025524298,0.000058294812,0.00424693],"category_scores_gemma":[0.00005066839,0.000077580495,0.00016791574,0.000152805,0.00035543376,0.000054574906,0.000088978944,0.00032268878,0.000054111508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005679841,0.00008577907,0.018971963,0.00013910598,0.00011249879,0.0000833005,0.0013807629,0.00014934753,0.92838687,0.000045678116,0.04685494,0.0032217447],"study_design_scores_gemma":[0.0012671556,0.00030786815,0.0105777895,0.00033506413,0.00009010969,0.0003236406,0.0011380123,0.00012933557,0.9764707,0.00026417154,0.008989159,0.000107006555],"about_ca_topic_score_codex":0.0020585658,"about_ca_topic_score_gemma":0.00072257227,"teacher_disagreement_score":0.04808379,"about_ca_system_score_codex":0.0005840561,"about_ca_system_score_gemma":0.0003744982,"threshold_uncertainty_score":0.99666333},"labels":[],"label_agreement":null}]}